PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Zhang, J; Zhang, XF; Guo, YQ; Xu, LL; Pei, DQ				Zhang, Juan; Zhang, Xiaofei; Guo, Yunqian; Xu, Liangliang; Pei, Duanqing			Sorting Nexin 33 Induces Mammalian Cell Micronucleated Phenotype and Actin Polymerization by Interacting with Wiskott-Aldrich Syndrome Protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; ARP2/3 COMPLEX; WASP; DOMAINS; SH3PX1; PHOSPHORYLATION; DEGRADATION; ACTIVATION; BINDING; ACK2	Sorting nexin 33 (SNX33) is a novel member of the sorting nexin superfamily with three predicted structural domains, SH3-PX-BAR. Very little is known about the cellular function of SNX33. In an effort to analyze its structure/function relationship, we attempted but failed to generate stable cell lines for short hairpin RNA or overexpression SNX33. Transient knockdown of SNX33 induces both HeLa and MCF7 cells to grow multiple long processes, delay the G(1)/M transition, and become more apoptotic, implying that SNX33 may control cell cycle process through influence the cytoskeleton. In vitro cell lineage analysis revealed that cells transfected with SNX33 failed to divide and became micronucleated, suggesting a specific defect in cytokinesis. Further analysis revealed that SNX33 induced the accumulation of actin at the perinuclear space, which might have disabled the cytokinetic machinery. However, SNX33 appears to mediate actin polymerization indirectly, as they do not interact with each other. SNX33 interacts with itself and SNX9. Interestingly, it also interacts with VCA domain of Wiskott-Aldrich syndrome protein (WASp), a protein known to be involved in actin polymerization. Indeed, cells overexpressing WASp failed to divide and form stable colonies as SNX33, consistent with the notion that SNX33 may interfere with cytokinesis. On the other hand, knockdown of WASp alleviates the phenotype induced by SNX33. Taken together, our results suggest that SNX33 plays a role in maintaining cell shape and cell cycle progression through its interaction with WASp.	[Zhang, Juan; Zhang, Xiaofei; Guo, Yunqian; Xu, Liangliang; Pei, Duanqing] Chinese Acad Sci, Guangzhou Inst Biomed, S China Inst Stem Cell Biol & Regenerat Med, Key Lab Regenerat Biol,Stem Cell & Canc Biol Grp, Guangzhou 510663, Guangdong, Peoples R China; [Zhang, Juan; Zhang, Xiaofei; Guo, Yunqian; Xu, Liangliang; Pei, Duanqing] Chinese Acad Sci, Guangzhou Inst Hlth, Guangzhou 510663, Guangdong, Peoples R China; [Zhang, Juan; Guo, Yunqian; Xu, Liangliang] Tsinghua Univ, Sch Med, Inst Biomed, Dept Biol Sci & Biotechnol,Lab Stem Cell Biol, Beijing 100084, Peoples R China	Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS; Chinese Academy of Sciences; Tsinghua University	Pei, DQ (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed, S China Inst Stem Cell Biol & Regenerat Med, Key Lab Regenerat Biol,Stem Cell & Canc Biol Grp, Guangzhou 510663, Guangdong, Peoples R China.	pei_duanqing@gibh.ac.cn	Zhang, Xiafoei/C-8471-2014; Guo, Yunqian/L-4716-2013; zhou, xingru/G-4442-2012		National Natural Science Foundation of China [30630039, 30725012, 30700410, 30871404, 90813033]; Knowledge Innovation Project of The Chinese Academy of Sciences [KSCX2-YW-R-48, KSCX1-YW-02-1]; Bureau of Science and Technology of Guangzhou Municipality, China [2008A1-E4011]; 973 Program of China [2006CB701504, 2006CB943600, 2007CB948002, 2007CB947804, 2007CB947900, 2009CB941102, 2009CB940902]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Knowledge Innovation Project of The Chinese Academy of Sciences(Knowledge Innovation Program of the Chinese Academy of Sciences); Bureau of Science and Technology of Guangzhou Municipality, China; 973 Program of China(National Basic Research Program of China)	This work was supported by National Natural Science Foundation of China Grants 30630039, 30725012, 30700410, 30871404, and 90813033; by Knowledge Innovation Project of The Chinese Academy of Sciences Grants KSCX2-YW-R-48 and KSCX1-YW-02-1; by Bureau of Science and Technology of Guangzhou Municipality, China, Grant 2008A1-E4011; and by 973 Program of China Grants 2006CB701504, 2006CB943600, 2007CB948002, 2007CB947804, 2007CB947900, 2009CB941102 and 2009CB940902.	Badour K, 2007, P NATL ACAD SCI USA, V104, P1593, DOI 10.1073/pnas.0610543104; Childress C, 2006, BIOCHEM J, V394, P693, DOI 10.1042/BJ20050576; Cory GOC, 2003, MOL CELL, V11, P1229, DOI 10.1016/S1097-2765(03)00172-2; Haft CR, 2000, MOL BIOL CELL, V11, P4105, DOI 10.1091/mbc.11.12.4105; Heiseke A, 2008, TRAFFIC, V9, P1116, DOI 10.1111/j.1600-0854.2008.00750.x; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Jiang AX, 2003, J BIOL CHEM, V278, P38765, DOI 10.1074/jbc.M306618200; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Kurten RC, 2001, J CELL SCI, V114, P1743; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; Macaulay SL, 2003, BIOCHEM J, V376, P123, DOI 10.1042/BJ20030130; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Moulding DA, 2007, J EXP MED, V204, P2213, DOI 10.1084/jem.20062324; Olivier A, 2006, MOL THER, V13, P729, DOI 10.1016/j.ymthe.2005.11.003; Otsuki M, 2003, J BIOL CHEM, V278, P6461, DOI 10.1074/jbc.M207433200; Pan GJ, 2004, J BIOL CHEM, V279, P37013, DOI 10.1074/jbc.M405117200; Parks WT, 2001, J BIOL CHEM, V276, P19332, DOI 10.1074/jbc.M100606200; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Qin BM, 2006, J BIOL CHEM, V281, P36891, DOI 10.1074/jbc.M608884200; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Schobel S, 2008, J BIOL CHEM, V283, P14257, DOI 10.1074/jbc.M801531200; Seet LF, 2006, BBA-MOL CELL BIOL L, V1761, P878, DOI 10.1016/j.bbalip.2006.04.011; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Thrasher AJ, 2002, NAT REV IMMUNOL, V2, P635, DOI 10.1038/nri884; Tsuboi S, 2006, EMBO REP, V7, P506, DOI 10.1038/sj.embor.7400665; Tsuboi S, 2007, J BIOL CHEM, V282, P34194, DOI 10.1074/jbc.M705999200; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Yarar D, 2008, TRAFFIC, V9, P133, DOI 10.1111/j.1600-0854.2007.00675.x	31	24	26	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	2009	284	32					21659	21669		10.1074/jbc.M109.007278	http://dx.doi.org/10.1074/jbc.M109.007278			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478CC	19487689	Green Published, hybrid			2022-12-25	WOS:000268564400059
J	Kobayashi, T; Patrick, SE; Kobayashi, M				Kobayashi, Tomoyoshi; Patrick, Stacey E.; Kobayashi, Minae			Ala Scanning of the Inhibitory Region of Cardiac Troponin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; MUSCLE THIN-FILAMENTS; REGULATORY PROPERTIES; STRUCTURAL BASIS; CALCIUM-BINDING; TROPOMYOSIN; ACTIN; MYOSIN; SITES	In skeletal and cardiac muscles, troponin (Tn), which resides on the thin filament, senses a change in intracellular Ca2+ concentration. Tn is composed of TnC, TnI, and TnT. Ca2+ binding to the regulatory domain of TnC removes the inhibitory effect by TnI on the contraction. The inhibitory region of cardiac TnI spans from residue 138 to 149. Upon Ca2+ activation, the inhibitory region is believed to be released from actin, thus triggering actin-activation of myosin ATPase. In this study, we created a series of Ala-substitution mutants of cTnI to delineate the functional contribution of each amino acid in the inhibitory region to myofilament regulation. We found that most of the point mutations in the inhibitory region reduced the ATPase activity in the presence of Ca2+, which suggests the same region also acts as an activator of the ATPase. The thin filaments can also be activated by strong myosin head (S1)-actin interactions. The binding of N-ethylmaleimide-treated myosin subfragment 1 (NEM-S1) to actin filaments mimics such strong interactions. Interestingly, in the absence of Ca2+ NEM-S1-induced activation of S1 ATPase was significantly less with the thin filaments containing TnI(T144A) than that with the wild-type TnI. However, in the presence of Ca2+, there was little difference in the activation of ATPase activity between these preparations.	[Kobayashi, Tomoyoshi] Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA; Univ Illinois, Cardiovasc Res Ctr, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kobayashi, T (corresponding author), Univ Illinois, Dept Physiol & Biophys, 835 S Wolcott Ave,M-C 901, Chicago, IL 60612 USA.	tkoba@uic.edu			National Institutes of Health [R01 HL082923]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082923] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported, in whole or in part, by National Institutes of Health Grant R01 HL082923.	Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Burkart EM, 2003, J BIOL CHEM, V278, P11265, DOI 10.1074/jbc.M210712200; Burton D, 2002, BIOCHEM J, V362, P443, DOI 10.1042/0264-6021:3620443; Chang AN, 2008, BIOCHEM BIOPH RES CO, V369, P74, DOI 10.1016/j.bbrc.2007.12.081; Craig R, 2001, J MOL BIOL, V311, P1027, DOI 10.1006/jmbi.2001.4897; Davis JP, 2007, BIOPHYS J, V92, P3195, DOI 10.1529/biophysj.106.095406; Elliott K, 2000, J BIOL CHEM, V275, P22069, DOI 10.1074/jbc.M002502200; Galinska-Rakoczy A, 2008, J MOL BIOL, V379, P929, DOI 10.1016/j.jmb.2008.04.062; Gomes AV, 2004, J BIOL CHEM, V279, P49579, DOI 10.1074/jbc.M407340200; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GREENE LE, 1987, P NATL ACAD SCI USA, V84, P3102, DOI 10.1073/pnas.84.10.3102; Harada K, 2004, JPN J PHYSIOL, V54, P307, DOI 10.2170/jjphysiol.54.307; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HILL LE, 1992, J BIOL CHEM, V267, P16106; Kobayashi T, 2006, J BIOL CHEM, V281, P13471, DOI 10.1074/jbc.M509561200; Kobayashi T, 2005, ANNU REV PHYSIOL, V67, P39, DOI 10.1146/annurev.physiol.67.040403.114025; Kobayashi T, 2005, J MOL CELL CARDIOL, V38, P213, DOI 10.1016/j.yjmcc.2004.10.014; Kobayashi T, 2000, BIOCHEMISTRY-US, V39, P86, DOI 10.1021/bi991903b; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; Kohler J, 2003, PHYSIOL GENOMICS, V14, P117, DOI 10.1152/physiolgenomics.00101.2002; Lang R, 2002, J BIOL CHEM, V277, P11670, DOI 10.1074/jbc.M108912200; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; Mathur MC, 2008, BIOPHYS J, V94, P542, DOI 10.1529/biophysj.107.113944; Mathur MC, 2009, BIOPHYS J, V96, P2237, DOI 10.1016/j.bpj.2008.12.3909; Matsumoto F, 2004, J MOL BIOL, V342, P1209, DOI 10.1016/j.jmb.2004.07.086; Maxwell SE, 2003, DESIGNING EXPT ANAL, DOI DOI 10.1158/2159-8290.CD-16-0040; Maytum R, 2003, J BIOL CHEM, V278, P6696, DOI 10.1074/jbc.M210690200; McKay RT, 1998, BIOCHEMISTRY-US, V37, P12419, DOI 10.1021/bi9809019; McKay RT, 1999, BIOCHEMISTRY-US, V38, P5478; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; Murakami K, 2005, J MOL BIOL, V352, P178, DOI 10.1016/j.jmb.2005.06.067; Narolska NA, 2006, CIRC RES, V99, P1012, DOI 10.1161/01.RES.0000248753.30340.af; PAN BS, 1987, J BIOL CHEM, V262, P7839; PAN BS, 1992, J BIOL CHEM, V267, P23052; Patchell VB, 2005, J BIOL CHEM, V280, P14469, DOI 10.1074/jbc.M414202200; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; Pirani A, 2006, J MOL BIOL, V357, P707, DOI 10.1016/j.jmb.2005.12.050; Pirani A, 2005, J MOL BIOL, V346, P761, DOI 10.1016/j.jmb.2004.12.013; Robinson JM, 2008, BIOPHYS J, V95, P4772, DOI 10.1529/biophysj.108.131318; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sumandea MP, 2003, J BIOL CHEM, V278, P35135, DOI 10.1074/jbc.M306325200; SWARTZ DR, 1992, J BIOL CHEM, V267, P20497; Tachampa K, 2008, J BIOL CHEM, V283, P15114, DOI 10.1074/jbc.M801636200; Tachampa K, 2007, CIRC RES, V101, P1081, DOI 10.1161/CIRCRESAHA.107.165258; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; Vinogradova MV, 2005, P NATL ACAD SCI USA, V102, P5038, DOI 10.1073/pnas.0408882102; Wang H, 2006, J MOL CELL CARDIOL, V41, P823, DOI 10.1016/j.yjmcc.2006.08.016; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; Xing J, 2008, BIOCHEMISTRY-US, V47, P13383, DOI 10.1021/bi801492x	54	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20052	20060		10.1074/jbc.M109.001396	http://dx.doi.org/10.1074/jbc.M109.001396			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19483081	hybrid, Green Published			2022-12-25	WOS:000268097400032
J	Singer, D; Camargo, SMR; Huggel, K; Romeo, E; Danilczyk, U; Kuba, K; Chesnov, S; Caron, MG; Penninger, JM; Verrey, F				Singer, Dustin; Camargo, Simone M. R.; Huggel, Katja; Romeo, Elisa; Danilczyk, Ursula; Kuba, Keiji; Chesnov, Serge; Caron, Marc G.; Penninger, Josef M.; Verrey, Francois			Orphan Transporter SLC6A18 Is Renal Neutral Amino Acid Transporter B(0)AT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-PRESSURE; MICE; KIDNEY; EXPRESSION; MOUSE; COTRANSPORTER; HYPERTENSION; GLYCINE; CELLS; GENE	The orphan transporter Slc6a18 (XT2) is highly expressed at the luminal membrane of kidney proximal tubules and displays similar to 50% identity with Slc6a19 (B(0)AT1), which is the main neutral amino acid transporter in both kidney and small intestine. As yet, the amino acid transport function of XT2 has only been experimentally supported by the urinary glycine loss observed in xt2 null mice. We report here that in Xenopus laevis oocytes, co-expressed ACE2 (angiotensin-converting enzyme 2) associates with XT2 and reveals its function as a Na+- and Cl--dependent neutral amino acid transporter. In contrast to its association with ACE2 observed in Xenopus laevis oocytes, our experiments with ace2 and collectrin null mice demonstrate that in vivo it is Collectrin, a smaller homologue of ACE2, that is required for functional expression of XT2 in kidney. To assess the function of XT2 in vivo, we reanalyzed its knock-out mouse model after more than 10 generations of backcrossing into C57BL/6 background. In addition to the previously published glycinuria, we observed a urinary loss of several other amino acids, in particular beta-branched and small neutral ones. Using telemetry, we confirmed the previously described link of XT2 absence with hypertension but only in physically restrained animals. Taken together, our data indicate that the formerly orphan transporter XT2 functions as a sodium and chloride-dependent neutral amino acid transporter that we propose to rename B(0)AT3.	[Verrey, Francois] Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; [Verrey, Francois] Univ Zurich, Ctr Integrat Human Physiol, CH-8057 Zurich, Switzerland; [Danilczyk, Ursula; Kuba, Keiji; Penninger, Josef M.] Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria; [Chesnov, Serge] Univ & ETH Zurich, Funct Genom Ctr Zurich, CH-8057 Zurich, Switzerland; [Caron, Marc G.] Duke Univ, Med Ctr, Dept Cell Biol Med & Neurobiol, Durham, NC 27710 USA	University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Swiss Federal Institutes of Technology Domain; ETH Zurich; Duke University	Verrey, F (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	Verrey@access.uzh.ch	Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777; Camargo, Simone/0000-0003-0091-7380; Verrey, Francois/0000-0003-3250-9824	Swiss National Science Foundation [31-59141.02]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This project was supported by Swiss National Science Foundation Grant 31-59141.02 (to F.V.).	Akpinar P, 2005, CELL METAB, V2, P385, DOI 10.1016/j.cmet.2005.11.001; Babu S V Suresh, 2002, Indian J Clin Biochem, V17, P7, DOI 10.1007/BF02867967; Butz GM, 2001, PHYSIOL GENOMICS, V5, P89, DOI 10.1152/physiolgenomics.2001.5.2.89; Camargo SMR, 2009, GASTROENTEROLOGY, V136, P872, DOI 10.1053/j.gastro.2008.10.055; Camargo SMR, 2005, PFLUG ARCH EUR J PHY, V451, P338, DOI 10.1007/s00424-005-1455-x; COHEN SA, 1994, J CHROMATOGR A, V661, P25, DOI 10.1016/0021-9673(93)E0821-B; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Danilczyk U, 2006, NATURE, V444, P1088, DOI 10.1038/nature05475; Ehnes C, 2004, J GEN PHYSIOL, V124, P475, DOI 10.1085/jgp.200409060; Eslami B, 2006, TOHOKU J EXP MED, V208, P25, DOI 10.1620/tjem.208.25; Lum C, 2004, HYPERTENSION, V43, P79, DOI 10.1161/01.HYP.0000107401.72456.50; Mills PA, 2000, J APPL PHYSIOL, V88, P1537, DOI 10.1152/jappl.2000.88.5.1537; Nash SR, 1998, RECEPTOR CHANNEL, V6, P113; Parks LD, 2002, AM J PHYSIOL-RENAL, V283, pF1208, DOI 10.1152/ajprenal.00021.2002; Paunescu TG, 2004, AM J PHYSIOL-CELL PH, V287, pC149, DOI 10.1152/ajpcell.00464.2003; Pfeiffer R, 1999, MOL BIOL CELL, V10, P4135, DOI 10.1091/mbc.10.12.4135; Qi ZH, 2004, AM J PHYSIOL-RENAL, V286, pF590, DOI 10.1152/ajprenal.00324.2003; Quan H, 2004, MOL CELL BIOL, V24, P4166, DOI 10.1128/MCB.24.10.4166-4173.2004; Ristic Z, 2006, AM J PHYSIOL-RENAL, V290, pF880, DOI 10.1152/ajprenal.00319.2005; Romeo E, 2006, AM J PHYSIOL-RENAL, V290, pF376, DOI 10.1152/ajprenal.00286.2005; SEATON B, 1984, MED LAB SCI, V41, P327; Van Abel M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022423.34922.2A; Van Vliet BN, 2003, J PHYSIOL-LONDON, V549, P313, DOI 10.1113/jphysiol.2003.041897; WASSERMAN JC, 1994, AM J PHYSIOL-RENAL, V267, pF688, DOI 10.1152/ajprenal.1994.267.4.F688; Wysocki J, 2006, DIABETES, V55, P2132, DOI 10.2337/db06-0033; Zecevic M, 2004, PFLUG ARCH EUR J PHY, V448, P29, DOI 10.1007/s00424-003-1222-9	26	39	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					19953	19960		10.1074/jbc.M109.011171	http://dx.doi.org/10.1074/jbc.M109.011171			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19478081	Green Accepted, hybrid, Green Published			2022-12-25	WOS:000268097400022
J	Barth, MC; Ahluwalia, N; Anderson, TJT; Hardy, GJ; Sinha, S; Alvarez-Cardona, JA; Pruitt, IE; Rhee, EP; Colvin, RA; Gerszten, RE				Barth, Marita C.; Ahluwalia, Neil; Anderson, Thomas J. T.; Hardy, Gregory J.; Sinha, Sumita; Alvarez-Cardona, Jose A.; Pruitt, Ivy E.; Rhee, Eugene P.; Colvin, Richard A.; Gerszten, Robert E.			Kynurenic Acid Triggers Firm Arrest of Leukocytes to Vascular Endothelium under Flow Conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED-RECEPTOR; INFLAMMATORY-BOWEL-DISEASE; FUNCTIONAL EXPRESSION; CHEMOTACTIC FACTORS; PATHWAY METABOLISM; MOLECULAR-CLONING; DENDRITIC CELLS; MICE REVEALS; ADHESION; TRYPTOPHAN	Recent studies have demonstrated that kynurenic acid (KYNA), a compound produced endogenously by the interferon-gamma-induced degradation of tryptophan by indoleamine 2,3-dioxygenase, activates the previously orphaned G protein-coupled receptor, GPR35. This receptor is expressed in immune tissues, although its potential function in immunomodulation remains to be explored. We determined that GPR35 was most highly expressed on human peripheral monocytes. In an in vitro vascular flow model, KYNA triggered the firm arrest of monocytes to both fibronectin and ICAM-1, via beta(1) integrin- and beta(2) integrin-mediated mechanisms, respectively. Incubation of monocytes with pertussis toxin prior to use in flow experiments significantly reduced the KYNA-induced monocyte adhesion, suggesting that adhesion is triggered by a G(i)-mediated process. Furthermore, KYNA-triggered adhesion of monocytic cells was reduced by short hairpin RNA-mediated silencing of GPR35. Although GPR35 is expressed at slightly lower levels on neutrophils, KYNA induced firm adhesion of these cells to an ICAM-1-expressing monolayer as well. KYNA also elicited neutrophil shedding of surface L-selectin, another indicator of leukocyte activation. Taken together, these data suggest that KYNA could be an important early mediator of leukocyte recruitment.	[Gerszten, Robert E.] Massachusetts Gen Hosp, Div Cardiol, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Gerszten, RE (corresponding author), Massachusetts Gen Hosp, Div Cardiol, Charlestown, MA 02129 USA.	Gerszten.Robert@mgh.harvard.edu		Anderson, Thomas/0000-0002-2762-6703	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065584] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL065584, HL65584] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amirkhani A, 2002, J CHROMATOGR B, V780, P381, DOI 10.1016/S1570-0232(02)00572-X; Baran H, 1997, PEDIATR RES, V41, P404, DOI 10.1203/00006450-199703000-00017; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; BURNS DL, 1988, MICROBIOL SCI, V5, P285; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Chen JC, 2003, EUR J PHARMACOL, V467, P57, DOI 10.1016/S0014-2999(03)01635-2; CLARK RA, 1996, CURRENT PROTOCOLS IM; Forrest CM, 2006, CLIN EXP PHARMACOL P, V33, P1078, DOI 10.1111/j.1440-1681.2006.04490.x; Forrest CM, 2003, ADV EXP MED BIOL, V527, P395; Forrest CM, 2002, J BIOMED SCI, V9, P436, DOI 10.1007/BF02256538; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Gerszten RE, 2001, J BIOL CHEM, V276, P26846, DOI 10.1074/jbc.M011235200; Hartai Z, 2007, NEUROCHEM INT, V50, P308, DOI 10.1016/j.neuint.2006.08.012; Heller EA, 2005, CIRCULATION, V112, P578, DOI 10.1161/CIRCULATIONAHA.105.545616; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; Hilmas C, 2001, J NEUROSCI, V21, P7463, DOI 10.1523/JNEUROSCI.21-19-07463.2001; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; King VL, 2009, CIRCULATION, V119, P426, DOI 10.1161/CIRCULATIONAHA.108.785949; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Lagerstrom MC, 2008, NAT REV DRUG DISCOV, V7, P339, DOI 10.1038/nrd2518; Liu CL, 2001, J PHARMACOL EXP THER, V299, P121; Liu CL, 2003, J BIOL CHEM, V278, P50765, DOI 10.1074/jbc.M308996200; Maes M, 2007, NEUROENDOCRINOL LETT, V28, P826; Means TK, 2003, J IMMUNOL, V170, P5165, DOI 10.4049/jimmunol.170.10.5165; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Papadopoulou C, 2008, CYTOKINE, V43, P181, DOI 10.1016/j.cyto.2008.05.009; Parsons CG, 1997, J PHARMACOL EXP THER, V283, P1264; Pawlak D., 2001, International Urology and Nephrology, V33, P399, DOI 10.1023/A:1015238418500; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stazka J, 2002, EUR J PHARMACOL, V448, P133, DOI 10.1016/S0014-2999(02)01943-X; STONE TW, 1993, PHARMACOL REV, V45, P309; Wang JH, 2006, J BIOL CHEM, V281, P34457, DOI 10.1074/jbc.M608019200; Wang JH, 2006, J BIOL CHEM, V281, P22021, DOI 10.1074/jbc.M603503200; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	41	103	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19189	19195		10.1074/jbc.M109.024042	http://dx.doi.org/10.1074/jbc.M109.024042			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19473985	Green Published, hybrid			2022-12-25	WOS:000267908300008
J	Yang, LC; Calingasan, NY; Thomas, B; Chaturvedi, RK; Kiaei, M; Wille, EJ; Liby, KT; Williams, C; Royce, D; Risingsong, R; Musiek, ES; Morrow, JD; Sporn, M; Beal, MF				Yang, Lichuan; Calingasan, Noel Y.; Thomas, Bobby; Chaturvedi, Rajnish K.; Kiaei, Mahmoud; Wille, Elizabeth J.; Liby, Karen T.; Williams, Charlotte; Royce, Darlene; Risingsong, Renee; Musiek, Eric S.; Morrow, Jason D.; Sporn, Michael; Beal, M. Flint			Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription	PLOS ONE			English	Article							TRANSGENIC MOUSE MODEL; 3-NITROPROPIONIC ACID; OXIDATIVE STRESS; ALPHA-SYNUCLEIN; IN-VIVO; MICE; MPTP; PROTECTION; INDUCTION; DISEASE	The NF-E2-related factor-2 (Nrf2)/antioxidant response element (ARE) signaling pathway regulates phase 2 detoxification genes, including a variety of antioxidative enzymes. We tested neuroprotective effects of the synthetic triterpenoid CDDO-MA, a potent activator of the Nrf2/ARE signaling. CDDO-MA treatment of neuroblastoma SH-SY5Y cells resulted in Nrf2 upregulation and translocation from cytosol to nucleus and subsequent activation of ARE pathway genes. CDDO-MA blocked t-butylhydroperoxide-induced production of reactive oxygen species (ROS) by activation of ARE genes only in wild type, but not Nrf2 knockout mouse embryonic fibroblasts. Oral administration of CDDO-MA resulted in significant protection against MPTP-induced nigrostriatal dopaminergic neurodegeneration, pathological alpha-synuclein accumulation and oxidative damage in mice. Additionally, CDDO-MA treatment in rats produced significant rescue against striatal lesions caused by the neurotoxin 3-NP, and associated increases in the oxidative damage markers malondialdehyde, F-2-Isoprostanes, 8-hydroxy-2-deoxyguanosine, 3-nitrotyrosine, and impaired glutathione homeostasis. Our results indicate that the CDDO-MA renders its neuroprotective effects through its potent activation of the Nrf2/ARE pathway, and suggest that triterpenoids may be beneficial for the treatment of neurodegenerative diseases like Parkinson's disease and Huntington's disease.			Yang, LC (corresponding author), Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Dept Neurol & Neurosci, New York, NY 10021 USA.	fbeal@med.cornell.edu	Chaturvedi, Rajnish/AAZ-9955-2020; Chaturvedi, Dr. Rajnish/E-2803-2010	Liby, Karen/0000-0003-3317-3437; Musiek, Erik/0000-0002-8873-0360	NCI NIH HHS [R01 CA078814, CA78814] Funding Source: Medline; NINDS NIH HHS [NS39258, R01 NS039258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agarwal R, 2002, J CHROMATOGR B, V775, P121, DOI 10.1016/S1570-0232(02)00273-8; BEAL MF, 1993, J NEUROSCI, V13, P4181; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Browne SE, 2004, NEUROCHEM RES, V29, P531, DOI 10.1023/B:NERE.0000014824.04728.dd; Burton NC, 2006, NEUROTOXICOLOGY, V27, P1094, DOI 10.1016/j.neuro.2006.07.019; Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; CALKINS MJ, 2008, ANTIOXID REDOX SIGNA; Chen PC, 2009, P NATL ACAD SCI USA, V106, P2933, DOI 10.1073/pnas.0813361106; Cleren C, 2005, NEUROBIOL DIS, V20, P701, DOI 10.1016/j.nbd.2005.05.022; Cleren C, 2005, J NEUROCHEM, V94, P995, DOI 10.1111/j.1471-4159.2005.03253.x; Dinkova-Kostova AT, 2005, P NATL ACAD SCI USA, V102, P4584, DOI 10.1073/pnas.0500815102; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Dumont M, 2009, J NEUROCHEM, V109, P502, DOI 10.1111/j.1471-4159.2009.05970.x; Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fornai F, 2005, P NATL ACAD SCI USA, V102, P3413, DOI 10.1073/pnas.0409713102; Hofer T, 2006, BIOL CHEM, V387, P103, DOI 10.1515/BC.2006.014; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Holtzclaw WD, 2004, ADV ENZYME REGUL, V44, P335, DOI 10.1016/j.advenzreg.2003.11.013; Honda T, 2002, BIOORG MED CHEM LETT, V12, P1027, DOI 10.1016/S0960-894X(02)00105-1; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Kiaei M, 2005, J NEUROCHEM, V93, P403, DOI 10.1111/j.1471-4159.2005.03024.x; Klivenyi P, 2004, J NEUROCHEM, V88, P576, DOI 10.1046/j.1471-4159.2003.02160.x; Klivenyi P, 2006, NEUROBIOL DIS, V21, P541, DOI 10.1016/j.nbd.2005.08.018; Klivenyi P, 2000, J NEUROSCI, V20, P1; Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04-2591hyp; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Leung L, 2003, J BIOL CHEM, V278, P48021, DOI 10.1074/jbc.M308439200; Liberatore GT, 1999, NAT MED, V5, P1403; Liby K, 2005, CANCER RES, V65, P4789, DOI 10.1158/0008-5472.CAN-04-4539; Liby KT, 2007, NAT REV CANCER, V7, P357, DOI 10.1038/nrc2129; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Liu GW, 2005, ANAL CHEM, V77, P6407, DOI 10.1021/ac050892r; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Manning-Bog AB, 2002, J BIOL CHEM, V277, P1641, DOI 10.1074/jbc.C100560200; Martin LJ, 2007, J COMP NEUROL, V500, P20, DOI 10.1002/cne.21160; Martin LJ, 2006, J NEUROSCI, V26, P41, DOI 10.1523/JNEUROSCI.4308-05.2006; Melnyk S, 1999, J NUTR BIOCHEM, V10, P490, DOI 10.1016/S0955-2863(99)00033-9; Milne GL, 2007, NAT PROTOC, V2, P221, DOI 10.1038/nprot.2006.375; Montine KS, 2004, CHEM PHYS LIPIDS, V128, P117, DOI 10.1016/j.chemphyslip.2003.10.010; Montine TJ, 1999, NEUROLOGY, V52, P1104, DOI 10.1212/WNL.52.5.1104; Norris EH, 2007, AM J PATHOL, V170, P658, DOI 10.2353/ajpath.2007.060359; Ouary S, 2000, NEUROSCIENCE, V97, P521, DOI 10.1016/S0306-4522(00)00020-8; Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005; Shih AY, 2005, J BIOL CHEM, V280, P22925, DOI 10.1074/jbc.M414635200; Suh NJ, 1999, CANCER RES, V59, P336; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Thimmulappa RK, 2006, BIOCHEM BIOPH RES CO, V351, P883, DOI 10.1016/j.bbrc.2006.10.102; Thomas B, 2007, HUM MOL GENET, V16, pR183, DOI 10.1093/hmg/ddm159; Thomas B, 2007, NEUROBIOL DIS, V26, P312, DOI 10.1016/j.nbd.2006.12.021; Trinh K, 2008, J NEUROSCI, V28, P465, DOI 10.1523/JNEUROSCI.4778-07.2008; van Muiswinkel FL, 2005, CNS NEUROL DISORD-DR, V4, P267, DOI 10.2174/1568007054038238; Vargas MR, 2008, J NEUROSCI, V28, P13574, DOI 10.1523/JNEUROSCI.4099-08.2008; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Yang LC, 2005, EXP NEUROL, V191, P86, DOI 10.1016/j.expneurol.2004.07.012; Yates MS, 2007, MOL CANCER THER, V6, P154, DOI 10.1158/1535-7163.MCT-06-0516; Yates MS, 2006, CANCER RES, V66, P2488, DOI 10.1158/0008-5472.CAN-05-3823	60	136	147	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2009	4	6							e5757	10.1371/journal.pone.0005757	http://dx.doi.org/10.1371/journal.pone.0005757			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	452GL	19484125	Green Published, gold, Green Submitted			2022-12-25	WOS:000266528200010
J	Agarwal, G; Rajavel, M; Gopal, B; Srinivasan, N				Agarwal, Garima; Rajavel, Malligarjunan; Gopal, Balasubramanian; Srinivasan, Narayanaswamy			Structure-Based Phylogeny as a Diagnostic for Functional Characterization of Proteins with a Cupin Fold	PLOS ONE			English	Article								Background: The members of cupin superfamily exhibit large variations in their sequences, functions, organization of domains, quaternary associations and the nature of bound metal ion, despite having a conserved beta-barrel structural scaffold. Here, an attempt has been made to understand structure-function relationships among the members of this diverse superfamily and identify the principles governing functional diversity. The cupin superfamily also contains proteins for which the structures are available through world-wide structural genomics initiatives but characterized as "hypothetical''. We have explored the feasibility of obtaining clues to functions of such proteins by means of comparative analysis with cupins of known structure and function. Methodology/Principal Findings: A 3-D structure-based phylogenetic approach was undertaken. Interestingly, a dendrogram generated solely on the basis of structural dissimilarity measure at the level of domain folds was found to cluster functionally similar members. This clustering also reflects an independent evolution of the two domains in bicupins. Close examination of structural superposition of members across various functional clusters reveals structural variations in regions that not only form the active site pocket but are also involved in interaction with another domain in the same polypeptide or in the oligomer. Conclusions/Significance: Structure-based phylogeny of cupins can influence identification of functions of proteins of yet unknown function with cupin fold. This approach can be extended to other proteins with a common fold that show high evolutionary divergence. This approach is expected to have an influence on the function annotation in structural genomics initiatives.			Agarwal, G (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.	ns@mbu.iisc.ernet.in	Gopal, Balasubramanian/K-4566-2012; Gopal, Balasubramanian/ABG-3754-2021		Wellcome Trust [078994] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adachi M, 2003, P NATL ACAD SCI USA, V100, P7395, DOI 10.1073/pnas.0832158100; Adachi M, 2001, J MOL BIOL, V305, P291, DOI 10.1006/jmbi.2000.4310; Anand R, 2002, BIOCHEMISTRY-US, V41, P7659, DOI 10.1021/bi0200965; Balaji S, 2001, PROTEIN ENG, V14, P219, DOI 10.1093/protein/14.4.219; Christendat D, 2000, J BIOL CHEM, V275, P24608, DOI 10.1074/jbc.C000238200; Cleasby A, 1996, NAT STRUCT BIOL, V3, P470, DOI 10.1038/nsb0596-470; Crowther RL, 2005, PROTEINS, V61, P680, DOI 10.1002/prot.20598; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dong C, 2007, J MOL BIOL, V365, P146, DOI 10.1016/j.jmb.2006.09.063; Dong CJ, 2003, STRUCTURE, V11, P715, DOI 10.1016/S0969-2126(03)00098-4; Dunwell JM, 2004, PHYTOCHEMISTRY, V65, P7, DOI 10.1016/j.phytochem.2003.08.016; Dunwell JM, 2001, TRENDS BIOCHEM SCI, V26, P740, DOI 10.1016/S0968-0004(01)01981-8; Dunwell JM, 2000, MICROBIOL MOL BIOL R, V64, P153, DOI 10.1128/MMBR.64.1.153-179.2000; Felsenstein J, PHYLIP PHYLOGENY INF; Finn RD, 2008, NUCLEIC ACIDS RES, V36, pD281, DOI 10.1093/nar/gkm960; Giraud MF, 2000, NAT STRUCT BIOL, V7, P398; Gopal B, 2005, BIOCHEMISTRY-US, V44, P193, DOI 10.1021/bi0484421; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huson DH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-460; Jaroszewski L, 2004, PROTEINS, V56, P611, DOI 10.1002/prot.20130; JOHNSON MS, 1990, J MOL EVOL, V30, P43, DOI 10.1007/BF02102452; Ko TP, 2000, ACTA CRYSTALLOGR D, V56, P411, DOI 10.1107/S0907444900002237; Konagurthu AS, 2006, PROTEINS, V64, P559, DOI 10.1002/prot.20921; LAWRENCE MC, 1994, J MOL BIOL, V238, P748, DOI 10.1006/jmbi.1994.1333; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Maruyama N, 2001, EUR J BIOCHEM, V268, P3595, DOI 10.1046/j.1432-1327.2001.02268.x; Maruyama Y, 2004, ACTA CRYSTALLOGR D, V60, P289, DOI 10.1107/S0907444903027367; McCoy JG, 2006, P NATL ACAD SCI USA, V103, P3084, DOI 10.1073/pnas.0509262103; McLuskey K, 2005, P NATL ACAD SCI USA, V102, P14221, DOI 10.1073/pnas.0504314102; McMullan D, 2004, PROTEINS, V56, P615, DOI 10.1002/prot.20139; Merkel AB, 2002, ACTA CRYSTALLOGR D, V58, P1226, DOI 10.1107/S0907444902007382; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Opaleye O, 2006, J BIOL CHEM, V281, P6428, DOI 10.1074/jbc.M510256200; Pang H, 2004, J BIOL CHEM, V279, P1491, DOI 10.1074/jbc.M310022200; Pochapsky TC, 2006, J BIOMOL NMR, V34, P117, DOI 10.1007/s10858-005-5735-8; Raymond S, 2005, PROTEINS, V61, P454, DOI 10.1002/prot.20537; Steiner RA, 2002, P NATL ACAD SCI USA, V99, P16625, DOI 10.1073/pnas.262506299; Swan MK, 2003, J BIOL CHEM, V278, P47261, DOI 10.1074/jbc.M308603200; Titus GP, 2000, NAT STRUCT BIOL, V7, P542; Woo EJ, 2002, EMBO J, V21, P2877, DOI 10.1093/emboj/cdf291; Xu QP, 2006, PROTEINS, V64, P808, DOI 10.1002/prot.20947; ZHANG Y, 2005, STRUCTURAL STUDIES 3, P7632; Zhou CZ, 2005, PROTEIN SCI, V14, P209, DOI 10.1110/ps.041121305	44	50	50	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5736	10.1371/journal.pone.0005736	http://dx.doi.org/10.1371/journal.pone.0005736			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451SH	19478949	Green Published, gold			2022-12-25	WOS:000266490000012
J	Wanderley, JLM; da Silva, LHP; Deolindo, P; Soong, L; Borges, VM; Prates, DB; de Souza, APA; Barral, A; Balanco, JMD; do Nascimento, MTC; Saraiva, EM; Barcinski, MA				Mendes Wanderley, Joao Luiz; Pinto da Silva, Lucia Helena; Deolindo, Poliana; Soong, Lynn; Borges, Valeria Matos; Prates, Deboraci Brito; Almeida de Souza, Ana Paula; Barral, Aldina; de Freitas Balanco, Jose Mario; Cunha do Nascimento, Michelle Tanny; Saraiva, Elvira Maria; Barcinski, Marcello Andre			Cooperation between Apoptotic and Viable Metacyclics Enhances the Pathogenesis of Leishmaniasis	PLOS ONE			English	Article							PROGRAMMED CELL-DEATH; EXPOSES PHOSPHATIDYLSERINE; L AMAZONENSIS; PUTATIVE ROLE; PROMASTIGOTES; DIFFERENTIATION; MIMICRY; METACASPASES; MECHANISMS; AUTOPHAGY	Mimicking mammalian apoptotic cells by exposing phosphatidylserine (PS) is a strategy used by virus and parasitic protozoa to escape host protective inflammatory responses. With Leishmania amazonensis (La), apoptotic mimicry is a prerogative of the intramacrophagic amastigote form of the parasite and is modulated by the host. Now we show that differently from what happens with amastigotes, promastigotes exposing PS are non-viable, non-infective cells, undergoing apoptotic death. As part of the normal metacyclogenic process occurring in axenic cultures and in the gut of sand fly vectors, a subpopulation of metacyclic promastigotes exposes PS. Apoptotic death of the purified PS-positive (PSPOS) sub-population was confirmed by TUNEL staining and DNA laddering. Transmission electron microscopy revealed morphological alterations in PSPOS metacyclics such as DNA condensation, cytoplasm degradation and mitochondrion and kinetoplast destruction, both in in vitro cultures and in sand fly guts. TUNELPOS promastigotes were detected only in the anterior midgut to foregut boundary of infected sand flies. Interestingly, caspase inhibitors modulated parasite death and PS exposure, when added to parasite cultures in a specific time window. Efficient in vitro macrophage infections and in vivo lesions only occur when PSPOS and PS-negative (PSNEG) parasites were simultaneously added to the cell culture or inoculated in the mammalian host. The viable PSNEG promastigote was the infective form, as shown by following the fate of fluorescently labeled parasites, while the PSPOS apoptotic sub-population inhibited host macrophage inflammatory response. PS exposure and macrophage inhibition by a subpopulation of promastigotes is a different mechanism than the one previously described with amastigotes, where the entire population exposes PS. Both mechanisms co-exist and play a role in the transmission and development of the disease in case of infection by La. Since both processes confer selective advantages to the infective microorganism they justify the occurrence of apoptotic features in a unicellular pathogen.			Wanderley, JLM (corresponding author), Natl Canc Inst, Div Expt Med, Rio De Janeiro, Brazil.	barcinsk@icb.usp.br	Pinto-da-Silva, Lucia/AAF-1318-2022; Balanco, Jose Mario F/P-5051-2015; Wanderley, Joao Luiz/J-6711-2014; Borges, Val/N-6647-2019; Balanco, José Mário de Freitas/AAD-9701-2022; Saraiva, Elvira M/L-2864-2017; nascimento, Michelle Tanny Cunha/O-7844-2018; Barral, Aldina/B-4191-2009; Pinto-da-Silva, Lucia/AFG-2678-2022; Borges, Valeria/G-2009-2014	Borges, Val/0000-0002-2775-5409; Saraiva, Elvira M/0000-0002-6388-5286; Barral, Aldina/0000-0002-7177-464X; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043003, R56AI043003] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43003, R01 AI043003, R56 AI043003] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Afonso L, 2008, J LEUKOCYTE BIOL, V84, P389, DOI 10.1189/jlb.0108018; Ambit A, 2008, CELL DEATH DIFFER, V15, P113, DOI 10.1038/sj.cdd.4402232; AMEISEN JC, 1995, CELL DEATH DIFFER, V2, P285; Araujo-Santos JM, 2003, BIOCHEM BIOPH RES CO, V306, P250, DOI 10.1016/S0006-291X(03)00947-1; Arnoult D, 2002, CELL DEATH DIFFER, V9, P65, DOI 10.1038/sj.cdd.4400951; Balanco JMD, 2001, CURR BIOL, V11, P1870, DOI 10.1016/S0960-9822(01)00563-2; Bates PA, 2008, CURR OPIN MICROBIOL, V11, P340, DOI 10.1016/j.mib.2008.06.003; Belenghi B, 2007, J BIOL CHEM, V282, P1352, DOI 10.1074/jbc.M608931200; Besteiro S, 2006, J BIOL CHEM, V281, P11384, DOI 10.1074/jbc.M512307200; Buttner S, 2006, J CELL BIOL, V175, P521, DOI 10.1083/jcb.200608098; DaMatta RA, 2007, FEMS MICROBIOL LETT, V266, P29, DOI 10.1111/j.1574-6968.2006.00495.x; Das M, 2001, J CELL SCI, V114, P2461; Debrabant Alain, 2003, Kinetoplastid Biology and Disease, V2, pUnpaginated, DOI 10.1186/1475-9292-2-7; Fabrizio P, 2004, J CELL BIOL, V166, P1055, DOI 10.1083/jcb.200404002; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Freire-de-Lima CG, 2000, NATURE, V404, P904, DOI 10.1038/35009154; Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208; Golstein P, 2005, CELL DEATH DIFFER, V12, P1490, DOI 10.1038/sj.cdd.4401607; Herker E, 2004, J CELL BIOL, V164, P501, DOI 10.1083/jcb.200310014; Holzmuller P, 2006, PARASITOLOGY, V132, pS19, DOI 10.1017/S0031182006000837; HOWARD MK, 1987, EXP PARASITOL, V64, P147, DOI 10.1016/0014-4894(87)90138-X; JAMES ER, 2002, TRENDS PARASITOL, V20, P280; Kamhawi S, 2006, TRENDS PARASITOL, V22, P439, DOI 10.1016/j.pt.2006.06.012; Kima PE, 2007, INT J PARASITOL, V37, P1087, DOI 10.1016/j.ijpara.2007.04.007; Lee N, 2002, CELL DEATH DIFFER, V9, P53, DOI 10.1038/sj.cdd.4400952; Lee N, 2007, EUKARYOT CELL, V6, P1745, DOI 10.1128/EC.00123-07; Longo VD, 2005, NAT REV GENET, V6, DOI 10.1038/nrg1706; Mazzoni C, 2008, BBA-MOL CELL RES, V1783, P1320, DOI 10.1016/j.bbamcr.2008.02.015; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; Mercer J, 2008, SCIENCE, V320, P531, DOI 10.1126/science.1155164; Moreira MEC, 2004, AN ACAD BRAS CIENC, V76, P93, DOI 10.1590/S0001-37652004000100009; Moreira MEC, 1996, J CELL PHYSIOL, V167, P305, DOI 10.1002/(SICI)1097-4652(199605)167:2&lt;305::AID-JCP15&gt;3.0.CO;2-6; Nguewa PA, 2004, TRENDS PARASITOL, V20, P375, DOI 10.1016/j.pt.2004.05.006; Paris C, 2004, ANTIMICROB AGENTS CH, V48, P852, DOI 10.1128/AAC.48.3.852-859.2004; Picot S, 1997, T ROY SOC TROP MED H, V91, P590, DOI 10.1016/S0035-9203(97)90039-0; PIMENTA PFP, 1991, EXP PARASITOL, V72, P191, DOI 10.1016/0014-4894(91)90137-L; Pinto-da-Silva LH, 2005, INT J PARASITOL, V35, P757, DOI 10.1016/j.ijpara.2005.03.004; Ridgley EL, 1999, BIOCHEM J, V340, P33, DOI 10.1042/0264-6021:3400033; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; Saraiva EM, 2005, EXP PARASITOL, V110, P39, DOI 10.1016/j.exppara.2005.01.004; Seabra SH, 2004, BIOCHEM BIOPH RES CO, V324, P744, DOI 10.1016/j.bbrc.2004.09.114; Soares MM, 2008, NAT MED, V14, P1357, DOI 10.1038/nm.1885; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Tripathi A, 2003, MOL BIOCHEM PARASIT, V128, P1, DOI 10.1016/S0166-6851(03)00024-0; van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521; van Zandbergen G, 2006, P NATL ACAD SCI USA, V103, P13837, DOI 10.1073/pnas.0600843103; Vercammen D, 2007, J CELL BIOL, V179, P375, DOI 10.1083/jcb.200705193; WALTERS LL, 1989, AM J TROP MED HYG, V41, P295, DOI 10.4269/ajtmh.1989.41.295; Wanderley JLM, 2005, BRAZ J MED BIOL RES, V38, P807, DOI 10.1590/S0100-879X2005000600001; Wanderley JLM, 2006, J IMMUNOL, V176, P1834, DOI 10.4049/jimmunol.176.3.1834; Welburn SC, 2006, PARASITOLOGY, V132, pS7, DOI 10.1017/S0031182006000825; Welburn SC, 1997, PARASITOL TODAY, V13, P22, DOI 10.1016/S0169-4758(96)10076-4; Williams RA, 2006, MOL MICROBIOL, V61, P655, DOI 10.1111/j.1365-2958.2006.05274.x	53	66	68	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5733	10.1371/journal.pone.0005733	http://dx.doi.org/10.1371/journal.pone.0005733			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451SH	19478944	gold, Green Published, Green Submitted			2022-12-25	WOS:000266490000009
J	Girgis, HS; Hottes, AK; Tavazoie, S				Girgis, Hany S.; Hottes, Alison K.; Tavazoie, Saeed			Genetic Architecture of Intrinsic Antibiotic Susceptibility	PLOS ONE			English	Article							ESCHERICHIA-COLI K-12; RCS PHOSPHORELAY; ANTIBACTERIAL RESISTANCE; PSEUDOMONAS-AERUGINOSA; MULTIDRUG-RESISTANCE; GENOME SEQUENCE; EFFLUX PUMP; WASTE-WATER; MECHANISMS; PROTEIN	Background: Antibiotic exposure rapidly selects for more resistant bacterial strains, and both a drug's chemical structure and a bacterium's cellular network affect the types of mutations acquired. Methodology/Principal Findings: To better characterize the genetic determinants of antibiotic susceptibility, we exposed a transposon-mutagenized library of Escherichia coli to each of 17 antibiotics that encompass a wide range of drug classes and mechanisms of action. Propagating the library for multiple generations with drug concentrations that moderately inhibited the growth of the isogenic parental strain caused the abundance of strains with even minor fitness advantages or disadvantages to change measurably and reproducibly. Using a microarray-based genetic footprinting strategy, we then determined the quantitative contribution of each gene to E. coli's intrinsic antibiotic susceptibility. We found both loci whose removal increased general antibiotic tolerance as well as pathways whose down-regulation increased tolerance to specific drugs and drug classes. The beneficial mutations identified span multiple pathways, and we identified pairs of mutations that individually provide only minor decreases in antibiotic susceptibility but that combine to provide higher tolerance. Conclusions/Significance: Our results illustrate that a wide-range of mutations can modulate the activity of many cellular resistance processes and demonstrate that E. coli has a large mutational target size for increasing antibiotic tolerance. Furthermore, the work suggests that clinical levels of antibiotic resistance might develop through the sequential accumulation of chromosomal mutations of small individual effect.			Girgis, HS (corresponding author), Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA.	tavazoie@genomics.princeton.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077562] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM071508] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD003787] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AKIYAMA M, 1992, J BIOL CHEM, V267, P22556; Albert TJ, 2005, NAT METHODS, V2, P951, DOI 10.1038/NMETH805; ALPER MD, 1978, J BACTERIOL, V133, P149, DOI 10.1128/JB.133.1.149-157.1978; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Baba Tomoya, 2006, Mol Syst Biol, V2; Baquero F, 2001, DRUG RESIST UPDATE, V4, P93, DOI 10.1054/drup.2001.0196; Barua S, 2002, MOL MICROBIOL, V43, P629, DOI 10.1046/j.1365-2958.2002.02768.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Breidenstein EBM, 2008, ANTIMICROB AGENTS CH, V52, P4486, DOI 10.1128/AAC.00222-08; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; Castanie-Cornet MP, 2006, J BACTERIOL, V188, P4264, DOI 10.1128/JB.00004-06; CAYLEY PJ, 1981, BIOCHEMISTRY-US, V20, P874, DOI 10.1021/bi00507a034; Chenia HY, 2006, J ANTIMICROB CHEMOTH, V58, P1274, DOI 10.1093/jac/dkl404; D'Costa VM, 2006, SCIENCE, V311, P374, DOI 10.1126/science.1120800; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Davies J, 2006, CURR OPIN MICROBIOL, V9, P445, DOI 10.1016/j.mib.2006.08.006; Deurenberg RH, 2007, CLIN MICROBIOL INFEC, V13, P222, DOI 10.1111/j.1469-0691.2006.01573.x; Deutscher J, 2008, CURR OPIN MICROBIOL, V11, P87, DOI 10.1016/j.mib.2008.02.007; Drlica K, 2007, CLIN INFECT DIS, V44, P681, DOI 10.1086/511642; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El'Garch F, 2007, ANTIMICROB AGENTS CH, V51, P1016, DOI 10.1128/AAC.00704-06; Fajardo A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001619; Fajardo A, 2008, CURR OPIN MICROBIOL, V11, P161, DOI 10.1016/j.mib.2008.02.006; Fishman N, 2006, AM J MED, V119, pS62, DOI 10.1016/j.amjmed.2006.04.004; Francez-Charlot A, 2003, MOL MICROBIOL, V49, P823, DOI 10.1046/j.1365-2958.2003.03601.x; Froelich JM, 2006, J BACTERIOL, V188, P1180, DOI 10.1128/JB.188.3.1180-1183.2006; Gardy JL, 2005, BIOINFORMATICS, V21, P617, DOI 10.1093/bioinformatics/bti057; Giladi M, 2003, J BACTERIOL, V185, P7015, DOI 10.1128/JB.185.23.7015-7018.2003; Girgis HS, 2007, PLOS GENET, V3, P1644, DOI 10.1371/journal.pgen.0030154; Gomez MJ, 2006, ANTIMICROB AGENTS CH, V50, P3562, DOI 10.1128/AAC.00579-06; GOTTESMAN S, 1985, J BACTERIOL, V162, P1111, DOI 10.1128/JB.162.3.1111-1119.1985; HANCOCK REW, 1984, ANNU REV MICROBIOL, V38, P237, DOI 10.1146/annurev.mi.38.100184.001321; Harms C, 2001, MICROBIOL-SGM, V147, P2991, DOI 10.1099/00221287-147-11-2991; HARTL DL, 1984, ANNU REV GENET, V18, P31, DOI 10.1146/annurev.ge.18.120184.000335; Haussmann C, 1997, J BACTERIOL, V179, P949, DOI 10.1128/jb.179.3.949-951.1997; Herrington MB, 1999, CAN J MICROBIOL, V45, P191, DOI 10.1139/cjm-45-3-191; Hirakawa H, 2003, J BACTERIOL, V185, P1851, DOI 10.1128/JB.185.6.1851-1856.2003; HOLTJE JV, 1978, EUR J BIOCHEM, V86, P345, DOI 10.1111/j.1432-1033.1978.tb12316.x; JACOBS C, 1994, EMBO J, V13, P4684, DOI 10.1002/j.1460-2075.1994.tb06792.x; Jishage M, 2002, GENE DEV, V16, P1260, DOI 10.1101/gad.227902; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Karp PD, 2007, NUCLEIC ACIDS RES, V35, P7577, DOI 10.1093/nar/gkm740; Kishony R, 2003, J BIOL, V2, P14, DOI [DOI 10.1186/1475-4924-2-14, 10.1186/1475-4924-2-14]; Kohanski MA, 2008, CELL, V135, P679, DOI 10.1016/j.cell.2008.09.038; Kohanski MA, 2007, CELL, V130, P797, DOI 10.1016/j.cell.2007.06.049; Kuroda A, 2001, SCIENCE, V293, P705, DOI 10.1126/science.1061315; Laubacher ME, 2008, J BACTERIOL, V190, P2065, DOI 10.1128/JB.01740-07; LECLERCQ R, 2008, EXPERT RULES ANTIMIC; Lee W, 2002, BIOTECHNIQUES, V33, P1334, DOI 10.2144/02336bc04; Lenski RE, 2002, P NATL ACAD SCI USA, V99, P556, DOI 10.1073/pnas.022641999; Levy SB, 2004, NAT MED, V10, pS122, DOI 10.1038/nm1145; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; Ma D, 1996, MOL MICROBIOL, V19, P101, DOI 10.1046/j.1365-2958.1996.357881.x; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; Majdalani N, 2005, ANNU REV MICROBIOL, V59, P379, DOI 10.1146/annurev.micro.59.050405.101230; Majdalani N, 2005, J BACTERIOL, V187, P6770, DOI 10.1128/JB.187.19.6770-6778.2005; Majdalani N, 2002, MOL MICROBIOL, V46, P813, DOI 10.1046/j.1365-2958.2002.03203.x; MALINVERNI JC, 2009, P NATL ACAD IN PRESS; MANNEL D, 1978, EUR J BIOCHEM, V86, P361, DOI 10.1111/j.1432-1033.1978.tb12318.x; McKeegan KS, 2002, TRENDS MICROBIOL, V10, pS8, DOI 10.1016/S0966-842X(02)02429-0; Minagawa S, 2003, J BACTERIOL, V185, P3696, DOI 10.1128/JB.185.13.3696-3702.2003; Mwangi MM, 2007, P NATL ACAD SCI USA, V104, P9451, DOI 10.1073/pnas.0609839104; Nambu T, 1999, J BACTERIOL, V181, P1555, DOI 10.1128/JB.181.5.1555-1561.1999; NEWMAN EB, 1982, J BACTERIOL, V150, P710, DOI 10.1128/JB.150.2.710-715.1982; Okusu H, 1996, J BACTERIOL, V178, P306, DOI 10.1128/JB.178.1.306-308.1996; Onan LJ, 2003, FEMS MICROBIOL LETT, V220, P15, DOI 10.1016/S0378-1097(03)00045-4; Patel OG, 2004, TRENDS PARASITOL, V20, P1, DOI 10.1016/j.pt.2003.10.009; Plumbridge J, 2002, CURR OPIN MICROBIOL, V5, P187, DOI 10.1016/S1369-5274(02)00296-5; RAINWATER S, 1990, J BACTERIOL, V172, P2456, DOI 10.1128/jb.172.5.2456-2461.1990; Rosenberg EY, 2003, MOL MICROBIOL, V48, P1609, DOI 10.1046/j.1365-2958.2003.03531.x; Ruiz N, 2005, CURR OPIN MICROBIOL, V8, P122, DOI 10.1016/j.mib.2005.02.013; Rybak MJ, 2006, AM J MED, V119, pS37, DOI 10.1016/j.amjmed.2006.04.001; SCHLOSSER A, 1995, J BACTERIOL, V177, P1908, DOI 10.1128/jb.177.7.1908-1910.1995; Schurek KN, 2008, ANTIMICROB AGENTS CH, V52, P4213, DOI 10.1128/AAC.00507-08; Schwartz T, 2003, FEMS MICROBIOL ECOL, V43, P325, DOI 10.1111/j.1574-6941.2003.tb01073.x; SCOTT GM, 2001, HDB ESSENTIAL ANTIBI; Silhavy T.J., 1984, EXPT GENE FUSIONS; Srivatsan A, 2008, CURR OPIN MICROBIOL, V11, P100, DOI 10.1016/j.mib.2008.02.001; Stafford GP, 2005, MICROBIOL-SGM, V151, P1779, DOI 10.1099/mic.0.27879-0; TABER HW, 1987, MICROBIOL REV, V51, P439, DOI 10.1128/MMBR.51.4.439-457.1987; Tamae C, 2008, J BACTERIOL, V190, P5981, DOI 10.1128/JB.01982-07; THANASSI DG, 1995, J BACTERIOL, V177, P998, DOI 10.1128/jb.177.4.998-1007.1995; THEN RL, 1982, REV INFECT DIS, V4, P261; Thiele-Bruhn S, 2003, J PLANT NUTR SOIL SC, V166, P145, DOI 10.1002/jpln.200390023; TORRESCABASSA AS, 1987, J BACTERIOL, V169, P981, DOI 10.1128/jb.169.3.981-989.1987; Travisano M, 1996, GENETICS, V143, P15; VERKLIN RM, 1977, J LAB CLIN MED, V89, P65; vonRechenberg M, 1996, MICROB DRUG RESIST, V2, P155, DOI 10.1089/mdr.1996.2.155; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219; Walsh C, 2003, NAT REV MICROBIOL, V1, P65, DOI 10.1038/nrmicro727; Walsh C., 2003, ANTIBIOTICS ACTIONS; Watkinson AJ, 2007, WATER RES, V41, P4164, DOI 10.1016/j.watres.2007.04.005; Whiteway J, 1998, J BACTERIOL, V180, P5529, DOI 10.1128/JB.180.21.5529-5539.1998; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; Wolfe AJ, 2008, J BACTERIOL, V190, P2314, DOI 10.1128/JB.01906-07; Wright GD, 2003, CURR OPIN CHEM BIOL, V7, P563, DOI 10.1016/j.cbpa.2003.08.004	96	118	122	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5629	10.1371/journal.pone.0005629	http://dx.doi.org/10.1371/journal.pone.0005629			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448AY	19462005	Green Submitted, Green Published, gold			2022-12-25	WOS:000266234700016
J	Bhat, UG; Halasi, M; Gartel, AL				Bhat, Uppoor G.; Halasi, Marianna; Gartel, Andrei L.			Thiazole Antibiotics Target FoxM1 and Induce Apoptosis in Human Cancer Cells	PLOS ONE			English	Article							M1 TRANSCRIPTION FACTOR; GENE-EXPRESSION PROFILES; GENOME-WIDE ANALYSIS; HEPATOCELLULAR CARCINOMAS; MICROARRAY ANALYSIS; CDNA MICROARRAY; TUMOR-CELLS; IDENTIFICATION; PROGRESSION; PROLIFERATION	Forkhead box M1 (FoxM1) oncogenic transcription factor represents an attractive therapeutic target in the fight against cancer, because it is overexpressed in a majority of human tumors. Recently, using a cell-based assay system we identified thiazole antibiotic Siomycin A as an inhibitor of FoxM1 transcriptional activity. Here, we report that structurally similar thiazole antibiotic, thiostrepton also inhibits the transcriptional activity of FoxM1. Furthermore, we found that these thiopeptides did not inhibit the transcriptional activity of other members of the Forkhead family or some non-related transcription factors. Further experiments revealed that thiazole antibiotics also inhibit FoxM1 expression, but not the expression of other members of the Forkhead box family. In addition, we found that the thiazole antibiotics efficiently inhibited the growth and induced potent apoptosis in human cancer cell lines of different origin. Thiopeptide-induced apoptosis correlated with the suppression of FoxM1 expression, while overexpression of FoxM1 partially protected cancer cells from the thiazole antibiotic-mediated cell death. These data suggest that Siomycin A and thiostrepton may specifically target FoxM1 to induce apoptosis in cancer cells and FoxM1 inhibitors/thiazole antibiotics could be potentially developed as novel anticancer drugs against human neoplasia.			Bhat, UG (corresponding author), Univ Illinois, Dept Med, Chicago, IL 60607 USA.	agartel@uic.edu			NCI NIH HHS [1R21CA134615-01, 1R01CA1294414-01A1, R21 CA134615] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA134615] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adami Guy R, 2007, Future Oncol, V3, P1, DOI 10.2217/14796694.3.1.1; Arden KC, 2007, CELL, V128, P235, DOI 10.1016/j.cell.2007.01.009; Bektas N, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-42; Bhat UG, 2008, CELL CYCLE, V7, P1851, DOI 10.4161/cc.7.12.6032; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gartel AL, 2008, EXPERT OPIN THER TAR, V12, P663, DOI 10.1517/14728222.12.6.663 ; Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; HALASI M, 2009, CELL CYCLE IN PRESS, V8; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Kim IM, 2005, J BIOL CHEM, V280, P22278, DOI 10.1074/jbc.M500936200; Krupczak-Hollis K, 2004, DEV BIOL, V276, P74, DOI 10.1016/j.ydbio.2004.08.022; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Lentzen G, 2003, CHEM BIOL, V10, P769, DOI 10.1016/S1074-5521(03)00173-X; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Nicolaou KC, 2005, J AM CHEM SOC, V127, P15042, DOI 10.1021/ja0552803; Obama K, 2005, HEPATOLOGY, V41, P1339, DOI 10.1002/hep.20718; Okabe H, 2001, CANCER RES, V61, P2129; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; Radhakrishnan Senthil K, 2008, Nat Rev Cancer, V8, pc2, DOI 10.1038/nrc2223-c1; Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576; Schuller U, 2007, MOL CELL BIOL, V27, P8259, DOI 10.1128/MCB.00707-07; Teh MT, 2002, CANCER RES, V62, P4773; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265; Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626	35	162	176	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5592	10.1371/journal.pone.0005592	http://dx.doi.org/10.1371/journal.pone.0005592			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440351	Green Submitted, Green Published, gold			2022-12-25	WOS:000266107500020
J	Boselt, I; Rompler, H; Hermsdorf, T; Thor, D; Busch, W; Schulz, A; Schoneberg, T				Boeselt, Iris; Roempler, Holger; Hermsdorf, Thomas; Thor, Doreen; Busch, Wibke; Schulz, Angela; Schoeneberg, Torsten			Involvement of the V2 Vasopressin Receptor in Adaptation to Limited Water Supply	PLOS ONE			English	Article								Mammals adapted to a great variety of habitats with different accessibility to water. In addition to changes in kidney morphology, e. g. the length of the loops of Henle, several hormone systems are involved in adaptation to limited water supply, among them the renal-neurohypophysial vasopressin/vasopressin receptor system. Comparison of over 80 mammalian V2 vasopressin receptor (V2R) orthologs revealed high structural and functional conservation of this key component involved in renal water reabsorption. Although many mammalian species have unlimited access to water there is no evidence for complete loss of V2R function indicating an essential role of V2R activity for survival even of those species. In contrast, several marsupial V2R orthologs show a significant increase in basal receptor activity. An increased vasopressin-independent V2R activity can be interpreted as a shift in the set point of the renal-neurohypophysial hormone circuit to realize sufficient water reabsorption already at low hormone levels. As found in other desert mammals arid-adapted marsupials show high urine osmolalities. The gain of basal V2R function in several marsupials may contribute to the increased urine concentration abilities and, therefore, provide an advantage to maintain water and electrolyte homeostasis under limited water supply conditions.			Boselt, I (corresponding author), Univ Leipzig, Inst Biochem, Fac Med, Leipzig, Germany.	schoberg@medizin.uni-leipzig.de	Thor, Doreen/P-6778-2019; Busch, Wibke/I-9348-2012	Thor, Doreen/0000-0002-9522-5098; Busch, Wibke/0000-0002-5497-6266				Acher R, 1996, GEN COMP ENDOCR, V102, P157, DOI 10.1006/gcen.1996.0057; Acher R, 1999, J EXP ZOOL, V284, P475, DOI 10.1002/(SICI)1097-010X(19991001)284:5<475::AID-JEZ2>3.0.CO;2-9; Adan RAH, 2006, TRENDS PHARMACOL SCI, V27, P183, DOI 10.1016/j.tips.2006.02.002; Adan RAH, 2003, TRENDS PHARMACOL SCI, V24, P315, DOI 10.1016/S0165-6147(03)00130-5; Arthus MF, 2000, J AM SOC NEPHROL, V11, P1044, DOI 10.1681/ASN.V1161044; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BEUCHAT CA, 1990, AM J PHYSIOL, V258, pR298, DOI 10.1152/ajpregu.1990.258.2.R298; Beuchat CA, 1996, AM J PHYSIOL-REG I, V271, pR157, DOI 10.1152/ajpregu.1996.271.1.R157; Bichet DG, 2008, SEMIN NEPHROL, V28, P245, DOI 10.1016/j.semnephrol.2008.03.005; Bradshaw D, 2007, GEN COMP ENDOCR, V152, P125, DOI 10.1016/j.ygcen.2006.12.026; Bradshaw SD, 2001, J COMP PHYSIOL B, V171, P23, DOI 10.1007/s003600000144; BROWNFIELD MS, 1976, COMP BIOCHEM PHYS A, V55, P69, DOI 10.1016/0300-9629(76)90125-0; Dawson TJ, 2006, J COMP PHYSIOL B, V176, P45, DOI 10.1007/s00360-005-0030-2; Feldman BJ, 2005, NEW ENGL J MED, V352, P1884, DOI 10.1056/NEJMoa042743; FIRSOV D, 1994, PFLUG ARCH EUR J PHY, V429, P79, DOI 10.1007/BF02584033; Fujiwara TM, 2005, J AM SOC NEPHROL, V16, P2836, DOI 10.1681/ASN.2005040371; Gaeth AP, 1999, P NATL ACAD SCI USA, V96, P5555, DOI 10.1073/pnas.96.10.5555; Gwee PC, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-93; Innamorati G, 1997, J BIOL CHEM, V272, P2486; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Kamperis K, 2000, PEDIATR NEPHROL, V15, P43, DOI 10.1007/s004670000431; King JM, 2008, GEN COMP ENDOCR, V155, P378, DOI 10.1016/j.ygcen.2007.07.004; Kleinau G, 2008, CELL MOL LIFE SCI, V65, P3664, DOI 10.1007/s00018-008-8450-2; Krause G, 2000, MOL PHARMACOL, V57, P232; Kubota Y, 1996, MOL CELL ENDOCRINOL, V124, P25, DOI 10.1016/S0303-7207(96)03923-8; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Liu AGSC, 2008, P NATL ACAD SCI USA, V105, P5786, DOI 10.1073/pnas.0800884105; LUZIUS H, 1992, J RECEPTOR RES, V12, P351, DOI 10.3109/10799899209074800; MBASSA GK, 1988, VET RES COMMUN, V12, P1, DOI 10.1007/BF00396399; McCormick SD, 2006, GEN COMP ENDOCR, V147, P3, DOI 10.1016/j.ygcen.2005.12.009; MURASAWA S, 1995, J BIOL CHEM, V270, P20042, DOI 10.1074/jbc.270.34.20042; Ortiz RM, 2001, J EXP BIOL, V204, P1831; PAN Y, 1994, J BIOL CHEM, V269, P31933; Pasel K, 2000, J CLIN ENDOCR METAB, V85, P1703, DOI 10.1210/jc.85.4.1703; PERROTT MN, 1993, GEN COMP ENDOCR, V89, P387, DOI 10.1006/gcen.1993.1046; Rovati GE, 2007, MOL PHARMACOL, V71, P959, DOI 10.1124/mol.106.029470; Sangkuhl K, 2004, HUM MOL GENET, V13, P893, DOI 10.1093/hmg/ddh105; Sangkuhl Katrin, 2005, Hum Mutat, V25, P505, DOI 10.1002/humu.9337; Sarmiento JM, 2004, J BIOL CHEM, V279, P47017, DOI 10.1074/jbc.M410011200; SCHMI.B, 1961, AM J PHYSIOL, V200, P1119, DOI 10.1152/ajplegacy.1961.200.6.1119; Schon D, 2007, CLIN J AM SOC NEPHRO, V2, P268, DOI 10.2215/CJN.01880606; Schoneberg T, 1998, HUM MUTAT, V12, P196, DOI 10.1002/(SICI)1098-1004(1998)12:3<196::AID-HUMU7>3.0.CO;2-F; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; SCHOTT HC, 1993, J VET INTERN MED, V7, P68; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; Schulz A, 2003, J BIOL CHEM, V278, P35531, DOI 10.1074/jbc.M303346200; Schulz A, 2002, J CLIN ENDOCR METAB, V87, P5247, DOI 10.1210/jc.2002-020286; SEIBOLD A, 1992, AM J HUM GENET, V51, P1078; Spanakis E, 2008, J CELL PHYSIOL, V217, P605, DOI 10.1002/jcp.21552; Staubert C, 2007, ENDOCRINOLOGY, V148, P4642, DOI 10.1210/en.2007-0138; SUZUKI M, 1995, J MOL ENDOCRINOL, V14, P67, DOI 10.1677/jme.0.0140067; Takei Y, 2006, J EXP ZOOL PART A, V305A, P787, DOI 10.1002/jez.a.309; Wildin RS, 1998, KIDNEY INT, V54, P1909, DOI 10.1046/j.1523-1755.1998.00214.x; WILDIN RS, 1994, AM J HUM GENET, V55, P266; Wu S, 2008, ANAL CHEM, V80, P6034, DOI 10.1021/ac8008548; Yun J, 2000, J CLIN INVEST, V106, P1361, DOI 10.1172/JCI9154	57	29	30	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5573	10.1371/journal.pone.0005573	http://dx.doi.org/10.1371/journal.pone.0005573			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440390	Green Submitted, Green Published, gold			2022-12-25	WOS:000266107500005
J	Seminario-Vidal, L; Kreda, S; Jones, L; O'Neal, W; Trejo, J; Boucher, RC; Lazarowski, ER				Seminario-Vidal, Lucia; Kreda, Silvia; Jones, Lisa; O'Neal, Wanda; Trejo, Joann; Boucher, Richard C.; Lazarowski, Eduardo R.			Thrombin Promotes Release of ATP from Lung Epithelial Cells through Coordinated Activation of Rho- and Ca2+-dependent Signaling Pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE LIQUID HOMEOSTASIS; HUMAN AIRWAY EPITHELIA; PROTEIN-KINASE-C; CYSTIC-FIBROSIS; INTRACELLULAR CALCIUM; ION-TRANSPORT; EXTRACELLULAR ATP; P2Y(2) RECEPTOR; FAMILY GTPASES; CALU-3 CELLS	Extracellular ATP controls key aspects of lung function via activation of epithelial cell purinergic receptors, but how ATP is released from cells remains poorly understood. To identify mechanistic components upstream of ATP release, we examined the effect of selected G protein coupled-receptor activation on ATP release from lung epithelial cells. The protease-activated receptor ( PAR) agonist thrombin elicited a rapid Ca2+-dependent release of ATP from A549 cells. In contrast, the P2Y(2) receptor agonist UTP caused negligible ATP release, despite promoting a robust Ca2+ response. Agonist-elicited ATP release was associated with Rho activation and was reduced in cells transfected with dominant negative mutants of p115-Rho GEF or RhoA, and by inhibitors of Rho kinase ( ROCK). However, RhoA activation alone did not promote ATP release if temporally separated from Ca2+ mobilization. PAR3 was the only PAR subtype detected in A549 cells by reverse transcription-PCR. Transfection of cells with human PAR3 cDNA increased thrombin-promoted ATP release, inositol phosphate formation, and RhoA activation. Conversely, small interference RNA against PAR3 diminished thrombin-evoked responses. Thrombin-elicited ATP release was accompanied by an enhanced cellular uptake of propidium iodide in a Ca2+- and ROCK-dependent manner and was inhibited by connexin/pannexin hemichannel blockers. Our data suggest that thrombin promotes ATP release from A549 cells via Rho- and Ca2+-dependent activation of connexin/pannexin hemichannels. The relevance of these findings is highlighted by the observation that exposure of primary cultures of well differentiated human bronchial epithelial cells to thrombin resulted in robust ATP release, which was inhibited by ROCK inhibitors and by connexin/pannexin hemichannel blockers.	[Lazarowski, Eduardo R.] Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Dept Med, Chapel Hill, NC 27599 USA; [Seminario-Vidal, Lucia] Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; [Trejo, Joann] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Diego	Lazarowski, ER (corresponding author), Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Dept Med, 7017 Thurston Bowles Bldg,CB 7248, Chapel Hill, NC 27599 USA.	eduardo_lazarowski@med.unc.edu	Seminario-Vidal, Lucia/AAR-3314-2020	Seminario-Vidal, Lucia/0000-0002-6004-2451; TREJO, JOANN/0000-0003-4405-6228	National Institutes of Health [P01-HL034322]; Cystic Fibrosis Foundation [CFF-SEMINA08FO]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322, R01HL073328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM090689] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant P01-HL034322. This work was also supported by Cystic Fibrosis Foundation Grant CFF-SEMINA08FO ( to L. S. V.).	Asokananthan N, 2002, J IMMUNOL, V168, P3577, DOI 10.4049/jimmunol.168.7.3577; Blackburn MR, 2003, J CLIN INVEST, V112, P332, DOI 10.1172/JCI200316815; Blum AE, 2008, AM J PHYSIOL-CELL PH, V295, pC231, DOI 10.1152/ajpcell.00175.2008; Boucher RC, 2002, ADV DRUG DELIVER REV, V54, P1359, DOI 10.1016/S0169-409X(02)00144-8; Boudreault F, 2004, J PHYSIOL-LONDON, V561, P499, DOI 10.1113/jphysiol.2004.072306; Button B, 2007, J PHYSIOL-LONDON, V580, P577, DOI 10.1113/jphysiol.2006.126086; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Cressman VL, 1999, J BIOL CHEM, V274, P26461, DOI 10.1074/jbc.274.37.26461; Dahl G, 2006, IUBMB LIFE, V58, P409, DOI 10.1080/15216540600794526; Danahay H, 2001, AM J PHYSIOL-CELL PH, V280, pC1455, DOI 10.1152/ajpcell.2001.280.6.C1455; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Davis CW, 2008, ANNU REV PHYSIOL, V70, P487, DOI 10.1146/annurev.physiol.70.113006.100638; De Vuyst E, 2006, EMBO J, V25, P34, DOI 10.1038/sj.emboj.7600908; Devor DC, 1999, AM J PHYSIOL-CELL PH, V276, pC827, DOI 10.1152/ajpcell.1999.276.4.C827; Factor P, 2007, P NATL ACAD SCI USA, V104, P4083, DOI 10.1073/pnas.0601117104; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Furstenau CR, 2004, CHEM-BIOL INTERACT, V148, P93, DOI 10.1016/j.cbi.2004.04.003; Gavard J, 2008, J BIOL CHEM, V283, P29888, DOI 10.1074/jbc.M803880200; Goel R, 2004, J BIOL CHEM, V279, P6701, DOI 10.1074/jbc.M308753200; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; Hains MD, 2004, METHOD ENZYMOL, V389, P71; Hains MD, 2006, MOL PHARMACOL, V69, P2068, DOI 10.1124/mol.105.017921; Hirakawa M, 2004, J PHYSIOL-LONDON, V558, P479, DOI 10.1113/jphysiol.2004.065334; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; Joseph SM, 2004, BRIT J PHARMACOL, V142, P1002, DOI 10.1038/sj.bjp.0705865; Joseph SM, 2003, J BIOL CHEM, V278, P23331, DOI 10.1074/jbc.M302680200; Koyama T, 2001, J PHYSIOL-LONDON, V532, P759, DOI 10.1111/j.1469-7793.2001.0759e.x; Kreda SM, 2008, BRIT J PHARMACOL, V153, P1528, DOI 10.1038/sj.bjp.0707692; Kreda SM, 2007, J PHYSIOL-LONDON, V584, P245, DOI 10.1113/jphysiol.2007.139840; Kunzelmann K, 2005, FASEB J, V19, P969, DOI 10.1096/fj.04-2469fje; Kunzelmann K, 2002, CELL BIOCHEM BIOPHYS, V36, P209, DOI 10.1385/CBB:36:2-3:209; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Lazarowski ER, 2004, J BIOL CHEM, V279, P36855, DOI 10.1074/jbc.M405367200; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; Lazarowski ER, 2003, MOL PHARMACOL, V63, P1190, DOI 10.1124/mol.63.5.1190; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; McLaughlin JN, 2007, P NATL ACAD SCI USA, V104, P5662, DOI 10.1073/pnas.0700763104; Morse DM, 2001, AM J PHYSIOL-CELL PH, V280, pC1485, DOI 10.1152/ajpcell.2001.280.6.C1485; Okada SF, 2006, J BIOL CHEM, V281, P22992, DOI 10.1074/jbc.M603019200; Ostrowska E, 2008, CELL MOL LIFE SCI, V65, P970, DOI 10.1007/s00018-008-7555-y; Palmer ML, 2006, AM J PHYSIOL-CELL PH, V290, pC1189, DOI 10.1152/ajpcell.00464.2005; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Picher M, 2004, J BIOL CHEM, V279, P20234, DOI 10.1074/jbc.M400305200; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rooney SA, 2001, COMP BIOCHEM PHYS A, V129, P233, DOI 10.1016/S1095-6433(01)00320-8; SAITOH M, 1987, J BIOL CHEM, V262, P7796; Schwartz M, 2004, J CELL SCI, V117, P5457, DOI 10.1242/jcs.01582; Sesma JI, 2009, J BIOL CHEM, V284, P12572, DOI 10.1074/jbc.M806759200; Seye CI, 2004, J BIOL CHEM, V279, P35679, DOI 10.1074/jbc.M401799200; Steinhoff M, 2005, ENDOCR REV, V26, P1, DOI 10.1210/er.2003-0025; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Sun CX, 2006, J CLIN INVEST, V116, P2173, DOI 10.1172/JCI27303; Tarran R, 2005, J BIOL CHEM, V280, P35751, DOI 10.1074/jbc.M505832200; Tatur S, 2008, PURINERG SIGNAL, V4, P139, DOI 10.1007/s11302-007-9059-x; Tatur S, 2007, J PHYSIOL-LONDON, V584, P419, DOI 10.1113/jphysiol.2007.133314; Trejo J, 2003, J PHARMACOL EXP THER, V307, P437, DOI 10.1124/jpet.103.052100; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; Yue G, 2002, J BIOL CHEM, V277, P11965, DOI 10.1074/jbc.M108951200; Zsembery A, 2004, J BIOL CHEM, V279, P10720, DOI 10.1074/jbc.M313391200	65	86	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20638	20648		10.1074/jbc.M109.004762	http://dx.doi.org/10.1074/jbc.M109.004762			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19439413	Green Published, hybrid			2022-12-25	WOS:000268316100025
J	Van Themsche, C; Leblanc, V; Parent, S; Asselin, E				Van Themsche, Celine; Leblanc, Valerie; Parent, Sophie; Asselin, Eric			X-linked Inhibitor of Apoptosis Protein (XIAP) Regulates PTEN Ubiquitination, Content, and Compartmentalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PTEN; CELL-DEATH; PROSTATE-CANCER; LIGASE ACTIVITY; DEGRADATION; MONOUBIQUITINATION; LOCALIZATION; INDUCTION; STABILITY; CASPASE-9	Apoptotic cell death plays a normal role in various physiological processes, and deregulated apoptosis is a hallmark of several diseases, including cancer. Cell fate is dictated by the balance between pro- and antiapoptotic factors. Akt is one of these antiapoptotic factors, which must be activated through phosphorylation. The phosphorylation of Akt has previously been shown to be promoted by X-linked inhibitor of apoptosis protein (XIAP), another antiapoptotic protein dictating the fate of normal and cancer cells. However, the underlying mechanisms are poorly understood. We have observed that XIAP associates with PTEN (phosphatase and tensin homolog deleted on chromosome ten), the best characterized negative regulator of Akt phosphorylation, in vitro and in vivo. XIAP knockdown reduces constitutive mono- and polyubiquitination of PTEN, increases PTEN protein levels, and prevents nuclear accumulation of PTEN. Overexpression of XIAP induces polyubiquitination of PTEN and proteasome-dependent decrease of PTEN protein levels. RNA interference experiments showed that XIAP-induced regulation of Akt phosphorylation is PTEN-dependent. Additional experiments confirmed that XIAP also regulates PTEN in vivo; primary mouse embryonic fibroblasts derived from XIAP(-/-) mice contain higher levels of PTEN protein, less mono- and polyubiquitinated PTEN, and less nuclear PTEN than primary mouse embryonic fibroblasts derived from XIAP(+/+) mice. Finally, we found that XIAP can directly ubiquitinate PTEN in vitro. We thus propose that XIAP acts as an E3 ubiquitin ligase for PTEN and promotes Akt activity by regulating PTEN content and compartmentalization.	[Van Themsche, Celine; Leblanc, Valerie; Parent, Sophie; Asselin, Eric] Univ Quebec, Dept Biol Chem, Trois Rivieres, PQ G9A 5H7, Canada	University of Quebec; University of Quebec Trois Rivieres	Asselin, E (corresponding author), Univ Quebec, Dept Biol Chem, 3351 Boul Des Forges,CP 500, Trois Rivieres, PQ G9A 5H7, Canada.	eric.asselin@uqtr.ca			Natural Sciences and Engineering Research Council of Canada	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	This work was supported by a research grant from the Canadian Institute of Health Research and a grant from Natural Sciences and Engineering Research Council of Canada.	Arora V, 2007, J BIOL CHEM, V282, P26202, DOI 10.1074/jbc.M700776200; Asselin E, 2001, ENDOCRINOLOGY, V142, P2451, DOI 10.1210/en.142.6.2451; Asselin E, 2001, CANCER RES, V61, P1862; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Dai Y, 2008, INT J CANCER, V122, P2858, DOI 10.1002/ijc.23443; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Fouladkou F, 2008, P NATL ACAD SCI USA, V105, P8585, DOI 10.1073/pnas.0803233105; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gallagher E, 2007, NAT IMMUNOL, V8, P57, DOI 10.1038/ni1421; Huang HK, 2000, J BIOL CHEM, V275, P26661; Hwang C, 2008, CELL DEATH DIFFER, V15, P831, DOI 10.1038/cdd.2008.15; Morizane Y, 2005, J BIOCHEM, V137, P125, DOI 10.1093/jb/mvi029; Schwab M, 2008, CARCINOGENESIS, V29, P1407, DOI 10.1093/carcin/bgn118; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Van Themsche C, 2007, J BIOL CHEM, V282, P4794, DOI 10.1074/jbc.M608497200; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu WD, 2003, J BIOL CHEM, V278, P28258, DOI 10.1074/jbc.M303318200; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	26	112	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20462	20466		10.1074/jbc.C109.009522	http://dx.doi.org/10.1074/jbc.C109.009522			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19473982	Green Published, hybrid			2022-12-25	WOS:000268316100007
J	Yi, L; Jenkins, PM; Leichert, LI; Jakob, U; Martens, JR; Ragsdale, SW				Yi, Li; Jenkins, Paul M.; Leichert, Lars I.; Jakob, Ursula; Martens, Jeffrey R.; Ragsdale, Stephen W.			Heme Regulatory Motifs in Heme Oxygenase-2 Form a Thiol/Disulfide Redox Switch That Responds to the Cellular Redox State	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE; BIOLOGICAL SIGNIFICANCE; IRR PROTEIN; DEGRADATION; SYSTEM; THIOREDOXIN; ENVIRONMENT; ACTIVATION; MOLECULE; BINDING	Heme oxygenase (HO) catalyzes the rate-limiting step in heme catabolism to generate CO, biliverdin, and free iron. Two isoforms of HO have been identified in mammals: inducible HO-1 and constitutively expressed HO-2. HO-1 and HO-2 share similar physical and kinetic properties but have different physiological roles and tissue distributions. Unlike HO-1, which lacks cysteine residues, HO-2 contains three Cys-Pro signatures, known as heme regulatory motifs (HRMs), which are known to control processes related to iron and oxidative metabolism in organisms from bacteria to humans. In HO-2, the C-terminal HRMs constitute a thiol/disulfide redox switch that regulates affinity of the enzyme for heme (Yi, L., and Ragsdale, S. W. (2007) J. Biol. Chem. 282, 20156-21067). Here, we demonstrate that the thiol/disulfide switch in human HO-2 is physiologically relevant. Its redox potential was measured to be -200 mV, which is near the ambient intracellular redox potential. We expressed HO-2 in bacterial and human cells and measured the redox state of the C-terminal HRMs in growing cells by thiol-trapping experiments using the isotope-coded affinity tag technique. Under normal growth conditions, the HRMs are 60-70% reduced, whereas oxidative stress conditions convert most (86-89%) of the HRMs to the disulfide state. Treatment with reductants converts the HRMs largely (81-87%) to the reduced dithiol state. Thus, the thiol/disulfide switch in HO-2 responds to cellular oxidative stress and reductive conditions, representing a paradigm for how HRMs can integrate heme homeostasis with CO signaling and redox regulation of cellular metabolism.	[Ragsdale, Stephen W.] Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; [Jenkins, Paul M.; Martens, Jeffrey R.] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; [Leichert, Lars I.; Jakob, Ursula] Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ragsdale, SW (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 1150 W Med Ctr Dr,5301 MSRB 3, Ann Arbor, MI 48109 USA.	sragsdal@umich.edu	Jenkins, Paul/C-9098-2015; Leichert, Lars I./B-4762-2009; Yi, Li/A-3967-2013	Jenkins, Paul/0000-0002-4207-5823; Leichert, Lars I./0000-0002-5666-9681; 	National Institutes of Health [R21HL089837, GM065318, AG027349]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL089837] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [T32DC000011] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was supported, in whole or in part, by National Institutes of Health Grants R21HL089837 ( to S. W. R. and J. R. M.) and GM065318 and AG027349 ( to U. J.).	Bauer M, 2008, INTENS CARE MED, V34, P640, DOI 10.1007/s00134-008-1010-2; Bianchetti CM, 2007, J BIOL CHEM, V282, P37624, DOI 10.1074/jbc.M707396200; Boehning D, 2002, SCIENCE, V298, P2339, DOI 10.1126/science.1080339; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; Dooley CT, 2004, J BIOL CHEM, V279, P22284, DOI 10.1074/jbc.M312847200; Einstein RS, 1998, J NUTR, V128, P2295, DOI 10.1093/jn/128.12.2295; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hen T, 2000, BIOCHEM BIOPH RES CO, V273, P584, DOI 10.1006/bbrc.2000.2995; Huang TJ, 2001, ANTIOXID REDOX SIGN, V3, P685, DOI 10.1089/15230860152543023; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; Jones DP, 2002, METHOD ENZYMOL, V348, P93, DOI 10.1016/S0076-6879(02)48630-2; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; Lee HC, 2003, MOL CELL BIOL, V23, P5857, DOI 10.1128/MCB.23.16.5857-5866.2003; Leichert LI, 2008, P NATL ACAD SCI USA, V105, P8197, DOI 10.1073/pnas.0707723105; Maines MD, 2005, BIOCHEM BIOPH RES CO, V338, P568, DOI 10.1016/j.bbrc.2005.08.121; Maines MD, 2005, PHYSIOLOGY, V20, P382, DOI 10.1152/physiol.00029.2005; Maines MD, 2004, ANTIOXID REDOX SIGN, V6, P797, DOI 10.1089/1523086041798105; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; McCoubrey WK, 1997, J BIOL CHEM, V272, P12568, DOI 10.1074/jbc.272.19.12568; Mense SM, 2006, CELL RES, V16, P681, DOI 10.1038/sj.cr.7310086; Munakata H, 2004, J BIOCHEM, V136, P233, DOI 10.1093/jb/mvh112; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Parfenova H, 2008, CURR PHARM DESIGN, V14, P443, DOI 10.2174/138161208783597380; Qi ZH, 1999, P NATL ACAD SCI USA, V96, P13056, DOI 10.1073/pnas.96.23.13056; Qiu WH, 2007, P NATL ACAD SCI USA, V104, P5366, DOI 10.1073/pnas.0608498104; Ragsdale S.W., 2008, REDOX BIOCH, P131; Rivera M, 2005, J INORG BIOCHEM, V99, P337, DOI 10.1016/j.jinorgbio.2004.09.016; Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005; Sassa S, 2004, ANTIOXID REDOX SIGN, V6, P819, DOI 10.1089/ars.2004.6.819; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Uma S, 2000, EUR J BIOCHEM, V267, P498, DOI 10.1046/j.1432-1327.2000.01021.x; Unno M, 2007, NAT PROD REP, V24, P553, DOI 10.1039/b604180a; Wu LY, 2005, PHARMACOL REV, V57, P585, DOI 10.1124/pr.57.4.3; Yang J, 2006, MOL MICROBIOL, V60, P209, DOI 10.1111/j.1365-2958.2006.05087.x; Yi L, 2007, J BIOL CHEM, V282, P21056, DOI 10.1074/jbc.M700664200; Yoshino K, 2007, J BIOCHEM, V142, P453, DOI 10.1093/jb/mvm159	37	66	67	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20556	20561		10.1074/jbc.M109.015651	http://dx.doi.org/10.1074/jbc.M109.015651			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19473966	hybrid, Green Published			2022-12-25	WOS:000268316100017
J	Agarwal, V; Hammerschmidt, S				Agarwal, Vaibhav; Hammerschmidt, Sven			Cdc42 and the Phosphatidylinositol 3-Kinase-Akt Pathway Are Essential for PspC-mediated Internalization of Pneumococci by Respiratory Epithelial Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; CANINE KIDNEY-CELLS; INTEGRIN-LINKED KINASE; EPSTEIN-BARR-VIRUS; COMPLEMENT FACTOR-H; STREPTOCOCCUS-PNEUMONIAE; RHO-GTPASES; IG RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; SECRETORY COMPONENT	The pneumococcal surface protein C (PspC) is a major adhesin of Streptococcus pneumoniae, the cause of lobar pneumonia and invasive diseases. PspC interacts in a human-specific manner with the ectodomain of the human polymeric immunoglobulin receptor (pIgR) produced by respiratory epithelial cells. By adopting the retrograde machinery of human pIgR, this protein-protein interaction promotes colonization and transcytosis across the epithelial layer. Here, we explored the role of Rho family guanosine triphosphatases (GTPases), phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt) for ingestion of pneumococci via the human pIgR. Inhibition experiments suggested that the host-cell actin microfilaments and microtubules are essential for this pneumococcal uptake mechanism. By using specific GTPase-modifying toxins, inhibitors, and GTPase expression constructs we demonstrate that Cdc42, but not Rac1 and RhoA are involved in PspC-mediated invasion of pneumococci into host cells. Accordingly, Cdc42 is time-dependently activated during ingestion of pneumococci. In addition, PI3K and Akt are essential for ingestion of pneumococci by respiratory epithelial cells via the PspC-pIgR interaction. The subunit p85 alpha of PI3K and Akt was activated during the infection process. Moreover, Akt activation upon pneumococcal invasion depends on PI3K. In conclusion, our results illustrate for the first time key signaling molecules of host cells that are required for PspC-pIgR-mediated invasion of pneumococci into epithelial cells. This unique and specific bacterial entry process is dependent on the cooperation and activation of Rho family GTPase Cdc42, PI3K, and Akt.	[Agarwal, Vaibhav; Hammerschmidt, Sven] Ernst Moritz Arndt Univ Greifswald, Dept Genet Microorganisms, Inst Genet & Funct Genom, D-17487 Greifswald, Germany; [Agarwal, Vaibhav; Hammerschmidt, Sven] Univ Munich, Max Von Pettenkofer Inst Hyg & Med Microbiol, D-80336 Munich, Germany; [Agarwal, Vaibhav; Hammerschmidt, Sven] Univ Wurzburg, Res Ctr Infect Dis, D-97070 Wurzburg, Germany	Ernst Moritz Arndt Universitat Greifswald; University of Munich; University of Wurzburg	Hammerschmidt, S (corresponding author), Ernst Moritz Arndt Univ Greifswald, Dept Genet Microorganisms, Inst Genet & Funct Genom, Friedrich Ludwig Jahn Str 15A, D-17487 Greifswald, Germany.	sven.hammerschmidt@uni-greifswald.de	Hammerschmidt, Sven/G-2598-2010	Hammerschmidt, Sven/0000-0002-6382-6681	Deutsche Forschungsgemeinschaft [Ha 3125/4-1]; Sonderforschungsbereich [479]; Teilprojekt [A7]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Sonderforschungsbereich(German Research Foundation (DFG)); Teilprojekt	This work was supported in part by the Deutsche Forschungsgemeinschaft (DFG, Sonderforschungsbereich 479, Teilprojekt A7 ( to S. H.) and DFG Ha 3125/4-1).	Aktories K, 2005, CURR TOP MICROBIOL, V291, P113; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bergmann S, 2009, J CELL SCI, V122, P256, DOI 10.1242/jcs.035600; Boudeau J, 2006, TRENDS CELL BIOL, V16, P443, DOI 10.1016/j.tcb.2006.07.003; Burnham CAD, 2007, FEMS MICROBIOL LETT, V272, P8, DOI 10.1111/j.1574-6968.2007.00768.x; Cardone MH, 1996, J CELL BIOL, V133, P997, DOI 10.1083/jcb.133.5.997; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Cartwright K, 2002, EUR J PEDIATR, V161, P188, DOI 10.1007/s00431-001-0907-3; Coombes BK, 2002, CELL MICROBIOL, V4, P447, DOI 10.1046/j.1462-5822.2002.00203.x; Cossart P, 2004, SCIENCE, V304, P242, DOI 10.1126/science.1090124; Dave S, 2004, J IMMUNOL, V173, P471, DOI 10.4049/jimmunol.173.1.471; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Elm C, 2004, J BIOL CHEM, V279, P6296, DOI 10.1074/jbc.M310528200; Finlay BB, 2005, CURR TOP MICROBIOL, V291, P1; Gan YJ, 1997, J VIROL, V71, P519, DOI 10.1128/JVI.71.1.519-526.1997; Genth H, 2008, INT J BIOCHEM CELL B, V40, P592, DOI 10.1016/j.biocel.2007.12.014; Giffroy D, 1998, INT IMMUNOL, V10, P347, DOI 10.1093/intimm/10.3.347; Giffroy D, 2001, SCAND J IMMUNOL, V53, P56, DOI 10.1046/j.1365-3083.2001.00843.x; Godding V, 1998, EUR RESPIR J, V11, P1043, DOI 10.1183/09031936.98.11051043; Hammerschmidt S, 2006, CURR OPIN MICROBIOL, V9, P12, DOI 10.1016/j.mib.2005.11.001; Hammerschmidt S, 2000, MOL MICROBIOL, V36, P726, DOI 10.1046/j.1365-2958.2000.01897.x; Hammerschmidt S, 2007, J IMMUNOL, V178, P5848, DOI 10.4049/jimmunol.178.9.5848; HANSEN SH, 1995, J BIOL CHEM, V270, P28425; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hippenstiel S, 2000, BLOOD, V95, P3044; Iliev AI, 2007, P NATL ACAD SCI USA, V104, P2897, DOI 10.1073/pnas.0608213104; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Jou TS, 2000, MOL BIOL CELL, V11, P287, DOI 10.1091/mbc.11.1.287; Just I, 2005, REV PHYSIOL BIOCH P, V152, P23, DOI 10.1007/s10254-004-0033-5; Kazmierczak BI, 2001, CELL MICROBIOL, V3, P85, DOI 10.1046/j.1462-5822.2001.00091.x; Kierbel A, 2005, MOL BIOL CELL, V16, P2577, DOI 10.1091/mbc.E04-08-0717; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Krause-Gruszczynska M, 2007, CELL MICROBIOL, V9, P2431, DOI 10.1111/j.1462-5822.2007.00971.x; Kwok T, 2002, INFECT IMMUN, V70, P2108, DOI 10.1128/IAI.70.4.2108-2120.2002; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leung SM, 1999, MOL BIOL CELL, V10, P4369, DOI 10.1091/mbc.10.12.4369; Lin CT, 1997, AM J PATHOL, V150, P1745; Lu L, 2003, J BIOL CHEM, V278, P48178, DOI 10.1074/jbc.M306906200; Lu L, 2008, J IMMUNOL, V181, P7138, DOI 10.4049/jimmunol.181.10.7138; Lu L, 2006, J BIOL CHEM, V281, P15464, DOI 10.1074/jbc.M602404200; Luo RS, 2005, EMBO J, V24, P34, DOI 10.1038/sj.emboj.7600490; Luton F, 1999, MOL CELL, V4, P627, DOI 10.1016/S1097-2765(00)80213-0; Luton F, 1999, MOL BIOL CELL, V10, P1409, DOI 10.1091/mbc.10.5.1409; Luton F, 1998, MOL BIOL CELL, V9, P1787, DOI 10.1091/mbc.9.7.1787; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Maples CJ, 1997, J BIOL CHEM, V272, P6741, DOI 10.1074/jbc.272.10.6741; Nalbant P, 2004, SCIENCE, V305, P1615, DOI 10.1126/science.1100367; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pelish HE, 2006, NAT CHEM BIOL, V2, P221, DOI 10.1038/nchembio0406-221b; Purushothaman SS, 2003, INFECT IMMUN, V71, P5823, DOI 10.1128/IAI.71.10.5823-5830.2003; Reddy MA, 2000, J BIOL CHEM, V275, P36769, DOI 10.1074/jbc.M007382200; Rennemeier C, 2007, FASEB J, V21, P3118, DOI 10.1096/fj.06-7992com; Rojas R, 2002, NAT REV MOL CELL BIO, V3, P944, DOI 10.1038/nrm972; Rojas R, 2001, MOL BIOL CELL, V12, P2257, DOI 10.1091/mbc.12.8.2257; Rottner K, 2004, J PATHOL, V204, P396, DOI 10.1002/path.1638; Sangari FJ, 2000, CELL MICROBIOL, V2, P561, DOI 10.1046/j.1462-5822.2000.00080.x; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Schmeck B, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-98; SIXBEY JW, 1992, SCIENCE, V255, P1578, DOI 10.1126/science.1312750; SONG WX, 1994, P NATL ACAD SCI USA, V91, P163, DOI 10.1073/pnas.91.1.163; Stokoe David, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405009361; TAMER CM, 1995, J IMMUNOL, V155, P707; Van Nhieu GT, 1999, EMBO J, V18, P3249, DOI 10.1093/emboj/18.12.3249; Xu B, 2006, ORG BIOMOL CHEM, V4, P4149, DOI 10.1039/b609143a; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4	68	41	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19427	19436		10.1074/jbc.M109.003442	http://dx.doi.org/10.1074/jbc.M109.003442			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19473971	Green Published, hybrid			2022-12-25	WOS:000267908300034
J	Gavalda, S; Leger, M; van der Rest, B; Stella, A; Bardou, F; Montrozier, H; Chalut, C; Burlet-Schiltz, O; Marrakchi, H; Daffe, M; Quemard, A				Gavalda, Sabine; Leger, Mathieu; van der Rest, Benoit; Stella, Alexandre; Bardou, Fabienne; Montrozier, Henri; Chalut, Christian; Burlet-Schiltz, Odile; Marrakchi, Hedia; Daffe, Mamadou; Quemard, Annaik			The Pks13/FadD32 Crosstalk for the Biosynthesis of Mycolic Acids in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA CARBOXYLASE; FATTY-ACID; CORYNEBACTERIUM-GLUTAMICUM; OUTER-MEMBRANE; COENZYME-A; IDENTIFICATION; GENE; CATALYZES	The last steps of the biosynthesis of mycolic acids, essential and specific lipids of Mycobacterium tuberculosis and related bacteria, are catalyzed by proteins encoded by the fadD32-pks13-accD4 cluster. Here, we produced and purified an active form of the Pks13 polyketide synthase, with a phosphopantetheinyl (P-pant) arm at both positions Ser-55 and Ser-1266 of its two acyl carrier protein (ACP) domains. Combination of liquid chromatography-tandem mass spectrometry of protein tryptic digests and radiolabeling experiments showed that, in vitro, the enzyme specifically loads long-chain 2-carboxyacyl-CoA substrates onto the P-pant arm of its C-terminal ACP domain via the acyltransferase domain. The acyl-AMPs produced by the FadD32 enzyme are specifically transferred onto the ketosynthase domain after binding to the P-pant moiety of the N-terminal ACP domain of Pks13 (N-ACP(Pks13)). Unexpectedly, however, the latter step requires the presence of active FadD32. Thus, the couple FadD32-(N-ACP(Pks13)) composes the initiation module of the mycolic condensation system. Pks13 ultimately condenses the two loaded fatty acyl chains to produce alpha-alkyl beta-ketoacids, the precursors of mycolic acids. The developed in vitro assay will constitute a strategic tool for antimycobacterial drug screening.	[Gavalda, Sabine; Leger, Mathieu; van der Rest, Benoit; Bardou, Fabienne; Montrozier, Henri; Chalut, Christian; Marrakchi, Hedia; Daffe, Mamadou; Quemard, Annaik] CNRS, IPBS, Dept Mecanismes Mol Infect Mycobacteriennes, F-31077 Toulouse, France; [Stella, Alexandre; Burlet-Schiltz, Odile] CNRS, IPBS, Dept Canc Biol, F-31077 Toulouse, France; [Gavalda, Sabine; Leger, Mathieu; van der Rest, Benoit; Stella, Alexandre; Bardou, Fabienne; Montrozier, Henri; Chalut, Christian; Burlet-Schiltz, Odile; Marrakchi, Hedia; Daffe, Mamadou; Quemard, Annaik] Univ Toulouse, UPS, IPBS, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Daffe, M (corresponding author), CNRS, IPBS, Dept Mecanismes Mol Infect Mycobacteriennes, 205 Route Narbonne, F-31077 Toulouse, France.	Mamadou.Daffe@ipbs.fr; Annaik.Quemard@ipbs.fr	Marrakchi, Hedia/AAF-2657-2020	Chalut, Christian/0000-0002-4849-1369; Quemard, Annaik/0000-0002-5545-3424; Marrakchi, Hedia/0000-0003-2749-5966; Schiltz, Odile/0000-0002-3606-2356	CNRS (France); Vaincre la Mucoviscidose [IC0716]; European Community [LSHP-CT-2006-037217]; Region Midi-Pyrenees; Fondation pour la Recherche Medicale ( France)	CNRS (France)(Centre National de la Recherche Scientifique (CNRS)); Vaincre la Mucoviscidose; European Community(European Commission); Region Midi-Pyrenees(Region Provence-Alpes-Cote d'AzurRegion Occitanie); Fondation pour la Recherche Medicale ( France)(Fondation pour la Recherche Medicale)	This work was supported by post-doctoral fellowships ( to S. G. and B. v. d. R.) from the CNRS ( France), the "Vaincre la Mucoviscidose" (IC0716, France), European Community Grant LSHP-CT-2006-037217, the Region Midi-Pyrenees, and the Fondation pour la Recherche Medicale ( France).	ADAMS R, 1941, ORG SYNTH, V1, P250; AHIBOCOFFY A, 1978, CHEM PHYS LIPIDS, V22, P185, DOI 10.1016/0009-3084(78)90025-7; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Chalut C, 2006, P NATL ACAD SCI USA, V103, P8511, DOI 10.1073/pnas.0511129103; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Gande R, 2004, J BIOL CHEM, V279, P44847, DOI 10.1074/jbc.M408648200; Gande R, 2007, J BACTERIOL, V189, P5257, DOI 10.1128/JB.00254-07; Gehring AM, 1998, BIOCHEMISTRY-US, V37, P11637, DOI 10.1021/bi9812571; GOLDMAN P, 1961, J BIOL CHEM, V236, P2620; Hoffmann C, 2008, P NATL ACAD SCI USA, V105, P3963, DOI 10.1073/pnas.0709530105; Lea-Smith DJ, 2007, J BIOL CHEM, V282, P11000, DOI 10.1074/jbc.M608686200; Marrakchi H, 2008, MYCOBACTERIAL CELL ENVELOPE, P41; Morsczeck C, 2001, BBA-GENE STRUCT EXPR, V1521, P59, DOI 10.1016/S0167-4781(01)00287-1; NAKANO MM, 1992, MOL GEN GENET, V232, P313, DOI 10.1007/BF00280011; Oh TJ, 2006, J BIOL CHEM, V281, P3899, DOI 10.1074/jbc.M511761200; PADMAKUMAR R, 1993, ANAL BIOCHEM, V214, P318, DOI 10.1006/abio.1993.1494; Portevin D, 2005, J BIOL CHEM, V280, P8862, DOI 10.1074/jbc.M408578200; Portevin D, 2004, P NATL ACAD SCI USA, V101, P314, DOI 10.1073/pnas.0305439101; Quadri LEN, 1998, CHEM BIOL, V5, P631, DOI 10.1016/S1074-5521(98)90291-5; Revill WP, 1996, J BACTERIOL, V178, P5660, DOI 10.1128/jb.178.19.5660-5667.1996; Schmoock G, 2005, J BIOL CHEM, V280, P4339, DOI 10.1074/jbc.M411026200; SHIMAKATA T, 1984, ARCH BIOCHEM BIOPHYS, V229, P329, DOI 10.1016/0003-9861(84)90159-0; SHIMAKATA T, 1986, ARCH BIOCHEM BIOPHYS, V247, P302, DOI 10.1016/0003-9861(86)90588-6; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Trivedi OA, 2004, NATURE, V428, P441, DOI 10.1038/nature02384; WALKER RW, 1973, BIOCHIM BIOPHYS ACTA, V326, P52, DOI 10.1016/0005-2760(73)90027-1; Zuber B, 2008, J BACTERIOL, V190, P5672, DOI 10.1128/JB.01919-07	27	80	83	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19255	19264		10.1074/jbc.M109.006940	http://dx.doi.org/10.1074/jbc.M109.006940			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19436070	Green Published, hybrid			2022-12-25	WOS:000267908300016
J	Liu, J; Rasul, I; Sun, YN; Wu, GS; Li, LX; Premont, RT; Suo, WZ				Liu, Jun; Rasul, Imtiaz; Sun, Yuning; Wu, Guisheng; Li, Longxuan; Premont, Richard T.; Suo, William Z.			GRK5 Deficiency Leads to Reduced Hippocampal Acetylcholine Level via Impaired Presynaptic M2/M4 Autoreceptor Desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED-RECEPTOR KINASES; INDUCED MICROGLIAL ACTIVATION; NERVE-CELL DEATH; ALZHEIMERS-DISEASE; KNOCKOUT MICE; SUPERSENSITIVITY; EXPRESSION; ARRESTINS; RAT	G protein-coupled receptor kinase 5 (GRK5) deficiency has been linked recently to early Alzheimer disease (AD), but the mechanism by which GRK5 deficiency may contribute to AD pathogenesis remains elusive. Here we report that overexpression of dominant negative mutant of GRK5 (dnGRK5) in a cholinergic neuronal cell line led to decreased acetylcholine (ACh) release. This reduction was fully corrected by pertussis toxin, atropine (a nonselective muscarinic antagonist), or methoctramine(a selective M2/M4 muscarinic receptor antagonist). Consistent with results in cultured cells, high potassium-evoked ACh release in hippocampal slices from young GRK5 knock-out mice was significantly reduced compared with wild type littermates, and this reduced ACh release was also fully corrected by methoctramine. In addition, following treatment with the nonselective muscarinic agonist oxotremorine-M, M2, and M4 receptors underwent significantly reduced internalization in GRK5KO slices compared with wild type slices, as assessed by plasma membrane retention of receptor immunoreactivity, whereas M1 receptor internalization was not affected by loss of GRK5 expression. Moreover, Western blotting revealed no synaptic or cholinergic degenerative changes in young GRK5 knock-out mice. Altogether, these results suggest that GRK5 deficiency leads to a reduced hippocampal ACh release and cholinergic hypofunction by selective impairment of desensitization of presynaptic M2/M4 autoreceptors. Because this nonstructural cholinergic hypofunction precedes the hippocampal cholinergic hypofunction associated with structural cholinergic degeneration and cognitive decline in aged GRK5 knock-out mice, this nonstructural alteration may be an early event contributing to cholinergic degeneration in AD.	[Liu, Jun; Rasul, Imtiaz; Sun, Yuning; Wu, Guisheng; Li, Longxuan; Suo, William Z.] Kansas City Vet Affairs Med Ctr, Lab Alzheimers Dis & Aging Res, Kansas City, MO 64128 USA; [Liu, Jun] Sun Yat Sen Univ, Dept Neurol, Affiliated Hosp 2, Guangzhou 510120, Guangdong, Peoples R China; [Suo, William Z.] Univ Kansas, Dept Neurol, Coll Med, Kansas City, KS 66170 USA; [Suo, William Z.] Univ Kansas, Dept Physiol, Coll Med, Kansas City, KS 66170 USA; [Li, Longxuan] Affiliated Hosp, Guangdong Med Coll, Dept Neurol, Zhanjian 524001, Guangdong, Peoples R China; [Sun, Yuning] Ningxia Med Univ, Dept Biochem & Mol Biol, Ningxia 750004, Peoples R China; [Premont, Richard T.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Sun Yat Sen University; University of Kansas; University of Kansas; Guangdong Medical University; Ningxia Medical University; Duke University	Suo, WZ (corresponding author), Vet Affairs Med Ctr, Lab Alzheimers Dis & Aging Res, 4801 Linwood Blvd, KS City, MO 64128 USA.	william.suo@va.gov		Premont, Richard/0000-0002-8053-5026	Medical Research and Development Service; Department of Veterans Affairs; American Federation for Aging Research; Midwest Biomedical Research Foundation	Medical Research and Development Service(US Department of Veterans Affairs); Department of Veterans Affairs(US Department of Veterans Affairs); American Federation for Aging Research; Midwest Biomedical Research Foundation	This work was supported by grants ( to W. Z. S.) from the Medical Research and Development Service, Department of Veterans Affairs, the American Federation for Aging Research, and resources from the Midwest Biomedical Research Foundation.	AMADEO A, 1995, NEUROSCI LETT, V184, P161, DOI 10.1016/0304-3940(94)11196-P; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; Gainetdinov RR, 2003, NEURON, V38, P291, DOI 10.1016/S0896-6273(03)00192-2; Gifford AN, 1999, J PHARMACOL EXP THER, V288, P478; Guidry G, 2005, AUTON NEUROSCI-BASIC, V123, P54, DOI 10.1016/j.autneu.2005.10.001; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Levey AI, 1996, P NATL ACAD SCI USA, V93, P13541, DOI 10.1073/pnas.93.24.13541; Li LX, 2009, BRAIN RES BULL, V78, P145, DOI 10.1016/j.brainresbull.2008.09.019; Li L, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-24; Li YH, 1998, P NATL ACAD SCI USA, V95, P7748, DOI 10.1073/pnas.95.13.7748; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Liu J, 2009, LIFE SCI, V84, P267, DOI 10.1016/j.lfs.2008.12.008; Matsui M, 2004, LIFE SCI, V75, P2971, DOI 10.1016/j.lfs.2004.05.034; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PITTEL Z, 1990, J NEUROCHEM, V55, P665, DOI 10.1111/j.1471-4159.1990.tb04185.x; Premont RT, 2007, ANNU REV PHYSIOL, V69, P511, DOI 10.1146/annurev.physiol.69.022405.154731; ROGERS SW, 1991, J NEUROSCI, V11, P2713; SUO Z, 2005, NEUROBIOL AGING, V25, pS2; Suo Z, 2007, NEUROBIOL AGING, V28, P1873, DOI 10.1016/j.neurobiolaging.2006.08.013; Suo ZM, 2004, J NEUROSCI, V24, P3444, DOI 10.1523/JNEUROSCI.4856-03.2004; Suo ZM, 2003, J BIOL CHEM, V278, P37681, DOI 10.1074/jbc.M301406200; Suo ZM, 2003, J BIOL CHEM, V278, P31177, DOI 10.1074/jbc.M302137200; Suo ZM, 2002, J NEUROCHEM, V80, P655, DOI 10.1046/j.0022-3042.2001.00745.x; Terry AV, 2003, J PHARMACOL EXP THER, V306, P821, DOI 10.1124/jpet.102.041616; Walker JKL, 2004, AM J PHYSIOL-LUNG C, V286, pL312, DOI 10.1152/ajplung.00255.2003; Wess J, 2004, ANNU REV PHARMACOL, V44, P423, DOI 10.1146/annurev.pharmtox.44.101802.121622; Zhang WL, 2002, J NEUROSCI, V22, P1709, DOI 10.1523/JNEUROSCI.22-05-01709.2002	29	37	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19564	19571		10.1074/jbc.M109.005959	http://dx.doi.org/10.1074/jbc.M109.005959			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19478075	Green Published, hybrid			2022-12-25	WOS:000267908300048
J	Gramatzki, D; Pantazis, G; Schittenhelm, J; Tabatabai, G; Kohle, C; Wick, W; Schwarz, M; Weller, M; Tritschler, I				Gramatzki, D.; Pantazis, G.; Schittenhelm, J.; Tabatabai, G.; Koehle, C.; Wick, W.; Schwarz, M.; Weller, M.; Tritschler, I.			Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells	ONCOGENE			English	Article						AhR; TGF-beta; Smad; LTBP-1; gliomas	GROWTH-FACTOR-BETA; MOUSE EMBRYO FIBROBLASTS; DIOXIN RECEPTOR; GLIOMA-CELLS; IN-VIVO; EXPRESSION; GENE; BINDING; MICE; APOPTOSIS	The dioxin/aryl hydrocarbon receptor (AhR) is a transcription factor, which has been attributed a role in human cancerogenesis, cell cycle progression and transforming growth factor-beta (TGF-beta) signaling. As TGF-beta is an important mediator of the malignant phenotype of human gliomas, we studied AhR expression and function in glioma cells. AhR was not only expressed in glioma cells in vitro, but was also detected in human gliomas in vivo by immunohistochemistry, with a predominantly nuclear staining in glioblastomas. The AhR agonist, 3-methylcholanthrene, induced AhR nuclear translocation and upregulated mRNA levels of the AhR target gene, cytochrome P450 1A1 (CYP1A1). Conversely, pharmacological inhibition of AhR using the novel AhR antagonist, CH-223191, or AhR gene silencing using small interfering RNA showed that constitutive AhR activity positively controls TGF-beta 1, TGF-beta 2 and latent TGF-beta-binding protein-1 protein levels in malignant glioma cells. Moreover, antagonism of AhR reduced clonogenic survival and invasiveness of glioma cells. In contrast, AhR regulates TGF-beta signaling negatively in non-neoplastic astrocytes. Thus, the pathogenesis of glioma formation may involve altered AhR regulation of the TGF-beta/Smad pathway, and AhR may represent a promising target for the treatment of human malignant gliomas and other diseases associated with pathological TGF-beta activity. Oncogene (2009) 28, 2593-2605; doi: 10.1038/onc.2009.104; published online 25 May 2009	[Weller, M.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; [Gramatzki, D.; Tabatabai, G.; Wick, W.; Weller, M.; Tritschler, I.] Univ Tubingen, Mol Neurooncol Lab, Dept Gen Neurol, Tubingen, Germany; [Gramatzki, D.; Tabatabai, G.; Wick, W.; Weller, M.; Tritschler, I.] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany; [Pantazis, G.; Schittenhelm, J.] Univ Tubingen, Inst Brain Res, Dept Neuropathol, D-7400 Tubingen, Germany; [Koehle, C.; Schwarz, M.] Univ Tubingen, Inst Pharmacol & Toxicol, Dept Toxicol, Tubingen, Germany; [Wick, W.] Univ Heidelberg, Dept Neurooncol, Heidelberg, Germany	University of Zurich; University Zurich Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Ruprecht Karls University Heidelberg	Weller, M (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	michael.weller@usz.ch	Tabatabai, Ghazaleh/A-6365-2015; Wick, Wolfgang/AAA-2545-2020	Tabatabai, Ghazaleh/0000-0003-3702-923X; Wick, Wolfgang/0000-0002-6171-634X; Weller, Michael/0000-0002-1748-174X; Tabatabai, Ghazaleh/0000-0002-3542-8782	Jacqueline Seroussi Memorial Foundation for Cancer Research; Swiss National Fund (NCCR Neuro)	Jacqueline Seroussi Memorial Foundation for Cancer Research; Swiss National Fund (NCCR Neuro)(Swiss National Science Foundation (SNSF))	We are indebted to Dr Gabrielle Haas for support with confocal microscopy. This study was supported by grants from the Jacqueline Seroussi Memorial Foundation for Cancer Research and the Swiss National Fund (NCCR Neuro) to MW.	Andersson P, 2002, P NATL ACAD SCI USA, V99, P9990, DOI 10.1073/pnas.152706299; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Carraro G, 2005, MOL CELL PROBE, V19, P181, DOI 10.1016/j.mcp.2004.11.004; Chang XQ, 2007, MOL CELL BIOL, V27, P6127, DOI 10.1128/MCB.00323-07; Corchero J, 2004, INT J EXP PATHOL, V85, P295, DOI 10.1111/j.0959-9673.2004.00397.x; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Elferink Cornelis J, 2003, Prog Cell Cycle Res, V5, P261; Friese MA, 2004, CANCER RES, V64, P7596, DOI 10.1158/0008-5472.CAN-04-1627; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; Gomez-Duran A, 2006, J CELL BIOCHEM, V97, P380, DOI 10.1002/jcb.20637; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HAARMANNSTEMMAN T, 2008, BIOCHEM PHARMACOL, V77, P508; Harper PA, 2006, BIOCHEM PHARMACOL, V72, P267, DOI 10.1016/j.bcp.2006.01.007; HUANG SX, 2004, COMPUTER INTEGRATED, V1, P1; Ito T, 2004, J BIOL CHEM, V279, P25204, DOI 10.1074/jbc.M402143200; Kim SH, 2006, MOL PHARMACOL, V69, P1871, DOI 10.1124/mol.105.021832; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kress S, 1998, EUR J BIOCHEM, V258, P803, DOI 10.1046/j.1432-1327.1998.2580803.x; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Maier MSV, 2007, NEUROTOXICOLOGY, V28, P594, DOI 10.1016/j.neuro.2007.01.002; Marlowe JL, 2005, J CELL BIOCHEM, V96, P1174, DOI 10.1002/jcb.20656; MASON GGF, 1994, J BIOL CHEM, V269, P4438; McGuire J, 2001, J BIOL CHEM, V276, P41841, DOI 10.1074/jbc.M105607200; Mimura J, 2003, BBA-GEN SUBJECTS, V1619, P263, DOI 10.1016/S0304-4165(02)00485-3; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Moennikes O, 2004, CANCER RES, V64, P4707, DOI 10.1158/0008-5472.CAN-03-0875; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Ohtake F, 2008, BIOCHEM BIOPH RES CO, V370, P541, DOI 10.1016/j.bbrc.2008.03.054; Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1976, J BIOL CHEM, V251, P4936; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Santiago-Josefat B, 2004, J CELL SCI, V117, P849, DOI 10.1242/jcs.00932; Schittenhelm J, 2008, BRAIN PATHOL, V18, P344, DOI 10.1111/j.1750-3639.2008.00127.x; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; TRITSCHLER I, 2009, INT J CANC IN PRESS; Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008-5472.CAN-04-1013; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Weller M, 1995, BRAIN RES REV, V21, P128, DOI 10.1016/0165-0173(95)00010-0; Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843; Wolff S, 2001, MOL PHARMACOL, V59, P716, DOI 10.1124/mol.59.4.716; Zaher H, 1998, MOL PHARMACOL, V54, P313, DOI 10.1124/mol.54.2.313; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zudaire E, 2008, J CLIN INVEST, V118, P640, DOI 10.1172/JCI30024	47	88	101	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2009	28	28					2593	2605		10.1038/onc.2009.104	http://dx.doi.org/10.1038/onc.2009.104			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	471LJ	19465936				2022-12-25	WOS:000268058900005
J	Kojima, K; Motohashi, K; Morota, T; Oshita, M; Hisabori, T; Hayashi, H; Nishiyama, Y				Kojima, Kouji; Motohashi, Ken; Morota, Takuya; Oshita, Masaru; Hisabori, Toru; Hayashi, Hidenori; Nishiyama, Yoshitaka			Regulation of Translation by the Redox State of Elongation Factor G in the Cyanobacterium Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODED D1 PROTEIN; PHOTOSYSTEM-II; TARGET PROTEINS; CALVIN CYCLE; THIOREDOXIN; PHOTOINHIBITION; REPAIR; PHOTODAMAGE; MEMBRANE; PSBA	Elongation factor G (EF-G), a key protein in translational elongation, was identified as a primary target of inactivation by reactive oxygen species within the translational machinery of the cyanobacterium Synechocystis sp. PCC 6803 (Kojima, K., Oshita, M., Nanjo, Y., Kasai, K., Tozawa, Y., Hayashi, H., and Nishiyama, Y. (2007) Mol. Microbiol. 65, 936-947). In the present study, we found that inactivation of EF-G (Slr1463) by H2O2 was attributable to the oxidation of two specific cysteine residues and formation of a disulfide bond. Substitution of these cysteine residues by serine residues protected EF-G from inactivation by H2O2 and allowed the EF-G to mediate translation in a translation system in vitro that had been prepared from Synechocystis. The disulfide bond in oxidized EF-G was reduced by thioredoxin, and the resultant reduced form of EF-G regained the activity to mediate translation in vitro. Western blotting analysis showed that levels of the oxidized form of EF-G increased under strong light in a mutant that lacked NADPH-thioredoxin reductase, indicating that EF-G is reduced by thioredoxin in vivo. These observations suggest that the translational machinery is regulated by the redox state of EF-G, which is oxidized by reactive oxygen species and reduced by thioredoxin, a transmitter of reducing signals generated by the photosynthetic transport of electrons.	[Kojima, Kouji; Morota, Takuya; Nishiyama, Yoshitaka] Saitama Univ, Dept Biochem & Mol Biol, Grad Sch Sci & Engn, Sakura Ku, Saitama 3388570, Japan; Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan; [Kojima, Kouji; Hayashi, Hidenori] Ehime Univ, Venture Business Lab, Matsuyama, Ehime 7908577, Japan; [Oshita, Masaru; Hayashi, Hidenori] Ehime Univ, Grad Sch Sci & Engn, Matsuyama, Ehime 7908577, Japan; [Hayashi, Hidenori] Ehime Univ, Cell Free Sci & Technol Res Ctr, Matsuyama, Ehime 7908577, Japan	Saitama University; Tokyo Institute of Technology; Ehime University; Ehime University; Ehime University	Nishiyama, Y (corresponding author), Saitama Univ, Dept Biochem & Mol Biol, Grad Sch Sci & Engn, Sakura Ku, 255 Shimo Okubo, Saitama 3388570, Japan.	nishiyama@molbiol.saitama-u.ac.jp	Motohashi, Ken/I-4970-2019; Nishiyama, Yoshitaka/K-3825-2012; Kojima, Kouji/L-8180-2013; Hisabori, Toru/E-5205-2014	Motohashi, Ken/0000-0002-8414-2836; Hisabori, Toru/0000-0003-2046-0277	Ministry of Education, Culture, Sports, Science, and Technology of Japan [19570043]	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by Grant-in-aid for Scientific Research 19570043 ( to Y. N.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and by the Research Project of Saitama University.	Allakhverdiev SI, 2005, PLANT PHYSIOL, V137, P263, DOI 10.1104/pp.104.054478; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Bald D, 2001, J BIOL CHEM, V276, P39505, DOI 10.1074/jbc.C100436200; Balmer Y, 2003, P NATL ACAD SCI USA, V100, P370, DOI 10.1073/pnas.232703799; Dukan S, 1999, J BIOL CHEM, V274, P26027, DOI 10.1074/jbc.274.37.26027; GLAZER AN, 1975, CHEM MODIFICATION PR, P21; Green R, 2000, CURR BIOL, V10, pR369, DOI 10.1016/S0960-9822(00)00481-4; Hakala M, 2005, BBA-BIOENERGETICS, V1706, P68, DOI 10.1016/j.bbabio.2004.09.001; Hisabori T, 2005, J EXP BOT, V56, P1463, DOI 10.1093/jxb/eri170; Hisabori T, 2007, PHOTOCHEM PHOTOBIOL, V83, P145, DOI 10.1562/2006-02-27-IR-816; Hishiya S, 2008, PLANT CELL PHYSIOL, V49, P11, DOI 10.1093/pcp/pcm158; Hosoya-Matsuda N, 2005, J BIOL CHEM, V280, P840, DOI 10.1074/jbc.M411493200; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; KLEIN RR, 1987, J BIOL CHEM, V262, P4341; Kojima K, 2007, MOL MICROBIOL, V65, P936, DOI 10.1111/j.1365-2958.2007.05836.x; Kumar JK, 2004, P NATL ACAD SCI USA, V101, P3759, DOI 10.1073/pnas.0308701101; Kuroda H, 1996, PLANT CELL PHYSIOL, V37, P754, DOI 10.1093/oxfordjournals.pcp.a029010; Lemaire SD, 2004, P NATL ACAD SCI USA, V101, P7475, DOI 10.1073/pnas.0402221101; Lindahl M, 2003, P NATL ACAD SCI USA, V100, P16107, DOI 10.1073/pnas.2534397100; Motohashi K, 2003, J BIOL CHEM, V278, P31848, DOI 10.1074/jbc.M304258200; Motohashi K, 2006, J BIOL CHEM, V281, P35039, DOI 10.1074/jbc.M605938200; Murata N, 2007, BBA-BIOENERGETICS, V1767, P414, DOI 10.1016/j.bbabio.2006.11.019; Nishiyama Y, 2004, BIOCHEMISTRY-US, V43, P11321, DOI 10.1021/bi036178q; Nishiyama Y, 2001, EMBO J, V20, P5587, DOI 10.1093/emboj/20.20.5587; Nishiyama Y, 2006, BBA-BIOENERGETICS, V1757, P742, DOI 10.1016/j.bbabio.2006.05.013; Ohnishi N, 2005, BIOCHEMISTRY-US, V44, P8494, DOI 10.1021/bi047518q; POWLES SB, 1984, ANNU REV PLANT PHYS, V35, P15, DOI 10.1146/annurev.pp.35.060184.000311; PRASIL O, 1992, PHOTOSYSTEMS STRUCTU, P295, DOI DOI 10.1016/B978-0-444-89440-3.50017-5; Schurmann P, 2008, ANTIOXID REDOX SIGN, V10, P1235, DOI 10.1089/ars.2007.1931; Takahashi S, 2006, BBA-BIOENERGETICS, V1757, P198, DOI 10.1016/j.bbabio.2006.02.002; Takahashi S, 2005, BBA-BIOENERGETICS, V1708, P352, DOI 10.1016/j.bbabio.2005.04.003; Takahashi S, 2008, TRENDS PLANT SCI, V13, P178, DOI 10.1016/j.tplants.2008.01.005; Takahashi S, 2007, PLANT PHYSIOL, V144, P487, DOI 10.1104/pp.107.097253; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; Trebitsh T, 2001, P NATL ACAD SCI USA, V98, P12289, DOI 10.1073/pnas.211440698; Tyystjarvi T, 2001, MOL MICROBIOL, V40, P476, DOI 10.1046/j.1365-2958.2001.02402.x; Tyystjarvi T, 2004, FEBS LETT, V576, P211, DOI 10.1016/j.febslet.2004.08.083; Ueoka-Nakanishi H, 2004, J BIOL CHEM, V279, P16272, DOI 10.1074/jbc.M400607200; Yamazaki D, 2004, PLANT CELL PHYSIOL, V45, P18, DOI 10.1093/pcp/pch019; Zhang LX, 2002, FEBS LETT, V512, P13, DOI 10.1016/S0014-5793(02)02218-4; Zhang LX, 2000, PLANT CELL, V12, P1769, DOI 10.1105/tpc.12.9.1769; Zsiros O, 2006, BBA-BIOENERGETICS, V1757, P123, DOI 10.1016/j.bbabio.2006.01.004	43	51	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18685	18691		10.1074/jbc.M109.015131	http://dx.doi.org/10.1074/jbc.M109.015131			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19447882	Green Published, hybrid			2022-12-25	WOS:000267711500017
J	Wong, SG; Tom-Yew, SAL; Lewin, A; Le Brun, NE; Moore, GR; Murphy, MEP; Mauk, AG				Wong, Steve G.; Tom-Yew, Stacey A. L.; Lewin, Allison; Le Brun, Nick E.; Moore, Geoffrey R.; Murphy, Michael E. P.; Mauk, A. Grant			Structural and Mechanistic Studies of a Stabilized Subunit Dimer Variant of Escherichia coli Bacterioferritin Identify Residues Required for Core Formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOBACTER-CAPSULATUS BACTERIOFERRITIN; IRON; HEME; SITE; BINDING; FERROXIDASE; MUTANTS	Bacterioferritin (BFR) is a bacterial member of the ferritin family that functions in iron metabolism and protects against oxidative stress. BFR differs from the mammalian protein in that it is comprised of 24 identical subunits and is able to bind 12 equivalents of heme at sites located between adjacent pairs of subunits. The mechanism by which iron enters the protein to form the dinuclear (ferroxidase) catalytic site present in every subunit and the mineralized iron core housed within the 24-mer is not well understood. To address this issue, the properties of a catalytically functional assembly variant (E128R/E135R) of Escherichia coli BFR are characterized by a combination of crystallography, site-directed mutagenesis, and kinetics. The three-dimensional structure of the protein (1.8 angstrom resolution) includes two ethylene glycol molecules located on either side of the dinuclear iron site. One of these ethylene glycol molecules is integrated into the surface of the protein that would normally be exposed to solvent, and the other is integrated into the surface of the protein that would normally face the iron core where it is surrounded by the anionic residues Glu(47), Asp(50), and Asp(126). We propose that the sites occupied by these ethylene glycol molecules define regions where iron interacts with the protein, and, in keeping with this proposal, ferroxidase activity decreases significantly when they are replaced with the corresponding amides.	[Wong, Steve G.; Mauk, A. Grant] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; [Tom-Yew, Stacey A. L.; Murphy, Michael E. P.] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; [Wong, Steve G.; Mauk, A. Grant] Univ British Columbia, Ctr Blood Res, Vancouver, BC V6T 1Z3, Canada; [Lewin, Allison; Le Brun, Nick E.; Moore, Geoffrey R.] Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England	University of British Columbia; University of British Columbia; University of British Columbia; University of East Anglia	Mauk, AG (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada.	mauk@interchange.ubc.ca	Murphy, Michael/R-6805-2017	Murphy, Michael/0000-0003-2589-0014; Le Brun, Nick/0000-0001-9780-4061	Canadian Institutes of Health Research/Canadian Blood Services; Canadian Institutes of Health Research [MOP-49597, 83/B14704, BB/D001943/1]; Biotechnology and Biological Sciences Research Council; Canadian Foundation for Innovation to the University of British Columbia Laboratory of Molecular Biophysics; Michael Smith Foundation for Health Sciences; University of British Columbia Laboratory of Molecular Biophysics; United States Department of Energy Office of Basic Energy Sciences and Office of Biological and Environmental Research; National Institutes of Health; National Center for Research Resources; Biomedical Technology Program; National Institute of General Medical Sciences; Biotechnology and Biological Sciences Research Council [BB/D001943/1] Funding Source: researchfish; BBSRC [BB/D001943/1] Funding Source: UKRI	Canadian Institutes of Health Research/Canadian Blood Services(Canadian Institutes of Health Research (CIHR)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Canadian Foundation for Innovation to the University of British Columbia Laboratory of Molecular Biophysics; Michael Smith Foundation for Health Sciences(Michael Smith Foundation for Health Research); University of British Columbia Laboratory of Molecular Biophysics; United States Department of Energy Office of Basic Energy Sciences and Office of Biological and Environmental Research(United States Department of Energy (DOE)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Biomedical Technology Program; National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by a Canadian Institutes of Health Research/Canadian Blood Services partnership grant (to A.G.M.), Canadian Institutes of Health Research Grant MOP-49597 (to M.E.P.M.), and Grants 83/B14704 and BB/D001943/1 from the Biotechnology and Biological Sciences Research Council (to G.R. M. and N.E.L.). This work was also supported in part by a grant from the Canadian Foundation for Innovation to the University of British Columbia Laboratory of Molecular Biophysics, an infrastructure support grant from the Michael Smith Foundation for Health Sciences to the University of British Columbia Centre for Blood Research and the University of British Columbia Laboratory of Molecular Biophysics, and funds from the United States Department of Energy Office of Basic Energy Sciences and Office of Biological and Environmental Research, the National Institutes of Health, the National Center for Research Resources, the Biomedical Technology Program, and the National Institute of General Medical Sciences.	Aitken-Rogers H, 2004, J BIOL INORG CHEM, V9, P161, DOI 10.1007/s00775-003-0504-1; ANDREWS SC, 1995, J BIOL CHEM, V270, P23268, DOI 10.1074/jbc.270.40.23268; Baaghil S, 2003, BIOCHEMISTRY-US, V42, P14047, DOI 10.1021/bi035253u; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bou-Abdallah F, 2002, J BIOL CHEM, V277, P37064, DOI 10.1074/jbc.M205712200; CHEESMAN MR, 1990, NATURE, V346, P771, DOI 10.1038/346771a0; Cobessi D, 2002, ACTA CRYSTALLOGR D, V58, P29, DOI 10.1107/S0907444901017267; Dautant A, 1998, ACTA CRYSTALLOGR D, V54, P16, DOI 10.1107/S0907444997006811; FROLOW F, 1994, NAT STRUCT BIOL, V1, P453, DOI 10.1038/nsb0794-453; FROLOW F, 2001, HDB METALLOPROTEINS, P782; Geiser M, 2001, BIOTECHNIQUES, V31, P88, DOI 10.2144/01311st05; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Kapust RB, 2001, PROTEIN ENG, V14, P993, DOI 10.1093/protein/14.12.993; Kapust RB, 2002, BIOCHEM BIOPH RES CO, V294, P949, DOI 10.1016/S0006-291X(02)00574-0; Kilic MA, 2003, PROTEIN SCI, V12, P1663, DOI 10.1110/ps.0301903; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; LEBRUN NE, 1993, FEBS LETT, V333, P197, DOI 10.1016/0014-5793(93)80404-I; LeBrun NE, 1996, FEBS LETT, V397, P159; LEBRUN NE, 1995, BIOCHEM J, V312, P385, DOI 10.1042/bj3120385; Levi S, 1996, BIOCHEM J, V317, P467, DOI 10.1042/bj3170467; Lewin A, 2005, DALTON T, P3597, DOI 10.1039/b506071k; Liu HL, 2004, FEBS LETT, V573, P93, DOI 10.1016/j.febslet.2004.07.054; Liu JL, 2004, J BIOL CHEM, V279, P42794, DOI 10.1074/jbc.M405008200; Macedo S, 2003, NAT STRUCT BIOL, V10, P285, DOI 10.1038/nsb909; Malone SA, 2004, J AM CHEM SOC, V126, P496, DOI 10.1021/ja036483z; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; STIEFEL EI, 1979, NATURE, V279, P81, DOI 10.1038/279081a0; STIEFEL EI, 1994, ADV EXP MED BIOL, V356, P157; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; Swartz L, 2006, BIOCHEMISTRY-US, V45, P4421, DOI 10.1021/bi060146w; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; van Eerde A, 2006, ACTA CRYSTALLOGR F, V62, P1061, DOI 10.1107/S1744309106039583; Vasil ML, 1999, MOL MICROBIOL, V34, P399, DOI 10.1046/j.1365-2958.1999.01586.x; Yang XO, 2000, BIOCHEMISTRY-US, V39, P4915, DOI 10.1021/bi992631f	35	19	21	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18873	18881		10.1074/jbc.M901747200	http://dx.doi.org/10.1074/jbc.M901747200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19439409	Green Published, hybrid			2022-12-25	WOS:000267711500037
J	Dydensborg, AB; Rose, AAN; Wilson, BJ; Grote, D; Paquet, M; Giguere, V; Siegel, PM; Bouchard, M				Dydensborg, A. B.; Rose, A. A. N.; Wilson, B. J.; Grote, D.; Paquet, M.; Giguere, V.; Siegel, P. M.; Bouchard, M.			GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis	ONCOGENE			English	Article						GATA3; breast cancer; lung metastasis	GENE-EXPRESSION PROFILES; LUMINAL CELL FATE; CARCINOMA IN-SITU; LYMPH-NODE; ESTROGEN-RECEPTOR; LUNG METASTASIS; MAMMARY-GLAND; DIFFERENTIATION; GLYCODELIN; MORPHOGENESIS	The loss of expression of the transcription factor GATA3 in breast tumors has been linked to aggressive tumor development and poor patient survival. In the present work, we address potential roles for GATA3 in breast tumor lung metastasis and progression. Using an aggressive breast cancer cell line, which metastasizes specifically to the lung, we show that GATA3 expression results in reduced tumor outgrowth in the mammary fat pad and lower lung metastatic burden in nude mice. Specifically, GATA3 expression inhibits breast cancer cell expansion inside the lung parenchyma. This phenotype correlates with the ability of GATA3 to negatively regulate the expression of several genes that promote breast cancer lung metastasis (ID1/-3, KRTHB1, LY6E and RARRES3). Conversely, the expression of genes encoding known inhibitors of lung metastasis (DLC1 (deleted in liver cancer 1) and PAEP (progestagen-associated endometrial protein)) is upregulated by GATA3. These data correlate with microarray data from human breast cancer patients, showing a strong correlation between high GATA3 expression and absence of metastases specifically to the lungs. We conclude that GATA3 inhibits primary breast tumor outgrowth and reduces lung metastatic burden by regulating key genes involved in metastatic breast tumor progression. Oncogene (2009) 28, 2634-2642; doi: 10.1038/onc.2009.126; published online 1 June 2009	[Dydensborg, A. B.; Rose, A. A. N.; Wilson, B. J.; Grote, D.; Giguere, V.; Siegel, P. M.; Bouchard, M.] McGill Univ, Dept Biochem, Goodman Canc Ctr, Montreal, PQ H3G 1Y6, Canada; [Paquet, M.] McGill Univ, Comparat Pathol Facil, Dept Med, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Bouchard, M (corresponding author), McGill Univ, Dept Biochem, Goodman Canc Ctr, 1160 Ave Des Pins Ouest, Montreal, PQ H3G 1Y6, Canada.	maxime.bouchard@mcgill.ca	Paquet, Marilene/L-3414-2019; Rose, April/AAR-8222-2020	Paquet, Marilene/0000-0002-3562-4636; Rose, April/0000-0002-9845-4603; Bouchard, Maxime/0000-0002-7619-9680; Giguere, Vincent/0000-0001-9567-3694	Canadian Institutes for Health Research [MOP-84470]; Canderel New Initiative Award; Carlsberg Foundation fellowship [2006_01_0102]; Canadian Institutes for Health Research Cancer Consortium Training Grant Fellowship Award; National Cancer Institute of Canada; Fonds de la Recherche en Sante ' du Que ' bec studentship	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canderel New Initiative Award; Carlsberg Foundation fellowship; Canadian Institutes for Health Research Cancer Consortium Training Grant Fellowship Award(Canadian Institutes of Health Research (CIHR)); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Fonds de la Recherche en Sante ' du Que ' bec studentship	The authors are grateful to Dr Perou (Division of Cancer Epidemiology and Genetics, the National Cancer Institute, MD 20852-7234, USA) for sharing cDNA constructs. The work was supported by the Canadian Institutes for Health Research grant MOP-84470 and a Canderel New Initiative Award to MB. ABD was supported by a fellowship from the Carlsberg Foundation (2006_01_0102) and a Canadian Institutes for Health Research Cancer Consortium Training Grant Fellowship Award. AANR is supported by a studentship from the Fonds de la Recherche en Sante ' du Que ' bec. PS is a research scientist of the National Cancer Institute of Canada. MB holds a Canada Research Chair in Developmental Genetics of the Urogenital System.	Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Buess M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r191; de Kok JB, 2005, LAB INVEST, V85, P154, DOI 10.1038/labinvest.3700208; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043; Grote D, 2006, DEVELOPMENT, V133, P53, DOI 10.1242/dev.02184; Gupta GP, 2007, P NATL ACAD SCI USA, V104, P19506, DOI 10.1073/pnas.0709185104; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hautala LC, 2008, INT J CANCER, V123, P2279, DOI 10.1002/ijc.23773; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jeschke U, 2005, ONCOL REP, V13, P413; JOHNSTON SRD, 2006, HDB METASTATIC BREAS, P232; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Murphy KM, 2005, IMMUNOL RES, V32, P193, DOI 10.1385/IR:32:1-3:193; Ni HH, 2005, ONCOGENE, V24, P6820, DOI 10.1038/sj.onc.1208848; Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755; Parikh P, 2005, J AM COLL SURGEONS, V200, P705, DOI 10.1016/j.jamcollsurg.2004.12.025; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Shabani N, 2005, ANTICANCER RES, V25, P1761; Solomayer EF, 2000, BREAST CANCER RES TR, V59, P271, DOI 10.1023/A:1006308619659; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Voduc D, 2008, CANCER EPIDEM BIOMAR, V17, P365, DOI 10.1158/1055-9965.EPI-06-1090; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1	36	102	105	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2009	28	29					2634	2642		10.1038/onc.2009.126	http://dx.doi.org/10.1038/onc.2009.126			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19483726				2022-12-25	WOS:000268211200002
J	Tubau, E; Lopez-Moliner, J				Tubau, Elisabet; Lopez-Moliner, Joan			Knowing What to Respond in the Future Does Not Cancel the Influence of Past Events	PLOS ONE			English	Article							2-CHOICE REACTION-TIME; CHOICE-REACTION-TIME; AUTOMATIC FACILITATION; EXPLICIT KNOWLEDGE; EXPECTANCY; SEQUENCE; TASKS; ACTIVATION	Everyday tasks seldom involve isolate actions but sequences of them. We can see whether previous actions influence the current one by exploring the response time to controlled sequences of stimuli. Specifically, depending on the response-stimulus temporal interval (RSI), different mechanisms have been proposed to explain sequential effects in two-choice serial response tasks. Whereas an automatic facilitation mechanism is thought to produce a benefit for response repetitions at short RSIs, subjective expectancies are considered to replace the automatic facilitation at longer RSIs, producing a cost-benefit pattern: repetitions are faster after other repetitions but they are slower after alternations. However, there is not direct evidence showing the impact of subjective expectancies on sequential effects. By using a fixed sequence, the results of the reported experiment showed that the repetition effect was enhanced in participants who acquired complete knowledge of the order. Nevertheless, a similar cost-benefit pattern was observed in all participants and in all learning blocks. Therefore, results of the experiment suggest that sequential effects, including the cost-benefit pattern, are the consequence of automatic mechanisms which operate independently of (and simultaneously with) explicit knowledge of the sequence or other subjective expectancies.			Tubau, E (corresponding author), Univ Barcelona, Fac Psicol, Dept Psicol Basica, Barcelona, Catalonia, Spain.	etubau@ub.edu	Tubau, Elisabet/C-6016-2011	Tubau, Elisabet/0000-0002-6632-3772; Lopez-Moliner, Joan/0000-0001-5040-8889				Ayton P, 2004, MEM COGNITION, V32, P1369, DOI 10.3758/BF03206327; BERTELSON P, 1965, NATURE, V206, P217, DOI 10.1038/206217a0; Eliassen JC, 2001, EXP BRAIN RES, V141, P269, DOI 10.1007/s002210100822; Fecteau JH, 2003, NAT REV NEUROSCI, V4, P435, DOI 10.1038/nrn1114; Fecteau JH, 2004, EXP BRAIN RES, V159, P84, DOI 10.1007/s00221-004-1935-9; Hoffmann J, 1997, PSYCHOL RES-PSYCH FO, V60, P87, DOI 10.1007/BF00419682; Huettel SA, 2002, NAT NEUROSCI, V5, P485, DOI 10.1038/nn841; Jentzsch I, 2002, ACTA PSYCHOL, V111, P265, DOI 10.1016/S0001-6918(02)00053-7; Jentzsch I, 2002, PERCEPT PSYCHOPHYS, V64, P1169, DOI 10.3758/BF03194765; KAHNEMAN D, 1982, VARIANTS UNCERTAINTY; KIRBY N, 1980, SEQUENTIAL EFFECTS C; KIRBY NH, 1976, J EXP PSYCHOL HUMAN, V2, P567, DOI 10.1037/0096-1523.2.4.567; MATT J, 1992, J EXP PSYCHOL LEARN, V18, P810, DOI 10.1037/0278-7393.18.4.810; Melis A, 2002, BRAIN COGNITION, V49, P420, DOI 10.1006/brcg.2001.1508; Perruchet P, 2006, J EXP PSYCHOL LEARN, V32, P955, DOI 10.1037/0278-7393.32.5.955; Smulders SFA, 2005, J EXP CHILD PSYCHOL, V90, P208, DOI 10.1016/j.jecp.2004.10.003; Soetens E, 2005, ACTA PSYCHOL, V119, P189, DOI 10.1016/j.actpsy.2005.01.003; Soetens E, 2004, PSYCHOL RES-PSYCH FO, V69, P124, DOI 10.1007/s00426-003-0163-4; Soetens E, 1998, J EXP PSYCHOL HUMAN, V24, P547, DOI 10.1037/0096-1523.24.2.547; SOETENS E, 1985, J EXP PSYCHOL HUMAN, V11, P598, DOI 10.1037/0096-1523.11.5.598; Tubau E, 2004, PSYCHOL RES-PSYCH FO, V68, P55, DOI 10.1007/s00426-003-0139-4; Tubau E, 2007, J EXP PSYCHOL GEN, V136, P43, DOI 10.1037/0096-3445.136.1.43; Whitwell RL, 2008, EXP BRAIN RES, V188, P603, DOI 10.1007/s00221-008-1395-8	23	3	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5607	10.1371/journal.pone.0005607	http://dx.doi.org/10.1371/journal.pone.0005607			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	451SH	19478951	Green Submitted, Green Published, gold			2022-12-25	WOS:000266490000003
J	Agherbi, H; Gaussmann-Wenger, A; Verthuy, C; Chasson, L; Serrano, M; Djabali, M				Agherbi, Hanane; Gaussmann-Wenger, Anne; Verthuy, Christophe; Chasson, Lionel; Serrano, Manuel; Djabali, Malek			Polycomb Mediated Epigenetic Silencing and Replication Timing at the INK4a/ARF Locus during Senescence	PLOS ONE			English	Article							METHYLTRANSFERASE ACTIVITY; MAMMALIAN TRITHORAX; DELAYED REPLICATION; CELLULAR SENESCENCE; GROUP GENE; HISTONE; METHYLATION; MLL; INACTIVATION; DOMAIN	Background: The INK4/ARF locus encodes three tumor suppressor genes (p15(Ink4b), Arf and p16(Ink4a)) and is frequently inactivated in a large number of human cancers. Mechanisms regulating INK4/ARF expression are not fully characterized. Principal Findings: Here we show that in young proliferating embryonic fibroblasts (MEFs) the Polycomb Repressive Complex 2 (PRC2) member EZH2 together with PRC1 members BMI1 and M33 are strongly expressed and localized at the INK4/ARF regulatory domain (RD) identified as a DNA replication origin. When cells enter senescence the binding to RD of both PRC1 and PRC2 complexes is lost leading to a decreased level of histone H3K27 trimethylation (H3K27me3). This loss is accompanied with an increased expression of the histone demethylase Jmjd3 and with the recruitment of the MLL1 protein, and correlates with the expression of the Ink4a/Arf genes. Moreover, we show that the Polycomb protein BMI1 interacts with CDC6, an essential regulator of DNA replication in eukaryotic cells. Finally, we demonstrate that Polycomb proteins and associated epigenetic marks are crucial for the control of the replication timing of the INK4a/ARF locus during senescence. Conclusions: We identified the replication licencing factor CDC6 as a new partner of the Polycomb group member BMI1. Our results suggest that in young cells Polycomb proteins are recruited to the INK4/ARF locus through CDC6 and the resulting silent locus is replicated during late S-phase. Upon senescence, Jmjd3 is overexpressed and the MLL1 protein is recruited to the locus provoking the dissociation of Polycomb from the INK4/ARF locus, its transcriptional activation and its replication during early S-phase. Together, these results provide a unified model that integrates replication, transcription and epigenetics at the INK4/ARF locus.			Agherbi, H (corresponding author), INSERM CNRS Marseille Luminy, Ctr Immunol, Marseille, France.	djabali@ciml.univ-mrs.fr	Serrano, Manuel/H-2634-2015	Serrano, Manuel/0000-0001-7177-9312				AGGER K, 2007, NATURE; Azuara V, 2006, NAT PROTOC, V1, P2171, DOI 10.1038/nprot.2006.353; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Campisi J, 2000, IN VIVO, V14, P183; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Coffee B, 2002, AM J HUM GENET, V71, P923, DOI 10.1086/342931; Core N, 2004, ONCOGENE, V23, P7660, DOI 10.1038/sj.onc.1207998; Core N, 1997, DEVELOPMENT, V124, P721; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; DIMRI GP, 1994, COLD SPRING HARB SYM, V59, P67, DOI 10.1101/SQB.1994.059.01.010; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Gilbert DM, 2002, CURR OPIN CELL BIOL, V14, P377, DOI 10.1016/S0955-0674(02)00326-5; Gonzalez AG, 2006, BIOSYSTEMS, V84, P91, DOI 10.1016/j.biosystems.2005.10.003; Gonzalez S, 2006, NATURE, V440, P702, DOI 10.1038/nature04585; Gonzalez S, 2006, CELL CYCLE, V5, P1382, DOI 10.4161/cc.5.13.2901; Goren A, 2008, GENE DEV, V22, P1319, DOI 10.1101/gad.468308; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; Hansen RS, 1997, P NATL ACAD SCI USA, V94, P4587, DOI 10.1073/pnas.94.9.4587; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; HAYASHI MT, 2009, NAT CELL BIOL; Hernandez-Munoz I, 2005, MOL CELL BIOL, V25, P11047, DOI 10.1128/MCB.25.24.11047-11058.2005; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Katoh-Fukui Y, 1998, NATURE, V393, P688, DOI 10.1038/31482; Klymenko T, 2006, GENE DEV, V20, P1110, DOI 10.1101/gad.377406; Klymenko T, 2004, EMBO REP, V5, P373, DOI 10.1038/sj.embor.7400111; Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Lan F., 2007, NATURE; Matheu A, 2005, J BIOL CHEM, V280, P42433, DOI 10.1074/jbc.M508270200; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Perry P, 2004, CELL CYCLE, V3, P1645; Pietersen AM, 2008, CURR OPIN CELL BIOL, V20, P201, DOI 10.1016/j.ceb.2008.01.004; Ringrose L, 2007, DEVELOPMENT, V134, P223, DOI 10.1242/dev.02723; Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298; Sasaki M, 2006, AM J PATHOL, V169, P831, DOI 10.2353/ajpath.2006.051237; Schoeftner S, 2006, EMBO J, V25, P3110, DOI 10.1038/sj.emboj.7601187; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Schuettengruber B, 2009, PLOS BIOL, V7, P146, DOI 10.1371/journal.pbio.1000013; Sherr CJ, 2005, COLD SH Q B, V70, P129, DOI 10.1101/sqb.2005.70.004; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Takeda S, 2006, GENE DEV, V20, P2397, DOI 10.1101/gad.1449406; Terranova R, 2006, P NATL ACAD SCI USA, V103, P6629, DOI 10.1073/pnas.0507425103; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	53	106	112	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5622	10.1371/journal.pone.0005622	http://dx.doi.org/10.1371/journal.pone.0005622			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448AY	19462008	Green Published, Green Submitted, gold			2022-12-25	WOS:000266234700009
J	Marinho, CRF; Neres, R; Epiphanio, S; Goncalves, LA; Catarino, MB; Penha-Goncalves, C				Marinho, Claudio R. F.; Neres, Rita; Epiphanio, Sabrina; Goncalves, Ligia A.; Catarino, Manuela Beirao; Penha-Goncalves, Carlos			Recrudescent Plasmodium berghei from Pregnant Mice Displays Enhanced Binding to the Placenta and Induces Protection in Multigravida	PLOS ONE			English	Article								Pregnancy-associated malaria (PAM) is associated with placenta pathology and poor pregnancy outcome but the mechanisms that control the malaria parasite expansion in pregnancy are still poorly understood and not amenable for study in human subjects. Here, we used a set of new tools to re-visit an experimental mouse model of pregnancy-induced malaria recrudescence, BALB/c with chronic Plasmodium berghei infection. During pregnancy 60% of the pre-exposed primiparous females showed pregnancy-induced malaria recrudescence and we demonstrated that the recrudescent P. berghei show an unexpected enhancement of the adherence to placenta tissue sections with a marked specificity for CSA. Furthermore, we showed that the intensity of parasitemia in primigravida was quantitatively correlated with the degree of thickening of the placental tissue and up-regulation of inflammation-related genes such as IL10. We also confirmed that the incidence of pregnancy-induced recrudescence, the intensity of the parasitemia peak and the impact on the pregnancy outcome decreased gradually from the first to the third pregnancy. Interestingly, placenta pathology and fetal impairment were also observed at low frequency among non-recrudescent females. Together, the data raise the hypothesis that recrudescent P. berghei displays selected specificity for the placenta tissue enabling on one hand, the triggering of the pathological process underlying PAM and on the other hand, the induction of PAM protection mechanisms that are revealed in subsequent pregnancies. Thus, by exploiting P. berghei pregnancy-induced recrudescence, this experimental system offers a mouse model to study the susceptibility to PAM and the mechanisms of disease protection in multigravida.			Marinho, CRF (corresponding author), Inst Gulbenkian Ciencias, Oeiras, Portugal.	cpenha@igc.gulbenkian.pt	Marinho, Claudio Romero Farias/F-7507-2012; Epiphanio, Sabrina/C-7572-2012; Penha-Goncalves, Carlos/F-4640-2012; Gonçalves, Lígia Antunes/F-6242-2014	Marinho, Claudio Romero Farias/0000-0002-1227-3845; Epiphanio, Sabrina/0000-0001-6094-9750; Gonçalves, Lígia Antunes/0000-0001-9804-6899; Neres, Rita/0000-0003-1794-4377; Penha-Goncalves, Carlos/0000-0001-7225-1907				Ahmed A, 2000, MOL MED, V6, P391, DOI 10.1007/BF03401783; [Anonymous], 2004, STRATEGIC FRAMEWORK; Beeson JG, 2000, NAT MED, V6, P86, DOI 10.1038/71582; Boeuf P, 2008, J INFECT DIS, V197, P757, DOI 10.1086/526521; Bourgeois C, 1997, J CLIN ENDOCR METAB, V82, P3116, DOI 10.1210/jc.82.9.3116; Brabin BJ, 2004, PLACENTA, V25, P359, DOI 10.1016/j.placenta.2003.10.019; Diouf I, 2004, J INFECT DIS, V189, P2235, DOI 10.1086/420791; Epiphanio S, 2008, CELL HOST MICROBE, V3, P331, DOI 10.1016/j.chom.2008.04.003; Fievet N, 2001, J INFECT DIS, V183, P1530, DOI 10.1086/320201; Freyre A, 2006, EXP PARASITOL, V113, P154, DOI 10.1016/j.exppara.2005.12.019; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Fried M, 2006, EXP PARASITOL, V113, P36, DOI 10.1016/j.exppara.2005.12.003; Guyatt HL, 2004, CLIN MICROBIOL REV, V17, P760, DOI 10.1128/CMR.17.4.760-769.2004; Hviid L, 2007, PARASITOLOGY, V134, P1871, DOI 10.1017/S0031182007000121; Hviid L, 2004, PARASITE IMMUNOL, V26, P477, DOI 10.1111/j.0141-9838.2004.00733.x; Janse CJ, 2006, NAT PROTOC, V1, P614, DOI 10.1038/nprot.2006.88; Janse CJ, 2006, NAT PROTOC, V1, P346, DOI 10.1038/nprot.2006.53; JANSE CJ, 1994, METHOD CELL BIOL, V42, P295; Janse CJ, 2006, MOL BIOCHEM PARASIT, V145, P60, DOI 10.1016/j.molbiopara.2005.09.007; Janssen CS, 2002, P ROY SOC B-BIOL SCI, V269, P431, DOI 10.1098/rspb.2001.1903; Kabyemela ER, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-26; Lucchi NW, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-42; Luty AJF, 2000, INFECT IMMUN, V68, P3909, DOI 10.1128/IAI.68.7.3909-3915.2000; MEGNEKOU R, 2009, INFECT IMMUN, V23, P23; Menendez C, 2006, CURR MOL MED, V6, P269, DOI 10.2174/156652406776055186; MENENDEZ C, 1995, PARASITOL TODAY, V11, P178, DOI 10.1016/0169-4758(95)80151-0; Menendez C, 2000, J INFECT DIS, V181, P1740, DOI 10.1086/315449; Muthusamy A, 2004, AM J PATHOL, V164, P2013, DOI 10.1016/S0002-9440(10)63761-3; Muthusamy A, 2007, AM J PATHOL, V170, P1989, DOI 10.2353/ajpath.2007.061238; Neres R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001608; Nosten F, 2004, TRENDS PARASITOL, V20, P425, DOI 10.1016/j.pt.2004.06.007; O'Neil-Dunne I, 2001, INFECT IMMUN, V69, P7487, DOI 10.1128/IAI.69.12.7487-7492.2001; Ordi J, 1998, AM J SURG PATHOL, V22, P1006, DOI 10.1097/00000478-199808000-00011; Othoro C, 2008, INFECT IMMUN, V76, P1678, DOI 10.1128/IAI.01420-07; Phillips RS, 1997, PARASITE IMMUNOL, V19, P427, DOI 10.1046/j.1365-3024.1997.d01-239.x; POELS LG, 1977, EXP PARASITOL, V43, P255, DOI 10.1016/0014-4894(77)90031-5; Rasti N, 2006, P NATL ACAD SCI USA, V103, P13795, DOI 10.1073/pnas.0601519103; Rogerson SJ, 2003, AM J TROP MED HYG, V68, P115, DOI 10.4269/ajtmh.2003.68.1.0680115; Salanti A, 2004, J EXP MED, V200, P1197, DOI 10.1084/jem.20041579; Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x; Schofield L, 2007, IMMUNOL CELL BIOL, V85, P130, DOI 10.1038/sj.icb.7100040; Shulman CE, 2001, TROP MED INT HEALTH, V6, P770, DOI 10.1046/j.1365-3156.2001.00786.x; Staalsoe T, 2001, J INFECT DIS, V184, P618, DOI 10.1086/322809; Steketee RW, 1996, AM J TROP MED HYG, V55, P33, DOI 10.4269/ajtmh.1996.55.33; Van Geertruyden JP, 2004, AM J TROP MED HYG, V71, P35, DOI 10.4269/ajtmh.2004.71.35; VANZON AAJC, 1980, TROPENMED PARASITOL, V31, P402; VANZON AAJC, 1980, INFECT IMMUN, V28, P630; VANZON AAJC, 1985, PARASITOLOGY, V91, P9, DOI 10.1017/S003118200005647X; WALTER PR, 1982, AM J PATHOL, V109, P330	49	26	26	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5630	10.1371/journal.pone.0005630	http://dx.doi.org/10.1371/journal.pone.0005630			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448AY	19461965	gold, Green Submitted, Green Published			2022-12-25	WOS:000266234700017
J	Monkhorst, K; de Hoon, B; Jonkers, I; Achame, EM; Monkhorst, W; Hoogerbrugge, J; Rentmeester, E; Westerhoff, HV; Grosveld, F; Grootegoed, JA; Gribnau, J				Monkhorst, Kim; de Hoon, Bas; Jonkers, Iris; Achame, Eskeatnaf Mulugeta; Monkhorst, Wouter; Hoogerbrugge, Jos; Rentmeester, Eveline; Westerhoff, Hans V.; Grosveld, Frank; Grootegoed, J. Anton; Gribnau, Joost			The Probability to Initiate X Chromosome Inactivation Is Determined by the X to Autosomal Ratio and X Chromosome Specific Allelic Properties	PLOS ONE			English	Article							DNA-REPAIR ENZYME; RED-BLOOD-CELLS; ANTISENSE TRANSCRIPTION; EXTRAEMBRYONIC TISSUES; COUNTING PROCESS; NUCLEAR VOLUME; XIST GENE; TSIX; MICE; UBIQUITIN	Background: In female mammalian cells, random X chromosome inactivation (XCI) equalizes the dosage of X-encoded gene products to that in male cells. XCI is a stochastic process, in which each X chromosome has a probability to be inactivated. To obtain more insight in the factors setting up this probability, we studied the role of the X to autosome (X:A) ratio in initiation of XCI, and have used the experimental data in a computer simulation model to study the cellular population dynamics of XCI. Methodology/Principal Findings: To obtain more insight in the role of the X:A ratio in initiation of XCI, we generated triploid mouse ES cells by fusion of haploid round spermatids with diploid female and male ES cells. These fusion experiments resulted in only XXY triploid ES cells. XYY and XXX ES lines were absent, suggesting cell death related either to insufficient X-chromosomal gene dosage (XYY) or to inheritance of an epigenetically modified X chromosome (XXX). Analysis of active (Xa) and inactive (Xi) X chromosomes in the obtained triploid XXY lines indicated that the initiation frequency of XCI is low, resulting in a mixed population of XaXiY and XaXaY cells, in which the XaXiY cells have a small proliferative advantage. This result, and findings on XCI in diploid and tetraploid ES cell lines with different X:A ratios, provides evidence that the X:A ratio determines the probability for a given X chromosome to be inactivated. Furthermore, we found that the kinetics of the XCI process can be simulated using a probability for an X chromosome to be inactivated that is proportional to the X:A ratio. These simulation studies re-emphasize our hypothesis that the probability is a function of the concentration of an X-encoded activator of XCI, and of X chromosome specific allelic properties determining the threshold for this activator. Conclusions: The present findings reveal that the probability for an X chromosome to be inactivated is proportional to the X:A ratio. This finding supports the presence of an X-encoded activator of the XCI process.			Monkhorst, K (corresponding author), Univ Med Ctr, Dept Reprod & Dev, Erasmus MC, Rotterdam, Netherlands.	j.gribnau@erasmusmc.nl	Westerhoff, Hans V/I-5762-2012; Mulugeta, Eskeatnaf/H-2640-2016; Mulugeta, Eskeatnaf/AAZ-7471-2020	Westerhoff, Hans V/0000-0002-0443-6114; Mulugeta, Eskeatnaf/0000-0003-4045-4835; Mulugeta, Eskeatnaf/0000-0003-4045-4835	Biotechnology and Biological Sciences Research Council [BB/C008219/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Augui S, 2007, SCIENCE, V318, P1632, DOI 10.1126/science.1149420; Baarends WM, 2003, MOL CELL BIOL, V23, P1151, DOI 10.1128/MCB.23.4.1151-1162.2003; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Burgoyne PS, 1995, PHILOS T R SOC B, V350, P253, DOI 10.1098/rstb.1995.0159; CATTANACH BM, 1967, GENETICS, V57, P331; Chadwick LH, 2006, GENETICS, V173, P2103, DOI 10.1534/genetics.105.054882; Clerc P, 1998, NAT GENET, V19, P249, DOI 10.1038/924; DUSART D, 1992, AM J MED GENET, V42, P156, DOI 10.1002/ajmg.1320420204; Gartler SM, 2006, BMC GENET, V7, DOI 10.1186/1471-2156-7-41; Hadjantonakis AK, 2001, GENESIS, V29, P133, DOI 10.1002/gene.1016; Heard E, 1999, MOL CELL BIOL, V19, P3156; HENDRIKSSON P, 1974, ACTA PAEDIATR SCAND, P447; HENERY CC, 1992, J EXP ZOOL, V261, P472, DOI 10.1002/jez.1402610414; HENERY CC, 1993, EUR J MORPHOL, V31, P237; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; Iliopoulos D, 2005, GENET MOL RES, V4, P755; KAUFMAN MH, 1989, CYTOGENET CELL GENET, V50, P98, DOI 10.1159/000132732; Lee JT, 2005, SCIENCE, V309, P768, DOI 10.1126/science.1113673; Lee JT, 1999, P NATL ACAD SCI USA, V96, P3836, DOI 10.1073/pnas.96.7.3836; Lee JT, 1999, CELL, V99, P47, DOI 10.1016/S0092-8674(00)80061-6; Lee JT, 2002, NAT GENET, V32, P195, DOI 10.1038/ng939; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LEISTI J, 1970, SCAND J CLIN LAB INV, V25, P60; Luikenhuis S, 2001, MOL CELL BIOL, V21, P8512, DOI 10.1128/MCB.21.24.8512-8520.2001; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MCMAHON A, 1983, GENET RES, V41, P69, DOI 10.1017/S0016672300021078; Monkhorst K, 2008, CELL, V132, P410, DOI 10.1016/j.cell.2007.12.036; Morey C, 2004, EMBO J, V23, P594, DOI 10.1038/sj.emboj.7600071; Nesterova TB, 2003, GENE DEV, V17, P2177, DOI 10.1101/gad.271203; Nicodemi M, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.108104; Ogawa Y, 2003, MOL CELL, V11, P731, DOI 10.1016/S1097-2765(03)00063-7; Ohhata T, 2008, DEVELOPMENT, V135, P227, DOI 10.1242/dev.008490; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; Roest HP, 2004, MOL CELL BIOL, V24, P5485, DOI 10.1128/MCB.24.12.5485-5495.2004; Sado T, 2001, DEVELOPMENT, V128, P1275; Sado T, 2006, DEVELOPMENT, V133, P4925, DOI 10.1242/dev.02670; SPEIRS S, 1990, GENET RES, V56, P107, DOI 10.1017/S0016672300035175; Sun BK, 2006, MOL CELL, V21, P617, DOI 10.1016/j.molcel.2006.01.028; TAKAGI N, 1983, CELL, V34, P1053, DOI 10.1016/0092-8674(83)90563-9; Turner JMA, 2007, DEVELOPMENT, V134, P1823, DOI 10.1242/dev.000018; UCHIDA IA, 1985, AM J OBSTET GYNECOL, V151, P65, DOI 10.1016/0002-9378(85)90426-0; Ulrich HD, 2005, CHEMBIOCHEM, V6, P1735, DOI 10.1002/cbic.200500139; Vigneau S, 2006, P NATL ACAD SCI USA, V103, P7390, DOI 10.1073/pnas.0602381103; WEBB S, 1992, GENET RES, V59, P205, DOI 10.1017/S0016672300030494; WILLARD HF, 1977, AM J HUM GENET, V29; Wutz A, 2000, MOL CELL, V5, P695, DOI 10.1016/S1097-2765(00)80248-8; Wutz A, 2002, NAT GENET, V30, P167, DOI 10.1038/ng820; Wutz A, 2007, CURR OPIN GENET DEV, V17, P387, DOI 10.1016/j.gde.2007.08.001	53	25	25	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5616	10.1371/journal.pone.0005616	http://dx.doi.org/10.1371/journal.pone.0005616			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19440388	Green Published, gold			2022-12-25	WOS:000266161200016
J	Gao, J; Davidson, MK; Wahls, WP				Gao, Jun; Davidson, Mari K.; Wahls, Wayne P.			Phosphorylation-Independent Regulation of Atf1-Promoted Meiotic Recombination by Stress-Activated, p38 Kinase Spc1 of Fission Yeast	PLOS ONE			English	Article							ATF1 TRANSCRIPTION FACTOR; HOT-SPOT M26; SCHIZOSACCHAROMYCES-POMBE; PROTEIN-KINASE; HISTONE DEACETYLASE; SEXUAL DEVELOPMENT; MISMATCH REPAIR; DNA-SEQUENCE; MATING-TYPE; ADE6 GENE	Background: Stress-activated protein kinases regulate multiple cellular responses to a wide variety of intracellular and extracellular conditions. The conserved, multifunctional, ATF/CREB protein Atf1 (Mts1, Gad7) of fission yeast binds to CRE-like (M26) DNA sites. Atf1 is phosphorylated by the conserved, p38-family kinase Spc1 (Sty1, Phh1) and is required for many Spc1-dependent stress responses, efficient sexual differentiation, and activation of Rec12 (Spo11)-dependent meiotic recombination hotspots like ade6-M26. Methodology/Principal Findings: We sought to define mechanisms by which Spc1 regulates Atf1 function at the ade6-M26 hotspot. The Spc1 kinase was essential for hotspot activity, but dispensable for basal recombination. Unexpectedly, a protein lacking all eleven MAPK phospho-acceptor sites and detectable phosphorylation (Atf1-11M) was fully proficient for hotspot recombination. Furthermore, tethering of Atf1 to ade6 in the chromosome by a heterologous DNA binding domain bypassed the requirement for Spc1 in promoting recombination. Conclusions/Significance: The Spc1 protein kinase regulates the pathway of Atf1-promoted recombination at or before the point where Atf1 binds to chromosomes, and this pathway regulation is independent of the phosphorylation status of Atf1. Since basal recombination is Spc1-independent, the principal function of the Spc1 kinase in meiotic recombination is to correctly position Atf1-promoted recombination at hotspots along chromosomes. We also propose new hypotheses on regulatory mechanisms for shared (e. g., DNA binding) and distinct (e. g., osmoregulatory vs. recombinogenic) activities of multifunctional, stress-activated protein Atf1.			Gao, J (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA.	wahlswaynep@uams.edu	GAO, JUN/K-3981-2014		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013787] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081766, R01GM062244] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES013787, ES13787] Funding Source: Medline; NIGMS NIH HHS [R01 GM081766, R01 GM062244, GM81766, GM62244] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alepuz PM, 2003, EMBO J, V22, P2433, DOI 10.1093/emboj/cdg243; Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; Davidson MK, 2004, J BIOL CHEM, V279, P50857, DOI 10.1074/jbc.M409079200; Davidson MK, 2004, NUCLEIC ACIDS RES, V32, P4400, DOI 10.1093/nar/gkh767; de Nadal E, 2004, NATURE, V427, P370, DOI 10.1038/nature02258; Degols G, 1997, MOL CELL BIOL, V17, P3356, DOI 10.1128/MCB.17.6.3356; Dernburg AF, 1998, CELL, V94, P387, DOI 10.1016/S0092-8674(00)81481-6; Fox ME, 1997, P NATL ACAD SCI USA, V94, P7446, DOI 10.1073/pnas.94.14.7446; Fox ME, 2000, GENETICS, V156, P59; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; Gao J, 2008, NUCLEIC ACIDS RES, V36, P2838, DOI 10.1093/nar/gkn037; GUTZ H, 1971, GENETICS, V69, P331; Gutz H, 1974, HDB GENETICS, P395, DOI 10.1007/978-1-4899-1710-2_25; Hassold T, 2007, HUM MOL GENET, V16, pR203, DOI 10.1093/hmg/ddm243; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kanoh J, 1996, GENES CELLS, V1, P391, DOI 10.1046/j.1365-2443.1996.d01-247.x; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; Kon N, 1998, MOL CELL BIOL, V18, P7575, DOI 10.1128/MCB.18.12.7575; Kon N, 1997, P NATL ACAD SCI USA, V94, P13765, DOI 10.1073/pnas.94.25.13765; Krawchuk MD, 1999, GENETICS, V153, P49; Lawrence CL, 2007, J BIOL CHEM, V282, P5160, DOI 10.1074/jbc.M608526200; Madrid M, 2004, J BIOL CHEM, V279, P41594, DOI 10.1074/jbc.M405509200; Mieczkowski PA, 2007, P NATL ACAD SCI USA, V104, P3955, DOI 10.1073/pnas.0700412104; Mizuno K, 2001, GENETICS, V159, P1467; Neely LA, 2000, MOL CELL BIOL, V20, P6426, DOI 10.1128/MCB.20.17.6426-6434.2000; Nishant KT, 2006, BIOESSAYS, V28, P45, DOI 10.1002/bies.20349; Page SL, 2003, SCIENCE, V301, P785, DOI 10.1126/science.1086605; Paredes V, 2004, YEAST, V21, P593, DOI 10.1002/yea.1128; Petes TD, 2001, NAT REV GENET, V2, P360, DOI 10.1038/35072078; PONTICELLI AS, 1988, GENETICS, V119, P491; PONTICELLI AS, 1989, GENETICS, V123, P45; Pryce D. W., 2009, V5, P1, DOI 10.1159/000166614; Quinn J, 2002, MOL BIOL CELL, V13, P805, DOI 10.1091/mbc.01-06-0288; Reiter W, 2008, J BIOL CHEM, V283, P9945, DOI 10.1074/jbc.M710428200; Romanienko PJ, 1999, GENOMICS, V61, P156, DOI 10.1006/geno.1999.5955; Rudolph C, 1999, MOL CELL BIOL, V19, P241; Sanso M, 2008, EUKARYOT CELL, V7, P826, DOI 10.1128/EC.00465-07; SCHAR P, 1993, GENETICS, V133, P825; SCHUCHERT P, 1991, EMBO J, V10, P2157, DOI 10.1002/j.1460-2075.1991.tb07750.x; Sharif Wallace D, 2002, Cell Chromosome, V1, P1, DOI 10.1186/1475-9268-1-1; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Soto T, 2002, EUR J BIOCHEM, V269, P5056, DOI 10.1046/j.1432-1033.2002.03214.x; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Steiner WW, 2002, MOL CELL, V9, P847, DOI 10.1016/S1097-2765(02)00489-6; Steiner WW, 2005, MOL CELL BIOL, V25, P9054, DOI 10.1128/MCB.25.20.9054-9062.2005; SUNNERHAGEN P, 1993, BIOTECHNIQUES, V14, P18; SZANKASI P, 1988, J MOL BIOL, V204, P917, DOI 10.1016/0022-2836(88)90051-4; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; WAHLS WP, 1994, GENE DEV, V8, P1693, DOI 10.1101/gad.8.14.1693; Wahls WP, 1998, CURR TOP DEV BIOL, V37, P37; Watanabe Y, 1996, MOL CELL BIOL, V16, P704; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; Yamada T, 2004, EMBO J, V23, P1792, DOI 10.1038/sj.emboj.7600138; Yamaguchi Y, 2004, J BIOL CHEM, V279, P15630, DOI 10.1074/jbc.M400355200	57	14	15	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2009	4	5							e5533	10.1371/journal.pone.0005533	http://dx.doi.org/10.1371/journal.pone.0005533			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FX	19436749	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107300003
J	Berthelemy, N; Kerdjoudj, H; Schaaf, P; Prin-Mathieu, C; Lacolley, P; Stoltz, JF; Voegel, JC; Menu, P				Berthelemy, Nicolas; Kerdjoudj, Halima; Schaaf, Pierre; Prin-Mathieu, Christine; Lacolley, Patrick; Stoltz, Jean-Francois; Voegel, Jean-Claude; Menu, Patrick			O-2 Level Controls Hematopoietic Circulating Progenitor Cells Differentiation into Endothelial or Smooth Muscle Cells	PLOS ONE			English	Article							ENGINEERED BLOOD-VESSELS; HUMAN UMBILICAL ARTERIES; PERIPHERAL-BLOOD; HYPOXIA; TRANSPLANTATION; EXPRESSION; CLONING; GRAFTS; GROWTH; MODEL	Background: Recent studies showed that progenitor cells could differentiate into mature vascular cells. The main physiological factors implicated in cell differentiation are specific growth factors. We hypothesized that simply by varying the oxygen content, progenitor cells can be differentiated either in mature endothelial cells (ECs) or contractile smooth muscle cells (SMCs) while keeping exactly the same culture medium. Methodology/Principal Findings: Mononuclear cells were isolated by density gradient were cultivated under hypoxic (5% O-2) or normoxic (21% O-2) environment. Differentiated cells characterization was performed by confocal microscopy examination and flow cytometry analyses. The phenotype stability over a longer time period was also performed. The morphological examination of the confluent obtained cells after several weeks (between 2 and 4 weeks) showed two distinct morphologies: cobblestone shape in normoxia and a spindle like shape in hypoxia. The cell characterization showed that cobblestone cells were positive to ECs markers while spindle like shape cells were positive to contractile SMCs markers. Moreover, after several further amplification (until 3(rd) passage) in hypoxic or normoxic conditions of the previously differentiated SMC, immunofluorescence studies showed that more than 80% cells continued to express SMCs markers whatever the cell environmental culture conditions with a higher contractile markers expression compared to control (aorta SMCs) signature of phenotype stability. Conclusion/Significance: We demonstrate in this paper that in vitro culture of peripheral blood mononuclear cells with specific angiogenic growth factors under hypoxic conditions leads to SMCs differentiation into a contractile phenotype, signature of their physiological state. Moreover after amplification, the differentiated SMC did not reverse and keep their contractile phenotype after the 3(rd) passage performed under hypoxic and normoxic conditions. These aspects are of the highest importance for tissue engineering strategies. These results highlight also the determinant role of the tissue environment in the differentiation process of vascular progenitor cells.			Berthelemy, N (corresponding author), UHP Nancy 1, Bioengn Grp, CNRS, Fac Med,UMR 7561, Vandoeuvre Les Nancy, France.	patrick.menu@medecine.uhp-nancy.fr	Lacolley, Patrick/G-3118-2013	KERDJOUDJ, Halima/0000-0002-8072-9728				Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Babu GJ, 2004, AM J PHYSIOL-CELL PH, V287, pC723, DOI 10.1152/ajpcell.00029.2004; Bach AD, 2003, CLIN PLAST SURG, V30, P589, DOI 10.1016/S0094-1298(03)00077-4; Berthelemy N, 2008, ADV MATER, V20, P2674, DOI 10.1002/adma.200702418; BISSELL MJ, 1987, J CELL SCI, P327; Cha JM, 2006, ARTIF ORGANS, V30, P250, DOI 10.1111/j.1525-1594.2006.00212.x; Chaouat M, 2006, BIOMATERIALS, V27, P5546, DOI 10.1016/j.biomaterials.2006.06.032; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Cramer T, 2004, OSTEOARTHR CARTILAGE, V12, P433, DOI 10.1016/j.joca.2004.02.003; Davie NJ, 2004, AM J PHYSIOL-LUNG C, V286, pL668, DOI 10.1152/ajplung.00108.2003; Davis MJ, 2001, AM J PHYSIOL-HEART C, V280, pH1427, DOI 10.1152/ajpheart.2001.280.4.H1427; FALANGA V, 1991, J INVEST DERMATOL, V97, P634, DOI 10.1111/1523-1747.ep12483126; Gerasimovskaya EV, 2008, ANGIOGENESIS, V11, P169, DOI 10.1007/s10456-007-9087-8; Grayson WL, 2006, J CELL PHYSIOL, V207, P331, DOI 10.1002/jcp.20571; Griese DP, 2003, CIRCULATION, V108, P2710, DOI 10.1161/01.CIR.0000096490.16596.A6; INGBER DE, 1994, INT REV CYTOL, V150, P173; Kerdjoudj H, 2008, J AM COLL CARDIOL, V52, P1589, DOI 10.1016/j.jacc.2008.08.009; Kerdjoudj H, 2007, ADV FUNCT MATER, V17, P2667, DOI 10.1002/adfm.200600795; L'Heureux N, 2006, NAT MED, V12, P361, DOI 10.1038/nm1364; L'Heureux N, 2001, FASEB J, V15, P515, DOI 10.1096/fj.00-0283com; Li SH, 2001, CIRC RES, V89, P517, DOI 10.1161/hh1801.097165; Liu JY, 2007, CARDIOVASC RES, V75, P618, DOI 10.1016/j.cardiores.2007.04.018; Malda J, 2007, TISSUE ENG, V13, P2153, DOI 10.1089/ten.2006.0417; Mellander S, 2005, EUR J VASC ENDOVASC, V30, P63, DOI 10.1016/j.ejvs.2005.02.051; MEYER D, 1991, MAYO CLIN PROC, V66, P516, DOI 10.1016/S0025-6196(12)62394-5; Muto A, 2007, J VASC SURG, V45, p15A, DOI 10.1016/j.jvs.2007.02.061; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; OWENS GK, 1995, PHYSIOL REV, V75, P487; Payne TR, 2007, J AM COLL CARDIOL, V50, P1677, DOI 10.1016/j.jacc.2007.04.100; Reusch P, 1996, CIRC RES, V79, P1046, DOI 10.1161/01.RES.79.5.1046; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; Rzucidlo EM, 2007, J VASC SURG, V45, p25A, DOI 10.1016/j.jvs.2007.03.001; Simon MC, 2008, NAT REV MOL CELL BIO, V9, P285, DOI 10.1038/nrm2354; Simper D, 2002, CIRCULATION, V106, P1199, DOI 10.1161/01.CIR.0000031525.61826.A8; Stenmark KR, 2006, CIRC RES, V99, P675, DOI 10.1161/01.RES.0000243584.45145.3f; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Xie SZ, 2008, J ZHEJIANG UNIV-SC B, V9, P923, DOI 10.1631/jzus.B0820257; Yeh ETH, 2003, CIRCULATION, V108, P2070, DOI 10.1161/01.CIR.0000099501.52718.70	38	22	24	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5514	10.1371/journal.pone.0005514	http://dx.doi.org/10.1371/journal.pone.0005514			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444WA	19436758	Green Submitted, gold, Green Published			2022-12-25	WOS:000266009900007
J	Tsolis, RM; Seshadri, R; Santos, RL; Sangari, FJ; Lobo, JMG; de Jong, MF; Ren, QH; Myers, G; Brinkac, LM; Nelson, WC; Deboy, RT; Angiuoli, S; Khouri, H; Dimitrov, G; Robinson, JR; Mulligan, S; Walker, RL; Elzer, PE; Hassan, KA; Paulsen, IT				Tsolis, Renee M.; Seshadri, Rekha; Santos, Renato L.; Sangari, Felix J.; Garcia Lobo, Juan M.; de Jong, Maarten F.; Ren, Qinghu; Myers, Garry; Brinkac, Lauren M.; Nelson, William C.; DeBoy, Robert T.; Angiuoli, Samuel; Khouri, Hoda; Dimitrov, George; Robinson, Jeffrey R.; Mulligan, Stephanie; Walker, Richard L.; Elzer, Philip E.; Hassan, Karl A.; Paulsen, Ian T.			Genome Degradation in Brucella ovis Corresponds with Narrowing of Its Host Range and Tissue Tropism	PLOS ONE			English	Article								Brucella ovis is a veterinary pathogen associated with epididymitis in sheep. Despite its genetic similarity to the zoonotic pathogens B. abortus, B. melitensis and B. suis, B. ovis does not cause zoonotic disease. Genomic analysis of the type strain ATCC25840 revealed a high percentage of pseudogenes and increased numbers of transposable elements compared to the zoonotic Brucella species, suggesting that genome degradation has occurred concomitant with narrowing of the host range of B. ovis. The absence of genomic island 2, encoding functions required for lipopolysaccharide biosynthesis, as well as inactivation of genes encoding urease, nutrient uptake and utilization, and outer membrane proteins may be factors contributing to the avirulence of B. ovis for humans. A 26.5 kb region of B. ovis ATCC25840 Chromosome II was absent from all the sequenced human pathogenic Brucella genomes, but was present in all of 17 B. ovis isolates tested and in three B. ceti isolates, suggesting that this DNA region may be of use for differentiating B. ovis from other Brucella spp. This is the first genomic analysis of a non-zoonotic Brucella species. The results suggest that inactivation of genes involved in nutrient acquisition and utilization, cell envelope structure and urease may have played a role in narrowing of the tissue tropism and host range of B. ovis.			Tsolis, RM (corresponding author), Univ Calif Davis, Davis, CA 95616 USA.	ipaulsen@cbms.mq.edu.au	Paulsen, Ian T/K-3832-2012; Angiuoli, Samuel V/H-7340-2014; de Lima Santos, Renato/A-1134-2008; Sangari, Félix J/K-9104-2014; Lobo, Juan M Garcia/K-2727-2014; brasileira, Inct Pecuaria/J-9542-2013; Nelson, William C/E-9263-2016; Myers, Garry/E-7708-2011; Hassan, Karl/B-2802-2013	Paulsen, Ian T/0000-0001-9015-9418; de Lima Santos, Renato/0000-0002-4830-0470; Sangari, Félix J/0000-0002-3298-6076; Lobo, Juan M Garcia/0000-0002-9187-0671; Nelson, William C/0000-0002-1873-3929; Myers, Garry/0000-0002-4756-4810; de jong, maarten/0000-0003-2278-286X; Tsolis, Renee/0000-0001-9131-6657; Hassan, Karl/0000-0003-2031-9679; Angiuoli, Samuel/0000-0001-9525-4350	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050553, U01AI049036] Funding Source: NIH RePORTER; NIAID NIH HHS [1U01AI49036-01, R01 AI050553, AI050553] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alcantara RB, 2004, INFECT IMMUN, V72, P4911, DOI 10.1128/IAI.72.8.4911-4917.2004; Allen CA, 1998, INFECT IMMUN, V66, P1008, DOI 10.1128/IAI.66.3.1008-1016.1998; ANDERSON JD, 1965, J GEN MICROBIOL, V38, P109, DOI 10.1099/00221287-38-1-109; Arellano-Reynoso B, 2005, NAT IMMUNOL, V6, P618, DOI 10.1038/ni1202; Bandara AB, 2005, VET MICROBIOL, V109, P95, DOI 10.1016/j.vetmic.2005.05.012; Bandara AB, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-57; BIBERSTEIN EL, 1964, CORNELL VET, V54, P27; Blasco J. M., 1990, Animal brucellosis., P351; Boschiroli ML, 2001, CURR OPIN MICROBIOL, V4, P58, DOI 10.1016/S1369-5274(00)00165-X; Bosse JT, 2000, CAN J VET RES, V64, P145; Brew SD, 1999, VET REC, V144, P483; Briones G, 2001, INFECT IMMUN, V69, P4528, DOI 10.1128/IAI.69.7.4528-4535.2001; BROWN GM, 1973, CORNELL VET, V63, P29; BUDDLE M. B., 1956, JOUR HYG, V54, P351; BURGESS GW, 1982, VET MICROBIOL, V7, P551, DOI 10.1016/0378-1135(82)90049-9; CARPENTER TE, 1987, J AM VET MED ASSOC, V190, P977; Chain PSG, 2005, INFECT IMMUN, V73, P8353, DOI 10.1128/IAI.73.12.8353-8361.2005; Corbel MJ, 1997, EMERG INFECT DIS, V3, P213, DOI 10.3201/eid0302.970219; Crasta OR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002193; DEJONG MF, 2008, MOL MICROBIOL; Delcher AL, 2002, NUCLEIC ACIDS RES, V30, P2478, DOI 10.1093/nar/30.11.2478; Delcher AL, 2007, BIOINFORMATICS, V23, P673, DOI 10.1093/bioinformatics/btm009; Delrue RM, 2005, CELL MICROBIOL, V7, P1151, DOI 10.1111/j.1462-5822.2005.00543.x; Delrue RM, 2001, CELL MICROBIOL, V3, P487, DOI 10.1046/j.1462-5822.2001.00131.x; DelVecchio VG, 2002, P NATL ACAD SCI USA, V99, P443, DOI 10.1073/pnas.221575398; Essenberg RC, 1997, MICROBIOL-UK, V143, P1549, DOI 10.1099/00221287-143-5-1549; EWALT DR, 1994, J VET DIAGN INVEST, V6, P448, DOI 10.1177/104063879400600408; Ficapal A, 1998, SMALL RUMINANT RES, V29, P13, DOI 10.1016/S0921-4488(97)00108-9; Foster G, 2007, INT J SYST EVOL MICR, V57, P2688, DOI 10.1099/ijs.0.65269-0; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Freer E, 1999, INFECT IMMUN, V67, P6181, DOI 10.1128/IAI.67.11.6181-6186.1999; Fretin D, 2005, CELL MICROBIOL, V7, P687, DOI 10.1111/j.1462-5822.2005.00502.x; Godfroid F, 1998, INFECT IMMUN, V66, P5485, DOI 10.1128/IAI.66.11.5485-5493.1998; Grillo MJ, 1999, VET REC, V144, P555, DOI 10.1136/vr.144.20.555; Guzman-Verri C, 2002, P NATL ACAD SCI USA, V99, P12375, DOI 10.1073/pnas.192439399; HALLING SM, 1994, MOL MICROBIOL, V14, P681, DOI 10.1111/j.1365-2958.1994.tb01306.x; Halling SM, 2005, J BACTERIOL, V187, P2715, DOI 10.1128/JB.187.8.2715-2726.2005; Halling SM, 2002, BBA-GENE STRUCT EXPR, V1574, P109, DOI 10.1016/S0167-4781(01)00352-9; Hayes CS, 2003, CELL, V112, P2, DOI 10.1016/S0092-8674(02)01282-5; Hong PC, 2000, INFECT IMMUN, V68, P4102, DOI 10.1128/IAI.68.7.4102-4107.2000; Izadjoo MJ, 2004, INFECT IMMUN, V72, P4031, DOI 10.1128/IAI.72.7.4031-4039.2004; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; KAHN D, 1989, J BACTERIOL, V171, P929, DOI 10.1128/jb.171.2.929-939.1989; Kohler S, 2002, P NATL ACAD SCI USA, V99, P15711, DOI 10.1073/pnas.232454299; Lapaque N, 2006, CELL MICROBIOL, V8, P401, DOI 10.1111/j.1462-5822.2005.00629.x; Lavigne JP, 2005, INFECT IMMUN, V73, P7779, DOI 10.1128/IAI.73.11.7779-7783.2005; Loisel-Meyer S, 2006, INFECT IMMUN, V74, P1973, DOI 10.1128/IAI.74.3.1973-1976.2006; MAGHALHAES A, 1996, PESQUISA VETERIINARI, V16, P75; Spera JM, 2006, P NATL ACAD SCI USA, V103, P16514, DOI 10.1073/pnas.0603362103; MARQUIS H, 1993, INFECT IMMUN, V61, P3785, DOI 10.1128/IAI.61.9.3785-3790.1993; Martin-Martin AI, 2008, MICROBES INFECT, V10, P706, DOI 10.1016/j.micinf.2008.02.013; McQuiston JR, 1999, INFECT IMMUN, V67, P3830, DOI 10.1128/IAI.67.8.3830-3835.1999; MEYER ME, 1969, AM J VET RES, V30, P1757; MichauxCharachon S, 1997, J BACTERIOL, V179, P3244, DOI 10.1128/jb.179.10.3244-3249.1997; Miller WG, 1999, J ZOO WILDLIFE MED, V30, P100; Monir Madkour M., 2001, MADKOURS BRUCELLOSIS; Moreno E, 2002, P NATL ACAD SCI USA, V99, P1, DOI 10.1073/pnas.022622699; Myers GSA, 2007, NAT BIOTECHNOL, V25, P569, DOI 10.1038/nbt1302; O'Callaghan D, 1999, MOL MICROBIOL, V33, P1210, DOI 10.1046/j.1365-2958.1999.01569.x; OUAHRANI S, 1993, J GEN MICROBIOL, V139, P3265, DOI 10.1099/00221287-139-12-3265; Paulsen IT, 2002, P NATL ACAD SCI USA, V99, P13148, DOI 10.1073/pnas.192319099; Rajashekara G, 2004, J BACTERIOL, V186, P5040, DOI 10.1128/jb.186.15.5040-5051.2004; Robles CA, 1998, VET RES COMMUN, V22, P435, DOI 10.1023/A:1006158514414; Rouot B, 2003, INFECT IMMUN, V71, P1075, DOI 10.1128/IAI.71.3.1075-1082.2003; Salcedo SP, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040021; Sangari FJ, 2007, INFECT IMMUN, V75, P774, DOI 10.1128/IAI.01244-06; Sangari FJ, 2000, MICROBIOL-UK, V146, P487, DOI 10.1099/00221287-146-2-487; SERGEANT ESG, 1994, NEW ZEAL VET J, V42, P97, DOI 10.1080/00480169.1994.35795; Sieira R, 2000, J BACTERIOL, V182, P4849, DOI 10.1128/JB.182.17.4849-4855.2000; SMITH H, 1962, NATURE, V193, P47, DOI 10.1038/193047a0; Sohn AH, 2003, EMERG INFECT DIS, V9, P485, DOI 10.3201/eid0904.020576; Sola-Landa A, 1998, MOL MICROBIOL, V29, P125, DOI 10.1046/j.1365-2958.1998.00913.x; SPERRY JF, 1975, J BACTERIOL, V124, P391, DOI 10.1128/JB.124.1.391-397.1975; Tettelin H, 1999, GENOMICS, V62, P500, DOI 10.1006/geno.1999.6048; TORRES EDN, 1997, VET MEXICO, V28, P241; Tsolis RM, 2002, P NATL ACAD SCI USA, V99, P12503, DOI 10.1073/pnas.212508599; VERGER JM, 1985, INT J SYST BACTERIOL, V35, P292, DOI 10.1099/00207713-35-3-292; Vizcaino N, 1996, INFECT IMMUN, V64, P3744; Vizcaino N, 2004, MICROBES INFECT, V6, P821, DOI 10.1016/j.micinf.2004.04.009; WALKER RL, 1986, J AM VET MED ASSOC, V188, P393; Xi HL, 2000, J BACTERIOL, V182, P5332, DOI 10.1128/JB.182.19.5332-5341.2000; Yost CK, 2006, MICROBIOL-SGM, V152, P2061, DOI 10.1099/mic.0.28938-0	82	91	424	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5519	10.1371/journal.pone.0005519	http://dx.doi.org/10.1371/journal.pone.0005519			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444WA	19436743	gold, Green Published, Green Submitted			2022-12-25	WOS:000266009900012
J	Fazal, F; Bijli, KM; Minhajuddin, M; Rein, T; Finkelstein, JN; Rahman, A				Fazal, Fabeha; Bijli, Kaiser M.; Minhajuddin, Mohd; Rein, Theo; Finkelstein, Jacob N.; Rahman, Arshad			Essential Role of Cofilin-1 in Regulating Thrombin-induced RelA/p65 Nuclear Translocation and Intercellular Adhesion Molecule 1 (ICAM-1) Expression in Endothelial Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIN DYNAMICS; PROTEIN-KINASE; TRANSCRIPTIONAL REGULATION; LIM-KINASE; F-ACTIN; BINDING PROTEINS; IN-VIVO; ACTIVATION; PHOSPHORYLATION	Activation of RhoA/Rho-associated kinase ( ROCK) pathway and the associated changes in actin cytoskeleton induced by thrombin are crucial for activation of NF-kappa B and expression of its target gene ICAM-1 in endothelial cells. However, the events acting downstream of RhoA/ROCK to mediate these responses remain unclear. Here, we show a central role of cofilin-1, an actin-binding protein that promotes actin depolymerization, in linking RhoA/ROCK pathway to dynamic alterations in actin cytoskeleton that are necessary for activation of NF-kappa B and thereby expression of ICAM-1 in these cells. Stimulation of human umbilical vein endothelial cells with thrombin resulted in Ser(3) phosphorylation/inactivation of cofilin and formation of actin stress fibers in a ROCK-dependent manner. RNA interference knockdown of cofilin-1 stabilized the actin filaments and inhibited thrombin- and RhoA-induced NF-kappa B activity. Similarly, constitutively inactive mutant of cofilin-1 (Cof1-S3D), known to stabilize the actin cytoskeleton, inhibited NF-kappa B activity by thrombin. Overexpression of wild type cofilin-1 or constitutively active cofilin-1 mutant (Cof1-S3A), known to destabilize the actin cytoskeleton, also impaired thrombin- induced NF-kappa B activity. Additionally, depletion of cofilin-1 was associated with a marked reduction in ICAM-1 expression induced by thrombin. The effect of cofilin-1 depletion on NF-kappa B activity and ICAM-1 expression occurred downstream of I kappa B alpha degradation and was a result of impaired RelA/p65 nuclear translocation and consequently, RelA/p65 binding to DNA. Together, these data show that cofilin-1 occupies a central position in RhoA-actin pathway mediating nuclear translocation of RelA/p65 and expression of ICAM-1 in endothelial cells.	[Fazal, Fabeha; Bijli, Kaiser M.; Minhajuddin, Mohd; Finkelstein, Jacob N.; Rahman, Arshad] Univ Rochester, Sch Med & Dent, Dept Pediat Neonatol, Lung Biol & Dis Program, Rochester, NY 14642 USA; [Rein, Theo] Max Planck Inst Psychiat, D-80804 Munich, Germany	University of Rochester; Max Planck Society	Fazal, F (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pediat, Box 850,601 Elmwood Ave, Rochester, NY 14642 USA.	Fabeha_Fazal@urmc.rochester.edu		Rein, Theo/0000-0003-2850-4289	National Institutes of Health [HL67424, ES-01247]; American Lung Association [FA9550-04-1-0430]; Environmental Protection Agency [R-827354]; National Science Foundation [EEC-0506968]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067424] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lung Association; Environmental Protection Agency(United States Environmental Protection Agency); National Science Foundation(National Science Foundation (NSF)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported, in whole or in part, by National Institutes of Health Grants HL67424 and ES-01247. This work was also supported by a biomedical research grant from the American Lung Association, Air Force Office of Scientific Research Grant FA9550-04-1-0430, Environmental Protection Agency Science to Achieve Results Particulate Matter Center Grant R-827354, and National Science Foundation Grant EEC-0506968.	Aird WC, 2005, CRIT CARE CLIN, V21, P417, DOI 10.1016/j.ccc.2005.04.004; Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Anwar KN, 2004, J IMMUNOL, V173, P6965, DOI 10.4049/jimmunol.173.11.6965; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bamburg JR, 2002, TRENDS CELL BIOL, V12, P598, DOI 10.1016/S0962-8924(02)02404-2; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Bijli KM, 2008, J BIOL CHEM, V283, P14674, DOI 10.1074/jbc.M802094200; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Chen H, 2000, TRENDS BIOCHEM SCI, V25, P19, DOI 10.1016/S0968-0004(99)01511-X; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Doerschuk CM, 2000, AM J RESP CELL MOL, V23, P133, DOI 10.1165/ajrcmb.23.2.f193; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Fazal F, 2005, MOL CELL BIOL, V25, P6259, DOI 10.1128/MCB.25.14.6259-6266.2005; Fazal F, 2007, J BIOL CHEM, V282, P3940, DOI 10.1074/jbc.M608074200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; Gorovoy M, 2005, J BIOL CHEM, V280, P26533, DOI 10.1074/jbc.M502921200; Hatziapostolou M, 2008, CANCER RES, V68, P1851, DOI 10.1158/0008-5472.CAN-07-5793; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawkitinarong K, 2004, AM J RESP CELL MOL, V31, P517, DOI 10.1165/rcmb.2003-0432OC; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Laroche G, 2005, J BIOL CHEM, V280, P23215, DOI 10.1074/jbc.M414071200; Lawler S, 1999, CURR BIOL, V9, pR800, DOI 10.1016/S0960-9822(99)80493-X; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Lin T, 2003, CIRC RES, V92, P1296, DOI 10.1161/01.RES.0000078780.65824.8B; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Minami T, 2005, TRENDS CARDIOVAS MED, V15, P174, DOI 10.1016/j.tcm.2005.06.002; Minhajuddin M, 2005, J IMMUNOL, V174, P5823, DOI 10.4049/jimmunol.174.9.5823; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Pandey D, 2006, BLOOD, V107, P575, DOI 10.1182/blood-2004-11-4377; Posern G, 2004, EMBO J, V23, P3973, DOI 10.1038/sj.emboj.7600404; Rahman A, 1999, J IMMUNOL, V162, P5466; Rahman A, 1999, MOL PHARMACOL, V55, P575; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Redondo PC, 2006, BLOOD, V107, P973, DOI 10.1182/blood-2005-05-2015; Ruegg J, 2004, MOL CELL BIOL, V24, P9371, DOI 10.1128/MCB.24.21.9371-9382.2004; Schouten M, 2008, J LEUKOCYTE BIOL, V83, P536, DOI 10.1189/jlb.0607373; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200; Theriot JA, 1997, J CELL BIOL, V136, P1165, DOI 10.1083/jcb.136.6.1165; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Volovyk ZM, 2006, J BIOL CHEM, V281, P9773, DOI 10.1074/jbc.M511435200; WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003	62	50	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					21047	21056		10.1074/jbc.M109.016444	http://dx.doi.org/10.1074/jbc.M109.016444			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19483084	Green Published, hybrid			2022-12-25	WOS:000268316100067
J	Rucktaschel, R; Thoms, S; Sidorovitch, V; Halbach, A; Pechlivanis, M; Volkmer, R; Alexandrov, K; Kuhlmann, J; Rottensteiner, H; Erdmann, R				Rucktaeschel, Robert; Thoms, Sven; Sidorovitch, Vadim; Halbach, Andre; Pechlivanis, Markos; Volkmer, Rudolf; Alexandrov, Kirill; Kuhlmann, Juergen; Rottensteiner, Hanspeter; Erdmann, Ralf			Farnesylation of Pex19p Is Required for Its Structural Integrity and Function in Peroxisome Biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; MEMBRANE-PROTEINS; MOLECULAR CHARACTERIZATION; ENDOPLASMIC-RETICULUM; IMPORT RECEPTOR; POTENTIAL ROLE; LOCALIZATION; YEAST; IDENTIFICATION	The conserved CaaX box peroxin Pex19p is known to be modified by farnesylation. The possible involvement of this lipid modification in peroxisome biogenesis, the degree to which Pex19p is farnesylated, and its molecular function are unknown or controversial. We resolve these issues by first showing that the complete pool of Pex19p is processed by farnesyltransferase in vivo and that this modification is independent of peroxisome induction or the Pex19p membrane anchor Pex3p. Furthermore, genomic mutations of PEX19 prove that farnesylation is essential for proper matrix protein import into peroxisomes, which is supposed to be caused indirectly by a defect in peroxisomal membrane protein (PMP) targeting or stability. This assumption is corroborated by the observation that mutants defective in Pex19p farnesylation are characterized by a significantly reduced steady-state concentration of prominent PMPs (Pex11p, Ant1p) but also of essential components of the peroxisomal import machinery, especially the RING peroxins, which were almost depleted from the importomer. In vivo and in vitro, PMP recognition is only efficient when Pex19p is farnesylated with affinities differing by a factor of 10 between the non-modified and wild-type forms of Pex19p. Farnesylation is likely to induce a conformational change in Pex19p. Thus, isoprenylation of Pex19p contributes to substrate membrane protein recognition for the topogenesis of PMPs, and our results highlight the importance of lipid modifications in protein-protein interactions.	[Erdmann, Ralf] Ruhr Univ Bochum, Inst Physiol Chem, Dept Syst Biochem, Abt Syst Biochem, D-44780 Bochum, Germany; [Sidorovitch, Vadim; Alexandrov, Kirill] Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44227 Dortmund, Germany; [Volkmer, Rudolf] Inst Med Immunol, Charite, Dept Mol Lib, D-10115 Berlin, Germany	Ruhr University Bochum; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Erdmann, R (corresponding author), Ruhr Univ Bochum, Inst Physiol Chem, Dept Syst Biochem, Abt Syst Biochem, Univ Str 150, D-44780 Bochum, Germany.	ralf.erdmann@rub.de	Thoms, Sven/K-4530-2019; Thoms, Sven/B-5763-2013; Alexandrov, Kirill/A-5830-2013	Thoms, Sven/0000-0003-3018-6363; Alexandrov, Kirill/0000-0002-0957-6511; Volkmer, Rudolf/0000-0003-4710-1143	Deutsche Forschungsgemeinschaft [SFB642]; FP6 EU Project [LSHG-CT-2004-512018]; Fonds der Chemischen Industrie	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); FP6 EU Project; Fonds der Chemischen Industrie(Fonds der Chemischen IndustrieEuropean Commission)	This work was supported by Deutsche Forschungsgemeinschaft Grant SFB642, by FP6 EU Project LSHG-CT-2004-512018, and by the Fonds der Chemischen Industrie.	Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Banerjee SK, 2005, MOL BIOCHEM PARASIT, V142, P47, DOI 10.1016/j.molbiopara.2005.03.008; Birschmann I, 2003, MOL BIOL CELL, V14, P2226, DOI 10.1091/mbc.E02-11-0752; Boudeau J, 2003, FEBS LETT, V546, P159, DOI 10.1016/S0014-5793(03)00642-2; BRAUN A, 1994, GENE, V146, P291, DOI 10.1016/0378-1119(94)90308-5; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Dursina B, 2006, J AM CHEM SOC, V128, P2822, DOI 10.1021/ja052196e; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; ERDMANN R, 1994, YEAST, V10, P1173, DOI 10.1002/yea.320100905; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; Fang Y, 2004, J CELL BIOL, V164, P863, DOI 10.1083/jcb.200311131; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fransen M, 2005, J MOL BIOL, V346, P1275, DOI 10.1016/j.jmb.2005.01.013; Fransen M, 2004, J BIOL CHEM, V279, P12615, DOI 10.1074/jbc.M304941200; Fransen M, 2002, MOL CELL PROTEOMICS, V1, P243, DOI 10.1074/mcp.M100025-MCP200; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; Gotte K, 1998, MOL CELL BIOL, V18, P616; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Gurvitz A, 1997, J BIOL CHEM, V272, P22140, DOI 10.1074/jbc.272.35.22140; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; Hoepfner D, 2005, CELL, V122, P85, DOI 10.1016/j.cell.2005.04.025; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; JAMES GL, 1994, J BIOL CHEM, V269, P14182; Jones JM, 2004, J CELL BIOL, V164, P57, DOI 10.1083/jcb.200304111; Kals M, 2005, YEAST, V22, P213, DOI 10.1002/yea.1204; Kammerer S, 1997, GENOMICS, V45, P200, DOI 10.1006/geno.1997.4914; Keeling PJ, 2000, NATURE, V405, P635, DOI 10.1038/35015167; Kho Y, 2004, P NATL ACAD SCI USA, V101, P12479, DOI 10.1073/pnas.0403413101; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; Lambkin GR, 2001, MOL BIOL CELL, V12, P3353, DOI 10.1091/mbc.12.11.3353; Magee T, 2005, CURR OPIN CELL BIOL, V17, P190, DOI 10.1016/j.ceb.2005.02.003; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Mayerhofer PU, 2002, BIOCHEM BIOPH RES CO, V291, P1180, DOI 10.1006/bbrc.2002.6568; Muntau AC, 2003, EUR J CELL BIOL, V82, P333, DOI 10.1078/0171-9335-00325; Otzen M, 2004, J BIOL CHEM, V279, P19181, DOI 10.1074/jbc.M314275200; PARK K, 1992, PROTEIN SCI, V1, P1032, DOI 10.1002/pro.5560010809; Platta H, 2004, BIOCHEM J, V384, P37, DOI 10.1042/BJ20040572; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Reid TS, 2004, J MOL BIOL, V343, P417, DOI 10.1016/j.jmb.2004.08.056; Reineke U, 2001, CURR OPIN BIOTECH, V12, P59, DOI 10.1016/S0958-1669(00)00178-6; Rost B, 1996, METHOD ENZYMOL, V266, P525; Rottensteiner H, 2004, MOL BIOL CELL, V15, P3406, DOI 10.1091/mbc.E04-03-0188; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Schafer A, 2004, MOL CELL BIOL, V24, P8895, DOI 10.1128/MCB.24.20.8895-8906.2004; Schliebs W, 2004, CURR BIOL, V14, pR397, DOI 10.1016/j.cub.2004.05.017; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Sebti SM, 2003, NAT REV CANCER, V3, P945, DOI 10.1038/nrc1234; Shibata H, 2004, J BIOL CHEM, V279, P38486, DOI 10.1074/jbc.M402204200; SIMON HU, 1994, BIOCHEM J, V297, P389, DOI 10.1042/bj2970389; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1529, P203, DOI 10.1016/S1388-1981(00)00149-9; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sreerama N, 2004, PROTEIN SCI, V13, P100, DOI 10.1110/ps.03258404; Thoms S, 2005, MOL B INT U, P125; Vastiau IMK, 2006, CELL MOL LIFE SCI, V63, P1686, DOI 10.1007/s00018-006-6110-y; Yalovsky S, 1999, TRENDS PLANT SCI, V4, P439, DOI 10.1016/S1360-1385(99)01492-2; Young SG, 2005, J LIPID RES, V46, P2531, DOI 10.1194/jlr.R500011-JLR200; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	66	37	37	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20885	20896		10.1074/jbc.M109.016584	http://dx.doi.org/10.1074/jbc.M109.016584			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19451657	Green Published, hybrid			2022-12-25	WOS:000268316100052
J	Tallack, MR; Keys, JR; Humbert, PO; Perkins, AC				Tallack, Michael R.; Keys, Janelle R.; Humbert, Patrick O.; Perkins, Andrew C.			EKLF/KLF1 Controls Cell Cycle Entry via Direct Regulation of E2f2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; HEMOGLOBIN-STABILIZING PROTEIN; KINASE INHIBITOR P18(INK4C); TRANSCRIPTION FACTOR GATA-1; EMBRYONIC STEM-CELLS; EKLF-DEFICIENT MICE; BETA-THALASSEMIA; GENE-EXPRESSION; NULL MICE; ERYTHROPOIESIS	Differentiation of erythroid cells requires precise control over the cell cycle to regulate the balance between cell proliferation and differentiation. The zinc finger transcription factor, erythroid Kruppel-like factor (EKLF/KLF1), is essential for proper erythroid cell differentiation and regulates many erythroid genes. Here we show that loss of EKLF leads to aberrant entry into S-phase of the cell cycle during both primitive and definitive erythropoiesis. This cell cycle defect was associated with a significant reduction in the expression levels of E2f2 and E2f4, key factors necessary for the induction of S-phase gene expression and erythropoiesis. We found and validated novel intronic enhancers in both the E2f2 and E2f4 genes, which contain conserved CACC, GATA, and E-BOX elements. The E2f2 enhancer was occupied by EKLF in vivo. Furthermore, we were able to partially restore cell cycle dynamics in EKLF-/- fetal liver upon additional genetic depletion of Rb, establishing a genetic causal link between reduced E2f2 and the EKLF cell cycle defect. Finally, we propose direct regulation of the E2f2 enhancer is a generic mechanism by which many KLFs regulate proliferation and differentiation.	[Tallack, Michael R.; Keys, Janelle R.; Perkins, Andrew C.] Univ Queensland, Inst Mol Biosci, Div Mol Genet & Dev, Brisbane, Qld 4072, Australia; [Humbert, Patrick O.] Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, Melbourne, Vic 3002, Australia	University of Queensland; Peter Maccallum Cancer Center	Perkins, AC (corresponding author), Univ Queensland, Inst Mol Biosci, Div Mol Genet & Dev, St Lucia, Qld 4072, Australia.	a.perkins@imb.uq.edu.au	Tallack, Michael/A-4760-2010; Perkins, Andrew C/M-3216-2014; Humbert, Patrick O/L-4264-2016; Perkins, Andrew/X-4180-2019; Perkins, Andrew/AAJ-9696-2020	Perkins, Andrew C/0000-0003-3644-7093; Humbert, Patrick O/0000-0002-1366-6691; Perkins, Andrew/0000-0003-3644-7093; Tallack, Michael/0000-0002-9991-670X	Cancer Council Queensland [519718]; Australian Research Council [DP0770471]	Cancer Council Queensland(Cancer Council Queensland); Australian Research Council(Australian Research Council)	This work was supported by Cancer Council Queensland Grant 519718 (to A.C.P.) and Australian Research Council Discovery Grant DP0770471 (to A.C.P.).	Blais A, 2002, J BIOL CHEM, V277, P31679, DOI 10.1074/jbc.M204554200; Bouilloux F, 2008, BLOOD, V112, P576, DOI 10.1182/blood-2007-07-098996; Bruce SJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-365; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Clark AJ, 2004, BLOOD, V104, P1324, DOI 10.1182/blood-2004-02-0618; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Coghill E, 2001, BLOOD, V97, P1861, DOI 10.1182/blood.V97.6.1861; CROSSLEY M, 1994, J BIOL CHEM, V269, P15440; Dirlam A, 2007, MOL CELL BIOL, V27, P8713, DOI 10.1128/MCB.01118-07; Drissen R, 2005, MOL CELL BIOL, V25, P5205, DOI 10.1128/MCB.25.12.5205-5214.2005; FENG WC, 1994, J BIOL CHEM, V269, P1493; Frontelo P, 2007, BLOOD, V110, P3871, DOI 10.1182/blood-2007-03-082065; Funnell APW, 2007, MOL CELL BIOL, V27, P2777, DOI 10.1128/MCB.01658-06; Gordon CT, 2005, BBA-GENE STRUCT EXPR, V1729, P74, DOI 10.1016/j.bbaexp.2005.03.004; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; Hodge D, 2006, BLOOD, V107, P3359, DOI 10.1182/blood-2005-07-2888; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiang JM, 2008, NAT CELL BIOL, V10, P353, DOI 10.1038/ncb1698; Karolchik D, 2008, NUCLEIC ACIDS RES, V36, pD773, DOI 10.1093/nar/gkm966; Keys JR, 2007, BRIT J HAEMATOL, V136, P150, DOI 10.1111/j.1365-2141.2006.06381.x; Kinross KM, 2006, BLOOD, V108, P886, DOI 10.1182/blood-2005-09-008656; Koury MJ, 2002, CURR OPIN HEMATOL, V9, P93, DOI 10.1097/00062752-200203000-00002; Lavia P, 1999, BIOESSAYS, V21, P221; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Li FX, 2003, MOL CELL BIOL, V23, P3607, DOI 10.1128/MCB.23.10.3607-3622.2003; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Nilson DG, 2006, EXP HEMATOL, V34, P705, DOI 10.1016/j.exphem.2006.02.018; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Ovcharenko I, 2004, NUCLEIC ACIDS RES, V32, pW280, DOI 10.1093/nar/gkh355; PERKINS AC, 1995, NATURE, V375, P318; Pilon AM, 2006, MOL CELL BIOL, V26, P4368, DOI 10.1128/MCB.02216-05; Pilon AM, 2008, MOL CELL BIOL, V28, P7394, DOI 10.1128/MCB.01087-08; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Rylski M, 2003, MOL CELL BIOL, V23, P5031, DOI 10.1128/MCB.23.14.5031-5042.2003; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Siatecka M, 2007, MOL CELL BIOL, V27, P8547, DOI 10.1128/MCB.00589-07; Surinya KH, 1998, J BIOL CHEM, V273, P16798, DOI 10.1074/jbc.273.27.16798; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tallack MR, 2007, J MOL BIOL, V369, P313, DOI 10.1016/j.jmb.2007.02.109; van Vliet J, 2006, GENOMICS, V87, P474, DOI 10.1016/j.ygeno.2005.12.011; Walkley CR, 2007, CELL, V129, P1081, DOI 10.1016/j.cell.2007.03.055; Wang H, 2006, GENOME RES, V16, P1480, DOI 10.1101/gr.5353806; Welch JJ, 2004, BLOOD, V104, P3136, DOI 10.1182/blood-2004-04-1603; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417	48	56	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20966	20974		10.1074/jbc.M109.006346	http://dx.doi.org/10.1074/jbc.M109.006346			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19457859	Green Published, hybrid			2022-12-25	WOS:000268316100060
J	Dickey, DM; Yoder, AR; Potter, LR				Dickey, Deborah M.; Yoder, Andrea R.; Potter, Lincoln R.			A Familial Mutation Renders Atrial Natriuretic Peptide Resistant to Proteolytic Degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL NEUTRAL ENDOPEPTIDASE; CLEARANCE RECEPTOR; HEART-FAILURE; RAT-KIDNEY; CYCLASE; EXPRESSION; MEMBRANES; DEPHOSPHORYLATION; FIBRILLATION; SELECTIVITY	A heterozygous frameshift mutation causing a 12-amino acid extension to the C terminus of atrial natriuretic peptide (ANP) was recently genetically linked to patients with familial atrial fibrillation (Hodgson-Zingman, D. M., Karst, M. L., Zingman, L. V., Heublein, D. M., Darbar, D., Herron, K. J., Ballew, J. D., de Andrade, M., Burnett, J. C., Jr., and Olson, T. M. ( 2008) N. Engl. J. Med. 359, 158-165). The frameshift product (fsANP), but not wild-type ANP (wtANP), was elevated in the serum of affected patients, but the molecular basis for the elevated peptide concentrations was not determined. Here, we measured the ability of fsANP to interact with natriuretic peptide receptors and to be proteolytically degraded. fsANP and wtANP bound and activated human NPR-A and NPR-C similarly, whereas fsANP had a slightly increased efficacy for human NPR-B. Proteolytic susceptibility was addressed with novel bioassays that measure the time required for kidney membranes or purified neutral endopeptidase to abolish ANP-dependent activation of NPR-A. The half-life of fsANP was markedly greater than that of wtANP in both assays. Additional membrane proteolysis studies indicated that wtANP and fsANP are preferentially degraded by neutral endopeptidase and serine peptidases, respectively. These data indicate that the familial ANP mutation associated with atrial fibrillation has only minor effects on natriuretic peptide receptor interactions but markedly modifies peptide proteolysis.	[Dickey, Deborah M.; Potter, Lincoln R.] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; [Yoder, Andrea R.; Potter, Lincoln R.] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Potter, LR (corresponding author), Univ Minnesota Twin Cities, 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	potter@umn.edu			Graduate School of the University of Minnesota; 3M Corporation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066397] Funding Source: NIH RePORTER	Graduate School of the University of Minnesota(University of Minnesota System); 3M Corporation(3M); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by a grant-in-aid from the Graduate School of the University of Minnesota ( to L. R. P.) and in part by a fellowship from the 3M Corporation ( to A. R. Y.).	Bryan PM, 2007, AM J PHYSIOL-RENAL, V292, pF1636, DOI 10.1152/ajprenal.00418.2006; Bryan PM, 2002, J BIOL CHEM, V277, P16041, DOI 10.1074/jbc.M110626200; Bukowska A, 2008, EUROPACE, V10, P1212, DOI 10.1093/europace/eun206; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CROZIER I, 1993, PACE, V16, P738, DOI 10.1111/j.1540-8159.1993.tb01653.x; Dickey DM, 2008, J BIOL CHEM, V283, P35003, DOI 10.1074/jbc.M804538200; FULLER F, 1988, J BIOL CHEM, V263, P9395; Hodgson-Zingman DM, 2008, NEW ENGL J MED, V359, P158, DOI 10.1056/NEJMoa0706300; KENNY AJ, 1988, FEBS LETT, V232, P1, DOI 10.1016/0014-5793(88)80375-2; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; Kishimoto I, 2001, CAN J PHYSIOL PHARM, V79, P715, DOI 10.1139/cjpp-79-8-715; Kishimoto I, 1996, P NATL ACAD SCI USA, V93, P6215, DOI 10.1073/pnas.93.12.6215; Knecht M, 2002, LIFE SCI, V71, P2701, DOI 10.1016/S0024-3205(02)01990-2; KOEHN JA, 1987, J BIOL CHEM, V262, P11623; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; Langenickel TH, 2006, P NATL ACAD SCI USA, V103, P4735, DOI 10.1073/pnas.0510019103; Lopez MJ, 1997, J BIOL CHEM, V272, P23064, DOI 10.1074/jbc.272.37.23064; LU B, 1995, J EXP MED, V181, P2271, DOI 10.1084/jem.181.6.2271; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.physiol.54.1.11; Matsukawa N, 1999, P NATL ACAD SCI USA, V96, P7403, DOI 10.1073/pnas.96.13.7403; OKOLICANY J, 1992, AM J PHYSIOL, V263, pF546, DOI 10.1152/ajprenal.1992.263.3.F546; Potter LR, 2006, ENDOCR REV, V27, P47, DOI 10.1210/er.2005-0014; POTTER LR, 1992, J BIOL CHEM, V267, P14531; Potthast R, 2004, J BIOL CHEM, V279, P48513, DOI 10.1074/jbc.M408247200; Rose RA, 2008, J PHYSIOL-LONDON, V586, P353, DOI 10.1113/jphysiol.2007.144253; SONNENBERG JL, 1988, PEPTIDES, V9, P173, DOI 10.1016/0196-9781(88)90024-1; Stambler BS, 2005, J CARDIOVASC ELECTR, V16, P1341, DOI 10.1111/j.1540-8167.2005.00259.x; STEPHENSON SL, 1987, BIOCHEM J, V243, P183, DOI 10.1042/bj2430183; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; Thomas CJ, 2008, HYPERTENSION, V52, P696, DOI 10.1161/HYPERTENSIONAHA.108.111302; VANNESTE Y, 1988, BIOCHEM J, V254, P531, DOI 10.1042/bj2540531; VANNESTE Y, 1990, BIOCHEM J, V269, P801, DOI 10.1042/bj2690801; YANDLE TG, 1989, PEPTIDES, V10, P891, DOI 10.1016/0196-9781(89)90131-9	33	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19196	19202		10.1074/jbc.M109.010777	http://dx.doi.org/10.1074/jbc.M109.010777			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19458086	hybrid, Green Published			2022-12-25	WOS:000267908300009
J	Talabot-Ayer, D; Lamacchia, C; Gabay, C; Palmer, G				Talabot-Ayer, Dominique; Lamacchia, Celine; Gabay, Cem; Palmer, Gaby			Interleukin-33 Is Biologically Active Independently of Caspase-1 Cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ANTAGONIST; IL-33; INFLAMMASOME; ACTIVATION; EXPRESSION; SUBSTRATE; CYTOKINE; CELLS; ST2	The new interleukin (IL)-1 family cytokine IL-33 is synthesized as a 30-kDa precursor. Like pro-IL-1 beta, human pro-IL-33 was reported to be cleaved by caspase-1 to generate an 18-kDa fragment, which is sufficient to activate signaling by the IL-33 receptor T1/ST2. However, the proposed caspase-1 cleavage site is poorly conserved between species. In addition, it is not clear whether caspase-1 cleavage of pro-IL-33 occurs in vivo and whether, as for IL-1 beta, this cleavage is a prerequisite for IL-33 secretion and bioactivity. In this study, we further investigated caspase-1 cleavage of mouse and human pro-IL-33 and assessed the potential bioactivity of the IL-33 precursor. We observed the generation of a 20-kDa IL-33 fragment in cell lysates, which was enhanced by incubation with caspase-1. However, in vitro assays of mouse and human pro-IL-33 indicated that IL-33 is not a direct substrate for this enzyme. Consistently, caspase-1 activation in THP-1 cells induced cleavage of pro-IL-1 beta but not of pro-IL-33, and activated THP-1 cells released full-length pro-IL-33 into culture supernatants. Finally, addition of full-length pro-IL-33 induced T1/ST2-dependent IL-6 secretion in mast cells. However, we observed in situ processing of pro-IL-33 in mast cell cultures, and it remains to be determined whether full-length pro-IL-33 itself indeed represents the bioactive species. In conclusion, our data indicate that pro-IL-33 is not a direct substrate for caspase-1. In addition, our results clearly show that caspase-1 cleavage is not required for pro-IL-33 secretion and bioactivity, highlighting major differences between IL-1 beta and IL-33.	[Palmer, Gaby] Univ Hosp, Div Rheumatol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Dept Pathol & Immunol, CH-1211 Geneva 4, Switzerland	University of Geneva; University of Geneva	Palmer, G (corresponding author), Ctr Med Univ Geneva, Dept Pathol & Immunol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	gaby.palmer@unige.ch	palmer, gaby/AAA-7117-2021	palmer, gaby/0000-0001-7567-1798	Swiss National Science Foundation Grants [320000-120319, 3200-107592]; Rheumasearch Foundation; Lotterie Romande	Swiss National Science Foundation Grants(Swiss National Science Foundation (SNSF)); Rheumasearch Foundation; Lotterie Romande	This work was supported by Swiss National Science Foundation Grants 320000-120319 ( to G. P.) and 3200-107592 ( to C. G.) and by the Rheumasearch Foundation and the Lotterie Romande.	Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Dunand-Sauthier I, 2005, J BIOL CHEM, V280, P7030, DOI 10.1074/jbc.M412228200; Fennewald SM, 2002, J VIROL, V76, P1154, DOI 10.1128/JVI.76.3.1154-1162.2002; Gabay C, 2001, EUR J IMMUNOL, V31, P490, DOI 10.1002/1521-4141(200102)31:2<490::AID-IMMU490>3.0.CO;2-H; HOWARD AD, 1991, J IMMUNOL, V147, P2964; Hudson CA, 2008, J LEUKOCYTE BIOL, V84, P631, DOI 10.1189/jlb.1207830; Keller M, 2008, CELL, V132, P818, DOI 10.1016/j.cell.2007.12.040; Kuchler AM, 2008, AM J PATHOL, V173, P1229, DOI 10.2353/ajpath.2008.080014; Lamkanfi M, 2008, MOL CELL PROTEOMICS, V7, P2350, DOI 10.1074/mcp.M800132-MCP200; Li HF, 2008, J IMMUNOL, V181, P17, DOI 10.4049/jimmunol.181.1.17; Luschen S, 1998, BIOCHEM BIOPH RES CO, V253, P92, DOI 10.1006/bbrc.1998.9754; Moulin D, 2007, CYTOKINE, V40, P216, DOI 10.1016/j.cyto.2007.09.013; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Palmer G, 2005, CYTOKINE, V31, P153, DOI 10.1016/j.cyto.2005.03.007; Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Vaisid T, 2005, BBA-MOL CELL RES, V1743, P223, DOI 10.1016/j.bbamcr.2005.01.001; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003	19	193	207	3	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19420	19426		10.1074/jbc.M901744200	http://dx.doi.org/10.1074/jbc.M901744200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19465481	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000267908300033
J	Zachos, NC; van Rossum, DB; Li, XH; Caraveo, G; Sarker, R; Cha, BY; Mohan, S; Desiderio, S; Patterson, RL; Donowitz, M				Zachos, Nicholas C.; van Rossum, Damian B.; Li, Xuhang; Caraveo, Gabriela; Sarker, Rafiquel; Cha, Boyoung; Mohan, Sachin; Desiderio, Stephen; Patterson, Randen L.; Donowitz, Mark			Phospholipase C-gamma Binds Directly to the Na+/H+ Exchanger 3 and Is Required for Calcium Regulation of Exchange Activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BRUSH-BORDER; MOLECULAR PHYSIOLOGY; NHE3 TRAFFICKING; TERMINAL DOMAINS; ABSORBING CELLS; INHIBITION; C-GAMMA-1; TRANSPORT; EZRIN	Multiple studies suggest that phospholipase C-gamma(PLC-gamma) contributes to regulation of sodium/hydrogen exchanger 3 (NHE3) in the small intestine, although the mechanism(s) for this regulation remain unknown. We demonstrate here that PLC-gamma binds directly to the C terminus of NHE3 and exists in similar sized multiprotein complexes as NHE3. This binding is dynamic and decreases with elevated [Ca2+](i). The PLC-gamma-binding site in NHE3 was identified (amino acids 586-605) and shown to be a critical regulatory domain for protein complex formation, because when it is mutated, NHE3 binding to PLC-gamma as well as NHERF2 is lost. An inhibitory peptide, which binds to the Src homology 2 domains contained in PLC-gamma without interrupting binding of PLC-gamma to NHE3, was used to probe a non-lipase-dependent role of PLC-gamma. In the presence of this peptide, carbachol-stimulated calcium inhibition of NHE3 was lost. These results mirror previous studies with the transient receptor potential channel and suggest that PLC-gamma may play a common role in regulating the cell-surface expression of ion transporters.	[Zachos, Nicholas C.; Li, Xuhang; Sarker, Rafiquel; Cha, Boyoung; Mohan, Sachin; Donowitz, Mark] Johns Hopkins Univ, Sch Med, Div Gastroenterol & Hepatol, Baltimore, MD 21205 USA; [Caraveo, Gabriela; Desiderio, Stephen] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; [Donowitz, Mark] Johns Hopkins Univ, Sch Med, Dept Physiol & Med, Baltimore, MD 21205 USA; [van Rossum, Damian B.; Patterson, Randen L.] Penn State Univ, Dept Biol, Ctr Computat Prote, University Pk, PA 16802 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Donowitz, M (corresponding author), 720 Rutland Ave,925 Ross Res Bldg, Baltimore, MD 21205 USA.	mdonowit@jhmi.edu	Zachos, Nicholas/GWC-7914-2022; mohan, sachin/H-4017-2015	van Rossum, Damian/0000-0003-1011-2586; Mohan, Sachin/0000-0002-6798-4767	National Institutes of Health Grants [R01-DK26523, R01-DK61765, PO1-DK72084, R24-DK64388]; The Hopkins Center for Epithelial Disorders Grants [T32-DK07632, K01-DK080930]; Searle Young Investigators award; Pennsylvania State University; Huck Life Science Institute Center for Computational Proteomics; Pennsylvania Department of Health using Tobacco Settlement Funds; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026523, T32DK007632, R01DK061765, K01DK080930, R24DK064388, P01DK072084] Funding Source: NIH RePORTER	National Institutes of Health Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); The Hopkins Center for Epithelial Disorders Grants; Searle Young Investigators award; Pennsylvania State University; Huck Life Science Institute Center for Computational Proteomics; Pennsylvania Department of Health using Tobacco Settlement Funds; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grants R01-DK26523, R01-DK61765, PO1-DK72084, and R24-DK64388 ( The Hopkins Basic Research Digestive Diseases Development Core Center) from NIDDK. This work was also supported by The Hopkins Center for Epithelial Disorders Grants T32-DK07632 and K01-DK080930, Searle Young Investigators award, start-up monies from Pennsylvania State University ( to R. L. P.), funds from the Huck Life Science Institute Center for Computational Proteomics ( to R. L. P. and D. B. v. R.), and a grant from the Pennsylvania Department of Health using Tobacco Settlement Funds ( to D. B. v. R.).	Akhter S, 2000, BIOCHEMISTRY-US, V39, P1990, DOI 10.1021/bi991739s; Boehning D, 2005, P NATL ACAD SCI USA, V102, P1466, DOI 10.1073/pnas.0409650102; Caraveo G, 2006, SCIENCE, V314, P122, DOI 10.1126/science.1127815; Cha B, 2005, J BIOL CHEM, V280, P16642, DOI 10.1074/jbc.M500505200; Cha B, 2006, MOL BIOL CELL, V17, P2661, DOI 10.1091/mbc.E05-09-0843; Chang JS, 2005, J BIOL CHEM, V280, P6897, DOI 10.1074/jbc.M406350200; Choi JH, 2004, J CELL SCI, V117, P3785, DOI 10.1242/jcs.01220; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; COHEN ME, 1991, J CLIN INVEST, V88, P855, DOI 10.1172/JCI115387; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; DEBER CM, 1986, BIOCHEM BIOPH RES CO, V134, P731, DOI 10.1016/S0006-291X(86)80481-8; DONOWITZ M, 1989, J CLIN INVEST, V83, P1953, DOI 10.1172/JCI114104; DONOWITZ M, 1986, ANNU REV PHYSIOL, V48, P135, DOI 10.1146/annurev.ph.48.030186.001031; Donowitz M, 2001, CURR TOP MEMBR, V50, P437; Donowitz M, 2007, PHYSIOL REV, V87, P825, DOI 10.1152/physrev.00030.2006; EMMER E, 1989, J MEMBRANE BIOL, V108, P207, DOI 10.1007/BF01871735; Janecki AJ, 1999, AM J PHYSIOL-GASTR L, V277, pG292, DOI 10.1152/ajpgi.1999.277.2.G292; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; Khurana S, 1996, BIOCHEM J, V313, P509, DOI 10.1042/bj3130509; Kim JH, 2002, J BIOL CHEM, V277, P23714, DOI 10.1074/jbc.M200835200; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; Li XH, 2004, J PHYSIOL-LONDON, V556, P791, DOI 10.1113/jphysiol.2004.060921; Morris AP, 2001, AM J PHYSIOL-GASTR L, V281, pG303, DOI 10.1152/ajpgi.2001.281.2.G303; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Sarker R, 2008, MOL BIOL CELL, V19, P3859, DOI 10.1091/mbc.E08-01-0019; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; TAPPER EJ, 1978, AM J PHYSIOL, V235, pE402, DOI 10.1152/ajpendo.1978.235.4.E402; van Rossum DB, 2005, NATURE, V434, P99, DOI 10.1038/nature03340; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zachos NC, 2005, ANNU REV PHYSIOL, V67, P411, DOI 10.1146/annurev.physiol.67.031103.153004	35	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19437	19444		10.1074/jbc.M109.006098	http://dx.doi.org/10.1074/jbc.M109.006098			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19473983	Green Published, hybrid			2022-12-25	WOS:000267908300035
J	Bour, T; Akaddar, A; Lorber, B; Blais, S; Balg, C; Candolfi, E; Frugier, M				Bour, Tania; Akaddar, Aziza; Lorber, Bernard; Blais, Sebastien; Balg, Christian; Candolfi, Ermanno; Frugier, Magali			Plasmodial Aspartyl-tRNA Synthetases and Peculiarities in Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL EXTENSION; DYNAMIC LIGHT-SCATTERING; PLASTID-LIKE DNA; ESCHERICHIA-COLI; ACTIVE-SITE; YEAST; MALARIA; ADENYLATE; SEQUENCE; AMINOACYLATION	Distinctive features of aspartyl-transfer RNA (tRNA) synthetases (AspRS) from the protozoan Plasmodium genus are described. These apicomplexan AspRSs contain 29-31 amino acid insertions in their anticodon binding domains, a remarkably long N-terminal appendix that varies in size from 110 to 165 amino acids and two potential initiation codons. This article focuses on the atypical functional and structural properties of Plasmodium falciparum cytosolic AspRS, the causative parasite of human malaria. This species encodes a 626 or 577 amino acids AspRS depending on whether initiation starts on the first or second in-frame initiation codon. The longer protein has poor solubility and a propensity to aggregate. Production of the short version was favored as shown by the comparison of the recombinant protein with endogenous AspRS. Comparison of the tRNA aminoacylation activity of wild-type and mutant parasite AspRSs with those of yeast and human AspRSs revealed unique properties. The N-terminal extension contains a motif that provides unexpectedly strong RNA binding to plasmodial AspRS. Furthermore, experiments demonstrated the requirement of the plasmodial insertion for AspRS dimerization and, therefore, tRNA aminoacylation and other putative functions. Implications for the parasite biology are proposed. These data provide a robust background for unraveling the precise functional properties of the parasite AspRS and for developing novel lead compounds against malaria, targeting its idiosyncratic domains.	[Bour, Tania; Lorber, Bernard; Frugier, Magali] Univ Strasbourg, Architecture & Reactivite ARN, CNRS, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France; [Akaddar, Aziza; Candolfi, Ermanno] Univ Strasbourg, Inst Parasitol & Pathol Trop, F-67000 Strasbourg, France; [Blais, Sebastien] Univ Laval, Dept Biochim & Microbiol, Quebec City, PQ G1V 0A6, Canada; [Balg, Christian] Univ Laval, Fac Sci & Genie, Dept Chim, Quebec City, PQ G1V 0A6, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Laval University; Laval University	Frugier, M (corresponding author), Univ Strasbourg, Architecture & Reactivite ARN, CNRS, Inst Biol Mol & Cellulaire, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	M.Frugier@ibmc.u-strasbg.fr			Universite Louis Pasteur; Agence Nationale de la Recherche [ANR-07-BLAN-006901]	Universite Louis Pasteur; Agence Nationale de la Recherche(French National Research Agency (ANR))	This work was supported by CNRS including a PICS project, the Universite Louis Pasteur, the Agence Nationale de la Recherche (ANR-07-BLAN-006901), and a "Bourse Formation Recherche" from Luxembourg (to T.B.).	Adl SM, 2005, J EUKARYOT MICROBIOL, V52, P399, DOI 10.1111/j.1550-7408.2005.00053.x; AGOU F, 1995, BIOCHEMISTRY-US, V34, P569, DOI 10.1021/bi00002a023; Ataide SF, 2006, ACS CHEM BIOL, V1, P285, DOI 10.1021/cb600200k; Balg C, 2007, BIOORGAN MED CHEM, V15, P295, DOI 10.1016/j.bmc.2006.09.056; Becker HD, 2000, BIOCHEMISTRY-US, V39, P3216, DOI 10.1021/bi992573y; Bernard D, 2007, J ENZYM INHIB MED CH, V22, P77, DOI 10.1080/14756360600952316; Bernier S, 2005, BIOORGAN MED CHEM, V13, P69, DOI 10.1016/j.bmc.2004.09.055; BONNET J, 1972, EUR J BIOCHEM, V31, P335, DOI 10.1111/j.1432-1033.1972.tb02538.x; Campanacci V, 2004, J MOL BIOL, V337, P273, DOI 10.1016/j.jmb.2004.01.027; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; Chan PP, 2009, NUCLEIC ACIDS RES, V37, pD93, DOI 10.1093/nar/gkn787; Chayen N, 2004, ANN NY ACAD SCI, V1027, P20, DOI 10.1196/annals.1324.003; Choi H, 2003, RNA, V9, P386, DOI 10.1261/rna.2139703; Depledge DP, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-122; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIANI G, 1991, EUR J BIOCHEM, V200, P337, DOI 10.1111/j.1432-1033.1991.tb16190.x; ERIANI G, 1995, J MOL EVOL, V40, P499; ERIANI G, 1993, P NATL ACAD SCI USA, V90, P10816, DOI 10.1073/pnas.90.22.10816; ESCALANTE C, 1993, J BIOL CHEM, V268, P6014; Feagin JE, 2000, INT J PARASITOL, V30, P371, DOI 10.1016/S0020-7519(99)00190-3; Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5; Feng L, 2005, J BIOL CHEM, V280, P20638, DOI 10.1074/jbc.M500874200; Foth BJ, 2003, SCIENCE, V299, P705, DOI 10.1126/science.1078599; FRUGIER M, 1994, BIOCHEMISTRY-US, V33, P9912, DOI 10.1021/bi00199a013; Frugier M, 2000, EMBO J, V19, P2371, DOI 10.1093/emboj/19.10.2371; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Giege R, 1996, BIOCHIMIE, V78, P605, DOI 10.1016/S0300-9084(96)80007-1; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; GIEGE R, 1982, BIOCHIMIE, V64, P357, DOI 10.1016/S0300-9084(82)80440-9; Giege R., 2005, AMINOACYL TRNA SYNTH, P210; Giege R, 2008, NAT STRUCT MOL BIOL, V15, P1007, DOI 10.1038/nsmb.1498; Ibba M., 2005, AMINOACYL TRNA SYNTH; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Martin D, 2000, MOL BIOCHEM PARASIT, V110, P93, DOI 10.1016/S0166-6851(00)00260-7; Martinis Susan A., 1999, EMBO (European Molecular Biology Organization) Journal, V18, P4591, DOI 10.1093/emboj/18.17.4591; Messmer M, 2009, BIOCHIMIE, V91, P596, DOI 10.1016/j.biochi.2009.02.005; Metlitskaya A, 2006, J BIOL CHEM, V281, P18033, DOI 10.1074/jbc.M513174200; MIKOL V, 1991, J CRYST GROWTH, V110, P195, DOI 10.1016/0022-0248(91)90885-9; Moras D, 1992, CURR OPIN STRUC BIOL, V2, P138; Moulinier L, 2001, EMBO J, V20, P5290, DOI 10.1093/emboj/20.18.5290; Mourier T, 2005, RNA, V11, P119, DOI 10.1261/rna.7185605; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Park SG, 2008, P NATL ACAD SCI USA, V105, P11043, DOI 10.1073/pnas.0802862105; Pizzi E, 2001, GENOME RES, V11, P218, DOI 10.1101/gr.GR-1522R; PREISER P, 1995, NUCLEIC ACIDS RES, V23, P4329, DOI 10.1093/nar/23.21.4329; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; Rees B, 2000, J MOL BIOL, V299, P1157, DOI 10.1006/jmbi.2000.3792; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Ryckelynck M, 2003, J BIOL CHEM, V278, P9683, DOI 10.1074/jbc.M211035200; Salinas T, 2008, TRENDS BIOCHEM SCI, V33, P320, DOI 10.1016/j.tibs.2008.04.010; Sauter C, 2000, J MOL BIOL, V299, P1313, DOI 10.1006/jmbi.2000.3791; Scheper GC, 2007, NAT GENET, V39, P534, DOI 10.1038/ng2013; SELLAMI M, 1986, NUCLEIC ACIDS RES, V14, P1657, DOI 10.1093/nar/14.4.1657; Stechmann A, 2002, SCIENCE, V297, P89, DOI 10.1126/science.1071196; THIBAULT F, 1992, J MOL BIOL, V225, P185, DOI 10.1016/0022-2836(92)91035-N; Trager W, 1997, INT J PARASITOL, V27, P989, DOI 10.1016/S0020-7519(97)00080-5; Tuteja R, 2007, FEBS J, V274, P4670, DOI 10.1111/j.1742-4658.2007.05997.x; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449	59	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18893	18903		10.1074/jbc.M109.015297	http://dx.doi.org/10.1074/jbc.M109.015297			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19443655	Green Published, hybrid			2022-12-25	WOS:000267711500039
J	Kleiner, S; Nguyen-Tran, V; Bare, O; Huang, XM; Spiegelman, B; Wu, ZD				Kleiner, Sandra; Nguyen-Tran, Van; Bare, Olivia; Huang, Xueming; Spiegelman, Bruce; Wu, Zhidan			PPAR delta Agonism Activates Fatty Acid Oxidation via PGC-1 alpha but Does Not Increase Mitochondrial Gene Expression and Function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; COACTIVATOR PGC-1-ALPHA; TRANSCRIPTIONAL CONTROL; METABOLIC SYNDROME; ENERGY-METABOLISM; RECEPTOR; CELLS; GAMMA; OBESITY; ALPHA	PPAR delta (peroxisome proliferator-activated receptor delta) is a regulator of lipid metabolism and has been shown to induce fatty acid oxidation (FAO). PPAR delta transgenic and knock-out mice indicate an involvement of PPAR delta in regulating mitochondrial biogenesis and oxidative capacity; however, the precise mechanisms by which PPAR delta regulates these pathways in skeletal muscle remain unclear. In this study, we determined the effect of selective PPAR delta agonism with the synthetic ligand, GW501516, on FAO and mitochondrial gene expression in vitro and in vivo. Our results show that activation of PPAR delta by GW501516 led to a robust increase in mRNA levels of key lipid metabolism genes. Mitochondrial gene expression and function were not induced under the same conditions. Additionally, the activation of Pdk4 transcription by PPAR delta was coactivated by PGC-1 alpha. PGC-1 alpha, but not PGC-1 beta, was essential for full activation of Cpt-1b and Pdk4 gene expression via PPAR beta agonism. Furthermore, the induction of FAO by PPAR delta agonism was completely abolished in the absence of both PGC-1 alpha and PGC-1 beta Conversely, PGC-1 alpha-driven FAO was independent of PPAR delta. Neither GW501516 treatment nor knockdown of PPAR delta affects PGC-1 alpha-induced mitochondrial gene expression in primary myotubes. These results demonstrate that pharmacological activation of PPAR delta induces FAO via PGC-1 alpha. However, PPAR delta agonism does not induce mitochondrial gene expression and function. PGC-1 alpha-induced FAO and mitochondrial biogenesis appear to be independent of PPAR delta.	[Nguyen-Tran, Van] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; [Kleiner, Sandra; Spiegelman, Bruce] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; [Kleiner, Sandra; Spiegelman, Bruce] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Kleiner, Sandra; Bare, Olivia; Huang, Xueming; Wu, Zhidan] Novartis Inst Biomed Res Inc, Cardiovasc & Metab Dis Area, Cambridge, MA 02139 USA	Novartis; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Novartis	Wu, ZD (corresponding author), 100 Technol Sq, Cambridge, MA 02139 USA.	zhidan.wu@novartis.com		Wu, Zhidan/0000-0001-7289-9420				Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079-9091.2004; Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013; Koves TR, 2005, J BIOL CHEM, V280, P33588, DOI 10.1074/jbc.M507621200; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; LUQUET S, 2003, FASEB J; Moyes CD, 1997, AM J PHYSIOL-CELL PH, V272, pC1345, DOI 10.1152/ajpcell.1997.272.4.C1345; Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051; Sabourin LA, 1999, J CELL BIOL, V144, P631, DOI 10.1083/jcb.144.4.631; Schuler M, 2006, CELL METAB, V4, P407, DOI 10.1016/j.cmet.2006.10.003; Semple RK, 2004, INT J OBESITY, V28, P176, DOI 10.1038/sj.ijo.0802482; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; Takahashi S, 2007, ENDOCR J, V54, P347, DOI 10.1507/endocrj.KR-99; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Wende AR, 2005, MOL CELL BIOL, V25, P10684, DOI 10.1128/MCB.25.24.10684-10694.2005; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Wu ZD, 2006, P NATL ACAD SCI USA, V103, P14379, DOI 10.1073/pnas.0606714103	25	109	113	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18624	18633		10.1074/jbc.M109.008797	http://dx.doi.org/10.1074/jbc.M109.008797			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19435887	Green Published, hybrid			2022-12-25	WOS:000267711500011
J	Tarrago, L; Laugier, E; Zaffagnini, M; Marchand, C; Le Marechal, P; Rouhier, N; Lemaire, SD; Rey, P				Tarrago, Lionel; Laugier, Edith; Zaffagnini, Mirko; Marchand, Christophe; Le Marechal, Pierre; Rouhier, Nicolas; Lemaire, Stephane D.; Rey, Pascal			Regeneration Mechanisms of Arabidopsis thaliana Methionine Sulfoxide Reductases B by Glutaredoxins and Thioredoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BIOCHEMICAL-CHARACTERIZATION; S-GLUTATHIONYLATION; CATALYTIC MECHANISM; REDOX REGULATION; REDUCING AGENT; ACTIVE-SITE; PROTEIN; PEROXIREDOXIN; POPLAR	Methionine oxidation leads to the formation of S- and R-diastereomers of methionine sulfoxide (MetSO), which are reduced back to methionine by methionine sulfoxide reductases (MSRs) A and B, respectively. MSRBs are classified in two groups depending on the conservation of one or two redox-active Cys; 2-Cys MSRBs possess a catalytic Cys-reducing MetSO and a resolving Cys, allowing regeneration by thioredoxins. The second type, 1-Cys MSRBs, possess only the catalytic Cys. The biochemical mechanisms involved in activity regeneration of 1-Cys MSRBs remain largely elusive. In the present work we used recombinant plastidial Arabidopsis thaliana MSRB1 and MSRB2 as models for 1-Cys and 2-Cys MSRBs, respectively, to delineate the Trx- and glutaredoxin-dependent reduction mechanisms. Activity assays carried out using a series of cysteine mutants and various reductants combined with measurements of free thiols under distinct oxidation conditions and mass spectrometry experiments show that the 2-Cys MSRB2 is reduced by Trx through a dithiol-disulfide exchange involving both redox-active Cys of the two partners. Regarding 1-Cys MSRB1, oxidation of the enzyme after substrate reduction leads to the formation of a stable sulfenic acid on the catalytic Cys, which is subsequently glutathionylated. The deglutathionylation of MSRB1 is achieved by both mono- and dithiol glutaredoxins and involves only their N-terminal conserved catalytic Cys. This study proposes a detailed mechanism of the regeneration of 1-Cys MSRB activity by glutaredoxins, which likely constitute physiological reductants for this type of MSR.	[Tarrago, Lionel; Laugier, Edith; Rey, Pascal] CEN Cadarache, Lab Ecophysiol Mol Plantes, Inst Biol Environm & Biotechnol, Direct Sci Vivant, F-13108 St Paul Les Durance, France; [Zaffagnini, Mirko; Lemaire, Stephane D.] Univ Paris 11, Inst Biotechnol Plantes, Unite Mixte Rech 8618, F-91405 Orsay, France; [Marchand, Christophe; Le Marechal, Pierre] Univ Paris 11, CNRS, Inst Biochim & Biophys Mol & Cellulaire, Unite Mixte Rech 8619, F-91405 Orsay, France; [Rouhier, Nicolas] Nancy Univ Interact Arbres Microorganismes, Inst Natl Rech Agron, Unite Mixte Rech 1136, IFR Genom Ecophysiol & Ecol Fonct 110, F-54506 Vandoeuvre Les Nancy, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; INRAE; Universite de Lorraine	Rey, P (corresponding author), CEN Cadarache, Lab Ecophysiol Mol Plantes, Inst Biol Environm & Biotechnol, Direct Sci Vivant, Batiment 158, F-13108 St Paul Les Durance, France.	pascal.rey@cea.fr	REY, Pascal/E-5794-2019; Lemaire, Stéphane D/A-3530-2008; Tarrago, Lionel/CAH-1308-2022; MARCHAND, Christophe H/B-5854-2008; Tarrago, Lionel/N-3534-2016	REY, Pascal/0000-0001-6512-1418; Lemaire, Stéphane D/0000-0001-6442-0547; Tarrago, Lionel/0000-0001-7115-8137; MARCHAND, Christophe H/0000-0002-0729-3841; Tarrago, Lionel/0000-0001-7115-8137; Zaffagnini, Mirko/0000-0001-5115-0859	Agence Nationale de la Recherche	Agence Nationale de la Recherche(French National Research Agency (ANR))	This work was supported by Agence Nationale de la Recherche, ANR-Geno-plante Grants GNP05010G (to P.R., E.L., and N.R.) and ANR-JC45751 (to M.Z. and S.D.L.). Financial support (to L.T.) from Region Provence-Alpes-Cotes-d'Azur is acknowledged.	Augusto LA, 2003, BIOCHEMISTRY-US, V42, P3929, DOI 10.1021/bi0268394; Behm M, 2000, PLANT PHYSIOL BIOCH, V38, P363, DOI 10.1016/S0981-9428(00)00760-9; Boschi-Muller S, 2000, J BIOL CHEM, V275, P35908, DOI 10.1074/jbc.M006137200; Boschi-Muller S, 2008, ARCH BIOCHEM BIOPHYS, V474, P266, DOI 10.1016/j.abb.2008.02.007; Broin M, 2002, PLANT CELL, V14, P1417, DOI 10.1105/tpc.001644; BROT N, 1981, P NATL ACAD SCI-BIOL, V78, P2155, DOI 10.1073/pnas.78.4.2155; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Couturier J, 2009, J BIOL CHEM, V284, P9299, DOI 10.1074/jbc.M807998200; Dalle-Donne I, 2007, FREE RADICAL BIO MED, V43, P883, DOI 10.1016/j.freeradbiomed.2007.06.014; Davies MJ, 2005, BBA-PROTEINS PROTEOM, V1703, P93, DOI 10.1016/j.bbapap.2004.08.007; Ding D, 2007, BIOCHEM BIOPH RES CO, V361, P629, DOI 10.1016/j.bbrc.2007.07.072; Dixon DP, 2005, BIOCHEMISTRY-US, V44, P7696, DOI 10.1021/bi047324a; Dos Santos CV, 2007, FEBS LETT, V581, P4371, DOI 10.1016/j.febslet.2007.07.081; Dos Santos CV, 2005, PLANT PHYSIOL, V138, P909, DOI 10.1104/pp.105.062430; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Gallogly MM, 2009, ANTIOXID REDOX SIGN, V11, P1059, DOI [10.1089/ars.2008.2291, 10.1089/ARS.2008.2291]; Getz EB, 1999, ANAL BIOCHEM, V273, P73, DOI 10.1006/abio.1999.4203; Grimaud R, 2001, J BIOL CHEM, V276, P48915, DOI 10.1074/jbc.M105509200; Holmgren A, 2005, BIOCHEM SOC T, V33, P1375, DOI 10.1042/BST0331375; JACQUOT JP, 1994, J MOL BIOL, V235, P1357, DOI 10.1006/jmbi.1994.1091; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Kim HY, 2008, BIOCHEM BIOPH RES CO, V371, P490, DOI 10.1016/j.bbrc.2008.04.101; Kim HY, 2005, PLOS BIOL, V3, P2080, DOI 10.1371/journal.pbio.0030375; Kumar RA, 2002, J BIOL CHEM, V277, P37527, DOI 10.1074/jbc.M203496200; Manevich Y, 2004, P NATL ACAD SCI USA, V101, P3780, DOI 10.1073/pnas.0400181101; Moskovitz J, 1997, P NATL ACAD SCI USA, V94, P9585, DOI 10.1073/pnas.94.18.9585; Neiers F, 2004, J BIOL CHEM, V279, P42462, DOI 10.1074/jbc.M407464200; Olry A, 2002, J BIOL CHEM, V277, P12016, DOI 10.1074/jbc.M112350200; Ralat LA, 2006, BIOCHEMISTRY-US, V45, P360, DOI 10.1021/bi0520737; Rey P, 2005, PLANT J, V41, P31, DOI 10.1111/j.1365-313X.2004.02271.x; Rey P, 1998, PLANT J, V13, P97, DOI 10.1046/j.1365-313X.1998.00015.x; Rouhier N, 2002, FEBS LETT, V511, P145, DOI 10.1016/S0014-5793(01)03302-6; Rouhier N, 2002, J BIOL CHEM, V277, P13609, DOI 10.1074/jbc.M111489200; Rouhier N, 2008, ANNU REV PLANT BIOL, V59, P143, DOI 10.1146/annurev.arplant.59.032607.092811; Rouhier N, 2007, J BIOL CHEM, V282, P3367, DOI 10.1074/jbc.M605007200; Ruegg U T, 1977, Methods Enzymol, V47, P111; Sagher D, 2006, J BIOL CHEM, V281, P31184, DOI 10.1074/jbc.M606962200; Saghert D, 2006, P NATL ACAD SCI USA, V103, P8656, DOI 10.1073/pnas.0602826103; Shelton MD, 2008, MOL CELLS, V25, P332; Silva GM, 2008, FEBS J, V275, P2942, DOI 10.1111/j.1742-4658.2008.06441.x; Tamarit J, 2003, J BIOL CHEM, V278, P25745, DOI 10.1074/jbc.M303477200; Tarrago L, 2009, MOL PLANT, V2, P202, DOI 10.1093/mp/ssn067; Zaffagnini M, 2008, J BIOL CHEM, V283, P8868, DOI 10.1074/jbc.M709567200; Zaffagnini M, 2007, FEBS J, V274, P212, DOI 10.1111/j.1742-4658.2006.05577.x	44	107	113	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18963	18971		10.1074/jbc.M109.015487	http://dx.doi.org/10.1074/jbc.M109.015487			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19457862	Green Published, hybrid			2022-12-25	WOS:000267711500046
J	Vankemmelbeke, M; Zhang, Y; Moore, GR; Kleanthous, C; Penfold, CN; James, R				Vankemmelbeke, Mireille; Zhang, Ying; Moore, Geoffrey R.; Kleanthous, Colin; Penfold, Christopher N.; James, Richard			Energy-dependent Immunity Protein Release during tol-dependent Nuclease Colicin Translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL OUTER-MEMBRANE; PROTON MOTIVE FORCE; C-TERMINAL DOMAIN; ESCHERICHIA-COLI; RECEPTOR-BINDING; INNER MEMBRANE; CELL-DIVISION; EVOLUTIONARY RELATIONSHIP; COMPETITIVE RECRUITMENT; MUTATIONAL ANALYSIS	Nuclease colicins bind their target receptor in the outer membrane of sensitive cells in the form of a high affinity complex with their cognate immunity proteins. Upon cell entry the immunity protein is lost from the complex by means that are poorly understood. We have developed a sensitive fluorescence assay that has enabled us to study the molecular requirements for immunity protein release. Nuclease colicins use members of the tol operon for their translocation across the outer membrane. We have demonstrated that the amino-terminal 80 residues of the colicin E9 molecule, which is the region that interacts with TolB, are essential for immunity protein release. Using tol deletion strains we analyzed the cellular components necessary for immunity protein release and found that in addition to a requirement for tolB, the tolA deletion strain was most affected. Complementation studies showed that the mutation H22A, within the transmembrane segment of TolA, abolishes immunity protein release. Investigation of the energy requirements demonstrated that the proton motive force of the cytoplasmic membrane is critical. Taken together these results demonstrate for the first time a clear energy requirement for the uptake of a nuclease colicin complex and suggest that energy transduced from the cytoplasmic membrane to the outer membrane by TolA could be the driving force for immunity protein release and concomitant translocation of the nuclease domain.	[Vankemmelbeke, Mireille; Zhang, Ying; Penfold, Christopher N.; James, Richard] Univ Nottingham, Sch Mol Med Sci, Nottingham NG7 2RD, England; [Vankemmelbeke, Mireille; Zhang, Ying; Penfold, Christopher N.; James, Richard] Univ Nottingham, Ctr Biomol Sci, Inst Infect Immun & Inflammat, Nottingham NG7 2RD, England; [Moore, Geoffrey R.] Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England; [Kleanthous, Colin] Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England	University of Nottingham; University of Nottingham; University of East Anglia; University of York - UK	Vankemmelbeke, M (corresponding author), Univ Nottingham, Sch Mol Med Sci, Nottingham NG7 2RD, England.	mireille.vankemmelbeke@nottingham.ac.uk	James, Richard/B-2252-2009; zhang, ying/E-2718-2017	Penfold, Christopher/0000-0003-3251-5650; Zhang, Ying/0000-0003-3074-9998; James, Richard/0000-0002-5086-788X; Vankemmelbeke, Mireille/0000-0002-8100-813X	Wellcome Trust; University of Nottingham; Biotechnology and Biological Sciences Research Council [BB/C516236/1] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); University of Nottingham; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by a program grant from The Wellcome Trust and by the University of Nottingham.	Baboolal TG, 2008, STRUCTURE, V16, P371, DOI 10.1016/j.str.2007.12.023; BASSFORD PJ, 1977, J BACTERIOL, V129, P265, DOI 10.1128/JB.129.1.265-275.1977; BAYER ME, 1968, J VIROL, V2, P346, DOI 10.1128/JVI.2.4.346-356.1968; Bernadac A, 1998, J BACTERIOL, V180, P4872, DOI 10.1128/JB.180.18.4872-4878.1998; Bolender N, 2008, EMBO REP, V9, P42, DOI 10.1038/sj.embor.7401126; Bonsor DA, 2007, J AM CHEM SOC, V129, P4800, DOI 10.1021/ja070153n; BRAUN V, 1993, MOL MICROBIOL, V8, P261, DOI 10.1111/j.1365-2958.1993.tb01570.x; Braun V, 2002, BIOCHIMIE, V84, P365, DOI 10.1016/S0300-9084(02)01427-X; Cascales E, 2001, MOL MICROBIOL, V42, P795, DOI 10.1046/j.1365-2958.2001.02673.x; Cascales E, 2000, MOL MICROBIOL, V38, P904, DOI 10.1046/j.1365-2958.2000.02190.x; Cascales E, 2007, MICROBIOL MOL BIOL R, V71, P158, DOI 10.1128/MMBR.00036-06; Clavel T, 1998, MOL MICROBIOL, V29, P359, DOI 10.1046/j.1365-2958.1998.00945.x; Collins ES, 2002, J MOL BIOL, V318, P787, DOI 10.1016/S0022-2836(02)00036-0; Davidov Y, 2000, MUTAT RES-GEN TOX EN, V466, P97, DOI 10.1016/S1383-5718(99)00233-8; de Zamaroczy M, 2002, BIOCHIMIE, V84, P423, DOI 10.1016/S0300-9084(02)01426-8; de Zamaroczy M, 2001, MOL CELL, V8, P159, DOI 10.1016/S1097-2765(01)00276-3; Dubuisson JF, 2002, J BACTERIOL, V184, P4620, DOI 10.1128/JB.184.16.4620-4625.2002; DUCHE D, 1994, J BIOL CHEM, V269, P24820; Duche D, 2007, J BACTERIOL, V189, P4217, DOI 10.1128/JB.00092-07; Duche D, 2006, J BACTERIOL, V188, P8593, DOI 10.1128/JB.00941-06; Edgar R, 2008, MOL MICROBIOL, V68, P1107, DOI 10.1111/j.1365-2958.2008.06205.x; GarinotSchneider C, 1997, MICROBIOL-SGM, V143, P2931, DOI 10.1099/00221287-143-9-2931; Gaspar JA, 2000, MOL MICROBIOL, V38, P262, DOI 10.1046/j.1365-2958.2000.02094.x; Gerding MA, 2007, MOL MICROBIOL, V63, P1008, DOI 10.1111/j.1365-2958.2006.05571.x; Germon P, 1998, J BACTERIOL, V180, P6433, DOI 10.1128/JB.180.24.6433-6439.1998; Germon P, 2001, J BACTERIOL, V183, P4110, DOI 10.1128/JB.183.14.4110-4114.2001; Goemaere EL, 2007, J BIOL CHEM, V282, P17749, DOI 10.1074/jbc.M701002200; Goemaere EL, 2007, J MOL BIOL, V366, P1424, DOI 10.1016/j.jmb.2006.12.020; GUDMUNDSDOTTIR A, 1988, J BIOL CHEM, V263, P14224; GUIHARD G, 1994, J BIOL CHEM, V269, P5874; Hands SL, 2005, J BACTERIOL, V187, P6733, DOI 10.1128/JB.187.19.6733-6741.2005; Hann E, 2007, BIOPHYS J, V92, pL79, DOI 10.1529/biophysj.106.102475; Housden NG, 2005, P NATL ACAD SCI USA, V102, P13849, DOI 10.1073/pnas.0503567102; JETTEN AM, 1975, BIOCHIM BIOPHYS ACTA, V387, P12, DOI 10.1016/0005-2728(75)90048-1; KRONCKE KD, 1990, J BACTERIOL, V172, P3469; Kutik S, 2007, J CELL BIOL, V179, P585, DOI 10.1083/jcb.200708199; Larsen RA, 1999, MOL MICROBIOL, V31, P1809, DOI 10.1046/j.1365-2958.1999.01317.x; Larsen RA, 2001, J BIOL CHEM, V276, P8111, DOI 10.1074/jbc.M007479200; Larsen RA, 2007, J BACTERIOL, V189, P2825, DOI 10.1128/JB.01925-06; Lazzaroni JC, 2002, BIOCHIMIE, V84, P391, DOI 10.1016/S0300-9084(02)01419-0; LEVENGOOD SK, 1991, P NATL ACAD SCI USA, V88, P5939, DOI 10.1073/pnas.88.14.5939; Li W, 1998, BIOCHEMISTRY-US, V37, P11771, DOI 10.1021/bi9808621; Lim JH, 2001, EMBO J, V20, P941, DOI 10.1093/emboj/20.5.941; Lloubes R, 2001, RES MICROBIOL, V152, P523, DOI 10.1016/S0923-2508(01)01226-8; Loftus SR, 2006, P NATL ACAD SCI USA, V103, P12353, DOI 10.1073/pnas.0603433103; MARTIN J, 1991, J BIOL CHEM, V266, P18051; Meury J, 1999, BIOL CELL, V91, P67, DOI 10.1016/S0248-4900(99)80032-X; Mokranjac D, 2008, BBA-BIOENERGETICS, V1777, P758, DOI 10.1016/j.bbabio.2008.04.009; Penfold CN, 2004, J BACTERIOL, V186, P4520, DOI 10.1128/JB.186.14.4520-4527.2004; PFANNER N, 1990, BIOCHIM BIOPHYS ACTA, V1018, P239, DOI 10.1016/0005-2728(90)90257-5; Postle K, 2007, BIOMETALS, V20, P453, DOI 10.1007/s10534-006-9071-6; ROTHFIELD LI, 1988, MICROBIOL SCI, V5, P182; Ruiz N, 2006, NAT REV MICROBIOL, V4, P57, DOI 10.1038/nrmicro1322; Sharma O, 2007, J BIOL CHEM, V282, P23163, DOI 10.1074/jbc.M703004200; Sharma O, 2007, J BACTERIOL, V189, P363, DOI 10.1128/JB.01344-06; Shi ZH, 2005, J BIOL CHEM, V280, P24663, DOI 10.1074/jbc.M501216200; Tefsen B, 2005, J BIOL CHEM, V280, P4504, DOI 10.1074/jbc.M409259200; Vankemmelbeke M, 2005, J BACTERIOL, V187, P4900, DOI 10.1128/JB.187.14.4900-4907.2005; Vianney A, 1996, J BACTERIOL, V178, P4031, DOI 10.1128/jb.178.14.4031-4038.1996; Walburger A, 2002, MOL MICROBIOL, V44, P695, DOI 10.1046/j.1365-2958.2002.02895.x; Walker D, 2007, J BIOL CHEM, V282, P31389, DOI 10.1074/jbc.M705883200; WALLIS R, 1992, EUR J BIOCHEM, V207, P687, DOI 10.1111/j.1432-1033.1992.tb17096.x; WALLIS R, 1995, BIOCHEMISTRY-US, V34, P13743, DOI 10.1021/bi00042a004; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x; Witty M, 2002, EMBO J, V21, P4207, DOI 10.1093/emboj/cdf417; YAMANE K, 1987, J BIOL CHEM, V262, P2358; Yamashita E, 2008, EMBO J, V27, P2171, DOI 10.1038/emboj.2008.137; Zakharov SD, 2004, BIOPHYS J, V87, P3901, DOI 10.1529/biophysj.104.046151; Zakharov SD, 2006, BIOCHEMISTRY-US, V45, P10199, DOI 10.1021/bi060694+; Zhai YF, 2003, BBA-BIOMEMBRANES, V1614, P201, DOI 10.1016/S0005-2736(03)00176-7; Zhang Y, 2008, J BACTERIOL, V190, P4342, DOI 10.1128/JB.00047-08	71	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18932	18941		10.1074/jbc.M806149200	http://dx.doi.org/10.1074/jbc.M806149200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19458090	Green Published, hybrid			2022-12-25	WOS:000267711500043
J	Argast, GM; Croy, CH; Couts, KL; Zhang, Z; Litman, E; Chan, DC; Ahn, NG				Argast, G. M.; Croy, C. H.; Couts, K. L.; Zhang, Z.; Litman, E.; Chan, D. C.; Ahn, N. G.			Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells	ONCOGENE			English	Article						plexin; semaphorin; B-Raf; melanoma; tumor suppressor	GTPASE-ACTIVATING PROTEIN; CONTROLS INVASIVE GROWTH; R-RAS; GENE-EXPRESSION; BRAF MUTATIONS; SEMAPHORIN RECEPTORS; EPITHELIAL-CELLS; AXON GUIDANCE; CANCER; RHO	Human melanomas show oncogenic B-Raf mutations, which activate the B-Raf/MKK/ERK cascade. We screened microarrays to identify cellular targets of this pathway, and found that genes upregulated by B-Raf/MKK/ERK showed highest association with cell-cycle regulators, whereas genes downregulated were most highly associated with axon guidance genes, including plexin-semaphorin family members. Plexin B1 was strongly inhibited by mitogen-activated protein kinase signaling in melanoma cells and melanocytes. In primary melanoma cells, plexin B1 blocked tumorigenesis as measured by growth of colonies in soft agar, spheroids in extracellular matrix and xenograft tumors. Tumor suppression depended on residues in the C-terminal domain of plexin B1, which mediate receptor GTPase activating protein activity, and also correlated with AKT inhibition. Interestingly, the inhibitory response to plexin B1 was reduced or absent in cells from a matched metastatic tumor, suggesting that changes occur in metastatic cells which bypass the tumor-suppressor mechanisms. Plexin B1 also inhibited cell migration, but this was seen in metastatic cells and not in matched primary cells. Thus, plexin B1 has tumor-suppressor function in early-stage cells, although suppressing migration in late-stage cells. Our findings suggest that B-Raf/MKK/ERK provides a permissive environment for melanoma genesis by modulating plexin B1. Oncogene (2009) 28, 2697-2709; doi:10.1038/onc.2009.133; published online 1 June 2009	[Litman, E.; Ahn, N. G.] Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA; [Zhang, Z.; Chan, D. C.] Univ Colorado, Hlth Sci Ctr, Dept Med, Div Med Oncol, Aurora, CO USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus	Ahn, NG (corresponding author), Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Campus Box 215,Room 76,Cristol Bldg, Boulder, CO 80309 USA.	natalie.ahn@colorado.edu			NIH [R01-CA118972, P50-CA058187, F32-CA105796, ACS-PF-04- 152, T32-GM008759]; NATIONAL CANCER INSTITUTE [R01CA118972, F32CA105796, P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008759] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Meenhard Herlyn for providing melanoma cell lines used in this study, and Silvio Gutkind, Kun-liang Guan, Xuedong Liu and Andrey Sorokin for expression plasmids. We also thank Norma Aumen for tumor sectioning, Helen Marshall for microarray analysis and Micah Hamady and Rob Knight for providing access to GO-Getter. This work was supported by NIH awards R01-CA118972 (NGA) and P50-CA058187 ( DC), and fellowship awards F32-CA105796 (GMA), ACS-PF-04- 152 (CHC) and T32-GM008759 (KLC).	Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Basile JR, 2007, J BIOL CHEM, V282, P34888, DOI 10.1074/jbc.M705467200; Basile JR, 2006, P NATL ACAD SCI USA, V103, P9017, DOI 10.1073/pnas.0508825103; Basile JR, 2004, CANCER RES, V64, P5212, DOI 10.1158/0008-5472.CAN-04-0126; Bielenberg DR, 2004, J CLIN INVEST, V114, P1260, DOI 10.1172/JCI200421378; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Bogenrieder T, 2002, CRIT REV ONCOL HEMAT, V44, P1, DOI 10.1016/S1040-8428(01)00196-2; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Brose MS, 2002, CANCER RES, V62, P6997; Charest PG, 2007, BIOCHEM J, V401, P377, DOI 10.1042/BJ20061432; Conrotto P, 2005, BLOOD, V105, P4321, DOI 10.1182/blood-2004-07-2885; Conrotto P, 2004, ONCOGENE, V23, P5131, DOI 10.1038/sj.onc.1207650; COX AD, 1994, ONCOGENE, V9, P3281; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Fujisawa H, 2004, J NEUROBIOL, V59, P24, DOI 10.1002/neu.10337; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Hingorani SR, 2003, CANCER RES, V63, P5198; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hsu MY, 1999, HUMAN CELL CULTURE, V1, P259; Ito Y, 2006, EMBO REP, V7, P704, DOI 10.1038/sj.embor.7400737; Johansson P, 2007, PIGM CELL RES, V20, P216, DOI 10.1111/j.1600-0749.2007.00375.x; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Kessler O, 2004, CANCER RES, V64, P1008, DOI 10.1158/0008-5472.CAN-03-3090; Koo HM, 2002, P NATL ACAD SCI USA, V99, P3052, DOI 10.1073/pnas.052707699; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Mora N, 2007, CANCER IMMUNOL IMMUN, V56, P535, DOI 10.1007/s00262-006-0205-z; Nakada M, 2005, AM J PATHOL, V167, P565, DOI 10.1016/S0002-9440(10)62998-7; Negishi M, 2005, CELL MOL LIFE SCI, V62, P1363, DOI 10.1007/s00018-005-5018-2; Nishigaki M, 2005, CANCER RES, V65, P2115, DOI 10.1158/0008-5472.CAN-04-3340; Oinuma I, 2004, J NEUROSCI, V24, P11473, DOI 10.1523/JNEUROSCI.3257-04.2004; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Osada M, 1999, MOL CELL BIOL, V19, P6333; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rincon-Arano H, 2003, CANCER, V97, P575, DOI 10.1002/cncr.11093; Rody A, 2007, CLIN CANCER RES, V13, P1115, DOI 10.1158/1078-0432.CCR-06-2433; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Shields JM, 2007, CANCER RES, V67, P1502, DOI 10.1158/0008-5472.CAN-06-3311; Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084; Swiercz JM, 2008, J BIOL CHEM, V283, P1893, DOI 10.1074/jbc.M706822200; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tian F, 2003, CANCER RES, V63, P8284; Vikis HG, 2002, GENE DEV, V16, P836, DOI 10.1101/gad.966402; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wong OGW, 2007, P NATL ACAD SCI USA, V104, P19040, DOI 10.1073/pnas.0702544104; Yu Y, 2002, ONCOGENE, V21, P7557, DOI 10.1038/sj.onc.1205961; Zhuang L, 2005, J CLIN PATHOL, V58, P1163, DOI 10.1136/jcp.2005.025957	54	43	44	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2697	2709		10.1038/onc.2009.133	http://dx.doi.org/10.1038/onc.2009.133			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19483722	Green Accepted			2022-12-25	WOS:000268452900001
J	Moustafa, A; Loram, JE; Hackett, JD; Anderson, DM; Plumley, FG; Bhattacharya, D				Moustafa, Ahmed; Loram, Jeannette E.; Hackett, Jeremiah D.; Anderson, Donald M.; Plumley, F. Gerald; Bhattacharya, Debashish			Origin of Saxitoxin Biosynthetic Genes in Cyanobacteria	PLOS ONE			English	Article							DATABASE; GENOMES; PROTEIN; IDENTIFICATION; PURIFICATION; PHYLOGENIES; SEQUENCES; STRAINS	Background: Paralytic shellfish poisoning (PSP) is a potentially fatal syndrome associated with the consumption of shellfish that have accumulated saxitoxin (STX). STX is produced by microscopic marine dinoflagellate algae. Little is known about the origin and spread of saxitoxin genes in these under-studied eukaryotes. Fortuitously, some freshwater cyanobacteria also produce STX, providing an ideal model for studying its biosynthesis. Here we focus on saxitoxin-producing cyanobacteria and their non-toxic sisters to elucidate the origin of genes involved in the putative STX biosynthetic pathway. Methodology/Principal Findings: We generated a draft genome assembly of the saxitoxin-producing (STX+) cyanobacterium Anabaena circinalis ACBU02 and searched for 26 candidate saxitoxin-genes (named sxtA to sxtZ) that were recently identified in the toxic strain Cylindrospermopsis raciborskii T3. We also generated a draft assembly of the nontoxic (STX2) sister Anabaena circinalis ACFR02 to aid the identification of saxitoxin-specific genes. Comparative phylogenomic analyses revealed that nine putative STX genes were horizontally transferred from non-cyanobacterial sources, whereas one key gene (sxtA) originated in STX+ cyanobacteria via two independent horizontal transfers followed by fusion. In total, of the 26 candidate saxitoxin-genes, 13 are of cyanobacterial provenance and are monophyletic among the STX+ taxa, four are shared amongst STX+ and STX-cyanobacteria, and the remaining nine genes are specific to STX+ cyanobacteria. Conclusions/Significance: Our results provide evidence that the assembly of STX genes in ACBU02 involved multiple HGT events from different sources followed presumably by coordination of the expression of foreign and native genes in the common ancestor of STX+ cyanobacteria. The ability to produce saxitoxin was subsequently lost multiple independent times resulting in a nested relationship of STX+ and STX2 strains among Anabaena circinalis strains.			Moustafa, A (corresponding author), Univ Iowa, Interdisciplinary Program Genet, Iowa City, IA 52242 USA.	debashi-bhattacharya@uiowa.edu	Moustafa, Ahmed/AAZ-3991-2020; Moustafa, Ahmed/C-5234-2009	Moustafa, Ahmed/0000-0002-0111-3555; Moustafa, Ahmed/0000-0002-0111-3555	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P50ES012742, R01ES013679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008629, R01GM098629] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES013679-01A2, R01 ES013679, P50 ES012742] Funding Source: Medline; NIGMS NIH HHS [T32 GM98629, T32 GM008629, R01 GM098629] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aziz RK, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-75; Beltran EC, 2000, APPL ENVIRON MICROB, V66, P4468, DOI 10.1128/AEM.66.10.4468-4474.2000; Besemer J, 2001, NUCLEIC ACIDS RES, V29, P2607, DOI 10.1093/nar/29.12.2607; Bolch CJS, 1996, J APPL PHYCOL, V8, P5, DOI 10.1007/BF02186215; Carmichael WW, 1997, APPL ENVIRON MICROB, V63, P3104, DOI 10.1128/AEM.63.8.3104-3110.1997; Chorus I., 1999, Toxic cyanobacteria in water: a guide to their public health consequences, monitoring and management; Christiansen G, 2008, MOL BIOL EVOL, V25, P1695, DOI 10.1093/molbev/msn120; FELSENSTEIN J, 1973, AM J HUM GENET, V25, P471; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; HAWSER SP, 1991, TOXICON, V29, P277, DOI 10.1016/0041-0101(91)90231-F; Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436; Kellmann R, 2008, APPL ENVIRON MICROB, V74, P4044, DOI 10.1128/AEM.00353-08; Kellmann R, 2007, J PHYCOL, V43, P497, DOI 10.1111/j.1529-8817.2007.00351.x; Kim JS, 1999, J PHYCOL, V35, P865, DOI 10.1046/j.1529-8817.1999.3540865.x; KROHN A, 2005, GENOME ANAL SAXITOXI; Lagesen K, 2007, NUCLEIC ACIDS RES, V35, P3100, DOI 10.1093/nar/gkm160; Laskowski RA, 1997, TRENDS BIOCHEM SCI, V22, P488, DOI 10.1016/S0968-0004(97)01140-7; Letunic I, 2006, NUCLEIC ACIDS RES, V34, pD257, DOI 10.1093/nar/gkj079; MOUSTAFA A, 2008, EASYCLUSTER SIMPLE P; Moustafa A, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-6; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nguyen TT, 2008, BIOCHEMISTRY-US, V47, P1194, DOI 10.1021/bi7017738; O'Brien EA, 2007, NUCLEIC ACIDS RES, V35, pD445, DOI 10.1093/nar/gkl770; Plumley FG, 2001, J PHYCOL, V37, P926; Pomati F, 2004, APPL ENVIRON MICROB, V70, P4711, DOI 10.1128/AEM.70.8.4711-4719.2004; Pruitt KD, 2007, NUCLEIC ACIDS RES, V35, pD61, DOI 10.1093/nar/gkl842; ROWAN R, 1991, MAR ECOL PROG SER, V71, P65, DOI 10.3354/meps071065; Sako Y, 2001, J PHYCOL, V37, P1044, DOI 10.1046/j.1529-8817.2001.00119.x; SHIMIZU Y, 1984, J AM CHEM SOC, V106, P6433, DOI 10.1021/ja00333a062; Stamatakis A, 2005, BIOINFORMATICS, V21, P456, DOI 10.1093/bioinformatics/bti191; Talavera G, 2007, SYST BIOL, V56, P564, DOI 10.1080/10635150701472164; Taroncher-Oldenburg G, 2000, APPL ENVIRON MICROB, V66, P2105, DOI 10.1128/AEM.66.5.2105-2112.2000; Tavare S., 1986, LECT MATH LIFE SCI, V17, P57, DOI DOI 10.1016/J.MARPOLBUL.2009.11.011; URIBE P, 2008, MAR BIOTECHNOL NY; Wheeler DL, 2008, NUCLEIC ACIDS RES, V36, pD13, DOI 10.1093/nar/gkm1000; Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851; WILSON K, 1990, CURRENT PROTOCOLS MO; Zhaxybayeva O, 2006, GENOME RES, V16, P1099, DOI 10.1101/gr.5322306; RAPID ANNOTATION USI	40	95	97	5	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2009	4	6							e5758	10.1371/journal.pone.0005758	http://dx.doi.org/10.1371/journal.pone.0005758			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	452GL	19484122	gold, Green Submitted, Green Published			2022-12-25	WOS:000266528200011
J	Wiswede, D; Munte, TF; Kramer, UM; Russeler, J				Wiswede, Daniel; Muente, Thomas F.; Kraemer, Ulrike M.; Ruesseler, Jascha			Embodied Emotion Modulates Neural Signature of Performance Monitoring	PLOS ONE			English	Article							FACIAL FEEDBACK HYPOTHESIS; ERROR-RELATED NEGATIVITY; POSITIVE AFFECT; COGNITIVE CONTROL; DOPAMINE NEURONS; FRONTAL-CORTEX; BRAIN ACTIVITY; REWARD; SYSTEM; PREDICTION	Background: Recent research on the "embodiment of emotion'' implies that experiencing an emotion may involve perceptual, somatovisceral, and motor feedback aspects. For example, manipulations of facial expression and posture appear to induce emotional states and influence how affective information is processed. The present study investigates whether performance monitoring, a cognitive process known to be under heavy control of the dopaminergic system, is modulated by induced facial expressions. In particular, we focused on the error-related negativity, an electrophysiological correlate of performance monitoring. Methods/Principal Findings: During a choice reaction task, participants held a Chinese chop stick either horizontally between the teeth ("smile'' condition) or, in different runs, vertically ("no smile'') with the upper lip. In a third control condition, no chop stick was used ("no stick''). It could be shown on a separate sample that the facial feedback procedure is feasible to induce mild changes in positive affect. In the ERP sample, the smile condition, hypothesized to lead to an increase in dopaminergic activity, was associated with a decrease of ERN amplitude relative to "no smile'' and "no stick'' conditions. Conclusion: Embodying emotions by induced facial expressions leads to a changes in the neural correlates of error detection. We suggest that this is due to the joint influence of the dopaminergic system on positive affect and performance monitoring.			Wiswede, D (corresponding author), Otto VonGuericke Univ Magdegurg, Dept Neuropsychol, D-39016 Magdeburg, Germany.	Thomas.Muente@med.ovgu.de	Krämer, Ulrike/AAF-2966-2020; Krämer, Ulrike M./A-8871-2019; Münte, Thomas/C-2077-2014	Krämer, Ulrike M./0000-0002-3841-1812; Wiswede, Daniel/0000-0002-2702-8316; Russeler, Jascha/0000-0002-5053-5914				Ashby F. G., 2002, EMOTIONAL COGNITION, P245, DOI [DOI 10.1075/AICR.44.11ASH, 10.1075/aicr.44.11ash]; Ashby FG, 1999, PSYCHOL REV, V106, P529, DOI 10.1037/0033-295X.106.3.529; Ashby FG, 2003, NEURAL NETWORKS, V16, P973, DOI 10.1016/S0893-6080(03)00051-0; Badre D, 2007, NEUROPSYCHOLOGIA, V45, P2883, DOI 10.1016/j.neuropsychologia.2007.06.015; Badre David, 2002, Behav Cogn Neurosci Rev, V1, P206, DOI 10.1177/1534582302001003002; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Debus G., 1978, EIGENSCHAFTSWORTERLI; Dreisbach G, 2004, J EXP PSYCHOL LEARN, V30, P343, DOI 10.1037/0278-7393.30.2.343; Dreisbach G, 2006, BRAIN COGNITION, V60, P11, DOI 10.1016/j.bandc.2005.08.003; EKMAN P, 1983, SCIENCE, V221, P1208, DOI 10.1126/science.6612338; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Garavan H, 2003, NEUROIMAGE, V20, P1132, DOI 10.1016/S1053-8119(03)00334-3; Gehring WJ, 2000, PSYCHOL SCI, V11, P1, DOI 10.1111/1467-9280.00206; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Hajcak G, 2005, PSYCHOPHYSIOLOGY, V42, P151, DOI 10.1111/j.1469-8986.2005.00270.x; Hajcak G, 2004, BRAIN COGNITION, V56, P189, DOI 10.1016/j.bandc.2003.11.001; Hajcak G, 2003, BIOL PSYCHOL, V64, P77, DOI 10.1016/S0301-0511(03)00103-0; Hajcak G, 2002, PSYCHIAT RES, V110, P63, DOI 10.1016/S0165-1781(02)00034-3; Havas DA, 2007, PSYCHON B REV, V14, P436, DOI 10.3758/BF03194085; HESS U, 1992, INT J PSYCHOPHYSIOL, V12, P251, DOI 10.1016/0167-8760(92)90064-I; Hollerman JR, 1998, NAT NEUROSCI, V1, P304, DOI 10.1038/1124; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; Isen AM, 2001, J CONSUM PSYCHOL, V11, P75, DOI 10.1207/S15327663JCP1102_01; ISEN AM, 1987, J PERS SOC PSYCHOL, V52, P1122, DOI 10.1037/0022-3514.52.6.1122; James W., 1884, MIND, V9, P34, DOI [10.1093/mind/os-IX.34.188, DOI 10.1093/MIND/OS-IX.34.188]; JANKE W, 1996, INT SKALEN PSYCHIAT, P43; Johannes S, 2001, PSYCHOPHARMACOLOGY, V155, P100, DOI 10.1007/s002130100680; Joyce CA, 2004, PSYCHOPHYSIOLOGY, V41, P313, DOI 10.1111/j.1469-8986.2003.00141.x; Lange CG., 1912, CLASSICAL PSYCHOL, P672; Lee AY, 1999, J CONSUM RES, V26, P115, DOI 10.1086/209554; MATSUMOTO D, 1987, J PERS SOC PSYCHOL, V52, P769, DOI 10.1037/0022-3514.52.4.769; MCCANNE TR, 1987, J PERS SOC PSYCHOL, V52, P759, DOI 10.1037/0022-3514.52.4.759; McIntosh DN, 1996, MOTIV EMOTION, V20, P121, DOI 10.1007/BF02253868; Munte TF, 2008, FRONT HUM NEUROSCI, V1, DOI 10.3389/neuro.09.011.2007; Niedenthal PM, 2007, SCIENCE, V316, P1002, DOI 10.1126/science.1136930; OHIRA H, 1993, PERCEPT MOTOR SKILL, V77, P1251, DOI 10.2466/pms.1993.77.3f.1251; Rabbit P.M.A., 1981, HUMAN SKILLS, P153; Rabbitt P, 2002, Q J EXP PSYCHOL-A, V55, P1081, DOI 10.1080/02724980244000080; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Ridderinkhof KR, 2002, SCIENCE, V298, P2209, DOI 10.1126/science.1076929; Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4; Schultz W, 2000, NAT REV NEUROSCI, V1, P199, DOI 10.1038/35044563; Schultz W, 1998, NEUROPHARMACOLOGY, V37, P421, DOI 10.1016/S0028-3908(98)00071-9; SCHWARTZ GE, 1980, PSYCHOPHYSIOLOGY, V17, P75, DOI 10.1111/j.1469-8986.1980.tb02463.x; Soussignan R, 2002, EMOTION, V2, P52, DOI 10.1037/1528-3542.2.1.52; STRACK F, 1988, J PERS SOC PSYCHOL, V54, P768, DOI 10.1037/0022-3514.54.5.768; Tobler PN, 2003, J NEUROSCI, V23, P10402; Ullsperger M, 2003, J NEUROSCI, V23, P4308, DOI 10.1523/jneurosci.23-10-04308.2003; Ungless MA, 2004, TRENDS NEUROSCI, V27, P702, DOI 10.1016/j.tins.2004.10.001; Weber CS, 2007, SCAND J PSYCHOL, V48, P459, DOI 10.1111/j.1467-9450.2007.00612.x; WISWEDE D, 2007, EMOTIONAL MODULATION; Wiswede D, 2009, NEUROPSYCHOLOGIA, V47, P83, DOI 10.1016/j.neuropsychologia.2008.08.016; ZUCKERMAN M, 1981, J PERS SOC PSYCHOL, V41, P929, DOI 10.1037/0022-3514.41.5.929	53	37	44	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2009	4	6							e5754	10.1371/journal.pone.0005754	http://dx.doi.org/10.1371/journal.pone.0005754			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	452GL	19484132	Green Published, gold, Green Submitted			2022-12-25	WOS:000266528200007
J	Li, H; Wang, DM; Singh, LS; Berk, M; Tan, HY; Zhao, ZW; Steinmetz, R; Kirmani, K; Wei, G; Xu, Y				Li, Hui; Wang, Dongmei; Singh, Lisam Shanjukumar; Berk, Michael; Tan, Haiyan; Zhao, Zhenwen; Steinmetz, Rosemary; Kirmani, Kashif; Wei, Gang; Xu, Yan			Abnormalities in Osteoclastogenesis and Decreased Tumorigenesis in Mice Deficient for Ovarian Cancer G Protein-Coupled Receptor 1	PLOS ONE			English	Article								Ovarian cancer G protein-coupled receptor 1 (OGR1) has been shown to be a proton sensing receptor in vitro. We have shown that OGR1 functions as a tumor metastasis suppressor gene when it is over-expressed in human prostate cancer cells in vivo. To examine the physiological functions of OGR1, we generated conditional OGR1 deficient mice by homologous recombination. OGR1 deficient mice were viable and upon gross-inspection appeared normal. Consistent with in vitro studies showing that OGR1 is involved in osteoclastogenesis, reduced osteoclasts were detected in OGR1 deficient mice. A pH-dependent osteoclasts survival effect was also observed. However, overall abnormality in the bones of these animals was not observed. In addition, melanoma cell tumorigenesis was significantly inhibited in OGR1 deficient mice. OGR1 deficient mice in the mixed background produced significantly less peritoneal macrophages when stimulated with thioglycolate. These macrophages also showed altered extracellular signal-regulated kinases (ERK) activation and nitric oxide (NO) production in response to lipopolysaccharide. OGR1-dependent pH responses assessed by cAMP production and cell survival in macrophages or brown fat cells were not observed, presumably due to the presence of other proton sensing receptors in these cells. Our results indicate that OGR1's role in osteoclastogenesis is not strong enough to affect overall bone development and its role in tumorigenesis warrants further investigation. The mice generated can be potentially used for several disease models, including cancers or osteoclast-related diseases.			Li, H (corresponding author), Indiana Univ, Sch Med, Dept Obstet & Gynecol, Ctr Canc, Indianapolis, IN 46202 USA.	xu2@iupui.edu	Berk, Michael/M-3585-2019; Berk, Michael/M-7891-2013	Berk, Michael/0000-0002-5554-6946; Berk, Michael/0000-0002-5554-6946	NATIONAL CANCER INSTITUTE [R01CA089228] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068804] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA89228, R01 CA089228] Funding Source: Medline; NHLBI NIH HHS [R01 HL68804, R01 HL068804] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AN SZ, 1995, FEBS LETT, V375, P121, DOI 10.1016/0014-5793(95)01196-L; Bolick DT, 2007, CIRC RES, V100, P572, DOI 10.1161/01.RES.0000258877.57836.d2; Giordano Antonio, 2008, V456, P83, DOI 10.1007/978-1-59745-245-8_6; Im DS, 2005, ACTA PHARMACOL SIN, V26, P1435, DOI 10.1111/j.1745-7254.2005.00237.x; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; Ishii S, 2005, J BIOL CHEM, V280, P9083, DOI 10.1074/jbc.M407832200; IWAI K, 2007, J BONE MINER RES; Jeon ES, 2006, J CELL SCI, V119, P4994, DOI 10.1242/jcs.03281; Johnson LE, 2008, HEPATOLOGY, V48, P1138, DOI 10.1002/hep.22433; Le LQ, 2001, IMMUNITY, V14, P561, DOI 10.1016/S1074-7613(01)00145-5; Lewandoski M, 1997, CURR BIOL, V7, P148, DOI 10.1016/S0960-9822(06)00059-5; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Mogi C, 2005, J PHARMACOL SCI, V99, P160, DOI 10.1254/jphs.FP0050599; Mogi C, 2009, J IMMUNOL, V182, P3243, DOI 10.4049/jimmunol.0803466; Murakami N, 2004, J BIOL CHEM, V279, P42484, DOI 10.1074/jbc.M406561200; Nardin A, 2008, FRONT BIOSCI-LANDMRK, V13, P3494; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; Parks BW, 2009, ARTERIOSCL THROM VAS, V29, P539, DOI 10.1161/ATVBAHA.108.179937; Parks BW, 2005, J LIPID RES, V46, P1405, DOI 10.1194/jlr.M500085-JLR200; Pereverzev A, 2008, BONE, V42, P150, DOI 10.1016/j.bone.2007.08.044; Radu CG, 2006, MOL CELL BIOL, V26, P668, DOI 10.1128/MCB.26.2.668-677.2006; Radu CG, 2005, P NATL ACAD SCI USA, V102, P1632, DOI 10.1073/pnas.0409415102; SCHREIBER RD, 1982, J EXP MED, V156, P677, DOI 10.1084/jem.156.3.677; Singh LS, 2007, JNCI-J NATL CANCER I, V99, P1313, DOI 10.1093/jnci/djm107; Soler C, 2001, J BIOL CHEM, V276, P30043, DOI 10.1074/jbc.M101807200; Tomura H, 2005, J BIOL CHEM, V280, P34458, DOI 10.1074/jbc.M505287200; Tomura H, 2005, CELL SIGNAL, V17, P1466, DOI 10.1016/j.cellsig.2005.06.002; TOMURA H, 2008, J BONE MINER RES; Tosa N, 2003, INT IMMUNOL, V15, P741, DOI 10.1093/intimm/dxg070; Valverde AM, 2005, MINI-REV MED CHEM, V5, P269, DOI 10.2174/1389557053175380; Wang JQ, 2004, J BIOL CHEM, V279, P45626, DOI 10.1074/jbc.M406966200; Warden CH, 2004, MAMM GENOME, V15, P460, DOI 10.1007/s00335-004-2353-9; Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133; Xu Y, 1996, GENOMICS, V35, P397, DOI 10.1006/geno.1996.0377; Yang LV, 2007, MOL CELL BIOL, V27, P1334, DOI 10.1128/MCB.01909-06; Yang LV, 2005, BLOOD, V105, P1127, DOI 10.1182/blood-2004-05-1916; Yang MH, 2006, J BIOL CHEM, V281, P23598, DOI 10.1074/jbc.M602191200	37	61	64	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2009	4	5							e5705	10.1371/journal.pone.0005705	http://dx.doi.org/10.1371/journal.pone.0005705			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QE	19479052	Green Published, gold			2022-12-25	WOS:000266415100008
J	Yordanova, J; Kolev, V; Wagner, U; Verleger, R				Yordanova, Juliana; Kolev, Vasil; Wagner, Ullrich; Verleger, Rolf			Covert Reorganization of Implicit Task Representations by Slow Wave Sleep	PLOS ONE			English	Article							LONG-TERM-MEMORY; LATE-NIGHT SLEEP; BRAIN POTENTIALS; CONSOLIDATION; INFORMATION; RETRIEVAL; HIPPOCAMPUS; AWARENESS; HUMANS; SYSTEM	Background: There is evidence that slow wave sleep (SWS) promotes the consolidation of memories that are subserved by mediotemporal- and hippocampo-cortical neural networks. In contrast to implicit memories, explicit memories are accompanied by conscious (attentive and controlled) processing. Awareness at pre-sleep encoding has been recognized as critical for the off-line memory consolidation. The present study elucidated the role of task-dependent cortical activation guided by attentional control at pre-sleep encoding for the consolidation of hippocampus-dependent memories during sleep. Methodology: A task with a hidden regularity was used (Number Reduction Task, NRT), in which the responses that can be implicitly predicted by the hidden regularity activate hippocampo-cortical networks more strongly than responses that cannot be predicted. Task performance was evaluated before and after early-night sleep, rich in SWS, and late-night sleep, rich in rapid eye movement (REM) sleep. In implicit conditions, slow cortical potentials (SPs) were analyzed to reflect the amount of controlled processing and the localization of activated neural task representations. Principal Findings: During implicit learning before sleep, the amount of controlled processing did not differ between unpredictable and predictable responses, nor between early-and late-night sleep groups. A topographic re-distribution of SPs indicating a spatial reorganization occurred only after early, not after late sleep, and only for predictable responses. These SP changes correlated with the amount of SWS and were covert because off-line RT decrease did not differentiate response types or sleep groups. Conclusions: It is concluded that SWS promotes the neural reorganization of task representations that rely on the hippocampal system despite absence of conscious access to these representations.			Yordanova, J (corresponding author), Med Univ Lubeck, Dept Neurol, D-23538 Lubeck, Germany.	jyord@gmx.net	Yordanova, Juliana/I-4690-2014; Kolev, Vasil/B-4595-2008	Yordanova, Juliana/0000-0003-4500-1122; Kolev, Vasil/0000-0002-2694-2149; Lauwereyns, Jan/0000-0003-0551-2550				Born J, 2006, NEUROSCIENTIST, V12, P410, DOI 10.1177/1073858406292647; Cohen NJ, 1999, HIPPOCAMPUS, V9, P83, DOI 10.1002/(SICI)1098-1063(1999)9:1<83::AID-HIPO9>3.0.CO;2-7; Degonda N, 2005, NEURON, V46, P505, DOI 10.1016/j.neuron.2005.02.030; Drosopoulos S, 2005, LEARN MEMORY, V12, P44, DOI 10.1101/lm.83805; Elsner B, 2002, NEUROIMAGE, V17, P364, DOI 10.1006/nimg.2002.1162; Fischer S, 2006, J COGNITIVE NEUROSCI, V18, P311, DOI 10.1162/089892906775990598; Forkstam C, 2005, CURR OPIN NEUROL, V18, P435, DOI 10.1097/01.wco.0000171951.82995.c4; Frensch PA, 2002, ATTENTION IMPLICIT L, P335; Gais S, 2004, LEARN MEMORY, V11, P679, DOI 10.1101/lm.80504; Gais S, 2000, NAT NEUROSCI, V3, P1335, DOI 10.1038/81881; Gais S, 2007, P NATL ACAD SCI USA, V104, P18778, DOI 10.1073/pnas.0705454104; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Graves LA, 2003, LEARN MEMORY, V10, P168, DOI 10.1101/lm.48803; Greene AJ, 2007, HIPPOCAMPUS, V17, P429, DOI 10.1002/hipo.20296; Haider H, 2007, METHODS, V42, P49, DOI 10.1016/j.ymeth.2006.12.004; Heil M, 1997, NEUROSCI LETT, V222, P45, DOI 10.1016/S0304-3940(97)13338-9; Henke K, 1999, P NATL ACAD SCI USA, V96, P5884, DOI 10.1073/pnas.96.10.5884; KARNI A, 1994, SCIENCE, V265, P679, DOI 10.1126/science.8036518; Khader P, 2005, NEUROIMAGE, V27, P805, DOI 10.1016/j.neuroimage.2005.05.006; Khader P, 2007, J COGNITIVE NEUROSCI, V19, P493, DOI 10.1162/jocn.2007.19.3.493; LANG S, 2006, J COGNITIVE NEUROSCI, V18, P1; Maquet P, 2001, SCIENCE, V294, P1048, DOI 10.1126/science.1062856; Marshall L, 2006, NATURE, V444, P610, DOI 10.1038/nature05278; Marshall U, 2007, TRENDS COGN SCI, V11, P442, DOI 10.1016/j.tics.2007.09.001; MCCARTHY G, 1985, ELECTROEN CLIN NEURO, V62, P203, DOI 10.1016/0168-5597(85)90015-2; Orban P, 2006, P NATL ACAD SCI USA, V103, P7124, DOI 10.1073/pnas.0510198103; Plihal W, 1999, PSYCHOPHYSIOLOGY, V36, P571, DOI 10.1111/1469-8986.3650571; Rasch B, 2007, CURR OPIN NEUROBIOL, V17, P698, DOI 10.1016/j.conb.2007.11.007; Rasch B, 2007, SCIENCE, V315, P1426, DOI 10.1126/science.1138581; REBER PJ, 1994, LEARN MEMORY, V1, P217; Rechtschaffen A, 1968, NIH PUBL, V204; Robertson EM, 2009, PLOS BIOL, V7, P11, DOI 10.1371/journal.pbio.1000019; Robertson EM, 2004, CURR BIOL, V14, P208, DOI 10.1016/j.cub.2004.01.027; Rockstroh B., 1989, SLOW CORTICAL POTENT; Rose M, 2005, J COGNITIVE NEUROSCI, V17, P918, DOI 10.1162/0898929054021193; Rose M, 2004, LEARN MEMORY, V11, P145, DOI 10.1101/lm.67204; Rose M, 2002, NEURON, V36, P1221, DOI 10.1016/S0896-6273(02)01105-4; ROSLER F, 1995, J COGNITIVE NEUROSCI, V7, P51, DOI 10.1162/jocn.1995.7.1.51; Rosler F, 1997, BIOL PSYCHOL, V45, P109, DOI 10.1016/S0301-0511(96)05225-8; RUCHKIN DS, 1988, HUMAN EVENT RELATED, V3, P7; Schabus M, 2004, SLEEP, V27, P1479, DOI 10.1093/sleep/27.7.1479; Spencer RMC, 2006, CURR BIOL, V16, P1001, DOI 10.1016/j.cub.2006.03.094; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Stickgold R, 2000, NAT NEUROSCI, V3, P1237, DOI 10.1038/81756; Stickgold R, 2005, NATURE, V437, P1272, DOI 10.1038/nature04286; Tse D, 2007, SCIENCE, V316, P76, DOI 10.1126/science.1135935; Verleger R, 2008, BRAIN COGNITION, V68, P180, DOI 10.1016/j.bandc.2008.04.006; Wagner U, 2004, NATURE, V427, P352, DOI 10.1038/nature02223; Walker MP, 2004, NEURON, V44, P121, DOI 10.1016/j.neuron.2004.08.031; Walker MP, 2002, NEURON, V35, P205, DOI 10.1016/S0896-6273(02)00746-8; Woltz DJ, 1996, J EXP PSYCHOL LEARN, V22, P438, DOI 10.1037/0278-7393.22.2.438; Yeshenko O, 2006, J SLEEP RES, V15, P11; Yordanova J, 2008, LEARN MEMORY, V15, P508, DOI 10.1101/lm.897908	53	20	20	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2009	4	5							e5675	10.1371/journal.pone.0005675	http://dx.doi.org/10.1371/journal.pone.0005675			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	449LI	19479080	gold, Green Submitted, Green Published			2022-12-25	WOS:000266331700004
J	Israel, S; Lerer, E; Shalev, I; Uzefovsky, F; Riebold, M; Laiba, E; Bachner-Melman, R; Maril, A; Bornstein, G; Knafo, A; Ebstein, RP				Israel, Salomon; Lerer, Elad; Shalev, Idan; Uzefovsky, Florina; Riebold, Mathias; Laiba, Efrat; Bachner-Melman, Rachel; Maril, Anat; Bornstein, Gary; Knafo, Ariel; Ebstein, Richard P.			The Oxytocin Receptor (OXTR) Contributes to Prosocial Fund Allocations in the Dictator Game and the Social Value Orientations Task	PLOS ONE			English	Article							NEURAL CIRCUITRY; UNIFIED APPROACH; GENE OXTR; VASOPRESSIN; ASSOCIATION; BEHAVIOR; AUTISM; AVPR1A; TESTS; TRUST	Background: Economic games observe social decision making in the laboratory that involves real money payoffs. Previously we have shown that allocation of funds in the Dictator Game (DG), a paradigm that illustrates costly altruistic behavior, is partially determined by promoter-region repeat region variants in the arginine vasopressin 1a receptor gene (AVPR1a). In the current investigation, the gene encoding the related oxytocin receptor (OXTR) was tested for association with the DG and a related paradigm, the Social Values Orientation (SVO) task. Methodology/Principal Findings: Association (101 male and 102 female students) using a robust-family based test between 15 single tagging SNPs (htSNPs) across the OXTR was demonstrated with both the DG and SVO. Three htSNPs across the gene region showed significant association with both of the two games. The most significant association was observed with rs1042778 (p = 0.001). Haplotype analysis also showed significant associations for both DG and SVO. Following permutation test adjustment, significance was observed for 2-5 locus haplotypes (p < 0.05). A second sample of 98 female subjects was subsequently and independently recruited to play the dictator game and was genotyped for the three significant SNPs found in the first sample. The rs1042778 SNP was shown to be significant for the second sample as well (p = 0.004, Fisher's exact test). Conclusions: The demonstration that genetic polymorphisms for the OXTR are associated with human prosocial decision making converges with a large body of animal research showing that oxytocin is an important social hormone across vertebrates including Homo sapiens. Individual differences in prosocial behavior have been shown by twin studies to have a substantial genetic basis and the current investigation demonstrates that common variants in the oxytocin receptor gene, an important element of mammalian social circuitry, underlie such individual differences.			Israel, S (corresponding author), Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel.	rpebstein@gmail.com	Bachner-Melman, Rachel/AAD-9411-2019; Shalev, Idan/H-1943-2011; Knafo-Noam, Ariel/E-8067-2011	Bachner-Melman, Rachel/0000-0002-8840-2914; Knafo-Noam, Ariel/0000-0003-0613-1960; Uzefovsky, Florina/0000-0003-4571-2514; Israel, Salomon/0000-0003-3629-2466; Ebstein, Richard/0000-0002-3626-541X				Bachner-Melman R, 2005, PLOS GENET, V1, P394, DOI 10.1371/journal.pgen.0010042; Bachner-Melman R, 2005, MOL PSYCHIATR, V10, P333, DOI 10.1038/sj.mp.4001635; Bachner-Melman R, 2004, INT J EAT DISORDER, V36, P451, DOI 10.1002/eat.20049; Bachner-Melman R., 2005, J INDIVID DIFFER, V26, P2, DOI DOI 10.1027/1614-0001.26.1.2; Bales KL, 2004, HORM BEHAV, V45, P354, DOI 10.1016/j.yhbeh.2004.01.004; Barberis C, 1998, J ENDOCRINOL, V156, P223, DOI 10.1677/joe.0.1560223; Bartels A, 2004, NEUROIMAGE, V21, P1155, DOI 10.1016/j.neuroimage.2003.11.003; Bartz JA, 2006, HORM BEHAV, V50, P518, DOI 10.1016/j.yhbeh.2006.06.018; Baumgartner T, 2008, NEURON, V58, P639, DOI 10.1016/j.neuron.2008.04.009; Bielsky IF, 2004, PEPTIDES, V25, P1565, DOI 10.1016/j.peptides.2004.05.019; Blanks AM, 2007, SEMIN REPROD MED, V25, P52, DOI 10.1055/s-2006-956775; BOSSMAR T, 1995, BRIT J OBSTET GYNAEC, V102, P907, DOI 10.1111/j.1471-0528.1995.tb10880.x; Carter CS, 1998, PSYCHONEUROENDOCRINO, V23, P779; Carter CS, 2006, BEHAV BRAIN RES; Cho MM, 1999, BEHAV NEUROSCI, V113, P1071, DOI 10.1037/0735-7044.113.5.1071; Crawford DC, 2005, ANNU REV MED, V56, P303, DOI 10.1146/annurev.med.56.082103.104540; Domes G, 2006, BIOL PSYCHIAT; Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025; Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252; Eckel CC, 1996, GAME ECON BEHAV, V16, P181, DOI 10.1006/game.1996.0081; Fehr E, 2007, TRENDS COGN SCI, V11, P419, DOI 10.1016/j.tics.2007.09.002; Fries ABW, 2005, P NATL ACAD SCI USA, V102, P17237, DOI 10.1073/pnas.0504767102; Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641; Gordon I., 2008, PSYCHOPHYSIOLOGY; GRANOT R, 2007, EVOLUTION H IN PRESS; Guastella A.J., 2007, BIOL PSYCHIAT; Halldorsson BV, 2004, HUM HERED, V58, P190, DOI 10.1159/000083546; Henrich J, 2005, BEHAV BRAIN SCI, V28, P795, DOI 10.1017/S0140525X05000142; Herbert A, 2006, SCIENCE, V312, P279, DOI 10.1126/science.1124779; Hirasawa M, 2003, J NEUROSCI, V23, P4270; Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.biopsych.2006.05.030; ISRAEL S, 2008, PROG BRAIN IN PRESS; Jacob S, 2007, NEUROSCI LETT, V417, P6, DOI 10.1016/j.neulet.2007.02.001; Kim SJ, 2002, MOL PSYCHIATR, V7, P503, DOI 10.1038/sj.mp.4001125; Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005; Knafo A, 2006, J PERS SOC PSYCHOL, V90, P147, DOI 10.1037/0022-3514.90.1.147; KNAFO A, ANN NEW YOR IN PRESS; KNAFO A, 2007, GENES BRAIN BEHAV; Knafo A, 2006, DEV PSYCHOL, V42, P771, DOI 10.1037/0012-1649.42.5.771; Koeleman BPC, 2000, ANN HUM GENET, V64, P207, DOI 10.1017/S0003480000008095; Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D; Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001; Lange C, 2004, AM J HUM GENET, V74, P367, DOI 10.1086/381563; Lerer E, 2008, MOL PSYCHIATR, V13, P980, DOI 10.1038/sj.mp.4002087; LOEWENSTEIN G, 2007, ANN REV PSYCHOL; Meinlschmidt G, 2007, BIOL PSYCHIAT, V61, P1109, DOI 10.1016/j.biopsych.2006.09.007; Mizumoto Y, 1997, MOL CELL ENDOCRINOL, V135, P129, DOI 10.1016/S0303-7207(97)00195-0; Pedersen CA, 2006, NEUROSCIENCE, V139, P843, DOI 10.1016/j.neuroscience.2006.01.002; PRICHARD ZM, 2007, ONLINE HUM MUTAT, V28, P1150; Rabinowitz D, 2000, HUM HERED, V50, P211, DOI 10.1159/000022918; Ragnauth AK, 2004, NEUROENDOCRINOLOGY, V80, P92, DOI 10.1159/000081844; Savaskan E., 2008, PSYCHONEUROENDOCRINO; Schinka JA, 2004, MOL PSYCHIATR, V9, P197, DOI 10.1038/sj.mp.4001405; STEEN KV, 2005, HUM GENOMICS, V2, P67; Storm EE, 2005, NEURON, V47, P483, DOI 10.1016/j.neuron.2005.08.004; Thompson R, 2004, PSYCHONEUROENDOCRINO, V29, P35, DOI 10.1016/S0306-4530(02)00133-6; Van Lange PAM, 1999, J PERS SOC PSYCHOL, V77, P337, DOI 10.1037/0022-3514.77.2.337; VanLange PAM, 1997, J PERS SOC PSYCHOL, V73, P733, DOI 10.1037/0022-3514.73.4.733; Wassink TH, 2004, MOL PSYCHIATR, V9, P968, DOI 10.1038/sj.mp.4001503; Wu SP, 2005, BIOL PSYCHIAT, V58, P74, DOI 10.1016/j.biopsych.2005.03.013; Yirmiya N, 2006, MOL PSYCHIATR, V11, P488, DOI 10.1038/sj.mp.4001812; Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327; Zak PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001128; Zak PJ, 2006, ECON HUM BIOL, V4, P412, DOI 10.1016/j.ehb.2006.06.004; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	67	189	198	4	71	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5535	10.1371/journal.pone.0005535	http://dx.doi.org/10.1371/journal.pone.0005535			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	448AY	19461999	Green Published, gold, Green Submitted			2022-12-25	WOS:000266234700002
J	Long, EM; Millen, B; Kubes, P; Robbins, SM				Long, Elizabeth M.; Millen, Brandie; Kubes, Paul; Robbins, Stephen M.			Lipoteichoic Acid Induces Unique Inflammatory Responses when Compared to Other Toll-Like Receptor 2 Ligands	PLOS ONE			English	Article								Toll-like receptors (TLRs) recognize evolutionarily-conserved molecular patterns originating from invading microbes. In this study, we were interested in determining if microbial ligands, which use distinct TLR2-containing receptor complexes, represent unique signals to the cell and can thereby stimulate unique cellular responses. Using the TLR2 ligands, R-FSL1, S-FSL1, Pam2CSK4, Pam3CSK4, and lipoteichoic acid (LTA), we demonstrate that these ligands activate NF-kappa B and MAP Kinase pathways with ligand-specific differential kinetics in murine macrophages. Most strikingly, LTA stimulation of these pathways was substantially delayed when compared with the other TLR2 ligands. These kinetics differences were associated with a delay in the LTA-induced expression of a subset of genes as compared with another TLR2 ligand, R-FSL1. However, this did not translate to overall differences in gene expression patterns four hours following stimulation with different TLR2 ligands. We extended this study to evaluate the in vivo responses to distinct TLR2 ligands using a murine model of acute inflammation, which employs intravital microscopy to monitor leukocyte recruitment into the cremaster muscle. We found that, although R-FSL1, S-FSL1, Pam2CSK4, and Pam3CSK4 were all able to stimulate robust leukocyte recruitment in vivo, LTA remained functionally inert in this in vivo model. Therefore distinct TLR2 ligands elicit unique cellular responses, as evidenced by differences in the kinetic profiles of signaling and gene expression responses in vitro, as well as the physiologically relevant differences in the in vivo responses to these ligands.			Long, EM (corresponding author), Univ Calgary, Dept Oncol, Calgary, AB, Canada.	srobbins@ucalgary.ca		Robbins, Stephen/0000-0001-7475-1665				Albrecht I, 2004, EMBO REP, V5, P172, DOI 10.1038/sj.embor.7400078; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; Bisson SA, 2002, ONCOGENE, V21, P3677, DOI 10.1038/sj.onc.1205510; BRAUN V, 1975, BIOCHIM BIOPHYS ACTA, V415, P335, DOI 10.1016/0304-4157(75)90013-1; Dessing MC, 2008, J INFECT DIS, V197, P245, DOI 10.1086/524873; Farhat K, 2008, J LEUKOCYTE BIOL, V83, P692, DOI 10.1189/jlb.0807586; Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836; Georgel P, 2007, VIROLOGY, V362, P304, DOI 10.1016/j.virol.2006.12.032; Gerold G, 2008, NAT IMMUNOL, V9, P761, DOI 10.1038/ni.1618; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jiang ZF, 2005, NAT IMMUNOL, V6, P565, DOI 10.1038/ni1207; Kagan JC, 2008, NAT IMMUNOL, V9, P361, DOI 10.1038/ni1569; Kanwar S, 1997, J EXP MED, V185, P1077, DOI 10.1084/jem.185.6.1077; Kruithof EKO, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-148; Litvak V, 2009, NAT IMMUNOL, V10, P437, DOI 10.1038/ni.1721; Morath S, 2001, J EXP MED, V193, P393, DOI 10.1084/jem.193.3.393; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Nilsen NJ, 2008, J LEUKOCYTE BIOL, V84, P280, DOI 10.1189/jlb.0907656; O'Neill L A, 2000, Sci STKE, V2000, pre1; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Robichon C, 2005, J BIOL CHEM, V280, P974, DOI 10.1074/jbc.M411059200; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Takeda K, 2002, J ENDOTOXIN RES, V8, P459, DOI 10.1179/096805102125001073; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Uematsu Satoshi, 2008, V183, P1; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Yipp BG, 2002, J IMMUNOL, V168, P4650, DOI 10.4049/jimmunol.168.9.4650	30	44	47	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5601	10.1371/journal.pone.0005601	http://dx.doi.org/10.1371/journal.pone.0005601			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19440307	Green Submitted, Green Published, gold			2022-12-25	WOS:000266161200004
J	Lu, JY; Jeong, H; Kong, N; Yang, YY; Carroll, J; Luo, HBR; Silberstein, LE; Ma, YP; Chai, L				Lu, Jiayun; Jeong, Hawon; Kong, Nikki; Yang, Youyang; Carroll, John; Luo, Hongbo R.; Silberstein, Leslie E.; Ma, Yupo; Chai, Li			Stem Cell Factor SALL4 Represses the Transcriptions of PTEN and SALL1 through an Epigenetic Repressor Complex	PLOS ONE			English	Article								Background: The embryonic stem cell (ESC) factor, SALL4, plays an essential role in both development and leukemogenesis. It is a unique gene that is involved in self-renewal in ESC and leukemic stem cell (LSC). Methodology/Principal Findings: To understand the mechanism(s) of SALL4 function(s), we sought to identify SALL4-associated proteins by tandem mass spectrometry. Components of a transcription repressor Mi-2/Nucleosome Remodeling and Deacetylase (NuRD) complex were found in the SALL4-immunocomplexes with histone deacetylase (HDAC) activity in ESCs with endogenous SALL4 expression and 293T cells overexpressing SALL4. The SALL4-mediated transcriptional regulation was tested on two potential target genes: PTEN and SALL1. Both genes were confirmed as SALL4 downstream targets by chromatin-immunoprecipitation, and their expression levels, when tested by quantitative reverse transcription polymerase chain reaction (qRT-PCR), were decreased in 293T cells overexpressing SALL4. Moreover, SALL4 binding sites at the promoter regions of PTEN and SALL1 were co-occupied by NuRD components, suggesting that SALL4 represses the transcriptions of PTEN and SALL1 through its interactions with the Mi-2/NuRD complex. The in vivo repressive effect( s) of SALL4 were evaluated in SALL4 transgenic mice, where decreased expressions of PTEN and SALL1 were associated with myeloid leukemia and cystic kidneys, respectively. Conclusions/Significance: In summary, we are the first to demonstrate that stem cell protein SALL4 represses its target genes, PTEN and SALL1, through the epigenetic repressor Mi-2/NuRD complex. Our novel finding provides insight into the mechanism(s) of SALL4 functions in kidney development and leukemogenesis.			Lu, JY (corresponding author), Harvard Univ, Brigham & Womens Hosp, Childrens Hosp Boston, Sch Med,Dept Pathol,Joint Program Transfus Med, Boston, MA 02115 USA.	lchai@partners.org		Chai, Li/0000-0003-1937-4750	NATIONAL CANCER INSTITUTE [K08CA097185] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016464] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK063220] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA097185] Funding Source: Medline; NCRR NIH HHS [P20 RR016464] Funding Source: Medline; NHLBI NIH HHS [R01 HL092437] Funding Source: Medline; NIDDK NIH HHS [K08 DK063220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Al-Baradie R, 2002, AM J HUM GENET, V71, P1195, DOI 10.1086/343821; Basson M, 1996, GENE DEV, V10, P1953, DOI 10.1101/gad.10.15.1953; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Borozdin W, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.019505; Camp E, 2003, DEV GENES EVOL, V213, P35, DOI 10.1007/s00427-002-0284-6; Cui W, 2006, MODERN PATHOL, V19, P1585, DOI 10.1038/modpathol.3800694; Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611; Dong PDS, 2003, P NATL ACAD SCI USA, V100, P10293, DOI 10.1073/pnas.1836391100; Elling U, 2006, P NATL ACAD SCI USA, V103, P16319, DOI 10.1073/pnas.0607884103; Hawkins PT, 2006, BIOCHEM SOC T, V34, P647, DOI 10.1042/BST0340647; Hollemann T, 1996, MECH DEVELOP, V55, P19, DOI 10.1016/0925-4773(95)00485-8; Hong W, 2005, EMBO J, V24, P2367, DOI 10.1038/sj.emboj.7600703; Kim SK, 2005, CLIN CANCER RES, V11, P5965, DOI 10.1158/1078-0432.CCR-05-0371; Kohlhase J, 2002, HUM MOL GENET, V11, P2979, DOI 10.1093/hmg/11.23.2979; Kohlhase J, 2003, J MED GENET, V40, P473, DOI 10.1136/jmg.40.7.473; Kohlhase J, 1999, GENOMICS, V62, P216, DOI 10.1006/geno.1999.6005; Kohlhase J, 1996, GENOMICS, V38, P291, DOI 10.1006/geno.1996.0631; Kohlhase J, 2000, MAMM GENOME, V11, P64, DOI 10.1007/s003350010012; Koster R, 1997, DEVELOPMENT, V124, P3147; Kuang SQ, 2008, LEUKEMIA, V22, P1529, DOI 10.1038/leu.2008.130; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; Lauberth SM, 2007, J BIOL CHEM, V282, P34858, DOI 10.1074/jbc.M703702200; Lauberth SM, 2006, J BIOL CHEM, V281, P23922, DOI 10.1074/jbc.M513461200; Lim CY, 2008, CELL STEM CELL, V3, P543, DOI 10.1016/j.stem.2008.08.004; Ma Y, 2002, J ENDOCRINOL, V173, DOI 10.1677/joe.0.1730437; Ma YP, 2001, PEDIATR NEPHROL, V16, P701, DOI 10.1007/s004670100624; Ma YP, 2006, BLOOD, V108, P2726, DOI 10.1182/blood-2006-02-001594; Marlin S, 1999, HUM MUTAT, V14, P377, DOI 10.1002/(SICI)1098-1004(199911)14:5<377::AID-HUMU3>3.0.CO;2-A; McDonel P, 2009, INT J BIOCHEM CELL B, V41, P108, DOI 10.1016/j.biocel.2008.07.022; Neff AW, 2005, DEV DYNAM, V233, P356, DOI 10.1002/dvdy.20363; Nicolson GL, 2003, CLIN EXP METASTAS, V20, P19, DOI 10.1023/A:1022534217769; Nishinakamura R, 2001, DEVELOPMENT, V128, P3105; Palomero T, 2008, CELL CYCLE, V7, P965, DOI 10.4161/cc.7.8.5753; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Rossi DJ, 2006, CELL, V125, P229, DOI 10.1016/j.cell.2006.04.006; Sharov AA, 2007, CELL STEM CELL, V1, P237, DOI 10.1016/j.stem.2007.08.015; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Sweetman D, 2006, DEV BIOL, V293, P285, DOI 10.1016/j.ydbio.2006.02.009; Takahashi K, 2005, BIOCHEM SOC T, V33, P1522, DOI 10.1042/BST0331522; Toker AS, 2003, DEVELOPMENT, V130, P3831, DOI 10.1242/dev.00398; Wong CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001955; Wu Q, 2006, J BIOL CHEM, V281, P24090, DOI 10.1074/jbc.C600122200; Yang JC, 2008, BLOOD, V112, P805, DOI 10.1182/blood-2007-11-126326; Yang JC, 2007, P NATL ACAD SCI USA, V104, P10494, DOI 10.1073/pnas.0704001104; Yilmaz OH, 2008, BLOOD CELL MOL DIS, V41, P73, DOI 10.1016/j.bcmd.2008.02.004; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	49	120	131	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5577	10.1371/journal.pone.0005577	http://dx.doi.org/10.1371/journal.pone.0005577			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440552	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107500008
J	Grimsrud, A; Stein, DJ; Seedat, S; Williams, D; Myer, L				Grimsrud, Anna; Stein, Dan J.; Seedat, Soraya; Williams, David; Myer, Landon			The Association between Hypertension and Depression and Anxiety Disorders: Results from a Nationally-Representative Sample of South African Adults	PLOS ONE			English	Article							BLOOD-PRESSURE; PSYCHOSOCIAL PREDICTORS; GLOBAL BURDEN; YOUNG-ADULTS; SYMPTOMS; HEALTH; RISK; PREVALENCE; SEVERITY; DISTRESS	Objective: Growing evidence suggests high levels of comorbidity between hypertension and mental illness but there are few data from low-and middle-income countries. We examined the association between hypertension and depression and anxiety in South Africa. Methods: Data come from a nationally-representative survey of adults (n = 4351). The Composite International Diagnostic Interview was used to measure DSM-IV mental disorders during the previous 12-months. The relationships between self-reported hypertension and anxiety disorders, depressive disorders and comorbid anxiety-depression were assessed after adjustment for participant characteristics including experience of trauma and other chronic physical conditions. Results: Overall 16.7% reported a previous medical diagnosis of hypertension, and 8.1% and 4.9% were found to have a 12-month anxiety or depressive disorder, respectively. In adjusted analyses, hypertension diagnosis was associated with 12-month anxiety disorders [Odds ratio (OR) = 1.55, 95% Confidence interval (CI) = 1.10-2.18] but not 12-month depressive disorders or 12-month comorbid anxiety-depression. Hypertension in the absence of other chronic physical conditions was not associated with any of the 12-month mental health outcomes (p-values all, <0.05), while being diagnosed with both hypertension and another chronic physical condition were associated with 12-month anxiety disorders (OR = 2.25, 95% CI = 1.46-3.45), but not 12-month depressive disorders or comorbid anxiety-depression. Conclusions: These are the first population-based estimates to demonstrate an association between hypertension and mental disorders in sub-Saharan Africa. Further investigation is needed into role of traumatic life events in the aetiology of hypertension as well as the temporality of the association between hypertension and mental disorders.			Grimsrud, A (corresponding author), Univ Cape Town, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa.	landon.myer@uct.ac.za	Stein, Dan/A-1752-2008; QQ, Simon/D-3888-2014	Stein, Dan/0000-0001-7218-7810; Seedat, Soraya/0000-0002-5118-786X	FOGARTY INTERNATIONAL CENTER [R03TW006481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH069864, R13MH066849, R01MH059575, R01MH070884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016558] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW006481, R01-TW006481] Funding Source: Medline; NIDA NIH HHS [R01 DA016558] Funding Source: Medline; NIMH NIH HHS [R01 MH059575, R01 MH070884, R01MH070884, R13-MH066849, R01 MH069864, R01-MH069864, R01-MH059575, R13 MH066849] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alonso A, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-94; ANDREWS G, 1998, SOC PSYCH PSYCH EPID, V33, P8; COELHO R, 1989, J PSYCHOSOM RES, V33, P187, DOI 10.1016/0022-3999(89)90046-9; Davidson K, 2000, ARCH INTERN MED, V160, P1495, DOI 10.1001/archinte.160.10.1495; Demyttenaere K, 2004, JAMA-J AM MED ASSOC, V291, P2581, DOI 10.1001/jama.291.21.2581; *DEP HLTH S AFR, 1998, S AFR DEM HLTH SURV; Dorn T, 2007, AM J EPIDEMIOL, V165, P410, DOI 10.1093/aje/kwk029; Ellis CG, 2003, SAMJ S AFR MED J, V93, P342; Evans DL, 2005, BIOL PSYCHIAT, V58, P175, DOI 10.1016/j.biopsych.2005.05.001; Goldman N, 2003, J CLIN EPIDEMIOL, V56, P148, DOI 10.1016/S0895-4356(02)00580-2; HAROOO J, 2006, INT J METHODS PSYCHI, V13; Harter MC, 2003, EUR ARCH PSY CLIN N, V253, P313, DOI 10.1007/s00406-003-0449-y; Jonas BS, 1997, ARCH FAM MED, V6, P43, DOI 10.1001/archfami.6.1.43; Jones DR, 2004, PSYCHIAT SERV, V55, P1250, DOI 10.1176/appi.ps.55.11.1250; JonesWebb R, 1996, ALCOHOL CLIN EXP RES, V20, P420, DOI 10.1111/j.1530-0277.1996.tb01069.x; Kadam UT, 2005, J CLIN EPIDEMIOL, V58, P909, DOI 10.1016/j.jclinepi.2005.02.007; Levenstein S, 2001, ARCH INTERN MED, V161, P1341, DOI 10.1001/archinte.161.10.1341; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Lowe B, 2004, PSYCHOSOM MED, V66, P831, DOI 10.1097/01.psy.0000145593.37594.39; MARKOVITZ JH, 1993, JAMA-J AM MED ASSOC, V270, P2439; *MED HSO, 2007, WORLD MENT HLTH SURV, V2005; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Myer L, 2004, EPIDEMIOL REV, V26, P112, DOI 10.1093/epirev/mxh004; Myer L, 2008, SOC SCI MED, V66, P1828, DOI 10.1016/j.socscimed.2008.01.025; Paterniti S, 1999, PSYCHOSOM MED, V61, P77, DOI 10.1097/00006842-199901000-00013; Scherrer JF, 2003, PSYCHOSOM MED, V65, P548, DOI 10.1097/01.PSY.0000077507.29863.CB; SCOTT K, 2006, AUSTR NZ J PSYCHIAT, V40, P7; SCOTT KM, 2007, J AFFECTIVE IN PRESS; Shinn EH, 2001, AM J HYPERTENS, V14, P660, DOI 10.1016/S0895-7061(01)01304-8; Smit J, 2006, Afr Health Sci, V6, P215; SOMOVA LI, 1995, J HYPERTENS, V13, P193; Stein DJ, 2008, BRIT J PSYCHIAT, V192, P112, DOI 10.1192/bjp.bp.106.029280; Steyn K, 2001, J HYPERTENS, V19, P1717, DOI 10.1097/00004872-200110000-00004; Tormo MJ, 2000, J EPIDEMIOL COMMUN H, V54, P221, DOI 10.1136/jech.54.3.221; Ustun TB, 1999, AM J PUBLIC HEALTH, V89, P1315, DOI 10.2105/AJPH.89.9.1315; Wei TM, 2006, INT J PSYCHIAT MED, V36, P315, DOI 10.2190/5LX9-D3BH-FUA3-PQF0; Wiehe M, 2006, J HUM HYPERTENS, V20, P434, DOI 10.1038/sj.jhh.1002017; Williams DR, 2008, PSYCHOL MED, V38, P211, DOI 10.1017/S0033291707001420; Williams DR, 2004, METAB BRAIN DIS, V19, P135, DOI 10.1023/B:MEBR.0000027424.86587.74; WITTCHEN HU, 1994, J PSYCHIAT RES, V28, P57, DOI 10.1016/0022-3956(94)90036-1; Yan LJL, 2003, JAMA-J AM MED ASSOC, V290, P2138, DOI 10.1001/jama.290.16.2138	41	73	81	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2009	4	5							e5552	10.1371/journal.pone.0005552	http://dx.doi.org/10.1371/journal.pone.0005552			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	446FX	19440241	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107300016
J	de Lavalette, AD; Barucq, L; Alric, J; Rappaport, F; Zito, F				de Lavalette, Agnes de Lacroix; Barucq, Lise; Alric, Jean; Rappaport, Fabrice; Zito, Francesca			Is the Redox State of the c(i) Heme of the Cytochrome b(6)f Complex Dependent on the Occupation and Structure of the Q(i) Site and Vice Versa?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ELECTRON-TRANSFER; CD(1) NITRITE REDUCTASE; CHLAMYDOMONAS-REINHARDTII; OXYGENIC PHOTOSYNTHESIS; BC(1) COMPLEX; DIRECTED MUTAGENESIS; PROXIMAL HISTIDINE; TRANSFER CHAIN; PHOTOSYSTEM-I; B/F COMPLEX	Oxidoreductases of the cytochrome bc(1)/b(6)f family transfer electrons from a liposoluble quinol to a soluble acceptor protein and contribute to the formation of a transmembrane electrochemical potential. The crystal structure of cyt b(6)f has revealed the presence in the Q(i) site of an atypical c-type heme, heme c(i). Surprisingly, the protein does not provide any axial ligand to the iron of this heme, and its surrounding structure suggests it can be accessed by exogenous ligand. In this work we describe a mutagenesis approach aimed at characterizing the c(i) heme and its interaction with the Q(i) site environment. We engineered a mutant of Chlamydomonas reinhardtii in which Phe(40) from subunit IV was substituted by a tyrosine. This results in a dramatic slowing down of the reoxidation of the b hemes under single flash excitation, suggesting hindered accessibility of the heme to its quinone substrate. This modified accessibility likely originates from the ligation of the heme iron by the phenol(ate) side chain introduced by the mutation. Indeed, it also results in a marked downshift of the c(i) heme midpoint potential (from +100 mV to -200 mV at pH 7). Yet the overall turnover rate of the mutant cytochrome b(6)f complex under continuous illumination was found similar to the wild type one, both in vitro and in vivo. We propose that, in the mutant, a change in the ligation state of the heme upon its reduction could act as a redox switch that would control the accessibility of the substrate to the heme and trigger the catalysis.	[Alric, Jean; Rappaport, Fabrice] Univ Paris 06, CNRS, UMR7141, F-75005 Paris, France; [de Lavalette, Agnes de Lacroix; Barucq, Lise; Zito, Francesca] Univ Paris 07, CNRS, UMR7099, Inst Biol Physicochim, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Rappaport, F (corresponding author), Univ Paris 06, CNRS, UMR7141, 13 Rue Curie, F-75005 Paris, France.	Fabrice.Rappaport@ibpc.fr; Francesca.Zito@ibpc.fr	Alric, Jean/E-3538-2013	Alric, Jean/0000-0003-3574-2234; Rappaport, Fabrice/0000-0001-9377-4934; Zito, Francesca/0000-0003-1783-5090				ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; Allen JF, 2004, TRENDS PLANT SCI, V9, P130, DOI 10.1016/j.tplants.2004.01.009; Alric J, 2005, P NATL ACAD SCI USA, V102, P15860, DOI 10.1073/pnas.0508102102; Andrew CR, 2005, BIOCHEMISTRY-US, V44, P8664, DOI 10.1021/bi050428g; Baniulis D, 2009, J BIOL CHEM, V284, P9861, DOI 10.1074/jbc.M809196200; Baymann F, 2007, P NATL ACAD SCI USA, V104, P519, DOI 10.1073/pnas.0606369104; Bennoun P, 1982, METHODS CHLOROPLAST, P25; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; Choquet Y, 2003, PLANT CELL, V15, P1443, DOI 10.1105/tpc.011692; CORNFORTH JW, 1956, BIOCHEM J, V63, P124, DOI 10.1042/bj0630124; Cramer WA, 2005, PHOTOSYNTH RES, V85, P133, DOI 10.1007/s11120-004-2149-5; Crofts AR, 2004, PHOTOSYNTH RES, V80, P223, DOI 10.1023/B:PRES.0000030444.52579.10; CROFTS AR, 1982, BIOCHEM SOC T, V10, P201, DOI 10.1042/bst0100201; Darrouzet E, 2004, PHOTOSYNTH RES, V79, P25, DOI 10.1023/B:PRES.0000011926.47778.4e; Das TK, 2001, BIOCHEMISTRY-US, V40, P10774, DOI 10.1021/bi002327i; de Lavalette AD, 2008, CR BIOL, V331, P510, DOI 10.1016/j.crvi.2008.04.003; de Vitry C, 2004, BIOCHEMISTRY-US, V43, P3956, DOI 10.1021/bi036093p; Ducluzeau AL, 2008, BBA-BIOENERGETICS, V1777, P1140, DOI 10.1016/j.bbabio.2008.04.026; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HILDEBRAND DP, 1995, BIOCHEMISTRY-US, V34, P1997, DOI 10.1021/bi00006a021; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; JOLIOT P, 1974, BIOCHIM BIOPHYS ACTA, V357, P267, DOI 10.1016/0005-2728(74)90066-8; JOLIOT P, 1988, BIOCHIM BIOPHYS ACTA, V933, P319, DOI 10.1016/0005-2728(88)90039-4; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; Joliot P, 2002, P NATL ACAD SCI USA, V99, P10209, DOI 10.1073/pnas.102306999; JUNGE W, 1968, Z NATURFORSCH PT B, VB 23, P244, DOI 10.1515/znb-1968-0222; Kuras R, 1997, J BIOL CHEM, V272, P32427, DOI 10.1074/jbc.272.51.32427; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; Kuras R, 2007, P NATL ACAD SCI USA, V104, P9906, DOI 10.1073/pnas.0702340104; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; LAVERGNE J, 1983, BIOCHIM BIOPHYS ACTA, V725, P25, DOI 10.1016/0005-2728(83)90220-7; LEMAIRE C, 1987, PROGR PHOTOSYNTHESIS, V4, P655; Lezhneva L, 2008, J BIOL CHEM, V283, P24608, DOI 10.1074/jbc.M803869200; Liu Y, 1999, BIOCHEMISTRY-US, V38, P3733, DOI 10.1021/bi982707s; MITCHELL P, 1975, FEBS LETT, V56, P1, DOI 10.1016/0014-5793(75)80098-6; Muller F, 2002, BIOCHEMISTRY-US, V41, P7866, DOI 10.1021/bi025581e; Muller FL, 2003, BIOCHEMISTRY-US, V42, P6493, DOI 10.1021/bi0342160; Musser SM, 1997, BIOCHEMISTRY-US, V36, P894, DOI 10.1021/bi961723r; Osyczka A, 2005, TRENDS BIOCHEM SCI, V30, P176, DOI 10.1016/j.tibs.2005.02.001; Perutz MF, 1998, ANNU REV BIOPH BIOM, V27, P1, DOI 10.1146/annurev.biophys.27.1.1; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; RICH PR, 1991, BIOCHIM BIOPHYS ACTA, V1058, P312, DOI 10.1016/S0005-2728(05)80252-X; Sacksteder CA, 2000, PHOTOSYNTH RES, V66, P145, DOI 10.1023/A:1010785912271; SELAK MA, 1984, PHOTOCHEM PHOTOBIOL, V39, P485; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STREKAS TC, 1974, BIOCHIM BIOPHYS ACTA, V351, P237, DOI 10.1016/0005-2795(74)90186-X; Stroebel D, 2003, NATURE, V426, P413, DOI 10.1038/nature02155; Wilson EK, 1999, BIOCHEMISTRY-US, V38, P7556, DOI 10.1021/bi990179u; Yamashita E, 2007, J MOL BIOL, V370, P39, DOI 10.1016/j.jmb.2007.04.011; Zhang HM, 2004, BIOCHEMISTRY-US, V43, P16329, DOI 10.1021/bi048363p; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972; Zito F, 1997, PLANT MOL BIOL, V33, P79, DOI 10.1023/A:1005734809834	54	19	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20822	20829		10.1074/jbc.M109.016709	http://dx.doi.org/10.1074/jbc.M109.016709			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19478086	Green Published, hybrid			2022-12-25	WOS:000268316100045
J	Huang, YH; Colgrave, ML; Daly, NL; Keleshian, A; Martinac, B; Craik, DJ				Huang, Yen-Hua; Colgrave, Michelle L.; Daly, Norelle L.; Keleshian, Asbed; Martinac, Boris; Craik, David J.			The Biological Activity of the Prototypic Cyclotide Kalata B1 Is Modulated by the Formation of Multimeric Pores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANOSENSITIVE ION-CHANNEL; CYCLIC CYSTINE KNOT; PLANT CYCLOTIDES; ANTIMICROBIAL PEPTIDES; MACROCYCLIC PEPTIDES; MEMBRANE INTERACTION; OLDENLANDIA-AFFINIS; SPATIAL STRUCTURE; STRUCTURAL MOTIF; ESCHERICHIA-COLI	The cyclotides are a large family of circular mini-proteins containing a cystine knot motif. They are expressed in plants as defense-related proteins, with insecticidal activity. Here we investigate their role in membrane interaction and disruption. Kalata B1, a prototypic cyclotide, was found to induce leakage of the self-quenching fluorophore, carboxyfluorescein, from phospholipid vesicles. Alanine-scanning mutagenesis of kalata B1 showed that residues essential for lytic activity are clustered, forming a bioactive face. Kalata B1 was sequestered at the membrane surface and showed slow dissociation from vesicles. Electrophysiological experiments showed that conductive pores were induced in liposome patches on incubation with kalata B1. The conductance calculated from the current-voltage relationship indicated that the diameter of the pores formed in the bilayer patches is 41-47 angstrom. Collectively, the findings provide a mechanistic explanation for the diversity of biological functions ascribed to this fascinating family of ultrastable macrocyclic peptides.	[Huang, Yen-Hua; Colgrave, Michelle L.; Daly, Norelle L.; Craik, David J.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; [Keleshian, Asbed; Martinac, Boris] Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; [Colgrave, Michelle L.] CSIRO, Div Livestock Ind, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@uq.edu.au	Craik, David/B-1695-2010; Martinac, Boris/A-7178-2018; Colgrave, Michelle/A-5710-2012; Huang, Yen-Hua/J-9056-2014; Daly, Norelle L/D-4302-2013	Craik, David/0000-0003-0007-6796; Martinac, Boris/0000-0001-8422-7082; Colgrave, Michelle/0000-0001-8463-805X; Huang, Yen-Hua/0000-0001-6937-2660; Daly, Norelle L/0000-0002-4697-6602	Australian Research Council; Australian Research Council-Commonwealth Scientific and Industrial Research Organization (CSIRO); Institute for Molecular Bioscience-CSIRO Ph.D. Scholarship	Australian Research Council(Australian Research Council); Australian Research Council-Commonwealth Scientific and Industrial Research Organization (CSIRO)(Australian Research CouncilCommonwealth Scientific & Industrial Research Organisation (CSIRO)); Institute for Molecular Bioscience-CSIRO Ph.D. Scholarship	This work was supported in part by grants from the Australian Research Council (to D. J.C. and B. M.) and by an Australian Research Council-Commonwealth Scientific and Industrial Research Organization (CSIRO) Linkage Grant (to M. L. C.).; Supported by an Institute for Molecular Bioscience-CSIRO Ph.D. Scholarship.	AIDLEY DJ, 1996, ION CHANNELS MOL ACT, P33; Barbeta BL, 2008, P NATL ACAD SCI USA, V105, P1221, DOI 10.1073/pnas.0710338104; Barry DG, 2003, BIOCHEMISTRY-US, V42, P6688, DOI 10.1021/bi027323n; Colgrave ML, 2008, CHEMBIOCHEM, V9, P1939, DOI 10.1002/cbic.200800174; Colgrave ML, 2008, BIOCHEMISTRY-US, V47, P5581, DOI 10.1021/bi800223y; Colgrave ML, 2009, ACTA TROP, V109, P163, DOI 10.1016/j.actatropica.2008.11.003; Colgrave ML, 2004, BIOCHEMISTRY-US, V43, P5965, DOI 10.1021/bi049711q; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2001, TOXICON, V39, P1809, DOI 10.1016/S0041-0101(01)00129-5; Craik DJ, 2004, CURR PROTEIN PEPT SC, V5, P297, DOI 10.2174/1389203043379512; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; Cruickshank CC, 1997, BIOPHYS J, V73, P1925, DOI 10.1016/S0006-3495(97)78223-7; Daly NL, 2000, J BIOL CHEM, V275, P19068, DOI 10.1074/jbc.M000450200; Daly NL, 2004, FEBS LETT, V574, P69, DOI 10.1016/j.febslet.2004.08.007; De los Rios V, 1998, EUR J BIOCHEM, V252, P284, DOI 10.1046/j.1432-1327.1998.2520284.x; EHRENSTEIN G, 1977, Q REV BIOPHYS, V10, P1, DOI 10.1017/S0033583500000123; Goransson U, 2004, J NAT PROD, V67, P1287, DOI 10.1021/np0499719; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; Ireland DC, 2008, BIOPOLYMERS, V90, P51, DOI 10.1002/bip.20886; Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898; Jennings CV, 2005, BIOCHEMISTRY-US, V44, P851, DOI 10.1021/bi047837h; Kamimori H, 2005, ANAL BIOCHEM, V337, P149, DOI 10.1016/j.ab.2004.10.028; Martinac B, 2002, P NATL ACAD SCI USA, V99, P4308, DOI 10.1073/pnas.072632899; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; MOLLEMAN A, 2002, PATCH CLAMPING INTRO, P1; NEHER E, 1978, PFLUG ARCH EUR J PHY, V375, P219, DOI 10.1007/BF00584247; NEHER E, 1976, NATURE, V260, P799, DOI 10.1038/260799a0; Nourse A, 2004, J BIOL CHEM, V279, P562, DOI 10.1074/jbc.M306826200; Plan MRR, 2007, CHEMBIOCHEM, V8, P1001, DOI 10.1002/cbic.200700097; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; Rex S, 1996, BIOPHYS CHEM, V58, P75, DOI 10.1016/0301-4622(95)00087-9; Rosengren KJ, 2003, J BIOL CHEM, V278, P8606, DOI 10.1074/jbc.M211147200; SCHWARZ G, 1990, BIOPHYS J, V58, P577, DOI 10.1016/S0006-3495(90)82401-2; SCHWARZ G, 1992, BIOPHYS CHEM, V42, P291, DOI 10.1016/0301-4622(92)80021-V; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shenkarev ZO, 2008, J INORG BIOCHEM, V102, P1246, DOI 10.1016/j.jinorgbio.2008.01.018; Shenkarev ZO, 2006, FEBS J, V273, P2658, DOI 10.1111/j.1742-4658.2006.05282.x; Simonsen SM, 2008, J BIOL CHEM, V283, P9805, DOI 10.1074/jbc.M709303200; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Svangard E, 2007, J NAT PROD, V70, P643, DOI 10.1021/np070007v; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; Wang CKL, 2008, J NAT PROD, V71, P47, DOI 10.1021/np070393g; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002; Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	47	125	127	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20699	20707		10.1074/jbc.M109.003384	http://dx.doi.org/10.1074/jbc.M109.003384			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19491108	Green Published, hybrid			2022-12-25	WOS:000268316100032
J	Li, D; Molldrem, JJ; Ma, Q				Li, Dan; Molldrem, Jeffrey J.; Ma, Qing			LFA-1 Regulates CD8(+) T Cell Activation via T Cell Receptor-mediated and LFA-1-mediated Erk1/2 Signal Pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ORGANIZING CENTER; IMMUNOLOGICAL SYNAPSE; TYROSINE KINASE; LIPID RAFTS; ADHESION; ANTIGEN; LYMPHOCYTES; POLARIZATION; CYTOSKELETON; MIGRATION	LFA-1 regulates T cell activation and signal transduction through the immunological synapse. T cell receptor (TCR) stimulation rapidly activates LFA-1, which provides unique LFA-1-dependent signals to promote T cell activation. However, the detailed molecular pathways that regulate these processes and the precise mechanism by which LFA-1 contributes to TCR activation remain unclear. We found LFA-1 directly participates in Erk1/2 signaling upon TCR stimulation in CD8(+) T cells. The presence of LFA-1, not ligand binding, is required for the TCR-mediated Erk1/2 signal pathway. LFA-1-deficient T cells have defects in sustained Erk1/2 signaling and TCR/CD3 clustering, which subsequently prevents MTOC reorientation, cell cycle progression, and mitosis. LFA-1 regulates the TCR-mediated Erk1/2 signal pathway in the context of immunological synapse for recruitment and amplification of the Erk1/2 signal. In addition, LFA-1 ligation with ICAM-1 generates an additional Erk1/2 signal, which synergizes with the existing TCR-mediated Erk1/2 signal to enhance T cell activation. Thus, LFA-1 contributes to CD8(+) T cell activation through two distinct signal pathways. We demonstrated that the function of LFA-1 is to enhance TCR signaling through the immunological synapse and deliver distinct signals in CD8(+) T cell activation.	[Li, Dan; Molldrem, Jeffrey J.; Ma, Qing] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Sect Transplantat Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Ma, Q (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Sect Transplantat Immunol, Unit 900,1515 Holcombe Blvd, Houston, TX 77030 USA.	qma@mdanderson.org			American Cancer Society [RSG-08-183-01]	American Cancer Society(American Cancer Society)	This work was supported by American Cancer Society Grant RSG-08-183-01 LIB (to Q. M.).	Berlin-Rufenach C, 1999, J EXP MED, V189, P1467, DOI 10.1084/jem.189.9.1467; Billadeau DD, 2007, NAT REV IMMUNOL, V7, P131, DOI 10.1038/nri2021; Bossi G, 1998, EUR J HISTOCHEM, V42, P277; Cairo CW, 2006, IMMUNITY, V25, P297, DOI 10.1016/j.immuni.2006.06.012; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Chen X, 2007, P NATL ACAD SCI USA, V104, P6329, DOI 10.1073/pnas.0611655104; Davis MM, 2003, ANNU REV BIOCHEM, V72, P717, DOI 10.1146/annurev.biochem.72.121801.161625; Ding ZM, 1999, J IMMUNOL, V163, P5029; Dustin ML, 2002, ARTHRITIS RES THER, V4, pS119, DOI 10.1186/ar559; Dustin ML, 2005, SEMIN IMMUNOL, V17, P400, DOI 10.1016/j.smim.2005.09.002; Dustin ML, 2003, ANN NY ACAD SCI, V987, P51, DOI 10.1111/j.1749-6632.2003.tb06032.x; Dustin ML, 2004, NAT IMMUNOL, V5, P363, DOI 10.1038/ni1057; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Endl E, 1997, CYTOMETRY, V29, P233, DOI 10.1002/(SICI)1097-0320(19971101)29:3<233::AID-CYTO6>3.0.CO;2-C; Fagerholm S, 2002, EUR J IMMUNOL, V32, P1670, DOI 10.1002/1521-4141(200206)32:6<1670::AID-IMMU1670>3.0.CO;2-M; GERDES J, 1984, J IMMUNOL, V133, P1710; Goda S, 2004, J IMMUNOL, V172, P5379, DOI 10.4049/jimmunol.172.9.5379; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hogg N, 2004, IMMUNOL LETT, V92, P51, DOI 10.1016/j.imlet.2003.10.014; Huppa JB, 2003, NAT REV IMMUNOL, V3, P973, DOI 10.1038/nri1245; Huppa JB, 2003, NAT IMMUNOL, V4, P749, DOI 10.1038/ni951; Hynes RO, 2003, SCIENCE, V300, P755, DOI 10.1126/science.1084854; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Kinashi T, 2005, NAT REV IMMUNOL, V5, P546, DOI 10.1038/nri1646; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Kuhn JR, 2002, IMMUNITY, V16, P111, DOI 10.1016/S1074-7613(02)00262-5; Leitinger B, 2002, J CELL SCI, V115, P963; Lin J, 2005, J CELL BIOL, V170, P177, DOI 10.1083/jcb.200503032; Marwali MR, 2004, J IMMUNOL, V173, P2960, DOI 10.4049/jimmunol.173.5.2960; MAZEROLLES F, 1994, J IMMUNOL, V152, P5670; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Mor A, 2007, NAT CELL BIOL, V9, P713, DOI 10.1038/ncb1592; Mueller KL, 2004, J IMMUNOL, V173, P2222, DOI 10.4049/jimmunol.173.4.2222; Perez OD, 2003, NAT IMMUNOL, V4, P1083, DOI 10.1038/ni984; Purbhoo MA, 2004, NAT IMMUNOL, V5, P524, DOI 10.1038/ni1058; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Sancho D, 2002, IMMUNOL REV, V189, P84, DOI 10.1034/j.1600-065X.2002.18908.x; Schmits R, 1996, J EXP MED, V183, P1415, DOI 10.1084/jem.183.4.1415; Sims TN, 2002, IMMUNOL REV, V186, P100, DOI 10.1034/j.1600-065X.2002.18610.x; Smits HH, 2002, J IMMUNOL, V168, P1710, DOI 10.4049/jimmunol.168.4.1710; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stinchcombe JC, 2006, NATURE, V443, P462, DOI 10.1038/nature05071; Suzuki J, 1999, TRANSPL IMMUNOL, V7, P65, DOI 10.1016/S0966-3274(99)80021-5; Woods ML, 2001, EMBO J, V20, P1232, DOI 10.1093/emboj/20.6.1232	45	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					21001	21010		10.1074/jbc.M109.002865	http://dx.doi.org/10.1074/jbc.M109.002865			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19483086	hybrid, Green Published			2022-12-25	WOS:000268316100063
J	Vielemeyer, O; Yuan, H; Moutel, S; Saint-Fort, R; Tang, DM; Nizak, C; Goud, B; Wang, YZ; Perez, F				Vielemeyer, Ole; Yuan, Hebao; Moutel, Sandrine; Saint-Fort, Renette; Tang, Danming; Nizak, Clement; Goud, Bruno; Wang, Yanzhuang; Perez, Franck			Direct Selection of Monoclonal Phosphospecific Antibodies without Prior Phosphoamino Acid Mapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI STACKING FACTOR; CELL-FREE SYSTEM; RECOMBINANT ANTIBODIES; IN-VIVO; GRASP65; PROTEINS; RESOURCE	In the current post-genomic era, large scale efforts are under-way to functionally explore the proteome by assembling large antibody libraries. However, because many proteins are modified post-translationally to regulate their function, collections of modification-specific sensors are also needed. Here we applied a novel approach to select monoclonal phosphospecific antibodies directly from the full-length protein and without up-front phosphoamino acid identification. We chose as antigen GRASP65, a well studied Golgi phosphoprotein. Bacterially produced full-length protein was first incubated with mitotic cytosol, thus allowing modification by naturally occurring kinases, and then used directly for affinity-based antibody selection using a single chain variable fragment phagemid library. In less than 1 week, three distinct and highly functional monoclonal phosphospecific antibodies against two GRASP65 epitopes were obtained and subsequently characterized. The presented approach is carried out fully in vitro, requires no prior knowledge of the phosphoamino acid identity, and is fast and inexpensive. It therefore has great potential to be an attractive alternative to classic animal-based protocols for the selection of post-translation modification sensors and thus to become an invaluable tool in our quest to understand the proteome in all its complexity.	[Yuan, Hebao; Tang, Danming; Wang, Yanzhuang] Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; [Vielemeyer, Ole; Moutel, Sandrine; Saint-Fort, Renette; Nizak, Clement; Goud, Bruno; Perez, Franck] Inst Curie, Res Sect, F-75248 Paris 5, France; [Moutel, Sandrine] Inst Curie, Translat Dept, F-75248 Paris 5, France; [Vielemeyer, Ole; Saint-Fort, Renette; Nizak, Clement; Goud, Bruno; Perez, Franck] Inst Curie, CNRS, UMR144, F-75248 Paris 5, France	University of Michigan System; University of Michigan; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Wang, YZ (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.	yzwang@umich.edu; franck.perez@curie.fr	Nizak, Clement/HGV-1085-2022; Goud, Bruno/GWC-4807-2022; Wang, Yanzhuang/AAE-5299-2019; Perez, Franck/A-1558-2014; Yuan, Hebao/E-2032-2011; Nizak, Clement/L-1334-2013	Nizak, Clement/0000-0002-4591-8240; Wang, Yanzhuang/0000-0002-1864-7094; Perez, Franck/0000-0002-9129-9401; Yuan, Hebao/0000-0003-4425-3678; Nizak, Clement/0000-0002-4591-8240; Moutel, Sandrine/0000-0002-9585-4855	National Institutes of Health [GM087364]; Pardee Cancer Research Foundation; Curie Institute; CNRS; Agence National de la Recherche; Association pour la Recherche Contre le Cancer; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087364] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pardee Cancer Research Foundation; Curie Institute; CNRS(Centre National de la Recherche Scientifique (CNRS)); Agence National de la Recherche(French National Research Agency (ANR)); Association pour la Recherche Contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant GM087364 (to Y.W.). This work was also supported by the Pardee Cancer Research Foundation, the Curie Institute, CNRS, and by grants from the "Agence National de la Recherche" and the "Association pour la Recherche Contre le Cancer" (to F. P.).	DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Dimitrov A, 2008, SCIENCE, V322, P1353, DOI 10.1126/science.1165401; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; Haab BB, 2006, MOL CELL PROTEOMICS, V5, P1996, DOI 10.1074/mcp.T600020-MCP200; Johnson L, 2007, BIOCHEM SOC T, V35, P7, DOI 10.1042/BST0350007; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Moutel S, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-14; NAIRN AC, 1982, NATURE, V299, P734, DOI 10.1038/299734a0; Nizak C, 2003, TRAFFIC, V4, P739, DOI 10.1034/j.1600-0854.2003.00132.x; Nizak C, 2003, SCIENCE, V300, P984, DOI 10.1126/science.1083911; Preisinger C, 2005, EMBO J, V24, P753, DOI 10.1038/sj.emboj.7600569; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; ROSS AH, 1981, NATURE, V294, P654, DOI 10.1038/294654a0; Shorter J, 1999, EMBO J, V18, P4949, DOI 10.1093/emboj/18.18.4949; Taussig MJ, 2007, NAT METHODS, V4, P13, DOI 10.1038/nmeth0107-13; Ventura Juan-Jose, 2006, Clin Transl Oncol, V8, P153, DOI 10.1007/s12094-006-0005-0; Wang YZ, 2005, J BIOL CHEM, V280, P4921, DOI 10.1074/jbc.M412407200; Wang YZ, 2003, EMBO J, V22, P3279, DOI 10.1093/emboj/cdg317; Yoshimura S, 2005, J BIOL CHEM, V280, P23048, DOI 10.1074/jbc.M502442200	19	17	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20791	20795		10.1074/jbc.M109.008730	http://dx.doi.org/10.1074/jbc.M109.008730			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19473967	Green Published, hybrid			2022-12-25	WOS:000268316100041
J	Wojtal, KA; Diskar, M; Herberg, FW; Hoekstra, D; van Ijzendoorn, SCD				Wojtal, Kacper A.; Diskar, Mandy; Herberg, Friedrich W.; Hoekstra, Dick; van Ijzendoorn, Sven C. D.			Regulatory Subunit I-controlled Protein Kinase A Activity Is Required for Apical Bile Canalicular Lumen Development in Hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED SPHINGOLIPID TRANSPORT; FETAL LIVER DEVELOPMENT; ENERGY-TRANSFER BRET; CELL POLARITY; ONCOSTATIN-M; CYCLIC-AMP; HEPG2 CELLS; CAMP-KINASE; SUBAPICAL COMPARTMENT; MEMBRANE BIOGENESIS	Signaling via cAMP plays an important role in apical cell surface dynamics in epithelial cells. In hepatocytes, elevated levels of cAMP as well as extracellular oncostatin M stimulate apical lumen development in a manner that depends on protein kinase A (PKA) activity. However, neither the identity of PKA isoforms involved nor the mechanisms of the cross-talk between oncostatin M and cAMP/PKA signaling pathways have been elucidated. Here we demonstrate that oncostatin M and PKA signaling converge at the level of the PKA holoenzyme downstream of oncostatin M-stimulated MAPK activation. Experiments were performed with chemically modified cAMP analogues that preferentially target regulatory subunit (R) I or RII holoenzymes, respectively, in hepatocytes. The data suggest that the dissociation of RI- but not RII-containing holoenzymes, as well as catalytic activity of PKA, is required for apical lumen development in response to elevated levels of cAMP and oncostatin M. However, oncostatin M signaling does not stimulate PKA holoenzyme dissociation in living cells. Based on pharmacological and cell biological studies, it is concluded that RI-controlled PKA activity is essential for cAMP- and oncostatin M-stimulated development of apical bile canalicular lumens.	[Wojtal, Kacper A.; Hoekstra, Dick; van Ijzendoorn, Sven C. D.] Univ Groningen, Univ Med Ctr Groningen, Sect Membrane Cell Biol, Dept Cell Biol, NL-9713 AV Groningen, Netherlands; [Diskar, Mandy; Herberg, Friedrich W.] Univ Kassel, Dept Biochem, D-34109 Kassel, Germany	University of Groningen; Universitat Kassel	van Ijzendoorn, SCD (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Sect Membrane Cell Biol, Dept Cell Biol, NL-9713 AV Groningen, Netherlands.	s.c.d.van.ijzendoorn@med.umcg.nl	Herberg, Friedrich W/B-5572-2015	Herberg, Friedrich W/0000-0001-7117-7653	Otto Braun Fund; European Union [LSHB-CT-2006-037189]; Royal Dutch Academy of Sciences	Otto Braun Fund; European Union(European Commission); Royal Dutch Academy of Sciences	Supported by the Otto Braun Fund.; Supported by European Union Grant LSHB-CT-2006-037189.; Supported by the Royal Dutch Academy of Sciences.	Abu-Absi SF, 2005, TISSUE ENG, V11, P415, DOI 10.1089/ten.2005.11.415; Alvarez-Curto E, 2007, BIOCHEM J, V401, P309, DOI 10.1042/BJ20060880; Amieux PS, 2002, ANN NY ACAD SCI, V968, P75, DOI 10.1111/j.1749-6632.2002.tb04328.x; Amieux PS, 2002, J BIOL CHEM, V277, P27294, DOI 10.1074/jbc.M200302200; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; BRIGNONI M, 1995, J CELL SCI, V108, P1931; Bryant DM, 2008, NAT REV MOL CELL BIO, V9, P887, DOI 10.1038/nrm2523; CHIU JH, 1990, HEPATOLOGY, V11, P834, DOI 10.1002/hep.1840110519; Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200; Cibrian-Uhalte E, 2007, J CELL BIOL, V176, P223, DOI 10.1083/jcb.200606116; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Decaens C, 2008, BIOL CELL, V100, P387, DOI 10.1042/BC20070127; Dong J, 2008, CYTOTECHNOLOGY, V57, P251, DOI 10.1007/s10616-008-9168-6; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Falasca L, 2001, CELLS TISSUES ORGANS, V168, P126, DOI 10.1159/000047828; Fouassier L, 2001, HEPATOLOGY, V33, P166, DOI 10.1053/jhep.2001.21143; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; Herrema H, 2006, MOL BIOL CELL, V17, P3291, DOI 10.1091/mbc.E06-01-0067; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; Imamura M, 2007, EXP CELL RES, V313, P1951, DOI 10.1016/j.yexcr.2007.03.010; Kamiya A, 2003, HEPATOLOGY, V37, P1375, DOI 10.1053/jhep.2003.50212; Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127; Kang GX, 2006, J PHYSIOL-LONDON, V573, P595, DOI 10.1113/jphysiol.2006.107391; KELLY JH, 1989, IN VITRO CELL DEV B, V25, P217; Kikuchi S, 2002, NAT GENET, V31, P320, DOI 10.1038/ng905; LECLUYSE EL, 1994, AM J PHYSIOL, V266, pC1764, DOI 10.1152/ajpcell.1994.266.6.C1764; Matsui T, 2002, EMBO J, V21, P1021, DOI 10.1093/emboj/21.5.1021; Medioni C, 2008, J CELL BIOL, V182, P249, DOI 10.1083/jcb.200801100; MUSAT AI, 1993, HEPATOLOGY, V18, P198, DOI 10.1002/hep.1840180129; OGREID D, 1989, EUR J BIOCHEM, V181, P19; Peng X, 2006, CELL TISSUE RES, V323, P233, DOI 10.1007/s00441-005-0067-2; Phillips HM, 2007, CIRC RES, V101, P137, DOI 10.1161/CIRCRESAHA.106.142406; Prinz A, 2006, CHEMBIOCHEM, V7, P1007, DOI 10.1002/cbic.200600048; Prinz A, 2006, CELL SIGNAL, V18, P1616, DOI 10.1016/j.cellsig.2006.01.013; Roelofsen H, 1998, J CELL SCI, V111, P1137; Santiago-Martinez E, 2008, J CELL BIOL, V182, P241, DOI 10.1083/jcb.200804120; Schwede F, 2000, BIOCHEMISTRY-US, V39, P8803, DOI 10.1021/bi000304y; SORMUNEN R, 1993, LAB INVEST, V68, P652; Sudo R, 2005, FASEB J, V19, P1695, DOI 10.1096/fj.04-3269fje; van der Wouden JM, 2002, EMBO J, V21, P6409, DOI 10.1093/emboj/cdf629; van Ijzendoorn SCD, 2004, MOL BIOL CELL, V15, P4115, DOI 10.1091/mbc.E04-04-0290; van IJzendoorn SCD, 2004, MOL BIOL CELL, V15, P4105, DOI 10.1091/mbc.e04-03-0201; van Ijzendoorn SCD, 1999, MOL BIOL CELL, V10, P3449, DOI 10.1091/mbc.10.10.3449; van Ijzendoorn SCD, 2000, MOL BIOL CELL, V11, P1093, DOI 10.1091/mbc.11.3.1093; Wang W, 2006, GASTROENTEROLOGY, V131, P878, DOI 10.1053/j.gastro.2006.06.013; Wojtal KA, 2008, BIOESSAYS, V30, P146, DOI 10.1002/bies.20705; Wojtal KA, 2007, MOL BIOL CELL, V18, P2745, DOI 10.1091/mbc.E06-08-0732; Zegers MMP, 1998, BIOCHEM J, V336, P257, DOI 10.1042/bj3360257; Zegers MMP, 1997, J CELL BIOL, V138, P307, DOI 10.1083/jcb.138.2.307	49	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20773	20780		10.1074/jbc.M109.013599	http://dx.doi.org/10.1074/jbc.M109.013599			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19465483	Green Published, hybrid			2022-12-25	WOS:000268316100039
J	Johnson, BS; Snead, D; Lee, JJ; McCaffery, JM; Shorter, J; Gitler, AD				Johnson, Brian S.; Snead, David; Lee, Jonathan J.; McCaffery, J. Michael; Shorter, James; Gitler, Aaron D.			TDP-43 Is Intrinsically Aggregation-prone, and Amyotrophic Lateral Sclerosis-linked Mutations Accelerate Aggregation and Increase Toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRONTOTEMPORAL LOBAR DEGENERATION; NUCLEIC-ACID BINDING; ALPHA-SYNUCLEIN; TARDBP MUTATIONS; IN-VITRO; NEURODEGENERATIVE DISEASES; CYTOPLASMIC INCLUSIONS; PARKINSONS-DISEASE; AMYLOID PORES; YEAST	Non-amyloid, ubiquitinated cytoplasmic inclusions containing TDP-43 and its C-terminal fragments are pathological hallmarks of amyotrophic lateral sclerosis (ALS), a fatal motor neuron disorder, and frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U). Importantly, TDP-43 mutations are linked to sporadic and non-SOD1 familial ALS. However, TDP-43 is not the only protein in disease-associated inclusions, and whether TDP-43 misfolds or is merely sequestered by other aggregated components is unclear. Here, we report that, in the absence of other components, TDP-43 spontaneously forms aggregates bearing remarkable ultrastructural similarities to TDP-43 deposits in degenerating neurons of ALS FTLD-U patients. The C-terminal domain of TDP-43 is critical for spontaneous aggregation. Several ALS-linked TDP-43 mutations within this domain (Q331K, M337V, Q343R, N345K, R361S, and N390D) increase the number of TDP-43 aggregates and promote toxicity in vivo. Importantly, mutations that promote toxicity in vivo accelerate aggregation of pure TDP-43 in vitro. Thus, TDP-43 is intrinsically aggregation-prone, and its propensity for toxic misfolding trajectories is accentuated by specific ALS-linked mutations.	[Johnson, Brian S.; Lee, Jonathan J.; Gitler, Aaron D.] Univ Penn, Dept Cell & Dev Biol, Sch Med, Philadelphia, PA 19104 USA; [Snead, David; Shorter, James] Univ Penn, Dept Biochem & Biophys, Sch Med, Philadelphia, PA 19104 USA; [McCaffery, J. Michael] Johns Hopkins Univ, Integrated Imaging Ctr, Baltimore, MD 21218 USA; [McCaffery, J. Michael] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	University of Pennsylvania; University of Pennsylvania; Johns Hopkins University; Johns Hopkins University	Shorter, J (corresponding author), 805B Stellar Chance Labs,422 Curie Blvd, Philadelphia, PA 19104 USA.	jshorter@mail.med.upenn.edu; gitler@mail.med.upenn.edu	Shorter, James/E-8207-2011	Johnson, Brian/0000-0003-3711-5920; Shorter, James/0000-0001-5269-8533; Gitler, Aaron/0000-0001-8603-1526	National Institutes of Health [1DP2OD004417-01, 1DP2OD002177-01]; University of Pennsylvania Institute on Aging; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS065317] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD002177, DP2OD004417] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Pennsylvania Institute on Aging; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported, in whole or in part, by National Institutes of Health Grants 1DP2OD004417-01 (Director's New Innovator Award to A. D. G.) and 1DP2OD002177-01 (Director's New Innovator Award to J.S.). This work was also supported by a pilot grant from the University of Pennsylvania Institute on Aging (to A. D. G.).	Arai T, 2006, BIOCHEM BIOPH RES CO, V351, P602, DOI 10.1016/j.bbrc.2006.10.093; Ayala YM, 2005, J MOL BIOL, V348, P575, DOI 10.1016/j.jmb.2005.02.038; Ayala YM, 2008, P NATL ACAD SCI USA, V105, P3785, DOI 10.1073/pnas.0800546105; Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448; Banks GT, 2008, MAMM GENOME, V19, P299, DOI 10.1007/s00335-008-9117-x; Buratti E, 2001, J BIOL CHEM, V276, P36337, DOI 10.1074/jbc.M104236200; Chernoff YO, 2002, METHOD ENZYMOL, V351, P499; Choi W, 2004, FEBS LETT, V576, P363, DOI 10.1016/j.febslet.2004.09.038; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Cooper AA, 2006, SCIENCE, V313, P324, DOI 10.1126/science.1129462; Daoud H, 2009, J MED GENET, V46, P112, DOI 10.1136/jmg.2008.062463; Forman MS, 2007, CURR OPIN NEUROBIOL, V17, P548, DOI 10.1016/j.conb.2007.08.005; Gitcho MA, 2008, ANN NEUROL, V63, P535, DOI 10.1002/ana.21344; Gitler AD, 2009, NAT GENET, V41, P308, DOI 10.1038/ng.300; Johnson BS, 2008, P NATL ACAD SCI USA, V105, P6439, DOI 10.1073/pnas.0802082105; Kabashi E, 2008, NAT GENET, V40, P572, DOI 10.1038/ng.132; Kaganovich D, 2008, NATURE, V454, P1088, DOI 10.1038/nature07195; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Kuo PH, 2009, NUCLEIC ACIDS RES, V37, P1799, DOI 10.1093/nar/gkp013; Kwong LK, 2008, NEUROSIGNALS, V16, P41, DOI 10.1159/000109758; Lashuel HA, 2003, J MOL BIOL, V332, P795, DOI 10.1016/S0022-2836(03)00927-6; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lin WL, 2008, ACTA NEUROPATHOL, V116, P205, DOI 10.1007/s00401-008-0408-9; Mackenzie IRA, 2007, ANN NEUROL, V61, P427, DOI 10.1002/ana.21147; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; Mori F, 2008, ACTA NEUROPATHOL, V116, P193, DOI 10.1007/s00401-008-0396-9; Morimoto RI, 2008, GENE DEV, V22, P1427, DOI 10.1101/gad.1657108; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Nishihira Y, 2008, ACTA NEUROPATHOL, V116, P169, DOI 10.1007/s00401-008-0385-z; Pamphlett R, 2009, NEUROPATH APPL NEURO, V35, P222, DOI 10.1111/j.1365-2990.2008.00982.x; Pamphlett R, 2008, ACTA NEUROPATHOL, V116, P221, DOI 10.1007/s00401-008-0392-0; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; Rothstein JD, 2007, ANN NEUROL, V61, P382, DOI 10.1002/ana.21155; Rutherford NJ, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000193; Sanelli T, 2007, J NEUROPATH EXP NEUR, V66, P1147, DOI 10.1097/nen.0b013e31815c5edd; Scheibel T, 2003, P NATL ACAD SCI USA, V100, P4527, DOI 10.1073/pnas.0431081100; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Shorter J, 2005, NAT REV GENET, V6, P435, DOI 10.1038/nrg1616; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Skovronsky DM, 2006, ANNU REV PATHOL-MECH, V1, P151, DOI 10.1146/annurev.pathol.1.110304.100113; Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584; Van Deerlin VM, 2008, LANCET NEUROL, V7, P409, DOI 10.1016/S1474-4422(08)70071-1; Xiao S, 2008, J NEUROSCI, V28, P1833, DOI 10.1523/JNEUROSCI.3222-07.2008; Yeger-Lotem E, 2009, NAT GENET, V41, P316, DOI 10.1038/ng.337; Yokoseki A, 2008, ANN NEUROL, V63, P538, DOI 10.1002/ana.21392	46	500	512	3	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20329	20339		10.1074/jbc.M109.010264	http://dx.doi.org/10.1074/jbc.M109.010264			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19465477	Green Published, hybrid			2022-12-25	WOS:000268097400059
J	Ali, F; Zakkar, M; Karu, K; Lidington, EA; Hamdulay, SS; Boyle, JJ; Zloh, M; Bauer, A; Haskard, DO; Evans, PC; Mason, JC				Ali, Faisal; Zakkar, Mustafa; Karu, Kersti; Lidington, Elaine A.; Hamdulay, Shahir S.; Boyle, Joseph J.; Zloh, Mire; Bauer, Andrea; Haskard, Dorian O.; Evans, Paul C.; Mason, Justin C.			Induction of the Cytoprotective Enzyme Heme Oxygenase-1 by Statins Is Enhanced in Vascular Endothelium Exposed to Laminar Shear Stress and Impaired by Disturbed Flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ATHEROSCLEROTIC LESION FORMATION; COMPLEMENT-MEDIATED INJURY; TRANSCRIPTION FACTOR NRF2; KRUPPEL-LIKE FACTOR-2; C-REACTIVE PROTEIN; HMG-COA REDUCTASE; INDUCED EXPRESSION; SIGNALING PATHWAY; GENE-EXPRESSION	In addition to cholesterol-lowering properties, statins exhibit lipid-independent immunomodulatory, anti-inflammatory actions. However, high concentrations are typically required to induce these effects in vitro, raising questions concerning therapeutic relevance. We present evidence that endothelial cell sensitivity to statins depends upon shear stress. Using heme oxygenase-1 expression as a model, we demonstrate differential heme oxygenase-1 induction by atorvastatin in athero-resistant compared with atheroprone sites of the murine aorta. In vitro, exposure of human endothelial cells to laminar shear stress significantly reduced the statin concentration required to induce heme oxygenase-1 and protect against H2O2-mediated injury. Synergy was observed between laminar shear stress and atorvastatin, resulting in optimal expression of heme oxygenase-1 and resistance to oxidative stress, a response inhibited by heme oxygenase-1 small interfering RNA. Moreover, treatment of laminar shear stress-exposed endothelial cells resulted in a significant fall in intracellular cholesterol. Mechanistically, synergy required Akt phosphorylation, activation of Kruppel-like factor 2, NF-E2-related factor-2 (Nrf2), increased nitric-oxide synthase activity, and enhanced HO-1 mRNA stability. In contrast, heme oxygenase-1 induction by atorvastatin in endothelial cells exposed to oscillatory flow was markedly attenuated. We have identified a novel relationship between laminar shear stress and statins, demonstrating that atorvastatin-mediated heme oxygenase-1-dependent antioxidant effects are laminar shear stress-dependent, proving the principle that biomechanical signaling contributes significantly to endothelial responsiveness to pharmacological agents. Our findings suggest statin pleiotropy may be suboptimal at disturbed flow atherosusceptible sites, emphasizing the need for more specific therapeutic agents, such as those targeting Kruppel-like factor 2 or Nrf2.	[Ali, Faisal; Zakkar, Mustafa; Lidington, Elaine A.; Hamdulay, Shahir S.; Boyle, Joseph J.; Bauer, Andrea; Haskard, Dorian O.; Evans, Paul C.; Mason, Justin C.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Bywaters Ctr Vasc Inflammat, Hammersmith Hosp, London W12 0NN, England; [Karu, Kersti; Zloh, Mire] Univ London, Sch Pharm, London WC1N 1AX, England	Imperial College London; University of London; University College London; University of London School of Pharmacy	Mason, JC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Bywaters Ctr Vasc Inflammat, Hammersmith Hosp, London W12 0NN, England.	justin.mason@imperial.ac.uk	Zloh, Mire/A-8124-2008; Ali, Faisal/I-4250-2018; Zloh, Mire/M-5597-2018	Zloh, Mire/0000-0002-4848-2737; Evans, Paul/0000-0001-7975-681X; Mason, Justin/0000-0001-7783-1660	British Heart Foundation [PG/06/026/20419]	British Heart Foundation(British Heart Foundation)	This work was supported by British Heart Foundation Project Grant PG/06/026/20419.	Ali F, 2007, J THROMB HAEMOST, V5, P2537, DOI 10.1111/j.1538-7836.2007.02787.x; Arnaud C, 2005, ARTERIOSCL THROM VAS, V25, P1231, DOI 10.1161/01.ATV.0000163840.63685.0c; Berk BC, 2008, CIRCULATION, V117, P1082, DOI 10.1161/CIRCULATIONAHA.107.720730; Bouton C, 2000, J BIOL CHEM, V275, P32688, DOI 10.1074/jbc.275.42.32688; Byfield FJ, 2004, BIOPHYS J, V87, P3336, DOI 10.1529/biophysj.104.040634; CARO CG, 1969, NATURE, V223, P1159, DOI 10.1038/2231159a0; Chen XL, 2003, J BIOL CHEM, V278, P703, DOI 10.1074/jbc.M203161200; Cilla DD, 1996, CLIN PHARMACOL THER, V60, P687, DOI 10.1016/S0009-9236(96)90218-0; Dai G, 2007, CIRC RES, V101, P723, DOI 10.1161/CIRCRESAHA.107.152942; Dekker RJ, 2005, AM J PATHOL, V167, P609, DOI 10.1016/S0002-9440(10)63002-7; Dekker RJ, 2006, BLOOD, V107, P4354, DOI 10.1182/blood-2005-08-3465; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI200113152; Dulak J, 2005, ENDOTHELIUM-J ENDOTH, V12, P233, DOI 10.1080/10623320500476559; Exner M, 2004, FREE RADICAL BIO MED, V37, P1097, DOI 10.1016/j.freeradbiomed.2004.07.008; Feron O, 2001, CIRCULATION, V103, P113; Fledderus JO, 2008, ARTERIOSCL THROM VAS, V28, P1339, DOI 10.1161/ATVBAHA.108.165811; Greenwood J, 2007, TRENDS IMMUNOL, V28, P88, DOI 10.1016/j.it.2006.12.003; Hajra L, 2000, P NATL ACAD SCI USA, V97, P9052, DOI 10.1073/pnas.97.16.9052; Hermann C, 1997, ARTERIOSCL THROM VAS, V17, P3588, DOI 10.1161/01.ATV.17.12.3588; Huddleson JP, 2005, J BIOL CHEM, V280, P23371, DOI 10.1074/jbc.M413839200; Jain MK, 2005, NAT REV DRUG DISCOV, V4, P977, DOI 10.1038/nrd1901; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; Kinderlerer AR, 2008, J BIOL CHEM, V283, P14636, DOI 10.1074/jbc.M800362200; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Landmesser U, 2005, CIRCULATION, V111, P2356, DOI 10.1161/01.CIR.0000164260.82417.3F; Lee TS, 2004, CIRCULATION, V110, P1296, DOI 10.1161/01.CIR.0000140694.67251.9C; Leonard MO, 2006, FASEB J, V20, P2624, DOI 10.1096/fj.06-5097fje; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Lin ZY, 2005, CIRC RES, V96, pE48, DOI 10.1161/01.RES.0000159707.05637.a1; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Loboda A, 2006, ATHEROSCLEROSIS, V187, P26, DOI 10.1016/j.atherosclerosis.2006.03.015; Lungu AO, 2004, J BIOL CHEM, V279, P48794, DOI 10.1074/jbc.M313897200; Mason JC, 2004, J BIOL CHEM, V279, P41611, DOI 10.1074/jbc.M407981200; Mason JC, 2003, CLIN SCI, V105, P251, DOI 10.1042/CS20030148; Mason JC, 2002, CIRC RES, V91, P696, DOI 10.1161/01.RES.0000038151.57577.19; Muchova L, 2007, CAN J PHYSIOL PHARM, V85, P800, DOI 10.1139/Y07-077; Ni CW, 2004, AM J PHYSIOL-CELL PH, V287, pC771, DOI 10.1152/ajpcell.00532.2003; Park H, 1998, J BIOL CHEM, V273, P32304, DOI 10.1074/jbc.273.48.32304; Parmar KM, 2006, J CLIN INVEST, V116, P49, DOI 10.1172/JCI24787; Pelat M, 2003, CIRCULATION, V107, P2480, DOI 10.1161/01.CIR.0000065601.83526.3E; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005; SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132; Stocker R, 2006, CIRCULATION, V114, P2178, DOI 10.1161/CIRCULATIONAHA.105.598698; Tsai CT, 2008, CIRCULATION, V117, P344, DOI 10.1161/CIRCULATIONAHA.107.695346; Uchiyama T, 2006, ATHEROSCLEROSIS, V188, P265, DOI 10.1016/j.atherosclerosis.2005.10.045; van Thienen JV, 2006, CARDIOVASC RES, V72, P231, DOI 10.1016/j.cardiores.2006.07.008; Wang LJ, 1998, AM J PATHOL, V152, P711; Wang YQ, 2007, BIOCHIMIE, V89, P182, DOI 10.1016/j.biochi.2006.10.008; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yamawaki H, 2005, J CLIN INVEST, V115, P733, DOI 10.1172/JCI200523001; Yet SF, 2003, FASEB J, V17, P1759, DOI 10.1096/fj.03-0187fje; Zhang XC, 2006, FASEB J, V20, P2156, DOI 10.1096/fj.06-5668fje	54	83	84	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18882	18892		10.1074/jbc.M109.009886	http://dx.doi.org/10.1074/jbc.M109.009886			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19457866	Green Published, hybrid			2022-12-25	WOS:000267711500038
J	Fukui, T; Kimura, T; Kadota, K; Shimojo, S; Gomi, H				Fukui, Takao; Kimura, Toshitaka; Kadota, Koji; Shimojo, Shinsuke; Gomi, Hiroaki			Odd Sensation Induced by Moving-Phantom which Triggers Subconscious Motor Program	PLOS ONE			English	Article							PLATFORM; DISORIENTATION; CONSEQUENCES; ESCALATORS; INTENTION; BEHAVIOR; ILLUSION; WALKING; HUMANS; MODEL	Our motor actions are sometimes not properly performed despite our having complete understanding of the environmental situation with a suitable action intention. In most cases, insufficient skill for motor control can explain the improper performance. A notable exception is the action of stepping onto a stopped escalator, which causes clumsy movements accompanied by an odd sensation. Previous studies have examined short-term sensorimotor adaptations to treadmills and moving sleds, but the relationship between the odd sensation and behavioral properties in a real stopped-escalator situation has never been examined. Understanding this unique action-perception linkage would help us to assess the brain function connecting automatic motor controls and the conscious awareness of action. Here we directly pose a question: Does the odd sensation emerge because of the unfamiliar motor behavior itself toward the irregular step-height of a stopped escalator or as a consequence of an automatic habitual motor program cued by the escalator itself. We compared the properties of motor behavior toward a stopped escalator (SE) with those toward moving escalator and toward a wooden stairs (WS) that mimicked the stopped escalator, and analyzed the subjective feeling of the odd sensation in the SE and WS conditions. The results show that moving escalator-specific motor actions emerged after participants had stepped onto the stopped escalator despite their full awareness that it was stopped, as if the motor behavior was guided by a "phantom'' of a moving escalator. Additionally, statistical analysis reveals that postural forward sway that occurred after the stepping action is directly linked with the odd sensation. The results suggest a dissociation between conscious awareness and subconscious motor control: the former makes us perfectly aware of the current environmental situation, but the latter automatically emerges as a result of highly habituated visual input no matter how unsuitable the motor control is. This dissociation appears to yield an attribution conflict, resulting in the odd sensation.			Fukui, T (corresponding author), NTT Corp, NTT, Commun Sci Labs, Kanagawa, Japan.	gomi@idea.brl.ntt.co.jp	Gomi, Hiroaki/C-5269-2013; Gomi, Hiroaki/AEL-2645-2022	Lauwereyns, Jan/0000-0003-0551-2550; Gomi, Hiroaki/0000-0003-3541-2251				ANSTIS S, 1995, EXP BRAIN RES, V103, P476; BENTLER PM, 1987, SOCIOL METHOD RES, V16, P78, DOI 10.1177/0049124187016001004; Blakemore SJ, 1998, J NEUROSCI, V18, P7511; Blakemore SJ, 2002, TRENDS COGN SCI, V6, P237, DOI 10.1016/S1364-6613(02)01907-1; Bunday KL, 2006, EXP BRAIN RES, V174, P270, DOI 10.1007/s00221-006-0446-2; Bunday KL, 2008, J NEUROPHYSIOL, V99, P1354, DOI 10.1152/jn.01214.2007; Cavaco S, 2004, BRAIN, V127, P1853, DOI 10.1093/brain/awh208; COHN TE, 1990, PERCEPTION, V19, P573, DOI 10.1068/p190573; DIETZ V, 1992, PHYSIOL REV, V72, P33, DOI 10.1152/physrev.1992.72.1.33; ESLINGER PJ, 1986, J NEUROSCI, V6, P3006; Fink GR, 1999, BRAIN, V122, P497, DOI 10.1093/brain/122.3.497; Graybiel AM, 2008, ANNU REV NEUROSCI, V31, P359, DOI 10.1146/annurev.neuro.29.051605.112851; Haggard P, 2005, TRENDS COGN SCI, V9, P290, DOI 10.1016/j.tics.2005.04.012; Jeannerod M, 2003, BEHAV BRAIN RES, V142, P1, DOI 10.1016/S0166-4328(02)00384-4; Kawagoe A, 1999, IEEE T APPL SUPERCON, V9, P727, DOI 10.1109/77.783398; Lacquaniti F, 1992, Curr Opin Neurobiol, V2, P807, DOI 10.1016/0959-4388(92)90138-B; Massion Jean, 1994, Current Opinion in Neurobiology, V4, P877, DOI 10.1016/0959-4388(94)90137-6; Miall RC, 1996, NEURAL NETWORKS, V9, P1265, DOI 10.1016/S0893-6080(96)00035-4; MUNCKFAIRWOOD RC, 1992, PERCEPTION, V21, P747, DOI 10.1068/p210747; NASHNER LM, 1980, J NEUROPHYSIOL, V44, P650, DOI 10.1152/jn.1980.44.4.650; NISBETT RE, 1977, PSYCHOL REV, V84, P231, DOI 10.1037/0033-295X.84.3.231; Norman D. A., 2000, COGNITIVE NEUROSCIEN, P376; Pelah A, 1996, NATURE, V381, P283, DOI 10.1038/381283a0; Reynolds RF, 2006, NEUROREPORT, V17, P1503, DOI 10.1097/01.wnr.0000234741.04700.3e; Reynolds RF, 2004, J NEUROPHYSIOL, V91, P92, DOI 10.1152/jn.00495.2003; Reynolds RF, 2003, EXP BRAIN RES, V151, P301, DOI 10.1007/s00221-003-1444-2; Schneider W, 2003, COGNITIVE SCI, V27, P525, DOI 10.1016/S0364-0213(03)00011-9; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; Synofzik M, 2008, CONSCIOUS COGN, V17, P219, DOI 10.1016/j.concog.2007.03.010; Ullman J. B., 2004, HDB DATA ANAL, P431; WESTERMANN R, 1985, APPL PSYCH MEAS, V9, P265, DOI 10.1177/014662168500900304; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931; Yamadori A, 1996, COGNITIVE BRAIN RES, V5, P49, DOI 10.1016/S0926-6410(96)00040-7	33	16	16	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2009	4	6							e5782	10.1371/journal.pone.0005782	http://dx.doi.org/10.1371/journal.pone.0005782			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	453PV	19492054	gold, Green Published, Green Accepted, Green Submitted			2022-12-25	WOS:000266624300018
J	Diaz-San Segundo, F; Rodriguez-Calvo, T; de Avila, A; Sevilla, N				Diaz-San Segundo, Fayna; Rodriguez-Calvo, Teresa; de Avila, Ana; Sevilla, Noemi			Immunosuppression during Acute Infection with Foot-and-Mouth Disease Virus in Swine Is Mediated by IL-10	PLOS ONE			English	Article							DENDRITIC CELLS; ANTIGEN PRESENTATION; VIRAL PERSISTENCE; IMMUNE-RESPONSE; FMDV PEPTIDES; T-CELLS; INTERLEUKIN-10; INDUCTION; MATURATION; ANTIBODY	Foot-and-mouth disease virus (FMDV) is one of the most contagious animal viruses, causing a devastating disease in cloven-hoofed animals with enormous economic consequences. Identification of the different parameters involved in the immune response elicited against FMDV remains unclear, and it is fundamental the understanding of such parameters before effective control measures can be put in place. In the present study, we show that interleukin-10 (IL-10) production by dendritic cells (DCs) is drastically increased during acute infection with FMDV in swine. In vitro blockade of IL-10 with a neutralizing antibody against porcine IL-10 restores T cell activation by DCs. Additionally, we describe that FMDV infects DC precursors and interferes with DC maturation and antigen presentation capacity. Thus, we propose a new mechanism of virus immunity in which a non-persistent virus, FMDV, induces immunosuppression by an increment in the production of IL-10, which in turn, reduces T cell function. This reduction of T cell activity may result in a more potent induction of neutralizing antibody responses, clearing the viral infection.	[Diaz-San Segundo, Fayna; Rodriguez-Calvo, Teresa; Sevilla, Noemi] INIA, Ctr Invest Sanidad Anim, Madrid, Spain; [de Avila, Ana; Sevilla, Noemi] Ctr Biol Mol Severo Ochoa, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Diaz-San Segundo, F (corresponding author), ARS, Plum Isl Anim Dis Ctr, North Atlantic Area, USDA, Greenport, NY 11944 USA.	sevilla@inia.es	Sevilla, Noemi/K-8648-2014; Rodriguez-Calvo, Teresa/AAH-2365-2019; Rodriguez-Calvo, Teresa/A-6831-2010	Sevilla, Noemi/0000-0003-0118-0376; de Avila Lucas, Ana Isabel/0000-0002-9381-0963				Andrews DM, 2001, NAT IMMUNOL, V2, P1077, DOI 10.1038/ni724; Balabanian K, 2002, BLOOD, V99, P427, DOI 10.1182/blood.V99.2.427; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bautista EA, 2005, J VIROL, V79, P4838, DOI 10.1128/JVI.79.8.4838-4847.2005; Bautista EM, 2003, VET IMMUNOL IMMUNOP, V92, P61, DOI 10.1016/S0165-2427(03)00004-7; Benedict CA, 2002, NAT IMMUNOL, V3, P1013, DOI 10.1038/ni1102-1013; Brady MT, 2003, EUR J IMMUNOL, V33, P3448, DOI 10.1002/eji.200324251; Brooks DG, 2006, NAT MED, V12, P1301, DOI 10.1038/nm1492; Carbonneil C, 2004, J IMMUNOL, V172, P7832, DOI 10.4049/jimmunol.172.12.7832; Cebulla CM, 2002, J IMMUNOL, V169, P167, DOI 10.4049/jimmunol.169.1.167; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Collen T, 1998, VIRUS RES, V56, P125, DOI 10.1016/S0168-1702(98)00035-5; COLLEN T, 1989, J GEN VIROL, V70, P395, DOI 10.1099/0022-1317-70-2-395; DELATORRE JC, 1988, J VIROL, V62, P2050, DOI 10.1128/JVI.62.6.2050-2058.1988; delaTorre JC, 1996, ADV VIRUS RES, V46, P311; Ejrnaes M, 2006, CLIN DEV IMMUNOL, V13, P337, DOI 10.1080/17402520600800721; FugierVivier I, 1997, J EXP MED, V186, P813, DOI 10.1084/jem.186.6.813; Fujii SI, 2004, J EXP MED, V199, P1607, DOI 10.1084/jem.20040317; Garcia-Arriaza J, 2004, J VIROL, V78, P11678, DOI 10.1128/JVI.78.21.11678-11685.2004; GLASS EJ, 1994, IMMUNOLOGY, V82, P1; Gonzalez-Lopez C, 2004, J VIROL, V78, P3319, DOI 10.1128/JVI.78.7.3319-3324.2004; Granelli-Piperno A, 2004, P NATL ACAD SCI USA, V101, P7669, DOI 10.1073/pnas.0402431101; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; Grubman MJ, 2008, FEMS IMMUNOL MED MIC, V53, P8, DOI 10.1111/j.1574-695X.2008.00409.x; Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004; Guzylack-Piriou L, 2006, EUR J IMMUNOL, V36, P1674, DOI 10.1002/eji.200635866; Harwood LJ, 2008, J VIROL, V82, P6379, DOI 10.1128/JVI.00021-08; Ho LJ, 2001, J IMMUNOL, V166, P1499, DOI 10.4049/jimmunol.166.3.1499; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Ji JX, 2005, INT IMMUNOL, V17, P729, DOI 10.1093/intimm/dxh252; Knight SC, 1997, ANNU REV IMMUNOL, V15, P593, DOI 10.1146/annurev.immunol.15.1.593; Kruse M, 2000, J VIROL, V74, P7127, DOI 10.1128/JVI.74.15.7127-7136.2000; Marin-Serrano E, 2006, J VIRAL HEPATITIS, V13, P230, DOI 10.1111/j.1365-2893.2005.00679.x; Montes CL, 2006, EUR J IMMUNOL, V36, P1474, DOI 10.1002/eji.200535537; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; Munz C, 2005, J EXP MED, V202, P203, DOI 10.1084/jem.20050810; OLDSTONE MBA, 1989, J INFECT DIS, V159, P384, DOI 10.1093/infdis/159.3.384; Oldstone MBA, 2002, CURR TOP MICROBIOL, V263, P83; Orange JS, 2002, NAT IMMUNOL, V3, P1006, DOI 10.1038/ni1102-1006; Ostrowski M, 2005, J IMMUNOL, V175, P3971, DOI 10.4049/jimmunol.175.6.3971; Ostrowski M, 2007, J VIROL, V81, P9357, DOI 10.1128/JVI.00677-07; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; Recher M, 2004, NAT IMMUNOL, V5, P934, DOI 10.1038/ni1102; Sousa CR, 2006, NAT REV IMMUNOL, V6, P476, DOI 10.1038/nri1845; ROUSE BT, 1986, REV INFECT DIS, V8, P850; RUECKERT RR, 1984, J VIROL, V50, P957, DOI 10.1128/JVI.50.3.957-959.1984; Segundo FDS, 2006, J VIROL, V80, P2369, DOI 10.1128/JVI.80.5.2369-2379.2006; Sevilla N, 2000, J EXP MED, V192, P1249, DOI 10.1084/jem.192.9.1249; Sevilla N, 2004, J CLIN INVEST, V113, P737, DOI 10.1172/JCI20243; Sierra S, 2000, J VIROL, V74, P8316, DOI 10.1128/JVI.74.18.8316-8323.2000; SOBRINO F, 1983, VIROLOGY, V128, P310, DOI 10.1016/0042-6822(83)90258-1; Sobrino F, 2001, VET RES, V32, P1, DOI 10.1051/vetres:2001106; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Stumptner-Cuvelette P, 2001, P NATL ACAD SCI USA, V98, P12144, DOI 10.1073/pnas.221256498; Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365-2567.2006.02321.x; VANLIEROP MJC, 1992, IMMUNOLOGY, V75, P406; Weigel BJ, 2002, BLOOD, V100, P4169, DOI 10.1182/blood-2002-04-1063; Yewdell JW, 2002, NAT IMMUNOL, V3, P1019, DOI 10.1038/ni1102-1019	59	43	47	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2009	4	5							e5659	10.1371/journal.pone.0005659	http://dx.doi.org/10.1371/journal.pone.0005659			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LB	19478852	Green Submitted, Green Published, gold			2022-12-25	WOS:000266331000017
J	Ellison, DW; Clark, TR; Sturdevant, DE; Virtaneva, K; Hackstadt, T				Ellison, Damon W.; Clark, Tina R.; Sturdevant, Daniel E.; Virtaneva, Kimmo; Hackstadt, Ted			Limited Transcriptional Responses of Rickettsia rickettsii Exposed to Environmental Stimuli	PLOS ONE			English	Article								Rickettsiae are strict obligate intracellular pathogens that alternate between arthropod and mammalian hosts in a zoonotic cycle. Typically, pathogenic bacteria that cycle between environmental sources and mammalian hosts adapt to the respective environments by coordinately regulating gene expression such that genes essential for survival and virulence are expressed only upon infection of mammals. Temperature is a common environmental signal for upregulation of virulence gene expression although other factors may also play a role. We examined the transcriptional responses of Rickettsia rickettsii, the agent of Rocky Mountain spotted fever, to a variety of environmental signals expected to be encountered during its life cycle. R. rickettsii exposed to differences in growth temperature (25 degrees C vs. 37 degrees C), iron limitation, and host cell species displayed nominal changes in gene expression under any of these conditions with only 0, 5, or 7 genes, respectively, changing more than 3-fold in expression levels. R. rickettsii is not totally devoid of ability to respond to temperature shifts as cold shock (37 degrees C vs. 4 degrees C) induced a change greater than 3-fold in up to 56 genes. Rickettsiae continuously occupy a relatively stable environment which is the cytosol of eukaryotic cells. Because of their obligate intracellular character, rickettsiae are believed to be undergoing reductive evolution to a minimal genome. We propose that their relatively constant environmental niche has led to a minimal requirement for R. rickettsii to respond to environmental changes with a consequent deletion of non-essential transcriptional response regulators. A minimal number of predicted transcriptional regulators in the R. rickettsii genome is consistent with this hypothesis.			Ellison, DW (corresponding author), NIAID, Rocky Mt Labs, Intracellular Parasites Lab, NIH, Hamilton, MT 59840 USA.	thackstadt@niaid.nih.gov		Hackstadt, Ted/0000-0003-1367-5528	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000977, ZIAAI000977] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS DL, 1988, BIOCHEM J, V252, P199, DOI 10.1042/bj2520199; Audia JP, 2008, APPL ENVIRON MICROB, V74, P7809, DOI 10.1128/AEM.00896-08; Azad AF, 1998, EMERG INFECT DIS, V4, P179, DOI 10.3201/eid0402.980205; Blanc G, 2005, ANN NY ACAD SCI, V1063, P83, DOI 10.1196/annals.1355.012; Briggs HL, 2008, INFECT IMMUN, V76, P2189, DOI 10.1128/IAI.01609-07; Bronstein PA, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-209; BURGDORFER W, 1967, ANNU REV ENTOMOL, V12, P347, DOI 10.1146/annurev.en.12.010167.002023; BURGDORFER W, 1966, B WORLD HEALTH ORGAN, V35, P149; Chen LF, 2008, INFECT DIS CLIN N AM, V22, P415, DOI 10.1016/j.idc.2008.03.008; CORY J, 1974, APPL MICROBIOL, V27, P1157, DOI 10.1128/AEM.27.6.1157-1161.1974; Dantas-Torres F, 2007, LANCET INFECT DIS, V7, P724, DOI 10.1016/S1473-3099(07)70261-X; Dautel H, 1996, J COMP PHYSIOL B, V166, P517, DOI 10.1007/BF02338295; Dreher-Lesnick SM, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-61; Dumler JS, 2005, NEW ENGL J MED, V353, P551, DOI 10.1056/NEJMp058138; Ellison DW, 2008, INFECT IMMUN, V76, P542, DOI 10.1128/IAI.00952-07; Galat A, 2003, CURR TOP MED CHEM, V3, P1315, DOI 10.2174/1568026033451862; Goodchild A, 2004, J PROTEOME RES, V3, P1164, DOI 10.1021/pr0498988; Hackstadt T, 1996, INFECT AGENT DIS, V5, P127; Han YP, 2004, MICROBIOL IMMUNOL, V48, P791, DOI 10.1111/j.1348-0421.2004.tb03605.x; Heinzen RA, 1996, INFECT IMMUN, V64, P796, DOI 10.1128/IAI.64.3.796-809.1996; Hirschberg HJHB, 2001, EUR J BIOCHEM, V268, P5037, DOI 10.1046/j.0014-2956.2001.02411.x; Horzempa J, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-172; Howe D, 1999, INFECT IMMUN, V67, P3236, DOI 10.1128/IAI.67.7.3236-3241.1999; Konkel ME, 2000, MICROBES INFECT, V2, P157, DOI 10.1016/S1286-4579(00)00272-0; La MV, 2007, J MICROBIOL METH, V71, P292, DOI 10.1016/j.mimet.2007.09.017; Lacz NL, 2006, J EUR ACAD DERMATOL, V20, P411, DOI 10.1111/j.1468-3083.2006.01489.x; Lo M, 2006, INFECT IMMUN, V74, P5848, DOI 10.1128/IAI.00755-06; MAURELLI AT, 1984, INFECT IMMUN, V43, P195, DOI 10.1128/IAI.43.1.195-201.1984; MCDADE JE, 1986, ANNU REV MICROBIOL, V40, P287, DOI 10.1146/annurev.mi.40.100186.001443; Merrell DS, 2003, INFECT IMMUN, V71, P6510, DOI 10.1128/IAI.71.11.6510-6525.2003; Miethke M, 2006, J BACTERIOL, V188, P8655, DOI 10.1128/JB.01049-06; Motin VL, 2004, J BACTERIOL, V186, P6298, DOI 10.1128/JB.186.18.6298-6305.2004; Muga A, 2008, CURR PROTEIN PEPT SC, V9, P552, DOI 10.2174/138920308786733903; Munderloh UG, 1999, J CLIN MICROBIOL, V37, P2518, DOI 10.1128/JCM.37.8.2518-2524.1999; Nelson CM, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-364; Ogata H, 2001, SCIENCE, V293, P2093, DOI 10.1126/science.1061471; Ogawa M, 2007, PROTEOMICS, V7, P1232, DOI 10.1002/pmic.200600721; Ojaimi C, 2003, INFECT IMMUN, V71, P1689, DOI 10.1128/IAI.71.4.1689-1705.2003; OJCIUS DM, 1995, INFECT IMMUN, V63, P3069, DOI 10.1128/IAI.63.8.3069-3072.1995; Perez-Rueda E, 2000, NUCLEIC ACIDS RES, V28, P1838, DOI 10.1093/nar/28.8.1838; Phadtare S, 2004, CURR ISSUES MOL BIOL, V6, P125; Policastro PF, 1997, J MED MICROBIOL, V46, P839, DOI 10.1099/00222615-46-10-839; PRICE WH, 1953, SCIENCE, V118, P49, DOI 10.1126/science.118.3054.49; Qin JH, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-51; Raulston JE, 1997, INFECT IMMUN, V65, P4539, DOI 10.1128/IAI.65.11.4539-4547.1997; Renesto P, 2005, FEMS MICROBIOL LETT, V245, P231, DOI 10.1016/j.femsle.2005.03.004; SCARLATO V, 1993, BIOESSAYS, V15, P99, DOI 10.1002/bies.950150205; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; SILVERMAN DJ, 1992, INFECT IMMUN, V60, P2733, DOI 10.1128/IAI.60.7.2733-2740.1992; Smoot LM, 2001, P NATL ACAD SCI USA, V98, P10416, DOI 10.1073/pnas.191267598; Spencer RR, 1923, PUBLIC HEALTH REP, V38, P333, DOI 10.2307/4576667; WALKER DH, 1989, CLIN MICROBIOL REV, V2, P227, DOI 10.1128/CMR.2.3.227-240.1989; Walker DH, 2001, AM J TROP MED HYG, V65, P936, DOI 10.4269/ajtmh.2001.65.936; WALKER DH, 1983, INFECT IMMUN, V40, P840, DOI 10.1128/IAI.40.2.840-842.1983; WEISS E, 1975, APPL MICROBIOL, V30, P456, DOI 10.1128/AEM.30.3.456-463.1975; Whitby PW, 2006, J BACTERIOL, V188, P5640, DOI 10.1128/JB.00417-06; WINKLER HH, 1990, ANNU REV MICROBIOL, V44, P131, DOI 10.1146/annurev.mi.44.100190.001023; WINKLER HH, 1989, INFECT IMMUN, V57, P36, DOI 10.1128/IAI.57.1.36-40.1989; WINKLER HH, 1980, INFECT IMMUN, V29, P316; Zhou DS, 2006, FEMS MICROBIOL LETT, V258, P9, DOI 10.1111/j.1574-6968.2006.00208.x	60	30	30	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5612	10.1371/journal.pone.0005612	http://dx.doi.org/10.1371/journal.pone.0005612			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19440298	gold, Green Submitted, Green Published			2022-12-25	WOS:000266161200013
J	Safdar, A; Abadi, A; Akhtar, M; Hettinga, BP; Tarnopolsky, MA				Safdar, Adeel; Abadi, Arkan; Akhtar, Mahmood; Hettinga, Bart P.; Tarnopolsky, Mark A.			miRNA in the Regulation of Skeletal Muscle Adaptation to Acute Endurance Exercise in C57Bl/6J Male Mice	PLOS ONE			English	Article							CONTROLLING MITOCHONDRIAL BIOGENESIS; PYRUVATE-DEHYDROGENASE COMPLEX; TRANSCRIPTIONAL COACTIVATOR; GENE-EXPRESSION; PPAR-ALPHA; MICRORNAS; PGC-1-ALPHA; METABOLISM; INCREASES; GLUCOSE	MicroRNAs (miRNAs) are evolutionarily conserved small non-coding RNA species involved in post-transcriptional gene regulation. In vitro studies have identified a small number of skeletal muscle-specific miRNAs which play a crucial role in myoblast proliferation and differentiation. In skeletal muscle, an acute bout of endurance exercise results in the upregulation of transcriptional networks that regulate mitochondrial biogenesis, glucose and fatty acid metabolism, and skeletal muscle remodelling. The purpose of this study was to assess the expressional profile of targeted miRNA species following an acute bout of endurance exercise and to determine relationships with previously established endurance exercise responsive transcriptional networks. C57Bl/6J wild-type male mice (N = 7/group) were randomly assigned to either sedentary or forced-endurance exercise (treadmill run @ 15 m/min for 90 min) group. The endurance exercise group was sacrificed three hours following a single bout of exercise. The expression of miR-181, 1, 133, 23, and 107, all of which have been predicted to regulate transcription factors and co-activators involved in the adaptive response to exercise, was measured in quadriceps femoris muscle. Endurance exercise significantly increased the expression of miR-181, miR-1, and miR-107 by 37%, 40%, and 56%, respectively, and reduced miR-23 expression by 84% (P <= 0.05 for all), with no change in miR-133. Importantly, decreased expression of miRNA-23, a putative negative regulator of PGC-1 alpha was consistent with increased expression of PGC-1 alpha mRNA and protein along with several downstream targets of PGC-1 alpha including ALAS, CS, and cytochrome c mRNA. PDK4 protein content remains unaltered despite an increase in its putative negative regulator, miR-107, and PDK4 mRNA expression. mRNA expression of miRNA processing machinery (Drosha, Dicer, and DGCR8) remained unchanged. We conclude that miRNA-mediated post-transcriptional regulation is potentially involved in the complex regulatory networks that govern skeletal muscle adaptation to endurance exercise in C57Bl/6J male mice.			Safdar, A (corresponding author), McMaster Univ, Dept Kinesiol, Hamilton, ON, Canada.	tarnopol@mcmaster.ca		Safdar, Adeel/0000-0003-2469-0467; Safdar, Adeel/0000-0002-7453-7770				Asli NS, 2008, CURR MOL MED, V8, P698, DOI 10.2174/156652408786733739; Baar K, 2003, FASEB J, V17, P1666, DOI 10.1096/fj.03-0049com; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Bonen A, 1999, AM J PHYSIOL-ENDOC M, V276, pE642, DOI 10.1152/ajpendo.1999.276.4.E642; Callis TE, 2008, EXP BIOL MED, V233, P131, DOI 10.3181/0709-MR-237; Cannell IG, 2008, BIOCHEM SOC T, V36, P1224, DOI 10.1042/BST0361224; Carter SL, 2001, AM J PHYSIOL-ENDOC M, V280, pE898, DOI 10.1152/ajpendo.2001.280.6.E898; Chakravarty EF, 2008, ARCH INTERN MED, V168, P1638, DOI 10.1001/archinte.168.15.1638; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Coffey VG, 2007, SPORTS MED, V37, P737, DOI 10.2165/00007256-200737090-00001; Eisenberg I, 2007, P NATL ACAD SCI USA, V104, P17016, DOI 10.1073/pnas.0708115104; Fluck M, 2006, J EXP BIOL, V209, P2239, DOI 10.1242/jeb.02149; GOLLNICK PD, 1982, CLIN PHYSIOL, V2, P1, DOI 10.1111/j.1475-097X.1982.tb00001.x; Hamilton MT, 2000, J APPL PHYSIOL, V88, P327, DOI 10.1152/jappl.2000.88.1.327; Hanai JI, 2007, J CLIN INVEST, V117, P3940, DOI 10.1172/JCI32741; Handschin C, 2007, GENE DEV, V21, P770, DOI 10.1101/gad.1525107; Hawley JA, 2006, ESSAYS BIOCHEM, V42, P1, DOI 10.1042/bse0420001; Hildebrandt AL, 2003, AM J PHYSIOL-ENDOC M, V285, pE1021, DOI 10.1152/ajpendo.00234.2003; HOLLOSZY JO, 1976, ANNU REV PHYSIOL, V38, P273, DOI 10.1146/annurev.ph.38.030176.001421; Holness MJ, 2000, DIABETES, V49, P775, DOI 10.2337/diabetes.49.5.775; Holness MJ, 2003, BIOCHEM SOC T, V31, P1143; Hoppeler H, 2007, ADV EXP MED BIOL, V618, P245; JACKSON RJ, 2007, SCI STKE, pRE1, DOI DOI 10.1126/STKE.3672007RE1; Joseph AM, 2006, ESSAYS BIOCHEM, V42, P13, DOI 10.1042/bse0420013; Keller P, 2007, BIOCHEM SOC T, V35, P1306, DOI 10.1042/BST0351306; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Lanza IR, 2008, DIABETES, V57, P2933, DOI 10.2337/db08-0349; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lefebvre P, 2006, J CLIN INVEST, V116, P571, DOI 10.1172/JCI27989; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Mahoney DJ, 2005, FASEB J, V19, P1498, DOI 10.1096/fj.04-3149fje; Mahoney DJ, 2004, PHYSIOL GENOMICS, V18, P226, DOI 10.1152/physiolgenomics.00067.2004; McCarthy JJ, 2007, J APPL PHYSIOL, V102, P306, DOI 10.1152/japplphysiol.00932.2006; Naguibneva I, 2006, NAT CELL BIOL, V8, P278, DOI 10.1038/ncb1373; Papagiannakopoulos T, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-15; Peters SJ, 2001, AM J PHYSIOL-REG I, V280, pR661, DOI 10.1152/ajpregu.2001.280.3.R661; Pilegaard H, 2002, J PHYSIOL-LONDON, V541, P261, DOI 10.1113/jphysiol.2002.016832; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Poy MN, 2007, DIABETES OBES METAB, V9, P67, DOI 10.1111/j.1463-1326.2007.00775.x; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Ramaswamy G, 2004, J LIPID RES, V45, P17, DOI 10.1194/jlr.M300279-JLR200; REN JM, 1994, J BIOL CHEM, V269, P14396; Rose AJ, 2005, J PHYSIOL-LONDON, V569, P223, DOI 10.1113/jphysiol.2005.097154; Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103; Skrede S, 1997, BBA-LIPID LIPID MET, V1344, P115, DOI 10.1016/S0005-2760(96)00138-5; Sokol NS, 2005, GENE DEV, V19, P2343, DOI 10.1101/gad.1356105; Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, pE855, DOI 10.1152/ajpendo.00526.2002; Teri L, 2003, JAMA-J AM MED ASSOC, V290, P2015, DOI 10.1001/jama.290.15.2015; van Rooij E, 2008, TRENDS GENET, V24, P159, DOI 10.1016/j.tig.2008.01.007; Vissing K, 2008, AM J PHYSIOL-ENDOC M, V294, pE408, DOI 10.1152/ajpendo.00403.2007; Walden TB, 2009, J CELL PHYSIOL, V218, P444, DOI 10.1002/jcp.21621; Wang WX, 2008, J NEUROSCI, V28, P1213, DOI 10.1523/JNEUROSCI.5065-07.2008; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379; Wilfred BR, 2007, MOL GENET METAB, V91, P209, DOI 10.1016/j.ymgme.2007.03.011; Wisloff U, 2005, SCIENCE, V307, P418, DOI 10.1126/science.1108177; Wright DC, 2007, J BIOL CHEM, V282, P194, DOI 10.1074/jbc.M606116200; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xu CQ, 2007, J CELL SCI, V120, P3045, DOI 10.1242/jcs.010728; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817	62	164	181	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5610	10.1371/journal.pone.0005610	http://dx.doi.org/10.1371/journal.pone.0005610			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19440340	Green Submitted, Green Published, gold			2022-12-25	WOS:000266161200012
J	Crow, A; Race, PR; Jubelin, G; Chavez, CV; Escoubas, JM; Oswald, E; Banfield, MJ				Crow, Allister; Race, Paul R.; Jubelin, Gregory; Chavez, Carolina Varela; Escoubas, Jean-Michel; Oswald, Eric; Banfield, Mark J.			Crystal Structures of Cif from Bacterial Pathogens Photorhabdus luminescens and Burkholderia pseudomallei	PLOS ONE			English	Article							HOST-CELL CYCLE; CYCLOMODULIN CIF; SECRETION; EFFECTOR; BLOCKS; DOMAIN	A pre-requisite for bacterial pathogenesis is the successful interaction of a pathogen with a host. One mechanism used by a broad range of Gram negative bacterial pathogens is to deliver effector proteins directly into host cells through a dedicated type III secretion system where they modulate host cell function. The cycle inhibiting factor (Cif) family of effector proteins, identified in a growing number of pathogens that harbour functional type III secretion systems and have a wide host range, arrest the eukaryotic cell cycle. Here, the crystal structures of Cifs from the insect pathogen/nematode symbiont Photorhabdus luminescens (a gamma-proteobacterium) and human pathogen Burkholderia pseudomallei (a beta-proteobacterium) are presented. Both of these proteins adopt an overall fold similar to the papain sub-family of cysteine proteases, as originally identified in the structure of a truncated form of Cif from Enteropathogenic E. coli (EPEC), despite sharing only limited sequence identity. The structure of an N-terminal region, referred to here as the 'tail-domain' (absent in the EPEC Cif structure), suggests a surface likely to be involved in host-cell substrate recognition. The conformation of the Cys-His-Gln catalytic triad is retained, and the essential cysteine is exposed to solvent and addressable by small molecule reagents. These structures and biochemical work contribute to the rapidly expanding literature on Cifs, and direct further studies to better understand the molecular details of the activity of these proteins.	[Crow, Allister; Banfield, Mark J.] John Innes Ctr, Dept Biol Chem, Norwich, Norfolk, England; [Race, Paul R.] Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Jubelin, Gregory; Oswald, Eric] Univ Toulouse, INRA, ENVT, UMR 1225, Toulouse, France; [Chavez, Carolina Varela; Escoubas, Jean-Michel] INRA, Lab EMIP UMR1133, F-34095 Montpellier, France	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Newcastle University - UK; INRAE; Universite de Toulouse; Ecole Nationale Veterinaire de Toulouse; INRAE	Banfield, MJ (corresponding author), John Innes Ctr, Dept Biol Chem, Norwich, Norfolk, England.	mark.banfield@bbsrc.ac.uk	ESCOUBAS, Jean-Michel/G-4027-2010; Crow, Allister/F-2147-2018; Banfield, Mark/C-7453-2013	ESCOUBAS, Jean-Michel/0000-0002-6138-1148; Crow, Allister/0000-0001-6856-5962; Banfield, Mark/0000-0001-8921-3835; Oswald, Eric/0000-0002-3017-0081; JUBELIN, Gregory/0000-0002-9902-0663	BBSRC [BB/F008732/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [F008732, BB/F008732/1] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOEMARE NE, 1993, INT J SYST BACTERIOL, V43, P249, DOI 10.1099/00207713-43-2-249; Charpentier X, 2004, J BACTERIOL, V186, P5486, DOI 10.1128/JB.186.16.5486-5495.2004; Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Galan JE, 2006, NATURE, V444, P567, DOI 10.1038/nature05272; Gerrard J, 2004, MICROBES INFECT, V6, P229, DOI 10.1016/j.micinf.2003.10.018; Holm L, 2008, BIOINFORMATICS, V24, P2780, DOI 10.1093/bioinformatics/btn507; Hsu Y, 2008, J MOL BIOL, V384, P465, DOI 10.1016/j.jmb.2008.09.051; Jubelin G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004855; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; KLEYWEGT GJ, 2001, INT TABLES CRYSTALLO, VF; Leslie AGW, 2006, ACTA CRYSTALLOGR D, V62, P48, DOI 10.1107/S0907444905039107; Marches O, 2003, MOL MICROBIOL, V50, P1553, DOI 10.1046/j.1365-2958.2003.03821.x; Miranda JJL, 2003, PROTEIN SCI, V12, P73, DOI 10.1110/ps.0224203; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Naktin J, 1999, CLIN LAB MED, V19, P523; Nougayrede JP, 2001, INFECT IMMUN, V69, P6785, DOI 10.1128/IAI.69.11.6785-6795.2001; REECE RJ, 1991, J BIOL CHEM, V266, P3540; Samba-Louaka A, 2008, CELL MICROBIOL, V10, P2496, DOI 10.1111/j.1462-5822.2008.01224.x; Stebbins CE, 2005, CELL MICROBIOL, V7, P1227, DOI 10.1111/j.1462-5822.2005.00564.x; Stebbins CE, 2001, NATURE, V412, P701, DOI 10.1038/35089000; Taieb F, 2006, CELL MICROBIOL, V8, P1910, DOI 10.1111/j.1462-5822.2006.00757.x; Wiersinga WJ, 2006, NAT REV MICROBIOL, V4, P272, DOI 10.1038/nrmicro1385; Yang ZR, 2005, BIOINFORMATICS, V21, P3369, DOI 10.1093/bioinformatics/bti534; YAO Q, 2009, P NATL ACAD SCI US; Zhu MF, 2004, P NATL ACAD SCI USA, V101, P302, DOI 10.1073/pnas.2036536100	31	26	29	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5582	10.1371/journal.pone.0005582	http://dx.doi.org/10.1371/journal.pone.0005582			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440549	Green Published, gold, Green Submitted			2022-12-25	WOS:000266107500012
J	Mate, KS; Bennett, B; Mphatswe, W; Barker, P; Rollins, N				Mate, Kedar S.; Bennett, Brandon; Mphatswe, Wendy; Barker, Pierre; Rollins, Nigel			Challenges for Routine Health System Data Management in a Large Public Programme to Prevent Mother-to-Child HIV Transmission in South Africa	PLOS ONE			English	Article								Background: Recent changes to South Africa's prevention of mother-to-child transmission of HIV (PMTCT) guidelines have raised hope that the national goal of reducing perinatal HIV transmission rates to less than 5% can be attained. While programmatic efforts to reach this target are underway, obtaining complete and accurate data from clinical sites to track progress presents a major challenge. We assessed the completeness and accuracy of routine PMTCT data submitted to the district health information system (DHIS) in three districts of Kwazulu-Natal province, South Africa. Methodology/Principal Findings: We surveyed the completeness and accuracy of data reported for six key PMTCT data elements between January and December 2007 from all 316 clinics and hospitals in three districts. Through visits to randomly selected sites, we reconstructed reports for the same six PMTCT data elements from clinic registers and assessed accuracy of the monthly reports previously submitted to the DHIS. Data elements were reported only 50.3% of the time and were "accurate'' (i.e. within 10% of reconstructed values) 12.8% of the time. The data element "Antenatal Clients Tested for HIV'' was the most accurate data element (i.e. consistent with the reconstructed value) 19.8% of the time, while "HIV PCR testing of baby born to HIV positive mother'' was the least accurate with only 5.3% of clinics meeting the definition of accuracy. Conclusions/Significance: Data collected and reported in the public health system across three large, high HIV-prevalence Districts was neither complete nor accurate enough to track process performance or outcomes for PMTCT care. Systematic data evaluation can determine the magnitude of the data reporting failure and guide site-specific improvements in data management. Solutions are currently being developed and tested to improve data quality.			Mate, KS (corresponding author), Inst Healthcare Improvement, Cambridge, MA USA.	kmate@partners.org		Mate, Kedar/0000-0001-7579-6697				Boerma T, 2009, B WORLD HEALTH ORGAN, V87, P2, DOI 10.2471/BLT.08.061945; Burger EH, 2007, SAMJ S AFR MED J, V97, P1077; Campbell B, 1996, DATA DECISION MAKING; Clements CJ, 2008, VACCINE, V26, P1926, DOI 10.1016/j.vaccine.2008.02.032; Garrib A, 2008, SAMJ S AFR MED J, V98, P549; Makombe SD, 2008, B WORLD HEALTH ORGAN, V86, P310, DOI 10.2471/BLT.07.044685; Mavimbe JC, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-108; Otwombe KN, 2007, B WORLD HEALTH ORGAN, V85, P315, DOI 10.2471/BLT.06.033712; Rollins N, 2007, AIDS, V21, P1341, DOI 10.1097/QAD.0b013e32814db7d4; Ronveaux O, 2005, B WORLD HEALTH ORGAN, V83, P503; *S AFR DEP HLTH, 2007, NAT STRAT PLAN HIV A; Shaw V, 2005, B WORLD HEALTH ORGAN, V83, P632; South African Department of Health, 2008, POL GUID IMPL PMTCT; The IATT on Prevention of HIV Infection in Pregnant Women MatC, 2007, GUID GLOB SCAL UP PR; Wilkins K, 2008, PUBLIC HEALTH, V122, P914, DOI 10.1016/j.puhe.2007.11.002; World Health Organization (WHO), 2008, TOOLK MON HLTH SYST	16	144	145	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2009	4	5							e5483	10.1371/journal.pone.0005483	http://dx.doi.org/10.1371/journal.pone.0005483			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444VZ	19434234	Green Published, gold			2022-12-25	WOS:000266009800004
J	Vandenburgh, H; Shansky, J; Benesch-Lee, F; Skelly, K; Spinazzola, JM; Saponjian, Y; Tseng, BS				Vandenburgh, Herman; Shansky, Janet; Benesch-Lee, Frank; Skelly, Kirsten; Spinazzola, Janelle M.; Saponjian, Yero; Tseng, Brian S.			Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts	FASEB JOURNAL			English	Article						tetanic force; glucocorticoids; mdx mouse; dietary supplements; cardiovascular drugs	DUCHENNE MUSCULAR-DYSTROPHY; THERAPEUTIC STRATEGIES; GLYCOPROTEIN COMPLEX; SKELETAL-MUSCLES; MDX MOUSE; MICE; STRENGTH; PREDNISOLONE; PROTEIN; TARGET	Identification of factors that improve muscle function in boys with Duchenne muscular dystrophy (DMD) could lead to an improved quality of life. To establish a functional in vitro assay for muscle strength, mdx murine myoblasts, the genetic homologue of DMD, were tissue engineered in 96-microwell plates into 3-dimensional muscle constructs with parallel arrays of striated muscle fibers. When electrically stimulated, they generated tetanic forces measured with an automated motion tracking system. Thirty-one compounds of interest as potential treatments for patients with DMD were tested at 3 to 6 concentrations. Eleven of the compounds (insulin-like growth factor-1, creatine, beta-hydroxy-beta-methylbutyrate, trichostatin A, lisinopril, and 6 from the glucocorticoid family) significantly increased tetanic force relative to placebo-treated controls. The glucocorticoids methylprednisolone, deflazacort, and prednisone increased tetanic forces at low doses (EC50 of 6, 19, and 56 nM, respectively), indicating a direct muscle mechanism by which they may be benefitting DMD patients. The tetanic force assay also identified beneficial compound interactions ( arginine plus deflazacort and prednisone plus creatine) as well as deleterious interactions ( prednisone plus creatine inhibited by pentoxifylline) of combinatorial therapies taken by some DMD patients. Since mdx muscle in vivo and DMD patients respond in a similar manner to many of these compounds, the in vitro assay will be a useful tool for the rapid identification of new potential treatments for muscle weakness in DMD and other muscle disorders.-Vandenburgh, H., Shansky, J., Benesch-Lee, F., Skelly, K., Spinazzola, J. M., Saponjian, Y., Tseng, B. S. Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts. FASEB J. 23, 3325-3334 ( 2009). www.fasebj.org	[Vandenburgh, Herman] Myomics Inc, Slater Biotechnol Ctr, Providence, RI 02906 USA; [Vandenburgh, Herman; Shansky, Janet] Miriam Hosp, Brown Med Sch, Dept Pathol, Providence, RI 02906 USA; [Saponjian, Yero; Tseng, Brian S.] Massachusetts Gen Hosp, Boston, MA 02114 USA	Brown University; Lifespan Health Rhode Island; Miriam Hospital; Harvard University; Massachusetts General Hospital	Vandenburgh, H (corresponding author), Myomics Inc, Slater Biotechnol Ctr, 5th Floor,4 Richmond Sq, Providence, RI 02906 USA.	hvandenburgh@myomics.com	Benesch-Lee, Frank/O-2482-2014	Benesch-Lee, Frank/0000-0002-4551-3163	Slater Technology Fund; National Institutes of Health [AG-029705, NS-059098, AR-052308]; National Science Foundation [0724445]; Hood, Sharp, and Jett Foundations; Charley's Fund; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR052308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R43NS059098, R44NS059098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R43AG029705] Funding Source: NIH RePORTER	Slater Technology Fund; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Hood, Sharp, and Jett Foundations; Charley's Fund; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr. Terry Partridge ( Children's National Medical Center, Washington, DC, USA) for providing the conditionally immortalized control and mdx skeletal muscle cells. This work was supported by the Slater Technology Fund; the National Institutes of Health (AG-029705, NS-059098, and AR-052308); the National Science Foundation ( award 0724445); the Hood, Sharp, and Jett Foundations; and Charley's Fund. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and not necessarily those of the granting agencies. H. V. and B. T. designed the experiments and wrote the paper; J.S., K. S., and J.M.S. performed the tissue engineering, compound screening, and force measurements; F.B.-L. developed the casting molds for the micropost plugs, wrote the LabView and MatLab software, and built the MAD device; and Y.S. performed histological analyses.	Acharyya S, 2005, CANCER CELL, V8, P421, DOI 10.1016/j.ccr.2005.10.004; Archer JD, 2006, FASEB J, V20, P738, DOI 10.1096/fj.05-4821fje; Asai A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000806; Bellinger AM, 2008, J CLIN INVEST, V118, P445, DOI 10.1172/JCI34006; Bonifati MD, 2000, MUSCLE NERVE, V23, P1344, DOI 10.1002/1097-4598(200009)23:9<1344::AID-MUS4>3.3.CO;2-6; Brunelli S, 2007, P NATL ACAD SCI USA, V104, P264, DOI 10.1073/pnas.0608277104; Catoire H, 2008, HUM MOL GENET, V17, P2108, DOI 10.1093/hmg/ddn109; Chamberlain J, 2006, DUCHENNE MUSCULAR DY; CHROMIAK JA, 1992, AM J PHYSIOL, V262, pC1471, DOI 10.1152/ajpcell.1992.262.6.C1471; Ciafaloni E, 2008, CURR TREAT OPTION N, V10, P86, DOI 10.1007/s11940-008-0010-4; Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009; Cohn RD, 2007, NAT MED, V13, P204, DOI 10.1038/nm1536; Courdier-Fruh I, 2002, NEUROMUSCULAR DISORD, V12, pS95, DOI 10.1016/S0960-8966(02)00089-5; Escolar D, 2008, NEUROMUSCULAR DISORD, V18, P824, DOI 10.1016/j.nmd.2008.06.345; Fisher I, 2005, FASEB J, V19, P834, DOI 10.1096/fj.04-2511fje; Franco-Obregon A, 2002, J PHYSIOL-LONDON, V539, P391, DOI 10.1113/jphysiol.2001.013043; Gaud A, 2004, NEUROMUSCULAR DISORD, V14, P365, DOI 10.1016/j.nmd.2004.02.011; Golumbek PT, 2007, NEUROMUSCULAR DISORD, V17, P376, DOI 10.1016/j.nmd.2007.02.005; Granchelli JA, 2000, NEUROMUSCULAR DISORD, V10, P235, DOI 10.1016/S0960-8966(99)00126-1; Grounds MD, 2008, CELL MOL LIFE SCI, V65, P1621, DOI 10.1007/s00018-008-7574-8; HUDECKI MS, 1993, RES COMMUN CHEM PATH, V79, P45; Johnson BD, 2005, P NATL ACAD SCI USA, V102, P4191, DOI 10.1073/pnas.0409695102; Khademhosseini A, 2006, P NATL ACAD SCI USA, V103, P2480, DOI 10.1073/pnas.0507681102; Khurana TS, 2003, NAT REV DRUG DISCOV, V2, P379, DOI 10.1038/nrd1085; Kumar A, 2004, FASEB J, V18, P102, DOI 10.1096/fj.03-0453com; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Leijendekker WJ, 1996, BRIT J PHARMACOL, V118, P611, DOI 10.1111/j.1476-5381.1996.tb15445.x; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; McClure WC, 2007, NEUROMUSCULAR DISORD, V17, P639, DOI 10.1016/j.nmd.2007.04.008; McNally EM, 2008, HEART, V94, P976, DOI 10.1136/hrt.2007.138461; METZINGER L, 1995, BRIT J PHARMACOL, V116, P2811, DOI 10.1111/j.1476-5381.1995.tb15930.x; Minetti GC, 2006, NAT MED, V12, P1147, DOI 10.1038/nm1479; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Ng R, 2008, AM J PHYSIOL-CELL PH, V295, pC146, DOI 10.1152/ajpcell.00017.2008; Nissen SL, 2003, J APPL PHYSIOL, V94, P651, DOI 10.1152/japplphysiol.00755.2002; Passaquin AC, 2002, NEUROMUSCULAR DISORD, V12, P174, DOI 10.1016/S0960-8966(01)00273-5; Payne ET, 2006, MUSCLE NERVE, V33, P66, DOI 10.1002/mus.20436; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Sampaolesi M, 2001, PFLUG ARCH EUR J PHY, V442, P161, DOI 10.1007/s004240100516; Schertzer JD, 2006, AM J PHYSIOL-ENDOC M, V291, pE499, DOI 10.1152/ajpendo.00101.2006; Siegel AL, 2009, NEUROMUSCULAR DISORD, V19, P131, DOI 10.1016/j.nmd.2008.10.006; Steen MS, 2009, MOL BIOL CELL, V20, P146, DOI 10.1091/mbc.E08-08-0811; Steffen LS, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-79; Sumukadas D, 2006, GERONTOLOGY, V52, P237, DOI 10.1159/000093656; Tanaka M, 2005, PLOS BIOL, V3, P764, DOI 10.1371/journal.pbio.0030128; Tarnopolsky MA, 2004, NEUROLOGY, V62, P1771, DOI 10.1212/01.WNL.0000125178.18862.9D; Terstappen GC, 2007, NAT REV DRUG DISCOV, V6, P891, DOI 10.1038/nrd2410; Tidball JG, 2004, PEDIATR RES, V56, P831, DOI 10.1203/01.PDR.0000145578.01985.D0; Vandenburgh H, 2008, MUSCLE NERVE, V37, P438, DOI 10.1002/mus.20931; VANDENBURGH HH, 1991, FASEB J, V5, P2860, DOI 10.1096/fasebj.5.13.1916108; Villalta SA, 2009, HUM MOL GENET, V18, P482, DOI 10.1093/hmg/ddn376; Welch EM, 2007, NATURE, V447, P87, DOI 10.1038/nature05756; Yeung EW, 2003, J PHYSIOL-LONDON, V552, P449, DOI 10.1113/jphysiol.2003.047373; Zhu CH, 2007, AGING CELL, V6, P515, DOI 10.1111/j.1474-9726.2007.00306.x	55	80	91	0	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3325	3334		10.1096/fj.09-134411	http://dx.doi.org/10.1096/fj.09-134411			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19487307	Green Published			2022-12-25	WOS:000270354300010
J	Sung, WK; Lu, YW; Lee, CWH; Zhang, DW; Ronaghi, M; Lee, CGL				Sung, Wing-Kin; Lu, Yiwei; Lee, Charlie W. H.; Zhang, Dongwei; Ronaghi, Mostafa; Lee, Caroline G. L.			Deregulated Direct Targets of the Hepatitis B Virus (HBV) Protein, HBx, Identified through Chromatin Immunoprecipitation and Expression Microarray Profiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING-SITES; X-PROTEIN; HEPATOCELLULAR-CARCINOMA; DNA-BINDING; TRANSACTIVATOR PROTEIN; TRANSCRIPTIONAL ACTIVATOR; C-MYC; CELLS; GENE; HEPATOCARCINOGENESIS	The hepatitis B-X (HBx) protein is strongly associated with hepatocellular carcinoma. It is implicated not to directly cause cancer but to play a role in hepatocellular carcinoma as a cofactor. The oncogenic potential of HBx primarily lies in its interaction with transcriptional regulators resulting in aberrant gene expression and deregulated cellular pathways. Utilizing ultraviolet irradiation to simulate a tumor-initiating event, we integrated chip-based chromatin immunoprecipitation (ChIP-chip) with expression microarray profiling and identified 184 gene targets directly deregulated by HBx. One-hundred forty-four transcription factors interacting with HBx were computationally inferred. We experimentally validated that HBx interacts with some of the predicted transcription factors (pTF) as well as the promoters of the deregulated target genes of these pTFs. Significantly, we demonstrated that the pTF interacts with the promoters of the deregulated HBx target genes and that deregulation by HBx of these HBx target genes carrying the pTF consensus sequences can be reversed using pTF small interfering RNAs. The roles of these deregulated direct HBx target genes and their relevance in cancer was inferred via querying against biogroup/cancer-related microarray databases using web-based NextBio (TM) software. Six pathways, including the Jak-STAT pathway, were predicted to be significantly deregulated when HBx binds indirectly to direct target gene promoters. In conclusion, this study represents the first ever demonstration of the utilization of ChIP-chip to identify deregulated direct gene targets from indirect protein-DNA binding as well as transcriptional factors directly interacting with HBx. Increased knowledge of the gene/transcriptional factor targets of HBx will enhance our understanding of the role of HBx in hepatocellular carcinogenesis and facilitate the design of better strategies in combating hepatitis B virus-associated hepatocellular carcinoma.	[Lu, Yiwei; Zhang, Dongwei; Lee, Caroline G. L.] Natl Canc Ctr Singapore, Div Med Sci, Singapore 169610, Singapore; [Sung, Wing-Kin; Lee, Charlie W. H.] Natl Univ Singapore, Dept Comp Sci, Singapore 119077, Singapore; [Zhang, Dongwei; Lee, Caroline G. L.] Natl Univ Singapore, Dept Biochem, Singapore 119077, Singapore; [Sung, Wing-Kin; Lee, Charlie W. H.] Genome Inst Singapore, Singapore 138672, Singapore; [Ronaghi, Mostafa] Stanford Univ, Stanford Genome Technol Ctr, Dept Biochem, Stanford, CA 94305 USA; [Lee, Caroline G. L.] Duke NUS Grad Med Sch, Singapore 169547, Singapore	National Cancer Centre Singapore (NCCS); National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Stanford University; National University of Singapore	Lee, CGL (corresponding author), Natl Canc Ctr Singapore, Div Med Sci, Level 6,Lab 5,11 Hosp Dr, Singapore 169610, Singapore.	bchleec@nus.edu.sg	Lee, Caroline G/M-8918-2019	Lee, Caroline G/0000-0002-4323-3635; Sung, Wing-Kin/0000-0001-7806-7086	BioMedical Research Council (BMRC) of Singapore [BMRC06/1/21/19/449]; Singapore Millennium Foundation; National Cancer Centre; DUKE-NUS Graduate Medical School	BioMedical Research Council (BMRC) of Singapore(Agency for Science Technology & Research (A*STAR)); Singapore Millennium Foundation(Singapore Millennium Foundation); National Cancer Centre; DUKE-NUS Graduate Medical School(National University of Singapore)	This work was supported by BioMedical Research Council (BMRC) of Singapore Grant BMRC06/1/21/19/449 and the Singapore Millennium Foundation (to C. G. L.) through the National Cancer Center, Block Grants from the National Cancer Centre, and the DUKE-NUS Graduate Medical School.	Andrisani OM, 1999, INT J ONCOL, V15, P373; Barnabas S, 1997, J BIOL CHEM, V272, P20684, DOI 10.1074/jbc.272.33.20684; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Cha MY, 2004, HEPATOLOGY, V39, P1683, DOI 10.1002/hep.20245; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; Ganem D, 2001, SCIENCE, V294, P2299, DOI 10.1126/science.1067850; Groisman IJ, 1999, CARCINOGENESIS, V20, P479, DOI 10.1093/carcin/20.3.479; Kirmizis A, 2004, EXP BIOL MED, V229, P705, DOI 10.1177/153537020422900803; Lee ATC, 2007, FRONT BIOSCI-LANDMRK, V12, P234, DOI 10.2741/2061; Lee ATC, 2005, J BIOL CHEM, V280, P33525, DOI 10.1074/jbc.M506628200; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Lee TK, 2006, CANCER RES, V66, P9948, DOI 10.1158/0008-5472.CAN-06-1092; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lim CA, 2007, MOL CELL, V27, P622, DOI 10.1016/j.molcel.2007.06.038; Lupberger J, 2007, WORLD J GASTROENTERO, V13, P74, DOI 10.3748/wjg.v13.i1.74; Madden CR, 2000, J VIROL, V74, P5266, DOI 10.1128/JVI.74.11.5266-5272.2000; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Martin-Lluesma S, 2008, HEPATOLOGY, V48, P1467, DOI 10.1002/hep.22542; Ng RK, 2004, BIOCHEM BIOPH RES CO, V322, P827, DOI 10.1016/j.bbrc.2004.07.188; Pavesi G, 2004, NUCLEIC ACIDS RES, V32, pW199, DOI 10.1093/nar/gkh465; Qadri I, 1996, J BIOL CHEM, V271, P15443, DOI 10.1074/jbc.271.26.15443; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wang Y, 2008, J BIOL CHEM, V283, P13205, DOI 10.1074/jbc.M707629200; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; Wu CG, 2002, FASEB J, V16, P1665, DOI 10.1096/fj.02-0074fje; Wu CG, 2001, ONCOGENE, V20, P3674, DOI 10.1038/sj.onc.1204481; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Yeh CT, 2000, J GASTROEN HEPATOL, V15, P339, DOI 10.1046/j.1440-1746.2000.02166.x; Yu FL, 2005, J HEPATOL, V42, P520, DOI 10.1016/j.jhep.2004.11.031; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103	40	37	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	2009	284	33					21941	21954		10.1074/jbc.M109.014563	http://dx.doi.org/10.1074/jbc.M109.014563			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481CE	19439406	hybrid, Green Published			2022-12-25	WOS:000268783700019
J	Zhang, DY; Li, SY; Cruz, P; Kone, BC				Zhang, Dongyu; Li, Shiyu; Cruz, Pedro; Kone, Bruce C.			Sirtuin 1 Functionally and Physically Interacts with Disruptor of Telomeric Silencing-1 to Regulate alpha-ENaC Transcription in Collecting Duct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3 METHYLTRANSFERASE; EPITHELIAL SODIUM-CHANNEL; SACCHAROMYCES-CEREVISIAE; CELL-SURVIVAL; METHYLATION; DEACETYLASE; REPRESSION; COMPLEX; PROTEIN; GENE	Aldosterone increases renal tubular Na+ absorption in large part by increasing transcription of the epithelial Na+ channel alpha-subunit (alpha-ENaC) expressed in the apical membrane of collecting duct principal cells. We recently reported that a complex containing the histone H3K79 methyltransferase disruptor of telomeric silencing-1 (Dot1) associates with and represses the alpha-ENaC promoter in mouse inner medullary collecting duct mIMCD3 cells, and that aldosterone acts to disrupt this complex and its inhibitory effects (Zhang, W., Xia, X., Reisenauer, M. R., Rieg, T., Lang, F., Kuhl, D., Vallon, V., and Kone, B. C. ( 2007) J. Clin. Invest. 117, 773-783). Here we demonstrate that the NAD(+)-dependent deacetylase sirtuin 1 (Sirt1) functionally and physically interacts with Dot1 to enhance the distributive activity of Dot1 on H3K79 methylation and thereby represses alpha-ENaC transcription in mIMCD3 cells. Sirt1 overexpression inhibited basal alpha-ENaC mRNA expression and alpha-ENaC promoter activity, surprisingly in a deacetylase-independent manner. The ability of Sirt1 to inhibit alpha-ENaC transcription was retained in a truncated Sirt1 construct expressing only its N-terminal domain. Conversely, Sirt1 knockdown enhanced alpha-ENaC mRNA levels and alpha-ENaC promoter activity, and inhibited global H3K79 methylation, particularly H3K79 trimethylation, in chromatin associated with the alpha-ENaC promoter. Sirt1 and Dot1 co-immunoprecipitated from mIMCD3 cells and colocalized in the nucleus. Sirt1 immunoprecipitated from chromatin associated with regions of the alpha-ENaC promoter known to associate with Dot1. Aldosterone inhibited Sirt1 association at two of these regions, as well as Sirt1 mRNA expression, in a coordinate manner with induction of alpha-ENaC transcription. Overexpressed Sirt1 inhibited aldosterone induction of alpha-ENaC transcription independent of effects on mineralocorticoid receptor trans-activation. These data identify Sirt1 as a novel modulator of alpha-ENaC, Dot1, and the aldosterone signaling pathway.	[Zhang, Dongyu; Li, Shiyu; Cruz, Pedro; Kone, Bruce C.] Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA; [Kone, Bruce C.] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kone, BC (corresponding author), Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA.	Bruce.C.Kone@uth.tmc.edu			National Institutes of Health [DK075565]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported, in whole or in part, by National Institutes of Health Grant DK075565 (to B. C. K.).	Altaf M, 2007, MOL CELL, V28, P1002, DOI 10.1016/j.molcel.2007.12.002; Amat R, 2007, J BIOL CHEM, V282, P34066, DOI 10.1074/jbc.M707114200; Avalos JL, 2005, MOL CELL, V17, P855, DOI 10.1016/j.molcel.2005.02.022; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Feige JN, 2008, CURR OPIN CELL BIOL, V20, P303, DOI 10.1016/j.ceb.2008.03.012; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Frederiks F, 2008, NAT STRUCT MOL BIOL, V15, P550, DOI 10.1038/nsmb.1432; Husted RF, 2007, AM J PHYSIOL-RENAL, V293, pF813, DOI 10.1152/ajprenal.00225.2007; Kim EJ, 2007, MOL CELL, V28, P277, DOI 10.1016/j.molcel.2007.08.030; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; Lee JS, 2007, CELL, V131, P1084, DOI 10.1016/j.cell.2007.09.046; Liou GG, 2005, CELL, V121, P515, DOI 10.1016/j.cell.2005.03.035; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Mick VE, 2001, MOL ENDOCRINOL, V15, P575, DOI 10.1210/me.15.4.575; Ng HH, 2003, J BIOL CHEM, V278, P33625, DOI 10.1074/jbc.C300270200; Pandithage R, 2008, J CELL BIOL, V180, P915, DOI 10.1083/jcb.200707126; Ronzaud C, 2007, J AM SOC NEPHROL, V18, P1679, DOI 10.1681/ASN.2006090975; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Schild L, 1996, NEPHROLOGIE, V17, P395; Singer MS, 1998, GENETICS, V150, P613; Tanno M, 2007, J BIOL CHEM, V282, P6823, DOI 10.1074/jbc.M609554200; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wong S, 2007, BIOCHEM J, V407, P451, DOI 10.1042/BJ20070151; Yang B, 2008, J MOL BIOL, V381, P826, DOI 10.1016/j.jmb.2008.06.059; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhang WZ, 2007, J CLIN INVEST, V117, P773, DOI 10.1172/JCI29850; Zhang WZ, 2006, J BIOL CHEM, V281, P18059, DOI 10.1074/jbc.M601903200; Zhang WZ, 2006, AM J PHYSIOL-CELL PH, V290, pC936, DOI 10.1152/ajpcell.00431.2005; Zhang WZ, 2004, BIOCHEM J, V377, P641, DOI 10.1042/BJ20030839; Zschoernig B, 2009, BIOCHEM BIOPH RES CO, V381, P372, DOI 10.1016/j.bbrc.2009.02.085	35	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20917	20926		10.1074/jbc.M109.020073	http://dx.doi.org/10.1074/jbc.M109.020073			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19491102	Green Published, hybrid			2022-12-25	WOS:000268316100055
J	Moss, NM; Wu, YI; Liu, YY; Munshi, HG; Stack, MS				Moss, Natalie M.; Wu, Yi I.; Liu, Yueying; Munshi, H. G.; Stack, M. Sharon			Modulation of the Membrane Type 1 Matrix Metalloproteinase Cytoplasmic Tail Enhances Tumor Cell Invasion and Proliferation in Three-dimensional Collagen Matrices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; PHOSPHORYLATION; ACTIVATION; PROGELATINASE; MT1-MMP; DOMAIN; CD44; INVADOPODIA; EXPRESSION	Increasing evidence suggests that the cytoplasmic tail of membrane type 1 matrix metalloproteinase (MT1-MMP) is subject to phosphorylation and that this modification may influence its enzymatic activity at the cell surface. In this study, phosphorylated MT1-MMP is detected using a phospho-specific antibody recognizing a protein kinase C consensus sequence (phospho-TXR), and a MT1-MMP tail peptide is phosphorylated by exogenous protein kinase C. To characterize the potential role of cytoplasmic residue Thr(567) in these processes, mutants that mimic a state of either constitutive (T567E) or defective phosphorylation (T567A) were expressed and analyzed for their functional effects on MT1-MMP activity and cellular behavior. Phospho-mimetic mutants of Thr(567) exhibit enhanced matrix invasion as well as more extensive growth within a three-dimensional type I collagen matrix. Together, these findings suggest that MT1-MMP surface action is regulated by phosphorylation at cytoplasmic tail residue Thr(567) and that this modification plays a critical role in processes that are linked to tumor progression.	[Liu, Yueying; Stack, M. Sharon] Univ Missouri, Dept Pathol & Anat Sci, Sch Med, Columbia, MO 65212 USA; [Moss, Natalie M.] Northwestern Univ, Feinberg Med Sch, Dept Cell & Mol Biol, Chicago, IL 60611 USA; [Munshi, H. G.] Northwestern Univ, Feinberg Med Sch, Div Hematol Oncol, Chicago, IL 60611 USA; [Wu, Yi I.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of Missouri System; University of Missouri Columbia; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Stack, MS (corresponding author), Univ Missouri, Dept Pathol & Anat Sci, Sch Med, 1 Hosp Dr,M214E Med Sci Bldg, Columbia, MO 65212 USA.	stackm@health.missouri.edu			National Institutes of Health, NCI [RO1 CA86984, RO1 CA109545, CA86984-07S1]; NATIONAL CANCER INSTITUTE [R01CA086984, R01CA109545] Funding Source: NIH RePORTER	National Institutes of Health, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by National Institutes of Health, NCI, Grant RO1 CA86984 (to M. S. S.), RO1 CA109545 (to M. S. S.), and CA86984-07S1 (to M. S. S. and N.M.M.).	ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Barbolina MV, 2008, SEMIN CELL DEV BIOL, V19, P24, DOI 10.1016/j.semcdb.2007.06.008; BOWEN S, 1991, J BIOL CHEM, V266, P1162; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; CHEN JD, 1994, DERMATOLOGY, V188, P6, DOI 10.1159/000247076; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P4080, DOI 10.1073/pnas.82.12.4080; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; GALLIS B, 1986, J BIOL CHEM, V261, P5075; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; LEWIS RE, 1990, BIOCHEMISTRY-US, V29, P1807, DOI 10.1021/bi00459a020; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Nyalendo C, 2007, J BIOL CHEM, V282, P15690, DOI 10.1074/jbc.M608045200; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SHACKELFORD DA, 1986, J BIOL CHEM, V261, P8334; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Tjia JS, 2002, ANN BIOMED ENG, V30, P851, DOI 10.1114/1.1492814; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; Yana I, 2002, CLIN EXP METASTAS, V19, P209, DOI 10.1023/A:1015527220537; Zhai YL, 2005, CANCER RES, V65, P6543, DOI 10.1158/0008-5472.CAN-05-0231; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	42	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					19791	19799		10.1074/jbc.M109.020362	http://dx.doi.org/10.1074/jbc.M109.020362			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19458085	Green Published, hybrid			2022-12-25	WOS:000268097400005
J	Ono, T; Kaneda, T; Muto, A; Yoshida, T				Ono, Takeshi; Kaneda, Toshio; Muto, Akihiro; Yoshida, Tadashi			Positive Transcriptional Regulation of the Human mu Opioid Receptor Gene by Poly(ADP-ribose) Polymerase-1 and Increase of Its DNA Binding Affinity Based on Polymorphism of G(-172) -> T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE NUCLEOTIDE POLYMORPHISMS; NF-KAPPA-B; ALLELIC VARIATION; NEURONAL CELLS; EXPRESSION; PROTEIN; PARP-1; COACTIVATOR; ACTIVATION; DESENSITIZATION	mu opioid receptor (MOR) agonists such as morphine are applied widely in clinical practice as pain therapy. The effects of morphine through MOR, such as analgesia and development of tolerance and dependence, are influenced by individual specificity. Recently, we analyzed single nucleotide polymorphisms on the human MOR gene to investigate the factors that contribute to individual specificity. In process of single nucleotide polymorphisms analysis, we found that specific nuclear proteins bound to G(-172) -> T region in exon 1 in MOR gene, and its affinity to DNA was increased by base substitution from G(-172) to T-172. The isolated protein was identified by mass spectrometry and was confirmed by Western blotting to be poly(ADPribose) polymerase-1 (PARP-1). The overexpressed PARP-1 bound to G(-172) -> T and enhanced the transcription of reporter vectors containing G(-172) and T-172. Furthermore, PARP-1 inhibitor (benzamide) decreased PARP-1 binding to G(-172) -> T without affecting mRNA or protein expression level of PARP-1 and down-regulated the subsequent MOR gene expression in SH-SY5Y cells. Moreover, we found that tumor necrosis factor-alpha enhanced MOR gene expression as well as increased PARP-1 binding to the G(-172) -> T region and G(-172) -> T-dependent transcription in SH-SY5Y cells. These effects were also inhibited by benzamide. In this study, our data suggest that PARP-1 positively regulates MOR gene transcription via G(-172) -> T, which might influence individual specificity in therapeutic opioid effects.	[Ono, Takeshi; Kaneda, Toshio; Muto, Akihiro; Yoshida, Tadashi] Hoshi Univ, Fac Pharmaceut Sci, Dept Pathophysiol, Shinagawa Ku, Tokyo 1420063, Japan	Hoshi University	Yoshida, T (corresponding author), Hoshi Univ, Fac Pharmaceut Sci, Dept Pathophysiol, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1420063, Japan.	tyoshida@hoshi.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	AGARWAL S, 1988, J IMMUNOL, V140, P4187; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; BAILEY DW, 1971, TRANSPLANTATION, V11, P419, DOI 10.1097/00007890-197104000-00014; Bayerer B, 2007, EUR J PAIN, V11, P421, DOI 10.1016/j.ejpain.2006.06.004; Bedini A, 2008, J NEUROCHEM, V105, P2166, DOI 10.1111/j.1471-4159.2008.05303.x; Beranger GE, 2006, J BONE MINER RES, V21, P1757, DOI 10.1359/JBMR.060809; Bergen AW, 1997, MOL PSYCHIATR, V2, P490, DOI 10.1038/sj.mp.4000331; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Chiba-Falek O, 2005, AM J HUM GENET, V76, P478, DOI 10.1086/428655; Chiba-Falek O, 2001, HUM MOL GENET, V10, P3101, DOI 10.1093/hmg/10.26.3101; Choi HS, 2008, J CELL MOL MED, V12, P2319, DOI 10.1111/j.1582-4934.2008.00259.x; Cohen-Armon M, 2007, MOL CELL, V25, P297, DOI 10.1016/j.molcel.2006.12.012; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Hassa PO, 2005, J BIOL CHEM, V280, P40450, DOI 10.1074/jbc.M507553200; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Hattori Y, 2007, J CONTROL RELEASE, V120, P122, DOI 10.1016/j.jconrel.2007.04.012; Hoehe MR, 2000, HUM MOL GENET, V9, P2895, DOI 10.1093/hmg/9.19.2895; Kameoka M, 2004, J VIROL, V78, P8931, DOI 10.1128/JVI.78.16.8931-8934.2004; Kauppinen TM, 2006, P NATL ACAD SCI USA, V103, P7136, DOI 10.1073/pnas.0508606103; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Koch T, 2000, MOL PHARMACOL, V58, P328, DOI 10.1124/mol.58.2.328; Kraus J, 2003, MOL PHARMACOL, V64, P876, DOI 10.1124/mol.64.4.876; Kraus J, 2001, J BIOL CHEM, V276, P43901, DOI 10.1074/jbc.M107543200; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Lee PW, 2004, MOL PHARMACOL, V66, P1580, DOI 10.1124/mol.66.6.; Lotsch J, 2002, PHARMACOGENETICS, V12, P3, DOI 10.1097/00008571-200201000-00002; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; Ono T, 2009, BIOL PHARM BULL, V32, P721, DOI 10.1248/bpb.32.721; Pottier N, 2007, HUM MOL GENET, V16, P2261, DOI 10.1093/hmg/ddm178; Shiokawa M, 2005, JPN J CLIN ONCOL, V35, P97, DOI 10.1093/jjco/hyi028; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wang DX, 2001, J BIOL CHEM, V276, P34624, DOI 10.1074/jbc.M104083200; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; Yu ZY, 2006, J BIOL CHEM, V281, P9101, DOI 10.1074/jbc.M511049200; Zaniolo K, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-96; Zhang S, 2007, CELL DEATH DIFFER, V14, P1001, DOI 10.1038/sj.cdd.4402088	40	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20175	20183		10.1074/jbc.M109.019414	http://dx.doi.org/10.1074/jbc.M109.019414			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19447888	Green Published, hybrid			2022-12-25	WOS:000268097400045
J	Qi, JH; Dai, GY; Luthert, P; Chaurasia, S; Hollyfield, J; Weber, BHF; Stohr, H; Anand-Apte, B				Qi, Jian Hua; Dai, Ganying; Luthert, Philip; Chaurasia, Shyam; Hollyfield, Joe; Weber, Bernhard H. F.; Stoehr, Heidi; Anand-Apte, Bela			S156C Mutation in Tissue Inhibitor of Metalloproteinases-3 Induces Increased Angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SORSBYS-FUNDUS-DYSTROPHY; UNUSUAL CLINICAL-FEATURES; PIGMENT EPITHELIAL-CELLS; CHOROIDAL NEOVASCULARIZATION; VEGF RECEPTOR-2; BRUCHS MEMBRANE; TIMP3; APOPTOSIS; DEATH; LOCALIZATION	Tissue Inhibitor of metalloproteinases-3 (TIMP-3) is a potent matrix-bound angiogenesis inhibitor. Mutations in TIMP-3 cause Sorsby Fundus Dystrophy, a dominant inherited, early onset macular degenerative disease, with choroidal neovascularization causing a loss of vision in the majority of patients. Here we report that expression of S156C TIMP-3 mutation in endothelial cells results in an abnormal localization of the protein, increased glycosylation, decreased matrix metalloproteinase inhibitory activity, and increased vascular endothelial growth factor (VEGF) binding with a consequent increase in VEGF-dependent migration and tube formation. These enhanced signaling events appear to be mediated as a consequence of a post-transcriptionally regulated increase in the expression of membrane-associated VEGFR-2 in endothelial cells of Timp-3(156/156) mutant mice as well as in human Sorsby fundus dystrophy eyes. Understanding the mechanism(s) by which mutant TIMP-3 can induce abnormal neovascularization provides important insight into the pathophysiology of a number of diseases with increased angiogenesis.	[Anand-Apte, Bela] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Opthalmol,Cole Eye Inst, Cleveland, OH 44195 USA; [Anand-Apte, Bela] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Mol Biol, Cleveland, OH 44195 USA; [Luthert, Philip] Inst Ophthalmol, Dept Pathol, London, England; [Weber, Bernhard H. F.; Stoehr, Heidi] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany	Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; University of London; University College London; University of Regensburg	Anand-Apte, B (corresponding author), Cleveland Clin, Dept Ophthalmol, Cole Eye Inst 13 161, 9500 Euclid Ave, Cleveland, OH 44195 USA.	anandab@ccf.org	Chaurasia, Shyam/AAB-4709-2019	Chaurasia, Shyam/0000-0001-8725-676X; Luthert, Philip/0000-0001-7276-6898; Weber, Bernhard H.F./0000-0002-8808-7723	National Institutes of Health [EY016490, CA106415, EY015638]; Foundation Fighting Blindness Center; Research to Prevent Blindness (RPB) Challenge; Ohio Biomedical Research and Technology Transfer Partnership Program [05-29]; RPB Lew Wasserman; Deutsche Forschungsgemeinschaft [STO 366/3-1]; NATIONAL CANCER INSTITUTE [R01CA106415] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R24EY015638, R01EY016490] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Foundation Fighting Blindness Center; Research to Prevent Blindness (RPB) Challenge(Research to Prevent Blindness (RPB)); Ohio Biomedical Research and Technology Transfer Partnership Program; RPB Lew Wasserman; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported, in whole or in part, by National Institutes of Health Grants EY016490, CA106415, and EY015638. This work was also supported by a Foundation Fighting Blindness Center grant, a Research to Prevent Blindness (RPB) Challenge grant, an Ohio Biomedical Research and Technology Transfer Partnership Program 05-29 and RPB Lew Wasserman award (to B.A.-A.), and Grant STO 366/3-1 from the Deutsche Forschungsgemeinschaft (to H. S.).	Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Barbazetto IA, 2005, ARCH OPHTHALMOL-CHIC, V123, P542, DOI 10.1001/archopht.123.4.542; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Boldicke T, 2007, J CELL MOL MED, V11, P54, DOI 10.1111/j.1582-4934.2007.00002.x; Boldicke T, 2005, J IMMUNOL METHODS, V300, P146, DOI 10.1016/j.jim.2005.03.007; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; CAPON MRC, 1988, EYE, V2, P114, DOI 10.1038/eye.1988.23; Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921; Ebos JML, 2004, MOL CANCER RES, V2, P315; Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329; Fariss RN, 1997, AM J PATHOL, V150, P323; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; FELBOR U, 1995, HUM MOL GENET, V4, P2415, DOI 10.1093/hmg/4.12.2415; Felbor U, 1997, ARCH OPHTHALMOL-CHIC, V115, P1569, DOI 10.1001/archopht.1997.01100160739011; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Fogarasi M, 2008, MATRIX BIOL, V27, P381, DOI 10.1016/j.matbio.2008.01.008; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; HOLZ FG, 1994, RETINA-J RET VIT DIS, V14, P329, DOI 10.1097/00006982-199414040-00006; JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27; Janssen A, 2008, INVEST OPHTH VIS SCI, V49, P2812, DOI 10.1167/iovs.07-1444; KALMUS H, 1976, J MED GENET, V13, P271, DOI 10.1136/jmg.13.4.271; Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367; Labrecque L, 2003, MOL BIOL CELL, V14, P334, DOI 10.1091/mbc.E02-07-0379; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; Langton KP, 2000, J BIOL CHEM, V275, P27027; Langton KP, 2005, HUM MOL GENET, V14, P3579, DOI 10.1093/hmg/ddi385; Li Zheng, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405010045; Lin RJ, 2006, AM J OPHTHALMOL, V142, P839, DOI 10.1016/j.ajo.2006.06.003; Majid MA, 2002, FEBS LETT, V529, P281, DOI 10.1016/S0014-5793(02)03359-8; Mannello F, 2001, APOPTOSIS, V6, P479, DOI 10.1023/A:1012493808790; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; POLKINGHORNE PJ, 1989, OPHTHALMOLOGY, V96, P1763; Prager F, 2007, ACTA OPHTHALMOL SCAN, V85, P904, DOI 10.1111/j.1600-0420.2007.00927.x; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Qi JH, 2002, J BIOL CHEM, V277, P13394, DOI 10.1074/jbc.M110870200; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Soboleva G, 2003, J CELL PHYSIOL, V197, P149, DOI 10.1002/jcp.10361; SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67; Tabata Y, 1998, HUM GENET, V103, P179, DOI 10.1007/PL00008707; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352	48	37	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					19927	19936		10.1074/jbc.M109.013763	http://dx.doi.org/10.1074/jbc.M109.013763			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19478078	Green Published, hybrid			2022-12-25	WOS:000268097400019
J	Chow, SY; Yu, CY; Guy, GR				Chow, Soah Yee; Yu, Chye Yun; Guy, Graeme R.			Sprouty2 Interacts with Protein Kinase C delta and Disrupts Phosphorylation of Protein Kinase D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; FACTOR RECEPTOR STIMULATION; PROSTATE-CANCER CELLS; PKC-DELTA; BREAST-CANCER; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; DROSOPHILA-SPROUTY; ESTROGEN-RECEPTOR; ACTIVATION	The Sprouty (Spry) proteins act as inhibitors of the Ras/ERK pathway downstream of receptor tyrosine kinases. In this study, we report a novel interaction between protein kinase C delta (PKC delta) and Spry2. Endogenous PKC delta and Spry2 interact in cells upon basic fibroblast growth factor stimulation, indicating a physiological relevance for the interaction. This interaction appeared to require the full-length Spry2 protein and was conformation-dependent. Conformational constraints were released upon FGFR1 activation, allowing the interaction to occur. Although this interaction did not affect the phosphorylation of PKC delta by another kinase, it reduced the phosphorylation of a PKC delta substrate, protein kinase D1 (PKD1). Spry2 was found to interact more strongly with PKC delta with increasing amounts of PKD1, which indicated that instead of competing with PKD1 for binding with PKC delta, it was more likely to form a trimeric complex with both PKC delta and PKD1. Formation of the complex was found to be dependent on an existing PKC delta-PKD1 interaction. By disrupting the interaction between PKC delta and PKD1, Spry2 was unable to associate with PKC delta to form the trimeric complex. As a consequence of this trimeric complex, the existing interaction between PKC delta and PKD1 was increased, and the transfer of phosphate groups from PKC delta to PKD1 was at least partly blocked by Spry2. The action of Spry2 on PKC delta resulted in the inhibition of both ERK phosphorylation and invasion of PC-3 cells via PKC delta signaling. By disrupting the capacity of PKC delta to phosphorylate its cognate substrates, Spry2 may serve to modulate PKC delta signaling downstream of receptor tyrosine kinases and to regulate the physiological outcome.	[Chow, Soah Yee; Guy, Graeme R.] Inst Mol & Cell Biol, Proteos 138673, Singapore; [Yu, Chye Yun] Natl Univ Singapore, Dept Physiol, Yong Loo Lin Sch Med, Singapore 117597, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Guy, GR (corresponding author), Inst Mol & Cell Biol, 61 Biopolis Dr, Proteos 138673, Singapore.	mcbgg@imcb.a-star.edu.sg			Agency of Science, Technology, and Research, Singapore	Agency of Science, Technology, and Research, Singapore(Agency for Science Technology & Research (A*STAR))	This work was supported by the Agency of Science, Technology, and Research, Singapore.	Aranda S, 2008, MOL CELL BIOL, V28, P5899, DOI 10.1128/MCB.00394-08; Aziz MH, 2007, CANCER RES, V67, P8828, DOI 10.1158/0008-5472.CAN-07-1604; Basu A, 2003, J CELL MOL MED, V7, P341, DOI 10.1111/j.1582-4934.2003.tb00237.x; Basu A, 2008, CANCER RES, V68, P5689, DOI 10.1158/0008-5472.CAN-07-6603; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Bradford MD, 2002, BIOCHEM J, V366, P745, DOI 10.1042/BJ20020358; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chandramouli S, 2008, J BIOL CHEM, V283, P1679, DOI 10.1074/jbc.M705457200; Chen D, 2007, J BIOL CHEM, V282, P33776, DOI 10.1074/jbc.M703320200; Chi LJ, 2004, DEVELOPMENT, V131, P3345, DOI 10.1242/dev.01200; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; De Servi B, 2005, ONCOGENE, V24, P4946, DOI 10.1038/sj.onc.1208676; Doppler H, 2007, J BIOL CHEM, V282, P31873, DOI 10.1074/jbc.M703584200; Edwin F, 2008, J BIOL CHEM, V283, P3181, DOI 10.1074/jbc.M706567200; Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200; Gao T, 2008, J BIOL CHEM, V283, P6300, DOI 10.1074/jbc.M707319200; Gliki G, 2001, BIOCHEM J, V353, P503, DOI 10.1042/0264-6021:3530503; Gomel R, 2007, MOL CANCER RES, V5, P627, DOI 10.1158/1541-7786.MCR-06-0255; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014-5793(01)02219-0; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; Kinoshita N, 2003, GENE DEV, V17, P1663, DOI 10.1101/gad.1101303; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Lao DH, 2007, J BIOL CHEM, V282, P9117, DOI 10.1074/jbc.M607563200; Lao DH, 2006, J BIOL CHEM, V281, P29993, DOI 10.1074/jbc.M604044200; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Lito P, 2009, J BIOL CHEM, V284, P848, DOI 10.1074/jbc.M808045200; Lo TL, 2004, CANCER RES, V64, P6127, DOI 10.1158/0008-5472.CAN-04-1207; McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394; Murakami M, 2002, J BIOL CHEM, V277, P20367, DOI 10.1074/jbc.M202501200; NAKAMOTO T, 1992, CANCER RES, V52, P571; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Qiu J, 2003, J NEUROSCI, V23, P9529; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Robles-Flores M, 2002, J BIOL CHEM, V277, P5247, DOI 10.1074/jbc.M109333200; Rybin VO, 2007, J BIOL CHEM, V282, P23631, DOI 10.1074/jbc.M701676200; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schreiber KL, 2001, AM J PHYSIOL-HEART C, V281, pH2062, DOI 10.1152/ajpheart.2001.281.5.H2062; Sivak JM, 2005, DEV CELL, V8, P689, DOI 10.1016/j.devcel.2005.02.011; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Villar J, 2007, CANCER RES, V67, P10859, DOI 10.1158/0008-5472.CAN-07-2041; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Wert MM, 2000, BIOCHEM J, V352, P175, DOI 10.1042/0264-6021:3520175; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	57	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19623	19636		10.1074/jbc.M109.021600	http://dx.doi.org/10.1074/jbc.M109.021600			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19458088	Green Published, hybrid			2022-12-25	WOS:000267908300054
J	Ediger, B; Melman, SD; Pappas, DL; Finch, M; Applen, J; Parra, KJ				Ediger, Benjamin; Melman, Sandra D.; Pappas, Donald L., Jr.; Finch, Mark; Applen, Jeremy; Parra, Karlett J.			The Tether Connecting Cytosolic (N Terminus) and Membrane (C Terminus) Domains of Yeast V-ATPase Subunit a (Vph1) Is Required for Assembly of V-0 Subunit d	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; ELASTIC POWER TRANSMISSION; MEDIATED CROSS-LINKING; IN-VIVO DISSOCIATION; MUTATIONAL ANALYSIS; 3-DIMENSIONAL STRUCTURE; ENDOPLASMIC-RETICULUM; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE	V-ATPases are molecular motors that reversibly disassemble in vivo. Anchored in the membrane is subunit a. Subunit a has a movable N terminus that switches positions during disassembly and reassembly. Deletions were made at residues securing the N terminus of subunit a (yeast isoform Vph1) to its membrane-bound C-terminal domain in order to understand the role of this conserved region for V-ATPase function. Shrinking of the tether made cells pH-sensitive (vma phenotype) because assembly of V-0 subunit d was harmed. Subunit d did not co-immunoprecipitate with subunit a and the c-ring. Cells contained pools of V-1 and V-0(-d) that failed to form V1V0, and very low levels of V-ATPase subunits were found at the membrane. Although subunit d expression was stable and at wild-type levels, growth defects were rescued by exogenous VMA6 (subunit d). Stable V1V0 assembled after yeast cells were co-transformed with VMA6 and mutant VPH1. Tether-less V1V0 was delivered to the vacuole and active. It retained 63-71% of the wild-type activity and was responsive to glucose. Tether-less V1V0 disassembled and reassembled after brief glucose depletion and readdition. The N terminus retained binding to V-1 subunits and the C terminus to phosphofructokinase. Thus, no major structural change was generated at the N and C termini of subunit a. We concluded that early steps of V-0 assembly and trafficking were likely impaired by shorter tethers and rescued by VMA6.	[Ediger, Benjamin; Melman, Sandra D.; Pappas, Donald L., Jr.; Finch, Mark; Applen, Jeremy; Parra, Karlett J.] Univ New Mexico, Sch Med, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA	University of New Mexico	Parra, KJ (corresponding author), Univ New Mexico, Sch Med, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA.	kjparra@salud.unm.edu			National Science Foundation [MCB-0728833]; University of New Mexico School of Medicine	National Science Foundation(National Science Foundation (NSF)); University of New Mexico School of Medicine	This work was supported by National Science Foundation CAREER Award MCB-0728833 (to K. J. P.). This project was also supported, in part, by the Dedicated Health Research Funds of the University of New Mexico School of Medicine (to K. J. P.).	BAUERLE C, 1993, J BIOL CHEM, V268, P12749; Breton S, 2007, AM J PHYSIOL-RENAL, V292, pF1, DOI 10.1152/ajprenal.00340.2006; Bryson K, 2005, NUCLEIC ACIDS RES, V33, pW36, DOI 10.1093/nar/gki410; Charsky CMH, 2000, J BIOL CHEM, V275, P37232, DOI 10.1074/jbc.M006640200; Curtis KK, 2002, J BIOL CHEM, V277, P2716, DOI 10.1074/jbc.M107777200; Curtis KK, 2002, J BIOL CHEM, V277, P8979, DOI 10.1074/jbc.M111708200; Diepholz M, 2008, STRUCTURE, V16, P1789, DOI 10.1016/j.str.2008.09.010; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; Drory O, 2004, EMBO REP, V5, P1148, DOI 10.1038/sj.embor.7400294; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Dunn SD, 2000, J BIOENERG BIOMEMBR, V32, P347, DOI 10.1023/A:1005571818730; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272; Graham LA, 1998, J CELL BIOL, V142, P39, DOI 10.1083/jcb.142.1.39; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; Inoue T, 2005, J BIOL CHEM, V280, P27896, DOI 10.1074/jbc.M504890200; Iwata M, 2004, P NATL ACAD SCI USA, V101, P59, DOI 10.1073/pnas.0305165101; Junge W, 2001, FEBS LETT, V504, P152, DOI 10.1016/S0014-5793(01)02745-4; Kane PA, 2006, MICROBIOL MOL BIOL R, V70, P177, DOI 10.1128/MMBR.70.1.177-191.2006; Kane PM, 2007, J BIOENERG BIOMEMBR, V39, P415, DOI 10.1007/s10863-007-9112-z; Kane PM, 1999, J BIOL CHEM, V274, P17275, DOI 10.1074/jbc.274.24.17275; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; Karet FE, 2005, J BIOENERG BIOMEMBR, V37, P425, DOI 10.1007/s10863-005-9484-x; Kawasaki-Nishi S, 2003, J BIOL CHEM, V278, P41908, DOI 10.1074/jbc.M308026200; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kawasaki-Nishi S, 2001, P NATL ACAD SCI USA, V98, P12397, DOI 10.1073/pnas.221291798; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P17941, DOI 10.1074/jbc.M010790200; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Liu ML, 2005, J BIOL CHEM, V280, P36978, DOI 10.1074/jbc.M505296200; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu M, 2007, J BIOL CHEM, V282, P24495, DOI 10.1074/jbc.M702598200; Makyio H, 2005, EMBO J, V24, P3974, DOI 10.1038/sj.emboj.7600859; Malkus P, 2004, MOL BIOL CELL, V15, P5075, DOI 10.1091/mbc.E04-06-0514; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ouyang ZQ, 2008, J BIOENERG BIOMEMBR, V40, P569, DOI 10.1007/s10863-008-9193-3; Owegi MA, 2005, J BIOL CHEM, V280, P18393, DOI 10.1074/jbc.M412567200; Owegi MA, 2006, J BIOL CHEM, V281, P30001, DOI 10.1074/jbc.M605006200; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; Qi J, 2008, J BIOL CHEM, V283, P19274, DOI 10.1074/jbc.M802442200; Ryan M, 2008, MOL BIOL CELL, V19, P5131, DOI 10.1091/mbc.E08-06-0629; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Sielaff H, 2008, P NATL ACAD SCI USA, V105, P17760, DOI 10.1073/pnas.0807683105; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; Su Y, 2003, J BIOL CHEM, V278, P20013, DOI 10.1074/jbc.M210077200; Su Y, 2008, AM J PHYSIOL-RENAL, V295, pF950, DOI 10.1152/ajprenal.90258.2008; Taranta A, 2003, AM J PATHOL, V162, P57, DOI 10.1016/S0002-9440(10)63798-4; Walker JE, 2006, BBA-BIOENERGETICS, V1757, P286, DOI 10.1016/j.bbabio.2006.01.001; Wang Y, 2007, J BIOL CHEM, V282, P34058, DOI 10.1074/jbc.M704331200; Wilkens S, 2005, MICRON, V36, P109, DOI 10.1016/j.micron.2004.10.002; Wilkens S, 2004, J BIOL CHEM, V279, P41942, DOI 10.1074/jbc.M407821200; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]; Yao GF, 2007, BIOCHEM BIOPH RES CO, V357, P821, DOI 10.1016/j.bbrc.2007.04.082; Yokoyama K, 2003, J BIOL CHEM, V278, P24255, DOI 10.1074/jbc.M303104200; Zhang ZY, 2008, J BIOL CHEM, V283, P35983, DOI 10.1074/jbc.M805345200	60	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19522	19532		10.1074/jbc.M109.013375	http://dx.doi.org/10.1074/jbc.M109.013375			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19473972	Green Published, hybrid			2022-12-25	WOS:000267908300044
J	Nojiri, M; Loyet, KM; Klenchin, VA; Kabachinski, G; Martin, TFJ				Nojiri, Mari; Loyet, Kelly M.; Klenchin, Vadim A.; Kabachinski, Gregory; Martin, Thomas F. J.			CAPS Activity in Priming Vesicle Exocytosis Requires CK2 Phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSE-CORE VESICLE; PROTEIN-KINASE CK2; SYNAPTOSOME-ASSOCIATED PROTEIN; DEPENDENT PHOSPHORYLATION; MEMBRANE-FUSION; INOSITOL PYROPHOSPHATES; PRESYNAPTIC PLASTICITY; SYNAPTIC VESICLES; CYTOSOLIC PROTEIN; SYNAPTOTAGMIN-I	CAPS (Ca2+-dependent activator protein for secretion) functions in priming Ca2+-dependent vesicle exocytosis, but the regulation of CAPS activity has not been characterized. Here we show that phosphorylation by protein kinase CK2 is required for CAPS activity. Dephosphorylation eliminated CAPS activity in reconstituting Ca2+-dependent vesicle exocytosis in permeable and intact PC12 cells. Ser-5, -6, and -7 and Ser-1281 were identified by mass spectrometry as the major phosphorylation sites in the 1289 residue protein. Ser-5, -6, and -7 but not Ser-1281 to Ala substitutions abolished CAPS activity. Protein kinase CK2 phosphorylated CAPS in vitro at these sites and restored the activity of dephosphorylated CAPS. CK2 is the likely in vivo CAPS protein kinase based on inhibition of phosphorylation by tetrabromo-2-benzotriazole in PC12 cells and by the identity of in vivo and in vitro phosphorylation sites. CAPS phosphorylation by CK2 was constitutive, but the elevation of Ca2+ in synaptosomes increased CAPS Ser-5 and -6 dephosphorylation, which terminates CAPS activity. These results identify a functionally important N-terminal phosphorylation site that regulates CAPS activity in priming vesicle exocytosis.	[Nojiri, Mari; Klenchin, Vadim A.; Kabachinski, Gregory; Martin, Thomas F. J.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; [Loyet, Kelly M.] Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA	University of Wisconsin System; University of Wisconsin Madison; Roche Holding; Genentech	Martin, TFJ (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	tfmartin@wisc.edu	Loyet, Kelly/AAD-7544-2021		National Institutes of Health [DK25861, DK40428]; American Heart Association; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK025861, R01DK040428, R01DK025861] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grants DK25861 and DK40428 ( to T. F. J. M.). This work was also supported by an American Heart Association fellowship ( to M. N.).	Ann K, 1997, J BIOL CHEM, V272, P19637, DOI 10.1074/jbc.272.32.19637; Arnott D, 2002, MOL CELL PROTEOMICS, V1, P148, DOI 10.1074/mcp.M100027-MCP200; Battistutta R, 2001, PROTEIN SCI, V10, P2200, DOI 10.1110/ps.19601; BENNETT MK, 1993, J NEUROSCI, V13, P1701; Berwin B, 1998, NEURON, V21, P137, DOI 10.1016/S0896-6273(00)80521-8; Bhandari R, 2007, P NATL ACAD SCI USA, V104, P15305, DOI 10.1073/pnas.0707338104; Blanquet PR, 2000, PROG NEUROBIOL, V60, P211, DOI 10.1016/S0301-0082(99)00026-X; Blanquet PR, 1998, NEUROSCIENCE, V86, P739, DOI 10.1016/S0306-4522(98)00087-6; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Brunk I, 2009, J BIOL CHEM, V284, P1050, DOI 10.1074/jbc.M805328200; CALVERT R, 1978, FEBS LETT, V86, P247, DOI 10.1016/0014-5793(78)80572-9; CHARRIAUTMARLANGUE C, 1991, P NATL ACAD SCI USA, V88, P10232, DOI 10.1073/pnas.88.22.10232; Chung HJ, 2004, J NEUROSCI, V24, P10248, DOI 10.1523/JNEUROSCI.0546-04.2004; Cousin MA, 2001, TRENDS NEUROSCI, V24, P659, DOI 10.1016/S0166-2236(00)01930-5; DAVLETOV B, 1993, J BIOL CHEM, V268, P6816; Foletti DL, 2000, J NEUROSCI, V20, P4535, DOI 10.1523/JNEUROSCI.20-12-04535.2000; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Grishanin RN, 2004, NEURON, V43, P551, DOI 10.1016/j.neuron.2004.07.028; Grishanin RN, 2002, J BIOL CHEM, V277, P22025, DOI 10.1074/jbc.M201614200; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; Illies C, 2007, SCIENCE, V318, P1299, DOI 10.1126/science.1146824; James DJ, 2008, J CELL BIOL, V182, P355, DOI 10.1083/jcb.200801056; Jockusch WJ, 2007, CELL, V131, P796, DOI 10.1016/j.cell.2007.11.002; Klenchin VA, 1998, METHODS, V16, P204, DOI 10.1006/meth.1998.0668; Korolchuk VI, 2005, J BIOL CHEM, V280, P40796, DOI 10.1074/jbc.M508988200; Leenders AGM, 2005, PHARMACOL THERAPEUT, V105, P69, DOI 10.1016/j.pharmthera.2004.10.012; LIAO PC, 1994, ANAL BIOCHEM, V219, P9, DOI 10.1006/abio.1994.1224; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Liu YY, 2008, J NEUROSCI, V28, P5594, DOI 10.1523/JNEUROSCI.5672-07.2008; Lonart G, 2002, TRENDS NEUROSCI, V25, P329, DOI 10.1016/S0166-2236(02)02193-8; Loyet KM, 2005, J PROTEOME RES, V4, P400, DOI 10.1021/pr049810q; Lynch KL, 2007, J CELL SCI, V120, P617, DOI 10.1242/jcs.03375; Lynch KL, 2008, MOL BIOL CELL, V19, P5093, DOI 10.1091/mbc.E08-03-0235; Malsam J, 2008, CELL MOL LIFE SCI, V65, P2814, DOI 10.1007/s00018-008-8352-3; Nagy G, 2004, NEURON, V41, P417, DOI 10.1016/S0896-6273(04)00038-8; Nagy G, 2002, J NEUROSCI, V22, P9278; NIELANDER HB, 1995, J NEUROCHEM, V65, P1712; NISHIZAKI T, 1992, J BIOL CHEM, V267, P23972; Posewitz MC, 1999, ANAL CHEM, V71, P2883, DOI 10.1021/ac981409y; Renden R, 2001, NEURON, V31, P421, DOI 10.1016/S0896-6273(01)00382-8; Risinger C, 1999, J NEUROCHEM, V72, P614, DOI 10.1046/j.1471-4159.1999.0720614.x; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Speese S, 2007, J NEUROSCI, V27, P6150, DOI 10.1523/JNEUROSCI.1466-07.2007; Speidel D, 2003, J BIOL CHEM, V278, P52802, DOI 10.1074/jbc.M304727200; Tandon A, 1998, NEURON, V21, P147, DOI 10.1016/S0896-6273(00)80522-X; Turner KM, 1999, TRENDS NEUROSCI, V22, P459, DOI 10.1016/S0166-2236(99)01436-8; Waites CL, 2001, J CELL BIOL, V152, P1159, DOI 10.1083/jcb.152.6.1159; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; Wassenberg JJ, 2002, ANN NY ACAD SCI, V971, P201, DOI 10.1111/j.1749-6632.2002.tb04464.x; Wojcik SM, 2007, NEURON, V55, P11, DOI 10.1016/j.neuron.2007.06.013	52	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18707	18714		10.1074/jbc.M109.017483	http://dx.doi.org/10.1074/jbc.M109.017483			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19460754	Green Published, hybrid			2022-12-25	WOS:000267711500020
J	Chigurupati, S; Wei, ZL; Belal, C; Vandermey, M; Kyriazis, GA; Arumugam, TV; Chan, SL				Chigurupati, Srinivasulu; Wei, Zelan; Belal, Cherine; Vandermey, Myriam; Kyriazis, George A.; Arumugam, Thiruma V.; Chan, Sic L.			The Homocysteine-inducible Endoplasmic Reticulum Stress Protein Counteracts Calcium Store Depletion and Induction of CCAAT Enhancer-binding Protein Homologous Protein in a Neurotoxin Model of Parkinson Disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; OXIDATIVE STRESS; PC12 CELLS; PERMEABILITY TRANSITION; SARCOPLASMIC-RETICULUM; DOPAMINERGIC-NEURONS; INDUCED APOPTOSIS; CA2+ HOMEOSTASIS; ER STRESS; HERP	The endoplasmic reticulum (ER) is a key organelle regulating intracellular Ca2+ homeostasis. Oxidants and mitochondria-derived free radicals can target ER-based Ca2+ regulatory proteins and cause uncontrolled Ca2+ release that may contribute to protracted ER stress and apoptosis. Several ER stress proteins have been suggested to counteract the deregulation of ER Ca2+ homeostasis and ER stress. Here we showed that knockdown of Herp, an ubiquitin-like domain containing ER stress protein, renders PC12 and MN9D cells vulnerable to 1-methyl-4-phenylpyridinium-induced cytotoxic cell death by a mechanism involving up-regulation of CHOP expression and ER Ca2+ depletion. Conversely, Herp overexpression confers protection by blocking 1-methyl-4-phenylpyridinium-induced CHOP upregulation, ER Ca2+ store depletion, and mitochondrial Ca2+ accumulation in a manner dependent on a functional ubiquitin-proteasomal protein degradation pathway. Deletion of the ubiquitin-like domain of Herp or treatment with a proteasomal inhibitor abolished the central function of Herp in ER Ca2+ homeostasis. Thus, elucidating the underlying molecular mechanism(s) whereby Herp counteracts Ca2+ disturbances will provide insights into the molecular cascade of cell death in dopaminergic neurons and may uncover novel therapeutic strategies to prevent and ameliorate Parkinson disease progression.	[Chigurupati, Srinivasulu; Wei, Zelan; Belal, Cherine; Vandermey, Myriam; Kyriazis, George A.; Chan, Sic L.] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32816 USA; [Arumugam, Thiruma V.] Texas Tech Univ Hlth Sci Ctr, Dept Pharmaceut Sci, Amarillo, TX 79106 USA	State University System of Florida; University of Central Florida; Texas Tech University System; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo	Chan, SL (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, 4000 Cent Florida Blvd, Orlando, FL 32816 USA.	schan@mail.ucf.edu	Arumugam, Thiruma Valavan/B-4898-2011; Arumugam, Thiruma/AAG-6958-2019; Arumugam, Thiruma/C-7969-2009	Kyriazis, George/0000-0001-9514-3482; Arumugam, Thiruma/0000-0002-3377-0939	American Federation on Aging Research	American Federation on Aging Research	This work was supported by funds from the American Federation on Aging Research ( to S. L. C.).	Benavides A, 2005, GLIA, V52, P261, DOI 10.1002/glia.20242; BORASO A, 1994, AM J PHYSIOL, V267, pH1010, DOI 10.1152/ajpheart.1994.267.3.H1010; Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cassarino DS, 1997, BBA-MOL BASIS DIS, V1362, P77, DOI 10.1016/S0925-4439(97)00070-7; Chan SL, 2006, J BIOL CHEM, V281, P37391, DOI 10.1074/jbc.M605552200; Chan SL, 2004, J BIOL CHEM, V279, P28733, DOI 10.1074/jbc.M404272200; Choi WS, 2008, BIOCHEM BIOPH RES CO, V371, P127, DOI 10.1016/j.bbrc.2008.04.020; Cookson MR, 2005, ANNU REV BIOCHEM, V74, P29, DOI 10.1146/annurev.biochem.74.082803.133400; Copanaki E, 2007, BBA-MOL CELL RES, V1773, P157, DOI 10.1016/j.bbamcr.2006.10.002; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Deniaud A, 2008, ONCOGENE, V27, P285, DOI 10.1038/sj.onc.1210638; Ferreiro E, 2006, NEUROBIOL DIS, V23, P669, DOI 10.1016/j.nbd.2006.05.011; Hajnoczky G, 2000, CELL CALCIUM, V28, P349, DOI 10.1054/ceca.2000.0169; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Holtz WA, 2003, J BIOL CHEM, V278, P19367, DOI 10.1074/jbc.M211821200; Holtz WA, 2006, J NEUROCHEM, V99, P54, DOI 10.1111/j.1471-4159.2006.04025.x; Hoozemans JJM, 2007, BIOCHEM BIOPH RES CO, V354, P707, DOI 10.1016/j.bbrc.2007.01.043; Hori O, 2004, GENES CELLS, V9, P457, DOI 10.1111/j.1356-9597.2004.00735.x; Jacobson J, 2002, J CELL SCI, V115, P1175; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Kahns S, 2003, J BIOL CHEM, V278, P23376, DOI 10.1074/jbc.M300495200; Kalivendi SV, 2003, BIOCHEM J, V371, P151, DOI 10.1042/BJ20021525; KASS GEN, 1988, ARCH BIOCHEM BIOPHYS, V260, P789, DOI 10.1016/0003-9861(88)90509-7; Kim J, 2008, J CELL SCI, V121, P3636, DOI 10.1242/jcs.028654; Kim TY, 2008, BIOCHEM BIOPH RES CO, V369, P741, DOI 10.1016/j.bbrc.2008.02.086; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Lee CS, 2005, NEUROCHEM INT, V46, P169, DOI 10.1016/j.neuint.2004.07.007; Lee CS, 2003, NEUROCHEM INT, V43, P147, DOI 10.1016/S0197-0186(02)00214-0; Lee DH, 2006, NEUROCHEM RES, V31, P851, DOI 10.1007/s11064-006-9088-9; Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778; Lotharius J, 1999, J NEUROSCI, V19, P1284; Madesh M, 2005, J CELL BIOL, V170, P1079, DOI 10.1083/jcb.200505022; Malli R, 2003, J BIOL CHEM, V278, P44769, DOI 10.1074/jbc.M302511200; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; Mattson MP, 2001, J MOL NEUROSCI, V17, P205, DOI 10.1385/JMN:17:2:205; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; McNaught KSP, 2001, NAT REV NEUROSCI, V2, P589, DOI 10.1038/35086067; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Okuda-Shimizu Y, 2007, MOL CELL, V28, P544, DOI 10.1016/j.molcel.2007.09.012; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Packer MA, 1996, BIOCHEM PHARMACOL, V51, P267, DOI 10.1016/0006-2952(95)02165-5; Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Ryu EJ, 2002, J NEUROSCI, V22, P10690; Schulze A, 2005, J MOL BIOL, V354, P1021, DOI 10.1016/j.jmb.2005.10.020; Smith WW, 2005, HUM MOL GENET, V14, P3801, DOI 10.1093/hmg/ddi396; SUZUKI YJ, 1992, AM J PHYSIOL, V262, pH114, DOI 10.1152/ajpheart.1992.262.1.H114; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Tuvia S, 2007, J CELL BIOL, V177, P51, DOI 10.1083/jcb.200611036; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wei HF, 1996, J NEUROCHEM, V67, P2390; Yamamuro A, 2006, NEUROCHEM RES, V31, P657, DOI 10.1007/s11064-006-9062-6; Yokouchi M, 2008, J BIOL CHEM, V283, P4252, DOI 10.1074/jbc.M705951200	58	37	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	2009	284	27					18323	18333		10.1074/jbc.M109.020891	http://dx.doi.org/10.1074/jbc.M109.020891			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BW	19447887	hybrid, Green Published			2022-12-25	WOS:000267712400045
J	Walter, M; Liang, S; Ghosh, S; Hornsby, PJ; Li, R				Walter, M.; Liang, S.; Ghosh, S.; Hornsby, P. J.; Li, R.			Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells	ONCOGENE			English	Article						adipose stromal cells; cofilin-1; IL-6; breast tumor cells; migration; invasion	BODY-MASS INDEX; CARCINOMA-CELLS; STEM-CELLS; COFILIN PHOSPHORYLATION; MAMMARY-GLAND; TUMOR-GROWTH; OBESITY; TISSUE; INCREASE; DISEASE	Excessive adiposity has long been associated with increased incidence of breast cancer in post-menopausal women, and with increased mortality from breast cancer, regardless of the menopausal status. Although adipose tissue-derived estrogen contributes to obesity-associated risk for estrogen receptor (ER)-positive breast cancer, the estrogen-independent impact of adipose tissue on tumor invasion and progression needs to be elucidated. Here, we show that adipose stromal cells (ASCs) significantly stimulate migration and invasion of ER-negative breast cancer cells in vitro and tumor invasion in a co-transplant xenograft mouse model. Our study also identifies cofilin-1, a known regulator of actin dynamics, as a determinant of the tumor-promoting activity of ASCs. The cofilin-1-dependent pathway affects the production of interleukin 6 (IL-6) in ASCs. Depletion of IL-6 from the ASC-conditioned medium abrogated the stimulatory effect of ASCs on the migration and invasion of breast tumor cells. Thus, our study uncovers a link between a cytoskeleton-based pathway in ASCs and the stromal impact on breast cancer cells. Oncogene (2009) 28, 2745-2755; doi:10.1038/onc.2009.130; published online 1 June 2009	[Walter, M.; Ghosh, S.; Li, R.] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; [Liang, S.; Hornsby, P. J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Li, R (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	lir3@uthscsa.edu			NCI [CA93506]; DOD [W81XWH-06-1-034]; NIA; Owens Medical Research Foundation; Glenn Foundation for Medical Research; NATIONAL CANCER INSTITUTE [R01CA093506] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Owens Medical Research Foundation; Glenn Foundation for Medical Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Adam Katz for ASCs. The work was supported by grants to RL from the NCI (CA93506) and DOD (W81XWH-06-1-034), and by grants to PJH from the NIA, the Owens Medical Research Foundation, and the Glenn Foundation for Medical Research.	Ailhaud G, 2006, CR BIOL, V329, P570, DOI 10.1016/j.crvi.2005.12.012; Amemori Sadahiro, 2007, Am J Physiol Gastrointest Liver Physiol, V292, pG923; Ara T, 2009, CANCER RES, V69, P329, DOI 10.1158/0008-5472.CAN-08-0613; Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x; Bulun SE, 2005, PHARMACOL REV, V57, P359, DOI 10.1124/pr.57.3.6; Carmichael AR, 2006, OBES REV, V7, P333, DOI 10.1111/j.1467-789X.2006.00261.x; Carmichael AR, 2006, BJOG-INT J OBSTET GY, V113, P1160, DOI 10.1111/j.1471-0528.2006.01021.x; Celis JE, 2005, MOL CELL PROTEOMICS, V4, P492, DOI 10.1074/mcp.M500030-MCP200; Cooke PS, 2004, EXP BIOL MED, V229, P1127, DOI 10.1177/153537020422901107; Dawood S, 2008, CLIN CANCER RES, V14, P1718, DOI 10.1158/1078-0432.CCR-07-1479; Ferrante AW, 2007, J INTERN MED, V262, P408, DOI 10.1111/j.1365-2796.2007.01852.x; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Ghosh S, 2007, AM J PHYSIOL-ENDOC M, V292, pE246, DOI 10.1152/ajpendo.00242.2006; Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Hjartaker A, 2008, ADV EXP MED BIOL, V630, P72; Hoene M, 2008, OBES REV, V9, P20, DOI 10.1111/j.1467-789X.2007.00410.x; Hong DS, 2007, CANCER-AM CANCER SOC, V110, P1911, DOI 10.1002/cncr.22999; Kamat A, 2002, TRENDS ENDOCRIN MET, V13, P122, DOI 10.1016/S1043-2760(02)00567-2; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Katz AJ, 2005, STEM CELLS, V23, P412, DOI 10.1634/stemcells.2004-0021; Kilroy GE, 2007, J CELL PHYSIOL, V212, P702, DOI 10.1002/jcp.21068; Knupfer H, 2007, BREAST CANCER RES TR, V102, P129, DOI 10.1007/s10549-006-9328-3; LaVecchia C, 1997, BRIT J CANCER, V75, P441, DOI 10.1038/bjc.1997.73; Li ZP, 2005, SURG CLIN N AM, V85, P681, DOI 10.1016/j.suc.2005.04.006; Lin SY, 2008, EXP CELL RES, V314, P3107, DOI 10.1016/j.yexcr.2008.07.028; Lin YF, 2006, MOL CELL BIOCHEM, V285, P69, DOI 10.1007/s11010-005-9056-8; Liu D, 2007, NEOPLASIA, V9, P418, DOI 10.1593/neo.07205; Liu D, 2007, CANCER RES, V67, P3117, DOI 10.1158/0008-5472.CAN-06-3452; Manabe Y, 2003, J PATHOL, V201, P221, DOI 10.1002/path.1430; Marcoux N, 2005, CELL SIGNAL, V17, P1449, DOI 10.1016/j.cellsig.2005.03.001; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Paduch R, 2005, CELL BIOL TOXICOL, V21, P247, DOI 10.1007/s10565-005-0002-z; Pederson T, 2008, J CELL BIOL, V180, P1061, DOI 10.1083/jcb.200709082; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sasser AK, 2007, FASEB J, V21, P3763, DOI 10.1096/fj.07-8832com; Schaffler A, 2007, NAT CLIN PRACT ENDOC, V3, P345, DOI 10.1038/ncpendmet0456; Song XY, 2006, J CELL SCI, V119, P2871, DOI 10.1242/jcs.03017; Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902; Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232; Tessitore L, 2004, INT J ONCOL, V24, P1529; Tholpady SS, 2006, CLIN PLAST SURG, V33, P55, DOI 10.1016/j.cps.2005.08.004; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Whiteman MK, 2005, CANCER EPIDEM BIOMAR, V14, P2009, DOI 10.1158/1055-9965.EPI-05-0106; Zalesin KC, 2008, ENDOCRIN METAB CLIN, V37, P663, DOI 10.1016/j.ecl.2008.06.004	49	227	231	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2745	2755		10.1038/onc.2009.130	http://dx.doi.org/10.1038/onc.2009.130			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19483720	Green Accepted			2022-12-25	WOS:000268452900005
J	Walsh, MP; Chintakuntlawar, A; Robinson, CM; Madisch, I; Harrach, B; Hudson, NR; Schnurr, D; Heim, A; Chodosh, J; Seto, D; Jones, MS				Walsh, Michael P.; Chintakuntlawar, Ashish; Robinson, Christopher M.; Madisch, Ijad; Harrach, Balazs; Hudson, Nolan R.; Schnurr, David; Heim, Albert; Chodosh, James; Seto, Donald; Jones, Morris S.			Evidence of Molecular Evolution Driven by Recombination Events Influencing Tropism in a Novel Human Adenovirus that Causes Epidemic Keratoconjunctivitis	PLOS ONE			English	Article							ACUTE RESPIRATORY-DISEASE; WORLD MONKEY ADENOVIRUS; BIOINFORMATICS ANALYSIS; GENOME SEQUENCE; DNA-REPLICATION; VIRUS TYPE-1; EXPRESSION; DEFICIENCY; POLYMERASE; REDUNDANT	In 2005, a human adenovirus strain (formerly known as HAdV-D22/H8 but renamed here HAdV-D53) was isolated from an outbreak of epidemic keratoconjunctititis (EKC), a disease that is usually caused by HAdV-D8, -D19, or -D37, not HAdV-D22. To date, a complete change of tropism compared to the prototype has never been observed, although apparent recombinant strains of other viruses from species Human adenovirus D (HAdV-D) have been described. The complete genome of HAdV-D53 was sequenced to elucidate recombination events that lead to the emergence of a viable and highly virulent virus with a modified tropism. Bioinformatic and phylogenetic analyses of this genome demonstrate that this adenovirus is a recombinant of HAdV-D8 (including the fiber gene encoding the primary cellular receptor binding site), HAdV-D22, (the e determinant of the hexon gene), HAdV-D37 (including the penton base gene encoding the secondary cellular receptor binding site), and at least one unknown or unsequenced HAdV-D strain. Bootscanning analysis of the complete genomic sequence of this novel adenovirus, which we have re-named HAdV-D53, indicated at least five recombination events between the aforementioned adenoviruses. Intrahexon recombination sites perfectly framed the epsilon neutralization determinant that was almost identical to the HAdV-D22 prototype. Additional bootscan analysis of all HAdV-D hexon genes revealed recombinations in identical locations in several other adenoviruses. In addition, HAdV-D53 but not HAdV-D22 induced corneal inflammation in a mouse model. Serological analysis confirmed previous results and demonstrated that HAdV-D53 has a neutralization profile representative of the e determinant of its hexon (HAdV-D22) and the fiber (HAdV-D8) proteins. Our recombinant hexon sequence is almost identical to the hexon sequences of the HAdV-D strain causing EKC outbreaks in Japan, suggesting that HAdV-D53 is pandemic as an emerging EKC agent. This documents the first genomic, bioinformatic, and biological descriptions of the molecular evolution events engendering an emerging pathogenic adenovirus.			Walsh, MP (corresponding author), George Mason Univ, Dept Bioinformat & Computat Biol, Manassas, VA USA.	drmorrisj@yahoo.com	Robinson, Christopher/FKL-4907-2022; Harrach, Balazs/AAC-2154-2020; Harrach, Balázs/A-3680-2008	Harrach, Balázs/0000-0002-1410-6469; Chintakuntlawar, Ashish/0000-0002-2907-6522	NATIONAL EYE INSTITUTE [R01EY013124] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adhikary AK, 2004, J CLIN PATHOL, V57, P411, DOI 10.1136/jcp.2003.012500; ALLARD A, 1990, J CLIN MICROBIOL, V28, P2659, DOI 10.1128/JCM.28.12.2659-2667.1990; Aoki K, 2008, J CLIN MICROBIOL, V46, P3259, DOI 10.1128/JCM.02354-07; Benko M, 2003, CURR TOP MICROBIOL, V272, P3; Benko M., 2005, VIRUS TAXONOMY 8 REP, P213; BOS A, 1978, BIOCHIM BIOPHYS ACTA, V525, P37, DOI 10.1016/0005-2744(78)90197-3; BOZIC CR, 1995, J IMMUNOL, V154, P6048; Carr DJJ, 2008, J INTERF CYTOK RES, V28, P245, DOI 10.1089/jir.2007.0110; Chintakuntlawar AV, 2007, INVEST OPHTH VIS SCI, V48, P781, DOI 10.1167/iovs.06-1036; CRAWFORDMIKSZA LK, 1994, J CLIN MICROBIOL, V32, P2331, DOI 10.1128/JCM.32.9.2331-2334.1994; Dan A, 2001, VIRUS GENES, V22, P175, DOI 10.1023/A:1008125324346; Davison AJ, 2003, J GEN VIROL, V84, P2895, DOI 10.1099/vir.0.19497-0; Del Rio L, 2001, J IMMUNOL, V167, P6503, DOI 10.4049/jimmunol.167.11.6503; Dhurandhar NV, 2000, INT J OBESITY, V24, P989, DOI 10.1038/sj.ijo.0801319; DINGLE JH, 1968, AM REV RESPIR DIS, V97, P1; Ebner K, 2005, J VIROL, V79, P12635, DOI 10.1128/JVI.79.20.12635-12642.2005; Engelmann I, 2006, CLIN INFECT DIS, V43, pE64, DOI 10.1086/507533; Evans J. D., 2002, ADENOVIRAL VECTORS G, P39; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Ginsberg HS, 1955, AM J PUBLIC HEALTH N, V45, P915, DOI 10.2105/AJPH.45.7.915; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gordon Y., 1996, OCULAR INFECT IMMUNI, P877; Harrach B., 1998, METH MOLEC MED, V21, P309; HATFIELD L, 1991, VIROLOGY, V184, P265, DOI 10.1016/0042-6822(91)90843-Z; HATFIELD L, 1993, J VIROL, V67, P3931, DOI 10.1128/JVI.67.7.3931-3939.1993; Heim A, 2003, J MED VIROL, V70, P228, DOI 10.1002/jmv.10382; HESTDAL K, 1991, J IMMUNOL, V147, P22; HILLEMAN MR, 1954, P SOC EXP BIOL MED, V85, P183, DOI 10.3181/00379727-85-20825; HIRSCH S, 1981, J EXP MED, V154, P713, DOI 10.1084/jem.154.3.713; Holland RCG, 2008, BIOINFORMATICS, V24, P2096, DOI 10.1093/bioinformatics/btn397; Johnson M, 2008, NUCLEIC ACIDS RES, V36, pW5, DOI 10.1093/nar/gkn201; Jones MS, 2007, J VIROL, V81, P5978, DOI 10.1128/JVI.02650-06; Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436; Kiss I, 1996, Acta Vet Hung, V44, P243; Kovacs GM, 2005, J GEN VIROL, V86, P1681, DOI 10.1099/vir.0.80757-0; Kovacs GM, 2004, J GEN VIROL, V85, P2799, DOI 10.1099/vir.0.80225-0; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lauer KP, 2004, J GEN VIROL, V85, P2615, DOI 10.1099/vir.0.80118-0; Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999; Louie JK, 2008, CLIN INFECT DIS, V46, P421, DOI 10.1086/525261; Madisch I, 2005, J VIROL, V79, P15265, DOI 10.1128/JVI.79.24.15265-15276.2005; Martin D, 2000, BIOINFORMATICS, V16, P562, DOI 10.1093/bioinformatics/16.6.562; MUL YM, 1990, J VIROL, V64, P5510, DOI 10.1128/JVI.64.11.5510-5518.1990; Purkayastha A, 2005, J CLIN MICROBIOL, V43, P3083, DOI 10.1128/JCM.43.7.3083-3094.2005; Purkayastha A, 2005, J VIROL, V79, P2559, DOI 10.1128/JVI.79.4.2559-2572.2005; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Robinson CM, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-213; Robinson CM, 2009, VIRUS RES, V139, P122, DOI 10.1016/j.virusres.2008.10.001; ROWE WP, 1953, P SOC EXP BIOL MED, V84, P570, DOI 10.3181/00379727-84-20714; Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944; SHULTZ J, 1965, ARCH BIOCHEM BIOPHYS, V96, P465; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; TEMPERLEY SM, 1992, EMBO J, V11, P761, DOI 10.1002/j.1460-2075.1992.tb05109.x; WOLPE SD, 1989, P NATL ACAD SCI USA, V86, P612, DOI 10.1073/pnas.86.2.612	54	168	176	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2009	4	6							e5635	10.1371/journal.pone.0005635	http://dx.doi.org/10.1371/journal.pone.0005635			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453PV	19492050	Green Published, Green Submitted, gold			2022-12-25	WOS:000266624300002
J	Antoine-Moussiaux, N; Cornet, A; Cornet, F; Glineur, S; Dermine, M; Desmecht, D				Antoine-Moussiaux, Nicolas; Cornet, Anne; Cornet, Francois; Glineur, Stephanie; Dermine, Martin; Desmecht, Daniel			A Non-Cytosolic Protein of Trypanosoma evansi Induces CD45-Dependent Lymphocyte Death	PLOS ONE			English	Article								In a recent study dealing with a mouse model of Trypanosoma evansi-associated disease, a remarkable synchrony between the parasitaemia peak and the white-blood-cell count nadir was noticed. The present study was designed to establish whether there is a direct causal link between the parasite load during its exponential phase of growth and the disappearance of peripheral blood leukocytes. In vitro experiments performed with trypanosomes and purified peripheral blood mononucleated cells revealed the existence of a lymphotoxin embedded in the T. evansi membrane: a protein sensitive to serine proteases, with a molecular mass of less than 30 kDa. Lymphocytes death induced by this protein was found to depend on the intervention of a lymphocytic protein tyrosine phosphatase. When lymphocytes were exposed to increasing quantities of a monoclonal antibody raised against the extracellular portion of CD45, a transmembrane protein tyrosine phosphatase covering over 10% of the lymphocyte surface, T. evansi membrane extracts showed a dose-dependent decrease in cytotoxicity. As the regulatory functions of CD45 concern not only the fate of lymphocytes but also the activation threshold of the TCR-dependent signal and the amplitude and nature of cytokinic effects, this demonstration of its involvement in T. evansi-dependent lymphotoxicity suggests that T. evansi might manipulate, via CD45, the host's cytokinic and adaptive responses.			Antoine-Moussiaux, N (corresponding author), Univ Liege, Fac Vet Med, Dept Pathol, Liege, Belgium.	daniel.desmecht@ulg.ac.be		Antoine-Moussiaux, Nicolas/0000-0003-1575-625X; Glineur, Stephanie/0000-0002-4053-0255				ADAH MI, 1993, VET PARASITOL, V47, P177, DOI 10.1016/0304-4017(93)90020-N; Antoine-Moussiaux N, 2008, ACTA TROP, V107, P139, DOI 10.1016/j.actatropica.2008.05.010; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Chen JC, 2002, BLOOD, V99, P561, DOI 10.1182/blood.V99.2.561; DOSREIS G, 1995, PARASITOL TODAY, V11, P391; ESIEVO KAN, 1983, J COMP PATHOL, V93, P165, DOI 10.1016/0021-9975(83)90002-6; Fortin M, 2002, J IMMUNOL, V168, P6084, DOI 10.4049/jimmunol.168.12.6084; Goossens B, 1998, VET PARASITOL, V79, P283, DOI 10.1016/S0304-4017(98)00171-X; Gregori S, 2005, J EXP MED, V201, P1293, DOI 10.1084/jem.20040912; Hermiston ML, 2003, ANNU REV IMMUNOL, V21, P107, DOI 10.1146/annurev.immunol.21.120601.140946; HERRERA HM, 2008, PARASITOLOGY RES; IKEDE B O, 1977, Tropical Animal Health and Production, V9, P93, DOI 10.1007/BF02236387; JACKSON DG, 1985, BIOCHEM J, V230, P195, DOI 10.1042/bj2300195; Kim J, 2006, CLIN EXP ALLERGY, V36, P122, DOI 10.1111/j.1365-2222.2005.02407.x; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Littell RC, 1998, J ANIM SCI, V76, P1216; Lopes MF, 1996, INFECT IMMUN, V64, P1559, DOI 10.1128/IAI.64.5.1559-1564.1996; MABBOTT N, 1995, INFECT IMMUN, V63, P1563, DOI 10.1128/IAI.63.4.1563-1566.1995; Mabbott NA, 1998, IMMUNOLOGY, V94, P476, DOI 10.1046/j.1365-2567.1998.00541.x; MACKENZIE PKI, 1978, RES VET SCI, V24, P4, DOI 10.1016/S0034-5288(18)33089-3; Magez S, 2004, J INFECT DIS, V189, P527, DOI 10.1086/381151; Magez S, 1998, J IMMUNOL, V160, P1949; MAXIE MG, 1979, TROPENMED PARASITOL, V30, P274; Onah DN, 1999, PARASITOL RES, V85, P263, DOI 10.1007/s004360050545; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Radwanska M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000078; Steff AM, 2003, CRIT REV IMMUNOL, V23, P421, DOI 10.1615/CritRevImmunol.v23.i56.40; Tchilian EZ, 2006, TRENDS IMMUNOL, V27, P146, DOI 10.1016/j.it.2006.01.001; Uzcanga GL, 2004, BIOCHEMISTRY-US, V43, P595, DOI 10.1021/bi0301946; WILLIAMS DJL, 1991, PARASITE IMMUNOL, V13, P171, DOI 10.1111/j.1365-3024.1991.tb00273.x; Zhang J, 1999, J MOL CELL CARDIOL, V31, P581, DOI 10.1006/jmcc.1998.0893	31	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5728	10.1371/journal.pone.0005728	http://dx.doi.org/10.1371/journal.pone.0005728			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451SH	19478957	Green Published, gold, Green Submitted			2022-12-25	WOS:000266490000006
J	Ragan, C; Cloonan, N; Grimmond, SM; Zuker, M; Ragan, MA				Ragan, Chikako; Cloonan, Nicole; Grimmond, Sean M.; Zuker, Michael; Ragan, Mark A.			Transcriptome-Wide Prediction of miRNA Targets in Human and Mouse Using FASTH	PLOS ONE			English	Article							TUMOR-SUPPRESSOR; MICRORNA; EXPRESSION; SEQUENCE; RNA; IMPACT; IDENTIFICATION; SPECIFICITY; APOPTOSIS; VARIANTS	Transcriptional regulation by microRNAs (miRNAs) involves complementary base-pairing at target sites on mRNAs, yielding complex secondary structures. Here we introduce an efficient computational approach and software (FASTH) for genome-scale prediction of miRNA target sites based on minimizing the free energy of duplex structure. We apply our approach to identify miRNA target sites in the human and mouse transcriptomes. Our results show that short sequence motifs in the 59 end of miRNAs frequently match mRNAs perfectly, not only at validated target sites but additionally at many other, energetically favourable sites. High-quality matching regions are abundant and occur at similar frequencies in all mRNA regions, not only the 3'UTR. About one-third of potential miRNA target sites are reassigned to different mRNA regions, or gained or lost altogether, among different transcript isoforms from the same gene. Many potential miRNA target sites predicted in human are not found in mouse, and vice-versa, but among those that do occur in orthologous human and mouse mRNAs most are situated in corresponding mRNA regions, i.e. these sites are themselves orthologous. Using a luciferase assay in HEK293 cells, we validate four of six predicted miRNA-mRNA interactions, with the mRNA level reduced by an average of 73%. We demonstrate that a thermodynamically based computational approach to prediction of miRNA binding sites on mRNAs can be scaled to analyse complete mammalian transcriptome datasets. These results confirm and extend the scope of miRNA-mediated species-and transcript-specific regulation in different cell types, tissues and developmental conditions.			Ragan, C (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia.	m.ragan@imb.uq.edu.au	Grimmond, Sean M/J-5304-2016; Cloonan, Nicole/B-5272-2008; Grimmond, Sean/K-3246-2019; Ragan, Mark A/A-9825-2014	Grimmond, Sean M/0000-0002-8102-7998; Cloonan, Nicole/0000-0001-7802-6647; Grimmond, Sean/0000-0002-8102-7998; Ragan, Mark A/0000-0003-1672-7020	NIGMS NIH HHS [R01 GM054250, GM54250] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054250] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abelson JF, 2005, SCIENCE, V310, P317, DOI 10.1126/science.1116502; Anderson C, 2006, NUCLEIC ACIDS RES, V34, P5863, DOI 10.1093/nar/gkl743; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Boutz PL, 2007, GENE DEV, V21, P71, DOI 10.1101/gad.1500707; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Didiano D, 2006, NAT STRUCT MOL BIOL, V13, P849, DOI 10.1038/nsmb1138; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Enright AJ, 2004, GENOME BIOL, V5; Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Garzon R, 2006, P NATL ACAD SCI USA, V103, P5078, DOI 10.1073/pnas.0600587103; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kato M, 2007, P NATL ACAD SCI USA, V104, P3432, DOI 10.1073/pnas.0611192104; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Long D, 2007, NAT STRUCT MOL BIOL, V14, P287, DOI 10.1038/nsmb1226; MANFIELD JH, 2004, NAT GENET, V36, P1079; Martin MM, 2006, J BIOL CHEM, V281, P18277, DOI 10.1074/jbc.M601496200; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Muckstein U, 2006, BIOINFORMATICS, V22, P1177, DOI 10.1093/bioinformatics/btl024; Naguibneva I, 2006, NAT CELL BIOL, V8, P278, DOI 10.1038/ncb1373; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Rosenberg MI, 2006, J CELL BIOL, V175, P77, DOI 10.1083/jcb.200603039; Saetrom O, 2005, RNA, V11, P995, DOI 10.1261/rna.7290705; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Sethupathy P, 2006, RNA, V12, P192, DOI 10.1261/rna.2239606; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Tafer H, 2008, BIOINFORMATICS, V24, P2657, DOI 10.1093/bioinformatics/btn193; Takeda J, 2006, NUCLEIC ACIDS RES, V34, P3917, DOI 10.1093/nar/gkl507; Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299; Tsuchiya Y, 2006, CANCER RES, V66, P9090, DOI 10.1158/0008-5472.CAN-06-1403; Tuddenham L, 2006, FEBS LETT, V580, P4214, DOI 10.1016/j.febslet.2006.06.080; Vella MC, 2004, GENE DEV, V18, P132, DOI 10.1101/gad.1165404; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Xiao JN, 2007, J CELL PHYSIOL, V212, P285, DOI 10.1002/jcp.21062; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Yoshinari K, 2004, NUCLEIC ACIDS RES, V32, P691, DOI 10.1093/nar/gkh221; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	62	22	23	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5745	10.1371/journal.pone.0005745	http://dx.doi.org/10.1371/journal.pone.0005745			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451SH	19478946	Green Published, gold			2022-12-25	WOS:000266490000019
J	Yan, CG; Liu, DQ; He, Y; Zou, QH; Zhu, CZ; Zuo, XN; Long, XY; Zang, YF				Yan, Chaogan; Liu, Dongqiang; He, Yong; Zou, Qihong; Zhu, Chaozhe; Zuo, Xinian; Long, Xiangyu; Zang, Yufeng			Spontaneous Brain Activity in the Default Mode Network Is Sensitive to Different Resting-State Conditions with Limited Cognitive Load	PLOS ONE			English	Article							MEDIAL PREFRONTAL CORTEX; BOLD SIGNAL FLUCTUATIONS; EMOTION-INDUCED CHANGES; FUNCTIONAL CONNECTIVITY; ALZHEIMERS-DISEASE; WORKING-MEMORY; MOTOR CORTEX; BASE-LINE; FMRI; MRI	Background: Recent functional MRI (fMRI) studies have demonstrated that there is an intrinsically organized default mode network (DMN) in the resting brain, primarily made up of the posterior cingulate cortex (PCC) and the medial prefrontal cortex (MPFC). Several previous studies have found that the DMN is minimally disturbed during different resting-state conditions with limited cognitive demand. However, this conclusion was drawn from the visual inspection of the functional connectivity patterns within the DMN and no statistical comparison was performed. Methodology/Principal Findings: Four resting-state fMRI sessions were acquired: 1) eyes-closed (EC) (used to generate the DMN mask); 2) EC; 3) eyes-open with no fixation (EO); and 4) eyes-open with a fixation (EO-F). The 2-4 sessions were counterbalanced across participants (n = 20, 10 males). We examined the statistical differences in both functional connectivity and regional amplitude of low frequency fluctuation (ALFF) within the DMN among the 2-4 resting-state conditions (i.e., EC, EO, and EO-F). Although the connectivity patterns of the DMN were visually similar across these three different conditions, we observed significantly higher functional connectivity and ALFF in both the EO and the EO-F conditions as compared to the EC condition. In addition, the first and second resting EC conditions showed significant differences within the DMN, suggesting an order effect on the DMN activity. Conclusions/Significance: Our findings of the higher DMN connectivity and regional spontaneous activities in the resting state with the eyes open suggest that the participants might have more non-specific or non-goal-directed visual information gathering and evaluation, and mind wandering or daydreaming during the resting state with the eyes open as compared to that with the eyes closed, thus providing insights into the understanding of unconstrained mental activity within the DMN. Our results also suggest that it should be cautious when choosing the type of a resting condition and designating the order of the resting condition in multiple scanning sessions in experimental design.			Yan, CG (corresponding author), Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China.	zangyf@bnu.edu.cn	He, Yong/C-2161-2009; Yan, Chao-Gan/D-1713-2015; ZANG, Yu-Feng/J-1558-2012; He, Yong/Q-5756-2018; Zuo, Xi-Nian/A-7273-2009	Yan, Chao-Gan/0000-0003-3413-5977; ZANG, Yu-Feng/0000-0003-1833-8010; Zuo, Xi-Nian/0000-0001-9110-585X				Binder JR, 1999, J COGNITIVE NEUROSCI, V11, P80, DOI 10.1162/089892999563265; Birn RM, 2006, NEUROIMAGE, V31, P1536, DOI 10.1016/j.neuroimage.2006.02.048; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Biswal BB, 2007, MAGN RESON IMAGING, V25, P1358, DOI 10.1016/j.mri.2007.03.022; Bluhm RL, 2007, SCHIZOPHRENIA BULL, V33, P1004, DOI 10.1093/schbul/sbm052; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Buckner RL, 2009, J NEUROSCI, V29, P1860, DOI 10.1523/JNEUROSCI.5062-08.2009; Cabeza R, 2002, NEUROIMAGE, V16, P317, DOI 10.1006/nimg.2002.1063; Castellanos FX, 2008, BIOL PSYCHIAT, V63, P332, DOI 10.1016/j.biopsych.2007.06.025; CHEN S, 2008, BRAIN RES; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Foster DJ, 2006, NATURE, V440, P680, DOI 10.1038/nature04587; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Fransson P, 2005, HUM BRAIN MAPP, V26, P15, DOI 10.1002/hbm.20113; Fransson P, 2006, NEUROPSYCHOLOGIA, V44, P2836, DOI 10.1016/j.neuropsychologia.2006.06.017; Garrity AG, 2007, AM J PSYCHIAT, V164, P450, DOI 10.1176/appi.ajp.164.3.450; Greicius MD, 2004, J COGNITIVE NEUROSCI, V16, P1484, DOI 10.1162/0898929042568532; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; He Y, 2007, NEUROIMAGE, V35, P488, DOI 10.1016/j.neuroimage.2006.11.042; HOROVITZ SG, 2007, HUM BRAIN MAPP; Kannurpatti SS, 2008, NEUROIMAGE, V40, P1567, DOI 10.1016/j.neuroimage.2007.09.040; Kiviniemi V, 2000, MAGN RESON MED, V44, P373, DOI 10.1002/1522-2594(200009)44:3<373::AID-MRM5>3.0.CO;2-P; Ledberg A, 1998, NEUROIMAGE, V8, P113, DOI 10.1006/nimg.1998.0336; Li SJ, 2000, MAGNET RESON MED, V43, P45, DOI 10.1002/(SICI)1522-2594(200001)43:1<45::AID-MRM6>3.0.CO;2-0; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; LONG XY, J NEUROSCI METHODS, V171, P349; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; Lu H, 2007, P NATL ACAD SCI USA, V104, P18265, DOI 10.1073/pnas.0705791104; Mason MF, 2007, SCIENCE, V315, P393, DOI 10.1126/science.1131295; Mazoyer B, 2001, BRAIN RES BULL, V54, P287, DOI 10.1016/S0361-9230(00)00437-8; Pelled G, 2004, MAGN RESON MED, V52, P913, DOI 10.1002/mrm.20229; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rombouts SARB, 2005, HUM BRAIN MAPP, V26, P231, DOI 10.1002/hbm.20160; Rosner B., 2006, FUNDAMENTALS BIOSTAT; Shehzad Z, 2009, CEREB CORTEX, V19, P2209, DOI 10.1093/cercor/bhn256; Shulman GL, 1997, J COGNITIVE NEUROSCI, V9, P648, DOI 10.1162/jocn.1997.9.5.648; Simpson JR, 2001, P NATL ACAD SCI USA, V98, P683, DOI 10.1073/pnas.98.2.683; Simpson JR, 2001, P NATL ACAD SCI USA, V98, P688, DOI 10.1073/pnas.98.2.688; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Talairach J., 1988, COPLANAR STEREOTAXIC; Tian LX, 2008, BRAIN DEV-JPN, V30, P342, DOI 10.1016/j.braindev.2007.10.005; Uddin LQ, 2008, J NEUROSCI METH, V169, P249, DOI 10.1016/j.jneumeth.2007.11.031; Vincent JL, 2007, NATURE, V447, P83, DOI 10.1038/nature05758; Wang K, 2007, HUM BRAIN MAPP, V28, P967, DOI 10.1002/hbm.20324; Wig GS, 2008, P NATL ACAD SCI USA, V105, P18555, DOI 10.1073/pnas.0804546105; Yang H, 2007, NEUROIMAGE, V36, P144, DOI 10.1016/j.neuroimage.2007.01.054; Zang YF, 2004, NEUROIMAGE, V22, P394, DOI 10.1016/j.neuroimage.2003.12.030; Zang YF, 2007, BRAIN DEV-JPN, V29, P83, DOI 10.1016/j.braindev.2006.07.002	52	247	251	3	57	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5743	10.1371/journal.pone.0005743	http://dx.doi.org/10.1371/journal.pone.0005743			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	451SH	19492040	Green Submitted, Green Published, gold			2022-12-25	WOS:000266490000017
J	Arnason, E; Hernandez, UB; Kristinsson, K				Arnason, Einar; Hernandez, Ubaldo Benitez; Kristinsson, Kristjan			Intense Habitat-Specific Fisheries-Induced Selection at the Molecular Pan I Locus Predicts Imminent Collapse of a Major Cod Fishery	PLOS ONE			English	Article							GADUS-MORHUA L.; ATLANTIC COD; NATURAL-SELECTION; GENETIC DIFFERENTIATION; ARCTIC POPULATIONS; NORTHERN NORWAY; REACTION NORMS; MATURATION; EVOLUTION; SIZE	Predation is a powerful agent in the ecology and evolution of predator and prey. Prey may select multiple habitats whereby different genotypes prefer different habitats. If the predator is also habitat-specific the prey may evolve different habitat occupancy. Drastic changes can occur in the relation of the predator to the evolved prey. Fisheries exert powerful predation and can be a potent evolutionary force. Fisheries-induced selection can lead to phenotypic changes that influence the collapse and recovery of the fishery. However, heritability of the phenotypic traits involved and selection intensities are low suggesting that fisheries-induced evolution occurs at moderate rates at decadal time scales. The Pantophysin I (Pan I) locus in Atlantic cod (Gadus morhua), representing an ancient balanced polymorphism predating the split of cod and its sister species, is under an unusual mix of balancing and directional selection including current selective sweeps. Here we show that Pan I alleles are highly correlated with depth with a gradient of 0.44% allele frequency change per meter. AA fish are shallow-water and BB deep-water adapted in accordance with behavioral studies using data storage tags showing habitat selection by Pan I genotype. AB fish are somewhat intermediate although closer to AA. Furthermore, using a sampling design covering space and time we detect intense habitat-specific fisheries-induced selection against the shallow-water adapted fish with an average 8% allele frequency change per year within year class. Genotypic fitness estimates (0.08, 0.27, 1.00 of AA, AB, and BB respectively) predict rapid disappearance of shallow-water adapted fish. Ecological and evolutionary time scales, therefore, are congruent. We hypothesize a potential collapse of the fishery. We find that probabilistic maturation reaction norms for Atlantic cod at Iceland show declining length and age at maturing comparable to changes that preceded the collapse of northern cod at Newfoundland, further supporting the hypothesis. We speculate that immediate establishment of large no-take reserves may help avert collapse.			Arnason, E (corresponding author), Univ Iceland, Inst Biol, Reykjavik, Iceland.	einararn@hi.is	Arnason, Einar/M-3090-2015	Arnason, Einar/0000-0003-3686-6407				Arnason E, 2004, GENETICS, V166, P1871, DOI 10.1534/genetics.166.4.1871; Barot S, 2004, ECOL APPL, V14, P1257, DOI 10.1890/03-5066; Barot S, 2004, EVOL ECOL RES, V6, P659; Begg GA, 2003, FISH RES, V59, P343, DOI 10.1016/S0165-7836(02)00025-5; BJORNSSON H, 2007, 131 HAFR MAR RES I; Blanchard JL, 2005, CAN J FISH AQUAT SCI, V62, P2001, DOI 10.1139/F05-109; Case RAJ, 2005, MAR ECOL PROG SER, V301, P267, DOI 10.3354/meps301267; Charlesworth B., 1994, EVOLUTION AGE STRUCT, DOI [10.1017/CBO9780511525711, DOI 10.1017/CBO9780511525711]; Conover DO, 2007, NATURE, V450, P179, DOI 10.1038/450179a; Conover DO, 2000, MAR ECOL PROG SER, V208, P303; de Meeus T, 2007, INFECT GENET EVOL, V7, P731, DOI 10.1016/j.meegid.2007.07.005; Endler J.A., 1986, Monographs in Population Biology, pviii; Ewers RM, 2008, TRENDS ECOL EVOL, V23, P113, DOI 10.1016/j.tree.2007.11.008; Fevolden SE, 1997, J FISH BIOL, V51, P895, DOI 10.1006/jfbi.1997.0491; Fisher R., 1970, STAT METHODS RES WOR; GALVANI AP, 2004, P ROY SOC LOND B BIO, V27, P171; Gell FR, 2003, TRENDS ECOL EVOL, V18, P448, DOI 10.1016/S0169-5347(03)00189-7; Goudet J, 2005, MOL ECOL NOTES, V5, P184, DOI 10.1111/j.1471-8286.2004.00828.x; Hedrick P. W., 2011, GENETICS POPULATIONS; Heino M, 2002, EVOLUTION, V56, P669, DOI 10.1111/j.0014-3820.2002.tb01378.x; Hutchings JA, 2004, NATURE, V428, P899, DOI 10.1038/428899a; Hutchings JA, 1996, CAN J FISH AQUAT SCI, V53, P943, DOI 10.1139/f96-097; Hutchings JA, 2000, NATURE, V406, P882, DOI 10.1038/35022565; Hutchings JA, 2008, MOL ECOL, V17, P294, DOI 10.1111/j.1365-294X.2007.03485.x; *ICES, 2008, 2008ACOM03 ICES; Johannesson K, 1997, EVOLUTION, V51, P402, DOI 10.1111/j.1558-5646.1997.tb02427.x; Jonsdottir IG, 2006, ICES J MAR SCI, V63, P1501, DOI 10.1016/j.icesjms.2006.05.006; Jorgensen C, 2007, SCIENCE, V318, P1247, DOI 10.1126/science.1148089; Karlsson S, 2003, MOL ECOL, V12, P3265, DOI 10.1046/j.1365-294X.2003.01993.x; Kingsolver JG, 2001, AM NAT, V157, P245, DOI 10.1086/319193; Kuparinen A, 2007, TRENDS ECOL EVOL, V22, P652, DOI 10.1016/j.tree.2007.08.011; Kurlansky Mark, 1997, COD BIOGRAPHY FISH C; Law R, 2000, ICES J MAR SCI, V57, P659, DOI 10.1006/jmsc.2000.0731; Law R, 2007, MAR ECOL PROG SER, V335, P271, DOI 10.3354/meps335271; LEWONTIN RC, 1959, EVOLUTION, V13, P561, DOI 10.2307/2406136; Marteinsdottir G, 2000, ICES J MAR SCI, V57, P1182, DOI 10.1006/jmsc.2000.0880; Maunder MN, 2006, ICES J MAR SCI, V63, P1373, DOI 10.1016/j.icesjms.2006.05.008; Myers RA, 1996, MAR ECOL PROG SER, V138, P293, DOI 10.3354/meps138293; Nielsen EE, 2006, MOL ECOL, V15, P3219, DOI 10.1111/j.1365-294X.2006.03025.x; Olsen E, 2005, CAN J FISH AQUAT SCI, V62, P811, DOI 10.1139/F05-065; Olsen EM, 2004, NATURE, V428, P932, DOI 10.1038/nature02430; Palsson OK, 2003, CAN J FISH AQUAT SCI, V60, P1409, DOI 10.1139/F03-117; Pampoulie C, 2008, BEHAV GENET, V38, P76, DOI 10.1007/s10519-007-9175-y; Pampoulie C, 2006, CAN J FISH AQUAT SCI, V63, P2660, DOI 10.1139/F06-150; Pogson GH, 2003, MOL ECOL, V12, P63, DOI 10.1046/j.1365-294X.2003.01713.x; Pogson GH, 2004, MOL BIOL EVOL, V21, P65, DOI 10.1093/molbev/msg237; Pogson GH, 2001, GENETICS, V157, P317; PROUT T, 1965, EVOLUTION, V19, P546, DOI 10.2307/2406251; R Development Core Team, 2007, R LANG ENV STAT COMP; RIJNSDORP AD, 1993, OECOLOGIA, V96, P391, DOI 10.1007/BF00317510; Roberts CM, 2001, SCIENCE, V294, P1920, DOI 10.1126/science.294.5548.1920; ROBERTSON A, 1965, ANIM PROD, V7, P319, DOI 10.1017/S0003356100025770; Sale PF, 2005, TRENDS ECOL EVOL, V20, P74, DOI 10.1016/j.tree.2004.11.007; Sarkar D., 2007, LATTICE LATTICE GRAP; Sarkar D, 2008, USE R, P1; Sarvas TH, 2005, FISH RES, V76, P307, DOI 10.1016/j.fishres.2005.07.013; Sarvas TH, 2005, J FISH BIOL, V67, P444, DOI 10.1111/j.0022-1112.2005.00738.x; SCHOPKA SA, 2007, 133 MAR RES I; Stockwell CA, 2003, TRENDS ECOL EVOL, V18, P94, DOI 10.1016/S0169-5347(02)00044-7; Swain DP, 2007, P ROY SOC B-BIOL SCI, V274, P1015, DOI 10.1098/rspb.2006.0275; SWAIN DP, 1994, ICES J MAR SCI, V51, P493, DOI 10.1006/jmsc.1994.1050; Venables W.N., 2002, MODERN APPL STAT S, V4th ed, DOI DOI 10.1007/978-0-387-21706-2; Wahlund S, 1928, HEREDITAS, V11, P65, DOI 10.1111/j.1601-5223.1928.tb02483.x; WALLACE B, 1958, EVOLUTION, V12, P113, DOI 10.2307/2405911; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; Waples RS, 1998, J HERED, V89, P438, DOI 10.1093/jhered/89.5.438; Westgaard JI, 2007, FISH RES, V85, P306, DOI 10.1016/j.fishres.2007.04.001; Wood S, 2017, GEN ADDITIVE MODELS, DOI 10.1201/9781315370279; Wood SN, 2008, J R STAT SOC B, V70, P495, DOI 10.1111/j.1467-9868.2007.00646.x; Yang RC, 1998, EVOLUTION, V52, P950, DOI 10.1111/j.1558-5646.1998.tb01824.x; 2001, 80 MAR RES I; 2007, 138 MAR RES I; 2000, 75 MAR RES I; 2007, 126 MAR RES I	74	50	51	1	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2009	4	5							e5529	10.1371/journal.pone.0005529	http://dx.doi.org/10.1371/journal.pone.0005529			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QD	19479037	Green Published, Green Submitted, gold			2022-12-25	WOS:000266415000001
J	Tickle, P; Nudds, R; Codd, J				Tickle, Peter; Nudds, Robert; Codd, Jonathan			Uncinate Process Length in Birds Scales with Resting Metabolic Rate	PLOS ONE			English	Article							BASAL; TEMPERATURE; MECHANICS; CAPACITY; ANATOMY; SYSTEM	A fundamental function of the respiratory system is the supply of oxygen to meet metabolic demand. Morphological constraints on the supply of oxygen, such as the structure of the lung, have previously been studied in birds. Recent research has shown that uncinate processes (UP) are important respiratory structures in birds, facilitating inspiratory and expiratory movements of the ribs and sternum. Uncinate process length (UPL) is important for determining the mechanical advantage for these respiratory movements. Here we report on the relationship between UPL, body size, metabolic demand and locomotor specialisation in birds. UPL was found to scale isometrically with body mass. Process length is greatest in specialist diving birds, shortest in walking birds and intermediate length in all others relative to body size. Examination of the interaction between the length of the UP and metabolic demand indicated that, relative to body size, species with high metabolic rates have corresponding elongated UP. We propose that elongated UP confer an advantage on the supply of oxygen, perhaps by improving the mechanical advantage and reducing the energetic cost of movements of the ribs and sternum.			Tickle, P (corresponding author), Univ Manchester, Fac Life Sci, Manchester, Lancs, England.	jonathan.codd@manchester.ac.uk		Codd, Jonathan/0000-0003-0211-1786	Biotechnology and Biological Sciences Research Council [G011338/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ASCHOFF J, 1970, FED PROC, V29, P1541; Aschoff J, 1970, J. Orn., Berl., V111, P38, DOI 10.1007/BF01668180; BENNETT PM, 1987, J ZOOL, V213, P327, DOI 10.1111/j.1469-7998.1987.tb03708.x; Bishop CM, 1997, PHILOS T R SOC B, V352, P447, DOI 10.1098/rstb.1997.0032; Bishop CM, 1999, P ROY SOC B-BIOL SCI, V266, P2275, DOI 10.1098/rspb.1999.0919; BRACKENBURY JH, 1972, J EXP BIOL, V57, P543; BRACKENBURY JH, 1973, COMP BIOCHEM PHYSIOL, V44, P599, DOI 10.1016/0300-9629(73)90511-2; CARRIER DR, 1991, AM ZOOL, V31, P644; CARRIER DR, 1992, BIOL J LINN SOC, V47, P61, DOI 10.1111/j.1095-8312.1992.tb00656.x; Codd JR, 2008, P ROY SOC B-BIOL SCI, V275, P157, DOI 10.1098/rspb.2007.1233; Codd JR, 2005, J EXP BIOL, V208, P849, DOI 10.1242/jeb.01489; Dunning J.B., 2007, CRC HDB AVIAN BODY M; Dutenhoffer MS, 1996, PHYSIOL ZOOL, V69, P1232, DOI 10.1086/physzool.69.5.30164255; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; Greenewalt C.H., 1962, SMITHSON MISC COLLNS, V144, P1, DOI DOI 10.1007/S00360-016-1016-Y; Jetz W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003261; KLEIBER MAX, 1932, HILGARDIA, V6, P315; LASIEWSKI RC, 1971, RESP PHYSIOL, V11, P152, DOI 10.1016/0034-5687(71)90020-X; LASIEWSKI RC, 1967, CONDOR, V69, P13, DOI 10.2307/1366368; Livezey BC, 2007, ZOOL J LINN SOC-LOND, V149, P1, DOI 10.1111/j.1096-3642.2006.00293.x; McKechnie AE, 2004, PHYSIOL BIOCHEM ZOOL, V77, P502, DOI 10.1086/383511; McKechnie AE, 2006, P ROY SOC B-BIOL SCI, V273, P931, DOI 10.1098/rspb.2005.3415; Nassar PN, 2001, J EXP BIOL, V204, P1641; Parkes R, 2002, J EXP BIOL, V205, P3945; Powell F.L., 2000, P233, DOI 10.1016/B978-012747605-6/50011-0; PURVIS A, 1995, COMPUT APPL BIOSCI, V11, P247; RAYNER JMV, 1985, J ZOOL, V206, P415; Rezende EL, 2002, J EXP BIOL, V205, P101; Schmidt-Nielsen K., 1984, SCALING WHY IS ANIMA; SCHUFELDT RW, 1890, MYOLOGY RAVEN, P300; Seymour RS, 2008, COMP BIOCHEM PHYS A, V150, P169, DOI 10.1016/j.cbpa.2006.03.018; Sokal R. R., 2012, BIOMETRY; TAYLOR CR, 1981, RESP PHYSIOL, V44, P1, DOI 10.1016/0034-5687(81)90073-6; Tickle PG, 2009, POULTRY SCI, V88, P179, DOI 10.3382/ps.2008-00349; Tickle PG, 2007, J EXP BIOL, V210, P3955, DOI 10.1242/jeb.008953; Walker WF, 1994, FUNCTIONAL ANATOMY V; Welty J.C., 1988, LIFE BIRDS, V4th edn; White CR, 2003, P NATL ACAD SCI USA, V100, P4046, DOI 10.1073/pnas.0436428100; White CR, 2006, BIOL LETTERS, V2, P125, DOI 10.1098/rsbl.2005.0378; White CR, 2007, P ROY SOC B-BIOL SCI, V274, P287, DOI 10.1098/rspb.2006.3727; Wilson RP, 2003, J EXP BIOL, V206, P1751, DOI 10.1242/jeb.00341; Zhang FC, 2001, CHINESE SCI BULL, V46, P945, DOI 10.1007/BF02900473; Zimmer K., 1935, ZOOLOGICA, V88, P1	43	10	10	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2009	4	5							e5667	10.1371/journal.pone.0005667	http://dx.doi.org/10.1371/journal.pone.0005667			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QD	19479074	gold, Green Published, Green Submitted			2022-12-25	WOS:000266415000005
J	Sui, HY; Zhao, GY; Huang, JD; Jin, DY; Yuen, KY; Zheng, BJ				Sui, Hong-Yan; Zhao, Guang-Yu; Huang, Jian-Dong; Jin, Dong-Yan; Yuen, Kwok-Yung; Zheng, Bo-Jian			Small Interfering RNA Targeting M2 Gene Induces Effective and Long Term Inhibition of Influenza A Virus Replication	PLOS ONE			English	Article							TO-PERSON TRANSMISSION; LENTIVIRAL VECTORS; EXPRESSION; CELLS; MICE; RESISTANT; PROTEIN; SIRNA; DELIVERY; REQUIRES	RNA interference (RNAi) provides a powerful new means to inhibit viral infection specifically. However, the selection of siRNA-resistant viruses is a major concern in the use of RNAi as antiviral therapeutics. In this study, we conducted a lentiviral vector with a H1-short hairpin RNA (shRNA) expression cassette to deliver small interfering RNAs (siRNAs) into mammalian cells. Using this vector that also expresses enhanced green fluorescence protein (EGFP) as surrogate marker, stable shRNA-expressing cell lines were successfully established and the inhibition efficiencies of rationally designed siRNAs targeting to conserved regions of influenza A virus genome were assessed. The results showed that a siRNA targeting influenza M2 gene (siM2) potently inhibited viral replication. The siM2 was not only effective for H1N1 virus but also for highly pathogenic avian influenza virus H5N1. In addition to its M2 inhibition, the siM2 also inhibited NP mRNA accumulation and protein expression. A long term inhibition effect of the siM2 was demonstrated and the emergence of siRNA-resistant mutants in influenza quasispecies was not observed. Taken together, our study suggested that M2 gene might be an optimal RNAi target for antiviral therapy. These findings provide useful information for the development of RNAi-based prophylaxis and therapy for human influenza virus infection.			Sui, HY (corresponding author), Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.	bzheng@hkucc.hku.hk	Sui, Hongyan/M-1305-2013; /C-4277-2009	/0000-0001-7531-2816; Yuen, Kwok-yung/0000-0002-2083-1552				An DS, 2003, HUM GENE THER, V14, P1207, DOI 10.1089/104303403322168037; APPASANI K, 2004, RNA INTERFERENCE TEC, pR33; Arrighi JF, 2004, J VIROL, V78, P10848, DOI 10.1128/JVI.78.20.10848-10855.2004; BEATON AR, 1986, P NATL ACAD SCI USA, V83, P6282, DOI 10.1073/pnas.83.17.6282; Beigel H, 2005, NEW ENGL J MED, V353, P1374, DOI 10.1056/NEJMra052211; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Das AT, 2004, J VIROL, V78, P2601, DOI 10.1128/JVI.78.5.2601-2605.2004; DEGELAU J, 1992, ARCH INTERN MED, V152, P390, DOI 10.1001/archinte.152.2.390; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; ENGELKE DR, 2004, RNA INTERFERENCE, pR37; Fish RJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-9; Garcia-Sastre A, 2002, MICROBES INFECT, V4, P647, DOI 10.1016/S1286-4579(02)01583-6; Ge Q, 2004, P NATL ACAD SCI USA, V101, P8676, DOI 10.1073/pnas.0402486101; Ge Q, 2003, P NATL ACAD SCI USA, V100, P2718, DOI 10.1073/pnas.0437841100; Gubareva LV, 1997, J VIROL, V71, P3385, DOI 10.1128/JVI.71.5.3385-3390.1997; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419; HOUCK P, 1995, ARCH INTERN MED, V155, P533, DOI 10.1001/archinte.155.5.533; Hui EKW, 2004, J GEN VIROL, V85, P1877, DOI 10.1099/vir.0.79906-0; Kandun IN, 2006, NEW ENGL J MED, V355, P2186, DOI 10.1056/NEJMoa060930; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; KINCHINGTON D, 2000, ANTIVIRAL METHODS PR, pR14; Konishi M, 2006, J VIRAL HEPATITIS, V13, P756, DOI 10.1111/j.1365-2893.2006.00752.x; Kumar M, 1998, MICROBIOL MOL BIOL R, V62, P1415, DOI 10.1128/MMBR.62.4.1415-1434.1998; Li BJ, 2005, NAT MED, V11, P944, DOI 10.1038/nm1280; Li YC, 2005, AVIAN DIS, V49, P562, DOI 10.1637/7365-041205R2.1; Moore MD, 2005, J GENE MED, V7, P918, DOI 10.1002/jgm.739; Scherr M, 2003, BLOOD, V101, P1566, DOI 10.1182/blood-2002-06-1685; SHAPIRO GI, 1988, J VIROL, V62, P2285, DOI 10.1128/JVI.62.7.2285-2290.1988; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Szulc J, 2006, NAT METHODS, V3, P109, DOI 10.1038/NMETH846; Tompkins SM, 2004, P NATL ACAD SCI USA, V101, P8682, DOI 10.1073/pnas.0402630101; Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021; Wang H, 2008, LANCET, V371, P1427, DOI 10.1016/S0140-6736(08)60493-6; Westerhout EM, 2005, NUCLEIC ACIDS RES, V33, P796, DOI 10.1093/nar/gki220; Wohlbold L, 2003, BLOOD, V102, P2236, DOI 10.1182/blood-2002-12-3899; Yen HL, 2005, J INFECT DIS, V192, P665, DOI 10.1086/432008; Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100; ZHENG BJ, 1993, VACCINE, V11, P1191, DOI 10.1016/0264-410X(93)90042-V; Zheng BJ, 2001, INT J CANCER, V92, P421, DOI 10.1002/ijc.1198; Zheng BJ, 2008, P NATL ACAD SCI USA, V105, P8091, DOI 10.1073/pnas.0711942105; ZHOU H, 2007, ANTIVIRAL RES	42	53	61	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2009	4	5							e5671	10.1371/journal.pone.0005671	http://dx.doi.org/10.1371/journal.pone.0005671			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LD	19479060	Green Published, gold, Green Submitted			2022-12-25	WOS:000266331200008
J	Beed, PS; Salmen, B; Schmitz, D				Beed, Prateep S.; Salmen, Benedikt; Schmitz, Dietmar			GluK2-Mediated Excitability within the Superficial Layers of the Entorhinal Cortex	PLOS ONE			English	Article								Recent analysis of genetically modified mice deficient in different kainate receptor (KAR) subunits have strongly pointed to a role of the GluK2 subunit, mediating the vulnerability of the brain towards seizures. Research concerning this issue has focused mainly on the hippocampus. However, several studies point to a potential role of other parts of the hippocampal formation, in particular the entorhinal cortex, in the development of epileptic seizures. There is extensive cell death after such seizures in layer III of the medial entorhinal cortex (LIII mEC), making this region of special interest for investigation into related pathological conditions. We therefore characterized KAR mediated currents in LIII mEC pyramidal neurons by several different approaches. Using patch-clamp technique, in combination with glutamate uncaging in horizontal brain slices, we show that LIII mEC neurons exhibit KAR currents. Use of genetically modified mice reveal that these currents are mediated by GluK2 containing KARs. The IV curve indicates the predominant presence of a Ca(2+) impermeable and edited form of the KAR. Finally, we show that GluK2 containing kainate receptors are essential for kainate-induced gamma oscillations within the entorhinal cortex.			Beed, PS (corresponding author), Univ Med Berlin, Neurosci Res Ctr, Berlin, Germany.	dietmar.schmitz@charite.de		Schmitz, Dietmar/0000-0003-2741-5241				BAHN S, 1994, J NEUROSCI, V14, P5525; Ben-Ari Y, 2000, TRENDS NEUROSCI, V23, P580, DOI 10.1016/S0166-2236(00)01659-3; BORLOTTO ZA, 2005, NEUROTOXICOLOGY, V25, P769; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; Chittajallu R, 1999, TRENDS PHARMACOL SCI, V20, P26, DOI 10.1016/S0165-6147(98)01286-3; Cunningham MO, 2006, J NEUROSCI, V26, P2767, DOI 10.1523/JNEUROSCI.5054-05.2006; Cunningham MO, 2003, J NEUROSCI, V23, P9761; Dhillon A, 2000, NEUROSCIENCE, V99, P413, DOI 10.1016/S0306-4522(00)00225-6; Dickson CT, 1997, NEUROSCIENCE, V81, P937, DOI 10.1016/S0306-4522(97)00263-7; Dickson CT, 2000, ANN NY ACAD SCI, V911, P127; Eder M, 2003, J NEUROSCI, V23, P6660; Fisahn A, 2005, J PHYSIOL-LONDON, V562, P65, DOI 10.1113/jphysiol.2004.077388; Frerking M, 2002, J NEUROSCI, V22, P7434; Gloveli T, 1997, J NEUROPHYSIOL, V78, P3444, DOI 10.1152/jn.1997.78.6.3444; Gloveli T, 1997, NEUROSCIENCE, V77, P629, DOI 10.1016/S0306-4522(96)00494-0; Grigorenko EV, 1998, NEUROREPORT, V9, P2219, DOI 10.1097/00001756-199807130-00013; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; Huettner JE, 2003, PROG NEUROBIOL, V70, P387, DOI 10.1016/S0301-0082(03)00122-9; Huxter JR, 2007, J NEUROSCI, V27, P2212, DOI 10.1523/JNEUROSCI.3954-06.2007; JARRARD LE, 1993, NEUROPATH APPL NEURO, V19, P381, DOI 10.1111/j.1365-2990.1993.tb00458.x; Kortenbruck G, 2000, EUR J NEUROSCI, V12, P107; Kortenbruck G, 2001, NEUROBIOL DIS, V8, P459, DOI 10.1006/nbdi.2001.0394; Lerma J, 2006, CURR OPIN PHARMACOL, V6, P89, DOI 10.1016/j.coph.2005.08.004; Liu QS, 2004, P NATL ACAD SCI USA, V101, P3172, DOI 10.1073/pnas.0306731101; LOMELI H, 1992, FEBS LETT, V307, P139, DOI 10.1016/0014-5793(92)80753-4; MacGregor DG, 1997, EXP NEUROL, V148, P110, DOI 10.1006/exnr.1997.6625; Motazacker MM, 2007, AM J HUM GENET, V81, P792, DOI 10.1086/521275; Mulle C, 2000, NEURON, V28, P475, DOI 10.1016/S0896-6273(00)00126-4; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; Musshoff U, 2002, KLIN NEUROPHYSIOL, V32, P178; Paschen W, 1996, J CEREBR BLOOD F MET, V16, P548, DOI 10.1097/00004647-199607000-00004; Pinheiro P, 2006, CELL TISSUE RES, V326, P457, DOI 10.1007/s00441-006-0265-6; Sailer A, 1999, J NEUROSCI, V19, P8757, DOI 10.1523/JNEUROSCI.19-20-08757.1999; Seeburg PH, 2003, CURR OPIN NEUROBIOL, V13, P279, DOI 10.1016/S0959-4388(03)00062-X; Seeburg PH, 1998, BRAIN RES REV, V26, P217, DOI 10.1016/S0165-0173(97)00062-3; Sprengel R, 1998, N-S ARCH PHARMACOL, V358, pR370; TOLLE TR, 1993, J NEUROSCI, V13, P5009, DOI 10.1523/JNEUROSCI.13-12-05009.1993; Tolner EA, 2005, EPILEPSIA, V46, P72, DOI 10.1111/j.1528-1167.2005.01012.x; Tolner EA, 2007, NEUROBIOL DIS, V26, P419, DOI 10.1016/j.nbd.2007.01.009; Vignes M, 1997, NATURE, V388, P179, DOI 10.1038/40639; Vissel B, 2001, NEURON, V29, P217, DOI 10.1016/S0896-6273(01)00192-1; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; West PJ, 2007, NEUROSCIENCE, V146, P1000, DOI 10.1016/j.neuroscience.2007.02.035; West PJ, 2005, EPILEPSIA, V46, P128; Whittington MA, 2000, PHARMACOL THERAPEUT, V86, P171, DOI 10.1016/S0163-7258(00)00038-3; WISDEN W, 1993, J NEUROSCI, V13, P3582	47	12	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5576	10.1371/journal.pone.0005576	http://dx.doi.org/10.1371/journal.pone.0005576			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440371	Green Accepted, Green Published, Green Submitted, gold			2022-12-25	WOS:000266107500007
J	Lee, HJ; Kim, MK; Kim, HJ; Kim, SU				Lee, Hong J.; Kim, Mi K.; Kim, Hee J.; Kim, Seung U.			Human Neural Stem Cells Genetically Modified to Overexpress Akt1 Provide Neuroprotection and Functional Improvement in Mouse Stroke Model	PLOS ONE			English	Article							BRAIN TRANSPLANTATION; NEURONAL SURVIVAL; GLIAL-CELLS; KINASE-B; RECOVERY; EXPRESSION; APOPTOSIS; RATS; PROLIFERATION; DIFFERENTIATE	In a previous study, we have shown that human neural stem cells (hNSCs) transplanted in brain of mouse intracerebral hemorrhage (ICH) stroke model selectively migrate to the ICH lesion and induce behavioral recovery. However, low survival rate of grafted hNSCs in the brain precludes long-term therapeutic effect. We hypothesized that hNSCs overexpressing Akt1 transplanted into the lesion site could provide long-term improved survival of hNSCs, and behavioral recovery in mouse ICH model. F3 hNSC was genetically modified with a mouse Akt1 gene using a retroviral vector. F3 hNSCs expressing Akt1 were found to be highly resistant to H2O2-induced cytotoxicity in vitro. Following transplantation in ICH mouse brain, F3. Akt1 hNSCs induced behavioral improvement and significantly increased cell survival (50-100% increase) at 2 and 8 weeks post-transplantation as compared to parental F3 hNSCs. Brain transplantation of hNSCs overexpressing Akt1 in ICH animals provided functional recovery, and survival and differentiation of grafted hNSCs. These results indicate that the F3. Akt1 human NSCs should be a great value as a cellular source for the cellular therapy in animal models of human neurological disorders including ICH.			Lee, HJ (corresponding author), Univ British Columbia, Dept Med, Div Neurol, UBC Hosp, Vancouver, BC V6T 1W5, Canada.	sukim@interchange.ubc.ca						Brognard J, 2001, CANCER RES, V61, P3986; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cho T, 2002, NEUROREPORT, V13, P1447, DOI 10.1097/00001756-200208070-00020; Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161; Chu K, 2004, NEUROSCI RES, V50, P459, DOI 10.1016/j.neures.2004.08.015; Chu K, 2003, NEUROSCI LETT, V343, P129, DOI 10.1016/S0304-3940(03)00174-5; Chu K, 2004, BRAIN RES, V1016, P145, DOI 10.1016/j.brainres.2004.04.038; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Fukunaga K, 2003, J PHARMACOL SCI, V92, P317; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gebel JM, 2000, NEUROL CLIN, V18, P419, DOI 10.1016/S0733-8619(05)70200-0; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; HWANG DH, 2008, GENE THER IN PRESS; Ishibashi S, 2004, J NEUROSCI RES, V78, P215, DOI 10.1002/jnr.20246; Jeong SW, 2003, STROKE, V34, P2258, DOI 10.1161/01.STR.0000083698.20199.1F; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kim Hyungchul, 2006, Journal of Electrical Engineering & Technology, V1, P129; Kim Seung U., 2008, V438, P103, DOI 10.1007/978-1-59745-133-8_10; KIM SU, 1986, J NEUROSCI RES, V15, P303, DOI 10.1002/jnr.490150303; Kim SU, 2004, NEUROPATHOLOGY, V24, P159, DOI 10.1111/j.1440-1789.2004.00552.x; KIM SU, 1985, J NEUROIMMUNOL, V8, P255, DOI 10.1016/S0165-5728(85)80066-7; LEE HJ, 2007, PLOS ONE, V2, P1; Lee HJ, 2007, STEM CELLS, V25, P1204, DOI 10.1634/stemcells.2006-0409; Lee ST, 2008, BRAIN, V131, P616, DOI 10.1093/brain/awm306; Lee ST, 2005, NEUROSCI RES, V52, P243, DOI 10.1016/j.neures.2005.03.016; Lindvall O, 2006, NATURE, V441, P1094, DOI 10.1038/nature04960; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Meng XL, 2003, J NEUROSCI RES, V74, P266, DOI 10.1002/jnr.10764; Morgenstern LB, 2005, STROKE, V36, pE23, DOI 10.1161/01.STR.0000155685.77775.4c; Muller FJ, 2006, NAT REV NEUROSCI, V7, P75, DOI 10.1038/nrn1829; Rojo AI, 2004, J NEUROSCI, V24, P7324, DOI 10.1523/JNEUROSCI.2111-04.2004; Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201; Ryu JK, 2004, NEUROBIOL DIS, V16, P68, DOI 10.1016/j.nbd.2004.01.016; Ryu JK, 2003, J NEUROSCI RES, V72, P352, DOI 10.1002/jnr.10507; Salinas M, 2004, FEBS LETT, V578, P90, DOI 10.1016/j.febslet.2004.10.077; Taylor JM, 2005, J NEUROCHEM, V92, P283, DOI 10.1111/j.1471-4159.2004.02863.x; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200	43	58	61	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5586	10.1371/journal.pone.0005586	http://dx.doi.org/10.1371/journal.pone.0005586			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440551	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107500015
J	Murphy, AJ; Guyre, PM; Wira, CR; Pioli, PA				Murphy, Amy J.; Guyre, Paul M.; Wira, Charles R.; Pioli, Patricia A.			Estradiol Regulates Expression of Estrogen Receptor ER alpha 46 in Human Macrophages	PLOS ONE			English	Article								Background: Monocytes and macrophages are key innate immune effector cells that produce cytokines and chemokines upon activation. We and others have shown that 17 beta-estradiol (E2) has a direct role in the modulation of monocyte and macrophage immune function. However, relatively little is known about the ability of E2 to regulate isoform expression of estrogen receptors (ERs) in these cells. Methodology/Principal Findings: In this study, we quantify expression of ER alpha and ER beta in human monocytes and macrophages. We also show for the first time that the N-terminal truncated ER alpha variant, ER alpha 46, is expressed in both cell types. Promoter utilization studies reveal that transcription of ER alpha in both cell types occurs from upstream promoters E and F. Treatment with E2 induces ER alpha expression in macrophages but has no effect on ER beta levels in either cell type. During monocyte-to-macrophage differentiation, ER alpha is upregulated in a time-dependent manner. Previous studies by our group demonstrated that E2 treatment attenuates production of the chemokine CXCL8 in an ER-dependent manner. We now show that ER alpha expression levels parallel the ability of E2 to suppress CXCL8 production. Conclusions/Significance: This work demonstrates for the first time that human macrophages predominantly express the truncated ER variant ER alpha p46, which is estradiol-inducible. This is mediated through usage of the ER alpha F promoter. Alternative promoter usage may account for tissue and cell type-specific differences in estradiol-induced effects on gene expression. These studies signify the importance of ER alpha expression and regulation in the ability of E2 to modulate innate immune responses.			Murphy, AJ (corresponding author), Dartmouth Med Sch, Dept Physiol, Lebanon, NH USA.	pioli@dartmouth.edu			NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051547, P01AI051877] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007576] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA023108] Funding Source: Medline; NIAID NIH HHS [P01 AI051877, AI51877, R01 AI051547, AI051547] Funding Source: Medline; NIAMS NIH HHS [T32 AR007576, T32AR007576] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adeyemo O, 1993, Afr J Med Med Sci, V22, P55; Angele Martin K., 2006, Clinics, V61, P479, DOI 10.1590/S1807-59322006000500017; Ashcroft GS, 2003, J CLIN INVEST, V111, P1309, DOI 10.1172/KCO200316288; BAIRD DT, 1974, J ENDOCRINOL, V63, P201, DOI 10.1677/joe.0.0630201; Bouman A, 2005, HUM REPROD UPDATE, V11, P411, DOI 10.1093/humupd/dmi008; Calippe B, 2008, J IMMUNOL, V180, P7980, DOI 10.4049/jimmunol.180.12.7980; Castles CG, 1997, J STEROID BIOCHEM, V62, P155, DOI 10.1016/S0960-0760(97)00023-X; Chen JL, 1997, STEM CELLS, V15, P368, DOI 10.1002/stem.150368; Creekmore AL, 2007, MOL CELL ENDOCRINOL, V267, P106, DOI 10.1016/j.mce.2007.01.001; Cvoro A, 2006, MOL CELL, V21, P555, DOI 10.1016/j.molcel.2006.01.014; Denger S, 2001, MOL CELL ENDOCRINOL, V178, P155, DOI 10.1016/S0303-7207(01)00417-8; Denger S, 2001, MOL ENDOCRINOL, V15, P2064, DOI 10.1210/me.15.12.2064; Donaghue C, 1999, MOL ENDOCRINOL, V13, P1934, DOI 10.1210/me.13.11.1934; Edwards DP, 2005, ANNU REV PHYSIOL, V67, P335, DOI 10.1146/annurev.physiol.67.040403.120151; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; GIRARD MT, 1987, J IMMUNOL, V138, P3235; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Hersh D, 1998, CURR OPIN MICROBIOL, V1, P43, DOI 10.1016/S1369-5274(98)80141-0; Hsieh YC, 2007, AM J PHYSIOL-LUNG C, V292, pL1227, DOI 10.1152/ajplung.00479.2006; Jones RL, 2004, J CLIN ENDOCR METAB, V89, P6155, DOI 10.1210/jc.2004-0507; Kato S, 1999, JPN J CLIN ONCOL, V29, P321, DOI 10.1093/jjco/29.7.321; Khan KN, 2005, HUM REPROD, V20, P2004, DOI 10.1093/humrep/deh897; Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057; Kramer PR, 2002, J STEROID BIOCHEM, V81, P203, DOI 10.1016/S0960-0760(02)00065-1; Lambert KC, 2005, J IMMUNOL, V175, P5716, DOI 10.4049/jimmunol.175.9.5716; Lambert KC, 2004, J LEUKOCYTE BIOL, V75, P1166, DOI 10.1189/jlb.1103589; Lambertini E, 2003, BIOCHEM J, V372, P831, DOI 10.1042/BJ20021633; Lambertini E, 2008, J CELL PHYSIOL, V216, P101, DOI 10.1002/jcp.21379; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; MENTZER SJ, 1986, CELL IMMUNOL, V101, P312, DOI 10.1016/0008-8749(86)90144-9; Messingham KAN, 2001, J LEUKOCYTE BIOL, V70, P887; Metivier R, 2004, EMBO J, V23, P3653, DOI 10.1038/sj.emboj.7600377; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mor G, 2003, J IMMUNOL, V170, P114, DOI 10.4049/jimmunol.170.1.114; Nalbandian G, 2005, J IMMUNOL, V175, P2666, DOI 10.4049/jimmunol.175.4.2666; Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785; Naz RK, 1996, AM J REPROD IMMUNOL, V35, P534; Penot G, 2005, ENDOCRINOLOGY, V146, P5474, DOI 10.1210/en.2005-0866; Pioli PA, 2006, J IMMUNOL, V176, P6647, DOI 10.4049/jimmunol.176.11.6647; Pioli PA, 2007, J IMMUNOL, V179, P6284, DOI 10.4049/jimmunol.179.9.6284; Reid G, 2002, CELL MOL LIFE SCI, V59, P821, DOI 10.1007/s00018-002-8470-2; Robertson JA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290125; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; SARDA IR, 1976, AM J OBSTET GYNECOL, V124, P234, DOI 10.1016/0002-9378(76)90149-6; SHEN L, 1986, CLIN EXP IMMUNOL, V65, P387; Soriano D, 2003, FERTIL STERIL, V79, P975, DOI 10.1016/S0015-0282(02)04853-7; Stevens TA, 2006, ONCOGENE, V25, P5426, DOI 10.1038/sj.onc.1209529; Stossi F, 2004, ENDOCRINOLOGY, V145, P3473, DOI 10.1210/en.2003-1682; Suzuki T, 2008, J CELL PHYSIOL, V214, P662, DOI 10.1002/jcp.21255; Suzuki T, 2007, AM J PHYSIOL-CELL PH, V293, pC978, DOI 10.1152/ajpcell.00092.2007; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; THIJSSEN JHH, 1984, J STEROID BIOCHEM, V20, P955, DOI 10.1016/0022-4731(84)90003-7; Treilleux I, 1997, MOL ENDOCRINOL, V11, P1319, DOI 10.1210/me.11.9.1319; Vegeto E, 2001, J NEUROSCI, V21, P1809, DOI 10.1523/JNEUROSCI.21-06-01809.2001; Wang H, 2005, INT J BIOL MACROMOL, V36, P66, DOI 10.1016/j.ijbiomac.2005.03.011; Wang ZY, 2006, P NATL ACAD SCI USA, V103, P9063, DOI 10.1073/pnas.0603339103; ZHANG B, 2005, COMPUTER ENG APPL, V6, P7; Zhao Chunyan, 2008, Nucl Recept Signal, V6, pe003, DOI 10.1621/nrs.06003	58	106	110	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5539	10.1371/journal.pone.0005539	http://dx.doi.org/10.1371/journal.pone.0005539			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440537	gold, Green Published, Green Submitted			2022-12-25	WOS:000266107500001
J	Banavali, NK; MacKerell, AD				Banavali, Nilesh K.; MacKerell, Alexander D., Jr.			Characterizing Structural Transitions Using Localized Free Energy Landscape Analysis	PLOS ONE			English	Article								Background: Structural changes in molecules are frequently observed during biological processes like replication, transcription and translation. These structural changes can usually be traced to specific distortions in the backbones of the macromolecules involved. Quantitative energetic characterization of such distortions can greatly advance the atomic-level understanding of the dynamic character of these biological processes. Methodology/Principal Findings: Molecular dynamics simulations combined with a variation of the Weighted Histogram Analysis Method for potential of mean force determination are applied to characterize localized structural changes for the test case of cytosine (underlined) base flipping in a GTCAG (C) under bar GCATGG DNA duplex. Free energy landscapes for backbone torsion and sugar pucker degrees of freedom in the DNA are used to understand their behavior in response to the base flipping perturbation. By simplifying the base flipping structural change into a two-state model, a free energy difference of upto 14 kcal/mol can be attributed to the flipped state relative to the stacked Watson-Crick base paired state. This two-state classification allows precise evaluation of the effect of base flipping on local backbone degrees of freedom. Conclusions/Significance: The calculated free energy landscapes of individual backbone and sugar degrees of freedom expectedly show the greatest change in the vicinity of the flipping base itself, but specific delocalized effects can be discerned upto four nucleotide positions away in both 59 and 39 directions. Free energy landscape analysis thus provides a quantitative method to pinpoint the determinants of structural change on the atomic scale and also delineate the extent of propagation of the perturbation along the molecule. In addition to nucleic acids, this methodology is anticipated to be useful for studying conformational changes in all macromolecules, including carbohydrates, lipids, and proteins.			Banavali, NK (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Div Genet, Lab Computat & Struct Biol, Albany, NY 12237 USA.	banavali@wadsworth.org; alex@outerbanks.umaryland.edu	MacKerell, Alex/Y-2469-2019; MacKerell, Alex/AAA-2560-2020	MacKerell, Alex/0000-0001-8287-6804; Banavali, Nilesh/0000-0003-2206-7049	NIGMS NIH HHS [R01 GM051501, GM51501, R29 GM051501] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051501, R01GM051501] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; Banavali NK, 2006, J PHYS CHEM B, V110, P10997, DOI 10.1021/jp0561322; Banavali NK, 2005, J AM CHEM SOC, V127, P6866, DOI 10.1021/ja050482k; Banavali NK, 2002, J MOL BIOL, V319, P141, DOI 10.1016/S0022-2836(02)00194-8; BEGLOV D, 1994, J CHEM PHYS, V98, P10089; Bernard D, 2007, J MED CHEM, V50, P1799, DOI 10.1021/jm0612463; Bolhuis PG, 2002, ANNU REV PHYS CHEM, V53, P291, DOI 10.1146/annurev.physchem.53.082301.113146; BROOKS BR, 1983, J COMPUT CHEM, V21, P105; Chene P, 2008, DRUG DISCOV TODAY, V13, P522, DOI 10.1016/j.drudis.2008.03.023; Chipot C, 2002, MOL SIMULAT, V28, P1, DOI 10.1080/08927020211974; Crouzy S, 1999, J COMPUT CHEM, V20, P1644, DOI 10.1002/(SICI)1096-987X(19991130)20:15<1644::AID-JCC5>3.0.CO;2-Y; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Dickerson RE, 1998, NUCLEIC ACIDS RES, V26, P1906, DOI 10.1093/nar/26.8.1906; Duderstadt KE, 2008, CRIT REV BIOCHEM MOL, V43, P163, DOI [10.1080/10409230802058296, 10.1080/10409230802058296 ]; Edgell DR, 2003, CURR BIOL, V13, P973, DOI 10.1016/S0960-9822(03)00340-3; FELLER SE, 1995, J CHEM PHYS, V103, P4613, DOI 10.1063/1.470648; Foloppe N, 1999, J PHYS CHEM B, V103, P10955, DOI 10.1021/jp992716q; Foloppe N, 1998, J PHYS CHEM B, V102, P6669, DOI 10.1021/jp9818683; Foster MP, 2007, BIOCHEMISTRY-US, V46, P331, DOI 10.1021/bi0621314; Gelbin A, 1996, J AM CHEM SOC, V118, P519, DOI 10.1021/ja9528846; Gross JD, 2003, CELL, V115, P739, DOI 10.1016/S0092-8674(03)00975-9; Gu B, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.088104; GUERON M, 1987, NATURE, V328, P89, DOI 10.1038/328089a0; Harrison SC, 2004, NAT STRUCT MOL BIOL, V11, P12, DOI 10.1038/nsmb0104-12; Horton JR, 2004, NUCLEIC ACIDS RES, V32, P3877, DOI 10.1093/nar/gkh701; Huang N, 2004, PHILOS T R SOC A, V362, P1439, DOI 10.1098/rsta.2004.1383; Huang N, 2003, P NATL ACAD SCI USA, V100, P68, DOI 10.1073/pnas.0135427100; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KUMAR S, 1992, J COMPUT CHEM, V13, P1011, DOI 10.1002/jcc.540130812; LEROY JL, 1988, J MOL BIOL, V200, P223, DOI 10.1016/0022-2836(88)90236-7; Lu XJ, 2003, NUCLEIC ACIDS RES, V31, P5108, DOI 10.1093/nar/gkg680; MacKerell AD, 2000, J COMPUT CHEM, V21, P105, DOI 10.1002/(SICI)1096-987X(20000130)21:2<105::AID-JCC3>3.0.CO;2-P; MacKerell AD, 2001, BIOPOLYMERS, V56, P257; Marquez VE, 2004, J AM CHEM SOC, V126, P543, DOI 10.1021/ja037929e; Mol CD, 2000, MUTAT RES-DNA REPAIR, V460, P211, DOI 10.1016/S0921-8777(00)00028-8; Olson WK, 2001, J MOL BIOL, V313, P229, DOI 10.1006/jmbi.2001.4987; Priyakumar UD, 2006, CHEM REV, V106, P489, DOI 10.1021/cr040475z; Priyakumar UD, 2006, J CHEM THEORY COMPUT, V2, P187, DOI 10.1021/ct0501957; Priyakumar UD, 2006, J AM CHEM SOC, V128, P678, DOI 10.1021/ja056445a; Rauch C, 2003, J AM CHEM SOC, V125, P14990, DOI 10.1021/ja037218g; Saenger W., 1984, PRINCIPLES NUCL ACID; Schneider B, 1997, BIOPOLYMERS, V42, P113, DOI 10.1002/(SICI)1097-0282(199707)42:1<113::AID-BIP10>3.0.CO;2-O; Schneider TD, 2001, NUCLEIC ACIDS RES, V29, P4881, DOI 10.1093/nar/29.23.4881; Schuler B, 2008, CURR OPIN STRUC BIOL, V18, P16, DOI 10.1016/j.sbi.2007.12.003; Sidorova NY, 2004, BIOPHYS J, V87, P2564, DOI 10.1529/biophysj.104.042390; Souaille M, 2001, COMPUT PHYS COMMUN, V135, P40, DOI 10.1016/S0010-4655(00)00215-0; Stivers JT, 2004, PROG NUCLEIC ACID RE, V77, P37, DOI 10.1016/S0079-6603(04)77002-6; TORRIE GM, 1977, J COMPUT PHYS, V23, P187, DOI 10.1016/0021-9991(77)90121-8; Varnai P, 2004, J AM CHEM SOC, V126, P14659, DOI 10.1021/ja0470721; Varnai P, 2002, NUCLEIC ACIDS RES, V30, P5398, DOI 10.1093/nar/gkf680; Varnai P, 2002, J AM CHEM SOC, V124, P7272, DOI 10.1021/ja025980x; Wang PY, 2000, J AM CHEM SOC, V122, P12422, DOI 10.1021/ja001989s; Wery JP, 1997, CURR OPIN CHEM BIOL, V1, P365, DOI 10.1016/S1367-5931(97)80075-0	54	7	7	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5525	10.1371/journal.pone.0005525	http://dx.doi.org/10.1371/journal.pone.0005525			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444WA	19436759	Green Published, Green Submitted, gold			2022-12-25	WOS:000266009900017
J	Sadagopal, S; Braunstein, M; Hager, CC; Wei, J; Daniel, AK; Bochan, MR; Crozier, I; Smith, NE; Gates, HO; Barnett, L; Van Kaer, L; Price, JO; Blackwell, TS; Kalams, SA; Kernodle, DS				Sadagopal, Shanmugalakshmi; Braunstein, Miriam; Hager, Cynthia C.; Wei, Jie; Daniel, Alexandria K.; Bochan, Markian R.; Crozier, Ian; Smith, Nathaniel E.; Gates, Hiriam O.; Barnett, Louise; Van Kaer, Luc; Price, James O.; Blackwell, Timothy S.; Kalams, Spyros A.; Kernodle, Douglas S.			Reducing the Activity and Secretion of Microbial Antioxidants Enhances the Immunogenicity of BCG	PLOS ONE			English	Article							BACILLUS-CALMETTE-GUERIN; MYCOBACTERIUM-TUBERCULOSIS INFECTION; CHRONIC GRANULOMATOUS-DISEASE; ALTERNATIVE SIGMA-FACTOR; CD8(+) T-CELLS; SUPEROXIDE-DISMUTASE; COMPARATIVE GENOMICS; ADAPTIVE IMMUNITY; ESCHERICHIA-COLI; VACCINE EFFICACY	Background: In early clinical studies, the live tuberculosis vaccine Mycobacterium bovis BCG exhibited 80% protective efficacy against pulmonary tuberculosis ( TB). Although BCG still exhibits reliable protection against TB meningitis and miliary TB in early childhood it has become less reliable in protecting against pulmonary TB. During decades of in vitro cultivation BCG not only lost some genes due to deletions of regions of the chromosome but also underwent gene duplication and other mutations resulting in increased antioxidant production. Methodology/Principal Findings: To determine whether microbial antioxidants influence vaccine immunogenicity, we eliminated duplicated alleles encoding the oxidative stress sigma factor SigH in BCG Tice and reduced the activity and secretion of iron co-factored superoxide dismutase. We then used assays of gene expression and flow cytometry with intracellular cytokine staining to compare BCG-specific immune responses in mice after vaccination with BCG Tice or the modified BCG vaccine. Compared to BCG, the modified vaccine induced greater IL-12p40, RANTES, and IL-21 mRNA in the spleens of mice at three days post-immunization, more cytokine-producing CD8+ lymphocytes at the peak of the primary immune response, and more IL-2-producing CD4+ lymphocytes during the memory phase. The modified vaccine also induced stronger secondary CD4+ lymphocyte responses and greater clearance of challenge bacilli. Conclusions/Significance: We conclude that antioxidants produced by BCG suppress host immune responses. These findings challenge the hypothesis that the failure of extensively cultivated BCG vaccines to prevent pulmonary tuberculosis is due to over-attenuation and suggest instead a new model in which BCG evolved to produce more immunity-suppressing antioxidants. By targeting these antioxidants it may be possible to restore BCG's ability to protect against pulmonary TB.			Sadagopal, S (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37235 USA.	doug.kernodle@vanderbilt.edu	Van Kaer, Luc/H-1033-2015	Van Kaer, Luc/0000-0001-5275-2309	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057157, T32AI007474, P30AI054999, R21AI051561, R01AI054540, R01AI051561] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-68518, R01 HL068518] Funding Source: Medline; NIAID NIH HHS [R21 AI051561, P30 AI-54999, AI-54540, U54 AI057157, P30 AI054999, AI-51561, R01 AI054540, T32 AI-007474, T32 AI007474, R01 AI051561, U54 AI 057157] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akhtar P, 2006, MICROBES INFECT, V8, P2855, DOI 10.1016/j.micinf.2006.09.004; ALAM MS, 2008, FEBS J; Allard EL, 2007, EUR J IMMUNOL, V37, P3069, DOI 10.1002/eji.200637017; Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211; ARONSON JD, 1958, ARCH INTERN MED, V101, P881, DOI 10.1001/archinte.1958.00260170037006; ARONSON JD, 1950, AM J PUBLIC HLTH, V40, P533; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Behr MA, 1997, NATURE, V389, P133, DOI 10.1038/38151; Bjartveit K, 2003, INT J TUBERC LUNG D, V7, P306; Blattman JN, 2003, NAT MED, V9, P540, DOI 10.1038/nm866; Brandau S, 2007, BIOMED PHARMACOTHER, V61, P299, DOI 10.1016/j.biopha.2007.05.004; Braunstein M, 2003, MOL MICROBIOL, V48, P453, DOI 10.1046/j.1365-2958.2003.03438.x; Braunstein M, 2002, METHOD ENZYMOL, V358, P67; Brosch R, 2000, YEAST, V17, P111, DOI 10.1002/1097-0061(20000630)17:2<111::AID-YEA17>3.0.CO;2-G; Brosch R, 2007, P NATL ACAD SCI USA, V104, P5596, DOI 10.1073/pnas.0700869104; BUNCHCHR.K, 1970, B WORLD HEALTH ORGAN, V43, P65; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; Carranza C, 2006, AM J RESP CRIT CARE, V173, P238, DOI 10.1164/rccm.200503-411OC; Chu SF, 2007, GENES IMMUN, V8, P475, DOI 10.1038/sj.gene.6364412; COLLINS FM, 1980, IMMUNOLOGY, V40, P529; COMSTOCK GW, 1988, AM REV RESPIR DIS, V138, P479, DOI 10.1164/ajrccm/138.2.479; COMSTOCK GW, 1994, EPIDEMIOL REV, V16, P77, DOI 10.1093/oxfordjournals.epirev.a036147; Comstock GW, 2000, CLIN INFECT DIS, V30, pS250, DOI 10.1086/313870; COOPER JB, 1995, J MOL BIOL, V246, P531, DOI 10.1006/jmbi.1994.0105; Corthay A, 2006, SCAND J IMMUNOL, V64, P93, DOI 10.1111/j.1365-3083.2006.01782.x; Davids V, 2006, J INFECT DIS, V193, P531, DOI 10.1086/499825; DUBOS R J, 1956, Am Rev Tuberc, V74, P683; DUBOS RJ, 1956, AM REV TUBERC PULM, V74, P699; DUBOS RJ, 1957, AM REV TUBERC PULM, V75, P692; Edwards KM, 2001, AM J RESP CRIT CARE, V164, P2213, DOI 10.1164/ajrccm.164.12.2106093; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; Filipe-Santos O, 2006, SEMIN IMMUNOL, V18, P347, DOI 10.1016/j.smim.2006.07.010; Forman HJ, 2001, IUBMB LIFE, V51, P365; FRIMODTMOLLER J, 1968, INDIAN J TUBERC, V15, P40; Gagliardi MC, 2005, J LEUKOCYTE BIOL, V78, P106, DOI 10.1189/jlb.0105037; Graham JE, 1999, P NATL ACAD SCI USA, V96, P11554, DOI 10.1073/pnas.96.20.11554; HART PD, 1977, BRIT MED J, V2, P293, DOI 10.1136/bmj.2.6082.293; HASUI M, 1993, J INFECT DIS, V167, P983, DOI 10.1093/infdis/167.4.983; HEIJNEN CJ, 1986, CLIN EXP IMMUNOL, V66, P111; Herr HW, 2008, J UROLOGY, V179, P53, DOI 10.1016/j.juro.2007.08.122; Hervas-Stubbs S, 2006, INFECT IMMUN, V74, P3396, DOI 10.1128/IAI.02086-05; Hinchey J, 2007, J CLIN INVEST, V117, P2279, DOI 10.1172/JCI31947; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horwitz MA, 2009, VACCINE, V27, P441, DOI 10.1016/j.vaccine.2008.10.058; IRVINE KN, 1949, BCG VACCINATION THEO; Jaeger T, 2004, ARCH BIOCHEM BIOPHYS, V423, P182, DOI 10.1016/j.abb.2003.11.021; Kamath AB, 2005, INFECT IMMUN, V73, P6110, DOI 10.1128/IAI.73.9.6110-6118.2005; Kamath A, 2006, J IMMUNOL, V177, P6361, DOI 10.4049/jimmunol.177.9.6361; Kantengwa S, 2003, AM J RESP CRIT CARE, V167, P431, DOI 10.1164/rccm.200205-425OC; Kaushal D, 2002, P NATL ACAD SCI USA, V99, P8330, DOI 10.1073/pnas.102055799; Kremer L, 1997, EUR J IMMUNOL, V27, P2450, DOI 10.1002/eji.1830270945; LADEFOGED A, 1976, B WORLD HEALTH ORGAN, V53, P435; LADEFOGED A, 1970, B WORLD HEALTH ORGAN, V43, P71; Lagranderie MRR, 1996, INFECT IMMUN, V64, P1; Lakey DL, 2000, INFECT IMMUN, V68, P233, DOI 10.1128/IAI.68.1.233-238.2000; Luther SA, 2001, NAT IMMUNOL, V2, P102, DOI 10.1038/84205; Mahomed H, 2006, PEDIATR INFECT DIS J, V25, P1167, DOI 10.1097/01.inf.0000243765.33880.54; Mak TK, 2008, LANCET, V372, P786, DOI 10.1016/S0140-6736(08)61318-5; Manganelli R, 2002, MOL MICROBIOL, V45, P365, DOI 10.1046/j.1365-2958.2002.03005.x; Mostowy S, 2003, VACCINE, V21, P4270, DOI 10.1016/S0264-410X(03)00484-5; Ng VH, 2004, MOL MICROBIOL, V52, P1291, DOI 10.1111/j.1365-2958.2004.04078.x; Oettinger T., 1999, Tubercle and Lung Disease, V79, P243, DOI 10.1054/tuld.1999.0206; Olsen AW, 2004, SCAND J IMMUNOL, V60, P273, DOI 10.1111/j.0300-9475.2004.01471.x; Raman S, 2001, J BACTERIOL, V183, P6119, DOI 10.1128/JB.183.20.6119-6125.2001; Romani L, 2008, NATURE, V451, P211, DOI 10.1038/nature06471; Saunders BM, 2002, CELL IMMUNOL, V216, P65, DOI 10.1016/S0008-8749(02)00510-5; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; SHER NA, 1973, INFECT IMMUN, V8, P736, DOI 10.1128/IAI.8.5.736-742.1973; Skeiky YAW, 2006, NAT REV MICROBIOL, V4, P469, DOI 10.1038/nrmicro1419; SUTER WE, 1951, J EXP MED, V93, P559, DOI 10.1084/jem.93.6.559; TENDAM HG, 1993, TUBERCULOSIS COMPREH, P251; Tree JA, 2004, CLIN EXP IMMUNOL, V138, P405, DOI 10.1111/j.1365-2249.2004.02648.x; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Tuberculosis Prevention Trial, 1979, B WORLD HEALTH ORGAN, V57, P819; van der Veen RC, 2004, J NEUROIMMUNOL, V153, P183, DOI 10.1016/j.jneuroim.2004.05.008; Via LE, 1997, J BIOL CHEM, V272, P13326, DOI 10.1074/jbc.272.20.13326; Vogelzang A, 2008, IMMUNITY, V29, P127, DOI 10.1016/j.immuni.2008.06.001; Whitmire JK, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000041; Wilkinson RJ, 1998, IMMUNOLOGY, V95, P585, DOI 10.1046/j.1365-2567.1998.00648.x; Williams MA, 2006, NATURE, V441, P890, DOI 10.1038/nature04790; Wilson T, 1998, MICROBIOL-UK, V144, P2687, DOI 10.1099/00221287-144-10-2687; Wojciechowski W, 1999, J IMMUNOL, V163, P2688; World Health Organization, 2008, GLOB TUB CONTR SURV; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488; [No title captured]	85	37	45	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5531	10.1371/journal.pone.0005531	http://dx.doi.org/10.1371/journal.pone.0005531			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444WA	19436730	Green Published, gold, Green Submitted			2022-12-25	WOS:000266009900022
J	Xilouri, M; Vogiatzi, T; Vekrellis, K; Park, D; Stefanis, L				Xilouri, Maria; Vogiatzi, Tereza; Vekrellis, Kostas; Park, David; Stefanis, Leonidas			Abberant alpha-Synuclein Confers Toxicity to Neurons in Part through Inhibition of Chaperone-Mediated Autophagy	PLOS ONE			English	Article								Background: The mechanisms through which aberrant alpha-synuclein (ASYN) leads to neuronal death in Parkinson's disease (PD) are uncertain. In isolated liver lysosomes, mutant ASYNs impair Chaperone Mediated Autophagy (CMA), a targeted lysosomal degradation pathway; however, whether this occurs in a cellular context, and whether it mediates ASYN toxicity, is unknown. We have investigated presently the effects of WT or mutant ASYN on the lysosomal pathways of CMA and macroautophagy in neuronal cells and assessed their impact on ASYN-mediated toxicity. Methods and Findings: Novel inducible SH-SY5Y and PC12 cell lines expressing human WT and A53T ASYN, as well as two mutant forms that lack the CMA-targeting motif were generated. Such forms were also expressed in primary cortical neurons, using adenoviral transduction. In each case, effects on long-lived protein degradation, LC3 II levels (as a macroautophagy index), and cell death and survival were assessed. In both PC12 and SH-SY5Y cycling cells, induction of A53T ASYN evoked a significant decrease in lysosomal degradation, largely due to CMA impairment. In neuronally differentiated SH-SH5Y cells, both WT and A53T ASYN induction resulted in gradual toxicity, which was partly dependent on CMA impairment and compensatory macroautophagy induction. In primary neurons both WT and A53T ASYN were toxic, but only in the case of A53T ASYN did CMA dysfunction and compensatory macroautophagy induction occur and participate in death. Conclusions: Expression of mutant A53T, and, in some cases, WT ASYN in neuronal cells leads to CMA dysfunction, and this in turn leads to compensatory induction of macroautophagy. Inhibition of these lysosomal effects mitigates ASYN toxicity. Therefore, CMA dysfunction mediates aberrant ASYN toxicity, and may be a target for therapeutic intervention in PD and related disorders. Furthermore, macroautophagy induction in the context of ASYN over-expression, in contrast to other settings, appears to be a detrimental response, leading to neuronal death.			Xilouri, M (corresponding author), Acad Athens, Biomed Res Fdn, Div Basic Neurosci, Athens, Greece.	lstefanis@bioacademy.gr	Stefanis, Leonidas/AAD-7192-2019	Park, David/0000-0002-4490-3784; Xilouri, Maria/0000-0001-7038-0780	NINDS NIH HHS [R21 NS055693] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS055693] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Burke WJ, 2003, CNS NEUROL DISORD-DR, V2, P143, DOI 10.2174/1568007033482913; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Cherra SJ, 2008, FUTUR NEUROL, V3, P309, DOI 10.2217/14796708.3.3.309; Chu YP, 2007, NEUROBIOL DIS, V25, P134, DOI 10.1016/j.nbd.2006.08.021; Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751; Cooper AA, 2006, SCIENCE, V313, P324, DOI 10.1126/science.1129462; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dietrich P, 2003, MOL CELL NEUROSCI, V24, P430, DOI 10.1016/S1044-7431(03)00201-X; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; EMMANOUILIDOU E, 2008, NEUROBIOL AGING; Farinelli SE, 1998, J NEUROSCI, V18, P5112, DOI 10.1523/JNEUROSCI.18-14-05112.1998; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; KIM C, 2008, J NEUROCHEM; Kirik D, 2002, J NEUROSCI, V22, P2780, DOI 10.1523/JNEUROSCI.22-07-02780.2002; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kourtis N, 2009, CELL DEATH DIFFER, V16, P21, DOI 10.1038/cdd.2008.120; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Ling DJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004201; Lo BC, 2002, P NATL ACAD SCI USA, V99, P10813; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; Maguire-Zeiss KA, 2005, MOL BRAIN RES, V134, P18, DOI 10.1016/j.molbrainres.2004.09.014; Majeski AE, 2004, INT J BIOCHEM CELL B, V36, P2435, DOI 10.1016/j.biocel.2004.02.013; Maraganore DM, 2006, JAMA-J AM MED ASSOC, V296, P661, DOI 10.1001/jama.296.6.661; Martinez-Vicente M, 2008, J CLIN INVEST, V118, P777, DOI 10.1172/JCI32806; Massey A, 2004, INT J BIOCHEM CELL B, V36, P2420, DOI 10.1016/j.biocel.2004.04.010; Massey AC, 2006, P NATL ACAD SCI USA, V103, P5805, DOI 10.1073/pnas.0507436103; Mosharov EV, 2006, J NEUROSCI, V26, P9304, DOI 10.1523/JNEUROSCI.0519-06.2006; Nixon RA, 2006, TRENDS NEUROSCI, V29, P528, DOI 10.1016/j.tins.2006.07.003; Nixon RA, 2006, J ALZHEIMERS DIS, V9, P277; Norris EH, 2005, J BIOL CHEM, V280, P21212, DOI 10.1074/jbc.M412621200; Pandey UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853; Periquet M, 2007, J NEUROSCI, V27, P3338, DOI 10.1523/JNEUROSCI.0285-07.2007; Plowey ED, 2008, J NEUROCHEM, V105, P1048, DOI 10.1111/j.1471-4159.2008.05217.x; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Rideout HJ, 2002, MOL CELL NEUROSCI, V21, P223, DOI 10.1006/mcne.2002.1173; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Saha AR, 2004, J CELL SCI, V117, P1017, DOI 10.1242/jcs.00967; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stefanis L, 1997, J NEUROCHEM, V69, P1425; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Stefanis L, 1999, J NEUROSCI, V19, P6235; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Vekrellis K, 2004, MOL NEUROBIOL, V30, P1, DOI 10.1385/MN:30:1:001; Vogiatzi T, 2008, J BIOL CHEM, V283, P23542, DOI 10.1074/jbc.M801992200; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Winslow AR, 2008, BBA-MOL BASIS DIS, V1782, P723, DOI 10.1016/j.bbadis.2008.06.010; Yang Q, 2009, SCIENCE, V323, P124, DOI 10.1126/science.1166088; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhu JH, 2007, AM J PATHOL, V170, P75, DOI 10.2353/ajpath.2007.060524	64	263	271	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5515	10.1371/journal.pone.0005515	http://dx.doi.org/10.1371/journal.pone.0005515			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444WA	19436756	gold, Green Submitted, Green Published			2022-12-25	WOS:000266009900008
J	Izzotti, A; Calin, GA; Steele, VE; Croce, CM; De Flora, S				Izzotti, Alberto; Calin, George A.; Steele, Vernon E.; Croce, Carlo M.; De Flora, Silvio			Relationships of microRNA expression in mouse lung with age and exposure to cigarette smoke and light	FASEB JOURNAL			English	Article						lung cancer; molecular mechanisms	CANCER CHEMOPREVENTIVE AGENTS; GENE-EXPRESSION; RESPIRATORY-TRACT; MICE; MODULATION; TUMORS; RATS; TRANSCRIPTOME; POLYMORPHISM; APOPTOSIS	MicroRNAs provide a formidable tool not only in cancer research but also to investigate physiological mechanisms and to assess the effect of environmental exposures in healthy tissues. Collectively, cigarette smoke and sunlight have been estimated to account for 40% of all human cancers, and not only smoke but also, surprisingly, UV light induced genomic and postgenomic alterations in mouse lung. Here we evaluated by microarray the expression of 484 microRNAs in the lungs of CD-1 mice, including new-borns, postweanling males and females, and their dams, either untreated or exposed to environmental cigarette smoke and/or UV-containing light. The results obtained highlighted age-related variations in microRNA profiles, especially during the weanling period, due to perinatal stress and postnatal maturation of the lung. UV light alone did not affect pulmonary microRNAs, whereas smoke produced dramatic changes, mostly in the sense of down-regulation, reflecting both adaptive mechanisms and activation of pathways involved in the pathogenesis of pulmonary diseases. Both gender and age affected smoke-related microRNA dysregulation in mice. The data presented provide supporting evidence that microRNAs play a fundamental role in both physiological and pathological changes occurring in mouse lung.-Izzotti, A., Calin, G. A., Vernon E. St., Croce, G. M., De Flora, S. Relationships of microRNA expression in mouse lung with age and exposure to cigarette smoke and light. FASEB J. 23, 3243-3250 ( 2009). www.fasebj.org	[Izzotti, Alberto; De Flora, Silvio] Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy; [Calin, George A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Steele, Vernon E.] NCI, Rockville, MD USA; [Croce, Carlo M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University of Genoa; University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	De Flora, S (corresponding author), Univ Genoa, Dept Hlth Sci, Via A Pastore 1, I-16132 Genoa, Italy.	sdf@unige.it	Calin, George/E-9390-2011; Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Calin, George/0000-0001-6704-5615; izzotti, alberto/0000-0002-8588-0347	National Cancer Institute [N01-CN 53301]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the National Cancer Institute ( contract N01-CN 53301).	Balansky RM, 2003, CARCINOGENESIS, V24, P1525, DOI 10.1093/carcin/bgg108; Balansky R, 2007, CARCINOGENESIS, V28, P2236, DOI 10.1093/carcin/bgm122; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bonner AE, 2004, ONCOGENE, V23, P1166, DOI 10.1038/sj.onc.1207234; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Couzin J, 2008, SCIENCE, V319, P1782, DOI 10.1126/science.319.5871.1782; D'Agostini F, 2005, MUTAT RES-FUND MOL M, V591, P173, DOI 10.1016/j.mrfmmm.2005.03.034; D'Agostini F, 2001, CARCINOGENESIS, V22, P375, DOI 10.1093/carcin/22.3.375; DAVIS WB, LUNG SCI FDN, P1821; De Flora S, 2003, CANCER RES, V63, P793; De Flora S, 2008, MUTAT RES-REV MUTAT, V659, P137, DOI 10.1016/j.mrrev.2007.11.004; De Flora S, 2007, CANCER RES, V67, P1001, DOI 10.1158/0008-5472.CAN-06-3882; DEFLORA S, 1989, CARCINOGENESIS, V10, P1089, DOI 10.1093/carcin/10.6.1089; Duan RH, 2007, HUM MOL GENET, V16, P1124, DOI 10.1093/hmg/ddm062; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; HIGGINSON J, 1979, JNCI-J NATL CANCER I, V63, P1291; Izzotti A, 2005, MUTAT RES-FUND MOL M, V591, P212, DOI 10.1016/j.mrfmmm.2005.03.032; Izzotti A, 2005, EUR J CANCER, V41, P1864, DOI 10.1016/j.ejca.2005.04.011; Izzotti A, 2004, CANCER RES, V64, P8566, DOI 10.1158/0008-5472.CAN-04-1420; Izzotti A, 2004, FASEB J, V18, P1559, DOI 10.1096/fj.04-1877fje; Izzotti A, 2003, MUTAT RES-REV MUTAT, V544, P441, DOI 10.1016/j.mrrev.2003.05.004; Izzotti A, 2007, CARCINOGENESIS, V28, P892, DOI 10.1093/carcin/bgl208; Izzotti A, 2009, FASEB J, V23, P806, DOI 10.1096/fj.08-121384; Jay C, 2007, DNA CELL BIOL, V26, P293, DOI 10.1089/dna.2006.0554; Kalscheuer S, 2008, CARCINOGENESIS, V29, P2394, DOI 10.1093/carcin/bgn209; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Liu X, 2009, CLIN CANCER RES, V15, P1177, DOI 10.1158/1078-0432.CCR-08-1355; Saunders MA, 2007, P NATL ACAD SCI USA, V104, P3300, DOI 10.1073/pnas.0611347104; Schembri F, 2009, P NATL ACAD SCI USA, V106, P2319, DOI 10.1073/pnas.0806383106; Spira A, 2004, P NATL ACAD SCI USA, V101, P10143, DOI 10.1073/pnas.0401422101; Williams AE, 2008, CELL MOL LIFE SCI, V65, P545, DOI 10.1007/s00018-007-7355-9; Williams AE, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-172; Yao RS, 2005, EXP LUNG RES, V31, P271, DOI 10.1080/0190214059090386	34	128	139	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3243	3250		10.1096/fj.09-135251	http://dx.doi.org/10.1096/fj.09-135251			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19465468	Green Published			2022-12-25	WOS:000270241000046
J	Trottier, C; Colombo, M; Mann, KK; Miller, WH; Ward, BJ				Trottier, Claire; Colombo, Myrian; Mann, Koren K.; Miller, Wilson H., Jr.; Ward, Brian J.			Retinoids inhibit measles virus through a type I IFN-dependent bystander effect	FASEB JOURNAL			English	Article						Vitamin A; paramyxovirus; all-trans retinoic acid	ACID-INDUCED DIFFERENTIATION; VITAMIN-A SUPPLEMENTATION; V-PROTEIN; SIGNALING PATHWAY; STAT PROTEIN; C-PROTEIN; INTERFERON; EXPRESSION; INFECTION; CELLS	Measles-associated mortality can be decreased in response to treatment with vitamin A. Our goal was to understand the mechanism by which vitamin A and other retinoids reduce measles virus (MeV) replication in vitro. MeV is known to inhibit type I interferon (IFN) signaling, and retinoids are increasingly implicated in modulating innate immunity. Type I IFN blocking antibodies abrogated the inhibitory effects of all-trans retinoic acid ( ATRA) on MeV replication (EC50 of ATRA: 3.17x10(-8) M). IFN-stimulated genes (ISGs) are up-regulated by ATRA in MeV-infected U937 cell cultures starting at 12 h and reaching a plateau at 24 h postinfection when compared to either treatment or infection alone. We found that this increased gene expression occurs in uninfected cells by using a transwell system where the uninfected cells were separated from infected cells by a membrane with 0.02-mu M pores. Uninfected bystander cells from the ATRA-treated transwells did not support substantial viral replication when subsequently infected with MeV. In the absence of ATRA, the cells from the uninfected chamber did not up-regulate ISG expression and were not protected from subsequent challenge with virus. These results demonstrate that retinoids inhibit MeV replication by up-regulating elements of the innate immune response in uninfected bystander cells, making them refractory to productive infection during subsequent rounds of viral replication.-Trottier, C., Colombo, M., Mann, K. K., Miller, W. H., Jr., Ward, B. J. Retinoids inhibit measles virus through a type I IFN-dependent bystander effect. FASEB J. 23, 3203-3212 ( 2009). www.fasebj.org	[Trottier, Claire; Ward, Brian J.] McGill Univ, Ctr Hlth, Res Inst, Dept Infect Dis, Montreal, PQ, Canada; [Trottier, Claire; Colombo, Myrian; Mann, Koren K.; Miller, Wilson H., Jr.] McGill Univ, Lady Davis Inst Med Res, Segal Canc Ctr, SMBD Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada	McGill University; Lady Davis Institute; McGill University	Ward, BJ (corresponding author), Montreal Gen Hosp, Res Inst, L10-309,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	wmiller@ldi.jgh.mcgill.ca; brian.ward@mcgill.ca						Benn CS, 2005, BMJ-BRIT MED J, V331, P1428, DOI 10.1136/bmj.38670.639340.55; Bocher WO, 2008, LIVER INT, V28, P347, DOI 10.1111/j.1478-3231.2007.01666.x; Caignard G, 2007, VIROLOGY, V368, P351, DOI 10.1016/j.virol.2007.06.037; Centers for Disease Control and Prevention (CDC), 2007, MMWR Morb Mortal Wkly Rep, V56, P1237; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; Chen QY, 2002, IMMUNOLOGY, V107, P199, DOI 10.1046/j.1365-2567.2002.01485.x; Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003; D'Souza RM, 2002, J TROP PEDIATRICS, V48, P323, DOI 10.1093/tropej/48.6.323; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Dimberg A, 2000, BLOOD, V96, P2870; ESOLEN LM, 1993, J INFECT DIS, V168, P47, DOI 10.1093/infdis/168.1.47; Fontana JM, 2008, VIROLOGY, V374, P71, DOI 10.1016/j.virol.2007.12.031; GHAZAL P, 1992, P NATL ACAD SCI USA, V89, P7630, DOI 10.1073/pnas.89.16.7630; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Gotoh B, 2002, REV MED VIROL, V12, P337, DOI 10.1002/rmv.357; Helin E, 1999, VIROLOGY, V253, P35, DOI 10.1006/viro.1998.9460; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Honda K, 2006, IMMUNITY, V25, P349, DOI 10.1016/j.immuni.2006.08.009; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Huiming YM, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001479.pub3; Irlam JH, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003650.pub2; Isaacs CE, 1997, ANTIVIR RES, V33, P117, DOI 10.1016/S0166-3542(96)01009-1; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Long KZ, 2007, J INFECT DIS, V196, P978, DOI 10.1086/521195; Luo XM, 2006, EXP BIOL MED, V231, P619; Maciaszek JW, 1998, J VIROL, V72, P5862, DOI 10.1128/JVI.72.7.5862-5869.1998; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; MOSCA JD, 1986, MOL CELL BIOL, V6, P2279, DOI 10.1128/MCB.6.6.2279; Naniche D, 2000, J VIROL, V74, P7478, DOI 10.1128/JVI.74.16.7478-7484.2000; Ni J, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003700.pub2; Ohno S, 2004, J GEN VIROL, V85, P2991, DOI 10.1099/vir.0.80308-0; OLSON JA, 1994, NUTR REV, V52, P67, DOI 10.1111/j.1753-4887.1994.tb01389.x; ONG DE, 1993, J NUTR, V123, P351, DOI 10.1093/jn/123.suppl_2.351; Palosaari H, 2003, J VIROL, V77, P7635, DOI 10.1128/JVI.77.13.7635-7644.2003; Parisien JP, 2002, J VIROL, V76, P4190, DOI 10.1128/JVI.76.9.4190-4198.2002; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Percario ZA, 1999, CELL GROWTH DIFFER, V10, P263; Perry Robert T., 2004, Journal of Infectious Diseases, V189, pS4, DOI 10.1086/377712; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Rodeheffer C, 2007, J NUTR, V137, P1916, DOI 10.1093/jn/137.8.1916; RUSSELL JK, 1984, BIOCHEM BIOPH RES CO, V122, P851, DOI 10.1016/S0006-291X(84)80112-6; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Shaffer JA, 2003, VIROLOGY, V315, P389, DOI 10.1016/S0042-6822(03)00537-3; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Sommer A, 2008, J NUTR, V138, P1835, DOI 10.1093/jn/138.10.1835; Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167; Takeuchi K, 2003, FEBS LETT, V545, P177, DOI 10.1016/S0014-5793(03)00528-3; Trottier C, 2008, ANTIVIR RES, V80, P45, DOI 10.1016/j.antiviral.2008.04.003; TURPIN JA, 1992, J IMMUNOL, V148, P2539; Villamor E, 2000, J INFECT DIS, V182, pS122, DOI 10.1086/315921; *WHO, 2007, WKLY EPIDEMIOL REC, V82, P418; Witcher M, 2008, NUCLEIC ACIDS RES, V36, P435, DOI 10.1093/nar/gkm1058; Xiao WH, 1997, J BIOL CHEM, V272, P9742, DOI 10.1074/jbc.272.15.9742; YAMAMOTO N, 1979, NATURE, V278, P553, DOI 10.1038/278553a0; Yokota S, 2003, VIROLOGY, V306, P135, DOI 10.1016/S0042-6822(02)00026-0; 1987, WKLY EPIDEMIOL REC, V19, P133	57	47	48	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3203	3212		10.1096/fj.09-129288	http://dx.doi.org/10.1096/fj.09-129288			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19447880				2022-12-25	WOS:000270241000042
J	Dong, MQ; Cox, RF; Miller, LJ				Dong, Maoqing; Cox, Richard F.; Miller, Laurence J.			Juxtamembranous Region of the Amino Terminus of the Family B G Protein-coupled Calcitonin Receptor Plays a Critical Role in Small-molecule Agonist Action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; SECRETIN RECEPTOR; PEPTIDE-1 RECEPTOR; BINDING; DETERMINANTS; ANTAGONIST; ACTIVATION; AFFINITY; DOMAINS; LIGAND	The Family B G protein-coupled calcitonin receptor is an important drug target. The aim of this work was to elucidate the molecular mechanism of action of small-molecule agonist ligands acting at this receptor, comparing it with the action mechanism of the receptor's natural peptide ligand. cAMP responses to four non-peptidyl ligands and calcitonin were studied in COS-1 cells expressing wild-type and chimeric calcitonin-secretin receptors. All compounds were full agonists at the calcitonin receptor with no activity at the secretin receptor. Only chimeric constructs including the calcitonin receptor amino terminus exhibited responses to any of these ligands. We progressively truncated this domain and tested constructs for cAMP responses. Although calcitonin was able to activate the calcitonin receptor fully with the first 58 residues absent, its potency was 3 orders of magnitude lower than that at the wildtype receptor. After truncation of 114 residues, there was no response to calcitonin. In contrast, small-molecule ligands were fully active at receptors having up to 149 amino-terminal residues absent. Those compounds finally became inactive after truncation of 153 residues. Deletion and/or alanine replacement of the region of the calcitonin receptor between residues 150 and 153 resulted in marked reduction in cAMP responses to these compounds, with some compound-specific differences observed, supporting a critical role for this region. Binding studies further supported distinct sites of action of small molecules relative to that of calcitonin. These findings focus attention on the potential importance of the juxtamembranous region of the amino terminus of the Family B calcitonin receptor for agonist drug action.	[Dong, Maoqing; Miller, Laurence J.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA; [Cox, Richard F.] GlaxoSmithKline Inc, Res Triangle Pk, NC 27709 USA	Mayo Clinic; Mayo Clinic Phoenix; GlaxoSmithKline	Dong, MQ (corresponding author), Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	dongmq@mayo.edu; miller@mayo.edu			National Institutes of Health [DK46577]; GlaxoSmithKline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046577, R01DK046577] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline(GlaxoSmithKline); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grant DK46577 (to L. J. M.). This work was also supported by a grant from GlaxoSmithKline (to L. J. M.).	Boros EE, 2005, J ORG CHEM, V70, P5331, DOI 10.1021/jo050370b; Brain Susan D., 2002, Trends in Pharmacological Sciences, V23, P51, DOI 10.1016/S0165-6147(02)01945-4; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; Chen DS, 2007, P NATL ACAD SCI USA, V104, P943, DOI 10.1073/pnas.0610173104; Dong MQ, 2007, MOL PHARMACOL, V72, P280, DOI 10.1124/mol.107.035402; Dong MQ, 2004, J BIOL CHEM, V279, P1167, DOI 10.1074/jbc.M305719200; Doods H, 2000, BRIT J PHARMACOL, V129, P420, DOI 10.1038/sj.bjp.0703110; FUNAHASHI Y, 1996, CHEM ABSTR 6553, V126; Ganguli SC, 1998, J PHARMACOL EXP THER, V286, P593; Gourlet P, 1996, PEPTIDES, V17, P825, DOI 10.1016/0196-9781(96)00107-6; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Hoare SRJ, 2006, BIOCHEM PHARMACOL, V72, P244, DOI 10.1016/j.bcp.2006.04.007; Holtmann MH, 1996, J PHARMACOL EXP THER, V279, P555; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; Katayama T, 2001, BBA-GEN SUBJECTS, V1526, P183, DOI 10.1016/S0304-4165(01)00125-8; Kehne J, 2002, CNS NEUROL DISORD-DR, V1, P467, DOI 10.2174/1568007023339049; Knudsen LB, 2007, P NATL ACAD SCI USA, V104, P937, DOI 10.1073/pnas.0605701104; Madsen P, 1999, CURR PHARM DESIGN, V5, P683; Mallee JJ, 2002, J BIOL CHEM, V277, P14294, DOI 10.1074/jbc.M109661200; Mayo KE, 2003, PHARMACOL REV, V55, P167, DOI 10.1124/pr.55.1.6; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Petersen KF, 2001, DIABETOLOGIA, V44, P2018, DOI 10.1007/s001250100006; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; Purdue BW, 2002, RECEPTOR CHANNEL, V8, P243, DOI 10.1080/10606820213681; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; Schwartz TW, 2006, ANNU REV PHARMACOL, V46, P481, DOI 10.1146/annurev.pharmtox.46.120604.141218; Sexton PM, 1999, CURR MED CHEM, V6, P1067; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; SU MH, 1998, CHEM ABSTR 239489, V128; Tibaduiza EC, 2001, J BIOL CHEM, V276, P37787; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895	34	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	2009	284	33					21839	21847		10.1074/jbc.M109.011924	http://dx.doi.org/10.1074/jbc.M109.011924			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481CE	19447889	Green Published, hybrid			2022-12-25	WOS:000268783700007
J	Malintan, NT; Nguyen, TH; Han, LP; Latham, CF; Osborne, SL; Wen, PJ; Lim, SJT; Sugita, S; Collins, BM; Meunier, FA				Malintan, Nancy T.; Nguyen, Tam H.; Han, Liping; Latham, Catherine F.; Osborne, Shona L.; Wen, Peter J.; Lim, Siew Joo Tiffany; Sugita, Shuzo; Collins, Brett M.; Meunier, Frederic A.			Abrogating Munc18-1-SNARE Complex Interaction Has Limited Impact on Exocytosis in PC12 Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL SNARE COMPLEX; SEC1/MUNC18 PROTEINS; VESICLE DOCKING; FUSION; SYNTAXIN; BINDING; GOLGI; TRAFFICKING; NEUROTOXINS; SPECIFICITY	Neuronal communication relies on the fusion of neurotransmitter-containing vesicles with the plasma membrane. The soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptor (SNARE) proteins initiate membrane fusion through the formation of the SNARE complex, a process tightly regulated by Sec1/Munc18-1 (SM) proteins. The emerging trend is that SM proteins promote SNARE-mediated membrane fusion by binding to a Syntaxin N-terminal motif. Here we report that mutations in the hydrophobic pocket of Munc18-1 (F115E and E132A), predicted to disrupt the N-terminal Sx1a interaction have a modest effect on binding to Sx1a in its free state, but abolish binding to the SNARE complex. Overexpression of the Munc18-1 mutant in PC12 cells lacking Munc18-1 rescues both neuroexocytosis and the plasma membrane localization of Syntaxin. However, total internal reflection fluorescence microscopy analysis reveals that expression of a Munc18-1 double mutant reduces the rate of vesicle fusion, an effect only detectable at the onset of stimulation. The Munc18-1 hydrophobic pocket is therefore critical for SNARE complex binding. However, mutations abrogating this interaction have a limited impact on Ca2+-dependent exocytosis in PC12 cells.	[Lim, Siew Joo Tiffany; Meunier, Frederic A.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia; [Lim, Siew Joo Tiffany; Meunier, Frederic A.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; [Collins, Brett M.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; [Han, Liping; Sugita, Shuzo] Univ Toronto, Dept Physiol, Univ Hlth Network, Toronto Western Res Inst,Div Fundamental Neurobio, Toronto, ON M5T 2S8, Canada	University of Queensland; University of Queensland; University of Queensland; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Meunier, FA (corresponding author), Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia.	f.meunier@uq.edu.au	Malintan, Nancy/U-8278-2018; Nguyen, Tam/H-3423-2011; Meunier, Frederic A/C-8161-2009; Collins, Brett/J-1563-2014; Osborne, Shona/C-8290-2009	Malintan, Nancy/0000-0002-1040-8021; Meunier, Frederic A/0000-0001-6400-1107; Collins, Brett/0000-0002-6070-3774; Sugita, Shuzo/0000-0002-9182-873X; Osborne, Shona/0000-0002-7012-9278	Australian National Health and Medical Research Council; Australian Research Council; Canadian Institute of Health Research [MOP-57825]	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by a grant from the Australian National Health and Medical Research Council (to F. A. M.), a Linkage Infrastructure, Equipment and Facilities grant from the Australian Research Council (to F. A. M.), and Canadian Institute of Health Research Grant MOP-57825 (to S. S.).	Arunachalam L, 2008, MOL BIOL CELL, V19, P722, DOI 10.1091/mbc.E07-07-0662; Bracher A, 2002, EMBO J, V21, P6114, DOI 10.1093/emboj/cdf608; Burkhardt P, 2008, EMBO J, V27, P923, DOI 10.1038/emboj.2008.37; Deak F, 2009, J CELL BIOL, V184, P751, DOI 10.1083/jcb.200812026; Dulubova I, 2007, P NATL ACAD SCI USA, V104, P2697, DOI 10.1073/pnas.0611318104; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Gallwitz D, 2003, TRENDS BIOCHEM SCI, V28, P113, DOI 10.1016/S0968-0004(03)00028-8; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gulyas-Kovacs A, 2007, J NEUROSCI, V27, P8676, DOI 10.1523/JNEUROSCI.0658-07.2007; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Hu SH, 2007, P NATL ACAD SCI USA, V104, P8773, DOI 10.1073/pnas.0701124104; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Johnson JR, 2009, BIOCHEM J, V418, P73, DOI 10.1042/BJ20081956; Khvotchev M, 2007, J NEUROSCI, V27, P12147, DOI 10.1523/JNEUROSCI.3655-07.2007; Lam AD, 2008, MOL BIOL CELL, V19, P485, DOI 10.1091/mbc.E07-02-0148; Latham CF, 2007, INT J BIOCHEM CELL B, V39, P1576, DOI 10.1016/j.biocel.2006.11.015; Latham CF, 2007, J NEUROCHEM, V100, P1543, DOI 10.1111/j.1471-4159.2006.04286.x; Latham CF, 2006, TRAFFIC, V7, P1408, DOI 10.1111/j.1600-0854.2006.00474.x; Meunier FA, 2005, MOL BIOL CELL, V16, P4841, DOI 10.1091/mbc.E05-02-0171; Meunier FA, 2002, J PHYSIOL-PARIS, V96, P105, DOI 10.1016/S0928-4257(01)00086-9; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Osborne SL, 2008, J BIOL CHEM, V283, P2804, DOI 10.1074/jbc.M704856200; Peng RW, 2004, EMBO J, V23, P3939, DOI 10.1038/sj.emboj.7600410; Peng RW, 2002, J CELL BIOL, V157, P645, DOI 10.1083/jcb.200202006; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Rickman C, 2007, J BIOL CHEM, V282, P12097, DOI 10.1074/jbc.M700227200; Saitsu H, 2008, NAT GENET, V40, P782, DOI 10.1038/ng.150; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Shen JS, 2007, CELL, V128, P183, DOI 10.1016/j.cell.2006.12.016; Sollner TH, 2003, MOL MEMBR BIOL, V20, P209, DOI 10.1080/0968768031000104953; Steyer JA, 1999, BIOPHYS J, V76, P2262, DOI 10.1016/S0006-3495(99)77382-0; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Wen PJ, 2008, MOL BIOL CELL, V19, P5593, DOI 10.1091/mbc.E08-06-0595; Yamaguchi T, 2002, DEV CELL, V2, P295, DOI 10.1016/S1534-5807(02)00125-9; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Zilly FE, 2006, PLOS BIOL, V4, P1789, DOI 10.1371/journal.pbio.0040330	42	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	2009	284	32					21637	21646		10.1074/jbc.M109.013508	http://dx.doi.org/10.1074/jbc.M109.013508			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478CC	19483085	Green Published, hybrid			2022-12-25	WOS:000268564400057
J	Gad, HH; Dellgren, C; Hamming, OJ; Vends, S; Paludan, SR; Hartmann, R				Gad, Hans Henrik; Dellgren, Christoffer; Hamming, Ole J.; Vends, Susanne; Paludan, Soren R.; Hartmann, Rune			Interferon-lambda Is Functionally an Interferon but Structurally Related to the Interleukin-10 Family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-LAMBDA; CRYSTAL-STRUCTURE; IL-10R2 BINDING; HOST-DEFENSE; III IFN; IL-22; CRYSTALLOGRAPHY; CYTOKINES; SOFTWARE; COMPLEX	Interferon-lambda (IFN-lambda) is an antiviral cytokine that signals through a distinct receptor complex, composed of the IFN-lambda R1 and interleukin-10R2 (IL-10R2) receptor chains. We have determined the crystal structure of human IFN-lambda 3 and characterized the interaction with its receptor complex through structure-based site-directed mutagenesis. The ability of IFN-lambda 3 mutants to signal was determined by measuring the antiviral activity and induced STAT2 phosphorylation. In conclusion, our data show that, although IFN-lambda is functionally an interferon, it is clearly structurally related to members of the IL-10 family. In particular, we found an interesting similarity between IFN-lambda and IL-22, and we suggest that IFN-lambda and IL-22 possess parallel functions, protecting epithelial tissue against viral and bacterial infections, respectively.	[Gad, Hans Henrik; Dellgren, Christoffer; Hamming, Ole J.; Vends, Susanne; Hartmann, Rune] Aarhus Univ, Dept Mol Biol, Struct Biol Ctr, DK-8000 Aarhus C, Denmark; [Paludan, Soren R.] Aarhus Univ, Dept Med Microbiol & Immunol, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University	Hartmann, R (corresponding author), Aarhus Univ, Dept Mol Biol, Struct Biol Ctr, DK-8000 Aarhus C, Denmark.	rh@mb.au.dk		Hartmann, Rune/0000-0003-1159-066X; Dellgren, Christoffer Dalsgaard/0000-0003-4841-5187; Gad, Hans Henrik/0000-0001-8449-1115	Danscatt consortium; Novo Nordisk Foundation; Danish Medical Research Council [22-04-0704]; Carlsberg Foundation; Arne Hansen stipend	Danscatt consortium; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Carlsberg Foundation(Carlsberg Foundation); Arne Hansen stipend	Beamline access was funded partly via the Danscatt consortium.; Supported by a Novo Nordisk Foundation senior research grant, by grants from The Danish Medical Research Council (Grant 22-04-0704) and The Carlsberg Foundation, and by an Arne Hansen stipend.	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Ank N, 2006, J VIROL, V80, P4501, DOI 10.1128/JVI.80.9.4501-4509.2006; Ank N, 2008, J IMMUNOL, V180, P2474, DOI 10.4049/jimmunol.180.4.2474; Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710; Bleicher L, 2008, FEBS LETT, V582, P2985, DOI 10.1016/j.febslet.2008.07.046; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dellgren C, 2009, GENES IMMUN, V10, P125, DOI 10.1038/gene.2008.87; Doyle SE, 2006, HEPATOLOGY, V44, P896, DOI 10.1002/hep.21312; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Jones BC, 2008, STRUCTURE, V16, P1333, DOI 10.1016/j.str.2008.06.005; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan WJ, 2007, GENES IMMUN, V8, P254, DOI 10.1038/sj.gene.6364382; Jordan WJ, 2007, GENES IMMUN, V8, P13, DOI 10.1038/sj.gene.6364348; Josephson K, 2001, IMMUNITY, V15, P35, DOI 10.1016/S1074-7613(01)00169-8; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Logsdon NJ, 2004, J MOL BIOL, V342, P503, DOI 10.1016/j.jmb.2004.07.069; Marcello T, 2006, GASTROENTEROLOGY, V131, P1887, DOI 10.1053/j.gastro.2006.09.052; Meager A, 2005, CYTOKINE, V31, P109, DOI 10.1016/j.cyto.2005.04.003; Mennechet FJD, 2006, BLOOD, V107, P4417, DOI 10.1182/blood-2005-10-4129; Mordstein M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000151; Onoguchi K, 2007, J BIOL CHEM, V282, P7576, DOI 10.1074/jbc.M608618200; Osterlund PI, 2007, J IMMUNOL, V179, P3434, DOI 10.4049/jimmunol.179.6.3434; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Robek MD, 2005, J VIROL, V79, P3851, DOI 10.1128/JVI.79.6.3851-3854.2005; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Sommereyns C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000017; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Ursby T, 2004, AIP CONF PROC, V705, P1241, DOI 10.1063/1.1758025; Wu PW, 2008, J MOL BIOL, V382, P1168, DOI 10.1016/j.jmb.2008.07.046; Yoon SI, 2006, J BIOL CHEM, V281, P35088, DOI 10.1074/jbc.M606791200; Zheng Y, 2008, NAT MED, V14, P282, DOI 10.1038/nm1720; Zhou ZL, 2007, J VIROL, V81, P7749, DOI 10.1128/JVI.02438-06	36	155	174	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20869	20875		10.1074/jbc.M109.002923	http://dx.doi.org/10.1074/jbc.M109.002923			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19457860	hybrid, Green Published			2022-12-25	WOS:000268316100050
J	Strasser, R; Castilho, A; Stadlmann, J; Kunert, R; Quendler, H; Gattinger, P; Jez, J; Rademacher, T; Altmann, F; Mach, L; Steinkellner, H				Strasser, Richard; Castilho, Alexandra; Stadlmann, Johannes; Kunert, Renate; Quendler, Heribert; Gattinger, Pia; Jez, Jakub; Rademacher, Thomas; Altmann, Friedrich; Mach, Lukas; Steinkellner, Herta			Improved Virus Neutralization by Plant-produced Anti-HIV Antibodies with a Homogeneous beta 1,4-Galactosylated N-Glycan Profile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; MONOCLONAL-ANTIBODY; GOLGI-APPARATUS; FC GLYCANS; GLYCOSYLATION; EXPRESSION; CELLS; GLYCOFORMS; EPITOPES; RECEPTOR	It is well established that proper N-glycosylation significantly influences the efficacy of monoclonal antibodies (mAbs). However, the specific immunological relevance of individual mAb-associated N-glycan structures is currently largely unknown, because of the heterogeneous N-glycan profiles of mAbs when produced in mammalian cells. Here we report on the generation of a plant-based expression platform allowing the efficient production of mAbs with a homogeneous beta 1,4-galactosylated N-glycosylation structure, the major N-glycan species present on serum IgG. This was achieved by the expression of a highly active modified version of the human beta 1,4-galactosyl-transferase in glycoengineered plants lacking plant-specific glycosylation. Moreover, we demonstrate that two anti-human immunodeficiency virus mAbs with fully beta 1,4-galactosylated N-glycans display improved virus neutralization potency when compared with other glycoforms produced in plants and Chinese hamster ovary cells. These findings indicate that mAbs containing such homogeneous N-glycan structures should display improved in vivo activities. Our system, using expression of mAbs in tobacco plants engineered for post-translational protein processing, provides a new means of overcoming the two hurdles that limit the therapeutic use of anti-human immunodeficiency virus mAbs in global health initiatives, low biological potency and high production costs.	[Strasser, Richard; Castilho, Alexandra; Gattinger, Pia; Jez, Jakub; Mach, Lukas; Steinkellner, Herta] Univ Nat Resources & Appl Life Sci, Dept Appl Genet, A-1190 Vienna, Austria; [Stadlmann, Johannes; Altmann, Friedrich] Univ Nat Resources & Appl Life Sci, Dept Chem, A-1190 Vienna, Austria; [Kunert, Renate] Univ Nat Resources & Appl Life Sci, Inst Appl Microbiol, A-1190 Vienna, Austria; [Quendler, Heribert] Polymun Sci GmbH, A-1190 Vienna, Austria; [Quendler, Heribert] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Rademacher, Thomas] Rhein Westfal TH Aachen, D-52074 Aachen, Germany	University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna; Scripps Research Institute; RWTH Aachen University	Steinkellner, H (corresponding author), Muthgasse 18, A-1190 Vienna, Austria.	herta.steinkellner@boku.ac.at	Strasser, Richard/AAD-2916-2020; Kunert, Renate E/B-9185-2018; Castilho, Alexandra/AAC-8927-2020; Steinkellner, Herta/N-4267-2016; Stadlmann, Johannes/AAC-3157-2021	Kunert, Renate E/0000-0002-3397-3621; Castilho, Alexandra/0000-0003-4114-7861; Steinkellner, Herta/0000-0003-4823-1505; Stadlmann, Johannes/0000-0001-5693-6690; Strasser, Richard/0000-0001-8764-6530; Altmann, Friedrich/0000-0002-0112-7877; Gattinger, Pia/0000-0001-6724-8543; Mach, Lukas/0000-0001-9013-5408; Jez, Jakub/0000-0002-6481-4383	Wiener Wissenschafts-, Forschungs-, und Technologiefonds [LS154]; Austrian Science Fund (FWF) [L 575] Funding Source: researchfish	Wiener Wissenschafts-, Forschungs-, und Technologiefonds; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	This work was supported by the Wiener Wissenschafts-, Forschungs-, und Technologiefonds Project LS154.	Bakker H, 2001, P NATL ACAD SCI USA, V98, P2899, DOI 10.1073/pnas.031419998; Bakker H, 2006, P NATL ACAD SCI USA, V103, P7577, DOI 10.1073/pnas.0600879103; Berger EG, 2001, HISTOCHEM CELL BIOL, V115, P157, DOI 10.1007/s004180000231; Boevink P, 1998, PLANT J, V15, P441, DOI 10.1046/j.1365-313X.1998.00208.x; Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011; Cox KM, 2006, NAT BIOTECHNOL, V24, P1591, DOI 10.1038/nbt1260; Fujiyama K, 2007, BIOCHEM BIOPH RES CO, V358, P85, DOI 10.1016/j.bbrc.2007.04.054; Giritch A, 2006, P NATL ACAD SCI USA, V103, P14701, DOI 10.1073/pnas.0606631103; Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106; Huber M, 2008, CURR TOP MICROBIOL, V317, P39; Krapp S, 2003, J MOL BIOL, V325, P979, DOI 10.1016/S0022-2836(02)01250-0; Leonard R, 2002, GLYCOBIOLOGY, V12, P299, DOI 10.1093/glycob/12.5.299; Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005; Marillonnet S, 2005, NAT BIOTECHNOL, V23, P718, DOI 10.1038/nbt1094; Mascola JR, 2005, J VIROL, V79, P10103, DOI 10.1128/JVI.79.16.10103-10107.2005; Masse PJ, 2008, ANNU REV MED, V59, P455, DOI 10.1146/annurev.med.59.061206.112737; Palacpac NQ, 1999, P NATL ACAD SCI USA, V96, P4692, DOI 10.1073/pnas.96.8.4692; Raju TS, 2008, CURR OPIN IMMUNOL, V20, P471, DOI 10.1016/j.coi.2008.06.007; REED LJ, 1938, AM J HYG, V27; Sainsbury F, 2008, PLANT PHYSIOL, V148, P1212, DOI 10.1104/pp.108.126284; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Scallon BJ, 2007, MOL IMMUNOL, V44, P1524, DOI 10.1016/j.molimm.2006.09.005; Schahs M, 2007, PLANT BIOTECHNOL J, V5, P657, DOI 10.1111/j.1467-7652.2007.00273.x; Schweizer A, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000109; Stadlmann J, 2008, PROTEOMICS, V8, P2858, DOI 10.1002/pmic.200700968; Strasser R, 2005, BIOCHEM J, V387, P385, DOI 10.1042/BJ20041686; Strasser R, 2008, PLANT BIOTECHNOL J, V6, P392, DOI 10.1111/j.1467-7652.2008.00330.x; Strasser R, 2007, PLANT CELL, V19, P2278, DOI 10.1105/tpc.107.052985; Trkola A, 2005, NAT MED, V11, P615, DOI 10.1038/nm1244; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; Wee EGT, 1998, PLANT CELL, V10, P1759, DOI 10.1105/tpc.10.10.1759; Yamane-Ohnuki N, 2004, BIOTECHNOL BIOENG, V87, P614, DOI 10.1002/bit.20151	32	130	142	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20479	20485		10.1074/jbc.M109.014126	http://dx.doi.org/10.1074/jbc.M109.014126			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19478090	Green Published, hybrid			2022-12-25	WOS:000268316100009
J	Qiu, S; Zhang, XM; Cao, JY; Yang, W; Yan, YG; Shan, L; Zheng, J; Luo, JH				Qiu, Shuang; Zhang, Xiao-min; Cao, Jing-yuan; Yang, Wei; Yan, Ying-gang; Shan, Ling; Zheng, Jie; Luo, Jian-hong			An Endoplasmic Reticulum Retention Signal Located in the Extracellular Amino-terminal Domain of the NR2A Subunit of N-Methyl-D-aspartate Receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; LIGAND-BINDING DOMAIN; NMDA RECEPTOR; GLUTAMATE RECEPTORS; QUALITY-CONTROL; NR1; TRAFFICKING; AFFINITY; PROTEIN; LUMEN	N-Methyl-D-aspartate (NMDA) receptors play critical roles in complex brain functions as well as pathogenesis of neurodegenerative diseases. There are many NMDA isoforms and subunit types that, together with subtype-specific assembly, give rise to significant functional heterogeneity of NMDA receptors. Conventional NMDA receptors are obligatory heterotetramers composed of two glycine-binding NR1 subunits and two glutamate-binding NR2 subunits. When individually expressed in heterogeneous cells, most of the NR1 splice variants and the NR2 subunits remain in the endoplasmic reticulum (ER) and do not form homomeric channels. The mechanisms underlying NMDA receptor trafficking and functional expression remain uncertain. Using truncated and chimeric NMDA receptor subunits expressed in heterogeneous cells and hippocampal neurons, together with immunostaining, biochemical, and functional analyses, we found that the NR2A amino-terminal domain (ATD) contains an ER retention signal, which can be specifically masked by the NR1a ATD. Interestingly, no such signal was found in the ATD of the NR2B subunit. We further identified the A2 segment of the NR2A ATD to be the primary determinant of ER retention. These findings indicate that NR2A-containing NMDA receptors may undergo a different ER quality control process from NR2B-containing NMDA receptors.	[Qiu, Shuang; Zhang, Xiao-min; Cao, Jing-yuan; Yang, Wei; Yan, Ying-gang; Shan, Ling; Luo, Jian-hong] Zhejiang Univ, Sch Med, Dept Neurobiol, Hangzhou 310058, Zhejiang, Peoples R China; [Zheng, Jie] Univ Calif Davis, Dept Physiol & Membrane Biol, Sch Med, Davis, CA 95616 USA	Zhejiang University; University of California System; University of California Davis	Luo, JH (corresponding author), Zhejiang Univ, Sch Med, Dept Neurobiol, 388 Yu Hang Tang Rd, Hangzhou 310058, Zhejiang, Peoples R China.	luojianhong@zju.edu.cn	Shan, Ling/E-4281-2012; Luo, jian/HGE-7331-2022; Shan, Ling/N-7075-2019	Shan, Ling/0000-0002-4765-2474; Shan, Ling/0000-0002-4765-2474; Zhang, Xiaomin/0000-0002-1179-979X	National Natural Science Foundation of China [30730038, 30800308]; National Basic Research Program of China [G2002CB713808]; National Institutes of Health [REY016754A]; American Heart Association [0665201Y]; NATIONAL EYE INSTITUTE [R21EY016754] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by National Natural Science Foundation of China Grants 30730038 and 30800308 and National Basic Research Program of China Grant G2002CB713808 (to J. H. L.). This work was also supported by the National Institutes of Health Grant REY016754A and American Heart Association Grant 0665201Y (to J. Z.).	Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Atlason PT, 2007, J BIOL CHEM, V282, P25299, DOI 10.1074/jbc.M702778200; Chen GQ, 1999, NATURE, V402, P817, DOI 10.1038/45568; Dingledine R, 1999, PHARMACOL REV, V51, P7; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; Fayyazuddin A, 2000, NEURON, V25, P683, DOI 10.1016/S0896-6273(00)81070-3; Fernandez-Monreal M, 2004, J BIOL CHEM, V279, P50850, DOI 10.1074/jbc.M407069200; Fleck MW, 2006, NEUROSCIENTIST, V12, P232, DOI 10.1177/1073858405283828; Flint AC, 1997, J NEUROSCI, V17, P2469; Fukaya M, 2003, P NATL ACAD SCI USA, V100, P4855, DOI 10.1073/PNAS.0830996100; Hawkins LM, 2004, J BIOL CHEM, V279, P28903, DOI 10.1074/jbc.M402599200; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; Horak M, 2008, J NEUROSCI, V28, P3500, DOI 10.1523/JNEUROSCI.5239-07.2008; Horak M, 2009, J BIOL CHEM, V284, P9683, DOI 10.1074/jbc.M807050200; Hsiao CD, 1996, J MOL BIOL, V262, P225, DOI 10.1006/jmbi.1996.0509; Lee SJ, 1998, EXP MOL MED, V30, P159, DOI 10.1038/emm.1998.23; Luo JH, 2002, NEUROPHARMACOLOGY, V42, P306, DOI 10.1016/S0028-3908(01)00188-5; LYNCH DR, 1995, J NEUROCHEM, V64, P1462; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Madry C, 2007, MOL PHARMACOL, V72, P1535, DOI 10.1124/mol.107.040071; McIlhinney RAJ, 1998, NEUROPHARMACOLOGY, V37, P1355, DOI 10.1016/S0028-3908(98)00121-X; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okabe S, 1999, J NEUROSCI, V19, P7781; Paoletti P, 2000, NEURON, V28, P911, DOI 10.1016/S0896-6273(00)00163-X; Pauly T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002681; Qiu S, 2005, J BIOL CHEM, V280, P24923, DOI 10.1074/jbc.M413915200; Saglietti L, 2007, NEURON, V54, P461, DOI 10.1016/j.neuron.2007.04.012; SHIN J, 1993, SCIENCE, V259, P1901, DOI 10.1126/science.8456316; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Stephenson FA, 2008, MOL MEMBR BIOL, V25, P311, DOI 10.1080/09687680801971367; Szklarczyk A, 2008, FASEB J, V22, P3757, DOI 10.1096/fj.07-101402; Vacher H, 2007, FASEB J, V21, P906, DOI 10.1096/fj.06-7229com; Yang W, 2007, J BIOL CHEM, V282, P9269, DOI 10.1074/jbc.M700050200; Zheng F, 2001, NAT NEUROSCI, V4, P894, DOI 10.1038/nn0901-894	39	42	42	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20285	20298		10.1074/jbc.M109.004960	http://dx.doi.org/10.1074/jbc.M109.004960			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19487695	Green Published, hybrid			2022-12-25	WOS:000268097400055
J	Hong, CF; Chou, YT; Lin, YS; Wu, CW				Hong, Chun-Fu; Chou, Yu-Ting; Lin, Young-Sun; Wu, Cheng-Wen			MAD2B, a Novel TCF4-binding Protein, Modulates TCF4-mediated Epithelial-Mesenchymal Transdifferentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLORECTAL-CANCER PROGRESSION; BETA-CATENIN; COLON-CANCER; SPINDLE CHECKPOINT; EXPRESSION; CELLS; TRANSITION; INTERACTS; WNT; TRANSACTIVATION	T cell factor 4 (TCF4) interacts with beta-catenin in the WNT signaling pathway and transactivates downstream target genes involved in cancer progression. To identify proteins that regulate TCF4-mediated biological responses, we performed a yeast two-hybrid screen to search for a TCF4-binding protein(s) and found that MAD2B interacts with TCF4. We confirmed that MAD2B is a TCF4-binding protein by co-immunoprecipitation. Using the TOPFLASH reporter assay, we found that MAD2B blocks TCF4-mediated transactivation. The MAD2B binding regions of TCF4 were identified by TCF4 deletion mapping and electrophoretic mobility shift assay analysis. TCF4 and MAD2B interactions abolished the DNA binding ability of TCF4. Knockdown of MAD2B in SW480 colorectal cancer cells led to the conversion of epithelial cells to a mesenchymal fibroblastoid phenotype (epithelial-mesenchymal transdifferentiation). An E-cadherin promoter reporter analysis showed that MAD2B modulates TCF4-mediated E-cadherin expression. MAD2B knockdown blocked E-cadherin expression and significantly induced mesenchymal markers, such as N-cadherin and vimentin. Mesenchymal induction was accompanied by F-actin redistribution and the appearance of a fibroblastoid phenotype. MAD2B knockdown also increased both mRNA and protein levels of Slug, a known TCF4-induced E-cadherin transcriptional repressor. A chromatin immunoprecipitation assay showed that MAD2B silencing enhances the ability of TCF4 to bind the Slug promoter. Thus, MAD2B is a novel TCF4-interacting protein. This study provides the first evidence for the involvement of MAD2B in TCF4-mediated epithelial-mesenchymal transdifferentiation.	[Wu, Cheng-Wen] Natl Yang Ming Univ, Taipei 11221, Taiwan; [Hong, Chun-Fu] Natl Def Med Ctr, Grad Inst Life Sci, Taipei 11490, Taiwan; [Hong, Chun-Fu; Chou, Yu-Ting; Wu, Cheng-Wen] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Lin, Young-Sun] Dev Ctr Biotechnol, Taipei 22180, Taiwan	National Yang Ming Chiao Tung University; National Defense Medical Center; Academia Sinica - Taiwan	Wu, CW (corresponding author), Natl Yang Ming Univ, 155 Sec 2,Linong St, Taipei 11221, Taiwan.	cwwu@ym.edu.tw		Chou, Yu-Ting/0000-0001-9274-8603	Academia Sinica, Department of Health [DOH97-TD-G-111-023]; National Science Council, Executive Yuan, Taiwan [NSC97-3111-B-010-005]	Academia Sinica, Department of Health(Academia Sinica - Taiwan); National Science Council, Executive Yuan, Taiwan(Ministry of Science and Technology, Taiwan)	This research was supported by Academia Sinica, Department of Health Grant DOH97-TD-G-111-023, and National Science Council Grant NSC97-3111-B-010-005, Executive Yuan, Taiwan.	Bates RC, 2005, CANCER BIOL THER, V4, P365; Bright-Thomas RM, 2003, EUR J SURG ONCOL, V29, P107, DOI 10.1053/ejso.2002.1331; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Chan SH, 2001, EUR J BIOCHEM, V268, P2107, DOI 10.1046/j.1432-1327.2001.02091.x; Chen J, 2001, GENE DEV, V15, P1765, DOI 10.1101/gad.898701; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; Clevers H, 2004, CANCER CELL, V5, P5, DOI 10.1016/S1535-6108(03)00339-8; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Gilles C, 2003, CANCER RES, V63, P2658; Held W, 2003, EUR J IMMUNOL, V33, P1393, DOI 10.1002/eji.200323840; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Iwai H, 2007, CELL, V130, P611, DOI 10.1016/j.cell.2007.06.043; Jamora C, 2003, NATURE, V422, P317, DOI 10.1038/nature01458; Jin TR, 2008, CELL SIGNAL, V20, P1697, DOI 10.1016/j.cellsig.2008.04.014; Katoh M, 2005, INT J ONCOL, V27, P1677; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Li L, 2007, MOL CELL BIOCHEM, V304, P297, DOI 10.1007/s11010-007-9512-8; Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Murakumo Y, 2000, J BIOL CHEM, V275, P4391, DOI 10.1074/jbc.275.6.4391; Naishiro Y, 2001, CANCER RES, V61, P2751; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Pfleger CM, 2001, GENE DEV, V15, P1759, DOI 10.1101/gad.897901; Pinto M, 2007, VIRCHOWS ARCH, V450, P379, DOI 10.1007/s00428-007-0386-7; Rimkus C, 2007, INT J CANCER, V120, P207, DOI 10.1002/ijc.22155; Sakai D, 2005, DEV GROWTH DIFFER, V47, P471, DOI 10.1111/j.1440-169X.2005.00821.x; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tzeng SL, 2006, J BIOL CHEM, V281, P15405, DOI 10.1074/jbc.M601807200; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vincan E, 2008, CLIN EXP METASTAS, V25, P657, DOI 10.1007/s10585-008-9156-4; Xia GH, 2004, EMBO J, V23, P3133, DOI 10.1038/sj.emboj.7600322; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Ying BL, 2003, VIROLOGY, V313, P224, DOI 10.1016/S0042-6822(03)00287-3; Yuan BB, 2006, CLIN CANCER RES, V12, P405, DOI 10.1158/1078-0432.CCR-05-0903; Zhang L, 2007, MOL CELL BIOL, V27, P2861, DOI 10.1128/MCB.02276-06	40	33	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19613	19622		10.1074/jbc.M109.005017	http://dx.doi.org/10.1074/jbc.M109.005017			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19443654	hybrid, Green Published			2022-12-25	WOS:000267908300053
J	Privalsky, ML; Lee, SH; Hahm, JB; Young, BM; Fong, RNG; Chan, IH				Privalsky, Martin L.; Lee, Sangho; Hahm, Johnnie B.; Young, Briana M.; Fong, Rebecca N. G.; Chan, Ivan H.			The p160 Coactivator PAS-B Motif Stabilizes Nuclear Receptor Binding and Contributes to Isoform-specific Regulation by Thyroid Hormone Receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; ANDROGEN RECEPTOR; LIGAND-BINDING; PITUITARY RESISTANCE; GENE-EXPRESSION; BETA-ISOFORMS; MUTANT MICE; LXXLL MOTIF; IN-VIVO; COMPLEX	Thyroid hormone receptors (TRs) are hormone-regulated transcription factors that play multiple roles in vertebrate endocrinology and development. TRs are expressed as a series of distinct receptor isoforms that mediate different biological functions. The TR beta 2 isoform is expressed primarily in the hypothalamus, pituitary, cochlea, and retina, and displays an enhanced response to hormone agonist relative to the other TR isoforms. We report here that the unusual transcriptional properties of TR beta 2 parallel the ability of this isoform to bind p160 coactivators cooperatively through multiple contact surfaces; the more broadly expressed TR beta 1 isoform, in contrast, utilizes a single contact mechanism. Intriguingly, the PAS-B domain in the p160 N terminus plays a previously unanticipated role in permitting TR beta 2 to recruit coactivator at limiting triiodothyronine concentrations. The PAS-B sequences also play an important role in coactivator binding by estrogen receptor-alpha. We propose that the PAS-B domain of the p160 coactivators is an important modulator of coactivator recruitment for a specific subset of nuclear receptors, permitting stronger transcriptional activation at lower hormone concentrations than would otherwise occur, and allowing isoform-specific mRNA splicing to customize the hormone response in different tissues.	[Privalsky, Martin L.; Lee, Sangho; Hahm, Johnnie B.; Young, Briana M.; Fong, Rebecca N. G.; Chan, Ivan H.] Univ Calif Davis, Dept Microbiol, Coll Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Dept Microbiol, Coll Biol Sci, 1 Shields Ave, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu	Chan, Ivan/B-7922-2010	Chan, Ivan/0000-0003-2834-2574; Lee, Sangho/0000-0003-3771-7761	National Institutes of Health Grant from the NIDDK [R01DK53528]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007377] Funding Source: NIH RePORTER	National Institutes of Health Grant from the NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant R01DK53528 from the NIDDK.	Abel ED, 1999, J CLIN INVEST, V103, P271, DOI 10.1172/JCI5205; Abel ED, 1999, J CLIN INVEST, V104, P291, DOI 10.1172/JCI6397; Abel ED, 2003, MOL ENDOCRINOL, V17, P1767, DOI 10.1210/me.2003-0109; Abel ED, 2001, J CLIN INVEST, V107, P1017, DOI 10.1172/JCI10858; Alen P, 1999, MOL CELL BIOL, V19, P6085; Apriletti JW, 1998, CLIN EXP PHARMACOL P, V25, pS2, DOI 10.1111/j.1440-1681.1998.tb02293.x; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bassett JHD, 2003, MOL CELL ENDOCRINOL, V213, P1, DOI 10.1016/j.mce.2003.10.033; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Bhat MK, 1999, THYROID, V9, P411, DOI 10.1089/thy.1999.9.411; Brent G A, 2000, Rev Endocr Metab Disord, V1, P27, DOI 10.1023/A:1010056202122; Chandra V, 2008, NATURE, V456, P350, DOI 10.1038/nature07413; Cheng S Y, 2000, Rev Endocr Metab Disord, V1, P9, DOI 10.1023/A:1010052101214; Cheng SY, 2005, STEROIDS, V70, P450, DOI 10.1016/j.steroids.2005.02.003; Christiaens V, 2002, J BIOL CHEM, V277, P49230, DOI 10.1074/jbc.M209322200; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Farboud B, 2003, MOL CELL BIOL, V23, P2844, DOI 10.1128/MCB.23.8.2844-2858.2003; Flamant F, 2003, TRENDS ENDOCRIN MET, V14, P85, DOI 10.1016/S1043-2760(02)00043-7; Flamant F, 2006, PHARMACOL REV, V58, P705, DOI 10.1124/pr.58.4.3; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; Forrest D, 2000, THYROID, V10, P41, DOI 10.1089/thy.2000.10.41; Gauthier K, 1999, EMBO J, V18, P623, DOI 10.1093/emboj/18.3.623; Goodson Michael L, 2007, Nucl Recept Signal, V5, pe002; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Kamiya Y, 2003, ENDOCRINOLOGY, V144, P4144, DOI 10.1210/en.2003-0239; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; Lee S, 2005, MOL ENDOCRINOL, V19, P863, DOI 10.1210/me.2004-0210; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; Lodrini M, 2008, NUCLEIC ACIDS RES, V36, P1847, DOI 10.1093/nar/gkn029; Ma H, 1999, MOL CELL BIOL, V19, P6164; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Mengeling BJ, 2005, MOL ENDOCRINOL, V19, P35, DOI 10.1210/me.2003-0289; Murata Y, 1998, Nagoya J Med Sci, V61, P103; NG L, 1995, MOL ENDOCRINOL, V9, P1202, DOI 10.1210/me.9.9.1202; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Northrop JP, 2000, MOL ENDOCRINOL, V14, P605, DOI 10.1210/me.14.5.605; Oberste-Berghaus C, 2000, J BIOL CHEM, V275, P1787, DOI 10.1074/jbc.275.3.1787; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Plevin MJ, 2005, TRENDS BIOCHEM SCI, V30, P66, DOI 10.1016/j.tibs.2004.12.001; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Reed larsen P, 2003, WILLIAMS TXB ENDOCRI, P331; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; Safer JD, 1997, MOL ENDOCRINOL, V11, P16, DOI 10.1210/me.11.1.16; Scheuermann TH, 2009, P NATL ACAD SCI USA, V106, P450, DOI 10.1073/pnas.0808092106; Schmidt S, 1998, NUCLEIC ACIDS RES, V26, P1191, DOI 10.1093/nar/26.5.1191; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; SJOBERG M, 1992, DEVELOPMENT, V114, P39; Takeuchi Y, 2002, ENDOCRINOLOGY, V143, P1346, DOI 10.1210/en.143.4.1346; Tian HH, 2006, MOL ENDOCRINOL, V20, P2036, DOI 10.1210/me.2005-0437; Tsai CC, 2004, VITAM HORM, V68, P93; Tzagarakis-Foster C, 1998, J BIOL CHEM, V273, P10926, DOI 10.1074/jbc.273.18.10926; Wan W, 2005, MOL ENDOCRINOL, V19, P1529, DOI 10.1210/me.2005-0014; Warnmark A, 2003, MOL ENDOCRINOL, V17, P1901, DOI 10.1210/me.2002-0384; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Xu Jianming, 2002, Rev Endocr Metab Disord, V3, P185, DOI 10.1023/A:1020016208071; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Yang ZH, 1999, J BIOL CHEM, V274, P37131, DOI 10.1074/jbc.274.52.37131; Yang ZH, 2001, MOL ENDOCRINOL, V15, P1170, DOI 10.1210/me.15.7.1170; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	68	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19554	19563		10.1074/jbc.M109.007542	http://dx.doi.org/10.1074/jbc.M109.007542			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19487700	hybrid, Green Published			2022-12-25	WOS:000267908300047
J	Dhar, SS; Ongwijitwat, S; Wong-Riley, MTT				Dhar, Shilpa S.; Ongwijitwat, Sakkapol; Wong-Riley, Margaret T. T.			Chromosome Conformation Capture of All 13 Genomic Loci in the Transcriptional Regulation of the Multisubunit Bigenomic Cytochrome c Oxidase in Neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RESPIRATORY FACTOR-2; CONTROLLING MITOCHONDRIAL BIOGENESIS; GENE-EXPRESSION; FUNCTIONAL-ACTIVITY; ENERGY-METABOLISM; FACTOR-I; COACTIVATOR; SUBUNITS; NRF-2; TRANSMISSION	Cytochrome c oxidase (COX) is the terminal enzyme of the electron transport chain composed of 13 subunits; three are mitochondria-encoded, and 10 are nucleus-inscribed on nine different chromosomes within the mammalian genome. The transcriptional regulation of such a multisubunit, multichromosomal, and bigenomic enzyme is mechanistically challenging. Transcription factories have been proposed as one mechanism by which genes from different genomic loci congregate to transcribe functionally related genes, and chromosome conformation capture (3C) is a means by which such interactions can be revealed. Thus far, however, only loci from the same chromosome or at most two chromosomes have been co-localized by 3C. The present study used 3C to test our hypothesis that not only the 10 genomic loci from nine chromosomes encoding the 10 nuclear subunits of COX, but also genes from three chromosomes encoding mitochondrial transcription factors A and B (Tfam, Tfb1m, and Tfb2m) critical for the transcription of the three mitochondria-encoded COX subunit genes all occupy common intranuclear sites in the murine neuronal nuclei. The pairing of various COX subunit genes and Tf genes indicates that interactions are present among all of them. On the other hand, genes for a non-mitochondrial protein (calreticulin) as well as a mitochondrial enzyme (citrate synthase) did not interact with COX genes. Furthermore, interactions between COX subunit and Tf genes were up-regulated by depolarizing stimulation and down-regulated by impulse blockade in primary neurons. Thus, a viable mechanism is in place for a synchronized, coordinated transcriptional regulation of this multisubunit, bigenomic COX enzyme in neurons.	[Dhar, Shilpa S.; Ongwijitwat, Sakkapol; Wong-Riley, Margaret T. T.] Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Wong-Riley, MTT (corresponding author), Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	mwr@mcw.edu	Wong-Riley, Margaret/AGM-6202-2022		National Institutes of Health [R01 EY018441]; NATIONAL EYE INSTITUTE [R01EY018441] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported, in whole or in part, by National Institutes of Health Grant R01 EY018441.	Andersson U, 2001, MOL CELL BIOL, V21, P3738, DOI 10.1128/MCB.21.11.3738-3749.2001; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Dhar SS, 2008, J BIOL CHEM, V283, P3120, DOI 10.1074/jbc.M707587200; Dhar SS, 2009, J NEUROCHEM, V108, P1595, DOI 10.1111/j.1471-4159.2009.05929.x; Dhar SS, 2009, J NEUROSCI, V29, P483, DOI 10.1523/JNEUROSCI.3704-08.2009; Eppig JT, 2007, NUCLEIC ACIDS RES, V35, pD630, DOI 10.1093/nar/gkl940; Escriva H, 1999, BIOCHIMIE, V81, P965, DOI 10.1016/S0300-9084(99)00223-0; Gleyzer N, 2005, MOL CELL BIOL, V25, P1354, DOI 10.1128/MCB.25.4.1354-1366.2005; HEVNER RF, 1993, J NEUROSCI, V13, P1805; Jackson DA, 1998, MOL BIOL CELL, V9, P1523, DOI 10.1091/mbc.9.6.1523; KADENBACH B, 1986, J BIOENERG BIOMEMBR, V18, P39, DOI 10.1007/BF00743611; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Liang HL, 2006, NEUROSCIENCE, V140, P177, DOI 10.1016/j.neuroscience.2006.01.056; Liang HL, 2006, NEUROREPORT, V17, P401, DOI 10.1097/01.wnr.0000204980.98876.11; Ling JQ, 2006, SCIENCE, V312, P269, DOI 10.1126/science.1123191; Lomvardas S, 2006, CELL, V126, P403, DOI 10.1016/j.cell.2006.06.035; Meng H, 2007, BRAIN RES, V1175, P10, DOI 10.1016/j.brainres.2007.07.063; Miele Adriana, 2008, V464, P105; *NAT RES COUNC, 1996, GUID CAR US LAB AN; Nie F, 1999, J COMP NEUROL, V404, P310, DOI 10.1002/(SICI)1096-9861(19990215)404:3<310::AID-CNE3>3.0.CO;2-4; Ongwijitwat S, 2005, GENE, V360, P65, DOI 10.1016/j.gene.2005.06.015; Ongwijitwat S, 2006, GENE, V374, P39, DOI 10.1016/j.gene.2006.01.009; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Pequignot MO, 2001, HUM MUTAT, V17, P374, DOI 10.1002/humu.1112.abs; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; Scarpulla RC, 2006, J CELL BIOCHEM, V97, P673, DOI 10.1002/jcb.20743; Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007; SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; TOPPER JN, 1989, MOL CELL BIOL, V9, P1200, DOI 10.1128/MCB.9.3.1200; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; Wikstrom M., 1981, CYTOCHROME OXIDASE S; Wong-Riley MTT, 1998, CYTOCHROME OXIDASE IN NEURONAL METABOLISM AND ALZHEIMER'S DISEASE, P1; WONGRILEY MT, 2008, UNDERSTANDING TRANSC, P209; WONGRILEY MTT, 1989, TRENDS NEUROSCI, V12, P94, DOI 10.1016/0166-2236(89)90165-3; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xu M, 2008, J CELL BIOL, V181, P615, DOI 10.1083/jcb.200710053; Yang SJ, 2006, NEUROSCIENCE, V141, P1181, DOI 10.1016/j.neuroscience.2006.04.063; Yang SJ, 2004, EUR J NEUROSCI, V19, P1153, DOI 10.1111/j.1460-9568.2004.03250.x; Zhou GL, 2006, MOL CELL BIOL, V26, P5096, DOI 10.1128/MCB.02454-05	43	25	26	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18644	18650		10.1074/jbc.M109.019976	http://dx.doi.org/10.1074/jbc.M109.019976			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19439416	hybrid, Green Published			2022-12-25	WOS:000267711500013
J	Goh, SL; Looi, Y; Shen, H; Fang, J; Bodner, C; Houle, M; Ng, ACH; Screaton, RA; Featherstone, M				Goh, Siew-Lee; Looi, Yvonne; Shen, Hui; Fang, Jun; Bodner, Caroline; Houle, Martin; Ng, Andy Cheuk-Him; Screaton, Robert A.; Featherstone, Mark			Transcriptional Activation by MEIS1A in Response to Protein Kinase A Signaling Requires the Transducers of Regulated CREB Family of CREB Co-activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOX-PBX COMPLEXES; DNA-BINDING; MYELOID-LEUKEMIA; GENE-EXPRESSION; SEQUENCE CRS1; CELL; INDUCTION; LEUKEMOGENESIS; ASSOCIATION; MECHANISM	The transcription factor encoded by the murine ecotropic integration site 1 gene (MEIS1) is a partner of HOX and PBX proteins. It has been implicated in embryonic patterning and leukemia, and causally linked to restless legs syndrome. The MEIS1A C terminus harbors a transcriptional activation domain that is stimulated by protein kinase A (PKA) in a manner dependent on the co-activator of cAMP response element-binding protein (CREB), CREB-binding protein (CBP). We explored the involvement of another mediator of PKA-inducible transcription, namely the CREB co-activators transducers of regulated CREB activity (TORCs). Overexpression of TORC1 or TORC2 bypassed PKA for activation by MEIS1A. Co-immunoprecipitation experiments demonstrated a physical interaction between MEIS1 and TORC2 that is dependent on the MEIS1AC terminus, whereas chromatin immunoprecipitation revealed PKA-inducible recruitment of MEIS1, PBX1, and TORC2 on the MEIS1 target genes Hoxb2 and Meis1. The MEIS1 interaction domain on TORC1 was mapped to the N-terminal coiled-coil region, and TORC1 mutants lacking this domain attenuated the response to PKA on a natural MEIS1A target enhancer. Thus, TORCs physically cooperate with MEIS1 to achieve PKA-inducible transactivation through the MEIS1A C terminus, suggesting a concerted action in developmental and oncogenic processes.	[Goh, Siew-Lee; Fang, Jun; Bodner, Caroline; Houle, Martin] McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; [Goh, Siew-Lee; Looi, Yvonne; Shen, Hui; Featherstone, Mark] Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore; [Ng, Andy Cheuk-Him; Screaton, Robert A.] Univ Ottawa, Dept Pediat, Childrens Hosp Eastern Ontario, Apoptosis Res Ctr, Ottawa, ON K1H 8L1, Canada; [Ng, Andy Cheuk-Him; Screaton, Robert A.] Univ Ottawa, Dept Biochem Immunol & Microbiol, Childrens Hosp Eastern Ontario, Apoptosis Res Ctr, Ottawa, ON K1H 8L1, Canada	McGill University; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Children's Hospital of Eastern Ontario	Featherstone, M (corresponding author), Rm 03n 41,60 Nanyang Dr, Singapore 637551, Singapore.	msfeatherstone@ntu.edu.sg	Featherstone, Mark/E-8057-2010	Featherstone, Mark/0000-0003-1576-046X	Canadian Institutes of Health Research and the Biomedical Research Council	Canadian Institutes of Health Research and the Biomedical Research Council(Canadian Institutes of Health Research (CIHR))	This work was supported in part by grants from the Canadian Institutes of Health Research and the Biomedical Research Council (Singapore) (to M.F.).	Argiropoulos B, 2008, EXP HEMATOL, V36, P845, DOI 10.1016/j.exphem.2008.02.011; Argiropoulos B, 2007, GENE DEV, V21, P2845, DOI 10.1101/gad.1619407; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Bijlsma MF, 2004, BIOESSAYS, V26, P387, DOI 10.1002/bies.20007; Bischof LJ, 1998, J BIOL CHEM, V273, P7941, DOI 10.1074/jbc.273.14.7941; Bittinger MA, 2004, CURR BIOL, V14, P2156, DOI 10.1016/j.cub.2004.11.002; Calvo KR, 1999, ONCOGENE, V18, P8033, DOI 10.1038/sj.onc.1203377; Canettieri G, 2009, P NATL ACAD SCI USA, V106, P1445, DOI 10.1073/pnas.0808749106; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Conkright MD, 2005, TRENDS CELL BIOL, V15, P457, DOI 10.1016/j.tcb.2005.07.007; Dibner C, 2001, DEVELOPMENT, V128, P3415; Featherstone M, 2003, AD DEV BIOL, V13, P1; Ferretti E, 2000, DEVELOPMENT, V127, P155; Fischbach NA, 2005, BLOOD, V105, P1456, DOI 10.1182/blood-2004-04-1583; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; Huang H, 2005, J BIOL CHEM, V280, P10119, DOI 10.1074/jbc.M413963200; Huang H, 2003, MOL CELL BIOL, V23, P3636, DOI 10.1128/MCB.23.10.3636-3645.2003; Inbal A, 2001, DEVELOPMENT, V128, P3405; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Johannessen M, 2004, CELL SIGNAL, V16, P1211, DOI 10.1016/j.cellsig.2004.05.001; KAGAWA N, 1994, J BIOL CHEM, V269, P18716; Koga H, 2004, J BIOL CHEM, V279, P52978, DOI 10.1074/jbc.M409021200; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Li ZJ, 2009, CANCER RES, V69, P1109, DOI 10.1158/0008-5472.CAN-08-3381; Mamo A, 2006, BLOOD, V108, P622, DOI 10.1182/blood-2005-06-2244; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Moens CB, 2006, DEV BIOL, V291, P193, DOI 10.1016/j.ydbio.2005.10.032; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Rastegar M, 2004, MOL CELL BIOL, V24, P8090, DOI 10.1128/MCB.24.18.8090-8103.2004; Saleh M, 2000, MOL CELL BIOL, V20, P8623, DOI 10.1128/MCB.20.22.8623-8633.2000; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shen WF, 2004, J BIOL CHEM, V279, P39895, DOI 10.1074/jbc.M404132200; Shen WF, 2001, MOL CELL BIOL, V21, P7509, DOI 10.1128/MCB.21.21.7509-7522.2001; Siu YT, 2006, J VIROL, V80, P7052, DOI 10.1128/JVI.00103-06; Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001; Vlachakis N, 2001, DEVELOPMENT, V128, P1299; Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608; Wang GG, 2006, MOL CELL BIOL, V26, P3902, DOI 10.1128/MCB.26.10.3902-3916.2006; Wang GG, 2005, BLOOD, V106, P254, DOI 10.1182/blood-2004-12-4664; Waskiewicz AJ, 2001, DEVELOPMENT, V128, P4139; Winkelmann J, 2007, NAT GENET, V39, P1000, DOI 10.1038/ng2099; Xiong L, 2009, HUM MOL GENET, V18, P1065, DOI 10.1093/hmg/ddn443	48	16	17	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18904	18912		10.1074/jbc.M109.005090	http://dx.doi.org/10.1074/jbc.M109.005090			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19473990	hybrid, Green Published			2022-12-25	WOS:000267711500040
J	Loimaranta, V; Hytonen, J; Pulliainen, AT; Sharma, A; Tenovuo, J; Stromberg, N; Finne, J				Loimaranta, Vuokko; Hytonen, Jukka; Pulliainen, Arto T.; Sharma, Ashu; Tenovuo, Jorma; Stromberg, Nicklas; Finne, Jukka			Leucine-rich Repeats of Bacterial Surface Proteins Serve as Common Pattern Recognition Motifs of Human Scavenger Receptor gp340	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCUS; INNATE IMMUNE PROTEINS; ANTIGEN-I/II FAMILY; TOLL-LIKE RECEPTORS; SALIVARY AGGLUTININ; CELL-SURFACE; ANTIINFLUENZA ACTIVITIES; GEL-ELECTROPHORESIS; SEQUENCE-ANALYSIS; EPITHELIAL-CELLS	Scavenger receptors are innate immune molecules recognizing and inducing the clearance of non-host as well as modified host molecules. To recognize a wide pattern of invading microbes, many scavenger receptors bind to common pathogen-associated molecular patterns, such as lipopolysaccharides and lipoteichoic acids. Similarly, the gp340/DMBT1 protein, a member of the human scavenger receptor cysteine-rich protein family, displays a wide ligand repertoire. The peptide motif VEVLXXXXW derived from its scavenger receptor cysteine-rich domains is involved in some of these interactions, but most of the recognition mechanisms are unknown. In this study, we used mass spectrometry sequencing, gene inactivation, and recombinant proteins to identify Streptococcus pyogenes protein Spy0843 as a recognition receptor of gp340. Antibodies against Spy0843 are shown to protect against S. pyogenes infection, but no function or host receptor have been identified for the protein. Spy0843 belongs to the leucine-rich repeat (Lrr) family of eukaryotic and prokaryotic proteins. Experiments with truncated forms of the recombinant proteins confirmed that the Lrr region is needed in the binding of Spy0843 to gp340. The same motif of two other Lrr proteins, LrrG from the Gram-positive S. agalactiae and BspA from the Gram-negative Tannerella forsythia, also mediated binding to gp340. Moreover, inhibition of Spy0843 binding occurred with peptides containing the VEVLXXXXW motif, but also peptides devoid of the XXXXW motif inhibited binding of Lrr proteins. These results thus suggest that the conserved Lrr motif in bacterial proteins serves as a novel pattern recognition motif for unique core peptides of human scavenger receptor gp340.	[Loimaranta, Vuokko; Hytonen, Jukka; Pulliainen, Arto T.; Finne, Jukka] Univ Turku, Dept Med Biochem & Genet, FI-20520 Turku, Finland; [Hytonen, Jukka] Univ Turku, Dept Med Microbiol & Immunol, FI-20520 Turku, Finland; [Tenovuo, Jorma] Univ Turku, Inst Dent, FI-20520 Turku, Finland; [Tenovuo, Jorma] Turku Univ Hosp, Dept Oral Dis, FI-20520 Turku, Finland; [Pulliainen, Arto T.] Univ Basel, Biozentrum, Basel, Switzerland; [Sharma, Ashu] SUNY Buffalo, Sch Dent Med, Dept Oral Biol, Buffalo, NY 14214 USA; [Stromberg, Nicklas] Umea Univ, Dept Odontol, SE-90187 Umea, Sweden	University of Turku; University of Turku; University of Turku; University of Turku; University of Basel; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Umea University	Loimaranta, V (corresponding author), Univ Turku, Dept Med Biochem & Genet, Kiinamyllynkatu 10, FI-20520 Turku, Finland.	vuokko.loimaranta@utu.fi	Pulliainen, Arto/AAX-2052-2021; Abrams, William R/A-5782-2008; Finne, Jukka/B-6881-2008	Loimaranta, Vuokko/0000-0002-6873-2270; Hytonen, Jukka/0000-0002-0585-9338; Finne, Jukka/0000-0002-8076-3344; Pulliainen, Arto Tapio/0000-0002-9361-8963	Academy of Finland [114100]	Academy of Finland(Academy of Finland)	This work was supported by Grant 114100 from the Academy of Finland.	AKESSON P, 1994, BIOCHEM J, V300, P877, DOI 10.1042/bj3000877; Bikker FJ, 2004, J BIOL CHEM, V279, P47699, DOI 10.1074/jbc.M406095200; Bikker FJ, 2002, J BIOL CHEM, V277, P32109, DOI 10.1074/jbc.M203788200; Brannstrom A, 2002, BIOCHEM BIOPH RES CO, V290, P1462, DOI 10.1006/bbrc.2002.6378; Chaussee MS, 1999, INFECT IMMUN, V67, P1715; CROWLEY PJ, 1993, INFECT IMMUN, V61, P1547, DOI 10.1128/IAI.61.4.1547-1552.1993; Edwards AM, 2008, MOL MICROBIOL, V68, P1378, DOI 10.1111/j.1365-2958.2008.06220.x; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; Graham MR, 2005, AM J PATHOL, V166, P455, DOI 10.1016/S0002-9440(10)62268-7; Hajishengallis G, 2002, CLIN DIAGN LAB IMMUN, V9, P403, DOI 10.1128/CDLI.9.2.403-411.2002; Hartshorn KL, 2006, BIOCHEM J, V393, P545, DOI 10.1042/BJ20050695; Hartshorn KL, 2003, AM J PHYSIOL-LUNG C, V285, pL1066, DOI 10.1152/ajplung.00057.2003; Holmes AR, 1998, INFECT IMMUN, V66, P4633, DOI 10.1128/IAI.66.10.4633-4639.1998; Holmskov U, 1997, J BIOL CHEM, V272, P13743, DOI 10.1074/jbc.272.21.13743; Holmskov U, 1999, P NATL ACAD SCI USA, V96, P10794, DOI 10.1073/pnas.96.19.10794; Hytonen J, 2003, INFECT IMMUN, V71, P784, DOI 10.1128/IAI.71.2.784-793.2003; Jakubovics NS, 2005, INFECT IMMUN, V73, P6629, DOI 10.1128/IAI.73.10.6629-6638.2005; Jenkinson HF, 1997, MOL MICROBIOL, V23, P183, DOI 10.1046/j.1365-2958.1997.2021577.x; Jonasson A, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-57; Kang W, 2002, CLIN EXP IMMUNOL, V130, P449, DOI 10.1046/j.1365-2249.2002.01992.x; Kang WQ, 2003, FEBS LETT, V540, P21, DOI 10.1016/S0014-5793(03)00217-5; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kussmann M, 1997, J MASS SPECTROM, V32, P483; Ligtenberg TJM, 2001, BIOCHEM J, V359, P243, DOI 10.1042/0264-6021:3590243; Loimaranta V, 2005, INFECT IMMUN, V73, P2245, DOI 10.1128/IAI.73.4.2245-2252.2005; Matsushima N, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-124; Mereghetti L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003143; Mollenhauer J, 2000, CANCER RES, V60, P1704; Mueller A, 2003, P NATL ACAD SCI USA, V100, P1292, DOI 10.1073/pnas.242741699; Nyman TA, 2000, EUR J BIOCHEM, V267, P4011, DOI 10.1046/j.1432-1327.2000.01433.x; Oho T, 1998, INFECT IMMUN, V66, P115, DOI 10.1128/IAI.66.1.115-121.1998; Onishi S, 2008, INFECT IMMUN, V76, P198, DOI 10.1128/IAI.01139-07; Prakobphol A, 2000, J BIOL CHEM, V275, P39860, DOI 10.1074/jbc.M006928200; Pulliainen AT, 2003, J BIOL CHEM, V278, P7996, DOI 10.1074/jbc.M210174200; Reid SD, 2003, INFECT IMMUN, V71, P7043, DOI 10.1128/IAI.71.12.7043-7052.2003; Reid SD, 2002, J BACTERIOL, V184, P6316, DOI 10.1128/JB.184.22.6316-6324.2002; Renner M, 2007, GASTROENTEROLOGY, V133, P1499, DOI 10.1053/j.gastro.2007.08.007; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Rosenstiel P, 2007, J IMMUNOL, V178, P8203, DOI 10.4049/jimmunol.178.12.8203; Sarrias MR, 2004, CRIT REV IMMUNOL, V24, P1; Schulz BL, 2002, BIOCHEM J, V366, P511, DOI 10.1042/BJ20011876; Seepersaud R, 2005, INFECT IMMUN, V73, P1671, DOI 10.1128/IAI.73.3.1671-1683.2005; Segers RPAM, 1998, FEMS MICROBIOL LETT, V167, P255, DOI 10.1111/j.1574-6968.1998.tb13236.x; Sharma A, 1998, INFECT IMMUN, V66, P5703, DOI 10.1128/IAI.66.12.5703-5710.1998; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Takamatsu D, 2006, INFECT IMMUN, V74, P1933, DOI 10.1128/IAI.74.3.1933-1940.2006; Virtaneva K, 2003, INFECT IMMUN, V71, P2199, DOI 10.1128/IAI.71.4.2199-2207.2003; White MR, 2005, AM J PHYSIOL-LUNG C, V289, pL606, DOI 10.1152/ajplung.00130.2005; White MR, 2005, AM J PHYSIOL-LUNG C, V288, pL831, DOI 10.1152/ajplung.00365.2004; Wu ZW, 2003, AIDS RES HUM RETROV, V19, P201, DOI 10.1089/088922203763315704	50	38	39	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18614	18623		10.1074/jbc.M900581200	http://dx.doi.org/10.1074/jbc.M900581200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19465482	hybrid, Green Published			2022-12-25	WOS:000267711500010
J	Rashid, S; Pilecka, I; Torun, A; Olchowik, M; Bielinska, B; Miaczynska, M				Rashid, Sajid; Pilecka, Iwona; Torun, Anna; Olchowik, Marta; Bielinska, Beata; Miaczynska, Marta			Endosomal Adaptor Proteins APPL1 and APPL2 Are Novel Activators of beta-Catenin/TCF-mediated Transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-FACTOR; NEGATIVE REGULATOR; CYCLIN D1; TARGET; GENE; SIGNAL; LOCALIZATION; INHIBITION; RECEPTOR; COMPLEX	Canonical Wnt signaling regulates many aspects of cellular physiology and tissue homeostasis during development and in adult organisms. In molecular terms, stimulation by Wnt ligands leads to the stabilization of beta-catenin, its translocation to the nucleus, and stimulation of TCF (T-cell factor)-dependent transcription of targetgenes. This process is controlled at various stages by a number of regulatory proteins, including transcriptional activators and repressors. Here we demonstrate that the endosomal proteins APPL1 and APPL2 are novel activators of beta-catenin/TCF-mediated transcription. APPL proteins are multifunctional adaptors and effectors of the small GTPase Rab5, which localize to a subpopulation of early endosomes but are also capable of nucleo-cytoplasmic shuttling. Overexpression of APPL1 or APPL2 protein stimulates the activity of beta-catenin/TCF-dependent reporter construct, whereas silencing of APPL1 reduces it. Both APPL proteins interact directly with Reptin, a transcriptional repressor binding to beta-catenin and HDAC1(histone deacetylase 1), and this interaction was mapped to the pleckstrin homology domain of APPL1. Moreover, APPL proteins are present in an endogenous complex containing Reptin, beta-catenin, HDAC1, and HDAC2. Overexpression of either APPL protein relieves Reptin-dependent transcriptional repression and correlates with the reduced amounts of HDAC sand beta-catenin associated with Reptin as well as with the lower levels of Reptin and HDAC1 on the promoters of beta-catenin target genes. We propose that APPL proteins exert their stimulatory effects on beta-catenin/TCF-dependent transcription by decreasing the activity of a Reptin-containing repressive complex.	[Rashid, Sajid; Pilecka, Iwona; Torun, Anna; Olchowik, Marta; Bielinska, Beata; Miaczynska, Marta] Int Inst Mol & Cell Biol, Cell Biol Lab, PL-02109 Warsaw, Poland	Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Miaczynska, M (corresponding author), Int Inst Mol & Cell Biol, Cell Biol Lab, Ks Trojdena 4, PL-02109 Warsaw, Poland.	miaczynska@iimcb.gov.pl	Pilecka, Iwona/AAT-9114-2021; Rashid, Sajid/K-8640-2019	Pilecka, Iwona/0000-0002-5057-346X; Miaczynska, Marta/0000-0003-0031-5267; Brewinska-Olchowik, Marta/0000-0002-2135-6220	Howard Hughes Medical Institute; Wellcome Trust Senior Research Fellowship [076469/Z/05/Z]; European Union [LSHG-CT2006-019050]; Polish Ministry of Science and Higher Education [2P04A03828]; Max Planck Society	Howard Hughes Medical Institute(Howard Hughes Medical Institute); Wellcome Trust Senior Research Fellowship(Wellcome Trust); European Union(European Commission); Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland); Max Planck Society(Max Planck SocietyFoundation CELLEX)	This work was supported in part by an International Research Scholar Grant from the Howard Hughes Medical Institute, Wellcome Trust Senior Research Fellowship 076469/Z/05/Z, European Union Grant LSHG-CT2006-019050 (EndoTrack), Polish Ministry of Science and Higher Education Grant 2P04A03828 and the Mobilitas. pl network, and the Max Planck Society (Partner Group Program).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128/JVI.78.21.11823-11832.2004; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cong F, 2004, P NATL ACAD SCI USA, V101, P2882, DOI 10.1073/pnas.0307344101; Cong F, 2003, MOL CELL BIOL, V23, P8462, DOI 10.1128/MCB.23.23.8462-8470.2003; DasGupta R, 2005, SCIENCE, V308, P826, DOI 10.1126/science.1109374; Deepa SS, 2009, AM J PHYSIOL-ENDOC M, V296, pE22, DOI 10.1152/ajpendo.90731.2008; Erdmann KS, 2007, DEV CELL, V13, P377, DOI 10.1016/j.devcel.2007.08.004; Gallant P, 2007, TRENDS CELL BIOL, V17, P187, DOI 10.1016/j.tcb.2007.02.005; Gan XQ, 2008, J CELL BIOL, V180, P1087, DOI 10.1083/jcb.200710050; Gao X, 2008, J BIOL CHEM, V283, P35679, DOI 10.1074/jbc.M804088200; Harte D, 1998, J NONLINEAR SCI, V8, P581, DOI 10.1007/s003329900060; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoeller D, 2005, CURR OPIN CELL BIOL, V17, P107, DOI 10.1016/j.ceb.2005.01.001; Huang H, 2008, CURR OPIN CELL BIOL, V20, P119, DOI 10.1016/j.ceb.2008.01.009; Huber O, 2008, CANCER RES, V68, P6873, DOI 10.1158/0008-5472.CAN-08-0547; Kanemaki M, 1999, J BIOL CHEM, V274, P22437, DOI 10.1074/jbc.274.32.22437; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kittler R, 2005, NAT METHODS, V2, P779, DOI 10.1038/nmeth1005-779; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Li FQ, 2007, MOL CELL BIOL, V27, P4347, DOI 10.1128/MCB.01640-06; Li J, 2007, STRUCTURE, V15, P525, DOI 10.1016/j.str.2007.03.011; Lin DC, 2006, MOL CELL BIOL, V26, P8928, DOI 10.1128/MCB.00228-06; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu J, 2002, J BIOL CHEM, V277, P26281, DOI 10.1074/jbc.M204679200; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Mao XM, 2006, NAT CELL BIOL, V8, P516, DOI 10.1038/ncb1404; Meares GP, 2007, J BIOL CHEM, V282, P16989, DOI 10.1074/jbc.M700610200; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Mitsuuchi Y, 1999, ONCOGENE, V18, P4891, DOI 10.1038/sj.onc.1203080; Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802; Olson LE, 2006, CELL, V125, P593, DOI 10.1016/j.cell.2006.02.046; Pilecka I, 2007, EUR J CELL BIOL, V86, P533, DOI 10.1016/j.ejcb.2007.04.004; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polo S, 2006, CELL, V124, P897, DOI 10.1016/j.cell.2006.02.025; Puri T, 2007, J MOL BIOL, V366, P179, DOI 10.1016/j.jmb.2006.11.030; Rottbauer W, 2002, CELL, V111, P661, DOI 10.1016/S0092-8674(02)01112-1; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sadowski L, 2009, EXP CELL RES, V315, P1601, DOI 10.1016/j.yexcr.2008.09.021; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schenck A, 2008, CELL, V133, P486, DOI 10.1016/j.cell.2008.02.044; Seto ES, 2006, J CELL BIOL, V173, P95, DOI 10.1083/jcb.200510123; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Sigala B, 2005, EXP CELL RES, V310, P357, DOI 10.1016/j.yexcr.2005.07.030; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Tang W, 2008, P NATL ACAD SCI USA, V105, P9697, DOI 10.1073/pnas.0804709105; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Varsano T, 2006, MOL CELL BIOL, V26, P8942, DOI 10.1128/MCB.00305-06; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Vietor I, 2005, J BIOL CHEM, V280, P39795, DOI 10.1074/jbc.M509836200; von Zastrow M, 2007, CURR OPIN CELL BIOL, V19, P436, DOI 10.1016/j.ceb.2007.04.021; Wiechens N, 2004, J BIOL CHEM, V279, P5263, DOI 10.1074/jbc.M307253200; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006	63	51	52	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	2009	284	27					18115	18128		10.1074/jbc.M109.007237	http://dx.doi.org/10.1074/jbc.M109.007237			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BW	19433865	Green Published, hybrid			2022-12-25	WOS:000267712400023
J	Dreyfus, DH				Dreyfus, David H.			Paleo-Immunology: Evidence Consistent with Insertion of a Primordial Herpes Virus-Like Element in the Origins of Acquired Immunity	PLOS ONE			English	Article								Background: The RAG encoded proteins, RAG-1 and RAG-2 regulate site-specific recombination events in somatic immune B-and T-lymphocytes to generate the acquired immune repertoire. Catalytic activities of the RAG proteins are related to the recombinase functions of a pre-existing mobile DNA element in the DDE recombinase/RNAse H family, sometimes termed the "RAG transposon''. Methodology/'Principal Findings: Novel to this work is the suggestion that the DDE recombinase responsible for the origins of acquired immunity was encoded by a primordial herpes virus, rather than a "RAG transposon.'' A subsequent "arms race'' between immunity to herpes infection and the immune system obscured primary amino acid similarities between herpes and immune system proteins but preserved regulatory, structural and functional similarities between the respective recombinase proteins. In support of this hypothesis, evidence is reviewed from previous published data that a modern herpes virus protein family with properties of a viral recombinase is co-regulated with both RAG-1 and RAG-2 by closely linked cis-acting co-regulatory sequences. Structural and functional similarity is also reviewed between the putative herpes recombinase and both DDE site of the RAG-1 protein and another DDE/RNAse H family nuclease, the Argonaute protein component of RISC (RNA induced silencing complex). Conclusions/Significance: A "co-regulatory'' model of the origins of V(D)J recombination and the acquired immune system can account for the observed linked genomic structure of RAG-1 and RAG-2 in non-vertebrate organisms such as the sea urchin that lack an acquired immune system and V(D)J recombination. Initially the regulated expression of a viral recombinase in immune cells may have been positively selected by its ability to stimulate innate immunity to herpes virus infection rather than V(D)J recombination Unlike the "RAG-transposon'' hypothesis, the proposed model can be readily tested by comparative functional analysis of herpes virus replication and V(D)J recombination.			Dreyfus, DH (corresponding author), Yale Univ, Sch Med, New Haven, CT 06520 USA.	dhdreyfus@pol.net			NIAID NIH HHS [T32 AI007365, T32-AI07365] Funding Source: Medline; NIGMS NIH HHS [T32 GM007288, T32-GM07288] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Balmelle N, 2004, J IMMUNOL, V173, P5054, DOI 10.4049/jimmunol.173.8.5054; Brandt VL, 2008, J IMMUNOL, V180, P3, DOI 10.4049/jimmunol.180.1.3; CAREY M, 1992, J VIROL, V66, P4803, DOI 10.1128/JVI.66.8.4803-4813.1992; Chatterji M, 2004, IMMUNOL REV, V200, P261, DOI 10.1111/j.0105-2896.2004.00167.x; Chen YM, 1996, VIROLOGY, V221, P281, DOI 10.1006/viro.1996.0377; CHOWDHURY SI, 1990, J VIROL, V64, P873, DOI 10.1128/JVI.64.2.873-880.1990; Dardari R, 2001, J CLIN MICROBIOL, V39, P3164, DOI 10.1128/JCM.39.9.3164-3170.2001; Delecluse HJ, 2000, J CLIN PATHOL-MOL PA, V53, P270, DOI 10.1136/mp.53.5.270; Dreyfus DH, 2006, ANN ALLERG ASTHMA IM, V97, P567, DOI 10.1016/S1081-1206(10)61083-6; Dreyfus DH, 1999, MED HYPOTHESES, V52, P545, DOI 10.1054/mehy.1997.0691; Dreyfus DH, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-12; DREYFUS DH, 1992, MOL IMMUNOL, V29, P807, DOI 10.1016/0161-5890(92)90191-Y; Dreyfus DH, 1999, MOL IMMUNOL, V36, P481, DOI 10.1016/S0161-5890(99)00034-6; Dreyfus DH, 1996, IMMUNOL REV, V152, P89, DOI 10.1111/j.1600-065X.1996.tb00912.x; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; Feschotte C, 2008, NAT REV GENET, V9, P397, DOI 10.1038/nrg2337; Feschotte C, 2007, ANNU REV GENET, V41, P331, DOI 10.1146/annurev.genet.40.110405.090448; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; Francis AL, 1997, J VIROL, V71, P3054, DOI 10.1128/JVI.71.4.3054-3061.1997; Fugmann SD, 2006, P NATL ACAD SCI USA, V103, P3728, DOI 10.1073/pnas.0509720103; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Gladow M, 2004, EUR J IMMUNOL, V34, P1882, DOI 10.1002/eji.200425041; Hah C, 2005, J BIOCHEM MOL BIOL, V38, P334; HAMMERSCHMIDT W, 1990, MOL BIOL MED, V7, P45; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Hung CH, 1999, J GEN VIROL, V80, P2747, DOI 10.1099/0022-1317-80-10-2747; Jones JM, 2004, IMMUNOL REV, V200, P233, DOI 10.1111/j.0105-2896.2004.00168.x; Jones JM, 2001, STRUCTURE, V9, P881, DOI 10.1016/S0969-2126(01)00658-X; Kapitonov VV, 2005, PLOS BIOL, V3, P998, DOI 10.1371/journal.pbio.0030181; KOLMAN JL, 1992, P NATL ACAD SCI USA, V89, P7772, DOI 10.1073/pnas.89.16.7772; Kolman JL, 1996, J VIROL, V70, P1493, DOI 10.1128/JVI.70.3.1493-1504.1996; KOPS AD, 1994, J VIROL, V68, P3512; KUHNHALLEK I, 1995, BLOOD, V85, P1289, DOI 10.1182/blood.V85.5.1289.bloodjournal8551289; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Lu CP, 2008, NUCLEIC ACIDS RES, V36, P2864, DOI 10.1093/nar/gkn128; Lu CP, 2006, NAT STRUCT MOL BIOL, V13, P1010, DOI 10.1038/nsmb1154; Makhov AM, 2004, BBA-PROTEINS PROTEOM, V1701, P101, DOI 10.1016/j.bbapap.2004.06.006; Mapelli M, 2005, J BIOL CHEM, V280, P2990, DOI 10.1074/jbc.M406780200; Melek M, 2002, P NATL ACAD SCI USA, V99, P134, DOI 10.1073/pnas.012610699; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P9324, DOI 10.1073/pnas.87.23.9324; Miller G, 2007, ADV CANCER RES, V97, P81, DOI 10.1016/S0065-230X(06)97004-3; Moody CA, 2003, J VIROL, V77, P8555, DOI 10.1128/JVI.77.15.8555-8561.2003; Oettinger MA, 2004, IMMUNOL REV, V200, P165, DOI 10.1111/j.0105-2896.2004.00172.x; Paramita DK, 2007, J MED VIROL, V79, P1710, DOI 10.1002/jmv.20987; Pritham EJ, 2007, GENE, V390, P3, DOI 10.1016/j.gene.2006.08.008; Reddy YVR, 2006, GENE DEV, V20, P1575, DOI 10.1101/gad.1432706; Schatz DG, 2004, SEMIN IMMUNOL, V16, P245, DOI 10.1016/j.smim.2004.08.004; Shih IH, 2002, EMBO J, V21, P6625, DOI 10.1093/emboj/cdf630; Song JJ, 2006, CURR OPIN STRUC BIOL, V16, P5, DOI 10.1016/j.sbi.2006.01.010; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Spain TA, 1997, VIROLOGY, V237, P137, DOI 10.1006/viro.1997.8770; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; SRINIVAS SK, 1995, J VIROL, V69, P8155, DOI 10.1128/JVI.69.12.8155-8158.1995; Srinivas SK, 1998, J INFECT DIS, V177, P1705, DOI 10.1086/517427; Sun R, 1997, J VIROL, V71, P6136, DOI 10.1128/JVI.71.8.6136-6143.1997; SWANSON DL, 2004, J ACAD ETHICS, V2, P1; Taylor TJ, 2004, J VIROL, V78, P5856, DOI 10.1128/JVI.78.11.5856-5866.2004; Taylor TJ, 2003, VIROLOGY, V309, P219, DOI 10.1016/S0042-6822(03)00108-9; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Tsai CL, 2003, EMBO J, V22, P1922, DOI 10.1093/emboj/cdg185; Uprichard SL, 2003, J VIROL, V77, P7467, DOI 10.1128/JVI.77.13.7467-7476.2003; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; Verkoczy L, 2005, IMMUNITY, V22, P519, DOI 10.1016/j.immuni.2005.03.006; Verkoczy LK, 2004, CURR OPIN IMMUNOL, V16, P808, DOI 10.1016/j.coi.2004.09.017; Wagner HJ, 2004, J INFECT DIS, V190, P979, DOI 10.1086/423211; Zhou CH, 2002, J VIROL, V76, P5893, DOI 10.1128/JVI.76.12.5893-5904.2002; ZIMMERMANN J, 1995, J VIROL, V69, P3147, DOI 10.1128/JVI.69.5.3147-3155.1995	69	23	23	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2009	4	6							e5778	10.1371/journal.pone.0005778	http://dx.doi.org/10.1371/journal.pone.0005778			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453PV	19492059	Green Published, Green Submitted, gold			2022-12-25	WOS:000266624300014
J	Koyanagi, M; Iwasaki, M; Haendeler, J; Leitges, M; Zeiher, AM; Dimmeler, S				Koyanagi, Masamichi; Iwasaki, Masayoshi; Haendeler, Judith; Leitges, Michael; Zeiher, Andreas M.; Dimmeler, Stefanie			Wnt5a Increases Cardiac Gene Expressions of Cultured Human Circulating Progenitor Cells via a PKC Delta Activation	PLOS ONE			English	Article								Background: Wnt signaling controls the balance between stem cell proliferation and differentiation and body patterning throughout development. Previous data demonstrated that non-canonical Wnts (Wnt5a, Wnt11) increased cardiac gene expression of circulating endothelial progenitor cells (EPC) and bone marrow-derived stem cells cultured in vitro. Since previous studies suggested a contribution of the protein kinase C (PKC) family to the Wnt5a-induced signalling, we investigated which PKC isoforms are activated by non-canonical Wnt5a in human EPC. Methodology/Principal Findings: Immunoblot experiments demonstrated that Wnt5a selectively activated the novel PKC isoform, PKC delta, as evidenced by phosphorylation and translocation. In contrast, the classical Ca(2+)-dependent PKC isoforms, PKC alpha and beta2, and one of the other novel PKC isoforms, PKC epsilon, were not activated by Wnt5a. The PKC delta inhibitor rottlerin significantly blocked co-culture-induced cardiac differentiation in vitro, whereas inhibitors directed against the classical Ca(2+)-dependent PKC isoforms or a PKC epsilon-inhibitory peptide did not block cardiac differentiation. In accordance, EPC derived from PKC delta heterozygous mice exhibited a significant reduction of Wnt5a-induced cardiac gene expression compared to wild type mice derived EPC. Conclusions/Significance: These data indicate that Wnt5a enhances cardiac gene expressions of EPC via an activation of PKC delta.			Koyanagi, M (corresponding author), Univ Frankfurt, Ctr Mol Med, Inst Cardiovasc Regenerat, Frankfurt, Germany.	dimmeler@em.uni-frankfurt.de	Leitges, Michael/AAN-1953-2021	Haendeler, Judith/0000-0001-8507-4540; Dimmeler, Stefanie/0000-0002-1045-2436; Leitges, Michael/0000-0003-4203-6995				Bedada FB, 2005, MOL CELL BIOL, V25, P9509, DOI 10.1128/MCB.25.21.9509-9519.2005; Brade T, 2006, CARDIOVASC RES, V72, P198, DOI 10.1016/j.cardiores.2006.06.025; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI200113152; Dissanayake SK, 2007, J BIOL CHEM, V282, P17259, DOI 10.1074/jbc.M700075200; Flaherty MP, 2008, CIRCULATION, V117, P2241, DOI 10.1161/CIRCULATIONAHA.107.741066; Gobbi G, 2007, STEM CELLS, V25, P2322, DOI 10.1634/stemcells.2006-0839; Heeschen C, 2003, BLOOD, V102, P1340, DOI 10.1182/blood-2003-01-0223; Koyanagi M, 2005, J BIOL CHEM, V280, P16838, DOI 10.1074/jbc.M500323200; Leitges M, 2001, J CLIN INVEST, V108, P1505; Marvin MJ, 2001, GENE DEV, V15, P316, DOI 10.1101/gad.855501; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Naito AT, 2006, P NATL ACAD SCI USA, V103, P19812, DOI 10.1073/pnas.0605768103; Nakamura T, 2003, P NATL ACAD SCI USA, V100, P5834, DOI 10.1073/pnas.0935626100; Nusse R, 2008, CELL RES, V18, P523, DOI 10.1038/cr.2008.47; Palpant NJ, 2007, J MOL CELL CARDIOL, V43, P362, DOI 10.1016/j.yjmcc.2007.06.012; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; Qyang Y, 2007, CELL STEM CELL, V1, P165, DOI 10.1016/j.stem.2007.05.018; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reyland ME, 2007, BIOCHEM SOC T, V35, P1001, DOI 10.1042/BST0351001; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Steinhart R, 2007, GLIA, V55, P224, DOI 10.1002/glia.20454; Zhou X, 2003, DEV BIOL, V255, P407, DOI 10.1016/S0012-1606(02)00080-5	24	24	26	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2009	4	6							e5765	10.1371/journal.pone.0005765	http://dx.doi.org/10.1371/journal.pone.0005765			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453CI	19492056	Green Published, Green Submitted, gold			2022-12-25	WOS:000266587400008
J	Friedrich, R; Friederici, AD				Friedrich, Roland; Friederici, Angela D.			Mathematical Logic in the Human Brain: Syntax	PLOS ONE			English	Article							HIERARCHICAL ORGANIZATION; PREFRONTAL CORTEX; NEURAL BASIS; LANGUAGE	Theory predicts a close structural relation of formal languages with natural languages. Both share the aspect of an underlying grammar which either generates (hierarchically) structured expressions or allows us to decide whether a sentence is syntactically correct or not. The advantage of rule-based communication is commonly believed to be its efficiency and effectiveness. A particularly important class of formal languages are those underlying the mathematical syntax. Here we provide brain-imaging evidence that the syntactic processing of abstract mathematical formulae, written in a first order language, is, indeed efficient and effective as a rule-based generation and decision process. However, it is remarkable, that the neural network involved, consisting of intraparietal and prefrontal regions, only involves Broca's area in a surprisingly selective way. This seems to imply that despite structural analogies of common and current formal languages, at the neural level, mathematics and natural language are processed differently, in principal.			Friedrich, R (corresponding author), Max Planck Inst Human Cognit & Brain Sci, Leipzig, Germany.	friedrich@cbs.mpg.de						Amunts K, 1999, J COMP NEUROL, V412, P319, DOI 10.1002/(SICI)1096-9861(19990920)412:2<319::AID-CNE10>3.0.CO;2-7; Anderson JR, 2008, TRENDS COGN SCI, V12, P136, DOI 10.1016/j.tics.2008.01.006; Badre D, 2007, J COGNITIVE NEUROSCI, V19, P2082, DOI 10.1162/jocn.2007.19.12.2082; Ben-Shachar M, 2003, PSYCHOL SCI, V14, P433, DOI 10.1111/1467-9280.01459; Butterworth B, 2005, J CHILD PSYCHOL PSYC, V46, P3, DOI 10.1111/j.1469-7610.2004.00374.x; Dehaene S, 2004, CURR OPIN NEUROBIOL, V14, P218, DOI 10.1016/j.conb.2004.03.008; Dehaene S, 1999, SCIENCE, V284, P970, DOI 10.1126/science.284.5416.970; Duncan J, 2000, SCIENCE, V289, P457, DOI 10.1126/science.289.5478.457; Fitch WT, 2004, SCIENCE, V303, P377, DOI 10.1126/science.1089401; Friederici AD, 2006, P NATL ACAD SCI USA, V103, P2458, DOI 10.1073/pnas.0509389103; Friederici AD, 2006, CEREB CORTEX, V16, P1709, DOI 10.1093/cercor/bhj106; Goel V, 2007, TRENDS COGN SCI, V11, P435, DOI 10.1016/j.tics.2007.09.003; Gruber O, 2003, NEUROIMAGE, V19, P797, DOI 10.1016/S1053-8119(03)00089-2; Hauser MD, 2002, SCIENCE, V298, P1569, DOI 10.1126/science.298.5598.1569; Koechlin E, 2007, SCIENCE, V318, P594, DOI 10.1126/science.1142995; Koechlin E, 2006, NEURON, V50, P963, DOI 10.1016/j.neuron.2006.05.017; Lohmann G, 2001, COMPUT MED IMAG GRAP, V25, P449, DOI 10.1016/S0895-6111(01)00008-8; Menon V, 2000, NEUROIMAGE, V12, P357, DOI 10.1006/nimg.2000.0613; Opitz B, 2007, HUM BRAIN MAPP, V28, P585, DOI 10.1002/hbm.20287; Roder B, 2002, NEUROIMAGE, V15, P1003, DOI 10.1006/nimg.2001.1026; Sanides F., 1962, ARCHITEKTONIK MENSCH, DOI [10.1007/978-3-642-86210-6, DOI 10.1007/978-3-642-86210-6]; SHAYWITZ BA, 1995, HUM BRAIN MAPP, V2, P149, DOI DOI 10.1002/HBM.460020304; Simons JS, 2003, NAT REV NEUROSCI, V4, P637, DOI 10.1038/nrn1178; Strange BA, 2001, CEREB CORTEX, V11, P1040, DOI 10.1093/cercor/11.11.1040; Talairach J, 1988, CO PLANAR STEREOTAXI; Tettamanti M, 2002, NEUROIMAGE, V17, P700, DOI 10.1006/nimg.2002.1201; Thompson-Schill SL, 1997, P NATL ACAD SCI USA, V94, P14792, DOI 10.1073/pnas.94.26.14792; Volz KG, 2004, NEUROIMAGE, V21, P848, DOI 10.1016/j.neuroimage.2003.10.028; Yoshida W, 2006, NEURON, V50, P781, DOI 10.1016/j.neuron.2006.05.006	29	42	43	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2009	4	5							e5599	10.1371/journal.pone.0005599	http://dx.doi.org/10.1371/journal.pone.0005599			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	450QE	19478999	Green Submitted, Green Published, gold			2022-12-25	WOS:000266415100002
J	Hallett, TB; Ghys, P; Barnighausen, T; Yan, P; Garnett, GP				Hallett, Timothy B.; Ghys, Peter; Baernighausen, Till; Yan, Ping; Garnett, Geoff P.			Errors in 'BED'-Derived Estimates of HIV Incidence Will Vary by Place, Time and Age	PLOS ONE			English	Article								Background: The BED Capture Enzyme Immunoassay, believed to distinguish recent HIV infections, is being used to estimate HIV incidence, although an important property of the test - how specificity changes with time since infection - has not been not measured. Methods: We construct hypothetical scenarios for the performance of BED test, consistent with current knowledge, and explore how this could influence errors in BED estimates of incidence using a mathematical model of six African countries. The model is also used to determine the conditions and the sample sizes required for the BED test to reliably detect trends in HIV incidence. Results: If the chance of misclassification by BED increases with time since infection, the overall proportion of individuals misclassified could vary widely between countries, over time, and across age-groups, in a manner determined by the historic course of the epidemic and the age-pattern of incidence. Under some circumstances, changes in BED estimates over time can approximately track actual changes in incidence, but large sample sizes (50,000+) will be required for recorded changes to be statistically significant. Conclusions: The relationship between BED test specificity and time since infection has not been fully measured, but, if it decreases, errors in estimates of incidence could vary by place, time and age-group. This means that post-assay adjustment procedures using parameters from different populations or at different times may not be valid. Further research is urgently needed into the properties of the BED test, and the rate of misclassification in a wide range of populations.			Hallett, TB (corresponding author), Univ London Imperial Coll Sci Technol & Med, London, England.	timothy.hallett@imperial.ac.uk	Garnett, Geoffrey P/A-9312-2008; Yan, Ping/AAD-2758-2019; Hallett, Timothy/A-2390-2011; Bärnighausen, Till/Y-2388-2019	Yan, Ping/0000-0001-6765-0735; Hallett, Timothy/0000-0002-9681-0424	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD058482] Funding Source: NIH RePORTER; Medical Research Council Funding Source: Medline; NICHD NIH HHS [1R01-HD058482-01, R01 HD058482] Funding Source: Medline; Wellcome Trust Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome Trust)		Baggaley RF, 2006, PLOS MED, V3, P493, DOI 10.1371/journal.pmed.0030124; BARNIGHAUSEN T, 2008, PLOS ONE; BARNIGHAUSEN T, 2008, USING TEST RECENT IN; BARNIGHAUSEN T, WORLDWIDE APPL UNPUB; Barnighausen T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003640; Cheluget B, 2006, SEX TRANSM INFECT, V82, pI21, DOI 10.1136/sti.2005.015990; Ghys PD, 2006, SEX TRANSM INFECT, V82, pI52, DOI 10.1136/sti.2005.016428; Hallett TB, 2006, SEX TRANSM INFECT, V82, pI1, DOI 10.1136/sti.2005.016014; Hallett TB, 2008, PLOS MED, V5, P611, DOI 10.1371/journal.pmed.0050080; Hargrove JW, 2008, AIDS, V22, P511, DOI 10.1097/QAD.0b013e3282f2a960; Hayashida T, 2008, AIDS RES HUM RETROV, V24, P495, DOI 10.1089/aid.2007.0150; HLADIK W, 2007, EFFECT ANTIRETROVIRA; Hubert JB, 2000, AIDS, V14, P123, DOI 10.1097/00002030-200001280-00007; Karita E, 2007, AIDS, V21, P403, DOI 10.1097/QAD.0b013e32801481b7; KIM A, 2007, 14 C RETR OPP INF; Kirkwood BR, 2003, ESSENTIAL MED STAT; LAEYENDECKER O, 2009, SESS 2 MEAS NEW HIV; Laeyendecker O, 2008, JAIDS-J ACQ IMM DEF, V48, P211, DOI 10.1097/QAI.0b013e3181743980; Lopman B, 2008, INT J EPIDEMIOL, V37, P88, DOI 10.1093/ije/dym255; Low-Beer D, 2007, PLOS MED, V4, P1308, DOI 10.1371/journal.pmed.0040219; MARINDA ET, 2009, AIDS UNPUB; McDougal JS, 2006, AIDS RES HUM RETROV, V22, P945, DOI 10.1089/aid.2006.22.945; McDougal JS, 2005, AIDS, V19, pS25, DOI 10.1097/01.aids.0000172874.90133.7a; Mermin J, 2008, JAMA-J AM MED ASSOC, V300, P540, DOI 10.1001/jama.300.5.540; *MIN HLTH KEN NAT, 2008, KEN AIDS IND SURV 20; Parekh BS, 2002, AIDS RES HUM RETROV, V18, P295, DOI 10.1089/088922202753472874; RABOUD JM, 1995, J ACQ IMMUN DEF SYND, V10, pS67; Rehle T, 2007, SAMJ S AFR MED J, V97, P194; Ross A, 2004, AIDS, V18, P799, DOI 10.1097/00002030-200403260-00012; Rutstein SO, 2006, GUIDE DHS STAT; Shafer LA, 2008, AIDS, V22, P1641, DOI 10.1097/QAD.0b013e32830a7502; Stover J, 2008, SEX TRANSM INFECT, V84, pI24, DOI 10.1136/sti.2008.029868; *SURV SURV LAB WOR, 2006, INT REC US BED CAPT; Todd J, 2007, AIDS, V21, pS55, DOI 10.1097/01.aids.0000299411.75269.e8; *UNAIDS, 2006, WKLY EPIDEMIOL REC, V81, P40; UNAIDS, 2008, REP GLOB AIDS EP; WELTE T, 2009, USING TESTS RE UNPUB; *WHO UNAIDS UNICEF, 2007, UN ACC SCAL PRIOR HI; World Bank, 1991, WORLD DEV REP 1991; YAN P, STAT OBSERVATI UNPUB; ZABA B, 2008, DIVERSE AGE PATTERNS	41	47	49	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2009	4	5							e5720	10.1371/journal.pone.0005720	http://dx.doi.org/10.1371/journal.pone.0005720			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QE	19479050	Green Published, Green Submitted, gold			2022-12-25	WOS:000266415100013
J	Han, L; Garcia, HG; Blumberg, S; Towles, KB; Beausang, JF; Nelson, PC; Phillips, R				Han, Lin; Garcia, Hernan G.; Blumberg, Seth; Towles, Kevin B.; Beausang, John F.; Nelson, Philip C.; Phillips, Rob			Concentration and Length Dependence of DNA Looping in Transcriptional Regulation	PLOS ONE			English	Article								In many cases, transcriptional regulation involves the binding of transcription factors at sites on the DNA that are not immediately adjacent to the promoter of interest. This action at a distance is often mediated by the formation of DNA loops: Binding at two or more sites on the DNA results in the formation of a loop, which can bring the transcription factor into the immediate neighborhood of the relevant promoter. These processes are important in settings ranging from the historic bacterial examples (bacterial metabolism and the lytic-lysogeny decision in bacteriophage), to the modern concept of gene regulation to regulatory processes central to pattern formation during development of multicellular organisms. Though there have been a variety of insights into the combinatorial aspects of transcriptional control, the mechanism of DNA looping as an agent of combinatorial control in both prokaryotes and eukaryotes remains unclear. We use single-molecule techniques to dissect DNA looping in the lac operon. In particular, we measure the propensity for DNA looping by the Lac repressor as a function of the concentration of repressor protein and as a function of the distance between repressor binding sites. As with earlier single-molecule studies, we find (at least) two distinct looped states and demonstrate that the presence of these two states depends both upon the concentration of repressor protein and the distance between the two repressor binding sites. We find that loops form even at interoperator spacings considerably shorter than the DNA persistence length, without the intervention of any other proteins to prebend the DNA. The concentration measurements also permit us to use a simple statistical mechanical model of DNA loop formation to determine the free energy of DNA looping, or equivalently, the J-factor for looping.	[Han, Lin; Blumberg, Seth; Phillips, Rob] CALTECH, Dept Appl Phys, Pasadena, CA 91125 USA; [Garcia, Hernan G.] CALTECH, Dept Phys, Pasadena, CA 91125 USA; [Towles, Kevin B.; Beausang, John F.; Nelson, Philip C.] Univ Penn, Dept Phys & Astron, Philadelphia, PA USA	California Institute of Technology; California Institute of Technology; University of Pennsylvania	Han, L (corresponding author), CALTECH, Dept Appl Phys, Pasadena, CA 91125 USA.	phillips@pboc.caltech.edu	Nelson, Philip C/I-6251-2015	Nelson, Philip C/0000-0002-1782-3076; Garcia, Hernan G./0000-0002-5212-3649	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD000217] Funding Source: NIH RePORTER; NIH HHS [DP1 OD000217] Funding Source: Medline	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ACKERS GK, 1982, P NATL ACAD SCI-BIOL, V79, P1129, DOI 10.1073/pnas.79.4.1129; ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; Balaeff A, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.031919; BARKLEY MD, 1981, BIOCHEMISTRY-US, V20, P3833, DOI 10.1021/bi00516a026; Barry JK, 1999, BIOCHEMISTRY-US, V38, P6520, DOI 10.1021/bi9900727; Becker NA, 2005, J MOL BIOL, V349, P716, DOI 10.1016/j.jmb.2005.04.035; Becker NA, 2007, NUCLEIC ACIDS RES, V35, P3988, DOI 10.1093/nar/gkm419; Bintu L, 2005, CURR OPIN GENET DEV, V15, P125, DOI 10.1016/j.gde.2005.02.006; Bintu L, 2005, CURR OPIN GENET DEV, V15, P116, DOI 10.1016/j.gde.2005.02.007; Blumberg S, 2005, BIOPHYS J, V88, P1692, DOI 10.1529/biophysj.104.054486; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; Buchler NE, 2003, P NATL ACAD SCI USA, V100, P5136, DOI 10.1073/pnas.0930314100; Cloutier TE, 2005, P NATL ACAD SCI USA, V102, P3645, DOI 10.1073/pnas.0409059102; Cloutier TE, 2004, MOL CELL, V14, P355, DOI 10.1016/S1097-2765(04)00210-2; Colquhoun David, 1995, P483; Czapla L, 2006, J CHEM THEORY COMPUT, V2, P685, DOI 10.1021/ct060025+; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P4777, DOI 10.1021/bi00641a003; Du Q, 2005, P NATL ACAD SCI USA, V102, P5397, DOI 10.1073/pnas.0500983102; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; Edelman LM, 2003, BIOPHYS J, V84, P1131, DOI 10.1016/S0006-3495(03)74929-7; Falcon CM, 1999, J BIOL CHEM, V274, P30849, DOI 10.1074/jbc.274.43.30849; FINZI L, 1995, SCIENCE, V267, P378, DOI 10.1126/science.7824935; Frank DE, 1997, J MOL BIOL, V267, P1186, DOI 10.1006/jmbi.1997.0920; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; Garcia HG, 2007, BIOPOLYMERS, V85, P115, DOI 10.1002/bip.20627; Geanacopoulos M, 2001, NAT STRUCT BIOL, V8, P432, DOI 10.1038/87595; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GOEDDEL DV, 1977, P NATL ACAD SCI USA, V74, P3292, DOI 10.1073/pnas.74.8.3292; Guerra RF, 2007, BIOPHYS J, V93, P176, DOI 10.1529/biophysj.106.099929; Horton N, 1997, J MOL BIOL, V265, P1, DOI 10.1006/jmbi.1996.0706; HSIEH WT, 1987, J BIOL CHEM, V262, P14583; KAOHUANG Y, 1977, P NATL ACAD SCI USA, V74, P4228, DOI 10.1073/pnas.74.10.4228; KRAMER H, 1988, EMBO J, V7, P547, DOI 10.1002/j.1460-2075.1988.tb02844.x; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; LAW SM, 1993, J MOL BIOL, V230, P161, DOI 10.1006/jmbi.1993.1133; LEE DH, 1989, P NATL ACAD SCI USA, V86, P476, DOI 10.1073/pnas.86.2.476; Levandoski MM, 1996, J MOL BIOL, V260, P697, DOI 10.1006/jmbi.1996.0431; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; M_uller-Hill B., 1996, LAC OPERON SHORT HIS; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; Mehta RA, 1999, J MOL BIOL, V294, P67, DOI 10.1006/jmbi.1999.3244; Morgan MA, 2005, BIOPHYS J, V89, P2588, DOI 10.1529/biophysj.105.067728; Moroz JD, 1998, MACROMOLECULES, V31, P6333, DOI 10.1021/ma971804a; MOSSING MC, 1985, J MOL BIOL, V186, P295, DOI 10.1016/0022-2836(85)90106-8; Muller J, 1996, J MOL BIOL, V257, P21, DOI 10.1006/jmbi.1996.0143; Nelson PC, 2007, CURR OPIN COLLOID IN, V12, P307, DOI 10.1016/j.cocis.2007.07.015; Nelson PC, 2006, J PHYS CHEM B, V110, P17260, DOI 10.1021/jp0630673; Normanno D, 2008, NUCLEIC ACIDS RES, V36, P2505, DOI 10.1093/nar/gkn071; OEHLER S, 1994, EMBO J, V13, P3348, DOI 10.1002/j.1460-2075.1994.tb06637.x; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; Pouget N, 2006, NUCLEIC ACIDS RES, V34, P4313, DOI 10.1093/nar/gkl420; Pouget N, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh073; Ptashne M, 2004, GENETIC SWITCH PHAGE; RECORD MT, 1981, ANNU REV BIOCHEM, V50, P997, DOI 10.1146/annurev.bi.50.070181.005025; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; REVZIN A, 1977, BIOCHEMISTRY-US, V16, P4769, DOI 10.1021/bi00641a002; Rosenfeld N, 2005, SCIENCE, V307, P1962, DOI 10.1126/science.1106914; Ruben GC, 1997, MICROSC RES TECHNIQ, V36, P400, DOI 10.1002/(SICI)1097-0029(19970301)36:5<400::AID-JEMT10>3.0.CO;2-W; Saiz L, 2005, P NATL ACAD SCI USA, V102, P17642, DOI 10.1073/pnas.0505693102; Saiz L, 2006, CURR OPIN STRUC BIOL, V16, P344, DOI 10.1016/j.sbi.2006.05.008; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979; Segall DE, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.088306; Semsey S, 2004, GENE DEV, V18, P1898, DOI 10.1101/gad.1209404; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; Strick T, 2000, PROG BIOPHYS MOL BIO, V74, P115, DOI 10.1016/S0079-6107(00)00018-3; Strick TR, 1998, P NATL ACAD SCI USA, V95, P10579, DOI 10.1073/pnas.95.18.10579; Swigon D, 2006, P NATL ACAD SCI USA, V103, P9879, DOI 10.1073/pnas.0603557103; Tolic-Norrelykke SF, 2006, BIOPHYS J, V90, P3694, DOI 10.1529/biophysj.105.074856; TOWLES K, 2009, PHYS BIOL IN PRESS; van den Broek B, 2006, NUCLEIC ACIDS RES, V34, P167, DOI 10.1093/nar/gkj432; Vanzi F, 2003, RNA, V9, P1174, DOI 10.1261/rna.5800303; Vanzi F, 2006, NUCLEIC ACIDS RES, V34, P3409, DOI 10.1093/nar/gkl393; Villa E, 2005, P NATL ACAD SCI USA, V102, P6783, DOI 10.1073/pnas.0409387102; WANG AC, 1977, NUCLEIC ACIDS RES, V4, P1579, DOI 10.1093/nar/4.5.1579; Wang MD, 1997, BIOPHYS J, V72, P1335, DOI 10.1016/S0006-3495(97)78780-0; WHITSON PA, 1987, J BIOL CHEM, V262, P14592; Wiggins PA, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.021909; Wiggins PA, 2006, NAT NANOTECHNOL, V1, P137, DOI 10.1038/nnano.2006.63; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6948, DOI 10.1021/bi00527a029; Wong OK, 2008, PLOS BIOL, V6, P2028, DOI 10.1371/journal.pbio.0060232; Yan J, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.108108; YIN H, 1994, BIOPHYS J, V67, P2468, DOI 10.1016/S0006-3495(94)80735-0; ZELLER RW, 1995, P NATL ACAD SCI USA, V92, P2989, DOI 10.1073/pnas.92.7.2989; ZHANG XL, 1993, BIOCHEMISTRY-US, V32, P11374, DOI 10.1021/bi00093a014; Zhang Y, 2006, BIOPHYS J, V90, P1903, DOI 10.1529/biophysj.105.070490; Zhang YL, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000136; Zurla C, 2006, J PHYS-CONDENS MAT, V18, pS225, DOI 10.1088/0953-8984/18/14/S07; Zurla C, 2007, BIOPHYS CHEM, V128, P245, DOI 10.1016/j.bpc.2007.04.012	92	72	72	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2009	4	5							e5621	10.1371/journal.pone.0005621	http://dx.doi.org/10.1371/journal.pone.0005621			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LI	19479049	Green Published, Green Accepted, Green Submitted, gold			2022-12-25	WOS:000266331700002
J	Casas, F; Pessemesse, L; Grandemange, S; Seyer, P; Baris, O; Gueguen, N; Ramonatxo, C; Perrin, F; Fouret, G; Lepourry, L; Cabello, G; Wrutniak-Cabello, C				Casas, Francois; Pessemesse, Laurence; Grandemange, Stephanie; Seyer, Pascal; Baris, Olivier; Gueguen, Naig; Ramonatxo, Christelle; Perrin, Florence; Fouret, Gilles; Lepourry, Laurence; Cabello, Gerard; Wrutniak-Cabello, Chantal			Overexpression of the Mitochondrial T3 Receptor Induces Skeletal Muscle Atrophy during Aging	PLOS ONE			English	Article								In previous studies, we characterized a new hormonal pathway involving a mitochondrial T3 receptor (p43) acting as a mitochondrial transcription factor. In in vitro and in vivo studies, we have shown that p43 increases mitochondrial transcription and mitochondrial biogenesis. In addition, p43 overexpression in skeletal muscle stimulates mitochondrial respiration and induces a shift in metabolic and contractile features of muscle fibers which became more oxidative. Here we have studied the influence of p43 overexpression in skeletal muscle of mice during aging. We report that p43 overexpression initially increased mitochondrial mass. However, after the early rise in mitochondrial DNA occurring at 2 months of age in transgenic mice, we observed a progressive decrease of mitochondrial DNA content which became 2-fold lower at 23 months of age relatively to control animals. Moreover, p43 overexpression induced an oxidative stress characterized by a strong increase of lipid peroxidation and protein oxidation in quadriceps muscle, although antioxidant enzyme activities (catalase and superoxide dismutase) were stimulated. In addition, muscle atrophy became detectable at 6 months of age, probably through a stimulation of the ubiquitin proteasome pathway via two muscle-specific ubiquitin ligases E3, Atrogin-1/MAFbx and MuRF1. Taken together, these results demonstrate that a prolonged stimulation of mitochondrial activity induces muscle atrophy. In addition, these data underline the importance of a tight control of p43 expression and suggest that a deregulation of the direct T3 mitochondrial pathway could be one of the parameters involved in the occurrence of sarcopenia.	[Casas, Francois; Pessemesse, Laurence; Grandemange, Stephanie; Seyer, Pascal; Baris, Olivier; Gueguen, Naig; Ramonatxo, Christelle; Fouret, Gilles; Lepourry, Laurence; Cabello, Gerard; Wrutniak-Cabello, Chantal] INRA, UMR866 Differenciat Cellulaire & Croissance, F-34060 Montpellier, France; [Casas, Francois; Pessemesse, Laurence; Grandemange, Stephanie; Seyer, Pascal; Baris, Olivier; Gueguen, Naig; Ramonatxo, Christelle; Fouret, Gilles; Lepourry, Laurence; Cabello, Gerard; Wrutniak-Cabello, Chantal] Univ Montpellier 1 & 2, Montpellier, France; [Perrin, Florence] Univ Montpellier 1 & 2, INSERM, U583 Inst Neurosci Montpellier, Montpellier, France	INRAE; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Casas, F (corresponding author), INRA, UMR866 Differenciat Cellulaire & Croissance, F-34060 Montpellier, France.	casasf@supagro.inra.fr	Grandemange, Stéphanie/G-7928-2015; Ramonatxo, Christelle/B-2929-2017; Baris, Olivier R/L-3463-2016	Ramonatxo, Christelle/0000-0001-6112-0864; Baris, Olivier R/0000-0003-0974-6856; PERRIN, Florence/0000-0002-7630-0515; Francois, Casas/0000-0002-5535-8195				Argiles JM, 2002, BIOCHEM BIOPH RES CO, V293, P1145, DOI 10.1016/S0006-291X(02)00355-8; BERGMEYER HU, 1963, ENZYMES BIOL REAGENT, V1, P443; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; Busquets S, 2005, FEBS LETT, V579, P717, DOI 10.1016/j.febslet.2004.12.050; BUTLERBROWNE GS, 1984, FEBS LETT, V166, P71, DOI 10.1016/0014-5793(84)80047-2; Casas F, 1999, MOL CELL BIOL, V19, P7913; Casas F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002501; Criswell DS, 1997, RESP PHYSIOL, V107, P149, DOI 10.1016/S0034-5687(96)02509-1; FLEMING JE, 1982, GERONTOLOGY, V28, P44, DOI 10.1159/000212510; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Grandemange S, 2005, CANCER RES, V65, P4282, DOI 10.1158/0008-5472.CAN-04-3652; Gueguen N, 2005, COMP BIOCHEM PHYS B, V140, P287, DOI 10.1016/j.cbpc.2004.10.014; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; Jackman RW, 2004, AM J PHYSIOL-CELL PH, V287, pC834, DOI 10.1152/ajpcell.00579.2003; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; KING DB, 1987, J EXP ZOOL, P291; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Lunde PK, 2001, CIRC RES, V88, P1299, DOI 10.1161/hh1201.092041; Lynch GS, 2000, EXP PHYSIOL, V85, P295, DOI 10.1111/j.1469-445X.2000.02018.x; McElhinny AS, 2002, J CELL BIOL, V157, P125, DOI 10.1083/jcb.200108089; Miura S, 2006, AM J PATHOL, V169, P1129, DOI 10.2353/ajpath.2006.060034; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; Rochard P, 2000, J BIOL CHEM, V275, P2733, DOI 10.1074/jbc.275.4.2733; Ryall JG, 2004, J PHYSIOL-LONDON, V555, P175, DOI 10.1113/jphysiol.2003.056770; Ryall JG, 2002, AM J PHYSIOL-REG I, V283, pR1386, DOI 10.1152/ajpregu.00324.2002; Sanchis D, 1998, FEBS LETT, V436, P415, DOI 10.1016/S0014-5793(98)01178-8; Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103; Seyer P, 2006, J CELL PHYSIOL, V207, P75, DOI 10.1002/jcp.20539; SUGIE H, 1985, MUSCLE NERVE, V8, P654, DOI 10.1002/mus.880080805; SUNDERMAN FW, 1985, ANN CLIN LAB SCI, V15, P229; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Wharton DC., 1967, METHOD ENZYMOL, P245; WRUTNIAK C, 1995, J BIOL CHEM, V270, P16347, DOI 10.1074/jbc.270.27.16347; Wrutniak-Cabello C, 2001, J MOL ENDOCRINOL, V26, P67, DOI 10.1677/jme.0.0260067	36	40	43	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5631	10.1371/journal.pone.0005631	http://dx.doi.org/10.1371/journal.pone.0005631			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448AY	19462004	Green Published, Green Submitted, gold			2022-12-25	WOS:000266234700018
J	Schoolmeesters, A; Eklund, T; Leake, D; Vermeulen, A; Smith, Q; Aldred, SF; Fedorov, Y				Schoolmeesters, Angela; Eklund, Teresa; Leake, Devin; Vermeulen, Annaleen; Smith, Queta; Aldred, Shelley Force; Fedorov, Yuriy			Functional Profiling Reveals Critical Role for miRNA in Differentiation of Human Mesenchymal Stem Cells	PLOS ONE			English	Article							CALCIUM-BINDING PROTEIN; OSTEOGENIC DIFFERENTIATION; MICRORNAS; EXPRESSION; GRANCALCIN; CHORDIN; CLONING	Background: Mesenchymal stem (MS) cells are excellent candidates for cell-based therapeutic strategies to regenerate injured tissue. Although human MS cells can be isolated from bone marrow and directed to differentiate by means of an osteogenic pathway, the regulation of cell-fate determination is not well understood. Recent reports identify critical roles for microRNAs (miRNAs), regulators of gene expression either by inhibiting the translation or by stimulating the degradation of target mRNAs. Methodology/Principal Findings: In this study, we employed a library of miRNA inhibitors to evaluate the role of miRNAs in early osteogenic differentiation of human MS cells. We discovered that miR-148b, -27a and -489 are essential for the regulation of osteogenesis: miR-27a and miR-489 down-regulate while miR-148b up-regulates differentiation. Modulation of these miRNAs induced osteogenesis in the absence of other external differentiation cues and restored osteogenic potential in high passage number human MS cells. Conclusions/Significance: Overall, we have demonstrated the utility of the functional profiling strategy for unraveling complex miRNA pathways. Our findings indicate that miRNAs regulate early osteogenic differentiation in human MS cells: miR-148b, -27a, and -489 were found to play a critical role in osteogenesis.			Schoolmeesters, A (corresponding author), Thermo Fisher Sci, Lafayette, CO USA.	Yuriy.Fedorov@thermofisher.com						Bentwich I, 2008, CURR TOP MICROBIOL, V320, P257; Berezikov E, 2006, GENOME RES, V16, P1289, DOI 10.1101/gr.5159906; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; BOYHAN A, 1992, J BIOL CHEM, V267, P2928; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; Callis TE, 2007, DNA CELL BIOL, V26, P219, DOI 10.1089/dna.2006.0556; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Fisher S, 1999, NAT GENET, V23, P442, DOI 10.1038/70557; Foshay Kara M, 2007, Curr Stem Cell Res Ther, V2, P264, DOI 10.2174/157488807782793781; FRIEDENSTEIN A, 1971, TRANSPLANTATION, V12, P99, DOI 10.1097/00007890-197108000-00001; Hobert O, 2006, COLD SPRING HARB SYM, V71, P181, DOI 10.1101/sqb.2006.71.006; Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I; John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264; Lakshmipathy U, 2008, STEM CELLS, V26, P356, DOI 10.1634/stemcells.2007-0625; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011; Maki M, 2002, BBA-PROTEINS PROTEOM, V1600, P51, DOI 10.1016/S1570-9639(02)00444-2; Mizuno Y, 2008, BIOCHEM BIOPH RES CO, V368, P267, DOI 10.1016/j.bbrc.2008.01.073; Newman JC, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r81; Palmieri A, 2008, BIO-MED MATER ENG, V18, P91, DOI 10.3233/BME-2008-0512; Palmieri A, 2007, J BIOMED SCI, V14, P777, DOI 10.1007/s11373-007-9193-z; Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637; Siddappa R, 2007, J ORTHOP RES, V25, P1029, DOI 10.1002/jor.20402; TANABE S, 2008, J BIOCH; TEAHAN CG, 1992, BIOCHEM J, V286, P549, DOI 10.1042/bj2860549; Vermeulen A, 2007, RNA, V13, P723, DOI 10.1261/rna.448107; Wagner W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002213; Wall ME, 2007, TISSUE ENG, V13, P1291, DOI 10.1089/ten.2006.0275; Zhang DH, 2002, J BONE MINER RES, V17, P293, DOI 10.1359/jbmr.2002.17.2.293	30	141	154	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5605	10.1371/journal.pone.0005605	http://dx.doi.org/10.1371/journal.pone.0005605			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19440384	gold, Green Submitted, Green Published			2022-12-25	WOS:000266161200008
J	Gunther, S; Matuschewski, K; Muller, S				Guenther, Svenja; Matuschewski, Kai; Mueller, Sylke			Knockout Studies Reveal an Important Role of Plasmodium Lipoic Acid Protein Ligase A1 for Asexual Blood Stage Parasite Survival	PLOS ONE			English	Article								Lipoic acid (LA) is a dithiol-containing cofactor that is essential for the function of alpha-keto acid dehydrogenase complexes. LA acts as a reversible acyl group acceptor and 'swinging arm' during acyl-coenzyme A formation. The cofactor is post-translationally attached to the acyl-transferase subunits of the multienzyme complexes through the action of octanoyl (lipoyl): N-octanoyl (lipoyl) transferase (LipB) or lipoic acid protein ligases (LplA). Remarkably, apicomplexan parasites possess LA biosynthesis as well as scavenging pathways and the two pathways are distributed between mitochondrion and a vestigial organelle, the apicoplast. The apicoplast-specific LipB is dispensable for parasite growth due to functional redundancy of the parasite's lipoic acid/octanoic acid ligases/transferases. In this study, we show that LplA1 plays a pivotal role during the development of the erythrocytic stages of the malaria parasite. Gene disruptions in the human malaria parasite P. falciparum consistently were unsuccessful while in the rodent malaria model parasite P. berghei the LplA1 gene locus was targeted by knock-in and knockout constructs. However, the LplA1((-)) mutant could not be cloned suggesting a critical role of LplA1 for asexual parasite growth in vitro and in vivo. These experimental genetics data suggest that lipoylation during expansion in red blood cells largely occurs through salvage from the host erythrocytes and subsequent ligation of LA to the target proteins of the malaria parasite.			Gunther, S (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.	s.muller@bio.gla.ac.uk		Matuschewski, Kai/0000-0001-6147-8591	Wellcome Trust [WT061173MA] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allary M, 2007, MOL MICROBIOL, V63, P1331, DOI 10.1111/j.1365-2958.2007.05592.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; Crawford MJ, 2006, EMBO J, V25, P3214, DOI 10.1038/sj.emboj.7601189; Cronan JE, 2005, ADV MICROB PHYSIOL, V50, P103, DOI 10.1016/S0065-2911(05)50003-1; Douce R, 2001, TRENDS PLANT SCI, V6, P167, DOI 10.1016/S1360-1385(01)01892-1; Foth BJ, 2005, MOL MICROBIOL, V55, P39, DOI 10.1111/j.1365-2958.2004.04407.x; Gueguen V, 2000, J BIOL CHEM, V275, P5016, DOI 10.1074/jbc.275.7.5016; Gunther S, 2007, PLOS PATHOG, V3, P1938, DOI 10.1371/journal.ppat.0030189; Gunther S, 2005, BIOCHEM SOC T, V33, P977, DOI 10.1042/BST20050977; Gunther S, 2009, INT J BIOCHEM CELL B, V41, P748, DOI 10.1016/j.biocel.2008.10.028; Janse CJ, 2006, MOL BIOCHEM PARASIT, V145, P60, DOI 10.1016/j.molbiopara.2005.09.007; Keeney KM, 2007, MOL MICROBIOL, V66, P758, DOI 10.1111/j.1365-2958.2007.05956.x; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Mazumdar J, 2006, P NATL ACAD SCI USA, V103, P13192, DOI 10.1073/pnas.0603391103; McMillan PJ, 2005, MOL MICROBIOL, V55, P27, DOI 10.1111/j.1365-2958.2004.04398.x; Mooney BP, 2002, ANNU REV PLANT BIOL, V53, P357, DOI 10.1146/annurev.arplant.53.100301.135251; O'Riordan M, 2003, SCIENCE, V302, P462, DOI 10.1126/science.1088170; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; REED LJ, 1990, J BIOL CHEM, V265, P8971; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Stephens JL, 2007, J BIOL CHEM, V282, P4427, DOI 10.1074/jbc.M609037200; Thathy Vandana, 2002, Methods Mol Med, V72, P317, DOI 10.1385/1-59259-271-6:317; Thomsen-Zieger N, 2003, FEBS LETT, V547, P80, DOI 10.1016/S0014-5793(03)00673-2; Tonkin CJ, 2004, MOL BIOCHEM PARASIT, V137, P13, DOI 10.1016/j.molbiopara.2004.05.009; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; UMLAS J, 1971, AM J TROP MED HYG, V20, P527, DOI 10.4269/ajtmh.1971.20.527; Witkowski A, 2007, J BIOL CHEM, V282, P14178, DOI 10.1074/jbc.M701486200; Wrenger C, 2004, MOL MICROBIOL, V53, P103, DOI 10.1111/j.1365-2958.2004.04112.x; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130; Yasuno R, 2002, FEBS LETT, V517, P110, DOI 10.1016/S0014-5793(02)02589-9	34	24	24	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2009	4	5							e5510	10.1371/journal.pone.0005510	http://dx.doi.org/10.1371/journal.pone.0005510			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444VZ	19434237	Green Published, Green Accepted, gold, Green Submitted			2022-12-25	WOS:000266009800008
J	Kim, TS; Kim, HD; Shin, HS; Kim, J				Kim, Tae-Sung; Kim, Hag Dong; Shin, Hyun-Seock; Kim, Joon			Phosphorylation Status of Nuclear Ribosomal Protein S3 Is Reciprocally Regulated by Protein Kinase C delta and Protein Phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PP2A; MEDIATED PHOSPHORYLATION; FUNCTIONAL INTERACTION; GROWTH-FACTOR; DNA-DAMAGE; B-SUBUNITS; IDENTIFICATION; COMPLEXES; CELLS; ERK	It has been shown previously that ribosomal protein S3 (rpS3) has an endonuclease activity, which is increased by protein kinase C delta (PKC delta)-dependent phosphorylation. However, the reciprocal mechanism for rpS3 dephosphorylation is not known. In this study, we examined phosphatases involved in rpS3 dephosphorylation, and we determined that rpS3 is specifically dephosphorylated by protein phosphatase 2A (PP2A). By immunoprecipitation assay, rpS3 only interacted with PP2Ac but not with protein phosphatase 1. The interaction between rpS3 and PP2Ac occurred only in the nuclear fraction. Moreover, the PP2Ac association with rpS3 was identified in cells transfected with wild-type rpS3 but not with mutant rpS3 lacking PKC delta phosphorylation sites. PP2A inhibition using okadaic acid induced rpS3 phosphorylation. The level of phosphorylated rpS3 in cells was decreased by the overexpression of PP2Ac and was increased by the down-regulation of PP2Ac. Taken together, these results suggest that oxidative stress regulates the phosphorylation status of nonribosomal rpS3 by both activating PKC delta and blocking the PP2A interaction with rpS3.	[Kim, Joon] Korea Univ, Sch Life Sci & Biotechnol, Biochem Lab, Seoul 136701, South Korea; Korea Univ, BioInst, Seoul 136701, South Korea	Korea University; Korea University	Kim, J (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Biochem Lab, Seoul 136701, South Korea.	joonkim@korea.ac.kr			Proteomics [FPR05C2-390]; Korea Science and Engineering Foundation [09-74777]	Proteomics; Korea Science and Engineering Foundation(Korea Science and Engineering Foundation)	This work was supported in part by Proteomics Grant FPR05C2-390 and Korea Science and Engineering Foundation Grant 09-74777.	Andjelkovic N, 1996, EMBO J, V15, P7156, DOI 10.1002/j.1460-2075.1996.tb01107.x; Begum N, 1999, BIOCHEM J, V344, P895, DOI 10.1042/0264-6021:3440895; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Bos CL, 2006, ONCOGENE, V25, P6447, DOI 10.1038/sj.onc.1209658; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Foley TD, 2004, BIOCHEM BIOPH RES CO, V315, P568, DOI 10.1016/j.bbrc.2004.01.096; Hashigasako A, 2004, J BIOL CHEM, V279, P26445, DOI 10.1074/jbc.M314254200; Horn V, 2007, MOL BIOL CELL, V18, P1233, DOI 10.1091/mbc.E06-12-1152; Howe CJ, 2004, J BIOL CHEM, V279, P44573, DOI 10.1074/jbc.M404175200; Jang CY, 2004, FEBS LETT, V560, P81, DOI 10.1016/S0014-5793(04)00074-2; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Junttila MR, 2005, PROTEOMICS, V5, P1199, DOI 10.1002/pmic.200400991; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kiely PA, 2008, J BIOL CHEM, V283, P22952, DOI 10.1074/jbc.M800802200; Kim HD, 2005, BIOCHEM BIOPH RES CO, V333, P110, DOI 10.1016/j.bbrc.2005.05.079; KIM J, 1995, J BIOL CHEM, V270, P13620, DOI 10.1074/jbc.270.23.13620; Kim SH, 2006, BBA-MOL CELL RES, V1763, P823, DOI 10.1016/j.bbamcr.2006.03.011; Kim SH, 2005, BIOCHEM BIOPH RES CO, V328, P962, DOI 10.1016/j.bbrc.2005.01.045; Kim TS, 2009, BBA-MOL CELL RES, V1793, P395, DOI 10.1016/j.bbamcr.2008.10.017; Kim TS, 2006, MOL BIOL CELL, V17, P824, DOI 10.1091/mbc.E05-08-0713; Lacroix I, 2002, J BIOL CHEM, V277, P9598, DOI 10.1074/jbc.M111444200; Lechward K, 2001, ACTA BIOCHIM POL, V48, P921; Lechward K, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1373; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; Magenta A, 2008, MOL CELL BIOL, V28, P873, DOI 10.1128/MCB.00480-07; Matsumoto M, 2005, PROTEOMICS, V5, P4145, DOI 10.1002/pmic.200401280; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Rao RK, 2002, BIOCHEM BIOPH RES CO, V293, P610, DOI 10.1016/S0006-291X(02)00268-1; Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047; Samanta AK, 2009, ONCOGENE, V28, P1669, DOI 10.1038/onc.2009.7; Schafer T, 2006, NATURE, V441, P651, DOI 10.1038/nature04840; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shouse GP, 2008, MOL CELL BIOL, V28, P448, DOI 10.1128/MCB.00983-07; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Strack S, 1998, J COMP NEUROL, V392, P515; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; Wan FY, 2007, CELL, V131, P927, DOI 10.1016/j.cell.2007.10.009; Westermarck J, 2008, TRENDS MOL MED, V14, P152, DOI 10.1016/j.molmed.2008.02.001; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263; Wykoff DD, 2005, MOL CELL PROTEOMICS, V4, P73, DOI 10.1074/mcp.M400166-MCP200; Xirodimas DP, 2008, EMBO REP, V9, P280, DOI 10.1038/embor.2008.10; Yadavilli S, 2007, DNA REPAIR, V6, P1453, DOI 10.1016/j.dnarep.2007.04.009; Yan L, 2008, J BIOL CHEM, V283, P7411, DOI 10.1074/jbc.M708083200	50	21	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	2009	284	32					21201	21208		10.1074/jbc.M109.018168	http://dx.doi.org/10.1074/jbc.M109.018168			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478CC	19458393	hybrid, Green Published			2022-12-25	WOS:000268564400013
J	Pedroja, BS; Kang, LE; Imas, AO; Carmeliet, P; Bernstein, AM				Pedroja, Benjamin S.; Kang, Leah E.; Imas, Alex O.; Carmeliet, Peter; Bernstein, Audrey M.			Plasminogen Activator Inhibitor-1 Regulates Integrin alpha v beta 3 Expression and Autocrine Transforming Growth Factor beta Signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROKINASE RECEPTOR; LATENT TGF-BETA-1; FIBROBLASTS; FIBROSIS; MYOFIBROBLAST; DISEASE; CELLS; BINDING; INJURY; LIVER	Fibrosis is characterized by elevated transforming growth factor beta (TGF beta) signaling, resulting in extracellular matrix accumulation and increased PAI-1 (plasminogen activator inhibitor) expression. PAI-1 induces the internalization of urokinase plasminogen activator/receptor and integrin alpha v beta 3 from the cell surface. Since increased alpha v beta 3 expression correlates with increased TGF beta signaling, we hypothesized that aberrant PAI-1-mediated alpha v beta 3 endocytosis could initiate an autocrine loop of TGF beta activity. We found that in PAI-1 knock-out (KO) mouse embryonic fibroblasts), alpha v beta 3 endocytosis was reduced by similar to 75%, leaving alpha v beta 3 in enlarged focal adhesions, similar to wild type cells transfected with PAI-1 small interfering RNA. TGF beta signaling was significantly enhanced in PAI-1 KO cells, as demonstrated by a 3-fold increase in SMAD2/3-containing nuclei and a 2.9-fold increase in TGF beta activity that correlated with an increase in alpha v beta 3 and TGF beta receptor II expression. As expected, PAI-1 KO cells had unregulated plasmin activity, which was only partially responsible for TGF beta activation, as evidenced by a mere 25% reduction in TGF beta activity when plasmin was inhibited. Treatment of cells with an alpha v beta 3-specific cyclic RGD peptide (Gpen-GRGD) led to a more profound (59%) TGF beta inhibition; a nonspecific RGD peptide (GRGDNP) inhibited TGF beta by only 23%. Human primary fibroblasts were used to confirm that PAI-1 inhibition and beta 3 overexpression led to an increase in TGF beta activity. Consistent with a fibrotic phenotype, PAI-1 KO cells were constitutively myofibroblasts that had a 1.6-fold increase in collagen deposition over wild type cells. These data suggest that PAI-1-mediated regulation of alpha v beta 3 integrin is critical for the control of TGF beta signaling and the prevention of fibrotic disease.	[Pedroja, Benjamin S.; Kang, Leah E.; Imas, Alex O.; Bernstein, Audrey M.] Mt Sinai Sch Med, Dept Ophthalmol, New York, NY 10029 USA; [Carmeliet, Peter] Katholieke Univ Leuven, B-3000 Leuven, Belgium; [Carmeliet, Peter] Vlaams Inst Biotechnol, Vesalius Res Ctr, B-3000 Leuven, Belgium	Icahn School of Medicine at Mount Sinai; KU Leuven; Flanders Institute for Biotechnology (VIB)	Bernstein, AM (corresponding author), Mt Sinai Sch Med, Dept Ophthalmol, Box 1183,1 Gustave L Levy Pl, New York, NY 10029 USA.	audrey.bernstein@mssm.edu	Imas, Alex/J-3426-2016; Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821; Bernstein, Audrey/0000-0002-2537-2594	National Institutes of Health (NIH), NEI [R01 EYO17030, P30-EY01867]; Research to Prevent Blindness grant; NIH, NCI [5R24 CA095823-04]; National Science Foundation Major Research Instrumentation [DBI-9724504]; NIH Shared Instrumentation [1 S10 RR0 9145-01]; NATIONAL CANCER INSTITUTE [R24CA095823] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY001867, R01EY017030] Funding Source: NIH RePORTER	National Institutes of Health (NIH), NEI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Research to Prevent Blindness grant(Research to Prevent Blindness (RPB)); NIH, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Science Foundation Major Research Instrumentation(National Science Foundation (NSF)); NIH Shared Instrumentation(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported, in whole or in part, by National Institutes of Health (NIH), NEI, Grant R01 EYO17030 (to A. M. B.), Core Grant P30-EY01867, and a Research to Prevent Blindness grant. Microscopy was performed at the Mount Sinai School of Medicine-Microscopy Shared Research Facility, supported, in part, with funding from NIH, NCI, Shared Resources Grant 5R24 CA095823-04, National Science Foundation Major Research Instrumentation Grant DBI-9724504, and NIH Shared Instrumentation Grant 1 S10 RR0 9145-01.	ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Arteel GE, 2008, J GASTROEN HEPATOL, V23, pS54, DOI 10.1111/j.1440-1746.2007.05285.x; Asano Y, 2005, J IMMUNOL, V175, P7708, DOI 10.4049/jimmunol.175.11.7708; Bernstein AM, 2007, MOL BIOL CELL, V18, P2716, DOI 10.1091/mbc.E06-10-0912; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; Desmouliere A, 2003, LAB INVEST, V83, P1689, DOI 10.1097/01.LAB.0000101911.53973.90; Galliher AJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1524; Gharaee-Kermani M, 2008, EXPERT OPIN INV DRUG, V17, P905, DOI 10.1517/13543784.17.6.905 ; Ha H, 2009, NAT REV NEPHROL, V5, P203, DOI 10.1038/nrneph.2009.15; Heng ECK, 2006, J CELL BIOCHEM, V98, P409, DOI 10.1002/jcb.20810; Hill C, 2000, ENDOCRINOLOGY, V141, P1196, DOI 10.1210/en.141.3.1196; Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613; Huang YF, 2007, CURR DRUG TARGETS, V8, P1007, DOI 10.2174/138945007781662373; Kubo M, 2002, J RHEUMATOL, V29, P2558; Lassila M, 2007, DIABETOLOGIA, V50, P1315, DOI 10.1007/s00125-007-0652-x; Ludbrook SB, 2003, BIOCHEM J, V369, P311, DOI 10.1042/BJ20020809; LUND LR, 1987, EMBO J, V6, P1286; Mogford JE, 1997, J CLIN INVEST, V100, P1647, DOI 10.1172/JCI119689; Moriwaki H, 2004, CIRC RES, V95, P637, DOI 10.1161/01.RES.0000141427.61023.f4; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; Ragno P, 2006, CELL MOL LIFE SCI, V63, P1028, DOI 10.1007/s00018-005-5428-1; Roberts AB, 2001, CHEST, V120, p43S, DOI 10.1378/chest.120.1_suppl.S43-a; Scaffidi AK, 2004, J BIOL CHEM, V279, P37726, DOI 10.1074/jbc.M403010200; Sieuwerts AM, 2002, THROMB HAEMOSTASIS, V87, P674; Sisson TH, 2007, CURR DRUG TARGETS, V8, P1016, DOI 10.2174/138945007781662319; Srivatsa SS, 1997, CARDIOVASC RES, V36, P408, DOI 10.1016/S0008-6363(97)00184-3; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Vaughan DE, 2007, CURR DRUG TARGETS, V8, P962, DOI 10.2174/138945007781662364; Wipff PJ, 2007, J CELL BIOL, V179, P1311, DOI 10.1083/jcb.200704042; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277	36	26	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20708	20717		10.1074/jbc.M109.018804	http://dx.doi.org/10.1074/jbc.M109.018804			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19487690	hybrid, Green Published			2022-12-25	WOS:000268316100033
J	Vaubourgeix, J; Bardou, F; Boissier, F; Julien, S; Constant, P; Ploux, O; Daffe, M; Quemard, A; Mourey, L				Vaubourgeix, Julien; Bardou, Fabienne; Boissier, Fanny; Julien, Sylviane; Constant, Patricia; Ploux, Olivier; Daffe, Mamadou; Quemard, Annaik; Mourey, Lionel			S-Adenosyl-N-decyl-aminoethyl, a Potent Bisubstrate Inhibitor of Mycobacterium tuberculosis Mycolic Acid Methyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; FATTY-ACIDS; CELL-WALL; BIOSYNTHESIS; SYNTHASE; REFINEMENT; SINEFUNGIN; VIRULENCE; PHASES; COLI	S-Adenosylmethionine- dependent methyltransferases (Ado-Met-MTs) constitute a large family of enzymes specifically transferring a methyl group to a range of biologically active molecules. Mycobacterium tuberculosis produces a set of paralogous AdoMet-MTs responsible for introducing key chemical modifications at defined positions of mycolic acids, which are essential and specific components of the mycobacterial cell envelope. We investigated the inhibition of these mycolic acid methyltransferases (MA-MTs) by structural analogs of the AdoMet cofactor. We found that S-adenosyl-N-decyl-aminoethyl, a molecule in which the amino acid moiety of AdoMet is substituted by a lipid chain, inhibited MA-MTs from Mycobacterium smegmatis and M. tuberculosis strains, both in vitro and in vivo, with IC50 values in the submicromolar range. By contrast, S-adenosylhomocysteine, the demethylated reaction product, and sinefungin, a general AdoMet-MT inhibitor, did not inhibit MA-MTs. The interaction between Hma (MmaA4), which is strictly required for the biosynthesis of oxygenated mycolic acids in M. tuberculosis, and the three cofactor analogs was investigated by x-ray crystallography. The high resolution crystal structures obtained illustrate the bisubstrate nature of S-adenosyl-N-decyl-aminoethyl and provide insight into its mode of action in the inhibition of MA-MTs. This study has potential implications for the design of new drugs effective against multidrug-resistant and persistent tubercle bacilli.	[Vaubourgeix, Julien; Bardou, Fabienne; Boissier, Fanny; Julien, Sylviane; Constant, Patricia; Daffe, Mamadou; Quemard, Annaik; Mourey, Lionel] CNRS, Inst Pharmacol & Biol Struct, Dept Mecanismes Mol Infect Mycobacteriennes, F-31077 Toulouse, France; [Vaubourgeix, Julien; Bardou, Fabienne; Boissier, Fanny; Julien, Sylviane; Constant, Patricia; Daffe, Mamadou; Quemard, Annaik; Mourey, Lionel] Univ Toulouse 3, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; [Ploux, Olivier] Ecole Natl Super Chim Paris, CNRS, UMR7573, Lab Biochim Microorganismes Enzymol,Metab & Anti, F-75231 Paris, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Chimie ParisTech	Quemard, A (corresponding author), CNRS, Inst Pharmacol & Biol Struct, Dept Mecanismes Mol Infect Mycobacteriennes, 205 Route Narbonne, F-31077 Toulouse, France.	annaik.quemard@ipbs.fr; lionel.mourey@ipbs.fr	Mourey, Lionel/B-5662-2009	Mourey, Lionel/0000-0002-8259-1259; Vaubourgeix, Julien/0000-0003-4872-0464; Quemard, Annaik/0000-0002-5545-3424				Alahari A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001343; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; Boissier F, 2006, J BIOL CHEM, V281, P4434, DOI 10.1074/jbc.M510250200; Carr RAE, 2005, DRUG DISCOV TODAY, V10, P987, DOI 10.1016/S1359-6446(05)03511-7; DAFFE M, 1983, ANN INST PASTEUR MIC, VB134, P241, DOI 10.1016/S0769-2609(83)80037-4; Dao DN, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000081; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dinadayala P, 2003, J BIOL CHEM, V278, P7310, DOI 10.1074/jbc.M210501200; Dubnau E, 2000, MOL MICROBIOL, V36, P630, DOI 10.1046/j.1365-2958.2000.01882.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Freire E, 2008, DRUG DISCOV TODAY, V13, P869, DOI 10.1016/j.drudis.2008.07.005; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; GOMEZFLORES R, 1995, J CLIN MICROBIOL, V33, P1842, DOI 10.1128/JCM.33.7.1842-1846.1995; Guianvarc'h D, 2008, BBA-PROTEINS PROTEOM, V1784, P1652, DOI 10.1016/j.bbapap.2008.04.019; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hoffmann C, 2008, P NATL ACAD SCI USA, V105, P3963, DOI 10.1073/pnas.0709530105; Huang CYF, 2002, J BIOL CHEM, V277, P34367, DOI 10.1074/jbc.M202468200; Kleywegt GJ, 2007, ACTA CRYSTALLOGR D, V63, P94, DOI [10.1107/S0907444906022657, 10.1107/S907444906022657]; LACAVE C, 1990, BIOCHIM BIOPHYS ACTA, V1045, P58, DOI 10.1016/0005-2760(90)90203-A; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laval F, 2008, J BIOL CHEM, V283, P1419, DOI 10.1074/jbc.M708859200; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; Marrakchi H, 2008, MYCOBACTERIAL CELL ENVELOPE, P41; MCCAMMON MT, 1981, J BACTERIOL, V145, P106, DOI 10.1128/JB.145.1.106-112.1981; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Osborne TC, 2007, BIOCHEMISTRY-US, V46, P13370, DOI 10.1021/bi701558t; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Peyron P, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000204; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Rao V, 2005, J EXP MED, V201, P535, DOI 10.1084/jem.20041668; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Sacchettini JC, 2008, NAT REV MICROBIOL, V6, P41, DOI 10.1038/nrmicro1816; Sankar Manimuthu Mani, 2008, Ann Clin Microbiol Antimicrob, V7, P15, DOI 10.1186/1476-0711-7-15; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; SMITH DD, 1980, BIOCHEM BIOPH RES CO, V94, P1458, DOI 10.1016/0006-291X(80)90583-5; WANG AY, 1992, BIOCHEMISTRY-US, V31, P11020, DOI 10.1021/bi00160a011; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wright A., 2006, Morbidity and Mortality Weekly Report, V55, P301; Yuan Y, 1998, J BIOL CHEM, V273, P21282, DOI 10.1074/jbc.273.33.21282; Zheng SS, 2006, J BIOL CHEM, V281, P35904, DOI 10.1074/jbc.M607292200; Zuber B, 2008, J BACTERIOL, V190, P5672, DOI 10.1128/JB.01919-07	44	23	30	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19321	19330		10.1074/jbc.M809599200	http://dx.doi.org/10.1074/jbc.M809599200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19439410	Green Published, hybrid			2022-12-25	WOS:000267908300023
J	Kar, R; Singha, PK; Venkatachalam, MA; Saikumar, P				Kar, R.; Singha, P. K.; Venkatachalam, M. A.; Saikumar, P.			A novel role for MAP1 LC3 in nonautophagic cytoplasmic vacuolation death of cancer cells	ONCOGENE			English	Article						cell death; cytoplasmic vacuolation; LC3; ER stress; MAPK; 15d-PGJ2	15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); OXIDATIVE STRESS; INDUCE APOPTOSIS; DRUG-RESISTANCE; DNA-BINDING; AUTOPHAGY; ACTIVATION; MECHANISMS; PROTEASOME; INHIBITION	Thiol reactive cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ2), induced a novel, nonapoptotic and microtubule-associated protein 1 light chain 3 (MAP1 LC3) dependent but nonautophagic form of cell death in colon, breast and prostate cancer cell lines, characterized by extensive cytoplasmic vacuolation with dilatation of endoplasmic reticulum (ER). Disruption of sulfhydryl homeostasis, which resulted in ER stress, accumulation of ubiquitinated proteins and subsequent ER dilation, contributed to peroxisome proliferator-activated receptor gamma (PPAR gamma)-independent cell death by 15d-PGJ2. Absence of intracellular organelles in these vacuoles, shown by electron microscopy and unique fragmentation of lamin B, suggested this form of cell death to be different from autophagy and apoptosis. Cell death induced by 15d-PGJ2 is prevented by cycloheximide and actinomycin D, suggesting a requirement of new protein synthesis for death with cytoplasmic vacuolation. Here, we report for the. first time that upregulation and processing of autophagy marker LC3 is an important event in nonautophagic cytoplasmic vacuolation and cell death. Notably, knockdown of LC3 conferred significant protection against 15d-PGJ2-induced cytoplasmic vacuolation and cell death, suggesting a novel role of LC3 in a death process other than autophagy. Oncogene (2009) 28, 2556-2568; doi: 10.1038/onc.2009.118; published online 18 May 2009	[Kar, R.; Singha, P. K.; Venkatachalam, M. A.; Saikumar, P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Saikumar, P (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	saikumar@uthscsa.edu			National Institutes of Health [DK54472, DK37139]; Morrison Trust; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054472, R01DK037139, R37DK037139] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Morrison Trust; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Tamotsu Yoshimori of Osaka University, Japan, for LC3 antibody and GFP-LC3 construct and Drs Anthony J Valente and Robert A Clark of UTHSCSA, TX, for Calreticulin antibody. This work was supported by National Institutes of Health grant DK54472 and Morrison Trust Grant to PS and National Institutes of Health grant DK37139 to MAV.	Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; Butler R, 2000, CELL GROWTH DIFFER, V11, P49; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Chambers KT, 2007, AM J PHYSIOL-ENDOC M, V292, pE1052, DOI 10.1152/ajpendo.00274.2006; Chen SY, 2002, ANTI-CANCER DRUG, V13, P759, DOI 10.1097/00001813-200208000-00011; Chen YC, 2005, BBA-MOL CELL RES, V1743, P291, DOI 10.1016/j.bbamcr.2004.10.016; Cho WH, 2006, NEUROCHEM RES, V31, P1247, DOI 10.1007/s11064-006-9157-0; Ghribi O, 2001, MOL BRAIN RES, V96, P30, DOI 10.1016/S0169-328X(01)00256-X; Hashimoto K, 2004, PANCREAS, V28, P153, DOI 10.1097/00006676-200403000-00006; He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200; Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; Ishii T, 2005, BIOCHEMISTRY-US, V44, P13893, DOI 10.1021/bi051336u; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaufmann SH, 2003, ONCOGENE, V22, P7414, DOI 10.1038/sj.onc.1206945; Kimura H, 2008, NEPHROL DIAL TRANSPL, V23, P2496, DOI 10.1093/ndt/gfn139; Li LY, 2001, J BIOL CHEM, V276, P38152; Lin MS, 2007, J DIGEST DIS, V8, P82, DOI 10.1111/j.1443-9573.2007.00290.x; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; MANN SS, 1994, J BIOL CHEM, V269, P11492; Mimnaugh EG, 2006, MOL CANCER RES, V4, P667, DOI 10.1158/1541-7786.MCR-06-0019; Morosetti R, 2004, INT J ONCOL, V25, P493; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Naito M, 2004, CANCER SCI, V95, P361, DOI 10.1111/j.1349-7006.2004.tb03216.x; Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Perez-Sala D, 2003, J BIOL CHEM, V278, P51251, DOI 10.1074/jbc.M309409200; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; Pursiheimo JP, 2009, ONCOGENE, V28, P334, DOI 10.1038/onc.2008.392; Ray DM, 2006, J IMMUNOL, V177, P5068, DOI 10.4049/jimmunol.177.8.5068; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Saikumar P, 1998, ONCOGENE, V17, P3341, DOI 10.1038/sj.onc.1202579; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Wang ZY, 2006, J BIOL CHEM, V281, P21377, DOI 10.1074/jbc.M601201200	43	97	102	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2009	28	28					2556	2568		10.1038/onc.2009.118	http://dx.doi.org/10.1038/onc.2009.118			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	471LJ	19448671	Green Accepted			2022-12-25	WOS:000268058900002
J	Jouhet, J; Gray, JC				Jouhet, Juliette; Gray, John C.			Interaction of Actin and the Chloroplast Protein Import Apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANE FORMATION; OUTER ENVELOPE; POLYACRYLAMIDE GELS; MESOPHYLL-CELLS; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONE; ROOT GRAVITROPISM; PLASTIDS; ARABIDOPSIS; PLANTS	Actin filaments are major components of the cytoskeleton and play numerous essential roles, including chloroplast positioning and plastid stromule movement, in plant cells. Actin is present in pea chloroplast envelope membrane preparations and is localized at the surface of the chloroplasts, as shown by agglutination of intact isolated chloroplasts by antibodies to actin. To identify chloroplast envelope proteins involved in actin binding, we have carried out actin co-immunoprecipitation and co-sedimentation experiments on detergent-solubilized pea chloroplast envelope membranes. Proteins co-immunoprecipitated with actin were identified by mass spectrometry and by Western blotting and included the Toc159, Toc75, Toc34, and Tic110 components of the TOC-TIC protein import apparatus. A direct interaction of actin with Escherichia coli-expressed Toc159, but not Toc33, was shown by co-sedimentation experiments, suggesting that Toc159 is the component of the TOC complex that interacts with actin on the cytosolic side of the outer envelope membrane. The physiological significance of this interaction is unknown, but it may play a role in the import of nuclear-encoded photosynthesis proteins.	[Jouhet, Juliette; Gray, John C.] Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England	University of Cambridge	Gray, JC (corresponding author), Univ Cambridge, Dept Plant Sci, Downing St, Cambridge CB2 3EA, England.	jcg2@cam.ac.uk			EMBO	EMBO(European Molecular Biology Organization (EMBO))	This project was supported by an EMBO long term fellowship.	Akita M, 1997, J CELL BIOL, V136, P983, DOI 10.1083/jcb.136.5.983; Aseeva E, 2007, PLANT PHYSIOL BIOCH, V45, P119, DOI 10.1016/j.plaphy.2007.01.005; Balsera M, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-43; Bauer J, 2000, NATURE, V403, P203, DOI 10.1038/35003214; Bolter B, 1999, EMBO J, V18, P5505, DOI 10.1093/emboj/18.20.5505; Boonsirichai K, 2002, ANNU REV PLANT BIOL, V53, P421, DOI 10.1146/annurev.arplant.53.100301.135158; Brautigam A, 2008, J BIOTECHNOL, V136, P44, DOI 10.1016/j.jbiotec.2008.02.007; BROGLIE RM, 1980, P NATL ACAD SCI-BIOL, V77, P87, DOI 10.1073/pnas.77.1.87; Chen KH, 2000, PLANT PHYSIOL, V122, P813, DOI 10.1104/pp.122.3.813; CLINE K, 1981, P NATL ACAD SCI-BIOL, V78, P3595, DOI 10.1073/pnas.78.6.3595; Gray JC, 2001, PLANT BIOLOGY, V3, P223, DOI 10.1055/s-2001-15204; Gutensohn M, 2006, J PLANT PHYSIOL, V163, P333, DOI 10.1016/j.jplph.2005.11.009; Hanson MR, 2008, PLANT CELL ENVIRON, V31, P646, DOI 10.1111/j.1365-3040.2007.01768.x; Heazlewood JL, 2007, NUCLEIC ACIDS RES, V35, pD213, DOI 10.1093/nar/gkl863; Higaki T, 2007, CURR OPIN PLANT BIOL, V10, P549, DOI 10.1016/j.pbi.2007.08.012; Hiltbrunner A, 2001, J CELL BIOL, V154, P309, DOI 10.1083/jcb.200104022; Holzinger A, 2007, PLANT BIOLOGY, V9, P400, DOI 10.1055/s-2006-924727; Hou GC, 2003, PLANT PHYSIOL, V131, P1360, DOI 10.1104/pp.014423; Ivanova Y, 2004, MOL BIOL CELL, V15, P3379, DOI 10.1091/mbc.E03-12-0923; Jarvis P, 2008, NEW PHYTOL, V179, P257, DOI 10.1111/j.1469-8137.2008.02452.x; Kandasamy MK, 1999, CELL MOTIL CYTOSKEL, V44, P110, DOI 10.1002/(SICI)1097-0169(199910)44:2<110::AID-CM3>3.0.CO;2-O; Kessler F, 2006, TRAFFIC, V7, P248, DOI 10.1111/j.1600-0854.2005.00382.x; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; Kroll D, 2001, P NATL ACAD SCI USA, V98, P4238, DOI 10.1073/pnas.061500998; Kumar NS, 2008, AM J BOT, V95, P177, DOI 10.3732/ajb.95.2.177; Kumatani T, 2006, PROTOPLASMA, V229, P45, DOI 10.1007/s00709-006-0189-8; Kwok EY, 2003, PLANT J, V35, P16, DOI 10.1046/j.1365-313X.2003.01777.x; Liebe S, 1995, BIOL CELL, V85, P207, DOI 10.1016/0248-4900(96)85282-8; Liu CM, 2005, MOL BIOL CELL, V16, P1165, DOI 10.1091/mbc.E04-08-0736; Liu CM, 2007, PLANT J, V50, P265, DOI 10.1111/j.1365-313X.2007.03047.x; Ma YK, 1996, J CELL BIOL, V134, P315, DOI 10.1083/jcb.134.2.315; Natesan SKA, 2005, J EXP BOT, V56, P787, DOI 10.1093/jxb/eri088; NEUHOFF V, 1985, ELECTROPHORESIS, V6, P427, DOI 10.1002/elps.1150060905; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; Oikawa K, 2003, PLANT CELL, V15, P2805, DOI 10.1105/tpc.016428; Oikawa K, 2008, PLANT PHYSIOL, V148, P829, DOI 10.1104/pp.108.123075; Oreb M, 2008, TRENDS CELL BIOL, V18, P19, DOI 10.1016/j.tcb.2007.10.002; Palmieri M, 2007, PHYSIOL PLANTARUM, V130, P613, DOI 10.1111/j.1399-3054.2007.00926.x; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; Schnell DJ, 1997, TRENDS CELL BIOL, V7, P303, DOI 10.1016/S0962-8924(97)01111-2; Servant Florence, 2002, Brief Bioinform, V3, P246, DOI 10.1093/bib/3.3.246; Sheahan MB, 2004, PLANT J, V37, P379, DOI 10.1046/j.1365-313X.2003.01967.x; Smith MD, 2004, J CELL BIOL, V165, P323, DOI 10.1083/jcb.200311074; Stanga JP, 2009, PLANT PHYSIOL, V149, P1896, DOI 10.1104/pp.109.135301; Suetsugu N, 2007, BIOL CHEM, V388, P927, DOI 10.1515/BC.2007.118; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; Takagi S, 2003, J EXP BIOL, V206, P1963, DOI 10.1242/jeb.00215; Teyssier E, 1996, PLANT J, V10, P903, DOI 10.1046/j.1365-313X.1996.10050903.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; von Braun SS, 2008, PLANTA, V227, P1151, DOI 10.1007/s00425-007-0688-7; Wang ZY, 2004, CELL MOTIL CYTOSKEL, V57, P218, DOI 10.1002/cm.10168; Weber H, 2002, TRENDS PLANT SCI, V7, P217, DOI 10.1016/S1360-1385(02)02250-1; Weibel P, 2003, J BIOL CHEM, V278, P37321, DOI 10.1074/jbc.M305946200; WERNERWASHBURNE M, 1983, PLANT PHYSIOL, V73, P569, DOI 10.1104/pp.73.3.569; Yamamoto K, 2002, PLANT PHYSIOL, V128, P669, DOI 10.1104/pp.010804	55	40	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					19132	19141		10.1074/jbc.M109.012831	http://dx.doi.org/10.1074/jbc.M109.012831			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19435889	hybrid, Green Published			2022-12-25	WOS:000267711500061
J	Yuan, J; Yang, BMP; Zhong, ZH; Shats, I; Milyavsky, M; Rotter, V; Lock, RB; Reddel, RR; MacKenzie, KL				Yuan, J.; Yang, B. M-P; Zhong, Z-H; Shats, I.; Milyavsky, M.; Rotter, V.; Lock, R. B.; Reddel, R. R.; MacKenzie, K. L.			Upregulation of survivin during immortalization of nontransformed human fibroblasts transduced with telomerase reverse transcriptase	ONCOGENE			English	Article						survivin; telomerase; apoptosis; immortalization; fibroblasts	ANTI-APOPTOSIS GENE; MALIGNANT-TRANSFORMATION; SPINDLE CHECKPOINT; CELL-DIVISION; CORD BLOOD; CANCER; INACTIVATION; INHIBITOR; GROWTH; EXPRESSION	These investigations demonstrate that expression of the inhibitor of apoptosis family member, survivin, is dramatically increased during immortalization of nontransformed human fibroblasts that were transduced with telomerase reverse transcriptase (hTERT). Expression of survivin in immortalized fibroblasts peaked during G(2)/M phase of the cell cycle. However, the upregulation of survivin was dissociated from the rate of proliferation and proportion of G(2)/M cells. Depletion of survivin from immortal flbroblasts increased sensitivity to stress-induced apoptosis and resulted in an accumulation of cells with 4N DNA content. Conversely, overexpression of survivin in mortal. broblasts conferred resistance to apoptosis. In contrast, very low levels of survivin in proliferating parental. broblasts had no bearing on sensitivity to apoptosis. The upregulation of survivin did not appear to be a direct consequence of hTERT transduction. However, repression of hTERT resulted in the rapid downregulation of survivin in telomerase-immortalized. broblasts and tumor cell lines, but not in cells immortalized via an Alternative Lengthening of Telomeres mechanism. These results have important therapeutic implications, as telomerase and survivin are both broadly expressed in human cancers. Selection during the immortalization process for cells expressing high levels of survivin may account for the abundance of survivin in diverse tumor types. Oncogene (2009) 28, 2678-2689; doi: 10.1038/onc.2009.136; published online 1 June 2009	[MacKenzie, K. L.] Sydney Childrens Hosp, Childrens Canc Inst Australia Med Res, Randwick, NSW 2031, Australia; [Yuan, J.; Yang, B. M-P; Lock, R. B.; MacKenzie, K. L.] Univ New S Wales, Fac Med, Sydney, NSW, Australia; [Zhong, Z-H; Reddel, R. R.] Childrens Med Res Inst, Westmead, NSW, Australia; [Zhong, Z-H; Reddel, R. R.] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; [Shats, I.; Milyavsky, M.; Rotter, V.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Children's Cancer Institute; University of New South Wales Sydney; Children's Medical Research Institute - Australia; University of Sydney; Weizmann Institute of Science	MacKenzie, KL (corresponding author), Sydney Childrens Hosp, Childrens Canc Inst Australia Med Res, Level 1,High St,POB 81, Randwick, NSW 2031, Australia.	k.mackenzie@unsw.edu.au	Reddel, Roger R/A-6635-2014; MacKenzie, Karen/N-5849-2019; Shats, Igor/AAD-8775-2019; Mackenzie, Karen/F-1310-2011; Lock, Richard/G-4253-2013; Milyavsky, Michael/E-8306-2011	Reddel, Roger R/0000-0002-6302-6107; Shats, Igor/0000-0001-6449-5979; Lock, Richard/0000-0002-3436-9071; MacKenzie, Karen/0000-0003-2996-1617				Adida C, 1998, AM J PATHOL, V152, P43; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Arora V, 2007, J BIOL CHEM, V282, P26202, DOI 10.1074/jbc.M700776200; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Cohen SB, 2007, SCIENCE, V315, P1850, DOI 10.1126/science.1138596; Colgin LM, 2000, NEOPLASIA, V2, P426, DOI 10.1038/sj.neo.7900112; Colnaghi R, 2006, J BIOL CHEM, V281, P33450, DOI 10.1074/jbc.C600164200; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Fukuda S, 2001, BLOOD, V98, P2091, DOI 10.1182/blood.V98.7.2091; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Gurbuxani S, 2005, P NATL ACAD SCI USA, V102, P11480, DOI 10.1073/pnas.0500303102; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Knauer SK, 2007, FASEB J, V21, P207, DOI 10.1096/fj.06-5741com; Knauer SK, 2006, EMBO REP, V7, P1259, DOI 10.1038/sj.embor.7400824; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; MacKenzie KL, 2002, ONCOGENE, V21, P4200, DOI 10.1038/sj.onc.1205425; MacKenzie KL, 2000, EXP CELL RES, V259, P336, DOI 10.1006/excr.2000.4982; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Milyavsky M, 2003, CANCER RES, V63, P7147; Milyavsky M, 2007, CANCER CELL, V11, P133, DOI 10.1016/j.ccr.2006.11.022; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Pennati M, 2007, CARCINOGENESIS, V28, P1133, DOI 10.1093/carcin/bgm047; Raj D, 2008, CARCINOGENESIS, V29, P194, DOI 10.1093/carcin/bgm219; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; Rodel F, 2005, CANCER RES, V65, P4881, DOI 10.1158/0008-5472.CAN-04-3028; Schuller CE, 2007, LEUKEMIA, V21, P983, DOI 10.1038/sj.leu.2404631; Stewart SA, 2006, ANNU REV CELL DEV BI, V22, P531, DOI 10.1146/annurev.cellbio.22.010305.104518; Taylor LM, 2004, J BIOL CHEM, V279, P43634, DOI 10.1074/jbc.M402388200; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Verhagen AM, 2001, GENOME BIOL, V2; Wang J, 2008, CANCER RES, V68, P3152, DOI 10.1158/0008-5472.CAN-07-5348; Wang ZX, 2005, CANCER RES, V65, P8224, DOI 10.1158/0008-5472.CAN-05-0303; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Weinstein IB, 2008, CANCER RES, V68, P3086; Wen VW, 2006, CANCER RES, V66, P10691, DOI 10.1158/0008-5472.CAN-06-0979; Wright WE, 1996, DEV GENET, V18, P173; Yang D, 2004, P NATL ACAD SCI USA, V101, P15100, DOI 10.1073/pnas.0406665101; Yang J, 2008, ONCOGENE, V27, P5326, DOI 10.1038/onc.2008.165; Zhang M, 2006, J EXP CLIN CANC RES, V25, P391	47	13	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2678	2689		10.1038/onc.2009.136	http://dx.doi.org/10.1038/onc.2009.136			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19483728				2022-12-25	WOS:000268211200006
J	Riazi, AM; Takeuchi, JK; Hornberger, LK; Zaidi, SH; Amini, F; Coles, J; Bruneau, BG; Van Arsdell, GS				Riazi, Ali M.; Takeuchi, Jun K.; Hornberger, Lisa K.; Zaidi, Syed Hassan; Amini, Fariba; Coles, John; Bruneau, Benoit G.; Van Arsdell, Glen S.			NKX2-5 Regulates the Expression of beta-Catenin and GATA4 in Ventricular Myocytes	PLOS ONE			English	Article								Background: The molecular pathway that controls cardiogenesis is temporally and spatially regulated by master transcriptional regulators such as NKX2-5, Isl1, MEF2C, GATA4, and beta-catenin. The interplay between these factors and their downstream targets are not completely understood. Here, we studied regulation of beta-catenin and GATA4 by NKX2-5 in human fetal cardiac myocytes. Methodology/Principal Findings: Using antisense inhibition we disrupted the expression of NKX2-5 and studied changes in expression of cardiac-associated genes. Down-regulation of NKX2-5 resulted in increased beta-catenin while GATA4 was decreased. We demonstrated that this regulation was conferred by binding of NKX2-5 to specific elements (NKEs) in the promoter region of the beta-catenin and GATA4 genes. Using promoter-luciferase reporter assay combined with mutational analysis of the NKEs we demonstrated that the identified NKX2-5 binding sites were essential for the suppression of beta-catenin, and upregulation of GATA4 by NKX2-5. Conclusions: This study suggests that NKX2-5 modulates the beta-catenin and GATA4 transcriptional activities in developing human cardiac myocytes.			Riazi, AM (corresponding author), Hosp Sick Children, Labatt Family Heart Ctr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	ali.riazi@sickkids.ca		Bruneau, Benoit/0000-0002-0804-7597				Brand T, 2003, DEV BIOL, V258, P1, DOI 10.1016/S0012-1606(03)00112-X; Brewer AC, 2005, STEM CELLS DEV, V14, P425, DOI 10.1089/scd.2005.14.425; Brown CO, 2004, J BIOL CHEM, V279, P10659, DOI 10.1074/jbc.M301648200; Bruneau BG, 2002, CIRC RES, V90, P509, DOI 10.1161/01.RES.0000013072.51957.B7; CHEN WS, 1995, ONCOL REP, V2, P5; Durocher D, 1996, MOL CELL BIOL, V16, P4648, DOI 10.1128/mcb.16.9.4648; Eisenberg LM, 2006, DEV BIOL, V293, P305, DOI 10.1016/j.ydbio.2006.02.014; Harvey RP, 2002, COLD SPRING HARB SYM, V67, P107, DOI 10.1101/sqb.2002.67.107; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kasahara H, 2003, J MOL CELL CARDIOL, V35, P243, DOI 10.1016/S0022-2828(03)00002-6; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Kwon C, 2008, CELL CYCLE, V7, P3815, DOI 10.4161/cc.7.24.7189; Lickert H, 2002, DEV CELL, V3, P171, DOI 10.1016/S1534-5807(02)00206-X; Lin LZ, 2007, P NATL ACAD SCI USA, V104, P9313, DOI 10.1073/pnas.0700923104; Liu ZQ, 2009, BBA-MOL CELL RES, V1793, P300, DOI 10.1016/j.bbamcr.2008.08.013; Marvin MJ, 2001, GENE DEV, V15, P316, DOI 10.1101/gad.855501; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Montgomery Mary K, 2004, Methods Mol Biol, V265, P3; Nollet F, 1996, GENOMICS, V32, P413, DOI 10.1006/geno.1996.0136; Qyang Y, 2007, CELL STEM CELL, V1, P165, DOI 10.1016/j.stem.2007.05.018; Riazi AM, 2005, J BIOL CHEM, V280, P10716, DOI 10.1074/jbc.M500028200; Schneider VA, 2001, GENE DEV, V15, P304, DOI 10.1101/gad.855601; Schwartz RJ, 1999, DEVELOPMENT, V126, P4187; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; Smagulova FO, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-67; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Ueno S, 2007, P NATL ACAD SCI USA, V104, P9685, DOI 10.1073/pnas.0702859104; van der Heyden MAG, 1998, J CELL SCI, V111, P1741; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; ZAIDI SHE, 1995, J BIOL CHEM, V270, P17292, DOI 10.1074/jbc.270.29.17292; Zeisberg EM, 2005, J CLIN INVEST, V115, P1522, DOI 10.1172/JCI23769	31	35	38	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2009	4	5							e5698	10.1371/journal.pone.0005698	http://dx.doi.org/10.1371/journal.pone.0005698			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QE	19479054	Green Published, gold, Green Submitted			2022-12-25	WOS:000266415100006
J	Yuan, XH; Ta, TC; Lin, M; Evans, JR; Dong, YC; Bolotin, E; Sherman, MA; Forman, BM; Sladek, FM				Yuan, Xiaohui; Ta, Tuong Chi; Lin, Min; Evans, Jane R.; Dong, Yinchen; Bolotin, Eugene; Sherman, Mark A.; Forman, Barry M.; Sladek, Frances M.			Identification of an Endogenous Ligand Bound to a Native Orphan Nuclear Receptor	PLOS ONE			English	Article							VITAMIN-D-RECEPTOR; X-RAY-STRUCTURE; REV-ERB-ALPHA; TRANSCRIPTION FACTOR; ESTROGEN-RECEPTOR; STEROID-RECEPTORS; GENE-EXPRESSION; BINDING DOMAIN; CENTRAL REGULATOR; CRYSTAL-STRUCTURE	Orphan nuclear receptors have been instrumental in identifying novel signaling pathways and therapeutic targets. However, identification of ligands for these receptors has often been based on random compound screens or other biased approaches. As a result, it remains unclear in many cases if the reported ligands are the true endogenous ligands, -i.e., the ligand that is bound to the receptor in an unperturbed in vivo setting. Technical limitations have limited our ability to identify ligands based on this rigorous definition. The orphan receptor hepatocyte nuclear factor 4 alpha (HNF4 alpha) is a key regulator of many metabolic pathways and linked to several diseases including diabetes, atherosclerosis, hemophilia and cancer. Here we utilize an affinity isolation/mass-spectrometry (AIMS) approach to demonstrate that HNF4 alpha is selectively occupied by linoleic acid (LA, C18:2 omega 6) in mammalian cells and in the liver of fed mice. Receptor occupancy is dramatically reduced in the fasted state and in a receptor carrying a mutation derived from patients with Maturity Onset Diabetes of the Young 1 (MODY1). Interestingly, however, ligand occupancy does not appear to have a significant effect on HNF4 alpha transcriptional activity, as evidenced by genome-wide expression profiling in cells derived from human colon. We also use AIMS to show that LA binding is reversible in intact cells, indicating that HNF4 alpha could be a viable drug target. This study establishes a general method to identify true endogenous ligands for nuclear receptors (and other lipid binding proteins), independent of transcriptional function, and to track in vivo receptor occupancy under physiologically relevant conditions.			Yuan, XH (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Gene Regulat & Drug Discovery, Gonda Diabet Res Ctr, Duarte, CA 91010 USA.	bmforman@earthlink.net; frances.sladek@ucr.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK072020, R01DK053892, U19DK062434, R56DK053892] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK053892, R56 DK053892, DK053892, U19 DK062434, DK072020, DK62434, R21 DK072020] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMOGHRABI S, 1995, J COMP PHYSIOL B, V165, P183; [Anonymous], 2001, NUCL RECEPTORS GENET; Benoit G, 2006, PHARMACOL REV, V58, P798, DOI 10.1124/pr.58.4.10; Bertrand W, 2004, MOL BIOL EVOL, V21, P1923, DOI 10.1093/molbev/msh200; Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; BOLOTIN E, 2008, TRANSCRIPTION FACTOR; Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Calleja C, 2006, GENE DEV, V20, P1525, DOI 10.1101/gad.368706; CRONAN JE, 1994, J BACTERIOL, V176, P3069, DOI 10.1128/JB.176.10.3069-3071.1994; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Duda K, 2004, J BIOL CHEM, V279, P23311, DOI 10.1074/jbc.M400864200; DuSell CD, 2008, MOL ENDOCRINOL, V22, P65, DOI 10.1210/me.2007-0383; EDELMAN IS, 1963, P NATL ACAD SCI USA, V50, P1169, DOI 10.1073/pnas.50.6.1169; Ellard S, 2006, HUM MUTAT, V27, P854, DOI 10.1002/humu.20357; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; Fisher CR, 1998, P NATL ACAD SCI USA, V95, P6965, DOI 10.1073/pnas.95.12.6965; Garrison WD, 2006, GASTROENTEROLOGY, V130, P1207, DOI 10.1053/j.gastro.2006.01.003; Grasso LC, 2001, MOL PHYLOGENET EVOL, V21, P93, DOI 10.1006/mpev.2001.0994; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Guido EC, 1996, MOL ENDOCRINOL, V10, P1178, DOI 10.1210/me.10.10.1178; Gupta RK, 2007, GENE DEV, V21, P756, DOI 10.1101/gad.1535507; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hammes SR, 2007, ENDOCR REV, V28, P726, DOI 10.1210/er.2007-0022; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hwang-Verslues WW, 2008, MOL ENDOCRINOL, V22, P78, DOI 10.1210/me.2007-0298; Ingraham HA, 2005, CURR OPIN STRUC BIOL, V15, P708, DOI 10.1016/j.sbi.2005.10.009; Ismail A, 2005, IUBMB LIFE, V57, P483, DOI 10.1080/15216540500147163; JENSEN E, 1996, FATE STEROID ESTROGE, P161; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Kumar S, 2006, MOL CELL ENDOCRINOL, V246, P147, DOI 10.1016/j.mce.2005.11.028; Kyrmizi I, 2006, GENE DEV, V20, P2293, DOI 10.1101/gad.390906; Larroux C, 2006, EVOL DEV, V8, P150, DOI 10.1111/j.1525-142X.2006.00086.x; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; McClintick JN, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-49; Moller AM, 1997, DIABETOLOGIA, V40, P980, DOI 10.1007/s001250050778; Navas MA, 1999, DIABETES, V48, P1459, DOI 10.2337/diabetes.48.7.1459; Norman AW, 2004, NAT REV DRUG DISCOV, V3, P27, DOI 10.1038/nrd1283; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Odom DT, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100059; Paris M, 2008, DEV GENES EVOL, V218, P667, DOI 10.1007/s00427-008-0255-7; Paris M, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-219; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Potier N, 2003, PROTEIN SCI, V12, P725, DOI 10.1110/ps.0232503; Raghuram S, 2007, NAT STRUCT MOL BIOL, V14, P1207, DOI 10.1038/nsmb1344; Rodgers JT, 2007, P NATL ACAD SCI USA, V104, P12861, DOI 10.1073/pnas.0702509104; Rosen J, 2005, ENDOCR REV, V26, P452, DOI 10.1210/er.2005-0002; Schulman IG, 2004, CHEM BIOL, V11, P639, DOI 10.1016/j.chembiol.2003.12.021; Sladek FM, 2002, MOL CELL, V10, P219, DOI 10.1016/S1097-2765(02)00605-6; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; Stegmann A, 2006, PHYSIOL GENOMICS, V27, P141, DOI 10.1152/physiolgenomics.00314.2005; Stehlin C, 2001, EMBO J, V20, P5822, DOI 10.1093/emboj/20.21.5822; Sun K, 2007, MOL ENDOCRINOL, V21, P1297, DOI 10.1210/me.2006-0300; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; van den Bemd GJCM, 2002, J BIOL CHEM, V277, P14539, DOI 10.1074/jbc.M111224200; Watt AJ, 2003, HEPATOLOGY, V37, P1249, DOI 10.1053/jhep.2003.50273; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Yin L, 2007, SCIENCE, V318, P1786, DOI 10.1126/science.1150179; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yuan Xiaohui, 2005, Nucl Recept Signal, V3, pe002	63	150	156	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5609	10.1371/journal.pone.0005609	http://dx.doi.org/10.1371/journal.pone.0005609			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19440305	Green Submitted, Green Published, gold			2022-12-25	WOS:000266161200011
J	Losito, O; Szijgyarto, Z; Resnick, AC; Saiardi, A				Losito, Oriana; Szijgyarto, Zsolt; Resnick, Adam Cain; Saiardi, Adolfo			Inositol Pyrophosphates and Their Unique Metabolic Complexity: Analysis by Gel Electrophoresis	PLOS ONE			English	Article								Background: Inositol pyrophosphates are a recently characterized cell signalling molecules responsible for the pyrophosphorylation of protein substrates. Though likely involved in a wide range of cellular functions, the study of inositol pyrophosphates has suffered from a lack of readily available methods for their analysis. Principal Finding: We describe a novel, sensitive and rapid polyacrylamide gel electrophoresis (PAGE)-based method for the analysis of inositol pyrophosphates. Using 4',6-diamidino-2-phenylindole (DAPI) and Toluidine Blue we demonstrate the unequivocal detection of various inositol pyrophosphate species. Conclusion: The use of the PAGE-based method reveals the likely underestimation of inositol pyrophosphates and their signalling contribution in cells when measured via traditional HPLC-based techniques. PAGE-based analyses also reveals the existence of a number of additional, previously uncharacterised pyrophosphorylated inositol reaction products, defining a more complex metabolism associated with the catalytically flexible kinase class responsible for the production of these highly energetic cell signalling molecules.				dmcbado@ucl.ac.uk			NATIONAL CANCER INSTITUTE [K99CA134914] Funding Source: NIH RePORTER; MRC [MC_U122680443] Funding Source: UKRI; Medical Research Council [MC_U122680443] Funding Source: Medline; NCI NIH HHS [1K99CA134914, K99 CA134914] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azevedo C, 2006, NAT PROTOC, V1, P2416, DOI 10.1038/nprot.2006.337; Bennett M, 2006, CELL MOL LIFE SCI, V63, P552, DOI 10.1007/s00018-005-5446-z; Bhandari R, 2008, P NATL ACAD SCI USA, V105, P2349, DOI 10.1073/pnas.0712227105; Bhandari R, 2007, P NATL ACAD SCI USA, V104, P15305, DOI 10.1073/pnas.0707338104; BURTON A, 2009, J CELL PHYSL; Choi JH, 2007, J BIOL CHEM, V282, P30763, DOI 10.1074/jbc.M704655200; Draskovic P, 2008, CHEM BIOL, V15, P274, DOI 10.1016/j.chembiol.2008.01.011; Fridy PC, 2007, J BIOL CHEM, V282, P30754, DOI 10.1074/jbc.M704656200; GLENNON MC, 1993, BIOCHEM J, V293, P583, DOI 10.1042/bj2930583; Huang CF, 1998, BIOCHEMISTRY-US, V37, P14998, DOI 10.1021/bi981920l; Illies C, 2007, SCIENCE, V318, P1299, DOI 10.1126/science.1146824; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Kornberg A, 1999, ANNU REV BIOCHEM, V68, P89, DOI 10.1146/annurev.biochem.68.1.89; Lin HY, 2009, J BIOL CHEM, V284, P1863, DOI 10.1074/jbc.M805686200; MAYR GW, 1988, BIOCHEM J, V254, P585, DOI 10.1042/bj2540585; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; Morrison BH, 2002, ONCOGENE, V21, P1882, DOI 10.1038/sj.onc.1205265; Mulugu S, 2007, SCIENCE, V316, P106, DOI 10.1126/science.1139099; Nagata E, 2005, J BIOL CHEM, V280, P1634, DOI 10.1074/jbc.M409416200; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2001, J BIOL CHEM, V276, P39179, DOI 10.1074/jbc.M106842200; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; Smith SA, 2007, ELECTROPHORESIS, V28, P3461, DOI 10.1002/elps.200700041; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; TIJSSEN JPF, 1982, BIOCHIM BIOPHYS ACTA, V721, P394, DOI 10.1016/0167-4889(82)90094-5; Voglmaier SM, 1996, P NATL ACAD SCI USA, V93, P4305, DOI 10.1073/pnas.93.9.4305	28	88	91	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5580	10.1371/journal.pone.0005580	http://dx.doi.org/10.1371/journal.pone.0005580			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440344	Green Submitted, Green Published, gold			2022-12-25	WOS:000266107500011
J	Yanamandra, K; Alexeyev, O; Zamotin, V; Srivastava, V; Shchukarev, A; Brorsson, AC; Tartaglia, GG; Vogl, T; Kayed, R; Wingsle, G; Olsson, J; Dobson, CM; Bergh, A; Elgh, F; Morozova-Roche, LA				Yanamandra, Kiran; Alexeyev, Oleg; Zamotin, Vladimir; Srivastava, Vaibhav; Shchukarev, Andrei; Brorsson, Ann-Christin; Tartaglia, Gian Gaetano; Vogl, Thomas; Kayed, Rakez; Wingsle, Gunnar; Olsson, Jan; Dobson, Christopher M.; Bergh, Anders; Elgh, Fredrik; Morozova-Roche, Ludmilla A.			Amyloid Formation by the Pro-Inflammatory S100A8/A9 Proteins in the Ageing Prostate	PLOS ONE			English	Article							CALCIUM-BINDING PROTEINS; ESCHERICHIA-COLI STRAINS; CORPORA-AMYLACEA; S100 PROTEINS; ALZHEIMERS-DISEASE; AGGREGATION-PRONE; FIBRIL FORMATION; EQUINE LYSOZYME; CANCER REGISTER; OLIGOMERS	Background: The conversion of soluble peptides and proteins into polymeric amyloid structures is a hallmark of many age-related degenerative disorders, including Alzheimer's disease, type II diabetes and a variety of systemic amyloidoses. We report here that amyloid formation is linked to another major age-related phenomenon 2 prostate tissue remodelling in middle-aged and elderly men. Methodology/Principal Findings: By using multidisciplinary analysis of corpora amylacea inclusions in prostate glands of patients diagnosed with prostate cancer we have revealed that their major components are the amyloid forms of S100A8 and S100A9 proteins associated with numerous inflammatory conditions and types of cancer. In prostate protease rich environment the amyloids are stabilized by dystrophic calcification and lateral thickening. We have demonstrated that material closely resembling CA can be produced from S100A8/A9 in vitro under native and acidic conditions and shows the characters of amyloids. This process is facilitated by calcium or zinc, both of which are abundant in ex vivo inclusions. These observations were supported by computational analysis of the S100A8/A9 calcium-dependent aggregation propensity profiles. We found DNA and proteins from Escherichia coli in CA bodies, suggesting that their formation is likely to be associated with bacterial infection. CA inclusions were also accompanied by the activation of macrophages and by an increase in the concentration of S100A8/A9 in the surrounding tissues, indicating inflammatory reactions. Conclusions/Significance: These findings, taken together, suggest a link between bacterial infection, inflammation and amyloid deposition of pro-inflammatory proteins S100A8/A9 in the prostate gland, such that a self-perpetuating cycle can be triggered and may increase the risk of malignancy in the ageing prostate. The results provide strong support for the prediction that the generic ability of polypeptide chains to convert into amyloids could lead to their involvement in an increasing number of otherwise apparently unrelated diseases, particularly those associated with ageing.			Yanamandra, K (corresponding author), Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden.	ludmilla.morozova-roche@medchem.umu.se	Morozova-Roche, Ludmilla/AAV-9983-2021; Srivastava, Vaibhav/H-1320-2015; Yanamandra, Kiran/M-4037-2014; Morozova-Roche, Ludmilla A./AAU-9044-2021; Tartaglia, Gian Gaetano/K-1229-2014	Morozova-Roche, Ludmilla/0000-0001-5886-2023; Srivastava, Vaibhav/0000-0003-1877-4154; Yanamandra, Kiran/0000-0002-4908-5848; Olsson, Jan/0000-0001-9094-319X; Tartaglia, Gian Gaetano/0000-0001-7524-6310; Zamotin, Vladimir/0000-0002-3661-8772	Medical Research Council [G0700990] Funding Source: Medline; MRC [G0700990] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adolfsson J, 2007, SCAND J UROL NEPHROL, V41, P456, DOI 10.1080/00365590701673625; Andreu A, 1997, J INFECT DIS, V176, P464, DOI 10.1086/514065; Backstrom S, 2007, MOL CELL, V26, P717, DOI 10.1016/j.molcel.2007.05.007; Bergh J, 2007, EUR UROL, V51, P457, DOI 10.1016/j.eururo.2006.06.008; BOSTWICK DG, 1993, HUM PATHOL, V24, P298, DOI 10.1016/0046-8177(93)90041-E; Cherny I, 2008, ANGEW CHEM INT EDIT, V47, P4062, DOI 10.1002/anie.200703133; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Christian JD, 2005, MODERN PATHOL, V18, P36, DOI 10.1038/modpathol.3800250; Chung MH, 1996, J NEUROPATH EXP NEUR, V55, P403, DOI 10.1097/00005072-199604000-00002; CISSE S, 1993, ACTA NEUROPATHOL, V85, P233; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; CROSS PA, 1992, J CLIN PATHOL, V45, P894, DOI 10.1136/jcp.45.10.894; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; DRACH GW, 1978, J UROLOGY, V120, P266, DOI 10.1016/S0022-5347(17)57135-9; Eikelenboom P, 2006, J NEURAL TRANSM, V113, P1685, DOI 10.1007/s00702-006-0575-6; Emberley ED, 2004, BIOCHEM CELL BIOL, V82, P508, DOI 10.1139/O04-052; Foell D, 2004, CLIN CHIM ACTA, V344, P37, DOI 10.1016/j.cccn.2004.02.023; Fowler DM, 2007, TRENDS BIOCHEM SCI, V32, P217, DOI 10.1016/j.tibs.2007.03.003; Fung KYC, 2004, PROSTATE, V61, P171, DOI 10.1002/pros.20089; Gati Istvan, 2001, Pathology and Oncology Research, V7, P140; Gebhardt C, 2002, ONCOGENE, V21, P4266, DOI 10.1038/sj.onc.1205521; Gebhardt C, 2006, BIOCHEM PHARMACOL, V72, P1622, DOI 10.1016/j.bcp.2006.05.017; Gueft B, 1972, Acta Pathol Microbiol Scand Suppl, V233, P132; GUEVARA J, 1985, CANCER RES, V45, P1766; Harris KA, 2003, J MED MICROBIOL, V52, P685, DOI 10.1099/jmm.0.05213-0; Heizmann C. W., 2007, V45, P93; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Hermani A, 2005, EXP CELL RES, V312, P184, DOI 10.1016/j.yexcr.2005.10.013; Hermani A, 2005, CLIN CANCER RES, V11, P5146, DOI 10.1158/1078-0432.CCR-05-0352; Higurashi T, 2005, J MOL BIOL, V351, P1057, DOI 10.1016/j.jmb.2005.07.006; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Hoyaux D, 2000, BRAIN RES, V867, P280, DOI 10.1016/S0006-8993(00)02393-3; Itzhaki RF, 2008, J NEUROVIROL, V14, P1, DOI 10.1080/13550280701802543; Jager GJ, 1997, EUR RADIOL, V7, P552, DOI 10.1007/s003300050202; Jun SY, 2003, J KOREAN MED SCI, V18, P447, DOI 10.3346/jkms.2003.18.3.447; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kayed R, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-18; KLIMAS R, 1985, PROSTATE, V7, P91, DOI 10.1002/pros.2990070110; Leone L, 2006, SURF INTERFACE ANAL, V38, P202, DOI 10.1002/sia.2184; Leukert N, 2005, BIOL CHEM, V386, P429, DOI 10.1515/BC.2005.051; Leukert N, 2006, J MOL BIOL, V359, P961, DOI 10.1016/j.jmb.2006.04.009; Lundmark K, 2005, P NATL ACAD SCI USA, V102, P6098, DOI 10.1073/pnas.0501814102; Malisauskas M, 2005, J BIOL CHEM, V280, P6269, DOI 10.1074/jbc.M407273200; Malisauskas M, 2003, J MOL BIOL, V330, P879, DOI 10.1016/S0022-2836(03)00551-5; MARX AJ, 1965, ARCH PATHOL, V80, P487; McCormick MM, 2005, J BIOL CHEM, V280, P41521, DOI 10.1074/jbc.M509442200; Morozova-Roche LA, 2004, BIOCHEMISTRY-US, V43, P9610, DOI 10.1021/bi0494121; Morozova-Roche LA, 2000, J STRUCT BIOL, V130, P339, DOI 10.1006/jsbi.2000.4264; Munch J, 2007, CELL, V131, P1059, DOI 10.1016/j.cell.2007.10.014; Nacken W, 2007, FEBS LETT, V581, P5127, DOI 10.1016/j.febslet.2007.09.060; NELSON SR, 1991, BIOCHEM J, V275, P67, DOI 10.1042/bj2750067; Ott HW, 2003, CANCER RES, V63, P7507; Otzen D, 2008, CELL MOL LIFE SCI, V65, P910, DOI 10.1007/s00018-007-7404-4; Pawar AP, 2005, J MOL BIOL, V350, P379, DOI 10.1016/j.jmb.2005.04.016; Rocken C, 1996, PATHOL RES PRACT, V192, P998; ROODVELDT C, 2008, J CELL MOL MED; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Shintaku M, 2005, NEUROPATHOLOGY, V25, P175, DOI 10.1111/j.1440-1789.2005.00613.x; Singh SK, 2005, INT UROL NEPHROL, V37, P495, DOI 10.1007/s11255-005-2088-x; SINGHRAO SK, 1993, NEUROPATH APPL NEURO, V19, P269, DOI 10.1111/j.1365-2990.1993.tb00437.x; Solomon A, 2008, ARCH PATHOL LAB MED, V132, P14, DOI 10.1043/1543-2165(2008)132[14b:IR]2.0.CO;2; Soto SM, 2007, J UROLOGY, V177, P365, DOI 10.1016/j.juro.2006.08.081; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Tanaka M, 2005, CELL, V121, P49, DOI 10.1016/j.cell.2005.03.008; Tartaglia GG, 2008, J MOL BIOL, V380, P425, DOI 10.1016/j.jmb.2008.05.013; Thingholm TE, 2006, NAT PROTOC, V1, P1929, DOI 10.1038/nprot.2006.185; Thomas BA, 1927, J UROLOGY, V18, P470, DOI 10.1016/S0022-5347(17)73300-9; TOKUTAKE S, 1995, NEUROPATH APPL NEURO, V21, P269, DOI 10.1111/j.1365-2990.1995.tb01059.x; Untergasser G, 2005, EXP GERONTOL, V40, P121, DOI 10.1016/j.exger.2004.12.008; Uversky VN, 2007, J NEUROCHEM, V103, P17, DOI 10.1111/j.1471-4159.2007.04764.x; van den Bos C, 1998, PROTEIN EXPRES PURIF, V13, P313, DOI 10.1006/prep.1998.0917; Varenhorst E, 2005, SCAND J UROL NEPHROL, V39, P117, DOI 10.1080/00365590510007793; Vogl T, 2006, BBA-MOL CELL RES, V1763, P1298, DOI 10.1016/j.bbamcr.2006.08.028; Wozniak MA, 2007, NEUROSCI LETT, V429, P95, DOI 10.1016/j.neulet.2007.09.077; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Zhao HX, 2004, BIOCHEMISTRY-US, V43, P10302, DOI 10.1021/bi049002c	77	77	79	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5562	10.1371/journal.pone.0005562	http://dx.doi.org/10.1371/journal.pone.0005562			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440546	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107400006
J	Tian, CH; Murrin, LC; Zheng, JLC				Tian, Changhai; Murrin, L. Charles; Zheng, Jialin C.			Mitochondrial Fragmentation Is Involved in Methamphetamine-Induced Cell Death in Rat Hippocampal Neural Progenitor Cells	PLOS ONE			English	Article								Methamphetamine (METH) induces neurodegeneration through damage and apoptosis of dopaminergic nerve terminals and striatal cells, presumably via cross-talk between the endoplasmic reticulum and mitochondria-dependent death cascades. However, the effects of METH on neural progenitor cells (NPC), an important reservoir for replacing neurons and glia during development and injury, remain elusive. Using a rat hippocampal NPC (rhNPC) culture, we characterized the METH-induced mitochondrial fragmentation, apoptosis, and its related signaling mechanism through immunocytochemistry, flow cytometry, and Western blotting. We observed that METH induced rhNPC mitochondrial fragmentation, apoptosis, and inhibited cell proliferation. The mitochondrial fission protein dynamin-related protein 1 (Drp1) and reactive oxygen species (ROS), but not calcium (Ca2+) influx, were involved in the regulation of METH-induced mitochondrial fragmentation. Furthermore, our results indicated that dysregulation of ROS contributed to the oligomerization and translocation of Drp1, resulting in mitochondrial fragmentation in rhNPC. Taken together, our data demonstrate that METH-mediated ROS generation results in the dysregulation of Drp1, which leads to mitochondrial fragmentation and subsequent apoptosis in rhNPC. This provides a potential mechanism for METH-related neurodegenerative disorders, and also provides insight into therapeutic strategies for the neurodegenerative effects of METH.			Tian, CH (corresponding author), Univ Nebraska Med Ctr, Ctr Neurovirol & Neurodegenerat Disorders, Lab Neurotoxicol, Omaha, NE USA.	jzheng@unmc.edu	Tian, Changhai/AAD-4856-2019		NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH083525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061642, P01NS043985, R01NS041858] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR015635, P20 RR15635-01] Funding Source: Medline; NIMH NIH HHS [R21 MH083525, R21 MH 083525-01] Funding Source: Medline; NINDS NIH HHS [R01 NS041858, R01 NS061642, R01 NS 41858-01, P01NS043985, P01 NS043985, R01 NS 061642-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; Cadet JL, 2007, NEUROTOX RES, V11, P183, DOI 10.1007/BF03033567; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Capano M, 2002, BIOCHEM J, V367, P169, DOI 10.1042/BJ20020805; Cerveny KL, 2007, TRENDS CELL BIOL, V17, P563, DOI 10.1016/j.tcb.2007.08.006; Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Copp J, 2005, AM J PHYSIOL-CELL PH, V288, pC403, DOI 10.1152/ajpcell.00095.2004; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Dawirs RR, 2001, ACTA PSYCHIAT SCAND, V104, P10, DOI 10.1034/j.1600-0447.2001.104s408010.x; Deng XL, 2000, MOL BRAIN RES, V83, P121, DOI 10.1016/S0169-328X(00)00169-8; Deng XL, 2002, MOL PHARMACOL, V62, P993, DOI 10.1124/mol.62.5.993; Deng XL, 2001, MOL BRAIN RES, V93, P64, DOI 10.1016/S0169-328X(01)00184-X; Eisch AJ, 2006, HIPPOCAMPUS, V16, P271, DOI 10.1002/hipo.20161; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fontana X, 2006, CEREB CORTEX, V16, P301, DOI 10.1093/cercor/bhi120; FRANCIS B, 2001, SEX ED, V1, P1; Haller O, 2002, TRAFFIC, V3, P710, DOI 10.1034/j.1600-0854.2002.31003.x; Hanson GR, 2004, NEUROPHARMACOLOGY, V47, P92, DOI 10.1016/j.neuropharm.2004.06.004; Harder Z, 2004, CURR BIOL, V14, P340, DOI 10.1016/j.cub.2004.02.004; Hendrickson H, 2006, AAPS J, V8, pE709, DOI 10.1208/aapsj080480; Hermann GJ, 1998, ANNU REV CELL DEV BI, V14, P265, DOI 10.1146/annurev.cellbio.14.1.265; Hom JR, 2007, J CELL PHYSIOL, V212, P498, DOI 10.1002/jcp.21051; Huang P, 2007, EUR J CELL BIOL, V86, P289, DOI 10.1016/j.ejcb.2007.04.002; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Jayanthi S, 2001, FASEB J, V15, P1745, DOI 10.1096/fj.01-0025com; Jayanthi S, 2004, FASEB J, V18, P238, DOI 10.1096/fj.03-0295com; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Karbowski M, 2004, J CELL BIOL, V166, P1027, DOI 10.1083/jcb.200407046; Karbowski M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082; Karbowski M, 2007, J CELL BIOL, V178, P71, DOI 10.1083/jcb.200611064; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lee CT, 2008, PLOS MED, V5, P987, DOI 10.1371/journal.pmed.0050117; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Lei XB, 2006, FASEB J, V20, P2147, DOI 10.1096/fj.05-5665fje; Liao XD, 2003, BIOCHEM BIOPH RES CO, V310, P405, DOI 10.1016/j.bbrc.2003.09.023; Maeda K, 2007, J PHARMACOL SCI, V103, P299, DOI 10.1254/jphs.FP0061424; McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054; Meredith CW, 2005, HARVARD REV PSYCHIAT, V13, P141, DOI 10.1080/10673220591003605; Miyatake M, 2005, EUR J NEUROSCI, V22, P1476, DOI 10.1111/j.1460-9568.2005.04325.x; MUNSCH T, 1995, J NEUROSCI METH, V57, P195, DOI 10.1016/0165-0270(94)00149-B; Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019; Parone PA, 2006, MOL CELL BIOL, V26, P7397, DOI 10.1128/MCB.02282-05; PARRA V, 2007, CHANGES MITOCHONDRIA; Peng H, 2004, J NEUROSCI RES, V76, P35, DOI 10.1002/jnr.20045; Peng H, 2006, GLIA, V54, P619, DOI 10.1002/glia.20409; Pubill D, 2003, N-S ARCH PHARMACOL, V367, P490, DOI 10.1007/s00210-003-0747-y; Raudensky J, 2007, BRAIN RES, V1135, P129, DOI 10.1016/j.brainres.2006.12.002; Riddle EL, 2006, AAPS J, V8, pE413, DOI 10.1007/BF02854914; Sever S, 2002, CURR OPIN CELL BIOL, V14, P463, DOI 10.1016/S0955-0674(02)00347-2; Shen HM, 2006, FREE RADICAL BIO MED, V40, P928, DOI 10.1016/j.freeradbiomed.2005.10.056; Shimazu K, 2006, LEARN MEMORY, V13, P307, DOI 10.1101/lm.76006; Simoes PF, 2007, NEUROSCIENCE, V150, P433, DOI 10.1016/j.neuroscience.2007.09.044; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; STANFIELD BB, 1988, EXP BRAIN RES, V72, P399; Suen DF, 2008, GENE DEV, V22, P1577, DOI 10.1101/gad.1658508; Sugioka R, 2004, J BIOL CHEM, V279, P52726, DOI 10.1074/jbc.M408910200; Talloczy Z, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040028; Tian CH, 2008, J NEUROCHEM, V105, P994, DOI 10.1111/j.1471-4159.2007.05197.x; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Volz TJ, 2007, J NEUROCHEM, V101, P883, DOI 10.1111/j.1471-4159.2006.04419.x; Wasiak S, 2007, J CELL BIOL, V177, P439, DOI 10.1083/jcb.200610042; Waterham HR, 2007, NEW ENGL J MED, V356, P1736, DOI 10.1056/NEJMoa064436; Whitney NP, 2008, FASEB J, V22, P2888, DOI 10.1096/fj.07-104661; Yoon Y, 2001, MOL BIOL CELL, V12, P2894, DOI 10.1091/mbc.12.9.2894; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Yu TZ, 2005, J CELL SCI, V118, P4141, DOI 10.1242/jcs.02537; Zhu PP, 2004, J BIOL CHEM, V279, P35967, DOI 10.1074/jbc.M404105200; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	81	62	62	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2009	4	5							e5546	10.1371/journal.pone.0005546	http://dx.doi.org/10.1371/journal.pone.0005546			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FX	19436752	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107300011
J	Matthew, T; Zhou, WX; Rupprecht, J; Lim, L; Thomas-Hall, SR; Doebbe, A; Kruse, O; Hankamer, B; Marx, UC; Smith, SM; Schenk, PM				Matthew, Timmins; Zhou, Wenxu; Rupprecht, Jens; Lim, Lysha; Thomas-Hall, Skye R.; Doebbe, Anja; Kruse, Olaf; Hankamer, Ben; Marx, Ute C.; Smith, Steven M.; Schenk, Peer M.			The Metabolome of Chlamydomonas reinhardtii following Induction of Anaerobic H-2 Production by Sulfur Depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PRODUCTION; GENE-EXPRESSION; GREEN-ALGAE; ACCLIMATION; PHOTOPRODUCTION; DEPRIVATION; MECHANISM; PATHWAYS; INSIGHTS; STARCH	The metabolome of the model species Chlamydomonas reinhardtii has been analyzed during 120 h of sulfur depletion to induce anaerobic hydrogen (H-2) production, using NMR spectroscopy, gas chromatography coupled to mass spectrometry, and TLC. The results indicate that these unicellular green algae consume freshly supplied acetate in the medium to accumulate energy reserves during the first 24 h of sulfur depletion. In addition to the previously reported accumulation of starch, large amounts of triacylglycerides were deposited in the cells. During the early 24- to 72-h time period fermentative energy metabolism lowered the pH, H-2 was produced, and amino acid levels generally increased. In the final phase from 72 to 120 h, metabolism slowed down leading to a stabilization of pH, even though some starch and most triacylglycerides remained. We conclude that H-2 production does not slow down due to depletion of energy reserves but rather due to loss of essential functions resulting from sulfur depletion or due to a build-up of the toxic fermentative products formate and ethanol.	[Matthew, Timmins; Rupprecht, Jens; Lim, Lysha; Hankamer, Ben; Marx, Ute C.] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; [Matthew, Timmins; Thomas-Hall, Skye R.; Schenk, Peer M.] Univ Queensland, Sch Biol Sci, St Lucia, Qld 4072, Australia; [Matthew, Timmins; Zhou, Wenxu; Smith, Steven M.] Univ Western Australia, ARC Ctr Excellence Plant Energy Biol, Crawley, WA 6009, Australia; [Zhou, Wenxu; Smith, Steven M.] Univ Western Australia, Ctr Excellence Plant Metabol, Crawley, WA 6009, Australia; [Doebbe, Anja; Kruse, Olaf] Univ Bielefeld, Dept Biol, AlgaeBioTech Grp, D-33615 Bielefeld, Germany	University of Queensland; University of Queensland; University of Western Australia; University of Western Australia; University of Bielefeld	Hankamer, B (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	b.hankamer@imb.uq.edu.au; ute.marx@bruker-biospin.de; ssmith@cyllene.uwa.edu.au	Smith, Steven M/G-7183-2015; Kruse, Olaf/O-1127-2015; Hankamer, Ben D/C-9688-2015; Smith, Steven/HDM-9496-2022; Zhou, Wenxu/T-6917-2019; Schenk, Peer/B-7879-2016	Smith, Steven M/0000-0001-5661-9994; Hankamer, Ben D/0000-0001-9284-4929; Schenk, Peer/0000-0003-4878-3799; Thomas-Hall, Skye/0000-0002-4208-5992; Kruse, Olaf/0000-0001-9874-382X	Australian Research Council [FF0457721, CE0561495]; Solar Biofuels Consortium; Centres of Excellence Program of the Government of Western Australia; German Federal Ministry of Education and Science [0315165A]; Deutsche Bundesstiftung Umwelt [DBU 20006/828]; ARC [DP0877147]	Australian Research Council(Australian Research Council); Solar Biofuels Consortium; Centres of Excellence Program of the Government of Western Australia; German Federal Ministry of Education and Science(Federal Ministry of Education & Research (BMBF)); Deutsche Bundesstiftung Umwelt; ARC(Australian Research Council)	This work was supported in part by the Australian Research Council (ARC Grants FF0457721 and CE0561495). This work was also supported by the Solar Biofuels Consortium, the Centres of Excellence Program of the Government of Western Australia, the German Federal Ministry of Education and Science (BMBF-ForSys Partner 0315165A), and the Deutsche Bundesstiftung Umwelt (Grant DBU 20006/828).; Supported by ARC Grant DP0877147.	BALL SG, 1990, PLANT SCI, V66, P1, DOI 10.1016/0168-9452(90)90162-H; Bernard L, 2006, FEBS J, V273, P3625, DOI 10.1111/j.1742-4658.2006.05370.x; BOICHENKO VA, 1994, PHOTOSYNTHETICA, V30, P527; Dubini A, 2009, J BIOL CHEM, V284, P7201, DOI 10.1074/jbc.M803917200; Fernandez E, 2008, EUKARYOT CELL, V7, P555, DOI 10.1128/EC.00431-07; Forestier M, 2003, EUR J BIOCHEM, V270, P2750, DOI 10.1046/j.1432-1033.2003.03656; Gaffron Hans, 1942, JOUR GEN PHYSIOL, V26, P219, DOI 10.1085/jgp.26.2.219; GFELLER RP, 1984, PLANT PHYSIOL, V75, P212, DOI 10.1104/pp.75.1.212; Greenway H, 2003, FUNCT PLANT BIOL, V30, P999, DOI 10.1071/PP98096; Grossman AR, 2007, CURR OPIN PLANT BIOL, V10, P190, DOI 10.1016/j.pbi.2007.01.012; HAPPE T, 1993, EUR J BIOCHEM, V214, P475, DOI 10.1111/j.1432-1033.1993.tb17944.x; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P780; Hemschemeier A, 2008, PLANTA, V227, P397, DOI 10.1007/s00425-007-0626-8; Kosourov S, 2003, PLANT CELL PHYSIOL, V44, P146, DOI 10.1093/pcp/pcg020; Kruse O, 2005, J BIOL CHEM, V280, P34170, DOI 10.1074/jbc.M503840200; Melis A, 2000, PLANT PHYSIOL, V122, P127, DOI 10.1104/pp.122.1.127; Melis A, 2007, PLANTA, V226, P1075, DOI 10.1007/s00425-007-0609-9; MENEGUS F, 1991, PLANT PHYSIOL, V95, P760, DOI 10.1104/pp.95.3.760; Mus F, 2007, J BIOL CHEM, V282, P25475, DOI 10.1074/jbc.M701415200; Nguyen AV, 2008, EUKARYOT CELL, V7, P1965, DOI 10.1128/EC.00418-07; Poerschmann J, 2004, MICROB ECOL, V48, P78, DOI 10.1007/s00248-003-0144-6; Pollock SV, 2005, PHOTOSYNTH RES, V86, P475, DOI 10.1007/s11120-005-4048-9; Posewitz MC, 2004, PLANT CELL, V16, P2151, DOI 10.1105/tpc.104.021972; Schonfeld C, 2004, J BIOL CHEM, V279, P50366, DOI 10.1074/jbc.M408477200; STOOP JM, 1996, TRENDS PLANT SCI, P139; STUART TS, 1972, PLANTA, V106, P101, DOI 10.1007/BF00383990; Timmins M, 2009, J EXP BOT, V60, P1691, DOI 10.1093/jxb/erp052; Zhang ZD, 2004, EUKARYOT CELL, V3, P1331, DOI 10.1128/EC.3.5.1331-1348.2004	28	111	113	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	2009	284	35					23415	23425		10.1074/jbc.M109.003541	http://dx.doi.org/10.1074/jbc.M109.003541			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	486EZ	19478077	Green Published, hybrid			2022-12-25	WOS:000269180000026
J	Rombouts, Y; Burguiere, A; Maes, E; Coddeville, B; Elass, E; Guerardel, Y; Kremer, L				Rombouts, Yoann; Burguiere, Adeline; Maes, Emmanuel; Coddeville, Bernadette; Elass, Elisabeth; Guerardel, Yann; Kremer, Laurent			Mycobacterium marinum Lipooligosaccharides Are Unique Caryophyllose-containing Cell Wall Glycolipids That Inhibit Tumor Necrosis Factor-alpha Secretion in Macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TREHALOSE-CONTAINING LIPOOLIGOSACCHARIDES; O-ACYLTREHALOSE CORE; BRANCHED-CHAIN SUGAR; IMMUNE-RESPONSE; GLYCOSYLATED ACYLTREHALOSE; TUBERCULOSIS; LIPOARABINOMANNAN; KANSASII; ANTIGENS; BIOSYNTHESIS	Earlier studies have reported a role for lipooligosaccharides (LOSs) in sliding motility, biofilm formation, and infection of host macrophages in Mycobacterium marinum. Although a LOS biosynthetic gene cluster has recently been identified in this species, many structural features of the different LOSs (LOS-I-IV) are still unknown. This clearly hampers assessing the contribution of each LOS in mycobacterial virulence as well as structure-function-based studies of these important cell wall-associated glycolipids. In this study, we have identified an M. marinum isolate, M. marinum 7 (Mma7), which failed to produce LOS-IV but instead accumulated large amounts of LOS-III. Local genomic comparison of the LOS biosynthetic cluster established the presence of a highly disorganized region in Mma7 compared with the standard M strain, characterized by multiple genetic lesions that are likely to be responsible for the defect in LOS-IV production in Mma7. Our results indicate that the glycosyltransferase LosA alone is not sufficient to ensure LOS-IV biosynthesis. The availability of different M. marinum strains allowed us to determine the precise structure of individual LOSs through the combination of mass spectrometric and NMR techniques. In particular, we established the presence of two related 4-C-branched monosaccharides within LOS-II to IV sequences, of which one was never identified before. In addition, we provided evidence that LOSs are capable of inhibiting the secretion of tumor necrosis factor-alpha in lipopolysaccharide-stimulated human macrophages. This unexpected finding suggests that these cell wall-associated glycolipids represent key effectors capable of interfering with the establishment of a pro-inflammatory response.	[Rombouts, Yoann; Maes, Emmanuel; Coddeville, Bernadette; Elass, Elisabeth; Guerardel, Yann] Univ Sci & Technol Lille, CNRS, UMR 8576, Unite Glycobiol Struct & Fonct,IFR 147, F-59655 Villeneuve Dascq, France; [Burguiere, Adeline; Kremer, Laurent] Univ Montpellier 2, CNRS, UMR 5235, Lab Dynam Interact Membranaires Normales & Pathol, F-34095 Montpellier 05, France; [Burguiere, Adeline; Kremer, Laurent] Univ Montpellier 1, CNRS, UMR 5235, Lab Dynam Interact Membranaires Normales & Pathol, F-34095 Montpellier 05, France; [Kremer, Laurent] INSERM, F-34095 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Guerardel, Y (corresponding author), Univ Sci & Technol Lille, CNRS, UMR 8576, Unite Glycobiol Struct & Fonct,IFR 147, F-59655 Villeneuve Dascq, France.	yann.guerardel@univ-lille1.fr	Kremer, Laurent/M-4935-2017	Kremer, Laurent/0000-0002-6604-4458; Rombouts, Yoann/0000-0003-4482-2199; elass, elisabeth/0000-0002-2573-2959; Guerardel, Yann/0000-0003-4967-9512	French National Research Agency [ANR-05-MIIM-025]; Ministere de l'Enseignement Superieur; Universite des Sciences et Technologies de Lille; Institut Federatif de Recherche [IFR 147]	French National Research Agency(French National Research Agency (ANR)); Ministere de l'Enseignement Superieur; Universite des Sciences et Technologies de Lille; Institut Federatif de Recherche	This work was supported by Grant ANR-05-MIIM-025 from the French National Research Agency (to Y.G. and L. K.), the Ministere de l'Enseignement Superieur (to Y.R.), Universite des Sciences et Technologies de Lille, and Institut Federatif de Recherche Grant (IFR 147).	ADINOLFI M, 1995, CARBOHYD RES, V274, P223, DOI 10.1016/0008-6215(95)00127-F; ADINOLFI M, 1995, CARBOHYD RES, V267, P307, DOI 10.1016/0008-6215(94)00302-V; Alexander DC, 2004, J BIOL CHEM, V279, P18824, DOI 10.1074/jbc.M400791200; Appelmelk BJ, 2008, CELL MICROBIOL, V10, P930, DOI 10.1111/j.1462-5822.2007.01097.x; BELISLE JT, 1989, J BACTERIOL, V171, P3465, DOI 10.1128/jb.171.6.3465-3470.1989; BESRA GS, 1993, BIOCHEMISTRY-US, V32, P12705, DOI 10.1021/bi00210a020; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Briken V, 2004, MOL MICROBIOL, V53, P391, DOI 10.1111/j.1365-2958.2004.04183.x; Burguiere A, 2005, J BIOL CHEM, V280, P42124, DOI 10.1074/jbc.M507500200; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Clay H, 2008, IMMUNITY, V29, P283, DOI 10.1016/j.immuni.2008.06.011; Clay H, 2007, CELL HOST MICROBE, V2, P29, DOI 10.1016/j.chom.2007.06.004; COLLINS FM, 1981, INFECT IMMUN, V32, P614, DOI 10.1128/IAI.32.2.614-624.1981; Cosma CL, 2004, NAT IMMUNOL, V5, P828, DOI 10.1038/ni1091; DAFFE M, 1991, BIOCHEMISTRY-US, V30, P378, DOI 10.1021/bi00216a011; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Davis JM, 2002, IMMUNITY, V17, P693, DOI 10.1016/S1074-7613(02)00475-2; DOMON B, 1988, BIOCHEMISTRY-US, V27, P1534, DOI 10.1021/bi00405a021; Etienne G, 2009, J BACTERIOL, V191, P2613, DOI 10.1128/JB.01235-08; GILLERON M, 1995, GLYCOCONJUGATE J, V12, P298, DOI 10.1007/BF00731333; GILLERON M, 1993, J BIOL CHEM, V268, P3168; GORSHKOVA RP, 1987, BIOORG KHIM+, V13, P1146; GORSHKOVA RP, 1984, CARBOHYD RES, V126, P308, DOI 10.1016/0008-6215(84)85389-6; Guerardel Y, 2003, J BIOL CHEM, V278, P36637, DOI 10.1074/jbc.M305427200; Guerardel Y, 2002, J BIOL CHEM, V277, P30635, DOI 10.1074/jbc.M204398200; HUNTER SW, 1984, J BIOL CHEM, V259, P9729; HUNTER SW, 1985, BIOCHEMISTRY-US, V24, P2798, DOI 10.1021/bi00332a030; HUNTER SW, 1988, BIOCHEMISTRY-US, V27, P1549, DOI 10.1021/bi00405a023; HUNTER SW, 1983, J BIOL CHEM, V258, P481; Karakousis PC, 2004, CELL MICROBIOL, V6, P105, DOI 10.1046/j.1462-5822.2003.00351.x; KHOO KH, 1995, CARBOHYD RES, V276, P449, DOI 10.1016/0008-6215(95)00184-U; Kremer L, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P173; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; LEMASSU A, 1992, J GEN MICROBIOL, V138, P1535, DOI 10.1099/00221287-138-7-1535; Malm S, 2008, INT J MED MICROBIOL, V298, P645, DOI 10.1016/j.ijmm.2008.03.010; Mattos KA, 2005, GLYCOBIOLOGY, V15, P313, DOI 10.1093/glycob/cwi009; MCNEIL M, 1987, J BACTERIOL, V169, P3312, DOI 10.1128/jb.169.7.3312-3320.1987; Minnikin DE, 2002, CHEM BIOL, V9, P545, DOI 10.1016/S1074-5521(02)00142-4; Molinaro A, 2001, J AM CHEM SOC, V123, P12605, DOI 10.1021/ja016471i; Munoz M, 1998, MICROBIOL-SGM, V144, P137, DOI 10.1099/00221287-144-1-137; Reed MB, 2004, NATURE, V431, P84, DOI 10.1038/nature02837; Ren HP, 2007, MOL MICROBIOL, V63, P1345, DOI 10.1111/j.1365-2958.2007.05603.x; Robinson N, 2008, TRAFFIC, V9, P1936, DOI 10.1111/j.1600-0854.2008.00804.x; Ryll R, 2001, MICROBIOL IMMUNOL, V45, P801, DOI 10.1111/j.1348-0421.2001.tb01319.x; Stinear TP, 2008, GENOME RES, V18, P729, DOI 10.1101/gr.075069.107; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; van der Sar AM, 2004, INFECT IMMUN, V72, P6306, DOI 10.1128/IAI.72.11.6306-6312.2004; VEY E, 1992, J IMMUNOL, V149, P2040; Vignal C, 2003, J IMMUNOL, V171, P2014, DOI 10.4049/jimmunol.171.4.2014	49	31	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20975	20988		10.1074/jbc.M109.011429	http://dx.doi.org/10.1074/jbc.M109.011429			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19491094	Green Published, hybrid			2022-12-25	WOS:000268316100061
J	Guerreiro, JR; Lameu, C; Oliveira, EF; Klitzke, CF; Melo, RL; Linares, E; Augusto, O; Fox, JW; Lebrun, I; Serrano, SMT; Camargo, ACM				Guerreiro, Juliano R.; Lameu, Claudiana; Oliveira, Eduardo F.; Klitzke, Clecio F.; Melo, Robson L.; Linares, Edlaine; Augusto, Ohara; Fox, Jay W.; Lebrun, Ivo; Serrano, Solange M. T.; Camargo, Antonio C. M.			Argininosuccinate Synthetase Is a Functional Target for a Snake Venom Anti-hypertensive Peptide ROLE IN ARGININE AND NITRIC OXIDE PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING-ENZYME; BRADYKININ-POTENTIATING PEPTIDES; PERFORMANCE LIQUID-CHROMATOGRAPHY; SPONTANEOUSLY HYPERTENSIVE-RATS; VASCULAR SMOOTH-MUSCLE; CITRULLINE-NO CYCLE; AMINO-ACID-ANALYSIS; BOTHROPS-JARARACA; PROLINE-RICH; ENDOTHELIAL-CELLS	Bj-BPP-10c is a bioactive proline-rich decapeptide, part of the C-type natriuretic peptide precursor, expressed in the brain and in the venom gland of Bothrops jararaca. We recently showed that Bj-BPP-10c displays a strong, sustained anti-hypertensive effect in spontaneous hypertensive rats (SHR), without causing any effect in normotensive rats, by a pharmacological effect independent of angiotensin-converting enzyme inhibition. Therefore, we hypothesized that another mechanism should be involved in the peptide activity. Here we used affinity chromatography to search for kidney cytosolic proteins with affinity for Bj-BPP-10c and demonstrate that argininosuccinate synthetase (AsS) is the major protein binding to the peptide. More importantly, this interaction activates the catalytic activity of AsS in a dose-dependent manner. AsS is recognized as an important player of the citrulline-NO cycle that represents a potential limiting step in NO synthesis. Accordingly, the functional interaction of Bj-BPP-10c and AsS was evidenced by the following effects promoted by the peptide: (i) increase of NO metabolite production in human umbilical vein endothelial cell culture and of arginine in human embryonic kidney cells and (ii) increase of arginine plasma concentration in SHR. Moreover, alpha-methyl-DL-aspartic acid, a specific AsS inhibitor, significantly reduced the anti-hypertensive activity of Bj-BPP-10c in SHR. Taken together, these results suggest that AsS plays a role in the anti-hypertensive action of Bj-BPP-10c. Therefore, we propose the activation of AsS as a new mechanism for the anti-hypertensive effect of Bj-BPP-10c in SHR and AsS as a novel target for the therapy of hypertension-related diseases.	[Serrano, Solange M. T.] Inst Butantan, Lab Especial Toxicol Aplicada, CAT CEPID, BR-05503900 Sao Paulo, Brazil; [Guerreiro, Juliano R.; Lameu, Claudiana; Linares, Edlaine; Augusto, Ohara] Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05513970 Sao Paulo, Brazil; [Oliveira, Eduardo F.] Univ Fed Sao Paulo, Dept Biol Mol, BR-04044020 Sao Paulo, Brazil; [Fox, Jay W.] Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; [Lebrun, Ivo] Inst Butantan, Lab Bioquim & Biofis, BR-05503900 Sao Paulo, Brazil	Instituto Butantan; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); University of Virginia; Instituto Butantan	Serrano, SMT (corresponding author), Inst Butantan, Lab Especial Toxicol Aplicada, CAT CEPID, Ave Vital Brasil, BR-05503900 Sao Paulo, Brazil.	solangeserrano@butantan.gov.br; acmcamargo@butantan.gov.br	Lameu, Claudiana/B-9089-2012; Linares, Edlaine/AAR-8753-2020; Toxicologia aplicada, Cepid/I-4891-2013; Serrano, Solange M. T./A-7132-2008; Klitzke, Clecio Fernando/A-8920-2010; Serrano, Solange/ABB-7569-2021; Augusto, Ohara/D-3839-2012; Melo, Robson/B-5798-2013	Lameu, Claudiana/0000-0002-6874-5864; Linares, Edlaine/0000-0001-8164-3013; Serrano, Solange M. T./0000-0001-8994-1904; Klitzke, Clecio Fernando/0000-0001-5973-6088; Serrano, Solange/0000-0001-8994-1904; Augusto, Ohara/0000-0002-7220-4286; 	Brazilian agencies Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [98/14307-9, 04/14250-0, 06/53139-2, 04/11359-0]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico	Brazilian agencies Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by the Brazilian agencies Fundacao de Amparo a Pesquisa do Estado de Sao Paulo Grants 98/14307-9, 04/14250-0, 06/53139-2, and 04/11359-0 and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico.	Atherton E., 1990, SOLID PHASE PEPTIDE; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Corbin KD, 2008, BIOCHEM BIOPH RES CO, V377, P1042, DOI 10.1016/j.bbrc.2008.10.056; Cotton J, 2002, BIOCHEMISTRY-US, V41, P6065, DOI 10.1021/bi012121x; DHANAKOTI SN, 1992, BIOCHEM J, V282, P369, DOI 10.1042/bj2820369; EBERT RF, 1986, ANAL BIOCHEM, V154, P431, DOI 10.1016/0003-2697(86)90010-2; FAKLER CR, 1995, ACTA PAEDIATR, V84, P460, DOI 10.1111/j.1651-2227.1995.tb13673.x; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; FERREIRA SH, 1970, BIOCHEMISTRY-US, V9, P2583, DOI 10.1021/bi00815a005; Flam BR, 2007, NITRIC OXIDE-BIOL CH, V17, P115, DOI 10.1016/j.niox.2007.07.001; Fox JW, 2007, CURR PHARM DESIGN, V13, P2927, DOI 10.2174/138161207782023739; GAVRAS H, 1974, NEW ENGL J MED, V291, P817, DOI 10.1056/NEJM197410172911603; GILES AR, 1987, THROMB HAEMOSTASIS, V58, P1078; Gomes CL, 2007, BIOCHEM PHARMACOL, V74, P1350, DOI 10.1016/j.bcp.2007.07.014; Goodwin BL, 2004, J BIOL CHEM, V279, P18353, DOI 10.1074/jbc.M308160200; Hanna SL, 2000, MICROBIOL-UK, V146, P2495, DOI 10.1099/00221287-146-10-2495; Hao G, 2004, J BIOL CHEM, V279, P36192, DOI 10.1074/jbc.M404866200; HASEGAWA T, 1992, BIOCHEM INT, V26, P653; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; Hayashi MAF, 2005, TOXICON, V45, P1163, DOI 10.1016/j.toxicon.2005.02.017; Hayashi MAF, 2003, J NEUROCHEM, V85, P969, DOI 10.1046/j.1471-4159.2003.01743.x; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; Husson A, 2003, EUR J BIOCHEM, V270, P1887, DOI 10.1046/j.1432-1033.2003.03559.x; Ianzer D, 2007, J PHARMACOL EXP THER, V322, P795, DOI 10.1124/jpet.107.120873; JONES MR, 1988, J NUTR, V118, P579, DOI 10.1093/jn/118.5.579; Karlberg T, 2008, ACTA CRYSTALLOGR D, V64, P279, DOI 10.1107/S0907444907067455; Koeners MP, 2007, HYPERTENSION, V50, P1077, DOI 10.1161/HYPERTENSIONAHA.107.095794; Kurz S, 1997, J CLIN INVEST, V99, P369, DOI 10.1172/JCI119166; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee Y, 2004, ANAL CHEM, V76, P545, DOI 10.1021/ac035065+; Lemke CT, 2002, J BIOL CHEM, V277, P13074, DOI 10.1074/jbc.M112436200; Linares E, 2008, FREE RADICAL BIO MED, V44, P1668, DOI 10.1016/j.freeradbiomed.2008.01.027; Menez A, 1998, TOXICON, V36, P1557, DOI 10.1016/S0041-0101(98)00148-2; Morris SM, 2004, J NUTR, V134, p2743S, DOI 10.1093/jn/134.10.2743S; NG KKF, 1970, NATURE, V225, P1142, DOI 10.1038/2251142b0; ONDETTI MA, 1977, SCIENCE, V196, P441, DOI 10.1126/science.191908; Pujals S, 2008, ADV DRUG DELIVER REV, V60, P473, DOI 10.1016/j.addr.2007.09.012; Ram CVS, 2008, CURR HYPERTENS REP, V10, P345, DOI 10.1007/s11906-008-0065-3; Shen LJ, 2005, BIOCHEM PHARMACOL, V69, P97, DOI 10.1016/j.bcp.2004.09.003; Silva CA, 2008, TOXICON, V51, P515, DOI 10.1016/j.toxicon.2007.11.003; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; Solomonson LP, 2003, J EXP BIOL, V206, P2083, DOI 10.1242/jeb.00361; TAYLOR PD, 1994, BRIT J PHARMACOL, V113, P801, DOI 10.1111/j.1476-5381.1994.tb17064.x; Teerlink T, 2002, ANAL BIOCHEM, V303, P131, DOI 10.1006/abio.2001.5575; Vukosavljevic N, 2006, MICROVASC RES, V71, P48, DOI 10.1016/j.mvr.2005.10.006; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Xie LJ, 1997, J BIOL CHEM, V272, P16624, DOI 10.1074/jbc.272.26.16624	47	53	60	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20022	20033		10.1074/jbc.M109.021089	http://dx.doi.org/10.1074/jbc.M109.021089			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19491403	Green Published, hybrid			2022-12-25	WOS:000268097400029
J	Guo, L; Song, ZQ; Li, MT; Wu, QG; Wang, D; Feng, H; Bernard, P; Daugherty, A; Huang, B; Li, XA				Guo, Ling; Song, Zhiqing; Li, Mengting; Wu, Qingan; Wang, Dan; Feng, Hong; Bernard, Philip; Daugherty, Alan; Huang, Bin; Li, Xiang-An			Scavenger Receptor BI Protects against Septic Death through Its Role in Modulating Inflammatory Response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; DENSITY-LIPOPROTEIN BINDING; SR-BI; HDL RECEPTOR; REDUCES ATHEROSCLEROSIS; APOLIPOPROTEIN-E; PREMATURE DEATH; UNITED-STATES; LIVER-INJURY; MICE	Sepsis is a leading cause of death that is characterized by uncontrolled inflammatory response. In this study, we report that scavenger receptor BI (SR-BI), a high density lipoprotein receptor, is a critical survival factor of sepsis. We induced sepsis using an established septic animal model, cecal ligation and puncture (CLP). CLP induced 100% fatality in SR-BI-null mice but only 21% fatality in wild type littermates. SR-BI-null mice exhibited aberrant inflammatory responses with delayed inflammatory cytokine generation at the early stage of sepsis and highly elevated inflammatory cytokine production 20 h after CLP treatment. To understand the mechanisms underlying SR-BI protection, we elucidated the effect of macrophage SR-BI on inflammatory cytokine generation. Macrophages from SR-BI-null mice produced significantly higher levels of inflammatory cytokines than those of wild type controls in response to LPS. Importantly, transgenic mice overexpressing SR-BI were more resistant to CLP-induced septic death. Using an HEK-Blue (TM) cell system, we demonstrated that expression of SR-BI suppressed TLR4-mediated NF-kappa B activation. To understand why SR-BI-null mice had a delayed inflammatory response, we elucidated the effect of SR-BI on LPS clearance during sepsis. Compared with wild type controls, SR-BI-null mice had lower plasma LPS levels in the early stage of sepsis and elevated plasma LPS levels 20 h following CLP treatment. In conclusion, our findings demonstrate that SR-BI is a critical protective modulator of sepsis in mice. SR-BI exerts its protective function through its role in modulating inflammatory response in macrophages and facilitating LPS recruitment and clearance.	[Li, Xiang-An] Univ Kentucky, Sch Med, Dept Pediat, Lexington, KY 40536 USA; [Daugherty, Alan] Univ Kentucky, Sch Med, Dept Internal Med, Lexington, KY 40536 USA; [Huang, Bin] Univ Kentucky, Sch Med, Kentucky Canc Registry, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Li, XA (corresponding author), BBSRB B365,741 S Limestone St, Lexington, KY 40536 USA.	xli2@uky.edu	Daugherty, Alan/C-8282-2009	Daugherty, Alan/0000-0003-2093-3775	National Institutes of Health [R01GM085231, 2P0RR015592]; American Heart Association [0530241N]; Children's Miracle Network; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021954, P20RR015592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM085231] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Children's Miracle Network; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants R01GM085231 (to X.-A.L.) and 2P0RR015592 (to T. Curry). This work was also supported by American Heart Association Grant 0530241N (to X.-A.L.) and the Children's Miracle Network (to X.-A.L.).	Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Berwin B, 2003, EMBO J, V22, P6127, DOI 10.1093/emboj/cdg572; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; Cai L, 2008, J CLIN INVEST, V118, P364, DOI 10.1172/JCI31539; Carmody RJ, 2007, CELL MOL IMMUNOL, V4, P31; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Covey SD, 2003, ARTERIOSCL THROM VAS, V23, P1589, DOI 10.1161/01.ATV.0000083343.19940.A0; ESKANDARI MK, 1992, J IMMUNOL, V148, P2724; Gong M, 2003, J CLIN INVEST, V111, P1579, DOI 10.1172/JCI200316777; Hoekstra M, 2008, J LIPID RES, V49, P738, DOI 10.1194/jlr.M700475-JLR200; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Kraemer FB, 2007, MOL CELL ENDOCRINOL, V265, P42, DOI 10.1016/j.mce.2006.12.001; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Letourneau I, 2002, NEPHRON, V90, P408, DOI 10.1159/000054728; Li XA, 2006, CIRC RES, V98, pE60, DOI 10.1161/01.RES.0000219310.00308.10; Li XA, 2005, J BIOL CHEM, V280, P19087, DOI 10.1074/jbc.M500944200; Li XM, 2002, J BIOL CHEM, V277, P27256, DOI 10.1074/jbc.M203267200; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Michelsen KS, 2004, P NATL ACAD SCI USA, V101, P10679, DOI 10.1073/pnas.0403249101; Mineo C, 2003, J BIOL CHEM, V278, P9142, DOI 10.1074/jbc.M211394200; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Sessler Curtis N, 2004, Curr Opin Crit Care, V10, P354, DOI 10.1097/01.ccx.0000139363.76068.7b; Steinman CR, 1997, ANAL BIOCHEM, V244, P328, DOI 10.1006/abio.1996.9896; Su GL, 2002, AM J PHYSIOL-GASTR L, V283, pG256, DOI 10.1152/ajpgi.00550.2001; Titheradge MA, 1999, BBA-BIOENERGETICS, V1411, P437, DOI 10.1016/S0005-2728(99)00031-6; Uesugi T, 2001, HEPATOLOGY, V34, P101, DOI 10.1053/jhep.2001.25350; ULEVITCH RJ, 1981, J CLIN INVEST, V67, P827, DOI 10.1172/JCI110100; ULEVITCH RJ, 1979, J CLIN INVEST, V64, P1516, DOI 10.1172/JCI109610; Van Eck M, 2004, AM J PATHOL, V165, P785, DOI 10.1016/S0002-9440(10)63341-X; Van Eck M, 2003, J BIOL CHEM, V278, P23699, DOI 10.1074/jbc.M211233200; Vishnyakova TG, 2006, P NATL ACAD SCI USA, V103, P16888, DOI 10.1073/pnas.0602126103; Vishnyakova TG, 2003, J BIOL CHEM, V278, P22771, DOI 10.1074/jbc.M211032200; Wesche-Soldato DE, 2005, BLOOD, V106, P2295, DOI 10.1182/blood-2004-10-4086; Yu H, 2006, ARTERIOSCL THROM VAS, V26, P150, DOI 10.1161/01.ATV.0000194096.89476.73; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986; Zhang WW, 2003, CIRCULATION, V108, P2258, DOI 10.1161/01.CIR.0000093189.97429.9D	46	78	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					19826	19834		10.1074/jbc.M109.020933	http://dx.doi.org/10.1074/jbc.M109.020933			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19491399	Green Published, hybrid			2022-12-25	WOS:000268097400009
J	Halling, DB; Georgiou, DK; Black, DJ; Yang, GJ; Fallon, JL; Quiocho, FA; Pedersen, SE; Hamilton, SL				Halling, D. Brent; Georgiou, Dimitra K.; Black, D. J.; Yang, Guojun; Fallon, Jennifer L.; Quiocho, Florante A.; Pedersen, Steen E.; Hamilton, Susan L.			Determinants in Ca(V)1 Channels That Regulate the Ca2+ Sensitivity of Bound Calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT INACTIVATION; CRYSTAL-STRUCTURE; CA2+-DEPENDENT INACTIVATION; BINDING-SITES; IQ MOTIFS; COMPLEX; DOMAIN; RECOGNITION; KINASE; FACILITATION	Calmodulin binds to IQ motifs in the alpha(1) subunit of Ca(V)1.1 and Ca(V)1.2, but the affinities of calmodulin for the motif and for Ca2+ are higher when bound to Ca(V)1.2 IQ. The Ca(V)1.1 IQ and Ca(V)1.2 IQ sequences differ by four amino acids. We determined the structure of calmodulin bound to Ca(V)1.1 IQ and compared it with that of calmodulin bound to Ca(V)1.2 IQ. Four methionines in Ca2+-calmodulin form a hydrophobic binding pocket for the peptide, but only one of the four nonconserved amino acids (His-1532 of Ca(V)1.1 and Tyr-1675 of Ca(V)1.2) contacts this calmodulin pocket. However, Tyr-1675 in Ca(V)1.2 contributes only modestly to the higher affinity of this peptide for calmodulin; the other three amino acids in Ca(V)1.2 contribute significantly to the difference in the Ca2+ affinity of the bound calmodulin despite having no direct contact with calmodulin. Those residues appear to allow an interaction with calmodulin with one lobe Ca2+-bound and one lobe Ca2+-free. Our data also provide evidence for lobe-lobe interactions in calmodulin bound to Ca(V)1.2.	[Halling, D. Brent; Georgiou, Dimitra K.; Yang, Guojun; Fallon, Jennifer L.; Quiocho, Florante A.; Pedersen, Steen E.; Hamilton, Susan L.] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; [Black, D. J.] Univ Missouri, Div Mol Biol & Biochem, Kansas City, MO 64110 USA; [Fallon, Jennifer L.; Quiocho, Florante A.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine; University of Missouri System; University of Missouri Kansas City; Baylor College of Medicine	Hamilton, SL (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza,410B, Houston, TX 77030 USA.	susanh@bcm.edu		Pedersen, Steen E./0000-0001-8755-8899; Hamilton, Susan/0000-0003-0241-9369	National Institutes of Health [AR44864, HL087099, GM021371]; Muscular Dystrophy Association; Welch Foundation [Q-0581]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021371] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association(Muscular Dystrophy Association); Welch Foundation(The Welch Foundation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants AR44864 (to S. L. H.), HL087099 (to S. E. P.), and GM021371 (to F. A. Q.). This work was also supported by the Muscular Dystrophy Association (to S. L. H.) and Welch Foundation Grant Q-0581 (to F. A. Q.).	Andre I, 2006, BIOPHYS J, V90, P2903, DOI 10.1529/biophysj.105.068718; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; Black DJ, 2000, BIOCHEMISTRY-US, V39, P13831, DOI 10.1021/bi001106+; Black DJ, 2005, AM J PHYSIOL-CELL PH, V288, pC669, DOI 10.1152/ajpcell.00191.2004; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dick IE, 2008, NATURE, V451, P830, DOI 10.1038/nature06529; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Elshorst B, 1999, BIOCHEMISTRY-US, V38, P12320, DOI 10.1021/bi9908235; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; Fallon JL, 2009, P NATL ACAD SCI USA, V106, P5135, DOI 10.1073/pnas.0807487106; Fallon JL, 2005, STRUCTURE, V13, P1881, DOI 10.1016/j.str.2005.09.021; Gaertner TR, 2004, J BIOL CHEM, V279, P39374, DOI 10.1074/jbc.M405352200; Houdusse A, 2006, P NATL ACAD SCI USA, V103, P19326, DOI 10.1073/pnas.0609436103; Hudmon A, 2005, J CELL BIOL, V171, P537, DOI 10.1083/jcb.200505155; Johnson JD, 1996, J BIOL CHEM, V271, P761, DOI 10.1074/jbc.271.2.761; Kim EY, 2008, STRUCTURE, V16, P1455, DOI 10.1016/j.str.2008.07.010; Kim J, 2004, NEURON, V41, P745, DOI 10.1016/S0896-6273(04)00081-9; Kobrinsky E, 2003, J BIOL CHEM, V278, P5021, DOI 10.1074/jbc.M211254200; Liang HY, 2003, NEURON, V39, P951, DOI 10.1016/S0896-6273(03)00560-9; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Mori MX, 2008, STRUCTURE, V16, P607, DOI 10.1016/j.str.2008.01.011; Mouton J, 2001, FEBS LETT, V505, P441, DOI 10.1016/S0014-5793(01)02866-6; Mukherjea P, 1996, PROTEIN SCI, V5, P468; Ohrtman J, 2008, J BIOL CHEM, V283, P29301, DOI 10.1074/jbc.M805152200; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; Peersen OB, 1997, PROTEIN SCI, V6, P794; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Rodney GG, 2000, BIOCHEMISTRY-US, V39, P7807, DOI 10.1021/bi0005660; Rossmann M. G., 1972, MOL REPLACEMENT METH; ROVATI GE, 1994, TRENDS PHARMACOL SCI, V15, P140, DOI 10.1016/0165-6147(94)90073-6; Sack JS, 1997, METHOD ENZYMOL, V277, P158, DOI 10.1016/S0076-6879(97)77011-3; Saucerman JJ, 2008, BIOPHYS J, V95, P4597, DOI 10.1529/biophysj.108.128728; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Sencer S, 2001, J BIOL CHEM, V276, P38237; Stroffekova K, 2008, PFLUG ARCH EUR J PHY, V455, P873, DOI 10.1007/s00424-007-0344-x; Tadross MR, 2008, CELL, V133, P1228, DOI 10.1016/j.cell.2008.05.025; Tang W, 2003, BIOPHYS J, V85, P1538, DOI 10.1016/S0006-3495(03)74586-X; Van Petegem F, 2005, NAT STRUCT MOL BIOL, V12, P1108, DOI 10.1038/nsmb1027; WALKER SW, 1984, BIOCHEM J, V217, P827, DOI 10.1042/bj2170827; Xiong LW, 2006, BIOPHYS J, V90, P173, DOI 10.1529/biophysj.105.066092; Xiong LW, 2005, J BIOL CHEM, V280, P7070, DOI 10.1074/jbc.M410558200; Xiong LW, 2002, J BIOL CHEM, V277, P40862, DOI 10.1074/jbc.M206763200; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	48	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20041	20051		10.1074/jbc.M109.013326	http://dx.doi.org/10.1074/jbc.M109.013326			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19473981	hybrid, Green Published			2022-12-25	WOS:000268097400031
J	Koh, DI; Choi, WI; Jeon, BN; Lee, CE; Yun, CO; Hur, MW				Koh, Dong-In; Choi, Won-Il; Jeon, Bu-Nam; Lee, Choong-Eun; Yun, Chae-Ok; Hur, Man-Wook			A Novel POK Family Transcription Factor, ZBTB5, Represses Transcription of p21CIP1 Gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN INTERACTION MOTIF; ACUTE PROMYELOCYTIC LEUKEMIA; DNA-BINDING DOMAIN; HISTONE DEACETYLASE; FINGER PROTEIN; SP1; FUSION; CELLS; BCL-6; P53	Transcriptional repression through chromatin remodeling and histone deacetylation has been postulated as a driving force for tumorigenesis. We isolated and characterized a novel POZ domain Kruppel-like zinc finger transcription repressor, ZBTB5 (zinc finger and BTB domain-containing 5). Serial analysis of gene expression (SAGE) analysis showed that ZBTB5 expression is higher in retinoblastoma and muscle cancer tissues. Immunocytochemistry showed that ZBTB5 was localized to the nucleus, particularly nuclear speckles. ZBTB5 directly repressed transcription of cell cycle arrest gene p21 by binding to the proximal GC-box 5/6 elements and the two distal p53-responsive elements (bp -2323 similar to -2299; bp -1416 similar to -1392). Chromatin immunoprecipitation assays showed that ZBTB5 and p53 competed with each other in occupying the p53 binding elements. ZBTB5 interacted with corepressor-histone deacetylase complexes such as BCoR(BCL-6-interacting corepressor), NCoR (nuclear receptor corepressor), and SMRT (silencing mediator for retinoid and thyroid receptors) via its POZ domain. These interactions resulted in deacetylation of histones Ac-H3 and Ac-H4 at the proximal promoter, which is important in the transcriptional repression of p21. MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays and fluorescent-activated cell sorter analysis revealed that ZBTB5 stimulated both cell proliferation and cell cycle progression, significantly increasing the number of cells in S-phase. Overall, our data suggest that ZBTB5 is a potent transcription repressor of cell cycle arrest gene p21 and a potential proto-oncogene stimulating cell proliferation.	[Koh, Dong-In; Choi, Won-Il; Jeon, Bu-Nam; Hur, Man-Wook] Yonsei Univ, Brain Korea Project Med Sci 21, Inst Genet Sci, Sch Med, Seoul 120752, South Korea; [Lee, Choong-Eun] Sungkyunkwan Univ, Dept Biol Sci, Suwon 440746, South Korea; [Yun, Chae-Ok] Yonsei Univ, Inst Canc Res, Sch Med, Seoul 120752, South Korea	Yonsei University; Sungkyunkwan University (SKKU); Yonsei University	Hur, MW (corresponding author), Yonsei Univ, Brain Korea Project Med Sci 21, Inst Genet Sci, Sch Med, 134 ShinChon Dong, Seoul 120752, South Korea.	mwhur2@yuhs.ac	Yun, Chae-Ok/P-3698-2015	Hur, Man-Wook/0000-0002-3416-1334; Yun, Chae-Ok/0000-0002-9466-4531; CHOI, WONIL/0000-0002-4837-0436	Korean Science and Engineering Foundation of the Korean Ministry of Science and Technology Medical Research Center [R13-2002-054-05002-0]	Korean Science and Engineering Foundation of the Korean Ministry of Science and Technology Medical Research Center	This work was supported by Korean Science and Engineering Foundation of the Korean Ministry of Science and Technology Medical Research Center Grant R13-2002-054-05002-0 (to M.-W.H.).	ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Choi WI, 2008, J BIOL CHEM, V283, P29341, DOI 10.1074/jbc.M802477200; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; EL DW, 1993, CELL, V75, P817; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Huynh KD, 2000, GENE DEV, V14, P1810; Jeon BN, 2008, J BIOL CHEM, V283, P33199, DOI 10.1074/jbc.M802935200; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P213, DOI 10.1016/0968-0004(92)90379-N; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Lee JA, 2005, J BIOL CHEM, V280, P28061, DOI 10.1074/jbc.M414134200; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Maeda T, 2005, NATURE, V433, P278, DOI 10.1038/nature03203; Maeda T, 2007, SCIENCE, V316, P860, DOI 10.1126/science.1140881; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Phan RT, 2005, NAT IMMUNOL, V6, P1054, DOI 10.1038/ni1245; Sun GP, 2005, NAT IMMUNOL, V6, P373, DOI 10.1038/ni1183; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334	35	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					19856	19866		10.1074/jbc.M109.025817	http://dx.doi.org/10.1074/jbc.M109.025817			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19491398	Green Published, hybrid			2022-12-25	WOS:000268097400012
J	Perrine, CL; Ganguli, A; Wu, P; Bertozzi, CR; Fritz, TA; Raman, J; Tabak, LA; Gerken, TA				Perrine, Cynthia L.; Ganguli, Anjali; Wu, Peng; Bertozzi, Carolyn R.; Fritz, Timothy A.; Raman, Jayalakshmi; Tabak, Lawrence A.; Gerken, Thomas A.			Glycopeptide-preferring Polypeptide GalNAc Transferase 10 (ppGalNAc T10), Involved in Mucin-type O-Glycosylation, Has a Unique GalNAc-O-Ser/Thr-binding Site in Its Catalytic Domain Not Found in ppGalNAc T1 or T2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GALACTOSAMINE; N-ACETYLGALACTOSAMINYLTRANSFERASE FAMILY; NEIGHBORING RESIDUE GLYCOSYLATION; PEPTIDE ACCEPTOR PREFERENCES; UDP-GALNAC; TANDEM REPEAT; FUNCTIONAL-CHARACTERIZATION; DROSOPHILA-MELANOGASTER; LINKED GLYCOSYLATION; STAUDINGER LIGATION	Mucin-type O-glycosylation is initiated by a large family of UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferases (ppGalNAc Ts) that transfer GalNAc from UDP-GalNAc to the Ser and Thr residues of polypeptide acceptors. Some members of the family prefer previously glycosylated peptides (ppGalNAc T7 and T10), whereas others are inhibited by neighboring glycosylation (ppGalNAc T1 and T2). Characterizing their peptide and glycopeptide substrate specificity is critical for understanding the biological role and significance of each isoform. Utilizing a series of random peptide and glycopeptide substrates, we have obtained the peptide and glycopeptide specificities of ppGalNAc T10 for comparison with ppGalNAc T1 and T2. For the glycopeptide substrates, ppGalNAc T10 exhibited a single large preference for Ser/Thr-O-GalNAc at the +1 (C-terminal) position relative to the Ser or Thr acceptor site. ppGalNAc T1 and T2 revealed no significant enhancements suggesting Ser/Thr-O-GalNAc was inhibitory at most positions for these isoforms. Against random peptide substrates, ppGalNAc T10 revealed no significant hydrophobic or hydrophilic residue enhancements, in contrast to what has been reported previously for ppGalNAc T1 and T2. Our results reveal that these transferases have unique peptide and glycopeptide preferences demonstrating their substrate diversity and their likely roles ranging from initiating transferases to filling-in transferases.	[Gerken, Thomas A.] Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; [Perrine, Cynthia L.; Gerken, Thomas A.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA; [Gerken, Thomas A.] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; [Gerken, Thomas A.] Case Western Reserve Univ, WA Bernbaum Ctr Cyst Fibrosis Res, Cleveland, OH 44106 USA; [Ganguli, Anjali; Wu, Peng; Bertozzi, Carolyn R.] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; [Bertozzi, Carolyn R.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; [Bertozzi, Carolyn R.] Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; [Bertozzi, Carolyn R.] Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; [Fritz, Timothy A.; Raman, Jayalakshmi; Tabak, Lawrence A.] NIDDK, Sect Biol Chem, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Gerken, TA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pediat, BRB 823,2109 Adelbert Rd, Cleveland, OH 44106 USA.	txg2@cwru.edu			National Institutes of Health [CA-78834]; NCI [GM66047]; NIDDK; NATIONAL CANCER INSTITUTE [R01CA078834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK070012, P30DK027651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066047] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants CA-78834 from NCI (to T. A. G.) and GM66047 (to C. R. B.) and an NIDDK intramural program grant (to L. A. T.).	Agard NJ, 2004, J AM CHEM SOC, V126, P15046, DOI 10.1021/ja044996f; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; Chan TR, 2004, ORG LETT, V6, P2853, DOI 10.1021/ol0493094; Cheng LM, 2004, FEBS LETT, V566, P17, DOI 10.1016/j.febslet.2004.03.108; Cheng LM, 2002, FEBS LETT, V531, P115, DOI 10.1016/S0014-5793(02)03399-9; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; Freire T, 2004, BIOCHEM J, V382, P501, DOI 10.1042/BJ20031877; Freire T, 2003, BIOCHEM BIOPH RES CO, V312, P1309, DOI 10.1016/j.bbrc.2003.11.060; Gerken TA, 2004, BIOCHEMISTRY-US, V43, P9888, DOI 10.1021/bi049178e; Gerken TA, 2002, J BIOL CHEM, V277, P49850, DOI 10.1074/jbc.M205851200; Gerken TA, 1997, J BIOL CHEM, V272, P9709; Gerken TA, 2006, J BIOL CHEM, V281, P32403, DOI 10.1074/jbc.M605149200; Gerken TA, 2008, GLYCOBIOLOGY, V18, P861, DOI 10.1093/glycob/cwn073; Guo JM, 2002, FEBS LETT, V524, P211, DOI 10.1016/S0014-5793(02)03007-7; Hanisch FG, 2001, GLYCOBIOLOGY, V11, P731, DOI 10.1093/glycob/11.9.731; Hassan H, 2000, J BIOL CHEM, V275, P38197, DOI 10.1074/jbc.M005783200; Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805; Herr P, 2008, DEVELOPMENT, V135, P1813, DOI 10.1242/dev.019323; HUISGEN R, 1984, 1 3 DIPOLAR CYCLOADD, P1; Kato K, 2006, J BIOL CHEM, V281, P18370, DOI 10.1074/jbc.M602469200; Kiick KL, 2002, P NATL ACAD SCI USA, V99, P19, DOI 10.1073/pnas.012583299; Koldas M, 2001, THROMB RES, V102, P221, DOI 10.1016/S0049-3848(01)00257-2; Kubota T, 2006, J MOL BIOL, V359, P708, DOI 10.1016/j.jmb.2006.03.061; Perrine C, 2009, GLYCOBIOLOGY, V19, P321, DOI 10.1093/glycob/cwn143; Pratt MR, 2004, CHEM BIOL, V11, P1009, DOI 10.1016/j.chembiol.2004.05.009; Raman J, 2008, J BIOL CHEM, V283, P22942, DOI 10.1074/jbc.M803387200; Robbe C, 2003, J BIOL CHEM, V278, P46337, DOI 10.1074/jbc.M302529200; Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4; Saxon E, 2002, J AM CHEM SOC, V124, P14893, DOI 10.1021/ja027748x; Saxon E, 2000, SCIENCE, V287, P2007, DOI 10.1126/science.287.5460.2007; Schwientek T, 2002, J BIOL CHEM, V277, P22623, DOI 10.1074/jbc.M202684200; Speers AE, 2004, CHEM BIOL, V11, P535, DOI 10.1016/j.chembiol.2004.03.012; Stwora-Wojczyk MM, 2004, ARCH BIOCHEM BIOPHYS, V426, P231, DOI 10.1016/j.abb.2004.02.013; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Ten Hagen KG, 2002, J BIOL CHEM, V277, P22616, DOI 10.1074/jbc.M201807200; Ten Hagen KG, 1999, J BIOL CHEM, V274, P27867; Ten Hagen KG, 2003, J BIOL CHEM, V278, P35039, DOI 10.1074/jbc.M303836200; Ten Hagen KG, 2001, J BIOL CHEM, V276, P17395, DOI 10.1074/jbc.M009638200; Tian E, 2007, J BIOL CHEM, V282, P606, DOI 10.1074/jbc.M606268200; Toba S, 2000, BBA-GENE STRUCT EXPR, V1493, P264, DOI 10.1016/S0167-4781(00)00180-9; Topaz O, 2004, NAT GENET, V36, P579, DOI 10.1038/ng1358; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wandall HH, 2007, GLYCOBIOLOGY, V17, P374, DOI 10.1093/glycob/cwl082; Wang H, 2003, BIOCHEM BIOPH RES CO, V300, P738, DOI 10.1016/S0006-291X(02)02908-X; Wang Q, 2003, J AM CHEM SOC, V125, P3192, DOI 10.1021/ja021381e; White KE, 2000, GENE, V246, P347, DOI 10.1016/S0378-1119(00)00050-0; Zhang LP, 2008, J BIOL CHEM, V283, P34076, DOI 10.1074/jbc.M804267200; Zhang XM, 2003, J BIOL CHEM, V278, P51232, DOI 10.1074/jbc.M309076200	51	43	48	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20387	20397		10.1074/jbc.M109.017236	http://dx.doi.org/10.1074/jbc.M109.017236			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19460755	Green Published, hybrid			2022-12-25	WOS:000268097400064
J	Fu, YX; Chang, A; Chang, L; Niessen, K; Eapen, S; Setiadi, A; Karsan, A				Fu, YangXin; Chang, Alex; Chang, Linda; Niessen, Kyle; Eapen, Shawn; Setiadi, Audi; Karsan, Aly			Differential Regulation of Transforming Growth Factor beta Signaling Pathways by Notch in Human Endothelial Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL HEART-DEFECTS; TGF-BETA; MESENCHYMAL TRANSITION; CARDIAC DEVELOPMENT; TRANSCRIPTIONAL ACTIVATION; INTRACELLULAR DOMAIN; VASCULAR DEVELOPMENT; GENE-EXPRESSION; TARGET GENES; SMAD3	Notch and transforming growth factor beta (TGF beta) play critical roles in endothelial-to-mesenchymal transition (EndMT), a process that is essential for heart development. Previously, we have shown that Notch and TGF beta signaling synergistically induce Snail expression in endothelial cells, which is required for EndMT in cardiac cushion morphogenesis. Here, we report that Notch activation modulates TGF beta signaling pathways in a receptor-activated Smad (R-Smad)-specific manner. Notch activation inhibits TGF beta/Smad1 and TGF beta/Smad2 signaling pathways by decreasing the expression of Smad1 and Smad2 and their target genes. In contrast, Notch increases SMAD3 mRNA expression and protein half-life and regulates the expression of TGF beta/Smad3 target genes in a gene-specific manner. Inhibition of Notch in the cardiac cushion of mouse embryonic hearts reduces Smad3 expression. Notch and TGF beta synergistically upregulate a subset of genes by recruiting Smad3 to both Smad and CSL binding sites and cooperatively inducing histone H4 acetylation. This is the first evidence that Notch activation affects R-Smad expression and that cooperative induction of histone acetylation at specific promoters underlies the selective synergy between Notch and TGF beta signaling pathways.	[Karsan, Aly] Univ British Columbia, British Columbia Canc Agcy, British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada; [Fu, YangXin; Karsan, Aly] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia	Karsan, A (corresponding author), Univ British Columbia, British Columbia Canc Agcy, British Columbia Canc Res Ctr, 675W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	akarsan@bccrc.ca	Karsan, Aly/K-2067-2015; Setiadi, Audi/AAD-2076-2022	Setiadi, Audi/0000-0002-2361-7391	Canadian Institutes of Health Research Grant [MOP-64354]; Heart and Stroke Foundation of British Columbia; Yukon; Canadian Cancer Society; Genome Canada; Genome British Columbia	Canadian Institutes of Health Research Grant(Canadian Institutes of Health Research (CIHR)); Heart and Stroke Foundation of British Columbia; Yukon; Canadian Cancer Society(Canadian Cancer Society (CCS)); Genome Canada(Genome Canada); Genome British Columbia	This work was supported in part by Canadian Institutes of Health Research Grant MOP-64354 and grants from the Heart and Stroke Foundation of British Columbia and the Yukon, the Canadian Cancer Society, Genome Canada, and Genome British Columbia.	Alva JA, 2006, DEV DYNAM, V235, P759, DOI 10.1002/dvdy.20643; Armstrong EJ, 2004, CIRC RES, V95, P459, DOI 10.1161/01.RES.0000141146.95728.da; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Blanco FJ, 2005, J CELL PHYSIOL, V204, P574, DOI 10.1002/jcp.20311; Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112; Bray S, 2001, CURR BIOL, V11, pR217, DOI 10.1016/S0960-9822(01)00109-9; Brown KA, 2007, J CELL BIOCHEM, V101, P9, DOI 10.1002/jcb.21255; Chen SJ, 2006, J BIOL CHEM, V281, P21183, DOI 10.1074/jbc.M603270200; Cinquetti R, 2008, HUM MUTAT, V29, P468, DOI 10.1002/humu.20711; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Donovan J, 2002, CURR BIOL, V12, P1605, DOI 10.1016/S0960-9822(02)01149-1; Fischer A, 2004, GENE DEV, V18, P901, DOI 10.1101/gad.291004; Fischer A, 2007, CIRC RES, V100, P856, DOI 10.1161/01.RES.0000260913.95642.3b; Fu YX, 2001, J BIOL CHEM, V276, P43004, DOI 10.1074/jbc.M106946200; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, TRENDS CARDIOVAS MED, V13, P301, DOI 10.1016/S1050-1738(03)00142-7; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; High FA, 2008, NAT REV GENET, V9, P49, DOI 10.1038/nrg2279; Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Kanai H, 2001, CIRC RES, V88, P30, DOI 10.1161/01.RES.88.1.30; Kennard S, 2008, J BIOL CHEM, V283, P1324, DOI 10.1074/jbc.M706651200; Krebs LT, 2004, GENE DEV, V18, P2469, DOI 10.1101/gad.1239204; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; Mailhos C, 2001, DIFFERENTIATION, V69, P135, DOI 10.1046/j.1432-0436.2001.690207.x; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Masuda S, 2005, CANCER SCI, V96, P274, DOI 10.1111/j.1349-7006.2005.00048.x; Murray SA, 2006, P NATL ACAD SCI USA, V103, P10300, DOI 10.1073/pnas.0602234103; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nam Y, 2003, J BIOL CHEM, V278, P21232, DOI 10.1074/jbc.M301567200; Niessen K, 2008, CIRC RES, V102, P1169, DOI 10.1161/CIRCRESAHA.108.174318; Niessen K, 2008, J CELL BIOL, V182, P315, DOI 10.1083/jcb.200710067; Niimi H, 2007, J CELL BIOL, V176, P695, DOI 10.1083/jcb.200612129; Ono Y, 2007, J CELL PHYSIOL, V210, P358, DOI 10.1002/jcp.20838; Phanish MK, 2006, BIOCHEM J, V393, P601, DOI 10.1042/BJ20051106; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Santibanez JF, 2007, J CELL PHYSIOL, V210, P456, DOI 10.1002/jcp.20878; Sun JF, 2005, P NATL ACAD SCI USA, V102, P128, DOI 10.1073/pnas.0403198102; Sun YP, 2005, ONCOGENE, V24, P5365, DOI 10.1038/sj.onc.1208528; ten Dijke P, 2007, NAT REV MOL CELL BIO, V8, P857, DOI 10.1038/nrm2262; Timmerman LA, 2004, GENE DEV, V18, P99, DOI 10.1101/gad.276304; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069	48	79	84	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19452	19462		10.1074/jbc.M109.011833	http://dx.doi.org/10.1074/jbc.M109.011833			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19473993	Green Published, hybrid			2022-12-25	WOS:000267908300037
J	Kimple, AJ; Soundararajan, M; Hutsell, SQ; Roos, AK; Urban, DJ; Setola, V; Temple, BRS; Roth, BL; Knapp, S; Willard, FS; Siderovski, DP				Kimple, Adam J.; Soundararajan, Meera; Hutsell, Stephanie Q.; Roos, Annette K.; Urban, Daniel J.; Setola, Vincent; Temple, Brenda R. S.; Roth, Bryan L.; Knapp, Stefan; Willard, Francis S.; Siderovski, David P.			Structural Determinants of G-protein alpha Subunit Selectivity by Regulator of G-protein Signaling 2 (RGS2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; MYOCARDIAL HYPERTROPHY; CIONA-INTESTINALIS; SEQUENCE ALIGNMENT; PHOSPHOLIPASE-C; RECEPTOR; PRESSURE; ANXIETY; DOMAIN; HYPERTENSION	"Regulator of G-protein signaling" (RGS) proteins facilitate the termination of G protein-coupled receptor (GPCR) signaling via their ability to increase the intrinsic GTP hydrolysis rate of G alpha subunits (known as GTPase-accelerating protein or "GAP" activity). RGS2 is unique in its in vitro potency and selectivity as a GAP for G alpha(q) subunits. As many vasoconstrictive hormones signal via G(q) heterotrimer-coupled receptors, it is perhaps not surprising that RGS2-deficient mice exhibit constitutive hypertension. However, to date the particular structural features within RGS2 determining its selectivity for G alpha(q) over G alpha(i/o) substrates have not been completely characterized. Here, we examine a trio of point mutations to RGS2 that elicits G alpha(i)-directed binding and GAP activities without perturbing its association with G alpha(q). Using x-ray crystallography, we determined a model of the triple mutant RGS2 in complex with a transition state mimetic form of G alpha(i) at 2.8-angstrom resolution. Structural comparison with unliganded, wild type RGS2 and of other RGS domain/G alpha complexes highlighted the roles of these residues in wild type RGS2 that weaken G alpha(i) subunit association. Moreover, these three amino acids are seen to be evolutionarily conserved among organisms with modern cardiovascular systems, suggesting that RGS2 arose from the R4-subfamily of RGS proteins to have specialized activity as a potent and selective G alpha(q) GAP that modulates cardiovascular function.	[Kimple, Adam J.; Urban, Daniel J.; Setola, Vincent; Roth, Bryan L.; Willard, Francis S.; Siderovski, David P.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; [Hutsell, Stephanie Q.; Temple, Brenda R. S.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; [Setola, Vincent; Roth, Bryan L.] Univ N Carolina, NIMH, Psychoact Drug Screening Program, Chapel Hill, NC 27599 USA; [Siderovski, David P.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Temple, Brenda R. S.] Univ N Carolina, RL Juliano Struct Bioinformat Core Facil, Chapel Hill, NC 27599 USA; [Soundararajan, Meera; Roos, Annette K.; Knapp, Stefan] Univ Oxford, Struct Genom Consortium, Oxford OX3 7DQ, England; [Knapp, Stefan] Univ Oxford, Dept Clin Pharmacol, Oxford OX3 7DQ, England	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Oxford; University of Oxford	Siderovski, DP (corresponding author), 4073 Genet Med Bldg,CB 7365, Chapel Hill, NC 27599 USA.	dsiderov@med.unc.edu	Roth, Bryan L/F-3928-2010; Knapp, Stefan/AAG-2347-2019; Siderovski, David Peter/AAA-9603-2019	Knapp, Stefan/0000-0001-5995-6494; Siderovski, David Peter/0000-0002-0688-8210; Setola, Vincent/0000-0002-9791-2270; Soundararajan, Meera/0000-0003-4687-0151; Kimple, Adam/0000-0003-1670-8401	National Institutes of Health [R01 GM082892, T32 GM008570, T32 GM008719, F30 MH074266]; American Heart Association Mid-Atlantic Affiliate Grant [0815239E]; NATIONAL CANCER INSTITUTE [P30CA016086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008719, R01GM082892, T32GM008570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [U19MH082441, F30MH074266] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association Mid-Atlantic Affiliate Grant(American Heart Association); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported, in whole or in part, by National Institutes of Health Grants R01 GM082892 ( to D. P. S.), T32 GM008570 ( to S. Q. H.), and T32 GM008719 and F30 MH074266 ( to A. J. K.). This work was also supported by American Heart Association Mid-Atlantic Affiliate Grant 0815239E ( to D. J. U.).. S The on-line version of this article ( available at http://www.jbc.org) contains supplemental Figs. S1-S3 and Tables S1 and S2.	Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Chiba S, 2004, ZOOL SCI, V21, P285, DOI 10.2108/zsj.21.285; Cladman W, 2002, MOL PHARMACOL, V62, P654, DOI 10.1124/mol.62.3.654; Cui H, 2008, NEUROPSYCHOPHARMACOL, V33, P1537, DOI 10.1038/sj.npp.1301557; Davidson B, 2007, SEMIN CELL DEV BIOL, V18, P16, DOI 10.1016/j.semcdb.2006.12.007; DAVISON IG, 1995, J EXP BIOL, V198, P2185; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans DH, 2006, PHYSL FISHES; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; Gu S, 2008, MOL PHARMACOL, V73, P1037, DOI 10.1124/mol.107.044214; Hains MD, 2004, METHOD ENZYMOL, V389, P71; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; HEXIMER SP, 2007, SCI STKE, pPE2; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Ingi T, 1998, J NEUROSCI, V18, P7178; Keys JR, 2002, HYPERTENSION, V40, P660, DOI 10.1161/01.HYP.0000035397.73223.CE; Kimple AJ, 2007, BBA-PROTEINS PROTEOM, V1774, P1213, DOI 10.1016/j.bbapap.2007.06.002; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Lutz S, 2007, SCIENCE, V318, P1923, DOI 10.1126/science.1147554; McCudden CR, 2005, CELL MOL LIFE SCI, V62, P551, DOI 10.1007/s00018-004-4462-3; McKenzie DJ, 2007, FISH PHYSIOL, V26, P1; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Offermanns S, 2003, PROG BIOPHYS MOL BIO, V83, P101, DOI 10.1016/S0079-6107(03)00052-X; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270; Pancer Z, 2004, P NATL ACAD SCI USA, V101, P13273, DOI 10.1073/pnas.0405529101; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Seack J, 1998, BBA-MOL CELL RES, V1401, P93, DOI 10.1016/S0167-4889(97)00121-3; Semplicini A, 2006, J HYPERTENS, V24, P1115, DOI 10.1097/01.hjh.0000226202.80689.8f; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; Sierra DA, 2002, GENOMICS, V79, P177, DOI 10.1006/geno.2002.6693; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Skiba NP, 1999, J BIOL CHEM, V274, P8770, DOI 10.1074/jbc.274.13.8770; Slep KC, 2008, P NATL ACAD SCI USA, V105, P6243, DOI 10.1073/pnas.0801569105; Smoller JW, 2008, ARCH GEN PSYCHIAT, V65, P298, DOI 10.1001/archgenpsychiatry.2007.48; Soundararajan M, 2008, P NATL ACAD SCI USA, V105, P6457, DOI 10.1073/pnas.0801508105; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; Stols L, 2007, PROTEIN EXPRES PURIF, V53, P396, DOI 10.1016/j.pep.2007.01.013; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Suga H, 1999, J MOL EVOL, V48, P646, DOI 10.1007/PL00006508; Sunahara Roger K, 2002, Mol Interv, V2, P168, DOI 10.1124/mi.2.3.168; Takimoto E, 2009, J CLIN INVEST, V119, P408, DOI 10.1172/JCI35620; Tang M, 2003, NAT MED, V9, P1506, DOI 10.1038/nm958; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tesmer VM, 2005, SCIENCE, V310, P1686, DOI 10.1126/science.1118890; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Wieland T, 2000, J BIOL CHEM, V275, P28500, DOI 10.1074/jbc.M004187200; Willard FS, 2007, CELL SIGNAL, V19, P428, DOI 10.1016/j.cellsig.2006.07.013; Willard FS, 2006, ANAL BIOCHEM, V353, P147, DOI 10.1016/j.ab.2006.02.004; Willard FS, 2005, ANAL BIOCHEM, V340, P341, DOI 10.1016/j.ab.2005.02.015; Willard FS, 2004, METHOD ENZYMOL, V389, P56; WILLARD MD, 2009, HDB CELL SI IN PRESS; Yalcin B, 2004, NAT GENET, V36, P1197, DOI 10.1038/ng1450	64	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19402	19411		10.1074/jbc.M109.024711	http://dx.doi.org/10.1074/jbc.M109.024711			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19478087	hybrid, Green Submitted, Green Published			2022-12-25	WOS:000267908300031
J	Miyake, T; Alli, NS; Aziz, A; Knudson, J; Fernando, P; Megeney, LA; McDermott, JC				Miyake, Tetsuaki; Alli, Nezeka S.; Aziz, Arif; Knudson, Jennifer; Fernando, Pasan; Megeney, Lynn A.; McDermott, John C.			Cardiotrophin-1 Maintains the Undifferentiated State in Skeletal Myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MUSCLE DIFFERENTIATION; TRANSCRIPTION FACTORS; GROWTH-FACTOR; CELL-DIFFERENTIATION; GENE-TRANSCRIPTION; POPULATION CELLS; STEM-CELLS; IN-VIVO; MYOD	Skeletal myogenesis is potently regulated by the extracellular milieu of growth factors and cytokines. We observed that cardiotrophin-1 (CT-1), a member of the interleukin-6 (IL-6) family of cytokines, is a potent regulator of skeletal muscle differentiation. The normal up-regulation of myogenic marker genes, myosin heavy chain (MyHC), myogenic regulatory factors (MRFs), and myocyte enhancer factor 2s (MEF2s) were inhibited by CT-1 treatment. CT-1 also represses myogenin (MyoG) promoter activation. CT-1 activated two signaling pathways: signal transducer and activator of transcription 3 (STAT3), and mitogen-activated protein kinase kinase (MEK), a component of the extracellular signal-regulated MAPK (ERK) pathway. In view of the known connection between CT-1 and STAT3 activation, we surprisingly found that pharmacological blockade of STAT3 activity had no effect on the inhibition of myogenesis by CT-1 suggesting that STAT3 signaling is dispensable for myogenic repression. Conversely, MEK inhibition potently reversed the inhibition of myotube formation and attenuated the repression of MRF transcriptional activity mediated by CT-1. Taken together, these data indicate that CT-1 represses skeletal myogenesis through interference with MRF activity by activation of MEK/ERK signaling. In agreement with these in vitro observations, exogenous systemic expression of CT-1 mediated by adenoviral vector delivery increased the number of myonuclei in normal post-natal mouse skeletal muscle and also delayed skeletal muscle regeneration induced by cardiotoxin injection. The expression pattern of CT-1 in embryonic and post-natal skeletal muscle and in vivo effects of CT-1 on myogenesis implicate CT-1 in the maintenance of the undifferentiated state in muscle progenitor cells.	[Miyake, Tetsuaki; Alli, Nezeka S.; Aziz, Arif; McDermott, John C.] York Univ, Dept Biol, LSB, N York, ON M3J 1P3, Canada; [Knudson, Jennifer; Fernando, Pasan; Megeney, Lynn A.] Ottawa Hlth Res Inst, Regenerat Med Program, Sprott Ctr Stem Cell Res, Ottawa, ON K1H 8L6, Canada	York University - Canada; University of Ottawa; Ottawa Hospital Research Institute	McDermott, JC (corresponding author), York Univ, Dept Biol, LSB, 327 Farquharson,4700 Keele St, N York, ON M3J 1P3, Canada.	jmcderm@yorku.ca		Megeney, Lynn/0000-0002-6824-8569	Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by grants from the Natural Sciences and Engineering Research Council of Canada and the Canadian Institutes of Health Research (to J.C.M.).	ALLEN RE, 1987, J CELL PHYSIOL, V133, P567, DOI 10.1002/jcp.1041330319; Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Bordet T, 1999, J CLIN INVEST, V104, P1077, DOI 10.1172/JCI6265; Brar BK, 2001, CYTOKINE, V16, P93, DOI 10.1006/cyto.2001.0951; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chen CM, 2004, BLOOD, V104, P73, DOI 10.1182/blood-2003-04-1340; Cox DM, 2003, J BIOL CHEM, V278, P15297, DOI 10.1074/jbc.M211312200; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; de la Serna IL, 2005, MOL CELL BIOL, V25, P3997, DOI 10.1128/MCB.25.10.3997-4009.2005; Donoviel DB, 1996, MOL CELL BIOL, V16, P1649; Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431; Freed DH, 2005, CARDIOVASC RES, V65, P782, DOI 10.1016/j.cardiores.2004.11.026; Freed DH, 2003, MOL CELL BIOCHEM, V254, P247, DOI 10.1023/A:1027332504861; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hierlihy AM, 2002, FEBS LETT, V530, P239, DOI 10.1016/S0014-5793(02)03477-4; Jackson JD, 2002, CELL TRANSPLANT, V11, P779; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; Jin HK, 1996, CYTOKINE, V8, P920, DOI 10.1006/cyto.1996.0123; Jo C, 2005, BBA-MOL CELL RES, V1743, P187, DOI 10.1016/j.bbamcr.2004.11.002; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Kassar-Duchossoy L, 2004, NATURE, V431, P466, DOI 10.1038/nature02876; Kataoka Y, 2003, J BIOL CHEM, V278, P44178, DOI 10.1074/jbc.M304884200; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; Kim CH, 2008, MOL CELL BIOL, V28, P2941, DOI 10.1128/MCB.01682-07; Kollias HD, 2006, MOL CELL BIOL, V26, P6248, DOI 10.1128/MCB.00384-06; Liao ZH, 2002, CARDIOVASC RES, V53, P902, DOI 10.1016/S0008-6363(01)00531-4; Lluis F, 2006, TRENDS CELL BIOL, V16, P36, DOI 10.1016/j.tcb.2005.11.002; Lluis F, 2005, EMBO J, V24, P974, DOI 10.1038/sj.emboj.7600528; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; McKinsey TA, 2002, CURR OPIN CELL BIOL, V14, P763, DOI 10.1016/S0955-0674(02)00389-7; Muskiewicz KR, 2005, J HISTOCHEM CYTOCHEM, V53, P861, DOI 10.1369/jhc.4A6573.2005; Myer A, 1997, DEV BIOL, V185, P127, DOI 10.1006/dbio.1997.8565; Myer A, 2001, DEV BIOL, V229, P340, DOI 10.1006/dbio.2000.9985; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; Page JL, 2004, J BIOL CHEM, V279, P30966, DOI 10.1074/jbc.M402224200; Pedranzini L, 2006, CANCER RES, V66, P9714, DOI 10.1158/0008-5472.CAN-05-4280; Penn BH, 2004, GENE DEV, V18, P2348, DOI 10.1101/gad.1234304; Pennica D, 1996, CYTOKINE, V8, P183, DOI 10.1006/cyto.1996.0026; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; Polesskaya A, 2001, MOL CELL BIOL, V21, P5312, DOI 10.1128/MCB.21.16.5312-5320.2001; Pownall ME, 2002, ANNU REV CELL DEV BI, V18, P747, DOI 10.1146/annurev.cellbio.18.012502.105758; Pradervand S, 2004, EMBO J, V23, P4517, DOI 10.1038/sj.emboj.7600454; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Reynaud EG, 2000, J BIOL CHEM, V275, P18767, DOI 10.1074/jbc.M907412199; Ridgeway AG, 2000, J BIOL CHEM, V275, P32398, DOI 10.1074/jbc.M004349200; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; Serra C, 2007, MOL CELL, V28, P200, DOI 10.1016/j.molcel.2007.08.021; Sheng ZL, 1996, DEVELOPMENT, V122, P419; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; Tapscott SJ, 2005, DEVELOPMENT, V132, P2685, DOI 10.1242/dev.01874; TEMPLETON TJ, 1992, DEV BIOL, V154, P169, DOI 10.1016/0012-1606(92)90057-N; Thompson JE, 2002, BIOORG MED CHEM LETT, V12, P1219, DOI 10.1016/S0960-894X(02)00106-3; WALSH K, 1992, J BIOL CHEM, V267, P13714; Wang KP, 2008, J BIOL CHEM, V283, P34029, DOI 10.1074/jbc.M803012200; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Winter B, 2000, J CELL SCI, V113, P4211; Xu Q, 2000, J BIOL CHEM, V275, P36750, DOI 10.1074/jbc.M005030200; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; Yip-Schneider MT, 2009, J PHARMACOL EXP THER, V329, P1063, DOI 10.1124/jpet.108.147306; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	70	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19679	19693		10.1074/jbc.M109.017319	http://dx.doi.org/10.1074/jbc.M109.017319			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19439412	hybrid, Green Published			2022-12-25	WOS:000267908300059
J	Leemans, JC; Butter, LM; Pulskens, WPC; Teske, GJD; Claessen, N; van der Poll, T; Florquin, S				Leemans, Jaklien C.; Butter, Loes M.; Pulskens, Wilco P. C.; Teske, Gwendoline J. D.; Claessen, Nike; van der Poll, Tom; Florquin, Sandrine			The Role of Toll-Like Receptor 2 in Inflammation and Fibrosis during Progressive Renal Injury	PLOS ONE			English	Article								Tissue fibrosis and chronic inflammation are common causes of progressive organ damage, including progressive renal disease, leading to loss of physiological functions. Recently, it was shown that Toll-like receptor 2 (TLR2) is expressed in the kidney and activated by endogenous danger signals. The expression and function of TLR2 during renal fibrosis and chronic inflammation has however not yet been elucidated. Therefore, we studied TLR2 expression in human and murine progressive renal diseases and explored its role by inducing obstructive nephropathy in TLR2(-/-) or TLR2(+/+) mice. We found that TLR2 is markedly upregulated on tubular and tubulointerstitial cells in patients with chronic renal injury. In mice with obstructive nephropathy, renal injury was associated with a marked upregulation and change in distribution of TLR2 and upregulation of murine TLR2 danger ligands Gp96, biglycan, and HMGB1. Notably, TLR2 enhanced inflammation as reflected by a significantly reduced influx of neutrophils and production of chemokines and TGF-beta in kidneys of TLR2(-/-) mice compared with TLR2(+/+) animals. Although, the obstructed kidneys of TLR2(-/-) mice had less interstitial myofibroblasts in the later phase of obstructive nephropathy, tubular injury and renal matrix accumulation was similar in both mouse strains. Together, these data demonstrate that TLR2 can initiate renal inflammation during progressive renal injury and that the absence of TLR2 does not affect the development of chronic renal injury and fibrosis.			Leemans, JC (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands.	j.c.leemans@amc.uva.nl	Leemans, Jaklien/AAM-4958-2020; Pulskens, Wilco/P-6023-2015; Florquin, Sandrine/B-8242-2012	Pulskens, Wilco/0000-0001-9697-3189; Florquin, Sandrine/0000-0002-9676-1722				Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Anders HJ, 2007, CURR OPIN NEPHROL HY, V16, P177, DOI 10.1097/MNH.0b013e32803fb767; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Becker GJ, 2000, CURR OPIN NEPHROL HY, V9, P133, DOI 10.1097/00041552-200003000-00006; Docherty NG, 2006, AM J PHYSIOL-RENAL, V290, pF4, DOI 10.1152/ajprenal.00045.2005; Duymelinck C, 2000, KIDNEY INT, V58, P1186, DOI 10.1046/j.1523-1755.2000.00274.x; Eddy AA, 2000, PEDIATR NEPHROL, V15, P290, DOI 10.1007/s004670000461; El-Achkar TM, 2006, NAT CLIN PRACT NEPHR, V2, P568, DOI 10.1038/ncpneph0300; Elass E, 2005, INFECT IMMUN, V73, P7064, DOI 10.1128/IAI.73.10.7064-7068.2005; Florquin S, 2002, AM J KIDNEY DIS, V39, P407, DOI 10.1053/ajkd.2002.30563; Gebbia JA, 2004, J INFECT DIS, V189, P113, DOI 10.1086/380414; Haas M, 1997, AM J KIDNEY DIS, V29, P829, DOI 10.1016/S0272-6386(97)90456-X; Hasan UA, 2005, J BIOL CHEM, V280, P20620, DOI 10.1074/jbc.M500877200; Iwano M, 2004, CURR OPIN NEPHROL HY, V13, P279, DOI 10.1097/00041552-200405000-00003; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Johnson GB, 2003, TRENDS IMMUNOL, V24, P19, DOI 10.1016/S1471-4906(02)00014-5; Kirschning CJ, 2002, CURR TOP MICROBIOL, V270, P121; Klahr S, 2002, AM J PHYSIOL-RENAL, V283, pF861, DOI 10.1152/ajprenal.00362.2001; Kuroda M, 2004, CLIN NEPHROL, V61, P7; Lang A, 2005, J AM SOC NEPHROL, V16, P383, DOI 10.1681/ASN.2004040276; Leemans JC, 2005, J CLIN INVEST, V115, P2894, DOI 10.1172/JCI22832; Li M, 2001, J IMMUNOL, V166, P7128, DOI 10.4049/jimmunol.166.12.7128; McCoy CE, 2008, FRONT BIOSCI-LANDMRK, V13, P62, DOI 10.2741/2660; Miyake K, 2007, SEMIN IMMUNOL, V19, P3, DOI 10.1016/j.smim.2006.12.002; Mueller T, 2003, PEDIATR NEPHROL, V18, P97, DOI 10.1007/s00467-002-1037-5; Otte JM, 2003, GASTROENTEROLOGY, V124, P1866, DOI 10.1016/S0016-5085(03)00403-7; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Pierer M, 2004, J IMMUNOL, V172, P1256, DOI 10.4049/jimmunol.172.2.1256; Pulskens WP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003596; Rouschop KMA, 2004, J AM SOC NEPHROL, V15, P674, DOI 10.1097/01.ASN.0000115703.30835.96; Saemann MD, 2005, J CLIN INVEST, V115, P468, DOI 10.1172/JCI200522720; Schaefer L, 2005, J CLIN INVEST, V115, P2223, DOI 10.1172/JCI23755; Scheibner KA, 2006, J IMMUNOL, V177, P1272, DOI 10.4049/jimmunol.177.2.1272; SEE WA, 2008, BJU INT; Seibl R, 2003, AM J PATHOL, V162, P1221, DOI 10.1016/S0002-9440(10)63918-1; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Stokman G, 2008, NEPHROL DIAL TRANSPL, V23, P483, DOI 10.1093/ndt/gfm607; Strutz F, 2003, SPRINGER SEMIN IMMUN, V24, P459, DOI 10.1007/s00281-003-0123-5; Strutz F, 2006, J AM SOC NEPHROL, V17, P2992, DOI 10.1681/ASN.2006050420; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Taylor KR, 2004, J BIOL CHEM, V279, P17079, DOI 10.1074/jbc.M310859200; Triantafilou M, 2006, J BIOL CHEM, V281, P31002, DOI 10.1074/jbc.M602794200; Tsuboi N, 2002, J IMMUNOL, V169, P2026, DOI 10.4049/jimmunol.169.4.2026; Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Valles P, 2003, PEDIATR NEPHROL, V18, P527, DOI 10.1007/s00467-003-1096-2; Warger T, 2006, J BIOL CHEM, V281, P22545, DOI 10.1074/jbc.M502900200; Wolfs TGAM, 2002, J IMMUNOL, V168, P1286, DOI 10.4049/jimmunol.168.3.1286; Wu HL, 2007, J CLIN INVEST, V117, P2847, DOI 10.1172/JCI31008; Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487; Zhang X, 2008, J PATHOL, V214, P161, DOI 10.1002/path.2284	54	96	104	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2009	4	5							e5704	10.1371/journal.pone.0005704	http://dx.doi.org/10.1371/journal.pone.0005704			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QD	19479087	gold, Green Published, Green Submitted			2022-12-25	WOS:000266415000015
J	Pandey, KC; Barkan, DT; Sali, A; Rosenthal, PJ				Pandey, Kailash C.; Barkan, David T.; Sali, Andrej; Rosenthal, Philip J.			Regulatory Elements within the Prodomain of Falcipain-2, a Cysteine Protease of the Malaria Parasite Plasmodium falciparum	PLOS ONE			English	Article							STRUCTURAL BASIS; PROCATHEPSIN B; INHIBITION; HEMOGLOBIN; MOTIF; SUBSTRATE; BINDING; PEPTIDE	Falcipain-2, a papain family cysteine protease of the malaria parasite Plasmodium falciparum, plays a key role in parasite hydrolysis of hemoglobin and is a potential chemotherapeutic target. As with many proteases, falcipain-2 is synthesized as a zymogen, and the prodomain inhibits activity of the mature enzyme. To investigate the mechanism of regulation of falcipain-2 by its prodomain, we expressed constructs encoding different portions of the prodomain and tested their ability to inhibit recombinant mature falcipain-2. We identified a C-terminal segment (Leu(155)-Asp(243)) of the prodomain, including two motifs (ERFNIN and GNFD) that are conserved in cathepsin L sub-family papain family proteases, as the mediator of prodomain inhibitory activity. Circular dichroism analysis showed that the prodomain including the C-terminal segment, but not constructs lacking this segment, was rich in secondary structure, suggesting that the segment plays a crucial role in protein folding. The falcipain-2 prodomain also efficiently inhibited other papain family proteases, including cathepsin K, cathepsin L, cathepsin B, and cruzain, but it did not inhibit cathepsin C or tested proteases of other classes. A structural model of pro-falcipain-2 was constructed by homology modeling based on crystallographic structures of mature falcipain-2, procathepsin K, procathepsin L, and procaricain, offering insights into the nature of the interaction between the prodomain and mature domain of falcipain-2 as well as into the broad specificity of inhibitory activity of the falcipain-2 prodomain.			Pandey, KC (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	prosenthal@medsfgh.ucsf.edu	Pandey, Kailash/H-5048-2011		NIAID NIH HHS [R56 AI035800, P01 AI035707, R01 AI035800, R29 AI035800] Funding Source: Medline; NIGMS NIH HHS [R01 GM054762, P01 GM071790, R29 GM054762] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; Cygler M, 1996, STRUCTURE, V4, P405, DOI 10.1016/S0969-2126(96)00046-9; Eramian D, 2008, PROTEIN SCI, V17, P1881, DOI 10.1110/ps.036061.108; Webb Benjamin, 2016, Curr Protoc Bioinformatics, V54, DOI [10.1002/0471140864.ps0209s50, 10.1002/cpps.20, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3]; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Greenwood BM, 2005, LANCET, V365, P1487, DOI 10.1016/S0140-6736(05)66420-3; Groves MR, 1996, STRUCTURE, V4, P1193, DOI 10.1016/S0969-2126(96)00127-X; Groves MR, 1998, PROTEINS, V32, P504, DOI 10.1002/(SICI)1097-0134(19980901)32:4<504::AID-PROT8>3.0.CO;2-F; Guay J, 2000, EUR J BIOCHEM, V267, P6311, DOI 10.1046/j.1432-1327.2000.01730.x; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; Korde R, 2008, J MED CHEM, V51, P3116, DOI 10.1021/jm070735f; Kreusch S, 2000, EUR J BIOCHEM, V267, P2965; LaLonde JM, 1999, BIOCHEMISTRY-US, V38, P862, DOI 10.1021/bi9822271; Marti-Renom MA, 2004, PROTEIN SCI, V13, P1071, DOI 10.1110/ps.03379804; Pandey KC, 2006, PLOS PATHOG, V2, P1031, DOI 10.1371/journal.ppat.0020117; Pandey KC, 2005, P NATL ACAD SCI USA, V102, P9138, DOI 10.1073/pnas.0502368102; Pandey KC, 2004, J BIOL CHEM, V279, P3484, DOI 10.1074/jbc.M310536200; Rosenthal PJ, 2004, INT J PARASITOL, V34, P1489, DOI 10.1016/j.ijpara.2004.10.003; Shen MY, 2006, PROTEIN SCI, V15, P2507, DOI 10.1110/ps.062416606; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; Sijwali PS, 2004, P NATL ACAD SCI USA, V101, P4384, DOI 10.1073/pnas.0307720101; Sijwali PS, 2002, J BIOL CHEM, V277, P14910, DOI 10.1074/jbc.M109680200; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; Subramanian S, 2007, J BIOL CHEM, V282, P24961, DOI 10.1074/jbc.M703316200; Turk D, 1996, FEBS LETT, V384, P211, DOI 10.1016/0014-5793(96)00309-2; VERNET T, 1995, J BIOL CHEM, V270, P10838, DOI 10.1074/jbc.270.18.10838; Wang SX, 2006, P NATL ACAD SCI USA, V103, P11503, DOI 10.1073/pnas.0600489103; Wiederanders B, 2003, CURR PROTEIN PEPT SC, V4, P309, DOI 10.2174/1389203033487081	28	42	42	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2009	4	5							e5694	10.1371/journal.pone.0005694	http://dx.doi.org/10.1371/journal.pone.0005694			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QD	19479029	Green Published, gold, Green Submitted			2022-12-25	WOS:000266415000007
J	Ramirez, O; Gigli, E; Bover, P; Alcover, JA; Bertranpetit, J; Castresana, J; Lalueza-Fox, C				Ramirez, Oscar; Gigli, Elena; Bover, Pere; Antoni Alcover, Josep; Bertranpetit, Jaume; Castresana, Jose; Lalueza-Fox, Carles			Paleogenomics in a Temperate Environment: Shotgun Sequencing from an Extinct Mediterranean Caprine	PLOS ONE			English	Article							MYOTRAGUS-BALEARICUS BATE; MITOCHONDRIAL GENOME; DNA-SEQUENCES; EVOLUTION; AMPLIFICATION; ARTIODACTYLA; ALIGNMENT	Background: Numerous endemic mammals, including dwarf elephants, goats, hippos and deers, evolved in isolation in the Mediterranean islands during the Pliocene and Pleistocene. Most of them subsequently became extinct during the Holocene. Recently developed high-throughput sequencing technologies could provide a unique tool for retrieving genomic data from these extinct species, making it possible to study their evolutionary history and the genetic bases underlying their particular, sometimes unique, adaptations. Methodology/Principals Findings: A DNA extraction of similar to 6,000 year-old bone sample from an extinct caprine (Myotragus balearicus) from the Balearic Islands in the Western Mediterranean, has been subjected to shotgun sequencing with the GS FLX 454 platform. Only 0.27% of the resulting sequences, identified from alignments with the cow genome and comprising 15,832 nucleotides, with an average length of 60 nucleotides, proved to be endogenous. Conclusions: A phylogenetic tree generated with Myotragus sequences and those from other artiodactyls displays an identical topology to that generated from mitochondrial DNA data. Despite being in an unfavourable thermal environment, which explains the low yield of endogenous sequences, our study demonstrates that it is possible to obtain genomic data from extinct species from temperate regions.	[Ramirez, Oscar; Gigli, Elena; Bertranpetit, Jaume; Castresana, Jose; Lalueza-Fox, Carles] UPF, CSIC, Inst Evolutionary Biol, Barcelona, Spain; [Bover, Pere; Antoni Alcover, Josep] CSIC UIB, Inst Mediterrani Estudis Avancats, Esporles, Mallorca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UPF - Institut de Biologia Evolutiva (IBE); Pompeu Fabra University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Mediterraneo de Estudios Avanzados (IMEDEA); Universitat de les Illes Balears; University of Barcelona	Lalueza-Fox, C (corresponding author), UPF, CSIC, Inst Evolutionary Biol, Barcelona, Spain.	carles.lalueza@upf.edu	LALUEZA-FOX, CARLES/AAG-5341-2020; Castresana, Jose/K-3437-2014; Ramirez, Oscar/E-7293-2012; Bertranpetit, Jaume/F-8550-2012; Alcover, Josep Antoni/Y-3796-2018	LALUEZA-FOX, CARLES/0000-0002-1730-5914; Castresana, Jose/0000-0002-9391-8050; Ramirez, Oscar/0000-0001-5164-6790; Bertranpetit, Jaume/0000-0003-0100-0590; Bover Arbos, Pedro/0000-0003-2942-2840; Alcover, Josep Antoni/0000-0001-9905-2588				Alcover J. A., 1981, QUIMERES PASSAT ELS; Alcover JA, 2008, J WORLD PREHIST, V21, P19, DOI 10.1007/s10963-008-9010-2; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andrews CW, 1915, PHILOS T R SOC LON B, V206, P281, DOI 10.1098/rstb.1915.0006; Bate D. M. A., 1909, GEOL MAG, V543, P385, DOI [10.1017/S0016756800124665, DOI 10.1017/S0016756800124665]; Beja-Pereira A, 2006, P NATL ACAD SCI USA, V103, P8113, DOI 10.1073/pnas.0509210103; Blow MJ, 2008, GENOME RES, V18, P1347, DOI 10.1101/gr.076091.108; Bover P, 1999, BIOL J LINN SOC, V68, P401; Bover P, 2003, J BIOGEOGR, V30, P771, DOI 10.1046/j.1365-2699.2003.00872.x; Bover P, 2008, QUATERN INT, V182, P135, DOI 10.1016/j.quaint.2007.06.039; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Encinas Jose Antonio, 1997, Endins, V21, P83; Gilbert MTP, 2007, SCIENCE, V317, P1927, DOI 10.1126/science.1146971; Gilbert MTP, 2007, NUCLEIC ACIDS RES, V35, P1, DOI 10.1093/nar/gkl483; Gilbert MTP, 2005, J ARCHAEOL SCI, V32, P785, DOI 10.1016/j.jas.2004.12.008; GILBERT MTP, 2008, NEXT GENERATION GENO, P183; Green RE, 2008, CELL, V134, P416, DOI 10.1016/j.cell.2008.06.021; Green RE, 2006, NATURE, V444, P330, DOI 10.1038/nature05336; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Hassanin A, 1999, MOL PHYLOGENET EVOL, V13, P227, DOI 10.1006/mpev.1999.0619; Hofreiter M, 2001, NUCLEIC ACIDS RES, V29, P4793, DOI 10.1093/nar/29.23.4793; Hofreiter M, 2008, CR PALEVOL, V7, P113, DOI 10.1016/j.crpv.2007.12.005; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Kohler M, 2004, BRAIN BEHAV EVOLUT, V63, P125, DOI 10.1159/000076239; Krause J, 2006, NATURE, V439, P724, DOI 10.1038/nature04432; Krause J, 2007, CURR BIOL, V17, P1908, DOI 10.1016/j.cub.2007.10.008; Lalueza-Fox C, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-70; Lalueza-Fox C, 2002, MOL PHYLOGENET EVOL, V25, P501, DOI 10.1016/S1055-7903(02)00290-7; Lalueza-Fox C, 2007, SCIENCE, V318, P1453, DOI 10.1126/science.1147417; LALUEZAFOX C, 2008, J EXP ZOOL PART B, V288, P56; Malmstrom H, 2007, MOL BIOL EVOL, V24, P998, DOI 10.1093/molbev/msm015; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Meyer M, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm566; Miller W, 2008, NATURE, V456, P387, DOI 10.1038/nature07446; Miller W, 2009, GENOME RES, V19, P213, DOI 10.1101/gr.082628.108; Noonan JP, 2006, SCIENCE, V314, P1113, DOI 10.1126/science.1131412; Noonan JP, 2005, SCIENCE, V309, P597, DOI 10.1126/science.1113485; POINAR HN, 2006, DNA SCI, V311, P392; RAMIS D, 2005, P INT S INS VERT EV, P309; Rompler H, 2006, SCIENCE, V313, P62, DOI 10.1126/science.1128994; Smith CI, 2003, J HUM EVOL, V45, P203, DOI 10.1016/S0047-2484(03)00106-4; SPOOR CF, 1988, P K NED AKAD B PHYS, V91, P285; SPOOR CF, 1988, P K NED AKAD B PHYS, V91, P295; Stiller M, 2006, P NATL ACAD SCI USA, V103, P13578, DOI 10.1073/pnas.0605327103; Wall JD, 2007, PLOS GENET, V3, P1862, DOI 10.1371/journal.pgen.0030175	45	25	25	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2009	4	5							e5670	10.1371/journal.pone.0005670	http://dx.doi.org/10.1371/journal.pone.0005670			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	449LD	19461892	Green Published, Green Submitted, gold			2022-12-25	WOS:000266331200007
J	Correia, DV; d'Orey, F; Cardoso, BA; Lanca, T; Grosso, AR; deBarros, A; Martins, LR; Barata, JT; Silva-Santos, B				Correia, Daniel V.; d'Orey, Francisco; Cardoso, Bruno A.; Lanca, Telma; Grosso, Ana R.; deBarros, Ana; Martins, Leila R.; Barata, Joao T.; Silva-Santos, Bruno			Highly Active Microbial Phosphoantigen Induces Rapid yet Sustained MEK/Erk- and PI-3K/Akt-Mediated Signal Transduction in Anti-Tumor Human gamma delta T-Cells	PLOS ONE			English	Article								Background: The unique responsiveness of V gamma 9V delta 2 T-cells, the major gamma delta subset of human peripheral blood, to non-peptidic prenyl pyrophosphate antigens constitutes the basis of current gamma delta T-cell-based cancer immunotherapy strategies. However, the molecular mechanisms responsible for phosphoantigen-mediated activation of human gamma delta T-cells remain unclear. In particular, previous reports have described a very slow kinetics of activation of T-cell receptor (TCR)-associated signal transduction pathways by isopentenyl pyrophosphate and bromohydrin pyrophosphate, seemingly incompatible with direct binding of these antigens to the V gamma 9V delta 2 TCR. Here we have studied the most potent natural phosphoantigen yet identified, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), produced by Eubacteria and Protozoa, and examined its gamma delta T-cell activation and anti-tumor properties. Methodology/Principal Findings: We have performed a comparative study between HMB-PP and the anti-CD3 epsilon monoclonal antibody OKT3, used as a reference inducer of bona fide TCR signaling, and followed multiple cellular and molecular gamma delta T-cell activation events. We show that HMB-PP activates MEK/Erk and PI-3K/Akt pathways as rapidly as OKT3, and induces an almost identical transcriptional profile in V gamma 9(+) T-cells. Moreover, MEK/Erk and PI-3K/Akt activities are indispensable for the cellular effects of HMB-PP, including gamma delta T-cell activation, proliferation and anti-tumor cytotoxicity, which are also abolished upon antibody blockade of the V gamma 9(+) TCR Surprisingly, HMB-PP treatment does not induce down-modulation of surface TCR levels, and thereby sustains gamma delta T-cell activation upon re-stimulation. This ultimately translates in potent human gamma delta T-cell anti-tumor function both in vitro and in vivo upon transplantation of human leukemia cells into lymphopenic mice, Conclusions/Significance: The development of efficient cancer immunotherapy strategies critically depends on our capacity to maximize anti-tumor effector T-cell responses. By characterizing the intracellular mechanisms of HMB-PP-mediated activation of the highly cytotoxic V gamma 9(+) T-cell subset, our data strongly support the usage of this microbial antigen in novel cancer clinical trials.			Correia, DV (corresponding author), Univ Lisbon, Fac Med, Inst Mol Med, Mol Immunol Unit, P-1699 Lisbon, Portugal.	bsilvasantos@gmail.com	Barata, João T./D-9181-2015; Grosso, Ana Rita/I-6656-2013	Barata, João T./0000-0002-4826-8976; Grosso, Ana Rita/0000-0001-6974-4209; Correia, Daniel/0000-0002-0784-0307; Cardoso, Bruno/0000-0002-6521-7257; de Barros, Ana/0000-0002-6493-4676; Silva-Santos, Bruno/0000-0003-4141-9302; Martins, Leila/0000-0002-5887-4734				Ali Z, 2007, J IMMUNOL, V179, P8287, DOI 10.4049/jimmunol.179.12.8287; Barata JT, 2004, J EXP MED, V200, P659, DOI 10.1084/jem.20040789; Bonneville M, 2006, CURR OPIN IMMUNOL, V18, P539, DOI 10.1016/j.coi.2006.07.002; Brandes M, 2005, SCIENCE, V309, P264, DOI 10.1126/science.1110267; Bukowski JF, 1998, J IMMUNOL, V161, P286; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; Casetti R, 2005, J IMMUNOL, V175, P1593, DOI 10.4049/jimmunol.175.3.1593; Chen Y, 2008, BLOOD, V111, P4220, DOI 10.1182/blood-2007-07-101691; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; Corvaisier M, 2005, J IMMUNOL, V175, P5481, DOI 10.4049/jimmunol.175.8.5481; Devilder MC, 2006, J IMMUNOL, V176, P1386, DOI 10.4049/jimmunol.176.3.1386; Dieli F, 2007, CANCER RES, V67, P7450, DOI 10.1158/0008-5472.CAN-07-0199; Dietrich J, 2002, J IMMUNOL, V168, P5434, DOI 10.4049/jimmunol.168.11.5434; Eberl M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000308; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500; Gomes AQ, 2007, EMBO REP, V8, P1024, DOI 10.1038/sj.embor.7401090; Ismaili J, 2002, CLIN IMMUNOL, V103, P296, DOI 10.1006/clim.2002.5218; Kabelitz D, 2004, J IMMUNOL, V173, P6767, DOI 10.4049/jimmunol.173.11.6767; Kunzmann V, 2005, LEUKEMIA LYMPHOMA, V46, P671, DOI 10.1080/10428190500051893; Lafont V, 2001, J BIOL CHEM, V276, P15961, DOI 10.1074/jbc.M008684200; Morita CT, 2007, IMMUNOL REV, V215, P59, DOI 10.1111/j.1600-065X.2006.00479.x; Naramura M, 2002, NAT IMMUNOL, V3, P1192, DOI 10.1038/ni855; Pennington DJ, 2005, ADV IMMUNOL, V87, P27, DOI 10.1016/S0065-2776(05)87002-6; Shu ST, 2007, CANCER RES, V67, P11859, DOI 10.1158/0008-5472.CAN-07-1701; Sireci G, 2001, EUR J IMMUNOL, V31, P1628, DOI 10.1002/1521-4141(200105)31:5<1628::AID-IMMU1628>3.0.CO;2-T; Stagg J, 2007, IMMUNOL REV, V220, P82, DOI 10.1111/j.1600-065X.2007.00566.x; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; Thedrez A, 2007, IMMUNOL REV, V215, P123, DOI 10.1111/j.1600-065X.2006.00468.x; Vermijlen D, 2007, J IMMUNOL, V178, P4304, DOI 10.4049/jimmunol.178.7.4304; Wei HY, 2008, J IMMUNOL, V181, P4798, DOI 10.4049/jimmunol.181.7.4798; Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood-2002-12-3665; Yamashita S, 2005, BIOCHEM BIOPH RES CO, V334, P349, DOI 10.1016/j.bbrc.2005.06.100	33	44	45	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2009	4	5							e5657	10.1371/journal.pone.0005657	http://dx.doi.org/10.1371/journal.pone.0005657			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LB	19479075	gold, Green Published, Green Submitted			2022-12-25	WOS:000266331000015
J	Schyns, PG; Petro, LS; Smith, ML				Schyns, Philippe G.; Petro, Lucy S.; Smith, Marie L.			Transmission of Facial Expressions of Emotion Co-Evolved with Their Efficient Decoding in the Brain: Behavioral and Brain Evidence	PLOS ONE			English	Article							VISUAL RECOGNITION; SPATIAL SCALES; ERP EVIDENCE; FACE; INFORMATION; AMYGDALA; PERCEPTION; RESPONSES; OBJECTS; DISCRIMINATION	Competent social organisms will read the social signals of their peers. In primates, the face has evolved to transmit the organism's internal emotional state. Adaptive action suggests that the brain of the receiver has co-evolved to efficiently decode expression signals. Here, we review and integrate the evidence for this hypothesis. With a computational approach, we co-examined facial expressions as signals for data transmission and the brain as receiver and decoder of these signals. First, we show in a model observer that facial expressions form a lowly correlated signal set. Second, using time-resolved EEG data, we show how the brain uses spatial frequency information impinging on the retina to decorrelate expression categories. Between 140 to 200 ms following stimulus onset, independently in the left and right hemispheres, an information processing mechanism starts locally with encoding the eye, irrespective of expression, followed by a zooming out to processing the entire face, followed by a zooming back in to diagnostic features (e.g. the opened eyes in "fear'', the mouth in "happy''). A model categorizer demonstrates that at 200 ms, the left and right brain have represented enough information to predict behavioral categorization performance.			Schyns, PG (corresponding author), Univ Glasgow, CCNi, Glasgow, Lanark, Scotland.	philippe@psy.gla.ac.uk	Smith, Marie/N-8491-2013; Schyns, Philippe/C-8127-2009; Schyns, Philippe/AAT-6989-2020	Schyns, Philippe/0000-0002-8542-7489; Petro, Lucy/0000-0002-8255-5776	Biotechnology and Biological Sciences Research Council Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 1996, J NEUROSCI, V16, P7678; BACKUS GE, 1967, GEOPHYS J ROY ASTR S, V13, P247, DOI 10.1111/j.1365-246X.1967.tb02159.x; Bar M, 2006, P NATL ACAD SCI USA, V103, P449, DOI 10.1073/pnas.0507062103; BARLOW H, 1989, COMP NEUR S, P54; Batty M, 2003, COGNITIVE BRAIN RES, V17, P613, DOI 10.1016/S0926-6410(03)00174-5; Bentin S, 2000, COGN NEUROPSYCHOL, V17, P35, DOI 10.1080/026432900380472; Bentin S, 1996, J COGNITIVE NEUROSCI, V8, P551, DOI 10.1162/jocn.1996.8.6.551; Bentin S, 2007, NAT NEUROSCI, V10, P801, DOI 10.1038/nn0707-801; BERSON DM, 1988, PROG BRAIN RES, V75, P17; Blair RJR, 1999, BRAIN, V122, P883, DOI 10.1093/brain/122.5.883; Bonnar L, 2002, PERCEPTION, V31, P683, DOI 10.1068/p3276; Bullier J, 2001, BRAIN RES REV, V36, P96, DOI 10.1016/S0165-0173(01)00085-6; Chauvin A, 2005, J VISION, V5, P659, DOI 10.1167/5.9.1; Dailey M., 2001, CALIFORNIA FAC UNPUB; Dailey MN, 1999, NEURAL NETWORKS, V12, P1053, DOI 10.1016/S0893-6080(99)00050-7; Darwin C., 1872, EXPRESS EMOT MAN, DOI [10.1037/h0076058, DOI 10.1037/10001-000]; Davidson RJ, 2004, P NATL ACAD SCI USA, V101, P11915, DOI 10.1073/pnas.0404264101; de Haan M, 1998, DEV NEUROPSYCHOL, V14, P495, DOI 10.1080/87565649809540725; Eimer M, 2007, NEUROPSYCHOLOGIA, V45, P15, DOI 10.1016/j.neuropsychologia.2006.04.022; Ekman P., 2003, UNMASKING FACE GUIDE; Ekman P, 1978, FACIAL ACTION CODING; Ekman P., 1999, HDB COGN EMOT, V98, P16; Fried I, 1997, NEURON, V18, P753, DOI 10.1016/S0896-6273(00)80315-3; Gerson AD, 2005, NEUROIMAGE, V28, P342, DOI 10.1016/j.neuroimage.2005.06.026; Goffaux V, 2003, COGNITIVE BRAIN RES, V16, P416, DOI 10.1016/S0926-6410(03)00056-9; Goffaux V, 2003, COGNITIVE SCI, V27, P313, DOI 10.1016/S0364-0213(03)00002-8; Gosselin F, 2001, VISION RES, V41, P2261, DOI 10.1016/S0042-6989(01)00097-9; Gosselin F, 2002, TRENDS COGN SCI, V6, P70, DOI 10.1016/S1364-6613(00)01838-6; HARMON LD, 1973, SCI AM, V229, P70, DOI 10.1038/scientificamerican1173-70; HARMON LD, 1973, SCIENCE, V180, P1194, DOI 10.1126/science.180.4091.1194; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Ishai A, 2004, P NATL ACAD SCI USA, V101, P9827, DOI 10.1073/pnas.0403559101; KUNSTWILSON WR, 1980, SCIENCE, V207, P557, DOI 10.1126/science.7352271; LeDoux J. E., 1996, EMOTIONAL BRAIN; LEDOUX JE, 1985, J COMP NEUROL, V242, P182, DOI 10.1002/cne.902420204; LEVENTHAL AG, 1985, J COMP NEUROL, V237, P216, DOI 10.1002/cne.902370206; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; Morris JS, 1999, P NATL ACAD SCI USA, V96, P1680, DOI 10.1073/pnas.96.4.1680; Morris JS, 1998, BRAIN, V121, P47, DOI 10.1093/brain/121.1.47; Morrison DJ, 2001, PSYCHON B REV, V8, P454, DOI 10.3758/BF03196180; Ohman A, 2002, CURR DIR PSYCHOL SCI, V11, P62, DOI 10.1111/1467-8721.00169; Ohman A., 1992, HDB EMOTIONS, P511; Oliva A, 1997, COGNITIVE PSYCHOL, V34, P72, DOI 10.1006/cogp.1997.0667; Papez JW, 1937, ARCH NEURO PSYCHIATR, V38, P725, DOI 10.1001/archneurpsyc.1937.02260220069003; Pizzagalli D, 1999, NEUROREPORT, V10, P2691, DOI 10.1097/00001756-199909090-00001; ROLLS ET, 1999, BRAIN EMOTION; Rousselet GA, 2004, TRENDS COGN SCI, V8, P363, DOI 10.1016/j.tics.2004.06.003; SCHILLER PH, 1979, J NEUROPHYSIOL, V42, P1124, DOI 10.1152/jn.1979.42.4.1124; Schyns PG, 1998, COGNITION, V67, P147, DOI 10.1016/S0010-0277(98)00016-X; SCHYNS PG, 1994, PSYCHOL SCI, V5, P195, DOI 10.1111/j.1467-9280.1994.tb00500.x; Schyns PG, 2003, NEUROREPORT, V14, P1665, DOI 10.1097/00001756-200309150-00002; Schyns PG, 2007, CURR BIOL, V17, P1580, DOI 10.1016/j.cub.2007.08.048; SMITH F, 2009, PSYCHOL SCI IN PRESS; Smith ML, 2005, PSYCHOL SCI, V16, P184, DOI 10.1111/j.0956-7976.2005.00801.x; Smith ML, 2006, P NATL ACAD SCI USA, V103, P5626, DOI 10.1073/pnas.0508972103; Sowden PT, 2006, TRENDS COGN SCI, V10, P538, DOI 10.1016/j.tics.2006.10.007; Sprengelmeyer R, 1998, P ROY SOC B-BIOL SCI, V265, P1927, DOI 10.1098/rspb.1998.0522; Taylor MJ, 2001, NEUROREPORT, V12, P1671, DOI 10.1097/00001756-200106130-00031; Ullman S, 2002, NAT NEUROSCI, V5, P682, DOI 10.1038/nn870; Ullman S., 1996, HIGH LEVEL VISION OB; VANRIJSBERGEN N, 2009, DYNAMICS REPRE UNPUB; Vuilleumier P, 2003, NAT NEUROSCI, V6, P624, DOI 10.1038/nn1057; Whalen PJ, 1998, J NEUROSCI, V18, P411; Winston JS, 2003, CURR BIOL, V13, P1824, DOI 10.1016/j.cub.2003.09.038	65	81	83	2	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5625	10.1371/journal.pone.0005625	http://dx.doi.org/10.1371/journal.pone.0005625			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	448AY	19462006	gold, Green Submitted, Green Published, Green Accepted			2022-12-25	WOS:000266234700012
J	Bondareva, A; Downey, CM; Ayres, F; Liu, W; Boyd, SK; Hallgrimsson, B; Jirik, FR				Bondareva, Alla; Downey, Charlene M.; Ayres, Fabio; Liu, Wei; Boyd, Steven K.; Hallgrimsson, Benedikt; Jirik, Frank R.			The Lysyl Oxidase Inhibitor, beta-Aminopropionitrile, Diminishes the Metastatic Colonization Potential of Circulating Breast Cancer Cells	PLOS ONE			English	Article								Lysyl oxidase (LOX), an extracellular matrix remodeling enzyme, appears to have a role in promoting breast cancer cell motility and invasiveness. In addition, increased LOX expression has been correlated with decreases in both metastases-free, and overall survival in breast cancer patients. With this background, we studied the ability of beta-aminopropionitrile (BAPN), an irreversible inhibitor of LOX, to regulate the metastatic colonization potential of the human breast cancer cell line, MDA-MB-231. BAPN was administered daily to mice starting either 1 day prior, on the same day as, or 7 days after intracardiac injection of luciferase expressing MDA-MB-231-Luc2 cells. Development of metastases was monitored by in vivo bioluminescence imaging, and tumor-induced osteolysis was assessed by micro-computed tomography (mu CT). We found that BAPN administration was able to reduce the frequency of metastases. Thus, when BAPN treatment was initiated the day before, or on the same day as the intra-cardiac injection of tumor cells, the number of metastases was decreased by 44%, and 27%, and whole-body photon emission rates (reflective of total tumor burden) were diminished by 78%, and 45%, respectively. In contrast, BAPN had no effect on the growth of established metastases. Our findings suggest that LOX activity is required during extravasation and/or initial tissue colonization by circulating MDA-MB-231 cells, lending support to the idea that LOX inhibition might be useful in metastasis prevention.			Bondareva, A (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada.	jirik@ucalgary.ca	Boyd, Steven K/E-9595-2010; Hallgrimsson, Benedikt/A-9616-2008	Boyd, Steven K/0000-0002-2930-5997; Hallgrimsson, Benedikt/0000-0002-7192-9103				AMER MH, 1982, J SURG ONCOL, V19, P101, DOI 10.1002/jso.2930190212; Ben Mahdi MH, 2000, IUBMB LIFE, V50, P291, DOI 10.1080/15216540051081038; Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434; Carbajal JM, 1998, BIOCHEM BIOPH RES CO, V249, P461, DOI 10.1006/bbrc.1998.9172; CASEY T, 2008, BREAST CANC RES TREA; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118; Choy A, 1996, BRIT J CANCER, V73, P79, DOI 10.1038/bjc.1996.14; Cowey S, 2007, CLIN EXP METASTAS, V24, P389, DOI 10.1007/s10585-007-9076-8; Crawford NPS, 2008, CLIN EXP METASTAS, V25, P357, DOI 10.1007/s10585-008-9146-6; Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703; Di Donato A, 1997, FEBS LETT, V419, P63, DOI 10.1016/S0014-5793(97)01420-8; Drake JM, 2005, CLIN EXP METASTAS, V22, P674, DOI 10.1007/s10585-006-9011-4; Duffy MJ, 2008, J PATHOL, V214, P283, DOI 10.1002/path.2282; Earley S, 2008, BIOCHEM BIOPH RES CO, V366, P476, DOI 10.1016/j.bbrc.2007.11.181; Erler JT, 2006, CANCER RES, V66, P10238, DOI 10.1158/0008-5472.CAN-06-3197; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Galan M, 2002, ANTICANCER RES, V22, P2877; Giampuzzi M, 2000, J BIOL CHEM, V275, P36341, DOI 10.1074/jbc.M003362200; Giampuzzi M, 2003, BBA-PROTEINS PROTEOM, V1647, P239, DOI 10.1016/S1570-9639(03)00058-X; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hornstra IK, 2003, J BIOL CHEM, V278, P14387, DOI 10.1074/jbc.M210144200; Jenkins DE, 2005, BREAST CANCER RES, V7, pR444, DOI 10.1186/bcr1026; Jenkins DE, 2003, CLIN EXP METASTAS, V20, P733, DOI 10.1023/B:CLIN.0000006815.49932.98; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kevil CG, 2001, AM J PHYSIOL-CELL PH, V281, pC1940, DOI 10.1152/ajpcell.2001.281.6.C1940; Kirschmann DA, 1999, BREAST CANCER RES TR, V55, P127; Kirschmann DA, 2002, CANCER RES, V62, P4478; Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911-005-5399-8; Lazarus HM, 1995, MATRIX BIOL, V14, P727, DOI 10.1016/S0945-053X(05)80015-0; Lee KC, 2007, CLIN CANCER RES, V13, P1839, DOI 10.1158/1078-0432.CCR-06-1657; LEE YTNM, 1983, J SURG ONCOL, V23, P175, DOI 10.1002/jso.2930230311; LEVENE CI, 1989, BRIT J EXP PATHOL, V70, P621; Li WD, 2000, J CELL BIOCHEM, V78, P550, DOI 10.1002/1097-4644(20000915)78:4<550::AID-JCB4>3.3.CO;2-#; Li XM, 2002, CLIN EXP METASTAS, V19, P347, DOI 10.1023/A:1015510207431; Lu X, 2007, J MAMMARY GLAND BIOL, V12, P153, DOI 10.1007/s10911-007-9047-3; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Maki JM, 2002, CIRCULATION, V106, P2503, DOI 10.1161/01.CIR.0000038109.84500.1E; Manders K, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-179; MELLO MLS, 1995, EXP CELL RES, V220, P374, DOI 10.1006/excr.1995.1328; Miles FL, 2008, CLIN EXP METASTAS, V25, P305, DOI 10.1007/s10585-007-9098-2; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Morris VL, 1997, INVAS METAST, V17, P281; Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265; Naumov GN, 1999, J CELL SCI, V112, P1835; Payne SL, 2005, CANCER RES, V65, P11429, DOI 10.1158/0008-5472.CAN-05-1274; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Payne SL, 2006, J CELL BIOCHEM, V98, P827, DOI 10.1002/jcb.20792; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Phadke PA, 2006, CLIN CANCER RES, V12, P1431, DOI 10.1158/1078-0432.CCR-05-1806; Postovit LM, 2008, J CELL BIOCHEM, V103, P1369, DOI 10.1002/jcb.21517; Rodriguez C, 2008, CARDIOVASC RES, V79, P7, DOI 10.1093/cvr/cvn102; Schluter K, 2006, AM J PATHOL, V169, P1064, DOI 10.2353/ajpath.2006.050566; Usatyuk PV, 2005, AM J PHYSIOL-LUNG C, V289, pL999, DOI 10.1152/ajplung.00211.2005; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Wu M, 2007, CELLS TISSUES ORGANS, V185, P100, DOI 10.1159/000101309; Yamauchi K, 2006, CANCER RES, V66, P4208, DOI 10.1158/0008-5472.CAN-05-3927	59	110	115	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5620	10.1371/journal.pone.0005620	http://dx.doi.org/10.1371/journal.pone.0005620			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19440335	gold, Green Submitted, Green Published			2022-12-25	WOS:000266161200020
J	Ahrne, K; Bengtsson, J; Elmqvist, T				Ahrne, Karin; Bengtsson, Jan; Elmqvist, Thomas			Bumble Bees (Bombus spp) along a Gradient of Increasing Urbanization	PLOS ONE			English	Article							FORAGING RANGE; LANDSCAPE CONTEXT; CROP POLLINATION; HYMENOPTERA; CONSERVATION; DECLINES; RARITY; SCALE; COMMUNITIES; CONSTANCY	Background: Bumble bees and other wild bees are important pollinators of wild flowers and several cultivated crop plants, and have declined in diversity and abundance during the last decades. The main cause of the decline is believed to be habitat destruction and fragmentation associated with urbanization and agricultural intensification. Urbanization is a process that involves dramatic and persistent changes of the landscape, increasing the amount of built-up areas while decreasing the amount of green areas. However, urban green areas can also provide suitable alternative habitats for wild bees. Methodology/Principal Findings: We studied bumble bees in allotment gardens, i.e. intensively managed flower rich green areas, along a gradient of urbanization from the inner city of Stockholm towards more rural (periurban) areas. Keeping habitat quality similar along the urbanization gradient allowed us to separate the effect of landscape change (e.g. proportion impervious surface) from variation in habitat quality. Bumble bee diversity (after rarefaction to 25 individuals) decreased with increasing urbanization, from around eight species on sites in more rural areas to between five and six species in urban allotment gardens. Bumble bee abundance and species composition were most affected by qualities related to the management of the allotment areas, such as local flower abundance. The variability in bumble bee visits between allotment gardens was higher in an urban than in a periurban context, particularly among small and long-tongued bumble bee species. Conclusions/Significance: Our results suggest that allotment gardens and other urban green areas can serve as important alternatives to natural habitats for many bumble bee species, but that the surrounding urban landscape influences how many species that will be present. The higher variability in abundance of certain species in the most urban areas may indicate a weaker reliability of the ecosystem service pollination in areas strongly influenced by human activity.			Ahrne, K (corresponding author), Swedish Univ Agr Sci, Dept Ecol, Uppsala, Sweden.	karin.ahrne@ekol.slu.se	Elmqvist, Thomas/AAY-6344-2021; Bengtsson, Jan/AAF-2325-2021	Elmqvist, Thomas/0000-0002-4617-6197; 				Allen-Wardell G, 1998, CONSERV BIOL, V12, P8; Andersson E, 2007, ECOL APPL, V17, P1267, DOI 10.1890/06-1116.1; Benton T., 2006, BUMBLEBEES NATURAL H; Bhattacharya M, 2003, BIOL CONSERV, V109, P37, DOI 10.1016/S0006-3207(02)00130-1; Biesmeijer JC, 2006, SCIENCE, V313, P351, DOI 10.1126/science.1127863; Buchmann SL, 1996, FORGOTTEN POLLINATOR; CANE JH, 2001, CONSERV ECOL, V0005; Carvell C, 2006, BIOL CONSERV, V132, P481, DOI 10.1016/j.biocon.2006.05.008; Chapman RE, 2003, MOL ECOL, V12, P2801, DOI 10.1046/j.1365-294X.2003.01957.x; CORBET SA, 1991, BEE WORLD, V72, P47, DOI 10.1080/0005772X.1991.11099079; Darvill B, 2004, OIKOS, V107, P471, DOI 10.1111/j.0030-1299.2004.13510.x; Dramstad WE, 2003, AGR ECOSYST ENVIRON, V95, P349, DOI 10.1016/S0167-8809(02)00043-9; Fitzpatrick U, 2007, BIOL CONSERV, V136, P185, DOI 10.1016/j.biocon.2006.11.012; FUSSELL M, 1992, J APPL ECOL, V29, P451, DOI 10.2307/2404513; Gathmann A, 2002, J ANIM ECOL, V71, P757, DOI 10.1046/j.1365-2656.2002.00641.x; Gotelli NJ, 2006, ECOSIM NULL MODELS S; Goulson D, 2005, BIOL CONSERV, V122, P1, DOI 10.1016/j.biocon.2004.06.017; Goulson D, 2004, APIDOLOGIE, V35, P55, DOI 10.1051/apido:2003062; GOULSON D, 2003, BUMBLE BEES BEHAV EC; Greenleaf SS, 2007, OECOLOGIA, V153, P589, DOI 10.1007/s00442-007-0752-9; HEINRICH B, 1976, ECOLOGY, V57, P874, DOI 10.2307/1941054; Heinrich B., 1979, BUMBLEBEE EC; Kearns CA, 1998, ANNU REV ECOL SYST, V29, P83, DOI 10.1146/annurev.ecolsys.29.1.83; Kells AR, 2001, J INSECT CONSERV, V5, P283, DOI 10.1023/A:1013307822575; Kells AR, 2003, BIOL CONSERV, V109, P165, DOI 10.1016/S0006-3207(02)00131-3; Kleijn D, 2006, BASIC APPL ECOL, V7, P201, DOI 10.1016/j.baae.2005.07.011; Klein AM, 2007, P ROY SOC B-BIOL SCI, V274, P303, DOI 10.1098/rspb.2006.3721; Knight ME, 2005, MOL ECOL, V14, P1811, DOI 10.1111/j.1365-294X.2005.02540.x; Kremen C, 2004, ECOL LETT, V7, P1109, DOI 10.1111/j.1461-0248.2004.00662.x; Kremen C, 2002, P NATL ACAD SCI USA, V99, P16812, DOI 10.1073/pnas.262413599; Kreyer D, 2004, BIOL CONSERV, V116, P111, DOI 10.1016/S0006-3207(03)00182-4; Lewontin RC, 1966, SYST ZOOL, V15, P141, DOI DOI 10.2307/2411632; LOKEN A, 1973, NORSK ENTOMOL TIDSSK, V20, P1; MAGURRAN A. E., 2004, MEASURING BIOLOGICAL; MANSSON L, 2002, PERENNER DIN TRADGAR; Matteson KC, 2008, ANN ENTOMOL SOC AM, V101, P140, DOI 10.1603/0013-8746(2008)101[140:BRAAIN]2.0.CO;2; McFrederick QS, 2006, BIOL CONSERV, V129, P372, DOI 10.1016/j.biocon.2005.11.004; McIntyre NE, 2001, BASIC APPL ECOL, V2, P209, DOI 10.1078/1439-1791-00051; McKinney ML, 2006, BIOL CONSERV, V127, P247, DOI 10.1016/j.biocon.2005.09.005; Osborne JL, 1999, J APPL ECOL, V36, P519, DOI 10.1046/j.1365-2664.1999.00428.x; Osborne JL, 2001, AGR ECOSYST ENVIRON, V83, P129, DOI 10.1016/S0167-8809(00)00262-0; RANTA E, 1981, OIKOS, V36, P28, DOI 10.2307/3544375; RISBERG J, 2004, THESIS SWEDISH U AGR; Saure Christoph, 1996, Linnean Society Symposium Series, V18, P47; Saville NM, 1997, AGR ECOSYST ENVIRON, V61, P145, DOI 10.1016/S0167-8809(96)01100-0; *SCB, 2006, STAT YB SWED STAT SW; SOKAL RR, 1980, SYST ZOOL, V29, P50, DOI 10.2307/2412626; Steffan-Dewenter I, 2002, ECOLOGY, V83, P1421, DOI 10.1890/0012-9658(2002)083[1421:SDEOLC]2.0.CO;2; Stenberg L., 1992, NORDISKA FLORAN; Svensson B, 2000, AGR ECOSYST ENVIRON, V77, P247, DOI 10.1016/S0167-8809(99)00106-1; Tilman D, 1997, P NATL ACAD SCI USA, V94, P1857, DOI 10.1073/pnas.94.5.1857; Tommasi D, 2004, CAN ENTOMOL, V136, P851; Walther-Hellwig K, 2000, J INSECT BEHAV, V13, P239, DOI 10.1023/A:1007740315207; Westphal C, 2006, OECOLOGIA, V149, P289, DOI 10.1007/s00442-006-0448-6; Williams P, 2005, BIOL CONSERV, V122, P33, DOI 10.1016/j.biocon.2004.06.019; Zanette LRS, 2005, LANDSCAPE URBAN PLAN, V71, P105, DOI 10.1016/j.landurbplan.2004.02.003	56	187	198	5	266	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5574	10.1371/journal.pone.0005574	http://dx.doi.org/10.1371/journal.pone.0005574			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440367	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107400016
J	Chan, LK; Ko, FCF; Ng, IOL; Yam, JWP				Chan, Lo-Kong; Ko, Frankie Chi Fat; Ng, Irene Oi-Lin; Yam, Judy Wai Ping			Deleted in Liver Cancer 1 (DLC1) Utilizes a Novel Binding Site for Tensin2 PTB Domain Interaction and Is Required for Tumor-Suppressive Function	PLOS ONE			English	Article								Background: Deleted in liver cancer 1 (DLC1) is a Rho GTPase-activating protein (RhoGAP) frequently deleted and underexpressed in hepatocellular carcinoma (HCC) as well as in other cancers. Recent independent studies have shown interaction of DLC1 with members of the tensin focal adhesion protein family in a Src Homology 2 (SH2) domain-dependent mechanism. DLC1 and tensins interact and co-localize to punctate structures at focal adhesions. However, the mechanisms underlying the interaction between DLC1 and various tensins remain controversial. Methodology/Principal Findings: We used a co-immunoprecipitation assay to identify a previously undocumented binding site at 375-385 of DLC1 that predominantly interacted with the phosphotyrosine binding (PTB) domain of tensin2. DLC1-tensin2 interaction is completely abolished in a DLC1 mutant lacking this novel PTB binding site (DLC1 Delta PTB). However, as demonstrated by immunofluorescence and co-immunoprecipitation, neither the focal adhesion localization nor the interaction with tensin1 and C-terminal tensin-like (cten) were affected. Interestingly, the functional significance of this novel site was exhibited by the partial reduction of the RhoGAP activity, which, in turn, attenuated the growth-suppressive activity of DLC1 upon its removal from DLC1. Conclusions/Significance: This study has provided new evidence that DLC1 also interacts with tensin2 in a PTB domain-dependent manner. In addition to properly localizing focal adhesions and preserving RhoGAP activity, DLC1 interaction with tensin2 through this novel focal adhesion binding site contributes to the growth-suppressive activity of DLC1.			Chan, LK (corresponding author), Univ Hong Kong, Dept Pathol, Liver Canc & Hepatitis Res Lab, Pokfulam, Hong Kong, Peoples R China.	judyyam@pathology.hku.hk	Kong, Chan Lo/AAI-9300-2020; Ko, Frankie Chi Fat/C-4759-2009; Yam, Judy Wai Ping/C-4454-2009	Kong, Chan Lo/0000-0003-3082-1013; Ko, Frankie Chi Fat/0000-0002-0393-9668; Yam, Judy Wai Ping/0000-0002-5637-121X; Ng, Irene Oi-lin/0000-0001-7532-2029				Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043; Guan M, 2006, CLIN CANCER RES, V12, P1412, DOI 10.1158/1078-0432.CCR-05-1906; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Healy KD, 2008, MOL CARCINOGEN, V47, P326, DOI 10.1002/mc.20389; Hers I, 2006, J BIOL CHEM, V281, P4762, DOI 10.1074/jbc.M511008200; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kamai T, 2003, BJU INT, V91, P234, DOI 10.1046/j.1464-410X.2003.03063.x; Kim TY, 2007, BIOCHEM BIOPH RES CO, V355, P72, DOI 10.1016/j.bbrc.2007.01.121; Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; KIM TY, 2008, J BIOL CHEM; Leung THY, 2005, P NATL ACAD SCI USA, V102, P15207, DOI 10.1073/pnas.0504501102; Liao YC, 2008, CANCER RES, V68, P7718, DOI 10.1158/0008-5472.CAN-08-2042; Liao YC, 2007, J CELL BIOL, V176, P43, DOI 10.1083/jcb.200608015; Lo SH, 2004, INT J BIOCHEM CELL B, V36, P31, DOI 10.1016/S1357-2725(03)00171-7; Ng IOL, 2000, CANCER RES, V60, P6581; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Peng D, 2006, ACTA BIOCH BIOPH SIN, V38, P349, DOI 10.1111/j.1745-7270.2006.00164.x; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qian XL, 2007, P NATL ACAD SCI USA, V104, P9012, DOI 10.1073/pnas.0703033104; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Seng TJ, 2007, ONCOGENE, V26, P934, DOI 10.1038/sj.onc.1209839; Ullmannova V, 2006, INT J ONCOL, V29, P1127; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Wong CM, 2003, CANCER RES, V63, P7646; Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Yam JWP, 2006, CANCER RES, V66, P8367, DOI 10.1158/0008-5472.CAN-05-2850; Yan KS, 2002, FEBS LETT, V513, P67, DOI 10.1016/S0014-5793(01)03305-1; Ying JM, 2007, EPIGENETICS-US, V2, P15, DOI 10.4161/epi.2.1.3883; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X; Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; Zhang Q, 2007, CANCER LETT, V249, P220, DOI 10.1016/j.canlet.2006.08.019; Zhou X, 2008, INT J ONCOL, V32, P1285; Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	43	40	40	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5572	10.1371/journal.pone.0005572	http://dx.doi.org/10.1371/journal.pone.0005572			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440389	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107400015
J	Dong, SM; Qutob, D; Tedman-Jones, J; Kuflu, K; Wang, YC; Tyler, BM; Gijzen, M				Dong, Suomeng; Qutob, Dinah; Tedman-Jones, Jennifer; Kuflu, Kuflom; Wang, Yuanchao; Tyler, Brett M.; Gijzen, Mark			The Phytophthora sojae Avirulence Locus Avr3c Encodes a Multi-Copy RXLR Effector with Sequence Polymorphisms among Pathogen Strains	PLOS ONE			English	Article								Root and stem rot disease of soybean is caused by the oomycete Phytophthora sojae. The avirulence (Avr) genes of P. sojae control race-cultivar compatibility. In this study, we identify the P. sojae Avr3c gene and show that it encodes a predicted RXLR effector protein of 220 amino acids. Sequence and transcriptional data were compared for predicted RXLR effectors occurring in the vicinity of Avr4/6, as genetic linkage of Avr3c and Avr4/6 was previously suggested. Mapping of DNA markers in a F(2) population was performed to determine whether selected RXLR effector genes co-segregate with the Avr3c phenotype. The results pointed to one RXLR candidate gene as likely to encode Avr3c. This was verified by testing selected genes by a co-bombardment assay on soybean plants with Rps3c, thus demonstrating functionality and confirming the identity of Avr3c. The Avr3c gene together with eight other predicted genes are part of a repetitive segment of 33.7 kb. Three near-identical copies of this segment occur in a tandem array. In P. sojae strain P6497, two identical copies of Avr3c occur within the repeated segments whereas the third copy of this RXLR effector has diverged in sequence. The Avr3c gene is expressed during the early stages of infection in all P. sojae strains examined. Virulent alleles of Avr3c that differ in amino acid sequence were identified in other strains of P. sojae. Gain of virulence was acquired through mutation and subsequent sequence exchanges between the two copies of Avr3c. The results illustrate the importance of segmental duplications and RXLR effector evolution in the control of race-cultivar compatibility in the P. sojae and soybean interaction.			Dong, SM (corresponding author), Agr & Agri Food Canada, London, ON, Canada.	mark.gijzen@agr.gc.ca	Gijzen, Mark/C-6284-2011; wang, yuanchao/G-9667-2011	Gijzen, Mark/0000-0002-3715-6389; wang, yuanchao/0000-0001-5803-5343				Allen RL, 2004, SCIENCE, V306, P1957, DOI 10.1126/science.1104022; Armstrong MR, 2005, P NATL ACAD SCI USA, V102, P7766, DOI 10.1073/pnas.0500113102; Bhattacharyya MK, 2005, THEOR APPL GENET, V111, P75, DOI 10.1007/s00122-005-1993-9; Block A, 2008, CURR OPIN PLANT BIOL, V11, P396, DOI 10.1016/j.pbi.2008.06.007; Bos JIB, 2006, PLANT J, V48, P165, DOI 10.1111/j.1365-313X.2006.02866.x; Chisholm ST, 2006, CELL, V124, P803, DOI 10.1016/j.cell.2006.02.008; Dou DL, 2008, PLANT CELL, V20, P1930, DOI 10.1105/tpc.107.056093; Dou DL, 2008, PLANT CELL, V20, P1118, DOI 10.1105/tpc.107.057067; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; Gao H, 2008, BMC PLANT BIOL, V8, DOI 10.1186/1471-2229-8-29; Gijzen M, 1996, CAN J BOT, V74, P800, DOI 10.1139/b96-100; Govers F, 2006, MOL PLANT MICROBE IN, V19, P1295, DOI 10.1094/MPMI-19-1295; Jiang RHY, 2008, P NATL ACAD SCI USA, V105, P4874, DOI 10.1073/pnas.0709303105; Jiang RHY, 2006, GENOME RES, V16, P827, DOI 10.1101/gr.5193806; Jones JDG, 2006, NATURE, V444, P323, DOI 10.1038/nature05286; Kamoun S, 2007, CURR OPIN PLANT BIOL, V10, P358, DOI 10.1016/j.pbi.2007.04.017; MacGregor T, 2002, GENETICS, V160, P949; May KJ, 2002, FUNGAL GENET BIOL, V37, P1, DOI 10.1016/S1087-1845(02)00027-0; Meyers BC, 2003, PLANT CELL, V15, P809, DOI 10.1105/tpc.009308; Moy P, 2004, MOL PLANT MICROBE IN, V17, P1051, DOI 10.1094/MPMI.2004.17.10.1051; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; Qutob D, 2000, PLANT PHYSIOL, V123, P243, DOI 10.1104/pp.123.1.243; Qutob D, 2002, PLANT J, V32, P361, DOI 10.1046/j.1365-313X.2002.01439.x; Qutob D, 2006, PLANT CELL, V18, P3721, DOI 10.1105/tpc.106.044180; Qutob D, 2006, TRENDS MICROBIOL, V14, P470, DOI 10.1016/j.tim.2006.09.004; Qutob D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005066; Rehmany AP, 2005, PLANT CELL, V17, P1839, DOI 10.1105/tpc.105.031807; Shan WX, 2004, MOL PLANT MICROBE IN, V17, P394, DOI 10.1094/MPMI.2004.17.4.394; Torto-Alalibo TA, 2007, MOL PLANT MICROBE IN, V20, P781, DOI 10.1094/MPMI-20-7-0781; TYLER BM, 1995, MOL PLANT MICROBE IN, V8, P515, DOI 10.1094/MPMI-8-0515; Tyler BM, 2006, SCIENCE, V313, P1261, DOI 10.1126/science.1128796; van der Lee T, 2001, GENETICS, V157, P949; van Poppel PMJA, 2008, MOL PLANT MICROBE IN, V21, P1460, DOI 10.1094/MPMI-21-11-1460; Vleeshouwers VGAA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002875; WARD EWB, 1979, PHYTOPATHOLOGY, V69, P951, DOI 10.1094/Phyto-69-951; WHISSON SC, 1994, CURR GENET, V27, P77, DOI 10.1007/BF00326582; Whisson SC, 2004, FUNGAL GENET BIOL, V41, P62, DOI 10.1016/j.fgb.2003.08.007; Whisson SC, 2007, NATURE, V450, P115, DOI 10.1038/nature06203; Win J, 2007, PLANT CELL, V19, P2349, DOI 10.1105/tpc.107.051037	39	75	82	2	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5556	10.1371/journal.pone.0005556	http://dx.doi.org/10.1371/journal.pone.0005556			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440541	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107400002
J	Duan, WR; Gao, L; Wu, X; Hade, EM; Gao, JX; Ding, HM; Barsky, SH; Otterson, GA; Villalona-Calero, MA				Duan, Wenrui; Gao, Li; Wu, Xin; Hade, Erinn M.; Gao, Jian-Xin; Ding, Haiming; Barsky, Sanford H.; Otterson, Gregory A.; Villalona-Calero, Miguel A.			Expression of a Mutant p53 Results in an Age-Related Demographic Shift in Spontaneous Lung Tumor Formation in Transgenic Mice	PLOS ONE			English	Article								Background: Mutations in the P53 gene are among the most common genetic abnormalities in human lung cancer. Codon 273 in the sequence-specific DNA binding domain is one of the most frequently mutated sites. Methodology: To investigate the role of mutant p53 in lung tumorigenesis, a lung specific p53(273H) transgenic mouse model was developed. Rates of lung cancer formation in the transgenic animals and their littermates were evaluated by necropsy studies performed in progressive age cohorts ranging from 4 to 24 months. In order to establish the influence of other common genetic abnormalities in lung tumor formation in the animals, K-Ras gene mutation and p16INK4a (p16) promoter methylation were evaluated in a total of 281 transgenic mice and 189 non-transgenic littermates. Principal Findings: At the age extremes of 4-12 and 22-24 months no differences were observed, with very low prevalence of tumors in animals younger than 12 months, and a relatively high prevalence at age 22 months or older. However, the transgenic mice had a significant higher lung tumor rate than their non-transgenic counterparts during the age of 13-21 months, suggesting an age-related shift in lung tumor formation induced by the lung-specific expression of the human mutant p53. Histopathology suggested a more aggressive nature for the transgenic tumors. Older mice (>13 months) had a significantly higher rate of p16 promoter methylation (17% v 82%). In addition, an age related effect was observed for K-Ras codons 12 or 13 mutations, but not for codon 61 mutations. Conclusions/Significance: These results would suggest that the mutant p53(273H) contributes to an acceleration in the development of spontaneous lung tumors in these mice. Combination with other genetic and epigenetic alterations occurring after the age of 13 months is intimately linked to its oncogenic potential.			Duan, WR (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Coll Med & Publ Hlth, Columbus, OH 43210 USA.	Wenrui.duan@osumc.edu; miguel.villalona@osumc.edu	Wu, Xin/B-2244-2010	duan, wenrui/0000-0001-6512-7350; Hade, Erinn/0000-0001-8977-6443	NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016058, CA76970, P30CA16058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberg AJ, 2005, J CLIN ONCOL, V23, P3175, DOI 10.1200/JCO.2005.10.462; Albor A, 1998, CANCER RES, V58, P2091; Anders CK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001373; Atwal GS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001951; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Busuttil R, 2007, NEUROSCIENCE, V145, P1341, DOI 10.1016/j.neuroscience.2006.09.060; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; DAMICO D, 1992, ONCOGENE, V7, P339; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Duan W, 2002, BIOTECHNIQUES, V33, P58, DOI 10.2144/02331st02; Duan WR, 2008, TRANSGENIC RES, V17, P355, DOI 10.1007/s11248-007-9154-3; Duan WR, 2004, JNCI-J NATL CANCER I, V96, P1718, DOI 10.1093/jnci/djh292; Duan WR, 2002, ONCOGENE, V21, P7831, DOI 10.1038/sj.onc.1205909; El-Hizawi S, 2002, CANCER RES, V62, P3264; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Hernandez-Boussard TM, 1998, ENVIRON HEALTH PERSP, V106, P385, DOI 10.2307/3434065; HOLM S, 1979, SCAND J STAT, V6, P65; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Kawamura M, 1996, ONCOGENE, V12, P2361; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651; Le Calvez F, 2005, CANCER RES, V65, P5076, DOI 10.1158/0008-5472.CAN-05-0551; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Liu Y, 2003, CARCINOGENESIS, V24, P1897, DOI 10.1093/carcin/bgg169; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; MAZARS R, 1992, CANCER RES, V52, P3918; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Ozols RF, 2007, J CLIN ONCOL, V25, P146, DOI 10.1200/JCO.2006.09.7030; PARK DJ, 1994, ONCOGENE, V9, P1899; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; RODENHUIS S, 1988, CANCER RES, V48, P5738; Sankoh AJ, 1997, STAT MED, V16, P2529, DOI 10.1002/(SICI)1097-0258(19971130)16:22<2529::AID-SIM692>3.0.CO;2-J; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sigal A, 2000, CANCER RES, V60, P6788; StataCorp L, 2007, STAT DAT AN STAT SOF; Takahashi T, 2002, ONCOGENE, V21, P6868, DOI 10.1038/sj.onc.1205830; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Wang YA, 2005, ONCOGENE, V24, P3042, DOI 10.1038/sj.onc.1208390; Wijnhoven SWP, 2007, CANCER RES, V67, P4648, DOI 10.1158/0008-5472.CAN-06-4681; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; ZHANG W, 1993, ONCOGENE, V8, P2555	67	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5563	10.1371/journal.pone.0005563	http://dx.doi.org/10.1371/journal.pone.0005563			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440353	Green Published, gold, Green Submitted			2022-12-25	WOS:000266107400007
J	Teran, E; Branscomb, AD; Seeling, JM				Teran, Evelyn; Branscomb, Aron D.; Seeling, Joni M.			Dpr Acts as a Molecular Switch, Inhibiting Wnt Signaling when Unphosphorylated, but Promoting Wnt Signaling when Phosphorylated by Casein Kinase I delta/epsilon	PLOS ONE			English	Article								The Wnt pathway is a key regulator of development and tumorigenesis. Dpr (Dact/Frodo) influences Wnt signaling in part through the interaction of its PDZ-B domain with Dsh's PDZ domain. Studies have shown that XDpr1a and its close relative, Frodo, are involved in multiple steps of the Wnt pathway in either inhibitory or activating roles. We found that XDpr1a is phosphorylated by casein kinase I delta/epsilon (CK1 delta/epsilon), an activator of Wnt signaling, in the presence of XDsh. Abrogating XDpr1a's ability to bind XDsh through mutation of XDpr1a's PDZ-B domain blocks CK1 delta/epsilon's phosphorylation of XDpr1a. Conversely, XDsh possessing a mutation in its PDZ domain that is unable to bind XDpr1a does not promote XDpr1a phosphorylation. Phosphorylation of XDpr1a and XDsh by CKI delta/epsilon decreases their interaction. Moreover, the phosphorylation of XDpr1a by CKI delta/epsilon not only abrogates XDpr1a's promotion of beta-catenin degradation but blocks beta-catenin degradation. Our data suggest that XDpr1a phosphorylation by CKI delta/epsilon is dependent on the interaction of XDpr1a's PDZ-B domain with XDsh's PDZ domain, and that the phosphorylation state of XDpr1a determines whether it inhibits or activates Wnt signaling.			Seeling, JM (corresponding author), CUNY, Queens Coll, Dept Biol, Flushing, NY USA.	joni.seeling@qc.cuny.edu			NCI NIH HHS [R15 CA127974, R15CA127974] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R15CA127974] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arce C, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000098; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5; Cong F, 2004, MOL CELL BIOL, V24, P2000, DOI 10.1128/MCB.24.5.2000-2011.2004; GAO X, 2008, J BIOL CHEM; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Gloy J, 2002, NAT CELL BIOL, V4, P351, DOI 10.1038/ncb784; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hendriksen J, 2008, J CELL SCI, V121, P1793, DOI 10.1242/jcs.025536; Hikasa H, 2004, DEVELOPMENT, V131, P4725, DOI 10.1242/dev.01369; Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; Price MA, 2006, GENE DEV, V20, P399, DOI 10.1101/gad.1394306; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Schwarz-Romond T, 2007, J CELL SCI, V120, P2402, DOI 10.1242/jcs.002956; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Waxman JS, 2004, DEVELOPMENT, V131, P5909, DOI 10.1242/dev.01520; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yau TO, 2005, ONCOGENE, V24, P1607, DOI 10.1038/sj.onc.1208340; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zhang L, 2006, J BIOL CHEM, V281, P8607, DOI 10.1074/jbc.M600274200; Zhang L, 2006, DEV BIOL, V299, P221, DOI 10.1016/j.ydbio.2006.07.025	30	24	26	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5522	10.1371/journal.pone.0005522	http://dx.doi.org/10.1371/journal.pone.0005522			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440376	Green Published, gold			2022-12-25	WOS:000266107400001
J	Le Verche, V; Kaindl, AM; Verney, C; Csaba, Z; Peineau, S; Olivier, P; Adle-Biassette, H; Leterrier, C; Vitalis, T; Renaud, J; Dargent, B; Gressens, P; Dournaud, P				Le Verche, Virginia; Kaindl, Angela M.; Verney, Catherine; Csaba, Zsolt; Peineau, Stephane; Olivier, Paul; Adle-Biassette, Homa; Leterrier, Christophe; Vitalis, Tania; Renaud, Julie; Dargent, Benedicte; Gressens, Pierre; Dournaud, Pascal			The Somatostatin 2A Receptor Is Enriched in Migrating Neurons during Rat and Human Brain Development and Stimulates Migration and Axonal Outgrowth	PLOS ONE			English	Article								The neuropeptide somatostatin has been suggested to play an important role during neuronal development in addition to its established modulatory impact on neuroendocrine, motor and cognitive functions in adults. Although six somatostatin G protein-coupled receptors have been discovered, little is known about their distribution and function in the developing mammalian brain. In this study, we have first characterized the developmental expression of the somatostatin receptor sst2A, the subtype found most prominently in the adult rat and human nervous system. In the rat, the sst2A receptor expression appears as early as E12 and is restricted to post-mitotic neuronal populations leaving the ventricular zone. From E12 on, migrating neuronal populations immunopositive for the receptor were observed in numerous developing regions including the cerebral cortex, hippocampus and ganglionic eminences. Intense but transient immunoreactive signals were detected in the deep part of the external granular layer of the cerebellum, the rostral migratory stream and in tyrosine hydroxylase- and serotonin-positive neurons and axons. Activation of the sst2A receptor in vitro in rat cerebellar microexplants and primary hippocampal neurons revealed stimulatory effects on neuronal migration and axonal growth, respectively. In the human cortex, receptor immunoreactivity was located in the preplate at early development stages (8 gestational weeks) and was enriched to the outer part of the germinal zone at later stages. In the cerebellum, the deep part of the external granular layer was strongly immunoreactive at 19 gestational weeks, similar to the finding in rodents. In addition, migrating granule cells in the internal granular layer were also receptor-positive. Together, theses results strongly suggest that the somatostatin sst2A receptor participates in the development and maturation of specific neuronal populations during rat and human brain ontogenesis.			Le Verche, V (corresponding author), INSERM, U676, Unite Mixte Rech, Paris, France.	pascal.dournaud@inserm.fr	Adle-Biassette, Homa/AAG-2751-2019; De Granzial, Nadine-Tania Vitalis/K-8485-2017; Leterrier, Christophe/G-6975-2011; gressens, pierre/M-7557-2017	De Granzial, Nadine-Tania Vitalis/0000-0002-5531-3771; Leterrier, Christophe/0000-0002-2957-2032; gressens, pierre/0000-0002-0909-4221; Peineau, Stephane/0000-0002-4721-6795; Csaba, Zsolt/0000-0002-3392-2605; Kaindl, Angela/0000-0001-9454-206X	Medical Research Council Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alderton F, 1998, BRIT J PHARMACOL, V125, P1630, DOI 10.1038/sj.bjp.0702282; Bassant MH, 2005, J NEUROSCI, V25, P2032, DOI 10.1523/JNEUROSCI.4619-04.2005; Batista-Brito R, 2008, CEREB CORTEX, V18, P2306, DOI 10.1093/cercor/bhm258; BODENANT C, 1991, NEUROSCIENCE, V41, P595, DOI 10.1016/0306-4522(91)90352-O; Bystron I, 2008, NAT REV NEUROSCI, V9, P110, DOI 10.1038/nrn2252; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Charrier C, 2006, NEUROSCIENCE, V138, P5, DOI 10.1016/j.neuroscience.2005.10.046; Coskun V, 2002, J NEUROSCI RES, V69, P795, DOI 10.1002/jnr.10336; Csaba Z, 2005, J NEUROPATH EXP NEUR, V64, P956, DOI 10.1097/01.jnen.0000186923.50215.50; Csaba Z, 2004, EUR J NEUROSCI, V19, P2531, DOI 10.1111/j.0953-816X.2004.03361.x; Csaba Z, 2003, ENDOCRINOLOGY, V144, P1564, DOI 10.1210/en.2002-221090; Csaba Z, 2002, J COMP NEUROL, V454, P192, DOI 10.1002/cne.10430; Csaba Z, 2001, MOL CELL NEUROSCI, V17, P646, DOI 10.1006/mcne.2000.0958; Csaba Z, 2001, NEUROPEPTIDES, V35, P1, DOI 10.1054/npep.2001.0848; Csaba Z, 2007, TRAFFIC, V8, P820, DOI 10.1111/j.1600-0854.2007.00580.x; DAIKOKU S, 1983, CELL TISSUE RES, V233, P347; de Lecea L, 2006, NAT CLIN PRACT ENDOC, V2, P356, DOI 10.1038/ncpendmet0219; deLecea L, 1997, J NEUROSCI, V17, P5868; EADIE LA, 1987, J NEUROCYTOL, V16, P445, DOI 10.1007/BF01668499; Englund C, 2006, J NEUROSCI, V26, P9184, DOI 10.1523/JNEUROSCI.1610-06.2006; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Falluel-Morel A, 2005, P NATL ACAD SCI USA, V102, P2637, DOI 10.1073/pnas.0409681102; Garrido JJ, 2003, SCIENCE, V300, P2091, DOI 10.1126/science.1085167; Garrido JJ, 2001, EMBO J, V20, P5950, DOI 10.1093/emboj/20.21.5950; GONZALEZ BJ, 1988, DEV BRAIN RES, V40, P154, DOI 10.1016/0165-3806(88)90018-1; GONZALEZ BJ, 1991, J COMP NEUROL, V305, P177, DOI 10.1002/cne.903050202; GONZALEZ BJ, 1990, J NEUROCHEM, V55, P729, DOI 10.1111/j.1471-4159.1990.tb04552.x; GONZALEZ BJ, 1989, NEUROSCIENCE, V29, P629, DOI 10.1016/0306-4522(89)90136-X; Goodyer CG, 2004, NEUROSCIENCE, V125, P441, DOI 10.1016/j.neuroscience.2004.02.001; GOSLIN K, 1989, J CELL BIOL, V108, P1507, DOI 10.1083/jcb.108.4.1507; Gutierrez-Mecinas M, 2005, EUR J NEUROSCI, V22, P1357, DOI 10.1111/j.1460-9568.2005.04328.x; Hansel DE, 2001, NATURE, V410, P940, DOI 10.1038/35073601; Helboe L, 1997, MOL BRAIN RES, V49, P82, DOI 10.1016/S0169-328X(97)00127-7; INAGAKI S, 1982, DEV BRAIN RES, V3, P509, DOI 10.1016/0165-3806(82)90051-7; Kalinichenko S G, 2005, Neurosci Behav Physiol, V35, P21, DOI 10.1023/B:NEAB.0000049648.20702.ad; Kerjan G, 2005, NAT NEUROSCI, V8, P1516, DOI 10.1038/nn1555; Kramer D, 2005, J NEUROCHEM, V94, P1374, DOI 10.1111/j.1471-4159.2005.03285.x; KUBBUTAT MHG, 1994, J CLIN PATHOL, V47, P524, DOI 10.1136/jcp.47.6.524; Lelouvier B, 2008, J NEUROSCI, V28, P4336, DOI 10.1523/JNEUROSCI.4379-07.2008; MACMILLAN FM, 1986, NEUROHISTOCHEMISTRY, P49; Marin O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058; Marin O, 2001, NAT REV NEUROSCI, V2, P780, DOI 10.1038/35097509; MAUBERT E, 1994, NEUROSCIENCE, V62, P317, DOI 10.1016/0306-4522(94)90335-2; MCDONALD JK, 1982, J NEUROCYTOL, V11, P809, DOI 10.1007/BF01153520; Monier A, 2007, J NEUROPATH EXP NEUR, V66, P372, DOI 10.1097/nen.0b013e3180517b46; Mor-Vaknin N, 2006, MOL CELL BIOL, V26, P9484, DOI 10.1128/MCB.01030-06; Mozzetti S, 2005, CLIN CANCER RES, V11, P298; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; NAGATA I, 1990, DEV BRAIN RES, V52, P63, DOI 10.1016/0165-3806(90)90222-K; Olias G, 2004, J NEUROCHEM, V89, P1057, DOI 10.1111/j.1471-4159.2004.02402.x; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; Pujol F, 2005, J CELL SCI, V118, P1071, DOI 10.1242/jcs.01694; Pyronnet S, 2008, MOL CELL ENDOCRINOL, V286, P230, DOI 10.1016/j.mce.2008.02.002; Rauca C, 1999, N-S ARCH PHARMACOL, V360, P633, DOI 10.1007/s002109900136; Renaud J, 2008, NAT NEUROSCI, V11, P440, DOI 10.1038/nn2064; Saito T, 2005, NAT MED, V11, P434, DOI 10.1038/nm1206; Salmaso N, 2006, HORM BEHAV, V50, P448, DOI 10.1016/j.yhbeh.2006.05.006; Sanchez-Gonzalez MA, 2005, J NEUROSCI, V25, P6076, DOI 10.1523/JNEUROSCI.0968-05.2005; Schindler M, 1998, BRIT J PHARMACOL, V125, P209, DOI 10.1038/sj.bjp.0702064; Schindler M, 1998, NEUROREPORT, V9, P521, DOI 10.1097/00001756-199802160-00027; Schwaller B, 1999, J NEUROSCI METH, V92, P137, DOI 10.1016/S0165-0270(99)00106-5; SHIOSAKA S, 1981, J COMP NEUROL, V203, P173, DOI 10.1002/cne.902030203; SHIOSAKA S, 1982, J COMP NEUROL, V204, P211, DOI 10.1002/cne.902040302; Stanic D, 2009, BRAIN RES, V1249, P101, DOI 10.1016/j.brainres.2008.10.024; Stewart R, 2003, STEM CELLS, V21, P248, DOI 10.1634/stemcells.21-3-248; Stumm RK, 2004, J NEUROSCI, V24, P11404, DOI 10.1523/JNEUROSCI.3834-04.2004; Susini C, 2006, ANN ONCOL, V17, P1733, DOI 10.1093/annonc/mdl105; TSALIKIAN E, 1984, PEDIATR RES, V18, P953, DOI 10.1203/00006450-198418100-00009; Varea E, 2005, NEUROSCIENCE, V136, P435, DOI 10.1016/j.neuroscience.2005.08.009; Varea E, 2007, J CHEM NEUROANAT, V33, P202, DOI 10.1016/j.jchemneu.2007.03.006; Vezzani A, 1999, EUR J NEUROSCI, V11, P3767, DOI 10.1046/j.1460-9568.1999.00838.x; Viollet C, 2008, MOL CELL ENDOCRINOL, V286, P75, DOI 10.1016/j.mce.2007.09.007; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Wong CH, 2005, ENDOCRINOLOGY, V146, P1192, DOI 10.1210/en.2004-1275; Yacubova E, 2002, NATURE, V415, P77, DOI 10.1038/415077a; ZECEVIC N, 1995, J COMP NEUROL, V351, P509, DOI 10.1002/cne.903510404	76	24	27	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2009	4	5							e5509	10.1371/journal.pone.0005509	http://dx.doi.org/10.1371/journal.pone.0005509			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444VZ	19434240	Green Published, gold			2022-12-25	WOS:000266009800007
J	Wang, H; Chumnarnsilpa, S; Loonchanta, A; Li, Q; Kuan, YM; Robine, S; Larsson, M; Mihalek, I; Burtnick, LD; Robinson, RC				Wang, Hui; Chumnarnsilpa, Sakesit; Loonchanta, Anantasak; Li, Qiang; Kuan, Yang-Mei; Robine, Sylvie; Larsson, Marten; Mihalek, Ivana; Burtnick, Leslie D.; Robinson, Robert C.			Helix Straightening as an Activation Mechanism in the Gelsolin Superfamily of Actin Regulatory Proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; BINDING PROTEINS; TERMINAL HALF; CALCIUM; VILLIN; HEADPIECE; SITES; DOMAINS	Villin and gelsolin consist of six homologous domains of the gelsolin/cofilin fold (V1-V6 and G1-G6, respectively). Villin differs from gelsolin in possessing at its C terminus an unrelated seventh domain, the villin headpiece. Here, we present the crystal structure of villin domain V6 in an environment in which intact villin would be inactive, in the absence of bound Ca2+ or phosphorylation. The structure of V6 more closely resembles that of the activated form of G6, which contains one bound Ca2+, rather than that of the calcium ion-free form of G6 within intact inactive gelsolin. Strikingly apparent is that the long helix in V6 is straight, as found in the activated form of G6, as opposed to the kinked version in inactive gelsolin. Molecular dynamics calculations suggest that the preferable conformation for this helix in the isolated G6 domain is also straight in the absence of Ca2+ and other gelsolin domains. However, the G6 helix bends in intact calcium ion-free gelsolin to allow interaction with G2 and G4. We suggest that a similar situation exists in villin. Within the intact protein, a bent V6 helix, when triggered by Ca2+, straightens and helps push apart adjacent domains to expose actin-binding sites within the protein. The sixth domain in this superfamily of proteins serves as a keystone that locks together a compact ensemble of domains in an inactive state. Perturbing the keystone initiates reorganization of the structure to reveal previously buried actin-binding sites.	[Burtnick, Leslie D.] Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; [Burtnick, Leslie D.] Univ British Columbia, Ctr Blood Res, Vancouver, BC V6T 1Z1, Canada; [Chumnarnsilpa, Sakesit; Kuan, Yang-Mei; Larsson, Marten; Robinson, Robert C.] ASTAR, Inst Mol & Cell Biol, Singapore 138673, Singapore; [Chumnarnsilpa, Sakesit] Uppsala Univ, Inst Med Biokemioch Mikrobiol, S-75123 Uppsala, Sweden; [Li, Qiang; Mihalek, Ivana] ASTAR, Bioinformat Inst, Singapore 138671, Singapore; [Robine, Sylvie] Inst Curie, UMR 144, F-75248 Paris 05, France	University of British Columbia; University of British Columbia; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Uppsala University; Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Burtnick, LD (corresponding author), Univ British Columbia, Dept Chem, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.	burtnick@chem.ubc.ca	Larsson, Marten/A-5992-2012; Wang, Hui/C-4051-2012; Robinson, Robert/G-9702-2011	Robinson, Robert/0000-0001-6367-6903; Loonchanta, Tackey A./0000-0001-7098-5376; Larsson, Marten/0000-0002-7855-9539	Heart and Stroke Foundation of British Columbia and Yukon; Biomedical Research Council; University of British Columbia Centre for Blood Research X-ray Crystallography; Canada Foundation for Innovation; Michael Smith Foundation for Health Research; Howard Hughes Medical Institute; Canadian Institutes of Health Research; National Synchrotron Radiation Research Center, Taiwan, China; National Science Council of Taiwan; Taiwan National Research Program for Genomic Medicine	Heart and Stroke Foundation of British Columbia and Yukon; Biomedical Research Council(Agency for Science Technology & Research (A*STAR)); University of British Columbia Centre for Blood Research X-ray Crystallography; Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Synchrotron Radiation Research Center, Taiwan, China; National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Taiwan National Research Program for Genomic Medicine(Ministry of Science and Technology, Taiwan)	This work was supported in part by a grant-in-aid from the Heart and Stroke Foundation of British Columbia and Yukon (to L. D. B.) and the Biomedical Research Council of A*STAR (to R. C. R. and I. M.). Funding for the University of British Columbia Centre for Blood Research X-ray Crystallography Hub is provided in part by grants from the Canada Foundation for Innovation, the Michael Smith Foundation for Health Research, the Howard Hughes Medical Institute, and the Canadian Institutes of Health Research. Portions of this research were carried out at the National Synchrotron Radiation Research Center, Taiwan, China, supported by the National Science Council of Taiwan. The Synchrotron Radiation Protein Crystallography Facility is supported by the Taiwan National Research Program for Genomic Medicine.	BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Burtnick LD, 2004, EMBO J, V23, P2713, DOI 10.1038/sj.emboj.7600280; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; Choe H, 2002, J MOL BIOL, V324, P691, DOI 10.1016/S0022-2836(02)01131-2; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; FINIDORI J, 1992, J CELL BIOL, V116, P1145, DOI 10.1083/jcb.116.5.1145; George SP, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M703617200; HESTERBERG LK, 1983, J BIOL CHEM, V258, P365; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; Khurana S, 2008, FEBS LETT, V582, P2128, DOI 10.1016/j.febslet.2008.02.040; Kolappan SL, 2003, J MOL BIOL, V329, P85, DOI 10.1016/S0022-2836(03)00383-8; Kumar N, 2004, J BIOL CHEM, V279, P45036, DOI 10.1074/jbc.M405424200; Kumar N, 2004, J BIOL CHEM, V279, P24915, DOI 10.1074/jbc.C400110200; Markus MA, 1997, PROTEIN SCI, V6, P1197; McGough AM, 2003, FEBS LETT, V552, P75, DOI 10.1016/S0014-5793(03)00932-3; Meng JM, 2005, BIOCHEMISTRY-US, V44, P11963, DOI 10.1021/bi050850x; Narayan K, 2003, FEBS LETT, V552, P82, DOI 10.1016/S0014-5793(03)00933-5; NORTHROP J, 1986, J BIOL CHEM, V261, P9274; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Robinson RC, 1999, SCIENCE, V286, P1939, DOI 10.1126/science.286.5446.1939; Smirnov SL, 2007, BIOCHEMISTRY-US, V46, P7488, DOI 10.1021/bi700110v; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Vardar D, 1999, J MOL BIOL, V294, P1299, DOI 10.1006/jmbi.1999.3321	23	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	2009	284	32					21265	21269		10.1074/jbc.M109.019760	http://dx.doi.org/10.1074/jbc.M109.019760			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478CC	19491107	hybrid, Green Published			2022-12-25	WOS:000268564400020
J	Mori, S; Chang, JT; Andrechek, ER; Matsumura, N; Baba, T; Yao, G; Kim, JW; Gatza, M; Murphy, S; Nevins, JR				Mori, S.; Chang, J. T.; Andrechek, E. R.; Matsumura, N.; Baba, T.; Yao, G.; Kim, J. W.; Gatza, M.; Murphy, S.; Nevins, J. R.			Anchorage-independent cell growth signature identifies tumors with metastatic potential	ONCOGENE			English	Article						anchorage-independent cell growth; phenotype; expression signature; metastatic potential; heterogeneity	WIDE EXPRESSION PROFILES; BREAST-CANCER CELLS; SUBCELLULAR-LOCALIZATION; GENES; CARCINOMA; METABOLISM; LINES; TRANSCRIPTION; ENRICHMENT; INCREASES	The oncogenic phenotype is complex, resulting from the accumulation of multiple somatic mutations that lead to the deregulation of growth regulatory and cell fate controlling activities and pathways. The ability to dissect this complexity, so as to reveal discrete aspects of the biology underlying the oncogenic phenotype, is critical to understanding the various mechanisms of disease as well as to reveal opportunities for novel therapeutic strategies. Previous work has characterized the process of anchorage-independent growth of cancer cells in vitro as a key aspect of the tumor phenotype, particularly with respect to metastatic potential. Nevertheless, it remains a major challenge to translate these cell biology findings into the context of human tumors. We previously used DNA microarray assays to develop expression signatures, which have the capacity to identify subtle distinctions in biological states and can be used to connect in vitro and in vivo states. Here we describe the development of a signature of anchorage-independent growth, show that the signature exhibits characteristics of deregulated mitochondrial function and then demonstrate that the signature identifies human tumors with the potential for metastasis. Oncogene ( 2009) 28, 2796-2805; doi:10.1038/onc.2009.139; published online 1 June 2009	[Mori, S.; Chang, J. T.; Andrechek, E. R.; Matsumura, N.; Baba, T.; Yao, G.; Kim, J. W.; Gatza, M.; Murphy, S.; Nevins, J. R.] Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, Durham, NC 27708 USA; [Matsumura, N.; Baba, T.; Murphy, S.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Durham, NC 27708 USA; [Matsumura, N.; Baba, T.] Kyoto Univ, Dept Gynecol & Obstet, Kyoto, Japan	Duke University; Duke University; Kyoto University	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, 2123 CIEMAS, Durham, NC 27708 USA.	j.nevins@duke.edu	Murphy, Susan/R-3903-2019	Murphy, Susan/0000-0001-8298-7272; Gatza, Michael/0000-0001-6796-7791; Andrechek, Eran/0000-0002-8680-3423; , Guang/0000-0003-0167-777X; Matsumura, Noriomi/0000-0002-4512-7975; BABA, Tsukasa/0000-0003-0066-3747	NIH/NCI [5U54CA-112952-05]; Uehara Memorial Foundation; NATIONAL CANCER INSTITUTE [U54CA112952] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R00LM009837] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Uehara Memorial Foundation(Uehara Memorial Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We thank Drs J-T Chi, T Hallstrom, L Kong, R Rempel, J Freedman, M Gatza, Dr B Balakumaran, H Dressman, Y Yokota, S Akiyama, T Inoue, M Oshimura, M Araki, H Saya, Aburatani, A Niida, K Araki, Y Taya and Y Ito for helpful discussions; A Bild, T Kitamura, M Eilers and H Hanafusa for providing materials; L Jakoi for help with experiments; and T Henry and K Culler for assistance with the preparation of the article. This work was supported by a grant (5U54CA-112952-05) from the NIH/NCI to JRN. SM was a research fellow of the Uehara Memorial Foundation	Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483; Chen EI, 2007, CANCER RES, V67, P1472, DOI 10.1158/0008-5472.CAN-06-3137; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140-6736(07)60781-8; Edelman E, 2006, BIOINFORMATICS, V22, pE108, DOI 10.1093/bioinformatics/btl231; Funes JM, 2007, P NATL ACAD SCI USA, V104, P6223, DOI 10.1073/pnas.0700690104; Giangrande PH, 2004, GENE DEV, V18, P2941, DOI 10.1101/gad.1239304; Guda C, 2005, BIOINFORMATICS, V21, P3963, DOI 10.1093/bioinformatics/bti650; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; JOHNS ME, 1983, CANCER, V52, P1401, DOI 10.1002/1097-0142(19831015)52:8<1401::AID-CNCR2820520811>3.0.CO;2-7; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kang D, 2005, ANN NY ACAD SCI, V1042, P101, DOI 10.1196/annals.1338.010; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; MATTOX DE, 1980, AM J SURG, V140, P527, DOI 10.1016/0002-9610(80)90205-6; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; Nevins JR, 2007, NAT REV GENET, V8, P601, DOI 10.1038/nrg2137; NICOLSON GL, 1988, CANCER RES, V48, P399; NOMURA Y, 1989, CANCER RES, V49, P5288; PRICE JE, 1986, J NATL CANCER I, V77, P529; Samuels Y, 2006, CURR OPIN ONCOL, V18, P77, DOI 10.1097/01.cco.0000198021.99347.b9; Scott MS, 2004, GENOME RES, V14, P1957, DOI 10.1101/gr.2650004; SHAFIE SM, 1980, CANCER LETT, V11, P81, DOI 10.1016/0304-3835(80)90097-X; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; SUTHERLAND CM, 1983, SURGERY, V94, P370; Telang S, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-77; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tong XM, 2009, CURR OPIN GENET DEV, V19, P32, DOI 10.1016/j.gde.2009.01.002; VANSLOOTEN HJ, 1995, BRIT J CANCER, V72, P22, DOI 10.1038/bjc.1995.271; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WARBURG O, 1956, SCIENCE, V124, P269; Weinberg RA, 2007, BIOL CANC; Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100; ZHANG RD, 1991, INVAS METAST, V11, P204; Zu XL, 2004, BIOCHEM BIOPH RES CO, V313, P459, DOI 10.1016/j.bbrc.2003.11.136	43	219	222	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28	31					2796	2805		10.1038/onc.2009.139	http://dx.doi.org/10.1038/onc.2009.139			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479TS	19483725	Green Accepted			2022-12-25	WOS:000268684400003
J	Chan-Schaminet, KY; Baniwal, SK; Bublak, D; Nover, L; Scharf, KD				Chan-Schaminet, Kwan Yu; Baniwal, Sanjeev K.; Bublak, Daniela; Nover, Lutz; Scharf, Klaus-Dieter			Specific Interaction between Tomato HsfA1 and HsfA2 Creates Hetero-oligomeric Superactivator Complexes for Synergistic Activation of Heat Stress Gene Expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK TRANSCRIPTION FACTORS; DNA-BINDING DOMAIN; INTRACELLULAR-DISTRIBUTION; MOLECULAR CHAPERONES; NUCLEAR IMPORT; ARABIDOPSIS; THERMOTOLERANCE; IDENTIFICATION; TRIMERIZATION; ACCLIMATION	In plants, a family of more than 20 heat stress transcription factors (Hsf) controls the expression of heat stress (hs) genes. There is increasing evidence for the functional diversification between individual members of the Hsf family fulfilling distinct roles in response to various environmental stress conditions and developmental signals. In response to hs, accumulation of both heat stress proteins (Hsp) and Hsfs is induced. In tomato, the physical interaction between the constitutively expressed HsfA1 and the hs-inducible HsfA2 results in synergistic transcriptional activation (superactivation) of hs gene expression. Here, we show that the interaction is strikingly specific and not observed with other class A Hsfs. Hetero-oligomerization of the two-component Hsfs is preferred to homo-oligomerization, and each Hsf in the HsfA1/HsfA2 hetero-oligomeric complex has its characteristic contribution to its function as superactivator. Distinct regions of the oligomerization domain are responsible for specific homo-and hetero-oligomeric interactions leading to the formation of hexameric complexes. The results are summarized in a model of assembly and function of HsfA1/A2 superactivator complexes in hs gene regulation.	[Chan-Schaminet, Kwan Yu; Baniwal, Sanjeev K.; Bublak, Daniela; Nover, Lutz; Scharf, Klaus-Dieter] Goethe Univ Frankfurt, Dept Mol Cell Biol, D-60438 Frankfurt, Germany	Goethe University Frankfurt	Scharf, KD (corresponding author), Goethe Univ Frankfurt, Dept Mol Cell Biol, Max von Laue Str 9-N200-R3-05, D-60438 Frankfurt, Germany.	scharf@bio.uni-frankfurt.de			Deutsche Forschungsgemeinschaft [249/4, Scha 577/6]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by the Deutsche Forschungsgemeinschaft (to L.N. (No 249/4) and K. D. S. (Scha 577/6)).	Akerfelt M, 2007, ANN NY ACAD SCI, V1113, P15, DOI 10.1196/annals.1391.005; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Baniwal SK, 2007, J BIOL CHEM, V282, P3605, DOI 10.1074/jbc.M609545200; Baniwal SK, 2004, J BIOSCIENCES, V29, P471, DOI 10.1007/BF02712120; Bharti K, 2000, PLANT J, V22, P355, DOI 10.1046/j.1365-313x.2000.00746.x; Bharti K, 2004, PLANT CELL, V16, P1521, DOI 10.1105/tpc.019927; Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014; Charng YY, 2007, PLANT PHYSIOL, V143, P251, DOI 10.1104/pp.106.091322; Chen TX, 2002, P NATL ACAD SCI USA, V99, P1200, DOI 10.1073/pnas.032681299; DAMBERGER FF, 1995, J MOL BIOL, V254, P704, DOI 10.1006/jmbi.1995.0649; Doring P, 2000, PLANT CELL, V12, P265, DOI 10.1105/tpc.12.2.265; Han JH, 2007, NAT REV MOL CELL BIO, V8, P319, DOI 10.1038/nrm2144; Heerklotz D, 2001, MOL CELL BIOL, V21, P1759, DOI 10.1128/MCB.21.5.1759-1768.2001; Horwich AL, 2007, ANNU REV CELL DEV BI, V23, P115, DOI 10.1146/annurev.cellbio.23.090506.123555; Kim BH, 2002, J EXP BOT, V53, P371, DOI 10.1093/jexbot/53.367.371; Kotak S, 2004, PLANT J, V39, P98, DOI 10.1111/j.1365-313X.2004.02111.x; Kotak S, 2007, CURR OPIN PLANT BIOL, V10, P310, DOI 10.1016/j.pbi.2007.04.011; Larkindale J, 2008, PLANT PHYSIOL, V146, P748, DOI 10.1104/pp.107.112060; Liu PCC, 1999, J BIOL CHEM, V274, P17219, DOI 10.1074/jbc.274.24.17219; Lohmann C, 2004, MOL GENET GENOMICS, V271, P11, DOI 10.1007/s00438-003-0954-8; Lyck R, 1997, PLANTA, V202, P117, DOI 10.1007/s004250050110; Millar AH, 2006, CURR OPIN PLANT BIOL, V9, P610, DOI 10.1016/j.pbi.2006.09.002; Miller G, 2006, ANN BOT-LONDON, V98, P279, DOI 10.1093/aob/mcl107; Mishra SK, 2002, GENE DEV, V16, P1555, DOI 10.1101/gad.228802; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Morimoto RI, 2008, GENE DEV, V22, P1427, DOI 10.1101/gad.1657108; Nakai A, 1999, CELL STRESS CHAPERON, V4, P86, DOI 10.1379/1466-1268(1999)004<0086:NAITVH>2.3.CO;2; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; Nishizawa A, 2006, PLANT J, V48, P535, DOI 10.1111/j.1365-313X.2006.02889.x; Nover L, 2001, CELL STRESS CHAPERON, V6, P177, DOI 10.1379/1466-1268(2001)006<0177:AATHST>2.0.CO;2; NOVER L., 1991, HEAT SHOCK RESPONSE; Oreb M, 2008, TRENDS CELL BIOL, V18, P19, DOI 10.1016/j.tcb.2007.10.002; PELHAM HRB, 1982, EMBO J, V1, P1473, DOI 10.1002/j.1460-2075.1982.tb01340.x; Peteranderl R, 1999, BIOCHEMISTRY-US, V38, P3559, DOI 10.1021/bi981774j; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Port M, 2004, PLANT PHYSIOL, V135, P1457, DOI 10.1104/pp.104.042820; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; Reichel C, 1996, P NATL ACAD SCI USA, V93, P5888, DOI 10.1073/pnas.93.12.5888; Sambrook J., 2001, MOL CLONING LAB MANU; Sandqvist A, 2009, MOL BIOL CELL, V20, P1340, DOI 10.1091/mbc.E08-08-0864; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; Scharf KD, 1998, MOL CELL BIOL, V18, P2240, DOI 10.1128/MCB.18.4.2240; Schoffl F, 1998, PLANT PHYSIOL, V117, P1135, DOI 10.1104/pp.117.4.1135; Schramm F, 2006, PLANT MOL BIOL, V60, P759, DOI 10.1007/s11103-005-5750-x; TOPFER R, 1988, NUCLEIC ACIDS RES, V16, P8725, DOI 10.1093/nar/16.17.8725; TREUTER E, 1993, MOL GEN GENET, V240, P113, DOI 10.1007/BF00276890; Voellmy R, 2007, ADV EXP MED BIOL, V594, P89; von Koskull-Doring P, 2007, TRENDS PLANT SCI, V12, P452, DOI 10.1016/j.tplants.2007.08.014; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Yamada K, 2007, J BIOL CHEM, V282, P37794, DOI 10.1074/jbc.M707168200; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	53	82	99	2	35	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20848	20857		10.1074/jbc.M109.007336	http://dx.doi.org/10.1074/jbc.M109.007336			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19491106	Green Published, hybrid			2022-12-25	WOS:000268316100048
J	Karamitri, A; Shore, AM; Docherty, K; Speakman, JR; Lomax, MA				Karamitri, Angeliki; Shore, Andrew M.; Docherty, Kevin; Speakman, John R.; Lomax, Michael A.			Combinatorial Transcription Factor Regulation of the Cyclic AMP-response Element on the Pgc-1 alpha Promoter in White 3T3-L1 and Brown HIB-1B Preadipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING-PROTEIN; MITOCHONDRIAL UNCOUPLING PROTEIN; STRESS-INDUCED PHOSPHORYLATION; CONVERTIBLE ADIPOSE-TISSUE; C/EBP-BETA; ADIPOCYTE DIFFERENTIATION; MESSENGER-RNA; HEPATIC GLUCONEOGENESIS; VENTRICULAR MYOCYTES; GENE-TRANSCRIPTION	Cold stress in rodents increases the expression of UCP1 and PGC-1 alpha in brown and white adipose tissue. We have previously reported that C/EBP beta specifically binds to the CRE on the proximal Pgc-1 alpha promoter and increases forskolin-sensitive Pgc-1 alpha and Ucp1 expression in white 3T3-L1 preadipocytes. Here we show that in mice exposed to a cold environment for 24 h, Pgc-1 alpha, Ucp1, and C/ebp beta but not C/ebp alpha or C/ebp delta expression were increased in BAT. Conversely, expression of the C/EBP dominant negative Chop10 was increased in WAT but not BAT during cold exposure. Reacclimatization of cold-exposed mice to a warm environment for 24 h completely reversed these changes in gene expression. In HIB-1B, brown preadipocytes, forskolin increased expression of Pgc-1 alpha, Ucp1, and C/ebp beta early in differentiation and inhibited Chop10 expression. Employing chromatin immunoprecipitation, we demonstrate that C/EBP beta, CREB, ATF-2, and CHOP10 are bound to the Pgc-1 alpha proximal CRE, but CHOP10 does not bind in HIB-1B cell lysates. Forskolin stimulation and C/EBP beta overexpression in 3T3-L1 cells increased C/EBP beta and CREB but displaced ATF-2 and CHOP10 binding to the Pgc-1 alpha proximal CRE. Overexpression of ATF-2 and CHOP10 in 3T3-L1 cells decreased Pgc-1 alpha transcription. Knockdown of Chop10 in 3T3-L1 cells using siRNA increased Pgc-1 alpha transcription, whereas siRNA against C/ebp beta in HIB-1B cells decreased Pgc-1 alpha and Ucp1 expression. We conclude that the increased cAMP stimulation of Pgc-1 alpha expression is regulated by the combinatorial effect of transcription factors acting at the CRE on the proximal Pgc-1 alpha promoter.	[Karamitri, Angeliki; Lomax, Michael A.] Univ Nottingham, Sch Biosci, Loughborough LE12 5RD, Leics, England; [Shore, Andrew M.] Bournemouth Univ, Kingston Maurward Coll, Dorchester DT2 8PY, Dorset, England; [Docherty, Kevin] Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland; [Speakman, John R.] Univ Aberdeen, Sch Biol Sci, Aberdeen AB25 2ZD, Scotland	University of Nottingham; Bournemouth University; University of Aberdeen; University of Aberdeen	Lomax, MA (corresponding author), Univ Nottingham, Sch Biosci, Sutton Bonington Campus, Loughborough LE12 5RD, Leics, England.	michael.lomax@nottingham.ac.uk	Speakman, John R./A-9494-2008	Speakman, John R./0000-0002-2457-1823; Karamitri, Angeliki/0000-0002-8397-5529; Docherty, Kevin/0000-0001-6765-2060	Biotechnology and Biological Sciences Research Council; Greek State Scholarship's Foundation	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Greek State Scholarship's Foundation(Greek Ministry of Development-GSRT)	This work was supported by the Biotechnology and Biological Sciences Research Council and the Greek State Scholarship's Foundation.	ASHWELL M, 1987, INT J OBESITY, V11, P357; Averous J, 2004, J BIOL CHEM, V279, P5288, DOI 10.1074/jbc.M311862200; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; Brenner S, 2003, J BIOL CHEM, V278, P5597, DOI 10.1074/jbc.M207448200; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; Cancello R, 1998, ENDOCRINOLOGY, V139, P4747, DOI 10.1210/en.139.11.4747; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cao WH, 2004, MOL CELL BIOL, V24, P3057, DOI 10.1128/MCB.24.7.3057-3067.2004; Cao WH, 2005, J BIOL CHEM, V280, P42731, DOI 10.1074/jbc.M506223200; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CASTEILLA L, 1989, BIOCHEM J, V257, P665, DOI 10.1042/bj2570665; CHAMPIGNY O, 1991, P NATL ACAD SCI USA, V88, P10774, DOI 10.1073/pnas.88.23.10774; Chen YC, 2003, MOL CELL BIOL, V23, P4066, DOI 10.1128/MCB.23.12.4066-4082.2003; Chin CH, 2004, GENE DEV, V18, P1970, DOI 10.1101/gad.1213104; Cinti S, 2006, NUTR METAB CARDIOVAS, V16, P569, DOI 10.1016/j.numecd.2006.07.009; Clerk A, 1997, BIOCHEM J, V325, P801, DOI 10.1042/bj3250801; COUSIN B, 1992, J CELL SCI, V103, P931; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; GARRUTI G, 1992, INT J OBESITY, V16, P383; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Himms-Hagen J, 2000, AM J PHYSIOL-CELL PH, V279, pC670, DOI 10.1152/ajpcell.2000.279.3.C670; Karamanlidis G, 2007, J BIOL CHEM, V282, P24660, DOI 10.1074/jbc.M703101200; Kovacs KA, 2003, J BIOL CHEM, V278, P36959, DOI 10.1074/jbc.M303147200; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEAN MEJ, 1986, CLIN SCI, V71, P291, DOI 10.1042/cs0710291; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lomax MA, 2007, ENDOCRINOLOGY, V148, P461, DOI 10.1210/en.2006-0918; LONCAR D, 1991, CELL TISSUE RES, V266, P149, DOI 10.1007/BF00678721; LONCAR D, 1989, J ULTRA MOL STRUCT R, V102, P9; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MANCHADO C, 1994, BIOCHEM J, V302, P695, DOI 10.1042/bj3020695; MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; Nedergaard J, 2005, BBA-MOL BASIS DIS, V1740, P293, DOI 10.1016/j.bbadis.2005.02.003; Nedergaard J, 2007, AM J PHYSIOL-ENDOC M, V293, pE444, DOI 10.1152/ajpendo.00691.2006; Oberkofler H, 1997, J LIPID RES, V38, P2125; PARK EA, 1993, J BIOL CHEM, V268, P613; Puigserver P, 1998, EUR J CELL BIOL, V77, P117, DOI 10.1016/S0171-9335(98)80079-4; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; REHNMARK S, 1993, FEBS LETT, V318, P235, DOI 10.1016/0014-5793(93)80519-Z; Rim JS, 2004, J BIOL CHEM, V279, P25916, DOI 10.1074/jbc.M402102200; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Ross HL, 2001, J VIROL, V75, P1842, DOI 10.1128/JVI.75.4.1842-1856.2001; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SOPPELA P, 1991, AM J PHYSIOL, V260, pR1229, DOI 10.1152/ajpregu.1991.260.6.R1229; Sugden PH, 1997, BIOCHEM SOC T, V25, pS221, DOI 10.1042/bst025221s; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tang QQ, 2000, P NATL ACAD SCI USA, V97, P12446, DOI 10.1073/pnas.220425597; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Tiraby C, 2003, J BIOL CHEM, V278, P33370, DOI 10.1074/jbc.M305235200; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tseng YH, 2008, NATURE, V454, P1000, DOI 10.1038/nature07221; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wang H, 2008, MOL ENDOCRINOL, V22, P1596, DOI 10.1210/me.2007-0388; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Xue BZ, 2007, J LIPID RES, V48, P41, DOI 10.1194/jlr.M600287-JLR200; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102	70	44	48	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20738	20752		10.1074/jbc.M109.021766	http://dx.doi.org/10.1074/jbc.M109.021766			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19491401	hybrid, Green Published			2022-12-25	WOS:000268316100036
J	Zhang, T; Berrocal, JG; Frizzell, KM; Gamble, MJ; DuMond, ME; Krishnakumar, R; Yang, TL; Sauve, AA; Kraus, WL				Zhang, Tong; Berrocal, Jhoanna G.; Frizzell, Kristine M.; Gamble, Matthew J.; DuMond, Michelle E.; Krishnakumar, Raga; Yang, Tianle; Sauve, Anthony A.; Kraus, W. Lee			Enzymes in the NAD(+) Salvage Pathway Regulate SIRT1 Activity at Target Gene Promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-ENHANCING FACTOR; NICOTINAMIDE MONONUCLEOTIDE ADENYLYLTRANSFERASE; WALLERIAN DEGENERATION; HISTONE ACETYLATION; BIOSYNTHETIC ENZYME; AXON DEGENERATION; MAMMALIAN-CELLS; EXPRESSION; PROTEIN; PHOSPHORIBOSYLTRANSFERASE	In mammals, nicotinamide phosphoribosyltransferase (NAMPT) and nicotinamide mononucleotide adenylyltransferase 1 (NMNAT-1) constitute a nuclear NAD(+) salvage pathway which regulates the functions of NAD(+)-dependent enzymes such as the protein deacetylase SIRT1. One of the major functions of SIRT1 is to regulate target gene transcription through modification of chromatin-associated proteins. However, little is known about the molecular mechanisms by which NAD(+) biosynthetic enzymes regulate SIRT1 activity to control gene transcription in the nucleus. In this study we show that stable short hairpin RNA-mediated knockdown of NAMPT or NMNAT-1 in MCF-7 breast cancer cells reduces total cellular NAD(+) levels and alters global patterns of gene expression. Furthermore, we show that SIRT1 plays a key role in mediating the gene regulatory effects of NAMPT and NMNAT-1. Specifically, we found that SIRT1 binds to the promoters of genes commonly regulated by NAMPT, NMNAT-1, and SIRT1 and that SIRT1 histone deacetylase activity is regulated by NAMPT and NMNAT-1 at these promoters. Most significantly, NMNAT-1 interacts with, and is recruited to target gene promoters by SIRT1. Collectively, our results reveal a mechanism for the direct control of SIRT1 deacetylase activity at a set of target gene promoters by NMNAT-1. This mechanism, in collaboration with NAMPT-dependent regulation of nuclear NAD(+) production, establishes an important pathway for transcription regulation by NAD(+).	[Krishnakumar, Raga; Kraus, W. Lee] Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA; [Berrocal, Jhoanna G.; Frizzell, Kristine M.; Krishnakumar, Raga; Kraus, W. Lee] Cornell Univ, Grad Field Biochem Mol & Cell Biol, Ithaca, NY 14853 USA; [Yang, Tianle; Sauve, Anthony A.; Kraus, W. Lee] Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Kraus, WL (corresponding author), Cornell Univ, Dept Mol Biol & Genet, 465 Biotechnol Bldg, Ithaca, NY 14853 USA.	wlk5@cornell.edu		Krishnakumar, Raga/0000-0002-2479-754X	National Institutes of Health [R01 DK069710, R01 DK73466]; Endocrine Society; Ellison Medical Foundation; New York State Health Research Science Board; American Heart Association; Alfred P. Sloan Foundation; AHA; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073466, R01DK069710] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Endocrine Society; Ellison Medical Foundation(Lawrence Ellison Foundation); New York State Health Research Science Board; American Heart Association(American Heart Association); Alfred P. Sloan Foundation(Alfred P. Sloan Foundation); AHA(American Heart Association); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grants R01 DK069710 (NIDDK, to W. L. K.) and R01 DK73466 (NIDDK, to A. A. S.). This work was also supported by grants from the Endocrine Society (to W. L. K.) and the Ellison Medical Foundation (to A. A. S.), postdoctoral fellowships from the New York State Health Research Science Board (to T. Z.) and the American Heart Association (AHA; to M. J. G.), and predoctoral fellowships from the Alfred P. Sloan Foundation (to J. G. B.) and the AHA (to K. M. F.).	Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Asaumi M, 2005, J BIOCHEM, V137, P147, DOI 10.1093/jb/mvi014; Berger F, 2005, J BIOL CHEM, V280, P36334, DOI 10.1074/jbc.M508660200; Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; Berger F, 2007, P NATL ACAD SCI USA, V104, P3765, DOI 10.1073/pnas.0609211104; Billington RA, 2008, J BIOL CHEM, V283, P6367, DOI 10.1074/jbc.M706204200; Conforti L, 2007, CELL DEATH DIFFER, V14, P116, DOI 10.1038/sj.cdd.4401944; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; Crawley JTB, 2008, ARTERIOSCL THROM VAS, V28, P233, DOI 10.1161/ATVBAHA.107.141606; Dvir-Ginzberg M, 2008, J BIOL CHEM, V283, P36300, DOI 10.1074/jbc.M803196200; Emanuelli M, 2001, J BIOL CHEM, V276, P406, DOI 10.1074/jbc.M008700200; Fainzilber M, 2006, NEURON, V50, P819, DOI 10.1016/j.neuron.2006.05.023; Feige JN, 2008, CURR OPIN CELL BIOL, V20, P303, DOI 10.1016/j.ceb.2008.03.012; Fulco M, 2008, DEV CELL, V14, P661, DOI 10.1016/j.devcel.2008.02.004; Garten A, 2009, TRENDS ENDOCRIN MET, V20, P130, DOI 10.1016/j.tem.2008.10.004; Gillingwater TH, 2006, HUM MOL GENET, V15, P625, DOI 10.1093/hmg/ddi478; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Grubisha O, 2005, FEBS J, V272, P4607, DOI 10.1111/j.1742-4658.2005.04862.x; Guarente L, 2000, GENE DEV, V14, P1021; Hollister RD, 1996, BRAIN RES, V728, P13; Hoopfer ED, 2006, NEURON, V50, P883, DOI 10.1016/j.neuron.2006.05.013; Imai S, 2009, CELL BIOCHEM BIOPHYS, V53, P65, DOI 10.1007/s12013-008-9041-4; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kim MY, 2006, MOL ENDOCRINOL, V20, P1479, DOI 10.1210/me.2005-0531; Kininis M, 2007, MOL CELL BIOL, V27, P5090, DOI 10.1128/MCB.00083-07; Kitani T, 2003, FEBS LETT, V544, P74, DOI 10.1016/S0014-5793(03)00476-9; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250; Lin S, 2004, NEUROPEPTIDES, V38, P189, DOI 10.1016/j.npep.2004.05.005; Lin X, 2005, CEREBELLUM, V4, P37, DOI 10.1080/14734220510007897; Lux A, 2005, J BIOL CHEM, V280, P8482, DOI 10.1074/jbc.M409197200; MacDonald JM, 2006, NEURON, V50, P869, DOI 10.1016/j.neuron.2006.04.028; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Nakahata Y, 2009, SCIENCE, V324, P654, DOI 10.1126/science.1170803; Nelson BR, 2004, DEV BIOL, V270, P322, DOI 10.1016/j.ydbio.2004.03.004; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Ohkawa N, 2008, GENES CELLS, V13, P1171, DOI 10.1111/j.1365-2443.2008.01235.x; Ono R, 2001, GENOMICS, V73, P232, DOI 10.1006/geno.2001.6494; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Raffaelli N, 2002, BIOCHEM BIOPH RES CO, V297, P835, DOI 10.1016/S0006-291X(02)02285-4; Ramsey KM, 2009, SCIENCE, V324, P651, DOI 10.1126/science.1171641; Revollo JR, 2007, CELL METAB, V6, P363, DOI 10.1016/j.cmet.2007.09.003; Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Rico-Bautista E, 2006, CYTOKINE GROWTH F R, V17, P431, DOI 10.1016/j.cytogfr.2006.09.008; Rongvaux A, 2003, BIOESSAYS, V25, P683, DOI 10.1002/bies.10297; Rongvaux A, 2002, EUR J IMMUNOL, V32, P3225, DOI 10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L; Rongvaux A, 2008, J IMMUNOL, V181, P4685, DOI 10.4049/jimmunol.181.7.4685; Sauve AA, 2008, J PHARMACOL EXP THER, V324, P883, DOI 10.1124/jpet.107.120758; Sauve AA, 2006, ANNU REV BIOCHEM, V75, P435, DOI 10.1146/annurev.biochem.74.082803.133500; Schweiger M, 2001, FEBS LETT, V492, P95, DOI 10.1016/S0014-5793(01)02180-9; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Takahashi H, 2006, MOL CELL, V23, P207, DOI 10.1016/j.molcel.2006.05.040; Turnley Ann M, 2005, Pediatr Endocrinol Rev, V2, P366; van der Veer E, 2005, CIRC RES, V97, P25, DOI 10.1161/01.RES.0000173298.38808.27; van der Veer E, 2007, J BIOL CHEM, V282, P10841, DOI 10.1074/jbc.C700018200; Vaquero A, 2007, ONCOGENE, V26, P5505, DOI 10.1038/sj.onc.1210617; Wang J, 2005, J CELL BIOL, V170, P349, DOI 10.1083/jcb.200504028; Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154; Yalowitz JA, 2004, BIOCHEM J, V377, P317, DOI 10.1042/BJ20030518; Yang HY, 2007, CELL, V130, P1095, DOI 10.1016/j.cell.2007.07.035; Yang TL, 2006, AAPS J, V8, pE632, DOI 10.1208/aapsj080472; Yang TL, 2006, TRENDS ENDOCRIN MET, V17, P186, DOI 10.1016/j.tem.2006.04.002; Yokoyama M, 1996, DNA Res, V3, P311, DOI 10.1093/dnares/3.5.311; Zhai RG, 2008, NATURE, V452, P887, DOI 10.1038/nature06721; Zhai RG, 2006, PLOS BIOL, V4, P2336, DOI 10.1371/journal.pbio.0040416	69	174	183	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20408	20417		10.1074/jbc.M109.016469	http://dx.doi.org/10.1074/jbc.M109.016469			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19478080	hybrid, Green Published			2022-12-25	WOS:000268097400066
J	Pinto, JR; Parvatiyar, MS; Jones, MA; Liang, JS; Ackerman, MJ; Potter, JD				Pinto, Jose Renato; Parvatiyar, Michelle S.; Jones, Michelle A.; Liang, Jingsheng; Ackerman, Michael J.; Potter, James D.			A Functional and Structural Study of Troponin C Mutations Related to Hypertrophic Cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CARDIAC TROPONIN; MUSCLE-CONTRACTION; CALCIUM-BINDING; CA2+ BINDING; STRIATED-MUSCLE; FORCE DEVELOPMENT; THIN-FILAMENTS; GENETIC-BASIS; N-DOMAIN; SITES	Recently four new hypertrophic cardiomyopathy mutations in cardiac troponin C (cTnC) (A8V, C84Y, E134D, and D145E) were reported, and their effects on the Ca2+ sensitivity of force development were evaluated (Landstrom, A. P., Parvatiyar, M. S., Pinto, J. R., Marquardt, M. L., Bos, J. M., Tester, D. J., Ommen, S. R., Potter, J. D., and Ackerman, M. J. (2008) J. Mol. Cell. Cardiol. 45, 281-288). We performed actomyosin ATPase and spectroscopic solution studies to investigate the molecular properties of these mutations. Actomyosin ATPase activity was measured as a function of [Ca2+] utilizing reconstituted thin filaments (TFs) with 50% mutant and 50% wild type (WT) and 100% mutant cardiac troponin (cTn) complexes: A8V, C84Y, and D145E increased the Ca2+ sensitivity with only A8V demonstrating lowered Ca2+ sensitization at the 50% ratio when compared with 100%; E134D was the same as WT at both ratios. Of these four mutants, only D145E showed increased ATPase activation in the presence of Ca2+. None of the mutants affected ATPase inhibition or the binding of cTn to the TF measured by co-sedimentation. Only D145E increased the Ca2+ affinity of site II measured by 2-(4'-(2 ''-iodoacetamido) phenyl) aminonaphthalene-6-sulfonic acid fluorescence in isolated cTnC or the cTn complex. In the presence of the TF, only A8V was further sensitized to Ca2+. Circular dichroism measurements in different metal-bound states of the isolated cTnCs showed changes in the secondary structure of A8V, C84Y, and D145E, whereas E134D was the same as WT. PyMol modeling of each cTnC mutant within the cTn complex revealed potential for local changes in the tertiary structure of A8V, C84Y, and D145E. Our results indicate that 1) three of the hypertrophic cardiomyopathy cTnC mutants increased the Ca2+ sensitivity of the myofilament; 2) the effects of the mutations on the Ca2+ affinity of isolated cTnC, cTn, and TF are not sufficient to explain the large Ca2+ sensitivity changes seen in reconstituted and fiber assays; and 3) changes in the secondary structure of the cTnC mutants may contribute to modified protein protein interactions along the sarcomere lattice disrupting the coupling between the cross-bridge and Ca2+ binding to cTnC.	[Pinto, Jose Renato; Parvatiyar, Michelle S.; Jones, Michelle A.; Liang, Jingsheng; Potter, James D.] Univ Miami, Dept Mol & Cellular Pharmacol, Miller Sch Med, Miami, FL 33136 USA; [Ackerman, Michael J.] Mayo Clin, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA	University of Miami; Mayo Clinic	Potter, JD (corresponding author), Univ Miami, Dept Mol & Cellular Pharmacol, Miller Sch Med, 1600 NW 10th Ave R-189, Miami, FL 33136 USA.	jdpotter@miami.edu	Pinto, Jose Renato/H-2631-2017; parvatiyar, michelle/ABH-7542-2020	Pinto, Jose Renato/0000-0001-9092-4976; Parvatiyar, Michelle/0000-0002-9416-0069	National Institutes of Health [HL-67415, HL-42325]; Windland Smith Rice Comprehensive Sudden Cardiac Death Program; American Heart Association Postdoctoral Fellowship [AHA 0825368E]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042325, R01HL067415, R37HL042325] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Windland Smith Rice Comprehensive Sudden Cardiac Death Program; American Heart Association Postdoctoral Fellowship(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported, in whole or in part, by National Institutes of Health Grants HL-67415 and HL-42325 (to J. D. P.). This work was also supported by the Windland Smith Rice Comprehensive Sudden Cardiac Death Program (to M. A. J.) and American Heart Association Postdoctoral Fellowship AHA 0825368E (to J. R.P)	Alcalai R, 2008, J CARDIOVASC ELECTR, V19, P104, DOI 10.1111/j.1540-8167.2007.00965.x; Baudenbacher F, 2008, J CLIN INVEST, V118, P3893, DOI 10.1172/JCI36642; Bers D.M., 2001, EXCITATION CONTRACTI, P39, DOI [10.1007/978-94-010-0658-3_3, DOI 10.1007/978-94-010-0658-3_3]; Biesiadecki BJ, 2007, CIRC RES, V100, P1486, DOI 10.1161/01.RES.0000267744.92677.7f; Blumenschein TMA, 2001, J BIOL CHEM, V276, P36606, DOI 10.1074/jbc.M105130200; BRITO RMM, 1993, J BIOL CHEM, V268, P20966; BRITO RMM, 1991, BIOCHEMISTRY-US, V30, P10236, DOI 10.1021/bi00106a023; CHANDRA M, 1994, J BIOL CHEM, V269, P14988; Dweck D, 2005, ANAL BIOCHEM, V347, P303, DOI 10.1016/j.ab.2005.09.025; Dweck D, 2008, J BIOL CHEM, V283, P33119, DOI 10.1074/jbc.M804070200; ELSALEH SC, 1987, J BIOL CHEM, V262, P17240; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Finley NL, 2004, J BIOL CHEM, V279, P54833, DOI 10.1074/jbc.M408304200; Finley NL, 2004, BIOCHEMISTRY-US, V43, P11371, DOI 10.1021/bi049672i; Fiske CH, 1925, J BIOL CHEM, V66, P375; Fredricksen RS, 1996, BIOCHEMISTRY-US, V35, P14012, DOI 10.1021/bi961270q; Gomes AV, 2004, ANN NY ACAD SCI, V1015, P214, DOI 10.1196/annals.1302.018; Gomes AV, 2004, MOL CELL BIOCHEM, V263, P99, DOI 10.1023/B:MCBI.0000041852.42291.aa; Gomes AV, 2002, J BIOL CHEM, V277, P35341, DOI 10.1074/jbc.M204118200; Gordon AM, 2001, NEWS PHYSIOL SCI, V16, P49; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GUTH K, 1987, J BIOL CHEM, V262, P13627; Heineke J, 2006, NAT REV MOL CELL BIO, V7, P589, DOI 10.1038/nrm1983; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; Hoffman RMB, 2006, J MOL BIOL, V361, P625, DOI 10.1016/j.jmb.2006.06.031; Hoffmann B, 2001, Hum Mutat, V17, P524, DOI 10.1002/humu.1143; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; JOHNSON JD, 1978, J BIOL CHEM, V253, P3775; KRUDY GA, 1992, BIOCHEMISTRY-US, V31, P1595, DOI 10.1021/bi00121a003; Landstrom AP, 2008, J MOL CELL CARDIOL, V45, P281, DOI 10.1016/j.yjmcc.2008.05.003; LEAVIS PC, 1978, ARCH BIOCHEM BIOPHYS, V186, P411, DOI 10.1016/0003-9861(78)90453-8; Liang B, 2008, PHYSIOL GENOMICS, V33, P257, DOI 10.1152/physiolgenomics.00154.2007; Liew CC, 2004, NAT REV GENET, V5, P811, DOI 10.1038/nrg1470; Lindhout DA, 2005, BIOCHEMISTRY-US, V44, P14750, DOI 10.1021/bi051580l; Marian AJ, 1998, J CARDIOVASC ELECTR, V9, P88, DOI 10.1111/j.1540-8167.1998.tb00871.x; Maron Barry J, 2002, Card Electrophysiol Rev, V6, P100, DOI 10.1023/A:1017903709361; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; MOEWS PC, 1975, J MOL BIOL, V91, P201, DOI 10.1016/0022-2836(75)90160-6; Murakami K, 2005, J MOL BIOL, V352, P178, DOI 10.1016/j.jmb.2005.06.067; NEGELE JC, 1992, J BIOL CHEM, V267, P825; Pinto JR, 2008, J BIOL CHEM, V283, P2156, DOI 10.1074/jbc.M707066200; Pinto JR, 2008, PFLUG ARCH EUR J PHY, V456, P1177, DOI 10.1007/s00424-008-0480-y; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; Putkey JA, 1997, BIOCHEMISTRY-US, V36, P970, DOI 10.1021/bi9617466; Robinson P, 2007, CIRC RES, V101, P1266, DOI 10.1161/CIRCRESAHA.107.156380; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; Schmidtmann A, 2005, FEBS J, V272, P6087, DOI 10.1111/j.1742-4658.2005.05001.x; Smith L, 1999, BIOPHYS J, V76, P400, DOI 10.1016/S0006-3495(99)77206-1; SMITH L, 1994, J BIOL CHEM, V269, P9857; SOLARO RJ, 1986, J PHARMACOL EXP THER, V238, P502; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Szczesna D, 1996, J BIOL CHEM, V271, P8381, DOI 10.1074/jbc.271.14.8381; Szczesna D, 2001, J BIOL CHEM, V276, P7086, DOI 10.1074/jbc.M009823200; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Towbin JA, 2002, NATURE, V415, P227, DOI 10.1038/415227a; Van Driest SL, 2003, CIRCULATION, V108, P445, DOI 10.1161/01.CIR.0000080896.52003.DF; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; Wen YH, 2008, J BIOL CHEM, V283, P20484, DOI 10.1074/jbc.M801661200; Zhang R, 1995, J BIOL CHEM, V270, P30773, DOI 10.1074/jbc.270.51.30773; ZOT AS, 1989, BIOCHEMISTRY-US, V28, P6751, DOI 10.1021/bi00442a031; ZOT HG, 1982, J BIOL CHEM, V257, P7678	65	70	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					19090	19100		10.1074/jbc.M109.007021	http://dx.doi.org/10.1074/jbc.M109.007021			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19439414	Green Published, hybrid			2022-12-25	WOS:000267711500057
J	Carpio, RVD; Silverstein, TD; Lone, S; Swan, MK; Choudhury, JR; Johnson, RE; Prakash, S; Prakash, L; Aggarwal, AK				Carpio, Rodrigo Vasquez-Del; Silverstein, Timothy D.; Lone, Samer; Swan, Michael K.; Choudhury, Jayati R.; Johnson, Robert E.; Prakash, Satya; Prakash, Louise; Aggarwal, Aneel K.			Structure of Human DNA Polymerase kappa Inserting dATP Opposite an 8-OxoG DNA Lesion	PLOS ONE			English	Article								Background: Oxygen-free radicals formed during normal aerobic cellular metabolism attack bases in DNA and 7,8-dihydro-8-oxoguanine (8-oxoG) is one of the major lesions formed. It is amongst the most mutagenic lesions in cells because of its dual coding potential, wherein 8-oxoG(syn) can pair with an A in addition to normal base pairing of 8-oxoG(anti) with a C. Human DNA polymerase kappa (Pol kappa) is a member of the newly discovered Y-family of DNA polymerases that possess the ability to replicate through DNA lesions. To understand the basis of Pol kappa's preference for insertion of an A opposite 8-oxoG lesion, we have solved the structure of Pol kappa in ternary complex with a template-primer presenting 8-oxoG in the active site and with dATP as the incoming nucleotide. Methodology and Principal Findings: We show that the Pol kappa active site is well-adapted to accommodate 8-oxoG in the syn conformation. That is, the polymerase and the bound template-primer are almost identical in their conformations to that in the ternary complex with undamaged DNA. There is no steric hindrance to accommodating 8-oxoG in the syn conformation for Hoogsteen base-paring with incoming dATP. Conclusions and Significance: The structure we present here is the first for a eukaryotic translesion synthesis (TLS) DNA polymerase with an 8-oxoG: A base pair in the active site. The structure shows why Pol kappa is more efficient at inserting an A opposite the 8-oxoG lesion than a C. The structure also provides a basis for why Pol kappa is more efficient at inserting an A opposite the lesion than other Y-family DNA polymerases.			Carpio, RVD (corresponding author), Mt Sinai Sch Med, Dept Struct & Chem Biol, New York, NY 10029 USA.	aneel.aggarwal@mssm.edu	Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Silverstein, Timothy/0000-0003-0931-6274; Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016666] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES016666, R01 ES016666] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Brieba LG, 2005, STRUCTURE, V13, P1653, DOI 10.1016/j.str.2005.07.020; Brieba LG, 2004, EMBO J, V23, P3452, DOI 10.1038/sj.emboj.7600354; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Freisinger E, 2004, EMBO J, V23, P1494, DOI 10.1038/sj.emboj.7600158; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Haracska L, 2002, P NATL ACAD SCI USA, V99, P16000, DOI 10.1073/pnas.252524999; Haracska L, 2002, J BIOL CHEM, V277, P15546, DOI 10.1074/jbc.M112146200; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Hsu GW, 2004, NATURE, V431, P217, DOI 10.1038/nature02908; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 2006, METHOD ENZYMOL, V408, P390, DOI 10.1016/S0076-6879(06)08024-4; Krahn JM, 2003, STRUCTURE, V11, P121, DOI 10.1016/S0969-2126(02)00930-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR A, V47, P110; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Lone S, 2007, MOL CELL, V25, P601, DOI 10.1016/j.molcel.2007.01.018; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Nair DT, 2008, STRUCTURE, V16, P239, DOI 10.1016/j.str.2007.12.009; Nair Deepak T, 2006, Nat Struct Mol Biol, V13, P619, DOI 10.1038/nsmb1118; Nair DT, 2005, STRUCTURE, V13, P1569, DOI 10.1016/j.str.2005.08.010; Nair DT, 2005, SCIENCE, V309, P2219, DOI 10.1126/science.1116336; Nair DT, 2004, NATURE, V430, P377, DOI 10.1038/nature02692; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Rechkoblit O, 2006, PLOS BIOL, V4, P25, DOI 10.1371/journal.pbio.0040011; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Uijon SN, 2004, STRUCTURE, V12, P1395, DOI 10.1016/j.str.2004.05.011; Washington MT, 2004, MOL CELL BIOL, V24, P5687, DOI 10.1128/MCB.24.13.5687-5693.2004; Washington MT, 2000, P NATL ACAD SCI USA, V97, P3094, DOI 10.1073/pnas.050491997; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; Wolfle WT, 2006, MOL CELL BIOL, V26, P381, DOI 10.1128/MCB.26.1.381-386.2006; Zang H, 2006, J BIOL CHEM, V281, P2358, DOI 10.1074/jbc.M510889200; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	44	44	45	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2009	4	6							e5766	10.1371/journal.pone.0005766	http://dx.doi.org/10.1371/journal.pone.0005766			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453CI	19492058	gold, Green Published, Green Submitted			2022-12-25	WOS:000266587400009
J	Kabeer, BSA; Sikhamani, R; Swaminathan, S; Perumal, V; Paramasivam, P; Raja, A				Kabeer, Basirudeen Syed Ahamed; Sikhamani, Rajasekaran; Swaminathan, Sowmya; Perumal, Venkatesan; Paramasivam, Paulkumaran; Raja, Alamelu			Role of Interferon Gamma Release Assay in Active TB Diagnosis among HIV Infected Individuals	PLOS ONE			English	Article								Background: A rapid and specific test is urgently needed for tuberculosis (TB) diagnosis especially among human immunodeficiency virus (HIV) infected individuals. In this study, we assessed the sensitivity of Interferon gamma release assay (IGRA) in active tuberculosis patients who were positive for HIV infection and compared it with that of tuberculin skin test (TST). Methodology/Principal Findings: A total of 105 HIV-TB patients who were naive for anti tuberculosis and anti retroviral therapy were included for this study out of which 53 (50%) were culture positive. Of 105 tested, QuantiFERON-TB Gold in-tube (QFT-G) was positive in 65% (95% CI: 56% to 74%), negative in 18% (95% CI: 11% to 25%) and indeterminate in 17% (95% CI: 10% to 24%) of patients. The sensitivity of QFT-G remained similar in pulmonary TB and extra-pulmonary TB patients. The QFT-G positivity was not affected by low CD4 count, but it often gave indeterminate results especially in individuals with CD4 count <200 cells/mu l. All of the QFT-G indeterminate patients whose sputum culture were positive, showed <= 0.25IU/ml of IFN-gamma response to phytohemagglutinin (PHA). TST was performed in all the 105 patients and yielded the sensitivity of 31% (95% CI: 40% to 22%). All the TST positives were QFT-G positives. The sensitivity of TST was decreased, when CD4 cell counts declined. Conclusions/Significance: Our study shows neither QFT-G alone or in combination with TST can be used to exclude the suspicion of active TB disease. However, unlike TST, QFT-G yielded fewer false negative results even in individuals with low CD4 count. The low PHA cut-off point for indeterminate results suggested in this study (<= 0.25 IU/ml) may improve the proportion of valid QFT-G results.				alameluraja@gmail.com	Kabeer, Basirudeen Syed Ahamed/AAQ-7599-2020	Kabeer, Basirudeen Syed Ahamed/0000-0002-7287-1636	NIAID NIH HHS [R03 AI064055-01, R03 AI064055] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI064055] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balcells ME, 2008, INT J INFECT DIS, V12, P645, DOI 10.1016/j.ijid.2008.03.005; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; Dewan PK, 2007, CLIN INFECT DIS, V44, P69, DOI 10.1086/509928; Dosanjh DPS, 2008, ANN INTERN MED, V148, P325, DOI 10.7326/0003-4819-148-5-200803040-00003; Ferrara G, 2005, AM J RESP CRIT CARE, V172, P631, DOI 10.1164/rccm.200502-196OC; Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6; Goletti D, 2006, CLIN MICROBIOL INFEC, V12, P544, DOI 10.1111/j.1469-0691.2006.01391.x; Hanson C A, 1989, Semin Respir Infect, V4, P182; Harada Nobuyuki, 2004, Kekkaku, V79, P725; Hussain R, 2002, J IMMUNOL METHODS, V264, P95, DOI 10.1016/S0022-1759(02)00092-3; Jafari C, 2006, AM J RESP CRIT CARE, V174, P1048, DOI 10.1164/rccm.200604-465OC; Janssens JP, 2007, EUR RESPIR J, V30, P722, DOI 10.1183/09031936.00028507; Janssens JP, 2007, EUR RESPIR J, V30, P183, DOI 10.1183/09031936.00042807; Kang YA, 2007, CHEST, V132, P959, DOI 10.1378/chest.06-2805; Karam F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001441; Kobashi Y, 2006, CLIN INFECT DIS, V43, P1540, DOI 10.1086/509327; Lagrange Philippe H, 2008, Open Respir Med J, V2, P52, DOI 10.2174/1874306400802010052; Lee JY, 2006, EUR RESPIR J, V28, P24, DOI 10.1183/09031936.06.00016906; Meier T, 2005, EUR J CLIN MICROBIOL, V24, P529, DOI 10.1007/s10096-005-1377-8; *MIN HLTH FAM WELF, 1998, REV NAT TUB CONTR PR; Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC; Pai M, 2007, INFECTION, V35, P98, DOI 10.1007/s15010-007-6114-z; Pai M, 2008, ANN INTERN MED, V149, P177, DOI 10.7326/0003-4819-149-3-200808050-00241; Pai M, 2007, LANCET INFECT DIS, V7, P428, DOI 10.1016/S1473-3099(07)70086-5; Raby E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002489; Rangaka MX, 2007, AM J RESP CRIT CARE, V175, P514, DOI 10.1164/rccm.200610-1439OC; Ravn P, 2005, CLIN DIAGN LAB IMMUN, V12, P491, DOI 10.1128/CDLI.12.4.491-496.2005; SHARP V, 1993, 9 INT C AIDS; Steinbrook R, 2007, NEW ENGL J MED, V356, P1197, DOI 10.1056/NEJMp078011; Swaminathan S, 2008, INT J TUBERC LUNG D, V12, P168; Tsiouris SJ, 2006, J CLIN MICROBIOL, V44, P2844, DOI 10.1128/JCM.02411-05; WHO, 2008, GLOBAL TUBERCULOSIS	32	61	61	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2009	4	5							e5718	10.1371/journal.pone.0005718	http://dx.doi.org/10.1371/journal.pone.0005718			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QE	19479058	Green Submitted, Green Accepted, gold, Green Published			2022-12-25	WOS:000266415100011
J	Stuart-Fox, D; Godinho, R; de Bellocq, JG; Irwin, NR; Brito, JC; Moussalli, A; Siroky, P; Hugall, AF; Baird, SJE				Stuart-Fox, Devi; Godinho, Raquel; de Bellocq, Joelle Gouey; Irwin, Nancy R.; Brito, Jose Carlos; Moussalli, Adnan; Siroky, Pavel; Hugall, Andrew F.; Baird, Stuart J. E.			Variation in Phenotype, Parasite Load and Male Competitive Ability across a Cryptic Hybrid Zone	PLOS ONE			English	Article							LIZARD LACERTA-SCHREIBERI; SEXUAL SELECTION; MITOCHONDRIAL-DNA; MATING SUCCESS; FEMALE CHOICE; MATE CHOICE; PHYLOGEOGRAPHY; EVOLUTION; PLUMAGE; HYBRIDIZATION	Background: Molecular genetic studies are revealing an increasing number of cryptic lineages or species, which are highly genetically divergent but apparently cannot be distinguished morphologically. This observation gives rise to three important questions: 1) have these cryptic lineages diverged in phenotypic traits that may not be obvious to humans; 2) when cryptic lineages come into secondary contact, what are the evolutionary consequences: stable co-existence, replacement, admixture or differentiation and 3) what processes influence the evolutionary dynamics of these secondary contact zones? Methodology/Principal Findings: To address these questions, we first tested whether males of the Iberian lizard Lacerta schreiberi from two highly genetically divergent, yet morphologically cryptic lineages on either side of an east-west secondary contact could be differentiated based on detailed analysis of morphology, coloration and parasite load. Next, we tested whether these differences could be driven by pre-copulatory intra-sexual selection (male-male competition). Compared to eastern males, western males had fewer parasites, were in better body condition and were more intensely coloured. Although subtle environmental variation across the hybrid zone could explain the differences in parasite load and body condition, these were uncorrelated with colour expression, suggesting that the differences in coloration reflect heritable divergence. The lineages did not differ in their aggressive behaviour or competitive ability. However, body size, which predicted male aggressiveness, was positively correlated with the colour traits that differed between genetic backgrounds. Conclusions/Significance: Our study confirms that these cryptic lineages differ in several aspects that are likely to influence fitness. Although there were no clear differences in male competitive ability, our results suggest a potential indirect role for intra-sexual selection. Specifically, if lizards use the colour traits that differ between genetic backgrounds to assess the size of potential rivals or mates, the resulting fitness differential favouring western males could result in net male-mediated gene flow from west to east across the current hybrid zone.			Stuart-Fox, D (corresponding author), Univ Melbourne, Dept Zool, Melbourne, Vic, Australia.	devis@unimelb.edu.au	Brito, José C./A-7831-2010; Baird, Stuart J. E./B-3872-2011; Irwin, Nancy R./G-3818-2015; Široký, Pavel/H-1674-2014; Godinho, Raquel/L-6804-2013; Gouy de Bellocq, Joelle/J-4733-2013	Brito, José C./0000-0001-5444-8132; Irwin, Nancy R./0000-0002-9384-0134; Godinho, Raquel/0000-0002-4260-4799; Gouy de Bellocq, Joelle/0000-0001-5831-6284; Stuart-Fox, Devi/0000-0003-3362-1412				Andersson Malte, 1994; Andersson S., 2006, BIRD COLORATION, P76; BARTON NH, 1985, ANNU REV ECOL SYST, V16, P113, DOI 10.1146/annurev.es.16.110185.000553; BARTON NH, 1989, NATURE, V341, P497, DOI 10.1038/341497a0; Brito JC, 1998, HERPETOL J, V8, P187; Bronson CL, 2003, ANIM BEHAV, V65, P489, DOI 10.1006/anbe.2003.2103; Buggs RJA, 2007, HEREDITY, V99, P301, DOI 10.1038/sj.hdy.6800997; Cooper WE, 1992, BIOL REPTILIA HORMON, V18, P298; DESSER SS, 1993, PARASITIC PROTOZOA, V4, P247; Estrada-Pena A, 2005, EXP APPL ACAROL, V37, P257, DOI 10.1007/s10493-005-3271-6; Fritz RS, 1999, ANNU REV ECOL SYST, V30, P565, DOI 10.1146/annurev.ecolsys.30.1.565; Godinho R, 2008, MOL ECOL, V17, P4670, DOI 10.1111/j.1365-294X.2008.03929.x; Godinho R, 2006, HEREDITY, V96, P454, DOI 10.1038/sj.hdy.6800823; Godinho R, 2003, HERPETOL J, V13, P35; Harrison RG, 1993, HYBRID ZONES EVOLUTI; Hewitt GM, 2001, MOL ECOL, V10, P537, DOI 10.1046/j.1365-294x.2001.01202.x; HEWS DK, 1990, EVOLUTION, V44, P1956, DOI 10.1111/j.1558-5646.1990.tb04302.x; Hill GE, 2005, ANIM BEHAV, V69, P387, DOI 10.1016/j.anbehav.2004.03.013; Hoskin CJ, 2005, NATURE, V437, P1353, DOI 10.1038/nature04004; Hoskin CJ, 2007, BIOL J LINN SOC, V92, P593, DOI 10.1111/j.1095-8312.2007.00862.x; HOUDE AE, 1992, BEHAV ECOL, V3, P346, DOI 10.1093/beheco/3.4.346; JOHN JL, 1995, OIKOS, V72, P395, DOI 10.2307/3546125; Kratochvil L, 2002, BIOL J LINN SOC, V76, P303, DOI 10.1046/j.1095-8312.2002.00064.x; Lailvaux SP, 2004, P ROY SOC B-BIOL SCI, V271, P2501, DOI 10.1098/rspb.2004.2891; Lappin AK, 2005, AM NAT, V166, P426, DOI 10.1086/432564; Leache AD, 2007, MOL ECOL, V16, P1035, DOI 10.1111/j.1365-294X.2006.03194.x; LEVINE N. D., 1988, PROTOZOAN PHYLUM API, VI; Lopez P, 2004, ETHOLOGY, V110, P543, DOI 10.1111/j.1439-0310.2004.00996.x; LOSOS JB, 1985, COPEIA, P905, DOI 10.2307/1445240; Mallet J, 2005, TRENDS ECOL EVOL, V20, P229, DOI 10.1016/j.tree.2005.02.010; Marco A, 1999, ETHOL ECOL EVOL, V11, P279, DOI 10.1080/08927014.1999.9522828; Martin J, 2007, FUNCT ECOL, V21, P568, DOI 10.1111/j.1365-2435.2007.01262.x; Martin J, 1999, ETHOLOGY, V105, P439, DOI 10.1046/j.1439-0310.1999.00418.x; Martin J, 2007, BIOL LETTERS, V3, P125, DOI 10.1098/rsbl.2006.0589; McDonald DB, 2001, EVOLUTION, V55, P1443; Moller AP, 1998, J EVOLUTION BIOL, V11, P703, DOI 10.1007/s000360050114; MORAZA ML, ZOOTAXA IN PRESS; Moulia C, 1999, ECOLOGY, V80, P392, DOI 10.1890/0012-9658(1999)080[0392:POPAAH]2.0.CO;2; O'Connor DE, 2004, ANIM BEHAV, V68, P1361, DOI 10.1016/j.anbehav.2004.02.014; OLSSON M, 1995, BEHAV ECOL SOCIOBIOL, V36, P179, DOI 10.1007/BF00177794; Ord TJ, 2001, P ROY SOC B-BIOL SCI, V268, P737, DOI 10.1098/rspb.2000.1417; Orr HA, 2007, J HERED, V98, P103, DOI 10.1093/jhered/esl060; PARSONS TJ, 1993, SCIENCE, V260, P1643, DOI 10.1126/science.260.5114.1643; Paulo OS, 2001, P ROY SOC B-BIOL SCI, V268, P1625, DOI 10.1098/rspb.2001.1706; Pearson SF, 2000, BEHAV ECOL, V11, P93, DOI 10.1093/beheco/11.1.93; PEREIRA R, 2005, THESIS U PORTO PORTO; Perry G, 2004, ANIM BEHAV, V67, P37, DOI 10.1016/j.anbehav.2003.02.003; Phillips BL, 2004, EVOLUTION, V58, P1536; Reichenow, 1913, ARB KAISERL GESUNDH, V45, P317; Reudink MW, 2006, BEHAV ECOL, V17, P56, DOI 10.1093/beheco/ari098; Reullier J, 2006, MOL ECOL, V15, P753, DOI 10.1111/j.1365-294X.2005.02826.x; Rohwer S, 2001, EVOLUTION, V55, P405; Schall JJ, 1997, OECOLOGIA, V111, P543, DOI 10.1007/s004420050269; Siroky P, 2007, FOLIA PARASIT, V54, P13, DOI 10.14411/fp.2007.002; Sorci G, 1997, TRENDS ECOL EVOL, V12, P196, DOI 10.1016/S0169-5347(97)01056-2; Stein AC, 2006, EVOLUTION, V60, P1476, DOI 10.1111/j.0014-3820.2006.tb01226.x; Stuart-Fox DM, 2005, BEHAVIOUR, V142, P329, DOI 10.1163/1568539053778265; Stuart-Fox DM, 2003, ANIM BEHAV, V66, P541, DOI 10.1006/anbe.2003.2235; Svahn K., 1975, Norwegian J Zool, V23, P277; TOKARZ RR, 1995, HERPETOLOGICAL MONOGRAPHS, NO 9, 1995, P17, DOI 10.2307/1466994; Veen T, 2001, NATURE, V411, P45, DOI 10.1038/35075000; Walther BA, 1999, OIKOS, V87, P157, DOI 10.2307/3547006; Whiting MJ, 2006, ANIM BEHAV, V72, P353, DOI 10.1016/j.anbehav.2005.10.018; Whiting MJ, 2003, LIZARD SOCIAL BEHAVIOR, P47; Whiting MJ, 1999, BEHAV ECOL SOCIOBIOL, V46, P210, DOI 10.1007/s002650050611; Wolinska J, 2008, TRENDS PARASITOL, V24, P121, DOI 10.1016/j.pt.2007.11.010	66	17	19	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2009	4	5							e5677	10.1371/journal.pone.0005677	http://dx.doi.org/10.1371/journal.pone.0005677			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LI	19479073	Green Published, gold			2022-12-25	WOS:000266331700005
J	Haston, KM; Tung, JY; Pera, RAR				Haston, Kelly M.; Tung, Joyce Y.; Pera, Renee A. Reijo			Dazl Functions in Maintenance of Pluripotency and Genetic and Epigenetic Programs of Differentiation in Mouse Primordial Germ Cells In Vivo and In Vitro	PLOS ONE			English	Article								Background: Mammalian germ cells progress through a unique developmental program that encompasses proliferation and migration of the nascent primordial germ cell (PGC) population, reprogramming of nuclear DNA to reset imprinted gene expression, and differentiation of mature gametes. Little is known of the genes that regulate quantitative and qualitative aspects of early mammalian germ cell development both in vivo, and during differentiation of germ cells from mouse embryonic stem cells (mESCs) in vitro. Methodology and Principal Findings: We used a transgenic mouse system that enabled isolation of small numbers of Oct4 Delta PE:GFP-positive germ cells in vivo, and following differentiation from mESCs in vitro, to uncover quantitate and qualitative phenotypes associated with the disruption of a single translational regulator, Dazl. We demonstrate that disruption of Dazl results in a post-migratory, pre-meiotic reduction in PGC number accompanied by aberrant expression of pluripotency genes and failure to erase and re-establish genomic imprints in isolated male and female PGCs, as well as subsequent defect in progression through meiosis. Moreover, the phenotypes observed in vivo were mirrored by those in vitro, with inability of isolated mutant PGCs to establish pluripotent EG (embryonic germ) cell lines and few residual Oct-4-expressing cells remaining after somatic differentiation of mESCs carrying a Dazl null mutation. Finally, we observed that even within undifferentiated mESCs, a nascent germ cell subpopulation exists that was effectively eliminated with ablation of Dazl. Conclusions and Significance: This report establishes the translational regulator Dazl as a component of pluripotency, genetic, and epigenetic programs at multiple time points of germ cell development in vivo and in vitro, and validates use of the ESC system to model and explore germ cell biology.			Haston, KM (corresponding author), Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Dept Obstet & Gynecol, Palo Alto, CA 94304 USA.	reneer@stanford.edu		Reijo Pera, Renee/0000-0002-6487-1329	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD055764] Funding Source: NIH RePORTER; NICHD NIH HHS [U54 HD055764, R01 HD047221, 5U54HD055764-02] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abeyta MJ, 2004, HUM MOL GENET, V13, P601, DOI 10.1093/hmg/ddh068; Anderson R, 1999, DEVELOPMENT, V126, P1655; Bendsen E, 2003, HUM REPROD, V18, P13, DOI 10.1093/humrep/deg057; Bendsen E, 2006, HUM REPROD, V21, P30, DOI 10.1093/humrep/dei280; Blyszczuk P, 2003, P NATL ACAD SCI USA, V100, P998, DOI 10.1073/pnas.0237371100; Cao F, 2007, STEM CELLS DEV, V16, P883, DOI 10.1089/scd.2007.0160; Clark AT, 2004, HUM MOL GENET, V13, P727, DOI 10.1093/hmg/ddh088; Clark AT, 2004, STEM CELLS, V22, P169, DOI 10.1634/stemcells.22-2-169; Collier B, 2005, EMBO J, V24, P2656, DOI 10.1038/sj.emboj.7600738; Cooke HJ, 1996, HUM MOL GENET, V5, P513, DOI 10.1093/hmg/5.4.513; Cooke MJ, 2006, STEM CELLS DEV, V15, P254, DOI 10.1089/scd.2006.15.254; Davis TL, 2000, HUM MOL GENET, V9, P2885, DOI 10.1093/hmg/9.19.2885; De Miguel MP, 2003, METHOD ENZYMOL, V365, P353; DOETSCHMAN T, 2009, METHOD MOL BIOL, V530, P1; Durcova-Hills G, 2006, P NATL ACAD SCI USA, V103, P11184, DOI 10.1073/pnas.0602621103; Eberhart CG, 1996, NATURE, V381, P783, DOI 10.1038/381783a0; Eisener-Dorman AF, 2009, BRAIN BEHAV IMMUN, V23, P318, DOI 10.1016/j.bbi.2008.09.001; Ensenat-Waser R, 2006, IN VITRO CELL DEV-AN, V42, P115, DOI 10.1290/0509063.1; Geijsen N, 2004, NATURE, V427, P148, DOI 10.1038/nature02247; GOMPERTS M, 1994, DEVELOPMENT, V120, P135; Gonsalves J, 2005, REPRODUCTION, V130, P223, DOI 10.1530/rep.1.00641; Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8; Hajkova P, 2008, NATURE, V452, P877, DOI 10.1038/nature06714; Hasegawa E, 2006, DEV BIOL, V295, P689, DOI 10.1016/j.ydbio.2006.04.002; Hayashi K, 2008, CELL STEM CELL, V3, P391, DOI 10.1016/j.stem.2008.07.027; Houston DW, 2000, CURR TOP DEV BIOL, V50, P155, DOI 10.1016/S0070-2153(00)50008-8; Hubner K, 2003, SCIENCE, V300, P1251, DOI 10.1126/science.1083452; Kee K, 2006, STEM CELLS DEV, V15, P831, DOI 10.1089/scd.2006.15.831; Lacham-Kaplan O, 2006, STEM CELLS, V24, P266, DOI 10.1634/stemcells.2005-0204; Lawson KA, 1999, GENE DEV, V13, P424, DOI 10.1101/gad.13.4.424; Li JY, 2004, GENOMICS, V84, P952, DOI 10.1016/j.ygeno.2004.08.012; Lin YF, 2008, SCIENCE, V322, P1685, DOI 10.1126/science.1166340; Lin YF, 2005, DEV BIOL, V288, P309, DOI 10.1016/j.ydbio.2005.06.032; Lucifero D, 2002, GENOMICS, V79, P530, DOI 10.1006/geno.2002.6732; Lucifero D, 2004, HUM MOL GENET, V13, P839, DOI 10.1093/hmg/ddh104; McClive PJ, 2001, MOL REPROD DEV, V60, P225, DOI 10.1002/mrd.1081; McLaren A, 2003, DEV BIOL, V262, P1, DOI 10.1016/S0012-1606(03)00214-8; Molyneaux KA, 2003, DEVELOPMENT, V130, P4287, DOI 10.1242/dev.00650; Molyneaux KA, 2001, DEV BIOL, V240, P488, DOI 10.1006/dbio.2001.0436; Moore FL, 2004, GENOMICS, V83, P834, DOI 10.1016/j.ygeno.2003.11.005; Moore FL, 2003, P NATL ACAD SCI USA, V100, P538, DOI 10.1073/pnas.0234478100; Nayernia K, 2006, DEV CELL, V11, P125, DOI 10.1016/j.devcel.2006.05.010; Ohinata Y, 2005, NATURE, V436, P207, DOI 10.1038/nature03813; Okamura D, 2005, MOL REPROD DEV, V70, P20, DOI 10.1002/mrd.20136; Reijo R, 1996, LANCET, V347, P1290, DOI 10.1016/S0140-6736(96)90938-1; Reynolds N, 2005, HUM MOL GENET, V14, P3899, DOI 10.1093/hmg/ddi414; Ruggiu M, 1997, NATURE, V389, P73, DOI 10.1038/37987; Saffman EE, 1999, CELL MOL LIFE SCI, V55, P1141, DOI 10.1007/s000180050363; Saitou M, 2002, NATURE, V418, P293, DOI 10.1038/nature00927; Saunders PTK, 2003, REPRODUCTION, V126, P589, DOI 10.1530/rep.0.1260589; Stebler J, 2004, DEV BIOL, V272, P351, DOI 10.1016/j.ydbio.2004.05.009; Surani MA, 2007, CELL, V128, P747, DOI 10.1016/j.cell.2007.02.010; Swain A, 2006, CURR BIOL, V16, pR507, DOI 10.1016/j.cub.2006.06.009; Teramura T, 2007, CLONING STEM CELLS, V9, P144, DOI 10.1089/clo.2006.0070; Tilly Jonathan L, 2003, Reprod Biol Endocrinol, V1, P11, DOI 10.1186/1477-7827-1-11; Toyooka Y, 2003, P NATL ACAD SCI USA, V100, P11457, DOI 10.1073/pnas.1932826100; Tung JY, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-40; Tung JY, 2006, HUM GENET, V118, P730, DOI 10.1007/s00439-005-0098-5; Ueda T, 2000, GENES CELLS, V5, P649, DOI 10.1046/j.1365-2443.2000.00351.x; Vincent SD, 2005, DEVELOPMENT, V132, P1315, DOI 10.1242/dev.01711; Wang R, 2008, DIFFERENTIATION, V76, P931, DOI 10.1111/j.1432-0436.2008.00272.x; Xu EY, 2001, P NATL ACAD SCI USA, V98, P7414, DOI 10.1073/pnas.131090498; Yamaguchi S, 2005, GENE EXPR PATTERNS, V5, P639, DOI 10.1016/j.modgep.2005.03.001; Yamaji M, 2008, NAT GENET, V40, P1016, DOI 10.1038/ng.186; Yen PH, 1996, HUM MOL GENET, V5, P2013, DOI 10.1093/hmg/5.12.2013; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Yoshimizu T, 1999, DEV GROWTH DIFFER, V41, P675	67	85	91	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2009	4	5							e5654	10.1371/journal.pone.0005654	http://dx.doi.org/10.1371/journal.pone.0005654			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LB	19468308	Green Published, Green Submitted, gold			2022-12-25	WOS:000266331000012
J	Blaho, VA; Buczynski, MW; Brown, CR; Dennis, EA				Blaho, Victoria A.; Buczynski, Matthew W.; Brown, Charles R.; Dennis, Edward A.			Lipidomic Analysis of Dynamic Eicosanoid Responses during the Induction and Resolution of Lyme Arthritis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE EPOXIDE HYDROLASE; EPOXYEICOSATRIENOIC ACIDS; FATTY-ACIDS; PPAR-GAMMA; INFLAMMATION-RESOLUTION; LIQUID-CHROMATOGRAPHY; BORRELIA-BURGDORFERI; MASS-SPECTROMETRY; LEUKOTRIENE B-4; LIPOXIN A(4)	Eicosanoids and other bioactive lipid mediators are indispensable regulators of biological processes, as demonstrated by the numerous inflammatory diseases resulting from their dysregulation, including cancer, hyperalgesia, atherosclerosis, and arthritis. Despite their importance, a robust strategy comparable with gene or protein array technology for comprehensively analyzing the eicosanoid metabolome has not been forthcoming. We have developed liquid chromatography-tandem mass spectrometry methodology that quantitatively and comprehensively analyzes the eicosanoid metabolome and utilized this approach to characterize eicosanoid production during experimental Lyme arthritis in mice infected with the bacterium Borrelia burgdorferi. Eicosanoids were extracted throughout infection from the joints of Lyme arthritis-resistant and -susceptible mice and subjected to lipidomic profiling. We identified temporal and quantitative differences between these mouse strains in the production of eicosanoids, which correlated with differences in arthritis development. The eicosanoid biosynthetic enzyme cyclooxygenase (COX)-2 has been implicated in the regulation of Lyme arthritis pathology, and subsequent lipidomic profiling of B. burgdorferi-infected COX-2(-/-) mice identified reductions not only in COX-2 products but, surprisingly, also significant off-target reductions in 5-lipoxygenase metabolites. Our results demonstrate the utility of a comprehensive lipidomic approach for identifying potential contributors to disease pathology and may facilitate the development of more precisely targeted treatment strategies.	[Brown, Charles R.] Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA; [Buczynski, Matthew W.; Dennis, Edward A.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Buczynski, Matthew W.; Dennis, Edward A.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of Missouri System; University of Missouri Columbia; University of California System; University of California San Diego; University of California System; University of California San Diego	Brown, CR (corresponding author), Univ Missouri, Dept Vet Pathobiol, 315 Connaway Hall, Columbia, MO 65211 USA.	BrownChar@missouri.edu; edennis@ucsd.edu	Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140; Brown, Charles/0000-0002-1914-9601; Blaho, Victoria/0000-0001-8499-2278	NIGMS [GM069338]; National Institutes of Health [R01-AR052748]; NIAMS; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM069338] Funding Source: NIH RePORTER	NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health LIPID MAPS Large Scale Collaborative Grant GM069338 from NIGMS (to E. A. D.) and National Institutes of Health Grant R01-AR052748 from NIAMS (to C. R. B.).	Aliberti J, 2002, J EXP MED, V196, P1253, DOI 10.1084/jem.20021183; Bafica A, 2005, J CLIN INVEST, V115, P1601, DOI 10.1172/JCI23949; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Barthold SW, 1997, CLIN INFECT DIS, V25, pS9, DOI 10.1086/516166; BARTHOLD SW, 1990, J INFECT DIS, V162, P133, DOI 10.1093/infdis/162.1.133; Binstadt BA, 2006, NAT IMMUNOL, V7, P284, DOI 10.1038/ni1306; Blaho VA, 2008, ARTHRITIS RHEUM-US, V58, P1485, DOI 10.1002/art.23371; Bolick DT, 2005, ARTERIOSCL THROM VAS, V25, P2301, DOI 10.1161/01.ATV.0000186181.19909.a6; Brown CR, 2000, J IMMUNOL, V165, P1446, DOI 10.4049/jimmunol.165.3.1446; Brown CR, 2003, J IMMUNOL, V171, P893, DOI 10.4049/jimmunol.171.2.893; Buczynski MW, 2007, J BIOL CHEM, V282, P22834, DOI 10.1074/jbc.M701831200; Buczynski MW, 2009, J LIPID RES, V50, P1015, DOI 10.1194/jlr.R900004-JLR200; Chen M, 2006, J EXP MED, V203, P837, DOI 10.1084/jem.20052371; Chen M, 2008, ARTHRITIS RHEUM, V58, P1354, DOI 10.1002/art.23453; Chizzolini C, 2008, BLOOD, V112, P3696, DOI 10.1182/blood-2008-05-155408; Crandall H, 2006, J IMMUNOL, V177, P7930, DOI 10.4049/jimmunol.177.11.7930; Deems R, 2007, METHOD ENZYMOL, V432, P59, DOI 10.1016/S0076-6879(07)32003-X; Dennis EA, 2009, P NATL ACAD SCI USA, V106, P2089, DOI 10.1073/pnas.0812636106; Dioszeghy V, 2008, J IMMUNOL, V181, P6514, DOI 10.4049/jimmunol.181.9.6514; Fahy E, 2005, J LIPID RES, V46, P839, DOI 10.1194/jlr.E400004-JLR200; Folco G, 2006, PHARMACOL REV, V58, P375, DOI 10.1124/pr.58.3.8; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gonzalez-Periz A, 2006, FASEB J, V20, P2537, DOI 10.1096/fj.06-6250fje; Harkewicz R, 2007, J BIOL CHEM, V282, P2899, DOI 10.1074/jbc.M610067200; HAYAKAWA M, 1986, BIOCHEM BIOPH RES CO, V137, P424, DOI 10.1016/0006-291X(86)91227-1; Hong S, 2008, J IMMUNOL, V180, P3512, DOI 10.4049/jimmunol.180.5.3512; Itoh T, 2008, NAT STRUCT MOL BIOL, V15, P924, DOI 10.1038/nsmb.1474; Jankov RP, 2002, J PHARMACOL EXP THER, V301, P435, DOI 10.1124/jpet.301.2.435; Kiss L, 2008, ANAL BIOANAL CHEM, V390, P697, DOI 10.1007/s00216-007-1718-9; Krause P, 2009, BLOOD, V113, P2451, DOI 10.1182/blood-2008-05-157123; Kuhn H, 2006, PROG LIPID RES, V45, P334, DOI 10.1016/j.plipres.2006.02.003; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748; Liu Y, 2005, P NATL ACAD SCI USA, V102, P16747, DOI 10.1073/pnas.0508081102; Ma Y, 1998, INFECT IMMUN, V66, P161, DOI 10.1128/IAI.66.1.161-168.1998; Mao JT, 2004, CLIN CANCER RES, V10, P6872, DOI 10.1158/1078-0432.CCR-04-0945; Marcouiller P, 2005, J RHEUMATOL, V32, P704; Masoodi M, 2008, RAPID COMMUN MASS SP, V22, P75, DOI 10.1002/rcm.3331; McCormick BA, 1998, J IMMUNOL, V160, P455; McCormick BA, 2007, FEBS J, V274, P3513, DOI 10.1111/j.1742-4658.2007.05911.x; Michaelis UR, 2006, PHARMACOL THERAPEUT, V111, P584, DOI 10.1016/j.pharmthera.2005.11.003; Moghaddam MF, 1997, NAT MED, V3, P562, DOI 10.1038/nm0597-562; Morisseau C, 2005, ANNU REV PHARMACOL, V45, P311, DOI 10.1146/annurev.pharmtox.45.120403.095920; Murphy RC, 2007, BIOCHEM J, V405, P379, DOI 10.1042/BJ20070289; Myers LK, 2000, ARTHRITIS RHEUM-US, V43, P2687, DOI 10.1002/1529-0131(200012)43:12<2687::AID-ANR8>3.0.CO;2-9; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; OHTA A, 1990, LIPIDS, V25, P742, DOI 10.1007/BF02544044; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; Powell WS, 2005, PROG LIPID RES, V44, P154, DOI 10.1016/j.plipres.2005.04.002; Powell WS, 2003, J CLIN INVEST, V112, P828, DOI 10.1172/JCI200319796; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Schmelzer K, 2007, METHOD ENZYMOL, V432, P171, DOI 10.1016/S0076-6879(07)32007-7; Schmelzer KR, 2006, P NATL ACAD SCI USA, V103, P13646, DOI 10.1073/pnas.0605908103; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2006, J IMMUNOL, V176, P1848, DOI 10.4049/jimmunol.176.3.1848; Sotiriou C, 2007, NAT REV CANCER, V7, P545, DOI 10.1038/nrc2173; Steere AC, 2004, NAT REV IMMUNOL, V4, P143, DOI 10.1038/nri1267; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Wen YH, 2008, AM J PHYSIOL-HEART C, V294, pH1933, DOI 10.1152/ajpheart.00260.2007; Wen YS, 2007, ENDOCRINOLOGY, V148, P1313, DOI 10.1210/en.2006-0665; WERTHEIM WA, 1993, J IMMUNOL, V151, P2166; Wilson KR, 2007, MICROBIOL-SGM, V153, P968, DOI 10.1099/mic.0.2006/002261-0; Woods JM, 2003, EXP MOL PATHOL, V74, P282, DOI 10.1016/S0014-4800(03)00019-4; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V316, P443, DOI 10.1006/abbi.1995.1059	66	86	88	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	2009	284	32					21599	21612		10.1074/jbc.M109.003822	http://dx.doi.org/10.1074/jbc.M109.003822			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478CC	19487688	Green Published, hybrid			2022-12-25	WOS:000268564400054
J	Kawanami, D; Mahabeleshwar, GH; Lin, ZY; Atkins, GB; Hamik, A; Haldar, SM; Maemura, K; LaManna, JC; Jain, MK				Kawanami, Daiji; Mahabeleshwar, Ganapati H.; Lin, Zhiyong; Atkins, G. Brandon; Hamik, Anne; Haldar, Saptarsi M.; Maemura, Koji; LaManna, Joseph C.; Jain, Mukesh K.			Kruppel-like Factor 2 Inhibits Hypoxia-inducible Factor 1 alpha Expression and Function in the Endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLF2 TRANSCRIPTION FACTOR; GROWTH-FACTOR; PROINFLAMMATORY ACTIVATION; ERYTHROPOIETIN GENE; CELLS; DEGRADATION; CANCER; STABILIZATION; ANGIOGENESIS; HIF-1-ALPHA	Hypoxia-inducible factor 1 (HIF-1) is a central regulator of the hypoxic response in many cell types. In endothelial cells, HIF-1 induces the expression of key proangiogenic factors to promote angiogenesis. Recent studies have identified Kruppel-like factor 2 (KLF2) as a potent inhibitor of angiogenesis. However, the role of KLF2 in regulating HIF-1 expression and function has not been evaluated. KLF2 expression was induced acutely by hypoxia in endothelial cells. Adenoviral overexpression of KLF2 inhibited hypoxia-induced expression of HIF-1 alpha and its target genes such as interleukin 8, angiopoietin-2, and vascular endothelial growth factor in endothelial cells. Conversely, knockdown of KLF2 increased expression of HIF-1 alpha and its targets. Furthermore, KLF2 inhibited hypoxia-induced endothelial tube formation, whereas endothelial cells from mice with haploinsufficiency of KLF2 showed increased tube formation in response to hypoxia. Consistent with this ex vivo observation, KLF2 heterozygous mice showed increased microvessel density in the brain. Mechanistically, KLF2 promoted HIF-1 alpha degradation in a von Hippel-Lindau protein-independent but proteasome-dependent manner. Finally, KLF2 disrupted the interaction between HIF-1 alpha and its chaperone Hsp90, suggesting that KLF2 promotes degradation of HIF-1 alpha by affecting its folding and maturation. These observations identify KLF2 as a novel inhibitor of HIF-1 alpha expression and function. Therefore, KLF2 may be a target for modulating the angiogenic response in disease states.	[Kawanami, Daiji; Mahabeleshwar, Ganapati H.; Lin, Zhiyong; Atkins, G. Brandon; Hamik, Anne; Haldar, Saptarsi M.; Jain, Mukesh K.] Case Western Reserve Univ, Univ Hosp Harrington, McLaughlin Heart & Vasc Inst, Sch Med, Cleveland, OH 44106 USA; [Kawanami, Daiji; Mahabeleshwar, Ganapati H.; Lin, Zhiyong; Atkins, G. Brandon; Hamik, Anne; Haldar, Saptarsi M.; Jain, Mukesh K.] Case Western Reserve Univ, Case Cardiovasc Res Inst, Sch Med, Cleveland, OH 44106 USA; [Maemura, Koji] Nagasaki Univ, Grad Sch Biomed Sci, Dept Cardiovasc Med, Nagasaki 852, Japan; [LaManna, Joseph C.] Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Nagasaki University; Case Western Reserve University	Jain, MK (corresponding author), 2103 Cornell Rd,Rm 4-522, Cleveland, OH 44106 USA.	mukesh.jain2@case.edu	LaManna, Joseph/D-3860-2013; LaManna, Joseph C/C-3347-2012	LaManna, Joseph/0000-0002-0159-4512; LaManna, Joseph C/0000-0002-0159-4512	National Institutes of Health [HL72952, HL75427, HL76754, HL086548, HL084154, P01 HL048743, HL087595, HL088740, HL083090, HL086614, NS38632]; Alliance for Cancer Gene Therapy; Robert Wood Johnson/Harold Amos Medical Faculty Development; Dominic Visconsi Scholar Award; American Heart Association [0635579T, 0725297B]; Kanae Foundation for the Promotion of Medical Science; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084154, R01HL086548, K99HL087595, R01HL076754, R01HL072952, K08HL086614, R00HL087595, K08HL083090, R01HL075427, K01HL088740, P01HL048743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038632] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alliance for Cancer Gene Therapy; Robert Wood Johnson/Harold Amos Medical Faculty Development(Robert Wood Johnson Foundation (RWJF)); Dominic Visconsi Scholar Award; American Heart Association(American Heart Association); Kanae Foundation for the Promotion of Medical Science; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported, in whole or in part, by National Institutes of Health Grants HL72952, HL75427, HL76754, HL086548, HL084154, and P01 HL048743 ( to M. K. J.); HL087595 ( to Z. L.); HL088740 ( to G. B. A.); HL083090 ( to A. H.); HL086614 ( to S. H.); and NS38632 ( to J. C. L.). This work was also supported by an Alliance for Cancer Gene Therapy grant ( to M. K. J.), a Robert Wood Johnson/Harold Amos Medical Faculty Development grant ( to G. B. A.), a Dominic Visconsi Scholar Award ( to G. B. A., A. H., and S. H.), American Heart Association Grants 0635579T ( to Z. L.) and 0725297B ( to D. K.), and a Kanae Foundation for the Promotion of Medical Science grant ( to D. K.).	ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Atkins GB, 2008, CIRC RES, V103, P690, DOI 10.1161/CIRCRESAHA.108.184663; Atkins GB, 2007, CIRC RES, V100, P1686, DOI 10.1161/01.RES.0000267856.00713.0a; Bhattacharya R, 2005, J BIOL CHEM, V280, P28848, DOI 10.1074/jbc.C500200200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; Das H, 2006, P NATL ACAD SCI USA, V103, P6653, DOI 10.1073/pnas.0508235103; Feinberg MW, 2004, TRENDS CARDIOVAS MED, V14, P241, DOI 10.1016/j.tcm.2004.06.005; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Hosogai N, 2007, DIABETES, V56, P901, DOI 10.2337/db06-0911; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Isaacs JS, 2004, J BIOL CHEM, V279, P16128, DOI 10.1074/jbc.M313342200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Kanaan A, 2006, AM J PHYSIOL-REG I, V290, pR1105, DOI 10.1152/ajpregu.00535.2005; Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029; Kim KS, 2006, J IMMUNOL, V177, P7211, DOI 10.4049/jimmunol.177.10.7211; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Kong XG, 2006, FEBS LETT, V580, P6182, DOI 10.1016/j.febslet.2006.10.019; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Lin ZY, 2006, ARTERIOSCL THROM VAS, V26, P1185, DOI 10.1161/01.ATV.0000215638.53414.99; Lin ZY, 2005, CIRC RES, V96, pE48, DOI 10.1161/01.RES.0000159707.05637.a1; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mahabeleshwar Ganapati H., 2006, V129, P197; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Minnnaugh EG, 2004, MOL CANCER THER, V3, P551; Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; Ndubuizu O, 2007, ANTIOXID REDOX SIGN, V9, P1207, DOI 10.1089/ars.2007.1634; Pichiule P, 2004, J BIOL CHEM, V279, P12171, DOI 10.1074/jbc.M305146200; Ravi R, 2000, GENE DEV, V14, P34; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sen-Banerjee S, 2005, CIRCULATION, V112, P720, DOI 10.1161/CIRCULATIONAHA.104.525774; SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Simon MP, 2008, J CELL PHYSIOL, V217, P809, DOI 10.1002/jcp.21558; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; van Vliet J, 2006, GENOMICS, V87, P474, DOI 10.1016/j.ygeno.2005.12.011; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wani MA, 1998, TRANSGENIC RES, V7, P229, DOI 10.1023/A:1008809809843; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Wu JH, 2005, BIOCHEMISTRY-US, V44, P11098, DOI 10.1021/bi050166i; Wu JH, 2008, J BIOL CHEM, V283, P3942, DOI 10.1074/jbc.M707882200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	54	68	76	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20522	20530		10.1074/jbc.M109.025346	http://dx.doi.org/10.1074/jbc.M109.025346			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19491109	hybrid, Green Published			2022-12-25	WOS:000268316100013
J	Schade, B; Rao, T; Dourdin, N; Lesurf, R; Hallett, M; Cardiff, RD; Muller, WJ				Schade, Babette; Rao, Trisha; Dourdin, Nathalie; Lesurf, Robert; Hallett, Michael; Cardiff, Robert D.; Muller, William J.			PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; TUMOR-SUPPRESSOR GENE; DIFFERENTIAL EXPRESSION; TRASTUZUMAB RESISTANCE; SIGNALING NETWORK; MICE; ACTIVATION; SURVIVAL; AMPLIFICATION; PHOSPHATASE	Overexpression and/or amplification of the ErbB-2 oncogene as well as inactivation of the PTEN tumor suppressor are two important genetic events in human breast carcinogenesis. To address the biological impact of conditional inactivation of PTEN on ErbB-2-induced mammary tumorigenesis, we generated a novel transgenic mouse model that utilizes the murine mammary tumor virus (MMTV) promoter to directly couple expression of activated ErbB-2 and Cre recombinase to the same mammary epithelial cell (MMTV-NIC). Disruption of PTEN in the mammary epithelium of the MMTV-NIC model system dramatically accelerated the formation of multifocal and highly metastatic mammary tumors, which exhibited homogenous pathology. PTEN-deficient/NIC-induced tumorigenesis was associated with an increase in angiogenesis. Moreover, inactivation of PTEN in the MMTV-NIC mouse model resulted in hyperactivation of the phosphatidylinositol 3'-kinase/Akt signaling pathway. However, like the parental strain, tumors obtained from PTEN-deficient/NIC mice displayed histopathological and molecular features of the luminal subtype of primary human breast cancer. Taken together, our findings provide important implications in understanding the molecular determinants of mammary tumorigenesis driven by PTEN deficiency and ErbB-2 activation and could provide a valuable tool for testing the efficacy of therapeutic strategies that target these critical signaling pathways.	[Schade, Babette; Rao, Trisha; Dourdin, Nathalie; Lesurf, Robert; Hallett, Michael; Muller, William J.] McGill Univ, Goodman Canc Ctr, Montreal, PQ H3G 0B1, Canada; [Lesurf, Robert; Hallett, Michael] McGill Ctr Bioinformat, Montreal, PQ H3G 0B1, Canada; [Cardiff, Robert D.] Univ Calif Davis, Sch Med, Dept Pathol & Lab Med, Davis, CA 95616 USA; [Cardiff, Robert D.] Univ Calif Davis, Sch Med, Ctr Comparat Med, Davis, CA 95616 USA	McGill University; McGill University; University of California System; University of California Davis; University of California System; University of California Davis	Muller, WJ (corresponding author), 1160 Pine Ave W, Montreal, PQ H3G 0B1, Canada.	william.muller@mcgill.ca		Hallett, Michael/0000-0001-6738-6786	Terry Fox Foundation New Frontiers Program [NCIC 017003]; Cancer Research Society/Quebec Breast Cancer Foundation; Canadian Institutes of Health Research Team [79857]; Natural Science and Engineering Research Council Postgraduate Scholarship	Terry Fox Foundation New Frontiers Program; Cancer Research Society/Quebec Breast Cancer Foundation; Canadian Institutes of Health Research Team(Canadian Institutes of Health Research (CIHR)); Natural Science and Engineering Research Council Postgraduate Scholarship	This work was supported by a Terry Fox Foundation New Frontiers Program Project Grant NCIC 017003, a Cancer Research Society/Quebec Breast Cancer Foundation grant, and Canadian Institutes of Health Research Team Grant 79857. Supported by a Natural Science and Engineering Research Council Postgraduate Scholarship.	Adelaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Da Silva L, 2007, J CLIN PATHOL, V60, P1328, DOI 10.1136/jcp.2006.041731; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202; Dourdin N, 2008, CANCER RES, V68, P2122, DOI 10.1158/0008-5472.CAN-07-5727; Durinck S, 2005, BIOINFORMATICS, V21, P3439, DOI 10.1093/bioinformatics/bti525; Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Garcia JM, 1999, BREAST CANCER RES TR, V57, P237, DOI 10.1023/A:1006273516976; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; LAZARD D, 1993, P NATL ACAD SCI USA, V90, P999, DOI 10.1073/pnas.90.3.999; Li G, 2002, DEVELOPMENT, V129, P4159; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maglione JE, 2001, CANCER RES, V61, P8298; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Sano T, 1999, CANCER RES, V59, P1820; Schade B, 2007, CANCER RES, V67, P7579, DOI 10.1158/0008-5472.CAN-06-4724; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2000, CANCER RES, V60, P3605; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki A, 2003, J EXP MED, V197, P657, DOI 10.1084/jem.20021101; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Takei Y, 2008, MOL CANCER THER, V7, P704, DOI 10.1158/1535-7163.MCT-06-0724; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Ursini-Siegel J, 2007, NAT REV CANCER, V7, P389, DOI 10.1038/nrc2127; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025	54	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					19018	19026		10.1074/jbc.M109.018937	http://dx.doi.org/10.1074/jbc.M109.018937			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19435886	hybrid, Green Published			2022-12-25	WOS:000267711500051
J	Pratt, MAC; Tibbo, E; Robertson, SJ; Jansson, D; Hurst, K; Perez-Iratxeta, C; Lau, R; Niu, MY				Pratt, M. A. C.; Tibbo, E.; Robertson, S. J.; Jansson, D.; Hurst, K.; Perez-Iratxeta, C.; Lau, R.; Niu, M. Y.			The canonical NF-kappa B pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population	ONCOGENE			English	Article						NF-kappa B; transgenic mice; mammary cancer; luminal; basal; squamous	BREAST-CANCER; THERAPEUTIC TARGET; TRANSGENIC MICE; EXPRESSION; GROWTH; ALPHA; KINASE; GLAND; IKK; TRANSFORMATION	The role of the canonical NF-kappa B pathway in mammary tumorigenesis was investigated using a transgenic (TG) mouse expressing a dominant-negative inhibitor of kappa B (I kappa B alpha(SR(S32A/S36A))) in the mammary gland under the control of the mouse mammary tumor virus promoter ( MMTV). TG and control mice were subjected to a chemical carcinogenesis protocol. Hyperkeratinized squamous metaplasias ( cytokeratin -6+/p63+) sometimes with a basaloid island component, were found in both TG and control mice whereas luminal (cytokeratin-19+/ MUC1+) ErbB2+ papillary and adenomatous lesions developed almost exclusively in control mice. p65/RelA- and NF-kappa B DNA-binding activity were detected in mammary luminal lesions, but rarely in squamous metaplasias. Analysis of NF-kappa B family proteins and target genes using microarray data from a cohort of human mammary tumors revealed the expression of a canonical NF-kappa B pathway, but not non-canonical pathway proteins in HER2 | luminal cancers. HER2 | tumors also showed differential regulation of specific NF-kappa B target genes relative to basal and ER+ luminal cancers. Isolation of mammary cell populations enriched for stem and progenitor cell characteristics from an NF-kappa B-EGFP reporter mouse by fluorescence-activated cell sorting demonstrated that luminal progenitors contain activated NF-kappa B whereas the mammary stem cell-enriched population, does not. Together these data suggest that the canonical NF-kappa B pathway is active in normal luminal progenitor cells before transformation and is required for the formation of mammary luminal-type epithelial neoplasias. Oncogene (2009) 28, 2710-2722; doi:10.1038/onc.2009.131; published online 1 June 2009	[Pratt, M. A. C.; Tibbo, E.; Jansson, D.; Hurst, K.; Lau, R.; Niu, M. Y.] Univ Ottawa, Dept Cellular & Mol Med, Breast Canc Res Lab, Ottawa, ON K1H 8M5, Canada; [Robertson, S. J.] Ottawa Hosp, Dept Pathol & Lab Med, Ottawa, ON, Canada; [Perez-Iratxeta, C.] Sprott Ctr Stem Cell Res, Ottawa Hlth Res Inst, Ottawa, ON, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Pratt, MAC (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Breast Canc Res Lab, 451 Smyth Rd,RGN Hall, Ottawa, ON K1H 8M5, Canada.	cpratt@uottawa.ca		Jansson, Deidre/0000-0001-9757-8682; Bone, Kathleen Marie/0000-0002-2690-0934	Canadian Institutes of Health Research/Canadian Breast Cancer Research Alliance [FRN 79304]; Cancer Research Society Inc.	Canadian Institutes of Health Research/Canadian Breast Cancer Research Alliance(Canadian Institutes of Health Research (CIHR)); Cancer Research Society Inc.	Our thanks to Jun Wang, Jian Xuan and Jessica Sanguiliano for expert technical assistance. Supported by Grant no. FRN 79304 from the Canadian Institutes of Health Research/Canadian Breast Cancer Research Alliance and the Cancer Research Society Inc. to MACP.	Ackerman A.B., 1993, NEOPLASMS FOLLICULAR; Biswas DK, 2001, P NATL ACAD SCI USA, V98, P10386, DOI 10.1073/pnas.151257998; Calza S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1517; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Chen DY, 2003, ONCOGENE, V22, P4348, DOI 10.1038/sj.onc.1206532; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Demicco EG, 2005, MOL CELL BIOL, V25, P10136, DOI 10.1128/MCB.25.22.10136-10147.2005; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Grenier J, 2007, ANTICANCER RES, V27, P547; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang WC, 2007, MOL CELL, V26, P75, DOI 10.1016/j.molcel.2007.02.019; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Magness ST, 2004, J IMMUNOL, V173, P1561, DOI 10.4049/jimmunol.173.3.1561; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Singh S, 2007, MOL CANCER THER, V6, P1973, DOI 10.1158/1535-7163.MCT-07-0063; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212; Tse GM, 2006, PATHOLOGY, V38, P16, DOI 10.1080/00313020500444625; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Wang XB, 2007, NAT CELL BIOL, V9, P470, DOI 10.1038/ncb1559; WIRAPATI P, 2008, BREAST CANCER RES, V10, P4; Zhou Y, 2005, ENDOCR-RELAT CANCER, V12, pS37, DOI 10.1677/erc.1.00977	37	62	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2710	2722		10.1038/onc.2009.131	http://dx.doi.org/10.1038/onc.2009.131			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19483731				2022-12-25	WOS:000268452900002
J	Rodriguez, S; Hall, AJ; Granell, R; McLean, WHI; Irvine, AD; Palmer, CNA; Smith, GD; Henderson, J; Day, INM				Rodriguez, Santiago; Hall, Amanda J.; Granell, Raquel; McLean, W. H. Irwin; Irvine, Alan D.; Palmer, Colin N. A.; Smith, George Davey; Henderson, John; Day, Ian N. M.			Carrier Status for the Common R501X and 2282del4 Filaggrin Mutations Is Not Associated with Hearing Phenotypes in 5377 Children from the ALSPAC Cohort	PLOS ONE			English	Article								Background: Filaggrin is a major protein in the epidermis. Several mutations in the filaggrin gene (FLG) have been associated with a number of conditions. Filaggrin is expressed in the tympanic membrane and could alter its mechanical properties, but the relationship between genetic variation in FLG and hearing has not yet been tested. Methodology/Principal Findings: We examined whether loss-of function mutations R501X and 2282del4 in the FLG gene affected hearing in children. Twenty eight hearing variables representing five different aspects of hearing at age nine years in 5,377 children from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort were tested for association with these mutations. No evidence of association was found between R501X or 2282del4 (or overall FLG mutation carrier status) and any of the hearing phenotypes analysed. Conclusions/Significance: In conclusion, carrier status for common filaggrin mutations does not affect hearing in children.			Rodriguez, S (corresponding author), Univ Bristol, Dept Social Med, BGEL, Bristol, Avon, England.	santi.rodriguez@bristol.ac.uk	Irvine, Alan D/A-3982-2008; Granell, Raquel/AAB-5256-2022; Palmer, Colin NA/C-7053-2008; Hall, Amanda/AAB-7570-2022; Granell, Raquel/AAY-4846-2020; Davey Smith, George/A-7407-2013; McLean, William HI/C-6352-2009	Irvine, Alan D/0000-0002-9048-2044; Granell, Raquel/0000-0002-4890-4012; Palmer, Colin NA/0000-0002-6415-6560; Davey Smith, George/0000-0002-1407-8314; Rodriguez, Santiago/0000-0001-6551-932X; Hall, Amanda/0000-0001-8520-6005; s, hema/0000-0002-3440-9475; Venkatasubramanian, Siddharth/0000-0002-5860-0768; McLean, William Henry Irwin/0000-0001-5539-5757	Medical Research Council [G0700314, G9815508, G0600705] Funding Source: Medline; Wellcome Trust Funding Source: Medline; Chief Scientist Office Funding Source: Medline; MRC [G0700314, G0600705] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Chief Scientist Office; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Broekaert D., 1995, Acta Oto-Rhino-Laryngologica Belgica, V49, P127; CHAO WY, 1989, ACTA OTO-LARYNGOL, V107, P249, DOI 10.3109/00016488909127505; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Gruber R, 2007, EUR J HUM GENET, V15, P179, DOI 10.1038/sj.ejhg.5201742; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Hoffjan S, 2007, BRIT J DERMATOL, V157, P441, DOI 10.1111/j.1365-2133.2007.07999.x; Jones RW, 2000, EUR J HUM GENET, V8, P653, DOI 10.1038/sj.ejhg.5200502; KINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848; McGrath JA, 2008, AUSTRALAS J DERMATOL, V49, P67, DOI 10.1111/j.1440-0960.2008.00443.x; McGrath JA, 2008, TRENDS MOL MED, V14, P20, DOI 10.1016/j.molmed.2007.10.006; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; STAMMBERGER M, 1995, AM J OTOL, V16, P527	14	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2009	4	6							e5784	10.1371/journal.pone.0005784	http://dx.doi.org/10.1371/journal.pone.0005784			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453PV	19492053	Green Submitted, Green Published, gold, Green Accepted			2022-12-25	WOS:000266624300019
J	Perez, SI; Bernal, V; Gonzalez, PN; Sardi, M; Politis, GG				Ivan Perez, S.; Bernal, Valeria; Gonzalez, Paula N.; Sardi, Marina; Politis, Gustavo G.			Discrepancy between Cranial and DNA Data of Early Americans: Implications for American Peopling	PLOS ONE			English	Article							DEL-FUEGO-PATAGONIA; HUMAN SKELETAL REMAINS; NEW-WORLD; MITOCHONDRIAL-DNA; MODERN HUMANS; GEOMETRIC MORPHOMETRICS; CRANIOFACIAL MORPHOLOGY; EXTINCT ABORIGINES; HUMAN-POPULATIONS; DENTAL VARIATION	Currently, one of the major debates about the American peopling focuses on the number of populations that originated the biological diversity found in the continent during the Holocene. The studies of craniometric variation in American human remains dating from that period have shown morphological differences between the earliest settlers of the continent and some of the later Amerindian populations. This led some investigators to suggest that these groups-known as Paleomericans and Amerindians respectively-may have arisen from two biologically different populations. On the other hand, most DNA studies performed over extant and ancient populations suggest a single migration of a population from Northeast Asia. Comparing craniometric and mtDNA data of diachronic samples from East Central Argentina dated from 8,000 to 400 years BP, we show here that even when the oldest individuals display traits attributable to Paleoamerican crania, they present the same mtDNA haplogroups as later populations with Amerindian morphology. A possible explanation for these results could be that the craniofacial differentiation was a local phenomenon resulting from random (i.e. genetic drift) and non-random factors (e.g. selection and plasticity). Local processes of morphological differentiation in America are a probable scenario if we take into consideration the rapid peopling and the great ecological diversity of this continent; nevertheless we will discuss alternative explanations as well.			Perez, SI (corresponding author), Univ Nacl La Plata, Fac Ciencias Nat & Museo, Div Antropol, CONICET, Buenos Aires, DF, Argentina.			Sardi, Marina L./0000-0003-3614-8341				Adams DC, 2004, ITAL J ZOOL, V71, P5, DOI 10.1080/11250000409356545; Amo T, 2007, BIOCHEM J, V404, P345, DOI 10.1042/BJ20061609; BAILLIET G, 1994, AM J HUM GENET, V55, P27; BERBERIAN EE, 2001, HIST ARGENTINA PREHI; Bernal V, 2008, MAGALLANIA, V36, P175, DOI 10.4067/S0718-22442008000200013; Borrero LA, 1999, J WORLD PREHIST, V13, P321, DOI 10.1023/A:1022341730119; Brace CL, 2001, P NATL ACAD SCI USA, V98, P10017, DOI 10.1073/pnas.171305898; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; Buikstra J.E., 1994, STANDARDS DATA COLLE, DOI 10.1002/ajhb.1310070519; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Correal Urrego G., 1977, INVESTIGACIONES ARQU; Currat M, 2005, P ROY SOC B-BIOL SCI, V272, P679, DOI 10.1098/rspb.2004.2999; Currat M, 2004, PLOS BIOL, V2, P2264, DOI 10.1371/journal.pbio.0020421; Currat M, 2008, EVOLUTION, V62, P1908, DOI 10.1111/j.1558-5646.2008.00413.x; Dillehay T., 2000, SETTLEMENT AM NEW PR; Fagundes NJR, 2008, AM J HUM GENET, V82, P583, DOI 10.1016/j.ajhg.2007.11.013; Figueiro G, 2007, REV ARG ANTROP BIOL, V9, P78; Garcia-Bour J, 2004, AM J PHYS ANTHROPOL, V123, P361, DOI 10.1002/ajpa.10337; Goebel T, 2008, SCIENCE, V319, P1497, DOI 10.1126/science.1153569; Gonzalez-Jose RG, 2003, NATURE, V425, P62, DOI 10.1038/nature01816; GREENBERG J, 1986, CURR ANTHROPOL, V4, P477; Hanihara T, 2000, AM J PHYS ANTHROPOL, V111, P105, DOI 10.1002/(SICI)1096-8644(200001)111:1<105::AID-AJPA7>3.0.CO;2-O; HOWELLS WW, 1989, SKULL SHAPE MAP PAPE; Hrdlicka A., 1912, BUREAU AM ETHNOLOGY, V52; Imbelloni J., 1938, TABLA CLASIFICATORIA; Jobling MA, 2003, NAT REV GENET, V4, P598, DOI 10.1038/nrg1124; Kemp BM, 2007, AM J PHYS ANTHROPOL, V132, P605, DOI 10.1002/ajpa.20543; Lalueza C, 1997, HUM MOL GENET, V6, P41, DOI 10.1093/hmg/6.1.41; Malhi RS, 2007, J ARCHAEOL SCI, V34, P642, DOI 10.1016/j.jas.2006.07.004; MERRIWETHER DA, 1995, AM J PHYS ANTHROPOL, V98, P411, DOI 10.1002/ajpa.1330980404; Moraga ML, 2000, AM J PHYS ANTHROPOL, V113, P19, DOI 10.1002/1096-8644(200009)113:1<19::AID-AJPA3>3.0.CO;2-X; Neves Walter A., 1989, Ciencia e Cultura (Sao Paulo), V41, P566; Neves WA, 2005, P NATL ACAD SCI USA, V102, P18309, DOI 10.1073/pnas.0507185102; Neves WA, 2003, J HUM EVOL, V45, P19, DOI 10.1016/S0047-2484(03)00081-2; Neves WA, 2007, AM J PHYS ANTHROPOL, V133, P1080, DOI 10.1002/ajpa.20637; Peres-Neto PR, 2001, OECOLOGIA, V129, P169, DOI 10.1007/s004420100720; Perez SI, 2007, AM J PHYS ANTHROPOL, V133, P1067, DOI 10.1002/ajpa.20633; Perez SI, 2006, J ANAT, V208, P769, DOI 10.1111/j.1469-7580.2006.00576.x; Perez SI, 2009, EVOLUTION, V63, P978, DOI 10.1111/j.1558-5646.2008.00539.x; POLITIS G, 2009, SERIE MONOG IN PRESS, V5; POLITIS G, 2009, PRIMEROS AM HIST ARQ; Powell JF, 1999, YEARB PHYS ANTHROPOL, V42, P153; Price TD, 2009, P NATL ACAD SCI USA, V106, P6427, DOI 10.1073/pnas.0902617106; R Core Team, 2022, R LANG ENV STAT COMP; Rohlf FJ, 2008, TPS SERIE SOFTWARES; Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434; Sardi ML, 2006, AM J PHYS ANTHROPOL, V130, P333, DOI 10.1002/ajpa.20379; SARDI ML, 2001, REV ARG ANTROP BIOL, V3, P96; SARDI ML, 2004, ANTHROPOL ANZ, V62, P120; SCABUZZO C, 2007, CURR RES PLEISTOCENE, V23, P64; Schurr TG, 2004, ANNU REV ANTHROPOL, V33, P551, DOI 10.1146/annurev.anthro.33.070203.143932; Sheets H. D., 2003, IMP INTEGRATED MORPH, V14208; Larsen CS, 2006, QUATERN INT, V150, P12, DOI 10.1016/j.quaint.2006.01.004; Steele J, 2009, J ARCHAEOL SCI, V36, P419, DOI 10.1016/j.jas.2008.09.024; Stynder DD, 2007, AM J PHYS ANTHROPOL, V134, P489, DOI 10.1002/ajpa.20696; Sun C, 2007, GENOMICS, V89, P338, DOI 10.1016/j.ygeno.2006.11.005; Tamm E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000829; Turner C G 2nd, 1984, Acta Anthropogenet, V8, P23; TURNER CG, 1987, AM J PHYS ANTHROPOL, V73, P305, DOI 10.1002/ajpa.1330730304; van Vark GN, 2003, AM J PHYS ANTHROPOL, V121, P181, DOI 10.1002/ajpa.10176; Zelditch M.L., 2004, GEOMETRIC MORPHOMETR, DOI DOI 10.1016/B978-0-12-778460-1.X5000-5	61	39	42	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5746	10.1371/journal.pone.0005746	http://dx.doi.org/10.1371/journal.pone.0005746			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	451SH	19478947	Green Published, Green Submitted, gold			2022-12-25	WOS:000266490000020
J	Baranov, PV; Venin, M; Provan, G				Baranov, Pavel V.; Venin, Maxime; Provan, Gregory			Codon Size Reduction as the Origin of the Triplet Genetic Code	PLOS ONE			English	Article							TRANSFER-RNA; ANTICODON LOOP; PROTEIN-SYNTHESIS; FROZEN ACCIDENT; AMINO-ACIDS; RIBOSOME; EVOLUTION; SELECTION; REASSIGNMENT; SUPPRESSORS	The genetic code appears to be optimized in its robustness to missense errors and frameshift errors. In addition, the genetic code is near-optimal in terms of its ability to carry information in addition to the sequences of encoded proteins. As evolution has no foresight, optimality of the modern genetic code suggests that it evolved from less optimal code variants. The length of codons in the genetic code is also optimal, as three is the minimal nucleotide combination that can encode the twenty standard amino acids. The apparent impossibility of transitions between codon sizes in a discontinuous manner during evolution has resulted in an unbending view that the genetic code was always triplet. Yet, recent experimental evidence on quadruplet decoding, as well as the discovery of organisms with ambiguous and dual decoding, suggest that the possibility of the evolution of triplet decoding from living systems with non-triplet decoding merits reconsideration and further exploration. To explore this possibility we designed a mathematical model of the evolution of primitive digital coding systems which can decode nucleotide sequences into protein sequences. These coding systems can evolve their nucleotide sequences via genetic events of Darwinian evolution, such as point-mutations. The replication rates of such coding systems depend on the accuracy of the generated protein sequences. Computer simulations based on our model show that decoding systems with codons of length greater than three spontaneously evolve into predominantly triplet decoding systems. Our findings suggest a plausible scenario for the evolution of the triplet genetic code in a continuous manner. This scenario suggests an explanation of how protein synthesis could be accomplished by means of long RNA-RNA interactions prior to the emergence of the complex decoding machinery, such as the ribosome, that is required for stabilization and discrimination of otherwise weak triplet codon-anticodon interactions.			Baranov, PV (corresponding author), Univ Coll Cork, Dept Biochem, Cork, Ireland.	p.baranov@ucc.ie	Baranov, Pavel/A-2782-2011	Baranov, Pavel/0000-0001-9017-0270; Provan, Gregory/0000-0003-3678-046X				Abascal F, 2006, PLOS BIOL, V4, P711, DOI 10.1371/journal.pbio.0040127; Anderson JC, 2004, P NATL ACAD SCI USA, V101, P7566, DOI 10.1073/pnas.0401517101; Anderson JC, 2002, CHEM BIOL, V9, P237, DOI 10.1016/S1074-5521(02)00094-7; Atkins JF, 2009, MICROBIOL MOL BIOL R, V73, P178, DOI 10.1128/MMBR.00010-08; Bernhardt HS, 2008, BIOL DIRECT, V3, DOI 10.1186/1745-6150-3-53; Cech TR, 2000, SCIENCE, V289, P878, DOI 10.1126/science.289.5481.878; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; Di Giulio M, 2005, BIOSYSTEMS, V80, P175, DOI 10.1016/j.biosystems.2004.11.005; Di Giulio M, 2008, BIOL DIRECT, V3, DOI 10.1186/1745-6150-3-37; Di Giulio Massimo, 2008, V1, P59; Dunham CM, 2007, RNA, V13, P817, DOI 10.1261/rna.367307; Freeland SJ, 2000, MOL BIOL EVOL, V17, P511, DOI 10.1093/oxfordjournals.molbev.a026331; Freeland SJ, 1998, J MOL EVOL, V47, P238, DOI 10.1007/PL00006381; Freeland SJ, 2000, TRENDS BIOCHEM SCI, V25, P44, DOI 10.1016/S0968-0004(99)01531-5; Gilis D, 2001, GENOME BIOL, V2; Gomes AC, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r206; Hirsh AE, 2001, NATURE, V411, P1046, DOI 10.1038/35082561; Hohsaka T, 1999, Nucleic Acids Symp Ser, P79; Itzkovitz S, 2007, GENOME RES, V17, P405, DOI 10.1101/gr.5987307; Klobutcher LA, 2005, EUKARYOT CELL, V4, P2098, DOI 10.1128/EC.4.12.2098-2105.2005; Klobutcher LA, 2002, CELL, V111, P763, DOI 10.1016/S0092-8674(02)01138-8; Knight RD, 2000, CELL, V101, P569, DOI 10.1016/S0092-8674(00)80866-1; Knight RD, 1999, TRENDS BIOCHEM SCI, V24, P241, DOI 10.1016/S0968-0004(99)01392-4; Knight RD, 2001, NAT REV GENET, V2, P49, DOI 10.1038/35047500; KOONIN EV, 2008, IUBMB LIFE; Korostelev A, 2007, TRENDS BIOCHEM SCI, V32, P434, DOI 10.1016/j.tibs.2007.08.002; Korostelev A, 2006, CELL, V126, P1065, DOI 10.1016/j.cell.2006.08.032; Li JN, 1997, J MOL BIOL, V271, P209, DOI 10.1006/jmbi.1997.1176; Maeshiro T, 1998, P NATL ACAD SCI USA, V95, P5088, DOI 10.1073/pnas.95.9.5088; Magliery TJ, 2001, J MOL BIOL, V307, P755, DOI 10.1006/jmbi.2001.4518; Miranda I, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000996; Moore B, 2000, J MOL BIOL, V298, P195, DOI 10.1006/jmbi.2000.3658; NieseltStruwe K, 1997, J THEOR BIOL, V187, P1, DOI 10.1006/jtbi.1997.0404; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; Ogle JM, 2005, ANNU REV BIOCHEM, V74, P129, DOI 10.1146/annurev.biochem.74.061903.155440; ORGEL LE, 1989, J MOL EVOL, V29, P465, DOI 10.1007/BF02602917; OSAWA S, 1989, J MOL EVOL, V28, P271, DOI 10.1007/BF02103422; Patel A, 2005, J THEOR BIOL, V233, P527, DOI 10.1016/j.jtbi.2004.10.029; Ramakrishnan V, 2008, BIOCHEM SOC T, V36, P567, DOI 10.1042/BST0360567; RIDDLE DL, 1973, NATURE-NEW BIOL, V242, P230, DOI 10.1038/newbio242230a0; Rodriguez EA, 2006, P NATL ACAD SCI USA, V103, P8650, DOI 10.1073/pnas.0510817103; Santos MAS, 2004, TRENDS GENET, V20, P95, DOI 10.1016/j.tig.2003.12.009; Schmeing TM, 2002, NAT STRUCT BIOL, V9, P225, DOI 10.1038/nsb758; Schultz DW, 1996, J MOL EVOL, V42, P597, DOI 10.1007/BF02352290; Seligmann H, 2004, DNA CELL BIOL, V23, P701, DOI 10.1089/1044549042476910; Sella G, 2002, J MOL EVOL, V54, P638, DOI 10.1007/s00239-001-0060-7; Sella G, 2006, J MOL EVOL, V63, P297, DOI 10.1007/s00239-004-0176-7; Selmer M, 2006, SCIENCE, V313, P1935, DOI 10.1126/science.1131127; Sengupta S, 2005, GENETICS, V170, P831, DOI 10.1534/genetics.104.037887; SROGA GE, 1992, NUCLEIC ACIDS RES, V20, P3463, DOI 10.1093/nar/20.13.3463; Steitz TA, 2003, TRENDS BIOCHEM SCI, V28, P411, DOI 10.1016/S0968-0004(03)00169-5; Steitz TA, 2008, NAT REV MOL CELL BIO, V9, P242, DOI 10.1038/nrm2352; Tamas I, 2008, P NATL ACAD SCI USA, V105, P14934, DOI 10.1073/pnas.0806554105; Tlusty T, 2008, P NATL ACAD SCI USA, V105, P8238, DOI 10.1073/pnas.0710274105; TUOHY TMF, 1992, J MOL BIOL, V228, P1042, DOI 10.1016/0022-2836(92)90313-9; Turanov AA, 2009, SCIENCE, V323, P259, DOI 10.1126/science.1164748; Wilhelm T, 2004, J MOL EVOL, V59, P598, DOI 10.1007/s00239-004-2650-7; Wills PR, 2009, J THEOR BIOL, V257, P345, DOI 10.1016/j.jtbi.2008.12.030; WOESE CR, 1965, P NATL ACAD SCI USA, V54, P71, DOI 10.1073/pnas.54.1.71; Wolf YI, 2007, BIOL DIRECT, V2, DOI 10.1186/1745-6150-2-14; WONG JTF, 1991, ORIGINS LIFE EVOL B, V21, P165, DOI 10.1007/BF01809445; Wu HL, 2005, J MOL EVOL, V61, P54, DOI 10.1007/s00239-004-0224-3; Yarus M, 2005, ANNU REV BIOCHEM, V74, P179, DOI 10.1146/annurev.biochem.74.082803.133119	63	36	37	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2009	4	5							e5708	10.1371/journal.pone.0005708	http://dx.doi.org/10.1371/journal.pone.0005708			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QD	19479032	Green Published, Green Submitted, gold			2022-12-25	WOS:000266415000018
J	Korsten, H; Ziel-van Der Made, A; Ma, XQ; van der Kwast, T; Trapman, J				Korsten, Hanneke; Ziel-van der Made, Angelique; Ma, Xiaoqian; van der Kwast, Theo; Trapman, Jan			Accumulating Progenitor Cells in the Luminal Epithelial Cell Layer Are Candidate Tumor Initiating Cells in a Pten Knockout Mouse Prostate Cancer Model	PLOS ONE			English	Article								The PSA-Cre;Pten-loxP/loxP mouse prostate cancer model displays clearly defined stages of hyperplasia and cancer. Here, the initial stages of hyperplasia development are studied. Immunohistochemical staining showed that accumulated pAkt(+) hyperplastic cells overexpress luminal epithelial cell marker CK8, and progenitor cell markers CK19 and Sca-1, but not basal epithelial cell markers. By expression profiling we identified novel hyperplastic cell markers, including Tacstd2 and Clu. Further we showed that at young age prostates of targeted Pten knockout mice contained in the luminal epithelial cell layer single pAkt(+)cells, which overexpressed CK8, Sca-1, Tacstd2 and Clu; basal epithelial cells were always pAkt(-). Importantly, in the luminal epithelial cell layer of normal prostates we detected rare Clu(+)Tacstd2(+)Sca-1(+)progenitor cells. These novel cells are candidate tumor initiating cells in Pten knockout mice. Remarkably, all luminal epithelial cells in the proximal region of normal prostates were Clu(+)Tacstd2(+)Sca-1(+). However, in PSA-Cre; Pten-loxP/loxP mice, the proximal prostate does not contain hyperplastic foci. Small hyperplastic foci in prostates of PSA-Cre; Pten-loxP/+ mice found at old age, showed complete Pten inactivation and a progenitor marker profile. Finally, we present a novel model of prostate development and renewal, including lineage-specific luminal epithelial progenitor cells. It is proposed that Pten deficiency induces a shift in the balance of differentiation to proliferation in these cells.			Korsten, H (corresponding author), Erasmus MC, Josephine Nefkens Inst, Dept Pathol, Rotterdam, Netherlands.	j.trapman@erasmusmc.nl		Van der Kwast, Theodorus/0000-0001-8640-5786				Acevedo VD, 2007, CANCER CELL, V12, P559, DOI 10.1016/j.ccr.2007.11.004; Adams JM, 2008, CANCER RES, V68, P4018, DOI 10.1158/0008-5472.CAN-07-6334; Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007; AKALA OO, 2006, CURR OPIN GENET DEV; Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Backman SA, 2002, CURR OPIN NEUROBIOL, V12, P516, DOI 10.1016/S0959-4388(02)00354-9; Baugh LR, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.5.e29; Bonkhoff H, 1996, PROSTATE, V28, P98; Burger PE, 2005, P NATL ACAD SCI USA, V102, P7180, DOI 10.1073/pnas.0502761102; Campbell LL, 2007, CELL CYCLE, V6, P2332, DOI 10.4161/cc.6.19.4914; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; Collins AT, 2006, EUR J CANCER, V42, P1213, DOI 10.1016/j.ejca.2006.01.037; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; FORNARO M, 1995, INT J CANCER, V62, P610, DOI 10.1002/ijc.2910620520; Goldstein AS, 2008, P NATL ACAD SCI USA, V105, P20882, DOI 10.1073/pnas.0811411106; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Groszer M, 2006, P NATL ACAD SCI USA, V103, P111, DOI 10.1073/pnas.0509939103; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; Hendriksen PJM, 2006, CANCER RES, V66, P5012, DOI 10.1158/0008-5472.CAN-05-3082; Hermans KG, 2008, CANCER RES, V68, P7541, DOI 10.1158/0008-5472.CAN-07-5930; Hermans KG, 2008, CANCER RES, V68, P3094, DOI 10.1158/0008-5472.CAN-08-0198; Hudson DL, 2001, J HISTOCHEM CYTOCHEM, V49, P271, DOI 10.1177/002215540104900214; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kim MJ, 2002, CANCER RES, V62, P2999; Kumar-Sinha C, 2008, NAT REV CANCER, V8, P497, DOI 10.1038/nrc2402; Lam JS, 2006, UROL ONCOL-SEMIN ORI, V24, P131, DOI 10.1016/j.urolonc.2005.11.038; Lawson DA, 2007, J CLIN INVEST, V117, P2044, DOI 10.1172/JCI32810; Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104; Leong KG, 2008, NATURE, V456, P804, DOI 10.1038/nature07427; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104; Ma XQ, 2005, CANCER RES, V65, P5730, DOI 10.1158/0008-5472.CAN-04-4519; Maddison LA, 2004, CANCER RES, V64, P6018, DOI 10.1158/0008-5472.CAN-03-2509; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Marino S, 2002, DEVELOPMENT, V129, P3513; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025; Parsons JK, 2001, UROLOGY, V58, P619, DOI 10.1016/S0090-4295(01)01311-5; Patrawala L, 2007, CANCER RES, V67, P6796, DOI 10.1158/0008-5472.CAN-07-0490; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rizzo S, 2005, CELL PROLIFERAT, V38, P363, DOI 10.1111/j.1365-2184.2005.00356.x; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Rossi DJ, 2006, CELL, V125, P229, DOI 10.1016/j.cell.2006.04.006; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Stiles B, 2004, DEV BIOL, V273, P175, DOI 10.1016/j.ydbio.2004.06.008; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Tsujimura A, 2002, J CELL BIOL, V157, P1257, DOI 10.1083/jcb.200202067; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang YZ, 2001, DIFFERENTIATION, V68, P270, DOI 10.1046/j.1432-0436.2001.680414.x; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Xin L, 2007, STEM CELLS, V25, P2760, DOI 10.1634/stemcells.2007-0355; Zhou ZX, 2007, CANCER RES, V67, P5683, DOI 10.1158/0008-5472.CAN-07-0768	65	51	53	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2009	4	5							e5662	10.1371/journal.pone.0005662	http://dx.doi.org/10.1371/journal.pone.0005662			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LD	19461893	Green Submitted, gold, Green Published			2022-12-25	WOS:000266331200002
J	Osborne, A; Reis, AH; Bach, L; Wangh, LJ				Osborne, Adam; Reis, Arthur H., Jr.; Bach, Loren; Wangh, Lawrence J.			Single-Molecule LATE-PCR Analysis of Human Mitochondrial Genomic Sequence Variations	PLOS ONE			English	Article							THE-EXPONENTIAL (LATE)-PCR; POINT MUTATIONS; DNA; QUANTIFICATION; HETEROPLASMY	It is thought that changes in mitochondrial DNA are associated with many degenerative diseases, including Alzheimer's and diabetes. Much of the evidence, however, depends on correlating disease states with changing levels of heteroplasmy within populations of mitochondrial genomes, rather than individual mitochondrial genomes. Thus these measurements are likely to either overestimate the extent of heteroplasmy due to technical artifacts, or underestimate the actual level of heteroplasmy because only the most abundant changes are observable. In contrast, Single Molecule (SM) LATE-PCR analysis achieves efficient amplification of single-stranded amplicons from single target molecules. The product molecules, in turn, can be accurately sequenced using a convenient Dilute-'N'-Go protocol, as shown here. Using these novel technologies we have rigorously analyzed levels of mitochondrial genome heteroplasmy found in single hair shafts of healthy adult individuals. Two of the single molecule sequences (7% of the samples) were found to contain mutations. Most of the mtDNA sequence changes, however, were due to the presence of laboratory contaminants. Amplification and sequencing errors did not result in mis-identification of mutations. We conclude that SM-LATE-PCR in combination with Dilute-'N'-Go Sequencing are convenient technologies for detecting infrequent mutations in mitochondrial genomes, provided great care is taken to control and document contamination. We plan to use these technologies in the future to look for age, drug, and disease related mitochondrial genome changes in model systems and clinical samples.			Osborne, A (corresponding author), Brandeis Univ, Dept Biol, Waltham, MA 02254 USA.	Wangh@brandeis.edu						ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; ANTONIO S, 2005, PLOS MED, V2, P1158; Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153; Bandelt HJ, 2006, J HUM GENET, V51, P1073, DOI 10.1007/s10038-006-0066-5; Bandelt HJ, 2005, J MED GENET, V42, P957, DOI 10.1136/jmg.2005.033589; Budowle B, 2002, FORENSIC SCI INT, V126, P30, DOI 10.1016/S0379-0738(02)00019-1; Cavelier L, 2000, EXP CELL RES, V259, P79, DOI 10.1006/excr.2000.4949; Cavelier L, 2000, HUM GENET, V107, P45, DOI 10.1007/s004390050009; Chen JJZ, 2004, J ENVIRON SCI HEAL C, V22, P1, DOI 10.1081/GNC-120037931; Chen TJ, 1999, CLIN CHEM, V45, P1162; Divne AM, 2005, J FORENSIC SCI, V50, P548; DOUGLAS CW, 1994, P NATL ACAD SCI USA, V91, P8739; HIGUCHI R, 1988, NATURE, V332, P543, DOI 10.1038/332543a0; HILARY AC, 2002, ANN NY ACAD SCI, V959, P434; JOHN ER, 2007, NATURE PROTOCOLS, V2, P2429; KENNETH EP, 2000, MOL HUM REPROD, V6, P1155; Lee HY, 2004, ELECTROPHORESIS, V25, P28, DOI 10.1002/elps.200305681; Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133; MARK S, 2000, AM J HUM GENET, V67, P1029; Pierce KE, 2005, P NATL ACAD SCI USA, V102, P8609, DOI 10.1073/pnas.0501946102; Pierce KE, 2002, BIOTECHNIQUES, V32, P1106, DOI 10.2144/02325pf01; Pravenec M, 2007, GENOME RES, V17, P1319, DOI 10.1101/gr.6548207; Sanchez JA, 2004, P NATL ACAD SCI USA, V101, P1933, DOI 10.1073/pnas.0305476101; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; Swerdlow RH, 2004, MED HYPOTHESES, V63, P8, DOI 10.1016/j.mehy.2003.12.045; VANDENBOSCH BJ, 2000, NUCLEIC ACIDS RES, V28, P1; Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988; Vermulst M, 2008, METHODS, V46, P263, DOI 10.1016/j.ymeth.2008.10.008; Wilson MR, 1997, HUM GENET, V100, P167, DOI 10.1007/s004390050485; Yao YG, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000681; YEVGENYA K, 2004, ANAL SOMATIC MUTATIO, P97; YEVGENYA K, 2005, EXPERT REV MOL DIAGN, V5, P809	33	10	12	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5636	10.1371/journal.pone.0005636	http://dx.doi.org/10.1371/journal.pone.0005636			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448AY	19461959	Green Submitted, Green Published, gold			2022-12-25	WOS:000266234700022
J	Lovelock, CE; Ball, MC; Martin, KC; Feller, IC				Lovelock, Catherine E.; Ball, Marilyn C.; Martin, Katherine C.; Feller, Ilka C.			Nutrient Enrichment Increases Mortality of Mangroves	PLOS ONE			English	Article							RHIZOPHORA-MANGLE; AVICENNIA-MARINA; HYDRAULIC CONDUCTANCE; PUERTO-RICO; WATER-USE; GROWTH; NITROGEN; PHOSPHORUS; SALINITY; PHOTOSYNTHESIS	Nutrient enrichment of the coastal zone places intense pressure on marine communities. Previous studies have shown that growth of intertidal mangrove forests is accelerated with enhanced nutrient availability. However, nutrient enrichment favours growth of shoots relative to roots, thus enhancing growth rates but increasing vulnerability to environmental stresses that adversely affect plant water relations. Two such stresses are high salinity and low humidity, both of which require greater investment in roots to meet the demands for water by the shoots. Here we present data from a global network of sites that documents enhanced mortality of mangroves with experimental nutrient enrichment at sites where high sediment salinity was coincident with low rainfall and low humidity. Thus the benefits of increased mangrove growth in response to coastal eutrophication is offset by the costs of decreased resilience due to mortality during drought, with mortality increasing with soil water salinity along climatic gradients.			Lovelock, CE (corresponding author), Univ Queensland, Ctr Marine Studies, St Lucia, Qld, Australia.	c.lovelock@uq.edu.au	Ball, Marilyn/D-1180-2009; Lovelock, Catherine E/G-7370-2012; Lovelock, Catherine E./AAF-7294-2020	Ball, Marilyn/0000-0001-9170-940X; Lovelock, Catherine E/0000-0002-2219-6855; Lovelock, Catherine E./0000-0002-2219-6855; Feller, Ilka/0000-0002-6391-1608				Alongi DM, 2008, ESTUAR COAST SHELF S, V76, P1, DOI 10.1016/j.ecss.2007.08.024; [Anonymous], 2001, PLANT STRATEGIES VEG; ARMENTANO TV, 1995, ANAL PATTERN POSSIBL; Atwell BJ, 2009, PLANT CELL ENVIRON, V32, P553, DOI 10.1111/j.1365-3040.2009.01949.x; BALL MC, 1988, AUST J PLANT PHYSIOL, V15, P447, DOI 10.1071/PP9880447; Ball MC, 1997, PLANT CELL ENVIRON, V20, P1158, DOI 10.1046/j.1365-3040.1997.d01-144.x; BOTO KG, 1983, MAR ECOL PROG SER, V11, P63, DOI 10.3354/meps011063; CHAPIN FS, 1991, BIOSCIENCE, V41, P29, DOI 10.2307/1311538; CHAPIN FS, 1980, ANNU REV ECOL SYST, V11, P233, DOI 10.1146/annurev.es.11.110180.001313; CINTRON G, 1978, BIOTROPICA, V10, P110, DOI 10.2307/2388013; Clarkson DT, 2000, J EXP BOT, V51, P61, DOI 10.1093/jexbot/51.342.61; Cloern JE, 2001, MAR ECOL PROG SER, V210, P223, DOI 10.3354/meps210223; Clough B.F., 1983, BIOL ECOLOGY MANGROV, V8, P151, DOI [10.1007/978-94-017-0914-9_17, DOI 10.1007/978-94-017-0914-9_17, DOI 10.1007/978-94-017-0914-9_]; Downing JA, 1999, BIOGEOCHEMISTRY, V46, P109, DOI 10.1007/BF01007576; Duke NC, 2005, MAR POLLUT BULL, V51, P308, DOI 10.1016/j.marpolbul.2004.10.040; Feller IC, 2003, OECOLOGIA, V134, P405, DOI 10.1007/s00442-002-1117-z; Feller IC, 2003, BIOGEOCHEMISTRY, V62, P145, DOI 10.1023/A:1021166010892; FELLER IC, 1995, ECOL MONOGR, V65, P477, DOI 10.2307/2963499; Fosberg F. R., 1961, US GEOL SOC PROF P D, V424-D, P216; Hughes TP, 2003, SCIENCE, V301, P929, DOI 10.1126/science.1085046; Jupiter Stacy D., 2007, Wetlands Ecology and Management, V15, P51, DOI 10.1007/s11273-006-9011-9; Koch MS, 1997, BIOTROPICA, V29, P427, DOI 10.1111/j.1744-7429.1997.tb00037.x; LAMBERS H, 1992, ADV ECOL RES, V23, P187, DOI 10.1016/S0065-2504(08)60148-8; Lapointe BE, 1997, LIMNOL OCEANOGR, V42, P1119, DOI 10.4319/lo.1997.42.5_part_2.1119; Levine JM, 1998, J ECOL, V86, P285, DOI 10.1046/j.1365-2745.1998.00253.x; LIN G, 1992, AUST J PLANT PHYSIOL, V19, P509, DOI 10.1071/PP9920509; LINDER S, 1987, CAN J FOREST RES, V17, P1157, DOI 10.1139/x87-179; Lovelock CE, 2007, ECOL LETT, V10, P1154, DOI 10.1111/j.1461-0248.2007.01112.x; Lovelock CE, 2007, OECOLOGIA, V153, P633, DOI 10.1007/s00442-007-0750-y; Lovelock CE, 2006, NEW PHYTOL, V172, P514, DOI 10.1111/j.1469-8137.2006.01851.x; Lovelock CE, 2006, PLANT CELL ENVIRON, V29, P793, DOI 10.1111/j.1365-3040.2005.01446.x; Lovelock CE, 2004, FUNCT ECOL, V18, P25, DOI 10.1046/j.0269-8463.2004.00805.x; Lovelock CE, 2003, OECOLOGIA, V134, P455, DOI 10.1007/s00442-002-1118-y; MARTIN KC, 2007, THESIS AUSTR NATL U; McCarthy HR, 2006, P NATL ACAD SCI USA, V103, P19356, DOI 10.1073/pnas.0609448103; NAIDOO G, 1987, NEW PHYTOL, V107, P317, DOI 10.1111/j.1469-8137.1987.tb00183.x; Naidoo G, 2009, AQUAT BOT, V90, P184, DOI 10.1016/j.aquabot.2008.10.001; Paerl HW, 1997, LIMNOL OCEANOGR, V42, P1154, DOI 10.4319/lo.1997.42.5_part_2.1154; Rabalais NN, 2002, ANNU REV ECOL SYST, V33, P235, DOI 10.1146/annurev.ecolsys.33.010802.150513; ROBERTSON AI, 1995, HYDROBIOLOGIA, V295, P311, DOI 10.1007/BF00029138; Scheffer M, 2001, NATURE, V413, P591, DOI 10.1038/35098000; TILMAN D, 1991, AM NAT, V138, P1269, DOI 10.1086/285283; Wier AM, 2000, BIOTROPICA, V32, P299, DOI 10.1646/0006-3606(2000)032[0299:DORMRM]2.0.CO;2; Wong YS, 1997, HYDROBIOLOGIA, V352, P49, DOI 10.1023/A:1003040920173	44	121	129	6	89	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5600	10.1371/journal.pone.0005600	http://dx.doi.org/10.1371/journal.pone.0005600			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19440554	Green Published, gold, Green Submitted			2022-12-25	WOS:000266161200003
J	Wares, JP; Pankey, MS; Pitombo, F; Daglio, LG; Achituv, Y				Wares, John P.; Pankey, M. Sabrina; Pitombo, Fabio; Daglio, Liza Gomez; Achituv, Yair			A "Shallow Phylogeny" of Shallow Barnacles (Chthamalus)	PLOS ONE			English	Article							TROPICAL EASTERN PACIFIC; CIRRIPEDIA; DNA; SPECIATION; BIOGEOGRAPHY; INCONGRUENCE; CRUSTACEA; AMPLIFICATION; SUBSTITUTION; SYSTEMATICS	Background: We present a multi-locus phylogenetic analysis of the shallow water (high intertidal) barnacle genus Chthamalus, focusing on member species in the western hemisphere. Understanding the phylogeny of this group improves interpretation of classical ecological work on competition, distributional changes associated with climate change, and the morphological evolution of complex cirripede phenotypes. Methodology and Findings: We use traditional and Bayesian phylogenetic and 'deep coalescent' approaches to identify a phylogeny that supports the monophyly of the mostly American 'fissus group' of Chthamalus, but that also supports a need for taxonomic revision of Chthamalus and Microeuraphia. Two deep phylogeographic breaks were also found within the range of two tropical American taxa (C. angustitergum and C. southwardorum) as well. Conclusions: Our data, which include two novel gene regions for phylogenetic analysis of cirripedes, suggest that much more evaluation of the morphological evolutionary history and taxonomy of Chthamalid barnacles is necessary. These data and associated analyses also indicate that the radiation of species in the late Pliocene and Pleistocene was very rapid, and may provide new insights toward speciation via transient allopatry or ecological barriers.			Wares, JP (corresponding author), Univ Georgia, Dept Genet, Athens, GA 30602 USA.	jpwares@uga.edu	Pitombo, Fabio B/G-1778-2012	Wares, John/0000-0003-1827-0669; Pankey, M Sabrina/0000-0002-7061-9613				Avise JC, 2008, SYST BIOL, V57, P503, DOI 10.1080/10635150802164587; BARRY JP, 1995, SCIENCE, V267, P672, DOI 10.1126/science.267.5198.672; Belfiore NM, 2008, SYST BIOL, V57, P294, DOI 10.1080/10635150802044011; Briggs J, 1974, MARINE ZOOGEOGRAPHY, DOI 10.2307/1442613; BURROWS MT, 1992, J EXP MAR BIOL ECOL, V160, P229, DOI 10.1016/0022-0981(92)90240-B; Carling MD, 2008, GENETICS, V178, P363, DOI 10.1534/genetics.107.076422; CONNELL JH, 1961, ECOLOGY, V42, P710, DOI 10.2307/1933500; Costa FO, 2007, CAN J FISH AQUAT SCI, V64, P272, DOI 10.1139/F07-008; Cunningham CW, 1997, MOL BIOL EVOL, V14, P733, DOI 10.1093/oxfordjournals.molbev.a025813; DANDO PR, 1980, J MAR BIOL ASSOC UK, V60, P787, DOI 10.1017/S0025315400040455; Darlu P, 2002, MOL BIOL EVOL, V19, P432, DOI 10.1093/oxfordjournals.molbev.a004098; Darwin C., 1854, MONOGRAPH SUBCLASS C; Degnan JH, 2005, EVOLUTION, V59, P24; Edwards SV, 2009, EVOLUTION, V63, P1, DOI 10.1111/j.1558-5646.2008.00549.x; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; FARRIS JS, 1994, CLADISTICS, V10, P315, DOI 10.1111/j.1096-0031.1996.tb00196.x; Fisher T, 2004, BIOL J LINN SOC, V83, P39, DOI 10.1111/j.1095-8312.2004.00371.x; Folmer O., 1994, Molecular Marine Biology and Biotechnology, V3, P294; Hastings PA, 2000, ZOOL J LINN SOC-LOND, V128, P319, DOI 10.1006/zjls.1998.0196; HEDGECOCK D, 1979, MAR BIOL, V54, P207; Jarman SN, 2002, MAR BIOTECHNOL, V4, P347, DOI 10.1007/s10126-002-0029-6; Kirby MX, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002791; KUO CH, 2008, MOL BIOL EVOL; Liu L, 2008, EVOLUTION, V62, P2080, DOI 10.1111/j.1558-5646.2008.00414.x; Maddison WP, 2007, SYST BIOL, V56, P701, DOI 10.1080/10635150701607033; Newman W.A., 1976, Memoirs of the San Diego Society of Natural History, VNo. 9, P1; Nilsson-Cantell CA, 1921, ZOOL BIDR UPPS, V7, P75; Nylander J. A. A., 2004, MRMODELTEST V2; Palumbi Stephen R., 1996, P205; Peters JL, 2007, EVOLUTION, V61, P1992, DOI 10.1111/j.1558-5646.2007.00149.x; Pfenninger M, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-121; Pilsbry HA., 1916, B US NATN MUS, V93, P1, DOI DOI 10.5479/SI.03629236.93.1; Pitombo FB, 2007, ZOOTAXA, P1; Poloczanska ES, 2008, ECOLOGY, V89, P3138, DOI 10.1890/07-1169.1; Poltarukha O., 1997, J ZOOL, V1, P463; POPE ELIZABETH C., 1965, PROC LINN SOC NEW SWALES, V90, P10; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Power AM, 1999, MAR ECOL PROG SER, V191, P251, DOI 10.3354/meps191251; Pringle A, 2005, EVOLUTION, V59, P1886, DOI 10.1111/j.0014-3820.2005.tb01059.x; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Rozas J, 1999, BIOINFORMATICS, V15, P174, DOI 10.1093/bioinformatics/15.2.174; Southward A.J., 1977, FAO FISHERIES REPORT, V200, P407; SOUTHWARD AJ, 1991, J MAR BIOL ASSOC UK, V71, P495, DOI 10.1017/S002531540005311X; Southward AJ, 2003, J MAR BIOL ASSOC UK, V83, P797, DOI 10.1017/S0025315403007835h; STANLEY SM, 1980, PALEOBIOLOGY, V6, P173, DOI 10.1017/S0094837300006734; Swofford DL, 2002, PHYLOGENETIC ANAL US; Towle DW, 2001, J EXP BIOL, V204, P4005; Tsang LM, 2008, MAR ECOL PROG SER, V364, P107, DOI 10.3354/meps07476; Wares JP, 2005, J MAR BIOL ASSOC UK, V85, P327, DOI 10.1017/S0025315405011227h; Wares JP, 2001, MOL PHYLOGENET EVOL, V18, P104, DOI 10.1006/mpev.2000.0857; Wethey DS, 2002, INTEGR COMP BIOL, V42, P872, DOI 10.1093/icb/42.4.872; Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371; Xia XH, 2003, MOL PHYLOGENET EVOL, V26, P1, DOI 10.1016/S1055-7903(02)00326-3; Yan Y, 2004, J CRUSTACEAN BIOL, V24, P519, DOI 10.1651/C-2491; Zardus JD, 2005, MOL ECOL, V14, P3719, DOI 10.1111/j.1365-294X.2005.02701.x; ZULLO VA, 1963, 16 INT C ZOOL, V1, P190	56	37	37	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5567	10.1371/journal.pone.0005567	http://dx.doi.org/10.1371/journal.pone.0005567			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440543	Green Submitted, gold, Green Published			2022-12-25	WOS:000266107400011
J	Aliverti, A; Bovio, D; Fullin, I; Dellaca, RL; Lo Mauro, A; Pedotti, A; Macklem, PT				Aliverti, Andrea; Bovio, Dario; Fullin, Irene; Dellaca, Raffaele L.; Lo Mauro, Antonella; Pedotti, Antonio; Macklem, Peter T.			The Abdominal Circulatory Pump	PLOS ONE			English	Article								Blood in the splanchnic vasculature can be transferred to the extremities. We quantified such blood shifts in normal subjects by measuring trunk volume by optoelectronic plethysmography, simultaneously with changes in body volume by whole body plethysmography during contractions of the diaphragm and abdominal muscles. Trunk volume changes with blood shifts, but body volume does not so that the blood volume shifted between trunk and extremities (Vbs) is the difference between changes in trunk and body volume. This is so because both trunk and body volume change identically with breathing and gas expansion or compression. During tidal breathing Vbs was 50-75 ml with an ejection fraction of 4-6% and an output of 750-1500 ml/min. Step increases in abdominal pressure resulted in rapid emptying presumably from the liver with a time constant of 0.61+/-0.1SE sec. followed by slower flow from non-hepatic viscera. The filling time constant was 0.57+/-0.09SE sec. Splanchnic emptying shifted up to 650 ml blood. With emptying, the increased hepatic vein flow increases the blood pressure at its entry into the inferior vena cava (IVC) and abolishes the pressure gradient producing flow between the femoral vein and the IVC inducing blood pooling in the legs. The findings are important for exercise because the larger the Vbs the greater the perfusion of locomotor muscles. During asystolic cardiac arrest we calculate that appropriate timing of abdominal compression could produce an output of 6 L/min. so that the abdominal circulatory pump might act as an auxiliary heart.			Aliverti, A (corresponding author), Politecn Milan, Dipartimento Bioingn, I-20133 Milan, Italy.	andrea.aliverti@polimi.it	Andrea, Aliverti/A-3901-2015; Dellaca', Raffaele/AAF-7078-2019	Andrea, Aliverti/0000-0002-2950-0231; Dellaca', Raffaele/0000-0002-3672-4591; LoMauro, Antonella/0000-0002-1408-6971; Bovio, Dario/0000-0002-2654-9734				Aliverti A, 2005, EUR J APPL PHYSIOL, V95, P229, DOI 10.1007/s00421-005-1386-4; Aliverti A, 2002, J APPL PHYSIOL, V92, P1953, DOI 10.1152/japplphysiol.01222.2000; Aliverti A, 1997, J APPL PHYSIOL, V83, P1256, DOI 10.1152/jappl.1997.83.4.1256; BARRANCO F, 1990, RESUSCITATION, V20, P67, DOI 10.1016/0300-9572(90)90088-V; BERRYMAN CR, 1984, ANN EMERG MED, V13, P226, DOI 10.1016/S0196-0644(84)80467-9; BRIENZA N, 1995, AM J RESP CRIT CARE, V152, P511, DOI 10.1164/ajrccm.152.2.7633700; BRIENZA N, 1995, AM J RESP CRIT CARE, V152, P504, DOI 10.1164/ajrccm.152.2.7633699; Cala SJ, 1996, J APPL PHYSIOL, V81, P2680, DOI 10.1152/jappl.1996.81.6.2680; CRILEY JM, 1976, JAMA-J AM MED ASSOC, V236, P1246, DOI 10.1001/jama.236.11.1246; DECRAMER M, 1984, J APPL PHYSIOL, V57, P1682, DOI 10.1152/jappl.1984.57.6.1682; EINAGLE V, 1988, CHEST, V93, P1206, DOI 10.1378/chest.93.6.1206; FROELICH JW, 1988, J NUCL MED, V29, P1714; GREENWAY CV, 1986, CAN J PHYSIOL PHARM, V64, P383, DOI 10.1139/y86-062; GUYTON AC, 1955, AM J PHYSIOL, V180, P463, DOI 10.1152/ajplegacy.1955.180.3.463; HOWARD M, 1987, ANN EMERG MED, V16, P253, DOI 10.1016/S0196-0644(87)80169-5; HYATT RE, 1958, J APPL PHYSIOL, V13, P331, DOI 10.1152/jappl.1958.13.3.331; Iandelli I, 2002, J APPL PHYSIOL, V92, P1943, DOI 10.1152/japplphysiol.00393.2000; JOHNSTONE FRC, 1956, AM J PHYSIOL, V185, P450, DOI 10.1152/ajplegacy.1956.185.3.450; MaassMoreno R, 1997, AM J PHYSIOL-HEART C, V272, pH2826, DOI 10.1152/ajpheart.1997.272.6.H2826; MATEER JR, 1985, AM J EMERG MED, V3, P143, DOI 10.1016/0735-6757(85)90038-5; MEAD J, 1967, J APPL PHYSIOL, V22, P95, DOI 10.1152/jappl.1967.22.1.95; Miller JD, 2005, J APPL PHYSIOL, V99, P1802, DOI 10.1152/japplphysiol.00278.2005; Miller JD, 2005, J PHYSIOL-LONDON, V563, P925, DOI 10.1113/jphysiol.2004.076422; MORENO AH, 1967, AM J PHYSIOL, V213, P455, DOI 10.1152/ajplegacy.1967.213.2.455; NIEMANN JT, 1980, CRIT CARE MED, V8, P141, DOI 10.1097/00003246-198003000-00011; PERMUTT S, 1963, J APPL PHYSIOL, V18, P924, DOI 10.1152/jappl.1963.18.5.924; RALSTON SH, 1982, ANESTH ANALG, V61, P645; RISOE C, 1991, J APPL PHYSIOL, V70, P818, DOI 10.1152/jappl.1991.70.2.818; Rothe CF, 2006, J APPL PHYSIOL, V101, P1262, DOI 10.1152/japplphysiol.00561.2006; ROTHE CF, 1983, PHYSIOL REV, V63, P1281, DOI 10.1152/physrev.1983.63.4.1281; ROWELL LB, 1990, J NUCL MED, V31, P160; SACK J B, 1992, Journal of the American Medical Association, V267, P379, DOI 10.1001/jama.267.3.379; SYLVESTER JT, 1981, CIRC RES, V49, P980, DOI 10.1161/01.RES.49.4.980; TAKATA M, 1992, J APPL PHYSIOL, V72, P597, DOI 10.1152/jappl.1992.72.2.597; TAKATA M, 1992, AM J PHYSIOL, V262, pH763, DOI 10.1152/ajpheart.1992.262.3.H763; TAKATA M, 1990, J APPL PHYSIOL, V69, P1961, DOI 10.1152/jappl.1990.69.6.1961; Tang WC, 1997, CIRCULATION, V95, P1335; WADE OL, 1956, CLIN SCI, V15, P457; WARD KR, 1989, ANN EMERG MED, V18, P831, DOI 10.1016/S0196-0644(89)80206-9; WEST JB, 1964, J APPL PHYSIOL, V19, P713, DOI 10.1152/jappl.1964.19.4.713; [No title captured]	41	38	47	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2009	4	5							e5550	10.1371/journal.pone.0005550	http://dx.doi.org/10.1371/journal.pone.0005550			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FX	19440240	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107300014
J	Qiu, XG; Fernando, L; Alimonti, JB; Melito, PL; Feldmann, F; Dick, D; Stroher, U; Feldmann, H; Jones, SM				Qiu, Xiangguo; Fernando, Lisa; Alimonti, Judie B.; Melito, P. Leno; Feldmann, Friedericke; Dick, Daryl; Stroeher, Ute; Feldmann, Heinz; Jones, Steven M.			Mucosal Immunization of Cynomolgus Macaques with the VSV Delta G/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses	PLOS ONE			English	Article							PROTECTS NONHUMAN-PRIMATES; HEMORRHAGIC-FEVER; VIRUS INFECTION; RHESUS-MONKEYS; MOUSE MODEL; IN-VITRO; MARBURG; GLYCOPROTEINS; MICE; TRANSMISSION	Background: Zaire ebolavirus (ZEBOV) produces a lethal viral hemorrhagic fever in humans and non-human primates. Methodology/Principal Findings: We demonstrate that the VSVDG/ZEBOVGP vaccine given 28 days pre-challenge either intranasally (IN), orally (OR), or intramuscularly (IM) protects non-human primates against a lethal systemic challenge of ZEBOV, and induces cellular and humoral immune responses. We demonstrated that ZEBOVGP-specific T-cell and humoral responses induced in the IN and OR groups, following an immunization and challenge, produced the most IFN-gamma and IL-2 secreting cells, and long term memory responses. Conclusions/Significance: We have shown conclusively that mucosal immunization can protect from systemic ZEBOV challenge and that mucosal delivery, particularly IN immunization, seems to be more potent than IM injection in the immune parameters we have tested. Mucosal immunization would be a huge benefit in any emergency mass vaccination campaign during a natural outbreak, or following intentional release, or for mucosal immunization of great apes in the wild.			Qiu, XG (corresponding author), Publ Hlth Agcy Canada, Natl Microbiol Lab, Special Pathogens Program, Winnipeg, MB, Canada.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001089] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Borio L, 2002, JAMA-J AM MED ASSOC, V287, P2391, DOI 10.1001/jama.287.18.2391; Bradfute SB, 2007, J INFECT DIS, V196, pS296, DOI 10.1086/520602; Bukreyev A, 2009, VIROLOGY, V383, P348, DOI 10.1016/j.virol.2008.09.030; Bukreyev A, 2007, J VIROL, V81, P6379, DOI 10.1128/JVI.00105-07; CHEPURNOV AA, 1995, VOP VIRUSOL+, V40, P74; Daddario-DiCaprio KM, 2006, J VIROL, V80, P9659, DOI 10.1128/JVI.00959-06; Ebihara H, 2007, J INFECT DIS, V196, pS313, DOI 10.1086/520590; Feldmann H, 2003, NAT REV IMMUNOL, V3, P677, DOI 10.1038/nri1154; Feldmann H, 2007, PLOS PATHOG, V3, P54, DOI 10.1371/journal.ppat.0030002; Formenty P, 1999, J INFECT DIS, V179, pS120, DOI 10.1086/514296; Garbutt M, 2004, J VIROL, V78, P5458, DOI 10.1128/JVI.78.10.5458-5465.2004; Geisbert TW, 2008, VACCINE, V26, P6894, DOI 10.1016/j.vaccine.2008.09.082; Geisbert TW, 2000, LAB INVEST, V80, P171, DOI 10.1038/labinvest.3780021; Geisbert TW, 2005, PLOS MED, V2, P537, DOI 10.1371/journal.pmed.0020183; Geisbert TW, 2004, NAT MED, V10, pS110, DOI 10.1038/nm1142; Geisbert TW, 2002, EMERG INFECT DIS, V8, P503; Groseth A, 2007, TRENDS MICROBIOL, V15, P408, DOI 10.1016/j.tim.2007.08.001; Gupta M, 2001, VIROLOGY, V284, P20, DOI 10.1006/viro.2001.0836; Gupta M, 2007, VIROLOGY, V364, P45, DOI 10.1016/j.virol.2007.02.017; Ignatyev GM, 1996, J BIOTECHNOL, V44, P111, DOI 10.1016/0168-1656(95)00104-2; Jaax N, 1995, LANCET, V346, P1669, DOI 10.1016/S0140-6736(95)92841-3; Jaax NK, 1996, ARCH PATHOL LAB MED, V120, P140; Jahrling PB, 1999, J INFECT DIS, V179, pS224, DOI 10.1086/514310; JOHNSON E, 1995, INT J EXP PATHOL, V76, P227; Jones SM, 2005, NAT MED, V11, P786, DOI 10.1038/nm1258; Jones SM, 2007, J INFECT DIS, V196, pS404, DOI 10.1086/520591; Leffel EK, 2004, BIOSECUR BIOTERROR, V2, P186, DOI 10.1089/bsp.2004.2.186; Leroy EM, 2004, SCIENCE, V303, P387, DOI 10.1126/science.1092528; Mason C, 2008, CAN MED ASSOC J, V178, P1266, DOI 10.1503/cmaj.080524; Peters C.J., 1996, FIELDS VIROLOGY, P1161; Pushko P, 2000, VACCINE, V19, P142, DOI 10.1016/S0264-410X(00)00113-4; Rao M, 2002, J VIROL, V76, P9176, DOI 10.1128/JVI.76.18.9176-9185.2002; Reed DS, 2004, VIRAL IMMUNOL, V17, P390, DOI 10.1089/vim.2004.17.390; Schnell MJ, 1996, P NATL ACAD SCI USA, V93, P11359, DOI 10.1073/pnas.93.21.11359; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Stroher U, 2001, J VIROL, V75, P11025, DOI 10.1128/JVI.75.22.11025-11033.2001; Sullivan NJ, 2006, PLOS MED, V3, P865, DOI 10.1371/journal.pmed.0030177; Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108; Sullivan NJ, 2003, NATURE, V424, P681, DOI 10.1038/nature01876; Swenson DL, 2008, CLIN VACCINE IMMUNOL, V15, P460, DOI 10.1128/CVI.00431-07; Towner JS, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000212; Vanderzanden L, 1998, VIROLOGY, V246, P134, DOI 10.1006/viro.1998.9176; Wahl-Jensen V, 2005, J VIROL, V79, P2413, DOI 10.1128/JVI.79.4.2413-2419.2005; Walsh PD, 2003, NATURE, V422, P611, DOI 10.1038/nature01566; Warfield KL, 2007, J INFECT DIS, V196, pS430, DOI 10.1086/520583; World Health Organization, 2008, Weekly Epidemiological Record, V83, P89	46	110	118	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2009	4	5							e5547	10.1371/journal.pone.0005547	http://dx.doi.org/10.1371/journal.pone.0005547			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FX	19440245	Green Published, gold, Green Submitted			2022-12-25	WOS:000266107300012
J	Mohamad, K; Olsson, M; van Tol, HTA; Mikko, S; Vlamings, BH; Andersson, G; Rodriguez-Martinez, H; Purwantara, B; Paling, RW; Colenbrander, B; Lenstra, JA				Mohamad, Kusdiantoro; Olsson, Mia; van Tol, Helena T. A.; Mikko, Sofia; Vlamings, Bart H.; Andersson, Goeran; Rodriguez-Martinez, Heriberto; Purwantara, Bambang; Paling, Robert W.; Colenbrander, Ben; Lenstra, Johannes A.			On the Origin of Indonesian Cattle	PLOS ONE			English	Article							MITOCHONDRIAL-DNA; DIVERSITY; AFRICAN; HYBRIDIZATION; ADMIXTURE; MARKERS; BANTENG; EAST	Background: Two bovine species contribute to the Indonesian livestock, zebu (Bos indicus) and banteng (Bos javanicus), respectively. Although male hybrid offspring of these species is not fertile, Indonesian cattle breeds are supposed to be of mixed species origin. However, this has not been documented and is so far only supported by preliminary molecular analysis. Methods and Findings: Analysis of mitochondrial, Y-chromosomal and microsatellite DNA showed a banteng introgression of 10-16% in Indonesian zebu breeds. East-Javanese Madura and Galekan cattle have higher levels of autosomal banteng introgression (20-30%) and combine a zebu paternal lineage with a predominant (Madura) or even complete (Galekan) maternal banteng origin. Two Madura bulls carried taurine Y-chromosomal haplotypes, presumably of French Limousin origin. In contrast, we did not find evidence for zebu introgression in five populations of the Bali cattle, a domestic form of the banteng. Conclusions: Because of their unique species composition Indonesian cattle represent a valuable genetic resource, which potentially may also be exploited in other tropical regions.			Mohamad, K (corresponding author), Bogor Agr Univ, Fac Vet Med, Bogor, Indonesia.	J.A.Lenstra@uu.nl	Andersson, Goran/AAK-6564-2020; Mikko, Sofia/F-1347-2017; Rodriguez, Heriberto/G-2675-2012; Lenstra, Johannes A./H-2988-2019; Rodriguez-Martinez, Heriberto/AAG-4076-2020; Mohamad, Kusdiantoro/GPG-3156-2022	Andersson, Goran/0000-0001-5131-3144; Mikko, Sofia/0000-0002-6375-1376; Rodriguez, Heriberto/0000-0002-5194-2124; Lenstra, Johannes A./0000-0003-1745-7739; Rodriguez-Martinez, Heriberto/0000-0002-5194-2124; Mohamad, Kusdiantoro/0000-0002-7143-168X				BARWEGEN M, 2005, GOUDEN HOORNS GESCHI; Bradley DG, 1996, P NATL ACAD SCI USA, V93, P5131, DOI 10.1073/pnas.93.10.5131; Bradshaw CJA, 2006, CONSERV BIOL, V20, P1306, DOI 10.1111/j.1523-1739.2006.00428.x; Bruford MW, 2003, NAT REV GENET, V4, P900, DOI 10.1038/nrg1203; Bryant D, 2004, MOL BIOL EVOL, V21, P255, DOI 10.1093/molbev/msh018; FELIUS M, 1995, CATTLE BREEDS ENCY M; Freeman AR, 2004, MOL ECOL, V13, P3477, DOI 10.1111/j.1365-294X.2004.02311.x; GINJA C, 2008, J HERED; Gotherstrom A, 2005, P ROY SOC B-BIOL SCI, V272, P2345, DOI 10.1098/rspb.2005.3243; Hall S.J.G., 2004, LIVESTOCK BIODIVERSI; Kikkawa Y, 2003, ANIM GENET, V34, P96, DOI 10.1046/j.1365-2052.2003.00956.x; KIKKAWA Y, 1995, BIOCHEM GENET, V33, P51, DOI 10.1007/BF00554558; KREDIET G, 1913, RUNDVEEFOKKERIJ JAVA; Kumar P, 2003, HEREDITY, V91, P43, DOI 10.1038/sj.hdy.6800277; Lenstra JA, 1999, GENETICS OF CATTLE, P1; LOFTUS RT, 1994, ANIM GENET, V25, P265, DOI 10.1111/j.1365-2052.1994.tb00203.x; MCCOOL C, 1992, TROP ANIM HEALTH PRO, V24, P165, DOI 10.1007/BF02359609; NAMIKAWA T, 1978, Japanese Journal of Zootechnical Science, V49, P817; NAMIKAWA T, 1981, Z TIERZ ZUCHTUNGSBIO, V98, P151; Nijman IJ, 2003, HEREDITY, V90, P10, DOI 10.1038/sj.hdy.6800174; Nijman IJ, 2008, CLADISTICS, V24, P723, DOI 10.1111/j.1096-0031.2008.00201.x; PAYNE W J A, 1976, Zeitschrift fuer Tierzuechtung und Zuechtungsbiologie, V93, P89; PAYNE WJA, 1973, WLD ANIM REV, V7, P13; Pritchard JK, 2000, GENETICS, V155, P945; ROLLINSON DHL, 1994, EVOLUTION DOMESTIC A; Rosenberg NA, 2004, MOL ECOL NOTES, V4, P137, DOI 10.1046/j.1471-8286.2003.00566.x; ROWLINSON P, 2008, LIVESTOCK GLOBAL CLI; Sambrook J, 1989, MOL CLONING; THOEN H, 1919, VEERASSEN VEETEELT N; Verkaar ELC, 2003, HEREDITY, V91, P565, DOI 10.1038/sj.hdy.6800359; Verkaar ELC, 2002, MEAT SCI, V60, P365, DOI 10.1016/S0309-1740(01)00144-9; Yu Y, 1999, ANIM GENET, V30, P245, DOI 10.1046/j.1365-2052.1999.00483.x	32	44	45	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5490	10.1371/journal.pone.0005490	http://dx.doi.org/10.1371/journal.pone.0005490			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444WA	19436739	gold, Green Published, Green Submitted			2022-12-25	WOS:000266009900003
J	James, CE; Mahendran, KR; Molitor, A; Bolla, JM; Bessonov, AN; Winterhalter, M; Page, JM				James, Chloe E.; Mahendran, Kozhinjampara R.; Molitor, Alexander; Bolla, Jean-Michel; Bessonov, Andrey N.; Winterhalter, Mathias; Page, Jean-Marie			How beta-Lactam Antibiotics Enter Bacteria: A Dialogue with the Porins	PLOS ONE			English	Article							GRAM-NEGATIVE BACTERIA; OUTER-MEMBRANE PERMEABILITY; ESCHERICHIA-COLI; ENTEROBACTER-AEROGENES; KLEBSIELLA-PNEUMONIAE; OMPF CHANNEL; MOLECULAR-BASIS; RESISTANCE; ERTAPENEM; EFFLUX	Background: Multi-drug resistant (MDR) infections have become a major concern in hospitals worldwide. This study investigates membrane translocation, which is the first step required for drug action on internal bacterial targets. beta-lactams, a major antibiotic class, use porins to pass through the outer membrane barrier of Gram-negative bacteria. Clinical reports have linked the MDR phenotype to altered membrane permeability including porin modification and efflux pump expression. Methodology/Principal Findings: Here influx of beta-lactams through the major Enterobacter aerogenes porin Omp36 is characterized. Conductance measurements through a single Omp36 trimer reconstituted into a planar lipid bilayer allowed us to count the passage of single beta-lactam molecules. Statistical analysis of each transport event yielded the kinetic parameters of antibiotic travel through Omp36 and distinguishable translocation properties of beta-lactams were quantified for ertapenem and cefepime. Expression of Omp36 in an otherwise porin-null bacterial strain is shown to confer increases in the killing rate of these antibiotics and in the corresponding bacterial susceptibility. Conclusions/Significance: We propose the idea of a molecular "passport'' that allows rapid transport of substrates through porins. Deciphering antibiotic translocation provides new insights for the design of novel drugs that may be highly effective at passing through the porin constriction zone. Such data may hold the key for the next generation of antibiotics capable of rapid intracellular accumulation to circumvent the further development MDR infections.			James, CE (corresponding author), Univ Aix Marseille 2, UMR MD 1, Fac Med, IFR 88, Marseille, France.	Jean-Marie.PAGES@univmed.fr	James, Chloe/G-2371-2010; Bolla, Jean Michel/D-3885-2014; Pages, Jean-Marie/F-2555-2013	Bolla, Jean Michel/0000-0003-3892-4340; Winterhalter, Mathias/0000-0002-1604-3318; Pages, Jean-Marie/0000-0001-7092-7977; James, Chloe/0000-0002-0131-7988				Ardanuy C, 1998, ANTIMICROB AGENTS CH, V42, P1636, DOI 10.1128/AAC.42.7.1636; Basle A, 2006, J MOL BIOL, V362, P933, DOI 10.1016/j.jmb.2006.08.002; Berezhkovskii AM, 2005, BIOPHYS J, V88, pL17, DOI 10.1529/biophysj.104.057588; Blot S, 2007, CURR OPIN INFECT DIS, V20, P391, DOI 10.1097/QCO.0b013e32818be6f7; Bolla Jean Michel, 2003, Methods Mol Biol, V228, P131, DOI 10.1385/1-59259-400-X:131; Bornet C, 2004, ANTIMICROB AGENTS CH, V48, P2153, DOI 10.1128/AAC.48.6.2153-2158.2004; Bornet C, 2000, J CLIN MICROBIOL, V38, P1048, DOI 10.1128/JCM.38.3.1048-1052.2000; Bredin J, 2002, BIOCHEM J, V363, P521, DOI 10.1042/0264-6021:3630521; Bryskier A, 2005, ANTIMICROBIAL AGENTS: ANTIBACTERIALS AND ANTIFUNGALS, P1; Chang AB, 2004, MOL MEMBR BIOL, V21, P171, DOI 10.1080/09687680410001720830; Chopra I, 2008, LANCET INFECT DIS, V8, P133, DOI 10.1016/S1473-3099(08)70018-5; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Danelon C, 2006, BIOPHYS J, V90, P1617, DOI 10.1529/biophysj.105.075192; Danelon C, 2003, BIOPHYS CHEM, V104, P591, DOI 10.1016/S0301-4622(03)00062-0; Davin-Regli A, 2008, CURR DRUG TARGETS, V9, P750, DOI 10.2174/138945008785747824; De E, 2001, MOL MICROBIOL, V41, P189, DOI 10.1046/j.1365-2958.2001.02501.x; Domenech-Sanchez A, 2003, ANTIMICROB AGENTS CH, V47, P3332, DOI 10.1128/AAC.47.10.3332-3335.2003; Elliott E, 2006, CLIN INFECT DIS, V42, pE95, DOI 10.1086/503264; GARAVITO RM, 1986, METHOD ENZYMOL, V125, P309; Gayet S, 2003, ANTIMICROB AGENTS CH, V47, P1555, DOI 10.1128/AAC.47.5.1555-1559.2003; Hammond ML, 2004, J ANTIMICROB CHEMOTH, V53, P7, DOI 10.1093/jac/dkh203; Hasdemir UO, 2004, J CLIN MICROBIOL, V42, P2701, DOI 10.1128/JCM.42.6.2701-2706.2004; Iyer R, 2000, J MOL BIOL, V297, P933, DOI 10.1006/jmbi.2000.3599; Jacoby GA, 2004, ANTIMICROB AGENTS CH, V48, P3203, DOI 10.1128/AAC.48.8.3203-3206.2004; JEANTEUR D, 1994, P NATL ACAD SCI USA, V91, P10675, DOI 10.1073/pnas.91.22.10675; KARSHIKOFF A, 1994, J MOL BIOL, V240, P372, DOI 10.1006/jmbi.1994.1451; Liu NZ, 1997, BBA-BIOMEMBRANES, V1326, P201, DOI 10.1016/S0005-2736(97)00024-2; Livermore DM, 2003, J ANTIMICROB CHEMOTH, V52, P331, DOI 10.1093/jac/dkg375; Mach T, 2008, J AM CHEM SOC, V130, P13301, DOI 10.1021/ja803188c; Mallea M, 1998, MICROBIOL-UK, V144, P3003, DOI 10.1099/00221287-144-11-3003; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; NEKOLLA S, 1994, BIOPHYS J, V66, P1388, DOI 10.1016/S0006-3495(94)80929-4; Nestorovich EM, 2002, P NATL ACAD SCI USA, V99, P9789, DOI 10.1073/pnas.152206799; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Pages JM, 2008, NAT REV MICROBIOL, V6, P893, DOI 10.1038/nrmicro1994; Prilipov A, 1998, FEMS MICROBIOL LETT, V163, P65, DOI 10.1111/j.1574-6968.1998.tb13027.x; Qing GL, 2004, NAT BIOTECHNOL, V22, P877, DOI 10.1038/nbt984; Rice LB, 2006, BIOCHEM PHARMACOL, V71, P991, DOI 10.1016/j.bcp.2005.09.018; Saier MH, 2007, J MOL MICROB BIOTECH, V12, P161, DOI 10.1159/000099638; Schwarz G, 2003, BIOPHYS J, V84, P2990, DOI 10.1016/S0006-3495(03)70025-3; Simonet V, 2000, ANTIMICROB AGENTS CH, V44, P311, DOI 10.1128/AAC.44.2.311-315.2000; Thiolas A, 2004, BIOCHEM BIOPH RES CO, V317, P851, DOI 10.1016/j.bbrc.2004.03.130; Vidal S, 2005, J MED CHEM, V48, P1395, DOI 10.1021/jm049652e; Weingart H, 2008, CURR DRUG TARGETS, V9, P789, DOI 10.2174/138945008785747752; YOSHIMURA F, 1985, ANTIMICROB AGENTS CH, V27, P84, DOI 10.1128/AAC.27.1.84; Zakharian E, 2003, FEBS LETT, V555, P229, DOI 10.1016/S0014-5793(03)01236-5	47	75	75	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2009	4	5							e5453	10.1371/journal.pone.0005453	http://dx.doi.org/10.1371/journal.pone.0005453			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444VZ	19434239	gold, Green Accepted, Green Published, Green Submitted			2022-12-25	WOS:000266009800002
J	Freude, S; Hettich, MM; Schumann, C; Stohr, O; Koch, L; Kohler, C; Udelhoven, M; Leeser, U; Muller, M; Kubota, N; Kadowaki, T; Krone, W; Schroder, H; Bruning, JC; Schubert, M				Freude, Susanna; Hettich, Moritz M.; Schumann, Christina; Stoehr, Oliver; Koch, Linda; Koehler, Christoph; Udelhoven, Michael; Leeser, Uschi; Mueller, Marita; Kubota, Naoto; Kadowaki, Takashi; Krone, Wilhelm; Schroeder, Hannsjoerg; Bruening, Jens C.; Schubert, Markus			Neuronal IGF-1 resistance reduces A beta accumulation and protects against premature death in a model of Alzheimer's disease	FASEB JOURNAL			English	Article						beta-amyloid; longevity; insulin receptor substrate; brain; Tg2576 mice	AMYLOID PRECURSOR PROTEIN; TYPE-2 DIABETES-MELLITUS; GROWTH-FACTOR EXPRESSION; INSULIN-RECEPTOR; LIFE-SPAN; SECRETASE CLEAVAGE; IMPAIRED INSULIN; PLAQUE-FORMATION; BRAIN INSULIN; RAT-BRAIN	Alzheimer's disease ( AD) is characterized by progressive neurodegeneration leading to loss of cognitive abilities and ultimately to death. Postmortem investigations revealed decreased expression of cerebral insulin-like growth factor (IGF)-1 receptor (IGF-1R) and insulin receptor substrate (IRS) proteins in patients with AD. To elucidate the role of insulin/IGF-1 signaling in AD, we crossed mice expressing the Swedish mutation of amyloid precursor protein (APP(SW), Tg2576 mice) as a model for AD with mice deficient for either IRS-2, neuronal IGF-1R (nIGF-1R(-/-)), or neuronal insulin receptor (nIR(-/-)), and analyzed survival, glucose, and APP metabolism. In the present study, we show that IRS-2 deficiency in Tg2576 mice completely reverses premature mortality in Tg2576 females and delays beta-amyloid (A beta) accumulation. Analysis of APP metabolism suggested that delayed A beta accumulation resulted from decreased APP processing. To delineate the upstream signal responsible for IRS-2-mediated disease protection, we analyzed mice with nIGF-1R or nIR deficiency predominantly in the hippocampus. Interestingly, both male and female nIGF1R(-/-) Tg2576 mice were protected from premature death in the presence of decreased A beta accumulation specifically in the hippocampus formation. However, neuronal IR deletion had no influence on lethality of Tg2576 mice. Thus, impaired IGF-1/IRS-2 signaling prevents premature death and delays amyloid accumulation in amodel of AD.-Freude, S., Hettich, M. M., Schumann, C., Stohr, O., Koch, L., Kohler, C., Udelhoven, M., Leeser, U., Muller, M., Kubota, N., Kadowaki, T., Krone, W., Schroder, H., Bruning, J. C., Schubert, M. Neuronal IGF-1 resistance reduces A beta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J. 23, 3315-3324 ( 2009). www.fasebj.org	[Freude, Susanna; Hettich, Moritz M.; Schumann, Christina; Stoehr, Oliver; Udelhoven, Michael; Leeser, Uschi; Mueller, Marita; Krone, Wilhelm; Bruening, Jens C.; Schubert, Markus] Univ Cologne, Dept Internal Med 2, D-50937 Cologne, Germany; [Freude, Susanna; Hettich, Moritz M.; Schumann, Christina; Stoehr, Oliver; Koch, Linda; Udelhoven, Michael; Leeser, Uschi; Mueller, Marita; Krone, Wilhelm; Bruening, Jens C.; Schubert, Markus] Univ Cologne, Ctr Mol Med Cologne, D-50937 Cologne, Germany; [Freude, Susanna; Hettich, Moritz M.; Stoehr, Oliver; Koch, Linda; Udelhoven, Michael; Leeser, Uschi; Mueller, Marita; Krone, Wilhelm; Bruening, Jens C.; Schubert, Markus] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, D-50937 Cologne, Germany; [Koch, Linda; Bruening, Jens C.] Univ Cologne, Inst Genet, Dept Mouse Genet & Metab, D-50937 Cologne, Germany; [Koehler, Christoph; Schroeder, Hannsjoerg] Univ Cologne, Dept Anat 2, D-50937 Cologne, Germany; [Kubota, Naoto; Kadowaki, Takashi] Univ Tokyo, Grad Sch Med, Dept Metab Dis, Tokyo, Japan; [Bruening, Jens C.] Max Planck Inst Biol Ageing, Cologne, Germany	University of Cologne; University of Cologne; University of Cologne; University of Cologne; University of Cologne; University of Tokyo; Max Planck Society	Schubert, M (corresponding author), Univ Cologne, Dept Internal Med 2, Kerpener Str 62,LFI 4-061, D-50937 Cologne, Germany.	markus.schubert@uni-koeln.de	Kubota, Naoto/N-7892-2015; Schubert, Markus/F-5150-2010	Koch, Linda/0000-0002-2943-1993	Fritz-Thyssen Foundation [10.06.2.209]; Alzheimer Forschungs-Initiative [08813]; Deutsche Forschungsgemeinschaft [Br-1492-7]; Fritz-Thyssen Foundation	Fritz-Thyssen Foundation; Alzheimer Forschungs-Initiative; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Fritz-Thyssen Foundation	This work was supported by the Fritz-Thyssen Foundation (AZ 10.06.2.209) and Alzheimer Forschungs-Initiative e. V. ( 08813) to M. S. and by funds to J.C.B. by the Deutsche Forschungsgemeinschaft (Br-1492-7) and the Fritz-Thyssen Foundation. We gratefully thank Prof. R. Wiesner and Prof. C. Niessen for helpful discussions on the data and the manuscript.	Adlerz L, 2007, J BIOL CHEM, V282, P10203, DOI 10.1074/jbc.M611183200; BASKIN DG, 1986, J NEUROSCI METH, V16, P119, DOI 10.1016/0165-0270(86)90044-0; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Burks DJ, 2000, NATURE, V407, P377, DOI 10.1038/35030105; Carlson GA, 1997, HUM MOL GENET, V6, P1951, DOI 10.1093/hmg/6.11.1951; Cohen E, 2006, SCIENCE, V313, P1604, DOI 10.1126/science.1124646; Cole AR, 2007, NEUROSCI BIOBEHAV R, V31, P1046, DOI 10.1016/j.neubiorev.2007.04.004; Costantini C, 2006, EMBO J, V25, P1997, DOI 10.1038/sj.emboj.7601062; Cukierman-Yaffe T, 2009, DIABETES CARE, V32, P221, DOI 10.2337/dc08-1153; de la Monte SM, 2006, J ALZHEIMERS DIS, V10, P89; Doria A, 2008, CELL METAB, V8, P186, DOI 10.1016/j.cmet.2008.08.006; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Finch CE, 2001, ANNU REV GENOM HUM G, V2, P435, DOI 10.1146/annurev.genom.2.1.435; Frolich L, 1999, ANN NY ACAD SCI, V893, P290, DOI 10.1111/j.1749-6632.1999.tb07839.x; Frolich L, 1998, J NEURAL TRANSM, V105, P423, DOI 10.1007/s007020050068; Haan MN, 2006, NAT CLIN PRACT NEURO, V2, P159, DOI 10.1038/ncpneuro0124; HILL JM, 1986, NEUROSCIENCE, V17, P1127, DOI 10.1016/0306-4522(86)90082-5; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kappeler L, 2008, PLOS BIOL, V6, P2144, DOI 10.1371/journal.pbio.0060254; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lovestone S, 1999, NEUROLOGY, V53, P1907, DOI 10.1212/WNL.53.9.1907; Luchsinger JA, 2004, NEUROLOGY, V63, P1187, DOI 10.1212/01.WNL.0000140292.04932.87; Matsubara E, 2003, J NEUROCHEM, V85, P1101, DOI 10.1046/j.1471-4159.2003.01654.x; McConlogue L, 2007, J BIOL CHEM, V282, P26326, DOI 10.1074/jbc.M611687200; Meilandt WJ, 2009, J NEUROSCI, V29, P1977, DOI 10.1523/JNEUROSCI.2984-08.2009; Moloney AM, 2010, NEUROBIOL AGING, V31, P224, DOI 10.1016/j.neurobiolaging.2008.04.002; Nathan C, 2005, J EXP MED, V202, P1163, DOI 10.1084/jem.20051529; Niedernhofer LJ, 2006, NATURE, V444, P1038, DOI 10.1038/nature05456; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; Pitcher H, 2006, LANCET NEUROL, V5, P388, DOI 10.1016/S1474-4422(06)70434-3; Puglielli L, 2003, J BIOL CHEM, V278, P19777, DOI 10.1074/jbc.M300466200; Puglielli L, 2008, NEUROBIOL AGING, V29, P795, DOI 10.1016/j.neurobiolaging.2007.01.010; Reger MA, 2008, NEUROLOGY, V70, P440, DOI 10.1212/01.WNL.0000265401.62434.36; Rivera EJ, 2005, J ALZHEIMERS DIS, V8, P247; Ronnemaa E, 2008, NEUROLOGY, V71, P1065, DOI 10.1212/01.wnl.0000310646.32212.3a; Schulingkamp RJ, 2000, NEUROSCI BIOBEHAV R, V24, P855, DOI 10.1016/S0149-7634(00)00040-3; Seibler J, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng012; Selman C, 2008, FASEB J, V22, P807, DOI 10.1096/fj.07-9261com; Stachelscheid H, 2008, EMBO J, V27, P2091, DOI 10.1038/emboj.2008.141; Steen E, 2005, J ALZHEIMERS DIS, V7, P63, DOI 10.3233/jad-2005-7107; Stein TD, 2002, J NEUROSCI, V22, P7380; Stewart R, 1999, DIABETIC MED, V16, P93, DOI 10.1046/j.1464-5491.1999.00027.x; Taguchi A, 2007, SCIENCE, V317, P369, DOI 10.1126/science.1142179; Tschanz JT, 2004, NEUROLOGY, V62, P1156, DOI 10.1212/01.WNL.0000118210.12660.C2; UNGER J, 1989, NEUROSCIENCE, V31, P143, DOI 10.1016/0306-4522(89)90036-5; Van Houten M, 1983, Adv Metab Disord, V10, P269; VANHOUTEN M, 1979, NATURE, V282, P623, DOI 10.1038/282623a0; Vardy ERLC, 2007, J ALZHEIMERS DIS, V12, P285; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WADSWORTH WG, 1989, DEV BIOL, V132, P167, DOI 10.1016/0012-1606(89)90214-5; WERTHER GA, 1987, ENDOCRINOLOGY, V121, P1562, DOI 10.1210/endo-121-4-1562; WHITMER RA, 2006, ALZHEIMERS DEMENT, V2, pS149; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; Zhao LX, 2004, J NEUROSCI, V24, P11120, DOI 10.1523/JNEUROSCI.2860-04.2004	61	158	162	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3315	3324		10.1096/fj.09-132043	http://dx.doi.org/10.1096/fj.09-132043			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19487308				2022-12-25	WOS:000270354300009
J	Salmon, AB; Perez, VI; Bokov, A; Jernigan, A; Kim, G; Zhao, H; Levine, RL; Richardson, A				Salmon, Adam B.; Perez, Viviana I.; Bokov, Alex; Jernigan, Amanda; Kim, Geumsoo; Zhao, Hang; Levine, Rodney L.; Richardson, Arlan			Lack of methionine sulfoxide reductase A in mice increases sensitivity to oxidative stress but does not diminish life span	FASEB JOURNAL			English	Article						longevity; free radical; stress resistance; aging; antioxidant	FIBROBLAST CELL-LINES; ANTIOXIDANT ENZYMES; MULTIPLE FORMS; KNOCKOUT MOUSE; DWARF MICE; RESISTANCE; MSRA; DAMAGE; GENE; OVEREXPRESSION	Methionine sulfoxide reductase A (MsrA) repairs oxidized methionine residues within proteins and may also function as a general antioxidant. Previous reports have suggested that modulation of MsrA in mice and mammalian cell culture can affect the accumulation of oxidized proteins and may regulate resistance to oxidative stress. Thus, under the oxidative stress theory of aging, these results would predict that MsrA regulates the aging process in mammals. We show here that MsrA(-/-) mice are more susceptible to oxidative stress induced by paraquat. Skin-derived fibroblasts do not express MsrA, but fibroblasts cultured from MsrA(-/-) mice were, nevertheless, also more susceptible to killing by various oxidative stresses. In contrast to previous reports, we find no evidence for neuromuscular dysfunction in MsrA(-/-) mice in either young adult or in older animals. Most important, we found no difference between MsrA(-/-) and control mice in either their median or maximum life span. Thus, our results show that MsrA regulates sensitivity to oxidative stress in mice but has no effect on aging, as determined by life span.-Salmon, A. B., Perez, V. I., Bokov, A., Jernigan, A., Kim, G., Zhao, H., Levine, R. L., Richardson, A. Lack of methionine sulfoxide reductase A in mice increases sensitivity to oxidative stress but does not diminish life span. FASEB J. 23, 3601-3608 (2009). www.fasebj.org	[Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA; [Kim, Geumsoo; Zhao, Hang; Levine, Rodney L.] NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; [Richardson, Arlan] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Richardson, A (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Sam & Ann Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA.	richardsona@uthscsa.edu	Levine, Rodney L/D-9885-2011; Zhao, Hang/A-2558-2012		National Institutes of Health (NIH) [T32 AG021890-05, R37AG026557]; San Antonio Nathan Shock Center for Excellence in the Basic Biology of Aging; National Heart, Lung, and Blood Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG021890, R37AG026557] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); San Antonio Nathan Shock Center for Excellence in the Basic Biology of Aging; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Jay Cox, Marian Sabia, and Quy Fung for assistance in animal care. We also thank Dr. James Harper for statistical analysis assistance and intellectual discourse. This study was supported by National Institutes of Health (NIH) training grant T32 AG021890-05 (A. B. S.), NIH MERIT grant R37AG026557 (A. R.), the San Antonio Nathan Shock Center for Excellence in the Basic Biology of Aging (A.R.), and the Intramural Research Program of the National Heart, Lung, and Blood Institute (G.K., H.Z., and R.L.L.).	Bokov A, 2004, MECH AGEING DEV, V125, P811, DOI 10.1016/j.mad.2004.07.009; BUS JS, 1976, TOXICOL APPL PHARM, V35, P501, DOI 10.1016/0041-008X(76)90073-9; Cocheme HM, 2008, J BIOL CHEM, V283, P1786, DOI 10.1074/jbc.M708597200; Erickson JR, 2008, CELL, V133, P462, DOI 10.1016/j.cell.2008.02.048; Fomenko DE, 2009, J BIOL CHEM, V284, P5986, DOI 10.1074/jbc.M805770200; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Harper JM, 2007, AGING CELL, V6, P1, DOI 10.1111/j.1474-9726.2006.00255.x; Harper JM, 2006, MECH AGEING DEV, V127, P687, DOI 10.1016/j.mad.2006.04.002; Hauck SJ, 2002, HORM METAB RES, V34, P481, DOI 10.1055/s-2002-34787; Kantorow M, 2004, P NATL ACAD SCI USA, V101, P9654, DOI 10.1073/pnas.0403532101; Khor HK, 2004, J BIOL CHEM, V279, P19486, DOI 10.1074/jbc.M310045200; Koc A, 2004, P NATL ACAD SCI USA, V101, P7999, DOI 10.1073/pnas.0307929101; Lee JW, 2006, EXP EYE RES, V82, P816, DOI 10.1016/j.exer.2005.10.003; Leiser SF, 2006, MECH AGEING DEV, V127, P821, DOI 10.1016/j.mad.2006.08.003; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Luo S, 2009, FASEB J, V23, P464, DOI 10.1096/fj.08-118414; Marchetti MA, 2006, EXP EYE RES, V83, P1281, DOI 10.1016/j.exer.2006.07.005; Miskin R, 1997, J GERONTOL A-BIOL, V52, pB118, DOI 10.1093/gerona/52A.2.B118; Moskovitz J, 1997, P NATL ACAD SCI USA, V94, P9585, DOI 10.1073/pnas.94.18.9585; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; MOSKOVITZ J, 1995, J BACTERIOL, V177, P502, DOI 10.1128/jb.177.3.502-507.1995; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; Murakami S, 2003, FASEB J, V17, P1565, DOI 10.1096/fj.02-1092fje; Oien DB, 2008, FREE RADICAL BIO MED, V45, P193, DOI 10.1016/j.freeradbiomed.2008.04.003; Pal R, 2007, EXP BRAIN RES, V180, P765, DOI 10.1007/s00221-007-0903-6; Perez VI, 2009, AGING CELL, V8, P73, DOI 10.1111/j.1474-9726.2008.00449.x; Picot CR, 2005, FREE RADICAL BIO MED, V39, P1332, DOI 10.1016/j.freeradbiomed.2005.06.017; Pletcher SD, 2000, J GERONTOL A-BIOL, V55, pB381, DOI 10.1093/gerona/55.8.B381; Prentice HM, 2008, BIOCHEM BIOPH RES CO, V366, P775, DOI 10.1016/j.bbrc.2007.12.043; Priest NK, 2002, EVOLUTION, V56, P927, DOI 10.1111/j.0014-3820.2002.tb01405.x; Ran Q, 2007, J GERONTOL A-BIOL, V62, P932, DOI 10.1093/gerona/62.9.932; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Ruan H, 2002, P NATL ACAD SCI USA, V99, P2748, DOI 10.1073/pnas.032671199; Salmon AB, 2005, AM J PHYSIOL-ENDOC M, V289, pE23, DOI 10.1152/ajpendo.00575.2004; Salmon AB, 2008, J GERONTOL A-BIOL, V63, P232, DOI 10.1093/gerona/63.3.232; Shahbazian MD, 2002, NEURON, V35, P243, DOI 10.1016/S0896-6273(02)00768-7; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Stadtman ER, 2005, BBA-PROTEINS PROTEOM, V1703, P135, DOI 10.1016/j.bbapap.2004.08.010; Stadtman ER, 2002, MOL CELL BIOCHEM, V234, P3, DOI 10.1023/A:1015916831583; Tirosh O, 2005, MECH AGEING DEV, V126, P1262, DOI 10.1016/j.mad.2005.07.003; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Wang CX, 2004, MECH AGEING DEV, V125, P629, DOI 10.1016/j.mad.2004.07.003; YUAN R, 2008, LONGITUDINAL ANAL LI	44	103	104	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3601	3608		10.1096/fj.08-127415	http://dx.doi.org/10.1096/fj.08-127415			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19487311	Green Published			2022-12-25	WOS:000270354300036
J	Ittner, LM; Ke, YD; Gotz, J				Ittner, Lars M.; Ke, Yazi D.; Goetz, Juergen			Phosphorylated Tau Interacts with c-Jun N-terminal Kinase-interacting Protein 1 (JIP1) in Alzheimer Disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXONAL-TRANSPORT; SCAFFOLD PROTEIN; NEUROFIBRILLARY TANGLES; KINESIN; JNK; BINDING; BRAIN; OVEREXPRESSION; MICROTUBULES; AXONOPATHY	In Alzheimer disease (AD) and frontotemporal dementia the microtubule-associated protein Tau becomes progressively hyperphosphorylated, eventually forming aggregates. However, how Tau dysfunction is associated with functional impairment is only partly understood, especially at early stages when Tau is mislocalized but has not yet formed aggregates. Impaired axonal transport has been proposed as a potential pathomechanism, based on cellular Tau models and Tau transgenic mice. We recently reported K369I mutant Tau transgenic K3 mice with axonal transport defects that suggested a cargo-selective impairment of kinesin-driven anterograde transport by Tau. Here, we show that kinesin motor complex formation is disturbed in the K3 mice. We show that under pathological conditions hyperphosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1), which is associated with the kinesin motor protein complex. As a result, transport of JIP1 into the axon is impaired, causing JIP1 to accumulate in the cell body. Because we found trapping of JIP1 and a pathological Tau/JIP1 interaction also in AD brain, this may have pathomechanistic implications in diseases with a Tau pathology. This is supported by JIP1 sequestration in the cell body of Tau-transfected primary neuronal cultures. The pathological Tau/JIP1 interaction requires phosphorylation of Tau, and Tau competes with the physiological binding of JIP1 to kinesin light chain. Because JIP1 is involved in regulating cargo binding to kinesin motors, our findings may, at least in part, explain how hyperphosphorylated Tau mediates impaired axonal transport in AD and frontotemporal dementia.	[Ittner, Lars M.; Ke, Yazi D.] Univ Sydney, Brain & Mind Res Inst, Alzheimers & Parkinsons Dis Lab, Camperdown, NSW 2050, Australia	University of Sydney	Ittner, LM (corresponding author), Univ Sydney, Brain & Mind Res Inst, Alzheimers & Parkinsons Dis Lab, 100 Mallett St, Camperdown, NSW 2050, Australia.	littner@med.usyd.edu.au; jgoetz@med.usyd.edu.au	Götz, Jürgen/C-2448-2014; Ke, Yazi/ABC-3052-2020	Götz, Jürgen/0000-0001-8501-7896; Ke, Yazi/0000-0002-1423-0451; Ittner, Lars/0000-0001-6738-3825	University of Sydney; National Health and Medical Research Council (NHMRC); Judith Jane Mason and Harold Stannett Williams Memorial Foundation; Australian Research Council (ARC); New South Wales Government; Ministry for Science and Medical Research; ARC; Deutsche Forschungsgemeinschaft	University of Sydney(University of Sydney); National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Judith Jane Mason and Harold Stannett Williams Memorial Foundation; Australian Research Council (ARC)(Australian Research Council); New South Wales Government; Ministry for Science and Medical Research; ARC(Australian Research Council); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This research was supported by grants from the University of Sydney, The Medical Foundation (University of Sydney), the National Health and Medical Research Council (NHMRC), the Judith Jane Mason and Harold Stannett Williams Memorial Foundation, the Australian Research Council (ARC), and the New South Wales Government through the Ministry for Science and Medical Research (BioFirst grant) (to J.G.) and by the NHMRC, the ARC, the University of Sydney, and the Deutsche Forschungsgemeinschaft (to L. M. I.).	Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; Baas PW, 2005, TRENDS CELL BIOL, V15, P183, DOI 10.1016/j.tcb.2005.02.001; Blasius TL, 2007, J CELL BIOL, V176, P11, DOI 10.1083/jcb.200605099; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Chen F, 2004, CURR DRUG TARGETS, V5, P503, DOI 10.2174/1389450043345236; Cruts M, 2008, TRENDS GENET, V24, P186, DOI 10.1016/j.tig.2008.01.004; Cuchillo-Ibanez I, 2008, FASEB J, V22, P3186, DOI 10.1096/fj.08-109181; David DC, 2005, J BIOL CHEM, V280, P23802, DOI 10.1074/jbc.M500356200; David DC, 2006, PROTEOMICS, V6, P6566, DOI 10.1002/pmic.200600634; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dixit R, 2008, SCIENCE, V319, P1086, DOI 10.1126/science.1152993; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Fath T, 2009, NAT PROTOC, V4, P78, DOI 10.1038/nprot.2008.199; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gotz J, 2008, NAT REV NEUROSCI, V9, P532, DOI 10.1038/nrn2420; Gotz J, 2006, J NEUROCHEM, V98, P993, DOI 10.1111/j.1471-4159.2006.03955.x; Helbecque N, 2003, MOL PSYCHIATR, V8, P413, DOI 10.1038/sj.mp.4001344; HELBECQUE N, 2003, MOL PSYCHIATR, V8, P363, DOI DOI 10.1038/SJ.MP.4001342; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; Hirokawa N, 2005, NAT REV NEUROSCI, V6, P201, DOI 10.1038/nrn1624; Horiuchi D, 2005, CURR BIOL, V15, P2137, DOI 10.1016/j.cub.2005.10.047; Horiuchi D, 2007, CURR BIOL, V17, P1313, DOI 10.1016/j.cub.2007.06.062; Inomata H, 2003, J BIOL CHEM, V278, P22946, DOI 10.1074/jbc.M212160200; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; Ittner LM, 2008, P NATL ACAD SCI USA, V105, P15997, DOI 10.1073/pnas.0808084105; Ittner Lars M, 2005, J Biol, V4, P11, DOI 10.1186/jbiol29; Ittner LM, 2005, BIOCHEMISTRY-US, V44, P5749, DOI 10.1021/bi048111o; Kelkar N, 2005, MOL CELL BIOL, V25, P2733, DOI 10.1128/MCB.25.7.2733-2743.2005; Kohrmann M, 1999, J NEUROSCI RES, V58, P831; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Mandelkow EM, 2004, J CELL BIOL, V167, P99, DOI 10.1083/jcb.200401085; Matsuda S, 2003, J BIOL CHEM, V278, P38601, DOI 10.1074/jbc.M304379200; Meberg PJ, 2000, J NEUROSCI, V20, P2459; Merrick SE, 1997, J NEUROSCI, V17, P5726; Morfini G, 2007, J NEUROSCI RES, V85, P2620, DOI 10.1002/jnr.21154; Morfini G, 2006, NAT NEUROSCI, V9, P907, DOI 10.1038/nn1717; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; Roy S, 2005, ACTA NEUROPATHOL, V109, P5, DOI 10.1007/s00401-004-0952-x; Spittaels K, 1999, AM J PATHOL, V155, P2153, DOI 10.1016/S0002-9440(10)65533-2; Stokin GB, 2006, ANNU REV BIOCHEM, V75, P607, DOI 10.1146/annurev.biochem.75.103004.142637; Taru H, 2002, J BIOL CHEM, V277, P20070, DOI 10.1074/jbc.M108372200; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yuan A, 2008, J NEUROSCI, V28, P1682, DOI 10.1523/JNEUROSCI.5242-07.2008	50	120	124	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20909	20916		10.1074/jbc.M109.014472	http://dx.doi.org/10.1074/jbc.M109.014472			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19491104	Green Published, hybrid			2022-12-25	WOS:000268316100054
J	Arthur, PK; Claussen, M; Koch, S; Tarbashevich, K; Jahn, O; Pieler, T				Arthur, Patrick K.; Claussen, Maike; Koch, Susanne; Tarbashevich, Katsiaryna; Jahn, Olaf; Pieler, Tomas			Participation of Xenopus Elr-type Proteins in Vegetal mRNA Localization during Oogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; TRANSLATIONAL REPRESSION; VG1; CORTEX; IDENTIFICATION; TRANSPORT; COMPLEX; ELEMENT; ELAV; GENE	Directional transport of specific mRNAs is of primary biological relevance. In Xenopus oocytes, mRNA localization to the vegetal pole is important for germ layer formation and germ cell development. Using a biochemical approach, we identified Xenopus Elr-type proteins, homologs of the Hu/ELAV proteins, as novel components of the vegetal mRNA localization machinery. They bind specifically to the localization elements of several different vegetally localizing Xenopus mRNAs, and they are part of one RNP together with other localization proteins, such as Vg1RBP and XStaufen 1. Blocking Elr-type protein binding by either localization element mutagenesis or antisense morpholino oligonucleotide-mediated masking of their target RNA structures, as well as overexpression of wild type and mutant ElrB proteins, interferes with vegetal localization in Xenopus oocytes.	[Pieler, Tomas] Univ Gottingen, Dept Dev Biochem, Gottingen Ctr Mol Biosci, D-37077 Gottingen, Germany; [Jahn, Olaf] Max Planck Inst Expt Med, Prote Grp, D-37075 Gottingen, Germany	University of Gottingen; Max Planck Society	Pieler, T (corresponding author), Univ Gottingen, Dept Dev Biochem, Gottingen Ctr Mol Biosci, Justus von Liebig Weg 11, D-37077 Gottingen, Germany.	tpieler@gwdg.de	Arthur, Patrick Kobina/Y-6109-2018; Jahn, Olaf/AAD-8212-2020	Arthur, Patrick Kobina/0000-0002-5974-3955; Jahn, Olaf/0000-0002-3397-8924	Deutsche Forschungsgemeinschaft [SFB523]; Faculty of Medicine, Georg-August-University Gottingen	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Faculty of Medicine, Georg-August-University Gottingen	This work was supported by funds from the Deutsche Forschungsgemeinschaft Grant SFB523 (to T.P.) and by the research program of the Faculty of Medicine, Georg-August-University Gottingen (to M.C.).	ABE S, 1986, Memoirs of the College of Agriculture Ehime University, V31, P187; Alarcon VB, 2001, J CELL SCI, V114, P1731; Allen L, 2003, DIFFERENTIATION, V71, P311, DOI 10.1046/j.1432-0436.2003.7106003.x; Allison R, 2004, RNA, V10, P1751, DOI 10.1261/rna.7450204; Aronov S, 2001, J NEUROSCI, V21, P6577, DOI 10.1523/JNEUROSCI.21-17-06577.2001; Atasoy U, 1998, J CELL SCI, V111, P3145; Atlas R, 2007, J NEUROSCI RES, V85, P173, DOI 10.1002/jnr.21099; Betley JN, 2004, CURR BIOL, V14, P219, DOI 10.1016/j.cub.2004.01.028; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Chan AP, 1999, DEVELOPMENT, V126, P4943; Chang P, 2004, MOL BIOL CELL, V15, P4669, DOI 10.1091/mbc.E04-03-0265; Chekulaeva M, 2006, CELL, V124, P521, DOI 10.1016/j.cell.2006.01.031; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Claussen M, 2004, DEVELOPMENT, V131, P4263, DOI 10.1242/dev.01283; Claussen M, 2004, DEV BIOL, V266, P270, DOI 10.1016/j.ydbio.2003.09.043; Colegrove-Otero LJ, 2005, MOL CELL BIOL, V25, P9028, DOI 10.1128/MCB.25.20.9028-9039.2005; Condeelis J, 2005, BIOL CELL, V97, P97; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; Czaplinski K, 2005, DEV CELL, V8, P505, DOI 10.1016/j.devcel.2005.01.012; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; Devaux A, 2006, FEBS LETT, V580, P4947, DOI 10.1016/j.febslet.2006.08.012; Dormoy-Raclet V, 2007, MOL CELL BIOL, V27, P5365, DOI 10.1128/MCB.00113-07; EVANS JP, 1991, METHOD CELL BIOL, V36, P133; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; Git A, 2002, RNA, V8, P1319, DOI 10.1017/S135583820202705X; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Gorg A, 2004, PROTEOMICS, V4, P3665, DOI 10.1002/pmic.200401031; Gorospe M, 2003, CELL CYCLE, V2, P412, DOI 10.4161/cc.2.5.491; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; Heasman J, 2001, DEV BIOL, V240, P377, DOI 10.1006/dbio.2001.0495; Hinman MN, 2008, CELL MOL LIFE SCI, V65, P3168, DOI 10.1007/s00018-008-8252-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hollemann T, 1999, ADV MOLEC BIOL, P279; Horvay K, 2006, DEV BIOL, V291, P1, DOI 10.1016/j.ydbio.2005.06.013; Hudson C, 1998, MECH DEVELOP, V73, P159, DOI 10.1016/S0925-4773(98)00047-1; Jahn O, 2006, ANAL BIOANAL CHEM, V386, P92, DOI 10.1007/s00216-006-0592-1; Jambhekar A, 2007, RNA, V13, P625, DOI 10.1261/rna.262607; King ML, 2005, BIOL CELL, V97, P19; Kloc M, 1999, ADV MOLEC BIOL, P256; Kloc M, 2005, DEVELOPMENT, V132, P3445, DOI 10.1242/dev.01919; KLOC M, 1995, DEVELOPMENT, V121, P287; KLOC M, 1994, SCIENCE, V265, P1101, DOI 10.1126/science.7520603; Koebernick K, 2003, DEV BIOL, V260, P325, DOI 10.1016/S0012-1606(03)00242-2; Kolev NG, 2003, MOL CELL, V11, P745, DOI 10.1016/S1097-2765(03)00071-6; Kress TL, 2004, J CELL BIOL, V165, P203, DOI 10.1083/jcb.200309145; Kroll TT, 2002, DEVELOPMENT, V129, P5609, DOI 10.1242/dev.00160; Ladomery M, 1997, NUCLEIC ACIDS RES, V25, P965, DOI 10.1093/nar/25.5.965; Lewis RA, 2008, MOL CELL BIOL, V28, P678, DOI 10.1128/MCB.00999-07; Lisbin MJ, 2000, GENETICS, V155, P1789; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lustig KD, 1996, DEVELOPMENT, V122, P4001; Marnef A, 2009, INT J BIOCHEM CELL B, V41, P977, DOI 10.1016/j.biocel.2008.06.015; Messitt TJ, 2008, DEV CELL, V15, P426, DOI 10.1016/j.devcel.2008.06.014; Minshall N, 2004, NUCLEIC ACIDS RES, V32, P1325, DOI 10.1093/nar/gkh303; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; Mowry KL, 1996, P NATL ACAD SCI USA, V93, P14608, DOI 10.1073/pnas.93.25.14608; Nakamura A, 2001, DEVELOPMENT, V128, P3233; Pannese M, 2000, MECH DEVELOP, V90, P111, DOI 10.1016/S0925-4773(99)00228-2; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; Reumann S, 2007, PLANT CELL, V19, P3170, DOI 10.1105/tpc.107.050989; Rudt F, 1996, EMBO J, V15, P1383, DOI 10.1002/j.1460-2075.1996.tb00480.x; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Stennard F, 1996, DEVELOPMENT, V122, P4179; Tanaka KJ, 2006, J BIOL CHEM, V281, P40096, DOI 10.1074/jbc.M609059200; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; Werner HB, 2007, J NEUROSCI, V27, P7717, DOI 10.1523/JNEUROSCI.1254-07.2007; White JA, 2008, J EXP ZOOL PART B, V310B, P73, DOI 10.1002/jez.b.21153; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289; Yoon YJ, 2004, DEVELOPMENT, V131, P3035, DOI 10.1242/dev.01170; Zearfoss NR, 2004, DEV BIOL, V267, P60, DOI 10.1016/j.ydbio.2003.10.032; Zhang J, 1996, DEVELOPMENT, V122, P4119; Zhang QH, 1999, MECH DEVELOP, V88, P101, DOI 10.1016/S0925-4773(99)00162-8; Zhao WM, 2001, EMBO J, V20, P2315, DOI 10.1093/emboj/20.9.2315; Zhou Y, 2004, IUBMB LIFE, V56, P19, DOI 10.1080/15216540310001658886; Zhou Y, 1996, DEV BIOL, V179, P173, DOI 10.1006/dbio.1996.0249	79	24	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					19982	19992		10.1074/jbc.M109.009928	http://dx.doi.org/10.1074/jbc.M109.009928			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19458392	Green Published, hybrid			2022-12-25	WOS:000268097400025
J	Darlyuk, I; Goldman, A; Roberts, SC; Ullman, B; Rentsch, D; Zilberstein, D				Darlyuk, Ilona; Goldman, Adele; Roberts, Sigrid C.; Ullman, Buddy; Rentsch, Doris; Zilberstein, Dan			Arginine Homeostasis and Transport in the Human Pathogen Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE DELETION MUTANTS; AMINO-ACID PERMEASE; SACCHAROMYCES-CEREVISIAE; ENDOPROTEOLYTIC ACTIVATION; METABOLISM; YEAST; PROMASTIGOTES; EXPRESSION; CAT-1; AMASTIGOTES	Arginine is an essential amino acid for the human pathogen Leishmania but not to its host. Thus, the mechanism by which this protozoan parasite regulates cellular homeostasis of arginine is critical for its survival and virulence. In a previous study, we cloned and functionally characterized a high affinity arginine-specific transporter, LdAAP3, from Leishmania donovani. In this investigation, we have characterized the relationship between arginine transport via LdAAP3 and amino acid availability. Starving promastigotes for amino acids decreased the cellular level of most amino acids including arginine but also increased the abundance of both LdAAP3 mRNA and protein and up-regulated arginine transport activity. Genetic obliteration of the polyamine biosynthesis pathway for which arginine is the sole precursor caused a significant decrease in the rate of arginine transport. Cumulatively, we established that LdAAP3 expression and activity changed whenever the cellular level of arginine changed. Our findings have led to the hypothesis that L. donovani promastigotes have a signaling pathway that senses cellular concentrations of arginine and subsequently activates a mechanism that regulates LdAAP3 expression and activity. Interestingly, this response of LdAAP3 to amino acid availability in L. donovani is identical to that of the mammalian cation amino acid transporter 1. Thus, we conjecture that Leishmania mimics the host response to amino acid availability to improve virulence.	[Darlyuk, Ilona; Goldman, Adele; Zilberstein, Dan] Technion Israel Inst Technol, Fac Biol, IL-32000 Haifa, Israel; [Roberts, Sigrid C.] Pacific Univ, Sch Pharm, Hillsboro, OR 97123 USA; [Ullman, Buddy] Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; [Rentsch, Doris] Univ Bern, Inst Plant Sci, CH-3013 Bern, Switzerland	Technion Israel Institute of Technology; Oregon Health & Science University; University of Bern	Zilberstein, D (corresponding author), Technion Israel Inst Technol, Fac Biol, IL-32000 Haifa, Israel.	danz@tx.technion.ac.il		Rentsch, Doris/0000-0003-4313-7683	NIAID [AI 41622]; The Academy of Sciences and Humanities [490/02]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI041622, R01AI041622] Funding Source: NIH RePORTER	NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); The Academy of Sciences and Humanities; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported, in whole or in part, by National Institutes of Health Grant AI 41622 from NIAID. This work was also supported by Grant 490/02 from The Israel Science Foundation founded by The Academy of Sciences and Humanities.	Abdel-Sater F, 2004, MOL CELL BIOL, V24, P9771, DOI 10.1128/MCB.24.22.9771-9785.2004; Akerman M, 2004, BIOCHEM BIOPH RES CO, V325, P353, DOI 10.1016/j.bbrc.2004.09.212; Andreasson C, 2002, GENE DEV, V16, P3158, DOI 10.1101/gad.239202; Aulak KS, 1999, J BIOL CHEM, V274, P30424, DOI 10.1074/jbc.274.43.30424; Barak E, 2005, MOL BIOCHEM PARASIT, V141, P99, DOI 10.1016/j.molbiopara.2005.02.004; Bilzer M, 2006, LIVER INT, V26, P1175, DOI 10.1111/j.1478-3231.2006.01342.x; CHANG KP, 1976, SCIENCE, V193, P678, DOI 10.1126/science.948742; Chattopadhyay S, 2002, EUKARYOT CELL, V1, P606, DOI 10.1128/EC.1.4.606-612.2002; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Didion T, 1998, MOL MICROBIOL, V27, P643, DOI 10.1046/j.1365-2958.1998.00714.x; FEKKES D, 1995, J CHROMATOGR B, V669, P177, DOI 10.1016/0378-4347(95)00111-U; Forsberg H, 2001, CURR GENET, V40, P91, DOI 10.1007/s002940100244; Hatzoglou M, 2004, ANNU REV NUTR, V24, P377, DOI 10.1146/annurev.nutr.23.011702.073120; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Hinnebusch AG, 2005, ANNU REV MICROBIOL, V59, P407, DOI 10.1146/annurev.micro.59.031805.133833; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; Iraqui I, 1999, MOL CELL BIOL, V19, P989; Jiang YQ, 1999, J BIOL CHEM, V274, P3781, DOI 10.1074/jbc.274.6.3781; Klasson H, 1999, MOL CELL BIOL, V19, P5405; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; Lopez AB, 2007, BIOCHEM J, V402, P163, DOI 10.1042/BJ20060941; Mazareb S, 1999, EXP PARASITOL, V91, P341, DOI 10.1006/expr.1998.4391; McConville MJ, 2007, TRENDS PARASITOL, V23, P368, DOI 10.1016/j.pt.2007.06.009; Opperdoes FR, 2007, TRENDS PARASITOL, V23, P149, DOI 10.1016/j.pt.2007.02.004; OSWALD IP, 1994, COMP BIOCHEM PHYS C, V108, P11, DOI 10.1016/1367-8280(94)90083-3; PIPER RC, 1995, J CELL BIOL, V128, P499, DOI 10.1083/jcb.128.4.499; Regenberg B, 1999, CURR GENET, V36, P317, DOI 10.1007/s002940050506; Roberts SC, 2004, J BIOL CHEM, V279, P23668, DOI 10.1074/jbc.M402042200; Roberts SC, 2001, MOL BIOCHEM PARASIT, V115, P217, DOI 10.1016/S0166-6851(01)00293-6; Rosenzweig D, 2008, FASEB J, V22, P590, DOI 10.1096/fj.07-9254com; Saar Y, 1998, MOL BIOCHEM PARASIT, V95, P9, DOI 10.1016/S0166-6851(98)00062-0; Shaked-Mishan P, 2006, MOL MICROBIOL, V60, P30, DOI 10.1111/j.1365-2958.2006.05060.x; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; Vieira LL, 1995, MOL BIOCHEM PARASIT, V75, P15, DOI 10.1016/0166-6851(95)02505-7; ZILBERSTEIN D, 1984, MOL BIOCHEM PARASIT, V12, P327, DOI 10.1016/0166-6851(84)90089-6	35	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					19800	19807		10.1074/jbc.M901066200	http://dx.doi.org/10.1074/jbc.M901066200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19439418	hybrid, Green Published			2022-12-25	WOS:000268097400006
J	Nerlich, A; Rohde, M; Talay, SR; Genth, H; Just, I; Chhatwal, GS				Nerlich, Andreas; Rohde, Manfred; Talay, Susanne R.; Genth, Harald; Just, Ingo; Chhatwal, Gursharan S.			Invasion of Endothelial Cells by Tissue-invasive M3 Type Group A Streptococci Requires Src Kinase and Activation of Rac1 by a Phosphatidylinositol 3-Kinase-independent Mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; RECEPTOR TYROSINE KINASE; INTEGRIN-LINKED KINASE; EXCHANGE FACTOR TIAM1; EPITHELIAL-CELLS; GROWTH-FACTOR; STAPHYLOCOCCUS-AUREUS; PYOGENES INFECTIONS; MEDIATED INVASION; BINDING PROTEIN	Streptococcus pyogenes can cause invasive diseases in humans, such as sepsis or necrotizing fasciitis. Among the various M serotypes of group A streptococci (GAS), M3 GAS lacks the major epithelial invasins SfbI/PrtF1 and M1 protein but has a high potential to cause invasive disease. We examined the uptake of M3 GAS into human endothelial cells and identified host signaling factors required to initiate streptococcal uptake. Bacterial uptake is accompanied by local F-actin accumulation and formation of membrane protrusions at the entry site. We found that Src kinases and Rac1 but not phosphatidylinositol 3-kinases (PI3Ks) are essential to mediate S. pyogenes internalization. Pharmacological inhibition of Src activity reduced bacterial uptake and abolished the formation of membrane protrusions and actin accumulation in the vicinity of adherent streptococci. We found that Src kinases are activated in a time-dependent manner in response to M3 GAS. We also demonstrated that PI3K is dispensable for internalization of M3 streptococci and the formation of F-actin accumulations at the entry site. Furthermore, Rac1 was activated in infected cells and accumulated with F-actin in a PI3K-independent manner at bacterial entry sites. Genetic interference with Rac1 function inhibited streptococcal internalization, demonstrating an essential role of Rac1 for the uptake process of streptococci into endothelial cells. In addition, we demonstrated for the first time accumulation of the actin nucleation complex Arp2/3 at the entry port of invading M3 streptococci.	[Nerlich, Andreas; Rohde, Manfred; Talay, Susanne R.; Chhatwal, Gursharan S.] Helmholtz Ctr Infect Res, Dept Microbial Pathogenesis, D-38124 Braunschweig, Germany; [Genth, Harald; Just, Ingo] Hannover Med Sch, Inst Toxicol, D-30625 Hannover, Germany	Helmholtz Association; Helmholtz-Center for Infection Research; Hannover Medical School	Rohde, M (corresponding author), Helmholtz Ctr Infect Res, Dept Microbial Pathogenesis, Inhoffenstr 7, D-38124 Braunschweig, Germany.	manfred.rohde@helmholtz-hzi.de	Genth, Harald/HHS-0118-2022; Nerlich, Andreas/F-9336-2012	Nerlich, Andreas/0000-0001-8577-2744				Agerer F, 2003, J BIOL CHEM, V278, P42524, DOI 10.1074/jbc.M302096200; Alrutz MA, 1998, P NATL ACAD SCI USA, V95, P13658, DOI 10.1073/pnas.95.23.13658; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bryant AE, 2003, INFECT IMMUN, V71, P1903, DOI 10.1128/IAI.71.4.1903-1910.2003; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Burns EH, 1998, MICROB PATHOGENESIS, V24, P333, DOI 10.1006/mpat.1998.0204; Carabeo RA, 2007, CELL MICROBIOL, V9, P2278, DOI 10.1111/j.1462-5822.2007.00958.x; Cue D, 1998, INFECT IMMUN, V66, P4593, DOI 10.1128/IAI.66.10.4593-4601.1998; Cywes C, 2001, NATURE, V414, P648, DOI 10.1038/414648a; Dombek PE, 1999, MOL MICROBIOL, V31, P859, DOI 10.1046/j.1365-2958.1999.01223.x; Eitel J, 2005, CELL MICROBIOL, V7, P63, DOI 10.1111/j.1462-5822.2004.00434.x; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Evans DJ, 2002, MICROB PATHOGENESIS, V33, P135, DOI 10.1006/mpat.2002.0521; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Forster B, 2004, MICROSC RES TECHNIQ, V65, P33, DOI 10.1002/jemt.20092; GRECO R, 1995, RES MICROBIOL, V146, P551, DOI 10.1016/0923-2508(96)80561-4; Hoffmann I, 2001, J CELL BIOL, V155, P133, DOI 10.1083/jcb.200106148; Hoppe AD, 2004, MOL BIOL CELL, V15, P3509, DOI 10.1091/mbc.E03-11-0847; Horn MP, 2008, J PHARMACOL EXP THER, V326, P135, DOI 10.1124/jpet.108.137927; Inoue T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003068; Kierbel A, 2005, MOL BIOL CELL, V16, P2577, DOI 10.1091/mbc.E04-08-0717; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lambotin M, 2005, J CELL SCI, V118, P3805, DOI 10.1242/jcs.02514; LAPENTA D, 1994, P NATL ACAD SCI USA, V91, P12115, DOI 10.1073/pnas.91.25.12115; Luca-Harari B, 2008, J CLIN MICROBIOL, V46, P79, DOI 10.1128/JCM.01626-07; McLaughlin R E, 1995, Methods Mol Biol, V47, P185; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Molinari G, 1997, INFECT IMMUN, V65, P1357, DOI 10.1128/IAI.65.4.1357-1363.1997; Munter S., 2006, SCI STKE, V2006, pre5, DOI DOI 10.1126/STKE.3352006RE5; Nakagawa I, 2001, CELL MICROBIOL, V3, P395, DOI 10.1046/j.1462-5822.2001.00122.x; NOBES CD, 1995, J CELL SCI, V108, P225; O'Brien KL, 2002, CLIN INFECT DIS, V35, P268, DOI 10.1086/341409; Olazabal IM, 2002, CURR BIOL, V12, P1413, DOI 10.1016/S0960-9822(02)01069-2; Ozeri V, 2001, MOL MICROBIOL, V41, P561, DOI 10.1046/j.1365-2958.2001.02535.x; Poppe M, 2007, ONCOGENE, V26, P3462, DOI 10.1038/sj.onc.1210139; Purushothaman SS, 2003, INFECT IMMUN, V71, P5823, DOI 10.1128/IAI.71.10.5823-5830.2003; Reddy MA, 2000, INFECT IMMUN, V68, P6423, DOI 10.1128/IAI.68.11.6423-6430.2000; Reddy MA, 2000, J BIOL CHEM, V275, P36769, DOI 10.1074/jbc.M007382200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rohde M, 2003, CELL MICROBIOL, V5, P323, DOI 10.1046/j.1462-5822.2003.00279.x; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Shen Y, 2000, CELL, V103, P501, DOI 10.1016/S0092-8674(00)00141-0; Shi J, 2005, J BIOL CHEM, V280, P29849, DOI 10.1074/jbc.M500617200; Shin S, 2006, MICROB PATHOGENESIS, V41, P168, DOI 10.1016/j.micpath.2006.07.003; STEVENS DL, 1992, CLIN INFECT DIS, V14, P2, DOI 10.1093/clinids/14.1.2; Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; Tran Van Nhieu G., 1997, EMBO J, V16, P2717; Ueyama T, 2006, MOL CELL BIOL, V26, P2160, DOI 10.1128/MCB.26.6.2160-2174.2006; Vlaminckx BJM, 2007, INFECT IMMUN, V75, P2603, DOI 10.1128/IAI.01291-06; Wahl RU, 2007, CLIN MICROBIOL INFEC, V13, P1173, DOI 10.1111/j.1469-0691.2007.01821.x; Wang BN, 2007, CELL MICROBIOL, V9, P1519, DOI 10.1111/j.1462-5822.2007.00889.x; Wang BN, 2006, CELL MICROBIOL, V8, P257, DOI 10.1111/j.1462-5822.2005.00618.x; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X	54	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20319	20328		10.1074/jbc.M109.016501	http://dx.doi.org/10.1074/jbc.M109.016501			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19473989	Green Published, hybrid			2022-12-25	WOS:000268097400058
J	Park, SY; Cho, JH; Oh, DY; Park, JW; Ahn, MJ; Han, JS; Oh, JW				Park, Shin-Young; Cho, Ju Hwan; Oh, Doo-Yi; Park, Jung-Won; Ahn, Myung-Ju; Han, Joong-Soo; Oh, Jae-Won			House Dust Mite Allergen Der f 2-induced Phospholipase D1 Activation Is Critical for the Production of Interleukin-13 through Activating Transcription Factor-2 Activation in Human Bronchial Epithelial Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; 15-LIPOXYGENASE GENE-EXPRESSION; P38 MAP KINASE; DERMATOPHAGOIDES-FARINAE; SIGNAL-TRANSDUCTION; ATOPIC-DERMATITIS; DENDRITIC CELLS; HUMAN MONOCYTES; PKC; PATHWAY	The purpose of this study was to identify the role of phospholipase D1 (PLD1) in Der f 2-induced interleukin (IL)-13 production. The major house dust mite allergen, Der f 2, increased PLD activity in human bronchial epithelial cells (BEAS-2B), and dominant negative PLD1 or PLD1 siRNA decreased Der f 2-induced IL-13 expression and production. Treatment of Der f 2 activated the phospholipase C gamma (PLC gamma)/protein kinase C alpha (PKC alpha)/p38 MAPK pathway. Der f 2-induced PLD activation was attenuated by PLC gamma inhibitors (U73122 and PAO), PKC alpha inhibitors (RO320432 and GO6976), and p38 MAPK inhibitors (SB203580 and SB202190). These results indicate that PLC gamma, PKC alpha, and p38 MAPK act as upstream activators of PLD in Der f 2-treated BEAS-2B cells. Furthermore, expression and production of IL-13 increased by Der f 2 were also blocked by inhibition of PLC gamma, PKC alpha, or p38 MAPK, indicating that IL-13 expression and production are related to a PLC gamma/PKC alpha/p38 MAPK pathway. We found that activating transcription factor-2 (ATF-2) was activated by Der f 2 in BEAS-2B cells and activation of ATF-2 was controlled by PLD1. When ATF-2 activity was blocked with ATF-2 siRNA, Der f 2-induced IL-13 expression and production were decreased. Thus, ATF-2 might be one of the transcriptional factors for the expression of IL-13 inDer f 2-treated BEAS-2B cells. Taken together, PLD1 acts as an important regulator in Der f 2-induced expression and production of IL-13 through activation of ATF-2 in BEAS-2B cells.	[Park, Shin-Young; Cho, Ju Hwan; Oh, Doo-Yi; Han, Joong-Soo] Hanyang Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 133791, Sungdong Gu, South Korea; [Oh, Jae-Won] Hanyang Univ, Coll Med, Dept Pediat, Seoul 133791, Sungdong Gu, South Korea; [Park, Jung-Won] Yonsei Univ, Coll Med, Dept Internal Med, Seoul 120749, South Korea; [Park, Jung-Won] Yonsei Univ, Coll Med, Inst Allergy, Seoul 120749, South Korea; [Ahn, Myung-Ju] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul 135710, South Korea	Hanyang University; Hanyang University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Sungkyunkwan University (SKKU); Samsung Medical Center	Han, JS (corresponding author), Hanyang Univ, Coll Med, Dept Biochem & Mol Biol, 17 Haengdang Dong, Seoul 133791, Sungdong Gu, South Korea.	jshan@hanyang.ac.kr; jaewonoh@hanyang.ac.kr	Han, Joong-Soo/P-2072-2015	Han, Joong-Soo/0000-0002-0875-6158	Korea Research Foundation [E00273]; Korea Science and Engineering Foundation, Ministry of Education, Science, and Technology (MEST) [RB-2008-026-01000-0]	Korea Research Foundation(National Research Foundation of Korea); Korea Science and Engineering Foundation, Ministry of Education, Science, and Technology (MEST)(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by Grant E00273 (2007) from the Korea Research Foundation and by Grant RB-2008-026-01000-0 from the Korea Science and Engineering Foundation funded by the Ministry of Education, Science, and Technology (MEST).	Abebe W, 1998, AM J PHYSIOL-LUNG C, V275, pL990, DOI 10.1152/ajplung.1998.275.5.L990; Adam E, 2006, J BIOL CHEM, V281, P6910, DOI 10.1074/jbc.M507140200; Arrighi JF, 2001, J IMMUNOL, V166, P3837, DOI 10.4049/jimmunol.166.6.3837; Bandyopadhaya A, 2009, MOL IMMUNOL, V46, P1129, DOI 10.1016/j.molimm.2008.11.003; Banno Y, 2003, BIOCHEM BIOPH RES CO, V312, P1087, DOI 10.1016/j.bbrc.2003.11.036; Bussmann C, 2006, J ALLERGY CLIN IMMUN, V118, P1292, DOI 10.1016/j.jaci.2006.07.054; Carneiro-Santos P, 2002, PARASITE IMMUNOL, V24, P493, DOI 10.1046/j.1365-3024.2002.00487.x; Chen Y, 2001, AM J RESP CELL MOL, V25, P409, DOI 10.1165/ajrcmb.25.4.4413; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cummings RJ, 2002, J BIOL CHEM, V277, P30227, DOI 10.1074/jbc.M111078200; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Fan HY, 2004, BIOL REPROD, V70, P1178, DOI 10.1095/biolreprod.103.024737; FREEMAN EJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P84, DOI 10.1006/abbi.1995.1269; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Gomez-Cambronero J, 1998, CELL SIGNAL, V10, P387, DOI 10.1016/S0898-6568(97)00197-6; Hagendorens MM, 2004, PEDIAT ALLERG IMM-UK, V15, P308, DOI 10.1111/j.1399-3038.2004.00169.x; Hodgkin MN, 1999, BIOCHEM J, V339, P87, DOI 10.1042/0264-6021:3390087; HOLCK A, 1986, ALLERGY, V41, P408, DOI 10.1111/j.1398-9995.1986.tb00320.x; Hsu HY, 2008, J CELL PHYSIOL, V215, P15, DOI 10.1002/jcp.21144; Humar M, 2007, INT J BIOCHEM CELL B, V39, P2278, DOI 10.1016/j.biocel.2007.06.013; Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017; Kanazawa H, 2002, J BIOL CHEM, V277, P20026, DOI 10.1074/jbc.M109218200; Kang HK, 2004, INT IMMUNOPHARMACOL, V4, P911, DOI 10.1016/j.intimp.2004.04.001; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; Kilpatrick LE, 2006, J LEUKOCYTE BIOL, V80, P1512, DOI 10.1189/jlb.0406284; Kim JH, 2005, MOL CELL BIOL, V25, P3194, DOI 10.1128/MCB.25.8.3194-3208.2005; Kim SY, 2004, EUR J BIOCHEM, V271, P3470, DOI 10.1111/j.0014-2956.2004.04242.x; Kiss Z, 1996, ARCH BIOCHEM BIOPHYS, V335, P191, DOI 10.1006/abbi.1996.0497; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Lee BS, 2007, J DERMATOL SCI, V46, P31, DOI 10.1016/j.jdermsci.2007.01.001; Lee CH, 2008, MOL IMMUNOL, V45, P3693, DOI 10.1016/j.molimm.2008.06.007; Lim JY, 2005, J MOL CELL CARDIOL, V39, P627, DOI 10.1016/j.yjmcc.2005.06.016; Lin CI, 2008, CELL SIGNAL, V20, P1804, DOI 10.1016/j.cellsig.2008.06.008; Makino C, 2006, GENES CELLS, V11, P1239, DOI 10.1111/j.1365-2443.2006.01016.x; Mwanjewe J, 2001, BIOCHEM J, V359, P211, DOI 10.1042/0264-6021:3590211; Oh DY, 2007, J CELL BIOCHEM, V101, P221, DOI 10.1002/jcb.21166; Oh JW, 2000, EXP MOL MED, V32, P67, DOI 10.1038/emm.2000.12; Oh JW, 2004, EXP MOL MED, V36, P486, DOI 10.1038/emm.2004.61; Parmentier JH, 2003, HYPERTENSION, V41, P794, DOI 10.1161/01.HYP.0000047873.76255.0B; Prescott SL, 1998, J IMMUNOL, V160, P4730; Rajaiya J, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-17; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rivedal E, 2001, CARCINOGENESIS, V22, P1543, DOI 10.1093/carcin/22.9.1543; Sangerman J, 2006, BLOOD, V108, P3590, DOI 10.1182/blood-2006-01-023713; Shimizu Y, 1998, CLIN EXP ALLERGY, V28, P497, DOI 10.1046/j.1365-2222.1998.00267.x; Sohn MH, 2007, RESPIRATION, V74, P447, DOI 10.1159/000099264; THOMAS AE, 1989, J ALLERGY CLIN IMMUN, V83, P416; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; Wang LX, 2002, BIOCHEM J, V367, P751, DOI 10.1042/BJ20020586; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wong CK, 2006, INT IMMUNOL, V18, P1327, DOI 10.1093/intimm/dxl065; Xu B, 2004, J BIOL CHEM, V279, P15954, DOI 10.1074/jbc.M400413200; Xu B, 2003, MOL CELL BIOL, V23, P3918, DOI 10.1128/MCB.23.11.3918-3928.2003; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214, DOI 10.1159/000234137; YASUEDA H, 1989, INT ARCH ALLER A IMM, V88, P402, DOI 10.1159/000234724; YUUKI T, 1991, AGR BIOL CHEM TOKYO, V55, P1233, DOI 10.1080/00021369.1991.10870757; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zhang SP, 2006, FEBS J, V273, P3779, DOI 10.1111/j.1742-4658.2006.05386.x; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	64	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20099	20110		10.1074/jbc.M109.010017	http://dx.doi.org/10.1074/jbc.M109.010017			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19487697	Green Published, hybrid			2022-12-25	WOS:000268097400037
J	Mancek-Keber, M; Gradisar, H; Pestana, MI; de Tejada, GM; Jerala, R				Mancek-Keber, Mateja; Gradisar, Helena; Inigo Pestana, Melania; Martinez de Tejada, Guillermo; Jerala, Roman			Free Thiol Group of MD-2 as the Target for Inhibition of the Lipopolysaccharide-induced Cell Activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LPS-INDUCED HOMODIMERIZATION; TRANSFER PROTEIN INHIBITOR; KAPPA-B KINASE; TLR4-MD-2 COMPLEX; LIPID-A; INFLAMMATORY RESPONSE; GOLD COMPOUND; RECEPTOR 4; TLR4; ENDOTOXIN	MD-2 is a part of the Toll-like 4 signaling complex with an indispensable role in activation of the lipopolysaccharide (LPS) signaling pathway and thus a suitable target for the therapeutic inhibition of TLR4 signaling. Elucidation of MD-2 structure provides a foundation for rational design of inhibitors that bind to MD-2 and inhibit LPS signaling. Since the hydrophobic binding pocket of MD-2 provides little specificity for inhibitors, we have investigated targeting the solvent-accessible cysteine residue within the hydrophobic binding pocket of MD-2. Compounds with affinity for the hydrophobic pocket that contain a thiol-reactive group, which mediates covalent bond formation with the free cysteine residue of MD-2, were tested. Fluorescent compounds 2-(4'-(iodoacetamido) anilino) naphthalene-6-sulfonic acid and N-pyrene maleimide formed a covalent bond with MD-2 through Cys(133) and inhibited LPS signaling. Cell activation was also inhibited by thiol-reactive compounds JTT-705 originally targeted against cholesterol ester transfer protein and antirheumatic compound auranofin. Oral intake of JTT-705 significantly inhibited endotoxin-triggered tumor necrosis factor alpha production in mice. The thiol group of MD-2 also represents the target of environmental or endogenous thiol-reactive compounds that are produced in inflammation.	[Mancek-Keber, Mateja; Gradisar, Helena; Jerala, Roman] Natl Inst Chem, Dept Biotechnol, Ljubljana 1000, Slovenia; [Jerala, Roman] Univ Ljubljana, Fac Chem & Chem Technol, Ljubljana 1000, Slovenia; [Inigo Pestana, Melania; Martinez de Tejada, Guillermo] Univ Navarra, Dept Microbiol & Parasitol, E-31080 Pamplona, Spain	National Institute of Chemistry - Slovenia; University of Ljubljana; University of Navarra	Jerala, R (corresponding author), Natl Inst Chem, Dept Biotechnol, Hajdrihova 19, Ljubljana 1000, Slovenia.	roman.jerala@ki.si	Martinez-de-Tejada, Guillermo/H-3849-2017; Martinez-de-Tejada, Guillermo/AAT-8535-2020; Jerala, Roman/H-9850-2015	Martinez-de-Tejada, Guillermo/0000-0003-3755-451X; Martinez-de-Tejada, Guillermo/0000-0003-3755-451X; Jerala, Roman/0000-0002-6337-5251; Lazaro-Anton, Leticia/0000-0001-7720-5627	Slovenian Research Agency [P4-176, J1-7206, J1-9793, Z4-9595]	Slovenian Research Agency(Slovenian Research Agency - Slovenia)	This work was supported by the state budget of the Slovenian Research Agency ( Program P4-176, Projects J1-7206, J1-9793, and Z4-9595).	Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; Andreakos E, 2005, FRONT BIOSCI-LANDMRK, V10, P2478, DOI 10.2741/1712; Aybay C, 1998, FEMS IMMUNOL MED MIC, V22, P263, DOI 10.1111/j.1574-695X.1998.tb01215.x; Barsness KA, 2004, AM J PHYSIOL-REG I, V287, pR592, DOI 10.1152/ajpregu.00412.2003; Bondeson J, 1995, BIOCHEM PHARMACOL, V50, P1753, DOI 10.1016/0006-2952(95)02030-6; de Grooth GJ, 2002, CIRCULATION, V105, P2159, DOI 10.1161/01.CIR.0000015857.31889.7B; Fang JG, 2005, J BIOL CHEM, V280, P25284, DOI 10.1074/jbc.M414645200; FEIST W, 1992, FEMS MICROBIOL IMMUN, V89, P73, DOI 10.1016/0378-1097(92)90264-O; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; Gradisar H, 2007, J LEUKOCYTE BIOL, V82, P968, DOI 10.1189/jlb.1206727; Gruber A, 2004, J BIOL CHEM, V279, P28475, DOI 10.1074/jbc.M400993200; Gunatilleke SS, 2006, J MED CHEM, V49, P3933, DOI 10.1021/jm060158f; Hawkins LD, 2004, CURR TOP MED CHEM, V4, P1147, DOI 10.2174/1568026043388123; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Jeon KI, 2003, EXP MOL MED, V35, P61, DOI 10.1038/emm.2003.9; Ji C, 2001, J BIOL CHEM, V276, P18223, DOI 10.1074/jbc.M101266200; Johnson DA, 2008, CURR TOP MED CHEM, V8, P64, DOI 10.2174/156802608783378882; Kawasaki K, 2003, J IMMUNOL, V170, P413, DOI 10.4049/jimmunol.170.1.413; Kim HM, 2007, CELL, V130, P906, DOI 10.1016/j.cell.2007.08.002; Lee JS, 2008, MOL CELLS, V25, P253; LEONG D, 1970, Infection and Immunity, V1, P174; Li L, 1999, AM J PHYSIOL-LUNG C, V277, pL550, DOI 10.1152/ajplung.1999.277.3.L550; Lindvall MK, 2002, CURR PHARM DESIGN, V8, P1673, DOI 10.2174/1381612023394142; Mancek-Keber M, 2006, FASEB J, V20, P1836, DOI 10.1096/fj.06-5862com; Maresso AW, 2007, J BIOL CHEM, V282, P23129, DOI 10.1074/jbc.M701857200; Michelsen KS, 2004, P NATL ACAD SCI USA, V101, P10679, DOI 10.1073/pnas.0403249101; Mollen KP, 2006, SHOCK, V26, P430, DOI 10.1097/01.shk.0000228797.41044.08; Mollnes TE, 2008, ADV EXP MED BIOL, V632, P253, DOI 10.1007/978-0-387-78952-1_18; Mullen GED, 2003, P NATL ACAD SCI USA, V100, P3919, DOI 10.1073/pnas.0630495100; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Ohto U, 2007, SCIENCE, V316, P1632, DOI 10.1126/science.1139111; Okamoto H, 2000, NATURE, V406, P203, DOI 10.1038/35018119; Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830; Resman N, 2009, J BIOL CHEM, V284, P15052, DOI 10.1074/jbc.M901429200; Resman N, 2008, FEBS LETT, V582, P3929, DOI 10.1016/j.febslet.2008.10.037; Rock KL, 2008, ANNU REV PATHOL-MECH, V3, P99, DOI 10.1146/annurev.pathmechdis.3.121806.151456; Saitoh S, 2004, INT IMMUNOL, V16, P961, DOI 10.1093/intimm/dxh097; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Tobias P, 2005, J LIPID RES, V46, P404, DOI 10.1194/jlr.R400015-JLR200; Tsung A, 2005, J IMMUNOL, V175, P7661, DOI 10.4049/jimmunol.175.11.7661; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Viriyakosol S, 2006, HYBRIDOMA, V25, P349, DOI 10.1089/hyb.2006.25.349; Visintin A, 2005, J IMMUNOL, V175, P6465, DOI 10.4049/jimmunol.175.10.6465; YANG JP, 1995, FEBS LETT, V361, P89, DOI 10.1016/0014-5793(95)00157-5; Youn HS, 2008, BIOCHEM PHARMACOL, V75, P494, DOI 10.1016/j.bcp.2007.08.033; Youn HS, 2006, BIOCHEM BIOPH RES CO, V350, P866, DOI 10.1016/j.bbrc.2006.09.097	47	38	41	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19493	19500		10.1074/jbc.M109.003756	http://dx.doi.org/10.1074/jbc.M109.003756			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19473973	Green Published, hybrid			2022-12-25	WOS:000267908300041
J	Ren, G; Helwani, FM; Verma, S; McLachlan, RW; Weed, SA; Yap, AS				Ren, Gang; Helwani, Falak M.; Verma, Suzie; McLachlan, Robert W.; Weed, Scott A.; Yap, Alpha S.			Cortactin Is a Functional Target of E-cadherin-activated Src Family Kinases in MCF7 Epithelial Monolayers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; TYROSINE PHOSPHORYLATION; ARP2/3 COMPLEX; C-SRC; ACTIN; CONTACTS; DYNAMICS; POLARIZATION; CYTOSKELETON; FIBROBLASTS	Src family kinases (SFKs) signal in response to E-cadherin to support cadherin adhesion and the integrity of cell-cell contacts (McLachlan, R. W., Kraemer, A., Helwani, F. M., Kovacs, E. M., and Yap, A. S. ( 2007) Mol. Biol. Cell 18, 3214-3223). We now identify the actin-regulatory protein, cortactin, as a target of E-cadherin-activated SFK signaling. Tyr-phosphorylated cortactin was found at cell-cell contacts in established epithelial monolayers, and cortactin became acutely tyrosine-phosphorylated when E-cadherin adhesion was engaged. In all circumstances, cortactin tyrosine phosphorylation was blocked by inhibiting SFK signaling. Importantly, Tyr-phosphorylated cortactin was necessary to preserve the integrity of cadherin contacts and the perijunctional actin cytoskeleton. Moreover, expression of a phosphomimetic cortactin mutant could prevent SFK blockade from disrupting cadherin organization, thereby placing cortactin functionally downstream of SFK signaling at cadherin adhesions. We conclude that SFK and cortactin constitute an important signaling pathway that functionally links E-cadherin adhesion and the actin cytoskeleton.	[Ren, Gang; Helwani, Falak M.; Verma, Suzie; McLachlan, Robert W.; Yap, Alpha S.] Univ Queensland, Inst Mol Biosci, Mol Cell Biol Div, Brisbane, Qld 4072, Australia; [Weed, Scott A.] W Virginia Univ, Mary Babb Randolph Canc Ctr, Program Canc Cell Biol, Dept Anat & Neurosci, Morgantown, WV 26506 USA	University of Queensland; West Virginia University	Yap, AS (corresponding author), Univ Queensland, Inst Mol Biosci, Mol Cell Biol Div, Bldg 80,Serv Rd, Brisbane, Qld 4072, Australia.	a.yap@uq.edu.au	Yap, Alpha S./J-1554-2014	Yap, Alpha S./0000-0002-1038-8956; Weed, Scott/0000-0001-7033-9999	National Health and Medical Research Council of Australia; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016440] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014578] Funding Source: NIH RePORTER	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported in part by the National Health and Medical Research Council of Australia.	Ammer AG, 2008, CELL MOTIL CYTOSKEL, V65, P687, DOI 10.1002/cm.20296; BARETTINO D, 1994, NUCLEIC ACIDS RES, V22, P541, DOI 10.1093/nar/22.3.541; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bennett HL, 2008, ONCOGENE, V27, P2693, DOI 10.1038/sj.onc.1210928; Boguslavsky S, 2007, P NATL ACAD SCI USA, V104, P10882, DOI 10.1073/pnas.0702731104; Boyle SN, 2007, CURR BIOL, V17, P445, DOI 10.1016/j.cub.2007.01.057; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Daly RJ, 2004, BIOCHEM J, V382, P13, DOI 10.1042/BJ20040737; El Sayegh TY, 2005, MOL BIOL CELL, V16, P5514, DOI 10.1091/mcbE05-05-0410; El Sayegh TY, 2004, J CELL SCI, V117, P5117, DOI 10.1242/jcs.01385; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; Helwani FM, 2004, J CELL BIOL, V164, P899, DOI 10.1083/jcb.200309034; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Kraemer A, 2007, AM J PHYSIOL-CELL PH, V292, pC1061, DOI 10.1152/ajpcell.00073.2006; Luxenburg C, 2006, J CELL SCI, V119, P4878, DOI 10.1242/jcs.03271; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; McLachlan RW, 2007, MOL BIOL CELL, V18, P3214, DOI 10.1091/mbc.E06-12-1154; McLachlan RW, 2007, J MOL MED-JMM, V85, P545, DOI 10.1007/s00109-007-0198-x; Mege RM, 2006, CURR OPIN CELL BIOL, V18, P541, DOI 10.1016/j.ceb.2006.08.004; Pang JH, 2005, J BIOL CHEM, V280, P3043, DOI 10.1074/jbc.M412148200; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; Takahashi M, 2005, DEVELOPMENT, V132, P2547, DOI 10.1242/dev.01850; Tehrani S, 2007, P NATL ACAD SCI USA, V104, P11933, DOI 10.1073/pnas.0701077104; Tehrani S, 2006, MOL BIOL CELL, V17, P2882, DOI 10.1091/mbc.E06-03-0187; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; Verma S, 2004, J BIOL CHEM, V279, P34062, DOI 10.1074/jbc.M404814200; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; ZHAN X, 1993, J BIOL CHEM, V268, P24427	38	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18913	18922		10.1074/jbc.M109.000307	http://dx.doi.org/10.1074/jbc.M109.000307			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19457864	Green Published, hybrid			2022-12-25	WOS:000267711500041
J	Stie, J; Bruni, G; Fox, D				Stie, Jamal; Bruni, Gillian; Fox, Deborah			Surface-Associated Plasminogen Binding of Cryptococcus neoformans Promotes Extracellular Matrix Invasion	PLOS ONE			English	Article							CANDIDA-ALBICANS ENOLASE; CELL-WALL; STREPTOCOCCUS-PNEUMONIAE; ALPHA-ENOLASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; BORRELIA-BURGDORFERI; IN-VITRO; PROTEINS; IDENTIFICATION; VIRULENCE	Background: The fungal pathogen Cryptococcus neoformans is a leading cause of illness and death in persons with predisposing factors, including: malignancies, solid organ transplants, and corticosteroid use. C. neoformans is ubiquitous in the environment and enters into the lungs via inhalation, where it can disseminate through the bloodstream and penetrate the central nervous system (CNS), resulting in a difficult to treat and often-fatal infection of the brain, called meningoencephalitis. Plasminogen is a highly abundant protein found in the plasma component of blood and is necessary for the degradation of fibrin, collagen, and other structural components of tissues. This fibrinolytic system is utilized by cancer cells during metastasis and several pathogenic species of bacteria have been found to manipulate the host plasminogen system to facilitate invasion of tissues during infection by modifying the activation of this process through the binding of plasminogen at their surface. Methodology: The invasion of the brain and the central nervous system by penetration of the protective blood-brain barrier is a prerequisite to the establishment of meningoencephalitis by the opportunistic fungal pathogen C. neoformans. In this study, we examined the ability of C. neoformans to subvert the host plasminogen system to facilitate tissue barrier invasion. Through a combination of biochemical, cell biology, and proteomic approaches, we have shown that C. neoformans utilizes the host plasminogen system to cross tissue barriers, providing support for the hypothesis that plasminogen-binding may contribute to the invasion of the blood-brain barrier by penetration of the brain endothelial cells and underlying matrix. In addition, we have identified the cell wall-associated proteins that serve as plasminogen receptors and characterized both the plasminogen-binding and plasmin-activation potential for this significant human pathogen. Conclusions: The results of this study provide evidence for the cooperative role of multiple virulence determinants in C. neoformans pathogenesis and suggest new avenues for the development of anti-infective agents in the prevention of fungal tissue invasion.			Stie, J (corresponding author), Louisiana State Univ, Childrens Hosp, Hlth Sci Ctr, Res Inst Children, New Orleans, LA USA.	dfox@chnola-research.org		Bruni, Gillian/0000-0002-5856-3274	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K22AI055302] Funding Source: NIH RePORTER; NIAID NIH HHS [K22 AI055302, AI055302] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andronicos NM, 1997, BBA-PROTEIN STRUCT M, V1337, P27, DOI 10.1016/S0167-4838(96)00146-X; Angiolella L, 1996, J INFECT DIS, V173, P684, DOI 10.1093/infdis/173.3.684; Barbosa MS, 2006, INFECT IMMUN, V74, P382, DOI 10.1128/IAI.74.1.382-389.2006; Bergmann S, 2004, INFECT IMMUN, V72, P2416, DOI 10.1128/IAI.72.4.2416-2419.2004; Bergmann S, 2001, MOL MICROBIOL, V40, P1273, DOI 10.1046/j.1365-2958.2001.02448.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bryan RA, 2005, EUKARYOT CELL, V4, P465, DOI 10.1128/EC.4.2.465-475.2005; BULMER GS, 1967, J BACTERIOL, V94, P1475, DOI 10.1128/JB.94.5.1475-1479.1967; Castillo L, 2008, PROTEOMICS, V8, P3871, DOI 10.1002/pmic.200800110; Chaffin WL, 1998, MICROBIOL MOL BIOL R, V62, P130, DOI 10.1128/MMBR.62.1.130-180.1998; Chang YC, 2004, INFECT IMMUN, V72, P4985, DOI 10.1128/IAI.72.9.4985-4995.2004; Charlier C, 2005, AM J PATHOL, V166, P421, DOI 10.1016/S0002-9440(10)62265-1; Chen SHM, 2003, J MED MICROBIOL, V52, P961, DOI 10.1099/jmm.0.05230-0; Chin C S, 1989, Med J Malaysia, V44, P194; Chretien F, 2002, J INFECT DIS, V186, P522, DOI 10.1086/341564; Coleman JL, 1999, J LAB CLIN MED, V134, P567, DOI 10.1016/S0022-2143(99)90095-1; COLEMAN JL, 1995, INFECT IMMUN, V63, P2478, DOI 10.1128/IAI.63.7.2478-2484.1995; Crowe JD, 2003, MOL MICROBIOL, V47, P1637, DOI 10.1046/j.1365-2958.2003.03390.x; de Groot PWJ, 2004, EUKARYOT CELL, V3, P955, DOI 10.1128/EC.3.4.955-965.2004; Derbise A, 2004, INFECT IMMUN, V72, P94, DOI 10.1128/IAI.72.1.94-105.2004; DEVOS AM, 1992, BIOCHEMISTRY-US, V31, P270, DOI 10.1021/bi00116a037; Eigenheer RA, 2007, FEMS YEAST RES, V7, P499, DOI 10.1111/j.1567-1364.2006.00198.x; Eisenman HC, 2005, BIOCHEMISTRY-US, V44, P3683, DOI 10.1021/bi047731m; Eroles P, 1997, MICROBIOL-SGM, V143, P313, DOI 10.1099/00221287-143-2-313; Foster AJ, 2007, J APPL MICROBIOL, V103, P390, DOI 10.1111/j.1365-2672.2006.03259.x; Fox D, 2001, MED MYCOL, V39, P495, DOI 10.1080/714031070; Fox DS, 2001, MOL MICROBIOL, V39, P835, DOI 10.1046/j.1365-2958.2001.02295.x; FRANKLYN KM, 1994, FEMS MICROBIOL LETT, V118, P219, DOI 10.1111/j.1574-6968.1994.tb06831.x; FROMTLING RA, 1982, MYCOPATHOLOGIA, V79, P23, DOI 10.1007/BF00636177; Gancedo C, 2008, MICROBIOL MOL BIOL R, V72, P197, DOI 10.1128/MMBR.00036-07; Gates MA, 2004, MOL MICROBIOL, V52, P13, DOI 10.1111/j.1365-2958.2003.03957.x; GOLDMAN D, 1994, INFECT IMMUN, V62, P4755, DOI 10.1128/IAI.62.11.4755-4761.1994; Goldman DL, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.5.e66; Grab DJ, 2005, INFECT IMMUN, V73, P1014, DOI 10.1128/IAI.73.2.1014-1022.2005; HADLEY S, 1995, INFECT DIS CLIN N AM, V9, P1045; Huang C, 2002, INFECT IMMUN, V70, P5485, DOI 10.1128/IAI.70.10.5485-5493.2002; Huang SH, 2001, CELL MICROBIOL, V3, P277, DOI 10.1046/j.1462-5822.2001.00116.x; IBRAHIM AS, 1995, INFECT IMMUN, V63, P4368, DOI 10.1128/IAI.63.11.4368-4374.1995; Ikeda R, 2003, MICROBIOL IMMUNOL, V47, P271, DOI 10.1111/j.1348-0421.2003.tb03395.x; Jong A, 2007, EUKARYOT CELL, V6, P1486, DOI 10.1128/EC.00120-07; Jong AY, 2003, J MED MICROBIOL, V52, P615, DOI 10.1099/jmm.0.05060-0; Jong AY, 2001, INFECT IMMUN, V69, P4536, DOI 10.1128/IAI.69.7.4536-4544.2001; Kakeya H, 1999, CLIN EXP IMMUNOL, V115, P485; Kakeya H, 1997, INFECT IMMUN, V65, P1653, DOI 10.1128/IAI.65.5.1653-1658.1997; Kapteyn JC, 1999, BBA-GEN SUBJECTS, V1426, P373, DOI 10.1016/S0304-4165(98)00137-8; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1111/j.1574-6976.2002.tb00613.x; Knaust A, 2007, J BACTERIOL, V189, P3246, DOI 10.1128/JB.01966-06; Kolberg J, 2006, MICROBIOL-SGM, V152, P1307, DOI 10.1099/mic.0.28747-0; KOZEL TR, 1982, J IMMUNOL, V129, P1675; KWONCHUNG KJ, 1986, INFECT IMMUN, V51, P218, DOI 10.1128/IAI.51.1.218-223.1986; Lahteenmaki K, 2000, METHODS, V21, P125, DOI 10.1006/meth.2000.0983; Lahteenmaki K, 2005, TRENDS MICROBIOL, V13, P79, DOI 10.1016/j.tim.2004.12.003; Lai HY, 2002, INT ARCH ALLERGY IMM, V127, P181, DOI 10.1159/000053862; LEVITZ SM, 1989, J IMMUNOL, V142, P659; Litvintseva AP, 2006, GENETICS, V172, P2223, DOI 10.1534/genetics.105.046672; Liu Zheng-Yin, 2003, Zhonghua Yi Xue Za Zhi, V83, P399; Loftus BJ, 2005, SCIENCE, V307, P1321, DOI 10.1126/science.1103773; Lopez-Villar E, 2006, PROTEOMICS, V6, pS107, DOI 10.1002/pmic.200500479; Maligie MA, 2005, ANTIMICROB AGENTS CH, V49, P2851, DOI 10.1128/AAC.49.7.2851-2856.2005; Mansour MK, 2004, INFECT IMMUN, V72, P1746, DOI 10.1128/IAI.72.3.1746-1754.2004; McDade HC, 2001, MED MYCOL, V39, P151, DOI 10.1080/714030997; MILES LA, 1986, BIOCHEMISTRY-US, V25, P6926, DOI 10.1021/bi00370a028; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MURPHY JW, 1988, INFECT IMMUN, V56, P424, DOI 10.1128/IAI.56.2.424-431.1988; NOVOKHATNY VV, 1984, J MOL BIOL, V179, P215, DOI 10.1016/0022-2836(84)90466-2; Olson GM, 2007, EUKARYOT CELL, V6, P222, DOI 10.1128/EC.00182-06; Orendi JM, 1997, CLIN EXP IMMUNOL, V107, P293, DOI 10.1111/j.1365-2249.1997.283-ce1169.x; Perfect JR, 1999, DRUG RESIST UPDATE, V2, P259, DOI 10.1054/drup.1999.0090; PERFECT JR, 1983, MEDICINE, V62, P98, DOI 10.1097/00005792-198303000-00003; Pietrella D, 2001, INFECT IMMUN, V69, P2808, DOI 10.1128/IAI.69.5.2808-2814.2001; Pitarch A, 2002, MOL CELL PROTEOMICS, V1, P967, DOI 10.1074/mcp.M200062-MCP200; Pitzurra L, 1997, J MED VET MYCOL, V35, P299; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; Poltermann S, 2007, J BIOL CHEM, V282, P37537, DOI 10.1074/jbc.M707280200; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; Reese AJ, 2003, MOL MICROBIOL, V50, P1401, DOI 10.1046/j.1365-2958.2003.03780.x; Rodrigues ML, 2008, EUKARYOT CELL, V7, P58, DOI 10.1128/EC.00370-07; Rodrigues ML, 2003, MICROB PATHOGENESIS, V34, P65, DOI 10.1016/S0882-4010(02)00195-X; Santos J, 1998, An Med Interna, V15, P523; Sar B, 2004, J ANTIMICROB CHEMOTH, V54, P563, DOI 10.1093/jac/dkh361; Smits GJ, 2001, MICROBIOL-SGM, V147, P781, DOI 10.1099/00221287-147-4-781; Steen BR, 2002, GENOME RES, V12, P1386, DOI 10.1101/gr.80202; STGEORGIEV V, 1993, MED RES REV, V13, P493, DOI 10.1002/med.2610130405; van Duin D, 2002, ANTIMICROB AGENTS CH, V46, P3394, DOI 10.1128/AAC.46.11.3394-3400.2002; VARTIVARIAN SE, 1989, J BACTERIOL, V171, P6850, DOI 10.1128/jb.171.12.6850-6852.1989; Walsh T J, 1999, Transpl Infect Dis, V1, P247, DOI 10.1034/j.1399-3062.1999.010404.x; Wang CY, 2005, NEW ENGL J MED, V352, P1271, DOI 10.1056/NEJM200503243521225; WANG YL, 1995, INFECT IMMUN, V63, P3131, DOI 10.1128/IAI.63.8.3131-3136.1995; Zaas AK, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000101	89	54	62	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2009	4	6							e5780	10.1371/journal.pone.0005780	http://dx.doi.org/10.1371/journal.pone.0005780			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453PV	19492051	Green Published, gold, Green Submitted			2022-12-25	WOS:000266624300016
J	Zhang, ZH; Zhang, JZ				Zhang, Zhihua; Zhang, Jianzhi			A Big World Inside Small-World Networks	PLOS ONE			English	Article								Real networks, including biological networks, are known to have the small-world property, characterized by a small "diameter'', which is defined as the average minimal path length between all pairs of nodes in a network. Because random networks also have short diameters, one may predict that the diameter of a real network should be even shorter than its random expectation, because having shorter diameters potentially increases the network efficiency such as minimizing transition times between metabolic states in the context of metabolic networks. Contrary to this expectation, we here report that the observed diameter is greater than the random expectation in every real network examined, including biological, social, technological, and linguistic networks. Simulations show that a modest enlargement of the diameter beyond its expectation allows a substantial increase of the network modularity, which is present in all real networks examined. Hence, short diameters appear to be sacrificed for high modularities, suggesting a tradeoff between network efficiency and advantages offered by modularity (e. g., multi-functionality, robustness, and/or evolvability).			Zhang, ZH (corresponding author), Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA.	jianzhi@umich.edu	zhang, zh/GWV-4677-2022					Adamic LA, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.046135; Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; Amaral LAN, 2000, P NATL ACAD SCI USA, V97, P11149, DOI 10.1073/pnas.200327197; Baldwin C. Y., 2000, POWER MODULARITY, V1; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; CHEN X, 2006, ARXIVPHYS0609239; COHEN R, 2002, CONDMAT0205476; Danon L, 2005, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2005/09/P09008; Dorogovtsev SN, 2000, PHYS REV LETT, V85, P4633, DOI 10.1103/PhysRevLett.85.4633; Dorogovtsev SN, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.066122; Erdos P, 1959, PUBL MATH-DEBRECEN, V6, P290, DOI DOI 10.2307/1999405; Goh KI, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.278701; Guimera R, 2005, NATURE, V433, P895, DOI 10.1038/nature03288; Guimera R, 2007, NAT PHYS, V3, P63, DOI 10.1038/nphys489; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Kashtan N, 2005, P NATL ACAD SCI USA, V102, P13773, DOI 10.1073/pnas.0503610102; Krapivsky PL, 2001, PHYS REV LETT, V86, P5401, DOI 10.1103/PhysRevLett.86.5401; Kumar R, 2000, ANN IEEE SYMP FOUND, P57, DOI 10.1109/SFCS.2000.892065; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Latora V, 2003, EUR PHYS J B, V32, P249, DOI 10.1140/epjb/e2003-00095-5; MILGRAM S, 1967, PSYCHOL TODAY, V1, P61; Milo R, 2004, ARXIVCONDMAT0312028V; Newman MEJ, 2004, PHYS REV E, V69, DOI [10.1103/PhysRevE.69.026113, 10.1103/PhysRevE.70.056131]; Newman MEJ, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.208701; Selby RW, 2005, IEEE T SOFTWARE ENG, V31, P495, DOI 10.1109/TSE.2005.69; Variano EA, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.188701; Wagner A, 2001, P ROY SOC B-BIOL SCI, V268, P1803, DOI 10.1098/rspb.2001.1711; Wang Z, 2007, PLOS COMPUT BIOL, V3, P1011, DOI 10.1371/journal.pcbi.0030107; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Yu HY, 2004, NUCLEIC ACIDS RES, V32, P328, DOI 10.1093/nar/gkh164	31	26	26	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2009	4	5							e5686	10.1371/journal.pone.0005686	http://dx.doi.org/10.1371/journal.pone.0005686			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LI	19479083	Green Published, gold, Green Submitted			2022-12-25	WOS:000266331700013
J	Perkins, JM; Khan, KT; Subramanian, SV				Perkins, Jessica M.; Khan, Kashif T.; Subramanian, S. V.			Patterns and Distribution of HIV among Adult Men and Women in India	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; SOCIOECONOMIC-STATUS; SOUTH-INDIA; HIV/AIDS; INFECTION; POVERTY; PREVALENCE; EPIDEMIC; WEALTH; PEOPLE	Background: While the estimated prevalence of HIV in India experienced a downward revision in 2007, the patterning and distribution of HIV in the population remains unclear. We examined the individual and state-level socioeconomic patterning of individual HIV status among adult men and women in India as well as the patterning of other individual demographic and behavioral determinants of HIV status. Methodology/Principal Findings: We conducted logistic regression models accounting for the survey design using nationally representative, cross-sectional data on 100,030 women and men from the 2005-2006 India National Family Health survey which, for the first time, provided objective assessments of HIV seroprevalence. Although there was a weak relationship between household wealth and risk of being HIV-positive, there was a clear negative relationship between individual education attainment and risk of being HIV-positive among both men and women. A 1000 Rupee change in the per capita net state domestic product was associated with a 4% and 5% increase in the risk for positive HIV status among men and women, respectively. State-level income inequality was associated with increased risk of HIV for men. Marital status and selected sexual behavior indicators were significant predictors of HIV status among women whereas the age effect was the most dominant predictor of HIV infection among men. Conclusions/Significance: Although the prevalence of HIV in India is low, the lack of strong wealth patterning in the risk of HIV suggests a more generalized distribution of HIV risk than some of India's high-risk group HIV prevention policies have assumed. The positive association between state economic development and individual risk for HIV is intriguing and requires further scrutiny.			Perkins, JM (corresponding author), Harvard Univ, Dept Hlth Policy, Cambridge, MA 02138 USA.	svsubram@hsph.harvard.edu	Perkins, Jessica M./ABG-2467-2020	Perkins, Jessica M./0000-0002-5475-8816	NHLBI NIH HHS [K25 HL081275] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K25HL081275] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barnard JMR, 2007, INVESTIG BIBLIOTECOL, V21, P7; Becker ML, 2007, AIDS, V21, P739, DOI 10.1097/QAD.0b013e328012b885; Buve A, 2001, AIDS, V15, pS117, DOI 10.1097/00002030-200108004-00013; Carter MW, 2007, AIDS BEHAV, V11, P822, DOI 10.1007/s10461-006-9203-6; Chu C, 2008, AIDS READ, V18, P144; Claeson M, 2008, HEALTH AFFAIR, V27, P1091, DOI 10.1377/hlthaff.27.4.1091; Cohen J, 2007, SCIENCE, V317, P179, DOI 10.1126/science.317.5835.179; Dandona L, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-308; Dandona L, 2007, LANCET, V370, P1811, DOI 10.1016/S0140-6736(07)61756-5; Dev S.M., 2007, ECON POLIT WEEKLY, V42, P509; Farmer P., 1999, INFECT INEQUALITIES; Fenton L, 2004, LANCET, V364, P1186, DOI 10.1016/S0140-6736(04)17109-2; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.1353/dem.2001.0003; Fortson JG, 2008, DEMOGRAPHY, V45, P303, DOI 10.1353/dem.0.0006; Gillespie S, 2007, AIDS, V21, pS5, DOI 10.1097/01.aids.0000300531.74730.72; Glynn JR, 2001, AIDS, V15, pS51, DOI 10.1097/00002030-200108004-00006; GWATKIN DR, 2000, SOCIOECONOMIC DIFFER; HARGREAVES J, 2006, GIRL POWER IMPACT GI; Hargreaves JR, 2002, TROP MED INT HEALTH, V7, P489, DOI 10.1046/j.1365-3156.2002.00889.x; IBRAHIM F, 2008, SOCIAL EC HARDSHIP P; *ICHAP I CCAP, 2004, HIDD EP HIV AIDS KAR; IIPS and Macro International, 2007, NAT FAM HLTH SURV NF, V1; *INT HFPSIAM, 2007, NAT FAM HLTH SURV NF, V2; *INT HFPSIAM, 2007, NAT FAM HLTH SURV NF, V1; *JLINT UN PROGR HI, 2007, 978929173621B978929; Kumar R, 2006, LANCET, V367, P1164, DOI 10.1016/S0140-6736(06)68435-3; Majumdar D, 2006, Indian J Public Health, V50, P28; Mishra V, 2007, AIDS, V21, pS17, DOI 10.1097/01.aids.0000300532.51860.2a; *NIHFW NACON, 2007, ANN HIV SENT SURV CO; *ORCMACRO, 2005, AN HIV TEST FIELD MA; *ORCMACRO, 2005, HIV TEST LAB MAN DEM; Piot P, 2001, NATURE, V410, P968, DOI 10.1038/35073639; Piot P, 2007, PLOS MED, V4, P1571, DOI 10.1371/journal.pmed.0040314; Rao JVRP, 2004, LANCET, V364, P1296, DOI 10.1016/S0140-6736(04)17205-X; RODRIGUES JJ, 1995, BRIT MED J, V311, P283, DOI 10.1136/bmj.311.7000.283; *SCI IFPSI INT M, 2007, NAT FAM HLTH SURV NF, V2; *SCI IFPSI INT M, 2007, NAT FAM HLTH SURV NF, V1; Shelton JD, 2005, LANCET, V366, P1057, DOI 10.1016/S0140-6736(05)67401-6; Steinbrook R, 2008, NEW ENGL J MED, V358, P107, DOI 10.1056/NEJMp0708474; *UN BUDG EC SURV M, 2007, EC SURV 2007 2008; Whiteside A, 2002, THIRD WORLD Q, V23, P313, DOI 10.1080/01436590220126667; Wojcicki JM, 2005, J BIOSOC SCI, V37, P1, DOI 10.1017/S0021932004006534; Zaba B, 2004, SEX TRANSM INFECT, V80, P28, DOI 10.1136/sti.2004.012674	43	16	16	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2009	4	5							e5648	10.1371/journal.pone.0005648	http://dx.doi.org/10.1371/journal.pone.0005648			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	449LB	19462003	gold, Green Published, Green Submitted			2022-12-25	WOS:000266331000007
J	Markel, G; Seidman, R; Besser, MJ; Zabari, N; Ortenberg, R; Shapira, R; Treves, AJ; Loewenthal, R; Orenstein, A; Nagler, A; Schachter, J				Markel, Gal; Seidman, Rachel; Besser, Michal J.; Zabari, Naama; Ortenberg, Rona; Shapira, Ronnie; Treves, Avraham J.; Loewenthal, Ron; Orenstein, Arie; Nagler, Arnon; Schachter, Jacob			Natural Killer Lysis Receptor (NKLR)/NKLR-Ligand Matching as a Novel Approach for Enhancing Anti-Tumor Activity of Allogeneic NK Cells	PLOS ONE			English	Article							INHIBITORY RECEPTORS; IMMUNOGLOBULIN SUPERFAMILY; SELF-MHC; MELANOMA; LIGANDS; MEMBER; TRANSPLANTATION; HEMAGGLUTININS; ALLOREACTIVITY; CYTOTOXICITY	Background: NK cells are key players in anti tumor immune response, which can be employed in cell-based therapeutic modalities. One of the suggested ways to amplify their anti tumor effect, especially in the field of stem cell transplantation, is by selecting donor/recipient mismatches in specific HLA, to reduce the inhibitory effect of killer Ig-like receptors (KIRs). Here we suggest an alternative approach for augmentation of anti tumor effect of allogeneic NK cells, which is founded on profile matching of donor NK lysis receptors (NKLR) phenotype with tumor lysis-ligands. Methodology/Principal Findings: We show that an NKLR-mediated killing directly correlates with the NKLR expression intensity on NK cells. Considerable donor variability in the expression of CD16, NKp46, NKG2D and NKp30 on circulating NK cells, combined with the stability of phenotype in several independently performed tests over two months, indicates that NKLR-guided selection of donors is feasible. As a proof of concept, we show that melanoma cells are dominantly recognized by three NKLRs: NKG2D, NKp30 and NKp44. Notably, the expression of NKp30 on circulating NK cells among metastatic melanoma patients was significantly decreased, which diminishes their ability to kill melanoma cells. Ex vivo expansion of NK cells results not only in increased amount of cells but also in a consistently superior and predictable expression of NKG2D, NKp30 and NKp44. Moreover, expanded NK cultures with high expression of NKG2D or NKp30 were mostly derived from the corresponding NKG2D(high) or NK30(high) donors. These NK cultures subsequently displayed an improved cytotoxic activity against melanoma in a HLA/KIR-ligand mismatched setup, which was NKLR-dependent, as demonstrated with blocking anti-NKG2D antibodies. Conclusions/Significance: NKLR/NKLR-ligand matching reproducibly elicits enhanced NK anti-tumor response. Common NKLR recognition patterns of tumors, as demonstrated here in melanoma, would allow implementation of this approach in solid malignancies and potentially in hematological malignancies, either independently or in adjunction to other modalities.			Markel, G (corresponding author), Sheba Med Ctr, Canc Res Ctr, Ella Inst Melanoma, Ramat Gan, Israel.	markel@post.tau.ac.il						Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Arnon TI, 2005, NAT IMMUNOL, V6, P515, DOI 10.1038/ni1190; Arnon TI, 2001, EUR J IMMUNOL, V31, P2680, DOI 10.1002/1521-4141(200109)31:9<2680::AID-IMMU2680>3.0.CO;2-A; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; Cantoni C, 1999, EUR J IMMUNOL, V29, P3148, DOI 10.1002/(SICI)1521-4141(199910)29:10<3148::AID-IMMU3148>3.0.CO;2-L; Cantoni C, 1999, J EXP MED, V189, P787, DOI 10.1084/jem.189.5.787; Cooley S, 2007, BLOOD, V110, P578, DOI 10.1182/blood-2006-07-036228; Dudley ME, 2008, J CLIN ONCOL, V26, P5233, DOI 10.1200/JCO.2008.16.5449; Dudley ME, 2007, SEMIN ONCOL, V34, P524, DOI 10.1053/j.seminoncol.2007.09.002; Dudley ME, 2005, J CLIN ONCOL, V23, P2346, DOI 10.1200/JCO.2005.00.240; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Fernandez NC, 2005, BLOOD, V105, P4416, DOI 10.1182/blood-2004-08-3156; Frohn C, 2000, J IMMUNOTHER, V23, P499, DOI 10.1097/00002371-200007000-00014; Gonzalez S, 2008, TRENDS IMMUNOL, V29, P397, DOI 10.1016/j.it.2008.04.007; Hamerman JA, 2005, CURR OPIN IMMUNOL, V17, P29, DOI 10.1016/j.coi.2004.11.001; Igarashi T, 2004, BLOOD, V104, P170, DOI 10.1182/blood-2003-12-4438; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; LAW TM, 1995, CANCER-AM CANCER SOC, V76, P824, DOI 10.1002/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO;2-N; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Mandelboim O, 1999, P NATL ACAD SCI USA, V96, P5640, DOI 10.1073/pnas.96.10.5640; Mandelboim O, 2001, NATURE, V409, P1055, DOI 10.1038/35059110; Markel G, 2002, J IMMUNOL, V168, P2803, DOI 10.4049/jimmunol.168.6.2803; Markel G, 2006, J IMMUNOL, V177, P6062, DOI 10.4049/jimmunol.177.9.6062; Markel G, 2009, IMMUNOLOGY, V126, P186, DOI 10.1111/j.1365-2567.2008.02888.x; Miller JS, 2005, BLOOD, V105, P3051, DOI 10.1182/blood-2004-07-2974; Moretta L, 2006, SEMIN IMMUNOL, V18, P151, DOI 10.1016/j.smim.2006.03.002; Nowbakht P, 2005, BLOOD, V105, P3615, DOI 10.1182/blood-2004-07-2585; Parham P, 2006, IMMUNOL REV, V214, P155, DOI 10.1111/j.1600-065X.2006.00462.x; Pascal V, 2004, EUR J IMMUNOL, V34, P2930, DOI 10.1002/eji.200425146; Pende D, 1999, J EXP MED, V190, P1505, DOI 10.1084/jem.190.10.1505; Pessino A, 1998, J EXP MED, V188, P953, DOI 10.1084/jem.188.5.953; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Ruggeri L, 1999, BLOOD, V94, P333, DOI 10.1182/blood.V94.1.333.413a31_333_339; Ruggeri L, 2007, BLOOD, V110, P433, DOI 10.1182/blood-2006-07-038687; Schwartz RN, 2002, ONCOLOGY-NY, V16, P11; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245; VANDEGRIEND RJ, 1987, J IMMUNOL, V138, P3137; Vitale C, 2005, MOL IMMUNOL, V42, P405, DOI 10.1016/j.molimm.2004.07.019; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Yano Hiroshi, 1999, Gastric Cancer, V2, P26, DOI 10.1007/s101200050017	41	20	23	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5597	10.1371/journal.pone.0005597	http://dx.doi.org/10.1371/journal.pone.0005597			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19440333	Green Published, Green Submitted, gold			2022-12-25	WOS:000266161200001
J	Molfetta, R; Gasparrini, F; Peruzzi, G; Vian, L; Piccoli, M; Frati, L; Santoni, A; Paolini, R				Molfetta, Rosa; Gasparrini, Francesca; Peruzzi, Giovanna; Vian, Laura; Piccoli, Mario; Frati, Luigi; Santoni, Angela; Paolini, Rossella			Lipid Raft-Dependent Fc epsilon RI Ubiquitination Regulates Receptor Endocytosis through the Action of Ubiquitin Binding Adaptors	PLOS ONE			English	Article							IMMUNOGLOBULIN-E RECEPTOR; GROWTH-FACTOR RECEPTOR; AFFINITY IGE RECEPTOR; CLATHRIN-COATED PITS; MAST-CELL ACTIVATION; ENDOSOMAL TRAFFICKING; SIGNAL-TRANSDUCTION; MEMBRANE DOMAINS; TYROSINE KINASE; RBL-2H3 CELLS	The best characterized role for ubiquitination of membrane receptors is to negatively regulate signaling by targeting receptors for lysosomal degradation. The high affinity receptor for IgE (Fc epsilon RI) expressed on mast cells and basophils is rapidly ubiquitinated upon antigen stimulation. However, the nature and the role of this covalent modification are still largelly unknown. Here, we show that Fc epsilon RI subunits are preferentially ubiquitinated at multiple sites upon stimulation, and provide evidence for a role of ubiquitin as an internalization signal: under conditions of impaired receptor ubiquitination a decrease of receptor entry is observed by FACS analysis and fluorescence microscopy. We also used biochemical approaches combined with fluorescence microscopy, to demonstrate that receptor endocytosis requires the integrity of specific membrane domains, namely lipid rafts. Additionally, by RNA interference we demonstrate the involvement of ubiquitin-binding endocytic adaptors in Fc epsilon RI internalization and sorting. Notably, the triple depletion of Eps15, Eps15R and Epsin1 negatively affects the early steps of Ag-induced receptor endocytosis, whereas Hrs depletion retains ubiquitinated receptors into early endosomes and partially prevents their sorting into lysosomes for degradation. Our results are compatible with a scenario in which the accumulation of engaged receptor subunits into lipid rafts is required for receptor ubiquitination, a prerequisite for efficient receptor internalization, sorting and delivery to a lysosomal compartment.			Molfetta, R (corresponding author), Univ Roma La Sapienza, Dept Expt Med, Inst Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy.	rossella.paolini@uniroma1.it	Molfetta, Rosa/N-4529-2015; santoni, angela/K-8997-2016; Frati, Luigi/ABI-7437-2020	Molfetta, Rosa/0000-0003-2904-6371; santoni, angela/0000-0003-1206-7731; PAOLINI, Rossella/0000-0001-7605-1531; Peruzzi, Giovanna/0000-0002-6517-9107	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Ciechanover A, 2000, J CELL BIOCHEM, P40; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Fattakhova G, 2006, TRAFFIC, V7, P673, DOI 10.1111/j.1600-0854.2006.00423.x; Fattakhova GV, 2009, MOL IMMUNOL, V46, P793, DOI 10.1016/j.molimm.2008.09.002; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Fujimuro M, 2005, METHOD ENZYMOL, V399, P75, DOI 10.1016/S0076-6879(05)99006-X; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x; Kovarova M, 2006, J EXP MED, V203, P1161, DOI 10.1084/jem.20051701; Kraft S, 2007, NAT REV IMMUNOL, V7, P365, DOI 10.1038/nri2072; Kusumi A, 2004, TRAFFIC, V5, P213, DOI 10.1111/j.1600-0854.2004.0178.x; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Mayor S, 2004, TRAFFIC, V5, P231, DOI 10.1111/j.1600-0854.2004.00172.x; Molfetta R, 2005, J IMMUNOL, V175, P4208, DOI 10.4049/jimmunol.175.7.4208; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Murai S, 2000, BIOCHEM BIOPH RES CO, V277, P752, DOI 10.1006/bbrc.2000.3749; Oliver C, 2007, J HISTOCHEM CYTOCHEM, V55, P315, DOI 10.1369/jhc.6A7037.2006; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; Paolini R, 2002, J BIOL CHEM, V277, P36940, DOI 10.1074/jbc.M204948200; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Puri C, 2005, MOL BIOL CELL, V16, P2704, DOI 10.1091/mbc.e04-07-0596; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Rivera J, 2008, ADV IMMUNOL, V98, P85, DOI 10.1016/S0065-2776(08)00403-3; Santini F, 1996, J CELL BIOL, V132, P1025, DOI 10.1083/jcb.132.6.1025; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Siraganian RP, 2003, CURR OPIN IMMUNOL, V15, P639, DOI 10.1016/j.coi.2003.09.010; Stang E, 2004, MOL BIOL CELL, V15, P3591, DOI 10.1091/mbc.E04-01-0041; Stoddart A, 2005, MOL BIOL CELL, V16, P2339, DOI 10.1091/mbc.e05-01-0025; Wilson BS, 2000, J CELL BIOL, V149, P1131, DOI 10.1083/jcb.149.5.1131; Wilson BS, 2004, MOL BIOL CELL, V15, P2580, DOI 10.1091/mbc.E03-08-0574; Yamasaki S, 2005, CHEM IMMUNOL ALLERGY, V87, P22, DOI 10.1159/000087568; Yang YL, 2007, CANCER RES, V67, P9472, DOI 10.1158/0008-5472.CAN-07-0568; Young RM, 2003, J BIOL CHEM, V278, P20746, DOI 10.1074/jbc.M211402200; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	45	24	24	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5604	10.1371/journal.pone.0005604	http://dx.doi.org/10.1371/journal.pone.0005604			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19440386	Green Published, Green Submitted, gold			2022-12-25	WOS:000266161200007
J	Sexton, A; Harman, S; Shattock, RJ; Ma, JKC				Sexton, Amy; Harman, Sarah; Shattock, Robin J.; Ma, Julian K. -C.			Design, expression, and characterization of a multivalent, combination HIV microbicide	FASEB JOURNAL			English	Article						b12; cyanovirin-N; fusion protein; transgenic plants; plant biotechnology	CYANOVIRIN-N; IMMUNODEFICIENCY-VIRUS; MONOCLONAL-ANTIBODY; GLYCOPROTEIN GP120; TRANSMISSION; BINDING; PROTEIN; EPITOPE; PANEL; AIDS	Many promising microbicide candidates are proteins or peptides, including neutralizing monoclonal antibodies (mAbs). Here, the expression of the HIV-neutralizing mAb b12 in transgenic plants is described. The plant-derived mAb b12 was shown to have gp120 binding activity and HIV-neutralizing activity in vitro. However, it is likely that a protein-based microbicide will need to comprise a combination of two or more products, in order to provide long-lasting and cross-clade protection. Building on the expression of mAb b12 and to address the need for a combinational agent, the expression of a fusion protein of mAb b12 with cyanovirin-N, another protein microbicide, has been explored. This fusion protein molecule is predicted to have four binding sites for HIV gp120 with two different specificities. The fusion protein was assembled and expressed in planta, and functionality was confirmed by gp120 binding and HIV neutralization in vitro. Each moiety of the fusion protein retained its binding ability to gp120. In addition, this fusion protein demonstrated increased anti-HIV potency compared to b12 or CV-N alone. This fusion protein addresses the requirement to combine microbicide products, and the production in plants is a step toward resolving the issues of manufacturing scalability and cost for developing countries. Sexton, A., Harman, S., Shattock, R. J., Ma, J. K.-C. Design, expression, and characterization of a multivalent, combination HIV microbicide. FASEB J. 23, 3590-3600 (2009). www.fasebj.org	[Sexton, Amy; Harman, Sarah; Shattock, Robin J.; Ma, Julian K. -C.] Univ London, St Georges Hosp, Sch Med, Dept Cellular & Mol Med, London SW17 0RE, England	St Georges University London; University of London	Ma, JKC (corresponding author), Univ London, St Georges Hosp, Sch Med, Dept Cellular & Mol Med, London SW17 0RE, England.	jma@sgul.ac.uk		Ma, Julian/0000-0003-0767-0042; Harman, Sarah/0000-0001-6443-0614	EU; UK Medical Research Council; EMPRO	EU(European Commission); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EMPRO	We are grateful to Dr. Dennis Burton (The Scripps Research Institute, La Jolla, CA, USA) for providing the mAb b12 clone, and to Biosyn Inc. (Baton Rouge, LA, USA) for their collaborative efforts and provision of the CV-N N30Q/P51G DNA template and the rabbit anti-CV-N polyclonal antisera. We also thank the National Cancer Institute (Rockville, MD, USA) for additional rabbit anti-CV-N polyclonal antisera. We thank Dr. Susan Zolla Pazner (New York University Langone Medical Center, New York, NY, USA) for the D30 mAb. We acknowledge the Centralised Facility for AIDS Reagents (Potters Bar, UK), supported by the EU program EVA/MRC and the UK Medical Research Council, for the provision of recombinant gp120. This work was supported by EMPRO (EU framework 6).	Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004; Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521, DOI 10.1128/AAC.41.7.1521; Bublil EM, 2006, FASEB J, V20, P1762, DOI 10.1096/fj.05-5509rev; Buffa V, 2009, J GEN VIROL, V90, P234, DOI 10.1099/vir.0.004358-0; Chargelegue D, 2005, INFECT IMMUN, V73, P5915, DOI 10.1128/IAI.73.9.5915-5922.2005; Esser MT, 1999, J VIROL, V73, P4360, DOI 10.1128/JVI.73.5.4360-4371.1999; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Hu QX, 2007, VIROLOGY, V368, P145, DOI 10.1016/j.virol.2007.06.029; MA JKC, 1995, SCIENCE, V268, P716, DOI 10.1126/science.7732380; Miranda LR, 2007, J IMMUNOL, V178, P7132, DOI 10.4049/jimmunol.178.11.7132; MONTEFIORI D, 2004, CURRENT PROTOCOLS IM; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; Moulard M, 2002, P NATL ACAD SCI USA, V99, P6913, DOI 10.1073/pnas.102562599; Nuttall J, 2002, EUR J BIOCHEM, V269, P6042, DOI 10.1046/j.1432-1033.2002.03302.x; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Rademacher T, 2008, PLANT BIOTECHNOL J, V6, P189, DOI 10.1111/j.1467-7652.2007.00306.x; Ramessar K, 2008, P NATL ACAD SCI USA, V105, P3727, DOI 10.1073/pnas.0708841104; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; Sambrook J., 2001, MOL CLONING LAB MANU; Sexton A, 2006, FASEB J, V20, P356, DOI 10.1096/fj.05-4742fje; Shattock R, 2004, LANCET, V363, P1002, DOI 10.1016/S0140-6736(04)15876-5; Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729; Tsai CC, 2003, AIDS RES HUM RETROV, V19, P535, DOI 10.1089/088922203322230897; Tsai CC, 2004, AIDS RES HUM RETROV, V20, P11, DOI 10.1089/088922204322749459; TSUJI T, 1981, BIOCHEM J, V195, P691, DOI 10.1042/bj1950691; Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833; Vitale A, 1999, PLANT CELL, V11, P615, DOI 10.1105/tpc.11.4.615; Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580	28	42	44	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3590	3600		10.1096/fj.09-131995	http://dx.doi.org/10.1096/fj.09-131995			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19470798				2022-12-25	WOS:000270354300035
J	Zhang, Y; Kang, YH; Chang, N; Lam, PPL; Liu, YF; Olkkonen, VM; Gaisano, HY				Zhang, Yi; Kang, You-hou; Chang, Nathan; Lam, Patrick P. L.; Liu, Yunfeng; Olkkonen, Vesa M.; Gaisano, Herbert Y.			Cab45b, a Munc18b-interacting Partner, Regulates Exocytosis in Pancreatic beta-Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; CA2+-BINDING PROTEIN; SECRETORY GRANULES; INSULIN EXOCYTOSIS; VESICLE EXOCYTOSIS; SYNTAXIN 3; B-CELLS; MEMBRANE; INTERACTS; TRAFFICKING	Cab45b is a cytosolic Ca2+-binding protein reported to regulate zymogen secretion in pancreatic acini. We now show that Cab45b is also expressed in pancreatic islet beta-cells and interacts there with the Sec1-Munc18 protein Munc18b. We employed patch clamp cell capacitance measurements to show that antibodies against Cab45b inhibited depolarization-evoked membrane capacitance increments, suggesting an impact on beta-cell granule exocytosis, both the readily releasable granule pool and refilling of this pool. Site-specific mutants in the Cab45b EF-hands were used to dissect the molecular interactions involved in Cab45b function. Mutants in EF-hands 2 and 3 had no detectable effects on interaction of Cab45b with Munc18b and did not affect the depolarization-evoked calcium currents, but remarkably, they facilitated the complex formation of Munc18b with syntaxin-2 and -3. As a result, these two EF-hand mutants inhibited beta-cell membrane capacitance increments. This inhibition is mediated via Munc18b because Munc18b silencing with small interfering RNA abolished the effects of these two mutants. The results suggest a mechanism for Cab45b action that involves regulating the dynamic association of Munc18b with SNAREs to impact beta-cell granule exocytosis.	[Zhang, Yi; Kang, You-hou; Chang, Nathan; Lam, Patrick P. L.; Liu, Yunfeng; Gaisano, Herbert Y.] Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; [Zhang, Yi; Kang, You-hou; Chang, Nathan; Lam, Patrick P. L.; Liu, Yunfeng; Gaisano, Herbert Y.] Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; [Olkkonen, Vesa M.] Univ Helsinki, Biomedicum, Natl Inst Hlth & Welf, FI-00251 Helsinki, Finland; [Olkkonen, Vesa M.] Univ Helsinki, Biomedicum, Inst Mol Med Finland FIMM, FI-00251 Helsinki, Finland	University of Toronto; University of Toronto; Finland National Institute for Health & Welfare; University of Helsinki; University of Helsinki	Gaisano, HY (corresponding author), Univ Toronto, Dept Med, Rm 7226 Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	herbert.gaisano@utoronto.ca		Olkkonen, Vesa/0000-0001-5553-7997; Liu, Yunfeng/0000-0003-2826-5804	Canadian Institutes for Health [MOP 89889]	Canadian Institutes for Health(Canadian Institutes of Health Research (CIHR))	This work was supported by Canadian Institutes for Health Research Grant MOP 89889.	Gallwitz D, 2003, TRENDS BIOCHEM SCI, V28, P113, DOI 10.1016/S0968-0004(03)00028-8; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Gopel S, 1999, J PHYSIOL-LONDON, V521, P717, DOI 10.1111/j.1469-7793.1999.00717.x; Gromada J, 1999, J PHYSIOL-LONDON, V518, P745, DOI 10.1111/j.1469-7793.1999.0745p.x; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; Jewell JL, 2008, J BIOL CHEM, V283, P10716, DOI 10.1074/jbc.M709876200; Ke B, 2007, J BIOL CHEM, V282, P21786, DOI 10.1074/jbc.M701661200; Koivu T, 1997, DNA SEQUENCE, V7, P217, DOI 10.3109/10425179709034038; Kwan EP, 2007, DIABETES, V56, P2579, DOI 10.2337/db06-1207; Kwan EP, 2005, DIABETES, V54, P2734, DOI 10.2337/diabetes.54.9.2734; Lam PPL, 2007, MOL BIOL CELL, V18, P2473, DOI 10.1091/mbc.E06-10-0950; Marti-Verdeaux S, 2003, J CELL SCI, V116, P325, DOI 10.1242/jcs.00216; Nemoto T, 2001, NAT CELL BIOL, V3, P253, DOI 10.1038/35060042; Nicoletta JA, 2004, AM J PHYSIOL-CELL PH, V287, pC1366, DOI 10.1152/ajpcell.00588.2003; Oh E, 2005, DIABETES, V54, P638, DOI 10.2337/diabetes.54.3.638; Oh E, 2007, J BIOL CHEM, V282, P32613, DOI 10.1074/jbc.M706591200; Oh E, 2009, DIABETES, V58, P1165, DOI 10.2337/db08-1059; Ohara-Imaizumi M, 2007, J CELL BIOL, V177, P695, DOI 10.1083/jcb.200608132; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Pickett JA, 2005, J BIOL CHEM, V280, P1506, DOI 10.1074/jbc.M411967200; Riento K, 1996, EUR J BIOCHEM, V239, P638, DOI 10.1111/j.1432-1033.1996.0638u.x; Riento K, 2000, J BIOL CHEM, V275, P13476, DOI 10.1074/jbc.275.18.13476; Riento K, 1998, J CELL SCI, V111, P2681; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Rothman JE, 2002, NAT MED, V8, P1059, DOI 10.1038/nm770; Scherer PE, 1996, J CELL BIOL, V133, P257, DOI 10.1083/jcb.133.2.257; Shen JS, 2007, CELL, V128, P183, DOI 10.1016/j.cell.2006.12.016; Spurlin BA, 2006, MOL ENDOCRINOL, V20, P183, DOI 10.1210/me.2005-0157; Takahashi N, 2004, J CELL BIOL, V165, P255, DOI 10.1083/jcb.200312033; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; Tomas A, 2008, TRAFFIC, V9, P813, DOI 10.1111/j.1600-0854.2008.00709.x; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Toonen RF, 2006, EMBO J, V25, P3725, DOI 10.1038/sj.emboj.7601256; Tsuboi T, 2006, MOL BIOL CELL, V17, P2101, DOI 10.1091/mbc.E05-11-1047; Zilly FE, 2006, PLOS BIOL, V4, P1789, DOI 10.1371/journal.pbio.0040330	37	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20840	20847		10.1074/jbc.M109.017467	http://dx.doi.org/10.1074/jbc.M109.017467			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19487699	Green Published, hybrid			2022-12-25	WOS:000268316100047
J	Bah, A; Carrell, CJ; Chen, ZW; Gandhi, PS; Di Cera, E				Bah, Alaji; Carrell, Christopher J.; Chen, Zhiwei; Gandhi, Prafull S.; Di Cera, Enrico			Stabilization of the E* Form Turns Thrombin into an Anticoagulant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE-ACTIVATED RECEPTORS; CRYSTAL-STRUCTURE; MUTANT W215A/E217A; BOVINE TRYPSINOGEN; NA+ BINDING; POTENT ANTICOAGULANT; ALPHA-CHYMOTRYPSIN; THROMBOMODULIN; SPECIFICITY; COMPLEX	Previous studies have shown that deletion of nine residues in the autolysis loop of thrombin produces a mutant with an anticoagulant propensity of potential clinical relevance, but the molecular origin of the effect has remained unresolved. The x-ray crystal structure of this mutant solved in the free form at 1.55 angstrom resolution reveals an inactive conformation that is practically identical (root mean square deviation of 0.154 angstrom) to the recently identified E* form. The side chain of Trp(215) collapses into the active site by shifting > 10 angstrom from its position in the active E form, and the oxyanion hole is disrupted by a flip of the Glu(192)-Gly(193) peptide bond. This finding confirms the existence of the inactive form E* in essentially the same incarnation as first identified in the structure of the thrombin mutant D102N. In addition, it demonstrates that the anticoagulant profile often caused by a mutation of the thrombin scaffold finds its likely molecular origin in the stabilization of the inactive E* form that is selectively shifted to the active E form upon thrombomodulin and protein C binding.	[Bah, Alaji; Carrell, Christopher J.; Chen, Zhiwei; Gandhi, Prafull S.; Di Cera, Enrico] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, Box 8231, St Louis, MO 63110 USA.	enrico@wustl.edu			National Institutes of Health [HL49413, HL58141, HL73813]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073813, R01HL049413, R29HL049413, R01HL058141] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported, in whole or in part, by National Institutes of Health Grants HL49413, HL58141, and HL73813 (to E. D. C.).	Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; Bah A, 2007, P NATL ACAD SCI USA, V104, P11603, DOI 10.1073/pnas.0704409104; Bah A, 2006, J BIOL CHEM, V281, P40049, DOI 10.1074/jbc.M608600200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrette-Ng IH, 2002, J BIOL CHEM, V277, P39960, DOI 10.1074/jbc.M206978200; Berny MA, 2008, ARTERIOSCL THROM VAS, V28, P329, DOI 10.1161/ATVBAHA.107.156273; BODE W, 1976, FEBS LETT, V68, P231, DOI 10.1016/0014-5793(76)80443-7; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; Cantwell AM, 2000, J BIOL CHEM, V275, P39827, DOI 10.1074/jbc.C000751200; Carrell CJ, 2006, BIOPHYS CHEM, V121, P177, DOI 10.1016/j.bpc.2005.12.008; Carter WJ, 2004, J BIOL CHEM, V279, P26387, DOI 10.1074/jbc.M402364200; Carvalho AL, 2002, J MOL BIOL, V322, P325, DOI 10.1016/S0022-2836(02)00705-2; Coughlin SR, 2005, J THROMB HAEMOST, V3, P1800, DOI 10.1111/j.1538-7836.2005.01377.x; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dang QD, 1997, J BIOL CHEM, V272, P19649, DOI 10.1074/jbc.272.32.19649; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; Di Cera E., 1995, THERMODYNAMIC THEORY; Di Cera E, 2008, MOL ASPECTS MED, V29, P203, DOI 10.1016/j.mam.2008.01.001; Di Cera E, 2009, IUBMB LIFE, V61, P510, DOI 10.1002/iub.186; DiBella EE, 1996, BIOCHEMISTRY-US, V35, P4427, DOI 10.1021/bi952617c; Eisenmesser EZ, 2002, SCIENCE, V295, P1520, DOI 10.1126/science.1066176; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Erlandson KJ, 2008, NATURE, V455, P984, DOI 10.1038/nature07439; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; Feistritzer C, 2006, J BIOL CHEM, V281, P20077, DOI 10.1074/jbc.M600506200; FERSHT AR, 1971, J MOL BIOL, V60, P279, DOI 10.1016/0022-2836(71)90294-4; FERSHT AR, 1972, J MOL BIOL, V64, P497, DOI 10.1016/0022-2836(72)90513-X; Gandhi PS, 2008, P NATL ACAD SCI USA, V105, P1832, DOI 10.1073/pnas.0710894105; Gianni S, 2007, BIOPHYS CHEM, V131, P111, DOI 10.1016/j.bpc.2007.09.009; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; GRIFFIN JH, 1995, NATURE, V378, P337, DOI 10.1038/378337a0; Gros P, 2008, NAT REV IMMUNOL, V8, P48, DOI 10.1038/nri2231; Gruber A, 2002, J BIOL CHEM, V277, P27581, DOI 10.1074/jbc.C200237200; Gruber A, 2007, BLOOD, V109, P3733, DOI 10.1182/blood-2006-07-035147; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; Hink-Schauer C, 2002, J BIOL CHEM, V277, P50923, DOI 10.1074/jbc.M207962200; Jing H, 1998, J MOL BIOL, V282, P1061, DOI 10.1006/jmbi.1998.2089; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; Levi M, 2008, CURR OPIN HEMATOL, V15, P481, DOI 10.1097/MOH.0b013e328304b3e3; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page MJ, 2008, CELL MOL LIFE SCI, V65, P1220, DOI 10.1007/s00018-008-7565-9; Papaconstantinou ME, 2008, CELL MOL LIFE SCI, V65, P1943, DOI 10.1007/s00018-008-8179-y; Pineda AO, 2006, J BIOL CHEM, V281, P32922, DOI 10.1074/jbc.M605530200; Pineda AO, 2002, J BIOL CHEM, V277, P32015, DOI 10.1074/jbc.M205009200; Pineda AO, 2004, J BIOL CHEM, V279, P39824, DOI 10.1074/jbc.M407272200; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; Ponnuraj K, 2004, MOL CELL, V14, P17, DOI 10.1016/S1097-2765(04)00160-1; Prasad S, 2003, P NATL ACAD SCI USA, V100, P13785, DOI 10.1073/pnas.2333109100; Reiling KK, 2003, BIOCHEMISTRY-US, V42, P2616, DOI 10.1021/bi020594d; Rickert KW, 2008, J BIOL CHEM, V283, P34864, DOI 10.1074/jbc.M805262200; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Rohr KB, 2006, J MOL BIOL, V357, P195, DOI 10.1016/j.jmb.2005.12.037; Shia S, 2005, J MOL BIOL, V346, P1335, DOI 10.1016/j.jmb.2004.12.048; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; Sytina OA, 2008, NATURE, V456, P1001, DOI 10.1038/nature07354; Tanaka KA, 2008, BLOOD COAGUL FIBRIN, V19, P465, DOI 10.1097/MBC.0b013e328304e044; Tsiang M, 1996, BIOCHEMISTRY-US, V35, P16449, DOI 10.1021/bi9616108; Vindigni A, 1997, NAT BIOTECHNOL, V15, P891, DOI 10.1038/nbt0997-891; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WANG DC, 1985, J MOL BIOL, V185, P595, DOI 10.1016/0022-2836(85)90074-9; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; Wyman J., 1990, BINDING LINKAGE; Xu H, 2005, J BIOL CHEM, V280, P7956, DOI 10.1074/jbc.M412869200; Zimmer J, 2008, NATURE, V455, P936, DOI 10.1038/nature07335	71	19	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20034	20040		10.1074/jbc.M109.012344	http://dx.doi.org/10.1074/jbc.M109.012344			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19473969	hybrid, Green Published			2022-12-25	WOS:000268097400030
J	Singh, AK; Singh, N; Sinha, M; Bhushan, A; Kaur, P; Srinivasan, A; Sharma, S; Singh, TP				Singh, Amit K.; Singh, Nagendra; Sinha, Mau; Bhushan, Asha; Kaur, Punit; Srinivasan, Alagiri; Sharma, Sujata; Singh, Tej P.			Binding Modes of Aromatic Ligands to Mammalian Heme Peroxidases with Associated Functional Implications CRYSTAL STRUCTURES OF LACTOPEROXIDASE COMPLEXES WITH ACETYLSALICYLIC ACID, SALICYLHYDROXAMIC ACID, AND BENZYLHYDROXAMIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTHROMYCES-RAMOSUS PEROXIDASE; RAY CRYSTALLOGRAPHIC ANALYSIS; HORSERADISH-PEROXIDASE; BOVINE LACTOPEROXIDASE; HUMAN MYELOPEROXIDASE; ASCORBATE PEROXIDASE; INTESTINAL PEROXIDASE; BENZHYDROXAMIC ACID; ANGSTROM RESOLUTION; OXIDATIVE STRESS	The binding and structural studies of bovine lactoperoxidase with three aromatic ligands, acetylsalicylic acid (ASA), salicylhydoxamic acid (SHA), and benzylhydroxamic acid (BHA) show that all the three compounds bind to lactoperoxidase at the substrate binding site on the distal heme side. The binding of ASA occurs without perturbing the position of conserved heme water molecule W-1, whereas both SHA and BHA displace it by the hydroxyl group of their hydroxamic acid moieties. The acetyl group carbonyl oxygen atom of ASA forms a hydrogen bond with W-1, which in turn makes three other hydrogen-bonds, one each with heme iron, His-109N(epsilon 2), and Gln-105 N-epsilon 2. In contrast, in the complexes of SHA and BHA, the OH group of hydroxamic acid moiety in both complexes interacts with heme iron directly with Fe-OH distances of 3.0 and 3.2 angstrom respectively. The OH is also hydrogen bonded to His-109N(epsilon 2) and Gln-105N(epsilon 2). The plane of benzene ring of ASA is inclined at 70.7 degrees from the plane of heme moiety, whereas the aromatic planes of SHA and BHA are nearly parallel to the heme plane with inclinations of 15.7 and 6.2, respectively. The mode of ASA binding provides the information about the mechanism of action of aromatic substrates, whereas the binding characteristics of SHA and BHA indicate the mode of inhibitor binding.	[Singh, Amit K.; Singh, Nagendra; Sinha, Mau; Bhushan, Asha; Kaur, Punit; Srinivasan, Alagiri; Sharma, Sujata; Singh, Tej P.] All India Inst Med Sci, Dept Biophys, New Delhi 110029, India	All India Institute of Medical Sciences (AIIMS) New Delhi	Singh, TP (corresponding author), All India Inst Med Sci, Dept Biophys, Ansari Nagar, New Delhi 110029, India.	tpsingh.aiims@gmail.com		SINHA, MAU/0000-0003-3011-9160; Singh, Nagendra/0000-0003-0419-0684	Council of Scientific and Industrial Research, New Delhi	Council of Scientific and Industrial Research, New Delhi(Council of Scientific & Industrial Research (CSIR) - India)	Supported by a Council of Scientific and Industrial Research, New Delhi fellowship.	Agner K., 1941, ACTA PHYSIOL SCAND, V2, P1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blair-Johnson M, 2001, BIOCHEMISTRY-US, V40, P13990, DOI 10.1021/bi0111808; CALS MM, 1991, EUR J BIOCHEM, V198, P733, DOI 10.1111/j.1432-1033.1991.tb16073.x; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; CHATTERJEE R, 1993, BIOCHIM BIOPHYS ACTA, V1161, P168, DOI 10.1016/0167-4838(93)90210-I; Davey CA, 1996, BIOCHEMISTRY-US, V35, P10967, DOI 10.1021/bi960577m; DAVIES B, 1989, BIOCHEM J, V258, P801, DOI 10.1042/bj2580801; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DOERGE DR, 1994, CHEM RES TOXICOL, V7, P164, DOI 10.1021/tx00038a008; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; FENNA R, 1995, ARCH BIOCHEM BIOPHYS, V316, P653, DOI 10.1006/abbi.1995.1086; FERRARI RP, 1993, SPECTROCHIM ACTA A, V49, P1261, DOI 10.1016/0584-8539(93)80034-8; Fiedler TJ, 2000, J BIOL CHEM, V275, P11964, DOI 10.1074/jbc.275.16.11964; Furtmuller PG, 2006, ARCH BIOCHEM BIOPHYS, V445, P199, DOI 10.1016/j.abb.2005.09.017; Gajhede M, 2001, BIOCHEM SOC T, V29, P91, DOI 10.1042/0300-5127:0290091; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; Ghibaudi EM, 2000, REDOX REP, V5, P229, DOI 10.1179/135100000101535672; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; HORI H, 1994, J BIOL CHEM, V269, P8388; IKEDASAITO M, 1991, J BIOL CHEM, V266, P3611; Itakura H, 1997, FEBS LETT, V412, P107, DOI 10.1016/S0014-5793(97)00751-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIMURA S, 1979, ARCH BIOCHEM BIOPHYS, V198, P580, DOI 10.1016/0003-9861(79)90534-4; KITAGAWA T, 1983, BIOCHEMISTRY-US, V22, P2788, DOI 10.1021/bi00281a003; Kooter IM, 1999, J BIOL CHEM, V274, P26794, DOI 10.1074/jbc.274.38.26794; KUMAR R, 1995, ACTA CRYSTALLOGR D, V51, P1094, DOI 10.1107/S0907444995004422; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LIPMANN F, 1945, J BIOL CHEM, V159, P21; METODIEWA D, 1989, BIOCHEM BIOPH RES CO, V160, P1183, DOI 10.1016/S0006-291X(89)80128-7; METODIEWA D, 1989, ARCH BIOCHEM BIOPHYS, V274, P601, DOI 10.1016/0003-9861(89)90475-X; Monzani E, 1997, BIOCHEMISTRY-US, V36, P1918, DOI 10.1021/bi961868y; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Oakley GG, 1996, CHEM RES TOXICOL, V9, P1285, DOI 10.1021/tx960103o; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oxvig C, 1999, J BIOL CHEM, V274, P16953, DOI 10.1074/jbc.274.24.16953; Poulos TL, 2007, NAT PROD REP, V24, P504, DOI 10.1039/b604195g; POULOS TL, 1980, J BIOL CHEM, V255, P575; POULOS TL, 1993, J BIOL CHEM, V268, P4429; RAMAKRISHNA NVS, 1993, CHEM RES TOXICOL, V6, P837, DOI 10.1021/tx00036a013; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; Sharp KH, 2004, BIOCHEMISTRY-US, V43, P8644, DOI 10.1021/bi049343q; Sharp KH, 2003, NAT STRUCT BIOL, V10, P303, DOI 10.1038/nsb913; Sheikh IA, 2009, J BIOL CHEM, V284, P14849, DOI 10.1074/jbc.M807644200; SIEVERS G, 1981, FEBS LETT, V127, P253; Singh AK, 2009, BIOPHYS J, V96, P646, DOI 10.1016/j.bpj.2008.09.019; Singh AK, 2008, J MOL BIOL, V376, P1060, DOI 10.1016/j.jmb.2007.12.012; SIPE HJ, 1994, CARCINOGENESIS, V15, P2637, DOI 10.1093/carcin/15.11.2637; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; Tsukamoto K, 1999, BIOCHEMISTRY-US, V38, P12558, DOI 10.1021/bi982925l; Wada K, 2003, J BIOCHEM, V134, P239, DOI 10.1093/jb/mvg136; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5; ZHANG HC, 1993, CAN J CHEM, V71, P1990, DOI 10.1139/v93-248	55	36	36	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20311	20318		10.1074/jbc.M109.010280	http://dx.doi.org/10.1074/jbc.M109.010280			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19465478	Green Published, hybrid			2022-12-25	WOS:000268097400057
J	Lee, SG; Jeon, HY; Su, ZZ; Richards, JE; Vozhilla, N; Sarkar, D; Van Maerken, T; Fisher, PB				Lee, S-G; Jeon, H-Y; Su, Z-Z; Richards, J. E.; Vozhilla, N.; Sarkar, D.; Van Maerken, T.; Fisher, P. B.			Astrocyte elevated gene-1 contributes to the pathogenesis of neuroblastoma	ONCOGENE			English	Article						neuroblastoma; AEG-1; MYCN; PI3K; Akt	RAPID SUBTRACTION HYBRIDIZATION; PHOSPHATIDYLINOSITOL 3-KINASE; N-MYC; C-MYC; CANCER PROGRESSION; TUMOR PROGRESSION; BREAST-CANCER; EXPRESSION; PATHWAY; CELLS	Neuroblastoma, derived from neural crest progenitor cells, is the most common extracranial solid tumor of childhood. Astrocyte elevated gene-1 (AEG-1) is a primary mediator of tumor progression and metastasis in several human cancers. In this study, we investigated the potential contribution of AEG-1 in human neuroblastoma pathogenesis. AEG-1 expression was significantly elevated in neuroblastoma patient-derived samples and neuroblastoma cell lines as compared with normal peripheral nerve tissues, normal astrocytes and immortalized melanocytes. Knockdown of AEG-1 by small interfering RNA reduced the tumorigenic properties of highly aggressive neuroblastoma cells. Conversely, over-expression of AEG-1 enhanced proliferation and expression of the transformed state in less aggressive neuroblastoma cells through activation of the phosphatidylinositol 3-kinase-Akt-signaling pathway and stabilization of MYCN. These provocative results indicate that AEG-1 may play a crucial role in the pathogenesis of neuroblastoma and could represent a potential target for therapeutic intervention. Oncogene (2009) 28, 2476-2484; doi:10.1038/onc.2009.93; published online 18 May 2009	[Lee, S-G; Jeon, H-Y; Su, Z-Z; Richards, J. E.; Vozhilla, N.; Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, Sch Med, Dept Human & Mol Genet, Richmond, VA 23298 USA; [Lee, S-G; Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, Sch Med, VCU Massey Canc Ctr, Richmond, VA 23298 USA; [Van Maerken, T.] Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium; [Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Ghent University; Ghent University Hospital; Virginia Commonwealth University	Fisher, PB (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Human & Mol Genet, 1101 E Marshall St,Sanger Hall Bldg,Room 11-015, Richmond, VA 23298 USA.	sglee@vcu.edu; pbfisher@vcu.edu	Lee, Seok-Geun/B-3408-2011	Lee, Seok-Geun/0000-0002-0060-5777	NATIONAL CANCER INSTITUTE [R01CA035675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031492] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA035675] Funding Source: Medline; NINDS NIH HHS [P01 NS31492] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029; Emdad L, 2007, PHARMACOL THERAPEUT, V114, P155, DOI 10.1016/j.pharmthera.2007.01.010; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Ishola TA, 2007, BBA-GEN SUBJECTS, V1770, P927, DOI 10.1016/j.bbagen.2007.02.002; Kang DC, 2005, GENE, V353, P8, DOI [10.1016/j.gene.2005.04.006, 10.1016/j.gene.2005.04.005]; Kang J, 2008, ONCOGENE, V27, P3999, DOI 10.1038/onc.2008.15; Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572; Lee SG, 2008, ONCOGENE, V27, P1114, DOI 10.1038/sj.onc.1210713; Lee SG, 2008, J BIOL CHEM, V283, P13116, DOI 10.1074/jbc.M707697200; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Sagulenko V, 2008, CARCINOGENESIS, V29, P1869, DOI 10.1093/carcin/bgn147; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Sarkar D, 2008, CANCER RES, V68, P1478, DOI 10.1158/0008-5472.CAN-07-6164; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Su ZZ, 2003, GENE, V306, P67, DOI 10.1016/S0378-1119(03)00404-9; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Van Maerken T, 2006, CANCER RES, V66, P9646, DOI 10.1158/0008-5472.CAN-06-0792; Van Maerken T, 2009, J CELL PHYSIOL, V219, P707, DOI 10.1002/jcp.21719; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yaari S, 2005, CLIN CANCER RES, V11, P4321, DOI 10.1158/1078-0432.CCR-04-2071; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yoo BK, 2009, J CLIN INVEST, V119, P465, DOI 10.1172/JCI36460; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245	35	98	114	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2476	2484		10.1038/onc.2009.93	http://dx.doi.org/10.1038/onc.2009.93			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19448665				2022-12-25	WOS:000267601400006
J	Liao, Y; Wei, Y; Zhou, X; Yang, JY; Dai, C; Chen, YJ; Agarwal, NK; Sarbassov, D; Shi, D; Yu, D; Hung, MC				Liao, Y.; Wei, Y.; Zhou, X.; Yang, J-Y; Dai, C.; Chen, Y-J; Agarwal, N. K.; Sarbassov, D.; Shi, D.; Yu, D.; Hung, M-C			Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation	ONCOGENE			English	Article						PKB/Akt; Pin1; peptidyl-prolyl cis/trans isomerase; breast cancer	PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTORS; BREAST-CANCER; AKT; PATHWAY; AKT/PKB; DISEASE; OVEREXPRESSION; TUMORIGENESIS; EXPRESSION	The serine/threonine protein kinase B (PKB, also known as Akt) plays a pivotal role in diverse cellular functions. Elevated expression of activated Akt has been detected in a wide variety of human cancers; however, the mechanism of Akt protein stability regulation remains unclear. In this study, we showed a strong correlation between the expression levels of an oncogenic peptidyl-prolyl cis/trans isomerase Pin1 and levels of Akt phosphorylation at S473 in multiple cancer types (P<0.0001). Akt-pS473 status combined with Pin1 expression levels predicted a poorer prognosis than did either one alone in patients with breast cancer (P = 0.0052). We further showed that Pin1 regulated Akt stability and phosphorylation on S473 through the phosphorylated Thr-Pro motifs of Akt. These motifs are conserved evolutionary and are required for the maintenance of Akt stability and its interaction with Pin1. In addition, repressing Pin1 expression through either homologue Pin1 knockout or small interfering RNA-mediated knockingdown compromised its ability to protect Akt from degradation. Our results show how Akt protein stability is regulated by the peptidyl-prolyl cis/trans isomerase Pin1 and highlight the importance of this oncogenic network in human disease pathogenesis. Oncogene (2009) 28, 2436-2445; doi: 10.1038/onc.2009.98; published online 18 May 2009	[Liao, Y.; Wei, Y.; Zhou, X.; Yang, J-Y; Chen, Y-J; Agarwal, N. K.; Sarbassov, D.; Yu, D.; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Liao, Y.; Dai, C.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; [Zhou, X.; Shi, D.] Fudan Univ, Canc Hosp, Dept Pathol, Shanghai 200433, Peoples R China; [Chen, Y-J; Hung, M-C] China Med Univ & Hosp, Ctr Mol Med, Taichung, Taiwan; [Chen, Y-J; Hung, M-C] China Med Univ & Hosp, Grad Inst Canc Biol, Taichung, Taiwan; [Hung, M-C] Asia Univ, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Fudan University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	yongliao@mdanderson.org; mhung@mdanderson.org	Sarbassov, Dos/AAS-4950-2020; Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Sarbassov, Dos/0000-0002-6848-1133; Yu, Dihua/0000-0001-6231-9381	NCI NIH HHS [P50 CA083639, P01 CA099031, P30 CA016672, P01 CA099031-01, R01 CA109311, P50 CA83639, P50-CA83639-A01, P20 CA101936-05, P50 CA083639-090009, P20 CA101936, P50 CA116199, P50 CA116199-04] Funding Source: Medline; PHS HHS [P01 099031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109311, P50CA083639, P30CA016672, P50CA116199, P01CA099031, P20CA101936] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Bayascas JR, 2005, MOL CELL, V18, P143, DOI 10.1016/j.molcel.2005.03.020; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHAN TO, 2001, SCI STKE, pPE1; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202; Du KY, 2005, ONCOGENE, V24, P7401, DOI 10.1038/sj.onc.1209099; Dummler B, 2007, BIOCHEM SOC T, V35, P231, DOI 10.1042/BST0350231; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Finn G, 2008, CURR CANCER DRUG TAR, V8, P223, DOI 10.2174/156800908784293622; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Liao Y, 2003, MOL CELL BIOL, V23, P6836, DOI 10.1128/MCB.23.19.6836-6848.2003; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu KP, 2006, MOL CARCINOGEN, V45, P397, DOI 10.1002/mc.20216; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Soung YH, 2006, ONCOLOGY-BASEL, V70, P285, DOI 10.1159/000096289; Takahashi K, 2008, CELL MOL LIFE SCI, V65, P359, DOI 10.1007/s00018-007-7270-0; Testa JR, 2005, ONCOGENE, V24, P7391, DOI 10.1038/sj.onc.1209100; Tokunaga E, 2008, CURR CANCER DRUG TAR, V8, P27, DOI 10.2174/156800908783497140; Wulf G, 2004, EMBO J, V23, P3397, DOI 10.1038/sj.emboj.7600323; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; Yang ZZ, 2004, BIOCHEM SOC T, V32, P350, DOI 10.1042/BST0320350; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yeh ES, 2007, NAT REV CANCER, V7, P381, DOI 10.1038/nrc2107; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120	45	69	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2436	2445		10.1038/onc.2009.98	http://dx.doi.org/10.1038/onc.2009.98			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19448664	Green Accepted			2022-12-25	WOS:000267601400002
J	Fonseca, NA; Vieira, CP; Vieira, J				Fonseca, Nuno A.; Vieira, Cristina P.; Vieira, Jorge			Gene Classification Based on Amino Acid Motifs and Residues: The DLX (distal-less) Test Case	PLOS ONE			English	Article								Background: Comparative studies using hundreds of sequences can give a detailed picture of the evolution of a given gene family. Nevertheless, retrieving only the sequences of interest from public databases can be difficult, in particular, when working with highly divergent sequences. The difficulty increases substantially when one wants to include in the study sequences from many (or less well studied) species whose genomes are non-annotated or incompletely annotated. Methodology/Principal Findings: In this work we evaluate the usefulness of different approaches of gene retrieval and classification, using the distal-less (DLX) gene family as a test case. Furthermore, we evaluate whether the use of a large number of gene sequences from a wide range of animal species, the use of multiple alternative alignments, and the use of amino acids aligned with high confidence only, is enough to recover the accepted DLX evolutionary history. Conclusions/Significance: The canonical DLX homeobox gene sequence here derived, together with the characteristic amino acid variants here identified in the DLX homeodomain region, can be used to retrieve and classify DLX genes in a simple and efficient way. A program is made available that allows the easy retrieval of synteny information that can be used to classify gene sequences. Maximum likelihood trees using hundreds of sequences can be used for gene identification. Nevertheless, for the DLX case, the proposed DLX evolutionary is not recovered even when multiple alignment algorithms are used.			Fonseca, NA (corresponding author), Univ Porto, IBMC, Rua Campo Alegre 823, P-4100 Oporto, Portugal.	jbvieira@ibmc.up.pt	Vieira, Cristina P./K-1775-2013; Fonseca, Nuno A./B-7801-2009; INESC-TEC, CRACS/F-7527-2012; Vieira, Jorge/J-7477-2013	Vieira, Cristina P./0000-0002-7139-2107; Fonseca, Nuno A./0000-0003-4832-578X; Vieira, Jorge/0000-0001-7032-5220				Adamska M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001031; Dunn CW, 2008, NATURE, V452, P745, DOI 10.1038/nature06614; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Ellies DL, 1997, GENOMICS, V45, P580, DOI 10.1006/geno.1997.4978; Essoussi N, 2008, BIOINFORMATION, V2, P452; Fonseca NA, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-200; Golubchik T, 2007, MOL BIOL EVOL, V24, P2433, DOI 10.1093/molbev/msm176; Holland PWH, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-47; Irvine SQ, 2007, J EXP ZOOL PART B, V308B, P428, DOI 10.1002/jez.b.21169; Kaiserman D, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-167; Monteiro AS, 2006, EVOL DEV, V8, P174, DOI 10.1111/j.1525-142X.2006.00087.x; Neidert AH, 2001, P NATL ACAD SCI USA, V98, P1665, DOI 10.1073/pnas.98.4.1665; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Sharkey M, 1997, TRENDS GENET, V13, P145, DOI 10.1016/S0168-9525(97)01096-2; Stock DW, 2005, GENETICS, V169, P807, DOI 10.1534/genetics.104.031831; Sumiyama Kenta, 2003, Journal of Structural and Functional Genomics, V3, P151, DOI 10.1023/A:1022682505914; Sundstrom G, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-254; Vieira J, 2008, J MOL EVOL, V67, P179, DOI 10.1007/s00239-008-9137-x; Wallace IM, 2006, NUCLEIC ACIDS RES, V34, P1692, DOI 10.1093/nar/gkl091; Zwickl D., 2006, GARLI GENETIC ALGORI	20	1	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2009	4	6							e5748	10.1371/journal.pone.0005748	http://dx.doi.org/10.1371/journal.pone.0005748			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	452GL	19484130	gold, Green Published, Green Submitted			2022-12-25	WOS:000266528200004
J	Habayeb, MS; Ekstrom, JO; Hultmark, D				Habayeb, Mazen S.; Ekstrom, Jens-Ola; Hultmark, Dan			Nora Virus Persistent Infections Are Not Affected by the RNAi Machinery	PLOS ONE			English	Article							DROSOPHILA-MELANOGASTER; ANTIVIRAL IMMUNITY; DISTINCT ROLES; DICER-2; DEFENSE; PATHWAY	Drosophila melanogaster is widely used to decipher the innate immune system in response to various pathogens. The innate immune response towards persistent virus infections is among the least studied in this model system. We recently discovered a picorna-like virus, the Nora virus which gives rise to persistent and essentially symptom-free infections in Drosophila melanogaster. Here, we have used this virus to study the interaction with its host and with some of the known Drosophila antiviral immune pathways. First, we find a striking variability in the course of the infection, even between flies of the same inbred stock. Some flies are able to clear the Nora virus but not others. This phenomenon seems to be threshold-dependent; flies with a high-titer infection establish stable persistent infections, whereas flies with a lower level of infection are able to clear the virus. Surprisingly, we find that both the clearance of low-level Nora virus infections and the stability of persistent infections are unaffected by mutations in the RNAi pathways. Nora virus infections are also unaffected by mutations in the Toll and Jak-Stat pathways. In these respects, the Nora virus differs from other studied Drosophila RNA viruses.			Habayeb, MS (corresponding author), Umea Univ, Dept Mol Biol, Umea, Sweden.	dan.hultmark@ucmp.umu.se	Hultmark, Dan/C-5058-2013	Hultmark, Dan/0000-0002-6506-5855				ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; BRUN G, 1980, GENET BIOL DROSOPHIL, P625; Cherry S, 2004, NAT IMMUNOL, V5, P81, DOI 10.1038/ni1019; Chotkowski HL, 2008, VIROLOGY, V377, P197, DOI 10.1016/j.virol.2008.04.021; Deddouche S, 2008, NAT IMMUNOL, V9, P1425, DOI 10.1038/ni.1664; Ding SW, 2007, CELL, V130, P413, DOI 10.1016/j.cell.2007.07.039; Dostert C, 2005, NAT IMMUNOL, V6, P946, DOI 10.1038/ni1237; Galiana-Arnoux D, 2006, NAT IMMUNOL, V7, P590, DOI 10.1038/ni1335; GOMARIZZILBER E, 1995, J INVERTEBR PATHOL, V65, P243, DOI 10.1006/jipa.1995.1037; Habayeb MS, 2006, J GEN VIROL, V87, P3045, DOI 10.1099/vir.0.81997-0; Habayeb MS, 2009, J INVERTEBR PATHOL, V101, P29, DOI 10.1016/j.jip.2009.02.003; Hammond SM, 2005, FEBS LETT, V579, P5822, DOI 10.1016/j.febslet.2005.08.079; JOUSSET FX, 1975, ANN INST PASTEUR MIC, VB126, P231; Kavi HH, 2008, CURR TOP MICROBIOL, V320, P37; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Lin HF, 1997, DEVELOPMENT, V124, P2463; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; TENINGES D, 1979, J GEN VIROL, V42, P241, DOI 10.1099/0022-1317-42-2-241; van Rij RP, 2006, GENE DEV, V20, P2985, DOI 10.1101/gad.1482006; Wang XH, 2006, SCIENCE, V312, P452, DOI 10.1126/science.1125694; Xu KY, 2004, CURR BIOL, V14, P1025, DOI 10.1016/j.cub.2004.05.055; Zambon RA, 2006, CELL MICROBIOL, V8, P880, DOI 10.1111/j.1462-5822.2006.00688.x; Zambon RA, 2005, P NATL ACAD SCI USA, V102, P7257, DOI 10.1073/pnas.0409181102; Zamore PD, 2007, NATURE, V446, P864, DOI 10.1038/446864a	26	27	27	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5731	10.1371/journal.pone.0005731	http://dx.doi.org/10.1371/journal.pone.0005731			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451SH	19478998	Green Submitted, gold, Green Published			2022-12-25	WOS:000266490000008
J	Vidali, L; Rounds, CM; Hepler, PK; Bezanilla, M				Vidali, Luis; Rounds, Caleb M.; Hepler, Peter K.; Bezanilla, Magdalena			Lifeact-mEGFP Reveals a Dynamic Apical F-Actin Network in Tip Growing Plant Cells	PLOS ONE			English	Article								Background: Actin is essential for tip growth in plants. However, imaging actin in live plant cells has heretofore presented challenges. In previous studies, fluorescent probes derived from actin-binding proteins often alter growth, cause actin bundling and fail to resolve actin microfilaments. Methodology/Principal Findings: In this report we use Lifeact-mEGFP, an actin probe that does not affect the dynamics of actin, to visualize actin in the moss Physcomitrella patens and pollen tubes from Lilium formosanum and Nicotiana tobaccum. Lifeact-mEGFP robustly labels actin microfilaments, particularly in the apex, in both moss protonemata and pollen tubes. Lifeact-mEGFP also labels filamentous actin structures in other moss cell types, including cells of the gametophore. Conclusions/Significance: Lifeact-mEGFP, when expressed at optimal levels does not alter moss protonemal or pollen tube growth. We suggest that Lifeact-mEGFP represents an exciting new versatile probe for further studies of actin's role in tip growing plant cells.			Vidali, L (corresponding author), Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.	bezanilla@bio.umass.edu	Vidali, Luis/F-6931-2014	Vidali, Luis/0000-0002-5835-4587	Div Of Molecular and Cellular Bioscience [0747231] Funding Source: National Science Foundation	Div Of Molecular and Cellular Bioscience(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))		Augustine RC, 2008, PLANT J, V54, P863, DOI 10.1111/j.1365-313X.2008.03451.x; Bezanilla M, 2005, PLANT BIOLOGY, V7, P251, DOI 10.1055/s-2005-837597; Bezanilla M, 2003, PLANT PHYSIOL, V133, P470, DOI 10.1104/pp.103.024901; Bove J, 2008, PLANT PHYSIOL, V147, P1646, DOI 10.1104/pp.108.120212; Cardenas L, 2008, PLANT PHYSIOL, V146, P1611, DOI 10.1104/pp.107.113035; Chen CY, 2002, PLANT CELL, V14, P2175, DOI 10.1105/tpc.003038; Cheung AY, 2008, MOL PLANT, V1, P686, DOI 10.1093/mp/ssn026; Cheung AY, 2004, PLANT CELL, V16, P257, DOI 10.1105/tpc.016550; Deeks MJ, 2005, NEW PHYTOL, V168, P529, DOI 10.1111/j.1469-8137.2005.01582.x; Fan XX, 2004, PLANT PHYSIOL, V136, P3979, DOI 10.1104/pp.104.046326; Finka A, 2008, CELL MOTIL CYTOSKEL, V65, P769, DOI 10.1002/cm.20298; Finka A, 2007, NEW PHYTOL, V174, P63, DOI 10.1111/j.1469-8137.2007.01989.x; Foissner I, 2002, PROTOPLASMA, V220, P1, DOI 10.1007/s00709-002-0032-9; Fu Y, 2001, J CELL BIOL, V152, P1019, DOI 10.1083/jcb.152.5.1019; Gu Y, 2003, J EXP BOT, V54, P93, DOI 10.1093/jxb/54.380.93; Hamilton DA, 1998, PLANT MOL BIOL, V38, P663, DOI 10.1023/A:1006083725102; Harries PA, 2005, PLANT CELL, V17, P2327, DOI 10.1105/tpc.105.033266; Hwang JU, 2005, MOL BIOL CELL, V16, P5385, DOI 10.1091/mbc.E05-05-0409; Ketelaar T, 2004, PLANT PHYSIOL, V136, P3990, DOI 10.1104/pp.104.050799; Kost B, 1998, PLANT J, V16, P393, DOI 10.1046/j.1365-313x.1998.00304.x; Kovar DR, 2004, P NATL ACAD SCI USA, V101, P14725, DOI 10.1073/pnas.0405902101; Li HB, 2008, NAT CELL BIOL, V10, P1301, DOI 10.1038/ncb1788; Li Y, 2001, PLANTA, V213, P722, DOI 10.1007/s004250100543; Lovy-Wheeler A, 2005, PLANTA, V221, P95, DOI 10.1007/s00425-004-1423-2; McKenna ST, 2004, PLANTA, V218, P906, DOI 10.1007/s00425-003-1174-5; Menand B, 2007, J EXP BOT, V58, P1843, DOI 10.1093/jxb/erm047; MESKE V, 1995, PROTOPLASMA, V188, P59, DOI 10.1007/BF01276796; Miller DD, 1996, PROTOPLASMA, V195, P123, DOI 10.1007/BF01279191; Perroud PF, 2006, CELL MOTIL CYTOSKEL, V63, P162, DOI 10.1002/cm.20114; Raudaskoski M, 2001, J PLANT GROWTH REGUL, V20, P113, DOI 10.1007/s003440010015; Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220; Staiger CJ, 2009, J CELL BIOL, V184, P269, DOI 10.1083/jcb.200806185; TANG XJ, 1989, CELL MOTIL CYTOSKEL, V12, P216, DOI 10.1002/cm.970120404; TIWARI SC, 1988, PROTOPLASMA, V147, P5, DOI 10.1007/BF01403873; TWELL D, 1990, DEVELOPMENT, V109, P705; Vidali L, 2001, MOL BIOL CELL, V12, P2534, DOI 10.1091/mbc.12.8.2534; Vidali L, 2007, PLANT CELL, V19, P3705, DOI 10.1105/tpc.107.053413; Walker LM, 1995, PROTOPLASMA, V189, P229, DOI 10.1007/BF01280177; Wilsen KL, 2006, SEX PLANT REPROD, V19, P51, DOI 10.1007/s00497-006-0021-9; Xiang Y, 2007, PLANT CELL, V19, P1930, DOI 10.1105/tpc.106.048413	40	161	166	2	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5744	10.1371/journal.pone.0005744	http://dx.doi.org/10.1371/journal.pone.0005744			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451SH	19478943	Green Published, gold, Green Submitted			2022-12-25	WOS:000266490000018
J	Conti, AC; Maas, JW; Moulder, KL; Jiang, XP; Dave, BA; Mennerick, S; Muglia, LJ				Conti, Alana C.; Maas, James W., Jr.; Moulder, Krista L.; Jiang, Xiaoping; Dave, Bhumy A.; Mennerick, Steven; Muglia, Louis J.			Adenylyl Cyclases 1 and 8 Initiate a Presynaptic Homeostatic Response to Ethanol Treatment	PLOS ONE			English	Article								Background: Although ethanol exerts widespread action in the brain, only recently has progress been made in understanding the specific events occurring at the synapse during ethanol exposure. Mice deficient in the calcium-stimulated adenylyl cyclases, AC1 and AC8 (DKO), demonstrate increased sedation duration and impaired phosphorylation by protein kinase A (PKA) following acute ethanol treatment. While not direct targets for ethanol, we hypothesize that these cyclases initiate a homeostatic presynaptic response by PKA to reactivate neurons from ethanol-mediated inhibition. Methodology/Principal Findings: Here, we have used phosphoproteomic techniques and identified several presynaptic proteins that are phosphorylated in the brains of wild type mice (WT) after ethanol exposure, including synapsin, a known PKA target. Phosphorylation of synapsins I and II, as well as phosphorylation of non-PKA targets, such as, eukaryotic elongation factor-2 (eEF-2) and dynamin is significantly impaired in the brains of DKO mice. This deficit is primarily driven by AC1, as AC1-deficient, but not AC8-deficient mice also demonstrate significant reductions in phosphorylation of synapsin and eEF-2 in cortical and hippocampal tissues. DKO mice have a reduced pool of functional recycling vesicles and fewer active terminals as measured by FM1-43 uptake compared to WT controls, which may be a contributing factor to the impaired presynaptic response to ethanol treatment. Conclusions/Significance: These data demonstrate that calcium-stimulated AC-dependent PKA activation in the presynaptic terminal, primarily driven by AC1, is a critical event in the reactivation of neurons following ethanol-induced activity blockade.			Conti, AC (corresponding author), Washington Univ, Dept Pediat, St Louis, MO 63130 USA.	contia@psychiatry.wustl.edu	Mennerick, Steven/O-2806-2017	Mennerick, Steven/0000-0003-0868-0664	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD049305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH078823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054174, P30NS057105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012957, R01AA012952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K01DA018109] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA12952, R01 AA012952, R01 AA012957, AA12957] Funding Source: Medline; NICHD NIH HHS [HD049305, T32 HD049305] Funding Source: Medline; NIDA NIH HHS [DA018109, K01 DA018109] Funding Source: Medline; NIMH NIH HHS [R01 MH078823, MH78823] Funding Source: Medline; NINDS NIH HHS [R01 NS054174, NS54174, P30NS057105, P30 NS057105] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anggono V, 2006, NAT NEUROSCI, V9, P752, DOI 10.1038/nn1695; Bredemeyer AJ, 2004, P NATL ACAD SCI USA, V101, P11785, DOI 10.1073/pnas.0402353101; CALI JJ, 1994, J BIOL CHEM, V269, P12190; Carpenter-Hyland EP, 2004, J NEUROSCI, V24, P7859, DOI 10.1523/JNEUROSCI.1902-04.2004; Carpenter-Hyland EP, 2006, EUR J NEUROSCI, V24, P3496, DOI 10.1111/j.1460-9568.2006.05247.x; Chi P, 2001, NAT NEUROSCI, V4, P1187, DOI 10.1038/nn756; Constantinescu A, 2004, J BIOL CHEM, V279, P43321, DOI 10.1074/jbc.M406994200; Constantinescu A, 2002, J BIOL CHEM, V277, P18810, DOI 10.1074/jbc.M112107200; Constantinescu A, 1999, J BIOL CHEM, V274, P26985, DOI 10.1074/jbc.274.38.26985; Conti AC, 2007, NEUROSCIENCE, V146, P713, DOI 10.1016/j.neuroscience.2007.01.045; Cousin MA, 1997, J NEUROCHEM, V69, P1927; Evans GJO, 2003, BIOCHEM SOC T, V31, P824, DOI 10.1042/bst0310824; Ferguson SM, 2007, SCIENCE, V316, P570, DOI 10.1126/science.1140621; Fujita K, 2006, FEMS YEAST RES, V6, P744, DOI 10.1111/j.1567-1364.2006.00040.x; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Harata N, 2001, TRENDS NEUROSCI, V24, P637, DOI 10.1016/S0166-2236(00)02030-0; Hong-Brown LQ, 2007, J BIOL CHEM, V282, P3702, DOI 10.1074/jbc.M606593200; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; Kuromi H, 2000, NEURON, V27, P133, DOI 10.1016/S0896-6273(00)00015-5; Lonart G, 2003, CELL, V115, P49, DOI 10.1016/S0092-8674(03)00727-X; Lu HC, 2006, J NEUROSCI, V26, P2692, DOI 10.1523/JNEUROSCI.3956-05.2006; Maas JW, 2005, J NEUROSCI, V25, P4118, DOI 10.1523/JNEUROSCI.4273-04.2005; Menegon A, 2006, J NEUROSCI, V26, P11670, DOI 10.1523/JNEUROSCI.3321-06.2006; Mozhayeva MG, 2002, J NEUROSCI, V22, P654, DOI 10.1523/JNEUROSCI.22-03-00654.2002; Murthy VN, 2001, NEURON, V32, P673, DOI 10.1016/S0896-6273(01)00500-1; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; REDPATH NT, 1993, BIOCHEM J, V293, P31, DOI 10.1042/bj2930031; Schaefer ML, 2000, J NEUROSCI, V20, P4809; Smillie KJ, 2005, BIOCHEM SOC SYMP, V72, P87, DOI 10.1042/bss0720087; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Sudhof TC, 2000, NEURON, V28, P317, DOI 10.1016/S0896-6273(00)00109-4; Sun JY, 2006, P NATL ACAD SCI USA, V103, P2880, DOI 10.1073/pnas.0511300103; TANG WJ, 1991, J BIOL CHEM, V266, P8595; Torok N, 1997, GASTROENTEROLOGY, V113, P1938, DOI 10.1016/S0016-5085(97)70014-3; VALTORTA F, 1992, J BIOL CHEM, V267, P7195; Villacres EC, 1998, J NEUROSCI, V18, P3186; Voss M, 2007, J BIOL CHEM, V282, P33735, DOI 10.1074/jbc.M703368200; Wand G, 2001, J NEUROSCI, V21, P5297, DOI 10.1523/JNEUROSCI.21-14-05297.2001; Wang HB, 2003, J NEUROSCI, V23, P9710; Wong ST, 1999, NEURON, V23, P787, DOI 10.1016/S0896-6273(01)80036-2; Yang XJ, 1996, J PHARMACOL EXP THER, V278, P338	41	23	23	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2009	4	5							e5697	10.1371/journal.pone.0005697	http://dx.doi.org/10.1371/journal.pone.0005697			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QD	19479030	Green Published, gold, Green Submitted			2022-12-25	WOS:000266415000010
J	Konno, H; Yamamoto, T; Yamazaki, K; Gohda, J; Akiyama, T; Semba, K; Goto, H; Kato, A; Yujiri, T; Imai, T; Kawaguchi, Y; Su, B; Takeuchi, O; Akira, S; Tsunetsugu-Yokota, Y; Inoue, J				Konno, Hiroyasu; Yamamoto, Takuya; Yamazaki, Kohsuke; Gohda, Jin; Akiyama, Taishin; Semba, Kentaro; Goto, Hideo; Kato, Atsushi; Yujiri, Toshiaki; Imai, Takahiko; Kawaguchi, Yasushi; Su, Bing; Takeuchi, Osamu; Akira, Shizuo; Tsunetsugu-Yokota, Yasuko; Inoue, Jun-ichiro			TRAF6 Establishes Innate Immune Responses by Activating NF-kappa B and IRF7 upon Sensing Cytosolic Viral RNA and DNA	PLOS ONE			English	Article								Background: In response to viral infection, the innate immune system recognizes viral nucleic acids and then induces production of proinflammatory cytokines and type I interferons (IFNs). Toll-like receptor 7 (TLR7) and TLR9 detect viral RNA and DNA, respectively, in endosomal compartments, leading to the activation of nuclear factor kappa B (NF-kappa B) and IFN regulatory factors (IRFs) in plasmacytoid dendritic cells. During such TLR signaling, TNF receptor-associated factor 6 (TRAF6) is essential for the activation of NF-kappa B and the production of type I IFN. In contrast, RIG-like helicases (RLHs), cytosolic RNA sensors, are indispensable for antiviral responses in conventional dendritic cells, macrophages, and fibroblasts. However, the contribution of TRAF6 to the detection of cytosolic viral nucleic acids has been controversial, and the involvement of TRAF6 in IRF activation has not been adequately addressed. Principal Findings: Here we first show that TRAF6 plays a critical role in RLH signaling. The absence of TRAF6 resulted in enhanced viral replication and a significant reduction in the production of IL-6 and type I IFNs after infection with RNA virus. Activation of NF-kappa B and IRF7, but not that of IRF3, was significantly impaired during RLH signaling in the absence of TRAF6. TGF beta-activated kinase 1 (TAK1) and MEKK3, whose activation by TRAF6 during TLR signaling is involved in NF-kappa B activation, were not essential for RLH-mediated NF-kappa B activation. We also demonstrate that TRAF6-deficiency impaired cytosolic DNA-induced antiviral responses, and this impairment was due to defective activation of NF-kappa B and IRF7. Conclusions/Significance: Thus, TRAF6 mediates antiviral responses triggered by cytosolic viral DNA and RNA in a way that differs from that associated with TLR signaling. Given its essential role in signaling by various receptors involved in the acquired immune system, TRAF6 represents a key molecule in innate and antigen-specific immune responses against viral infection.			Konno, H (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol, Tokyo, Japan.	jun-i@ims.u-tokyo.ac.jp	Takeuchi, Osamu/AAG-9359-2019; Takeuchi, Osamu/D-6007-2011; Akira, Shizuo/C-3134-2009; Yamamoto, Takuya/L-2642-2013; Yujiri, Toshiaki/AAY-8150-2020	Takeuchi, Osamu/0000-0002-1260-6232; Yamamoto, Takuya/0000-0003-3753-1211; Yujiri, Toshiaki/0000-0001-6838-3456; Kawaguchi, Yasushi/0000-0001-8232-6925; Akiyama, Taishin/0000-0002-0341-6154				Ahonen CL, 2002, NAT IMMUNOL, V3, P451, DOI 10.1038/ni792; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Balachandran S, 2007, J IMMUNOL, V178, P2429, DOI 10.4049/jimmunol.178.4.2429; Bidere N, 2006, CURR BIOL, V16, P1666, DOI 10.1016/j.cub.2006.06.062; Bowie AG, 2008, NAT REV IMMUNOL, V8, P911, DOI 10.1038/nri2436; Burckstummer T, 2009, NAT IMMUNOL, V10, P266, DOI 10.1038/ni.1702; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Gitlin L, 2006, P NATL ACAD SCI USA, V103, P8459, DOI 10.1073/pnas.0603082103; Gohda J, 2004, J IMMUNOL, V173, P2913, DOI 10.4049/jimmunol.173.5.2913; Guo BC, 2007, J BIOL CHEM, V282, P11817, DOI 10.1074/jbc.M700017200; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Hoshino K, 2006, NATURE, V440, P949, DOI 10.1038/nature04641; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishii KJ, 2006, TRENDS IMMUNOL, V27, P525, DOI 10.1016/j.it.2006.09.002; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kato A, 1997, EMBO J, V16, P578, DOI 10.1093/emboj/16.3.578; Kato A, 2007, J VIROL, V81, P3264, DOI 10.1128/JVI.02590-06; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; King CG, 2006, NAT MED, V12, P1088, DOI 10.1038/nm1449; Kitamura T, 1998, INT J HEMATOL, V67, P351; Komatsu T, 2004, VIROLOGY, V325, P137, DOI 10.1016/j.virol.2004.04.025; Kumagai Y, 2007, IMMUNITY, V27, P240, DOI 10.1016/j.immuni.2007.07.013; Kumar H, 2006, J EXP MED, V203, P1795, DOI 10.1084/jem.20060792; Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Ning SB, 2008, MOL CELL BIOL, V28, P6536, DOI 10.1128/MCB.00785-08; Nomura F, 2000, GENES CELLS, V5, P191; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Paz S, 2006, CELL MOL BIOL, V52, P17, DOI 10.1170/T694; Pichlmair A, 2007, IMMUNITY, V27, P370, DOI 10.1016/j.immuni.2007.08.012; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Prakash A, 2006, BIOCHEM BIOPH RES CO, V342, P50, DOI 10.1016/j.bbrc.2006.01.122; Roberts TL, 2009, SCIENCE, V323, P1057, DOI 10.1126/science.1169841; Rothenfusser S, 2005, J IMMUNOL, V175, P5260, DOI 10.4049/jimmunol.175.8.5260; Saha SK, 2006, EMBO J, V25, P3257, DOI 10.1038/sj.emboj.7601220; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Stetson DB, 2006, IMMUNITY, V24, P93, DOI 10.1016/j.immuni.2005.12.003; Sun QM, 2006, IMMUNITY, V24, P633, DOI 10.1016/j.immuni.2006.04.004; Takahashi K, 2006, J IMMUNOL, V176, P4520, DOI 10.4049/jimmunol.176.8.4520; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Takaoka A, 2007, NATURE, V448, P501, DOI 10.1038/nature06013; Tanaka M, 2003, J VIROL, V77, P1382, DOI 10.1128/JVI.77.2.1382-1391.2003; Uematsu S, 2005, J EXP MED, V201, P915, DOI 10.1084/jem.20042372; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang XY, 2007, J IMMUNOL, V178, P6770, DOI 10.4049/jimmunol.178.11.6770; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yanai H, 2007, P NATL ACAD SCI USA, V104, P3402, DOI 10.1073/pnas.0611559104; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Yoshida R, 2008, J BIOL CHEM, V283, P36211, DOI 10.1074/jbc.M806576200; Yujiri T, 2003, J BIOL CHEM, V278, P3846, DOI 10.1074/jbc.M206087200; Zhao TJ, 2007, NAT IMMUNOL, V8, P592, DOI 10.1038/ni1465	73	78	92	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2009	4	5							e5674	10.1371/journal.pone.0005674	http://dx.doi.org/10.1371/journal.pone.0005674			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LI	19479062	Green Published, Green Submitted, gold			2022-12-25	WOS:000266331700003
J	Watts, SW; Priestley, JRC; Thompson, JM				Watts, Stephanie W.; Priestley, Jessica R. C.; Thompson, Janice M.			Serotonylation of Vascular Proteins Important to Contraction	PLOS ONE			English	Article								Background: Serotonin (5-hydroxytryptamine, 5-HT) was named for its source (sero-) and ability to modify smooth muscle tone (tonin). The biological effects of 5-HT are believed to be carried out by stimulation of serotonin receptors at the plasma membrane. Serotonin has recently been shown to be synthesized in vascular smooth muscle and taken up from external sources, placing 5-HT inside the cell. The enzyme transglutaminase uses primary amines such as 5-HT to covalently modify proteins on glutamine residues. We tested the hypothesis that 5-HT is a substrate for transglutaminase in arterial vascular smooth muscle, with protein serotonylation having physiological function. Methodology/Principal Findings: The model was the rat aorta and cultured aortic smooth muscle cells. Western analysis demonstrated that transglutaminase II was present in vascular tissue, and transglutaminase activity was observed as a cystamine-inhibitable incorporation of the free amine pentylamine-biotin into arterial proteins. Serotonin-biotin was incorporated into alpha-actin, beta-actin, gamma-actin, myosin heavy chain and filamin A as shown through tandem mass spectrometry. Using antibodies directed against biotin or 5-HT, immunoprecipitation and immunocytochemistry confirmed serotonylation of smooth muscle alpha-actin. Importantly, the alpha-actin-dependent process of arterial isometric contraction to 5-HT was reduced by cystamine. Conclusions: 5-HT covalently modifies proteins integral to contractility and the cytoskeleton. These findings suggest new mechanisms of action for 5-HT in vascular smooth muscle and consideration for intracellular effects of primary amines.			Watts, SW (corresponding author), Michigan State Univ, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA.	wattss@msu.edu	Priestley, Jessica/AAF-1665-2022; Priestley, Jessica/AFG-7149-2022; Priestley, Jessica/AAE-5410-2022	Priestley, Jessica/0000-0001-5457-7188	NHLBI NIH HHS [R01 HL081115, HL81115] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081115] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER JS, 1987, BIOCHEM BIOPH RES CO, V143, P152, DOI 10.1016/0006-291X(87)90643-7; Bakker ENTP, 2005, CIRC RES, V96, P119, DOI 10.1161/01.RES.0000151333.56089.66; Begg GE, 2006, P NATL ACAD SCI USA, V103, P19683, DOI 10.1073/pnas.0609283103; Bernassola F, 1999, ANN NY ACAD SCI, V887, P83, DOI 10.1111/j.1749-6632.1999.tb07924.x; Candi E, 2004, BIOCHEM J, V381, P313, DOI 10.1042/BJ20031474; Chowdhury ZA, 1997, EXP CELL RES, V231, P38, DOI 10.1006/excr.1996.3448; Dale GL, 2002, NATURE, V415, P175, DOI 10.1038/415175a; Dempsie Y, 2008, BRIT J PHARMACOL, V155, P455, DOI 10.1038/bjp.2008.241; Eddahibi S, 2006, ARCH MAL COEUR VAISS, V99, P621; Esposito C, 2007, CURR MED CHEM, V14, P2572, DOI 10.2174/092986707782023343; Fanburg BL, 1997, AM J PHYSIOL-LUNG C, V272, pL795, DOI 10.1152/ajplung.1997.272.5.L795; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Guilluy C, 2007, J BIOL CHEM, V282, P2918, DOI 10.1074/jbc.M604195200; Gupta M, 2007, J VASC RES, V44, P339, DOI 10.1159/000102277; Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091-3057(01)00746-8; IISMAA SE, 2006, SCI STKE, V353, pPE34; Jeitner TM, 2005, BIOCHEM PHARMACOL, V69, P961, DOI 10.1016/j.bcp.2004.12.011; Johnson TS, 1997, J CLIN INVEST, V99, P2950, DOI 10.1172/JCI119490; Kang SK, 2004, J BIOL CHEM, V279, P36593, DOI 10.1074/jbc.M402084200; KAUMANN AJ, 2006, PHARMACOL THERAPEUT, V111, P67; Kim SY, 2006, FRONT BIOSCI-LANDMRK, V11, P3026, DOI 10.2741/2030; Lai TS, 2007, FASEB J, V21, P4131, DOI 10.1096/fj.06-7598com; Lai TS, 2001, BIOCHEMISTRY-US, V40, P4904, DOI 10.1021/bi002321t; LINDER AE, 2008, J PHARMACOL EXP THER, V325, P1031; Miyazaki M, 2007, J CARDIOVASC PHARM, V49, P221, DOI 10.1097/FJC.0b013e3180325af3; NEMECEK GM, 1986, P NATL ACAD SCI USA, V83, P674, DOI 10.1073/pnas.83.3.674; Nguelefack TB, 2005, PHYTOTHER RES, V19, P207, DOI 10.1002/ptr.1646; Ni W, 2008, BRIT J PHARMACOL, V154, P663, DOI 10.1038/bjp.2008.111; Ni W, 2004, J CARDIOVASC PHARM, V43, P770, DOI 10.1097/00005344-200406000-00006; Ogden K, 2006, AM J PHYSIOL-HEART C, V291, pH2857, DOI 10.1152/ajpheart.00229.2006; Ou HS, 2000, CIRC RES, V87, P881, DOI 10.1161/01.RES.87.10.881; Pardin C, 2008, J ORG CHEM, V73, P5766, DOI 10.1021/jo8004843; Pistea A, 2008, J VASC RES, V45, P10, DOI 10.1159/000109073; Popowicz GM, 2006, TRENDS BIOCHEM SCI, V31, P411, DOI 10.1016/j.tibs.2006.05.006; Sakurada S, 2003, CIRC RES, V93, P548, DOI 10.1161/01.RES.0000090998.08629.60; Siegel M, 2007, PHARMACOL THERAPEUT, V115, P232, DOI 10.1016/j.pharmthera.2007.05.003; SMALL DH, 1984, P NATL ACAD SCI-BIOL, V81, P959, DOI 10.1073/pnas.81.3.959; Szasz R, 2002, BLOOD, V100, P2827, DOI 10.1182/blood-2002-02-0354; Villalon CM, 2007, N-S ARCH PHARMACOL, V376, P45, DOI 10.1007/s00210-007-0179-1; Walther DJ, 2003, CELL, V115, P851, DOI 10.1016/S0092-8674(03)01014-6; Watts SW, 2005, CLIN SCI, V108, P399, DOI 10.1042/CS20040364; Woo CH, 2006, BIOCHEM BIOPH RES CO, V351, P972, DOI 10.1016/j.bbrc.2006.10.154; Yildiz O, 1998, LIFE SCI, V62, P1723, DOI 10.1016/S0024-3205(97)01166-1	43	75	76	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2009	4	5							e5682	10.1371/journal.pone.0005682	http://dx.doi.org/10.1371/journal.pone.0005682			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LI	19479059	Green Published, gold, Green Submitted			2022-12-25	WOS:000266331700010
J	Prabakaran, M; Prabhu, N; He, F; Hongliang, Q; Ho, HT; Qiang, J; Meng, T; Goutama, M; Kwang, J				Prabakaran, Mookkan; Prabhu, Nayana; He, Fang; Hongliang, Qian; Ho, Hui-Ting; Qiang, Jia; Meng, Tao; Goutama, Michael; Kwang, Jimmy			Combination Therapy Using Chimeric Monoclonal Antibodies Protects Mice from Lethal H5N1 Infection and Prevents Formation of Escape Mutants	PLOS ONE			English	Article							AVIAN INFLUENZA; VIRUS; HEMAGGLUTININ; NEUTRALIZATION; EFFICACY; IMMUNITY; ELISA	Background: Given that there is a possibility of a human H5N1 pandemic and the fact that the recent H5N1 viruses are resistant to the anti-viral drugs, newer strategies for effective therapy are warranted. Previous studies show that single mAbs in immune prophylaxis can be protective against H5N1 infection. But a single mAb may not be effective in neutralization of a broad range of different strains of H5N1 and control of potential neutralization escape mutants. Methods/Principal Findings: We selected two mAbs which recognized different epitopes on the hemagglutinin molecule. These two mAbs could each neutralize in vitro escape mutants to the other and in combination could effectively neutralize viruses from clades 0, 1, 2.1, 2.2, 2.3, 4, 7 and 8 of influenza A H5N1 viruses. This combination of chimeric mAbs when administered passively, pre or post challenge with 10 MLD50 (50% mouse lethal dose) HPAI H5N1 influenza A viruses could protect 100% of the mice from two different clades of viruses (clades 1 and 2.1). We also tested the efficacy of a single dose of the combination of mAbs versus two doses. Two doses of the combination therapy not only affected early clearance of the virus from the lung but could completely prevent lung pathology of the H5N1 infected mice. No escape variants were detected after therapy. Conclusions/Significance: Our studies provide proof of concept that the synergistic action of two or more mAbs in combination is required for preventing the generation of escape mutants and also to enhance the therapeutic efficacy of passive therapy against H5N1 infection. Combination therapy may allow for a lower dose of antibody to be administered for passive therapy of influenza infection and hence can be made available at reduced economic costs during an outbreak.			Prabakaran, M (corresponding author), Natl Univ Singapore, Temasek Life Sci Lab, Singapore 117548, Singapore.	kwang@tll.org.sg		Prabakaran, Mookkan/0000-0002-9816-5908; Prabhu, Nayana/0000-0002-2350-6552				Bakker ABH, 2005, J VIROL, V79, P9062, DOI 10.1128/JVI.79.14.9062-9068.2005; Casadevall A, 2004, NAT REV MICROBIOL, V2, P695, DOI 10.1038/nrmicro974; de Jong MD, 2006, J CLIN VIROL, V35, P2, DOI 10.1016/j.jcv.2005.09.002; de Kruif J, 2007, ANNU REV MED, V58, P359, DOI 10.1146/annurev.med.58.061705.145053; Eren R, 2006, J VIROL, V80, P2654, DOI 10.1128/JVI.80.6.2654-2664.2006; Hanson BJ, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-126; He QG, 2007, CLIN VACCINE IMMUNOL, V14, P617, DOI 10.1128/CVI.00444-06; Jostock T, 2004, J IMMUNOL METHODS, V289, P65, DOI 10.1016/j.jim.2004.03.014; Kaverin NV, 2002, J GEN VIROL, V83, P2497, DOI 10.1099/0022-1317-83-10-2497; Le QM, 2005, NATURE, V437, P1108, DOI 10.1038/4371108a; Li A, 1998, J VIROL, V72, P3235, DOI 10.1128/JVI.72.4.3235-3240.1998; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; Lu JH, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-43; Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139; Prabakaran M, 2008, VIROLOGY, V380, P412, DOI 10.1016/j.virol.2008.08.002; Prabakaran M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004566; Prabhu N, 2009, J VIROL, V83, P2553, DOI 10.1128/JVI.02165-08; REED LJ, 1938, AM J HYG, V27; Sawyer LA, 2000, ANTIVIR RES, V47, P57, DOI 10.1016/S0166-3542(00)00111-X; SHAWLER DL, 1985, J IMMUNOL, V135, P1530; Simmons CP, 2007, PLOS MED, V4, P928, DOI 10.1371/journal.pmed.0040178; Suguitan AL, 2006, PLOS MED, V3, P1541, DOI 10.1371/journal.pmed.0030360; ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237; *US CDCP, 1999, BIOS MICR BIOM LAB; Veits J, 2008, VACCINE, V26, P1688, DOI 10.1016/j.vaccine.2008.01.016; Velumani S, 2008, J VIROL METHODS, V147, P219, DOI 10.1016/j.jviromet.2007.09.004; WEBSTER RG, 1991, VACCINE, V9, P303, DOI 10.1016/0264-410X(91)90055-B; World Health Organization, 2004, LAB BIOS MAN, V3rd; Xu WD, 2002, VACCINE, V20, P1956, DOI 10.1016/S0264-410X(02)00077-4; YOKOYAMA WM, 2004, CURRENT PROTOCOLS IM; Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359; Zwick MB, 2001, J VIROL, V75, P12198, DOI 10.1128/JVI.75.24.12198-12208.2001; 1995, ANN 1 SUPER SANITA, V31, P1	33	44	53	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2009	4	5							e5672	10.1371/journal.pone.0005672	http://dx.doi.org/10.1371/journal.pone.0005672			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LD	19478856	Green Published, gold, Green Submitted			2022-12-25	WOS:000266331200009
J	Daley, P; Michael, JS; Kalaiselvan, S; Latha, A; Mathai, D; John, KR; Pai, M				Daley, Peter; Michael, Joy Sarojini; Kalaiselvan, S.; Latha, Asha; Mathai, Dilip; John, K. R.; Pai, Madhukar			A Pilot Study of Short-Duration Sputum Pretreatment Procedures for Optimizing Smear Microscopy for Tuberculosis	PLOS ONE			English	Article							PULMONARY TUBERCULOSIS; DIAGNOSIS; CULTURE; SENSITIVITY; METHODOLOGY; PCR	Background: Direct sputum smear microscopy for tuberculosis (TB) lacks sensitivity for the detection of acid fast bacilli. Sputum pretreatment procedures may enhance sensitivity. We did a pilot study to compare the diagnostic accuracy and incremental yield of two short-duration (< 1 hour) sputum pretreatment procedures to optimize direct smears among patients with suspected TB at a referral hospital in India. Methodology/Findings: Blinded laboratory comparison of bleach and universal sediment processing (USP) pretreated centrifuged auramine smears to direct Ziehl-Neelsen (ZN) and direct auramine smears and to solid (Loweinstein-Jensen (LJ)) and liquid (BACTEC 460) culture. 178 pulmonary and extrapulmonary TB suspects were prospectively recruited during a one year period. Thirty six (20.2%) were positive by either solid or liquid culture. Direct ZN smear detected 22 of 36 cases and direct auramine smears detected 26 of 36 cases. Bleach and USP centrifugation detected 24 cases each, providing no incremental yield beyond direct smears. When compared to combined culture, pretreated smears were not more sensitive than direct smears (66.6% vs 61.1 (ZN) or 72.2 (auramine)), and were not more specific (92.3% vs 93.0 (ZN) or 97.2 (auramine). Conclusions/Significance: Short duration sputum pretreatment with bleach and USP centrifugation did not increase yield as compared to direct sputum smears. Further work is needed to confirm this in a larger study and also determine if longer duration pre-treatment might be effective in optimizing smear microscopy for TB.			Daley, P (corresponding author), Christian Med Coll Vellore, Dept Med, Vellore, Tamil Nadu, India.	madhukar.pai@mcgill.ca	Daley, Peter/J-8908-2017; PAL, MRINAL/ABG-9676-2020; Pai, Madhukar/AAX-9901-2021	Daley, Peter/0000-0001-7068-8056; PAL, MRINAL/0000-0002-1032-272X; Pai, Madhukar/0000-0003-3667-4536	CIHR [89918] Funding Source: Medline	CIHR(Canadian Institutes of Health Research (CIHR))		Angeby KAK, 2004, INT J TUBERC LUNG D, V8, P806; Bonnet M, 2008, CLIN INFECT DIS, V46, P1710, DOI 10.1086/587891; Bossuyt PM, 2003, CLIN CHEM LAB MED, V41, P68, DOI 10.1515/CCLM.2003.012; Cattamanchi A, 2008, J CLIN MICROBIOL, V46, P3325, DOI 10.1128/JCM.01175-08; Chakravorty S, 2005, J CLIN MICROBIOL, V43, P2703, DOI 10.1128/JCM.43.6.2703-2708.2005; Chakravorty S, 2005, J CLIN MICROBIOL, V43, P2697, DOI 10.1128/JCM.43.6.2697-2702.2005; Chakravorty S, 2005, J CLIN MICROBIOL, V43, P4357, DOI 10.1128/JCM.43.9.4357-4362.2005; den Hertog AL, 2009, INT J TUBERC LUNG D, V13, P466; Dinnes J, 2007, HEALTH TECHNOL ASSES, V11, P1, DOI 10.3310/hta11030; Frais S, 2001, INT ENDOD J, V34, P206, DOI 10.1046/j.1365-2591.2001.00371.x; Hargreaves NJ, 2001, INT J TUBERC LUNG D, V5, P847; Lawson L, 2007, TUBERCULOSIS, V87, P368, DOI 10.1016/j.tube.2007.02.002; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; Merid Y, 2009, INT J TUBERC LUNG D, V13, P136; Murray P.R., 2003, MANUAL CLIN MICROBIO, V8th; Pai M, 2006, EXPERT REV MOL DIAGN, V6, P509, DOI 10.1586/14737159.6.4.509; Pai M, 2008, PLOS MED, V5, P1043, DOI 10.1371/journal.pmed.0050156; Steingart K, 2006, LANCET INFECT DIS, V6, P570, DOI 10.1016/S1473-3099(06)70578-3; Ramsay A, 2006, INT J TUBERC LUNG D, V10, P256; SIDDIQI SH, 1984, AM REV RESPIR DIS, V130, P634; SLOSAREK M, 1977, J HYG EPID MICROB IM, V21, P7; Steingart KR, 2007, EXPERT REV ANTI-INFE, V5, P327, DOI 10.1586/14787210.5.3.327; Steingart KR, 2006, LANCET INFECT DIS, V6, P664, DOI 10.1016/S1473-3099(06)70602-8; Van Deun A, 2007, PRIORITIES TUBERCULO, P11; Warren JR, 2000, AM J RESP CRIT CARE, V161, P1559, DOI 10.1164/ajrccm.161.5.9908063; *WHO, 2005, IMPR DIAGN TUB OPT S; World Health Organization, 2008, GLOB TUB CONTR SURV; World Health Organization, 2006, GLOB PLAN STOP TB 20	28	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5626	10.1371/journal.pone.0005626	http://dx.doi.org/10.1371/journal.pone.0005626			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448AY	19461963	gold, Green Published, Green Submitted			2022-12-25	WOS:000266234700013
J	Watson, A; Ramirez, CV; Salud, E				Watson, Andrew; Ramirez, Cesar V.; Salud, Ellen			Predicting Visibility of Aircraft	PLOS ONE			English	Article							CONTRAST-SENSITIVITY; VISION RESEARCH; PERFORMANCE; QUEST	Visual detection of aircraft by human observers is an important element of aviation safety. To assess and ensure safety, it would be useful to be able to be able to predict the visibility, to a human observer, of an aircraft of specified size, shape, distance, and coloration. Examples include assuring safe separation among aircraft and between aircraft and unmanned vehicles, design of airport control towers, and efforts to enhance or suppress the visibility of military and rescue vehicles. We have recently developed a simple metric of pattern visibility, the Spatial Standard Observer (SSO). In this report we examine whether the SSO can predict visibility of simulated aircraft images. We constructed a set of aircraft images from three-dimensional computer graphic models, and measured the luminance contrast threshold for each image from three human observers. The data were well predicted by the SSO. Finally, we show how to use the SSO to predict visibility range for aircraft of arbitrary size, shape, distance, and coloration.			Watson, A (corresponding author), NASA, Ames Res Ctr, Moffett Field, VA USA.	Andrew.b.watson@nasa.gov						Ahumada A., 2007, J VISION, V7, P337, DOI [10.1167/7.9.337, DOI 10.1167/7.9.337]; Andrews J.W., 1977, AIR TO AIR VISUAL AC; ANDREWS JW, 1991, UNALERTED AIR TO AIR; Carney T, 2000, P SOC PHOTO-OPT INS, V3959, P140, DOI 10.1117/12.387150; COLVIN K, 2005, P 13 INT S AV, V13, P104; DUNTLEY SQ, 1964, APPL OPTICS, V3, P549, DOI 10.1364/AO.3.000549; Ginsburg A. P., 1983, Proceedings of the Human Factors Society 27th Annual Meeting, P269; GINSBURG AP, 1982, AM J OPTOM PHYS OPT, V59, P105; GRAHAM W, 1970, PR INST ELECTR ELECT, V58, P337, DOI 10.1109/PROC.1970.7639; HARRIS JL, 1973, VISUAL ASPECTS AIR C, P26; Howell W.D., 1957, DETERMINATION DAYTIM; OWSLEY C, 1983, VISION RES, V23, P689, DOI 10.1016/0042-6989(83)90210-9; ROHALY AM, 1993, J OPT SOC AM A, V10, P1591, DOI 10.1364/JOSAA.10.001591; Rosenkrans W., 2008, AEROSAFETY WORLD, P34; Vollmerhausen RH, 2004, OPT ENG, V43, P2806, DOI 10.1117/1.1799111; Watson AB, 1999, PERCEPTION, V28, P45; WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828; Watson AB, 2005, J VISION, V5, P717, DOI 10.1167/5.9.6; Watson AB, 2005, PROC SPIE, V5666, P1, DOI 10.1117/12.601935; WATSON AB, 1979, VISION RES, V19, P515, DOI 10.1016/0042-6989(79)90136-6; WATSON AB, 1986, BEHAV RES METH INSTR, V18, P587, DOI 10.3758/BF03201433; Watson AB, 1997, SPATIAL VISION, V10, P447, DOI 10.1163/156856897X00384; WATSON AB, 2000, SHOWTIME WEB SITE; Watson AB, 2008, J VISION, V8, DOI 10.1167/8.4.17; Wolfram S., 2003, MATH BOOK	25	11	13	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5594	10.1371/journal.pone.0005594	http://dx.doi.org/10.1371/journal.pone.0005594			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448AY	19462007	Green Published, gold, Green Submitted			2022-12-25	WOS:000266234700007
J	Al-Balas, Q; Anthony, NG; Al-Jaidi, B; Alnimr, A; Abbott, G; Brown, AK; Taylor, RC; Besra, GS; McHugh, TD; Gillespie, SH; Johnston, BF; Mackay, SP; Coxon, GD				Al-Balas, Qosay; Anthony, Nahoum G.; Al-Jaidi, Bilal; Alnimr, Amani; Abbott, Grainne; Brown, Alistair K.; Taylor, Rebecca C.; Besra, Gurdyal S.; McHugh, Timothy D.; Gillespie, Stephen H.; Johnston, Blair F.; Mackay, Simon P.; Coxon, Geoffrey D.			Identification of 2-Aminothiazole-4-Carboxylate Derivatives Active against Mycobacterium tuberculosis H37Rv and the beta-Ketoacyl-ACP Synthase mtFabH	PLOS ONE			English	Article								Background: Tuberculosis (TB) is a disease which kills two million people every year and infects approximately over one-third of the world's population. The difficulty in managing tuberculosis is the prolonged treatment duration, the emergence of drug resistance and co-infection with HIV/AIDS. Tuberculosis control requires new drugs that act at novel drug targets to help combat resistant forms of Mycobacterium tuberculosis and reduce treatment duration. Methodology/Principal Findings: Our approach was to modify the naturally occurring and synthetically challenging antibiotic thiolactomycin (TLM) to the more tractable 2-aminothiazole-4-carboxylate scaffold to generate compounds that mimic TLM's novel mode of action. We report here the identification of a series of compounds possessing excellent activity against M. tuberculosis H37Rv and, dissociatively, against the beta-ketoacyl synthase enzyme mtFabH which is targeted by TLM. Specifically, methyl 2-amino-5-benzylthiazole-4-carboxylate was found to inhibit M. tuberculosis H37Rv with an MIC of 0.06 mu g/ml (240 nM), but showed no activity against mtFabH, whereas methyl 2-(2-bromoacetamido)-5-(3-chlorophenyl)thiazole-4-carboxylate inhibited mtFabH with an IC50 of 0.95 +/- 0.05 mu g/ml (2.43 +/- 0.13 mu M) but was not active against the whole cell organism. Conclusions/Significance: These findings clearly identify the 2-aminothiazole-4-carboxylate scaffold as a promising new template towards the discovery of a new class of anti-tubercular agents.			Al-Balas, Q (corresponding author), Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland.	geoff.coxon@strath.ac.uk	McHugh, Timothy D/AAF-7231-2020; Alnimr, Amani/AAJ-3067-2020; Alnimr, Amani/A-4531-2015; Al-Balas, Qosay/AAG-4877-2020; Anthony, Nahoum/G-5121-2011; Johnston, Blair/X-3569-2019; McHugh, Timothy/O-3683-2019	McHugh, Timothy D/0000-0003-4658-8594; Johnston, Blair/0000-0001-9785-6822; Besra, Gurdyal/0000-0002-5605-0395; , Amani/0000-0001-5105-6002	Medical Research Council [G0802079, G0500590] Funding Source: Medline; MRC [G0802079, G0500590] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ashek A, 2006, BIOORGAN MED CHEM, V14, P1474, DOI 10.1016/j.bmc.2005.10.001; BARTON A, 1982, J CHEM SOC PERK T 1, P159, DOI 10.1039/p19820000159; Bhowruth V, 2007, BIOORG MED CHEM LETT, V17, P5643, DOI 10.1016/j.bmcl.2007.07.082; Bloom BR, 1998, NEW ENGL J MED, V338, P677, DOI 10.1056/NEJM199803053381008; Brown AK, 2005, J BIOL CHEM, V280, P32539, DOI 10.1074/jbc.M413216200; Choi KH, 2000, J BIOL CHEM, V275, P28201; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9; Kamal A, 2005, BIOORG MED CHEM LETT, V15, P1927, DOI 10.1016/j.bmcl.2005.01.084; Kim P, 2006, J MED CHEM, V49, P159, DOI 10.1021/jm050825p; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; Kremer L, 2002, BIOCHEM J, V364, P423, DOI 10.1042/BJ20011628; KREMER L, 2000, GENETICS MYCOLIC ACI; Migliori GB, 2007, EMERG INFECT DIS, V13, P780, DOI 10.3201/eid1305.070200; Mitchison DA, 2004, FRONT BIOSCI-LANDMRK, V9, P1059, DOI 10.2741/1293; NOTO T, 1982, J ANTIBIOT, V35, P401, DOI 10.7164/antibiotics.35.401; OISHI H, 1982, J ANTIBIOT, V35, P391, DOI 10.7164/antibiotics.35.391; Palomino JC, 2002, ANTIMICROB AGENTS CH, V46, P2720, DOI 10.1128/AAC.46.8.2720-2722.2002; Portevin D, 2004, P NATL ACAD SCI USA, V101, P314, DOI 10.1073/pnas.0305439101; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; Sachdeva S, 2008, CHEM BIOL, V15, P402, DOI 10.1016/j.chembiol.2008.03.007; Schaeffer ML, 2001, J BIOL CHEM, V276, P47029, DOI 10.1074/jbc.M108903200; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; Senior SJ, 2004, BIOORG MED CHEM LETT, V14, P373, DOI 10.1016/j.bmcl.2003.10.061; Senior SJ, 2003, BIOORG MED CHEM LETT, V13, P3685, DOI 10.1016/j.bmcl.2003.08.015; Slayden RA, 1996, ANTIMICROB AGENTS CH, V40, P2813, DOI 10.1128/AAC.40.12.2813; Takayama K, 2005, CLIN MICROBIOL REV, V18, P81, DOI 10.1128/CMR.18.1.81-101.2005; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630	29	43	44	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5617	10.1371/journal.pone.0005617	http://dx.doi.org/10.1371/journal.pone.0005617			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19440303	Green Submitted, Green Accepted, Green Published, gold			2022-12-25	WOS:000266161200017
J	Hughes, JN; Washington, JM; Zheng, ZQ; Lau, XWK; Yap, C; Rathjen, PD; Rathjen, J				Hughes, James N.; Washington, Jennifer M.; Zheng, Zhiqiang; Lau, Xiuwen K.; Yap, Charlotte; Rathjen, Peter D.; Rathjen, Joy			Manipulation of Cell:Cell Contacts and Mesoderm Suppressing Activity Direct Lineage Choice from Pluripotent Primitive Ectoderm-Like Cells in Culture	PLOS ONE			English	Article								In the mammal, the pluripotent cells of embryo differentiate and commit to either the mesoderm/endoderm lineages or the ectoderm lineage during gastrulation. In culture, the ability to direct lineage choice from pluripotent cells into the mesoderm/endoderm or ectoderm lineages will enable the development of technologies for the formation of highly enriched or homogenous populations of cells. Here we show that manipulation of cell: cell contact and a mesoderm suppressing activity in culture affects the outcome of pluripotent cell differentiation and when both variables are manipulated appropriately they can direct differentiation to either the mesoderm or ectoderm lineage. The disruption of cell: cell contacts and removal of a mesoderm suppressor activity results in the differentiation of pluripotent, primitive ectoderm-like cells to the mesoderm lineage, while maintenance of cell: cell contacts and inclusion, within the culture medium, of a mesoderm suppressing activity results in the formation of near homogenous populations of ectoderm. Understanding the contribution of these variables in lineage choice provides a framework for the development of directed differentiation protocols that result in the formation of specific cell populations from pluripotent cells in culture.			Hughes, JN (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia.	jrathjen@unimelb.edu.au	Washington, Jennifer/C-1199-2008	, Jennifer/0000-0002-5551-9913; Zheng, Zhiqiang/0000-0003-1028-3246				Cameron A, 2000, J BIOL CHEM, V275, P36741, DOI 10.1074/jbc.M003848200; Camus A, 2006, DEV BIOL, V295, P743, DOI 10.1016/j.ydbio.2006.03.047; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; CONLON FL, 1994, DEVELOPMENT, V120, P1919; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DICKSON MC, 1993, DEVELOPMENT, V117, P625; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Edgar D, 2004, PEDIATR SURG INT, V20, P737, DOI 10.1007/s00383-004-1288-2; Elefanty AG, 1997, BLOOD, V90, P1435, DOI 10.1182/blood.V90.4.1435.1435_1435_1447; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fu YX, 2003, BIOCHEM BIOPH RES CO, V310, P391, DOI 10.1016/j.bbrc.2003.09.021; Gadue P, 2006, P NATL ACAD SCI USA, V103, P16806, DOI 10.1073/pnas.0603916103; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; JOHANSSON MW, 1995, TECHNIQUES FISH IMMU, V4, P141; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Lake JA, 2000, J CELL SCI, V113, P555; Larue L, 1996, DEVELOPMENT, V122, P3185; Levine AJ, 2007, DEV BIOL, V308, P247, DOI 10.1016/j.ydbio.2007.05.036; Lindsley RC, 2006, DEVELOPMENT, V133, P3787, DOI 10.1242/dev.02551; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Ng ES, 2005, DEVELOPMENT, V132, P873, DOI 10.1242/dev.01657; NIETO MA, 1992, DEVELOPMENT, V116, P227; Nostro MC, 2008, CELL STEM CELL, V2, P60, DOI 10.1016/j.stem.2007.10.011; Pappano WN, 1998, GENOMICS, V52, P236, DOI 10.1006/geno.1998.5474; Pearce JJH, 1999, MECH DEVELOP, V87, P189, DOI 10.1016/S0925-4773(99)00135-5; Pelton TA, 2002, J CELL SCI, V115, P329; Pelton TA, 1998, REPROD FERT DEVELOP, V10, P535, DOI 10.1071/RD98084; Pevny LH, 1998, DEVELOPMENT, V125, P1967; Rathjen J, 1999, J CELL SCI, V112, P601; Rathjen J, 2003, METHOD ENZYMOL, V365, P3; Rathjen J, 2003, BIOL REPROD, V69, P1863, DOI 10.1095/biolreprod.103.017384; Rathjen J, 2002, DEVELOPMENT, V129, P2649; Rathjen J, 2001, REPROD FERT DEVELOP, V13, P15, DOI 10.1071/RD00079; Rathjen J, 2001, CURR OPIN GENET DEV, V11, P587, DOI 10.1016/S0959-437X(00)00237-9; Rodda SJ, 2002, INT J DEV BIOL, V46, P449; Rozen S, 2000, Methods Mol Biol, V132, P365; Simon P, 2003, BIOINFORMATICS, V19, P1439, DOI 10.1093/bioinformatics/btg157; Singh AM, 2007, STEM CELLS, V25, P2534, DOI 10.1634/stemcells.2007-0126; SMITH DE, 1992, DEVELOPMENT, V116, P1033; Tada S, 2005, DEVELOPMENT, V132, P4363, DOI 10.1242/dev.02005; Tam PPL, 2004, CURR BIOL, V14, pR239, DOI 10.1016/j.cub.2004.02.056; VALENZUELA DM, 1995, J NEUROSCI, V15, P6077; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105	48	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5579	10.1371/journal.pone.0005579	http://dx.doi.org/10.1371/journal.pone.0005579			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440553	Green Published, gold			2022-12-25	WOS:000266107500010
J	Heinemann, L; Kleinschmidt, A; Muller, NG				Heinemann, Linda; Kleinschmidt, Andreas; Mueller, Notger G.			Exploring BOLD Changes during Spatial Attention in Non-Stimulated Visual Cortex	PLOS ONE			English	Article								Blood oxygen level-dependent (BOLD) responses were measured in parts of primary visual cortex that represented unstimulated visual field regions at different distances from a stimulated central target location. The composition of the visual scene varied by the presence or absence of additional peripheral distracter stimuli. Bottom-up effects were assessed by comparing peripheral activity during central stimulation vs. no stimulation. Top-down effects were assessed by comparing active vs. passive conditions. In passive conditions subjects simply watched the central letter stimuli and in active conditions they had to report occurrence of pre-defined targets in a rapid serial letter stream. Onset of the central letter stream enhanced activity in V1 representations of the stimulated region. Within representations of the periphery activation decreased and finally turned into deactivation with increasing distance from the stimulated location. This pattern was most pronounced in the active conditions and during the presence of peripheral stimuli. Active search for a target did not lead to additional enhancement at areas representing the attentional focus but to a stronger deactivation in the vicinity. Suppressed neuronal activity was also found in the non distracter condition suggesting a top-down attention driven effect. Our observations suggest that BOLD signal decreases in primary visual cortex are modulated by bottom-up sensory-driven factors such as the presence of distracters in the visual field as well as by top-down attentional processes.			Heinemann, L (corresponding author), Univ Frankfurt, Neurol Clin, Cognit Neurol Unit, Frankfurt, Germany.	heinemann@med.uni-frankfurt.de		Mueller, Notger/0000-0002-5483-6423				Baier B, 2006, J NEUROSCI, V26, P12260, DOI 10.1523/JNEUROSCI.1457-06.2006; Beard BL, 1997, VISION RES, V37, P325, DOI 10.1016/S0042-6989(96)00109-5; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; Brefczynski JA, 1999, NAT NEUROSCI, V2, P370, DOI 10.1038/7280; Bressler D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000410; Cavanaugh JR, 2002, J NEUROPHYSIOL, V88, P2530, DOI 10.1152/jn.00692.2001; Engel AK, 1997, CEREB CORTEX, V7, P571, DOI 10.1093/cercor/7.6.571; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; Hopf JM, 2006, P NATL ACAD SCI USA, V103, P1053, DOI 10.1073/pnas.0507746103; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; Laurienti PJ, 2002, J COGNITIVE NEUROSCI, V14, P420, DOI 10.1162/089892902317361930; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; Muller NG, 2008, NEUROIMAGE, V40, P818, DOI 10.1016/j.neuroimage.2007.11.060; Muller NG, 2005, VISION RES, V45, P1129, DOI 10.1016/j.visres.2004.11.003; Muller NG, 2004, NEUROREPORT, V15, P977, DOI 10.1097/01.wnr.000012504766941.17; Ohtani Y, 2002, VISION RES, V42, P1825, DOI 10.1016/S0042-6989(02)00103-7; Ress D, 2000, NAT NEUROSCI, V3, P940, DOI 10.1038/78856; Reynolds JH, 1999, J NEUROSCI, V19, P1736; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; Shmuel A, 2006, NAT NEUROSCI, V9, P569, DOI 10.1038/nn1675; Slotnick SD, 2001, CLIN NEUROPHYSIOL, V112, P1349, DOI 10.1016/S1388-2457(01)00561-2; Smith AJ, 2002, P NATL ACAD SCI USA, V99, P10765, DOI 10.1073/pnas.132272199; Smith AT, 2000, NEUROREPORT, V11, P271, DOI 10.1097/00001756-200002070-00010; Somers DC, 1999, P NATL ACAD SCI USA, V96, P1663, DOI 10.1073/pnas.96.4.1663; Talairach J., 1988, COPLANAR STEREOTAXIC; Tootell RBH, 1998, NEURON, V21, P1409, DOI 10.1016/S0896-6273(00)80659-5; Vanduffel W, 2000, CEREB CORTEX, V10, P109, DOI 10.1093/cercor/10.2.109	28	19	19	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5560	10.1371/journal.pone.0005560	http://dx.doi.org/10.1371/journal.pone.0005560			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440362	Green Published, gold			2022-12-25	WOS:000266107400004
J	Zochowska, M; Paca, A; Schoehn, G; Andrieu, JP; Chroboczek, J; Dublet, B; Szolajska, E				Zochowska, Monika; Paca, Agnieszka; Schoehn, Guy; Andrieu, Jean-Pierre; Chroboczek, Jadwiga; Dublet, Bernard; Szolajska, Ewa			Adenovirus Dodecahedron, as a Drug Delivery Vector	PLOS ONE			English	Article								Background: Bleomycin (BLM) is an anticancer antibiotic used in many cancer regimens. Its utility is limited by systemic toxicity and dose-dependent pneumonitis able to progress to lung fibrosis. The latter can affect up to nearly 50% of the total patient population, out of which 3% will die. We propose to improve BLM delivery by tethering it to an efficient delivery vector. Adenovirus (Ad) dodecahedron base (DB) is a particulate vector composed of 12 copies of a pentameric viral protein responsible for virus penetration. The vector efficiently penetrates the plasma membrane, is liberated in the cytoplasmand has a propensity to concentrate around the nucleus; up to 300000 particles can be observed in one cell in vitro. Principal Findings: Dodecahedron (Dd) structure is preserved at up to about 50 degrees C at pH 7-8 and during dialysis, freezing and drying in the speed-vac in the presence of 150 mM ammonium sulfate, as well as during lyophilization in the presence of cryoprotectants. The vector is also stable in human serum for 2 h at 37 degrees C. We prepared a Dd-BLM conjugate which upon penetration induced death of transformed cells. Similarly to free bleomycin, Dd-BLM caused dsDNA breaks. Significantly, effective cytotoxic concentration of BLM delivered with Dd was 100 times lower than that of free bleomycin. Conclusions/Significance: Stability studies show that Dds can be conveniently stored and transported, and can potentially be used for therapeutic purposes under various climates. Successful BLM delivery by Ad Dds demonstrates that the use of virus like particle (VLP) results in significantly improved drug bioavailability. These experiments open new vistas for delivery of non-permeant labile drugs.			Zochowska, M (corresponding author), Polish Acad Sci, Inst Biochem & Biophys, Warsaw, Poland.	wisia@ibs.fr; ewasz@ibb.waw.pl	Chroboczek, Jadwiga/M-6554-2014	Szolajska, Ewa/0000-0002-7400-4333; Schoehn, Guy/0000-0002-1459-3201; Zochowska, Monika/0000-0002-3824-4962	PHS HHS [2P04B02329] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arndt D, 2001, DRUG DELIV, V8, P1; Balakireva L, 2003, J VIROL, V77, P4858, DOI 10.1128/JVI.77.8.4858-4866.2003; Berg K, 2005, CLIN CANCER RES, V11, P8476, DOI 10.1158/1078-0432.CCR-05-1245; BRADY JN, 1977, J VIROL, V23, P717, DOI 10.1128/JVI.23.3.717-724.1977; Chen JY, 2005, NAT REV CANCER, V5, P102, DOI 10.1038/nrc1547; Chen PL, 2001, FEBS LETT, V500, P109, DOI 10.1016/S0014-5793(01)02598-4; Cobbold SP, 2006, IMMUNOL REV, V213, P239, DOI 10.1111/j.1600-065X.2006.00428.x; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Fabry CMS, 2005, EMBO J, V24, P1645, DOI 10.1038/sj.emboj.7600653; Fender P, 1997, NAT BIOTECHNOL, V15, P52, DOI 10.1038/nbt0197-52; Fender P, 2005, VIROLOGY, V340, P167, DOI 10.1016/j.virol.2005.06.030; Fender P, 2008, VIROLOGY, V371, P155, DOI 10.1016/j.virol.2007.09.026; GABIZON A, 1990, CANCER RES, V50, P6371; GALLEGOS CO, 1989, VIROLOGY, V172, P616, DOI 10.1016/0042-6822(89)90204-3; Garcel A, 2006, J GENE MED, V8, P524, DOI 10.1002/jgm.862; Hecht SM, 2000, J NAT PROD, V63, P158, DOI 10.1021/np990549f; HECHT SM, 1994, BIOCONJUGATE CHEM, V5, P513, DOI 10.1021/bc00030a006; Horiuchi A, 2000, INT J CANCER, V88, P640, DOI 10.1002/1097-0215(20001115)88:4<640::AID-IJC19>3.0.CO;2-K; Ishizu KI, 2001, J VIROL, V75, P61, DOI 10.1128/JVI.75.1.61-72.2001; Kinner A, 2008, NUCLEIC ACIDS RES, V36, P5678, DOI 10.1093/nar/gkn550; Larkin JO, 2008, ULTRASOUND MED BIOL, V34, P406, DOI 10.1016/j.ultrasmedbio.2007.09.005; LEHANE DE, 1975, CANCER RES, V35, P2724; Lenz P, 2001, J IMMUNOL, V166, P5346, DOI 10.4049/jimmunol.166.9.5346; Li TC, 2003, VIROLOGY, V311, P115, DOI 10.1016/S0042-6822(03)00141-7; LOCK RB, 1994, CANCER RES, V54, P4933; Lock RB, 1996, CANCER RES, V56, P4006; McCarthy MP, 1998, J VIROL, V72, P32, DOI 10.1128/JVI.72.1.32-41.1998; Mir LM, 1996, GEN PHARMACOL-VASC S, V27, P745, DOI 10.1016/0306-3623(95)02101-9; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7; NORRBY E, 1968, J GEN VIROL, V2, P135, DOI 10.1099/0022-1317-2-1-135; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; PODDEVIN B, 1991, BIOCHEM PHARMACOL, V42, pS67, DOI 10.1016/0006-2952(91)90394-K; Pron G, 1999, BIOCHEM PHARMACOL, V57, P45, DOI 10.1016/S0006-2952(98)00282-2; Puig PE, 2008, CELL BIOL INT, V32, P1031, DOI 10.1016/j.cellbi.2008.04.021; Rexroad J, 2006, J PHARM SCI-US, V95, P237, DOI 10.1002/jps.20496; SEBTI SM, 1991, CANCER RES, V51, P227; SEBTI SM, 1988, PHARMACOL THERAPEUT, V38, P321, DOI 10.1016/0163-7258(88)90009-5; Sersa G, 2008, EJSO-EUR J SURG ONC, V34, P232, DOI 10.1016/j.ejso.2007.05.016; Shi L, 2005, J PHARM SCI-US, V94, P1538, DOI 10.1002/jps.20377; Sleijfer S, 2001, CHEST, V120, P617, DOI 10.1378/chest.120.2.617; SLIWINSKA MA, 2008, MECH AGEING DEV; Song LZ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002257; Sonoda S, 2007, CANCER BIOL THER, V6, P1276; TAKESHITA M, 1978, P NATL ACAD SCI USA, V75, P5983, DOI 10.1073/pnas.75.12.5983; Vives RR, 2004, VIROLOGY, V321, P332, DOI 10.1016/j.virol.2004.01.015; Wang CG, 2008, INT J PHARMACEUT, V351, P219, DOI 10.1016/j.ijpharm.2007.09.045; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; XI JA, 1992, J VIROL, V66, P6527, DOI 10.1128/JVI.66.11.6527-6532.1992; Yanai H, 2002, BJU INT, V89, P438, DOI 10.1046/j.1464-4096.2001.01836.x; Zubieta C, 2005, MOL CELL, V17, P121, DOI 10.1016/j.molcel.2004.11.041	52	47	49	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5569	10.1371/journal.pone.0005569	http://dx.doi.org/10.1371/journal.pone.0005569			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440379	Green Submitted, Green Published, gold			2022-12-25	WOS:000266107400013
J	An, CJ; Ishibashi, J; Ragan, EJ; Jiang, HB; Kanost, MR				An, Chunju; Ishibashi, Jun; Ragan, Emily J.; Jiang, Haobo; Kanost, Michael R.			Functions of Manduca sexta Hemolymph Proteinases HP6 and HP8 in Two Innate Immune Pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPHENOLOXIDASE-ACTIVATING PROTEINASE-2; SERINE PROTEASES; TOBACCO HORNWORM; DROSOPHILA TOLL; IN-VITRO; RECOGNITION; SYSTEM; INSECT; PEPTIDOGLYCAN; INFECTION	Serine proteinases in insect plasma have been implicated in two types of immune responses; that is, activation of prophenoloxidase (proPO) and activation of cytokine-like proteins. We have identified more than 20 serine proteinases in hemolymph of the tobacco hornworm, Manduca sexta, but functions are known for only a few of them. We report here functions of two additional M. sexta proteinases, hemolymph proteinases 6 and 8 (HP6 and HP8). HP6 and HP8 are each composed of an amino-terminal clip domain and a carboxyl-terminal proteinase domain. HP6 is an apparent ortholog of Drosophila Persephone, whereas HP8 is most similar to Drosophila and Tenebrio spatzle-activating enzymes, all of which activate the Toll pathway. proHP6 and proHP8 are expressed constitutively in fat body and hemocytes and secreted into plasma, where they are activated by proteolytic cleavage in response to infection. To investigate activation and biological activity of HP6 and HP8, we purified recombinant proHP8, proHP6, and mutants of proHP6 in which the catalytic serine was replaced with alanine, and/or the activation site was changed to permit activation by bovine factor Xa. HP6 was found to activate proPO-activating proteinase (proPAP1) in vitro and induce proPO activation in plasma. HP6 was also determined to activate proHP8. Active HP6 or HP8 injected into larvae induced expression of antimicrobial peptides and proteins, including attacin, cecropin, gloverin, moricin, and lysozyme. Our results suggest that proHP6 becomes activated in response to microbial infection and participates in two immune pathways; activation of PAP1, which leads to proPO activation and melanin synthesis, and activation of HP8, which stimulates a Toll-like pathway.	[An, Chunju; Ragan, Emily J.; Kanost, Michael R.] Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; [Ishibashi, Jun] Natl Inst Agrobiol Sci, Tsukuba, Ibaraki 3058634, Japan; [Jiang, Haobo] Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA	Kansas State University; National Institute of Agrobiological Sciences - Japan; Oklahoma State University System; Oklahoma State University - Stillwater	Kanost, MR (corresponding author), Kansas State Univ, Dept Biochem, 141 Chalmers Hall, Manhattan, KS 66506 USA.	kanost@ksu.edu		Kanost, Michael/0000-0002-6827-0061; Jiang, Haobo/0000-0003-1357-1315	National Institutes of Health [GM41247, GM58643]; National Center for Research Resources, Department of Health and Human Services, National Institutes of Health [P20 RR-016464]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041247, R01GM041247, R37GM041247] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources, Department of Health and Human Services, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants GM41247 and GM58643. This is Contribution 07-125 from the Kansas Agricultural Experiment Station.; We thank Peter Dunn for antiserum to M. sexta lysozyme and Maureen Gorman for helpful comments on the manuscript. Protein digestion and mass spectrometry was performed by the Nevada Proteomics Center at the University of Nevada, which is supported by P20 RR-016464 from the IDeA Network of Biomedical Research Excellence Program of the National Center for Research Resources, Department of Health and Human Services, National Institutes of Health.	Ashida Masaaki, 1998, P135; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113; Cerenius L, 2008, TRENDS IMMUNOL, V29, P263, DOI 10.1016/j.it.2008.02.009; Coligan JE, 1995, CURRENT PROTOCOLS PR; DeLotto Y, 1998, MECH DEVELOP, V72, P141, DOI 10.1016/S0925-4773(98)00024-0; DUNN PE, 1983, J INVERTEBR PATHOL, V41, P77, DOI 10.1016/0022-2011(83)90238-0; El Chamy L, 2008, NAT IMMUNOL, V9, P1165, DOI 10.1038/ni.1643; Ferrandon D, 2007, NAT REV IMMUNOL, V7, P862, DOI 10.1038/nri2194; Gorman MJ, 2007, J BIOL CHEM, V282, P11742, DOI 10.1074/jbc.M611243200; Gottar M, 2006, CELL, V127, P1425, DOI 10.1016/j.cell.2006.10.046; Gupta S, 2005, INSECT BIOCHEM MOLEC, V35, P241, DOI 10.1016/j.ibmb.2004.12.003; Huang RD, 2007, BIOCHEMISTRY-US, V46, P11431, DOI 10.1021/bi7010724; HULTMARK D, 1982, EUR J BIOCHEM, V127, P207, DOI 10.1111/j.1432-1033.1982.tb06857.x; Jang IH, 2006, DEV CELL, V10, P45, DOI 10.1016/j.devcel.2005.11.013; Jenny RJ, 2003, PROTEIN EXPRES PURIF, V31, P1, DOI 10.1016/S1046-5928(03)00168-2; Jiang HB, 2005, INSECT BIOCHEM MOLEC, V35, P931, DOI 10.1016/j.ibmb.2005.03.009; Jiang HB, 2003, INSECT BIOCHEM MOLEC, V33, P1049, DOI 10.1016/S0965-1748(03)00123-1; Jiang HB, 2003, J BIOL CHEM, V278, P3552, DOI 10.1074/jbc.M205743200; Jiang HB, 2000, INSECT BIOCHEM MOLEC, V30, P95, DOI 10.1016/S0965-1748(99)00113-7; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Kambris Z, 2006, CURR BIOL, V16, P808, DOI 10.1016/j.cub.2006.03.020; Kan H, 2008, J BIOL CHEM, V283, P25316, DOI 10.1074/jbc.M804364200; Kanost MR, 2008, INSECT IMMUNOLOGY, P69, DOI 10.1016/B978-012373976-6.50006-9; Kim CH, 2008, J BIOL CHEM, V283, P7599, DOI 10.1074/jbc.M710216200; Kurata S, 2006, IMMUNOBIOLOGY, V211, P237, DOI 10.1016/j.imbio.2005.10.016; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Saux A, 2008, J MOL BIOL, V377, P902, DOI 10.1016/j.jmb.2008.01.045; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Levitin A, 2008, CELL MICROBIOL, V10, P1021, DOI 10.1111/j.1462-5822.2008.01120.x; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Liu H, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M706113200; Osaki T, 2004, CELL MOL LIFE SCI, V61, P1257, DOI 10.1007/s00018-004-3396-5; Park JW, 2007, P NATL ACAD SCI USA, V104, P6602, DOI 10.1073/pnas.0610924104; Piao S, 2005, EMBO J, V24, P4404, DOI 10.1038/sj.emboj.7600891; Ross J, 2003, GENE, V304, P117, DOI 10.1016/S0378-1119(02)01187-3; Sim RB, 2004, BIOCHEM SOC T, V32, P21, DOI 10.1042/BST0320021; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Tang HP, 2006, J BIOL CHEM, V281, P28097, DOI 10.1074/jbc.M601642200; Theopold U, 2004, TRENDS IMMUNOL, V25, P289, DOI 10.1016/j.it.2004.03.004; Tong YR, 2005, J BIOL CHEM, V280, P14932, DOI 10.1074/jbc.M500532200; Tong YR, 2005, J BIOL CHEM, V280, P14923, DOI 10.1074/jbc.M500531200; Volz J, 2006, CELL MICROBIOL, V8, P1392, DOI 10.1111/j.1462-5822.2006.00718.x; Wang Y, 2006, J BIOL CHEM, V281, P9271, DOI 10.1074/jbc.M513797200; Wang Y, 2008, INSECT BIOCHEM MOLEC, V38, P763, DOI 10.1016/j.ibmb.2008.04.008; Wang Y, 2007, INSECT BIOCHEM MOLEC, V37, P1015, DOI 10.1016/j.ibmb.2007.05.013; Wang Y, 2007, DEV COMP IMMUNOL, V31, P1002, DOI 10.1016/j.dci.2007.01.001; Yu XQ, 2003, INSECT BIOCHEM MOLEC, V33, P197, DOI 10.1016/S0965-1748(02)00191-1; Yu XQ, 2002, INSECT BIOCHEM MOLEC, V32, P1287, DOI 10.1016/S0965-1748(02)00091-7; Yu XQ, 2000, J BIOL CHEM, V275, P37373, DOI 10.1074/jbc.M003021200; Zhao PC, 2007, INSECT BIOCHEM MOLEC, V37, P952, DOI 10.1016/j.ibmb.2007.05.001; Zhu YF, 2003, J BIOL CHEM, V278, P46556, DOI 10.1074/jbc.M309682200; Zou Z, 2008, INSECT BIOCHEM MOLEC, V38, P677, DOI 10.1016/j.ibmb.2008.03.009; Zou Z, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r177	54	126	138	3	46	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19716	19726		10.1074/jbc.M109.007112	http://dx.doi.org/10.1074/jbc.M109.007112			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19487692	Green Published, hybrid			2022-12-25	WOS:000267908300062
J	Molle, D; Segura-Morales, C; Camus, G; Berlioz-Torrent, C; Kjems, J; Basyuk, E; Bertrand, E				Molle, Dorothee; Segura-Morales, Carolina; Camus, Gregory; Berlioz-Torrent, Clarisse; Kjems, Jorgen; Basyuk, Eugenia; Bertrand, Edouard			Endosomal Trafficking of HIV-1 Gag and Genomic RNAs Regulates Viral Egress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATE-BUDDING DOMAINS; VIRUS TYPE-1 GAG; PLASMA-MEMBRANE; LIVE CELLS; MULTIVESICULAR BODIES; PRIMARY MACROPHAGES; ENV INCORPORATION; INFECTIOUS HIV-1; MATRIX PROTEIN; IN-VITRO	HIV-1 Gag can assemble and generate virions at the plasma membrane, but it is also present in endosomes where its role remains incompletely characterized. Here, we show that HIV-1 RNAs and Gag are transported on endosomal vesicles positive for TiVamp, a v-SNARE involved in fusion events with the plasma membrane. Inhibition of endosomal traffic did not prevent viral release. However, inhibiting lysosomal degradation induced an accumulation of Gag in endosomes and increased viral production 7-fold, indicating that transport of Gag to lysosomes negatively regulates budding. This also suggested that endosomal Gag-RNA complexes could access retrograde pathways to the cell surface and indeed, depleting cells of TiVamp-reduced viral production. Moreover, inhibition of endosomal transport prevented the accumulation of Gag at sites of cellular contact. HIV-1 Gag could thus generate virions using two pathways, either directly from the plasma membrane or through an endosome-dependent route. Endosomal Gag-RNA complexes may be delivered at specific sites to facilitate cell-to-cell viral transmission.	[Molle, Dorothee; Segura-Morales, Carolina; Basyuk, Eugenia; Bertrand, Edouard] IGMM, CNRS, UMR5535, Inst Federatif Rech 3, F-34293 Montpellier 5, France; [Camus, Gregory; Berlioz-Torrent, Clarisse] Univ Paris 05, CNRS, UMR8104, Inst Cochin, Paris, France; [Camus, Gregory; Berlioz-Torrent, Clarisse] INSERM, U567, F-75014 Paris, France; [Kjems, Jorgen] Aarhus Univ, DK-8000 Aarhus C, Denmark	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Aarhus University	Bertrand, E (corresponding author), IGMM, CNRS, UMR5535, Inst Federatif Rech 3, 1919 Route Mende, F-34293 Montpellier 5, France.	Edouard.Bertrand@igmm.cnrs.fr	Morales, Carolina Segura/AAL-1694-2021; Kjems, Jorgen/I-3490-2016; BERLIOZ-TORRENT, clarisse/F-2570-2013; Segura Morales, Carolina/H-7862-2015	Morales, Carolina Segura/0000-0002-1746-6865; Kjems, Jorgen/0000-0003-4128-9317; Segura Morales, Carolina/0000-0002-1746-6865; bertrand, edouard/0000-0002-9642-7994; Basyuk, Eugenia/0000-0001-9768-4557	EURASNET; ANRS; SIDACTION	EURASNET; ANRS(ANRSFrench National Research Agency (ANR)); SIDACTION	This work was supported in part by EURASNET, ANRS, and SIDACTION.	Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000; Adams SR, 2002, J AM CHEM SOC, V124, P6063, DOI 10.1021/ja017687n; Advani RJ, 1999, J CELL BIOL, V146, P765, DOI 10.1083/jcb.146.4.765; Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Basyuk E, 2003, DEV CELL, V5, P161, DOI 10.1016/S1534-5807(03)00188-6; Bieniasz PD, 2006, VIROLOGY, V344, P55, DOI 10.1016/j.virol.2005.09.044; Blot G, 2003, J VIROL, V77, P6931, DOI 10.1128/JVI.77.12.6931-6945.2003; Boireau S, 2007, J CELL BIOL, V179, P291, DOI 10.1083/jcb.200706018; Camus G, 2007, MOL BIOL CELL, V18, P3193, DOI 10.1091/mbc.E06-12-1147; Cantin R, 2008, J IMMUNOL METHODS, V338, P21, DOI 10.1016/j.jim.2008.07.007; Chung HY, 2008, J VIROL, V82, P4884, DOI 10.1128/JVI.02667-07; Demirov DG, 2004, VIRUS RES, V106, P87, DOI 10.1016/j.virusres.2004.08.007; Demirov DG, 2002, J VIROL, V76, P105, DOI 10.1128/JVI.76.1.105-117.2002; Denek M, 2007, J CELL BIOL, V177, P329, DOI 10.1083/jcb.200609050; Fang DY, 2004, P NATL ACAD SCI USA, V101, P14782, DOI 10.1073/pnas.0404445101; Finzi A, 2007, J VIROL, V81, P7476, DOI 10.1128/JVI.00308-07; Fusco D, 2003, CURR BIOL, V13, P161, DOI 10.1016/S0960-9822(02)01436-7; Gaietta G, 2002, SCIENCE, V296, P503, DOI 10.1126/science.1068793; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Goff A, 2003, J VIROL, V77, P9173, DOI 10.1128/JVI.77.17.9173-9182.2003; Gottlinger HG, 2001, AIDS, V15, pS13; Gousset K, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000015; Grigorov B, 2006, J MOL BIOL, V359, P848, DOI 10.1016/j.jmb.2006.04.017; Harila K, 2006, J VIROL, V80, P3765, DOI 10.1128/JVI.80.8.3765-3772.2006; Harila K, 2007, VIROLOGY, V369, P299, DOI 10.1016/j.virol.2007.08.009; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hurley JH, 2008, CURR OPIN CELL BIOL, V20, P4, DOI 10.1016/j.ceb.2007.12.002; Ikeda Y, 2003, NAT BIOTECHNOL, V21, P569, DOI 10.1038/nbt815; Jouve M, 2007, CELL HOST MICROBE, V2, P85, DOI 10.1016/j.chom.2007.06.011; Jouvenet N, 2008, NATURE, V454, P236, DOI 10.1038/nature06998; Jouvenet N, 2006, PLOS BIOL, V4, P2296, DOI 10.1371/journal.pbio.0040435; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Le PU, 2002, J BIOL CHEM, V277, P3371, DOI 10.1074/jbc.M111240200; Lodge R, 1997, EMBO J, V16, P695, DOI 10.1093/emboj/16.4.695; Lopez-Verges S, 2006, P NATL ACAD SCI USA, V103, P14947, DOI 10.1073/pnas.0602941103; Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Martin-Serrano J, 2007, TRAFFIC, V8, P1297, DOI 10.1111/j.1600-0854.2007.00609.x; Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216; Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350; Muller B, 2004, J VIROL, V78, P10803, DOI 10.1128/JVI.78.19.10803-10813.2004; Muriaux D, 2001, P NATL ACAD SCI USA, V98, P5246, DOI 10.1073/pnas.091000398; Muzerelle A, 2003, NEUROSCIENCE, V122, P59, DOI 10.1016/S0306-4522(03)00567-0; Neil SJD, 2008, NATURE, V451, P425, DOI 10.1038/nature06553; Neil Stuart J. D., 2006, PLoS Pathogens, V2, DOI 10.1371/jounral.ppat.0020039; Nguyen DG, 2003, J BIOL CHEM, V278, P52347, DOI 10.1074/jbc.M309009200; Nydegger S, 2003, TRAFFIC, V4, P902, DOI 10.1046/j.1600-0854.2003.00145.x; Nydegger S, 2006, J CELL BIOL, V173, P795, DOI 10.1083/jcb.200508165; Pelchen-Matthews A, 2004, TRENDS MICROBIOL, V12, P310, DOI 10.1016/j.tim.2004.05.004; Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008; Perez-Caballero D, 2004, J VIROL, V78, P9560, DOI 10.1128/JVI.78.17.9560-9563.2004; Perlman M, 2006, TRAFFIC, V7, P731, DOI 10.1111/j.1398-9219.2006.00428.x; Piper RC, 2007, CURR OPIN CELL BIOL, V19, P459, DOI 10.1016/j.ceb.2007.07.002; Proux-Gillardeaux V, 2005, TRAFFIC, V6, P366, DOI 10.1111/j.1600-0854.2005.00288.x; Raposo G, 2002, TRAFFIC, V3, P718, DOI 10.1034/j.1600-0854.2002.31004.x; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043; Rudner L, 2005, J VIROL, V79, P4055, DOI 10.1128/JVI.79.7.4055-4065.2005; Saad JS, 2007, J MOL BIOL, V366, P574, DOI 10.1016/j.jmb.2006.11.068; Saad JS, 2006, P NATL ACAD SCI USA, V103, P11364, DOI 10.1073/pnas.0602818103; Sharova N, 2005, EMBO J, V24, P2481, DOI 10.1038/sj.emboj.7600707; Sherer NM, 2003, TRAFFIC, V4, P785, DOI 10.1034/j.1600-0854.2003.00135.x; Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Tang C, 2004, P NATL ACAD SCI USA, V101, P517, DOI 10.1073/pnas.0305665101; Tritel M, 2000, J VIROL, V74, P5845, DOI 10.1128/JVI.74.13.5845-5855.2000; Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538; Usami Y, 2008, J VIROL, V82, P4898, DOI 10.1128/JVI.02675-07; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Welsch S, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030036; Williams RL, 2007, NAT REV MOL CELL BIO, V8, P355, DOI 10.1038/nrm2162	75	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19727	19743		10.1074/jbc.M109.019844	http://dx.doi.org/10.1074/jbc.M109.019844			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19451649	Green Published, hybrid			2022-12-25	WOS:000267908300063
J	Nguyen, T; Lindner, R; Tedeschi, A; Forsberg, K; Green, A; Wuttke, A; Gaub, P; Di Giovanni, S				Nguyen, Tuan; Lindner, Ricco; Tedeschi, Andrea; Forsberg, Kirsi; Green, Andrew; Wuttke, Anja; Gaub, Perrine; Di Giovanni, Simone			NFAT-3 Is a Transcriptional Repressor of the Growth-associated Protein 43 during Neuronal Maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; GENE-EXPRESSION; NUCLEAR-LOCALIZATION; GAP-43 PROMOTER; AXON GROWTH; MOUSE-BRAIN; CALCINEURIN; ACTIVATION; DIFFERENTIATION; REGENERATION	Transcription is essential for neurite and axon outgrowth during development. Recent work points to the involvement of nuclear factor of activated T cells ( NFAT) in the regulation of genes important for axon growth and guidance. However, NFAT has not been reported to directly control the transcription of axon outgrowth-related genes. To identify transcriptional targets, we performed an in silico promoter analysis and found a putative NFAT site within the GAP-43 promoter. Using in vitro and in vivo experiments, we demonstrated that NFAT-3 regulates GAP-43, but unexpectedly, does not promote but represses the expression of GAP-43 in neurons and in the developing brain. Specifically, in neuron-like PC-12 cells and in cultured cortical neurons, the overexpression of NFAT-3 represses GAP-43 activation mediated by neurotrophin signaling. Using chromatin immunoprecipitation assays, we also show that prior to neurotrophin activation, endogenous NFAT-3 occupies the GAP-43 promoter in PC-12 cells, in cultured neurons, and in the mouse brain. Finally, we observe that NFAT-3 is required to repress the physiological expression of GAP-43 and other proaxon outgrowth genes in specific developmental windows in the mouse brain. Taken together, our data reveal an unexpected role for NFAT-3 as a direct transcriptional repressor of GAP-43 expression and suggest a more general role for NFAT-3 in the control of the neuronal outgrowth program.	[Nguyen, Tuan; Lindner, Ricco; Tedeschi, Andrea; Forsberg, Kirsi; Green, Andrew; Wuttke, Anja; Gaub, Perrine; Di Giovanni, Simone] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurol, Lab NeuroRegenerat & Repair, D-72076 Tubingen, Germany; [Lindner, Ricco; Tedeschi, Andrea; Forsberg, Kirsi; Gaub, Perrine] Univ Tubingen, Grad Sch Cellular & Mol Neurosci, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen	Di Giovanni, S (corresponding author), Otfried Mueller Str 27, D-72076 Tubingen, Germany.	simone.digiovanni@medizin.uni-tuebingen.de		Green, Andrew/0000-0002-1077-7417	National Institutes of Health [R21 NS052640]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS052640] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported, in whole or in part, by National Institutes of Health Grant R21 NS052640 (to S. D. I.). This work was also supported by grants from the Hertie Foundation; the Fortune Grant, University of Tuebingen; and Deutsche Forschungsgemeinschaft Grant DI 1497/1-1 ( to S. D. I.).	AIGNER L, 1993, J CELL BIOL, V123, P417, DOI 10.1083/jcb.123.2.417; AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; BENOWITZ LI, 1990, PROG BRAIN RES, V86, P309; Bradley KC, 2005, J NEUROSCI RES, V82, P762, DOI 10.1002/jnr.20695; Chen Lin, 1999, Current Opinion in Structural Biology, V9, P48; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DELAMONTE SM, 1989, DEV BRAIN RES, V46, P161, DOI 10.1016/0165-3806(89)90279-4; Di Giovanni S, 2006, EMBO J, V25, P4084, DOI 10.1038/sj.emboj.7601292; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; Gianola S, 2004, EUR J NEUROSCI, V19, P819, DOI 10.1111/j.0953-816X.2004.03190.x; Graef IA, 2003, CELL, V113, P657, DOI 10.1016/S0092-8674(03)00390-8; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Graef IA, 2001, P NATL ACAD SCI USA, V98, P5740, DOI 10.1073/pnas.101602398; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Groth RD, 2008, EUR J NEUROSCI, V27, P31, DOI 10.1111/j.1460-9568.2007.05980.x; Groth RD, 2007, J NEUROCHEM, V102, P1162, DOI 10.1111/j.1471-4159.2007.04632.x; Groth RD, 2003, J NEUROSCI, V23, P8125; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Im SH, 2004, MOL CELLS, V18, P1; JACOBSON RD, 1986, J NEUROSCI, V6, P1843; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Ma QF, 2006, J PHYSIOL-LONDON, V575, P379, DOI 10.1113/jphysiol.2006.113449; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; MAHALIK TJ, 1992, DEV BRAIN RES, V67, P75, DOI 10.1016/0165-3806(92)90027-T; Namgung U, 2000, EUR J NEUROSCI, V12, P3124, DOI 10.1046/j.1460-9568.2000.00196.x; NEDIVI E, 1992, J NEUROSCI, V12, P691; Nguyen T, 2008, INT J DEV NEUROSCI, V26, P141, DOI 10.1016/j.ijdevneu.2007.10.004; Ogata K, 2003, CURR OPIN STRUC BIOL, V13, P40, DOI 10.1016/S0959-440X(03)00012-5; Okamura H, 2004, MOL CELL BIOL, V24, P4184, DOI 10.1128/MCB.24.10.4184-4195.2004; Ooi L, 2008, BIOCHEM J, V414, P327, DOI 10.1042/BJ20080963; Plyte S, 2001, J BIOL CHEM, V276, P14350, DOI 10.1074/jbc.M007854200; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; REINHARD E, 1994, DEVELOPMENT, V120, P1767; Reinhard E, 1992, Perspect Dev Neurobiol, V1, P29; Remenyi A, 2004, NAT STRUCT MOL BIOL, V11, P812, DOI 10.1038/nsmb820; Seybold VS, 2006, J NEUROCHEM, V97, P397, DOI 10.1111/j.1471-4159.2006.03744.x; STARR RG, 1994, BRAIN RES, V638, P211, DOI 10.1016/0006-8993(94)90652-1; Tedeschi A, 2009, CELL DEATH DIFFER, V16, P543, DOI 10.1038/cdd.2008.175; VANDERZEE CEEM, 1989, J NEUROSCI, V9, P3505; Vihma H, 2008, GENOMICS, V92, P279, DOI 10.1016/j.ygeno.2008.06.011; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; Wu H, 2007, TRENDS CELL BIOL, V17, P251, DOI 10.1016/j.tcb.2007.04.006; Yoshida T, 2005, J NEUROSCI, V25, P3067, DOI 10.1523/JNEUROSCI.3738-04.2005	51	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18816	18823		10.1074/jbc.M109.015719	http://dx.doi.org/10.1074/jbc.M109.015719			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19443652	Green Published, hybrid			2022-12-25	WOS:000267711500031
J	Zhou, JG; Feng, X; Ban, B; Liu, JX; Wang, Z; Xiao, WH				Zhou, Jiangang; Feng, Xi; Ban, Bin; Liu, Jingxia; Wang, Zhou; Xiao, Wuhan			Elongation Factor ELL (Eleven-Nineteen Lysine-rich Leukemia) Acts as a Transcription Factor for Direct Thrombospondin-1 Regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED LINEAGE LEUKEMIA; ACUTE MYELOID-LEUKEMIA; MLL-ELL; TUMOR-GROWTH; STEM-CELLS; GENE; EXPRESSION; ANGIOGENESIS; P53; POLYMERASE	The eleven-nineteen lysine-rich leukemia (ELL) gene undergoes translocation and fuses in-frame to the multiple lineage leukemia gene in a substantial proportion of patients suffering from acute forms of leukemia. Studies show that ELL indirectly modulates transcription by serving as a regulator for transcriptional elongation as well as for p53, U19/Eaf2, and steroid receptor activities. Our in vitro and in vivo data demonstrate that ELL could also serve as a transcriptional factor to directly induce transcription of the thrombospondin-1 (TSP-1) gene. Experiments using ELL deletion mutants established that full-length ELL is required for the TSP-1 up-regulation and that the trans-activation domain likely resides in the carboxyl terminus. Moreover, the DNA binding domain may localize to the first 45 amino acids of ELL. Not surprisingly, multiple lineage leukemia-ELL, which lacks these amino acids, did not induce expression from the TSP-1 promoter. In addition, the ELL core-response element appears to localize in the -1426 to -1418 region of the TSP-1 promoter. Finally, studies using zebrafish confirmed that ELL regulates TSP-1 mRNA expression in vivo, and ELL could inhibit zebrafish vasculogenesis, at least in part, through up-regulating TSP-1. Given the importance of TSP-1 as an anti-angiogenic protein, our findings may have important ramifications for better understanding cancer.	[Zhou, Jiangang; Feng, Xi; Ban, Bin; Liu, Jingxia; Xiao, Wuhan] Chinese Acad Sci, Inst Hydrobiol, Key Lab Biodivers & Conservat Aquat Organisms, Wuhan 430072, Peoples R China; [Wang, Zhou] Univ Pittsburgh, Inst Canc, Dept Urol, Sch Med, Pittsburgh, PA 15232 USA	Chinese Academy of Sciences; Institute of Hydrobiology, CAS; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Xiao, WH (corresponding author), Chinese Acad Sci, Inst Hydrobiol, Key Lab Biodivers & Conservat Aquat Organisms, Wuhan 430072, Peoples R China.	w-xiao@ihb.ac.cn	Feng, Xi/N-7160-2016; Xiao, Wuhan/GLU-7352-2022	Feng, Xi/0000-0002-6920-1519; 	National Natural Science Foundation of China Grant (Youth Foundation) [30700440]	National Natural Science Foundation of China Grant (Youth Foundation)(National Natural Science Foundation of China (NSFC))	Supported by National Natural Science Foundation of China Grant (Youth Foundation) 30700440.	Agah A, 2002, AM J PATHOL, V161, P831, DOI 10.1016/S0002-9440(10)64243-5; Argiropoulos B, 2007, ONCOGENE, V26, P6766, DOI 10.1038/sj.onc.1210760; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Cinatl J, 1999, AM J PATHOL, V155, P285, DOI 10.1016/S0002-9440(10)65122-X; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DiMartino JF, 2000, BLOOD, V96, P3887, DOI 10.1182/blood.V96.12.3887.h8003887_3887_3893; Dou YL, 2008, INT J HEMATOL, V87, P10, DOI 10.1007/s12185-007-0009-8; Eguchi M, 2005, INT J HEMATOL, V82, P9, DOI 10.1532/IJH97.05042; Ernst P, 2004, CURR BIOL, V14, P2063, DOI 10.1016/j.cub.2004.11.012; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Hahn J, 2007, PROSTATE, V67, P146, DOI 10.1002/pros.20481; Hess JL, 2004, CRIT REV EUKAR GENE, V14, P235, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.10; Jiang F, 2007, CANCER LETT, V253, P265, DOI 10.1016/j.canlet.2007.02.003; Johnstone RW, 2001, MOL CELL BIOL, V21, P1672, DOI 10.1128/MCB.21.5.1672-1681.2001; Kong CT, 2006, LEUKEMIA, V20, P1829, DOI 10.1038/sj.leu.2404342; Kranenburg O, 2004, BBA-REV CANCER, V1654, P23, DOI 10.1016/j.bbcan.2003.09.004; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lawler J, 2001, AM J PATHOL, V159, P1949, DOI 10.1016/S0002-9440(10)63042-8; Liu H, 2008, CELL CYCLE, V7, P428, DOI 10.4161/cc.7.4.5426; Luo RT, 2001, MOL CELL BIOL, V21, P5678, DOI 10.1128/MCB.21.16.5678-5687.2001; Maki K, 1999, BLOOD, V93, P3216, DOI 10.1182/blood.V93.10.3216.410k45_3216_3224; Miller T, 2000, J BIOL CHEM, V275, P32052, DOI 10.1074/jbc.M005175200; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Mitani K, 2000, BIOCHEM BIOPH RES CO, V279, P563, DOI 10.1006/bbrc.2000.3970; Pascual-Le Tallec L, 2005, MOL ENDOCRINOL, V19, P1158, DOI 10.1210/me.2004-0331; Reiher FK, 2001, J UROLOGY, V165, P2075, DOI 10.1016/S0022-5347(05)66297-0; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Sheibani N, 1996, CANCER LETT, V107, P45, DOI 10.1016/0304-3835(96)04341-8; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 1997, J BIOL CHEM, V272, P22355, DOI 10.1074/jbc.272.35.22355; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; Simone F, 2003, BLOOD, V101, P2355, DOI 10.1182/blood-2002-06-1664; Simone F, 2001, BLOOD, V98, P201, DOI 10.1182/blood.V98.1.201; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Wiederschain D, 2005, J BIOL CHEM, V280, P24315, DOI 10.1074/jbc.M412237200; Wiederschain D, 2003, MOL CELL BIOL, V23, P4230, DOI 10.1128/MCB.23.12.4230-4246.2003; Xiao W, 2008, ONCOGENE, V27, P1536, DOI 10.1038/sj.onc.1210786; Xiao WH, 2006, PROSTATE, V66, P1, DOI 10.1002/pros.20309; Xiao WH, 2003, CANCER RES, V63, P4698; Yang ZG, 2001, DEV BIOL, V231, P138, DOI 10.1006/dbio.2000.0139; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; Zhong HB, 2006, P NATL ACAD SCI USA, V103, P16800, DOI 10.1073/pnas.0603959103	48	24	24	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					19142	19152		10.1074/jbc.M109.010439	http://dx.doi.org/10.1074/jbc.M109.010439			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19447890	Green Published, hybrid			2022-12-25	WOS:000267711500062
J	Gohli, J; Hogstedt, G				Gohli, Jostein; Hogstedt, Goran			Explaining the Evolution of Warning Coloration: Secreted Secondary Defence Chemicals May Facilitate the Evolution of Visual Aposematic Signals	PLOS ONE			English	Article								Several pathways have been postulated to explain the evolution of warning coloration, which is a perplexing phenomenon. Many of these attempt to circumvent the problem of naive predators by inferring kin selection or neophobia. Through a stochastic model, we show that a secreted secondary defence chemical can provide selective pressure, on the individual level, towards developing warning coloration. Our fundamental assumption is that increased conspicuousness will result in longer assessment periods and divergence from the predators' searching image, thus reducing the probability of a predator making mistakes. We conclude that strong olfactory signaling by means of chemical secretions can lead to the evolution of warning coloration.			Gohli, J (corresponding author), Univ Bergen, Dept Biol, Bergen, Norway.	Jostein.Gohli@gmail.com	Gohli, Jostein/A-1145-2013					Cott H.B., 1940, ADAPTIVE COLORATION; EISNER T, 1981, SCIENCE, V213, P476, DOI 10.1126/science.7244647; Eisner T., 2005, SECRET WEAPONS DEFEN; Fisher R.A., 1930, GENETICAL THEORY NAT; Gamberale-Stille G, 2000, ANIM BEHAV, V60, P95, DOI 10.1006/anbe.2000.1435; HARVEY PH, 1981, OIKOS, V37, P391, DOI 10.2307/3544135; HARVEY PH, 1982, AM NAT, V119, P710, DOI 10.1086/283944; Malakoff D, 1999, SCIENCE, V286, P704, DOI 10.1126/science.286.5440.704; Merilaita S, 2007, J THEOR BIOL, V245, P268, DOI 10.1016/j.jtbi.2006.10.022; Prudic KL, 2008, J CHEM ECOL, V34, P734, DOI 10.1007/s10886-008-9480-9; Rothschild M., 1961, Transactions of the Royal Entomological Society of London, V113, P101; Rowe C, 1999, ANIM BEHAV, V58, P921, DOI 10.1006/anbe.1999.1242; Rowe C, 1999, EVOL ECOL, V13, P655, DOI 10.1023/A:1011021630244; Skelhorn J, 2006, BIOL LETT-UK, V2, P348, DOI 10.1098/rsbl.2006.0483; Speed MP, 2005, EVOLUTION, V59, P2499; Steiger SS, 2008, P ROY SOC B-BIOL SCI, V275, P2309, DOI 10.1098/rspb.2008.0607; WALLACE AR, 1867, P ENT SOC LOND 4 MAR	17	13	13	3	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2009	4	6							e5779	10.1371/journal.pone.0005779	http://dx.doi.org/10.1371/journal.pone.0005779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453PV	19492013	Green Published, Green Submitted, gold			2022-12-25	WOS:000266624300015
J	Lehmann, J; Cibils, M; Libchaber, A				Lehmann, Jean; Cibils, Michel; Libchaber, Albert			Emergence of a Code in the Polymerization of Amino Acids along RNA Templates	PLOS ONE			English	Article							GENETIC-CODE; SELF-ORGANIZATION; PROTEIN-SYNTHESIS; ORIGIN; RIBOSOME; EFFICIENCY; ENTROPY	The origin of the genetic code in the context of an RNA world is a major problem in the field of biophysical chemistry. In this paper, we describe how the polymerization of amino acids along RNA templates can be affected by the properties of both molecules. Considering a system without enzymes, in which the tRNAs (the translation adaptors) are not loaded selectively with amino acids, we show that an elementary translation governed by a Michaelis-Menten type of kinetics can follow different polymerization regimes: random polymerization, homopolymerization and coded polymerization. The regime under which the system is running is set by the relative concentrations of the amino acids and the kinetic constants involved. We point out that the coding regime can naturally occur under prebiotic conditions. It generates partially coded proteins through a mechanism which is remarkably robust against non-specific interactions (mismatches) between the adaptors and the RNA template. Features of the genetic code support the existence of this early translation system.			Lehmann, J (corresponding author), Rockefeller Univ, Ctr Studies Phys & Biol, 1230 York Ave, New York, NY 10021 USA.	jlehmann@rockefeller.edu		Lehmann, Jean/0000-0002-9887-8123				Agmon F, 2005, BIOL CHEM, V386, P833, DOI 10.1515/BC.2005.098; Agris PF, 2004, NUCLEIC ACIDS RES, V32, P223, DOI 10.1093/nar/gkh185; Armstrong AA, 2003, J AM CHEM SOC, V125, P14596, DOI 10.1021/ja0344359; Auffinger P, 2001, RNA, V7, P334, DOI 10.1017/S1355838201002382; BERG P, 1961, J BIOL CHEM, V236, P1726; Delarue M, 2007, RNA, V13, P161, DOI 10.1261/rna.257607; EIGEN M, 1978, NATURWISSENSCHAFTEN, V65, P341, DOI 10.1007/BF00439699; Gromadski KB, 2004, MOL CELL, V13, P191, DOI 10.1016/S1097-2765(04)00005-X; GROSJEAN HJ, 1978, P NATL ACAD SCI USA, V75, P610, DOI 10.1073/pnas.75.2.610; Ikehara K, 2002, J MOL EVOL, V54, P530, DOI 10.1007/s00239-001-0053-6; Illangasekare M, 1999, RNA, V5, P1482, DOI 10.1017/S1355838299991264; Jung ME, 2005, CHEM REV, V105, P1735, DOI 10.1021/cr940337h; LACEY JC, 1992, ORIGINS LIFE EVOL B, V22, P243, DOI 10.1007/BF01810856; LACEY JC, 1983, ORIGINS LIFE EVOL B, V13, P3, DOI 10.1007/BF00928761; Ledoux S, 2008, MOL CELL, V31, P114, DOI 10.1016/j.molcel.2008.04.026; Lehmann J, 2004, J THEOR BIOL, V227, P381, DOI 10.1016/j.jtbi.2003.11.015; Lehmann J, 2000, J THEOR BIOL, V202, P129, DOI 10.1006/jtbi.1999.1045; Lehmann J, 2007, RNA, V13, P1191, DOI 10.1261/rna.500907; Lightstone FC, 1996, J AM CHEM SOC, V118, P2595, DOI 10.1021/ja952589l; MATTHAEI JH, 1966, COLD SPRING HARB SYM, V31, P25, DOI 10.1101/SQB.1966.031.01.009; MILLER SL, 1987, COLD SPRING HARB SYM, V52, P17, DOI 10.1101/SQB.1987.052.01.005; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Olejniczak M, 2005, NAT STRUCT MOL BIOL, V12, P788, DOI 10.1038/nsmb978; Rodin SN, 2008, HEREDITY, V100, P341, DOI 10.1038/sj.hdy.6801086; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; Sievers A, 2004, P NATL ACAD SCI USA, V101, P7897, DOI 10.1073/pnas.0402488101; TURNER DH, 1987, COLD SPRING HARB SYM, V52, P123, DOI 10.1101/SQB.1987.052.01.017; WOESE CR, 1966, P NATL ACAD SCI USA, V55, P966, DOI 10.1073/pnas.55.4.966; WOESE CR, 1965, P NATL ACAD SCI USA, V54, P71, DOI 10.1073/pnas.54.1.71	29	15	16	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2009	4	6							e5773	10.1371/journal.pone.0005773	http://dx.doi.org/10.1371/journal.pone.0005773			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453PV	19492048	Green Published, Green Submitted, gold			2022-12-25	WOS:000266624300010
J	Benn, CL; Butler, R; Mariner, L; Nixon, J; Moffitt, H; Mielcarek, M; Woodman, B; Bates, GP				Benn, Caroline L.; Butler, Rachel; Mariner, Lydia; Nixon, Jude; Moffitt, Hilary; Mielcarek, Michal; Woodman, Ben; Bates, Gillian P.			Genetic Knock-Down of HDAC7 Does Not Ameliorate Disease Pathogenesis in the R6/2 Mouse Model of Huntington's Disease	PLOS ONE			English	Article								Huntington's disease (HD) is an inherited, progressive neurological disorder caused by a CAG/polyglutamine repeat expansion, for which there is no effective disease modifying therapy. In recent years, transcriptional dysregulation has emerged as a pathogenic process that appears early in disease progression. Administration of histone deacetylase (HDAC) inhibitors such as suberoylanilide hydroxamic acid (SAHA) have consistently shown therapeutic potential in models of HD, at least partly through increasing the association of acetylated histones with down-regulated genes and by correcting mRNA abnormalities. The HDAC enzyme through which SAHA mediates its beneficial effects in the R6/2 mouse model of HD is not known. Therefore, we have embarked on a series of genetic studies to uncover the HDAC target that is relevant to therapeutic development for HD. HDAC7 is of interest in this context because SAHA has been shown to decrease HDAC7 expression in cell culture systems in addition to inhibiting enzyme activity. After confirming that expression levels of Hdac7 are decreased in the brains of wild type and R6/2 mice after SAHA administration, we performed a genetic cross to determine whether genetic reduction of Hdac7 would alleviate phenotypes in the R6/2 mice. We found no improvement in a number of physiological or behavioral phenotypes. Similarly, the dysregulated expression levels of a number of genes of interest were not improved suggesting that reduction in Hdac7 does not alleviate the R6/2 HD-related transcriptional dysregulation. Therefore, we conclude that the beneficial effects of HDAC inhibitors are not predominantly mediated through the inhibition of HDAC7.			Benn, CL (corresponding author), Kings Coll London, Sch Med, Dept Med & Mol Genet, London WC2R 2LS, England.	gillian.bates@kcl.ac.uk	Mielcarek, Michal/M-6302-2018; Longo, Kenneth A/A-5631-2010; Bates, Gillian P/E-1146-2012	Mielcarek, Michal/0000-0002-9874-6753; Bates, Gillian P/0000-0002-4041-6305	Medical Research Council Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Bates EA, 2006, J NEUROSCI, V26, P2830, DOI 10.1523/JNEUROSCI.3344-05.2006; BATES G, 2002, HUNTINGTONS DIS; Benn CL, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-17; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Broide RS, 2007, J MOL NEUROSCI, V31, P47, DOI 10.1007/BF02686117; Butler R, 2006, NAT REV NEUROSCI, V7, P784, DOI 10.1038/nrn1989; Carter RJ, 1999, J NEUROSCI, V19, P3248; Cha JHJ, 2007, PROG NEUROBIOL, V83, P228, DOI 10.1016/j.pneurobio.2007.03.004; Chang SR, 2006, CELL, V126, P321, DOI 10.1016/j.cell.2006.05.040; CODD R, 2008, INT J BIOCH CELL BIO; Cong SY, 2005, MOL CELL NEUROSCI, V30, P560, DOI 10.1016/j.mcn.2005.10.015; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dokmanovic M, 2007, MOL CANCER THER, V6, P2525, DOI 10.1158/1535-7163.MCT-07-0251; Gallinari P, 2007, CELL RES, V17, P195, DOI 10.1038/sj.cr.7310149; Gao CZ, 2008, MOL BIOL CELL, V19, P3020, DOI 10.1091/mbc.E07-11-1203; Gao CZ, 2008, MOL CELL BIOL, V28, P5658, DOI 10.1128/MCB.00874-08; Gao CZ, 2006, FEBS LETT, V580, P5096, DOI 10.1016/j.febslet.2006.08.038; Gardian G, 2005, J BIOL CHEM, V280, P556, DOI 10.1074/jbc.M410210200; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Ha CH, 2008, ARTERIOSCL THROM VAS, V28, P1782, DOI 10.1161/ATVBAHA.108.172528; Hockly E, 2006, NEUROBIOL DIS, V21, P228, DOI 10.1016/j.nbd.2005.07.007; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Hockly E, 2003, BRAIN RES BULL, V61, P469, DOI 10.1016/S0361-9230(03)00185-0; Hodges A, 2006, HUM MOL GENET, V15, P965, DOI 10.1093/hmg/ddl013; Hughes RE, 2001, P NATL ACAD SCI USA, V98, P13201, DOI 10.1073/pnas.191498198; Jensen ED, 2008, J BONE MINER RES, V23, P361, DOI 10.1359/JBMR.071104; Jensen ED, 2009, J BIOL CHEM, V284, P2225, DOI 10.1074/jbc.M800586200; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kao HY, 2000, GENE DEV, V14, P55; Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Kuhn A, 2007, HUM MOL GENET, V16, P1845, DOI 10.1093/hmg/ddm133; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Lione LA, 1999, J NEUROSCI, V19, P10428; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martin M, 2007, ONCOGENE, V26, P5450, DOI 10.1038/sj.onc.1210613; Martin M, 2008, P NATL ACAD SCI USA, V105, P4727, DOI 10.1073/pnas.0708455105; McCampbell A, 2001, P NATL ACAD SCI USA, V98, P15179, DOI 10.1073/pnas.261400698; Pallos J, 2008, HUM MOL GENET, V17, P3767, DOI 10.1093/hmg/ddn273; Parra M, 2005, J BIOL CHEM, V280, P13762, DOI 10.1074/jbc.M413396200; Parra M, 2007, GENE DEV, V21, P638, DOI 10.1101/gad.1513107; Richon VM, 2001, BLOOD CELL MOL DIS, V27, P260, DOI 10.1006/bcmd.2000.0376; Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Sadri-Vakili G, 2007, HUM MOL GENET, V16, P1293, DOI 10.1093/hmg/ddm078; Sadri-Vakili Ghazaleh, 2006, Current Alzheimer Research, V3, P403, DOI 10.2174/156720506778249407; Schuettengruber B, 2003, MOL CELL BIOL, V23, P6993, DOI 10.1128/MCB.23.19.6993-7004.2003; Schuetz A, 2008, J BIOL CHEM, V283, P11355, DOI 10.1074/jbc.M707362200; Sengupta N, 2004, J CELL BIOCHEM, V93, P57, DOI 10.1002/jcb.20179; Stack EC, 2005, J COMP NEUROL, V490, P354, DOI 10.1002/cne.20680; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Strand AD, 2005, HUM MOL GENET, V14, P1863, DOI 10.1093/hmg/ddi192; Thomas EA, 2008, P NATL ACAD SCI USA, V105, P15564, DOI 10.1073/pnas.0804249105; Woodman B, 2007, BRAIN RES BULL, V72, P83, DOI 10.1016/j.brainresbull.2006.11.004; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346; Zhang YJ, 2008, CURR MED CHEM, V15, P2840, DOI 10.2174/092986708786242796	62	57	60	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2009	4	6							e5747	10.1371/journal.pone.0005747	http://dx.doi.org/10.1371/journal.pone.0005747			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	452GL	19484127	Green Published, gold, Green Submitted			2022-12-25	WOS:000266528200003
J	Lindstrom, LS; Hall, P; Hartman, M; Wiklund, F; Czene, K				Lindstrom, Linda S.; Hall, Per; Hartman, Mikael; Wiklund, Fredrik; Czene, Kamila			Is Genetic Background Important in Lung Cancer Survival?	PLOS ONE			English	Article							IMPORTANT DETERMINANT; SMOKING-HABITS; FAMILY; POLYMORPHISMS; PROGRESSION; CHROMOSOME; HAPLOTYPES; BEHAVIOR; RISK	Background: In lung cancer, a patient's survival is poor with a wide variation in survival within the stage of disease. The aim of this study was to investigate the familial concordance in lung cancer survival by means of analyses of pairs with different degrees of familial relationships. Methods: Our population-based Swedish family database included three million families and over 58 100 lung cancer patients. We modelled the proband (parent, sibling, spouse) survival utilizing a multivariate proportional hazard (Cox) model adjusting for possible confounders of survival. Subsequently, the survival in proband's relative (child, sibling, spouse) was analysed with a Cox model. Findings: By use of Cox modelling with 5 years follow-up, we noted a decreased hazard ratio for death in children with good parental survival (Hazard Ratio [HR] = 0.71, 95% CI = 0.51 to 0.99), compared to those with poor parental survival. Also for siblings, a very strong protective effect was seen (HR = 0.14, 95% CI = 0.030 to 0.65). Finally, in spouses no correlation in survival was found. Interpretation: Our findings suggest that genetic factors are important in lung cancer survival. In a clinical setting, information on prognosis in a relative may be vital in foreseeing the survival in an individual newly diagnosed with lung cancer. Future molecular studies enhancing the understanding of the underlying mechanisms and pathways are needed.			Lindstrom, LS (corresponding author), Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.	Linda.Lindstrom@ki.se	Lindstrom, Linda LS/J-3215-2012; Hartman, Mikael/B-4324-2011	Lindstrom, Linda Sofie/0000-0002-7722-7532; Hartman, Mikael/0000-0001-5726-9965; Czene, Kamila/0000-0002-3233-5695				Bermejo JL, 2005, CANCER EPIDEM BIOMAR, V14, P1738, DOI 10.1158/1055-9965.EPI-05-0201; BLOTH B, 1976, ACTA MED SCAND, V200, P281; Bricker JB, 2006, ADDICTION, V101, P128, DOI 10.1111/j.1360-0443.2005.01297.x; *CANC SIFFR, 2005, POP FAKT CANC; Chen HY, 2007, NEW ENGL J MED, V356, P11, DOI 10.1056/NEJMoa060096; Clark AE, 2006, J HEALTH ECON, V25, P958, DOI 10.1016/j.jhealeco.2006.02.002; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; *CTR EP CANC INC S, 2002, NAT BOARD HLTH WELF; Dubey S, 2006, J THORAC ONCOL, V1, P406, DOI 10.1097/01243894-200606000-00005; Ebbert JO, 2005, LUNG CANCER-J IASLC, V47, P165, DOI 10.1016/j.lungcan.2004.07.045; Griesbach D, 2003, SOC SCI MED, V56, P41, DOI 10.1016/S0277-9536(02)00014-X; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; Hunter K, 2003, NAT GENET, V34, P23, DOI 10.1038/ng0503-23b; Hunter KW, 2003, CANCER LETT, V200, P97, DOI 10.1016/S0304-3835(03)00420-8; Isla D, 2004, ANN ONCOL, V15, P1194, DOI 10.1093/annonc/mdh319; Jemal A, 2004, CANCER-AM CANCER SOC, V101, P3, DOI 10.1002/cncr.20288; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Larsson L G, 1996, J Med Screen, V3, P129; Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8; Lindstrom LS, 2007, LANCET ONCOL, V8, P1001, DOI 10.1016/S1470-2045(07)70282-6; Liu G, 2005, SEMIN RESP CRIT CARE, V26, P265, DOI 10.1055/s-2005-871983; MACINTYRE S, 1991, LANCET, V338, P869, DOI 10.1016/0140-6736(91)91513-T; Matakidou A, 2007, HUM MOL GENET, V16, P2333, DOI 10.1093/hmg/ddm190; Pine SR, 2007, J NATL CANCER I, V99, P1401, DOI 10.1093/jnci/djm128; PRICE RA, 1980, BEHAV GENET, V10, P59, DOI 10.1007/BF01067319; RUTQVIST LE, 1985, ACTA RADIOL ONCOL, V24, P385, DOI 10.3109/02841868509134405; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Sun T, 2006, CLIN CANCER RES, V12, P7009, DOI 10.1158/1078-0432.CCR-06-0464; SUTTON GC, 1980, ANN HUM BIOL, V7, P449, DOI 10.1080/03014468000004561; Sykes B, 2000, AM J HUM GENET, V66, P1417, DOI 10.1086/302850; Tammemagi CM, 2004, CHEST, V125, P27, DOI 10.1378/chest.125.1.27; Welch DR, 2003, J NATL CANCER I, V95, P839, DOI 10.1093/jnci/95.12.839; West P, 1999, ADDICTION, V94, P1397, DOI 10.1046/j.1360-0443.1999.949139711.x; Yang P, 2002, LUNG CANCER, V35, P221, DOI 10.1016/S0169-5002(01)00426-3; Yoon SM, 2005, INT J RADIAT ONCOL, V63, P885, DOI 10.1016/j.ijrobp.2005.07.951; Yoshino I, 2007, SURG TODAY, V37, P725, DOI 10.1007/s00595-007-3516-6; Zhou W, 2006, LUNG CANCER-J IASLC, V53, P375, DOI 10.1016/j.lungcan.2006.05.017	37	78	79	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5588	10.1371/journal.pone.0005588	http://dx.doi.org/10.1371/journal.pone.0005588			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	451SH	19478952	gold, Green Submitted, Green Published			2022-12-25	WOS:000266490000002
J	Miller, HB; Saunders, KO; Tomaras, GD; Garcia-Blanco, MA				Miller, Heather B.; Saunders, Kevin O.; Tomaras, Georgia D.; Garcia-Blanco, Mariano A.			Tat-SF1 Is Not Required for Tat Transactivation but Does Regulate the Relative Levels of Unspliced and Spliced HIV-1 RNAs	PLOS ONE			English	Article								Background: HIV-1 relies on several host proteins for productive viral transcription. HIV-1 Tat-specific factor 1 (Tat-SF1) is among these cofactors that were identified by in vitro reconstituted transcription reactions with immunodepleted nuclear extracts. At the onset of this work, the prevailing hypothesis was that Tat-SF1 was a required cofactor for the viral regulatory protein, Tat; however, this had not previously been formally tested in vivo. Methodology/Principal Findings: To directly address the involvement of Tat-SF1 in HIV-1 gene expression, we depleted Tat-SF1 in HeLa cells by conventional expression of shRNAs and in T-Rex-293 cells containing tetracycline-inducible shRNAs targeting Tat-SF1. We achieved efficient depletion of Tat-SF1 and demonstrated that this did not affect cell viability. HIV-1 infectivity decreased in Tat-SF1-depleted cells, but only when multiple rounds of infection occurred. Neither Tat-dependent nor basal transcription from the HIV-1 LTR was affected by Tat-SF1 depletion, suggesting that the decrease in infectivity was due to a deficiency at a later step in the viral lifecycle. Finally, Tat-SF1 depletion resulted in an increase in the ratio of unspliced to spliced viral transcripts. Conclusions/Significance: Tat-SF1 is not required for regulating HIV-1 transcription, but is required for maintaining the ratios of different classes of HIV-1 transcripts. These new findings highlight a novel, post-transcriptional role for Tat-SF1 in the HIV-1 life cycle.			Miller, HB (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27706 USA.	garci001@mc.duke.edu	Miller, Heather B./M-1540-2019; Miller, Heather/R-4812-2019; Tomaras, Georgia/J-5041-2016	Miller, Heather/0000-0003-1400-7716; 	NIAID NIH HHS [R01-AI052779, R01 AI052779, P30 AI064518, P30 AI 64518, UC6 AI058607] Funding Source: Medline; NIGMS NIH HHS [R01 GM071037, R01-GM071037] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI064518, UC6AI058607, R01AI052779] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071037] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRIGO SJ, 1989, J VIROL, V63, P4875, DOI 10.1128/JVI.63.11.4875-4881.1989; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; Bonano VI, 2007, NAT PROTOC, V2, P2166, DOI 10.1038/nprot.2007.292; Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725; Bres V, 2005, GENE DEV, V19, P1211, DOI 10.1101/gad.1291705; CHEN CH, 1993, AIDS RES HUM RETROV, V9, P1079, DOI 10.1089/aid.1993.9.1079; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; Exline CM, 2008, J VIROL, V82, P3921, DOI 10.1128/JVI.01558-07; Fong YW, 2000, MOL CELL BIOL, V20, P5897, DOI 10.1128/MCB.20.16.5897-5907.2000; Fong YW, 2001, NATURE, V414, P929, DOI 10.1038/414929a; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Goff SP, 2007, NAT REV MICROBIOL, V5, P253, DOI 10.1038/nrmicro1541; Gorry PR, 1999, J VIROL, V73, P352, DOI 10.1128/JVI.73.1.352-361.1999; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Isel C, 1999, J MOL BIOL, V290, P929, DOI 10.1006/jmbi.1999.2933; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Kameoka S, 2004, EMBO J, V23, P1782, DOI 10.1038/sj.emboj.7600187; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Kim JB, 1999, MOL CELL BIOL, V19, P5960; Konig R, 2008, CELL, V135, P49, DOI 10.1016/j.cell.2008.07.032; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005; Li XY, 1998, GENE DEV, V12, P2992, DOI 10.1101/gad.12.19.2992; Lin J, 2007, J VIROL, V81, P12218, DOI 10.1128/JVI.01390-07; Lu J, 2004, J VIROL, V78, P4628, DOI 10.1128/JVI.78.9.4628-4637.2004; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Misse D, 2005, AIDS, V19, P897, DOI 10.1097/01.aids.0000171403.07995.92; Naito T, 2007, P NATL ACAD SCI USA, V104, P18235, DOI 10.1073/pnas.0705856104; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Overman R Glenn, 2007, Open Virol J, V1, P1, DOI 10.2174/1874357900701010001; Parada CA, 1999, EMBO J, V18, P3688, DOI 10.1093/emboj/18.13.3688; Ping Yueh-Hsin, 2004, Retrovirology, V1, P46, DOI 10.1186/1742-4690-1-46; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; Sanchez-Alvarez M, 2006, MOL CELL BIOL, V26, P4998, DOI 10.1128/MCB.01991-05; Simmons A, 2001, IMMUNITY, V14, P763, DOI 10.1016/S1074-7613(01)00158-3; Smith MJ, 2004, MOL CELL BIOL, V24, P9274, DOI 10.1128/MCB.24.21.9274-9285.2004; Sonza S, 2002, J VIROL, V76, P12611, DOI 10.1128/JVI.76.24.12611-12621.2002; Sune C, 1997, MOL CELL BIOL, V17, P6029, DOI 10.1128/MCB.17.10.6029; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Tokunaga K, 2001, J VIROL, V75, P6776, DOI 10.1128/JVI.75.15.6776-6785.2001; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; Wu-Baer F, 1998, J MOL BIOL, V277, P179, DOI 10.1006/jmbi.1997.1601; Yan D, 1998, MOL CELL BIOL, V18, P5000, DOI 10.1128/MCB.18.9.5000; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Zhou HL, 2008, CELL HOST MICROBE, V4, P495, DOI 10.1016/j.chom.2008.10.004; Zhou MS, 2004, J VIROL, V78, P13522, DOI 10.1128/JVI.78.24.13522-13533.2004; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605	58	11	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2009	4	5							e5710	10.1371/journal.pone.0005710	http://dx.doi.org/10.1371/journal.pone.0005710			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QD	19479034	Green Published, gold, Green Submitted			2022-12-25	WOS:000266415000019
J	Chen, K; Maaskola, J; Siegal, ML; Rajewsky, N				Chen, Kevin; Maaskola, Jonas; Siegal, Mark L.; Rajewsky, Nikolaus			Reexamining microRNA Site Accessibility in Drosophila: A Population Genomics Study	PLOS ONE			English	Article							SYSTEMATIC DISCOVERY; BINDING-SITES; GENES; POLYMORPHISM; PREDICTION; EVOLUTION; DATABASE; TARGETS; UPDATE; MOTIFS	Kertesz et al. (Nature Genetics 2008) described PITA, a miRNA target prediction algorithm based on hybridization energy and site accessibility. In this note, we used a population genomics approach to reexamine their data and found that the PITA algorithm had lower specificity than methods based on evolutionary conservation at comparable levels of sensitivity. We also showed that deeply conserved miRNAs tend to have stronger hybridization energies to their targets than do other miRNAs. Although PITA had higher specificity in predicting targets than a naive seed-match method, this signal was primarily due to the use of a single cutoff score for all miRNAs and to the observed correlation between conservation and hybridization energy. Overall, our results clarify the accuracy of different miRNA target prediction algorithms in Drosophila and the role of site accessibility in miRNA target prediction.			Chen, K (corresponding author), NYU, Dept Biol, Ctr Genom & Syst Biol, New York, NY 10003 USA.	kc1111@nyu.edu		Rajewsky, Nikolaus/0000-0002-4785-4332; Siegal, Mark/0000-0001-6930-2988				Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Begun DJ, 2007, PLOS BIOL, V5, P2534, DOI 10.1371/journal.pbio.0050310; Boffelli D, 2004, GENOME RES, V14, P2406, DOI 10.1101/gr.3199704; Chen K, 2006, COLD SH Q B, V71, P149; Chen K, 2006, NAT GENET, V38, P1452, DOI 10.1038/ng1910; Clark AG, 2005, GENOME RES, V15, P1496, DOI 10.1101/gr.4107905; Diederichs S, 2006, CANCER RES, V66, P6097, DOI 10.1158/0008-5472.CAN-06-0537; Ehrenreich IM, 2008, PLANT PHYSIOL, V146, P1974, DOI 10.1104/pp.108.116582; Fairbrother WG, 2004, PLOS BIOL, V2, P1388, DOI 10.1371/journal.pbio.0020268; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Grun D, 2005, PLOS COMPUT BIOL, V1, P51, DOI 10.1371/journal.pcbi.0010013; Iwai N, 2005, BIOCHEM BIOPH RES CO, V331, P1439, DOI 10.1016/j.bbrc.2005.04.051; Karginov FV, 2007, P NATL ACAD SCI USA, V104, P19291, DOI 10.1073/pnas.0709971104; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kuhn RM, 2007, NUCLEIC ACIDS RES, V35, pD668, DOI 10.1093/nar/gkl928; Lai EC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r42; Lall S, 2006, CURR BIOL, V16, P460, DOI 10.1016/j.cub.2006.01.050; Landthaler M, 2008, RNA, V14, P2580, DOI 10.1261/rna.1351608; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lu J, 2008, MOL BIOL EVOL, V25, P929, DOI 10.1093/molbev/msn040; Lunter G, 2006, PLOS COMPUT BIOL, V2, P2, DOI 10.1371/journal.pcbi.0020005; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Papadopoulos GL, 2009, NUCLEIC ACIDS RES, V37, pD155, DOI 10.1093/nar/gkn809; Rabani M, 2008, P NATL ACAD SCI USA, V105, P14885, DOI 10.1073/pnas.0803169105; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Saunders MA, 2007, P NATL ACAD SCI USA, V104, P3300, DOI 10.1073/pnas.0611347104; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Singh ND, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-37; Stark A, 2007, GENOME RES, V17, P1865, DOI 10.1101/gr.6593807; Stark A, 2007, NATURE, V450, P219, DOI 10.1038/nature06340; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Zeng Y, 2005, EMBO J, V24, P138, DOI 10.1038/sj.emboj.7600491	34	12	12	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2009	4	5							e5681	10.1371/journal.pone.0005681	http://dx.doi.org/10.1371/journal.pone.0005681			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LI	19478854	Green Submitted, Green Accepted, Green Published, gold			2022-12-25	WOS:000266331700009
J	Rotunno, M; Yu, K; Lubin, JH; Consonni, D; Pesatori, AC; Goldstein, AM; Goldin, LR; Wacholder, S; Welch, R; Burdette, L; Chanock, SJ; Bertazzi, PA; Tucker, MA; Caporaso, NE; Chatterjee, N; Bergen, AW; Landi, MT				Rotunno, Melissa; Yu, Kai; Lubin, Jay H.; Consonni, Dario; Pesatori, Angela C.; Goldstein, Alisa M.; Goldin, Lynn R.; Wacholder, Sholom; Welch, Robert; Burdette, Laurie; Chanock, Stephen J.; Bertazzi, Pier Alberto; Tucker, Margaret A.; Caporaso, Neil E.; Chatterjee, Nilanjan; Bergen, Andrew W.; Landi, Maria Teresa			Phase I Metabolic Genes and Risk of Lung Cancer: Multiple Polymorphisms and mRNA Expression	PLOS ONE			English	Article							MICROSOMAL EPOXIDE HYDROLASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; POLYCYCLIC AROMATIC-HYDROCARBONS; HUMAN CYP1A1; SUSCEPTIBILITY LOCUS; NICOTINE METABOLISM; CYTOCHROME P4501B1; CIGARETTE-SMOKING; DNA-ADDUCTS; CYP2A6	Polymorphisms in genes coding for enzymes that activate tobacco lung carcinogens may generate inter-individual differences in lung cancer risk. Previous studies had limited sample sizes, poor exposure characterization, and a few single nucleotide polymorphisms (SNPs) tested in candidate genes. We analyzed 25 SNPs (some previously untested) in 2101 primary lung cancer cases and 2120 population controls from the Environment And Genetics in Lung cancer Etiology (EAGLE) study from six phase I metabolic genes, including cytochrome P450s, microsomal epoxide hydrolase, and myeloperoxidase. We evaluated the main genotype effects and genotype-smoking interactions in lung cancer risk overall and in the major histology subtypes. We tested the combined effect of multiple SNPs on lung cancer risk and on gene expression. Findings were prioritized based on significance thresholds and consistency across different analyses, and accounted for multiple testing and prior knowledge. Two haplotypes in EPHX1 were significantly associated with lung cancer risk in the overall population. In addition, CYP1B1 and CYP2A6 polymorphisms were inversely associated with adenocarcinoma and squamous cell carcinoma risk, respectively. Moreover, the association between CYP1A1 rs2606345 genotype and lung cancer was significantly modified by intensity of cigarette smoking, suggesting an underling dose-response mechanism. Finally, increasing number of variants at CYP1A1/A2 genes revealed significant protection in never smokers and risk in ever smokers. Results were supported by differential gene expression in non-tumor lung tissue samples with down-regulation of CYP1A1 in never smokers and up-regulation in smokers from CYP1A1/A2 SNPs. The significant haplotype associations emphasize that the effect of multiple SNPs may be important despite null single SNP-associations, and warrants consideration in genome-wide association studies (GWAS). Our findings emphasize the necessity of post-GWAS fine mapping and SNP functional assessment to further elucidate cancer risk associations.			Rotunno, M (corresponding author), NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.	landim@mail.nih.gov	Consonni, Dario/AAM-2947-2020; bertazzi, pietro alberto/D-5039-2017; Wang, Weili/D-1546-2011; Tucker, Margaret A/B-4297-2015; pesatori, angela/K-5742-2016	Consonni, Dario/0000-0002-8935-3843; bertazzi, pietro alberto/0000-0003-3475-2449; pesatori, angela/0000-0002-0261-3252; Bergen, Andrew/0000-0002-1237-7644	NATIONAL INSTITUTE ON DRUG ABUSE [U01DA020830] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIDA NIH HHS [U01 DA020830] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Aklillu E, 2005, CANCER RES, V65, P5105, DOI 10.1158/0008-5472.CAN-05-0113; Alexandrov K, 2002, CARCINOGENESIS, V23, P1969, DOI 10.1093/carcin/23.12.1969; Ariyoshi N, 2002, CANCER EPIDEM BIOMAR, V11, P890; Cascorbi I, 1996, CANCER RES, V56, P4965; Coller JK, 2001, HISTOCHEM J, V33, P329, DOI 10.1023/A:1012414806166; Cote ML, 2007, LUNG CANCER, V55, P255, DOI 10.1016/j.lungcan.2006.11.002; Feyler A, 2002, CANCER EPIDEM BIOMAR, V11, P1550; Fretland AJ, 2000, CHEM-BIOL INTERACT, V129, P41, DOI 10.1016/S0009-2797(00)00197-6; GRAZIANO C, 2008, LUNG CANC; Gresner P, 2007, LUNG CANCER, V57, P1, DOI 10.1016/j.lungcan.2007.02.002; Hanna IH, 2000, CANCER RES, V60, P3440; HASSETT C, 1994, HUM MOL GENET, V3, P421, DOI 10.1093/hmg/3.3.421; Hoffmann D, 2001, CHEM RES TOXICOL, V14, P767, DOI 10.1021/tx000260u; Houlston RS, 2000, PHARMACOGENETICS, V10, P105, DOI 10.1097/00008571-200003000-00002; Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; KADLUBAR FF, 1992, ENVIRON HEALTH PERSP, V98, P69, DOI 10.2307/3431249; Kamataki T, 2005, BIOCHEM BIOPH RES CO, V338, P306, DOI 10.1016/j.bbrc.2005.08.268; Kim JH, 1998, CARCINOGENESIS, V19, P1847, DOI 10.1093/carcin/19.10.1847; Kiyohara C, 2006, EPIDEMIOLOGY, V17, P89, DOI 10.1097/01.ede.0000187627.70026.23; Kiyohara Chikako, 2007, Future Oncol, V3, P617, DOI 10.2217/14796694.3.6.617; Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651; Landi MT, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-203; LE ML, 2003, CANC CAUSES CONT5ROL, V14, P339; Lewis DFV, 1999, TOXICOLOGY, V133, P1, DOI 10.1016/S0300-483X(98)00149-8; Liang GY, 2005, CANCER LETT, V223, P265, DOI 10.1016/j.canlet.2004.12.042; London SJ, 1999, LANCET, V353, P898, DOI 10.1016/S0140-6736(98)04984-8; Lubin JH, 2007, INT J EPIDEMIOL, V36, P236, DOI 10.1093/ije/dym043; MALLET WG, 1991, CARCINOGENESIS, V12, P521, DOI 10.1093/carcin/12.3.521; McKay JD, 2008, NAT GENET, V40, P1404, DOI 10.1038/ng.254; Nakajima M, 2006, CLIN PHARMACOL THER, V80, P282, DOI 10.1016/j.clpt.2006.05.012; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; OESCH F, 1973, XENOBIOTICA, V3, P305, DOI 10.3109/00498257309151525; Pianezza ML, 1998, NATURE, V393, P750, DOI 10.1038/31623; Raaka S, 1998, CARCINOGENESIS, V19, P387, DOI 10.1093/carcin/19.3.387; Schmekel B, 2000, RESP MED, V94, P564, DOI 10.1053/rmed.2000.0776; SCHOTTENFELD D, 1996, CANC EPIDEMIOLOGY PR, P641; SEIDEGARD J, 1983, BIOCHIM BIOPHYS ACTA, V695, P251, DOI 10.1016/0304-419X(83)90014-8; Shah PP, 2008, MUTAT RES-FUND MOL M, V643, P4, DOI 10.1016/j.mrfmmm.2008.05.001; Shah PP, 2008, MUTAT RES-FUND MOL M, V639, P1, DOI 10.1016/j.mrfmmm.2007.10.006; Shields PG, 1999, ANN ONCOL, V10, P7, DOI 10.1023/A:1008331616378; Shimada T, 2004, CANCER SCI, V95, P1, DOI 10.1111/j.1349-7006.2004.tb03162.x; Sorensen M, 2005, CANCER LETT, V221, P185, DOI 10.1016/j.canlet.2004.11.012; Spink DC, 1998, CARCINOGENESIS, V19, P291, DOI 10.1093/carcin/19.2.291; Spitz Margaret R, 2008, J Natl Cancer Inst, V100, P1552, DOI 10.1093/jnci/djn363; Spivack SD, 2003, CLIN CANCER RES, V9, P6002; TEFRE T, 1991, PHARMACOGENETICS, V1, P20, DOI 10.1097/00008571-199110000-00004; Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846; To-Figueras J, 2001, CANCER LETT, V173, P155, DOI 10.1016/S0304-3835(01)00626-7; TRUSH MA, 1985, P NATL ACAD SCI USA, V82, P5194, DOI 10.1073/pnas.82.15.5194; Ueda R, 2006, MOL PHARMACOL, V69, P1924, DOI 10.1124/mol.105.021220; Van Schooten FJ, 2004, CANCER EPIDEM BIOMAR, V13, P828; Voho A, 2006, CANCER LETT, V237, P102, DOI 10.1016/j.canlet.2005.05.029; Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075; Wang S, 2008, CANCER EPIDEM BIOMAR, V17, P405, DOI 10.1158/1055-9965.EPI-07-0695; Wang YF, 2008, NAT GENET, V40, P1407, DOI 10.1038/ng.273; Watanabe J, 2000, PHARMACOGENETICS, V10, P25, DOI 10.1097/00008571-200002000-00004; Wright GS, 2000, CURR OPIN ONCOL, V12, P143, DOI 10.1097/00001622-200003000-00008; Xu LL, 2002, CANCER EPIDEM BIOMAR, V11, P1555; Zhu QS, 2003, BBA-MOL BASIS DIS, V1638, P208, DOI 10.1016/S0925-4439(03)00085-1; Zienolddiny S, 2008, CARCINOGENESIS, V29, P1164, DOI 10.1093/carcin/bgn020	61	69	75	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2009	4	5							e5652	10.1371/journal.pone.0005652	http://dx.doi.org/10.1371/journal.pone.0005652			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LB	19479063	Green Submitted, Green Published, gold			2022-12-25	WOS:000266331000011
J	Tamburini, BA; Trapp, S; Phang, TL; Schappa, JT; Hunter, LE; Modiano, JF				Tamburini, Beth A.; Trapp, Susan; Phang, Tzu Lip; Schappa, Jill T.; Hunter, Lawrence E.; Modiano, Jaime F.			Gene Expression Profiles of Sporadic Canine Hemangiosarcoma Are Uniquely Associated with Breed	PLOS ONE			English	Article							TUMOR-GROWTH; AFRICAN-AMERICAN; DOGS; CELLS; THROMBOSPONDIN-1; CANCER; VEGF; ANGIOGENESIS; PREVALENCE; RECEPTOR-2	The role an individual's genetic background plays on phenotype and biological behavior of sporadic tumors remains incompletely understood. We showed previously that lymphomas from Golden Retrievers harbor defined, recurrent chromosomal aberrations that occur less frequently in lymphomas from other dog breeds, suggesting spontaneous canine tumors provide suitable models to define how heritable traits influence cancer genotypes. Here, we report a complementary approach using gene expression profiling in a naturally occurring endothelial sarcoma of dogs (hemangiosarcoma). Naturally occurring hemangiosarcomas of Golden Retrievers clustered separately from those of non-Golden Retrievers, with contributions from transcription factors, survival factors, and from pro-inflammatory and angiogenic genes, and which were exclusively present in hemangiosarcoma and not in other tumors or normal cells (i.e., they were not due simply to variation in these genes among breeds). Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) was among genes preferentially enriched within known pathways derived from gene set enrichment analysis when characterizing tumors from Golden Retrievers versus other breeds. Heightened VEGFR1 expression in these tumors also was apparent at the protein level and targeted inhibition of VEGFR1 increased proliferation of hemangiosarcoma cells derived from tumors of Golden Retrievers, but not from other breeds. Our results suggest heritable factors mold gene expression phenotypes, and consequently biological behavior in sporadic, naturally occurring tumors.			Tamburini, BA (corresponding author), Univ Colorado, Integrated Dept Immunol, Denver, CO 80202 USA.	modiano@umn.edu	Fiumefreddo, Andrea/T-2977-2019; MODIANO, JAIME/K-3583-2019	MODIANO, JAIME/0000-0001-6398-7648; Hunter, Lawrence/0000-0003-1455-3370	NATIONAL CANCER INSTITUTE [P30CA077598, P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007405] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM008111] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA077598, P30 CA046934] Funding Source: Medline; NIAID NIH HHS [T32 AI007405] Funding Source: Medline; NLM NIH HHS [R01 LM008111-07, R01 LM008111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Akhtar N, 2004, NEOPLASIA, V6, P106, DOI 10.1593/neo.03334; APPLEBY EC, 1978, VET REC, V102, P449, DOI 10.1136/vr.102.20.449-b; BROWN NO, 1985, J AM VET MED ASSOC, V186, P56; Burton-Wurster N, 2005, J HERED, V96, P821, DOI 10.1093/jhered/esi105; Chen H, 1996, FEBS LETT, V387, P36, DOI 10.1016/0014-5793(96)00460-7; Clifford CA, 2001, J VET INTERN MED, V15, P131, DOI 10.1892/0891-6640(2001)015&lt;0131:PVEGFC&gt;2.3.CO;2; Dickerson EB, 2005, VET PATHOL, V42, P618, DOI 10.1354/vp.42-5-618; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Ferguson SE, 2006, GYNECOL ONCOL, V101, P209, DOI 10.1016/j.ygyno.2005.11.028; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferreira JA, 2006, STAT APPL GENET MOL, V5; Fosmire SP, 2004, LAB INVEST, V84, P562, DOI 10.1038/labinvest.3700080; Glickman L, 2000, GOLDEN RETRIEVER CLU; GLICKMAN LT, 2003, IRISH SETTER CLUB AM; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hankenson KD, 2005, MOL CELL BIOL, V25, P5599, DOI 10.1128/MCB.25.13.5599-5606.2005; Haviv F, 2005, J MED CHEM, V48, P2838, DOI 10.1021/jm0401560; Hiratsuka S, 2005, MOL CELL BIOL, V25, P355, DOI 10.1128/MCB.25.1.355-363.2005; Hogan C, 2007, MUTAT RES-FUND MOL M, V618, P41, DOI 10.1016/j.mrfmmm.2006.07.010; Irizarry RA., 2003, STAT APPL GENET MOL, V2, pArticl; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jubala CM, 2005, VET PATHOL, V42, P468, DOI 10.1354/vp.42-4-468; Khanna C, 2006, NAT BIOTECHNOL, V24, P1065, DOI 10.1038/nbt0906-1065b; Lamerato-Kozicki AR, 2006, EXP HEMATOL, V34, P870, DOI 10.1016/j.exphem.2006.04.013; Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338; MODIANO JF, 1991, J BIOL CHEM, V266, P10552; MODIANO JF, 1994, J BIOL CHEM, V269, P32972; Modiano JF, 2005, CANCER RES, V65, P5654, DOI 10.1158/0008-5472.CAN-04-4613; Modiano JF, 1999, DNA CELL BIOL, V18, P357, DOI 10.1089/104454999315259; Ostrander EA, 2000, TRENDS GENET, V16, P117, DOI 10.1016/S0168-9525(99)01958-7; Page GP, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-84; Peterson MR, 2000, J VET INTERN MED, V14, P140, DOI 10.1892/0891-6640(2000)014&lt;0140:ASOTLO&gt;2.3.CO;2; Priester W A, 1980, Natl Cancer Inst Monogr, P1; PRYMAK C, 1988, J AM VET MED ASSOC, V193, P706; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Rusk A, 2006, CLIN CANCER RES, V12, P7444, DOI 10.1158/1078-0432.CCR-06-0109; Selzner M, 2001, CANCER RES, V61, P1233; Shibuya M, 2003, CANCER SCI, V94, P751, DOI 10.1111/j.1349-7006.2003.tb01514.x; Shibuya M, 2006, J BIOCHEM MOL BIOL, V39, P469; SPANGLER WL, 1992, J AM VET MED ASSOC, V200, P829; Spielman RS, 2007, NAT GENET, V39, P226, DOI 10.1038/ng1955; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sutter NB, 2004, GENOME RES, V14, P2388, DOI 10.1101/gr.3147604; Tate G, 2007, CANCER GENET CYTOGEN, V178, P160, DOI 10.1016/j.cancergencyto.2007.07.017; Thamm DH, 2006, RES VET SCI, V81, P76, DOI 10.1016/j.rvsc.2005.09.005; Thomson SAM, 2005, VET PATHOL, V42, P550, DOI 10.1354/vp.42-5-550; Tschoep K, 2007, CRIT REV ONCOL HEMAT, V63, P111, DOI 10.1016/j.critrevonc.2007.04.001; U'Ren LW, 2007, J VET INTERN MED, V21, P113, DOI 10.1892/0891-6640(2007)21[113:EOANTV]2.0.CO;2; Vail DM, 2000, CANCER INVEST, V18, P781, DOI 10.3109/07357900009012210; Volpert OV, 2003, CANCER CELL, V3, P199, DOI 10.1016/S1535-6108(03)00056-4; Wagner JL, 1999, J HERED, V90, P35, DOI 10.1093/jhered/90.1.35; Wallace TA, 2008, CANCER RES, V68, P927, DOI 10.1158/0008-5472.CAN-07-2608; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471	53	60	61	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5549	10.1371/journal.pone.0005549	http://dx.doi.org/10.1371/journal.pone.0005549			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448AY	19461996	Green Published, gold			2022-12-25	WOS:000266234700005
J	Moresi, V; Garcia-Alvarez, G; Pristera, A; Rizzuto, E; Albertini, MC; Rocchi, M; Marazzi, G; Sassoon, D; Adamo, S; Coletti, D				Moresi, Viviana; Garcia-Alvarez, Gisela; Pristera, Alessandro; Rizzuto, Emanuele; Albertini, Maria C.; Rocchi, Marco; Marazzi, Giovanna; Sassoon, David; Adamo, Sergio; Coletti, Dario			Modulation of Caspase Activity Regulates Skeletal Muscle Regeneration and Function in Response to Vasopressin and Tumor Necrosis Factor	PLOS ONE			English	Article								Muscle homeostasis involves de novo myogenesis, as observed in conditions of acute or chronic muscle damage. Tumor Necrosis Factor (TNF) triggers skeletal muscle wasting in several pathological conditions and inhibits muscle regeneration. We show that intramuscular treatment with the myogenic factor Arg(8)-vasopressin (AVP) enhanced skeletal muscle regeneration and rescued the inhibitory effects of TNF on muscle regeneration. The functional analysis of regenerating muscle performance following TNF or AVP treatments revealed that these factors exerted opposite effects on muscle function. Principal component analysis showed that TNF and AVP mainly affect muscle tetanic force and fatigue. Importantly, AVP counteracted the effects of TNF on muscle function when delivered in combination with the latter. Muscle regeneration is, at least in part, regulated by caspase activation, and AVP abrogated TNF-dependent caspase activation. The contrasting effects of AVP and TNF in vivo are recapitulated in myogenic cell cultures, which express both PW1, a caspase activator, and Hsp70, a caspase inhibitor. We identified PW1 as a potential Hsp70 partner by screening for proteins interacting with PW1. Hsp70 and PW1 co-immunoprecipitated and co-localized in muscle cells. In vivo Hsp70 protein level was upregulated by AVP, and Hsp70 overexpression counteracted the TNF block of muscle regeneration. Our results show that AVP counteracts the effects of TNF through cross-talk at the Hsp70 level. Therefore, muscle regeneration, both in the absence and in the presence of cytokines may be enhanced by increasing Hsp70 expression.			Moresi, V (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, Rome, Italy.	sergio.adamo@uniroma1.it	Moresi, Viviana/N-7977-2013; Coletti, Dario/U-2219-2018; Coletti, Dario/CAG-9308-2022; Rizzuto, Emanuele/K-9437-2016; Adamo, Sergio/E-9058-2012; Albertini, Maria Cristina/AAG-6980-2019; Rocchi, Marco BL/AAK-5926-2021; SASSOON, David A/G-2502-2013	Rizzuto, Emanuele/0000-0003-2314-6128; Adamo, Sergio/0000-0002-1409-0452; Albertini, Maria Cristina/0000-0003-4549-1475; SASSOON, David A/0000-0001-6074-048X; Rocchi, marco/0000-0002-0056-5795; Moresi, viviana/0000-0003-1912-0339; Marazzi, giovanna/0000-0002-5388-1038; Coletti, Dario/0000-0001-7373-1953	NCI NIH HHS [P01 CA080058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA080058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertini MC, 2006, CYTOM PART A, V69A, P260, DOI 10.1002/cyto.a.20263; Albertini MC, 2003, CYTOM PART A, V52A, P12, DOI 10.1002/cyto.a.10019; ALEXANDER SL, 1991, ENDOCRINOLOGY, V128, P65, DOI 10.1210/endo-128-1-65; Alvisi M, 2008, DIFFERENTIATION, V76, P371, DOI 10.1111/j.1432-0436.2007.00231.x; Anderson TW, 1984, INTRO MULTIVARIATE S; Breton C, 2002, J CLIN ENDOCR METAB, V87, P1415, DOI 10.1210/jc.87.3.1415; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Chen SE, 2007, AM J PHYSIOL-CELL PH, V292, pC1660, DOI 10.1152/ajpcell.00486.2006; Clark IA, 2007, CYTOKINE GROWTH F R, V18, P335, DOI 10.1016/j.cytogfr.2007.04.002; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Coletti D, 2002, EMBO J, V21, P631, DOI 10.1093/emboj/21.4.631; Coletti D, 2005, GENESIS, V43, P120, DOI 10.1002/gene.20160; COLETTI D, 2008, BASIC APPL MYOL, V18, P109; Coletti D, 2007, CYTOM PART A, V71A, P846, DOI 10.1002/cyto.a.20447; CONVERTINO VA, 1983, J APPL PHYSIOL, V54, P508, DOI 10.1152/jappl.1983.54.2.508; Costelli P, 2006, AM J PHYSIOL-REG I, V291, pR674, DOI 10.1152/ajpregu.00104.2006; De Arcangelis V, 2003, MOL BIOL CELL, V14, P1392, DOI 10.1091/mbc.E02-03-0156; Decramer M, 2001, Verh K Acad Geneeskd Belg, V63, P577; Dehoux M, 2007, AM J PHYSIOL-ENDOC M, V292, pE145, DOI 10.1152/ajpendo.00085.2006; DEL PZ, 2008, ANN BIOMED ENG, V36, P1281; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Denti MA, 2008, HUM GENE THER, V19, P601, DOI 10.1089/hum.2008.012; Duguez S, 2003, AM J PHYSIOL-ENDOC M, V285, pE206, DOI 10.1152/ajpendo.00331.2002; Frost RA, 2003, ENDOCRINOLOGY, V144, P1770, DOI 10.1210/en.2002-220808; Fujita J, 2008, CELL STEM CELL, V2, P595, DOI 10.1016/j.stem.2008.04.001; Graupe D, 2008, NEUROL RES, V30, P123, DOI 10.1179/174313208X281136; Grounds MD, 2004, FASEB J, V18, P676, DOI 10.1096/fj.03-1024com; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Hodgetts S, 2006, NEUROMUSCULAR DISORD, V16, P591, DOI 10.1016/j.nmd.2006.06.011; Irintchev A, 1997, NEUROMUSCULAR DISORD, V7, P117, DOI 10.1016/S0960-8966(96)00422-1; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Kayani AC, 2008, REJUV RES, V11, P1021, DOI 10.1089/rej.2008.0795; Kojima A, 2007, J ORTHOP SCI, V12, P74, DOI 10.1007/s00776-006-1083-0; Komati H, 2005, MOL BIOL CELL, V16, P1232, DOI 10.1091/mbc.E04-06-0459; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Langen RCJ, 2004, FASEB J, V18, P227, DOI 10.1096/fj.03-0251com; Layne MD, 1999, EXP CELL RES, V249, P177, DOI 10.1006/excr.1999.4465; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; McArdle A, 2003, FASEB J, V17, P355, DOI 10.1096/fj.03-0395fje; MELIN B, 1980, EUR J APPL PHYSIOL O, V44, P141, DOI 10.1007/BF00421092; Minotti S, 1998, CELL GROWTH DIFFER, V9, P155; Mitchell PO, 2004, AM J PHYSIOL-CELL PH, V287, pC1753, DOI 10.1152/ajpcell.00292.2004; Mitchell PO, 2001, AM J PHYSIOL-CELL PH, V281, pC1706, DOI 10.1152/ajpcell.2001.281.5.C1706; Miyabara EH, 2006, AM J PHYSIOL-CELL PH, V290, pC1128, DOI 10.1152/ajpcell.00399.2005; Moresi V, 2008, STEM CELLS, V26, P997, DOI 10.1634/stemcells.2007-0493; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Naro F, 2003, J BIOL CHEM, V278, P49308, DOI 10.1074/jbc.M306941200; NERVI C, 1995, CELL GROWTH DIFFER, V6, P81; Nieto-Vazquez Iria, 2008, Archives of Physiology and Biochemistry, V114, P183, DOI [10.1080/13813450802181047, 10.1080/13813450802181047 ]; Olguin HC, 2007, J CELL BIOL, V177, P769, DOI 10.1083/jcb.200608122; Ostrovsky O, 2003, J BIOL CHEM, V278, P21221, DOI 10.1074/jbc.M211357200; Oustanina S, 2004, EMBO J, V23, P3430, DOI 10.1038/sj.emboj.7600346; Pelosi L, 2007, FASEB J, V21, P1393, DOI 10.1096/fj.06-7690com; Perniconi B, 2008, BASIC APPL MYOL, V18, P105; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Reid MB, 2002, AM J RESP CRIT CARE, V166, P479, DOI 10.1164/rccm.2202005; Relaix F, 1996, DEV BIOL, V177, P383, DOI 10.1006/dbio.1996.0172; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897; Riederer I, 2008, TRANSPL P, V40, P624, DOI 10.1016/j.transproceed.2008.01.026; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Schwarzkopf M, 2006, GENE DEV, V20, P3440, DOI 10.1101/gad.412606; Scicchitano BM, 2005, MOL BIOL CELL, V16, P3632, DOI 10.1091/mbc.E05-01-0055; Scicchitano BM, 2002, MOL ENDOCRINOL, V16, P1407, DOI 10.1210/me.16.6.1407; Senf SM, 2008, FASEB J, V22, P3836, DOI 10.1096/fj.08-110163; Serrano AL, 2008, CELL METAB, V7, P33, DOI 10.1016/j.cmet.2007.11.011; Setsuta K, 2008, CIRC J, V72, P569; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Supinski GS, 2006, J APPL PHYSIOL, V100, P1770, DOI 10.1152/japplphysiol.01288.2005; TETI A, 1993, AM J PHYSIOL, V265, pC113, DOI 10.1152/ajpcell.1993.265.1.C113; Thibonnier M, 1996, GENOMICS, V31, P327, DOI 10.1006/geno.1996.0055; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	74	30	33	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5570	10.1371/journal.pone.0005570	http://dx.doi.org/10.1371/journal.pone.0005570			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440308	gold, Green Submitted, Green Published			2022-12-25	WOS:000266107500004
J	Sirchia, SM; Tabano, S; Monti, L; Recalcati, MP; Gariboldi, M; Grati, FR; Porta, G; Finelli, P; Radice, P; Miozzo, M				Sirchia, Silvia M.; Tabano, Silvia; Monti, Laura; Recalcati, Maria P.; Gariboldi, Manuela; Grati, Francesca R.; Porta, Giovanni; Finelli, Palma; Radice, Paolo; Miozzo, Monica			Misbehaviour of XIST RNA in Breast Cancer Cells	PLOS ONE			English	Article								A role of X chromosome inactivation process in the development of breast cancer have been suggested. In particular, the relationship between the breast cancer predisposing gene BRCA1 and XIST, the main mediator of X chromosome inactivation, has been intensely investigated, but still remains controversial. We investigated this topic by assessing XIST behaviour in different groups of breast carcinomas and in a panel of breast cancer cell lines both BRCA1 mutant and wild type. In addition, we evaluated the occurrence of broader defects of heterochromatin in relation to BRCA1 status in breast cancer cells. We provide evidence that in breast cancer cells BRCA1 is involved in XIST regulation on the active X chromosome, but not in its localization as previously suggested, and that XIST can be unusually expressed by an active X and can decorate it. This indicates that the detection of XIST cloud in cancer cell is not synonymous of the presence of an inactive X chromosome. Moreover, we show that global heterochromatin defects observed in breast tumor cells are independent of BRCA1 status. Our observations sheds light on a possible previously uncharacterized mechanism of breast carcinogenesis mediated by XIST misbehaviour, particularly in BRCA1-related cancers. Moreover, the significant higher levels of XIST-RNA detected in BRCA1-associated respect to sporadic basal-like cancers, opens the possibility to use XIST expression as a marker to discriminate between the two groups of tumors.			Sirchia, SM (corresponding author), Univ Milan, Dept Med Surg & Dent, Med Genet Unit, Milan, Italy.	silvia.sirchia@unimi.it	Tabano, Silvia/P-1498-2017; Miozzo, Monica Rosa/AAC-6401-2022; Sirchia, Silvia/AAB-2620-2019; Finelli, Palma/A-3578-2016; Grati, Francesca Romana/H-7397-2019; RECALCATI, MARIA PAOLA/AAA-2215-2020; Radice, Paolo/O-3119-2013; Gariboldi, Manuela/K-4744-2016	Miozzo, Monica Rosa/0000-0002-6523-4575; Finelli, Palma/0000-0001-8464-6906; Radice, Paolo/0000-0001-6298-4111; Gariboldi, Manuela/0000-0001-8406-165X; Tabano, Silvia Maria/0000-0002-5260-6691; porta, giovanni/0000-0001-5260-2415; Sirchia, Silvia/0000-0002-6106-3721; Recalcati, Maria Paola/0000-0003-1780-9837	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		BALAZS M, 1991, CANCER GENET CYTOGEN, V57, P93, DOI 10.1016/0165-4608(91)90194-Y; Beever CL, 2003, AM J HUM GENET, V72, P399, DOI 10.1086/346119; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; CAMARGO M, 1980, HUM GENET, V55, P81, DOI 10.1007/BF00329131; Chadwick BP, 2004, P NATL ACAD SCI USA, V101, P17450, DOI 10.1073/pnas.0408021101; Clemson CM, 2006, P NATL ACAD SCI USA, V103, P7688, DOI 10.1073/pnas.0601069103; Colombo M, 2008, MODERN PATHOL, V21, P1262, DOI 10.1038/modpathol.2008.43; Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773; Deng CX, 2000, BIOESSAYS, V22, P728; El-Rehim DMA, 2004, J PATHOL, V203, P661, DOI 10.1002/path.1559; Erwin JA, 2008, CURR OPIN CELL BIOL, V20, P349, DOI 10.1016/j.ceb.2008.04.007; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Heard E, 2004, CURR OPIN CELL BIOL, V16, P247, DOI 10.1016/j.ceb.2004.03.005; Honrado E, 2006, ONCOGENE, V25, P5837, DOI 10.1038/sj.onc.1209875; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; LICHTER P, 1988, P NATL ACAD SCI USA, V85, P9664, DOI 10.1073/pnas.85.24.9664; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Ogilvie CM, 2005, J HISTOCHEM CYTOCHEM, V53, P285, DOI 10.1369/jhc.4B6409.2005; Pageau GJ, 2007, NAT REV CANCER, V7, P628, DOI 10.1038/nrc2172; Pageau GJ, 2007, J CELL BIOCHEM, V100, P835, DOI 10.1002/jcb.21188; Palacios J, 2005, BREAST CANCER RES TR, V90, P5, DOI 10.1007/s10549-004-1536-0; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Plath K, 2002, ANNU REV GENET, V36, P233, DOI 10.1146/annurev.genet.36.042902.092433; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Silver DP, 2007, CELL, V128, P991, DOI 10.1016/j.cell.2007.02.025; Sirchia SM, 2005, CANCER RES, V65, P2139, DOI 10.1158/0008-5472.CAN-04-3465; Song MA, 2007, ELECTROPHORESIS, V28, P2379, DOI 10.1002/elps.200600852; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Squire JA, 2000, GENOMICS, V65, P234, DOI 10.1006/geno.2000.6155; Takagi N, 2003, SEMIN CELL DEV BIOL, V14, P319, DOI 10.1016/j.semcdb.2003.09.027; Tam R, 2004, J CELL BIOL, V167, P269, DOI 10.1083/jcb.200403128; Turner NC, 2006, ONCOGENE, V25, P5846, DOI 10.1038/sj.onc.1209876; Vincent-Salomon A, 2007, CANCER RES, V67, P5134, DOI 10.1158/0008-5472.CAN-07-0465; WOLMAN SR, 1995, MODERN PATHOL, V8, P239; Xiao CY, 2007, CELL, V128, P977, DOI 10.1016/j.cell.2007.01.034; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049	41	51	61	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5559	10.1371/journal.pone.0005559	http://dx.doi.org/10.1371/journal.pone.0005559			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440381	gold, Green Published, Green Submitted			2022-12-25	WOS:000266107400003
J	Tetteh, KKA; Stewart, LB; Ochola, LI; Amambua-Ngwa, A; Thomas, AW; Marsh, K; Weedall, GD; Conway, DJ				Tetteh, Kevin K. A.; Stewart, Lindsay B.; Ochola, Lynette Isabella; Amambua-Ngwa, Alfred; Thomas, Alan W.; Marsh, Kevin; Weedall, Gareth D.; Conway, David J.			Prospective Identification of Malaria Parasite Genes under Balancing Selection	PLOS ONE			English	Article								Background: Endemic human pathogens are subject to strong immune selection, and interrogation of pathogen genome variation for signatures of balancing selection can identify important target antigens. Several major antigen genes in the malaria parasite Plasmodium falciparum have shown such signatures in polymorphism-versus-divergence indices (comparing with the chimpanzee parasite P. reichenowi), and in allele frequency based indices. Methodology/Principal Findings: To compare methods for prospective identification of genes under balancing selection, 26 additional genes known or predicted to encode surface-exposed proteins of the invasive blood stage merozoite were first sequenced from a panel of 14 independent P. falciparum cultured lines and P. reichenowi. Six genes at the positive extremes of one or both of the Hudson-Kreitman-Aguade (HKA) and McDonald-Kreitman (MK) indices were identified. Allele frequency based analysis was then performed on a Gambian P. falciparum population sample for these six genes and three others as controls. Tajima's D (TjD) index was most highly positive for the msp3/6-like PF10_0348 (TjD = 1.96) as well as the positive control ama1 antigen gene (TjD = 1.22). Across the genes there was a strong correlation between population TjD values and the relative HKA indices (whether derived from the population or the panel of cultured laboratory isolates), but no correlation with the MK indices. Conclusions/Significance: Although few individual parasite genes show significant evidence of balancing selection, analysis of population genomic and comparative sequence data with the HKA and TjD indices should discriminate those that do, and thereby identify likely targets of immunity.			Tetteh, KKA (corresponding author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.	dconway@mrc.gm	Amambua-Ngwa, Alfred/AHD-7882-2022; Tetteh, Kevin/GYQ-9704-2022; Amambua-Ngwa, Alfred/HGU-8062-2022; Amambua-Ngwa, Alfred/ABA-7305-2020	Amambua-Ngwa, Alfred/0000-0003-4478-3601; Tetteh, Kevin/0000-0003-2733-0037; Amambua-Ngwa, Alfred/0000-0003-4478-3601; Weedall, Gareth/0000-0002-8927-1063; Conway, David/0000-0002-8711-3037; Ochola-Oyier, Lynette/0000-0003-4393-0470	MRC [MC_U190081993] Funding Source: UKRI; Medical Research Council [MC_U190081993] Funding Source: Medline; Wellcome Trust [074695/Z/04/B] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Akey JM, 2002, GENOME RES, V12, P1805, DOI 10.1101/gr.631202; Baum J, 2003, GENETICS, V163, P1327; Bethke LL, 2006, MOL BIOCHEM PARASIT, V150, P10, DOI 10.1016/j.molbiopara.2006.06.004; Bull PC, 2008, MOL MICROBIOL, V68, P1519, DOI 10.1111/j.1365-2958.2008.06248.x; Carlson CS, 2005, GENOME RES, V15, P1553, DOI 10.1101/gr.4326505; Charlesworth D, 2006, PLOS GENET, V2, P379, DOI 10.1371/journal.pgen.0020064; Charlesworth J, 2008, MOL BIOL EVOL, V25, P1007, DOI 10.1093/molbev/msn005; Conway DJ, 2000, NAT MED, V6, P689, DOI 10.1038/76272; Conway DJ, 2002, PARASITOLOGY, V125, pS3, DOI 10.1017/S0031182002002214; Cortes A, 2005, INT J PARASITOL, V35, P125, DOI 10.1016/j.ijpara.2004.11.004; Cortes A, 2003, INFECT IMMUN, V71, P1416, DOI 10.1128/IAI.71.3.1416-1426.2003; DIECKMANN U, 2002, PURSUIT VIRULENCE MA; Dutta S, 2007, P NATL ACAD SCI USA, V104, P12488, DOI 10.1073/pnas.0701464104; Escalante AA, 1998, GENETICS, V149, P189; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; FU YX, 1993, GENETICS, V133, P693; Fumagalli M, 2009, GENOME RES, V19, P199, DOI 10.1101/gr.082768.108; Gilson PR, 2006, MOL CELL PROTEOMICS, V5, P1286, DOI 10.1074/mcp.M600035-MCP200; Gray JC, 2007, CLIN CHEM, V53, P1244, DOI 10.1373/clinchem.2006.081695; Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717; Healer J, 2004, MOL MICROBIOL, V52, P159, DOI 10.1111/j.1365-2958.2003.03974.x; HUDSON RR, 1987, GENETICS, V116, P153; HUGHES MK, 1995, MOL BIOCHEM PARASIT, V71, P99, DOI 10.1016/0166-6851(95)00037-2; Innan H, 2006, GENETICS, V173, P1725, DOI 10.1534/genetics.106.056242; Iriko H, 2008, MOL BIOCHEM PARASIT, V158, P11, DOI 10.1016/j.molbiopara.2007.11.004; Jeffares DC, 2007, NAT GENET, V39, P120, DOI 10.1038/ng1931; Joy DA, 2003, SCIENCE, V300, P318, DOI 10.1126/science.1081449; Kennedy MC, 2002, INFECT IMMUN, V70, P6948, DOI 10.1128/IAI.70.12.6948-6960.2002; Kocken CHM, 2002, INFECT IMMUN, V70, P4471, DOI 10.1128/IAI.70.8.4471-4476.2002; Kozarewa I, 2009, NAT METHODS, V6, P291, DOI [10.1038/nmeth.1311, 10.1038/NMETH.1311]; Li YF, 2008, EVOLUTION, V62, P2984, DOI 10.1111/j.1558-5646.2008.00486.x; Lipsitch M, 2007, J R SOC INTERFACE, V4, P787, DOI 10.1098/rsif.2007.0229; Martin MJ, 2005, P NATL ACAD SCI USA, V102, P12819, DOI 10.1073/pnas.0503819102; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Mu JB, 2007, NAT GENET, V39, P126, DOI 10.1038/ng1924; Nachman MW, 1996, GENETICS, V142, P953; Nielsen R, 2005, ANNU REV GENET, V39, P197, DOI 10.1146/annurev.genet.39.073003.112420; Osier FHA, 2008, INFECT IMMUN, V76, P2240, DOI 10.1128/IAI.01585-07; Polley SD, 2003, GENETICS, V165, P555; Polley SD, 2001, GENETICS, V158, P1505; Polley SD, 2007, J INFECT DIS, V195, P279, DOI 10.1086/509806; Rand DM, 1996, MOL BIOL EVOL, V13, P735, DOI 10.1093/oxfordjournals.molbev.a025634; Rayner JC, 2005, AM J TROP MED HYG, V72, P666, DOI 10.4269/ajtmh.2005.72.666; Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359; Sam-Yellowe TY, 2004, J PROTEOME RES, V3, P995, DOI 10.1021/pr049926m; Sanders PR, 2005, J BIOL CHEM, V280, P40169, DOI 10.1074/jbc.M509631200; TAJIMA F, 1989, GENETICS, V123, P597; TAJIMA F, 1989, GENETICS, V123, P585; Verra F, 2006, MOL BIOCHEM PARASIT, V149, P182, DOI 10.1016/j.molbiopara.2006.05.010; Volkman SK, 2007, NAT GENET, V39, P113, DOI 10.1038/ng1930; Weedall GD, 2007, INT J PARASITOL, V37, P77, DOI 10.1016/j.ijpara.2006.09.001; Weedall GD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002281; Zhai WW, 2009, MOL BIOL EVOL, V26, P273, DOI 10.1093/molbev/msn231	53	62	62	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5568	10.1371/journal.pone.0005568	http://dx.doi.org/10.1371/journal.pone.0005568			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440377	Green Published, Green Submitted, Green Accepted, gold			2022-12-25	WOS:000266107400012
J	Engler, C; Gruetzner, R; Kandzia, R; Marillonnet, S				Engler, Carola; Gruetzner, Ramona; Kandzia, Romy; Marillonnet, Sylvestre			Golden Gate Shuffling: A One-Pot DNA Shuffling Method Based on Type IIs Restriction Enzymes	PLOS ONE			English	Article								We have developed a protocol to assemble in one step and one tube at least nine separate DNA fragments together into an acceptor vector, with 90% of recombinant clones obtained containing the desired construct. This protocol is based on the use of type IIs restriction enzymes and is performed by simply subjecting a mix of 10 undigested input plasmids (nine insert plasmids and the acceptor vector) to a restriction-ligation and transforming the resulting mix in competent cells. The efficiency of this protocol allows generating libraries of recombinant genes by combining in one reaction several fragment sets prepared from different parental templates. As an example, we have applied this strategy for shuffling of trypsinogen from three parental templates (bovine cationic trypsinogen, bovine anionic trypsinogen and human cationic trypsinogen) each divided in 9 separate modules. We show that one round of shuffling using the 27 trypsinogen entry plasmids can easily produce the 19,683 different possible combinations in one single restriction-ligation and that expression screening of a subset of the library allows identification of variants that can lead to higher expression levels of trypsin activity. This protocol, that we call 'Golden Gate shuffling', is robust, simple and efficient, can be performed with templates that have no homology, and can be combined with other shuffling protocols in order to introduce any variation in any part of a given gene.			Engler, C (corresponding author), Icon Genet GmbH, Biozentrum, Halle, Germany.	marillonnet@icongenetics.de						Bolchi A, 2005, BIOTECHNOL APPL BIOC, V42, P205, DOI 10.1042/BA20050050; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Coco WM, 2002, NAT BIOTECHNOL, V20, P1246, DOI 10.1038/nbt757; Coco WM, 2001, NAT BIOTECHNOL, V19, P354, DOI 10.1038/86744; Cost GJ, 2007, NAT PROTOC, V2, P2198, DOI 10.1038/nprot.2007.325; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Eggert T, 2005, CHEMBIOCHEM, V6, P1062, DOI 10.1002/cbic.200400417; Engler C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003647; Hiraga K, 2003, J MOL BIOL, V330, P287, DOI 10.1016/S0022-2836(03)00590-4; Jezequel L, 2008, BIOTECHNIQUES, V45, P523, DOI 10.2144/000112954; Kotera I, 2008, J BIOTECHNOL, V137, P1, DOI 10.1016/j.jbiotec.2008.07.1816; Li MZ, 2007, NAT METHODS, V4, P251, DOI 10.1038/NMETH1010; Lutz S, 2004, CURR OPIN BIOTECH, V15, P291, DOI 10.1016/j.copbio.2004.05.004; Marillonnet S, 2004, P NATL ACAD SCI USA, V101, P6852, DOI 10.1073/pnas.0400149101; MEYER MM, 2006, CURR PROTOC PROTEIN, pCH26; Ness JE, 2002, NAT BIOTECHNOL, V20, P1251, DOI 10.1038/nbt754; Ostermeier M, 1999, NAT BIOTECHNOL, V17, P1205, DOI 10.1038/70754; Richardson TH, 2002, J BIOL CHEM, V277, P26501, DOI 10.1074/jbc.M203183200; Sen S, 2007, APPL BIOCHEM BIOTECH, V143, P212, DOI 10.1007/s12010-007-8003-4; Sieber V, 2001, NAT BIOTECHNOL, V19, P456, DOI 10.1038/88129; Silverman J, 2005, NAT BIOTECHNOL, V23, P1556, DOI 10.1038/nbt1166; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Trefzer A, 2007, APPL ENVIRON MICROB, V73, P4317, DOI 10.1128/AEM.02676-06; VOLKOV AA, 1999, NUCL ACIDS RES; Wang TW, 2006, MOL BIOTECHNOL, V34, P55, DOI 10.1385/MB:34:1:55; Woodard SL, 2003, BIOTECHNOL APPL BIOC, V38, P123, DOI 10.1042/BA20030026; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	28	600	724	11	211	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2009	4	5							e5553	10.1371/journal.pone.0005553	http://dx.doi.org/10.1371/journal.pone.0005553			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FX	19436741	Green Published, gold, Green Submitted			2022-12-25	WOS:000266107300017
J	Schmid, MC; Panagiotaropoulos, T; Augath, MA; Logothetis, NK; Smirnakis, SM				Schmid, Michael C.; Panagiotaropoulos, Theofanis; Augath, Mark A.; Logothetis, Nikos K.; Smirnakis, Stelios M.			Visually Driven Activation in Macaque Areas V2 and V3 without Input from the Primary Visual Cortex	PLOS ONE			English	Article							LATERAL GENICULATE-NUCLEUS; MONKEY SUPERIOR COLLICULUS; TEMPORAL POLYSENSORY AREA; STRIATE CORTEX; REVERSIBLE INACTIVATION; RESPONSE PROPERTIES; RETINOTOPIC ORGANIZATION; PRESTRIATE CORTEX; NEURONAL-ACTIVITY; AFFERENT BASIS	Creating focal lesions in primary visual cortex (V1) provides an opportunity to study the role of extra-geniculo-striate pathways for activating extrastriate visual cortex. Previous studies have shown that more than 95% of neurons in macaque area V2 and V3 stop firing after reversibly cooling V1 [1,2,3]. However, no studies on long term recovery in areas V2, V3 following permanent V1 lesions have been reported in the macaque. Here we use macaque fMRI to study area V2, V3 activity patterns from 1 to 22 months after lesioning area V1. We find that visually driven BOLD responses persist inside the V1-lesion projection zones (LPZ) of areas V2 and V3, but are reduced in strength by similar to 70%, on average, compared to prelesion levels. Monitoring the LPZ activity over time starting one month following the V1 lesion did not reveal systematic changes in BOLD signal amplitude. Surprisingly, the retinotopic organization inside the LPZ of areas V2, V3 remained similar to that of the non-lesioned hemisphere, suggesting that LPZ activation in V2, V3 is not the result of input arising from nearby (non-lesioned) V1 cortex. Electrophysiology recordings of multi-unit activity corroborated the BOLD observations: visually driven multi-unit responses could be elicited inside the V2 LPZ, even when the visual stimulus was entirely contained within the scotoma induced by the V1 lesion. Restricting the stimulus to the intact visual hemi-field produced no significant BOLD modulation inside the V2, V3 LPZs. We conclude that the observed activity patterns are largely mediated by parallel, V1-bypassing, subcortical pathways that can activate areas V2 and V3 in the absence of V1 input. Such pathways may contribute to the behavioral phenomenon of blindsight.			Schmid, MC (corresponding author), Max Planck Inst Biol Cybernet, D-72076 Tubingen, Germany.	schmidmicha@gmail.com; ssmirnakis@cns.bcm.edu	Panagiotaropoulos, Theofanis/A-6053-2013; Schmid, Michael Christoph/AAH-4835-2020; Logothetis, Nikos/U-9282-2019; Schmid, Michael C./G-1867-2010	Panagiotaropoulos, Theofanis/0000-0002-4621-1183; Schmid, Michael Christoph/0000-0003-1424-130X; Schmid, Michael C./0000-0003-1424-130X	Howard Hughes Medical Institute Funding Source: Medline; NEI NIH HHS [R01 EY019272] Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abel PL, 2000, J COMP NEUROL, V428, P278, DOI 10.1002/1096-9861(20001211)428:2<278::AID-CNE7>3.0.CO;2-R; Adams MM, 2000, J COMP NEUROL, V419, P377, DOI 10.1002/(SICI)1096-9861(20000410)419:3<377::AID-CNE9>3.0.CO;2-E; Anderson JC, 2006, J COMP NEUROL, V495, P709, DOI 10.1002/cne.20914; Azzopardi P, 2003, NEUROPSYCHOLOGIA, V41, P1738, DOI 10.1016/S0028-3932(03)00176-3; BARBUR JL, 1980, BRAIN, V103, P905, DOI 10.1093/brain/103.4.905; BARBUR JL, 1993, BRAIN, V116, P1293, DOI 10.1093/brain/116.6.1293; Baseler HA, 1999, J NEUROSCI, V19, P2619; BENDER DB, 1981, J NEUROPHYSIOL, V46, P672, DOI 10.1152/jn.1981.46.3.672; Berman RA, 2008, PROG BRAIN RES, V171, P467, DOI 10.1016/S0079-6123(08)00668-7; Brewer AA, 2002, J NEUROSCI, V22, P10416; BRUCE CJ, 1986, J NEUROPHYSIOL, V55, P1057, DOI 10.1152/jn.1986.55.5.1057; BULLIER J, 1983, EXP BRAIN RES, V53, P168; Collins CE, 2005, P NATL ACAD SCI USA, V102, P5594, DOI 10.1073/pnas.0501762102; Collins CE, 2003, J NEUROSCI, V23, P2251; COWEY A, 1962, NATURE, V193, P302, DOI 10.1038/193302a0; COWEY A, 1995, NATURE, V373, P247, DOI 10.1038/373247a0; Engel SA, 1997, CEREB CORTEX, V7, P181, DOI 10.1093/cercor/7.2.181; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Ffytche DH, 1996, BRAIN, V119, P1971, DOI 10.1093/brain/119.6.1971; FRIES W, 1981, PROC R SOC SER B-BIO, V213, P73, DOI 10.1098/rspb.1981.0054; GATTASS R, 1988, J NEUROSCI, V8, P1831; GATTASS R, 1981, J COMP NEUROL, V201, P519, DOI 10.1002/cne.902010405; Gilbert CD, 1998, PHYSIOL REV, V78, P467, DOI 10.1152/physrev.1998.78.2.467; GIRARD P, 1991, J NEUROPHYSIOL, V66, P1493, DOI 10.1152/jn.1991.66.5.1493; GIRARD P, 1992, J NEUROPHYSIOL, V67, P1437, DOI 10.1152/jn.1992.67.6.1437; GIRARD P, 1991, NEUROREPORT, V2, P81, DOI 10.1097/00001756-199102000-00004; GIRARD P, 1989, J NEUROPHYSIOL, V62, P1287, DOI 10.1152/jn.1989.62.6.1287; Goebel R, 2001, VISION RES, V41, P1459, DOI 10.1016/S0042-6989(01)00069-4; GROSS CG, 1991, NEUROPSYCHOLOGIA, V29, P497, DOI 10.1016/0028-3932(91)90007-U; GRUETTER R, 1993, MAGNET RESON MED, V29, P804, DOI 10.1002/mrm.1910290613; HARTING JK, 1980, J COMP NEUROL, V192, P853, DOI 10.1002/cne.901920414; HUMPHREY NK, 1967, NATURE, V215, P595, DOI 10.1038/215595a0; KAAS JH, 1992, VISUAL NEUROSCI, V9, P399, DOI 10.1017/S0952523800010804; KENNEDY H, 1985, J NEUROSCI, V5, P2815; Kim DS, 2004, NEUROIMAGE, V21, P876, DOI 10.1016/j.neuroimage.2003.10.018; LEE JH, 1995, MAGN RESON MED, V34, P308, DOI 10.1002/mrm.1910340305; Lerner Y, 2001, CEREB CORTEX, V11, P287, DOI 10.1093/cercor/11.4.287; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Logothetis NK, 1999, NAT NEUROSCI, V2, P555, DOI 10.1038/9210; MALPELI JG, 1975, J COMP NEUROL, V161, P569, DOI 10.1002/cne.901610407; MANSFIELD P, 1977, J PHYS C SOLID STATE, V10, pL55, DOI 10.1088/0022-3719/10/3/004; Mathiesen C, 1998, J PHYSIOL-LONDON, V512, P555, DOI 10.1111/j.1469-7793.1998.555be.x; MAUNSELL JHR, 1983, J NEUROSCI, V3, P2563; MCKINNON GC, 1993, MAGNET RESON MED, V30, P609, DOI 10.1002/mrm.1910300512; MOHLER CW, 1977, J NEUROPHYSIOL, V40, P74, DOI 10.1152/jn.1977.40.1.74; PERRY VH, 1984, NEUROSCIENCE, V12, P1125, DOI 10.1016/0306-4522(84)90007-1; Riddoch G, 1917, BRAIN, V40, P15, DOI 10.1093/brain/40.1.15; ROCHAMIRANDA CE, 1975, J NEUROPHYSIOL, V38, P475, DOI 10.1152/jn.1975.38.3.475; Rockland KS, 1999, J COMP NEUROL, V406, P221, DOI 10.1002/(SICI)1096-9861(19990405)406:2<221::AID-CNE7>3.0.CO;2-K; RODMAN HR, 1989, J NEUROSCI, V9, P2033; RODMAN HR, 1990, J NEUROSCI, V10, P1154; Rosa MGP, 2000, J NEUROSCI, V20, P5552, DOI 10.1523/JNEUROSCI.20-14-05552.2000; SCHILLER PH, 1977, BRAIN RES, V126, P366, DOI 10.1016/0006-8993(77)90734-X; SCHILLER PH, 1974, J NEUROPHYSIOL, V37, P181, DOI 10.1152/jn.1974.37.1.181; SHIPP S, 1989, EUR J NEUROSCI, V1, P333, DOI 10.1111/j.1460-9568.1989.tb00799.x; Shipp S, 2001, J COMP NEUROL, V439, P469, DOI 10.1002/cne.1363; Shmuel A, 2006, NAT NEUROSCI, V9, P569, DOI 10.1038/nn1675; Sincich LC, 2004, NAT NEUROSCI, V7, P1123, DOI 10.1038/nn1318; Smirnakis SM, 2005, NATURE, V435, P300, DOI 10.1038/nature03495; SMIRNAKIS SM, 2007, J CEREB BLOOD FLOW M; Soares JGM, 2004, CLIN EXP PHARMACOL P, V31, P580, DOI 10.1111/j.1440-1681.2004.04051.x; Stoerig P, 2002, CEREB CORTEX, V12, P565, DOI 10.1093/cercor/12.6.565; Stoerig P, 1997, BRAIN, V120, P535, DOI 10.1093/brain/120.3.535; Teo PC, 1997, IEEE T MED IMAGING, V16, P852, DOI 10.1109/42.650881; UGURBIL K, 1993, MAGN RESON QUART, V9, P259; VANESSEN DC, 1982, J NEUROSCI, V2, P265; Vincent JL, 2007, NATURE, V447, P83, DOI 10.1038/nature05758; Weiskrantz L, 2003, PROG BRAIN RES, V144, P229, DOI 10.1016/S0079-6123(03)14401-6; WEISKRANTZ L, 1974, BRAIN, V97, P709, DOI 10.1093/brain/97.1.709; YUKIE M, 1981, J COMP NEUROL, V201, P81, DOI 10.1002/cne.902010107; Zeki S, 1998, BRAIN, V121, P25, DOI 10.1093/brain/121.1.25; ZEKI S, 1989, EUR J NEUROSCI, V1, P494, DOI 10.1111/j.1460-9568.1989.tb00356.x; ZEKI SM, 1978, J PHYSIOL-LONDON, V277, P245, DOI 10.1113/jphysiol.1978.sp012271	73	66	67	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5527	10.1371/journal.pone.0005527	http://dx.doi.org/10.1371/journal.pone.0005527			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444WA	19436733	Green Published, gold			2022-12-25	WOS:000266009900019
J	Won, KJ; Agarwal, S; Shen, L; Shoemaker, R; Ren, B; Wang, W				Won, Kyoung-Jae; Agarwal, Saurabh; Shen, Li; Shoemaker, Robert; Ren, Bing; Wang, Wei			An Integrated Approach to Identifying Cis-Regulatory Modules in the Human Genome	PLOS ONE			English	Article							HIDDEN MARKOV-MODELS; CLUSTERS; PREDICTION; DISCOVERY; PROMOTERS; MOTIFS	In eukaryotic genomes, it is challenging to accurately determine target sites of transcription factors (TFs) by only using sequence information. Previous efforts were made to tackle this task by considering the fact that TF binding sites tend to be more conserved than other functional sites and the binding sites of several TFs are often clustered. Recently, ChIP-chip and ChIP-sequencing experiments have been accumulated to identify TF binding sites as well as survey the chromatin modification patterns at the regulatory elements such as promoters and enhancers. We propose here a hidden Markov model (HMM) to incorporate sequence motif information, TF-DNA interaction data and chromatin modification patterns to precisely identify cis-regulatory modules (CRMs). We conducted ChIP-chip experiments on four TFs, CREB, E2F1, MAX, and YY1 in 1% of the human genome. We then trained a hidden Markov model (HMM) to identify the labels of the CRMs by incorporating the sequence motifs recognized by these TFs and the ChIP-chip ratio. Chromatin modification data was used to predict the functional sites and to further remove false positives. Cross-validation showed that our integrated HMM had a performance superior to other existing methods on predicting CRMs. Incorporating histone signature information successfully penalized false prediction and improved the whole performance. The dataset we used and the software are available at http://nash.ucsd.edu/CIS/.			Won, KJ (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.	biren@ucsd.edu; wei-wang@ucsd.edu	Hu, Ruogu/B-2203-2008; Shen, Li/B-3562-2008	Shen, Li/0000-0002-5190-2851; Won, Kyoung Jae/0000-0002-2924-9630				Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Blanchette M, 2006, GENOME RES, V16, P656, DOI 10.1101/gr.4866006; Bulyk ML, 2004, GENOME BIOL, V5; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Durbin R., 1998, BIOL SEQUENCE ANAL P; Frith MC, 2003, NUCLEIC ACIDS RES, V31, P3666, DOI 10.1093/nar/gkg540; Frith MC, 2002, NUCLEIC ACIDS RES, V30, P3214, DOI 10.1093/nar/gkf438; Frith MC, 2001, BIOINFORMATICS, V17, P878, DOI 10.1093/bioinformatics/17.10.878; Gupta M, 2005, P NATL ACAD SCI USA, V102, P7079, DOI 10.1073/pnas.0408743102; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; JI H, 2006, NUCL ACIDS RES E, V146, P1188; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Krogh A, 2000, GENOME RES, V10, P523, DOI 10.1101/gr.10.4.523; KROGH A, 1997, 2 METHODS IMPROVING, P179; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; RABINER LR, 1989, P IEEE, V77, P257, DOI 10.1109/5.18626; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Robertson G, 2007, NAT METHODS, V4, P651, DOI 10.1038/NMETH1068; Roh TY, 2004, NAT BIOTECHNOL, V22, P1013, DOI 10.1038/nbt990; Rokas A, 2007, CURR BIOL, V17, pR626, DOI 10.1016/j.cub.2007.06.025; SHEN L, 2008, REWIRING YY1 T UNPUB; Sinha S, 2003, BIOINFORMATICS, V19, pi292, DOI 10.1093/bioinformatics/btg1040; Won KJ, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-547; Xie D, 2008, GENOME RES, V18, P1325, DOI 10.1101/gr.072769.107; Yuh CH, 1998, SCIENCE, V279, P1896, DOI 10.1126/science.279.5358.1896; Zhou Q, 2004, P NATL ACAD SCI USA, V101, P12114, DOI 10.1073/pnas.0402858101; Zhou Q, 2007, ANN APPL STAT, V1, P36, DOI 10.1214/07-AOAS103	30	15	15	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2009	4	5							e5501	10.1371/journal.pone.0005501	http://dx.doi.org/10.1371/journal.pone.0005501			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444VZ	19434238	Green Submitted, Green Published, gold			2022-12-25	WOS:000266009800005
J	Beste, DJV; Espasa, M; Bonde, B; Kierzek, AM; Stewart, GR; McFadden, J				Beste, Dany J. V.; Espasa, Mateus; Bonde, Bhushan; Kierzek, Andrzej M.; Stewart, Graham R.; McFadden, Johnjoe			The Genetic Requirements for Fast and Slow Growth in Mycobacteria	PLOS ONE			English	Article								Mycobacterium tuberculosis infects a third of the world's population. Primary tuberculosis involving active fast bacterial replication is often followed by asymptomatic latent tuberculosis, which is characterised by slow or non-replicating bacteria. Reactivation of the latent infection involving a switch back to active bacterial replication can lead to post-primary transmissible tuberculosis. Mycobacterial mechanisms involved in slow growth or switching growth rate provide rational targets for the development of new drugs against persistent mycobacterial infection. Using chemostat culture to control growth rate, we screened a transposon mutant library by Transposon site hybridization (TraSH) selection to define the genetic requirements for slow and fast growth of Mycobacterium bovis (BCG) and for the requirements of switching growth rate. We identified 84 genes that are exclusively required for slow growth (69 hours doubling time) and 256 genes required for switching from slow to fast growth. To validate these findings we performed experiments using individual M. tuberculosis and M. bovis BCG knock out mutants. We have demonstrated that growth rate control is a carefully orchestrated process which requires a distinct set of genes encoding several virulence determinants, gene regulators, and metabolic enzymes. The mce1 locus appears to be a component of the switch to slow growth rate, which is consistent with the proposed role in virulence of M. tuberculosis. These results suggest novel perspectives for unravelling the mechanisms involved in the switch between acute and persistent TB infections and provide a means to study aspects of this important phenomenon in vitro.			Beste, DJV (corresponding author), Univ Surrey, FHMS, Guildford GU2 5XH, Surrey, England.	j.mcfadden@surrey.ac.uk	ESPASA, MATEU/L-4587-2014	ESPASA, MATEU/0000-0003-4822-1024; Kierzek, Andrzej/0000-0002-2605-9057; McFadden, Johnjoe/0000-0003-2145-0046; Beste, Dany/0000-0001-6579-1366; Stewart, Graham/0000-0002-6867-6248	Biotechnology and Biological Sciences Research Council [BB/D007208/1] Funding Source: Medline; Wellcome Trust Funding Source: Medline; BBSRC [BB/D007208/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ARRUDA S, 1993, SCIENCE, V261, P1454, DOI 10.1126/science.8367727; Baganz F, 1998, YEAST, V14, P1417, DOI 10.1002/(SICI)1097-0061(199811)14:15<1417::AID-YEA334>3.0.CO;2-N; Beste DJV, 2007, J BACTERIOL, V189, P3969, DOI 10.1128/JB.01787-06; Beste DJV, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r89; Beste DJV, 2005, J BACTERIOL, V187, P1677, DOI 10.1128/JB.187.5.1677-1684.2005; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Camacho LR, 2001, J BIOL CHEM, V276, P19845, DOI 10.1074/jbc.M100662200; Chan K, 2005, INFECT IMMUN, V73, P5438, DOI 10.1128/IAI.73.9.5438-5449.2005; Chen P, 2000, INFECT IMMUN, V68, P5575, DOI 10.1128/IAI.68.10.5575-5580.2000; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; De Voss JJ, 2000, P NATL ACAD SCI USA, V97, P1252, DOI 10.1073/pnas.97.3.1252; Domenech P, 2005, INFECT IMMUN, V73, P3492, DOI 10.1128/IAI.73.6.3492-3501.2005; Downing KJ, 2004, TUBERCULOSIS, V84, P167, DOI 10.1016/j.tube.2003.12.004; El Hajji M, 2009, MATH BIOSCI, V218, P33, DOI 10.1016/j.mbs.2008.12.003; Garton NJ, 2008, PLOS MED, V5, P634, DOI 10.1371/journal.pmed.0050075; Geiman DE, 2004, INFECT IMMUN, V72, P1733, DOI 10.1128/IAI.72.3.1733-1745.2004; Glover RT, 2007, J BACTERIOL, V189, P5495, DOI 10.1128/JB.00190-07; GOLDMAN DS, 1963, J BACTERIOL, V86, P30, DOI 10.1128/JB.86.1.30-37.1963; Gu XL, 2006, BIOCHEM BIOPH RES CO, V339, P897, DOI 10.1016/j.bbrc.2005.11.088; Hett EC, 2007, MOL MICROBIOL, V66, P658, DOI 10.1111/j.1365-2958.2007.05945.x; Hong FX, 2008, BIOINFORMATICS, V24, P374, DOI 10.1093/bioinformatics/btm620; Hong FX, 2006, BIOINFORMATICS, V22, P2825, DOI 10.1093/bioinformatics/btl476; Hu YM, 2004, FEMS MICROBIOL LETT, V237, P415, DOI 10.1016/j.femsle.2004.07.005; Joshi SM, 2006, P NATL ACAD SCI USA, V103, P11760, DOI 10.1073/pnas.0603179103; Kana BD, 2008, MOL MICROBIOL, V67, P672, DOI 10.1111/j.1365-2958.2007.06078.x; Karls RK, 2006, MICROBIOL-SGM, V152, P1591, DOI 10.1099/mic.0.28591-0; Keating LA, 2005, MOL MICROBIOL, V56, P163, DOI 10.1111/j.1365-2958.2005.04524.x; Kendall SL, 2004, TRENDS MICROBIOL, V12, P537, DOI 10.1016/j.tim.2004.10.005; Lima P, 2007, MICROBES INFECT, V9, P1285, DOI 10.1016/j.micinf.2007.05.020; LIN ECC, 1976, ANNU REV MICROBIOL, V30, P535, DOI 10.1146/annurev.mi.30.100176.002535; Lobry C, 2006, CR BIOL, V329, P40, DOI 10.1016/j.crvi.2005.10.004; Movahedzadeh F, 2004, MICROBIOL-SGM, V150, P3499, DOI 10.1099/mic.0.27204-0; Pandey AK, 2008, P NATL ACAD SCI USA, V105, P4376, DOI 10.1073/pnas.0711159105; Pandey DP, 2005, NUCLEIC ACIDS RES, V33, P966, DOI 10.1093/nar/gki201; Pang XH, 2007, MICROBIOL-SGM, V153, P1229, DOI 10.1099/mic.0.29281-0; Parish T, 2000, MICROBIOL-SGM, V146, P1969, DOI 10.1099/00221287-146-8-1969; R Development Core Team, 2006, R LANG ENV STAT COMP; Rengarajan J, 2005, P NATL ACAD SCI USA, V102, P8327, DOI 10.1073/pnas.0503272102; Rickman L, 2004, BIOCHEM BIOPH RES CO, V314, P259, DOI 10.1016/j.bbrc.2003.12.082; Rodriguez GM, 2002, INFECT IMMUN, V70, P3371, DOI 10.1128/IAI.70.7.3371-3381.2002; Rousseau C, 2004, CELL MICROBIOL, V6, P277, DOI 10.1046/j.1462-5822.2004.00368.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Shimono N, 2003, P NATL ACAD SCI USA, V100, P15918, DOI 10.1073/pnas.2433882100; Stewart GR, 2003, NAT REV MICROBIOL, V1, P97, DOI 10.1038/nrmicro749; Stewart GR, 2002, MICROBIOL-SGM, V148, P3129, DOI 10.1099/00221287-148-10-3129; Stewart GR, 2001, NAT MED, V7, P732, DOI 10.1038/89113; Stewart GR, 2005, PLOS PATHOG, V1, P269, DOI 10.1371/journal.ppat.0010033; Uchida Y, 2007, CELL MICROBIOL, V9, P1275, DOI 10.1111/j.1462-5822.2006.00870.x; Vulic M, 2001, GENETICS, V158, P519; *WHO, 2008, TUB FACT SHEET; Williams EP, 2007, J BACTERIOL, V189, P4234, DOI 10.1128/JB.00201-07; Zahrt TC, 2001, P NATL ACAD SCI USA, V98, P12706, DOI 10.1073/pnas.221272198	54	85	86	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2009	4	4							e5349	10.1371/journal.pone.0005349	http://dx.doi.org/10.1371/journal.pone.0005349			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437VL	19479006	Green Published, Green Submitted, gold			2022-12-25	WOS:000265514900012
J	Martellini, JA; Cole, AL; Venkataraman, N; Quinn, GA; Svoboda, P; Gangrade, BK; Pohl, J; Sorensen, OE; Cole, AM				Martellini, Julie A.; Cole, Amy L.; Venkataraman, Nitya; Quinn, Gerry A.; Svoboda, Pavel; Gangrade, Bhushan K.; Pohl, Jan; Sorensen, Ole E.; Cole, Alexander M.			Cationic polypeptides contribute to the anti-HIV-1 activity of human seminal plasma	FASEB JOURNAL			English	Article						antigens; epitopes; AIDS; reproductive immunology; viral; antimicrobial	IMMUNODEFICIENCY-VIRUS TYPE-1; POLYACRYLAMIDE-GEL ELECTROPHORESIS; PROSTATE-SPECIFIC ANTIGEN; SPERM MOTILITY INHIBITOR; ANTIMICROBIAL PEPTIDES; SEMENOGELIN-I; ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; PROTEIN; LACTOFERRIN	Mucosal surfaces of the reproductive tract as well as their secretions have important roles in preventing sexual transmission of HIV-1. In the current study, the majority of the intrinsic anti-HIV-1 activity of human seminal plasma (SP) was determined to reside in the cationic polypeptide fraction. Antiviral assays utilizing luciferase reporter cells and lymphocytic cells revealed the ability of whole SP to prevent HIV-1 infection, even when SP was diluted 3200-fold. Subsequent fractionation by continuous flow acid-urea (AU)-PAGE and antiviral testing revealed that cationic polypeptides within SP were responsible for the majority of anti-HIV-1 activity. A proteomic approach was utilized to resolve and identify 52 individual cationic polypeptides that contribute to the aggregate anti-HIV-1 activity of SP. One peptide fragment of semenogelin I, termed SG-1, was purified from SP by a multistep chromatographic approach, protein sequenced, and determined to exhibit anti-HIV-1 activity against HIV-1. Anti-HIV-1 activity was transient, as whole SP incubated for prolonged time intervals exhibited a proportional decrease in anti-HIV-1 activity that was directly attributed to the degradation of semenogelin I peptides. Collectively, these results indicate that the cationic polypeptide fraction of SP is active against HIV-1, and that semenogelin-derived peptides contribute to the intrinsic anti-HIV-1 activity of SP.-Martellini, J. A., Cole, A. C., Venkataraman, N., Quinn, G. A., Svoboda, P., Gangrade, B. K., Pohl, J., Sorensen, O. E., Cole, A. M. Cationic polypeptides contribute to the anti-HIV-1 activity of human seminal plasma. FASEB J. 23, 3609-3618 (2009). www.fasebj.org	[Martellini, Julie A.; Cole, Amy L.; Venkataraman, Nitya; Quinn, Gerry A.; Cole, Alexander M.] Univ Cent Florida, Burnett Sch Biomed Sci, Biomol Sci Ctr, Dept Mol Biol & Microbiol, Orlando, FL 32816 USA; [Svoboda, Pavel; Pohl, Jan] Ctr Dis Control & Prevent, Div Safety Res, Biotechnol Core Facil Branch, Atlanta, GA USA; [Gangrade, Bhushan K.] Ctr Reprod Med, Orlando, FL USA; [Sorensen, Ole E.] Lund Univ, Dept Clin Sci, Div Infect Med, Lund, Sweden	State University System of Florida; University of Central Florida; Centers for Disease Control & Prevention - USA; Lund University	Cole, AM (corresponding author), 4000 Cent Florida Blvd,Bldg 20,Rm 236, Orlando, FL 32816 USA.	ole_e.sorensen@med.lu.se; acole@mail.ucf.edu		Sorensen, Ole E./0000-0001-8681-6921	NIAID NIH HHS [R01 AI052017-08, R01 AI052017-09, R01 AI052017-06, R01 AI052017-07, R01 AI052017, R01 AI052017-10] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052017] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Autiero M, 1997, EUR J BIOCHEM, V245, P208, DOI 10.1111/j.1432-1033.1997.00208.x; Berkhout B, 2004, BIOMETALS, V17, P291, DOI 10.1023/B:BIOM.0000027707.82911.be; BJORCK L, 1990, MOL MICROBIOL, V4, P1439, DOI 10.1111/j.1365-2958.1990.tb02054.x; Bourgeon F, 2004, BIOL REPROD, V70, P768, DOI 10.1095/biolreprod.103.022533; Brillard-Bourdet M, 2002, EUR J BIOCHEM, V269, P390, DOI 10.1046/j.0014-2956.2001.02667.x; CHRISTOPHERHENN.J, 2008, ANIM HEALTH RES REV, P1; Cole AM, 2003, CURR PHARM DESIGN, V9, P1463, DOI 10.2174/1381612033454667; Cole AM, 2002, J IMMUNOL, V169, P6985, DOI 10.4049/jimmunol.169.12.6985; Cole AL, 2006, J IMMUNOL, V176, P6900, DOI 10.4049/jimmunol.176.11.6900; Com E, 2003, BIOL REPROD, V68, P95, DOI 10.1095/biolreprod.102.005389; da Costa AO, 1999, BIOCELL, V23, P65; Edstrom AML, 2008, J IMMUNOL, V181, P3413, DOI 10.4049/jimmunol.181.5.3413; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Ganz T, 2004, J LEUKOCYTE BIOL, V75, P34, DOI 10.1189/jlb.0403150; Ganz T, 1997, SEMIN HEMATOL, V34, P343; Groot F, 2005, J VIROL, V79, P3009, DOI 10.1128/JVI.79.5.3009-3015.2005; HARWIG SSL, 1993, ANAL BIOCHEM, V208, P382, DOI 10.1006/abio.1993.1065; Jonsson M, 2006, CELL MOL LIFE SCI, V63, P2886, DOI 10.1007/s00018-006-6287-0; Klotman ME, 2006, NAT REV IMMUNOL, V6, P447, DOI 10.1038/nri1860; Lehrer RI, 2002, CURR OPIN HEMATOL, V9, P18, DOI 10.1097/00062752-200201000-00004; LILJA H, 1990, ANDROLOGIA, V22, P132; LILJA H, 1985, FEBS LETT, V182, P181, DOI 10.1016/0014-5793(85)81179-0; LILJA H, 1993, WORLD J UROL, V11, P188; Malm J, 2000, INFECT IMMUN, V68, P4297, DOI 10.1128/IAI.68.7.4297-4302.2000; Munch J, 2007, CELL, V131, P1059, DOI 10.1016/j.cell.2007.10.014; Robert M, 1997, BIOCHEMISTRY-US, V36, P3811, DOI 10.1021/bi9626158; Robert M, 1999, CELL MOL LIFE SCI, V55, P944, DOI 10.1007/s000180050346; ROBERT M, 1995, HUM REPROD, V10, P2192, DOI 10.1093/oxfordjournals.humrep.a136267; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shukeir N, 2003, CANCER RES, V63, P2072; Swart PJ, 1998, ADV EXP MED BIOL, V443, P205; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Udby L, 2005, BIOCHEM BIOPH RES CO, V333, P555, DOI 10.1016/j.bbrc.2005.05.139; van der Strate BWA, 2001, ANTIVIR RES, V52, P225, DOI 10.1016/S0166-3542(01)00195-4; Venkataraman N, 2005, J IMMUNOL, V175, P7560, DOI 10.4049/jimmunol.175.11.7560; Vray B, 2002, CELL MOL LIFE SCI, V59, P1503, DOI 10.1007/s00018-002-8525-4; Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411; Zhao H, 2008, PEPTIDES, V29, P505, DOI 10.1016/j.peptides.2008.01.009	38	59	63	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3609	3618		10.1096/fj.09-131961	http://dx.doi.org/10.1096/fj.09-131961			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19487309	Green Published, Green Submitted			2022-12-25	WOS:000270354300037
J	Rangarajan, ES; Proteau, A; Cui, QZ; Logan, SM; Potetinova, Z; Whitfield, D; Purisima, EO; Cygler, M; Matte, A; Sulea, T; Schoenhofen, IC				Rangarajan, Erumbi S.; Proteau, Ariane; Cui, Qizhi; Logan, Susan M.; Potetinova, Zhanna; Whitfield, Dennis; Purisima, Enrico O.; Cygler, Miroslaw; Matte, Allan; Sulea, Traian; Schoenhofen, Ian C.			Structural and Functional Analysis of Campylobacter jejuni PseG A UDP-SUGAR HYDROLASE FROM THE PSEUDAMINIC ACID BIOSYNTHETIC PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE MANNOSYL HYDROLASE; N-ACETYLGLUCOSAMINE 2-EPIMERASE; SOLVATED INTERACTION ENERGY; ESCHERICHIA-COLI MURG; UNUSUAL NUDIX ENZYME; HELICOBACTER-PYLORI; CRYSTAL-STRUCTURE; FLAGELLIN GLYCOSYLATION; PSEUDOMONAS-AERUGINOSA; MOLECULAR-DYNAMICS	Flagella of the bacteria Helicobacter pylori and Campylobacter jejuni are important virulence determinants, whose proper assembly and function are dependent upon glycosylation at multiple positions by sialic acid-like sugars, such as 5,7-diacetamido-3,5,7,9-tetradeoxy-L-glycero-L-manno-nonulosonic acid (pseudaminic acid (Pse)). The fourth enzymatic step in the pseudaminic acid pathway, the hydrolysis of UDP-2,4-diacetamido2,4,6-trideoxy-beta-L-altropyranose to generate 2,4-diacetamido-2,4,6-trideoxy-L-altropyranose, is performed by the nucleotide sugar hydrolase PseG. To better understand the molecular basis of the PseG catalytic reaction, we have determined the crystal structures of C. jejuni PseG in apo-form and as a complex with its UDP product at 1.8 and 1.85 angstrom resolution, respectively. In addition, molecular modeling was utilized to provide insight into the structure of the PseG-substrate complex. This modeling identifies a His(17)-coordinated water molecule as the putative nucleophile and suggests the UDP-sugar substrate adopts a twist-boat conformation upon binding to PseG, enhancing the exposure of the anomeric bond cleaved and favoring inversion at C-1. Furthermore, based on these structures a series of amino acid substitution derivatives were constructed, altering residues within the active site, and each was kinetically characterized to examine its contribution to PseG catalysis. In conjunction with structural comparisons, the almost complete inactivation of the PseG H17F and H17L derivatives suggests that His(17) functions as an active site base, thereby activating the nucleophilic water molecule for attack of the anomeric C-O bond of the UDP-sugar. As the PseG structure reveals similarity to those of glycosyltransferase family-28 members, in particular that of Escherichia coli MurG, these findings may also be of relevance for the mechanistic understanding of this important enzyme family.	[Proteau, Ariane; Cui, Qizhi; Purisima, Enrico O.; Cygler, Miroslaw; Matte, Allan; Sulea, Traian] Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; [Rangarajan, Erumbi S.; Cygler, Miroslaw] McGill Univ, Dept Biochem, Montreal, PQ H3G 1V6, Canada; [Logan, Susan M.; Potetinova, Zhanna; Whitfield, Dennis; Schoenhofen, Ian C.] Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada; McGill University; National Research Council Canada	Sulea, T (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	traian.sulea@nrc-cnrc.gc.ca; ian.schoenhofen@nrc-cnrc.gc.ca			National Research Council Canada; Canadian Institutes of Health [GSP-48370]	National Research Council Canada; Canadian Institutes of Health(Canadian Institutes of Health Research (CIHR))	This work was supported by the National Research Council Canada (to S. M. L., E. O. P., and M. C.) and Canadian Institutes of Health Research Operating Grant GSP-48370 (to M. C.). This is publication number NRC49599 from the National Research Council Canada.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andreeva A, 2008, NUCLEIC ACIDS RES, V36, pD419, DOI 10.1093/nar/gkm993; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Biarnes X, 2006, J BIOL CHEM, V281, P1432, DOI 10.1074/jbc.M507643200; BLACK RE, 1988, J INFECT DIS, V157, P472, DOI 10.1093/infdis/157.3.472; Bouhss A, 2008, FEMS MICROBIOL REV, V32, P208, DOI 10.1111/j.1574-6976.2007.00089.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buschiazzo A, 2004, EMBO J, V23, P3196, DOI 10.1038/sj.emboj.7600324; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P14993, DOI 10.1021/bi001627x; Canals R, 2007, MICROBIOL-SGM, V153, P1165, DOI 10.1099/mic.0.2006/000687-0; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; Castric P, 2001, J BIOL CHEM, V276, P26479, DOI 10.1074/jbc.M102685200; Chen L, 2002, BIOCHEMISTRY-US, V41, P6824, DOI 10.1021/bi0256678; Chou WK, 2005, J BIOL CHEM, V280, P35922, DOI 10.1074/jbc.M507483200; CORNELL WD, 1995, J AM CHEM SOC, V117, P5197; Crouvoisier M, 2007, BIOCHIMIE, V89, P1498, DOI 10.1016/j.biochi.2007.06.011; Cui QZ, 2008, J MOL BIOL, V379, P787, DOI 10.1016/j.jmb.2008.04.035; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Davies GJ, 2003, BIOCHEM SOC T, V31, P523, DOI 10.1042/BST0310523; Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gabelli SB, 2006, BIOCHEMISTRY-US, V45, P11290, DOI 10.1021/bi061239g; Geremia S, 2002, J MOL BIOL, V322, P413, DOI 10.1016/S0022-2836(02)00771-4; Gibson RP, 2002, CHEM BIOL, V9, P1337, DOI 10.1016/S1074-5521(02)00292-2; Gordon JC, 2005, NUCLEIC ACIDS RES, V33, pW368, DOI 10.1093/nar/gki464; GOSSELIN S, 1994, ANAL BIOCHEM, V220, P92, DOI 10.1006/abio.1994.1303; Gryllos I, 2001, INFECT IMMUN, V69, P65, DOI 10.1128/IAI.69.1.65-74.2001; Guerry P, 2006, MOL MICROBIOL, V60, P299, DOI 10.1111/j.1365-2958.2006.05100.x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Horcajada C, 2006, J BIOL CHEM, V281, P2923, DOI 10.1074/jbc.M507394200; Hsu KL, 2006, NAT CHEM BIOL, V2, P153, DOI 10.1038/nchembio767; Hu YN, 2003, P NATL ACAD SCI USA, V100, P845, DOI 10.1073/pnas.0235749100; Ishiyama N, 2006, J BIOL CHEM, V281, P24489, DOI 10.1074/jbc.M602393200; Jakalian A, 2000, J COMPUT CHEM, V21, P132, DOI 10.1002/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.0.CO;2-P; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Josenhans C, 2002, FEMS MICROBIOL LETT, V210, P165, DOI 10.1016/S0378-1097(02)00638-9; Kiss E, 2001, MOL PLANT MICROBE IN, V14, P1395, DOI 10.1094/MPMI.2001.14.12.1395; Knirel YA, 2003, ADV CARBOHYD CHEM BI, V58, P371, DOI 10.1016/S0065-2318(03)58007-6; KNIREL YA, 1984, CARBOHYD RES, V133, pC5, DOI 10.1016/0008-6215(84)85213-1; Lairson LL, 2008, ANNU REV BIOCHEM, V77, P521, DOI 10.1146/annurev.biochem.76.061005.092322; Lariviere L, 2003, J MOL BIOL, V330, P1077, DOI 10.1016/S0022-2836(03)00635-1; Le Quere AJL, 2006, J BIOL CHEM, V281, P28981, DOI 10.1074/jbc.M513639200; Legler PM, 2000, BIOCHEMISTRY-US, V39, P8603, DOI 10.1021/bi000537p; Legler PM, 2002, BIOCHEMISTRY-US, V41, P10834, DOI 10.1021/bi020362e; Legler PM, 2002, BIOCHEMISTRY-US, V41, P4655, DOI 10.1021/bi012118d; LI ZQ, 1987, P NATL ACAD SCI USA, V84, P6611, DOI 10.1073/pnas.84.19.6611; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; Liu F, 2006, J BIOL CHEM, V281, P20902, DOI 10.1074/jbc.M602972200; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McNally DJ, 2006, CHEMBIOCHEM, V7, P1865, DOI 10.1002/cbic.200600298; Megraud F, 2007, GUT, V56, P1502, DOI 10.1136/gut.2007.132514; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Mulichak AM, 2001, STRUCTURE, V9, P547, DOI 10.1016/S0969-2126(01)00616-5; Murkin AS, 2004, BIOCHEMISTRY-US, V43, P14290, DOI 10.1021/bi048606d; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Naim M, 2007, J CHEM INF MODEL, V47, P122, DOI 10.1021/ci600406v; Ni LS, 2007, BIOCHEMISTRY-US, V46, P6288, DOI 10.1021/bi700346w; Rangarajan ES, 2008, BIOCHEMISTRY-US, V47, P1827, DOI 10.1021/bi702032r; Raymond CK, 2002, J BACTERIOL, V184, P3614, DOI 10.1128/JB.184.13.3614-3622.2002; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Schirm M, 2005, ANAL CHEM, V77, P7774, DOI 10.1021/ac051316y; Schirm M, 2003, MOL MICROBIOL, V48, P1579, DOI 10.1046/j.1365-2958.2003.03527.x; Schoenhofen IC, 2006, GLYCOBIOLOGY, V16, p8C, DOI 10.1093/glycob/cwl010; Schoenhofen IC, 2006, J BIOL CHEM, V281, P8907, DOI 10.1074/jbc.M512987200; Schoenhofen IC, 2006, J BIOL CHEM, V281, P723, DOI 10.1074/jbc.M511021200; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; STEWART JJP, 1989, J COMPUT CHEM, V10, P209, DOI 10.1002/jcc.540100208; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Vetting MW, 2008, J BIOL CHEM, V283, P15834, DOI 10.1074/jbc.M801017200; Vimr ER, 2004, MICROBIOL MOL BIOL R, V68, P132, DOI 10.1128/MMBR.68.1.132-153.2004; Walker RC, 2008, J COMPUT CHEM, V29, P1019, DOI 10.1002/jcc.20857; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Wrabl JO, 2001, J MOL BIOL, V314, P365, DOI 10.1006/jmbi.2001.5151	75	18	19	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20989	21000		10.1074/jbc.M109.012351	http://dx.doi.org/10.1074/jbc.M109.012351			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19483088	hybrid, Green Published			2022-12-25	WOS:000268316100062
J	Halai, R; Clark, RJ; Nevin, ST; Jensen, JE; Adams, DJ; Craik, DJ				Halai, Reena; Clark, Richard J.; Nevin, Simon T.; Jensen, Jonas E.; Adams, David J.; Craik, David J.			Scanning Mutagenesis of alpha-Conotoxin Vc1.1 Reveals Residues Crucial for Activity at the alpha 9 alpha 10 Nicotinic Acetylcholine Receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIR-CELLS; PHARMACOLOGICAL-PROPERTIES; CHOLINERGIC-RECEPTOR; CONUS PEPTIDES; SUBUNIT; NEURONS; BINDING; RGIA; PAIN; CONOPEPTIDES	Vc1.1 is a disulfide-rich peptide inhibitor of nicotinic acetylcholine receptors that has stimulated considerable interest in these receptors as potential therapeutic targets for the treatment of neuropathic pain. Here we present an extensive series of mutational studies in which all residues except the conserved cysteines were mutated separately to Ala, Asp, or Lys. The effect on acetylcholine (ACh)-evoked membrane currents at the alpha 9 alpha 10 nicotinic acetylcholine receptor (nAChR), which has been implicated as a target in the alleviation of neuropathic pain, was then observed. The analogs were characterized by NMR spectroscopy to determine the effects of mutations on structure. The structural fold was found to be preserved in all peptides except where Pro was substituted. Electrophysiological studies showed that the key residues for functional activity are Asp(5)-Arg(7) and Asp(11)-Ile(15), because changes at these positions resulted in the loss of activity at the alpha 9 alpha 10 nAChR. Interestingly, the S4K and N9A analogs were more potent than Vc1.1 itself. A second generation of mutants was synthesized, namely N9G, N9I, N9L, S4R, and S4K + N9A, all of which were more potent than Vc1.1 at both the rat alpha 9 alpha 10 and the human alpha 9/rat alpha 10 hybrid receptor, providing a mechanistic insight into the key residues involved in eliciting the biological function of Vc1.1. The most potent analogs were also tested at the alpha 3 beta 2, alpha 3 beta 4, and alpha 7 nAChR subtypes to determine their selectivity. All mutants tested were most selective for the alpha 9 alpha 10 nAChR. These findings provide valuable insight into the interaction of Vc1.1 with the alpha 9 alpha 10 nAChR subtype and will help in the further development of analogs of Vc1.1 as analgesic drugs.	[Halai, Reena; Clark, Richard J.; Jensen, Jonas E.; Craik, David J.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; [Nevin, Simon T.; Adams, David J.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@uq.edu.au	Adams, David John/K-3578-2019; Craik, David/B-1695-2010; Adams, David/J-9125-2014; Clark, Richard J/G-8848-2012; Jensen, Jonas/A-6393-2010; Halai, Reena/C-3311-2014; Nevin, Simon/B-2663-2014	Adams, David John/0000-0002-7030-2288; Craik, David/0000-0003-0007-6796; Adams, David/0000-0002-7030-2288; Clark, Richard J/0000-0002-6807-5426; 	National Health and Medical Research Council (NHMRC); Australian Research Council (ARC)	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council (ARC)(Australian Research Council)	The work was supported in part by a grant from the National Health and Medical Research Council (NHMRC). Work in our laboratory on conotoxins is supported by a grant from the Australian Research Council (ARC).	Adams DJ, 1999, DRUG DEVELOP RES, V46, P219; Armishaw C, 2009, J BIOL CHEM, V284, P9498, DOI 10.1074/jbc.M806136200; Baker ER, 2004, MOL PHARMACOL, V65, P453, DOI 10.1124/mol.65.2.453; Callaghan B, 2008, J NEUROSCI, V28, P10943, DOI 10.1523/JNEUROSCI.3594-08.2008; Clark RJ, 2008, FEBS LETT, V582, P597, DOI 10.1016/j.febslet.2008.01.027; Clark RJ, 2006, J BIOL CHEM, V281, P23254, DOI 10.1074/jbc.M604550200; Clark RJ, 2005, P NATL ACAD SCI USA, V102, P13767, DOI 10.1073/pnas.0504613102; Dutertre S, 2005, J BIOL CHEM, V280, P30460, DOI 10.1074/jbc.M504229200; Dutton JL, 2001, CURR MED CHEM, V8, P327, DOI 10.2174/0929867013373453; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; Elgoyhen AB, 2001, P NATL ACAD SCI USA, V98, P3501, DOI 10.1073/pnas.051622798; Ellison M, 2006, BIOCHEMISTRY-US, V45, P1511, DOI 10.1021/bi0520129; Ellison M, 2008, J MOL BIOL, V377, P1216, DOI 10.1016/j.jmb.2008.01.082; Gehrmann J, 1998, J MOL BIOL, V278, P401, DOI 10.1006/jmbi.1998.1701; Gomez-Casati ME, 2005, J PHYSIOL-LONDON, V566, P103, DOI 10.1113/jphysiol.2005.087155; Hogg RC, 2003, J BIOL CHEM, V278, P26908, DOI 10.1074/jbc.M212628200; Hu SH, 1997, BIOCHEMISTRY-US, V36, P11323, DOI 10.1021/bi9713052; Itier V, 2001, FEBS LETT, V504, P118, DOI 10.1016/S0014-5793(01)02702-8; Jakubowski JA, 2004, J MASS SPECTROM, V39, P548, DOI 10.1002/jms.624; Lips KS, 2002, NEUROSCIENCE, V115, P1, DOI 10.1016/S0306-4522(02)00274-9; Livett BG, 2004, CURR MED CHEM, V11, P1715, DOI 10.2174/0929867043364928; Livett BG, 2006, TOXICON, V48, P810, DOI 10.1016/j.toxicon.2006.07.023; Lovelace ES, 2006, J MED CHEM, V49, P6561, DOI 10.1021/jm060299h; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Miljanich GP, 2004, CURR MED CHEM, V11, P3029, DOI 10.2174/0929867043363884; Nevin ST, 2007, MOL PHARMACOL, V72, P1406, DOI 10.1124/mol.107.040568; Nguyen VT, 2000, AM J PATHOL, V157, P1377, DOI 10.1016/S0002-9440(10)64651-2; Olivera BM, 2008, CHANNELS, V2, P143, DOI 10.4161/chan.2.2.6276; Olivera BM, 2007, MOL INTERV, V7, P251, DOI 10.1124/mi.7.5.7; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; Peng HS, 2004, LIFE SCI, V76, P263, DOI 10.1016/j.lfs.2004.05.031; Plazas PV, 2005, J NEUROSCI, V25, P10905, DOI 10.1523/JNEUROSCI.3805-05.2005; Quiram PA, 1998, J BIOL CHEM, V273, P11007, DOI 10.1074/jbc.273.18.11007; Sandall DW, 2003, BIOCHEMISTRY-US, V42, P6904, DOI 10.1021/bi034043e; Satkunanathan N, 2005, BRAIN RES, V1059, P149, DOI 10.1016/j.brainres.2005.08.009; Sgard F, 2002, MOL PHARMACOL, V61, P150, DOI 10.1124/mol.61.1.150; Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003; Vincler M, 2006, P NATL ACAD SCI USA, V103, P17880, DOI 10.1073/pnas.0608715103; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471	41	72	79	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20275	20284		10.1074/jbc.M109.015339	http://dx.doi.org/10.1074/jbc.M109.015339			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19447885	hybrid, Green Published			2022-12-25	WOS:000268097400054
J	Cohen-Gonsaud, M; Barthe, P; Canova, MJ; Stagier-Simon, C; Kremer, L; Roumestand, C; Molle, V				Cohen-Gonsaud, Martin; Barthe, Philippe; Canova, Marc J.; Stagier-Simon, Charlotte; Kremer, Laurent; Roumestand, Christian; Molle, Virginie			The Mycobacterium tuberculosis Ser/Thr Kinase Substrate Rv2175c Is a DNA-binding Protein Regulated by Phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE KINASES; CHEMICAL-SHIFT; DOMAIN; EMBR; PKNB; IDENTIFICATION; PHOSPHATASES; RECOGNITION; RESTRAINTS; PHYLOGENY	Recent efforts have underlined the role of serine/threonine protein kinases in growth, pathogenesis, and cell wall metabolism in Mycobacterium tuberculosis. Although most kinases have been investigated for their physiological roles, little information is available regarding how serine/threonine protein kinase-dependent phosphorylation regulates the activity of kinase substrates. Herein, we focused on M. tuberculosis Rv2175c, a protein of unknown function, conserved in actinomycetes, and recently identified as a substrate of the PknL kinase. We solved the solution structure of Rv2175c by multidimensional NMR and demonstrated that it possesses an original winged helix-turn-helix motif, indicative of a DNA-binding protein. The DNA-binding activity of Rv2175c was subsequently confirmed by fluorescence anisotropy, as well as in electrophoretic mobility shift assays. Mass spectrometry analyses using a combination of MALDI-TOF and LC-ESI/MS/MS identified Thr(9) as the unique phosphoacceptor. This was further supported by complete loss of PknL-dependent phosphorylation of an Rv2175c_T9A mutant. Importantly, the DNA-binding activity was completely abrogated in a Rv2175c_T9D mutant, designed to mimic constitutive phosphorylation, but not in a mutant lacking the first 13 residues. This implies that the function of the N-terminal extension is to provide a phosphoacceptor (Thr(9)), which, following phosphorylation, negatively regulates the Rv2175c DNA-binding activity. Interestingly, the N-terminal disordered extension, which bears the phosphoacceptor, was found to be restricted to members of the M. tuberculosis complex, thus suggesting the existence of an original mechanism that appears to be unique to the M. tuberculosis complex.	[Cohen-Gonsaud, Martin; Barthe, Philippe; Stagier-Simon, Charlotte; Roumestand, Christian] CNRS, UMR 5048, Ctr Biochim Struct, F-34090 Montpellier, France; [Cohen-Gonsaud, Martin; Barthe, Philippe; Stagier-Simon, Charlotte; Roumestand, Christian] INSERM, U554, Montpellier, France; [Cohen-Gonsaud, Martin; Barthe, Philippe; Stagier-Simon, Charlotte; Roumestand, Christian] Univ Montpellier I, F-34090 Montpellier, France; [Canova, Marc J.; Molle, Virginie] Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot,IFR128 BioSci, F-69367 Lyon, France; [Kremer, Laurent] Univ Montpellier 2, Lab Dynam Interact Membranaires Normales & Pathol, F-34095 Montpellier 05, France; [Kremer, Laurent] CNRS, UMR 5235, F-34095 Montpellier 05, France; [Kremer, Laurent] INSERM, DIMNP, F-34095 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Cohen-Gonsaud, M (corresponding author), CNRS, UMR 5048, Ctr Biochim Struct, F-34090 Montpellier, France.	martin@cbs.cnrs.fr; vmolle@ibcp.fr	Kremer, Laurent/M-4935-2017; MOLLE, Virginie/D-4050-2019	Kremer, Laurent/0000-0002-6604-4458; MOLLE, Virginie/0000-0002-6573-3411; ROUMESTAND, Christian/0000-0002-4082-3293; Barthe, Philippe/0000-0003-4282-6604; Cohen-Gonsaud, Martin/0000-0002-0150-9912	Agence Nationale de la Recherche [JC07_203251, ANR-06-MIME-027-01]	Agence Nationale de la Recherche(French National Research Agency (ANR))	This work was supported by Agence Nationale de la Recherche Grants JC07_203251 ( to M. C.- G.) and ANR-06-MIME-027-01 ( to V. M. and L. K.). NMR experiments were recorded and analyzed using the facilities of the Structural Biology platform RIO (CBS, Montpellier, France).	Alderwick LJ, 2006, P NATL ACAD SCI USA, V103, P2558, DOI 10.1073/pnas.0507766103; Av-Gay Y, 2000, TRENDS MICROBIOL, V8, P238, DOI 10.1016/S0966-842X(00)01734-0; Barthe P, 2009, STRUCTURE, V17, P568, DOI 10.1016/j.str.2009.02.012; Canova MJ, 2008, PLASMID, V60, P149, DOI 10.1016/j.plasmid.2008.05.002; Canova MJ, 2008, PROTEOMICS, V8, P521, DOI 10.1002/pmic.200700442; Canova MJ, 2009, J BACTERIOL, V191, P2876, DOI 10.1128/JB.01569-08; Cohen-Gonsaud M, 2004, J BIOMOL NMR, V30, P373, DOI 10.1007/s10858-004-3466-x; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cottin V, 1999, J BIOL CHEM, V274, P32975, DOI 10.1074/jbc.274.46.32975; Dasgupta A, 2006, MICROBIOL-SGM, V152, P493, DOI 10.1099/mic.0.28630-0; Fiuza M, 2008, J BIOL CHEM, V283, P18099, DOI 10.1074/jbc.M802615200; Garvie CW, 2001, MOL CELL, V8, P937, DOI 10.1016/S1097-2765(01)00392-6; Greenstein AE, 2007, PLOS PATHOG, V3, P475, DOI 10.1371/journal.ppat.0030049; Guntert Peter, 2004, Methods Mol Biol, V278, P353; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kang CM, 2008, MICROBIOL-SGM, V154, P725, DOI 10.1099/mic.0.2007/014076-0; Kang CM, 2005, GENE DEV, V19, P1692, DOI 10.1101/gad.1311105; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Kumar P, 2009, J BIOL CHEM, V284, P11090, DOI 10.1074/jbc.M808705200; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Molle V, 2003, BIOCHEMISTRY-US, V42, P15300, DOI 10.1021/bi035150b; Molle V, 2006, J BIOL CHEM, V281, P30094, DOI 10.1074/jbc.M601691200; Narayan A, 2007, PHYSIOL GENOMICS, V29, P66, DOI 10.1152/physiolgenomics.00221.2006; Nederveen AJ, 2005, PROTEINS, V59, P662, DOI 10.1002/prot.20408; O'Hare HM, 2008, MOL MICROBIOL, V70, P1408, DOI 10.1111/j.1365-2958.2008.06489.x; Park ST, 2008, P NATL ACAD SCI USA, V105, P13105, DOI 10.1073/pnas.0801143105; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; Sam MD, 2004, J MOL BIOL, V338, P229, DOI 10.1016/j.jmb.2004.02.053; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Sharma K, 2006, J BACTERIOL, V188, P2936, DOI 10.1128/JB.188.8.2936-2944.2006; Sharma K, 2006, FEBS J, V273, P2711, DOI 10.1111/j.1742-4658.2006.05289.x; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Veyron-Churlet R, 2009, J BIOL CHEM, V284, P6414, DOI 10.1074/jbc.M806537200; Villarino A, 2005, J MOL BIOL, V350, P953, DOI 10.1016/j.jmb.2005.05.049; Wehenkel A, 2008, BBA-PROTEINS PROTEOM, V1784, P193, DOI 10.1016/j.bbapap.2007.08.006; [No title captured]	39	32	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19290	19300		10.1074/jbc.M109.019653	http://dx.doi.org/10.1074/jbc.M109.019653			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19457863	Green Published, hybrid			2022-12-25	WOS:000267908300020
J	Li, X; Molina, H; Huang, HY; Zhang, YY; Liu, M; Qian, SW; Slawson, C; Dias, WB; Pandey, A; Hart, GW; Lane, MD; Tang, QQ				Li, Xi; Molina, Henrik; Huang, Haiyan; Zhang, You-you; Liu, Mei; Qian, Shu-wen; Slawson, Chad; Dias, Wagner B.; Pandey, Akhilesh; Hart, Gerald W.; Lane, M. Daniel; Tang, Qi-Qun			O-Linked N-Acetylglucosamine Modification on CCAAT Enhancer-binding Protein beta ROLE DURING ADIPOCYTE DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; C/EBP-BETA; NUCLEOCYTOPLASMIC PROTEINS; MYELOMONOCYTIC CELLS; 3T3-L1 PREADIPOCYTES; TRANSCRIPTION FACTOR; CYTOSOLIC PROTEINS; GLCNAC TRANSFERASE; TERMINAL DOMAIN; FAMILY-MEMBERS	CCAAT enhancer-binding protein (C/EBP)beta is a basic leucine zipper transcription factor family member, and can be phosphorylated, acetylated, and sumoylated. C/EBP beta undergoes sequential phosphorylation during 3T3-L1 adipocyte differentiation. Phosphorylation on Thr(188) by MAPK or cyclin A/cdk2 primes the phosphorylations on Ser(184)/Thr(179) by GSK3 beta, and these phosphorylations are required for the acquisition of DNA binding activity of C/EBP beta. Here we show that C/EBP beta is modified by O-GlcNAc, a dynamic single sugar modification found on nucleocytoplasmic proteins. The GlcNAcylation sites are Ser(180) and Ser(181), which are in the regulation domain and are very close to the phosphorylation sites (Thr(188), Ser(184), and Thr(179)) required for the gain of DNA binding activity. Both in vitro and ex vivo experiments demonstrate that GlcNAcylation on Ser(180) and Ser(181) prevents phosphorylation on Thr(188), Ser(184), and Thr(179), as indicated by the decreased relative phosphorylation and DNA binding activity of C/EBP beta delayed the adipocyte differentiation program. Mutation of both Ser(180) and Ser(181) to Ala significantly increase the transcriptional activity of C/EBP beta. These data suggest that GlcNAcylation regulates both the phosphorylation and DNA binding activity of C/EBP beta.	[Li, Xi; Huang, Haiyan; Zhang, You-you; Liu, Mei; Qian, Shu-wen; Tang, Qi-Qun] Fudan Univ, Shanghai Med Coll, Key Lab Mol Med, Minist Educ, Shanghai 200032, Peoples R China; [Li, Xi; Huang, Haiyan; Zhang, You-you; Liu, Mei; Qian, Shu-wen; Tang, Qi-Qun] Fudan Univ, Shanghai Med Coll, Dept Biochem & Microbiol, Shanghai 200032, Peoples R China; [Li, Xi; Huang, Haiyan; Zhang, You-you; Qian, Shu-wen; Tang, Qi-Qun] Fudan Univ, Inst Biomed Sci, Inst Stem Cell & Regenerat Med, Shanghai 200032, Peoples R China; [Molina, Henrik; Slawson, Chad; Dias, Wagner B.; Pandey, Akhilesh; Hart, Gerald W.; Lane, M. Daniel] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21218 USA	Fudan University; Fudan University; Fudan University; Johns Hopkins University	Tang, QQ (corresponding author), Fudan Univ, Shanghai Med Coll, Key Lab Mol Med, Minist Educ, 138 Yi Xue Yuan Rd,POB 238, Shanghai 200032, Peoples R China.	qqtang@shmu.edu.cn	Pandey, Akhilesh/B-4127-2009; Zhang, Youyou/H-9677-2017; Li, Xi/W-4034-2019; Dias, Wagner/B-1401-2016	Pandey, Akhilesh/0000-0001-9943-6127; Dias, Wagner/0000-0002-8378-8846; Hart, Gerald/0000-0001-7812-4351	National Key Basic Research [2006CB943704]; National Natural Science Foundation for Distinguished Scholars [30625015]; Program for Outstanding Medical Academic Leader [B-LJ06032]; Shanghai Key Science and Technology Research Project [08dj1400603]; National Natural Science Foundation [30700121]; Shanghai Rising Star Program [08QA14012]; National Institutes of Health [DK61671, HD13563]; Shanghai Leading Academic Discipline [B110]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013563, R37HD013563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061671] Funding Source: NIH RePORTER	National Key Basic Research(National Basic Research Program of China); National Natural Science Foundation for Distinguished Scholars(National Natural Science Foundation of China (NSFC)); Program for Outstanding Medical Academic Leader; Shanghai Key Science and Technology Research Project; National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Shanghai Rising Star Program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Shanghai Leading Academic Discipline(Shanghai Leading Academic Discipline Project); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Key Basic Research Project Grant 2006CB943704, National Natural Science Foundation for Distinguished Scholars Grant 30625015, Program for Outstanding Medical Academic Leader Grant B-LJ06032, Shanghai Key Science and Technology Research Project 08dj1400603 ( to Q.- Q. T.); by National Natural Science Foundation Grant 30700121 and Shanghai Rising Star Program 08QA14012 ( to X. L.), and by National Institutes of Health Grants DK61671 and HD13563 ( to G. W. H.). This work was also supported in part by Shanghai Leading Academic Discipline Project B110.	CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Cesena TI, 2008, MOL CELL ENDOCRINOL, V289, P94, DOI 10.1016/j.mce.2008.03.009; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; HOLT GD, 1986, J BIOL CHEM, V261, P8049; Housley MP, 2008, J BIOL CHEM, V283, P16283, DOI 10.1074/jbc.M802240200; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Khidekel N, 2003, J AM CHEM SOC, V125, P16162, DOI 10.1021/ja038545r; Kim J, 2007, P NATL ACAD SCI USA, V104, P1800, DOI 10.1073/pnas.0611137104; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Li X, 2007, P NATL ACAD SCI USA, V104, P11597, DOI 10.1073/pnas.0703771104; Liu S, 1999, J CLIN INVEST, V103, P207, DOI 10.1172/JCI4243; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; SCOTT LM, 1992, BLOOD, V80, P1725; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Tang QQ, 2005, P NATL ACAD SCI USA, V102, P9766, DOI 10.1073/pnas.0503891102; TORRES CR, 1984, J BIOL CHEM, V259, P3308; Wang Z, 2009, DIABETES, V58, P309, DOI 10.2337/db08-0994; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	32	55	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19248	19254		10.1074/jbc.M109.005678	http://dx.doi.org/10.1074/jbc.M109.005678			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19478079	Green Published, hybrid			2022-12-25	WOS:000267908300015
J	Walmacq, C; Kireeva, ML; Irvin, J; Nedialkov, Y; Lubkowska, L; Malagon, F; Strathern, JN; Kashlev, M				Walmacq, Celine; Kireeva, Maria L.; Irvin, Jordan; Nedialkov, Yuri; Lubkowska, Lucyna; Malagon, Francisco; Strathern, Jeffrey N.; Kashlev, Mikhail			Rpb9 Subunit Controls Transcription Fidelity by Delaying NTP Sequestration in RNA Polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-ANALYSIS; STRUCTURAL BASIS; SACCHAROMYCES-CEREVISIAE; DRIVEN TRANSLOCATION; TRIGGER LOOP; IN-VIVO; DEPENDENT RNA-POLYMERASE-(3D(POL)); RIBONUCLEOTIDE INCORPORATION; SEQUENCE INSERTIONS; CLEAVAGE ACTIVITY	Rpb9 is a small non-essential subunit of yeast RNA polymerase II located on the surface on the enzyme. Deletion of the RPB9 gene shows synthetic lethality with the low fidelity rpb1-E1103G mutation localized in the trigger loop, a mobile element of the catalytic Rpb1 subunit, which has been shown to control transcription fidelity. Similar to the rpb1-E1103G mutation, the RPB9 deletion substantially enhances NTP misincorporation and increases the rate of mismatch extension with the next cognate NTP in vitro. Using pre-steady state kinetic analysis, we show that RPB9 deletion promotes sequestration of NTPs in the polymerase active center just prior to the phosphodiester bond formation. We propose a model in which the Rpb9 subunit controls transcription fidelity by delaying the closure of the trigger loop on the incoming NTP via interaction between the C-terminal domain of Rpb9 and the trigger loop. Our findings reveal a mechanism for regulation of transcription fidelity by protein factors located at a large distance from the active center of RNA polymerase II.	[Walmacq, Celine; Kireeva, Maria L.; Irvin, Jordan; Nedialkov, Yuri; Lubkowska, Lucyna; Malagon, Francisco; Strathern, Jeffrey N.; Kashlev, Mikhail] NCI, Ctr Canc Res, NIH, Frederick, MD 21702 USA; [Nedialkov, Yuri] NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; [Malagon, Francisco] Aarhus Univ, Inst Mol Biol, DK-8000 Aarhus C, Denmark	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); New York University; Aarhus University	Kashlev, M (corresponding author), NCI, Ctr Canc Res, NIH, Frederick, MD 21702 USA.	mkashlev@mail.ncifcrf.gov	Malagon, Francisco/A-7059-2013; Kireeva, Maria/B-4391-2018	Kireeva, Maria/0000-0003-0527-3182; Irvin, Jordan/0000-0001-8504-5985	National Institutes of Health; NATIONAL CANCER INSTITUTE [ZIABC010795, Z01BC010795, ZIABC011202] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by the Intramural Research Program of the National Institutes of Health through the NCI. The contents of this publication do not necessarily reveal the views of the policy of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement of the U. S. government.	Alic N, 2007, P NATL ACAD SCI USA, V104, P10400, DOI 10.1073/pnas.0704116104; Arnold JJ, 2005, J BIOL CHEM, V280, P25706, DOI 10.1074/jbc.M503444200; Arnold JJ, 2004, BIOCHEMISTRY-US, V43, P5126, DOI 10.1021/bi035212y; Arnold JJ, 2004, BIOCHEMISTRY-US, V43, P5138, DOI 10.1021/bi035213q; Artsimovitch I, 2000, J BACTERIOL, V182, P6027, DOI 10.1128/JB.182.21.6027-6035.2000; Artsimovitch I, 2003, J BIOL CHEM, V278, P12344, DOI 10.1074/jbc.M211214200; Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; Bar-Nahum G, 2005, CELL, V120, P183, DOI 10.1016/j.cell.2004.11.045; Bischler N, 2002, EMBO J, V21, P4136, DOI 10.1093/emboj/cdf392; Brueckner F, 2008, NAT STRUCT MOL BIOL, V15, P811, DOI 10.1038/nsmb.1458; Burton ZF, 2005, BIOCHEM CELL BIOL, V83, P486, DOI 10.1139/O05-059; Castro C, 2005, VIRUS RES, V107, P141, DOI 10.1016/j.virusres.2004.11.004; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; Chlenov M, 2005, J MOL BIOL, V353, P138, DOI 10.1016/j.jmb.2005.07.073; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Ederth J, 2002, J BIOL CHEM, V277, P37456, DOI 10.1074/jbc.M207038200; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; Fish RN, 2002, BBA-GENE STRUCT EXPR, V1577, P287, DOI 10.1016/S0167-4781(02)00459-1; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Hausner W, 2000, J BIOL CHEM, V275, P12393, DOI 10.1074/jbc.275.17.12393; Hemming SA, 2000, J BIOL CHEM, V275, P35506, DOI 10.1074/jbc.M004721200; Hemming SA, 2000, J BIOL CHEM, V275, P2288, DOI 10.1074/jbc.275.4.2288; HUMPHREY W, 1996, J MOL GRAPHICS, V14, P27, DOI DOI 10.1016/0263-7855(96)00018-5; Jeon C, 1996, P NATL ACAD SCI USA, V93, P13677, DOI 10.1073/pnas.93.24.13677; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z; Kaplan CD, 2008, MOL CELL, V30, P547, DOI 10.1016/j.molcel.2008.04.023; Kashkina E, 2006, MOL CELL, V24, P257, DOI 10.1016/j.molcel.2006.10.001; Keene RG, 1999, NUCLEIC ACIDS RES, V27, P3173, DOI 10.1093/nar/27.15.3173; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; Kettenberger H, 2003, CELL, V114, P347, DOI 10.1016/S0092-8674(03)00598-1; Kireeva ML, 2008, MOL CELL, V30, P557, DOI 10.1016/j.molcel.2008.04.017; Kireeva ML, 2003, METHOD ENZYMOL, V370, P138; Komissarova N, 2003, METHOD ENZYMOL, V371, P233; Koyama H, 2003, GENES CELLS, V8, P779, DOI 10.1046/j.1365-2443.2003.00677.x; Koyama H, 2007, GENES CELLS, V12, P547, DOI 10.1111/j.1365-2443.2007.01072.x; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; Kuhn CD, 2007, CELL, V131, P1260, DOI 10.1016/j.cell.2007.10.051; Lange U, 2004, MOL MICROBIOL, V52, P1133, DOI 10.1111/j.1365-2958.2004.04039.x; Lorenzen K, 2007, STRUCTURE, V15, P1237, DOI 10.1016/j.str.2007.07.016; Malagon F, 2006, GENETICS, V172, P2201, DOI 10.1534/genetics.105.052415; MIZRAHI V, 1985, BIOCHEMISTRY-US, V24, P4010, DOI 10.1021/bi00336a031; Mnaimneh S, 2004, CELL, V118, P31, DOI 10.1016/j.cell.2004.06.013; Nedialkov YA, 2003, J BIOL CHEM, V278, P18303, DOI 10.1074/jbc.M301103200; Nesser NK, 2006, P NATL ACAD SCI USA, V103, P3268, DOI 10.1073/pnas.0511330103; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Shaw RJ, 2002, J BIOL CHEM, V277, P24420, DOI 10.1074/jbc.M202059200; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; Toulokhonov I, 2007, MOL CELL, V27, P406, DOI 10.1016/j.molcel.2007.06.008; Tuske S, 2005, CELL, V122, P541, DOI 10.1016/j.cell.2005.07.017; Van Mullem V, 2002, MOL MICROBIOL, V43, P1105; Wang D, 2006, CELL, V127, P941, DOI 10.1016/j.cell.2006.11.023; Westover KD, 2004, CELL, V119, P481, DOI 10.1016/j.cell.2004.10.016; Westover KD, 2004, SCIENCE, V303, P1014, DOI 10.1126/science.1090839; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Xiong YL, 2007, J BIOL CHEM, V282, P36582, DOI 10.1074/jbc.M707014200; Zhang CF, 2005, MOL CELL BIOL, V25, P3583, DOI 10.1128/MCB.25.9.3583-3595.2005; Zhang CF, 2004, J MOL BIOL, V342, P1085, DOI 10.1016/j.jmb.2004.07.070	59	60	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19601	19612		10.1074/jbc.M109.006908	http://dx.doi.org/10.1074/jbc.M109.006908			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19439405	Green Published, hybrid			2022-12-25	WOS:000267908300052
J	Chen, SH; Zhou, HL				Chen, Sheng-hong; Zhou, Huilin			Reconstitution of Rad53 Activation by Mec1 through Adaptor Protein Mrc1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; S-PHASE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; REPLICATION FORKS; FHA DOMAIN; IN-VITRO; FISSION YEAST; KINASE CDS1; DPB11; PHOSPHORYLATION	Upon DNA replication stress, stalled DNA replication forks serve as a platform to recruit many signaling proteins, leading to the activation of the DNA replication checkpoint. Activation of Rad53, a key effector kinase in the budding yeast Saccharomyces cerevisiae, is essential for stabilizing DNA replication forks during replication stress. Using an activity-based assay for Rad53, we found that Mrc1, a replication fork-associated protein, cooperates with Mec1 to activate Rad53 directly. Reconstitution of Rad53 activation using purified Mec1 and Mrc1 showed that the addition of Mrc1 stimulated a more than 70-fold increase in the ability of Mec1 to activate Rad53. Instead of increasing the catalytic activity of Mec1, Mrc1 was found to facilitate the phosphorylation of Rad53 by Mec1 via promotion of a stronger enzyme-substrate interaction between them. Further, the conserved C-terminal domain of Mrc1 was found to be required for Rad53 activation. These results thus provide insights into the role of the adaptor protein Mrc1 in activating Rad53 in the DNA replication checkpoint.	[Chen, Sheng-hong] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; [Chen, Sheng-hong; Zhou, Huilin] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; [Zhou, Huilin] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Zhou, HL (corresponding author), CMM E, Rm 3050,9500 Gilman Dr, La Jolla, CA 92093 USA.	huzhou@ucsd.edu	Chen, Sheng-hong/AAU-4018-2021	Chen, Sheng-hong/0000-0002-7722-2221; Zhou, Huilin/0000-0002-1350-4430	National Institutes of Health [GM080469]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080469] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant GM080469 ( to H. Z.).	Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Bonilla CY, 2008, MOL CELL, V30, P267, DOI 10.1016/j.molcel.2008.03.023; Chen SH, 2007, J BIOL CHEM, V282, P986, DOI 10.1074/jbc.M609322200; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Gambus A, 2006, NAT CELL BIOL, V8, P358, DOI 10.1038/ncb1382; Garcia V, 2005, DNA REPAIR, V4, P1227, DOI 10.1016/j.dnarep.2005.04.001; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Kamimura Y, 1998, MOL CELL BIOL, V18, P6102, DOI 10.1128/MCB.18.10.6102; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Lee H, 2008, MOL CELL, V30, P767, DOI 10.1016/j.molcel.2008.05.013; Lee SJ, 2004, MOL BIOL CELL, V15, P5443, DOI 10.1091/mbc.E04-07-0608; Lee SJ, 2003, MOL CELL BIOL, V23, P6300, DOI 10.1128/MCB.23.17.6300-6314.2003; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Lou HQ, 2008, MOL CELL, V32, P106, DOI 10.1016/j.molcel.2008.08.020; Majka J, 2003, P NATL ACAD SCI USA, V100, P2249, DOI 10.1073/pnas.0437148100; Majka J, 2006, MOL CELL, V24, P891, DOI 10.1016/j.molcel.2006.11.027; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Mordes DA, 2008, P NATL ACAD SCI USA, V105, P18730, DOI 10.1073/pnas.0806621105; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; Nakada D, 2005, MOL BIOL CELL, V16, P5227, DOI 10.1091/mbc.E05-05-0405; Navadgi-Patil VM, 2008, J BIOL CHEM, V283, P35853, DOI 10.1074/jbc.M807435200; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Pasero P, 1999, METHODS, V18, P368, DOI 10.1006/meth.1999.0794; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Smolka MB, 2006, J CELL BIOL, V175, P743, DOI 10.1083/jcb.200605081; Sweeney FD, 2005, CURR BIOL, V15, P1364, DOI 10.1016/j.cub.2005.06.063; Szyjka SJ, 2005, MOL CELL, V19, P691, DOI 10.1016/j.molcel.2005.06.037; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Tanaka K, 2001, MOL CELL BIOL, V21, P3398, DOI 10.1128/MCB.21.10.3398-3404.2001; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Usui T, 2007, P NATL ACAD SCI USA, V104, P2797, DOI 10.1073/pnas.0611259104; Wang H, 2002, GENETICS, V160, P1295; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Xu YJ, 2006, GENE DEV, V20, P990, DOI 10.1101/gad.1406706; Zhao H, 2004, J BIOL CHEM, V279, P53023, DOI 10.1074/jbc.M410449200; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	44	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18593	18604		10.1074/jbc.M109.018242	http://dx.doi.org/10.1074/jbc.M109.018242			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19457865	hybrid, Green Published			2022-12-25	WOS:000267711500008
J	Menon, BRK; Waltho, JP; Scrutton, NS; Heyes, DJ				Menon, Binuraj R. K.; Waltho, Jonathan P.; Scrutton, Nigel S.; Heyes, Derren J.			Cryogenic and Laser Photoexcitation Studies Identify Multiple Roles for Active Site Residues in the Light-driven Enzyme Protochlorophyllide Oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRODUCT RELEASE STEPS; CATALYTIC CYCLE; DIRECTED MUTAGENESIS; REDUCTASE; NADPH; IDENTIFICATION; DEHYDROGENASE; ENZYMOLOGY; DYNAMICS; INSIGHTS	The light-activated enzyme NADPH-protochlorophyllide oxidoreductase (POR) catalyzes the trans addition of hydrogen across the C-17-C-18 double bond of protochlorophyllide ( Pchlide), a key step in chlorophyll biosynthesis. Similar to other members of the short chain alcohol dehydrogenase/reductase family of enzymes, POR contains a conserved Tyr and Lys residue in the enzyme active site, which are implicated in a proposed reaction mechanism involving proton transfer from the Tyr hydoxyl group to Pchlide. We have analyzed a number of POR variant enzymes altered in these conserved residues using a combination of steady-state turnover, laser photoexcitation studies, and low temperature fluorescence spectroscopy. None of the mutations completely abolished catalytic activity. We demonstrate their importance to catalysis by defining multiple roles in the overall reaction pathway. Mutation of either residue impairs formation of the ground state ternary enzyme-substrate complex, pointing to a key role in substrate binding. By analyzing the most active variant (Y193F), we show that Tyr-193 participates in proton transfer to Pchlide and stabilizes the Pchlide excited state, enabling hydride transfer from NADPH to Pchilde. Thus, in addition to confirming the probable identity of the proton donor in Pchlide reduction, our work defines additional roles for these residues in facilitating hydride transfer through stabilization of the ground and excited states of the ternary enzyme complex.	[Menon, Binuraj R. K.; Waltho, Jonathan P.; Scrutton, Nigel S.; Heyes, Derren J.] Univ Manchester, Fac Life Sci, Manchester Interdisciplinary Bioctr, Manchester M1 7DN, Lancs, England	University of Manchester	Scrutton, NS (corresponding author), Univ Manchester, Fac Life Sci, Manchester Interdisciplinary Bioctr, 131 Princess St, Manchester M1 7DN, Lancs, England.	nigel.scrutton@manchester.ac.uk; derren.heyes@manchester.ac.uk	Menon, Binuraj/AAO-7752-2021; menon, binuraj/D-6731-2015	Menon, Binuraj/0000-0001-6852-8053; Waltho, Jonathan/0000-0002-7402-5492; Heyes, Derren/0000-0002-7453-1571	Biotechnology and Biological Sciences Research Council, Swindon, United Kingdom; BBSRC [BB/D01798X/1, BB/D01963X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D01963X/1, BB/D01798X/1] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council, Swindon, United Kingdom(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by the Biotechnology and Biological Sciences Research Council, Swindon, United Kingdom.	BEGLEY TP, 1989, J AM CHEM SOC, V111, P3095, DOI 10.1021/ja00190a071; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Boehr DD, 2006, SCIENCE, V313, P1638, DOI 10.1126/science.1130258; Brocker MJ, 2008, J BIOL CHEM, V283, P10559, DOI 10.1074/jbc.M708010200; CHEN Z, 1993, BIOCHEMISTRY-US, V32, P3342, DOI 10.1021/bi00064a017; DEONARAIN MP, 1989, BIOCHEMISTRY-US, V28, P9602, DOI 10.1021/bi00451a008; Dietzek B, 2006, J PHYS CHEM B, V110, P4399, DOI 10.1021/jp0556456; Dietzek B, 2009, CHEMPHYSCHEM, V10, P144, DOI 10.1002/cphc.200800536; ENSOR CM, 1991, BIOCHEM BIOPH RES CO, V176, P840, DOI 10.1016/S0006-291X(05)80262-1; Hammes-Schiffer S, 2002, BIOCHEMISTRY-US, V41, P13335, DOI 10.1021/bi0267137; HENNEKE CM, 1975, ARCH BIOCHEM BIOPHYS, V168, P436, DOI 10.1016/0003-9861(75)90272-6; Heyes DJ, 2008, BIOCHEMISTRY-US, V47, P10991, DOI 10.1021/bi801521c; Heyes DJ, 2007, J BIOL CHEM, V282, P32015, DOI 10.1074/jbc.M706098200; Heyes DJ, 2006, J BIOL CHEM, V281, P26847, DOI 10.1074/jbc.M602943200; Heyes DJ, 2009, J BIOL CHEM, V284, P3762, DOI 10.1074/jbc.M808548200; Heyes DJ, 2005, TRENDS BIOCHEM SCI, V30, P642, DOI 10.1016/j.tibs.2005.09.001; Heyes DJ, 2004, BIOCHEMISTRY-US, V43, P8265, DOI 10.1021/bi049576h; Heyes DJ, 2003, NAT STRUCT BIOL, V10, P491, DOI 10.1038/nsb929; Heyes DJ, 2003, BIOCHEMISTRY-US, V42, P523, DOI 10.1021/bi0268448; Heyes DJ, 2002, BIOCHEM SOC T, V30, P601, DOI 10.1042/bst0300601; Heyes DJ, 2002, P NATL ACAD SCI USA, V99, P11145, DOI 10.1073/pnas.182274199; Jimenez MC, 2005, CHEM SOC REV, V34, P783, DOI 10.1039/b416410p; Kohen A, 2000, J AM CHEM SOC, V122, P10738, DOI 10.1021/ja002229k; Kohen A, 1999, NATURE, V399, P496, DOI 10.1038/20981; Lebedev N, 2001, BIOCHEMISTRY-US, V40, P12562, DOI 10.1021/bi0105025; Lebedev N, 1998, PHOTOSYNTH RES, V58, P5, DOI 10.1023/A:1006082119102; Masuda T, 2004, PHOTOSYNTH RES, V81, P1, DOI 10.1023/B:PRES.0000028392.80354.7c; Mees A, 2004, SCIENCE, V306, P1789, DOI 10.1126/science.1101598; OBEID J, 1992, BIOCHEM BIOPH RES CO, V188, P222, DOI 10.1016/0006-291X(92)92373-6; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Sutcliffe MJ, 2000, TRENDS BIOCHEM SCI, V25, P405, DOI 10.1016/S0968-0004(00)01642-X; Sytina OA, 2008, NATURE, V456, P1001, DOI 10.1038/nature07354; Townley HE, 2001, PROTEINS, V44, P329, DOI 10.1002/prot.1098; VALERA V, 1987, BIOCHEM BIOPH RES CO, V148, P515, DOI 10.1016/0006-291X(87)91141-7; VARUGHESE KI, 1994, P NATL ACAD SCI USA, V91, P5582, DOI 10.1073/pnas.91.12.5582; WILKS HM, 1995, P NATL ACAD SCI USA, V92, P724, DOI 10.1073/pnas.92.3.724; Zhao GJ, 2008, BIOPHYS J, V94, P38, DOI 10.1529/biophysj.107.113738; Zheng YJ, 1997, J AM CHEM SOC, V119, P1523, DOI 10.1021/ja961667h	39	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	2009	284	27					18160	18166		10.1074/jbc.M109.020719	http://dx.doi.org/10.1074/jbc.M109.020719			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BW	19439417	Green Published, hybrid			2022-12-25	WOS:000267712400027
J	Taliaferro-Smith, L; Nagalingam, A; Zhong, D; Zhou, W; Saxena, NK; Sharma, D				Taliaferro-Smith, L.; Nagalingam, A.; Zhong, D.; Zhou, W.; Saxena, N. K.; Sharma, D.			LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells	ONCOGENE			English	Article						adiponectin; LKB1; invasion; migration; breast cancer	FATTY-ACID OXIDATION; ACTIVATED PROTEIN-KINASE; BODY-MASS INDEX; TUMOR-SUPPRESSOR; GLOBULAR ADIPONECTIN; THERAPEUTIC TARGET; METABOLIC SYNDROME; SERUM ADIPONECTIN; SIGNALING PATHWAY; SKELETAL-MUSCLE	Adiponectin is widely known as an adipocytokine with therapeutic potential for its markedly protective function in the pathogenesis of obesity-related disorders, metabolic syndrome, systemic insulin resistance, cardiovascular disease and more recently carcinogenesis. In the present study, we show that adiponectin inhibits adhesion, invasion and migration of breast cancer cells. Further analysis of the underlying molecular mechanisms revealed that adiponectin treatment increased AMP-activated protein kinase (AMPK) phosphorylation and activity as evident by increased phosphorylation of downstream target of AMPK, acetyl-coenzyme A carboxylase and inhibition of p70S6 kinase (S6K). Intriguingly, we discovered that adiponectin treatment increases the expression of tumor suppressor gene LKB1 in breast cancer cells. Overexpression of LKB1 in breast cancer cells further increased adiponectin-mediated phosphorylation of AMPK. Using isogenic LKB1 knockdown cell line pair, we found that LKB1 is required for adiponectin-mediated modulation of AMPK -S6K axis and more importantly, inhibition of adhesion, migration and invasion of breast cancer cells. Taken together these data present a novel mechanism involving specific upregulation of tumor suppressor gene LKB1 by which adiponectin inhibits adhesion, invasion and migration of breast cancer cells. Our findings indicate the possibility of using adiponectin analogues to inhibit invasion and migration of breast cancer cells. Oncogene (2009) 28, 2621 -2633; doi: 10.1038/onc.2009.129; published online 1 June 2009	[Taliaferro-Smith, L.; Nagalingam, A.; Zhong, D.; Zhou, W.; Saxena, N. K.; Sharma, D.] Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Saxena, N. K.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA	Emory University	Sharma, D (corresponding author), Winship Canc Inst, Dept Hematol & Med Oncol, Rm 4010,1701 Uppergate Dr, Atlanta, GA 30322 USA.	nksaxen@emory.edu; dsharma@emory.edu			NATIONAL CANCER INSTITUTE [P01CA116676, R01CA131294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK076742, R03DK089130, K01DK077137] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA131294, 5P01CA116676-030002, R01 CA131294] Funding Source: Medline; NIDDK NIH HHS [K01 DK076742, K01DK076742, R03 DK089130, K01 DK077137-05, K01 DK077137-02, K01 DK077137, K01 DK077137-01A1, R03 DK089130-02, K01 DK077137-04, R03 DK089130-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933; Arditi JD, 2007, HORM METAB RES, V39, P9, DOI 10.1055/s-2007-956518; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Barb D, 2006, EXPERT OPIN INV DRUG, V15, P917, DOI 10.1517/13543784.15.8.917; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Boudeau J, 2004, J CELL SCI, V117, P6365, DOI 10.1242/jcs.01571; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Cacicedo JM, 2004, BIOCHEM BIOPH RES CO, V324, P1204, DOI 10.1016/j.bbrc.2004.09.177; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Chen DC, 2006, CANCER LETT, V237, P109, DOI 10.1016/j.canlet.2005.05.047; Chen MB, 2005, J CLIN ENDOCR METAB, V90, P3665, DOI 10.1210/jc.2004-1980; Daling JR, 2001, CANCER, V92, P720, DOI 10.1002/1097-0142(20010815)92:4<720::AID-CNCR1375>3.0.CO;2-T; Dieudonne MN, 2006, BIOCHEM BIOPH RES CO, V345, P271, DOI 10.1016/j.bbrc.2006.04.076; Dos Santos E, 2008, ONCOL REP, V20, P971, DOI 10.3892/or_00000098; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Fenton H, 2006, APPL IMMUNOHISTO M M, V14, P146, DOI 10.1097/01.pai.0000176157.07908.20; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Goldstein BJ, 2004, J CLIN ENDOCR METAB, V89, P2563, DOI 10.1210/jc.2004-0518; Grossmann ME, 2008, BRIT J CANCER, V98, P370, DOI 10.1038/sj.bjc.6604166; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101; Jarde T, 2008, HISTOPATHOLOGY, V53, P484, DOI 10.1111/j.1365-2559.2008.03121.x; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Kelesidis I, 2006, BRIT J CANCER, V94, P1221, DOI 10.1038/sj.bjc.6603051; Korner A, 2007, J CLIN ENDOCR METAB, V92, P1041, DOI 10.1210/jc.2006-1858; Liu J, 2008, CARCINOGENESIS, V29, P2195, DOI 10.1093/carcin/bgn194; Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021; Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011; Maahs DM, 2005, CIRCULATION, V111, P747, DOI 10.1161/01.CIR.0000155251.03724.A5; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Mantzoros C, 2004, J CLIN ENDOCR METAB, V89, P1102, DOI 10.1210/jc.2003-031804; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Matsuzawa Y, 2004, ARTERIOSCL THROM VAS, V24, P29, DOI 10.1161/01.ATV.0000099786.99623.EF; Miyoshi Y, 2003, CLIN CANCER RES, V9, P5699; Motoshima H, 2006, J PHYSIOL-LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803; Nakayama S, 2008, BREAST CANCER RES TR, V112, P405, DOI 10.1007/s10549-007-9874-3; Petrelli JM, 2002, CANCER CAUSE CONTROL, V13, P325, DOI 10.1023/A:1015288615472; Phoenix KN, 2009, BREAST CANCER RES TR, V113, P101, DOI 10.1007/s10549-008-9916-5; Rosenau F, 2004, CHEMBIOCHEM, V5, P153, DOI 10.1002/cbic.200300761; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Sapkota GP, 2002, BIOCHEM J, V362, P481, DOI 10.1042/0264-6021:3620481; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Saxena NK, 2007, J BIOL CHEM, V282, P13316, DOI 10.1074/jbc.M609798200; Saxena NK, 2007, CANCER RES, V67, P2497, DOI 10.1158/0008-5472.CAN-06-3075; Saxena NK, 2008, CANCER RES, V68, P9712, DOI 10.1158/0008-5472.CAN-08-1952; Schaffler A, 2007, NAT CLIN PRACT ENDOC, V3, P345, DOI 10.1038/ncpendmet0456; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shen Z, 2002, CLIN CANCER RES, V8, P2085; Spranger J, 2003, LANCET, V361, P226, DOI 10.1016/S0140-6736(03)12255-6; Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066; Swarbrick Michael M., 2008, Metabolic Syndrome and Related Disorders, V6, P87, DOI 10.1089/met.2007.0029; Takahata C, 2007, CANCER LETT, V250, P229, DOI 10.1016/j.canlet.2006.10.006; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Vona-Davis L, 2007, ENDOCR-RELAT CANCER, V14, P189, DOI 10.1677/ERC-06-0068; Wang Y, 2005, J BIOL CHEM, V280, P18341, DOI 10.1074/jbc.M501149200; Wang Y, 2006, CANCER RES, V66, P11462, DOI 10.1158/0008-5472.CAN-06-1969; Witters LA, 2006, TRENDS BIOCHEM SCI, V31, P13, DOI 10.1016/j.tibs.2005.11.009; Xu AM, 2003, J CLIN INVEST, V112, P91, DOI 10.1172/JCI200317797; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yoon MJ, 2006, DIABETES, V55, P2562, DOI 10.2337/db05-1322; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zhong DS, 2008, CANCER RES, V68, P7270, DOI 10.1158/0008-5472.CAN-08-1484; Zhuang Yongxian, 2008, J Mol Signal, V3, P18, DOI 10.1186/1750-2187-3-18	71	135	142	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2621	2633		10.1038/onc.2009.129	http://dx.doi.org/10.1038/onc.2009.129			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19483724	Green Accepted			2022-12-25	WOS:000268211200001
J	Kamath, AT; Rochat, AF; Christensen, D; Agger, EM; Andersen, P; Lambert, PH; Siegrist, CA				Kamath, Arun T.; Rochat, Anne-Francoise; Christensen, Dennis; Agger, Else Marie; Andersen, Peter; Lambert, Paul-Henri; Siegrist, Claire-Anne			A Liposome-Based Mycobacterial Vaccine Induces Potent Adult and Neonatal Multifunctional T Cells through the Exquisite Targeting of Dendritic Cells	PLOS ONE			English	Article								Background: In the search for more potent and safer tuberculosis vaccines, CAF01 was identified as a remarkable formulation. Based on cationic liposomes and including a synthetic mycobacterial glycolipid as TLR-independent immunomodulator, it induces strong and protective T helper-1 and T helper-17 adult murine responses to Ag85B-ESAT-6, a major mycobacterial fusion protein. Here, we assessed whether these properties extend to early life and how CAF01 mediates its adjuvant properties in vivo. Methods/Findings: Following adult or neonatal murine immunization, Ag85B-ESAT-6/CAF01 similarly reduced the post-challenge bacterial growth of M. bovis BCG, whereas no protection was observed using Alum as control. This protection was mediated by the induction of similarly strong Th1 and Th17 responses in both age groups. Multifunctional Th1 cells were already elicited after a single vaccine dose and persisted at high levels for at least 6 months even after neonatal priming. Unexpectedly, this potent adjuvanticity was not mediated by a massive targeting/activation of dendritic cells: in contrast, very few DCs in the draining lymph nodes were bearing the labeled antigen/adjuvant. The increased expression of the CD40 and CD86 activation markers was restricted to the minute portion of adjuvant-bearing DCs. However, vaccine-associated activated DCs were recovered several days after immunization. Conclusion: The potent adult and neonatal adjuvanticity of CAF01 is associated in vivo with an exquisite but prolonged DC uptake and activation, fulfilling the preclinical requirements for novel tuberculosis vaccines to be used in early life.			Kamath, AT (corresponding author), Univ Geneva, Fac Med, Collaborating Ctr Vaccinol & Neonatal Immunol, WHO,Dept Pathol Immunol, Geneva, Switzerland.	Claire-Anne.Siegrist@unige.ch	Christensen, Dennis/C-6378-2008	Christensen, Dennis/0000-0003-2382-8639; Andersen, Peter/0000-0002-5869-2551				Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394; Agger EM, 2006, VACCINE, V24, P5452, DOI 10.1016/j.vaccine.2006.03.072; Agger EM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003116; Barrios C, 1996, EUR J IMMUNOL, V26, P2666, DOI 10.1002/eji.1830261118; Baumann S, 2006, CURR OPIN IMMUNOL, V18, P438, DOI 10.1016/j.coi.2006.05.016; Cendron D, 2007, EUR J IMMUNOL, V37, P549, DOI 10.1002/eji.200636343; Cooper AM, 2008, IMMUNOL REV, V226, P191, DOI 10.1111/j.1600-065X.2008.00702.x; Dadaglio G, 2002, J IMMUNOL, V168, P2219, DOI 10.4049/jimmunol.168.5.2219; Davidsen J, 2005, BBA-BIOMEMBRANES, V1718, P22, DOI 10.1016/j.bbamem.2005.10.011; de Jong R, 1998, SCIENCE, V280, P1435; GILLIS S, 1978, J IMMUNOL, V120, P2027; Giri PK, 2008, EXPERT OPIN BIOL TH, V8, P1759, DOI [10.1517/14712598.8.11.1759, 10.1517/14712598.8.11.1759 ]; Henri S, 2001, J IMMUNOL, V167, P741, DOI 10.4049/jimmunol.167.2.741; Hoft DF, 2008, LANCET, V372, P164, DOI 10.1016/S0140-6736(08)61036-3; Holten-Andersen L, 2004, INFECT IMMUN, V72, P1608, DOI 10.1128/IAI.72.3.1608-1617.2004; Hou WS, 2004, NAT IMMUNOL, V5, P583, DOI 10.1038/ni1071; Kamath AT, 2008, EUR J IMMUNOL, V38, P1247, DOI 10.1002/eji.200737889; Kamath AT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003683; Kamath AT, 2002, BLOOD, V100, P1734, DOI 10.1182/blood.V100.5.1734.h81702001734_1734_1741; Kaufmann SHE, 2008, SCAND J INFECT DIS, V40, P595, DOI 10.1080/00365540802032759; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Knuf M, 2008, J PEDIATR-US, V152, P655, DOI 10.1016/j.jpeds.2007.09.034; KORSHOLM KS, 2007, IMMUNOLOGY; Kovarik J, 2000, VIROLOGY, V268, P122, DOI 10.1006/viro.1999.0159; Langermans JAM, 2005, VACCINE, V23, P2740, DOI 10.1016/j.vaccine.2004.11.051; Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075; Mandalakas Anna M, 2005, Semin Pediatr Infect Dis, V16, P93, DOI 10.1053/j.spid.2005.01.001; Martin GH, 2003, LIBRARY, V4, P428, DOI 10.1093/library/4.4.428; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Miles DJC, 2008, CLIN VACCINE IMMUNOL, V15, P995, DOI 10.1128/CVI.00037-08; Olsen AW, 2001, INFECT IMMUN, V69, P2773, DOI 10.1128/IAI.69.5.2773-2778.2001; Olsen AW, 2004, INFECT IMMUN, V72, P6148, DOI 10.1128/IAI.72.10.6148-6150.2004; Randolph GJ, 2008, ANNU REV IMMUNOL, V26, P293, DOI 10.1146/annurev.immunol.26.021607.090254; Regner M, 2004, J IMMUNOL, V173, P2669, DOI 10.4049/jimmunol.173.4.2669; Reichenbach J, 2001, CURR OPIN ALLERGY CL, V1, P503, DOI 10.1097/00130832-200112000-00003; Riedl K, 2008, VACCINE, V26, P3461, DOI 10.1016/j.vaccine.2008.04.029; Roduit C, 2002, INFECT IMMUN, V70, P3521, DOI 10.1128/IAI.70.7.3521-3528.2002; Ruedl C, 2000, J IMMUNOL, V165, P4910, DOI 10.4049/jimmunol.165.9.4910; Schellack C, 2006, VACCINE, V24, P5461, DOI 10.1016/j.vaccine.2006.03.071; Scriba TJ, 2008, J IMMUNOL, V180, P1962, DOI 10.4049/jimmunol.180.3.1962; Siegrist CA, 2007, J COMP PATHOL, V137, pS4, DOI 10.1016/j.jcpa.2007.04.004; Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7; Soares AP, 2008, J IMMUNOL, V180, P3569, DOI 10.4049/jimmunol.180.5.3569; Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173; Teoh D, 2009, J IMMUNOL, V182, P2425, DOI 10.4049/jimmunol.0803661; Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3; Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1; Weeratna RD, 2001, FEMS IMMUNOL MED MIC, V32, P65, DOI 10.1016/S0928-8244(01)00267-X; Werninghaus K, 2009, J EXP MED, V206, P89, DOI 10.1084/jem.20081445; WHO, 2007, WKLY EPIDEMIOL REC, V82, P18; Willems F, 2009, EUR J IMMUNOL, V39, P26, DOI 10.1002/eji.200838391; Winthrop KL, 2006, NAT CLIN PRACT RHEUM, V2, P602, DOI 10.1038/ncprheum0336	52	72	75	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2009	4	6							e5771	10.1371/journal.pone.0005771	http://dx.doi.org/10.1371/journal.pone.0005771			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453PV	19492047	Green Published, gold, Green Submitted			2022-12-25	WOS:000266624300008
J	Kelso, JAS; de Guzman, GC; Reveley, C; Tognoli, E				Kelso, J. A. Scott; de Guzman, Gonzalo C.; Reveley, Colin; Tognoli, Emmanuelle			Virtual Partner Interaction (VPI): Exploring Novel Behaviors via Coordination Dynamics	PLOS ONE			English	Article							PHASE-TRANSITIONS; HUMAN BRAIN; SYNCHRONIZATION; NETWORKS; MODEL; CLAMP; INTERFACES; EXCITATOR; COMPLEX; ROBOTS	Inspired by the dynamic clamp of cellular neuroscience, this paper introduces VPI-Virtual Partner Interaction-a coupled dynamical system for studying real time interaction between a human and a machine. In this proof of concept study, human subjects coordinate hand movements with a virtual partner, an avatar of a hand whose movements are driven by a computerized version of the Haken-Kelso-Bunz (HKB) equations that have been shown to govern basic forms of human coordination. As a surrogate system for human social coordination, VPI allows one to examine regions of the parameter space not typically explored during live interactions. A number of novel behaviors never previously observed are uncovered and accounted for. Having its basis in an empirically derived theory of human coordination, VPI offers a principled approach to human-machine interaction and opens up new ways to understand how humans interact with human-like machines including identification of underlying neural mechanisms.			Kelso, JAS (corresponding author), Florida Atlantic Univ, Human Brain & Behav Lab, Ctr Complex Syst & Brain Sci, Boca Raton, FL 33431 USA.	kelso@ccs.fau.edu		Tognoli, Emmanuelle/0000-0003-3674-504X	NIMH NIH HHS [R01 MH042900, MH 42900, R01 MH080838, MH 80038, R37 MH042900] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH042900, R37MH042900, R01MH080838] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aramaki Y, 2006, CEREB CORTEX, V16, P1338, DOI 10.1093/cercor/bhj075; Barakova E., 2007, P 6 INT C INT DES CH, P73; Bartos M, 1999, J NEUROSCI, V19, P6650; Billard A, 2003, ROBOT AUTON SYST, V42, P259, DOI 10.1016/S0921-8890(02)00380-9; Braha D., 2006, COMPLEX ENG SYSTEMS; BREAZEAL M, 2002, INT J EXPT ROBOTICS, V11, P883; DAUTENHAHN K, 1999, SPRINGER LECT NOTES, V1562, P102; Dautenhahn K, 2007, PHILOS T R SOC B, V362, P679, DOI 10.1098/rstb.2006.2004; EDSINGER A, 2007, IEEE INT S ROBOT HUM, V16, P1167; Fink PW, 2009, J MOTOR BEHAV, V41, P147, DOI 10.3200/JMBR.41.2.147-157; Fisher NI, 1995, STAT ANAL CIRCULAR D; Forlizzi J, 2004, HUM-COMPUT INTERACT, V19, P25, DOI 10.1207/s15327051hci1901&2_3; Frith CD, 2007, CURR BIOL, V17, pR724, DOI 10.1016/j.cub.2007.05.068; Fuchs A., 2009, ENCY COMPLEXITY SYST; Fuchs A, 2008, UNDERST COMPLEX SYST, P327, DOI 10.1007/978-3-540-74479-5_16; GEYER W, 2001, P 2001 INT ACM SIGGR; Gibson J.J., 1977, PERCEIVING ACTING KN, P67; Goaillard JM, 2006, PHYSIOLOGY, V21, P197, DOI 10.1152/physiol.00063.2005; Goodman PH, 2008, FRONT NEUROSCI-SWITZ, V2, P123, DOI 10.3389/neuro.01.007.2008; Grillner S, 1999, CURR OPIN NEUROBIOL, V9, P663, DOI 10.1016/S0959-4388(99)00036-7; HAKEN H, 1985, BIOL CYBERN, V51, P347, DOI 10.1007/BF00336922; Hoc JM, 2000, ERGONOMICS, V43, P833, DOI 10.1080/001401300409044; HOLLAN J, 2000, ACM T COMPUT-HUM INT, V7, P75; Huys R, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000061; Inamura T, 2001, IEEE ASME INT C ADV, P159, DOI 10.1109/AIM.2001.936447; Jantzen KJ, 2004, P NATL ACAD SCI USA, V101, P6815, DOI 10.1073/pnas.0401300101; Jirsa VK, 2005, J MOTOR BEHAV, V37, P35, DOI 10.3200/JMBR.37.1.35-51; Kaplan F, 2008, FRONT NEUROSCI-SWITZ, V2, P22, DOI 10.3389/neuro.01.023.2008; Kath WL, 2007, SCIENCE, V316, P1857, DOI 10.1126/science.1145111; KAY BA, 1987, J EXP PSYCHOL HUMAN, V13, P178, DOI 10.1037/0096-1523.13.2.178; KAZEROONI H, 1990, IEEE T SYST MAN CYB, V20, P450, DOI 10.1109/21.52555; Kelso J, 1984, AM J PHYSIOL-REG I, V15, pR1000, DOI DOI 10.1152/ajpregu.1984.246.6.R1000; KELSO JAS, 1987, PHYS SCRIPTA, V35, P79, DOI 10.1088/0031-8949/35/1/020; KELSO JAS, 1990, ATTENTION PERFORM, V8, P139; KELSO JAS, 1992, PHYS LETT A, V169, P134, DOI 10.1016/0375-9601(92)90583-8; KELSO JAS, 1981, B PSYCHONOMIC SOC, V18, P63; Kiss IZ, 2007, SCIENCE, V316, P1886, DOI 10.1126/science.1140858; Krach S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002597; KRAMER NC, HUMAN COMMU IN PRESS; Kuniyoshi Y, 2004, LECT NOTES ARTIF INT, V3139, P202; Lachaux JP, 1999, HUM BRAIN MAPP, V8, P194, DOI 10.1002/(SICI)1097-0193(1999)8:4<194::AID-HBM4>3.0.CO;2-C; Lebedev MA, 2006, TRENDS NEUROSCI, V29, P536, DOI 10.1016/j.tins.2006.07.004; Lungarella M, 2006, PLOS COMPUT BIOL, V2, P1301, DOI 10.1371/journal.pcbi.0020144; Mayville JM, 1999, EXP BRAIN RES, V127, P371, DOI 10.1007/s002210050805; Meyer-Lindenberg A, 2002, P NATL ACAD SCI USA, V99, P10948, DOI 10.1073/pnas.162114799; Netoff TI, 2005, J NEUROPHYSIOL, V93, P1197, DOI 10.1152/jn.00982.2004; Nowotny T, 2003, J NEUROSCI, V23, P9776; Oprisan SA, 2004, BIOPHYS J, V87, P2283, DOI 10.1529/biophysj.104.046193; Oullier O, 2009, ENCY COMPLEXITY SYST; Oullier O, 2008, SOC NEUROSCI, V3, P178, DOI 10.1080/17470910701563392; Park DC, 2007, J GERONTOL B-PSYCHOL, V62, P45, DOI 10.1093/geronb/62.special_issue_1.45; Patil PG, 2008, NEUROTHERAPEUTICS, V5, P137, DOI 10.1016/j.nurt.2007.11.002; PEPER CE, 2003, HUM MOVEMENT SCI, V18, P263; Pfeifer R, 2007, SCIENCE, V318, P1088, DOI 10.1126/science.1145803; Preiss DD, 2005, EDUC PSYCHO, P183; Prinz AA, 2004, TRENDS NEUROSCI, V27, P218, DOI 10.1016/j.tins.2004.02.004; REGER BD, 2006, ARTIF LIFE, V6, P307; Repp BH, 2008, HUM MOVEMENT SCI, V27, P423, DOI 10.1016/j.humov.2008.02.016; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Roy David M, 1994, C COMP HUM FACT COMP C COMP HUM FACT COMP, P313; SALVINI P, 2007, P 2007 IEEE INT C RO; SCHMIDT RC, 1994, BIOL CYBERN, V70, P369, DOI 10.1007/BF00200334; Schmidt RC, 2008, UNDERST COMPLEX SYST, P281, DOI 10.1007/978-3-540-74479-5_14; SCHOLTZ J, 2003, 36 ANN HAW INT C SYS, P125; SCHONER G, 1988, SCIENCE, V239, P1513, DOI 10.1126/science.3281253; SHARP AA, 1993, J NEUROPHYSIOL, V69, P992, DOI 10.1152/jn.1993.69.3.992; Swinnen SP, 2002, NAT REV NEUROSCI, V3, P350, DOI 10.1038/nrn807; Tognoli E, 2007, P NATL ACAD SCI USA, V104, P8190, DOI 10.1073/pnas.0611453104; Tognoli E, 2009, PROG NEUROBIOL, V87, P31, DOI 10.1016/j.pneurobio.2008.09.014; Tognoli E, 2008, UNDERST COMPLEX SYST, P309, DOI 10.1007/978-3-540-74479-5_15; Wegner P, 1997, COMMUN ACM, V40, P80, DOI 10.1145/253769.253801; West R. L., 2001, Cognitive Systems Research, V1, P221, DOI 10.1016/S1389-0417(00)00014-0; Wolpaw JR, 2002, CLIN NEUROPHYSIOL, V113, P767, DOI 10.1016/S1388-2457(02)00057-3; Yamashita Y, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000220; Zlatev J, 2001, MIND MACH, V11, P155, DOI 10.1023/A:1011218919464	75	77	77	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2009	4	6							e5749	10.1371/journal.pone.0005749	http://dx.doi.org/10.1371/journal.pone.0005749			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	453PV	19492044	gold, Green Published			2022-12-25	WOS:000266624300005
J	Kashuba, VI; Pavlova, TV; Grigorieva, EV; Kutsenko, A; Yenamandra, SP; Li, JF; Wang, FL; Protopopov, AI; Zabarovska, VI; Senchenko, V; Haraldson, K; Eshchenko, T; Kobliakova, J; Vorontsova, O; Kuzmin, I; Braga, E; Blinov, VM; Kisselev, LL; Zeng, YX; Ernberg, I; Lerman, MI; Klein, G; Zabarovsky, ER				Kashuba, Vladimir I.; Pavlova, Tatiana V.; Grigorieva, Elvira V.; Kutsenko, Alexey; Yenamandra, Surya Pavan; Li, Jingfeng; Wang, Fuli; Protopopov, Alexei I.; Zabarovska, Veronika I.; Senchenko, Vera; Haraldson, Klas; Eshchenko, Tatiana; Kobliakova, Julia; Vorontsova, Olga; Kuzmin, Igor; Braga, Eleonora; Blinov, Vladimir M.; Kisselev, Lev L.; Zeng, Yi-Xin; Ernberg, Ingemar; Lerman, Michael I.; Klein, George; Zabarovsky, Eugene R.			High Mutability of the Tumor Suppressor Genes RASSF1 and RBSP3 (CTDSPL) in Cancer	PLOS ONE			English	Article								Background: Many different genetic alterations are observed in cancer cells. Individual cancer genes display point mutations such as base changes, insertions and deletions that initiate and promote cancer growth and spread. Somatic hypermutation is a powerful mechanism for generation of different mutations. It was shown previously that somatic hypermutability of proto-oncogenes can induce development of lymphomas. Methodology/Principal Findings: We found an exceptionally high incidence of single-base mutations in the tumor suppressor genes RASSF1 and RBSP3 (CTDSPL) both located in 3p21.3 regions, LUCA and AP20 respectively. These regions contain clusters of tumor suppressor genes involved in multiple cancer types such as lung, kidney, breast, cervical, head and neck, nasopharyngeal, prostate and other carcinomas. Altogether in 144 sequenced RASSF1A clones (exons 1-2), 129 mutations were detected (mutation frequency, MF = 0.23 per 100 bp) and in 98 clones of exons 3-5 we found 146 mutations (MF = 0.29). In 85 sequenced RBSP3 clones, 89 mutations were found (MF = 0.10). The mutations were not cytidine-specific, as would be expected from alterations generated by AID/APOBEC family enzymes, and appeared de novo during cell proliferation. They diminished the ability of corresponding transgenes to suppress cell and tumor growth implying a loss of function. These high levels of somatic mutations were found both in cancer biopsies and cancer cell lines. Conclusions/Significance: This is the first report of high frequencies of somatic mutations in RASSF1 and RBSP3 in different cancers suggesting it may underlay the mutator phenotype of cancer. Somatic hypermutations in tumor suppressor genes involved in major human malignancies offer a novel insight in cancer development, progression and spread.			Kashuba, VI (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden.	lermanmi@gmail.com	Senchenko, Vera N/C-8992-2014; Grigorieva, Elvira/A-4937-2010; Kashuba, Vladimir/AAO-7742-2020; Kashuba, Vladimir I/N-3732-2017; Braga, Eleonora A./P-5574-2016	Senchenko, Vera N/0000-0002-3119-515X; Grigorieva, Elvira/0000-0003-2457-9179; Kashuba, Vladimir I/0000-0001-9416-8282; Braga, Eleonora/0000-0001-5188-4094; Pavlova, Tatiana/0000-0002-2857-5696	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alimov A, 2000, ONCOGENE, V19, P1392, DOI 10.1038/sj.onc.1203449; Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Braga E, 2002, INT J CANCER, V100, P534, DOI 10.1002/ijc.10511; Brulliard M, 2007, P NATL ACAD SCI USA, V104, P7522, DOI 10.1073/pnas.0611076104; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CHUMAKOV IM, 1982, GENE, V17, P19, DOI 10.1016/0378-1119(82)90097-X; Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Gearhart PJ, 2001, NAT REV IMMUNOL, V1, P187, DOI 10.1038/35105009; Imreh S, 2003, GENE CHROMOSOME CANC, V38, P307, DOI 10.1002/gcc.10271; Kashuba VI, 2004, P NATL ACAD SCI USA, V101, P4906, DOI 10.1073/pnas.0401238101; Kuzmin I, 2002, CANCER RES, V62, P3498; Lerman MI, 2000, CANCER RES, V60, P6116; Li F, 2004, CANCER RES, V64, P6438, DOI 10.1158/0008-5472.CAN-03-3869; Li JF, 2004, ONCOGENE, V23, P5941, DOI 10.1038/sj.onc.1207789; Li JF, 2002, P NATL ACAD SCI USA, V99, P10724, DOI 10.1073/pnas.132271699; Li JF, 1999, FEBS LETT, V451, P289, DOI 10.1016/S0014-5793(99)00598-0; Muto T, 2000, GENOMICS, V68, P85, DOI 10.1006/geno.2000.6268; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Pan ZG, 2005, CANCER BIOL THER, V4, P1116, DOI 10.4161/cbt.4.10.2023; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Protopopov A, 2003, CANCER RES, V63, P404; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; Senchenko V, 2003, ONCOGENE, V22, P2984, DOI 10.1038/sj.onc.1206429; Senchenko VN, 2004, ONCOGENE, V23, P5719, DOI 10.1038/sj.onc.1207760; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; SPANDIDOS DA, 1986, BIOSCIENCE REP, V6, P691, DOI 10.1007/BF01116536; Strauss BS, 2000, MUTAT RES-FUND MOL M, V457, P93, DOI 10.1016/S0027-5107(00)00135-4; Wang JC, 2007, P NATL ACAD SCI USA, V104, P8403, DOI 10.1073/pnas.0610902104; Yang Y, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000264; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740	36	28	30	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5231	10.1371/journal.pone.0005231	http://dx.doi.org/10.1371/journal.pone.0005231			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451SH	19478941	Green Published, Green Submitted, gold			2022-12-25	WOS:000266490000001
J	Cailotto, C; Lei, J; van der Vliet, J; van Heijningen, C; van Eden, CG; Kalsbeek, A; Pevet, P; Buijs, RM				Cailotto, Cathy; Lei, Jun; van der Vliet, Jan; van Heijningen, Caroline; van Eden, Corbert G.; Kalsbeek, Andries; Pevet, Paul; Buijs, Ruud M.			Effects of Nocturnal Light on (Clock) Gene Expression in Peripheral Organs: A Role for the Autonomic Innervation of the Liver	PLOS ONE			English	Article							SUPRACHIASMATIC NUCLEUS; CIRCADIAN-RHYTHMS; PLASMA-GLUCOSE; DIFFERENTIAL CONTROL; N-ACETYLTRANSFERASE; MELATONIN SYNTHESIS; INDUCED INHIBITION; NERVOUS-SYSTEM; ADRENAL-GLAND; RAT	Background: The biological clock, located in the hypothalamic suprachiasmatic nucleus (SCN), controls the daily rhythms in physiology and behavior. Early studies demonstrated that light exposure not only affects the phase of the SCN but also the functional activity of peripheral organs. More recently it was shown that the same light stimulus induces immediate changes in clock gene expression in the pineal and adrenal, suggesting a role of peripheral clocks in the organ-specific output. In the present study, we further investigated the immediate effect of nocturnal light exposure on clock genes and metabolism-related genes in different organs of the rat. In addition, we investigated the role of the autonomic nervous system as a possible output pathway of the SCN to modify the activity of the liver after light exposure. Methodology and Principal Findings: First, we demonstrated that light, applied at different circadian times, affects clock gene expression in a different manner, depending on the time of day and the organ. However, the changes in clock gene expression did not correlate in a consistent manner with those of the output genes (i.e., genes involved in the functional output of an organ). Then, by selectively removing the autonomic innervation to the liver, we demonstrated that light affects liver gene expression not only via the hormonal pathway but also via the autonomic input. Conclusion: Nocturnal light immediately affects peripheral clock gene expression but without a clear correlation with organ-specific output genes, raising the question whether the peripheral clock plays a "decisive" role in the immediate (functional) response of an organ to nocturnal light exposure. Interestingly, the autonomic innervation of the liver is essential to transmit the light information from the SCN, indicating that the autonomic nervous system is an important gateway for the SCN to cause an immediate resetting of peripheral physiology after phase-shift inducing light exposures.			Cailotto, C (corresponding author), Netherlands Inst Neurosci, Amsterdam, Netherlands.	c.cailotto@amc.uva.nl	Buijs, Rudolf/AAD-5707-2020; Kalsbeek, Andries/H-3076-2019; Jansen, Heiko T./A-5770-2008	Kalsbeek, Andries/0000-0001-9606-8453; Jansen, Heiko T./0000-0003-0178-396X				Balsalobre A, 2000, CURR BIOL, V10, P1291, DOI 10.1016/S0960-9822(00)00758-2; Bando H, 2007, J NEUROSCI, V27, P4359, DOI 10.1523/JNEUROSCI.4131-06.2007; BOS NPA, 1990, BRAIN RES, V511, P158, DOI 10.1016/0006-8993(90)90235-4; Buijs RM, 1998, PROG BRAIN RES, V119, P365; Buijs RM, 1999, EUR J NEUROSCI, V11, P1535, DOI 10.1046/j.1460-9568.1999.00575.x; Buijs RM, 2003, J COMP NEUROL, V464, P36, DOI 10.1002/cne.10765; Cailotto C, 2005, EUR J NEUROSCI, V22, P2531, DOI 10.1111/j.1460-9568.2005.04439.x; Cailotto C, 2008, ENDOCRINOLOGY, V149, P1914, DOI 10.1210/en.2007-0816; Chansard M, 2005, MOL BRAIN RES, V139, P333, DOI 10.1016/j.molbrainres.2005.06.004; Colle I, 2004, ANAT REC PART A, V280A, P924, DOI 10.1002/ar.a.20097; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Davidson AJ, 2004, LIVER INT, V24, P179, DOI 10.1111/j.1478-3231.2004.00917.x; DELAIGLESIA HO, 1995, NEUROREPORT, V6, P1715, DOI 10.1097/00001756-199509000-00004; Doi M, 2006, CELL, V125, P497, DOI 10.1016/j.cell.2006.03.033; Drijfhout WJ, 1996, NEUROSCI LETT, V202, P185, DOI 10.1016/0304-3940(95)12245-1; Engeland WC, 2005, ENDOCRINE, V28, P325, DOI 10.1385/ENDO:28:3:325; Foulkes NS, 1997, BIOL CELL, V89, P487, DOI 10.1016/S0248-4900(98)80004-X; Fukuhara C, 2004, MOL BRAIN RES, V130, P109, DOI 10.1016/j.molbrainres.2004.07.014; Gerendai I, 2000, EXP CLIN ENDOCR DIAB, V108, P389, DOI 10.1055/s-2000-8134; GREEN DJ, 1982, BRAIN RES, V245, P198, DOI 10.1016/0006-8993(82)90361-4; Guo HN, 2005, P NATL ACAD SCI USA, V102, P3111, DOI 10.1073/pnas.0409734102; Hirota T, 2002, J BIOL CHEM, V277, P44244, DOI 10.1074/jbc.M206233200; HOLMES SW, 1976, BRIT J PHARMACOL, V56, pP360; Ishida A, 2005, CELL METAB, V2, P297, DOI 10.1016/j.cmet.2005.09.009; Izumo M, 2003, P NATL ACAD SCI USA, V100, P16089, DOI 10.1073/pnas.2536313100; Kaasik K, 2004, NATURE, V430, P467, DOI 10.1038/nature02724; Kalsbeek A, 2000, EUR J NEUROSCI, V12, P3146, DOI 10.1046/j.1460-9568.2000.00202.x; Kalsbeek A, 1999, NEUROSCIENCE, V91, P453, DOI 10.1016/S0306-4522(98)00635-6; Kalsbeek A, 2004, J NEUROSCI, V24, P7604, DOI 10.1523/JNEUROSCI.5328-03.2004; Kalsbeek A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003194; KAMINSKY YG, 1987, COMP BIOCHEM PHYS B, V86, P763, DOI 10.1016/0305-0491(87)90224-0; KANEKO M, 1981, ENDOCRINOLOGY, V109, P70, DOI 10.1210/endo-109-1-70; Kennaway DJ, 2002, AM J PHYSIOL-REG I, V282, pR358, DOI 10.1152/ajpregu.00360.2001; KLEIN DC, 1972, SCIENCE, V177, P532, DOI 10.1126/science.177.4048.532; Klieverik LP, 2008, AM J PHYSIOL-ENDOC M, V294, pE513, DOI 10.1152/ajpendo.00659.2007; la Fleur SE, 1999, J NEUROENDOCRINOL, V11, P643; la Fleur SE, 2003, DIABETES, V52, P2321, DOI 10.2337/diabetes.52.9.2321; Lam TKT, 2005, NAT MED, V11, P320, DOI 10.1038/nm1201; Larsen PJ, 1998, EUR J NEUROSCI, V10, P128; Lee CC, 2006, CANCER CAUSE CONTROL, V17, P525, DOI 10.1007/s10552-005-9003-8; LOH DH, 2008, NEUROENDOCRINOLOGY; Meijer JH, 1998, J NEUROSCI, V18, P9078; Meyer-Bernstein EL, 1999, ENDOCRINOLOGY, V140, P207, DOI 10.1210/en.140.1.207; MOORE RY, 1972, BRAIN RES, V42, P201, DOI 10.1016/0006-8993(72)90054-6; Morrison SF, 2001, AM J PHYSIOL-REG I, V281, pR683, DOI 10.1152/ajpregu.2001.281.3.R683; Nagai K, 1996, PROG BRAIN RES, V111, P253, DOI 10.1016/S0079-6123(08)60413-6; Nagoshi E, 2004, CELL, V119, P693, DOI 10.1016/j.cell.2004.11.015; Nishide S, 2006, GENES CELLS, V11, P1173, DOI 10.1111/j.1365-2443.2006.01015.x; NISHINO H, 1976, BRAIN RES, V112, P45, DOI 10.1016/0006-8993(76)90333-4; Oishi K, 2003, J BIOL CHEM, V278, P41519, DOI 10.1074/jbc.M304564200; Oster H, 2006, J BIOL RHYTHM, V21, P350, DOI 10.1177/0748730406293053; PERET J, 1978, J NUTR, V108, P265, DOI 10.1093/jn/108.2.265; Perreau-Lenz S, 2004, EUR J NEUROSCI, V19, P318, DOI 10.1111/j.0953-816X.2003.03132.x; Perreau-Lenz S, 2003, EUR J NEUROSCI, V17, P221, DOI 10.1046/j.1460-9568.2003.02442.x; Pocai A, 2005, CELL METAB, V1, P53, DOI 10.1016/j.cmet.2004.11.001; Pocai A, 2005, NATURE, V434, P1026, DOI 10.1038/nature03439; Radziuk J, 2001, DIABETES-METAB RES, V17, P250, DOI 10.1002/dmrr.217; Redlin U, 1999, J COMP PHYSIOL A, V184, P439, DOI 10.1007/s003590050343; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Scheer FAJL, 2005, NEUROSCIENCE, V132, P465, DOI 10.1016/j.neuroscience.2004.12.012; Scheer FAJL, 2001, AM J PHYSIOL-HEART C, V280, pH1391, DOI 10.1152/ajpheart.2001.280.3.H1391; Schibler U, 2005, CELL METAB, V2, P278, DOI 10.1016/j.cmet.2005.10.001; Schioth HB, 2003, GENOMICS, V81, P504, DOI 10.1016/S0888-7543(03)00028-4; Simonneaux V, 2004, MOL BRAIN RES, V120, P164, DOI 10.1016/j.molbrainres.2003.10.019; Slotten HA, 2000, BRAIN RES, V876, P10, DOI 10.1016/S0006-8993(00)02590-7; STEFFENS AB, 1969, PHYSIOL BEHAV, V4, P833, DOI 10.1016/0031-9384(69)90126-7; Sujino M, 2007, EUR J NEUROSCI, V26, P2731, DOI 10.1111/j.1460-9568.2007.05926.x; Teclemariam-Mesbah R, 1999, J COMP NEUROL, V406, P171, DOI 10.1002/(SICI)1096-9861(19990405)406:2<171::AID-CNE3>3.0.CO;2-U; Uno K, 2006, SCIENCE, V312, P1656, DOI 10.1126/science.1126010; VUJOVIC N, 2008, AM J PHYSL REGUL INT; Weaver DR, 1998, J BIOL RHYTHM, V13, P100, DOI 10.1177/074873098128999952; Yamamoto T, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-18; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; YOO SH, 2004, P NATL ACAD SCI US; Young ME, 2002, J MOL CELL CARDIOL, V34, P223, DOI 10.1006/jmcc.2001.1504; Young ME, 2001, CIRC RES, V88, P1142, DOI 10.1161/hh1101.091190	76	85	87	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2009	4	5							e5650	10.1371/journal.pone.0005650	http://dx.doi.org/10.1371/journal.pone.0005650			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LB	19478857	Green Published, Green Submitted, gold			2022-12-25	WOS:000266331000009
J	Carlsson, B; Kindberg, E; Buesa, J; Rydell, GE; Lidon, MF; Montava, R; Abu Mallouh, R; Grahn, A; Rodriguez-Diaz, J; Bellido, J; Arnedo, A; Larson, G; Svensson, L				Carlsson, Beatrice; Kindberg, Elin; Buesa, Javier; Rydell, Gustaf E.; Lidon, Marta Fos; Montava, Rebeca; Abu Mallouh, Reem; Grahn, Ammi; Rodriguez-Diaz, Jesus; Bellido, Juan; Arnedo, Alberto; Larson, Goran; Svensson, Lennart			The G428A Nonsense Mutation in FUT2 Provides Strong but Not Absolute Protection against Symptomatic GII.4 Norovirus Infection	PLOS ONE			English	Article							BLOOD GROUP ANTIGENS; ROUND-STRUCTURED VIRUSES; ACUTE GASTROENTERITIS; UNITED-STATES; P2 DOMAIN; SECRETOR FUT2; OUTBREAKS; SUSCEPTIBILITY; RESISTANCE; BINDING	In November 2004, 116 individuals in an elderly nursing home in El Grao de Castellon, Spain were symptomatically infected with genogroup II.4 (GII.4) norovirus. The global attack rate was 54.2%. Genotyping of 34 symptomatic individuals regarding the FUT2 gene revealed that one patient was, surprisingly, a non-secretor, hence indicating secretor-independent infection. Lewis genotyping revealed that Lewis-positive and negative individuals were susceptible to symptomatic norovirus infection indicating that Lewis status did not predict susceptibility. Saliva based ELISA assays were used to determine binding of the outbreak virus to saliva samples. Saliva from a secretor-negative individual bound the authentic outbreak GII.4 Valencia/2004/Es virus, but did not in contrast to secretor-positive saliva bind VLP of other strains including the GII.4 Dijon strain. Amino acid comparison of antigenic A and B sites located on the external loops of the P2 domain revealed distinct differences between the Valencia/2004/Es and Dijon strains. All three aa in each antigenic site as well as 10/11 recently identified evolutionary hot spots, were unique in the Valencia/2004/Es strain compared to the Dijon strain. To the best of our knowledge, this is the first example of symptomatic GII.4 norovirus infection of a Le(a+b-) individual homozygous for the G428A nonsense mutation in FUT2. Taken together, our study provides new insights into the host genetic susceptibility to norovirus infections and evolution of the globally dominating GII.4 viruses.			Carlsson, B (corresponding author), Linkoping Univ, Div Mol Virol, Linkoping, Sweden.	lennart.t.svensson@liu.se	Rodriguez-Diaz, Jesus/B-2091-2012; Larson, Göran/AAF-3404-2019; svensson, lennart/K-6163-2019; Buesa, Javier/D-8927-2014	Rodriguez-Diaz, Jesus/0000-0002-9698-7684; Buesa, Javier/0000-0002-3328-3428				Allen DJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001485; Blanton LH, 2006, J INFECT DIS, V193, P413, DOI 10.1086/499315; Bucardo F, 2009, J MED VIROL, V81, P728, DOI 10.1002/jmv.21426; Cao S, 2007, J VIROL, V81, P5949, DOI 10.1128/JVI.00219-07; Chakravarty S, 2005, J VIROL, V79, P554, DOI 10.1128/JVI.79.1.554-568.2005; Choi JM, 2008, P NATL ACAD SCI USA, V105, P9175, DOI 10.1073/pnas.0803275105; DOLIN R, 1972, P SOC EXP BIOL MED, V140, P578, DOI 10.3181/00379727-140-36508; Donaldson EF, 2008, IMMUNOL REV, V225, P190, DOI 10.1111/j.1600-065X.2008.00680.x; Fankhauser RL, 1998, J INFECT DIS, V178, P1571, DOI 10.1086/314525; Gallimore CI, 2004, J CLIN MICROBIOL, V42, P1396, DOI 10.1128/JCM.42.4.1396-1401.2004; GARY GW, 1987, J CLIN MICROBIOL, V25, P2001, DOI 10.1128/JCM.25.10.2001-2003.1987; Glass RI, 2000, J INFECT DIS, V181, pS254, DOI 10.1086/315588; Grahn A, 2001, Hum Mutat, V18, P358, DOI 10.1002/humu.1204; GREEN K, 2001, HUMAN CALICIVIRUSES, P841; Harrington PR, 2002, J VIROL, V76, P12335, DOI 10.1128/JVI.76.23.12335-12343.2002; Henry S, 1996, VOX SANG, V70, P21, DOI 10.1111/j.1423-0410.1996.tb00991.x; Henry S, 1996, GLYCOCONJUGATE J, V13, P985, DOI 10.1007/BF01053194; Huang PW, 2005, J VIROL, V79, P6714, DOI 10.1128/JVI.79.11.6714-6722.2005; Huang PW, 2003, J INFECT DIS, V188, P19, DOI 10.1086/375742; Hutson AM, 2005, J MED VIROL, V77, P116, DOI 10.1002/jmv.20423; Johansson PJH, 2002, J CLIN MICROBIOL, V40, P794, DOI 10.1128/JCM.40.3.794-798.2002; JOHNSON PC, 1990, J INFECT DIS, V161, P18, DOI 10.1093/infdis/161.1.18; KELLEY WN, 1995, NAT MED, V1, P2, DOI 10.1038/nm0195-2a; Kindberg E, 2006, AIDS, V20, P685, DOI 10.1097/01.aids.0000216368.23325.bc; Kindberg E, 2007, J CLIN MICROBIOL, V45, P2720, DOI 10.1128/JCM.00162-07; Koda Y, 2001, Leg Med (Tokyo), V3, P2, DOI 10.1016/S1344-6223(01)00005-0; Kroneman A, 2008, J CLIN MICROBIOL, V46, P2959, DOI 10.1128/JCM.00499-08; Larson G, 1999, VOX SANG, V77, P227, DOI 10.1046/j.1423-0410.1999.7740227.x; Larsson MM, 2006, J INFECT DIS, V194, P1422, DOI 10.1086/508430; Le Pendu J, 2006, SEMIN IMMUNOL, V18, P375, DOI 10.1016/j.smim.2006.07.009; Lindesmith L, 2005, J VIROL, V79, P2900, DOI 10.1128/JVI.79.5.2900-2909.2005; Lindesmith L, 2003, NAT MED, V9, P548, DOI 10.1038/nm860; Lindesmith LC, 2008, PLOS MED, V5, P269, DOI 10.1371/journal.pmed.0050031; Liu YH, 1998, HUM GENET, V103, P204, DOI 10.1007/s004390050808; Lopmam BA, 2003, EMERG INFECT DIS, V9, P90; Nilsson M, 2003, J VIROL, V77, P13117, DOI 10.1128/JVI.77.24.13117-13124.2003; Noel JS, 1997, J MED VIROL, V53, P372, DOI 10.1002/(SICI)1096-9071(199712)53:4&lt;372::AID-JMV10&gt;3.0.CO;2-H; PARRINO TA, 1977, NEW ENGL J MED, V297, P86, DOI 10.1056/NEJM197707142970204; Pezzlo M, 1992, CLIN MICROBIOLOGY PR; Rockx BHG, 2005, J INFECT DIS, V191, P749, DOI 10.1086/427779; Rydell GE, 2009, GLYCOBIOLOGY, V19, P309, DOI 10.1093/glycob/cwn139; Sdiri-Loulizi K, 2009, J CLIN MICROBIOL, V47, P421, DOI 10.1128/JCM.01852-08; Siebenga JJ, 2007, J VIROL, V81, P9932, DOI 10.1128/JVI.00674-07; Siebenga JJ, 2007, EMERG INFECT DIS, V13, P144; Tamura M, 2004, J VIROL, V78, P3817, DOI 10.1128/JVI.78.8.3817-3826.2004; Tan M, 2003, J VIROL, V77, P12562, DOI 10.1128/JVI.77.23.12562-12571.2003; Tan M, 2008, J INFECT DIS, V198, P940, DOI 10.1086/589810; Tan M, 2008, J MED VIROL, V80, P1296, DOI 10.1002/jmv.21200; TAUBE S, 2009, J VIROL; Thorven M, 2005, J VIROL, V79, P15351, DOI 10.1128/JVI.79.24.15351-15355.2005; Vinje J, 1996, J INFECT DIS, V174, P610, DOI 10.1093/infdis/174.3.610; WYATT RG, 1974, J INFECT DIS, V129, P709, DOI 10.1093/infdis/129.6.709	52	107	112	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5593	10.1371/journal.pone.0005593	http://dx.doi.org/10.1371/journal.pone.0005593			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440360	Green Published, gold, Green Submitted			2022-12-25	WOS:000266107500021
J	Murph, MM; Liu, WB; Yu, SX; Lu, YL; Hall, H; Hennessy, BT; Lahad, J; Schaner, M; Helland, A; Kristensen, G; Borresen-Dale, AL; Mills, GB				Murph, Mandi M.; Liu, Wenbin; Yu, Shuangxing; Lu, Yiling; Hall, Hassan; Hennessy, Bryan T.; Lahad, John; Schaner, Marci; Helland, Aslaug; Kristensen, Gunnar; Borresen-Dale, Anne-Lise; Mills, Gordon B.			Lysophosphatidic Acid-Induced Transcriptional Profile Represents Serous Epithelial Ovarian Carcinoma and Worsened Prognosis	PLOS ONE			English	Article							EXPRESSION ANALYSIS; CANCER; TARGET; LPA; LYSOPHOSPHOLIPIDS; METASTASIS; EFFUSIONS; SECRETION; DISCOVERY; PATHWAYS	Background: Lysophosphatidic acid (LPA) governs a number of physiologic and pathophysiological processes. Malignant ascites fluid is rich in LPA, and LPA receptors are aberrantly expressed by ovarian cancer cells, implicating LPA in the initiation and progression of ovarian cancer. However, there is an absence of systematic data critically analyzing the transcriptional changes induced by LPA in ovarian cancer. Methodology and Principal Findings: In this study, gene expression profiling was used to examine LPA-mediated transcription by exogenously adding LPA to human epithelial ovarian cancer cells for 24 h to mimic long-term stimulation in the tumor microenvironment. The resultant transcriptional profile comprised a 39-gene signature that closely correlated to serous epithelial ovarian carcinoma. Hierarchical clustering of ovarian cancer patient specimens demonstrated that the signature is associated with worsened prognosis. Patients with LPA-signature-positive ovarian tumors have reduced disease-specific and progression-free survival times. They have a higher frequency of stage IIIc serous carcinoma and a greater proportion is deceased. Among the 39-gene signature, a group of seven genes associated with cell adhesion recapitulated the results. Out of those seven, claudin-1, an adhesion molecule and phenotypic epithelial marker, is the only independent biomarker of serous epithelial ovarian carcinoma. Knockdown of claudin-1 expression in ovarian cancer cells reduces LPA-mediated cellular adhesion, enhances suspended cells and reduces LPA-mediated migration. Conclusions: The data suggest that transcriptional events mediated by LPA in the tumor microenvironment influence tumor progression through modulation of cell adhesion molecules like claudin-1 and, for the first time, report an LPA-mediated expression signature in ovarian cancer that predicts a worse prognosis.			Murph, MM (corresponding author), Univ Georgia, Coll Pharm, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA.	mmurph@rx.uga.edu	Helland, Åslaug/H-3910-2015; liu, wen/HGE-3071-2022	Helland, Åslaug/0000-0002-5520-0275; Hennessy, Bryan/0000-0002-7871-6477	NATIONAL CANCER INSTITUTE [P50CA098258, P01CA099031, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016672, P50 CA098258, P01 CA099031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; Baker DL, 2006, J BIOL CHEM, V281, P22786, DOI 10.1074/jbc.M512486200; Bignotti E, 2007, AM J OBSTET GYNECOL, V196, P245, DOI 10.1016/j.ajog.2006.10.874; Bonome T, 2005, CANCER RES, V65, P10602, DOI 10.1158/0008-5472.CAN-05-2240; CHECOVICH WJ, 1993, ARTERIOSCLER THROMB, V13, P1662, DOI 10.1161/01.ATV.13.11.1662; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; DiSaia PJ, 2007, CLIN GYNECOLOGIC ONC; Eder AM, 2000, CLIN CANCER RES, V6, P2482; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Hasegawa Y, 2008, MOL ONCOL, V2, P54, DOI 10.1016/j.molonc.2008.03.009; Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694; Hennessy BT, 2008, ADV EXP MED BIOL, V617, P23, DOI 10.1007/978-0-387-69080-3_3; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kleinberg L, 2008, HUM PATHOL, V39, P747, DOI 10.1016/j.humpath.2007.10.002; Kleinberg L, 2007, AM J CLIN PATHOL, V127, P928, DOI 10.1309/V025QRN3R9CJGNPX; Lee Z, 2006, CANCER RES, V66, P2740, DOI 10.1158/0008-5472.CAN-05-2947; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Murph Mandi, 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000476; Murph MM, 2008, BBA-MOL CELL BIOL L, V1781, P547, DOI 10.1016/j.bbalip.2008.04.007; MURPH MM, 2008, BIOCH BIOPHYS ACTA; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Ouellet V, 2005, ONCOGENE, V24, P4672, DOI 10.1038/sj.onc.1208214; Partheen K, 2006, EUR J CANCER, V42, P2846, DOI 10.1016/j.ejca.2006.06.026; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; Reiser COA, 1998, BIOCHEM J, V330, P1107; Sakamoto S, 2004, ENDOCRINOLOGY, V145, P2929, DOI 10.1210/en.2003-1350; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Seidman JD, 2003, HEMATOL ONCOL CLIN N, V17, P909, DOI 10.1016/S0889-8588(03)00061-3; Shen ZZ, 1998, GYNECOL ONCOL, V71, P364, DOI 10.1006/gyno.1998.5193; Sobel G, 2006, GYNECOL ONCOL, V103, P591, DOI 10.1016/j.ygyno.2006.04.005; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Tanyi JL, 2003, CANCER RES, V63, P1073; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Umezu-Goto M, 2004, J CELL BIOCHEM, V92, P1115, DOI 10.1002/jcb.20113; Valenick LV, 2006, MATRIX BIOL, V25, P223, DOI 10.1016/j.matbio.2006.01.002; Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154; Weinberg RA, 2007, BIOL CANC; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Yu SX, 2008, JNCI-J NATL CANCER I, V100, P1630, DOI 10.1093/jnci/djn378	46	37	38	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5583	10.1371/journal.pone.0005583	http://dx.doi.org/10.1371/journal.pone.0005583			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440550	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107400018
J	Retamal, P; Castillo-Ruiz, M; Mora, GC				Retamal, Patricio; Castillo-Ruiz, Mario; Mora, Guido C.			Characterization of MgtC, a Virulence Factor of Salmonella enterica Serovar Typhi	PLOS ONE			English	Article								The MgtC is a virulence factor in Salmonella Typhimurium that is required for growth at low-Mg(2+) concentrations and intramacrophage survival. This gene is codified in a conserved region of the Salmonella pathogenicity island 3 (SPI-3), and is also present in the chromosome of other Salmonella serovars. In this study we characterized the MgtC factor in S. Typhi, a human specific pathogen, by using mgtC and SPI-3 mutant strains. We found that MgtC is the most important factor codified in the SPI-3 of S. Typhi for growth in low-Mg(2+) media and survival within human cells. In addition, by using reporter genes we determined that the low-Mg(2+) concentration, acidic media and PhoP regulator induce mgtC expression in S. Typhi. We suggest that MgtC is the most important virulence factor codified in the SPI-3 of S. Typhi.			Retamal, P (corresponding author), Univ Andres Bello, Dept Ciencias Biol, Santiago, Chile.	gmora@unab.cl	Retamal, Patricio/G-3054-2013	Retamal, Patricio/0000-0001-8597-9550; Castillo-Ruiz, Mario/0000-0002-0005-408X				Alix E, 2008, EMBO J, V27, P546, DOI 10.1038/sj.emboj.7601983; Alix E, 2007, TRENDS MICROBIOL, V15, P252, DOI 10.1016/j.tim.2007.03.007; Amavisit P, 2003, J BACTERIOL, V185, P3624, DOI 10.1128/JB.185.12.3624-3635.2003; Bijlsma JJE, 2005, MOL MICROBIOL, V57, P85, DOI 10.1111/j.1365-2958.2005.04668.x; Blanc-Potard AB, 2003, J MOL EVOL, V57, P479, DOI 10.1007/s00239-003-2496-4; Blanc-Potard AB, 1999, J BACTERIOL, V181, P998, DOI 10.1128/JB.181.3.998-1004.1999; BlancPotard AB, 1997, EMBO J, V16, P5376, DOI 10.1093/emboj/16.17.5376; Bucarey SA, 2005, INFECT IMMUN, V73, P6210, DOI 10.1128/IAI.73.10.6210-6219.2005; Bucarey SA, 2006, GENETICS, V173, P25, DOI 10.1534/genetics.105.054700; Buchmeier N, 2000, MOL MICROBIOL, V35, P1375, DOI 10.1046/j.1365-2958.2000.01797.x; Chamnongpol S, 2002, MOL MICROBIOL, V44, P561, DOI 10.1046/j.1365-2958.2002.02917.x; Chaudhuri RR, 2004, NUCLEIC ACIDS RES, V32, pD296, DOI 10.1093/nar/gkh031; Contreras I, 1997, MICROBIOL-UK, V143, P2665, DOI 10.1099/00221287-143-8-2665; Cromie MJ, 2006, CELL, V125, P71, DOI 10.1016/j.cell.2006.01.043; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dorsey CW, 2005, MOL MICROBIOL, V57, P196, DOI 10.1111/j.1365-2958.2005.04666.x; Ellermeier CD, 2002, GENE, V290, P153, DOI 10.1016/S0378-1119(02)00551-6; Eriksson S, 2003, MOL MICROBIOL, V47, P103, DOI 10.1046/j.1365-2958.2003.03313.x; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Gunzel D, 2006, J BACTERIOL, V188, P5586, DOI 10.1128/JB.00296-06; Lavigne JP, 2005, INFECT IMMUN, V73, P3160, DOI 10.1128/IAI.73.5.3160-3163.2005; Maguire ME, 2002, BIOMETALS, V15, P203, DOI 10.1023/A:1016058229972; MILLER FD, 1984, GENE, V29, P247, DOI 10.1016/0378-1119(84)90185-9; Moncrief MBC, 1998, INFECT IMMUN, V66, P3802, DOI 10.1128/IAI.66.8.3802-3809.1998; Morgan E, 2004, MOL MICROBIOL, V54, P994, DOI 10.1111/j.1365-2958.2004.04323.x; Pang T, 1998, TRENDS MICROBIOL, V6, P131, DOI 10.1016/S0966-842X(98)01236-0; Rang C, 2007, MOL MICROBIOL, V63, P605, DOI 10.1111/j.1365-2958.2006.05542.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIEGER H, 1972, MOL GEN GENET, V119, P75, DOI 10.1007/BF00270447; Smith RL, 1998, MICROBIOL-SGM, V144, P1835, DOI 10.1099/00221287-144-7-1835; Smith RL, 1998, MOL MICROBIOL, V28, P217, DOI 10.1046/j.1365-2958.1998.00810.x; Spinelli SV, 2008, FEMS MICROBIOL LETT, V280, P226, DOI 10.1111/j.1574-6968.2008.01065.x; Tu X, 2006, P NATL ACAD SCI USA, V103, P13503, DOI 10.1073/pnas.0606026103; TUKEL C, 2007, J BACTERIOL; Uzzau S, 2001, P NATL ACAD SCI USA, V98, P15264, DOI 10.1073/pnas.261348198	35	32	34	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2009	4	5							e5551	10.1371/journal.pone.0005551	http://dx.doi.org/10.1371/journal.pone.0005551			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FX	19436747	Green Submitted, Green Published, gold			2022-12-25	WOS:000266107300015
J	Dugan, LL; Ali, SS; Shekhtman, G; Roberts, AJ; Lucero, J; Quick, KL; Behrens, MM				Dugan, Laura L.; Ali, Sameh S.; Shekhtman, Grigoriy; Roberts, Amanda J.; Lucero, Jacinta; Quick, Kevin L.; Behrens, M. Margarita			IL-6 Mediated Degeneration of Forebrain GABAergic Interneurons and Cognitive Impairment in Aged Mice through Activation of Neuronal NADPH Oxidase	PLOS ONE			English	Article							INTERLEUKIN-6 GENE-EXPRESSION; FACTOR-KAPPA-B; SYNAPTIC PLASTICITY; WORKING-MEMORY; SUPEROXIDE-DISMUTASE; HIPPOCAMPAL MEMORY; PATTERN SEPARATION; DENTATE GYRUS; DISEASE; BRAIN	Background: Multiple studies have shown that plasma levels of the pro-inflammatory cytokine interleukin-6 (IL-6) are elevated in patients with important and prevalent adverse health conditions, including atherosclerosis, diabetes, obesity, obstructive sleep apnea, hypertension, and frailty. Higher plasma levels of IL-6, in turn, increase the risk of many conditions associated with aging including age-related cognitive decline. However, the mechanisms underlying this association between IL-6 and cognitive vulnerability remain unclear. Methods and Findings: We investigated the role of IL-6 in brain aging in young (4 mo) and aged (24 mo) wild-type C57BL6 and genetically-matched IL-6(-/-) mice, and determined that IL-6 was necessary and sufficient for increased neuronal expression of the superoxide-producing immune enzyme, NADPH-oxidase, and this was mediated by non-canonical NFkB signaling. Furthermore, superoxide production by NADPH-oxidase was directly responsible for age-related loss of parvalbumin (PV)-expressing GABAergic interneurons, neurons essential for normal information processing, encoding, and retrieval in hippocampus and cortex. Targeted deletion of IL-6 or elimination of superoxide by chronic treatment with a superoxide-dismutase mimetic prevented age-related loss of PV-interneurons and reversed age-related cognitive deficits on three standard tests of spatial learning and recall. Conclusions: Present results indicate that IL-6 mediates age-related loss of critical PV-expressing GABAergic interneurons through increased neuronal NADPH-oxidase-derived superoxide production, and that rescue of these interneurons preserves cognitive performance in aging mice, suggesting that elevated peripheral IL-6 levels may be directly and mechanistically linked to long-lasting cognitive deficits in even normal older individuals. Further, because PV-interneurons are also selectively affected by commonly used anesthetic agents and drugs, our findings imply that IL-6 levels may predict adverse CNS effects in older patients exposed to these compounds through specific derangements in inhibitory interneurons, and that therapies directed at lowering IL-6 may have cognitive benefits clinically.			Dugan, LL (corresponding author), Univ Calif San Diego, Dept Med, Div Geriatr Med, La Jolla, CA 92093 USA.	ladugan@ucsd.edu	Behrens, M. Margarita/K-2576-2014	Ali, Sameh Saad/0000-0002-0339-6106	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS057096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K25AG026379, R21AG030320] Funding Source: NIH RePORTER; NIA NIH HHS [K25 AG026379, AG030320, R21 AG030320] Funding Source: Medline; NINDS NIH HHS [NS057096, P30 NS057096] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ali SS, 2006, AGING CELL, V5, P565, DOI 10.1111/j.1474-9726.2006.00252.x; Bai L, 2004, NEUROBIOL AGING, V25, P201, DOI 10.1016/S0197-4580(03)00091-5; Bakker A, 2008, SCIENCE, V319, P1640, DOI 10.1126/science.1152882; Bartos M, 2007, NAT REV NEUROSCI, V8, P45, DOI 10.1038/nrn2044; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Behrens MM, 2007, SCIENCE, V318, P1645, DOI 10.1126/science.1148045; Behrens MM, 2008, J NEUROSCI, V28, P13957, DOI 10.1523/JNEUROSCI.4457-08.2008; Benice TS, 2008, J NEUROSCI METH, V168, P422, DOI 10.1016/j.jneumeth.2007.11.002; Bermejo P, 2008, IMMUNOL LETT, V117, P198, DOI 10.1016/j.imlet.2008.02.002; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; Bu J, 2003, EXP NEUROL, V182, P220, DOI 10.1016/S0014-4886(03)00094-3; Burke SN, 2006, NAT REV NEUROSCI, V7, P30, DOI 10.1038/nrn1809; Buxbaum JN, 2008, P NATL ACAD SCI USA, V105, P2681, DOI 10.1073/pnas.0712197105; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Cartmell T, 2000, J PHYSIOL-LONDON, V526, P653, DOI 10.1111/j.1469-7793.2000.00653.x; Choi DK, 2005, J NEUROSCI, V25, P6594, DOI 10.1523/JNEUROSCI.0970-05.2005; DAYNES RA, 1993, J IMMUNOL, V150, P5219; de Erausquin GA, 2003, MOL PHARMACOL, V63, P784, DOI 10.1124/mol.63.4.784; Driscoll I, 2005, HORM BEHAV, V47, P326, DOI 10.1016/j.yhbeh.2004.11.013; ERSHLER WB, 1993, J AM GERIATR SOC, V41, P176, DOI 10.1111/j.1532-5415.1993.tb02054.x; Ershler WB, 2000, ANNU REV MED, V51, P245, DOI 10.1146/annurev.med.51.1.245; EVERSE J, 2007, NEURODEGENERATION PE; Gazzaley A, 2005, NAT NEUROSCI, V8, P1298, DOI 10.1038/nn1543; Gilbert PE, 2006, BEHAV BRAIN RES, V169, P142, DOI 10.1016/j.bbr.2006.01.002; Giuliani N, 2001, EXP GERONTOL, V36, P547, DOI 10.1016/S0531-5565(00)00220-5; HALL D, 2009, IN VIVO OPTICAL IMAG; Heumuller S, 2008, HYPERTENSION, V51, P211, DOI 10.1161/HYPERTENSIONAHA.107.100214; Hu DY, 2007, ANTIOXID REDOX SIGN, V9, P201, DOI 10.1089/ars.2007.9.201; Hunsaker MR, 2008, HIPPOCAMPUS, V18, P1064, DOI 10.1002/hipo.20464; Hunsaker MR, 2008, HIPPOCAMPUS, V18, P699, DOI 10.1002/hipo.20429; Infanger DW, 2006, ANTIOXID REDOX SIGN, V8, P1583, DOI 10.1089/ars.2006.8.1583; Jackman KA, 2009, BRIT J PHARMACOL, V156, P680, DOI 10.1111/j.1476-5381.2008.00073.x; Kausler D. H., 1994, LEARNING MEMORY NORM; Keller Evan T., 1996, Frontiers in Bioscience (online), V1, pD340; Kesner RP, 2007, LEARN MEMORY, V14, P771, DOI 10.1101/lm.688207; Kinney JW, 2006, J NEUROSCI, V26, P1604, DOI 10.1523/JNEUROSCI.4722-05.2006; Kishida KT, 2007, ANTIOXID REDOX SIGN, V9, P233, DOI 10.1089/ars.2007.9.233; Kishida KT, 2006, MOL CELL BIOL, V26, P5908, DOI 10.1128/MCB.00269-06; Krabbe KS, 2004, EXP GERONTOL, V39, P687, DOI 10.1016/j.exger.2004.01.009; Luebke JI, 2003, J COMP NEUROL, V460, P573, DOI 10.1002/cne.10668; Maggio M, 2006, J GERONTOL A-BIOL, V61, P575, DOI 10.1093/gerona/61.6.575; Magnusson KR, 2003, BEHAV NEUROSCI, V117, P485, DOI 10.1037/0735-7044.117.3.485; Maki RA, 2009, J BIOL CHEM, V284, P3158, DOI 10.1074/jbc.M807731200; Marsland AL, 2006, PSYCHOSOM MED, V68, P895, DOI 10.1097/01.psy.0000238451.22174.92; Martyn KD, 2006, CELL SIGNAL, V18, P69, DOI 10.1016/j.cellsig.2005.03.023; Moffat SD, 2001, NEUROBIOL AGING, V22, P787, DOI 10.1016/S0197-4580(01)00251-2; Paulsen O, 1998, TRENDS NEUROSCI, V21, P273, DOI 10.1016/S0166-2236(97)01205-8; Prut L, 2007, BEHAV BRAIN RES, V179, P107, DOI 10.1016/j.bbr.2007.01.017; Pugliese M, 2004, J NEUROSCI RES, V77, P913, DOI 10.1002/jnr.20223; Qiu ZH, 2003, J NEUROIMMUNOL, V139, P51, DOI 10.1016/S0165-5728(03)00158-9; Quick KL, 2008, NEUROBIOL AGING, V29, P117, DOI 10.1016/j.neurobiolaging.2006.09.014; Sarkar D, 2006, CANCER LETT, V236, P13, DOI 10.1016/j.canlet.2005.04.009; Sarkisian CA, 2008, J AM GERIATR SOC, V56, P2292, DOI 10.1111/j.1532-5415.2008.02041.x; SERRANDER L, 2007, BIOCH J; Serrander L, 2007, BIOCHEM J, V406, P105, DOI 10.1042/BJ20061903; Serrano F, 2003, BRAIN RES, V988, P193, DOI 10.1016/S0006-8993(03)03364-X; Stefanska J, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/106507; Thiels E, 2002, PHYSIOL BEHAV, V77, P601, DOI 10.1016/S0031-9384(02)00900-9; Trikha M, 2003, CLIN CANCER RES, V9, P4653; Vela J, 2003, J NEUROCHEM, V85, P368, DOI 10.1046/j.1471-4159.2003.01681.x; Wallenstein GV, 1997, J NEUROPHYSIOL, V78, P393, DOI 10.1152/jn.1997.78.1.393; Walston J, 2006, J AM GERIATR SOC, V54, P991, DOI 10.1111/j.1532-5415.2006.00745.x; Wilson IA, 2006, TRENDS NEUROSCI, V29, P662, DOI 10.1016/j.tins.2006.10.002; YANG J, 2007, GENES DEV; Ye SM, 2001, J NEUROIMMUNOL, V117, P87, DOI 10.1016/S0165-5728(01)00316-2	65	111	114	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5518	10.1371/journal.pone.0005518	http://dx.doi.org/10.1371/journal.pone.0005518			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	444WA	19436757	Green Published, gold, Green Submitted			2022-12-25	WOS:000266009900011
J	Bertuccio, CA; Chapin, HC; Cai, YQ; Mistry, K; Chauvet, V; Somlo, S; Caplan, MJ				Bertuccio, Claudia A.; Chapin, Hannah C.; Cai, Yiqiang; Mistry, Kavita; Chauvet, Veronique; Somlo, Stefan; Caplan, Michael J.			Polycystin-1 C-terminal Cleavage Is Modulated by Polycystin-2 Expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; KIDNEY-DISEASE; GENE-PRODUCT; NUCLEAR TRANSLOCATION; TRANSCRIPTION FACTOR; CALCIUM-RELEASE; CATION CHANNEL; PKD1; ACTIVATION; CELLS	Autosomal dominant polycystic kidney disease is caused by mutations in the genes encoding polycystin-1 (PC-1) and polycystin-2 (PC-2). PC-1 cleavage releases its cytoplasmic C-terminal tail (CTT), which enters the nucleus. To determine whether PC-1 CTT cleavage is influenced by PC-2, a quantitative cleavage assay was utilized, in which the DNA binding and activation domains of Gal4 and VP16, respectively, were appended to PC-1 downstream of its CTT domain (PKDgalvp). Cells cotransfected with the resultant PKDgalvp fusion protein and PC-2 showed an increase in luciferase activity and in CTT expression, indicating that the C- terminal tail of PC-1 is cleaved and enters the nucleus. To assess whether CTT cleavage depends upon Ca2+ signaling, cells transfected with PKDgalvp alone or together with PC-2 were incubated with several agents that alter intracellular Ca2+ concentrations. PC-2 enhancement of luciferase activity was not altered by any of these treatments. Using a series of PC-2 C-terminal truncated mutations, we identified a portion of the PC-2 protein that is required to stimulate PC-1 CTT accumulation. These data demonstrate that release of the CTT from PC-1 is influenced and stabilized by PC-2. This effect is independent of Ca2+ but is regulated by sequences contained within the PC-2 C-terminal tail, suggesting a mechanism through which PC-1 and PC-2 may modulate a novel signaling pathway.	[Bertuccio, Claudia A.; Chapin, Hannah C.; Mistry, Kavita; Chauvet, Veronique; Caplan, Michael J.] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; [Cai, Yiqiang; Somlo, Stefan] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University; Yale University	Caplan, MJ (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, POB 208026, New Haven, CT 06520 USA.	michael.caplan@yale.edu		Caplan, Michael/0000-0001-5768-4405	National Institutes of Health [DK57328]; National Kidney Foundation; National Science Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK057328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Kidney Foundation; National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant DK57328 (to S. S. and M.J.C.). This work was also supported by fellowships from the National Kidney Foundation (to C. A. B.) and the National Science Foundation (to H. C. C.).	Anyatonwu GI, 2007, P NATL ACAD SCI USA, V104, P6454, DOI 10.1073/pnas.0610324104; Arnould T, 1999, MOL CELL BIOL, V19, P3423; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Bandyopadhyay A, 2000, BIOCHEM J, V348, P173, DOI 10.1042/0264-6021:3480173; Barr MM, 2001, CURR BIOL, V11, P1341, DOI 10.1016/S0960-9822(01)00423-7; Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; Boletta A, 2003, TRENDS CELL BIOL, V13, P484, DOI 10.1016/S0962-8924(03)00169-7; Boletta A, 2000, MOL CELL, V6, P1267, DOI 10.1016/S1097-2765(00)00123-4; BURN TC, 1995, HUM MOL GENET, V4, P575, DOI 10.1093/hmg/4.4.575; Cai YQ, 2004, J BIOL CHEM, V279, P19987, DOI 10.1074/jbc.M312031200; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Charron AJ, 2000, J CELL BIOL, V149, P111, DOI 10.1083/jcb.149.1.111; Chauvet V, 2004, J CLIN INVEST, V114, P1433, DOI 10.1172/JCI200421753; Delmas P, 2002, J BIOL CHEM, V277, P11276, DOI 10.1074/jbc.M110483200; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Grimm DH, 2003, J BIOL CHEM, V278, P36786, DOI 10.1074/jbc.M306536200; Hackmann K, 2005, HUM MOL GENET, V14, P3249, DOI 10.1093/hmg/ddi356; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Hayashi T, 1997, GENOMICS, V44, P131, DOI 10.1006/geno.1997.4851; Hiesberger T, 2006, J BIOL CHEM, V281, P34357, DOI 10.1074/jbc.M606740200; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim H, 2004, J AM SOC NEPHROL, V15, P2042, DOI 10.1097/01.ASN.0000133490.00348.59; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; LAN Z, 2004, J AM SOC NEPHROL, V15, pA218; Li Q, 2002, FEBS LETT, V516, P270, DOI 10.1016/S0014-5793(02)02513-9; Li XH, 2002, P NATL ACAD SCI USA, V99, P9260, DOI 10.1073/pnas.132051799; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Low SH, 2006, DEV CELL, V10, P57, DOI 10.1016/j.devcel.2005.12.005; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Ong ACM, 2005, KIDNEY INT, V67, P1234, DOI 10.1111/j.1523-1755.2005.00201.x; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; Qian F, 2002, P NATL ACAD SCI USA, V99, P16981, DOI 10.1073/pnas.252484899; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reynolds DM, 1999, J AM SOC NEPHROL, V10, P2342; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vandorpe DH, 2001, J BIOL CHEM, V276, P4093, DOI 10.1074/jbc.M006252200	42	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					21011	21026		10.1074/jbc.M109.017756	http://dx.doi.org/10.1074/jbc.M109.017756			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19491093	Green Published, hybrid			2022-12-25	WOS:000268316100064
J	Melicoff, E; Sansores-Garcia, L; Gomez, A; Moreira, DC; Datta, P; Thakur, P; Petrova, Y; Siddiqi, T; Murthy, JN; Dickey, BF; Heidelberger, R; Adachi, R				Melicoff, Ernestina; Sansores-Garcia, Leticia; Gomez, Alejandra; Moreira, Daniel C.; Datta, Proleta; Thakur, Pratima; Petrova, Youlia; Siddiqi, Tanya; Murthy, Jayasimha N.; Dickey, Burton F.; Heidelberger, Ruth; Adachi, Roberto			Synaptotagmin-2 Controls Regulated Exocytosis but Not Other Secretory Responses of Mast Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTRANSMITTER RELEASE; CAPACITANCE MEASUREMENTS; INFLAMMATORY ARTHRITIS; CENTRAL SYNAPSE; MICE; CALCIUM; INFLUX; DEGRANULATION; MEDIATORS; VESICLES	Mast cell degranulation is a highly regulated, calcium-dependent process, which is important for the acute release of inflammatory mediators during the course of many pathological conditions. We previously found that Synaptotagmin-2, a calcium sensor in neuronal exocytosis, was expressed in a mast cell line. We postulated that this protein may be involved in the control of mast cell-regulated exocytosis, and we generated Synaptotagmin-2 knock-out mice to test our hypothesis. Mast cells from this mutant animal conferred an abnormally decreased passive cutaneous anaphylaxis reaction on mast cell-deficient mice that correlated with a specific defect in mast cell-regulated exocytosis, leaving constitutive exocytosis and nonexocytic mast cell effector responses intact. This defect was not secondary to abnormalities in the development, maturation, migration, morphology, synthesis, and storage of inflammatory mediators, or intracellular calcium transients of the mast cells. Unlike neurons, the lack of Synaptotagmin-2 in mast cells was not associated with increased spontaneous exocytosis.	[Melicoff, Ernestina; Sansores-Garcia, Leticia; Petrova, Youlia; Siddiqi, Tanya; Murthy, Jayasimha N.; Dickey, Burton F.; Adachi, Roberto] Univ Texas MD Anderson Canc Ctr, Dept Pulm Med, Houston, TX 77030 USA; [Gomez, Alejandra; Moreira, Daniel C.] Tecnol Monterrey, Sch Med, Monterrey 64710, Nuevo Leon, Mexico; [Datta, Proleta; Thakur, Pratima; Heidelberger, Ruth] Univ Texas Med Sch Houston, Dept Neurobiol & Anat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Tecnologico de Monterrey; University of Texas System; University of Texas Health Science Center Houston	Adachi, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pulm Med, 2121 Holcombe Blvd,703D,Box 1100, Houston, TX 77030 USA.	radachi@mdanderson.org	Datta, Proleta/AAK-2377-2021	Dickey, Burton/0000-0002-4780-1847; Moreira, Daniel/0000-0003-4082-156X; Melicoff, Ernestina/0000-0001-5696-7112; Datta, Proleta/0000-0002-1772-8845; Heidelberger, Ruth/0000-0002-8033-2050; Sansores-Garcia, Leticia/0000-0003-2510-225X; Adachi, Roberto/0000-0002-0146-0768	American Heart Association [0655003Y]; NATIONAL EYE INSTITUTE [R01EY012128] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by Grant 0655003Y from the American Heart Association ( to R. A.).	ADACHI R, 2003, MAST CELL EXOCYTOSIS, P327; Baram D, 1999, J EXP MED, V189, P1649, DOI 10.1084/jem.189.10.1649; Carr CM, 2007, EMBO REP, V8, P834, DOI 10.1038/sj.embor.7401051; Catterall WA, 1999, ANN NY ACAD SCI, V868, P144, DOI 10.1111/j.1749-6632.1999.tb11284.x; Chakrabarti S, 2003, J CELL BIOL, V162, P543, DOI 10.1083/jcb.200305131; Chapman ER, 2008, ANNU REV BIOCHEM, V77, P615, DOI 10.1146/annurev.biochem.77.062005.101135; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HEIDELBERGER R, 1992, J PHYSIOL-LONDON, V447, P235, DOI 10.1113/jphysiol.1992.sp019000; INAGAKI N, 1986, INT ARCH ALLER A IMM, V81, P58, DOI 10.1159/000234108; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; McNeil HP, 2008, ARTHRITIS RHEUM-US, V58, P2338, DOI 10.1002/art.23639; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; Pang ZPP, 2006, J NEUROSCI, V26, P13493, DOI 10.1523/JNEUROSCI.3519-06.2006; Peterson DA, 1999, METHODS, V18, P493, DOI 10.1006/meth.1999.0818; Puri N, 2008, P NATL ACAD SCI USA, V105, P2580, DOI 10.1073/pnas.0707854105; Riedel D, 2002, MOL CELL BIOL, V22, P6487, DOI 10.1128/MCB.22.18.6487-6497.2002; Sander LE, 2008, EUR J IMMUNOL, V38, P855, DOI 10.1002/eji.200737634; Schoch S, 2001, SCIENCE, V294, P1117, DOI 10.1126/science.1064335; Sun J, 2007, NATURE, V450, P676, DOI 10.1038/nature06308; Thakurdas SM, 2007, J BIOL CHEM, V282, P20809, DOI 10.1074/jbc.M611842200; Theoharides TC, 2007, IMMUNOL REV, V217, P65, DOI 10.1111/j.1600-065X.2007.00519.x; Tiwari N, 2008, BLOOD, V111, P3665, DOI 10.1182/blood-2007-07-103309; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Tuvim MJ, 2009, J BIOL CHEM, V284, P9781, DOI 10.1074/jbc.M807849200; Verhage M, 2007, CURR OPIN CELL BIOL, V19, P402, DOI 10.1016/j.ceb.2007.05.002; Vig M, 2007, CELL CALCIUM, V42, P157, DOI 10.1016/j.ceca.2007.03.008; Washbourne P, 2002, NAT NEUROSCI, V5, P19, DOI 10.1038/nn783; Wolters PJ, 2005, CLIN EXP ALLERGY, V35, P82, DOI 10.1111/j.1365-2222.2005.02136.x; WONG A, 1991, BIOCHEMISTRY-US, V30, P9346, DOI 10.1021/bi00102a030; Xu J, 2007, NEURON, V54, P567, DOI 10.1016/j.neuron.2007.05.004; Yu M, 2006, J CLIN INVEST, V116, P1633, DOI 10.1172/JCI25702; Zhou ZY, 2006, J NEUROPHYSIOL, V96, P2539, DOI 10.1152/jn.00688.2006	37	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19445	19451		10.1074/jbc.M109.002550	http://dx.doi.org/10.1074/jbc.M109.002550			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19473977	hybrid, Green Published			2022-12-25	WOS:000267908300036
J	Tharp, AC; Laha, M; Panizzi, P; Thompson, MW; Fuentes-Prior, P; Bock, PE				Tharp, Anthony C.; Laha, Malabika; Panizzi, Peter; Thompson, Michael W.; Fuentes-Prior, Pablo; Bock, Paul E.			Plasminogen Substrate Recognition by the Streptokinase-Plasminogen Catalytic Complex Is Facilitated by Arg(253), Lys(256), and Lys(257) in the Streptokinase beta-Domain and Kringle 5 of the Substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE CHLOROMETHYL KETONES; BLOOD-COAGULATION PROTEINASES; STREPTOCOCCAL SURFACE PROTEIN; EPSILON-AMINOCAPROIC ACID; LYSINE-BINDING-SITE; ACTIVE-SITE; FLUORESCENCE PROBES; CRYSTAL-STRUCTURE; CONFORMATIONAL ACTIVATION; EQUIMOLAR COMPLEXES	Streptokinase (SK) conformationally activates the central zymogen of the fibrinolytic system, plasminogen (Pg). The SK.Pg* catalytic complex binds Pg as a specific substrate and cleaves it into plasmin (Pm), which binds SK to form the SK.Pm complex that propagates Pm generation. Catalytic complex formation is dependent on lysine-binding site (LBS) interactions between a Pg/Pm kringle and the SK COOH-terminal Lys(414). Pg substrate recognition is also LBS-dependent, but the kringle and SK structural element(s) responsible have not been identified. SK mutants lacking Lys(414) with Ala substitutions of charged residues in the SK beta-domain 250-loop were evaluated in kinetic studies that resolved conformational and proteolytic Pg activation. Activation of [Lys] Pg and mini-Pg (containing only kringle 5 of Pg) by SK with Ala substitutions of Arg(253), Lys(256), and Lys(257) showed decreases in the bimolecular rate constant for Pm generation, with nearly total inhibition for the SK Lys(256)/Lys(257) double mutant. Binding of bovine Pg (BPg) to the SK.Pm complex containing fluorescently labeled Pm demonstrated LBS-dependent assembly of a SK.labeled Pm.BPg ternary complex, whereas BPg did not bind to the complex containing the SK Lys(256)/Lys(257) mutant. BPg was activated by SK.Pm with a K-m indistinguishable from the K-D for BPg binding to form the ternary complex, whereas the SK Lys(256)/Lys(257) mutant did not support BPg activation. We conclude that SK residues Arg(253), Lys(256), and Lys(257) mediate Pg substrate recognition through kringle 5 of the [Lys] Pg and mini-Pg substrates. A molecular model of the SK.kringle 5 complex identifies the putative interactions involved in LBS-dependent Pg substrate recognition.	[Tharp, Anthony C.; Laha, Malabika; Panizzi, Peter; Thompson, Michael W.; Bock, Paul E.] Vanderbilt Univ, Dept Pathol, Sch Med, Nashville, TN 37232 USA; [Fuentes-Prior, Pablo] Hosp Santa Creu & Sant Pau, Inst Recerca, Barcelona 08025, Spain	Vanderbilt University; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital of Santa Creu i Sant Pau	Bock, PE (corresponding author), C3321A Med Ctr N, Nashville, TN 37232 USA.	paul.bock@vanderbilt.edu	Panizzi, Peter/A-6072-2019	Panizzi, Peter/0000-0003-0141-8807; Fuentes-Prior, Pablo/0000-0002-6618-3204; Thompson, Michael/0000-0003-1850-5579	National Institutes of Health, NHLBI [RO1 HL056181]; Spanish Ministerio de Ciencia e Innovacion ( MICINN) [SAF2007-64140]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007751, R01HL056181, R00HL094533] Funding Source: NIH RePORTER	National Institutes of Health, NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Spanish Ministerio de Ciencia e Innovacion ( MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported, in whole or in part, by National Institutes of Health, NHLBI, Grant RO1 HL056181 ( to P. E. B.) and by Spanish Ministerio de Ciencia e Innovacion ( MICINN) Grant SAF2007-64140 ( to P. F.-P.).	BAJAJ SP, 1977, J BIOL CHEM, V252, P492; Bean RR, 2005, J BIOL CHEM, V280, P7504, DOI 10.1074/jbc.M411637200; Bergmann S, 2003, MOL MICROBIOL, V49, P411, DOI 10.1046/j.1365-2958.2003.03557.x; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; Bock PE, 1996, J BIOL CHEM, V271, P1072, DOI 10.1074/jbc.271.2.1072; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1992, J BIOL CHEM, V267, P14974; Boxrud PD, 2000, J BIOL CHEM, V275, P14579, DOI 10.1074/jbc.275.19.14579; Boxrud PD, 2000, BIOCHEMISTRY-US, V39, P13974, DOI 10.1021/bi000594i; Boxrud PD, 2004, J BIOL CHEM, V279, P36633, DOI 10.1074/jbc.M405264200; Boxrud PD, 2004, J BIOL CHEM, V279, P36642, DOI 10.1074/jbc.M405265200; Boxrud PD, 2001, J BIOL CHEM, V276, P26084, DOI 10.1074/jbc.M101966200; Brown Philip J., 2003, Journal of Structural and Functional Genomics, V4, P227, DOI 10.1023/B:JSFG.0000016118.87333.03; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; CASTELLINO FJ, 1997, CIBA F SYMP, V212, P60; Chang Y, 1998, BIOCHEMISTRY-US, V37, P3258, DOI 10.1021/bi972284e; Chaudhary A, 1999, PROTEIN SCI, V8, P2791; Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389; CHRISTENSEN U, 1984, BIOCHEM J, V223, P413, DOI 10.1042/bj2230413; Cnudde SE, 2006, BIOCHEMISTRY-US, V45, P11052, DOI 10.1021/bi060914j; COLLEN D, 1991, BLOOD, V78, P3114; Conejero-Lara F, 1998, PROTEIN SCI, V7, P2190, DOI 10.1002/pro.5560071017; DAMASCHUN G, 1992, EUR BIOPHYS J BIOPHY, V20, P355; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dhar J, 2002, J BIOL CHEM, V277, P13257, DOI 10.1074/jbc.M108422200; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; Ehinger S, 2004, J MOL BIOL, V343, P997, DOI 10.1016/j.jmb.2004.08.088; Fu QH, 2008, J BIOL CHEM, V283, P1580, DOI 10.1074/jbc.M705063200; JACKSON KW, 1982, BIOCHEMISTRY-US, V21, P6620, DOI 10.1021/bi00269a001; Kalia A, 2004, J BACTERIOL, V186, P110, DOI 10.1128/JB.186.1.110-121.2004; Kim DM, 2000, THROMB RES, V99, P93, DOI 10.1016/S0049-3848(00)00225-5; Lin LF, 1996, BIOCHEMISTRY-US, V35, P16879, DOI 10.1021/bi961531w; Lin LF, 2000, BIOCHEMISTRY-US, V39, P4740, DOI 10.1021/bi992028x; Liu L, 2000, J BIOL CHEM, V275, P37686, DOI 10.1074/jbc.M003963200; Loy JA, 2001, BIOCHEMISTRY-US, V40, P14686, DOI 10.1021/bi011309d; MARSHALL JM, 1994, BIOCHEMISTRY-US, V33, P3599, DOI 10.1021/bi00178a017; Marti DN, 1999, BIOCHEMISTRY-US, V38, P15741, DOI 10.1021/bi9917378; Marti DN, 1997, BIOCHEMISTRY-US, V36, P11591, DOI 10.1021/bi971316v; Mathews II, 1996, BIOCHEMISTRY-US, V35, P2567, DOI 10.1021/bi9521351; NIEUWENHUIZEN W, 1989, THROMB HAEMOSTASIS, V61, P208; Nihalani D, 1997, PROTEIN SCI, V6, P1284, DOI 10.1002/pro.5560060616; Nihalani D, 1998, PROTEIN SCI, V7, P637, DOI 10.1002/pro.5560070313; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PADMANABHAN K, 1994, PROTEIN SCI, V3, P898; Panizzi P, 2006, J BIOL CHEM, V281, P26774, DOI 10.1074/jbc.C600171200; PONTING CP, 1992, BIOCHIM BIOPHYS ACTA, V1159, P155, DOI 10.1016/0167-4838(92)90020-E; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; Rios-Steiner JL, 2001, J MOL BIOL, V308, P705, DOI 10.1006/jmbi.2001.4646; SCHALLER J, 1985, EUR J BIOCHEM, V149, P267, DOI 10.1111/j.1432-1033.1985.tb08921.x; SCHICK LA, 1974, BIOCHEM BIOPH RES CO, V57, P47, DOI 10.1016/S0006-291X(74)80355-4; SJOHOLM I, 1973, EUR J BIOCHEM, V39, P471, DOI 10.1111/j.1432-1033.1973.tb03146.x; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; Sun HM, 2004, SCIENCE, V305, P1283, DOI 10.1126/science.1101245; THEWES T, 1990, J BIOL CHEM, V265, P3906; Tordai H, 1999, FEBS LETT, V461, P63, DOI 10.1016/S0014-5793(99)01416-7; Verhamme IM, 2008, J BIOL CHEM, V283, P26137, DOI 10.1074/jbc.M804038200; VIOLAND BN, 1976, J BIOL CHEM, V251, P3906; Wakeham N, 2002, PROTEIN ENG, V15, P753, DOI 10.1093/protein/15.9.753; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang SG, 2000, EUR J BIOCHEM, V267, P3994, DOI 10.1046/j.1432-1327.2000.01434.x; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; Wang XQ, 1999, FEBS LETT, V459, P85, DOI 10.1016/S0014-5793(99)01214-4; WOHL RC, 1983, BIOCHIM BIOPHYS ACTA, V745, P20, DOI 10.1016/0167-4838(83)90165-6; WOHL RC, 1978, J BIOL CHEM, V253, P1402; WU TP, 1991, BIOCHEMISTRY-US, V30, P10589, DOI 10.1021/bi00107a030; Yadav S, 2008, BBA-PROTEINS PROTEOM, V1784, P1310, DOI 10.1016/j.bbapap.2008.05.013; Young KC, 1998, J BIOL CHEM, V273, P3110, DOI 10.1074/jbc.273.5.3110	68	23	25	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19511	19521		10.1074/jbc.M109.005512	http://dx.doi.org/10.1074/jbc.M109.005512			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19473980	hybrid, Green Published			2022-12-25	WOS:000267908300043
J	Faure, L; Coulon, D; Laroche-Traineau, J; Le Guedard, M; Schmitter, JM; Testet, E; Lessire, R; Bessoule, JJ				Faure, Lionel; Coulon, Denis; Laroche-Traineau, Jeanny; Le Guedard, Marina; Schmitter, Jean-Marie; Testet, Eric; Lessire, Rene; Bessoule, Jean-Jacques			Discovery and Characterization of an Arabidopsis thaliana N-Acylphosphatidylethanolamine Synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ACYLTRANSFERASE; ACYLETHANOLAMINES; EXPRESSION; ANANDAMIDE; RECEPTOR; PATHWAY; CELLS; LAUROYLETHANOLAMINE; ENDOCANNABINOIDS	N-Acylethanolamines (NAEs) are lipids involved in several physiological processes in animal and plant cells. In brain, NAEs are ligands of endocannabinoid receptors, which modulate various signaling pathways. In plant, NAEs regulate seed germination and root development, and they are involved in plant defense against pathogen attack. This signaling activity is started by an enzyme called N-acylphosphatidylethanolamine (NAPE) synthase. This catalyzes the N-acylation of phosphatidylethanolamine to form NAPE, which is most likely hydrolyzed by phospholipase D beta/gamma isoforms to generate NAE. This compound is further catabolized by fatty amide hydrolase. The genes encoding the enzymes involved in NAE metabolism are well characterized except for the NAPE synthase gene(s). By heterologous expression in Escherichia coli and overexpression in plants, we characterized an acyltransferase from Arabidopsis thaliana (At1g78690p) catalyzing the synthesis of lipids identified as NAPEs (two-dimensional TLC, phospholipase D hydrolysis assay, and electrospray ionization-tandem mass spectrometry analyses). The ability of free fatty acid and acyl-CoA to be used as acyl donor was compared in vitro with E. coli membranes and purified enzyme (obtained by immobilized metal ion affinity chromatography). In both cases, NAPE was synthesized only in the presence of acyl-CoA. beta-Glucuronidase promoter experiments revealed a strong expression in roots and young tissues of plants. Using yellow fluorescent protein fusion, we showed that the NAPE synthase is located in the plasmalemma of plant cells.	[Faure, Lionel; Coulon, Denis; Laroche-Traineau, Jeanny; Le Guedard, Marina; Testet, Eric; Lessire, Rene; Bessoule, Jean-Jacques] Univ Bordeaux 2, Lab Biogenese Membranaire, CNRS, UMR 5200, F-33076 Bordeaux, France; [Schmitter, Jean-Marie] Univ Bordeaux, UMR 5248, CNRS, ENITAB,IECB,UBX1, F-33607 Pessac, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite de Bordeaux	Coulon, D (corresponding author), Univ Bordeaux 2, Lab Biogenese Membranaire, CNRS, UMR 5200, 146 Rue Leo Saignat,Case 92, F-33076 Bordeaux, France.	denis.coulon@estbb.u-bordeaux2.fr		Faure, Lionel/0000-0002-7022-3934; Le Guedard, Marina/0000-0002-9797-7584; COULON, Denis/0000-0002-3943-1970	Conseil Regional d'Aquitaine	Conseil Regional d'Aquitaine(Region Nouvelle-Aquitaine)	This work was supported by the Conseil Regional d'Aquitaine.	Beeckman T., 1994, Plant Molecular Biology Reporter, V12, P37, DOI 10.1007/BF02668662; BESSOULE JJ, 1989, BIOCHIM BIOPHYS ACTA, V983, P35, DOI 10.1016/0005-2736(89)90377-5; Blancaflor EB, 2003, PLANTA, V217, P206, DOI 10.1007/s00425-003-0985-8; Chapman KD, 1999, PLANT PHYSIOL, V120, P1157, DOI 10.1104/pp.120.4.1157; Chapman KD, 1997, PLANT CELL PHYSIOL, V38, P1359, DOI 10.1093/oxfordjournals.pcp.a029130; CHAPMAN KD, 1993, ARCH BIOCHEM BIOPHYS, V301, P21, DOI 10.1006/abbi.1993.1110; CHAPMAN KD, 1993, PLANT PHYSIOL, V102, P761, DOI 10.1104/pp.102.3.761; Chatre L, 2005, PLANT PHYSIOL, V139, P1244, DOI 10.1104/pp.105.067447; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; De Petrocellis L, 2000, CHEM PHYS LIPIDS, V108, P191, DOI 10.1016/S0009-3084(00)00196-1; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; Fu J, 2003, NATURE, V425, P90, DOI 10.1038/nature01921; Hansen HH, 1999, J MASS SPECTROM, V34, P761, DOI 10.1002/(SICI)1096-9888(199907)34:7<761::AID-JMS832>3.0.CO;2-R; Hansen HS, 2002, PHARMACOL THERAPEUT, V95, P119, DOI 10.1016/S0163-7258(02)00251-6; Jin XH, 2007, J BIOL CHEM, V282, P3614, DOI 10.1074/jbc.M606369200; Kang L, 2008, PLANT J, V56, P336, DOI 10.1111/j.1365-313X.2008.03603.x; Kilaru A, 2007, CHEM BIODIVERS, V4, P1933, DOI 10.1002/cbdv.200790161; Kim HU, 2005, PLANT CELL, V17, P1073, DOI 10.1105/tpc.104.030403; Kumar RN, 2001, ANAESTHESIA, V56, P1059, DOI 10.1046/j.1365-2044.2001.02269.x; Lambert DM, 2002, CURR MED CHEM, V9, P663, DOI 10.2174/0929867023370707; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Liu J, 2006, P NATL ACAD SCI USA, V103, P13345, DOI 10.1073/pnas.0601832103; McAndrew RS, 1998, BBA-LIPID LIPID MET, V1390, P21, DOI 10.1016/S0005-2760(97)00166-5; Nielsen MJ, 2004, J LIPID RES, V45, P1027, DOI 10.1194/jlr.C300008-JLR200; Paria BC, 2000, CHEM PHYS LIPIDS, V108, P211, DOI 10.1016/S0009-3084(00)00197-3; SANDOVAL JA, 1995, PLANT PHYSIOL, V109, P269, DOI 10.1104/pp.109.1.269; Sarker KP, 2000, FEBS LETT, V472, P39, DOI 10.1016/S0014-5793(00)01425-3; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; Shiratsuchi A, 2009, J BIOCHEM, V145, P43, DOI 10.1093/jb/mvn139; SIMON GM, 2006, P NATL ACAD SCI USA, V281, P26465; Terrazzino S, 2004, FASEB J, V18, P1580, DOI 10.1096/fj.03-1080fje; Testet E, 2002, J LIPID RES, V43, P1150, DOI 10.1194/jlr.M200075-JLR200; Testet E, 2005, BIOCHEM J, V387, P617, DOI 10.1042/BJ20041491; Tripathy S, 1999, PLANT PHYSIOL, V121, P1299, DOI 10.1104/pp.121.4.1299; Wang YS, 2006, P NATL ACAD SCI USA, V103, P12197, DOI 10.1073/pnas.0603571103; Zhang Y, 2007, J PLANT PHYSIOL, V164, P993, DOI 10.1016/j.jplph.2006.07.003	36	23	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18734	18741		10.1074/jbc.M109.005744	http://dx.doi.org/10.1074/jbc.M109.005744			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19447891	Green Published, hybrid			2022-12-25	WOS:000267711500023
J	Iwahori, S; Murata, T; Kudoh, A; Sato, Y; Nakayama, S; Isomura, H; Kanda, T; Tsurumi, T				Iwahori, Satoko; Murata, Takayuki; Kudoh, Ayumi; Sato, Yoshitaka; Nakayama, Sanae; Isomura, Hiroki; Kanda, Teru; Tsurumi, Tatsuya			Phosphorylation of p27(Kip1) by Epstein-Barr Virus Protein Kinase Induces Its Degradation through SCFSkp2 Ubiquitin Ligase Actions during Viral Lytic Replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE; CDK INHIBITOR P27; S-PHASE; NUCLEAR ANTIGEN; LINE AKATA; BGLF4; COMPLEX; CELLS; HERPESVIRUSES; BZLF1	Epstein-Barr virus (EBV) productive replication occurs in an S-phase-like cellular environment with high cyclin-dependent kinase (CDK) activity. The EBV protein kinase (PK), encoded by the viral BGLF4 gene, is a Ser/Thr protein kinase, which phosphorylates both viral and cellular proteins, modifying the cellular environment for efficient viral productive replication. We here provide evidence that the EBV PK phosphorylates the CDK inhibitor p27(Kip1), resulting in ubiquitination and degradation in a proteasome-dependent manner during EBV productive replication. Experiments with BGLF4 knockdown by small interfering RNA and BGLF4 knock-out viruses clarified that EBV PK is involved in p27(Kip1) degradation upon lytic replication. Transfection of the BGLF4 expression vector revealed that EBV PK alone could phosphorylate the Thr-187 residue of p27(Kip1) and that the ubiquitination and degradation of p27(Kip1) occurred in an SCFSkp2 ubiquitin ligase-dependent manner. In vitro, EBV PK proved capable of phosphorylating p27(Kip1) at Thr-187. Unlike cyclin E-CDK2 activity, the EBV PK activity was not inhibited by p27(Kip1). Overall, EBV PK enhances p27(Kip1) degradation effectively upon EBV productive replication, contributing to establishment of an S-phase-like cellular environment with high CDK activity.	[Iwahori, Satoko; Murata, Takayuki; Kudoh, Ayumi; Sato, Yoshitaka; Nakayama, Sanae; Isomura, Hiroki; Kanda, Teru; Tsurumi, Tatsuya] Aichi Canc Ctr Res Inst, Div Virol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center	Tsurumi, T (corresponding author), Aichi Canc Ctr Res Inst, Div Virol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	ttsurumi@aichi-cc.jp	Kanda, Teru/J-7313-2019; Murata, Takayuki/I-2621-2013; Sato, Yoshitaka/P-9728-2015; Iwahori, Satoko/L-1948-2019	Murata, Takayuki/0000-0001-7228-0839; Sato, Yoshitaka/0000-0002-8541-6413; Kanda, Teru/0000-0002-1391-3349	Ministry of Education, Science, Sports, Culture, and Technology of Japan. [21022055, 20012056, 20390137]	Ministry of Education, Science, Sports, Culture, and Technology of Japan.(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by Grants-in-aid for Scientific Research 21022055, 20012056, and 20390137 from the Ministry of Education, Science, Sports, Culture, and Technology of Japan.	Asai R, 2006, J VIROL, V80, P5125, DOI 10.1128/JVI.02674-05; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen MR, 2000, J VIROL, V74, P3093, DOI 10.1128/JVI.74.7.3093-3104.2000; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Deng XB, 2004, J BIOL CHEM, V279, P22498, DOI 10.1074/jbc.M400479200; Ellis M, 1999, EMBO J, V18, P644, DOI 10.1093/emboj/18.3.644; Gershburg E, 2008, BBA-PROTEINS PROTEOM, V1784, P203, DOI 10.1016/j.bbapap.2007.08.009; Gershburg E, 2007, J VIROL, V81, P5407, DOI 10.1128/JVI.02398-06; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kato K, 2003, J GEN VIROL, V84, P3381, DOI 10.1099/vir.0.19454-0; Kato K, 2001, J GEN VIROL, V82, P1457, DOI 10.1099/0022-1317-82-6-1457; Kawaguchi Y, 2003, REV MED VIROL, V13, P331, DOI 10.1002/rmv.402; Kawaguchi Y, 2003, J VIROL, V77, P2359, DOI 10.1128/JVI.77.4.2359-2368.2003; Knight JS, 2005, MOL CELL BIOL, V25, P1749, DOI 10.1128/MCB.25.5.1749-1763.2005; Knipe DM, 2007, FIELDS VIROLOGY; Kudoh A, 2005, J BIOL CHEM, V280, P8156, DOI 10.1074/jbc.M411405200; Kudoh A, 2004, J VIROL, V78, P104, DOI 10.1128/JVI.78.1.104-115.2004; Kudoh A, 2003, J VIROL, V77, P851, DOI 10.1128/JVI.77.2.851-861.2003; Kudoh A, 2006, J VIROL, V80, P10064, DOI 10.1128/JVI.00678-06; Lee CP, 2007, J VIROL, V81, P5166, DOI 10.1128/JVI.00120-07; Lee CP, 2008, J VIROL, V82, P11913, DOI 10.1128/JVI.01100-08; LeRoux F, 1996, J GEN VIROL, V77, P501, DOI 10.1099/0022-1317-77-3-501; Mann DJ, 1999, EMBO J, V18, P654, DOI 10.1093/emboj/18.3.654; Murata T, 2006, J BIOL CHEM, V281, P20788, DOI 10.1074/jbc.M600563200; Murata T, 2009, VIROLOGY, V389, P75, DOI 10.1016/j.virol.2009.04.007; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Parker GA, 2000, ONCOGENE, V19, P700, DOI 10.1038/sj.onc.1203327; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sato Y, 2009, VIROLOGY, V388, P204, DOI 10.1016/j.virol.2009.03.017; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHIMIZU N, 1994, J VIROL, V68, P6069, DOI 10.1128/JVI.68.9.6069-6073.1994; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; TAKADA K, 1991, VIRUS GENES, V5, P147, DOI 10.1007/BF00571929; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Yarmishyn A, 2008, EXP CELL RES, V314, P204, DOI 10.1016/j.yexcr.2007.09.016; Yue W, 2005, J VIROL, V79, P5880, DOI 10.1128/JVI.79.9.5880-5885.2005; Zhu J, 2009, J VIROL, V83, P5219, DOI 10.1128/JVI.02378-08	46	21	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18923	18931		10.1074/jbc.M109.015123	http://dx.doi.org/10.1074/jbc.M109.015123			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19451650	Green Published, hybrid			2022-12-25	WOS:000267711500042
J	Kwak, SY; Wiedemann-Bidlack, FB; Beniash, E; Yamakoshi, Y; Simmer, JP; Litman, A; Margolis, HC				Kwak, Seo-Young; Wiedemann-Bidlack, Felicitas B.; Beniash, Elia; Yamakoshi, Yasuo; Simmer, James P.; Litman, Amy; Margolis, Henry C.			Role of 20-kDa Amelogenin (P148) Phosphorylation in Calcium Phosphate Formation in Vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY STAGE; ENAMEL; HYDROXYAPATITE; GROWTH; NUCLEATION; CARBONATE; PROTEINS; CRYSTALS; CLEAVAGE; TISSUES	The potential role of amelogenin phosphorylation in enamel formation is elucidated through in vitro mineralization studies. Studies focused on the native 20-kDa porcine amelogenin proteolytic cleavage product P148 that is prominent in developing enamel. Experimental conditions supported spontaneous calcium phosphate precipitation with the initial formation of amorphous calcium phosphate (ACP). In the absence of protein, ACP was found to undergo relatively rapid transformation to randomly oriented plate-like apatitic crystals. In the presence of non-phosphorylated recombinant full-length amelogenin, rP172, a longer induction period was observed during which relatively small ACP nanoparticles were transiently stabilized. In the presence of rP172, these nanoparticles were found to align to form linear needle-like particles that subsequently transformed and organized into parallel arrays of apatitic needle-like crystals. In sharp contrast to these findings, P148, with a single phosphate group on serine 16, was found to inhibit calcium phosphate precipitation and stabilize ACP formation for more than 1 day. Additional studies using non- phosphorylated recombinant (rP147) and partially dephosphorylated forms of P148 (dephoso-P148) showed that the single phosphate group in P148 was responsible for the profound effect on mineral formation in vitro. The present study has provided, for the first time, evidence suggesting that the native proteolytic cleavage product P148 may have an important functional role in regulating mineralization during enamel formation by preventing unwanted mineral formation within the enamel matrix during the secretory stage of amelogenesis. Results obtained have also provided new insights into the functional role of the highly conserved hydrophilic C terminus found in full-length amelogenin. found in full-length amelogenin.	[Kwak, Seo-Young; Wiedemann-Bidlack, Felicitas B.; Litman, Amy; Margolis, Henry C.] Forsyth Inst, Dept Biomineralizat, Boston, MA 02115 USA; [Beniash, Elia] Univ Pittsburgh, Dept Oral Biol, Pittsburgh, PA 15261 USA; [Yamakoshi, Yasuo; Simmer, James P.] Univ Michigan, Dent Res Lab, Ann Arbor, MI 48109 USA	Harvard University; Forsyth Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan	Margolis, HC (corresponding author), 140 Fenway, Boston, MA 02115 USA.	hmargolis@forsyth.org		Simmer, James/0000-0002-7192-6105; Bidlack, Felicitas/0000-0001-8105-223X	National Institutes of Health [DE-016376, T32 DE-007327]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE016376, R01DE016376] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported, in whole or in part, by National Institutes of Health Grant DE-016376 (to H.C.M.) from NIDCR.; The on-line version of this article (available at http://www.jbc.org) contains Supplemental material, a reference, and Figs. S1-S5.; Supported in part by National Institutes of Health Grant T32 DE-007327.	Aizenberg J, 2002, J AM CHEM SOC, V124, P32, DOI 10.1021/ja016990l; AOBA T, 1987, CALCIFIED TISSUE INT, V41, P86, DOI 10.1007/BF02555250; AOBA T, 1989, J DENT RES, V68, P1331, DOI 10.1177/00220345890680090901; AOBA T, 1987, CALCIFIED TISSUE INT, V41, P281, DOI 10.1007/BF02555230; Aparicio S, 2002, CALCIFIED TISSUE INT, V70, P422, DOI 10.1007/s00223-001-1016-z; Beniash E, 2005, J STRUCT BIOL, V149, P182, DOI 10.1016/j.jsb.2004.11.001; Beniash E, 1997, P ROY SOC B-BIOL SCI, V264, P461, DOI 10.1098/rspb.1997.0066; Beniash E, 2009, J STRUCT BIOL, V166, P133, DOI 10.1016/j.jsb.2009.02.001; Bodier-Houlle P, 2000, CELL TISSUE RES, V301, P389, DOI 10.1007/s004410000241; Crane NJ, 2006, BONE, V39, P434, DOI 10.1016/j.bone.2006.02.059; Deshpande AS, 2008, CRYST GROWTH DES, V8, P3084, DOI 10.1021/cg800252f; Diekwisch TGH, 1998, CONNECT TISSUE RES, V38, P101, DOI 10.3109/03008209809017026; Eanes E D, 2001, Monogr Oral Sci, V18, P130; Fan YW, 2007, BIOMATERIALS, V28, P3034, DOI 10.1016/j.biomaterials.2007.02.016; FUKAE M, 2002, P INT S OR SCI TSUR, P73; Gajjeraman S, 2007, J BIOL CHEM, V282, P1193, DOI 10.1074/jbc.M604732200; GEE A, 1953, ANAL CHEM, V25, P1320, DOI 10.1021/ac60081a006; Gericke A, 2005, CALCIFIED TISSUE INT, V77, P45, DOI 10.1007/s00223-004-1288-1; Habelitz S, 2006, EUR J ORAL SCI, V114, P315, DOI 10.1111/j.1600-0722.2006.00312.x; Kim HM, 2005, BIOMATERIALS, V26, P4366, DOI 10.1016/j.biomaterials.2004.11.022; Levi-Kalisman Y, 2000, J CHEM SOC DALTON, P3977, DOI 10.1039/b003242p; LOWENSTAM HA, 1985, SCIENCE, V227, P51, DOI 10.1126/science.227.4682.51; Mahamid J, 2008, P NATL ACAD SCI USA, V105, P12748, DOI 10.1073/pnas.0803354105; Margolis HC, 2006, J DENT RES, V85, P775, DOI 10.1177/154405910608500902; Moradian-Oldak J, 2002, MATRIX BIOL, V21, P197, DOI 10.1016/S0945-053X(01)00190-1; Robinson C, 2007, J DENT RES, V86, P677, DOI 10.1177/154405910708600801; ROBINSON C, 1988, ARCH ORAL BIOL, V33, P159, DOI 10.1016/0003-9969(88)90040-4; Ryu OH, 1999, J DENT RES, V78, P743, DOI 10.1177/00220345990780030601; SCHWARTZ SS, 1992, CALCIFIED TISSUE INT, V50, P511, DOI 10.1007/BF00582164; Sikes C.S., 1991, SURFACE REACTIVE PEP; SIKES CS, 1988, CHEM ASPECTS REGULAT; Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128, DOI 10.1177/10454411980090020101; Suvorova EI, 2001, CRYSTALLOGR REP+, V46, P722, DOI 10.1134/1.1405856; TANABE T, 1992, CALCIFIED TISSUE INT, V51, P213, DOI 10.1007/BF00334549; Tao JH, 2007, J PHYS CHEM B, V111, P13410, DOI 10.1021/jp0732918; Tarasevich BJ, 2007, J CRYST GROWTH, V304, P407, DOI 10.1016/j.jcrysgro.2007.02.035; UCHIDA T, 1991, HISTOCHEMISTRY, V96, P129, DOI 10.1007/BF00315983; Wang LJ, 2008, J PHYS CHEM C, V112, P5892, DOI 10.1021/jp077105+; Wang LJ, 2007, J PHYS CHEM C, V111, P6398, DOI 10.1021/jp0675429; Weiner S, 2005, SCIENCE, V309, P1027, DOI 10.1126/science.1114920; Wiedemann-Bidlack FB, 2007, J STRUCT BIOL, V160, P57, DOI 10.1016/j.jsb.2007.06.007; Wu LNY, 1997, J BIOL CHEM, V272, P4404, DOI 10.1074/jbc.272.7.4404; YAMAKOSHI Y, 1994, CALCIFIED TISSUE INT, V54, P69, DOI 10.1007/BF00316293	43	84	87	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18972	18979		10.1074/jbc.M109.020370	http://dx.doi.org/10.1074/jbc.M109.020370			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19443653	hybrid, Green Published			2022-12-25	WOS:000267711500047
J	Morrish, F; Isern, N; Sadilek, M; Jeffrey, M; Hockenbery, DM				Morrish, F.; Isern, N.; Sadilek, M.; Jeffrey, M.; Hockenbery, D. M.			c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry	ONCOGENE			English	Review						NMR; isotopomer; stable isotope labeling; O-linked N-acetylglucosamine; glucose	BETA-N-ACETYLGLUCOSAMINE; PROGRESSION; PROLIFERATION; TRANSCRIPTION; GENES	Cell proliferation requires the coordinated activity of cytosolic and mitochondrial metabolic pathways to provide ATP and building blocks for DNA, RNA and protein synthesis. Many metabolic pathway genes are targets of the c-myc oncogene and cell-cycle regulator. However, the contribution of c-Myc to the activation of cytosolic and mitochondrial metabolic networks during cell-cycle entry is unknown. Here, we report the metabolic fates of [U-C-13] glucose in serum-stimulated myc(-/-) and myc(+/+) fibroblasts by C-13 isotopomer NMR analysis. We demonstrate that endogenous c-myc increased C-13 labeling of ribose sugars, purines and amino acids, indicating partitioning of glucose carbons into C1/folate and pentose phosphate pathways, and increased tricarboxylic acid cycle turnover at the expense of anaplerotic flux. Myc expression also increased global O-linked N-acetylglucosamine protein modi. cation, and inhibition of hexosamine biosynthesis selectively reduced growth of Myc-expressing cells, suggesting its importance in Myc-induced proliferation. These data reveal a central organizing function for the Myc oncogene in the metabolism of cycling cells. The pervasive deregulation of this oncogene in human cancers may be explained by its function in directing metabolic networks required for cell proliferation. Oncogene ( 2009) 28, 2485-2491; doi: 10.1038/onc.2009.112; published online 18 May 2009	[Morrish, F.; Hockenbery, D. M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; [Isern, N.] Pacific NW Natl Lab, High Field NMR Facil, WR Wiley Environm Mol Sci Lab, Richland, WA 99352 USA; [Sadilek, M.] Univ Washington, Dept Chem, Seattle, WA 98195 USA; [Sadilek, M.] Univ Texas SW, Adv Imaging Res Ctr, Dallas, TX USA	Fred Hutchinson Cancer Center; United States Department of Energy (DOE); Pacific Northwest National Laboratory; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Southwestern Medical Center Dallas	Hockenbery, DM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D2-190, Seattle, WA 98109 USA.	dhockenb@fhcrc.org		Isern, Nancy/0000-0001-9571-8864	NIH [R21 DK070297, P41 RR02301]; Human Metabolome database; MDL database; Department of Energy's Office of Biological and Environmental Research at Pacific Northwest National Laboratory; Development of the program tca-CALC [RO1CA106650-02]; University of Texas Southwestern Medical Center [H47669-16]; Department of Veterans Affairs Merit Review Award to CR Malloy [RR02584]; NATIONAL CANCER INSTITUTE [R01CA106650] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002584, P41RR002301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK070297] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Human Metabolome database; MDL database; Department of Energy's Office of Biological and Environmental Research at Pacific Northwest National Laboratory; Development of the program tca-CALC; University of Texas Southwestern Medical Center; Department of Veterans Affairs Merit Review Award to CR Malloy(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank John Sedivy for cell lines. This work utilized the MMC database supported by NIH grants R21 DK070297 and P41 RR02301, the MDL database (www.mdl.imb.liu.se) and the Human Metabolome database (www.hmbd.ca). A portion of this research was performed at EMSL, a national scienti. c user facility sponsored by the Department of Energy's Office of Biological and Environmental Research at Pacific Northwest National Laboratory. This work was funded by RO1CA106650-02 (DH). Development of the program tca-CALC (University of Texas Southwestern Medical Center) was supported by H47669-16, a Department of Veterans Affairs Merit Review Award to CR Malloy, and RR02584.	Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; DEAN M, 1986, J BIOL CHEM, V261, P9161; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Hunt AN, 2004, ADV ENZYME REGUL, V44, P173; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Lawlor ER, 2006, CANCER RES, V66, P4591, DOI 10.1158/0008-5472.CAN-05-3826; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; Mandal S, 2005, DEV CELL, V9, P843, DOI 10.1016/j.devcel.2005.11.006; Mannava S, 2008, CELL CYCLE, V7, P2392, DOI 10.4161/cc.6390; Morrish F, 2008, CELL CYCLE, V7, P1054, DOI 10.4161/cc.7.8.5739; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Peet AC, 2007, NMR BIOMED, V20, P692, DOI 10.1002/nbm.1181; Schorl C, 2003, MOL BIOL CELL, V14, P823, DOI 10.1091/mbc.E02-10-0649; Slawson C, 2005, J BIOL CHEM, V280, P32944, DOI 10.1074/jbc.M503396200; TOLLEFSBOL TO, 1990, BIOCHEM MED METAB B, V44, P282, DOI 10.1016/0885-4505(90)90073-A; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103	21	124	132	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2485	2491		10.1038/onc.2009.112	http://dx.doi.org/10.1038/onc.2009.112			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448666	Green Accepted			2022-12-25	WOS:000267806800001
J	Yamada, D; Perez-Torrado, R; Filion, G; Caly, M; Jammart, B; Devignot, V; Sasai, N; Ravassard, P; Mallet, J; Sastre-Garau, X; Schmitz, ML; Defossez, PA				Yamada, D.; Perez-Torrado, R.; Filion, G.; Caly, M.; Jammart, B.; Devignot, V.; Sasai, N.; Ravassard, P.; Mallet, J.; Sastre-Garau, X.; Schmitz, M. L.; Defossez, P-A			The human protein kinase HIPK2 phosphorylates and downregulates the methyl-binding transcription factor ZBTB4	ONCOGENE			English	Article						transcription; protein kinase; epigenetics	DNA-DAMAGE; GENE-EXPRESSION; P53 ACTIVITY; APOPTOSIS; CANCER; CELLS; DEGRADATION; ACTIVATION; INTERACTS; SER-46	HIPK2 is a eukaryotic Serine-Threonine kinase that controls cellular proliferation and survival in response to exogenous signals. Here, we show that the human transcription factor ZBTB4 is a new target of HIPK2. The two proteins interact in vitro, colocalize and associate in vivo, and HIPK2 phosphorylates several conserved residues of ZBTB4. Overexpressing HIPK2 causes the degradation of ZBTB4, whereas overexpressing a kinase-deficient mutant of HIPK2 has no effect. The chemical activation of HIPK2 also decreases the amount of ZBTB4 in cells. Conversely, the inhibition of HIPK2 by drugs or by RNA interference causes a large increase in ZBTB4 levels. This negative regulation of ZBTB4 by HIPK2 occurs under normal conditions of cell growth. In addition, the degradation is increased by DNA damage. These findings have two consequences. First, we have recently shown that ZBTB4 inhibits the transcription of p21. Therefore, the activation of p21 by HIPK2 is two-pronged: stimulation of the activator p53, and simultaneous repression of the inhibitor ZBTB4. Second, ZBTB4 is also known to bind methylated DNA and repress methylated sequences. Consequently, our findings raise the possibility that HIPK2 might influence the epigenetic regulation of gene expression at loci that remain to be identified. Oncogene ( 2009) 28, 2535-2544; doi: 10.1038/onc.2009.109; published online 18 May 2009	[Sasai, N.; Defossez, P-A] Univ Paris 07, CNRS, Epigenet & Cell Fate UMR7216, F-75205 Paris 13, France; [Yamada, D.; Perez-Torrado, R.; Filion, G.; Jammart, B.; Devignot, V.; Sasai, N.; Defossez, P-A] Inst Curie, CNRS, UMR218, F-75231 Paris, France; [Caly, M.; Sastre-Garau, X.] Inst Curie, Med Sect, F-75231 Paris, France; [Ravassard, P.; Mallet, J.] Univ Paris 06, CNRS, UMR7091, Paris, France; [Schmitz, M. L.] Univ Giessen, Fac Med, Inst Biochem, Giessen, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Justus Liebig University Giessen	Defossez, PA (corresponding author), Univ Paris 07, CNRS, UMR7216, Batiment Lamarck,Case 7042,35 Rue Helene Brion, F-75205 Paris 13, France.	pierre-antoine.defossez@univ-paris-diderot.fr	Schmitz, M. Lienhard/D-9328-2017; Filion, Guillaume/G-9619-2015; Perez Torrado, Roberto/E-7613-2012	Schmitz, M. Lienhard/0000-0002-6984-7192; Filion, Guillaume/0000-0002-3473-1632; Perez Torrado, Roberto/0000-0002-3118-6755; Defossez, Pierre-Antoine/0000-0002-6463-9263; ravassard, philippe/0000-0002-0393-9262; Sastre-Garau, Xavier/0000-0001-5992-2083	Centre National de la Recherche Scientifique (CNRS); Institut National du Cancer ( ATIP Plus); Association pour la Recherche contre le Cancer [3727, 4859]; Ligue contre le Cancer; Deutsche Forschungsgemeinschaft (DFG)	Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Institut National du Cancer ( ATIP Plus)(Institut National du Cancer (INCA) France); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue contre le Cancer(Ligue nationale contre le cancer); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	We thank the following colleagues for reagents: Nelson Dusetti, Roger Tsien, Phillip James, Jacques Camonis, Silvia Soddu. We are especially grateful to Gabriella d'Orazi for the HIPK2 knockdown cells, and to Patricia Le Baccon for her help. DY was supported by postdoctoral fellowships from the Curie Institute, and from Association pour la Recherche contre le Cancer. RPT was supported by a fellowship from Centre National de la Recherche Scientifique (CNRS). The Defossez lab is supported by CNRS ( programme ATIP and programme PICS France-Russie), by Institut National du Cancer ( ATIP Plus), by Association pour la Recherche contre le Cancer ( grants no 3727 and no 4859), and by Ligue contre le Cancer. The work of MLS is supported by the Deutsche Forschungsgemeinschaft (DFG).	Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Calzado MA, 2007, CELL CYCLE, V6, P139, DOI 10.4161/cc.6.2.3788; Clouaire T, 2008, CELL MOL LIFE SCI, V65, P1509, DOI 10.1007/s00018-008-7324-y; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dauth I, 2007, CANCER RES, V67, P2274, DOI 10.1158/0008-5472.CAN-06-2884; Defossez PA, 2005, J BIOL CHEM, V280, P43017, DOI 10.1074/jbc.M510802200; Deshmukh H, 2008, ONCOGENE, V27, P4745, DOI 10.1038/onc.2008.110; Di Stefano V, 2005, ONCOGENE, V24, P5431, DOI 10.1038/sj.onc.1208717; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; Engelhardt OG, 2003, EXP CELL RES, V283, P36, DOI 10.1016/S0014-4827(02)00025-3; Filion GJP, 2006, MOL CELL BIOL, V26, P169, DOI 10.1128/MCB.26.1.169-181.2006; Filion GJP, 2006, ANAL BIOCHEM, V357, P156, DOI 10.1016/j.ab.2006.07.021; Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Isono K, 2006, MOL CELL BIOL, V26, P2758, DOI 10.1128/MCB.26.7.2758-2771.2006; James P, 1996, GENETICS, V144, P1425; KANDURI C, 2002, J BIOL CHEM, V4, P4; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Lee W, 2009, DEVELOPMENT, V136, P241, DOI 10.1242/dev.025460; Li XL, 2007, ONCOGENE, V26, P7231, DOI 10.1038/sj.onc.1210523; Moller A, 2003, ONCOGENE, V22, P8731, DOI 10.1038/sj.onc.1207079; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ovcharenko D, 2005, RNA, V11, P985, DOI 10.1261/rna.7288405; Perez-Torrado R, 2006, BIOESSAYS, V28, P1194, DOI 10.1002/bies.20500; Phan RT, 2005, NAT IMMUNOL, V6, P1054, DOI 10.1038/ni1245; Pierantoni GM, 2007, J CLIN INVEST, V117, P693, DOI 10.1172/JCI29852; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; Rinaldo C, 2008, BBA-MOL CELL RES, V1783, P2124, DOI 10.1016/j.bbamcr.2008.06.006; Rinaldo C, 2007, BIOCHEM CELL BIOL, V85, P411, DOI 10.1139/O07-071; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Roscic A, 2006, MOL CELL, V24, P77, DOI 10.1016/j.molcel.2006.08.004; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; van Roy FM, 2005, NAT REV CANCER, V5, P956, DOI 10.1038/nrc1752; Weber A, 2008, EMBO J, V27, P1563, DOI 10.1038/emboj.2008.85; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Wesierska-Gadek J, 2007, J CELL BIOCHEM, V100, P865, DOI 10.1002/jcb.21211; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2005, P NATL ACAD SCI USA, V102, P2802, DOI 10.1073/pnas.0409373102; Zhang QC, 2007, J PROTEOME RES, V6, P4711, DOI 10.1021/pr700571d	40	27	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2535	2544		10.1038/onc.2009.109	http://dx.doi.org/10.1038/onc.2009.109			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448668				2022-12-25	WOS:000267806800006
J	Jensen, JK; Dolmer, K; Gettins, PGW				Jensen, Jan K.; Dolmer, Klavs; Gettins, Peter G. W.			Specificity of Binding of the Low Density Lipoprotein Receptor-related Protein to Different Conformational States of the Clade E Serpins Plasminogen Activator Inhibitor-1 and Proteinase Nexin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR SOLUTION STRUCTURE; METHYL-D-ASPARTATE; LDL RECEPTOR; ALPHA(2)-MACROGLOBULIN RECEPTOR; ALPHA(1)-PROTEINASE INHIBITOR; COVALENT COMPLEXES; ENDOCYTIC RECEPTOR; RAP COMPLEX; SITE; LRP	The low density lipoprotein receptor-related protein (LRP) is the principal clearance receptor for serpins and serpin-proteinase complexes. The ligand binding regions of LRP consist of clusters of cysteine-rich similar to 40-residue complement-like repeats (CR), with cluster II being the principal ligand-binding region. To better understand the specificity of binding at different sites within the cluster and the ability of LRP to discriminate in vivo between uncomplexed and proteinase-complexed serpins, we have systematically examined the affinities of plasminogen activator inhibitor-1 (PAI-1) and proteinase nexin-1 (PN-1) in their native, cleaved, and proteinase-complexed states to (CR)(2) and (CR)(3) fragments of LRP cluster II. A consistent blue shift of the CR domain tryptophan fluorescence suggested a common mode of serpin binding, involving lysines on the serpin engaging the acidic region around the calcium binding site of the CR domain. High affinity binding of non-proteinase-complexed PAI-1 and PN-1 occurred to all fragments containing three CR domains (3 -59 nM) and most that contain only two CR domains, although binding energies to different (CR)(3) fragments differed by up to 18% for PAI-1 and 9% for PN-1. No detectable difference in affinity was seen between native and cleaved serpin. However, the presence of proteinase in complex with the serpin enhanced affinity modestly and presumably nonspecifically. This may be sufficient to give preferential binding of such complexes in vivo at the relevant physiological concentrations.	[Jensen, Jan K.; Dolmer, Klavs; Gettins, Peter G. W.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gettins, PGW (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, 900 S Ashland,M-C 669, Chicago, IL 60607 USA.	pgettins@uic.edu	Dolmer, Klavs/G-5512-2012	Dolmer, Klavs/0000-0001-7359-360X	National Institutes of Health [R01 GM54414, R01HL79430]; Danish Research Council; Carlsberg Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054414] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Danish Research Council(Det Frie Forskningsrad (DFF)); Carlsberg Foundation(Carlsberg Foundation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants R01 GM54414 and R01HL79430. This work was also supported by fellowships from the Danish Research Council and the Carlsberg Foundation (to J. K. J.).	Arandjelovic S, 2005, ARCH BIOCHEM BIOPHYS, V438, P29, DOI 10.1016/j.abb.2005.03.019; Backovic M, 2002, PROTEIN SCI, V11, P1182, DOI 10.1110/ps.4320102; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Beglova N, 2001, BIOCHEMISTRY-US, V40, P2808, DOI 10.1021/bi0027276; CONARD J, 1983, HAEMOSTASIS, V13, P363; Dementiev A, 2006, J BIOL CHEM, V281, P3452, DOI 10.1074/jbc.M510564200; DESMET BJGL, 1993, BLOOD, V81, P56, DOI 10.1182/blood.V81.1.56.bloodjournal81156; Dobo J, 2004, J BIOL CHEM, V279, P9264, DOI 10.1074/jbc.M311731200; Dolmer K, 1998, BIOCHEMISTRY-US, V37, P17016, DOI 10.1021/bi982022s; Dolmer K, 2000, J BIOL CHEM, V275, P3264, DOI 10.1074/jbc.275.5.3264; Dolmer K, 2006, J BIOL CHEM, V281, P34189, DOI 10.1074/jbc.M604389200; Fisher C, 2006, MOL CELL, V22, P277, DOI 10.1016/j.molcel.2006.02.021; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; GUENTHER J, 1985, EMBO J, V4, P1963, DOI 10.1002/j.1460-2075.1985.tb03878.x; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Horn IR, 1998, THROMB HAEMOSTASIS, V80, P822; Huang W, 1999, J BIOL CHEM, V274, P14130, DOI 10.1074/jbc.274.20.14130; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Jensen GA, 2006, J MOL BIOL, V362, P700, DOI 10.1016/j.jmb.2006.07.013; Jensen JK, 2008, PROTEIN SCI, V17, P1844, DOI 10.1110/ps.036707.108; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; Kasza A, 1997, EUR J BIOCHEM, V248, P270, DOI 10.1111/j.1432-1033.1997.00270.x; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; Lee D, 2006, MOL CELL, V22, P423, DOI 10.1016/j.molcel.2006.04.011; LEIPER K, 1994, J CLIN PATHOL, V47, P214, DOI 10.1136/jcp.47.3.214; Li YH, 2002, BIOCHEMISTRY-US, V41, P4921, DOI 10.1021/bi011894i; Lutz C, 2002, J BIOL CHEM, V277, P43143, DOI 10.1074/jbc.M204426200; Malek R, 1996, CLIN EXP IMMUNOL, V105, P191, DOI 10.1046/j.1365-2249.1996.d01-714.x; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; Meijer AB, 2007, BBA-PROTEINS PROTEOM, V1774, P714, DOI 10.1016/j.bbapap.2007.04.003; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; Panizzi P, 2006, J BIOL CHEM, V281, P26774, DOI 10.1074/jbc.C600171200; Picard V, 1999, J BIOL CHEM, V274, P4586, DOI 10.1074/jbc.274.8.4586; Qiu ZH, 2002, J BIOL CHEM, V277, P14458, DOI 10.1074/jbc.M112066200; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Skeldal S, 2006, FEBS J, V273, P5143, DOI 10.1111/j.1742-4658.2006.05511.x; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; Stout TJ, 2000, BIOCHEMISTRY-US, V39, P8460, DOI 10.1021/bi000290w; Tesch LD, 2005, PROTEIN SCI, V14, P533, DOI 10.1110/ps.041104905; Verdaguer N, 2004, NAT STRUCT MOL BIOL, V11, P429, DOI 10.1038/nsmb753	43	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	2009	284	27					17989	17997		10.1074/jbc.M109.009530	http://dx.doi.org/10.1074/jbc.M109.009530			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BW	19439404	hybrid, Green Published			2022-12-25	WOS:000267712400010
J	DeSantis, LRG; Feranec, RS; MacFadden, BJ				DeSantis, Larisa R. G.; Feranec, Robert S.; MacFadden, Bruce J.			Effects of Global Warming on Ancient Mammalian Communities and Their Environments	PLOS ONE			English	Article							STABLE-ISOTOPES; CLIMATE-CHANGE; HORSE EQUUS; NORTH-AMERICA; BISON BISON; CARBON; FORESTS; ENAMEL; RECORD; TEETH	Background: Current global warming affects the composition and dynamics of mammalian communities and can increase extinction risk; however, long-term effects of warming on mammals are less understood. Dietary reconstructions inferred from stable isotopes of fossil herbivorous mammalian tooth enamel document environmental and climatic changes in ancient ecosystems, including C-3/C-4 transitions and relative seasonality. Methodology/Principal Findings: Here, we use stable carbon and oxygen isotopes preserved in fossil teeth to document the magnitude of mammalian dietary shifts and ancient floral change during geologically documented glacial and interglacial periods during the Pliocene (similar to 1.9 million years ago) and Pleistocene (similar to 1.3 million years ago) in Florida. Stable isotope data demonstrate increased aridity, increased C-4 grass consumption, inter-faunal dietary partitioning, increased isotopic niche breadth of mixed feeders, niche partitioning of phylogenetically similar taxa, and differences in relative seasonality with warming. Conclusion/Significance: Our data show that global warming resulted in dramatic vegetation and dietary changes even at lower latitudes (similar to 28 degrees N). Our results also question the use of models that predict the long term decline and extinction of species based on the assumption that niches are conserved over time. These findings have immediate relevance to clarifying possible biotic responses to current global warming in modern ecosystems.			DeSantis, LRG (corresponding author), Univ Florida, Dept Biol, Gainesville, FL 32610 USA.	larisa.desantis@gmail.com		DeSantis, Larisa/0000-0003-1159-9154				Barnosky AD, 2004, P NATL ACAD SCI USA, V101, P9297, DOI 10.1073/pnas.0402592101; Bell Christopher J., 2004, P232; Bocherens H, 1996, PALAIOS, V11, P306, DOI 10.2307/3515241; Cerling TE, 1999, OECOLOGIA, V120, P347, DOI 10.1007/s004420050868; Cerling TE, 2004, OECOLOGIA, V138, P5, DOI 10.1007/s00442-003-1375-4; Cerling TE, 1997, NATURE, V389, P153, DOI 10.1038/38229; COPLEN TB, 1994, PURE APPL CHEM, V66, P273, DOI 10.1351/pac199466020273; DANSGAARD W, 1964, TELLUS, V16, P273; DENIRO MJ, 1978, GEOCHIM COSMOCHIM AC, V42, P495, DOI 10.1016/0016-7037(78)90199-0; DeSantis LRG, 2008, PALAEOGEOGR PALAEOCL, V266, P59, DOI 10.1016/j.palaeo.2008.03.032; DeSantis LRG, 2007, COUR FOR SEKENBG, V258, P147; EASLEY M C, 1990, Castanea, V55, P142; Ehleringer JR, 2002, PLANT BIOLOGY, V4, P181, DOI 10.1055/s-2002-25733; Feranec Robert S., 2004, P327; Feranec RS, 2009, PALAEOGEOGR PALAEOCL, V271, P153, DOI 10.1016/j.palaeo.2008.10.005; FRIEDLI H, 1986, NATURE, V324, P237, DOI 10.1038/324237a0; GRIMM EC, 1993, SCIENCE, V261, P198, DOI 10.1126/science.261.5118.198; Higgins P, 2004, PALAEOGEOGR PALAEOCL, V206, P337, DOI 10.1016/j.palaeo.2004.01.011; Hoppe KA, 2004, PALAEOGEOGR PALAEOCL, V206, P355, DOI 10.1016/j.palaeo.2004.01.012; Huffman Jean M., 1998, Castanea, V63, P25; Koch PL, 1997, J ARCHAEOL SCI, V24, P417, DOI 10.1006/jasc.1996.0126; Koch PL, 1998, CHEM GEOL, V152, P119, DOI 10.1016/S0009-2541(98)00101-6; Kohn MJ, 1996, GEOCHIM COSMOCHIM AC, V60, P4811, DOI 10.1016/S0016-7037(96)00240-2; Levin NE, 2006, P NATL ACAD SCI USA, V103, P11201, DOI 10.1073/pnas.0604719103; LEVINSKY I, 2007, BIODIVERS CONSERV, V11, P453; MacFadden BJ, 1999, GLOBAL ECOL BIOGEOGR, V8, P137, DOI 10.1046/j.1466-822X.1999.00127.x; Martinez-Meyer E, 2004, GLOBAL ECOL BIOGEOGR, V13, P305, DOI 10.1111/j.1466-822X.2004.00107.x; Morgan Gary S., 1995, Bulletin of the Florida Museum of Natural History, V37, P1; Parmesan C, 2003, NATURE, V421, P37, DOI 10.1038/nature01286; Passey BH, 2005, GEOCHIM COSMOCHIM AC, V69, P4101, DOI 10.1016/j.gca.2004.12.002; Passey BH, 2002, GEOCHIM COSMOCHIM AC, V66, P3225, DOI 10.1016/S0016-7037(02)00933-X; Post E, 2004, P NATL ACAD SCI USA, V101, P9286, DOI 10.1073/pnas.0305029101; STOWE LG, 1978, AM NAT, V112, P609, DOI 10.1086/283301; TEERI JA, 1978, CAN J BOT, V56, P1750, DOI 10.1139/b78-208; TEERI JA, 1976, OECOLOGIA, V23, P1, DOI 10.1007/BF00351210; Thomas CD, 2004, NATURE, V427, P145, DOI 10.1038/nature02121; Thuiller W, 2005, GLOBAL ECOL BIOGEOGR, V14, P347, DOI 10.1111/j.1466-822x.2005.00162.x; VANDERMERWE NJ, 1989, GEOCHIM COSMOCHIM AC, V53, P1091, DOI 10.1016/0016-7037(89)90213-5; VANDERMERWE NJ, 1991, J ARCHAEOL SCI, V18, P249, DOI 10.1016/0305-4403(91)90064-V; Walther GR, 2002, NATURE, V416, P389, DOI 10.1038/416389a; WANG Y, 1994, PALAEOGEOGR PALAEOCL, V107, P281, DOI 10.1016/0031-0182(94)90100-7	41	54	57	1	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2009	4	6							e5750	10.1371/journal.pone.0005750	http://dx.doi.org/10.1371/journal.pone.0005750			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	453PV	19492043	Green Published, Green Submitted, gold			2022-12-25	WOS:000266624300006
J	Jacobi, AM; Zhang, J; Mackay, M; Aranow, C; Diamond, B				Jacobi, Annett M.; Zhang, Jie; Mackay, Meggan; Aranow, Cynthia; Diamond, Betty			Phenotypic Characterization of Autoreactive B Cells - Checkpoints of B Cell Tolerance in Patients with Systemic Lupus Erythematosus	PLOS ONE			English	Article								DNA-reactive B cells play a central role in systemic lupus erythematosus (SLE); DNA antibodies precede clinical disease and in established disease correlate with renal inflammation and contribute to dendritic cell activation and high levels of type 1 interferon. A number of central and peripheral B cell tolerance mechanisms designed to control the survival, differentiation and activation of autoreactive B cells are thought to be disturbed in patients with SLE. The characterization of DNA-reactive B cells has, however, been limited by their low frequency in peripheral blood. Using a tetrameric configuration of a peptide mimetope of DNA bound by pathogenic anti-DNA antibodies, we can identify B cells producing potentially pathogenic DNA-reactive antibodies. We, therefore, characterized the maturation and differentiation states of peptide, (ds) double stranded DNA cross-reactive B cells in the peripheral blood of lupus patients and correlated these with clinical disease activity. Flow cytometric analysis demonstrated a significantly higher frequency of tetramer-binding B cells in SLE patients compared to healthy controls. We demonstrated the existence of a novel tolerance checkpoint at the transition of antigen-naive to antigen-experienced. We further demonstrate that patients with moderately active disease have more autoreactive B cells in both the antigen-naive and antigen-experienced compartments consistent with greater impairment in B cell tolerance in both early and late checkpoints in these patients than in patients with quiescent disease. This methodology enables us to gain insight into the development and fate of DNA-reactive B cells in individual patients with SLE and paves the way ultimately to permit better and more customized therapies.			Jacobi, AM (corresponding author), N Shore Long Isl Jewish Hlth Syst, Feinstein Inst Med Res, Ctr Autoimmune & Musculoskeletal Dis, Manhasset, NY USA.	bdiamond@nshs.edu						Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933; Batten M, 2000, J EXP MED, V192, P1453, DOI 10.1084/jem.192.10.1453; Borrero M, 2002, J IMMUNOL, V168, P13, DOI 10.4049/jimmunol.168.1.13; BRIERE F, 1994, J EXP MED, V179, P757, DOI 10.1084/jem.179.2.757; Christensen SR, 2007, SEMIN IMMUNOL, V19, P11, DOI 10.1016/j.smim.2006.12.005; Culton DA, 2006, J IMMUNOL, V176, P790, DOI 10.4049/jimmunol.176.2.790; Fukuyama H, 2005, NAT IMMUNOL, V6, P99, DOI 10.1038/ni1151; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; Gaynor B, 1997, P NATL ACAD SCI USA, V94, P1955, DOI 10.1073/pnas.94.5.1955; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; Grimaldi CM, 2002, J CLIN INVEST, V109, P1625, DOI 10.1172/JCI200214873; Grimaldi CM, 2001, J IMMUNOL, V167, P1886, DOI 10.4049/jimmunol.167.4.1886; Hoyer BF, 2004, J EXP MED, V199, P1577, DOI 10.1084/jem.20040168; Huerta PT, 2006, P NATL ACAD SCI USA, V103, P678, DOI 10.1073/pnas.0510055103; Jacobi AM, 2008, ARTHRITIS RHEUM-US, V58, P1762, DOI 10.1002/art.23498; Kowal C, 2006, P NATL ACAD SCI USA, V103, P19854, DOI 10.1073/pnas.0608397104; Kuo P, 1999, EUR J IMMUNOL, V29, P3168, DOI 10.1002/(SICI)1521-4141(199910)29:10<3168::AID-IMMU3168>3.0.CO;2-H; Lanzavecchia A, 2007, CURR OPIN IMMUNOL, V19, P268, DOI 10.1016/j.coi.2007.04.002; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Mackay M, 2006, J EXP MED, V203, P2157, DOI 10.1084/jem.20051503; Nemazee D, 2000, J EXP MED, V191, P1813, DOI 10.1084/jem.191.11.1813; NEMAZEE D, 1989, P NATL ACAD SCI USA, V86, P8039, DOI 10.1073/pnas.86.20.8039; Newman J, 2003, J IMMUNOL METHODS, V272, P177, DOI 10.1016/S0022-1759(02)00499-4; NOSSAL GJV, 1980, P NATL ACAD SCI-BIOL, V77, P1602, DOI 10.1073/pnas.77.3.1602; Paul E, 2007, INT IMMUNOL, V19, P365, DOI 10.1093/intimm/dxm002; Peeva E, 2003, J CLIN INVEST, V111, P275, DOI 10.1172/JCI200316530; Pene J, 2004, J IMMUNOL, V172, P5154, DOI 10.4049/jimmunol.172.9.5154; Petri M, 2008, ARTHRITIS RHEUM, V58, P2453, DOI 10.1002/art.23678; Pugh-Bernard AE, 2001, J CLIN INVEST, V108, P1061, DOI 10.1172/JCI12462; Putterman C, 1998, J EXP MED, V188, P29, DOI 10.1084/jem.188.1.29; Qian Y, 2001, J IMMUNOL, V166, P2412, DOI 10.4049/jimmunol.166.4.2412; Rahman ZSM, 2007, J IMMUNOL, V178, P897, DOI 10.4049/jimmunol.178.2.897; Rice JS, 2005, P NATL ACAD SCI USA, V102, P1608, DOI 10.1073/pnas.0409217102; ROARK JH, 1995, J EXP MED, V181, P1157, DOI 10.1084/jem.181.3.1157; Santulli-Marotto S, 2001, J IMMUNOL, V166, P5292, DOI 10.4049/jimmunol.166.8.5292; Schmidt KN, 1998, J EXP MED, V187, P929, DOI 10.1084/jem.187.6.929; Sharma A, 2003, RHEUMATOLOGY, V42, P453, DOI 10.1093/rheumatology/keg161; TAN EM, 1991, CELL, V67, P841, DOI 10.1016/0092-8674(91)90356-4; Thien M, 2004, IMMUNITY, V20, P785, DOI 10.1016/j.immuni.2004.05.010; Tsuiji M, 2006, J EXP MED, V203, P393, DOI 10.1084/jem.20052033; VLAHAKOS DV, 1992, KIDNEY INT, V41, P1690, DOI 10.1038/ki.1992.242; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Wei C, 2007, J IMMUNOL, V178, P6624, DOI 10.4049/jimmunol.178.10.6624; William J, 2005, J IMMUNOL, V174, P6872, DOI 10.4049/jimmunol.174.11.6872; XIANG Z, 2007, NAT IMMUNOL; Yoshio T, 2006, ARTHRITIS RHEUM, V54, P675, DOI 10.1002/art.21547; Yurasov S, 2005, J EXP MED, V201, P703, DOI 10.1084/jem.20042251; Yurasov S, 2006, J EXP MED, V203, P2255, DOI 10.1084/jem.20061446; Zhang J, 2008, J IMMUNOL METHODS, V338, P79, DOI 10.1016/j.jim.2008.07.015	49	32	34	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2009	4	6							e5776	10.1371/journal.pone.0005776	http://dx.doi.org/10.1371/journal.pone.0005776			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453CI	19488401	Green Published, gold, Green Submitted			2022-12-25	WOS:000266587400013
J	Hong, QY; Sze, CI; Lin, SR; Lee, MH; He, RY; Schultz, L; Chang, JY; Chen, SJ; Boackle, RJ; Hsu, LJ; Chang, NS				Hong, Qunying; Sze, Chun-I; Lin, Sing-Ru; Lee, Ming-Hui; He, Ruei-Yu; Schultz, Lori; Chang, Jean-Yun; Chen, Shean-Jen; Boackle, Robert J.; Hsu, Li-Jin; Chang, Nan-Shan			Complement C1q Activates Tumor Suppressor WWOX to Induce Apoptosis in Prostate Cancer Cells	PLOS ONE			English	Article								Background: Tissue exudates contain low levels of serum complement proteins, and their regulatory effects on prostate cancer progression are largely unknown. We examined specific serum complement components in coordinating the activation of tumor suppressors p53 and WWOX (also named FOR or WOX1) and kinases ERK, JNK1 and STAT3 in human prostate DU145 cells. Methodology/Principal Findings: DU145 cells were cultured overnight in 1% normal human serum, or in human serum depleted of an indicated complement protein. Under complement C1q- or C6-free conditions, WOX1 and ERK were mainly present in the cytoplasm without phosphorylation, whereas phosphorylated JNK1 was greatly accumulated in the nuclei. Exogenous C1q rapidly restored the WOX1 activation (with Tyr33 phosphorylation) in less than 2 hr. Without serum complement C9, p53 became activated, and hyaluronan (HA) reversed the effect. Under C6-free conditions, HA induced activation of STAT3, an enhancer of metastasis. Notably, exogenous C1q significantly induced apoptosis of WOX1-overexpressing DU145 cells, but not vehicle-expressing cells. A dominant negative and Y33R mutant of WOX1 blocked the apoptotic effect. C1q did not enhance p53-mediated apoptosis. By total internal reflection fluorescence (TIRF) microscopy, it was determined that C1q destabilized adherence of WOX1-expressing DU145 cells by partial detaching and inducing formation of clustered microvilli for focal adhesion particularly in between cells. These cells then underwent shrinkage, membrane blebbing and death. Remarkably, as determined by immunostaining, benign prostatic hyperplasia and prostate cancer were shown to have a significantly reduced expression of tissue C1q, compared to age-matched normal prostate tissues. Conclusions/Significance: We conclude that complement C1q may induce apoptosis of prostate cancer cells by activating WOX1 and destabilizing cell adhesion. Downregulation of C1q enhances prostate hyperplasia and cancerous formation due to failure of WOX1 activation.			Hong, QY (corresponding author), Guthrie Res Inst, Lab Mol Immunol, Sayre, PA USA.	lijin.hsu@gmail.com; changns@mail.ncku.edu.tw	Hsu, Li-Jin/G-7822-2011					Ajona D, 2004, CANCER RES, V64, P6310, DOI 10.1158/0008-5472.CAN-03-2328; ALMEDA S, 1983, J BIOL CHEM, V258, P785; Aqeilan RI, 2008, J BIOL CHEM, V283, P21629, DOI 10.1074/jbc.M800855200; Aqeilan RI, 2007, J CELL PHYSIOL, V212, P307, DOI 10.1002/jcp.21099; Bajgelman MC, 2006, PROSTATE, V66, P1455, DOI 10.1002/pros.20462; Bhole D, 2004, IMMUNOBIOLOGY, V209, P559, DOI 10.1016/j.imbio.2004.08.001; Bogoyevitch MA, 2006, BIOESSAYS, V28, P923, DOI 10.1002/bies.20458; Buras JA, 2004, IMMUNOBIOLOGY, V209, P629, DOI 10.1016/j.imbio.2004.09.004; Caragine TA, 2002, CANCER RES, V62, P1110; Cattaruzza S, 2005, MATRIX BIOL, V24, P400, DOI 10.1016/j.matbio.2005.06.005; Chang NS, 2007, TRENDS MOL MED, V13, P12, DOI 10.1016/j.molmed.2006.11.006; Chang NS, 2005, J BIOL CHEM, V280, P43100, DOI 10.1074/jbc.M505590200; Chang NS, 2005, ONCOGENE, V24, P714, DOI 10.1038/sj.onc.1208124; CHANG NS, 1985, MOL IMMUNOL, V22, P843; Chang NS, 2003, BIOCHEM PHARMACOL, V66, P1347, DOI 10.1016/S0006-2952(03)00484-2; Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200; CHANG NS, 1985, MOL IMMUNOL, V22, P391; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Chen JG, 2005, CANCER RES, V65, P4614, DOI 10.1158/0008-5472.CAN-04-2253; Chen ST, 2005, NEUROSCIENCE, V130, P397, DOI 10.1016/j.neuroscience.2004.07.054; D'Andrea Michael R, 2005, Am J Alzheimers Dis Other Demen, V20, P144, DOI 10.1177/153331750502000303; DEMESSIAS IT, 1994, J INVEST ALLERG CLIN, V4, P172; Eikelenboom P, 2008, NEURODEGENER DIS, V5, P190, DOI 10.1159/000113699; Groves JT, 2008, ANNU REV BIOMED ENG, V10, P311, DOI 10.1146/annurev.bioeng.10.061807.160431; He RY, 2006, OPT EXPRESS, V14, P9307, DOI 10.1364/OE.14.009307; He RY, 2009, OPT EXPRESS, V17, P5987, DOI 10.1364/OE.17.005987; Hong QY, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-50; Hong QY, 2007, INT J MOL MED, V19, P173; Horinaga M, 2005, UROLOGY, V66, P671, DOI 10.1016/j.urology.2005.03.066; HSU LJ, 2009, J BIOL CHEM IN PRESS; Jin CJ, 2006, BIOCHEM BIOPH RES CO, V341, P784, DOI 10.1016/j.bbrc.2006.01.023; Lee MH, 2006, SEMIN CANCER BIOL, V16, P225, DOI 10.1016/j.semcancer.2006.03.009; Lisignoli G, 2006, J CELL PHYSIOL, V207, P364, DOI 10.1002/jcp.20572; Lo CP, 2008, EUR J NEUROSCI, V27, P1634, DOI 10.1111/j.1460-9568.2008.06139.x; Lokeshwar V, 1999, PROSTATE CANCER P D, V2, pS21, DOI 10.1038/sj.pcan.4500346; Lokeshwar VB, 2005, CANCER RES, V65, P7782, DOI 10.1158/0008-5472.CAN-05-1022; Mahajan NP, 2005, CANCER RES, V65, P10514, DOI 10.1158/0008-5472.CAN-05-1127; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Oka R, 2001, EUR J CANCER, V37, P1158, DOI 10.1016/S0959-8049(01)00089-2; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; Racila E, 2006, IMMUNOGENETICS, V58, P1, DOI 10.1007/s00251-005-0077-y; Rozanov DV, 2004, J BIOL CHEM, V279, P50321, DOI 10.1074/jbc.M409174200; Smith DI, 2007, SEMIN CANCER BIOL, V17, P31, DOI 10.1016/j.semcancer.2006.10.003; Stern R, 2004, EUR J CELL BIOL, V83, P317, DOI 10.1078/0171-9335-00392; Sze CI, 2004, J BIOL CHEM, V279, P30498, DOI 10.1074/jbc.M401399200; Takami A, 2006, CANCER SCI, V97, P80, DOI 10.1111/j.1349-7006.2006.00138.x; Taylor KR, 2006, FASEB J, V20, P9, DOI 10.1096/fj.05-4682rev; Toole BP, 2002, AM J PATHOL, V161, P745, DOI 10.1016/S0002-9440(10)64232-0; Waggoner SN, 2005, J IMMUNOL, V175, P4706, DOI 10.4049/jimmunol.175.7.4706; Watanabe A, 2003, CANCER RES, V63, P8629; Wuillemin WA, 1997, J IMMUNOL, V159, P1953; Yamada M, 2004, EUR J IMMUNOL, V34, P221, DOI 10.1002/eji.200324026; Yen HT, 1996, ARCH DERMATOL RES, V288, P157, DOI 10.1007/BF02505826; Yu HN, 2005, BBA-GEN SUBJECTS, V1726, P168, DOI 10.1016/j.bbagen.2005.08.003; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Zhou W, 2006, BRIT J CANCER, V95, P164, DOI 10.1038/sj.bjc.6603234	57	77	80	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2009	4	6							e5755	10.1371/journal.pone.0005755	http://dx.doi.org/10.1371/journal.pone.0005755			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	452GL	19484134	Green Published, gold, Green Submitted			2022-12-25	WOS:000266528200008
J	Ayles, H; Schaap, A; Nota, A; Sismanidis, C; Tembwe, R; De Haas, P; Muyoyeta, M; Beyers, N; Godfrey-Faussett, P				Ayles, Helen; Schaap, Albertus; Nota, Amos; Sismanidis, Charalambos; Tembwe, Ruth; De Haas, Petra; Muyoyeta, Monde; Beyers, Nulda; Godfrey-Faussett, Peter		ZAMSTAR Study Team	Prevalence of Tuberculosis, HIV and Respiratory Symptoms in Two Zambian Communities: Implications for Tuberculosis Control in the Era of HIV	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PULMONARY TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; UNDIAGNOSED TUBERCULOSIS; OUTPATIENTS; DIAGNOSIS; IMPACT	Background: The Stop TB Partnership target for tuberculosis is to have reduced the prevalence of tuberculosis by 50% comparing 2015 to 1990. This target is challenging as few prevalence surveys have been conducted, especially in high burden tuberculosis and HIV countries. Current tuberculosis control strategies in high HIV prevalent settings are therefore based on limited epidemiological evidence and more evidence is needed from community-based surveys to inform improved policy formulation. Methods and Findings: 8044 adults were sampled from 2 sub-districts (wards) in Lusaka province, Zambia. Questionnaires were used to screen for symptoms, respiratory samples were obtained for culture and oral secretions collected for HIV testing. 79 individuals were found to have Mycobacterium tuberculosis in their sputum, giving an adjusted overall prevalence of tuberculosis of 870/100,000 (95% CI 570-1160/100,000). The adjusted overall prevalence of HIV was 28.61% (95% CI 26.04-31.19). HIV-infection was significantly associated with prevalent tuberculosis (Adj OR 2.3, 95% CI 1.42-3.74) and the population attributable fraction of HIV for prevalent tuberculosis was 36%. Symptoms such as prolonged cough (adj OR 12.72, 95% CI 7.05-22.94) and fever (Adj OR 2.04, 95% CI 1.23-3.39), were associated with prevalent tuberculosis, but 8 (10%) individuals with prevalent tuberculosis denied having any symptoms at all and only 34 (43%) would have been classified as a TB suspect by current guidelines. Conclusions: Undiagnosed tuberculosis is a challenge for tuberculosis control and new approaches are needed if we are to reach international targets. Epidemiological studies can inform screening algorithms for both detection and prevention of active tuberculosis.			Ayles, H (corresponding author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.	Helen@zambart.org.zm		Ayles, Helen/0000-0003-4108-2842	Medical Research Council [G0700837] Funding Source: Medline; MRC [G0700837] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALUOCH JA, 1982, T ROY SOC TROP MED H, V76, P679, DOI 10.1016/0035-9203(82)90240-1; ALUOCH JA, 1983, E AFR MED J, V60, P360; ALUOCH JA, 1978, TUBERCLE, V59, P233, DOI 10.1016/0041-3879(78)90001-6; ALUOCH JA, 1984, AM REV RESPIR DIS, V129, P915; ALUOCH JA, 1985, TUBERCLE, V66, P237, DOI 10.1016/0041-3879(85)90061-3; ALUOCH JA, 1983, E AFR MED J, V60, P542; Ayles H, 2006, TROP DOCT, V36, P83, DOI 10.1258/004947506776593521; Bucher HC, 1999, AIDS, V13, P501, DOI 10.1097/00002030-199903110-00009; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Corbett EL, 2004, AM J RESP CRIT CARE, V170, P673, DOI 10.1164/rccm.200405-590OC; Corbett EL, 2007, PLOS MED, V4, P164, DOI 10.1371/journal.pmed.0040022; Currie CSM, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-130; den Boon S, 2007, EMERG INFECT DIS, V13, P1189, DOI 10.3201/eid1308.051327; DYE C, 2008, LANCET INFECT D 0116; ELLIOTT AM, 1993, AIDS, V7, P981, DOI 10.1097/00002030-199307000-00012; Godfrey-Faussett P, 2003, TUBERCULOSIS, V83, P68, DOI 10.1016/S1472-9792(02)00083-5; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Hernandez-Garduno E, 2004, THORAX, V59, P286, DOI 10.1136/thx.2003.011759; Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907, DOI 10.1128/JCM.35.4.907-914.1997; KLAUSNER JD, 1993, J INFECT DIS, V168, P106, DOI 10.1093/infdis/168.1.106; Mtei L, 2005, CLIN INFECT DIS, V40, P1500, DOI 10.1086/429825; Sonnenberg P, 2004, AIDS, V18, P657, DOI 10.1097/00002030-200403050-00010; *STOP TB PARTN WHO, 2006, WHOHTMSTB200635 STOP; Styblo K, 2001, INT J TUBERC LUNG D, V5, P103; United Nations, 2000, MILL DEV GOALS; van Soolingen D, 2001, Methods Mol Med, V54, P165, DOI 10.1385/1-59259-147-7:165; *WHO, 2008, TB HIV FACT SHEET; WHO, 2008, GLOBAL TUBERCULOSIS; WHO, 2004, INT POL COLL TB HIV; Wood R, 2007, AM J RESP CRIT CARE, V175, P87, DOI 10.1164/rccm.200606-759OC; World Health Organization, 2008, EP COUNTR PROF HIV A; World Health Organization, 2007, ASS TB PREV POP BAS; World Health Organization, 2006, WHOHTMTB2006362	33	99	100	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5602	10.1371/journal.pone.0005602	http://dx.doi.org/10.1371/journal.pone.0005602			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19440346	Green Published, gold, Green Accepted			2022-12-25	WOS:000266161200005
J	Ruvinsky, I; Katz, M; Dreazen, A; Gielchinsky, Y; Saada, A; Freedman, N; Mishani, E; Zimmerman, G; Kasir, J; Meyuhas, O				Ruvinsky, Igor; Katz, Maximiliano; Dreazen, Avigail; Gielchinsky, Yuval; Saada, Ann; Freedman, Nanette; Mishani, Eyal; Zimmerman, Gabriel; Kasir, Judith; Meyuhas, Oded			Mice Deficient in Ribosomal Protein S6 Phosphorylation Suffer from Muscle Weakness that Reflects a Growth Defect and Energy Deficit	PLOS ONE			English	Article							SKELETAL-MUSCLE; CELL-SIZE; MOUSE PHENOTYPE; KINASE; CONTRACTION; METABOLISM; ACTIVATION; INCREASES; DELETION; REVEALS	Background: Mice, whose ribosomal protein S6 cannot be phosphorylated due to replacement of all five phosphorylatable serine residues by alanines (rpS6(P-/-)), are viable and fertile. However, phenotypic characterization of these mice and embryo fibroblasts derived from them, has established the role of these modifications in the regulation of the size of several cell types, as well as pancreatic beta-cell function and glucose homeostasis. A relatively passive behavior of these mice has raised the possibility that they suffer from muscle weakness, which has, indeed, been confirmed by a variety of physical performance tests. Methodology/Principal Findings: A large variety of experimental methodologies, including morphometric measurements of histological preparations, high throughput proteomic analysis, positron emission tomography (PET) and numerous biochemical assays, were used in an attempt to establish the mechanism underlying the relative weakness of rpS6(P-/-) muscles. Collectively, these experiments have demonstrated that the physical inferiority appears to result from two defects: a) a decrease in total muscle mass that reflects impaired growth, rather than aberrant differentiation of myofibers, as well as a diminished abundance of contractile proteins; and b) a reduced content of ATP and phosphocreatine, two readily available energy sources. The abundance of three mitochondrial proteins has been shown to diminish in the knockin mouse. However, the apparent energy deficiency in this genotype does not result from a lower mitochondrial mass or compromised activity of enzymes of the oxidative phosphorylation, nor does it reflect a decline in insulin-dependent glucose uptake, or diminution in storage of glycogen or triacylglycerol (TG) in the muscle. Conclusions/Significance: This study establishes rpS6 phosphorylation as a determinant of muscle strength through its role in regulation of myofiber growth and energy content. Interestingly, a similar role has been assigned for ribosomal protein S6 kinase 1, even though it regulates myoblast growth in an rpS6 phosphorylation-independent fashion.			Ruvinsky, I (corresponding author), Novamed Ltd, Jerusalem, Israel.	meyuhas@cc.huji.ac.il	Ruvinsky, Igal/AAC-3348-2021; Saada, Ann/J-6864-2017	Ruvinsky, Igal/0000-0002-9741-0457; Saada, Ann/0000-0003-2951-0656				Aguilar V, 2007, CELL METAB, V5, P476, DOI 10.1016/j.cmet.2007.05.006; BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Greenberg CC, 2006, AM J PHYSIOL-ENDOC M, V291, pE1, DOI 10.1152/ajpendo.00652.2005; GRESSNER AM, 1974, J BIOL CHEM, V249, P6917; Hardie DG, 2006, J PHYSIOL-LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; HEINZ F, 1985, METHOD ENZYMAT AN, P507; Huang SH, 2007, CELL METAB, V5, P237, DOI 10.1016/j.cmet.2007.03.006; Huijing PA, 2005, SCAND J MED SCI SPOR, V15, P349, DOI 10.1111/j.1600-0838.2005.00457.x; Isfort RJ, 2000, ELECTROPHORESIS, V21, P2228, DOI 10.1002/1522-2683(20000601)21:11<2228::AID-ELPS2228>3.0.CO;2-V; Jorgensen SB, 2004, DIABETES, V53, P3074, DOI 10.2337/diabetes.53.12.3074; Kiens B, 2006, PHYSIOL REV, V86, P205, DOI 10.1152/physrev.00023.2004; Kim TS, 2006, MOL BIOL CELL, V17, P824, DOI 10.1091/mbc.E05-08-0713; Kim YB, 2005, MOL CELL BIOL, V25, P9713, DOI 10.1128/MCB.25.21.9713-9723.2005; Le Grand F, 2007, DEVELOPMENT, V134, P3953, DOI 10.1242/dev.005934; Lee CH, 2007, ANNU REV PHARMACOL, V47, P443, DOI 10.1146/annurev.pharmtox.47.120505.105359; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malicdan MCV, 2008, PHYSIOL GENOMICS, V35, P106, DOI 10.1152/physiolgenomics.90219.2008; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Meyuhas O, 2008, INT REV CEL MOL BIO, V268, P1, DOI 10.1016/S1937-6448(08)00801-0; Ohanna M, 2005, NAT CELL BIOL, V7, P286, DOI 10.1038/ncb1231; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Piec I, 2005, FASEB J, V19, P1143, DOI 10.1096/fj.04-3084fje; Reisch AS, 2007, METHOD CELL BIOL, V80, P199, DOI 10.1016/S0091-679X(06)80010-5; Richardson MK, 2004, EVOL DEV, V6, P1, DOI 10.1111/j.1525-142X.2004.04008.x; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Sakamoto K, 2006, AM J PHYSIOL-ENDOC M, V291, pE1031, DOI 10.1152/ajpendo.00204.2006; Schumacher AM, 2006, BIOCHEMISTRY-US, V45, P13614, DOI 10.1021/bi060413y; Shearer J, 2005, AM J PHYSIOL-ENDOC M, V289, pE508, DOI 10.1152/ajpendo.00100.2005; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Trautschold I., 1985, METHODS ENZYMATIC AN, V3rd, P346; TULINIUS MH, 1991, J PEDIATR-US, V119, P242, DOI 10.1016/S0022-3476(05)80734-6; Watchko JF, 1996, PEDIATR RES, V40, P53, DOI 10.1203/00006450-199607000-00010; Wijers SLJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001777; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	47	69	69	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5618	10.1371/journal.pone.0005618	http://dx.doi.org/10.1371/journal.pone.0005618			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19479038	Green Published, Green Submitted, gold			2022-12-25	WOS:000266161200018
J	Montero, JC; Ocana, A; Abad, M; Ortiz-Ruiz, MJ; Pandiella, A; Esparis-Ogando, A				Carlos Montero, Juan; Ocana, Alberto; Abad, Mar; Jesus Ortiz-Ruiz, Maria; Pandiella, Atanasio; Esparis-Ogando, Azucena			Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target	PLOS ONE			English	Article								Background: Breast cancer is the most common neoplasia in women. Even though advances in its treatment have improved disease outcome, some patients relapse. Therefore, attempts to better define the molecular determinants that drive breast cancer cell proliferation may help in defining potential therapeutic targets. Mitogen-activated protein kinases (MAPK) play important roles in tumorigenesis. One of them, Erk5, has been linked to the proliferation of breast cancer cells in vitro. Here we have investigated the expression and prognostic value of Erk5 in human breast cancer. Methodology/Principal Findings: Animal and cellular models were used to study Erk5 expression and function in breast cancer. In 84 human breast tumours the expression of Erk5 was analyzed by immunohistochemistry. Active Erk5 (pErk5) was studied by Western blotting. Correlation of Erk5 with clinicopathological parameters and with disease-free survival in early stage breast cancer patients was analyzed. Expression of Erk5 was detected in most patients, and overexpression was found in 20%. Active Erk5 was present in a substantial number of samples, as well as in tumours from an animal breast cancer model. Overexpression of Erk5 was associated with a decrease in disease-free survival time, which was independent of other clinicopathological parameters of prognosis. Transient transfection of a short hairpin RNA (shRNA) targeting Erk5, and a stable cell line expressing a dominant negative form of Erk5 (Erk5(AEF)), were used to investigate the influence of Erk5 on drugs used in the clinic to treat breast tumours. We found that inhibition of Erk5 decreased cancer cell proliferation and also sensitized these cells to the action of anti-HER2 therapies. Conclusions/Significance: Overexpression of Erk5 is an independent predictor of disease-free survival in breast cancer, and may represent a future therapeutic target.			Montero, JC (corresponding author), Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, E-37008 Salamanca, Spain.	esparis@usal.es	2009, Secribsal/A-1266-2012; Esparís-Ogando, Aucena/O-5326-2017; Pandiella, Atanasio/O-5180-2014; Montero, Juan Carlos/AAO-1780-2020	Esparís-Ogando, Aucena/0000-0003-4550-4192; Pandiella, Atanasio/0000-0002-4704-8971; Montero, Juan Carlos/0000-0003-4773-053X; Ocana, Alberto/0000-0002-1067-9630				Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; AMERICAN CANCER SOCIETY, 2007, CANC FACTS FIG; Baselga J, 2006, ONCOLOGIST, V11, P4, DOI 10.1634/theoncologist.11-90001-4; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; Carvajal-Vergara X, 2005, BLOOD, V105, P4492, DOI 10.1182/blood-2004-08-2985; de Alava E, 2007, J CLIN ONCOL, V25, P2656, DOI 10.1200/JCO.2006.08.6850; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Garaude J, 2006, J IMMUNOL, V177, P7607, DOI 10.4049/jimmunol.177.11.7607; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Hayashi M, 2005, CANCER RES, V65, P7699, DOI 10.1158/0008-5472.CAN-04-4540; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Ocana A, 2008, CLIN CANCER RES, V14, P961, DOI 10.1158/1078-0432.CCR-07-1630; Oshima RG, 2004, CANCER RES, V64, P169, DOI 10.1158/0008-5472.CAN-03-1944; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Wang X, 2006, CELL SIGNAL, V18, P753, DOI 10.1016/j.cellsig.2005.11.003; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143	21	74	81	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5565	10.1371/journal.pone.0005565	http://dx.doi.org/10.1371/journal.pone.0005565			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440538	Green Submitted, Green Published, gold			2022-12-25	WOS:000266107400009
J	Perales, C; Agudo, R; Domingo, E				Perales, Celia; Agudo, Ruben; Domingo, Esteban			Counteracting Quasispecies Adaptability: Extinction of a Ribavirin-Resistant Virus Mutant by an Alternative Mutagenic Treatment	PLOS ONE			English	Article							HEPATITIS-C VIRUS; MOUTH-DISEASE VIRUS; DEPENDENT RNA-POLYMERASE; HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL-RNA; ERROR CATASTROPHE; LETHAL MUTAGENESIS; ANTIVIRAL ACTIVITY; DRUG-RESISTANCE; INCREASED FIDELITY	Background: Lethal mutagenesis, or virus extinction promoted by mutagen-induced elevation of mutation rates of viruses, may meet with the problem of selection of mutagen-resistant variants, as extensively documented for standard, non-mutagenic antiviral inhibitors. Previously, we characterized a mutant of foot-and-mouth disease virus that included in its RNA-dependent RNA polymerase replacement M296I that decreased the sensitivity of the virus to the mutagenic nucleoside analogue ribavirin. Methodology and Principal Findings: Replacement M296I in the viral polymerase impedes the extinction of the mutant foot-and-mouth disease virus by elevated concentrations of ribavirin. In contrast, wild type virus was extinguished by the same ribavirin treatment and, interestingly, no mutants resistant to ribavirin were selected from the wild type populations. Decreases of infectivity and viral load of the ribavirin-resistant M296I mutant were attained with a combination of the mutagen 5-fluorouracil and the non-mutagenic inhibitor guanidine hydrocloride. However, extinction was achieved with a sequential treatment, first with ribavirin, and then with a minimal dose of 5-fluorouracil in combination with guanidine hydrochloride. Both, wild type and ribavirin-resistant mutant M296I exhibited equal sensitivity to this combination, indicating that replacement M296I in the polymerase did not confer a significant cross-resistance to 5-fluorouracil. We discuss these results in relation to antiviral designs based on lethal mutagenesis. Conclusions: (i) When dominant in the population, a mutation that confers partial resistance to a mutagenic agent can jeopardize virus extinction by elevated doses of the same mutagen. (ii)A wild type virus, subjected to identical high mutagenic treatment, need not select a mutagen-resistant variant, and the population can be extinguished. (iii) Extinction of the mutagen-resistant variant can be achieved by a sequential treatment of a high dose of the same mutagen, followed by a combination of another mutagen with an antiviral inhibitor.			Perales, C (corresponding author), UAM, CSIC, Ctr Biol Mol Severo Ochoa, Campus Cantoblanco, Madrid, Spain.	edomingo@cbm.uam.es	Agudo Torres, Rubén/K-9173-2017; Domingo, Esteban/K-3937-2014	Domingo, Esteban/0000-0002-0573-1676; Perales Viejo, Celia Belen/0000-0003-1618-1937; Agudo Torres, Ruben/0000-0002-4784-3318				Agudo R, 2008, J MOL BIOL, V382, P652, DOI 10.1016/j.jmb.2008.07.033; Airaksinen A, 2003, VIROLOGY, V311, P339, DOI 10.1016/S0042-6822(03)00144-2; Anderson JP, 2004, ANNU REV MICROBIOL, V58, P183, DOI 10.1146/annurev.micro.58.030603.123649; Arias A, 2008, J VIROL, V82, P12346, DOI 10.1128/JVI.01297-08; Arnold JJ, 2005, J BIOL CHEM, V280, P25706, DOI 10.1074/jbc.M503444200; Asahina Y, 2005, J HEPATOL, V43, P623, DOI 10.1016/j.jhep.2005.05.032; Belsham GJ, 2008, J GEN VIROL, V89, P485, DOI 10.1099/vir.0.83385-0; Bonhoeffer S, 1997, P NATL ACAD SCI USA, V94, P6971, DOI 10.1073/pnas.94.13.6971; Bull JJ, 2008, ORIGIN AND EVOLUTION OF VIRUSES, 2ND EDITION, P207, DOI 10.1016/B978-0-12-374153-0.00009-6; Castro C, 2005, VIRUS RES, V107, P141, DOI 10.1016/j.virusres.2004.11.004; Chevaliez S, 2007, J VIROL, V81, P7732, DOI 10.1128/JVI.00382-07; CONNOR E, 1993, ANTIMICROB AGENTS CH, V37, P532, DOI 10.1128/AAC.37.3.532; *CONS PAN, 2002, HEPATOLOGY, V36, pS3; Contreras AM, 2002, J VIROL, V76, P8505, DOI 10.1128/JVI.76.17.8505-8517.2002; Crotty S, 2000, NAT MED, V6, P1375, DOI 10.1038/82191; Crotty S, 2002, J MOL MED, V80, P86, DOI 10.1007/s00109-001-0308-0; Crotty S, 2001, P NATL ACAD SCI USA, V98, P6895, DOI 10.1073/pnas.111085598; Cubero M, 2008, VIROLOGY, V370, P237, DOI 10.1016/j.virol.2007.10.006; DELATORRE JC, 1987, J VIROL, V61, P233, DOI 10.1128/JVI.61.1.233-235.1987; Dixit NM, 2004, NATURE, V432, P922, DOI 10.1038/nature03153; Domingo E, 2005, VIRUS RES, V107, P115, DOI 10.1016/j.virusres.2004.11.001; Domingo E, 2005, VIRUS RES, V107, P129, DOI 10.1016/j.virusres.2004.11.003; DOMINGO E, 1980, GENE, V11, P333, DOI 10.1016/0378-1119(80)90073-6; Domingo E, 1989, Prog Drug Res, V33, P93; Domingo E., 2006, CURRENT TOPICS MICRO, VVolume 299; Domingo E, 2008, EXPERT OPIN BIOL TH, V8, P1455, DOI 10.1517/14712598.8.10.1455 ; Domingo E, 2008, ORIGIN AND EVOLUTION OF VIRUSES, 2ND EDITION, P87, DOI 10.1016/B978-0-12-374153-0.00004-7; Drake JW, 1999, P NATL ACAD SCI USA, V96, P13910, DOI 10.1073/pnas.96.24.13910; Escarmis C, 1999, J MOL BIOL, V285, P495, DOI 10.1006/jmbi.1998.2366; Escarmis C, 2002, J MOL BIOL, V315, P647, DOI 10.1006/jmbi.2001.5259; Escarmis C, 1996, J MOL BIOL, V264, P255, DOI 10.1006/jmbi.1996.0639; Escarmis C, 2008, J MOL BIOL, V376, P367, DOI 10.1016/j.jmb.2007.11.042; Ferrer-Orta C, 2006, CURR OPIN STRUC BIOL, V16, P27, DOI 10.1016/j.sbi.2005.12.002; Ferrer-Orta C, 2004, J BIOL CHEM, V279, P47212, DOI 10.1074/jbc.M405465200; Ferrer-Orta C, 2007, P NATL ACAD SCI USA, V104, P9463, DOI 10.1073/pnas.0700518104; Figlerowicz M, 2003, MED RES REV, V23, P488, DOI 10.1002/med.10045; Freistadt MS, 2004, DRUG RESIST UPDATE, V7, P19, DOI 10.1016/j.drup.2003.12.003; Garcia-Arriaza J, 2004, J VIROL, V78, P11678, DOI 10.1128/JVI.78.21.11678-11685.2004; Garcia-Arriaza J, 2006, J MOL BIOL, V360, P558, DOI 10.1016/j.jmb.2006.05.027; Ghoshal K, 1997, BIOCHEM PHARMACOL, V53, P1569, DOI 10.1016/S0006-2952(97)00040-3; GILBERT BE, 1986, ANTIMICROB AGENTS CH, V30, P201, DOI 10.1128/AAC.30.2.201; Gonzalez-Lopez C, 2004, J VIROL, V78, P3319, DOI 10.1128/JVI.78.7.3319-3324.2004; Gonzalez-Lopez Claudia, 2005, Infection Genetics and Evolution, V5, P366, DOI 10.1016/j.meegid.2005.05.001; Graci JD, 2006, REV MED VIROL, V16, P37, DOI 10.1002/rmv.483; Graci JD, 2002, VIROLOGY, V298, P175, DOI 10.1006/viro.2002.1487; Grande-Perez A, 2005, P NATL ACAD SCI USA, V102, P4448, DOI 10.1073/pnas.0408871102; HANLEY KH, 2008, ORIGIN EVOLUTION VIR; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255; HOLLAND JJ, 1990, J VIROL, V64, P3960, DOI 10.1128/JVI.64.8.3960-3962.1990; Hong Z, 2003, HEPATOLOGY, V38, P807, DOI 10.1053/jhep.2003.50464; Johnson JA, 2008, PLOS MED, V5, P1112, DOI 10.1371/journal.pmed.0050158; Kanda T, 2004, J VIRAL HEPATITIS, V11, P479, DOI 10.1111/j.1365-2893.2004.00531.x; Kuntzen T, 2008, HEPATOLOGY, V48, P1769, DOI 10.1002/hep.22549; Lanford RE, 2001, J VIROL, V75, P8074, DOI 10.1128/JVI.75.17.8074-8081.2001; LE MV, 2002, AIDS, V16, P21; Lutchman G, 2007, GASTROENTEROLOGY, V132, P1757, DOI 10.1053/j.gastro.2007.03.035; Maag D, 2001, J BIOL CHEM, V276, P46094, DOI 10.1074/jbc.C100349200; Meng XJ, 2000, VET MICROBIOL, V74, P309, DOI 10.1016/S0378-1135(00)00196-6; Muller V, 2008, ORIGIN AND EVOLUTION OF VIRUSES, 2ND EDITION, P279, DOI 10.1016/B978-0-12-374153-0.00014-X; NAJERA I, 1994, AIDS RES HUM RETROV, V10, P1479, DOI 10.1089/aid.1994.10.1479; NAJERA I, 1995, J VIROL, V69, P23; Nijhuis M., 2009, V189, P299, DOI 10.1007/978-3-540-79086-0_11; NOVELLA IS, 1995, P NATL ACAD SCI USA, V92, P5841, DOI 10.1073/pnas.92.13.5841; OGLE JW, 1989, J INFECT DIS, V159, P748, DOI 10.1093/infdis/159.4.748; PAGE T, 1990, INT J BIOCHEM, V22, P379, DOI 10.1016/0020-711X(90)90140-X; Pariente N, 2005, VIRUS RES, V107, P183, DOI 10.1016/j.virusres.2004.11.008; Pariente N, 2003, J VIROL, V77, P7131, DOI 10.1128/JVI.77.12.7131-7138.2003; Pariente N, 2001, J VIROL, V75, P9723, DOI 10.1128/JVI.75.20.9723-9730.2001; PARK JH, 1990, INT J GERIATR PSYCH, V5, P381, DOI 10.1002/gps.930050606; Parker WB, 2005, VIRUS RES, V107, P165, DOI 10.1016/j.virusres.2004.11.006; Perales C, 2007, J MOL BIOL, V369, P985, DOI 10.1016/j.jmb.2007.03.074; Perelson AS, 2007, GASTROENTEROLOGY, V132, P2050, DOI 10.1053/j.gastro.2007.03.077; Pfeiffer JK, 2003, P NATL ACAD SCI USA, V100, P7289, DOI 10.1073/pnas.1232294100; Pfeiffer JK, 2005, J VIROL, V79, P2346, DOI 10.1128/JVI.79.4.2346-2355.2005; Pfeiffer JK, 2005, PLOS PATHOG, V1, P102, DOI 10.1371/journal.ppat.0010011; PINCUS SE, 1986, J VIROL, V60, P793, DOI 10.1128/JVI.60.2.793-796.1986; Quer J, 2008, ORIGIN AND EVOLUTION OF VIRUSES, 2ND EDITION, P303, DOI 10.1016/B978-0-12-374153-0.00015-1; Sanz-Ramos M, 2008, J VIROL, V82, P10465, DOI 10.1128/JVI.00825-08; SCHEIDEL LM, 1987, VIROLOGY, V158, P1, DOI 10.1016/0042-6822(87)90230-3; Sierra M, 2007, J VIROL, V81, P2012, DOI 10.1128/JVI.01606-06; Sierra S, 2000, J VIROL, V74, P8316, DOI 10.1128/JVI.74.18.8316-8323.2000; Smidansky ED, 2008, ORIGIN AND EVOLUTION OF VIRUSES, 2ND EDITION, P135, DOI 10.1016/B978-0-12-374153-0.00006-0; Snell N J, 2001, Expert Opin Pharmacother, V2, P1317, DOI 10.1517/14656566.2.8.1317; SOBRINO F, 1983, VIROLOGY, V128, P310, DOI 10.1016/0042-6822(83)90258-1; Van Vaerenbergh K, 2002, AIDS RES HUM RETROV, V18, P419, DOI 10.1089/088922202753614182; Vignuzzi M, 2006, NATURE, V439, P344, DOI 10.1038/nature04388; Vignuzzi M, 2008, NAT MED, V14, P154, DOI 10.1038/nm1726; Villarreal LP, 2008, ORIGIN AND EVOLUTION OF VIRUSES, 2ND EDITION, P477, DOI 10.1016/B978-0-12-374153-0.00021-7; Vo NV, 2003, BIOCHEMISTRY-US, V42, P10462, DOI 10.1021/bi0344681; Young KC, 2003, HEPATOLOGY, V38, P869, DOI 10.1053/jhep.2003.50445; Zhang YH, 2003, J VIROL, V77, P5933, DOI 10.1128/JVI.77.10.5933-5947.2003; Zhou SF, 2003, VIROLOGY, V310, P333, DOI 10.1016/S0042-6822(03)00152-1	93	31	31	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2009	4	5							e5554	10.1371/journal.pone.0005554	http://dx.doi.org/10.1371/journal.pone.0005554			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FX	19436746	Green Published, gold, Green Submitted			2022-12-25	WOS:000266107300018
J	Chung, S; Furihata, M; Tamura, K; Uemura, M; Daigo, Y; Nasu, Y; Miki, T; Shuin, T; Fujioka, T; Nakamura, Y; Nakagawa, H				Chung, S.; Furihata, M.; Tamura, K.; Uemura, M.; Daigo, Y.; Nasu, Y.; Miki, T.; Shuin, T.; Fujioka, T.; Nakamura, Y.; Nakagawa, H.			Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways	ONCOGENE			English	Article						CRPC; PKIB; protein kinase A; Akt phosphorylation	DEPENDENT PROTEIN-KINASE; REGULATORY SUBUNITS; SIGNAL-TRANSDUCTION; ANDROGEN RECEPTOR; CATALYTIC SUBUNIT; GENE-EXPRESSION; PHOSPHORYLATION; CAMP; MITOXANTRONE; PREDNISONE	Prostate cancer (PC) is the most common malignancy in males. Despite high response rates and clinical benefits, androgen-ablation therapy is ineffective for advanced or relapsed PC because of the emergence of aggressive castration-resistant prostate cancer (CRPC). Through our genome-wide gene expression analysis of PC cells purified from clinical CRPC tissues, we here identified a novel molecular target, PKIB (cAMP-dependent protein kinase inhibitor-beta), which was overexpressed specifically in CRPCs and aggressive PCs. Immunohistochemical analysis confirmed its overexpression in CRPCs and its strong correlation with high Gleason scores of PCs. Knockdown of PKIB by siRNA resulted in drastic growth suppression of PC cells, and, concordantly, exogenous introduction of PKIB into PC cells enhanced their growth and mobility. We found the direct interaction between PKIB and cAMP-dependent protein kinase A catalytic subunit (PKA-C), and showed that knockdown of PKIB in PC cells diminished the nuclear translocation of PKA-C. Knockdown of PKIB also decreased the phosphorylation level of Akt at Ser473 in PC cells, and exogenous PKIB introduction enhanced Akt phosphorylation in PC cells by incorporating with endogenous PKA-C kinase. In vitro kinase assay validated the recombinant PKIB enhanced phosphorylation of Akt at Ser473 by PKA-C kinase. These findings show that PKIB and PKA-C kinase can have critical functions of aggressive phenotype of PCs through Akt phosphorylation and that they should be a promising molecular target for PC treatment. Oncogene (2009) 28, 2849-2859; doi:10.1038/onc.2009.144; published online 1 June 2009	[Nakagawa, H.] RIKEN, Ctr Genom Med, Lab Biomarker Dev, Minato Ku, Tokyo 1088639, Japan; [Chung, S.; Tamura, K.; Uemura, M.; Daigo, Y.; Nakamura, Y.; Nakagawa, H.] Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome, Tokyo, Japan; [Furihata, M.] Kochi Med Sch, Dept Pathol, Nankoku, Kochi, Japan; [Tamura, K.; Shuin, T.] Kochi Med Sch, Dept Urol, Nankoku, Kochi, Japan; [Nasu, Y.] Okayama Univ, Sch Med, Dept Urol, Okayama 700, Japan; [Miki, T.] Kyoto Prefectural Univ Med, Dept Urol, Kyoto, Japan; [Fujioka, T.] Iwate Med Univ, Dept Urol, Morioka, Iwate 020, Japan	RIKEN; University of Tokyo; Kochi University; Kochi University; Okayama University; Kyoto Prefectural University of Medicine; Iwate Medical University	Nakagawa, H (corresponding author), RIKEN, Ctr Genom Med, Lab Biomarker Dev, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	hidewaki@ims.u-tokyo.ac.jp	uemura, motohide/G-6101-2011	Daigo, Yataro/0000-0002-0915-3025	Japan Society for the Promotion of Science [18590323, 00L01402]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We would like to thank Ms Mami U and Ms Hitomi Uchida for their technical assistance, and Dr Ryo Takada at Iwate Medical University for his preparation of prostate cancer tissues. This work was supported by Grant-in-Aid for Scientific Research #18590323 (H Nakagawa) and Research for the Future Program Grants #00L01402 (Y Nakamura) from the Japan Society for the Promotion of Science.	Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Chio CC, 2004, CELL SIGNAL, V16, P565, DOI 10.1016/j.cellsig.2003.10.003; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Dalton GD, 2006, NEUROPEPTIDES, V40, P23, DOI 10.1016/j.npep.2005.10.002; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deeble PD, 2007, CANCER RES, V67, P3663, DOI 10.1158/0008-5472.CAN-06-2616; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Filippa N, 1999, MOL CELL BIOL, V19, P4989; GAMM DM, 1995, J BIOL CHEM, V270, P7227, DOI 10.1074/jbc.270.13.7227; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hsing AW, 2001, EPIDEMIOL REV, V23, P3, DOI 10.1093/oxfordjournals.epirev.a000792; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; LALLI E, 1994, J BIOL CHEM, V269, P17359; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Malik SN, 2002, CLIN CANCER RES, V8, P1168; McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869; Miller WR, 2002, ANN NY ACAD SCI, V968, P37, DOI 10.1111/j.1749-6632.2002.tb04325.x; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Orloff MS, 2008, ONCOGENE, V27, P5387, DOI 10.1038/onc.2008.237; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Tamura K, 2007, CANCER RES, V67, P5117, DOI 10.1158/0008-5472.CAN-06-4040; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Taylor SS, 2005, BBA-PROTEINS PROTEOM, V1754, P25, DOI 10.1016/j.bbapap.2005.08.024; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WEN W, 1994, J BIOL CHEM, V269, P32214; Wiley JC, 1999, J BIOL CHEM, V274, P6381, DOI 10.1074/jbc.274.10.6381	38	25	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2849	2859		10.1038/onc.2009.144	http://dx.doi.org/10.1038/onc.2009.144			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19483721				2022-12-25	WOS:000268917100001
J	Shi, ZC; Cai, ZY; Wen, S; Chen, CY; Gendron, C; Sanchez, A; Patterson, K; Fu, SB; Yang, J; Wildman, D; Finnell, RH; Zhang, DK				Shi, Zhongcheng; Cai, Zhenyu; Wen, Shu; Chen, Caoyi; Gendron, Christi; Sanchez, Amir; Patterson, Kevin; Fu, Songbin; Yang, Jianhua; Wildman, Derek; Finnell, Richard H.; Zhang, Dekai			Transcriptional Regulation of the Novel Toll-like Receptor Tlr13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INNATE IMMUNITY; MACROPHAGE DIFFERENTIATION; GENE-EXPRESSION; ACTIVATION; PROMOTER; ETS; PU.1; RECOGNITION; MONOCYTES	Little has been known about Tlr13 (Toll-like receptor 13), a novel member of the Toll-like receptor family. To elucidate the molecular basis of murine Tlr13 gene expression, the activity of the Tlr13 gene promoter was characterized. Reporter gene analysis and electrophoretic mobility shift assays demonstrated that Tlr13 gene transcription was regulated through three cis-acting elements that interacted with the Ets2, Sp1, and PU.1 transcription factors. Furthermore, our work suggests that these transcription factors may cooperate, culminating in maximal transcription of the Tlr13 gene. In contrast, NF-kappa B appeared to act as an inhibitor of Tlr13 transcription. Overexpression of Ets2 caused a strong increase in the transcriptional activity of the Tlr13 promoter; however, overexpression of NF-kappa B p65 dramatically inhibited it. Additionally, interferon-beta is capable of acting Tlr13 transcription, but the activated signaling of lipopolysaccharide/TLR4 and peptidoglycan/TLR2 strongly inhibited the Tlr13 gene promoter. Thus, these findings reveal the mechanism of Tlr13 gene regulation, thereby providing insight into the function of Tlr13 in the immune response to pathogen.	[Shi, Zhongcheng; Cai, Zhenyu; Gendron, Christi; Sanchez, Amir; Patterson, Kevin; Zhang, Dekai] Texas A&M Univ, Hlth Sci Ctr, Ctr Infect & Inflammatory Dis, Houston, TX 77030 USA; [Wen, Shu; Finnell, Richard H.] Texas A&M Univ, Hlth Sci Ctr, Ctr Environm & Genet Med, Inst Biosci & Technol, Houston, TX 77030 USA; [Chen, Caoyi; Wildman, Derek] Wayne State Univ, Dept Med & Mol Genet, Detroit, MI 48201 USA; [Shi, Zhongcheng; Fu, Songbin] Harbin Med Coll, Med Genet Lab, Harbin 150081, Peoples R China; [Yang, Jianhua] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Wayne State University; Harbin Medical University; Baylor College of Medicine	Zhang, DK (corresponding author), 2121 W Holcombe Blvd, Houston, TX 77030 USA.	dzhang@ibt.tamhsc.edu	Finnell, Richard/D-8174-2018	Finnell, Richard/0000-0002-5962-8754; Wildman, Derek/0000-0002-6374-5136	National Institutes of Health [AI072263]; Texas A&M University Health Science Center; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI072263] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Texas A&M University Health Science Center; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported, in whole or in part, by National Institutes of Health Grant AI072263. This work was also supported by the Texas A&M University Health Science Center.	Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Anderson A F, 2000, Am J Knee Surg, V13, P19; Andreakos E, 2004, IMMUNOL REV, V202, P250, DOI 10.1111/j.0105-2896.2004.00202.x; Armstrong L, 2004, CLIN EXP IMMUNOL, V136, P312, DOI 10.1111/j.1365-2249.2004.02433.x; Beutler B, 2002, CURR OPIN HEMATOL, V9, P2, DOI 10.1097/00062752-200201000-00002; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Bowie AG, 2008, NAT IMMUNOL, V9, P348, DOI 10.1038/ni0408-348; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; Haehnel V, 2002, J IMMUNOL, V168, P5629, DOI 10.4049/jimmunol.168.11.5629; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Iwahashi M, 2004, ARTHRITIS RHEUM-US, V50, P1457, DOI 10.1002/art.20219; Janeway CA, 1999, CURR BIOL, V9, pR879, DOI 10.1016/S0960-9822(00)80073-1; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; JIN DI, 1995, MOL CELL BIOL, V15, P693; Johnson CM, 2007, J BIOL CHEM, V282, P31197, DOI 10.1074/jbc.M705151200; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Kim YM, 2008, NATURE, V452, P234, DOI 10.1038/nature06726; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Ma XJ, 1996, ANN NY ACAD SCI, V795, P357, DOI 10.1111/j.1749-6632.1996.tb52692.x; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; MEDZHITOV R, 1997, NATURE, V388, P397; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; Rees LEN, 2002, CELL MOL LIFE SCI, V59, P560, DOI 10.1007/s00018-002-8448-0; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; Roach JC, 2005, P NATL ACAD SCI USA, V102, P9577, DOI 10.1073/pnas.0502272102; Sevilla L, 2001, J BIOL CHEM, V276, P17800, DOI 10.1074/jbc.M008270200; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shibata Y, 2001, IMMUNITY, V15, P557, DOI 10.1016/S1074-7613(01)00218-7; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Tabeta K, 2006, NAT IMMUNOL, V7, P156, DOI 10.1038/ni1297; Takeshita F, 2004, J IMMUNOL, V173, P2552, DOI 10.4049/jimmunol.173.4.2552; Totemeyer S, 2003, INFECT IMMUN, V71, P6653, DOI 10.1128/IAI.71.11.6653-6657.2003; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; Wang TY, 2001, J IMMUNOL, V167, P6924, DOI 10.4049/jimmunol.167.12.6924; Wei G, 2004, J IMMUNOL, V173, P1374, DOI 10.4049/jimmunol.173.2.1374; Yarovinsky F, 2005, SCIENCE, V308, P1626, DOI 10.1126/science.1109893; Zaldumbide A, 2002, J IMMUNOL, V169, P4873, DOI 10.4049/jimmunol.169.9.4873; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351; Zhang DK, 2001, CANCER RES, V61, P6899	48	25	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20540	20547		10.1074/jbc.M109.022541	http://dx.doi.org/10.1074/jbc.M109.022541			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19487701	Green Published, hybrid			2022-12-25	WOS:000268316100015
J	He, H; Li, W; Tseng, DY; Zhang, S; Chen, SY; Day, AJ; Tseng, SCG				He, Hua; Li, Wei; Tseng, David Y.; Zhang, Shan; Chen, Szu-Yu; Day, Anthony J.; Tseng, Scheffer C. G.			Biochemical Characterization and Function of Complexes Formed by Hyaluronan and the Heavy Chains of Inter-alpha-inhibitor (HC.HA) Purified from Extracts of Human Amniotic Membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-STIMULATED GENE-6; TUBULAR EPITHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; TRYPSIN INHIBITOR; EXTRACELLULAR-MATRIX; LINK MODULE; MYOFIBROBLAST DIFFERENTIATION; CHROMOSOMAL LOCALIZATION; OOCYTE COMPLEXES; BINDING-PROTEINS	Clinically, amniotic membrane (AM) suppresses inflammation, scarring, and angiogenesis. AM contains abundant hyaluronan (HA) but its function in exerting these therapeutic actions remains unclear. Herein, AM was extracted sequentially with buffers A, B, and C, or separately by phosphate-buffered saline (PBS) alone. Agarose gel electrophoresis showed that high molecular weight (HMW) HA (an average of similar to 3000 kDa) was predominantly extracted in isotonic Extract A (70.1 +/- 6.0%) and PBS (37.7 +/- 3.2%). Western blot analysis of these extracts with hyaluronidase digestion or NaOH treatment revealed that HMW HA was covalently linked with the heavy chains (HCs) of inter-alpha-inhibitor (I alpha I) via a NaOH-sensitive bond, likely transferred by the tumor necrosis factor-alpha stimulated gene-6 protein (TSG-6). This HC.HA complex (nHC.HA) could be purified from Extract PBS by two rounds of CsCl/guanidine HCl ultracentrifugation as well as in vitro reconstituted (rcHC.HA) by mixing HMW HA, serum I alpha I, and recombinant TSG-6. Consistent with previous reports, Extract PBS suppressed transforming growth factor-beta 1 promoter activation in corneal fibroblasts and induced macrophage apoptosis. However, these effects were abolished by hyaluronidase digestion or heat treatment. More importantly, the effects were retained in the nHC.HA or rcHC.HA. These data collectively suggest that the HC.HA complex is the active component in AM responsible in part for clinically observed anti-inflammatory and anti-scarring actions.	[He, Hua; Li, Wei; Zhang, Shan; Chen, Szu-Yu; Tseng, Scheffer C. G.] TissueTech Inc, Miami, FL 33173 USA; [He, Hua; Li, Wei; Zhang, Shan; Chen, Szu-Yu; Tseng, Scheffer C. G.] Ocular Surface Ctr, Miami, FL 33173 USA; [Tseng, David Y.] Ocular Surface Res Educ Fdn, Miami, FL 33173 USA; [Day, Anthony J.] Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Day, AJ (corresponding author), Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	anthony.day@manchester.ac.uk; stseng@ocularsurface.com	Day, Anthony/O-1658-2015; Li, Wei/P-8985-2015	Day, Anthony/0000-0002-1415-3134; Li, Wei/0000-0001-7458-2590	National Institutes of Health [R01 EY06819, EY15735]; NEI; TissueTech, Inc.; Ocular Surface Research & Education Foundation, Miami, FL; Medical Research Council [MC_U138274352] Funding Source: researchfish; MRC [MC_U138274352] Funding Source: UKRI; NATIONAL EYE INSTITUTE [R01EY006819, R01EY015735] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NEI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); TissueTech, Inc.; Ocular Surface Research & Education Foundation, Miami, FL; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported, in whole or in part, by National Institutes of Health Grants R01 EY06819 and EY15735 (to S. C. G. T.) from the NEI. This work was also supported by a research grant from TissueTech, Inc. and an unrestricted grant from Ocular Surface Research & Education Foundation, Miami, FL.	ADZICK NS, 1991, CLIN EXPT APPROACHES; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Banerji S, 2007, NAT STRUCT MOL BIOL, V14, P234, DOI 10.1038/nsmb1201; Blom AM, 1999, J BIOL CHEM, V274, P298, DOI 10.1074/jbc.274.1.298; Bouchard Charles S, 2004, Ocul Surf, V2, P201; Carrette O, 2001, BIOL REPROD, V65, P301, DOI 10.1095/biolreprod65.1.301; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; Day AJ, 2005, TRENDS IMMUNOL, V26, P637, DOI 10.1016/j.it.2005.09.009; Dua HS, 2004, SURV OPHTHALMOL, V49, P51, DOI 10.1016/j.survophthal.2003.10.004; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; Espana EM, 2004, INVEST OPHTH VIS SCI, V45, P2985, DOI 10.1167/iovs.04-0201; Forteza R, 2007, AM J RESP CELL MOL, V36, P20, DOI 10.1165/rcmb.2006-0018OC; Frost GI, 1997, ANAL BIOCHEM, V251, P263, DOI 10.1006/abio.1997.2262; Fujimoto T, 2002, AM J PATHOL, V160, P1495, DOI 10.1016/S0002-9440(10)62575-8; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Getting SJ, 2002, J BIOL CHEM, V277, P51068, DOI 10.1074/jbc.M205121200; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; HARDINGHAM TE, 1972, BIOCHEM J, V126, P791, DOI 10.1042/bj1260791; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; He H, 2008, INVEST OPHTH VIS SCI, V49, P4468, DOI 10.1167/iovs.08-1781; Heng BC, 2008, J BIOL CHEM, V283, P32294, DOI 10.1074/jbc.M804155200; Higa K, 2005, CORNEA, V24, P206, DOI 10.1097/01.ico.0000133999.45262.83; HOLMES MWA, 1988, BIOCHEM J, V250, P435, DOI 10.1042/bj2500435; HUANG L, 1993, J BIOL CHEM, V268, P26725; Ito T, 2004, J BIOL CHEM, V279, P25326, DOI 10.1074/jbc.M403135200; Ito T, 2004, AM J PATHOL, V164, P1979, DOI 10.1016/S0002-9440(10)63758-3; JESSEN TE, 1994, BIOL CHEM H-S, V375, P521, DOI 10.1515/bchm3.1994.375.8.521; Jessen TE, 2003, REPRODUCTION, V125, P27, DOI 10.1530/rep.0.1250027; Kawakita T, 2005, J BIOL CHEM, V280, P27085, DOI 10.1074/jbc.M409567200; Kawakita T, 2006, INVEST OPHTH VIS SCI, V47, P1918, DOI 10.1167/iovs.05-1040; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Lee SB, 2000, CURR EYE RES, V20, P325, DOI 10.1076/0271-3683(200004)20:4;1-5;FT325; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; Lesley J, 2004, J BIOL CHEM, V279, P25745, DOI 10.1074/jbc.M313319200; Li W, 2006, EXP EYE RES, V82, P282, DOI 10.1016/j.exer.2005.06.022; Li W, 2008, J CELL PHYSIOL, V215, P657, DOI 10.1002/jcp.21345; MAST BA, 1992, SURG GYNECOL OBSTET, V174, P441; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Meinert M, 2001, AM J OBSTET GYNECOL, V184, P679, DOI 10.1067/mob.2001.110294; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Nentwich HA, 2002, J BIOL CHEM, V277, P15354, DOI 10.1074/jbc.M110765200; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P4376, DOI 10.1210/en.2003-0487; ROONEY P, 1993, J CELL SCI, V105, P213; Rugg MS, 2005, J BIOL CHEM, V280, P25674, DOI 10.1074/jbc.M501332200; Sandson J, 1965, Trans Assoc Am Physicians, V78, P304; Sanggaard KW, 2008, J BIOL CHEM, V283, P33919, DOI 10.1074/jbc.M804240200; Sanggaard KW, 2005, J BIOL CHEM, V280, P11936, DOI 10.1074/jbc.M409016200; Selbi W, 2006, J AM SOC NEPHROL, V17, P1553, DOI 10.1681/ASN.2005080879; Slevin M, 2007, MATRIX BIOL, V26, P58, DOI 10.1016/j.matbio.2006.08.261; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Tseng SCG, 1999, J CELL PHYSIOL, V179, P325, DOI 10.1002/(SICI)1097-4652(199906)179:3<325::AID-JCP10>3.0.CO;2-X; Tseng Scheffer C G, 2004, Ocul Surf, V2, P177; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; Wisniewski HG, 2005, J BIOL CHEM, V280, P14476, DOI 10.1074/jbc.M411734200; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; Yingsung W, 2003, J BIOL CHEM, V278, P32710, DOI 10.1074/jbc.M303658200; YONEDA M, 1990, J BIOL CHEM, V265, P5247; Yoshihara Y, 2008, OSTEOARTHR CARTILAGE, V16, P1343, DOI 10.1016/j.joca.2008.04.004; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; Zhuo LS, 2006, J BIOL CHEM, V281, P20303, DOI 10.1074/jbc.M506703200	67	90	111	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20136	20146		10.1074/jbc.M109.021881	http://dx.doi.org/10.1074/jbc.M109.021881			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19491101	Green Published, hybrid			2022-12-25	WOS:000268097400041
J	Fernandez-Sanchez, E; Martinez-Villarreal, J; Gimenez, C; Zafra, F				Fernandez-Sanchez, Enrique; Martinez-Villarreal, Jaime; Gimenez, Cecilio; Zafra, Francisco			Constitutive and Regulated Endocytosis of the Glycine Transporter GLYT1b Is Controlled by Ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DOPAMINE TRANSPORTER; NMDA RECEPTOR; GLUTAMATE TRANSPORTER; MEDIATED INTERNALIZATION; DEPENDENT ENDOCYTOSIS; IN-VIVO; GLYCINE-TRANSPORTER-1; DEGRADATION; MODULATION	The glycine transporter GLYT1 regulates both glycinergic and glutamatergic neurotransmission by controlling the reuptake of glycine at synapses. Trafficking of GLYT1 to and from the cell surface is critical for its function. Activation of PKC down-regulates the activity of GLYT1 through a mechanism that has so far remained uncharacterized. Here we show that GLYT1b undergoes fast constitutive endocytosis that is accelerated by phorbol esters. Both constitutive and regulated endocytosis occur through a dynamin 2- and clathrin-dependent pathway, accumulating in the transporter in transferrin-containing endosomes. A chimera with the extracellular and transmembrane domains of the nerve growth factor receptor and the COOH-terminal tail of GLYT1 was efficiently internalized through this clathrin pathway, suggesting the presence of molecular determinants for GLYT1b endocytosis in its COOH-terminal tail. Extensive site-directed mutagenesis in this region of the chimera highlighted the involvement of lysine residues in its internalization. In the context of the full-length transporter, lysine 619 played a prominent role in both the constitutive and phorbol 12-myristate 13-acetate-induced endocytosis of GLYT1b, suggesting the involvement of ubiquitin modification of GLYT1b during the internalization process. Indeed, we show that GLYT1b undergoes ubiquitination and that this process is stimulated by phorbol 12-myristate 13-acetate. In addition, this endocytosis is impaired in an ubiquitination-deficient cell line, further evidence that constitutive and regulated endocytosis of GLYT1b is ubiquitin-dependent. It remains to be determined whether GLYT1b recycling might be affected in pathologies involving alterations to the ubiquitin system, thereby interfering with its influence on inhibitory and excitatory neurotransmission.	[Fernandez-Sanchez, Enrique; Martinez-Villarreal, Jaime; Gimenez, Cecilio; Zafra, Francisco] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias,Ctr Invest Red Enfermedades Raras, Consejo Super Invest Cient, E-28049 Madrid, Spain	Autonomous University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Zafra, F (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias,Ctr Invest Red Enfermedades Raras, Consejo Super Invest Cient, C Nicolas Cabrera 1, E-28049 Madrid, Spain.	fzafra@cbm.uam.es	Gimenez, Cecilio/K-8027-2014; Zafra, Francisco/A-6121-2008	Gimenez, Cecilio/0000-0001-6726-8405; Zafra, Francisco/0000-0003-3801-3109; Martinez Villarreal, Jaime/0000-0002-3003-7766	Spanish Direccion General de Investigacion Cientifica y Tecnica Grant [SAF2008-01059]; Fondo de Investigaciones Sanitarias (CIBERER); Comunidad Autonoma de Madrid; Fundacion Ramon Areces	Spanish Direccion General de Investigacion Cientifica y Tecnica Grant; Fondo de Investigaciones Sanitarias (CIBERER)(Instituto de Salud Carlos III); Comunidad Autonoma de Madrid(Comunidad de Madrid); Fundacion Ramon Areces	This work was supported by Spanish Direccion General de Investigacion Cientifica y Tecnica Grant SAF2008-01059, a grant from the Fondo de Investigaciones Sanitarias (CIBERER), a grant from the Comunidad Autonoma de Madrid, and an institutional grant from the Fundacion Ramon Areces.	BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; Benmerah A, 1999, J CELL SCI, V112, P1303; Bergeron R, 1998, P NATL ACAD SCI USA, V95, P15730, DOI 10.1073/pnas.95.26.15730; Betz H, 2006, BIOCHEM SOC T, V34, P55, DOI 10.1042/BST0340055; Butterworth MB, 2007, J BIOL CHEM, V282, P37885, DOI 10.1074/jbc.M707989200; Chen L, 2003, J NEUROPHYSIOL, V89, P691, DOI 10.1152/jn.00680.2002; Cubelos B, 2005, J NEUROCHEM, V95, P1047, DOI 10.1111/j.1471-4159.2005.03438.x; Cubelos B, 2005, CEREB CORTEX, V15, P448, DOI 10.1093/cercor/bhh147; Deken SL, 2003, J NEUROSCI, V23, P1563; Fernandez-Sanchez E, 2008, BIOCHEM J, V409, P669, DOI 10.1042/BJ20070533; Fournier KM, 2004, J BIOL CHEM, V279, P34505, DOI 10.1074/jbc.M404032200; Gabernet L, 2005, NEUROSCI LETT, V373, P79, DOI 10.1016/j.neulet.2004.09.064; Gomeza J, 2003, NEURON, V40, P785, DOI 10.1016/S0896-6273(03)00672-X; GOMEZA J, 1995, BBA-BIOMEMBRANES, V1233, P41, DOI 10.1016/0005-2736(94)00249-O; Gonzalez-Gonzalez IM, 2008, GLIA, V56, P963, DOI 10.1002/glia.20670; Granas C, 2003, J BIOL CHEM, V278, P4990, DOI 10.1074/jbc.M205058200; Hatanaka T, 2006, J BIOL CHEM, V281, P35922, DOI 10.1074/jbc.M606577200; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; KEMP JA, 1993, TRENDS PHARMACOL SCI, V14, P20, DOI 10.1016/0165-6147(93)90108-V; Kinney GG, 2003, J NEUROSCI, V23, P7586; Melikian HE, 1999, J NEUROSCI, V19, P7699; Miranda M, 2005, J BIOL CHEM, V280, P35617, DOI 10.1074/jbc.M506618200; Miranda M, 2007, MOL INTERV, V7, P157, DOI 10.1124/mi.7.3.7; Miranda M, 2007, MOL BIOL CELL, V18, P313, DOI 10.1091/mbc.E06-08-0704; Morioka N, 2008, NEUROCHEM INT, V53, P248, DOI 10.1016/j.neuint.2008.08.002; OLIVARES L, 1995, J BIOL CHEM, V270, P9437, DOI 10.1074/jbc.270.16.9437; POTAU N, 1984, ENDOCRINOLOGY, V115, P205, DOI 10.1210/endo-115-1-205; Poyatos I, 2000, MOL CELL NEUROSCI, V15, P99, DOI 10.1006/mcne.1999.0807; SATO K, 1995, J NEUROCHEM, V65, P1967; Sheldon AL, 2008, NEUROCHEM INT, V53, P296, DOI 10.1016/j.neuint.2008.07.010; Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012; Sorkina T, 2005, TRAFFIC, V6, P157, DOI 10.1111/j.1600-0854.2005.00259.x; Sorkina T, 2006, J NEUROSCI, V26, P8195, DOI 10.1523/JNEUROSCI.1301-06.2006; Sur C, 2007, CURR DRUG TARGETS, V8, P643, DOI 10.2174/138945007780618535; Tsai G, 2004, P NATL ACAD SCI USA, V101, P8485, DOI 10.1073/pnas.0402662101; Yee BK, 2006, J NEUROSCI, V26, P3169, DOI 10.1523/JNEUROSCI.5120-05.2006; Zafra F, 2008, IUBMB LIFE, V60, P810, DOI 10.1002/iub.128	38	21	22	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19482	19492		10.1074/jbc.M109.005165	http://dx.doi.org/10.1074/jbc.M109.005165			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19473961	hybrid, Green Published			2022-12-25	WOS:000267908300040
J	Lin, YP; Lee, DW; McDonough, SP; Nicholson, LK; Sharma, Y; Chang, YF				Lin, Yi-Pin; Lee, Dae-Won; McDonough, Sean P.; Nicholson, Linda K.; Sharma, Yogendra; Chang, Yung-Fu			Repeated Domains of Leptospira Immunoglobulin-like Proteins Interact with Elastin and Tropoelastin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; PULMONARY HEMORRHAGE; C-TERMINUS; INTERROGANS; BINDING; FIBRONECTIN; LIGB; MSCRAMM; GLYCOSAMINOGLYCANS; IDENTIFICATION	Leptospira spp., the causative agents of leptospirosis, adhere to components of the extracellular matrix, a pivotal role for colonization of host tissues during infection. Previously, we and others have shown that Leptospira immunoglobulin-like proteins (Lig) of Leptospira spp. bind to fibronectin, laminin, collagen, and fibrinogen. In this study, we report that Leptospira can be immobilized by human tropoelastin (HTE) or elastin from different tissues, including lung, skin, and blood vessels, and that Lig proteins can bind to HTE or elastin. Moreover, both elastin and HTE bind to the same LigB immunoglobulin-like domains, including LigBCon4, LigBCen7'-8, LigBCen9, and LigBCen12 as demonstrated by enzyme-linked immunosorbent assay (ELISA) and competition ELISAs. The LigB immunoglobulin-like domain binds to the 17th to 27th exons of HTE (17-27HTE) as determined by ELISA ( LigBCon4, K-D = 0.50 mu M; LigBCen7'-8, K-D = 0.82 mu M; LigBCen9, K-D = 1.54 mu M; and LigBCen12, K-D = 0.73 mu M). The interaction of LigBCon4 and 17-27HTE was further confirmed by steady state fluorescence spectroscopy (K-D = 0.49 mu M) and ITC (K-D = 0.54 mu M). Furthermore, the binding was enthalpy-driven and affected by environmental pH, indicating it is a charge-charge interaction. The binding affinity of LigBCon4D341N to 17-27HTE was 4.6-fold less than that of wild type LigBCon4. In summary, we show that Lig proteins of Leptospira spp. interact with elastin and HTE, and we conclude this interaction may contribute to Leptospira adhesion to host tissues during infection.	[Lin, Yi-Pin; Lee, Dae-Won; Chang, Yung-Fu] Cornell Univ, Dept Populat Med & Diagnost Sci, Coll Vet Med, Ithaca, NY 14853 USA; [McDonough, Sean P.] Cornell Univ, Dept Biomed Sci, Coll Vet Med, Ithaca, NY 14853 USA; [Nicholson, Linda K.] Cornell Univ, Dept Mol Biol & Genet, Coll Agr & Life Sci, Ithaca, NY 14853 USA; [Sharma, Yogendra] Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Cornell University; Cornell University; Cornell University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Chang, YF (corresponding author), Cornell Univ, Dept Populat Med & Diagnost Sci, Coll Vet Med, Ithaca, NY 14853 USA.	yc42@cornell.edu	LEE, Daewon/GWZ-8418-2022		Harry M. Zweig Memorial Fund; New York State Science and Technology Foundation; Biotechnology Research and Development Corp.	Harry M. Zweig Memorial Fund; New York State Science and Technology Foundation; Biotechnology Research and Development Corp.	This work was supported in part by the Harry M. Zweig Memorial Fund for Equine Research, the New York State Science and Technology Foundation ( Center for Advanced Technology), and the Biotechnology Research and Development Corp.	Atzingen MV, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-70; Barbosa AS, 2006, INFECT IMMUN, V74, P6356, DOI 10.1128/IAI.00460-06; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Broekelmann TJ, 2005, J BIOL CHEM, V280, P40939, DOI 10.1074/jbc.M507309200; Choy HA, 2007, INFECT IMMUN, V75, P2441, DOI 10.1128/IAI.01635-06; Croda J, 2008, INFECT IMMUN, V76, P5826, DOI 10.1128/IAI.00989-08; Dolhnikoff M, 2007, CURR OPIN PULM MED, V13, P230, DOI 10.1097/MCP.0b013e3280f9df74; Donahue JM, 2000, VET CLIN N AM-EQUINE, V16, P443, DOI 10.1016/S0749-0739(17)30088-3; FAINE S, 1999, LEPTOSPIRA LEPTOSPIR, P67; Faisal SM, 2008, VACCINE, V26, P277, DOI 10.1016/j.vaccine.2007.10.029; Faisal SM, 2009, VACCINE, V27, P378, DOI 10.1016/j.vaccine.2008.10.089; Graf R, 1996, CELL TISSUE RES, V283, P133; Hauk P, 2008, INFECT IMMUN, V76, P2642, DOI 10.1128/IAI.01639-07; Hoke DE, 2008, INFECT IMMUN, V76, P2063, DOI 10.1128/IAI.01643-07; HONG CB, 1993, J VET DIAGN INVEST, V5, P56, DOI 10.1177/104063879300500113; Keane FM, 2007, MOL MICROBIOL, V63, P711, DOI 10.1111/j.1365-2958.2006.05552.x; Keane FM, 2007, BIOCHEMISTRY-US, V46, P7226, DOI 10.1021/bi700454x; Levett PN, 2001, CLIN MICROBIOL REV, V14, P296, DOI 10.1128/CMR.14.2.296-326.2001; Lin XP, 2008, J VET SCI, V9, P133; Lin YP, 2008, J BIOL CHEM, V283, P25140, DOI 10.1074/jbc.M801350200; Lin YP, 2007, BIOCHEM BIOPH RES CO, V362, P443, DOI 10.1016/j.bbrc.2007.07.196; Marotto PCF, 1999, CLIN INFECT DIS, V29, P1561, DOI 10.1086/313501; Matsunaga J, 2003, MOL MICROBIOL, V49, P929, DOI 10.1046/j.1365-2958.2003.03619.x; Matsunaga J, 2007, INFECT IMMUN, V75, P2864, DOI 10.1128/IAI.01619-06; Merien F, 2000, FEMS MICROBIOL LETT, V185, P17, DOI 10.1111/j.1574-6968.2000.tb09034.x; Mithieux SM, 2005, ADV PROTEIN CHEM, V70, P437, DOI 10.1016/S0065-3233(05)70013-9; Murray GL, 2008, MICROBES INFECT, V10, P791, DOI 10.1016/j.micinf.2008.04.010; Murray GL, 2009, MICROBES INFECT, V11, P311, DOI 10.1016/j.micinf.2008.11.014; Murray GL, 2009, INFECT IMMUN, V77, P952, DOI 10.1128/IAI.01370-08; Palaniappan RUM, 2007, CURR OPIN INFECT DIS, V20, P284, DOI 10.1097/QCO.0b013e32814a5729; Palaniappan RUM, 2006, INFECT IMMUN, V74, P1745, DOI 10.1128/IAI.74.3.1745-1750.2006; Palaniappan RUM, 2004, J MED MICROBIOL, V53, P975, DOI 10.1099/jmm.0.45568-0; Palaniappan RUM, 2002, INFECT IMMUN, V70, P5924, DOI 10.1128/IAI.70.11.5924-5930.2002; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Piontkivska H, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-31; Roche FM, 2004, J BIOL CHEM, V279, P38433, DOI 10.1074/jbc.M402122200; Rodgers UR, 2004, BIOCHIMIE, V86, P173, DOI 10.1016/j.biochi.2004.03.002; SANDELL LJ, 1990, EXTRACELLULAR MATRIX, P224; Sebastian M, 2005, VET PATHOL, V42, P659, DOI 10.1354/vp.42-5-659; Seijo A, 2002, EMERG INFECT DIS, V8, P1004, DOI 10.3201/eid0809.010499; SILVERTHORN DU, 2001, HUMAN PHYSL INTEGRAT, P590; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; STARCHER BC, 1986, THORAX, V41, P577, DOI 10.1136/thx.41.8.577; Stevenson B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001188; Verma A, 2008, CLIN VACCINE IMMUNOL, V15, P1019, DOI 10.1128/CVI.00203-07; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x; Vrhovski B, 1997, EUR J BIOCHEM, V250, P92, DOI 10.1111/j.1432-1033.1997.00092.x; Wachi H, 2007, BIOCHEM J, V402, P63, DOI 10.1042/BJ20061145; Wagenaar JFP, 2004, J TRAVEL MED, V11, P379, DOI 10.2310/7060.2004.19208; Walsh EJ, 2008, MICROBIOL-SGM, V154, P550, DOI 10.1099/mic.0.2007/010868-0; Wise SG, 2009, INT J BIOCHEM CELL B, V41, P494, DOI 10.1016/j.biocel.2008.03.017; Wu WJ, 1999, J BIOL CHEM, V274, P21719, DOI 10.1074/jbc.274.31.21719; Yan WW, 2009, MICROBES INFECT, V11, P230, DOI 10.1016/j.micinf.2008.11.008	54	89	89	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19380	19391		10.1074/jbc.M109.004531	http://dx.doi.org/10.1074/jbc.M109.004531			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19473986	Green Published, hybrid			2022-12-25	WOS:000267908300029
J	Suemasu, S; Tanaka, KI; Namba, T; Ishihara, T; Katsu, T; Fujimoto, M; Adachi, H; Sobue, G; Takeuchi, K; Nakai, A; Mizushima, T				Suemasu, Shintaro; Tanaka, Ken-Ichiro; Namba, Takushi; Ishihara, Tomoaki; Katsu, Takashi; Fujimoto, Mitsuaki; Adachi, Hiroaki; Sobue, Gen; Takeuchi, Koji; Nakai, Akira; Mizushima, Tohru			A Role for HSP70 in Protecting against Indomethacin-induced Gastric Lesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HEAT-SHOCK PROTEINS; WATER-IMMERSION STRESS; MUCOSAL CELLS; INDUCED APOPTOSIS; GERANYLGERANYLACETONE PROTECTS; UP-REGULATION; APAF-1 APOPTOSOME; GENETIC-EVIDENCE; PRIMARY CULTURE	A major clinical problem encountered with the use of nonsteroidal anti-inflammatory drugs (NSAIDs), such as indomethacin, is gastrointestinal complications. Both NSAID-dependent cyclooxygenase inhibition and gastric mucosal apoptosis are involved in NSAID-produced gastric lesions, and this apoptosis is mediated by the endoplasmic reticulum stress response and resulting activation of Bax. Heat shock proteins (HSPs) have been suggested to protect gastric mucosa from NSAID-induced lesions; here we have tested this idea genetically. The severity of gastric lesions produced by indomethacin was worse in mice lacking heat shock factor 1 (HSF1), a transcription factor for hsp genes, than in control mice. Indomethacin administration up-regulated the expression of gastric mucosal HSP70. Indomethacin-induced gastric lesions were ameliorated in transgenic mice expressing HSP70. After indomethacin administration, fewer apoptotic cells were observed in the gastric mucosa of transgenic mice expressing HSP70 than in wild-type mice, whereas the gastric levels of prostaglandin E-2 for the two were indistinguishable. This suggests that expression of HSP70 ameliorates indomethacin-induced gastric lesions by affecting mucosal apoptosis. Suppression of HSP70 expression in vitro stimulated indomethacin-induced apoptosis and activation of Bax but not the endoplasmic reticulum stress response. Geranylgeranylacetone induced HSP70 at gastric mucosa in an HSF1-dependent manner and suppressed the formation of indomethacin-induced gastric lesions in wild-type mice but not in HSF1-null mice. The results of this study provide direct genetic evidence that expression of HSP70 confers gastric protection against indomethacin-induced lesions by inhibiting the activation of Bax. The HSP inducing activity of geranylgeranylacetone seems to contribute to its gastro-protective activity against indomethacin.	[Suemasu, Shintaro; Tanaka, Ken-Ichiro; Namba, Takushi; Ishihara, Tomoaki; Mizushima, Tohru] Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Kumamoto 8620973, Japan; [Katsu, Takashi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008530, Japan; [Fujimoto, Mitsuaki; Nakai, Akira] Yamaguchi Univ, Sch Med, Yamaguchi 7558505, Japan; [Adachi, Hiroaki; Sobue, Gen] Nagoya Univ, Grad Sch Med, Nagoya, Aichi 4668550, Japan; [Takeuchi, Koji] Kyoto Pharmaceut Univ, Kyoto 6078414, Japan	Kumamoto University; Okayama University; Yamaguchi University; Nagoya University; Kyoto Pharmaceutical University	Mizushima, T (corresponding author), Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Kumamoto 8620973, Japan.	mizu@gpo.kumamoto-u.ac.jp	Longo, Kenneth A/A-5631-2010; Tanaka, Ken-ichiro/J-8557-2013; Adachi, Hiroaki/AAM-7812-2020; KATSU, Takashi/B-1640-2011	Adachi, Hiroaki/0000-0002-9302-4663; 	Ministry of Health, Labour, and Welfare of Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Science and Technology Agency	Ministry of Health, Labour, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Science and Technology Agency(Japan Science & Technology Agency (JST))	This work was supported by grants-in-aid of scientific research from the Ministry of Health, Labour, and Welfare of Japan, grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and grants-in-aid of the Japan Science and Technology Agency.	Aburaya M, 2006, J BIOL CHEM, V281, P33422, DOI 10.1074/jbc.M602074200; Appleton EL, 1996, DATAMATION, V42, P48; BARRIER CH, 1989, ARTHRITIS RHEUM, V32, P926; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Ebert MPA, 2005, J PATHOL, V207, P177, DOI 10.1002/path.1815; FRIES JF, 1989, GASTROENTEROLOGY, V96, P647, DOI 10.1016/S0016-5085(89)80061-7; Fujimoto M, 2005, J BIOL CHEM, V280, P34908, DOI 10.1074/jbc.M506288200; Gehrmann M, 2004, CLIN CANCER RES, V10, P3354, DOI 10.1158/1078-0432.CCR-03-0382; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; Hawkey CJ, 2000, GASTROENTEROLOGY, V119, P521, DOI 10.1053/gast.2000.9561; Hirakawa T, 1996, GASTROENTEROLOGY, V111, P345, DOI 10.1053/gast.1996.v111.pm8690199; Hoshino T, 2003, J BIOL CHEM, V278, P12752, DOI 10.1074/jbc.M212097200; Ishihara T, 2007, BIOCHEM BIOPH RES CO, V356, P711, DOI 10.1016/j.bbrc.2007.03.034; Itoh YH, 2000, INT J HYPERTHER, V16, P183, DOI 10.1080/026567300285376; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; KUNISAKI C, 1992, DIGESTION, V53, P45, DOI 10.1159/000200970; Lichtenberger LM, 2001, BIOCHEM PHARMACOL, V61, P631, DOI 10.1016/S0006-2952(00)00576-1; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Mathew A, 1998, ANN NY ACAD SCI, V851, P99, DOI 10.1111/j.1749-6632.1998.tb08982.x; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Mizushima T, 1999, DIGEST DIS SCI, V44, P510, DOI 10.1023/A:1026692920848; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; NAKAMURA K, 1991, GASTROENTEROLOGY, V101, P161, DOI 10.1016/0016-5085(91)90473-X; Namba T, 2007, MOL PHARMACOL, V71, P860, DOI 10.1124/mol.106.027698; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Saika M, 2000, DIGEST DIS SCI, V45, P2455, DOI 10.1023/A:1005615714451; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; SANTUCCI L, 1995, GASTROENTEROLOGY, V108, P393, DOI 10.1016/0016-5085(95)90065-9; SMALLEY WE, 1995, AM J EPIDEMIOL, V141, P539, DOI 10.1093/oxfordjournals.aje.a117469; Stankiewicz AR, 2005, J BIOL CHEM, V280, P38729, DOI 10.1074/jbc.M509497200; Takano T, 2002, DIGEST DIS SCI, V47, P1546, DOI 10.1023/A:1015819203084; Tanaka K, 2005, J BIOL CHEM, V280, P31059, DOI 10.1074/jbc.M502956200; Tanaka KI, 2007, J BIOL CHEM, V282, P23240, DOI 10.1074/jbc.M704081200; Tanaka KI, 2007, MOL PHARMACOL, V71, P985, DOI 10.1124/mol.106.033282; TERANO A, 1986, DIGESTION, V33, P206, DOI 10.1159/000199296; Tomisato W, 2004, BIOCHEM BIOPH RES CO, V323, P1032, DOI 10.1016/j.bbrc.2004.08.205; Tomisato W, 2004, BIOCHEM PHARMACOL, V67, P575, DOI 10.1016/j.bcp.2003.09.020; Tomisato W, 2001, BIOL PHARM BULL, V24, P887, DOI 10.1248/bpb.24.887; Tomisato W, 2001, AM J PHYSIOL-GASTR L, V281, pG1092, DOI 10.1152/ajpgi.2001.281.4.G1092; Tomisato W, 2000, DIGEST DIS SCI, V45, P1674, DOI 10.1023/A:1005597902470; Tsutsumi S, 2006, ONCOGENE, V25, P1018, DOI 10.1038/sj.onc.1209139; Tsutsumi S, 2004, CELL DEATH DIFFER, V11, P1009, DOI 10.1038/sj.cdd.4401436; Tsutsumi S, 2002, BBA-MOL CELL RES, V1589, P168, DOI 10.1016/S0167-4889(02)00171-4; Ushijima H, 2005, MOL PHARMACOL, V68, P1156, DOI 10.1124/mol.105.015784; WALLACE JL, 1990, AM J PHYSIOL, V259, pG462, DOI 10.1152/ajpgi.1990.259.3.G462; Yanaka A, 2007, DIGESTION, V75, P148, DOI 10.1159/000106756; ZENIYA A, 1995, J GASTROENTEROL, V30, P572, DOI 10.1007/BF02367781	48	72	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19705	19715		10.1074/jbc.M109.006817	http://dx.doi.org/10.1074/jbc.M109.006817			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19439408	Green Published, hybrid			2022-12-25	WOS:000267908300061
J	Wang, HS; Fukushima, H; Kida, S; Zhuo, M				Wang, Hansen; Fukushima, Hotaka; Kida, Satoshi; Zhuo, Min			Ca2+/Calmodulin-dependent Protein Kinase IV Links Group I Metabotropic Glutamate Receptors to Fragile X Mental Retardation Protein in Cingulate Cortex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM DEPRESSION; NEURONAL GENE-EXPRESSION; CONTEXTUAL FEAR MEMORY; SYNAPTIC PLASTICITY; MOUSE MODEL; MOLECULAR-MECHANISMS; CREB PHOSPHORYLATION; CULTURED NEURONS; BINDING PROTEIN; RNA-BINDING	Fragile X syndrome is caused by a lack of fragile X mental retardation protein (FMRP) due to silencing of the FMR1 gene. The metabotropic glutamate receptors (mGluRs) in the central nervous system contribute to higher brain functions including learning/memory, persistent pain, and mental disorders. Our recent study has shown that activation of Group I mGluR up-regulated FMRP in anterior cingulate cortex (ACC), a key region for brain cognitive and executive functions; Ca2+ signaling pathways could be involved in the regulation of FMRP by Group I mGluRs. In this study we demonstrate that stimulating Group I mGluRs activates Ca2+/calmodulin-dependent protein kinase IV (CaMKIV) in ACC neurons. In ACC neurons of adult mice overexpressing CaMKIV, the up-regulation of FMRP by stimulating Group I mGluR is enhanced. The enhancement occurs at the transcriptional level as the Fmr1 mRNA level was further elevated compared with wild-type mice. Using pharmacological approaches, we found that inhibition of CaMKIV could attenuate the up-regulation of FMRP by Group I mGluRs. CaMKIV contribute to the regulation of FMRP by Group I mGluRs probably through cyclic AMP-responsive element binding protein (CREB) activation, as manipulation of CaMKIV could simultaneously cause the change of CREB phosphorylation induced by Group I mGluR activation. Our study has provided strong evidence for CaMKIV as a molecular link between Group I mGluRs and FMRP in ACC neurons and may help us to elucidate the pathogenesis of fragile X syndrome.	[Wang, Hansen; Zhuo, Min] Univ Toronto, Fac Med, Dept Physiol, Toronto, ON M5S 1A8, Canada; [Fukushima, Hotaka; Kida, Satoshi] Tokyo Univ Agr, Fac Appl Biosci, Dept Biosci, Tokyo 1568502, Japan	University of Toronto; Tokyo University of Agriculture	Zhuo, M (corresponding author), Univ Toronto, Fac Med, Dept Physiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	min.zhuo@utoronto.ca	wang, hansen/I-2510-2019; Zhuo, Min/A-2072-2008	wang, hansen/0000-0003-4414-3372; Zhuo, Min/0000-0001-9062-3241	EJLB-Canadian Institutes of Health Research (CIHR); CIHR [CIHR81086, CIHR84256]	EJLB-Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR))	This work was supported by grants from the EJLB-Canadian Institutes of Health Research (CIHR) Michael Smith Chair in Neurosciences and Mental Health, Canada Research Chair, NeuroCanada, and CIHR Operating Grants CIHR81086 and CIHR84256 (to M.Z.).	Antar LN, 2004, J NEUROSCI, V24, P2648, DOI 10.1523/JNEUROSCI.0099-04.2004; Bagni C, 2005, NAT REV NEUROSCI, V6, P376, DOI 10.1038/nrn1667; Bassell GJ, 2008, NEURON, V60, P201, DOI 10.1016/j.neuron.2008.10.004; Bear MF, 2004, TRENDS NEUROSCI, V27, P370, DOI 10.1016/j.tins.2004.04.009; Belmonte MK, 2006, NAT NEUROSCI, V9, P1221, DOI 10.1038/nn1765; Bianchi R, 1999, J NEUROPHYSIOL, V81, P2903, DOI 10.1152/jn.1999.81.6.2903; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Brown V, 1998, J BIOL CHEM, V273, P15521, DOI 10.1074/jbc.273.25.15521; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; CHAVIS P, 1995, NEUROPHARMACOLOGY, V34, P929, DOI 10.1016/0028-3908(95)00082-H; Chow FA, 2005, J BIOL CHEM, V280, P20530, DOI 10.1074/jbc.M500067200; Colomer J., 2007, V45, P169; Costa-Mattioli M, 2009, NEURON, V61, P10, DOI 10.1016/j.neuron.2008.10.055; Coutinho V, 2002, NEUROSCIENTIST, V8, P551, DOI 10.1177/1073858402238514; Fahling M, 2009, J BIOL CHEM, V284, P4255, DOI 10.1074/jbc.M807354200; FENG Y, 1995, SCIENCE, V268, P731, DOI 10.1126/science.7732383; Fitzjohn SM, 2001, J PHYSIOL-LONDON, V537, P421, DOI 10.1111/j.1469-7793.2001.00421.x; Fog JU, 2006, NEURON, V51, P417, DOI 10.1016/j.neuron.2006.06.028; Frankland PW, 2004, SCIENCE, V304, P881, DOI 10.1126/science.1094804; Frankland PW, 2001, NATURE, V411, P309, DOI 10.1038/35077089; Fukushima H, 2008, J NEUROSCI, V28, P9910, DOI 10.1523/JNEUROSCI.2625-08.2008; Garber K, 2006, CURR OPIN GENET DEV, V16, P270, DOI 10.1016/j.gde.2006.04.010; Garber KB, 2008, EUR J HUM GENET, V16, P666, DOI 10.1038/ejhg.2008.61; Gong B, 2007, EUR J NEUROSCI, V26, P275, DOI 10.1111/j.1460-9568.2007.05669.x; Greenough WT, 2001, P NATL ACAD SCI USA, V98, P7101, DOI 10.1073/pnas.141145998; Grossman AW, 2006, J NEUROSCI, V26, P7151, DOI 10.1523/JNEUROSCI.1790-06.2006; Han CJ, 2003, P NATL ACAD SCI USA, V100, P13087, DOI 10.1073/pnas.2132313100; Hayashi ML, 2007, P NATL ACAD SCI USA, V104, P11489, DOI 10.1073/pnas.0705003104; He XP, 2000, J CELL BIOL, V149, P783, DOI 10.1083/jcb.149.4.783; Heinke B, 2005, PAIN, V118, P145, DOI 10.1016/j.pain.2005.08.004; Heinke B, 2007, NEUROPHARMACOLOGY, V52, P1015, DOI 10.1016/j.neuropharm.2006.10.020; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Hou LF, 2006, NEURON, V51, P441, DOI 10.1016/j.neuron.2006.07.005; Hu HJ, 2002, J NEUROSCI, V22, P7444; Huber KM, 2002, P NATL ACAD SCI USA, V99, P7746, DOI 10.1073/pnas.122205699; Hwu WL, 1997, DNA CELL BIOL, V16, P449, DOI 10.1089/dna.1997.16.449; Jin P, 2003, TRENDS BIOCHEM SCI, V28, P152, DOI 10.1016/S0968-0004(03)00033-1; Kasahara J, 2001, J BIOL CHEM, V276, P24044, DOI 10.1074/jbc.M100247200; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Kushnareva YE, 2005, J BIOL CHEM, V280, P28894, DOI 10.1074/jbc.M503090200; Lu YF, 1999, J NEUROSCI, V19, P10250; Mao LM, 2003, EUR J NEUROSCI, V17, P741, DOI 10.1046/j.1460-9568.2003.02495.x; Moult PR, 2006, J NEUROSCI, V26, P2544, DOI 10.1523/JNEUROSCI.4322-05.2006; Nakamoto M, 2007, P NATL ACAD SCI USA, V104, P15537, DOI 10.1073/pnas.0707484104; Narayanan U, 2008, J BIOL CHEM, V283, P18478, DOI 10.1074/jbc.C800055200; Narayanan U, 2007, J NEUROSCI, V27, P14349, DOI 10.1523/JNEUROSCI.2969-07.2007; Nosyreva ED, 2006, J NEUROPHYSIOL, V95, P3291, DOI 10.1152/jn.01316.2005; Rae MG, 2004, NEUROPHARMACOLOGY, V46, P1057, DOI 10.1016/j.neuropharm.2004.02.002; Rae MG, 2000, J NEUROSCI, V20, P8628; Richter JD, 2009, GENE DEV, V23, P1, DOI 10.1101/gad.1735809; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Sharma AK, 2004, J BIOL CHEM, V279, P35564, DOI 10.1074/jbc.M401037200; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Smith KT, 2006, NUCLEIC ACIDS RES, V34, P1205, DOI 10.1093/nar/gkj521; Tamminga CA, 2007, AM J PSYCHIAT, V164, P556, DOI 10.1176/appi.ajp.164.4.556; Tang JR, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-6; Thuault SJ, 2002, NEUROPHARMACOLOGY, V43, P141, DOI 10.1016/S0028-3908(02)00095-3; Todd PK, 2003, P NATL ACAD SCI USA, V100, P14374, DOI 10.1073/pnas.2336265100; Tremper-Wells B, 2005, J BIOL CHEM, V280, P2165, DOI 10.1074/jbc.M410591200; Wang H, 2008, NEURON, V59, P634, DOI 10.1016/j.neuron.2008.06.027; Wang HS, 2008, J NEUROSCI, V28, P4385, DOI 10.1523/JNEUROSCI.0646-08.2008; Wang HS, 2007, J BIOL CHEM, V282, P1507, DOI 10.1074/jbc.M607291200; Wayman GA, 2008, NEURON, V59, P914, DOI 10.1016/j.neuron.2008.08.021; Wei F, 1999, J NEUROSCI, V19, P9346; Wei F, 2002, NAT NEUROSCI, V5, P573, DOI 10.1038/nn0602-855; Weiler IJ, 1997, P NATL ACAD SCI USA, V94, P5395, DOI 10.1073/pnas.94.10.5395; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Zhao MG, 2005, J NEUROSCI, V25, P7385, DOI 10.1523/JNEUROSCI.1520-05.2005; Zhao MG, 2005, NEURON, V47, P859, DOI 10.1016/j.neuron.2005.08.014; Zhuo M, 2008, TRENDS NEUROSCI, V31, P199, DOI 10.1016/j.tins.2008.01.003; Zhuo M, 2006, J NEUROSCI RES, V84, P927, DOI 10.1002/jnr.21003	73	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18953	18962		10.1074/jbc.M109.019141	http://dx.doi.org/10.1074/jbc.M109.019141			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19436069	Green Published, hybrid			2022-12-25	WOS:000267711500045
J	Yap, LF; Jenei, V; Robinson, CM; Moutasim, K; Benn, TM; Threadgold, SP; Lopes, V; Wei, W; Thomas, GJ; Paterson, IC				Yap, L. F.; Jenei, V.; Robinson, C. M.; Moutasim, K.; Benn, T. M.; Threadgold, S. P.; Lopes, V.; Wei, W.; Thomas, G. J.; Paterson, I. C.			Upregulation of Eps8 in oral squamous cell carcinoma promotes cell migration and invasion through integrin-dependent Rac1 activation	ONCOGENE			English	Article						Eps8; oral cancer; integrin; migration; Rac1; invasion	EXTRACAPSULAR SPREAD; CANCER; EXPRESSION; IDENTIFICATION; GROWTH; HEAD; INTEGRIN-ALPHA(V)BETA(6); TRANSFORMATION; PROGRESSION; MOTILITY	Oral squamous cell carcinoma (OSCC) is a lethal disease and early death usually occurs as a result of local invasion and regional lymph node metastases. Current treatment regimens are, to a certain degree, inadequate, with a 5-year mortality rate of around 50% and novel therapeutic targets are urgently required. Using expression microarrays, we identified the eps8 gene as being overexpressed in OSCC cell lines relative to normal oral keratinocytes, and confirmed these findings using RT-PCR and western blotting. In human tissues, we found that Eps8 was upregulated in OSCC (32% of primary tumors) compared with normal oral mucosa, and that expression correlated significantly with lymph node metastasis (P = 0.032), suggesting a disease-promoting effect. Using OSCC cell lines, we assessed the functional role of Eps8 in tumor cells. Although suppression of Eps8 produced no effect on cell proliferation, both cell spreading and migration were markedly inhibited. The latter cell functions may be modulated through the small GTP-ase, Rac1 and we used pull-down assays to investigate the role of Eps8 in Rac1 signaling. We found that alpha v beta 6- and alpha 5 beta 1-integrin-dependent activation of Rac1 was mediated through Eps8. Knockdown of either Eps8 or Rac1, inhibited integrin-dependent cell migration similarly and transient expression of constitutively active Rac1 restored migration of cells in which Eps8 expression had been suppressed. We also showed that knockdown of Eps8 inhibited tumor cell invasion in an organotypic model of OSCC. These data suggest that Eps8 and Rac1 are part of an integrated signaling pathway modulating integrin-dependent tumour cell motility and identify Eps8 as a possible therapeutic target. Oncogene ( 2009) 28, 2524-2534; doi: 10.1038/onc.2009.105; published online 18 May 2009	[Jenei, V.; Moutasim, K.; Thomas, G. J.] Univ Southampton, Sch Med, Canc Sci Div, Southampton, Hants, England; [Yap, L. F.; Benn, T. M.; Threadgold, S. P.; Paterson, I. C.] Univ Bristol, Dept Oral & Dent Sci, Bristol, Avon, England; [Yap, L. F.] Canc Res Initiat Fdn, Kuala Lumpur, Malaysia; [Jenei, V.; Moutasim, K.; Thomas, G. J.] Barts & London Queen Marys Sch Med & Dent, Inst Canc, Tumor Biol Ctr, London, England; [Robinson, C. M.] Univ Newcastle, Sch Dent Sci, Newcastle Upon Tyne, Tyne & Wear, England; [Lopes, V.] Univ Edinburgh, Edinburgh Dent Inst, Edinburgh, Midlothian, Scotland; [Wei, W.] Univ Birmingham, Inst Canc Studies, Birmingham, W Midlands, England	University of Southampton; University of Bristol; University of London; Queen Mary University London; Newcastle University - UK; University of Edinburgh; University of Birmingham	Thomas, GJ (corresponding author), Univ Southampton, Sch Med, Canc Sci Div, Tremona Rd, Southampton, Hants, England.	g.thomas@soton.ac.uk	Paterson, Ian/G-8688-2011; Yap, Lee-Fah/M-1065-2016; Robinson, Max/R-5280-2018	Paterson, Ian/0000-0001-9156-401X; Yap, Lee-Fah/0000-0002-6815-3607; Robinson, Max/0000-0003-4491-6865; Wei, Wenbin/0000-0003-1288-6999	Cancer Research Initiatives Foundation, Malaysia; Health Foundation	Cancer Research Initiatives Foundation, Malaysia; Health Foundation	The Cancer Research Initiatives Foundation, Malaysia and The Health Foundation supported the research.	Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; Croce A, 2004, NAT CELL BIOL, V6, P1173, DOI 10.1038/ncb1198; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Disanza A, 2004, NAT CELL BIOL, V6, P1180, DOI 10.1038/ncb1199; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Elayadi AN, 2007, CANCER RES, V67, P5889, DOI 10.1158/0008-5472.CAN-07-0245; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; Funato Y, 2004, CANCER RES, V64, P5237, DOI 10.1158/0008-5472.CAN-04-0327; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; Inobe M, 1999, BIOCHEM BIOPH RES CO, V266, P216, DOI 10.1006/bbrc.1999.1782; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jeon GA, 2004, INT J CANCER, V112, P249, DOI 10.1002/ijc.20399; Kim MM, 2004, INT J CANCER, V112, P545, DOI 10.1002/ijc.20379; Maa MC, 2001, ONCOGENE, V20, P106, DOI 10.1038/sj.onc.1204069; Maa MC, 2007, J BIOL CHEM, V282, P19399, DOI 10.1074/jbc.M610280200; Marsh D, 2008, CANCER RES, V68, P3295, DOI 10.1158/0008-5472.CAN-08-0174; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Myers JN, 2001, CANCER-AM CANCER SOC, V92, P3030, DOI 10.1002/1097-0142(20011215)92:12<3030::AID-CNCR10148>3.0.CO;2-P; Nystrom ML, 2006, CANCER RES, V66, P10833, DOI 10.1158/0008-5472.CAN-06-1640; Nystrom ML, 2005, J PATHOL, V205, P468, DOI 10.1002/path.1716; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; PRIME SS, 1990, J PATHOL, V160, P259, DOI 10.1002/path.1711600313; Ramsay AG, 2007, CANCER RES, V67, P5275, DOI 10.1158/0008-5472.CAN-07-0318; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Scita G, 2001, J CELL BIOL, V154, P1031, DOI 10.1083/jcb.200103146; Thirthagiri E, 2007, CANCER LETT, V258, P276, DOI 10.1016/j.canlet.2007.09.008; Thomas GJ, 2002, BRIT J CANCER, V87, P859, DOI 10.1038/sj.bjc.6600545; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Welsch T, 2007, CANCER LETT, V255, P205, DOI 10.1016/j.canlet.2007.04.008; Woolgar JA, 2003, ORAL ONCOL, V39, P130, DOI 10.1016/S1368-8375(02)00030-1; Yao J, 2006, CANCER RES, V66, P4065, DOI 10.1158/0008-5472.CAN-05-4083; Yeudall WA, 2005, ORAL ONCOL, V41, P698, DOI 10.1016/j.oraloncology.2005.03.004	38	64	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2524	2534		10.1038/onc.2009.105	http://dx.doi.org/10.1038/onc.2009.105			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448673				2022-12-25	WOS:000267806800005
J	Chen, WY; Marcellin, E; Hung, J; Nielsen, LK				Chen, Wendy Yiting; Marcellin, Esteban; Hung, Jacky; Nielsen, Lars Keld			Hyaluronan Molecular Weight Is Controlled by UDP-N-acetylglucosamine Concentration in Streptococcus zooepidemicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; TYPE-3 CAPSULAR POLYSACCHARIDE; CONSERVED CYSTEINE RESIDUES; ACID PRODUCTION; LACTOCOCCUS-LACTIS; SODIUM HYALURONATE; SUGAR NUCLEOTIDES; SYNTHASE; BIOSYNTHESIS; PNEUMONIAE	The molecular weight of hyaluronan is important for its rheological and biological function. The molecular mechanisms underlying chain termination and hence molecular weight control remain poorly understood, not only for hyaluronan synthases but also for other beta-polysaccharide synthases, e. g. cellulose, chitin, and 1,3-betaglucan synthases. In this work, we manipulated metabolite concentrations in the hyaluronan pathway by overexpressing the five genes of the hyaluronan synthesis operon in Streptococcus equi subsp. zooepidemicus. Overexpression of genes involved in UDP-glucuronic acid biosynthesis decreased molecular weight, whereas overexpression of genes involved in UDP-N-acetylglucosamine biosynthesis increased molecular weight. The highest molecular mass observed was at 3.4 +/- 0.1 MDa twice that observed in the wild-type strain, 1.8 +/- 0.1 MDa. The data indicate that (a) high molecular weight is achieved when an appropriate balance of UDP-N-acetylglucosamine and UDP-glucuronic acid is achieved, (b) UDP-N-acetylglucosamine exerts the dominant effect on molecular weight, and (c) the wild-type strain has suboptimal levels of UDP-Nacetylglucosamine. Consistent herewith molecular weight correlated strongly (rho = 0.84, p = 3 x 10(-5)) with the concentration of UDP-N-acetylglucosamine. Data presented in this paper represent the first model for hyaluronan molecular weight control based on the concentration of activated sugar precursors. These results can be used to engineer strains producing high molecular weight hyaluronan and may provide insight into similar polymerization mechanisms in other polysaccharides.	[Chen, Wendy Yiting; Marcellin, Esteban; Hung, Jacky; Nielsen, Lars Keld] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld 4072, Australia; [Chen, Wendy Yiting; Hung, Jacky; Nielsen, Lars Keld] Univ Queensland, Cooperat Res Ctr Sugar Ind Innovat Biotechnol, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Nielsen, LK (corresponding author), Univ Queensland, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld 4072, Australia.	lars.nielsen@uq.edu.au	Nielsen, Lars K/A-5519-2011	Nielsen, Lars K/0000-0001-8191-3511; Marcellin, Esteban/0000-0003-3173-7956	Australian Institute for Bioengineering and Nanotechnology; CRC Sugar Industry Innovation through Biotechnology; Mexican Council of Science and Technology	Australian Institute for Bioengineering and Nanotechnology; CRC Sugar Industry Innovation through Biotechnology(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); Mexican Council of Science and Technology(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	This work was financially supported by the Australian Institute for Bioengineering and Nanotechnology, the CRC Sugar Industry Innovation through Biotechnology, and the Mexican Council of Science and Technology. 1 Both authors contributed equally to this work.	Armstrong DC, 1997, APPL ENVIRON MICROB, V63, P2759, DOI 10.1128/AEM.63.7.2759-2764.1997; Blank LM, 2008, J MOL EVOL, V67, P13, DOI 10.1007/s00239-008-9117-1; Blank LM, 2005, BIOTECHNOL BIOENG, V90, P685, DOI 10.1002/bit.20466; Cartee RT, 2000, J BIOL CHEM, V275, P3907, DOI 10.1074/jbc.275.6.3907; Chien LJ, 2007, APPL MICROBIOL BIOT, V77, P339, DOI 10.1007/s00253-007-1153-z; Chong BF, 2003, BIOCHEM ENG J, V16, P153, DOI 10.1016/S1369-703X(03)00031-7; Chong BF, 2003, J BIOTECHNOL, V100, P33, DOI 10.1016/S0168-1656(02)00239-0; Chong BF, 2005, APPL MICROBIOL BIOT, V66, P341, DOI 10.1007/s00253-004-1774-4; CHONG BF, 2002, THESIS U QUEENSLAND; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; Degeest B, 2000, APPL ENVIRON MICROB, V66, P3519, DOI 10.1128/AEM.66.8.3519-3527.2000; DIFERRANTE N, 1956, J BIOL CHEM, V220, P303; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; Forsee WT, 2000, J BIOL CHEM, V275, P25972, DOI 10.1074/jbc.M002613200; Forsee WT, 2006, J BIOL CHEM, V281, P6283, DOI 10.1074/jbc.M511124200; FOUISSAC E, 1993, MACROMOLECULES, V26, P6945, DOI 10.1021/ma00077a036; GASSON MJ, 1983, J BACTERIOL, V154, P1; Goh L.T., 1998, THESIS U QUEENSLAND; Grobben GJ, 1996, APPL MICROBIOL BIOT, V46, P279, DOI 10.1007/s002530050817; Heldermon CD, 2001, GLYCOBIOLOGY, V11, P1017, DOI 10.1093/glycob/11.12.1017; Huang WC, 2006, BIOCHEM ENG J, V32, P239, DOI 10.1016/j.bej.2006.10.011; JANG PM, 1996, Patent No. 5496726; Jensen NBS, 1999, BIOTECHNOL BIOENG, V63, P356, DOI 10.1002/(SICI)1097-0290(19990505)63:3&lt;356::AID-BIT12&gt;3.0.CO;2-1; JOHNS MR, 1994, BIOTECHNOL LETT, V16, P507, DOI 10.1007/BF01023334; Kumari K, 2006, J BIOL CHEM, V281, P11755, DOI 10.1074/jbc.M600727200; Kumari K, 2002, J BIOL CHEM, V277, P13943, DOI 10.1074/jbc.M110638200; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; Marcellin Esteban, 2009, Biotechnology Journal, V4, P58, DOI 10.1002/biot.200800197; Mierau I, 2005, APPL MICROBIOL BIOT, V68, P705, DOI 10.1007/s00253-005-0107-6; Pummill PE, 2003, J BIOL CHEM, V278, P19808, DOI 10.1074/jbc.M301097200; SAETTONE MF, 1991, INT J PHARMACEUT, V72, P131, DOI 10.1016/0378-5173(91)90051-O; Sambrook J, 2001, MOL CLONING LAB MANU; Saso L, 1999, RES COMMUN MOL PATH, V104, P277; SLOMA A, 2003, Patent No. 20030175902; Spicer AP, 1998, J BIOL CHEM, V273, P25117, DOI 10.1074/jbc.273.39.25117; Spurlock SL, 1999, J EQUINE VET SCI, V19, P338, DOI 10.1016/S0737-0806(06)82052-6; SUZUKI Y, 1993, AGENTS ACTIONS, V38, P32, DOI 10.1007/BF02027210; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; Ventura CL, 2006, MOL MICROBIOL, V61, P723, DOI 10.1111/j.1365-2958.2006.05259.x; Weigel PH, 2007, J BIOL CHEM, V282, P36777, DOI 10.1074/jbc.R700036200; Weigel PH, 2002, IUBMB LIFE, V54, P201, DOI 10.1080/15216540214931; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; Widner B, 2005, APPL ENVIRON MICROB, V71, P3747, DOI 10.1128/AEM.71.7.3747-3752.2005; Yu HM, 2008, METAB ENG, V10, P24, DOI 10.1016/j.ymben.2007.09.001	47	69	76	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	2009	284	27					18007	18014		10.1074/jbc.M109.011999	http://dx.doi.org/10.1074/jbc.M109.011999			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BW	19451654	Green Published, hybrid			2022-12-25	WOS:000267712400012
J	Funabara, D; Osawa, R; Ueda, M; Kanoh, S; Hartshorne, DJ; Watabe, S				Funabara, Daisuke; Osawa, Rika; Ueda, Miki; Kanoh, Satoshi; Hartshorne, David J.; Watabe, Shugo			Myosin Loop 2 Is Involved in the Formation of a Trimeric Complex of Twitchin, Actin, and Myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLLUSCAN CATCH MUSCLE; HEAD DETACHMENT; PHOSPHORYLATION; PROTEIN; PHOSPHATASE; PARAMYOSIN; CALCIUM	Molluscan smooth muscles exhibit a low energy cost contraction called catch. Catch is regulated by twitchin phosphorylation and dephosphorylation. Recently, we found that the D2 fragment of twitchin containing the D2 site (Ser-4316) and flanking immunoglobulin motifs (TWD2-S) formed a heterotrimeric complex with myosin and with actin in the region that interacts with myosin loop 2 (Funabara, D., Hamamoto, C., Yamamoto, K., Inoue, A., Ueda, M., Osawa, R., Kanoh, S., Hartshorne, D. J., Suzuki, S., and Watabe, S. (2007) J. Exp. Biol. 210, 4399-4410). Here, we show that TWD2-S interacts directly with myosin loop 2 in a phosphorylation-sensitive manner. A synthesized peptide, CAQNKEAETTGTHKKRKSSA, based on the myosin loop 2 sequence (loop 2 peptide), competitively inhibited the formation of the trimeric complex. Isothermal titration calorimetry showed that TWD2-S binds to the loop 2 peptide with a K-a of (2.44 +/- 0.09) x 10(5) M-1 with two binding sites. The twitchin-binding peptide of actin, AGFAGDDAP, which also inhibited formation of the trimeric complex, bound to TWD2-S with a K-a of (5.83 +/- 0.05) x 10(4) M-1 with two binding sites. The affinity of TWD2-S to actin and myosin was slightly decreased with an increase of pH, but this effect could not account for the marked pH dependence of catch in permeabilized fibers. The complex formation also showed a moderate Ca2+ sensitivity in that in the presence of Ca2+ complex formation was reduced.	[Funabara, Daisuke; Osawa, Rika; Ueda, Miki; Kanoh, Satoshi] Mie Univ, Grad Sch Bioresources, Tsu, Mie 5148507, Japan; [Hartshorne, David J.] Univ Arizona, Muscle Biol Grp, Tucson, AZ 85721 USA; [Watabe, Shugo] Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan	Mie University; University of Arizona; University of Tokyo	Watabe, S (corresponding author), Yayoi 1-1-1,Bunkyo Ku, Tokyo 1138657, Japan.	awatabe@ecc.mail.u-tokyo.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan; Japan Science and Technology Agency	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Science and Technology Agency(Japan Science & Technology Agency (JST))	This work was supported by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and from the Regional Research and Development Resources Utilization Program, Japan Science and Technology Agency (to D. F.).	Andruchova O, 2005, PFLUG ARCH EUR J PHY, V450, P326, DOI 10.1007/s00424-005-1447-x; Butler TM, 2006, BIOPHYS J, V90, P3193, DOI 10.1529/biophysj.105.077453; CASTELLANI L, 1992, FEBS LETT, V309, P321, DOI 10.1016/0014-5793(92)80798-L; Funabara D, 2003, J BIOL CHEM, V278, P29308, DOI 10.1074/jbc.M303272200; Funabara D, 2001, BIOCHEMISTRY-US, V40, P2087, DOI 10.1021/bi0022691; Funabara D, 2007, J EXP BIOL, V210, P4399, DOI 10.1242/jeb.008722; Hopflinger MC, 2006, J EXP BIOL, V209, P668, DOI 10.1242/jeb.02033; ISHII N, 1989, SCIENCE, V243, P1367, DOI 10.1126/science.2922614; JOHARA M, 1993, P NATL ACAD SCI USA, V90, P2127, DOI 10.1073/pnas.90.6.2127; LOWY J, 1964, PROC R SOC SER B-BIO, V160, P525, DOI 10.1098/rspb.1964.0068; MOMMAERTS WFHM, 1951, J BIOL CHEM, V188, P559; Shelud'ko NS, 2007, ARCH BIOCHEM BIOPHYS, V466, P125, DOI 10.1016/j.abb.2007.07.014; Siegman MJ, 1997, J MUSCLE RES CELL M, V18, P655, DOI 10.1023/A:1018683823020; Siegman MJ, 1998, P NATL ACAD SCI USA, V95, P5383, DOI 10.1073/pnas.95.9.5383; SZENTGYORGYI AG, 1994, MYOLOGY, P506; Takahashi I, 2003, COMP BIOCHEM PHYS A, V134, P117; TWAROG BM, 1976, PHYSIOL REV, V56, P829, DOI 10.1152/physrev.1976.56.4.829; Van Dijk J, 1998, BIOCHEMISTRY-US, V37, P8385, DOI 10.1021/bi980139a; WATABE S, 1990, COMP BIOCHEM PHYS B, V96, P639, DOI 10.1016/0305-0491(90)90207-A; Yamada A, 2004, J BIOL CHEM, V279, P40762, DOI 10.1074/jbc.M405191200; Yamada A, 2000, J MOL BIOL, V295, P169, DOI 10.1006/jmbi.1999.3349	21	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	2009	284	27					18015	18020		10.1074/jbc.M109.016485	http://dx.doi.org/10.1074/jbc.M109.016485			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BW	19439402	Green Published, hybrid			2022-12-25	WOS:000267712400013
J	Liu, Y; Pixley, R; Fusaro, M; Godoy, G; Kim, E; Bromberg, ME; Colman, RW				Liu, Y.; Pixley, R.; Fusaro, M.; Godoy, G.; Kim, E.; Bromberg, M. E.; Colman, R. W.			Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway	ONCOGENE			English	Article						Hka; prostate cancer; EGFR; uPAR	PLASMINOGEN-ACTIVATOR RECEPTOR; HUMAN ENDOTHELIAL-CELLS; UROKINASE RECEPTOR; HUMAN CARCINOMA; TUBE FORMATION; TUMOR-GROWTH; IN-VIVO; KALLIKREIN; DORMANCY; PLASMA	Upregulation and activation of epidermal growth factor receptor and/or urokinase-type plasminogen activator receptor in a variety of cancers have been shown to be associated with poor prognosis. High-molecular-weight kininogen can be hydrolysed by plasma kallikrein to bradykinin and cleaved high-molecular-weight kininogen (HKa). HKa and its domain 5 (D5) both have been shown to have potent anti-angiogenic activity. We now show that HKa blocks human prostate cancer cell (DU145) migration by 76.0 +/- 2.4% at 300 nM and invasion by 78.0 +/- 12.9% at 11.1 nM. D5 inhibits tumor migration and invasion in a concentration-dependent manner. Stimulation by basic fibroblast growth factor (bFGF) or vascular endothelial growth factor results in clustering of urokinase-type plasminogen activator receptor (uPAR) and epidermal growth factor receptor (EGFR) on the surface of DU145 cells. The co-localization of uPAR and EGFR is prevented by HKa. Immunoprecipitation suggests that uPAR, EGFR and alpha 5 beta 1 integrin formed a ternary complex. Immunoblotting shows that HKa significantly decreases the bFGF-transactivated phosphorylation of EGFR at Tyr 1173 between 30 min and 4 h. The phosphorylation of extracellular signal-regulated kinase (ERK) and AKT, which are downstream effectors of EGFR, is also inhibited by HKa. These novel data indicate that HKa and D5 inhibit migration and invasion of human prostate cancer cells through an EGFR/uPAR pathway, suggesting the therapeutic potential of HKa and D5 to decrease metastasis of human prostate cancer. Oncogene (2009) 28, 2756-2765; doi:10.1038/onc.2009.132; published online 1 June 2009	[Liu, Y.; Pixley, R.; Fusaro, M.; Godoy, G.; Kim, E.; Bromberg, M. E.; Colman, R. W.] Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liu, Y (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St,Room 808 OMS, Philadelphia, PA 19140 USA.	yuchuan@temple.edu	fusaro, maria/R-3386-2016; Fusaro, Maria/AAA-5509-2019	fusaro, maria/0000-0001-9478-4851; Fusaro, Maria/0000-0001-9478-4851	National Institutes of Health [R01 CA83121, R01 AR051713, T32 HL07777]; NATIONAL CANCER INSTITUTE [R01CA083121] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051713] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This study was supported by National Institutes of Health Grants R01 CA83121, R01 AR051713 and T32 HL07777 to RW Colman.	Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Cao DJ, 2004, CIRC RES, V94, P1227, DOI 10.1161/01.RES.0000126567.75232.46; Chaurasia P, 2006, J BIOL CHEM, V281, P14852, DOI 10.1074/jbc.M512311200; Colman RW, 1998, CLIN REV ALLERG IMMU, V16, P365, DOI 10.1007/BF02737657; Colman RW, 2006, CURR PHARM DESIGN, V12, P2599, DOI 10.2174/138161206777698710; Colman RW, 1999, IMMUNOPHARMACOLOGY, V43, P103, DOI 10.1016/S0162-3109(99)00068-5; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Katkade V, 2005, THROMB HAEMOSTASIS, V94, P606, DOI 10.1160/TH04-12-0834; KIRCHHEIMER JC, 1985, INVAS METAST, V5, P344; Li Y, 2007, CANCER TREAT REV, V33, P521, DOI 10.1016/j.ctrv.2007.06.003; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Liu YC, 2004, J BIOL CHEM, V279, P36142, DOI 10.1074/jbc.M405039200; Liu YC, 2008, AM J PHYSIOL-CELL PH, V295, pC257, DOI 10.1152/ajpcell.00569.2007; Liu Y, 2008, EXP CELL RES, V314, P774, DOI 10.1016/j.yexcr.2007.10.008; Ma Z, 2001, J CELL SCI, V114, P3387; Mahdi F, 2004, J BIOL CHEM, V279, P16621, DOI 10.1074/jbc.M313850200; Mamoune A, 2004, EXP CELL RES, V299, P91, DOI 10.1016/j.yexcr.2004.05.008; Mazzieri R, 2006, MOL BIOL CELL, V17, P367, DOI 10.1091/mbc.E05-07-0635; Miyake H, 1999, INT J ONCOL, V14, P535; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; Pixley RA, 2003, J THROMB HAEMOST, V1, P1791, DOI 10.1046/j.1538-7836.2003.00291.x; Prager GW, 2004, BLOOD, V103, P955, DOI 10.1182/blood-2003-07-2214; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schlomm T, 2007, CLIN CANCER RES, V13, P6579, DOI 10.1158/1078-0432.CCR-07-1257; Schmaier AH, 2007, J THROMB HAEMOST, V5, P2323, DOI 10.1111/j.1538-7836.2007.02770.x; Wang XQ, 2005, J INVEST DERMATOL, V124, P839, DOI 10.1111/j.0022-202X.2005.23669.x; Yarden Y, 2001, EUR J CANCER, V37, pS3	31	23	25	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2756	2765		10.1038/onc.2009.132	http://dx.doi.org/10.1038/onc.2009.132			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19483730	Green Accepted			2022-12-25	WOS:000268452900006
J	Romanish, MT; Nakamura, H; Lai, CB; Wang, YZ; Mager, DL				Romanish, Mark T.; Nakamura, Hisae; Lai, C. Benjamin; Wang, Yuzhuo; Mager, Dixie L.			A Novel Protein Isoform of the Multicopy Human NAIP Gene Derives from Intragenic Alu SINE Promoters	PLOS ONE			English	Article								The human neuronal apoptosis inhibitory protein (NAIP) gene is no longer principally considered a member of the Inhibitor of Apoptosis Protein (IAP) family, as its domain structure and functions in innate immunity also warrant inclusion in the Nod-Like Receptor (NLR) superfamily. NAIP is located in a region of copy number variation, with one full length and four partly deleted copies in the reference human genome. We demonstrate that several of the NAIP paralogues are expressed, and that novel transcripts arise from both internal and upstream transcription start sites. Remarkably, two internal start sites initiate within Alu short interspersed element (SINE) retrotransposons, and a third novel transcription start site exists within the final intron of the GUSBP1 gene, upstream of only two NAIP copies. One Alu functions alone as a promoter in transient assays, while the other likely combines with upstream L1 sequences to form a composite promoter. The novel transcripts encode shortened open reading frames and we show that corresponding proteins are translated in a number of cell lines and primary tissues, in some cases above the level of full length NAIP. Interestingly, some NAIP isoforms lack their caspase-sequestering motifs, suggesting that they have novel functions. Moreover, given that human and mouse NAIP have previously been shown to employ endogenous retroviral long terminal repeats as promoters, exaptation of Alu repeats as additional promoters provides a fascinating illustration of regulatory innovations adopted by a single gene.			Romanish, MT (corresponding author), BC Canc Agcy, Terry Fox Lab, Vancouver, BC, Canada.	dmager@bccrc.ca		Mager, Dixie/0000-0002-5955-2550; Lai, Chieh Min Benjamin/0000-0002-4130-9413; Wang, Yuzhuo/0000-0002-9749-8591				ARCOT SS, 1995, GENOMICS, V29, P136, DOI 10.1006/geno.1995.1224; Brosius J, 1999, GENE, V238, P115, DOI 10.1016/S0378-1119(99)00227-9; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789; Chen CJ, 2009, MOL BIOL EVOL, V26, P327, DOI 10.1093/molbev/msn249; Chen QF, 1998, GENOMICS, V48, P121, DOI 10.1006/geno.1997.5141; Damiano JS, 2004, BIOCHEM J, V381, P213, DOI 10.1042/BJ20031506; Davoodi J, 2004, J BIOL CHEM, V279, P40622, DOI 10.1074/jbc.M405963200; Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223; Diez E, 2003, NAT GENET, V33, P55, DOI 10.1038/ng1065; DOOLITTLE WF, 1980, NATURE, V284, P601, DOI 10.1038/284601a0; ECONOMOU EP, 1990, P NATL ACAD SCI USA, V87, P2951, DOI 10.1073/pnas.87.8.2951; Ferrigno O, 2001, NAT GENET, V28, P77, DOI 10.1038/ng0501-77; Feschotte C, 2008, NAT REV GENET, V9, P397, DOI 10.1038/nrg2337; Fritz JH, 2006, NAT IMMUNOL, V7, P1250, DOI 10.1038/ni1412; Harton JA, 2002, J IMMUNOL, V169, P4088, DOI 10.4049/jimmunol.169.8.4088; Hasler J, 2007, CELL MOL LIFE SCI, V64, P1793, DOI 10.1007/s00018-007-7084-0; Hebb ALO, 2008, MULT SCLER J, V14, P577, DOI 10.1177/1352458507087468; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Jordan IK, 2003, TRENDS GENET, V19, P68, DOI 10.1016/S0168-9525(02)00006-9; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kim DDY, 2004, GENOME RES, V14, P1719, DOI 10.1101/gr.2855504; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LAI CB, NUCLEIC ACI IN PRESS; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Langemeijer SMC, 2008, EXPERT OPIN THER TAR, V12, P981, DOI 10.1517/14728222.12.8.981 ; Lee JY, 2008, NUCLEIC ACIDS RES, V36, P5581, DOI 10.1093/nar/gkn540; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lev-Maor G, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000204; Lin L, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000225; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Lowe CB, 2007, P NATL ACAD SCI USA, V104, P8005, DOI 10.1073/pnas.0611223104; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Maier JKX, 2007, J HISTOCHEM CYTOCHEM, V55, P911, DOI 10.1369/jhc.6A7144.2007; MAKALOWSKI W, 1994, TRENDS GENET, V10, P188, DOI 10.1016/0168-9525(94)90254-2; Makalowski W, 2000, GENE, V259, P61, DOI 10.1016/S0378-1119(00)00436-4; MCCLINTOCK B, 1953, GENETICS, V38, P579; MCDADE JE, 1977, NEW ENGL J MED, V297, P1197, DOI 10.1056/NEJM197712012972202; Medstrand P, 2002, GENOME RES, V12, P1483, DOI 10.1101/gr.388902; Molofsky AB, 2006, J EXP MED, V203, P1093, DOI 10.1084/jem.20051659; Nakagawa S, 2008, NUCLEIC ACIDS RES, V36, P861, DOI 10.1093/nar/gkm1102; Nigumann P, 2002, GENOMICS, V79, P628, DOI 10.1006/geno.2002.6758; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Pennacchio LA, 2006, NATURE, V444, P499, DOI 10.1038/nature05295; Raulet DH, 2001, ANNU REV IMMUNOL, V19, P291, DOI 10.1146/annurev.immunol.19.1.291; Ren T, 2006, PLOS PATHOG, V2, P175, DOI 10.1371/journal.ppat.0020018; Romanish MT, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030010; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Schmutz J, 2004, NATURE, V431, P268, DOI 10.1038/nature02919; Seidl R, 1999, J NEURAL TRANSM-SUPP, P283; Shankar R, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-37; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Singer SS, 2004, J MOL BIOL, V341, P883, DOI 10.1016/j.jmb.2004.06.070; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Sorek R, 2002, GENOME RES, V12, P1060, DOI 10.1101/gr.229302; Tomilin NV, 2008, BIOESSAYS, V30, P338, DOI 10.1002/bies.20741; Tran VK, 2008, PEDIATR INT, V50, P346, DOI 10.1111/j.1442-200X.2008.02590.x; van de Lagemaat LN, 2003, TRENDS GENET, V19, P530, DOI 10.1016/j.tig.2003.08.004; Vinzing M, 2008, J IMMUNOL, V180, P6808, DOI 10.4049/jimmunol.180.10.6808; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Xu M, 2002, BBA-GENE STRUCT EXPR, V1574, P35, DOI 10.1016/S0167-4781(01)00343-8; Zamboni DS, 2006, NAT IMMUNOL, V7, P318, DOI 10.1038/ni1305	65	41	41	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2009	4	6							e5761	10.1371/journal.pone.0005761	http://dx.doi.org/10.1371/journal.pone.0005761			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453CI	19488400	gold, Green Submitted, Green Published			2022-12-25	WOS:000266587400004
J	Myers, BR; Sigal, YM; Julius, D				Myers, Benjamin R.; Sigal, Yaron M.; Julius, David			Evolution of Thermal Response Properties in a Cold-Activated TRP Channel	PLOS ONE			English	Article								Animals sense changes in ambient temperature irrespective of whether core body temperature is internally maintained (homeotherms) or subject to environmental variation (poikilotherms). Here we show that a cold-sensitive ion channel, TRPM8, displays dramatically different thermal activation ranges in frogs versus mammals or birds, consistent with variations in these species' cutaneous and core body temperatures. Thus, somatosensory receptors are not static through evolution, but show functional diversity reflecting the characteristics of an organism's ecological niche.			Myers, BR (corresponding author), Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA.	julius@cmp.ucsf.edu						BANKER G, 1998, CULTURING NERVE CELL; Bautista DM, 2007, NATURE, V448, P204, DOI 10.1038/nature05910; CASTERLIN ME, 1980, HYDROBIOLOGIA, V75, P3; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chuang HH, 2004, NEURON, V43, P859, DOI 10.1016/j.neuron.2004.08.038; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Colburn RW, 2007, NEURON, V54, P379, DOI 10.1016/j.neuron.2007.04.017; Dhaka A, 2007, NEURON, V54, P371, DOI 10.1016/j.neuron.2007.02.024; Dhaka A, 2006, ANNU REV NEUROSCI, V29, P135, DOI 10.1146/annurev.neuro.29.051605.112958; Hirsch N, 2002, DEV DYNAM, V225, P422, DOI 10.1002/dvdy.10178; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Julius David, 2005, Harvey Lect, V101, P89; Lee HS, 2005, J NEUROSCI, V25, P1304, DOI 10.1523/JNEUROSCI.4745.04.2005; Lin H, 2005, POULTRY SCI, V84, P1166, DOI 10.1093/ps/84.8.1166; LOUMONT C, 1984, REV SUISSE ZOOL, V91, P725, DOI 10.5962/bhl.part.81578; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Nathans J, 1999, NEURON, V24, P299, DOI 10.1016/S0896-6273(00)80845-4; Niimura Y, 2006, J HUM GENET, V51, P505, DOI 10.1007/s10038-006-0391-8; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Rohacs T, 2005, NAT NEUROSCI, V8, P626, DOI 10.1038/nn1451; Saito S, 2006, PHYSIOL GENOMICS, V27, P219, DOI 10.1152/physiolgenomics.00322.2005; Seebacher F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000281; Tsuruda PR, 2006, NEURON, V51, P201, DOI 10.1016/j.neuron.2006.06.023; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; YOCHIM JM, 1976, AM J PHYSIOL, V231, P361, DOI 10.1152/ajplegacy.1976.231.2.361	25	52	52	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5741	10.1371/journal.pone.0005741	http://dx.doi.org/10.1371/journal.pone.0005741			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451SH	19492038	gold, Green Published, Green Submitted			2022-12-25	WOS:000266490000015
J	Ticini, LF; Klose, U; Nagele, T; Karnath, HO				Ticini, Luca Francesco; Klose, Uwe; Naegele, Thomas; Karnath, Hans-Otto			Perfusion Imaging in Pusher Syndrome to Investigate the Neural Substrates Involved in Controlling Upright Body Position	PLOS ONE			English	Article								Brain damage may induce a dysfunction of upright body position termed "pusher syndrome''. Patients with such disorder suffer from an alteration of their sense of body verticality. They experience their body as oriented upright when actually tilted nearly 20 degrees to the ipsilesional side. Pusher syndrome typically is associated with posterior thalamic stroke; less frequently with extra-thalamic lesions. This argued for a fundamental role of these structures in our control of upright body posture. Here we investigated whether such patients may show additional functional or metabolic abnormalities outside the areas of brain lesion. We investigated 19 stroke patients with thalamic or with extra-thalamic lesions showing versus not showing misperception of body orientation. We measured fluid-attenuated inversion-recovery (FLAIR) imaging, diffusion-weighted imaging (DWI), and perfusion-weighted imaging (PWI). This allowed us to determine the structural damage as well as to identify the malperfused but structural intact tissue. Pusher patients with thalamic lesions did not show dysfunctional brain areas in addition to the ones found to be structurally damaged. In the pusher patients with extra-thalamic lesions, the thalamus was neither structurally damaged nor malperfused. Rather, these patients showed small regions of abnormal perfusion in the structurally intact inferior frontal gyrus, middle temporal gyrus, inferior parietal lobule, and parietal white matter. The results indicate that these extra-thalamic brain areas contribute to the network controlling upright body posture. The data also suggest that damage of the neural tissue in the posterior thalamus itself rather than additional malperfusion in distant cortical areas is associated with pusher syndrome. Hence, it seems as if the normal functioning of both extra-thalamic as well as posterior thalamic structures is integral to perceiving gravity and controlling upright body orientation in humans.			Ticini, LF (corresponding author), Univ Tubingen, Hertie Inst Clin Brain Res, Ctr Neurol, Sect Neuropsychol, Tubingen, Germany.	Karnath@uni-tuebingen.de	Klose, Uwe/M-7110-2013; Ticini, Luca/D-2532-2014	Klose, Uwe/0000-0001-5236-3450; Ticini, Luca/0000-0002-4967-2460				Aubert-Broche B, 2003, PHYS MED BIOL, V48, P1505, DOI 10.1088/0031-9155/48/11/302; BARON JC, 1986, BRAIN, V109, P1243, DOI 10.1093/brain/109.6.1243; BARON JC, 1992, J NEUROL NEUROSUR PS, V55, P935, DOI 10.1136/jnnp.55.10.935; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; BELLIVEAU JW, 1990, MAGNET RESON MED, V14, P538, DOI 10.1002/mrm.1910140311; Bisdorff AR, 1996, BRAIN, V119, P1523, DOI 10.1093/brain/119.5.1523; Bohning DE, 2001, INVEST RADIOL, V36, P470, DOI 10.1097/00004424-200108000-00006; BRANDT T, 1994, ANN NEUROL, V35, P403, DOI 10.1002/ana.410350406; BrantZawadzki M, 1996, STROKE, V27, P1187, DOI 10.1161/01.STR.27.7.1187; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Burgel U, 2006, NEUROIMAGE, V29, P1092, DOI 10.1016/j.neuroimage.2005.08.040; Calamante F, 2002, STROKE, V33, P1146, DOI 10.1161/01.STR.0000014208.05597.33; Cappe C, 2007, NEUROSCIENCE, V146, P1371, DOI 10.1016/j.neuroscience.2007.02.033; Chae JH, 2003, J PSYCHIATR RES, V37, P443, DOI 10.1016/S0022-3956(03)00074-8; Dieterich M, 2005, BRAIN, V128, P2052, DOI 10.1093/brain/awh551; DIETERICH M, 1993, NEUROLOGY, V43, P1732, DOI 10.1212/WNL.43.9.1732; Dieterich M, 2007, BRAIN, V130, P2108, DOI 10.1093/brain/awm130; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Engelborghs S, 1998, ACTA NEUROL BELG, V98, P252; Fasold O, 2002, NEUROIMAGE, V17, P1384, DOI 10.1006/nimg.2002.1241; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Fruhmann-Berger M, 2005, J NEUROL, V252, P1194, DOI 10.1007/s00415-005-0831-y; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; Hillis AE, 2001, ANN NEUROL, V50, P561, DOI 10.1002/ana.1265; HORAK FB, 1994, EXP BRAIN RES, V100, P93; Johannsen L, 2006, J NEUROL, V253, P455, DOI 10.1007/s00415-005-0025-7; Johannsen L, 2004, J CLIN EXP NEUROPSYC, V26, P251, DOI 10.1076/jcen.26.2.251.28085; Johannsen L, 2006, J NEUROL, V253, P1367, DOI 10.1007/s00415-006-0216-x; Johansen-Berg H, 2005, CEREB CORTEX, V15, P31, DOI 10.1093/cercor/bhh105; Jones EG, 1995, THALAMUS; Kahane P, 2003, ANN NEUROL, V54, P615, DOI 10.1002/ana.10726; Karnath HO, 2007, NEUROREHAB NEURAL RE, V21, P370, DOI 10.1177/1545968307300702; Karnath HO, 2007, J NEUROL, V254, P415, DOI 10.1007/s00415-006-0341-6; Karnath HO, 2005, NEUROLOGY, V64, P1014, DOI 10.1212/01.WNL.0000154527.72841.4A; Karnath HO, 2003, PHYS THER, V83, P1119, DOI 10.1093/ptj/83.12.1119; Karnath HO, 2005, BRAIN, V128, P2462, DOI 10.1093/brain/awh629; Karnath HO, 2000, NEUROLOGY, V55, P1298, DOI 10.1212/WNL.55.9.1298; Karnath HO, 2000, P NATL ACAD SCI USA, V97, P13931, DOI 10.1073/pnas.240279997; Klose U, 1999, ROFO-FORTSCHR RONTG, V170, P474, DOI 10.1055/s-2007-1011076; Liu YJ, 2002, J NEUROIMAGING, V12, P330, DOI 10.1111/j.1552-6569.2002.tb00141.x; MASDEU JC, 1988, ANN NEUROL, V23, P596, DOI 10.1002/ana.410230612; Massion Jean, 1994, Current Opinion in Neurobiology, V4, P877, DOI 10.1016/0959-4388(94)90137-6; Mittelstaedt H., 1964, Symposia of the Society for Experimental Biology, V18, P365; Mittelstaedt H, 1998, NEUROSCI BIOBEHAV R, V22, P473, DOI 10.1016/S0149-7634(97)00032-8; Mullins ME, 2002, RADIOLOGY, V224, P353, DOI 10.1148/radiol.2242010873; Narayanan JT, 2002, EPILEPSIA, V43, P1509, DOI 10.1046/j.1528-1157.2002.16102.x; Neumann-Haefelin T, 1999, STROKE, V30, P1591, DOI 10.1161/01.STR.30.8.1591; Noguchi K, 1997, NEURORADIOLOGY, V39, P406, DOI 10.1007/s002340050433; Padberg J, 2006, J COMP NEUROL, V497, P416, DOI 10.1002/cne.21005; Palmer E, 1996, NEUROLOGY, V46, P471, DOI 10.1212/WNL.46.2.471; Ricci PE, 1999, AM J NEURORADIOL, V20, P1535; Rorden C, 2004, NAT REV NEUROSCI, V5, P813, DOI 10.1038/nrn1521; Rorden C, 2007, J COGNITIVE NEUROSCI, V19, P1081, DOI 10.1162/jocn.2007.19.7.1081; Santos-Pontelli TEG, 2004, J NEUROL, V251, P1324, DOI 10.1007/s00415-004-0532-y; Schaefer PW, 2002, AM J NEURORADIOL, V23, P1785; Schlindwein P, 2008, NEUROIMAGE, V39, P19, DOI 10.1016/j.neuroimage.2007.08.016; Spinazzola L, 2003, BRAIN, V126, P2656, DOI 10.1093/brain/awg266; Thijs VN, 2004, STROKE, V35, P94, DOI 10.1161/01.STR.0000106136.15163.73; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Weintraub S., 1985, PRINCIPLES BEHAV NEU, P71; Yamada K, 2002, STROKE, V33, P87, DOI 10.1161/hs0102.101893	61	38	43	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5737	10.1371/journal.pone.0005737	http://dx.doi.org/10.1371/journal.pone.0005737			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451SH	19478939	Green Published, Green Submitted, gold			2022-12-25	WOS:000266490000013
J	Lu, J; Fiala, JC; Lichtman, JW				Lu, Ju; Fiala, John C.; Lichtman, Jeff W.			Semi-Automated Reconstruction of Neural Processes from Large Numbers of Fluorescence Images	PLOS ONE			English	Article								We introduce a method for large scale reconstruction of complex bundles of neural processes from fluorescent image stacks. We imaged yellow fluorescent protein labeled axons that innervated a whole muscle, as well as dendrites in cerebral cortex, in transgenic mice, at the diffraction limit with a confocal microscope. Each image stack was digitally re-sampled along an orientation such that the majority of axons appeared in cross-section. A region growing algorithm was implemented in the open-source Reconstruct software and applied to the semi-automatic tracing of individual axons in three dimensions. The progression of region growing is constrained by user-specified criteria based on pixel values and object sizes, and the user has full control over the segmentation process. A full montage of reconstructed axons was assembled from the similar to 200 individually reconstructed stacks. Average reconstruction speed is similar to 0.5 mm per hour. We found an error rate in the automatic tracing mode of similar to 1 error per 250 um of axonal length. We demonstrated the capacity of the program by reconstructing the connectome of motor axons in a small mouse muscle.			Lu, J (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	jeff@mcb.harvard.edu						Al-Kofahi KA, 2003, IEEE T INF TECHNOL B, V7, P302, DOI 10.1109/TITB.2003.816564; Al-Kofahi KA, 2002, IEEE T INF TECHNOL B, V6, P171, DOI 10.1109/TITB.2002.1006304; Cai HM, 2006, NEUROIMAGE, V32, P1608, DOI 10.1016/j.neuroimage.2006.05.036; Castleman K. R., 1996, DIGITAL IMAGE PROCES; CONCHELLO JA, 1994, APPL OPTICS, V33, P3740, DOI 10.1364/AO.33.003740; Dima A, 2002, IEEE T IMAGE PROCESS, V11, P790, DOI 10.1109/TIP.2002.800888; Dodt HU, 2007, NAT METHODS, V4, P331, DOI 10.1038/NMETH1036; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Fiala JC, 2005, J MICROSC-OXFORD, V218, P52, DOI 10.1111/j.1365-2818.2005.01466.x; HALL DH, 1991, J NEUROSCI, V11, P1; Jurrus E, 2009, MED IMAGE ANAL, V13, P180, DOI 10.1016/j.media.2008.05.002; Livet J, 2007, NATURE, V450, P56, DOI 10.1038/nature06293; Lu J, 2009, PLOS BIOL, V7, P265, DOI 10.1371/journal.pbio.1000032; Macke JH, 2008, J NEUROSCI METH, V167, P349, DOI 10.1016/j.jneumeth.2007.07.021; Meijering E, 2004, CYTOM PART A, V58A, P167, DOI 10.1002/cyto.a.20022; Micheva KD, 2007, NEURON, V55, P25, DOI 10.1016/j.neuron.2007.06.014; Verveer PJ, 2007, NAT METHODS, V4, P311, DOI 10.1038/NMETH1017; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	18	48	48	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2009	4	5							e5655	10.1371/journal.pone.0005655	http://dx.doi.org/10.1371/journal.pone.0005655			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LB	19479070	Green Published, Green Submitted, gold			2022-12-25	WOS:000266331000013
J	Shroff, EH; Snyder, CM; Budinger, GRS; Jain, M; Chew, TL; Khuon, S; Perlman, H; Chandel, NS				Shroff, Emelyn H.; Snyder, Colleen M.; Budinger, G. R. Scott; Jain, Manu; Chew, Teng-Leong; Khuon, Satya; Perlman, Harris; Chandel, Navdeep S.			BH3 Peptides Induce Mitochondrial Fission and Cell Death Independent of BAX/BAK	PLOS ONE			English	Article								BH3 only proteins trigger cell death by interacting with pro- and anti-apoptotic members of the BCL-2 family of proteins. Here we report that BH3 peptides corresponding to the death domain of BH3-only proteins, which bind all the pro-survival BCL-2 family proteins, induce cell death in the absence of BAX and BAK. The BH3 peptides did not cause the release of cytochrome c from isolated mitochondria or from mitochondria in cells. However, the BH3 peptides did cause a decrease in mitochondrial membrane potential but did not induce the opening of the mitochondrial permeability transition pore. Interestingly, the BH3 peptides induced mitochondria to undergo fission in the absence of BAX and BAK. The binding of BCL-XL with dynamin-related protein 1 (DRP1), a GTPase known to regulate mitochondrial fission, increased in the presence of BH3 peptides. These results suggest that pro-survival BCL-2 proteins regulate mitochondrial fission and cell death in the absence of BAX and BAK.			Shroff, EH (corresponding author), Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA.	nav@northwestern.edu			NHLBI NIH HHS [P01 HL071643, HL071643-06A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL071643] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alirol E, 2006, MOL BIOL CELL, V17, P4593, DOI 10.1091/mbc.E06-05-0377; Breckenridge DG, 2008, MOL CELL, V31, P586, DOI 10.1016/j.molcel.2008.07.015; Brunelle JK, 2007, MOL CELL BIOL, V27, P1222, DOI 10.1128/MCB.01535-06; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Cepero E, 2005, ONCOGENE, V24, P6354, DOI 10.1038/sj.onc.1208793; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045; FRANCIS B, 2001, SEX ED, V1, P1; Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Goldstein JC, 2005, CELL DEATH DIFFER, V12, P453, DOI 10.1038/sj.cdd.4401596; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hoppins S, 2007, ANNU REV BIOCHEM, V76, P751, DOI 10.1146/annurev.biochem.76.071905.090048; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316; James DI, 2008, DEV CELL, V15, P341, DOI 10.1016/j.devcel.2008.08.011; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lettre G, 2006, NAT REV MOL CELL BIO, V7, P97, DOI 10.1038/nrm1836; Li H, 2008, P NATL ACAD SCI USA, V105, P2169, DOI 10.1073/pnas.0711647105; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Parone PA, 2006, MOL CELL BIOL, V26, P7397, DOI 10.1128/MCB.02282-05; Rinkenberger JL, 2000, GENE DEV, V14, P23; Sheridan C, 2008, MOL CELL, V31, P570, DOI 10.1016/j.molcel.2008.08.002; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Wei MC, 2000, GENE DEV, V14, P2060; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Yamaguchi R, 2008, MOL CELL, V31, P557, DOI 10.1016/j.molcel.2008.07.010; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	40	22	23	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2009	4	5							e5646	10.1371/journal.pone.0005646	http://dx.doi.org/10.1371/journal.pone.0005646			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LB	19468307	Green Published, Green Submitted, gold			2022-12-25	WOS:000266331000005
J	Deguchi, A; Miyamoto, K; Kuwahara, T; Miki, Y; Kaneko, I; Li, JH; McClane, BA; Akimoto, S				Deguchi, Agi; Miyamoto, Kazuaki; Kuwahara, Tomomi; Miki, Yasuhiro; Kaneko, Ikuko; Li, Jihong; McClane, Bruce A.; Akimoto, Shigeru			Genetic Characterization of Type A Enterotoxigenic Clostridium perfringens Strains	PLOS ONE			English	Article								Clostridium perfringens type A, is both a ubiquitous environmental bacterium and a major cause of human gastrointestinal disease, which usually involves strains producing C. perfringens enterotoxin (CPE). The gene (cpe) encoding this toxin can be carried on the chromosome or a large plasmid. Interestingly, strains carrying cpe on the chromosome and strains carrying cpe on a plasmid often exhibit different biological characteristics, such as resistance properties against heat. In this study, we investigated the genetic properties of C. perfringens by PCR-surveying 21 housekeeping genes and genes on representative plasmids and then confirmed those results by Southern blot assay (SB) of five genes. Furthermore, sequencing analysis of eight housekeeping genes and multilocus sequence typing (MLST) analysis were also performed. Fifty-eight C. perfringens strains were examined, including isolates from: food poisoning cases, human gastrointestinal disease cases, foods in Japan or the USA, or feces of healthy humans. In the PCR survey, eight of eleven housekeeping genes amplified positive reactions in all strains tested. However, by PCR survey and SB assay, one representative virulence gene, pfoA, was not detected in any strains carrying cpe on the chromosome. Genes involved in conjugative transfer of the cpe plasmid were also absent from almost all chromosomal cpe strains. MLST showed that, regardless of their geographic origin, date of isolation, or isolation source, chromosomal cpe isolates, i) assemble into one definitive cluster ii) lack pfoA and iii) lack a plasmid related to the cpe plasmid. Similarly, independent of their origin, strains carrying a cpe plasmid also appear to be related, but are more variable than chromosomal cpe strains, possibly because of the instability of cpe-borne plasmid(s) and/or the conjugative transfer of cpe-plasmid(s) into unrelated C. perfringens strains.			Deguchi, A (corresponding author), Wakayama Med Univ, Dept Microbiol, Sch Med, Wakayama, Japan.	kazuaki@wakayama-med.ac.jp			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI019844] Funding Source: NIH RePORTER; NIAID NIH HHS [R37AI19844, R37 AI019844] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bannam TL, 2006, J BACTERIOL, V188, P4942, DOI 10.1128/JB.00298-06; Brynestad S, 1999, FEMS MICROBIOL LETT, V170, P281, DOI 10.1016/S0378-1097(98)00557-6; Brynestad S, 2001, INFECT IMMUN, V69, P3483, DOI 10.1128/IAI.69.5.3483-3487.2001; Chalmers G, 2008, J CLIN MICROBIOL, V46, P3957, DOI 10.1128/JCM.01548-08; Collie RE, 1998, J CLIN MICROBIOL, V36, P30, DOI 10.1128/JCM.36.1.30-36.1998; Enright MC, 1999, TRENDS MICROBIOL, V7, P482, DOI 10.1016/S0966-842X(99)01609-1; GARNIER T, 1988, PLASMID, V19, P134, DOI 10.1016/0147-619X(88)90052-2; Harry KH, 2009, J BACTERIOL, V191, P2728, DOI 10.1128/JB.01839-08; Johansson A, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-47; Jost BH, 2006, VET MICROBIOL, V116, P158, DOI 10.1016/j.vetmic.2006.03.025; KAWAI T, 1998, OSAKA FURITU KOSHU E, V36, P191; Lahti P, 2008, J CLIN MICROBIOL, V46, P371, DOI 10.1128/JCM.01650-07; Li JH, 2007, APPL ENVIRON MICROB, V73, P7218, DOI 10.1128/AEM.01075-07; Li JH, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000056; Li JH, 2006, APPL ENVIRON MICROB, V72, P4561, DOI 10.1128/AEM.00177-06; Li JH, 2006, APPL ENVIRON MICROB, V72, P7620, DOI 10.1128/AEM.01911-06; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; MATCHES JR, 1974, APPL MICROBIOL, V28, P655, DOI 10.1128/AEM.28.4.655-660.1974; McClane Bruce A., 2005, P385, DOI 10.1201/9780203489819.ch18; MEREDITH L, 2007, J BACTERIOL, V189, P7531; Miki Y, 2008, APPL ENVIRON MICROB, V74, P5366, DOI 10.1128/AEM.00783-08; Miyamoto K, 2006, J BACTERIOL, V188, P1585, DOI 10.1128/JB.188.4.1585-1598.2006; Miyamoto K, 2004, J CLIN MICROBIOL, V42, P1552, DOI 10.1128/JCM.42.4.1552-1558.2004; Miyamoto K, 2002, INFECT IMMUN, V70, P4261, DOI 10.1128/IAI.70.8.4261-4272.2002; Myers GSA, 2006, GENOME RES, V16, P1031, DOI 10.1101/gr.5238106; Parsons JA, 2007, J BACTERIOL, V189, P7782, DOI 10.1128/JB.00783-07; Rooney AP, 2006, GENETICS, V172, P2081, DOI 10.1534/genetics.105.054601; Sarker MR, 2000, APPL ENVIRON MICROB, V66, P3234, DOI 10.1128/AEM.66.8.3234-3240.2000; Sayeed S, 2008, MOL MICROBIOL, V67, P15, DOI 10.1111/j.1365-2958.2007.06007.x; Shimizu T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/pnas.022493799; SUTTON RGA, 1965, J HYG CAMB, V66, P135; Tanaka D, 2003, JPN J INFECT DIS, V56, P137; Tanaka D, 2007, JPN J INFECT DIS, V60, P68; Urwin R, 2003, TRENDS MICROBIOL, V11, P479, DOI 10.1016/j.tim.2003.08.006; Wen QY, 2004, APPL ENVIRON MICROB, V70, P2685, DOI 10.1128/AEM.70.5.2685-2691.2004; YAMAGISHI T, 1983, MICROBIOL IMMUNOL, V27, P291, DOI 10.1111/j.1348-0421.1983.tb03591.x	36	59	60	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5598	10.1371/journal.pone.0005598	http://dx.doi.org/10.1371/journal.pone.0005598			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19479065	gold, Green Published, Green Accepted			2022-12-25	WOS:000266161200002
J	Agouni, A; Lagrue-Lak-Hal, AH; Mostefai, HA; Tesse, A; Mulder, P; Rouet, P; Desmoulin, F; Heymes, C; Martinez, MC; Andriantsitohaina, R				Agouni, Abdelali; Lagrue-Lak-Hal, Anne-Helene; Mostefai, Hadj Ahmed; Tesse, Angela; Mulder, Paul; Rouet, Philippe; Desmoulin, Franck; Heymes, Christophe; Martinez, Maria Carmen; Andriantsitohaina, Ramaroson			Red Wine Polyphenols Prevent Metabolic and Cardiovascular Alterations Associated with Obesity in Zucker Fatty Rats (Fa/Fa)	PLOS ONE			English	Article							PORCINE CORONARY-ARTERIES; EDHF-MEDIATED RELAXATIONS; INSULIN-RESISTANCE; ENDOTHELIAL DYSFUNCTION; BLOOD-PRESSURE; GRAPE JUICE; HYPERTENSION; MODEL; SUSCEPTIBILITY; CONSUMPTION	Background: Obesity is associated with increased risks for development of cardiovascular diseases. Epidemiological studies report an inverse association between dietary flavonoid consumption and mortality from cardiovascular diseases. We studied the potential beneficial effects of dietary supplementation of red wine polyphenol extract, Provinols (TM), on obesity-associated alterations with respect to metabolic disturbances and cardiovascular functions in Zucker fatty (ZF) rats. Methodology/Principal Findings: ZF rats or their lean littermates received normal diet or supplemented with Provinols (TM) for 8 weeks. Provinols (TM) improved glucose metabolism by reducing plasma glucose and fructosamine in ZF rats. Moreover, it reduced circulating triglycerides and total cholesterol as well as LDL-cholesterol in ZF rats. Echocardiography measurements demonstrated that Provinols (TM) improved cardiac performance as evidenced by an increase in left ventricular fractional shortening and cardiac output associated with decreased peripheral arterial resistances in ZF rats. Regarding vascular function, Provinols (TM) corrected endothelial dysfunction in aortas from ZF rats by improving endothelium-dependent relaxation in response to acetylcholine (Ach). Provinols (TM) enhanced NO bioavailability resulting from increased nitric oxide (NO) production through enhanced endothelial NO-synthase (eNOS) activity and reduced superoxide anion release via decreased expression of NADPH oxidase membrane sub-unit, Nox-1. In small mesenteric arteries, although Provinols (TM) did not affect the endothelium-dependent response to Ach; it enhanced the endothelial-derived hyperpolarizing factor component of the response. Conclusions/Significance: Use of red wine polyphenols may be a potential mechanism for prevention of cardiovascular and metabolic alterations associated with obesity.			Agouni, A (corresponding author), Univ Aberdeen, Inst Biol & Environm Sci, Aberdeen, Scotland.	ramaroson.andriantsitohaina@univ-angers.fr	Heymes, Christophe/Y-9368-2019; DESMOULIN, Franck/O-1895-2018; ANDRIANTSITOHAINA, Ramaroson/H-5286-2018; Agouni, Abdelali/AAP-5298-2020; desmoulin, franck/AAU-4544-2020; Tesse, Angela/D-4803-2015	Heymes, Christophe/0000-0002-6666-6193; DESMOULIN, Franck/0000-0003-0560-6266; Agouni, Abdelali/0000-0002-8363-1582; desmoulin, franck/0000-0003-0560-6266; Tesse, Angela/0000-0002-2153-4357; andriantsitohaina, ramaroson/0000-0002-4770-3585; Martinez, M Carmen/0000-0003-3897-7397; Rouet, Philippe/0000-0001-6204-2079; Mulder, Paul/0000-0002-5936-5704				Agouni A, 2007, FASEB J, V21, P2735, DOI 10.1096/fj.07-8079com; Andriambeloson E, 1997, BRIT J PHARMACOL, V120, P1053, DOI 10.1038/sj.bjp.0701011; Baron-Menguy C, 2007, FASEB J, V21, P3511, DOI 10.1096/fj.06-7782com; Bernatova I, 2002, AM J PHYSIOL-HEART C, V282, pH942, DOI 10.1152/ajpheart.00724.2001; Cersosimo E, 2006, DIABETES-METAB RES, V22, P423, DOI 10.1002/dmrr.634; Conseil G, 1998, P NATL ACAD SCI USA, V95, P9831, DOI 10.1073/pnas.95.17.9831; Curin Y., 2006, Cardiovascular & Hematological Agents in Medicinal Chemistry, V4, P277, DOI 10.2174/187152506778520691; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DeFronzo RA, 2006, ATHEROSCLEROSIS SUPP, V7, P11, DOI 10.1016/j.atherosclerosissup.2006.05.002; Diebolt M, 2001, HYPERTENSION, V38, P159, DOI 10.1161/01.HYP.38.2.159; Fornoni A, 2005, CURR HYPERTENS REP, V7, P88, DOI 10.1007/s11906-005-0080-6; Galisteo M, 2005, J NUTR, V135, P2399, DOI 10.1093/jn/135.10.2399; Hsueh WA, 2004, AM J MED, V117, P109, DOI 10.1016/j.amjmed.2004.02.042; Iida M, 1996, BIOCHEM BIOPH RES CO, V222, P19, DOI 10.1006/bbrc.1996.0691; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; KURTZ TW, 1989, HYPERTENSION, V13, P896, DOI 10.1161/01.HYP.13.6.896; Lee SD, 2008, J APPL PHYSIOL, V104, P1144, DOI 10.1152/japplphysiol.00152.2007; Lerman A, 2005, CIRCULATION, V111, P363, DOI 10.1161/01.CIR.0000153339.27064.14; Leslie EM, 2001, MOL PHARMACOL, V59, P1171, DOI 10.1124/mol.59.5.1171; Middleton E, 2000, PHARMACOL REV, V52, P673; Montagne CT, 2000, DIABETES, V49, P883, DOI 10.2337/diabetes.49.6.883; Napoli R, 2005, METABOLISM, V54, P306, DOI 10.1016/j.metabol.2004.09.010; Ndiaye M, 2004, BRIT J PHARMACOL, V142, P1131, DOI 10.1038/sj.bjp.0705774; Ndiaye M, 2003, BIOCHEM BIOPH RES CO, V310, P371, DOI 10.1016/j.bbrc.2003.09.028; Nigdikar SV, 1998, AM J CLIN NUTR, V68, P258, DOI 10.1093/ajcn/68.2.258; Ohlmann P, 1997, BRIT J PHARMACOL, V121, P657, DOI 10.1038/sj.bjp.0701169; Pechanova O, 2006, PHYSIOL RES, V55, pS17, DOI 10.33549/physiolres.930000.55.S1.17; Pechanova O, 2004, J HYPERTENS, V22, P1551, DOI 10.1097/01.hjh.0000133734.32125.c7; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Puzserova A, 2006, PHYSIOL RES, V55, pS39, DOI 10.33549/physiolres.930000.55.S1.39; Ranaivo HR, 2004, BRIT J PHARMACOL, V142, P671, DOI 10.1038/sj.bjp.0705833; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; Ritz MF, 2008, J NUTR, V138, P519, DOI 10.1093/jn/138.3.519; Rivera L, 2009, BIOCHEM PHARMACOL, V77, P1053, DOI 10.1016/j.bcp.2008.11.027; Sarr M, 2006, CARDIOVASC RES, V71, P794, DOI 10.1016/j.cardiores.2006.05.022; Stein JH, 1999, CIRCULATION, V100, P1050, DOI 10.1161/01.CIR.100.10.1050; Steinberg HO, 1996, J CLIN INVEST, V97, P2601, DOI 10.1172/JCI118709; STURM W, 2009, OBESITY SILVER SPRIN; Su HC, 2006, AM J PHYSIOL-ENDOC M, V290, pE1339, DOI 10.1152/ajpendo.00487.2005; Subramanian R, 2003, EUR J PHARMACOL, V477, P143, DOI 10.1016/j.ejphar.2003.08.003; TERRETTAZ J, 1986, ENDOCRINOLOGY, V118, P674, DOI 10.1210/endo-118-2-674; Vinson JA, 2001, ATHEROSCLEROSIS, V156, P67, DOI 10.1016/S0021-9150(00)00625-0; ZUCKER LM, 1972, ENDOCRINOLOGY, V90, P1320, DOI 10.1210/endo-90-5-1320	43	90	95	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5557	10.1371/journal.pone.0005557	http://dx.doi.org/10.1371/journal.pone.0005557			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440378	Green Submitted, Green Published, gold			2022-12-25	WOS:000266107500003
J	Schuck, SD; Mueller, H; Kunitz, F; Neher, A; Hoffmann, H; Franken, KLCM; Repsilber, D; Ottenhoff, THM; Kaufmann, SHE; Jacobsen, M				Schuck, Sebastian D.; Mueller, Henrik; Kunitz, Frank; Neher, Albert; Hoffmann, Harald; Franken, Kees L. C. M.; Repsilber, Dirk; Ottenhoff, Tom H. M.; Kaufmann, Stefan H. E.; Jacobsen, Marc			Identification of T-Cell Antigens Specific for Latent Mycobacterium Tuberculosis Infection	PLOS ONE			English	Article							DORMANCY REGULON; PROTEINS; VACCINATION; PROTECTION; RESPONSES; ASSAY; REACTIVITY; DISEASE; GENES	Background: T-cell responses against dormancy-, resuscitation-, and reactivation-associated antigens of Mycobacterium tuberculosis are candidate biomarkers of latent infection in humans. Methodology/Principal Findings: We established an assay based on two rounds of in vitro restimulation and intracellular cytokine analysis that detects T-cell responses to antigens expressed during latent M. tuberculosis infection. Comparison between active pulmonary tuberculosis (TB) patients and healthy latently M. tuberculosis-infected donors (LTBI) revealed significantly higher T-cell responses against 7 of 35 tested M. tuberculosis latency-associated antigens in LTBI. Notably, T cells specific for Rv3407 were exclusively detected in LTBI but not in TB patients. The T-cell IFN gamma response against Rv3407 in individual donors was the most influential factor in discrimination analysis that classified TB patients and LTBI with 83% accuracy using cross-validation. Rv3407 peptide pool stimulations revealed distinct candidate epitopes in four LTBI. Conclusions: Our findings further support the hypothesis that the latency-associated antigens can be exploited as biomarkers for LTBI.			Schuck, SD (corresponding author), Max Planck Inst Infect Biol, Dept Immunol, Berlin, Germany.	kaufmann@mpiib-berlin.mpg.de	Franken, Kees/ABA-7095-2021; Kaufmann, Stefan HE/I-5454-2014	Franken, Kees/0000-0002-4747-6060; Kaufmann, Stefan HE/0000-0001-9866-8268; Jacobsen, Marc/0000-0002-4703-5652				Agranoff D, 2006, LANCET, V368, P1012, DOI 10.1016/S0140-6736(06)69342-2; Biketov S, 2000, FEMS IMMUNOL MED MIC, V29, P233, DOI 10.1016/S0928-8244(00)00210-8; Brahmbhatt S, 2006, CLIN EXP IMMUNOL, V146, P243, DOI 10.1111/j.1365-2249.2006.03211.x; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Cehovin A, 2007, CLIN VACCINE IMMUNOL, V14, P796, DOI 10.1128/CVI.00093-07; Chan J, 2004, CLIN IMMUNOL, V110, P2, DOI 10.1016/S1521-6616(03)00210-9; Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592; Downing KJ, 2004, TUBERCULOSIS, V84, P167, DOI 10.1016/j.tube.2003.12.004; Franken KLMC, 2000, PROTEIN EXPRES PURIF, V18, P95, DOI 10.1006/prep.1999.1162; Hanekom WA, 2004, J IMMUNOL METHODS, V291, P185, DOI 10.1016/j.jim.2004.06.010; JACOBSEN M, 2008, BIOL CHEM; Jacobsen M, 2007, J MOL MED, V85, P613, DOI 10.1007/s00109-007-0157-6; Kana BD, 2008, MOL MICROBIOL, V67, P672, DOI 10.1111/j.1365-2958.2007.06078.x; Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558; Krammer PH, 2007, NAT REV IMMUNOL, V7, P532, DOI 10.1038/nri2115; Lalvani A, 2007, CHEST, V131, P1898, DOI 10.1378/chest.06-2471; Leyten EMS, 2007, CLIN VACCINE IMMUNOL, V14, P880, DOI 10.1128/CVI.00132-07; Leyten EMS, 2006, MICROBES INFECT, V8, P2052, DOI 10.1016/j.micinf.2006.03.018; Maecker HT, 2001, J IMMUNOL METHODS, V255, P27, DOI 10.1016/S0022-1759(01)00416-1; Mattow J, 2001, ELECTROPHORESIS, V22, P2936, DOI 10.1002/1522-2683(200108)22:14<2936::AID-ELPS2936>3.0.CO;2-S; Mittrucker HW, 2007, P NATL ACAD SCI USA, V104, P12434, DOI 10.1073/pnas.0703510104; Mollenkopf HJ, 2004, INFECT IMMUN, V72, P6471, DOI 10.1128/IAI.72.11.6471-6479.2004; Mueller H, 2008, CYTOKINE, V43, P143, DOI 10.1016/j.cyto.2008.05.002; Ottenhoff THM, 2002, NAT GENET, V32, P97, DOI 10.1038/ng0902-97; Park HD, 2003, MOL MICROBIOL, V48, P833, DOI 10.1046/j.1365-2958.2003.03474.x; Regner M, 2001, IMMUNOL CELL BIOL, V79, P91, DOI 10.1046/j.1440-1711.2001.00994.x; Roupie V, 2007, INFECT IMMUN, V75, P941, DOI 10.1128/IAI.01137-06; Wayne LG, 1996, INFECT IMMUN, V64, P2062, DOI 10.1128/IAI.64.6.2062-2069.1996; Weir RE, 1999, CLIN EXP IMMUNOL, V116, P263; Yeremeev VV, 2003, INFECT IMMUN, V71, P4789, DOI 10.1128/IAI.71.8.4789-4794.2003	30	116	125	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5590	10.1371/journal.pone.0005590	http://dx.doi.org/10.1371/journal.pone.0005590			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440342	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107500018
J	van 't Wout, M; van Rijn, S; Jellema, T; Kahn, RS; Aleman, A				van 't Wout, Mascha; van Rijn, Sophie; Jellema, Tjeerd; Kahn, Rene S.; Aleman, Andre			Deficits in Implicit Attention to Social Signals in Schizophrenia and High Risk Groups: Behavioural Evidence from a New Illusion	PLOS ONE			English	Article							EMOTION-RECOGNITION DEFICIT; NEUROCOGNITIVE DEFICITS; KLINEFELTER-SYNDROME; FACIAL EMOTIONS; CUE PERCEPTION; VISUAL CONTEXT; NEURAL BASIS; CINGULATE; RELATIVES; SYMPTOMATOLOGY	Background: An increasing body of evidence suggests that the apparent social impairments observed in schizophrenia may arise from deficits in social cognitive processing capacities. The ability to process basic social cues, such as gaze direction and biological motion, effortlessly and implicitly is thought to be a prerequisite for establishing successful social interactions and for construing a sense of "social intuition." However, studies that address the ability to effortlessly process basic social cues in schizophrenia are lacking. Because social cognitive processing deficits may be part of the genetic vulnerability for schizophrenia, we also investigated two groups that have been shown to be at increased risk of developing schizophrenia-spectrum pathology: first-degree relatives of schizophrenia patients and men with Klinefelter syndrome (47, XXY). Results: We compared 28 patients with schizophrenia, 29 siblings of patients with schizophrenia, and 29 individuals with Klinefelter syndrome with 46 matched healthy control subjects on a new paradigm. This paradigm measures one's susceptibility for a bias in distance estimation between two agents that is induced by the implicit processing of gaze direction and biological motion conveyed by these agents. Compared to control subjects, patients with schizophrenia, as well as siblings of patients and Klinefelter men, showed a lack of influence of social cues on their distance judgments. Conclusions: We suggest that the insensitivity for social cues is a cognitive aspect of schizophrenia that may be seen as an endophenotype as it appears to be present both in relatives who are at increased genetic risk and in a genetic disorder at risk for schizophrenia-spectrum psychopathology. These social cue-processing deficits could contribute, in part, to the difficulties in higher order social cognitive tasks and, hence, to decreased social competence that has been observed in these groups.			van 't Wout, M (corresponding author), Univ Utrecht, Dept Expt Psychol, Helmholtz Inst, Utrecht, Netherlands.	maschavantwout@gmail.com	van 't Wout, Mascha/AAO-5710-2021; Aleman, Andre/E-1341-2012	van 't Wout, Mascha/0000-0002-1497-1989; van rijn, sophie/0000-0002-9179-7515				Aleman A, 2003, ARCH GEN PSYCHIAT, V60, P565, DOI 10.1001/archpsyc.60.6.565; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P615; APA, 1994, DIAGN STAT MAN MENT; Argyle M., 1976, GAZE MUTUAL GAZE; Ashton L, 1999, BEHAV NEUROL, V12, P93, DOI 10.1155/2000/913731; Baron-Cohen Simon, 1995, MINDBLINDNESS ESSAY; BAUM KM, 1995, SCHIZOPHR RES, V16, P111, DOI 10.1016/0920-9964(94)00071-F; BELLACK AS, 1990, BRIT J PSYCHIAT, V156, P809, DOI 10.1192/bjp.156.6.809; Bolte S, 2007, J AUTISM DEV DISORD, V37, P243, DOI 10.1007/s10803-006-0165-3; Bojesen A, 2006, J CLIN ENDOCR METAB, V91, P1254, DOI 10.1210/jc.2005-0697; Bojesen A, 2003, J CLIN ENDOCR METAB, V88, P622, DOI 10.1210/jc.2002-021491; Boks MPM, 2007, SCHIZOPHR RES, V93, P399, DOI 10.1016/j.schres.2007.03.015; Bruner J. S., 1960, PROCESS ED, DOI 10.1002/BS.3830090108; CORCORAN R, 1995, SCHIZOPHR RES, V17, P5, DOI 10.1016/0920-9964(95)00024-G; CORRIGAN PW, 1993, AM J PSYCHIAT, V150, P589; CORRIGAN PW, 1995, SCHIZOPHRENIA BULL, V21, P395, DOI 10.1093/schbul/21.3.395; CORRIGAN PW, 1994, SCHIZOPHR RES, V13, P73, DOI 10.1016/0920-9964(94)90062-0; CORRIGAN PW, 1994, PSYCHIAT RES, V53, P141, DOI 10.1016/0165-1781(94)90105-8; CUTTING JE, 1977, B PSYCHONOMIC SOC, V9, P353, DOI 10.3758/BF03337021; Dakin S, 2005, CURR BIOL, V15, pR822, DOI 10.1016/j.cub.2005.10.015; DeLisi LE, 2005, AM J MED GENET B, V135B, P15, DOI 10.1002/ajmg.b.30163; DELISI LE, 1994, SCHIZOPHRENIA BULL, V20, P495, DOI 10.1093/schbul/20.3.495; Dickerson F, 1999, SCHIZOPHR RES, V37, P13, DOI 10.1016/S0920-9964(98)00134-0; Dickerson F, 1996, SCHIZOPHR RES, V21, P75, DOI 10.1016/0920-9964(96)00040-0; DITTRICH WH, 1993, PERCEPTION, V22, P15, DOI 10.1068/p220015; DOLAN RJ, 1995, NATURE, V378, P180, DOI 10.1038/378180a0; Edwards J, 2002, CLIN PSYCHOL REV, V22, P789, DOI 10.1016/S0272-7358(02)00130-7; Fletcher P, 1999, NEUROIMAGE, V9, P337, DOI 10.1006/nimg.1998.0411; Frith CD, 1999, SCIENCE, V286, P1692, DOI 10.1126/science.286.5445.1692; Gottesman I.I., 1991, SCHIZOPHRENIA GENESI; HANS SL, 1992, PSYCHIATRY, V55, P314; Jellema T, 2005, COGNITIVE NEUROSCIENCE OF SOCIAL BEHAVIOUR, P81, DOI 10.4324/9780203311875_chapter_4; JOHANSSON G, 1973, PERCEPT PSYCHOPHYS, V14, P201, DOI 10.3758/BF03212378; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; KLEINKE CL, 1986, PSYCHOL BULL, V100, P78, DOI 10.1037/0033-2909.100.1.78; Kohler CG, 2004, CURR OPIN PSYCHIATR, V17, P81, DOI 10.1097/00001504-200403000-00003; Kohler CG, 2000, BIOL PSYCHIAT, V48, P127, DOI 10.1016/S0006-3223(00)00847-7; KOZLOWSKI LT, 1977, PERCEPTION PSYCHOPHY, V21; Leitman DI, 2005, BIOL PSYCHIAT, V58, P56, DOI 10.1016/j.biopsych.2005.02.034; Lenzenweger MF, 1996, BRIT J PSYCHIAT, V168, P432, DOI 10.1192/bjp.168.4.432; Lezak M.D., 2012, NEUROPSYCHOLOGICAL A; Lieberman MD, 2000, PSYCHOL BULL, V126, P109, DOI 10.1037/0033-2909.126.1.109; Loughland CM, 2004, SCHIZOPHR RES, V67, P11, DOI 10.1016/S0920-9964(03)00094-X; Mandal MK, 1998, SCHIZOPHRENIA BULL, V24, P399, DOI 10.1093/oxfordjournals.schbul.a033335; Mandal MK, 1999, PSYCHIAT RES, V87, P39, DOI 10.1016/S0165-1781(99)00047-5; Martin F, 2005, PSYCHIAT RES, V134, P43, DOI 10.1016/j.psychres.2003.12.031; Mitelman SA, 2005, SCHIZOPHR RES, V72, P91, DOI 10.1016/j.schres.2004.02.011; Perrett DI, 1999, DESIGN OF ANIMAL COMMUNICATION, P159; Pinkham AE, 2003, AM J PSYCHIAT, V160, P815, DOI 10.1176/appi.ajp.160.5.815; Rajarethinam RP, 2000, SCHIZOPHR RES, V41, P303, DOI 10.1016/S0920-9964(99)00083-3; Raven J. C, 1993, MANUAL RAVENS PROGRE; Russell TA, 2006, SCHIZOPHR RES, V81, P101, DOI 10.1016/j.schres.2005.10.002; Schmand B, 1991, Tijdschr Gerontol Geriatr, V22, P15; SCHNEIDER F, 1995, SCHIZOPHR RES, V17, P67, DOI 10.1016/0920-9964(95)00031-G; Scholten MRM, 2005, SCHIZOPHR RES, V78, P61, DOI 10.1016/j.schres.2005.06.019; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P34, DOI 10.4088/JCP.09m05305whi; Shen DG, 2004, NEUROIMAGE, V23, P648, DOI 10.1016/j.neuroimage.2004.08.018; Shenton ME, 2001, SCHIZOPHR RES, V49, P1, DOI 10.1016/S0920-9964(01)00163-3; Sitskoom MM, 2004, SCHIZOPHR RES, V71, P285, DOI 10.1016/j.schres.2004.03.007; Skuse D, 2003, NOVART FDN SYMP, V251, P84; Skuse DH, 2005, BRAIN, V128, P2084, DOI 10.1093/brain/awh562; SUMI S, 1984, PERCEPTION, V13, P283, DOI 10.1068/p130283; Takahashi H, 2004, NEUROIMAGE, V22, P1247, DOI 10.1016/j.neuroimage.2004.03.028; Toomey R, 1999, SCHIZOPHR RES, V40, P121, DOI 10.1016/S0920-9964(99)00036-5; Uhlhaas PJ, 2004, SCHIZOPHR RES, V68, P249, DOI 10.1016/s0920-9964(03)00184-1; van Rijn S, 2006, SCHIZOPHR RES, V84, P194, DOI 10.1016/j.schres.2006.02.020; van Rijn S, 2008, J AUTISM DEV DISORD, V38, P1634, DOI 10.1007/s10803-008-0542-1; van Rijn S, 2007, J INT NEUROPSYCH SOC, V13, P1065, DOI 10.1017/S1355617707071044; Van Rijn S, 2006, BRIT J PSYCHIAT, V189, P459, DOI 10.1192/bjp.bp.105.008961; VanderDoes AJW, 1996, SCHIZOPHR RES, V19, P61, DOI 10.1016/0920-9964(95)00046-1; WALKER EF, 1994, SCHIZOPHRENIA BULL, V20, P453, DOI 10.1093/schbul/20.3.453; van t'wout M, 2007, PSYCHIAT RES, V150, P227, DOI 10.1016/j.psychres.2006.03.010	72	21	21	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5581	10.1371/journal.pone.0005581	http://dx.doi.org/10.1371/journal.pone.0005581			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	446FY	19440352	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107400017
J	Du, J; Sun, B; Chen, K; Zhang, L; Liu, SB; Gu, QQ; Fan, L; Zhao, NM; Wang, Z				Du, Jing; Sun, Bing; Chen, Kui; Zhang, Lang; Liu, Shubo; Gu, Qingquan; Fan, Li; Zhao, Nanming; Wang, Zhao			Metabolites of Cerebellar Neurons and Hippocampal Neurons Play Opposite Roles in Pathogenesis of Alzheimer's Disease	PLOS ONE			English	Article								Metabolites of neural cells, is known to have a significant effect on the normal physiology and function of neurons in brain. However, whether they play a role in pathogenesis of neurodegenerative diseases is unknown. Here, we show that metabolites of neurons play essential role in the pathogenesis of Alzheimer's disease (AD). Firstly, in vivo and in vitro metabolites of cerebellar neurons both significantly induced the expression of A beta-degrading enzymes in the hippocampus and cerebral cortex and promoted Ab clearance. Moreover, metabolites of cerebellar neurons significantly reduced brain Ab levels and reversed cognitive impairments and other AD-like phenotypes of APP/PS1 transgenic mice, in both early and late stages of AD pathology. On the other hand, metabolites of hippocampal neurons reduced the expression of A beta-degrading enzymes in the cerebellum and caused cerebellar neurodegeneration in APP/PS1 transgenic mice. Thus, we report, for the first time, that metabolites of neurons not only are required for maintaining the normal physiology of neurons but also play essential role in the pathogenesis of AD and may be responsible for the regional-specificity of Ab deposition and AD pathology.			Du, J (corresponding author), Tsinghua Univ, Sch Med, Dept Biol Sci & Biotechnol, Minist Educ,Prot Sci Key Lab, Beijing 100084, Peoples R China.	zwang@tsinghua.edu.cn	Sun, Bing/AAB-4304-2020	Sun, Bing/0000-0002-1992-3767; Du, Jing/0000-0003-1142-0433				Bobinski M, 1998, BRAIN RES, V805, P267, DOI 10.1016/S0006-8993(98)00759-8; Caccamo A, 2005, NEUROBIOL AGING, V26, P645, DOI 10.1016/j.neurobiolaging.2004.06.013; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; Citron M, 2002, NAT NEUROSCI, V5, P1055, DOI 10.1038/nn940; Cummings JL, 2004, NEW ENGL J MED, V351, P56, DOI 10.1056/NEJMra040223; Du J, 2009, FLUIDS BARRIERS CNS, V6, DOI 10.1186/1743-8454-6-3; Giannakopoulos P, 1997, BRAIN RES REV, V25, P217, DOI 10.1016/S0165-0173(97)00023-4; Greene JDW, 1996, NEUROPSYCHOLOGIA, V34, P537, DOI 10.1016/0028-3932(95)00151-4; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; Hempstead Barbara L., 2006, Current Alzheimer Research, V3, P19, DOI 10.2174/156720506775697061; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Janus C, 2000, NEUROBIOL AGING, V21, P541, DOI 10.1016/S0197-4580(00)00107-X; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kelly PH, 2003, NEUROBIOL AGING, V24, P365, DOI 10.1016/S0197-4580(02)00098-2; Kim HJ, 2002, FASEB J, V16, P118, DOI 10.1096/fj.01-0987fje; LI YT, 1994, NEUROBIOL AGING, V15, P1, DOI 10.1016/0197-4580(94)90139-2; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Miyan JA, 2003, CAN J PHYSIOL PHARM, V81, P317, DOI 10.1139/Y03-027; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; PILLON B, 1993, ARCH NEUROL-CHICAGO, V50, P374, DOI 10.1001/archneur.1993.00540040036010; Qu HY, 2008, EUR J PHARMACOL, V594, P93, DOI 10.1016/j.ejphar.2008.06.109; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Saido TC, 1998, NEUROBIOL AGING, V19, pS69, DOI 10.1016/S0197-4580(98)00033-5; Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Shimizu E, 2008, J IMMUNOL, V181, P6503, DOI 10.4049/jimmunol.181.9.6503; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.278.16.1363; SMITH QR, 1981, J NEUROCHEM, V37, P107, DOI 10.1111/j.1471-4159.1981.tb05297.x; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; VENABLE N, 1990, PSYCHOPHARMACOLOGY, V100, P215, DOI 10.1007/BF02244409; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; WEST MJ, 1994, LANCET, V344, P769, DOI 10.1016/S0140-6736(94)92338-8; Zhao LX, 2004, J NEUROSCI, V24, P11120, DOI 10.1523/JNEUROSCI.2860-04.2004; Zlokovic BV, 2004, J NEUROCHEM, V89, P807, DOI 10.1111/j.1471-4159.2004.02385.x	35	13	13	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5530	10.1371/journal.pone.0005530	http://dx.doi.org/10.1371/journal.pone.0005530			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444WA	19436731	Green Submitted, Green Published, gold			2022-12-25	WOS:000266009900021
J	Ruschke, K; Ebelt, H; Kloeting, N; Boettger, T; Raum, K; Bluher, M; Braun, T				Ruschke, Karen; Ebelt, Henning; Kloeting, Nora; Boettger, Thomas; Raum, Kay; Blueher, Matthias; Braun, Thomas			Defective Peripheral Nerve Development Is Linked to Abnormal Architecture and Metabolic Activity of Adipose Tissue in Nscl-2 Mutant Mice	PLOS ONE			English	Article								Background: In mammals the interplay between the peripheral nervous system (PNS) and adipose tissue is widely unexplored. We have employed mice, which develop an adult onset of obesity due to the lack the neuronal specific transcription factor Nscl-2 to investigate the interplay between the nervous system and white adipose tissue (WAT). Methodology: Changes in the architecture and innervation of WAT were compared between wildtype, Nscl22/2, ob/ob and Nscl-/-//ob/ob mice using morphological methods, immunohistochemistry and flow cytometry. Metabolic alterations in mutant mice and in isolated cells were investigated under basal and stimulated conditions. Principal Findings: We found that Nscl-2 mutant mice show a massive reduction of innervation of white epididymal and paired subcutaneous inguinal fat tissue including sensory and autonomic nerves as demonstrated by peripherin and neurofilament staining. Reduction of innervation went along with defects in the formation of the microvasculature, accumulation of cells of the macrophage/preadipocyte lineage, a bimodal distribution of the size of fat cells, and metabolic defects of isolated adipocytes. Despite a relative insulin resistance of white adipose tissue and isolated Nscl-2 mutant adipocytes the serum level of insulin in Nscl-2 mutant mice was only slightly increased. Conclusions: We conclude that the reduction of the innervation and vascularization of WAT in Nscl-2 mutant mice leads to the increase of preadipocyte/macrophage-like cells, a bimodal distribution of the size of adipocytes in WAT and an altered metabolic activity of adipocytes.			Ruschke, K (corresponding author), Univ Halle Wittenberg, Inst Physiol Chem, Halle, Germany.	thomas.braun@mpi-bn.mpg.de	Braun, Thomas/B-2310-2008; Raum, Kay/A-5576-2013; Ruschke, Karen/E-6320-2014; Boettger, Thomas/E-3406-2012	Raum, Kay/0000-0003-0573-1622; Ruschke, Karen/0000-0001-5285-9675; Boettger, Thomas/0000-0003-4280-8449; Braun, Thomas/0000-0002-6165-4804				Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Bamshad M, 1998, AM J PHYSIOL-REG I, V275, pR291, DOI 10.1152/ajpregu.1998.275.1.R291; Bartness TJ, 1998, AM J PHYSIOL-REG I, V275, pR1399, DOI 10.1152/ajpregu.1998.275.5.R1399; Blagoev B, 2002, J BIOL CHEM, V277, P42011, DOI 10.1074/jbc.M206975200; Bluher M, 2005, BEST PRACT RES CL EN, V19, P605, DOI 10.1016/j.beem.2005.07.006; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Caprio M, 2001, TRENDS ENDOCRIN MET, V12, P65, DOI 10.1016/S1043-2760(00)00352-0; Cousin B, 1999, FASEB J, V13, P305, DOI 10.1096/fasebj.13.2.305; Coyle CA, 2002, PHYSIOL BEHAV, V77, P387, DOI 10.1016/S0031-9384(02)00885-5; CUSHMAN SW, 1978, J LIPID RES, V19, P269; Dodt C, 2003, ACTA PHYSIOL SCAND, V177, P351, DOI 10.1046/j.1365-201X.2003.01077.x; Fisher SJ, 2003, J CLIN INVEST, V111, P463, DOI 10.1172/JCI16426; Fornaro M, 2008, NEUROSCIENCE, V153, P1153, DOI 10.1016/j.neuroscience.2008.02.080; Foster MT, 2006, AM J PHYSIOL-REG I, V291, pR1630, DOI 10.1152/ajpregu.00197.2006; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fu YC, 2005, J LIPID RES, V46, P1369, DOI 10.1194/jlr.M400373-JLR200; Good DJ, 1997, NAT GENET, V15, P397, DOI 10.1038/ng0497-397; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; JANSSON PA, 1994, J CLIN INVEST, V93, P240, DOI 10.1172/JCI116951; Jing EX, 2004, ENDOCRINOLOGY, V145, P1503, DOI 10.1210/en.2003-0834; Jobst EE, 2006, ENDOCRINE, V29, P33, DOI 10.1385/ENDO:29:1:33; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kosacka J, 2006, J NEUROSCI RES, V83, P1160, DOI 10.1002/jnr.20811; Kruger M, 2006, EUR J NEUROSCI, V24, P1581, DOI 10.1111/j.1460-9568.2006.05051.x; Kruger M, 2004, EMBO J, V23, P4353, DOI 10.1038/sj.emboj.7600431; Kruger M, 2002, MOL CELL BIOL, V22, P792, DOI 10.1128/MCB.22.3.792-800.2002; LEENEN PJM, 1994, J IMMUNOL METHODS, V174, P5, DOI 10.1016/0022-1759(94)90005-1; Muse ED, 2004, J CLIN INVEST, V114, P232, DOI 10.1172/JCI200421270; NELSON JF, 1990, BIOL REPROD, V42, P649, DOI 10.1095/biolreprod42.4.649; Nilaweera KN, 2002, EUR J NEUROSCI, V15, P644, DOI 10.1046/j.1460-9568.2002.01894.x; Schmid T, 2007, J NEUROCHEM, V102, P2061, DOI 10.1111/j.1471-4159.2007.04694.x; Sweeney G, 2002, CELL SIGNAL, V14, P655, DOI 10.1016/S0898-6568(02)00006-2; Torii I, 2003, J CELL PHYSIOL, V197, P42, DOI 10.1002/jcp.10326; Turtzo LC, 2001, P NATL ACAD SCI USA, V98, P12385, DOI 10.1073/pnas.231478898; Villena JA, 2002, HORM METAB RES, V34, P664, DOI 10.1055/s-2002-38244; Whitehead JP, 2006, DIABETES OBES METAB, V8, P264, DOI 10.1111/j.1463-1326.2005.00510.x; YOUN JH, 1993, DIABETES, V42, P757, DOI 10.2337/diabetes.42.5.757; Zacchigna S, 2008, CURR TOP DEV BIOL, V80, P1, DOI 10.1016/S0070-2153(07)80001-9	41	16	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5516	10.1371/journal.pone.0005516	http://dx.doi.org/10.1371/journal.pone.0005516			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444WA	19436734	gold, Green Submitted, Green Published			2022-12-25	WOS:000266009900009
J	Yalcin, A; Clem, BF; Simmons, A; Lane, A; Nelson, K; Clem, AL; Brock, E; Siow, D; Wattenberg, B; Telang, S; Chesney, J				Yalcin, Abdullah; Clem, Brian F.; Simmons, Alan; Lane, Andrew; Nelson, Kristin; Clem, Amy L.; Brock, Erin; Siow, Deanna; Wattenberg, Binks; Telang, Sucheta; Chesney, Jason			Nuclear Targeting of 6-Phosphofructo-2-kinase (PFKFB3) Increases Proliferation via Cyclin-dependent Kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; FRUCTOSE 2,6-BISPHOSPHATE; LIVER 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE; CARBOHYDRATE-METABOLISM; BISPHOSPHATASE REACTION; INHIBITOR P27; P27(KIP1); CANCER; PHOSPHORYLATION; DEGRADATION	The regulation of metabolism and growth must be tightly coupled to guarantee the efficient use of energy and anabolic substrates throughout the cell cycle. Fructose 2,6-bisphosphate (Fru-2,6-BP) is an allosteric activator of 6-phosphofructo-1-kinase (PFK-1), a rate-limiting enzyme and essential control point in glycolysis. The concentration of Fru-2,6-BP in mammalian cells is set by four 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFKFB1-4), which interconvert fructose 6-phosphate and Fru-2,6-BP. The relative functions of the PFKFB3 and PFKFB4 enzymes are of particular interest because they are activated in human cancers and increased by mitogens and low oxygen. We examined the cellular localization of PFKFB3 and PFKFB4 and unexpectedly found that whereas PFKFB4 localized to the cytoplasm (i.e. the site of glycolysis), PFKFB3 localized to the nucleus. We then overexpressed PFKFB3 and observed no change in glucose metabolism but rather a marked increase in cell proliferation. These effects on proliferation were completely abrogated by mutating either the active site or nuclear localization residues of PFKFB3, demonstrating a requirement for nuclear delivery of Fru-2,6-BP. Using protein array analyses, we then found that ectopic expression of PFKFB3 increased the expression of several key cell cycle proteins, including cyclin-dependent kinase (Cdk)-1, Cdc25C, and cyclinD3 and decreased the expression of the cell cycle inhibitor p27, a universal inhibitor of Cdk-1 and the cell cycle. We also observed that the addition of Fru-2,6-BP to HeLa cell lysates increased the phosphorylation of the Cdk-specific Thr-187 site of p27. Taken together, these observations demonstrate an unexpected role for PFKFB3 in nuclear signaling and indicate that Fru-2,6-BP may couple the activation of glucose metabolism with cell proliferation.	[Yalcin, Abdullah; Clem, Brian F.; Simmons, Alan; Lane, Andrew; Nelson, Kristin; Clem, Amy L.; Brock, Erin; Siow, Deanna; Wattenberg, Binks; Telang, Sucheta; Chesney, Jason] Univ Louisville, James Graham Brown Canc Ctr, Mol Targets Grp, Div Med Oncol, Louisville, KY 40202 USA; [Yalcin, Abdullah] Uludag Univ, Sch Vet Med, Dept Biochem, TR-16059 Bursa, Turkey	University of Louisville; Uludag University	Chesney, J (corresponding author), 580 S Preston St,204E, Louisville, KY 40202 USA.	jason.chesney@louisville.edu	Yalcin, Abdullah/ABI-4164-2020; Yalcin, Abdullah/AAA-6938-2022	Yalcin, Abdullah/0000-0001-8519-8375; 	National Institutes of Health [1 R01 CA11642801]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported, in whole or in part, by National Institutes of Health Grant 1 R01 CA11642801 (to J. C.).	ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ARGAUD D, 1995, J BIOL CHEM, V270, P24229, DOI 10.1074/jbc.270.41.24229; Arooz T, 2000, BIOCHEMISTRY-US, V39, P9494, DOI 10.1021/bi0009643; Atsumi T, 2002, CANCER RES, V62, P5881; Bando H, 2005, CLIN CANCER RES, V11, P5784, DOI 10.1158/1078-0432.CCR-05-0149; Bauer DE, 2004, FASEB J, V18, P1303, DOI 10.1096/fj.03-1001fje; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Besson A, 2006, GENE DEV, V20, P47, DOI 10.1101/gad.1384406; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Boada J, 2000, FEBS LETT, V480, P261, DOI 10.1016/S0014-5793(00)01950-5; Bohnsack BL, 2004, ANNU REV NUTR, V24, P433, DOI 10.1146/annurev.nutr.23.011702.073203; Borriello A, 2007, CELL CYCLE, V6, P1053, DOI 10.4161/cc.6.9.4142; Bruni P, 1999, EUR J BIOCHEM, V259, P756, DOI 10.1046/j.1432-1327.1999.00104.x; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; CHIU RW, 1975, J BIOL CHEM, V250, P7951; DalSanto P, 1996, J CELL SCI, V109, P1919; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; EREMENKO T, 1975, EUR J BIOCHEM, V52, P203, DOI 10.1111/j.1432-1033.1975.tb03988.x; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Hamilton JA, 1997, MOL ENDOCRINOL, V11, P490, DOI 10.1210/me.11.4.490; Han HJ, 2004, AM J PHYSIOL-CELL PH, V287, pC1058, DOI 10.1152/ajpcell.00063.2004; HUE L, 1993, ADV ENZYME REGUL, V33, P97; Kakunaga S, 2004, J BIOL CHEM, V279, P36419, DOI 10.1074/jbc.M406340200; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kessler R, 2001, MOL BRAIN RES, V87, P190, DOI 10.1016/S0169-328X(01)00014-6; Kim SG, 2006, J BIOL CHEM, V281, P2939, DOI 10.1074/jbc.M511019200; LANE A, 2007, BIOPHYSICAL TOOLS BI; Lane AN, 2008, METHOD CELL BIOL, V84, P541, DOI 10.1016/S0091-679X(07)84018-0; Larochelle S, 2007, MOL CELL, V25, P839, DOI 10.1016/j.molcel.2007.02.003; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2007, CURR OPIN GENET DEV, V17, P60, DOI 10.1016/j.gde.2006.12.008; McAndrew CW, 2007, CELL CYCLE, V6, P1937, DOI 10.4161/cc.6.15.4520; Michels PAM, 2006, IUBMB LIFE, V58, P133, DOI 10.1080/15216540600688280; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakagawa Hiroshi, 2007, Methods Mol Biol, V371, P167; Newcomb LL, 2003, EUKARYOT CELL, V2, P143, DOI 10.1128/EC.2.1.143-149.2003; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Okar DA, 1999, BIOCHEMISTRY-US, V38, P4471, DOI 10.1021/bi9828728; Okar DA, 2000, BIOCHEMISTRY-US, V39, P9754, DOI 10.1021/bi000815k; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6; Ramaiah A, 1974, Curr Top Cell Regul, V8, P297; Riera L, 2003, FEBS LETT, V550, P23, DOI 10.1016/S0014-5793(03)00808-1; Riera L, 2002, BBA-MOL CELL RES, V1589, P89, DOI 10.1016/S0167-4889(02)00169-6; Sakakibara R, 1997, J BIOCHEM-TOKYO, V122, P122; Sanchez I, 2005, SEMIN CELL DEV BIOL, V16, P311, DOI 10.1016/j.semcdb.2005.02.007; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Smith WE, 2007, MOL ENDOCRINOL, V21, P1478, DOI 10.1210/me.2006-0356; STANISZ J, 1983, J CELL PHYSIOL, V115, P320, DOI 10.1002/jcp.1041150316; Telang S, 2006, ONCOGENE, V25, P7225, DOI 10.1038/sj.onc.1209709; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P3483; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P263, DOI 10.1042/bj1920263; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P897, DOI 10.1042/bj1920897; Vizan P, 2005, CANCER RES, V65, P5512, DOI 10.1158/0008-5472.CAN-05-0074; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang Q, 2008, CELL DEATH DIFFER, V15, P908, DOI 10.1038/cdd.2008.2; Watanabe F, 1999, FEBS LETT, V458, P304, DOI 10.1016/S0014-5793(99)01174-6; Watanabe F, 1997, J NEUROCHEM, V69, P1; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49; Wu CD, 2006, ADV ENZYME REGUL, V46, P72, DOI 10.1016/j.advenzreg.2006.01.010; WU R, 1959, J BIOL CHEM, V234, P1036; Zhu XH, 2004, MOL CELL BIOL, V24, P6058, DOI 10.1128/MCB.24.13.6058-6066.2004	70	148	158	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	2009	284	36					24223	24232		10.1074/jbc.M109.016816	http://dx.doi.org/10.1074/jbc.M109.016816			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488WE	19473963	Green Published, hybrid			2022-12-25	WOS:000269380200036
J	Corcoran, CA; Montalbano, J; Sun, H; He, Q; Huang, Y; Sheikh, MS				Corcoran, Chad A.; Montalbano, JoAnne; Sun, Hong; He, Qin; Huang, Ying; Sheikh, M. Saeed			Identification and Characterization of Two Novel Isoforms of Pirh2 Ubiquitin Ligase That Negatively Regulate p53 Independent of RING Finger Domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARF TUMOR-SUPPRESSOR; PROTEIN LIGASE; MDM2 GENE; P53-MEDIATED TRANSCRIPTION; HUMAN CANCER; E3; DEGRADATION; EXPRESSION; PROMOTER; PUMA	Pirh2 is a newly identified E3 ubiquitin ligase known to inhibit tumor suppressor p53 function via ubiquitination and proteasomal degradation. We have identified two novel Pirh2 splice variants that encode different Pirh2 isoforms and named these Pirh2B and Pirh2C. Accordingly, the full-length protein is now classified as isoform Pirh2A. The central region of Pirh2 harbors a RING finger domain that is critical for its ubiquitin ligase function. The Pirh2B isoform lacks amino acids 171-179, whereas Pirh2C is missing C-terminal amino acids 180-261, which for each isoform results in a RING domain deletion and the abrogation of ubiquitin ligase activity. Our findings further indicate that the Pirh2B isoform but not the Pirh2C isoform is capable of binding to Pirh2A, suggesting that the C-terminal region absent in Pirh2C is critical for Pirh2-Pirh2 interactions. Similar to Pirh2A, both Pirh2B and Pirh2C interact with p53; however, interactions between p53 and Pirh2B appear stronger than those between p53 and Pirh2C. Interestingly, although both Pirh2B and Pirh2C are not able to promote in vitro p53 ubiquitination, both are capable of negatively regulating p53 protein stability and promoting the intracellular ubiquitination of p53. Furthermore, like Pirh2A, both isoforms are able to inhibit p53 transcriptional activity. We have also for the first time demonstrated that Pirh2A as well as the novel isoforms also interact directly with MDM2 within a region encompassing MDM2 acidic and zinc finger domains. It is therefore possible that Pirh2A and the novel Pirh2 isoforms identified in this study may also modulate p53 function by engaging MDM2.	[Corcoran, Chad A.; Montalbano, JoAnne; Sun, Hong; He, Qin; Huang, Ying; Sheikh, M. Saeed] SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA.	sheikhm@upstate.edu			National Institutes of Health [ES014489, ES005633, CA113868]; NATIONAL CANCER INSTITUTE [R21CA113868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES005633, R21ES014489] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported, in whole or in part, by National Institutes of Health Grants ES014489 and ES005633 (to M. S. S.) and CA113868 (to Y. H.).	BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Bartel F, 2004, MOL CANCER RES, V2, P29; Beitel LK, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290041; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Buchwald G, 2006, EMBO J, V25, P2465, DOI 10.1038/sj.emboj.7601144; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Cheng TH, 2007, MOL CELL BIOL, V27, P111, DOI 10.1128/MCB.00235-06; Corcoran CA, 2005, ONCOGENE, V24, P1634, DOI 10.1038/sj.onc.1208353; Corcoran CA, 2004, CANCER BIOL THER, V3, P721, DOI 10.4161/cbt.3.8.1068; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Duan WR, 2004, JNCI-J NATL CANCER I, V96, P1718, DOI 10.1093/jnci/djh292; Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Inoue T, 2001, J BIOL CHEM, V276, P45255, DOI 10.1074/jbc.M107477200; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Katoh Kazutaka, 2005, Genome Inform, V16, P22; Kawai H, 2007, CANCER RES, V67, P6026, DOI 10.1158/0008-5472.CAN-07-1313; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kostic M, 2006, J MOL BIOL, V363, P433, DOI 10.1016/j.jmb.2006.08.027; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Logan IR, 2006, MOL CELL BIOL, V26, P6502, DOI 10.1128/MCB.00147-06; Logan IR, 2004, J BIOL CHEM, V279, P11696, DOI 10.1074/jbc.M312712200; Lukashchuk N, 2007, MOL CELL BIOL, V27, P8284, DOI 10.1128/MCB.00050-07; Luo XQ, 2003, ONCOGENE, V22, P7247, DOI 10.1038/sj.onc.1207010; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Montes de Oca LR, 1995, NATURE, V378, P203; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Pozzoli U, 2005, CELL MOL LIFE SCI, V62, P1579, DOI 10.1007/s00018-005-5030-6; Rajendra R, 2004, J BIOL CHEM, V279, P36440, DOI 10.1074/jbc.C400300200; Schuster K, 2007, MOL CANCER RES, V5, P403, DOI 10.1158/1541-7786.MCR-06-0146; Sheng Y, 2008, NAT STRUCT MOL BIOL, V15, P1334, DOI 10.1038/nsmb.1521; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Singh RK, 2007, J BIOL CHEM, V282, P10901, DOI 10.1074/jbc.M610879200; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Wallace M, 2006, MOL CELL, V23, P251, DOI 10.1016/j.molcel.2006.05.029; Wang WG, 2003, CANCER BIOL THER, V2, P196, DOI 10.4161/cbt.2.2.347; Yamasaki S, 2007, EMBO J, V26, P113, DOI 10.1038/sj.emboj.7601490; Yang W, 2007, CANCER BIOL THER, V6, P1676, DOI 10.4161/cbt.6.11.4939; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zheng G, 2007, BIOCHEM BIOPH RES CO, V364, P344, DOI 10.1016/j.bbrc.2007.10.003	57	16	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	2009	284	33					21955	21970		10.1074/jbc.M109.024232	http://dx.doi.org/10.1074/jbc.M109.024232			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481CE	19483087	Green Published, hybrid			2022-12-25	WOS:000268783700020
J	Turner, JD; Langley, RS; Johnston, KL; Gentil, K; Ford, L; Wu, B; Graham, M; Sharpley, F; Slatko, B; Pearlman, E; Taylor, MJ				Turner, Joseph D.; Langley, R. Stuart; Johnston, Kelly L.; Gentil, Katrin; Ford, Louise; Wu, Bo; Graham, Maia; Sharpley, Faye; Slatko, Barton; Pearlman, Eric; Taylor, Mark J.			Wolbachia Lipoprotein Stimulates Innate and Adaptive Immunity through Toll-like Receptors 2 and 6 to Induce Disease Manifestations of Filariasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDOGLYCAN-ASSOCIATED LIPOPROTEIN; WUCHERERIA-BANCROFTI INFECTION; ONCHOCERCIASIS RIVER-BLINDNESS; HUMAN ENDOTHELIAL-CELLS; DENDRITIC CELLS; LYMPHATIC FILARIASIS; BRUGIA-MALAYI; DIACYLATED LIPOPEPTIDES; BACTERIAL ENDOSYMBIONTS; INDUCED KERATITIS	Wolbachia endosymbiotic bacteria have been implicated in the inflammatory pathogenesis of filariasis. Inflammation induced by Brugia malayi female worm extract (BMFE) is dependent on Toll-like receptors 2 and 6 (TLR2/6) with only a partial requirement for TLR1. Removal of Wolbachia, lipids, or proteins eliminates all inflammatory activity. Wolbachia bacteria contain the lipoprotein biosynthesis genes Ltg and LspA but not Lnt, suggesting Wolbachia proteins cannot be triacylated, accounting for recognition by TLR2/6. Lipoprotein databases revealed 3-11 potential lipoproteins from Wolbachia. Peptidoglycan-associated lipoprotein (PAL) and Type IV secretion system-VirB6 were consistently predicted, and B. malayi Wolbachia PAL (wBmPAL) was selected for functional characterization. Diacylated 20-mer peptides of wBmPAL (Diacyl Wolbachia lipopeptide (Diacyl WoLP)) showed a near identical TLR2/6 and TLR2/1 usage compared with BMFE and bound directly to TLR2. Diacyl WoLP induced systemic tumor necrosis factor-alpha and neutrophil-mediated keratitis in mice. Diacyl WoLP activated monocytes induce up-regulation of gp38 on human lymphatic endothelial cells and induced dendritic cell maturation and activation. Dendritic cells primed with BMFE generated a non-polarized Th1/Th2 CD4(+) T cell profile, whereas priming with Wolbachia depleted extracts (following tetracycline treatment; BMFEtet) polarized to a Th2 profile that could be reversed by reconstitution with Diacyl WoLP. BMFE generated IgG1 and IgG2c antibody responses, whereas BMFEtet or inoculation of TLR2 or MyD88(-/-) mice produced defective IgG2c responses. Thus, in addition to innate inflammatory activation, Wolbachia lipoproteins drive interferon-gamma-dependent CD4(+) T cell polarization and antibody switching.	[Turner, Joseph D.; Langley, R. Stuart; Johnston, Kelly L.; Ford, Louise; Graham, Maia; Sharpley, Faye; Taylor, Mark J.] Univ Liverpool, Liverpool Sch Trop Med, Filariasis Res Lab, Liverpool L3 5QA, Merseyside, England; [Gentil, Katrin; Pearlman, Eric] Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA; [Wu, Bo; Slatko, Barton] New England Biolabs Inc, Ipswich, MA 01938 USA	Liverpool School of Tropical Medicine; University of Liverpool; Case Western Reserve University; New England Biolabs	Taylor, MJ (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Filariasis Res Lab, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.	mark.taylor@liverpool.ac.uk		Ford, Louise/0000-0001-7919-2866; Turner, Joseph/0000-0002-2185-5476; Taylor, Mark/0000-0003-3396-9275	Wellcome Trust; Bill and Melinda Gates Foundation; German Research Foundation [DA1024/1-1]; National Institutes of Health [EY10320, EY11373]; Research to Prevent Blindness Foundation; Ohio Lions Eye Research Foundation; NATIONAL EYE INSTITUTE [P30EY011373, R01EY010320] Funding Source: NIH RePORTER	Wellcome Trust(Wellcome TrustEuropean Commission); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); German Research Foundation(German Research Foundation (DFG)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research to Prevent Blindness Foundation(Research to Prevent Blindness (RPB)); Ohio Lions Eye Research Foundation; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by the Wellcome Trust for Senior Fellowship support (to M. T., J. T., S. L., and K. J.), by the Bill and Melinda Gates Foundation for A-WOL consortium support (to M. T., K. J., L. F., B. W., and B. S.), and by Grant DA1024/1-1 from the German Research Foundation (to K. G.). This work was also supported, in whole or in part, by National Institutes of Health Grant EY10320 (to E. P.) and EY11373 (to E. P.) and by the Research to Prevent Blindness Foundation and the Ohio Lions Eye Research Foundation (to E. P.).	Al-Rawi MAA, 2005, INT J ONCOL, V27, P721; Babu S, 2005, J IMMUNOL, V175, P1170, DOI 10.4049/jimmunol.175.2.1170; Bagchi A, 2007, J IMMUNOL, V178, P1164, DOI 10.4049/jimmunol.178.2.1164; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Brattig NW, 2000, MICROBES INFECT, V2, P1147, DOI 10.1016/S1286-4579(00)01269-7; Brattig NW, 2004, J IMMUNOL, V173, P437, DOI 10.4049/jimmunol.173.1.437; Brattig NW, 2001, MICROBES INFECT, V3, P439, DOI 10.1016/S1286-4579(01)01399-5; Buwitt-Beckmann U, 2005, EUR J IMMUNOL, V35, P282, DOI 10.1002/eji.200424955; Cascales E, 2002, J BACTERIOL, V184, P754, DOI 10.1128/JB.184.3.754-759.2002; Cross HF, 2001, LANCET, V358, P1873, DOI 10.1016/S0140-6736(01)06899-4; Daehnel K, 2007, PARASITE IMMUNOL, V29, P455, DOI 10.1111/j.1365-3024.2007.00962.x; Debrah AY, 2007, AM J TROP MED HYG, V77, P601, DOI 10.4269/ajtmh.2007.77.601; Debrah AY, 2006, PLOS PATHOG, V2, P829, DOI 10.1371/journal.ppat.0020092; Dreyer G, 2000, PARASITOL TODAY, V16, P544, DOI 10.1016/S0169-4758(00)01778-6; Esterre P, 2005, PARASITE IMMUNOL, V27, P9, DOI 10.1111/j.1365-3024.2005.00732.x; Foster J, 2005, PLOS BIOL, V3, P599, DOI 10.1371/journal.pbio.0030121; Gillette-Ferguson I, 2006, INFECT IMMUN, V74, P2442, DOI 10.1128/IAI.74.4.2442-2445.2006; Gillette-Ferguson I, 2004, INFECT IMMUN, V72, P5687, DOI 10.1128/IAI.72.10.5687-5692.2004; Gillette-Ferguson I, 2007, INFECT IMMUN, V75, P5908, DOI 10.1128/IAI.00991-07; Groger M, 2004, J IMMUNOL, V173, P7161, DOI 10.4049/jimmunol.173.12.7161; Hellman J, 2002, J BIOL CHEM, V277, P14274, DOI 10.1074/jbc.M109696200; Hise AG, 2007, J IMMUNOL, V178, P1068, DOI 10.4049/jimmunol.178.2.1068; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Hoerauf A, 2005, PARASITE IMMUNOL, V27, P417, DOI 10.1111/j.1365-3024.2005.00792.x; Imanishi T, 2007, J IMMUNOL, V178, P6715, DOI 10.4049/jimmunol.178.11.6715; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jenkins SJ, 2005, INFECT IMMUN, V73, P395, DOI 10.1128/IAI.73.1.395-402.2005; Jiang HR, 2006, J IMMUNOL, V177, P4288, DOI 10.4049/jimmunol.177.7.4288; Kaisho T, 2001, J IMMUNOL, V166, P5688, DOI 10.4049/jimmunol.166.9.5688; Kaneko M, 2004, J BIOL CHEM, V279, P38838, DOI 10.1074/jbc.M407210200; Keiser PB, 2002, J INFECT DIS, V185, P805, DOI 10.1086/339344; Kirschning CJ, 2002, CURR TOP MICROBIOL, V270, P121; Korten S, 2008, MICROBES INFECT, V10, P313, DOI 10.1016/j.micinf.2007.12.004; Liang MD, 2005, J INFECT DIS, V191, P939, DOI 10.1086/427815; Maruyama K, 2005, J CLIN INVEST, V115, P2363, DOI 10.1172/JCI23874; Molyneux DH, 2003, TRENDS PARASITOL, V19, P516, DOI 10.1016/j.pt.2003.09.004; Parsons LM, 2006, BIOCHEMISTRY-US, V45, P2122, DOI 10.1021/bi052227i; Pasare C, 2005, NATURE, V438, P364, DOI 10.1038/nature04267; Punkosdy GA, 2003, INFECT IMMUN, V71, P5104, DOI 10.1128/IAI.71.9.5104-5114.2003; Saint Andre AV, 2002, SCIENCE, V295, P1892, DOI 10.1126/science.1068732; Sato S, 2000, J IMMUNOL, V165, P7096, DOI 10.4049/jimmunol.165.12.7096; Schroder NWJ, 2004, J IMMUNOL, V173, P2683, DOI 10.4049/jimmunol.173.4.2683; Semnani RT, 2006, INFECT IMMUN, V74, P4409, DOI 10.1128/IAI.01106-05; Sher A, 2003, CURR OPIN IMMUNOL, V15, P421, DOI 10.1016/S0952-7915(03)00072-4; Suba N, 2007, EXP PARASITOL, V116, P291, DOI 10.1016/j.exppara.2006.12.006; Supali T, 2008, CLIN INFECT DIS, V46, P1385, DOI 10.1086/586753; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Taylor MJ, 2005, ADV PARASIT, V60, P245, DOI 10.1016/S0065-308X(05)60004-8; Taylor MJ, 2000, J EXP MED, V191, P1429, DOI 10.1084/jem.191.8.1429; Triantafilou M, 2006, J BIOL CHEM, V281, P31002, DOI 10.1074/jbc.M602794200; Turner JD, 2006, CLIN INFECT DIS, V42, P1081, DOI 10.1086/501351; Turner JD, 2006, J IMMUNOL, V177, P1240, DOI 10.4049/jimmunol.177.2.1240; Vasselon T, 2004, J IMMUNOL, V173, P7401, DOI 10.4049/jimmunol.173.12.7401; Whelan M, 2000, J IMMUNOL, V164, P6453, DOI 10.4049/jimmunol.164.12.6453; Zhu XS, 2007, CRIT CARE MED, V35, P886, DOI 10.1097/01.CCM.0000256723.37586.A2	57	105	105	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	2009	284	33					22364	22378		10.1074/jbc.M901528200	http://dx.doi.org/10.1074/jbc.M901528200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481CE	19458089	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000268783700059
J	Awai, T; Kimura, S; Tomikawa, C; Ochi, A; Ihsanawati; Bessho, Y; Yokoyama, S; Ohno, S; Nishikawa, K; Yokogawa, T; Suzuki, T; Hori, H				Awai, Takako; Kimura, Satoshi; Tomikawa, Chie; Ochi, Anna; Ihsanawati; Bessho, Yoshitaka; Yokoyama, Shigeyuki; Ohno, Satoshi; Nishikawa, Kazuya; Yokogawa, Takashi; Suzuki, Tsutomu; Hori, Hiroyuki			Aquifex aeolicus tRNA (N-2, N-2-Guanine)-dimethyltransferase (Trm1) Catalyzes Transfer of Methyl Groups Not Only to Guanine 26 but Also to Guanine 27 in tRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; SACCHAROMYCES-CEREVISIAE; RECOGNITION MECHANISM; PYROCOCCUS-FURIOSUS; NUCLEOTIDE-SEQUENCE; ENZYMATIC FORMATION; IDENTITY ELEMENTS; CELL-GROWTH; METHYLTRANSFERASE; GENE	Transfer RNA (N-2, N-2-guanine)-dimethyltransferase (Trm1) catalyzes N-2, N-2-dimethylguanine formation at position 26 (m(2)(2)G26) in tRNA. In the reaction, N-2-guanine at position 26 (m(2)G26) is generated as an intermediate. The trm1 genes are found only in archaea and eukaryotes, although it has been reported that Aquifex aeolicus, a hyper-thermophilic eubacterium, has a putative trm1 gene. To confirm whether A. aeolicus Trm1 has tRNA methyltransferase activity, we purified recombinant Trm1 protein. In vitro methyl transfer assay revealed that the protein has a strong tRNA methyltransferase activity. We confirmed that this gene product is expressed in living A. aeolicus cells and that the enzymatic activity exists in cell extract. By preparing 22 tRNA transcripts and testing their methyl group acceptance activities, it was demonstrated that this Trm1 protein has a novel tRNA specificity. Mass spectrometry analysis revealed that it catalyzes methyl transfers not only to G26 but also to G27 in substrate tRNA. Furthermore, it was confirmed that native tRNA(Cys) has an m(2)(2)G26m(2)G27 or m(2)(2)G26m(2)(2)G27 sequence, demonstrating that these modifications occur in living cells. Kinetic studies reveal that the m(2)G26 formation is faster than the m(2)G27 formation and that disruption of the G27-C43 base pair accelerates velocity of the G27 modification. Moreover, we prepared an additional 22 mutant tRNA transcripts and clarified that the recognition sites exist in the T-arm structure. This long distance recognition results in multisite recognition by the enzyme.	[Awai, Takako; Tomikawa, Chie; Ochi, Anna; Hori, Hiroyuki] Ehime Univ, Grad Sch Sci & Engn, Dept Mat Sci & Biotechnol, Matsuyama, Ehime 7908577, Japan; [Kimura, Satoshi; Suzuki, Tsutomu] Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; [Ihsanawati; Bessho, Yoshitaka; Yokoyama, Shigeyuki; Hori, Hiroyuki] RIKEN, Yokohama Inst, Syst & Struct Biol Ctr, Tsurumi Ku, Kanagawa 2300045, Japan; [Bessho, Yoshitaka; Yokoyama, Shigeyuki] RIKEN, SPring Ctr 8, Harima Inst, Sayo, Hyogo 6795148, Japan; [Yokoyama, Shigeyuki] Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; [Ohno, Satoshi; Nishikawa, Kazuya; Yokogawa, Takashi] Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan; [Hori, Hiroyuki] Ehime Univ, Venture Business Lab, Matsuyama, Ehime 7908577, Japan	Ehime University; University of Tokyo; RIKEN; RIKEN; University of Tokyo; Gifu University; Ehime University	Hori, H (corresponding author), Ehime Univ, Grad Sch Sci & Engn, Dept Mat Sci & Biotechnol, Bunkyo 3, Matsuyama, Ehime 7908577, Japan.	hori@eng.ehime-u.ac.jp	Hori, Hiroyuki/AAB-3911-2021; Bessho, Yoshitaka/K-7702-2012; Yokoyama, Shigeyuki/N-6911-2015; Suzuki, Tsutomu/J-1776-2015	Bessho, Yoshitaka/0000-0001-9297-7473; Yokoyama, Shigeyuki/0000-0003-3133-7338; Suzuki, Tsutomu/0000-0002-9731-1731; Kimura, Satoshi/0000-0003-3555-5877	Japan Society for the Promotion of Science Research Fellowship for Young Scientists [20-4827]; Ministry of Education, Science, Sports, and Culture of Japan [20034041, 19350087]	Japan Society for the Promotion of Science Research Fellowship for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Science, Sports, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by Japan Society for the Promotion of Science Research Fellowship for Young Scientists 20-4827 ( to C. T.), Grant-in-aid for Science Research on Priority Areas 20034041 ( to H. H.), and Grant-in-aid for Science Research 19350087 ( to H. H.) from the Ministry of Education, Science, Sports, and Culture of Japan.	Armengaud J, 2004, J BIOL CHEM, V279, P37142, DOI 10.1074/jbc.M403845200; Auffinger P, 1998, MODIFICATION EDITING, P569; Auxilien S, 2007, J BIOL CHEM, V282, P18711, DOI 10.1074/jbc.M607459200; Bujnicki JM, 2002, J MOL MICROB BIOTECH, V4, P405; BURGGRAF S, 1992, SYST APPL MICROBIOL, V15, P352, DOI 10.1016/S0723-2020(11)80207-9; Constantinesco F, 1999, NUCLEIC ACIDS RES, V27, P1308, DOI 10.1093/nar/27.5.1308; Constantinesco F, 1999, J MOL BIOL, V291, P375, DOI 10.1006/jmbi.1999.2976; Constantinesco F, 1998, NUCLEIC ACIDS RES, V26, P3753, DOI 10.1093/nar/26.16.3753; De Bie LGS, 2003, J BACTERIOL, V185, P3238, DOI 10.1128/JB.185.10.3238-3243.2003; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Droogmans L, 2003, NUCLEIC ACIDS RES, V31, P2148, DOI 10.1093/nar/gkg314; Dunin-Horkawicz S, 2006, NUCLEIC ACIDS RES, V34, pD145, DOI 10.1093/nar/gkj084; EDQVIST J, 1992, NUCLEIC ACIDS RES, V20, P6575, DOI 10.1093/nar/20.24.6575; EDQVIST J, 1994, BIOCHEMISTRY-US, V33, P9546, DOI 10.1021/bi00198a021; ELLIS SR, 1986, J BIOL CHEM, V261, P9703; Gabant G, 2006, NUCLEIC ACIDS RES, V34, P2483, DOI 10.1093/nar/gkl145; GARCIA GR, 1998, MODIFICATION EDITING, P555; GLICK JM, 1978, BIOCHIM BIOPHYS ACTA, V518, P158, DOI 10.1016/0005-2787(78)90125-9; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Griffiths E, 2006, INT J SYST EVOL MICR, V56, P99, DOI 10.1099/ijs.0.63927-0; Griffiths E, 2001, MICROBIOL-SGM, V147, P2611, DOI 10.1099/00221287-147-9-2611; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; Grosjean H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-470; GUPTA R, 1984, J BIOL CHEM, V259, P9461; Hori H, 2003, J BIOL CHEM, V278, P25081, DOI 10.1074/jbc.M212577200; Hur S, 2007, MOL CELL, V26, P189, DOI 10.1016/j.molcel.2007.02.027; Ihsanawati, 2008, J MOL BIOL, V383, P871, DOI 10.1016/j.jmb.2008.08.068; Ikeuchi Y, 2006, MOL CELL, V21, P97, DOI 10.1016/j.molcel.2005.11.001; Ikeuchi Y, 2008, EMBO J, V27, P2194, DOI 10.1038/emboj.2008.154; JOHNSON GD, 1985, ARCH BIOCHEM BIOPHYS, V236, P448, DOI 10.1016/0003-9861(85)90647-2; KAMMEN HO, 1988, J BIOL CHEM, V263, P2255; Kaneko T, 2003, EMBO J, V22, P657, DOI 10.1093/emboj/cdg066; KEITH G, 1995, BIOCHIMIE, V77, P142, DOI 10.1016/0300-9084(96)88118-1; KUCHINO Y, 1970, BIOCHEM BIOPH RES CO, V40, P306, DOI 10.1016/0006-291X(70)91010-7; Liu JM, 1999, GENE, V226, P73, DOI 10.1016/S0378-1119(98)00550-2; Liu JM, 2000, NUCLEIC ACIDS RES, V28, P3445, DOI 10.1093/nar/28.18.3445; Motorin Y, 1999, RNA, V5, P1105, DOI 10.1017/S1355838299982201; Niederberger C, 1999, FEBS LETT, V464, P67, DOI 10.1016/S0014-5793(99)01679-8; Noma A, 2006, EMBO J, V25, P2142, DOI 10.1038/sj.emboj.7601105; Okamoto H, 2004, J BIOL CHEM, V279, P49151, DOI 10.1074/jbc.M408209200; PHILLIPS JH, 1967, J MOL BIOL, V26, P509, DOI 10.1016/0022-2836(67)90318-X; Pintard L, 2002, EMBO J, V21, P1811, DOI 10.1093/emboj/21.7.1811; Purushothaman SK, 2005, MOL CELL BIOL, V25, P4359, DOI 10.1128/MCB.25.11.4359-4370.2005; REINHART MP, 1986, NUCLEIC ACIDS RES, V14, P1131, DOI 10.1093/nar/14.3.1131; Roovers M, 2004, NUCLEIC ACIDS RES, V32, P465, DOI 10.1093/nar/gkh191; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; Shigi N, 2006, J BIOL CHEM, V281, P2104, DOI 10.1074/jbc.M510771200; Shigi N, 2006, J BIOL CHEM, V281, P14296, DOI 10.1074/jbc.M511675200; Shigi N, 2008, EMBO J, V27, P3267, DOI 10.1038/emboj.2008.246; STANGE N, 1987, EMBO J, V6, P2811, DOI 10.1002/j.1460-2075.1987.tb02577.x; Suzuki T, 2007, METHOD ENZYMOL, V425, P211, DOI 10.1016/S0076-6876(07)25009-8; Takeda H, 2006, GENES CELLS, V11, P1353, DOI 10.1111/j.1365-2443.2006.01022.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomikawa C, 2008, PROTEINS, V71, P1400, DOI 10.1002/prot.21827; Toyooka T, 2008, GENES CELLS, V13, P807, DOI 10.1111/j.1365-2443.2008.01207.x; TSURUI H, 1994, ANAL BIOCHEM, V221, P166, DOI 10.1006/abio.1994.1393; Urbonavicius J, 2006, J MOL BIOL, V357, P387, DOI 10.1016/j.jmb.2005.12.087; VANTOL H, 1987, EMBO J, V6, P35, DOI 10.1002/j.1460-2075.1987.tb04715.x; WATANABE K, 1976, BIOCHEM BIOPH RES CO, V72, P1137, DOI 10.1016/S0006-291X(76)80250-1	60	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20467	20478		10.1074/jbc.M109.020024	http://dx.doi.org/10.1074/jbc.M109.020024			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19491098	Green Published, hybrid			2022-12-25	WOS:000268316100008
J	Reininger, L; Tewari, R; Fennell, C; Holland, Z; Goldring, D; Ranford-Cartwright, L; Billker, O; Doerig, C				Reininger, Luc; Tewari, Rita; Fennell, Clare; Holland, Zoe; Goldring, Dean; Ranford-Cartwright, Lisa; Billker, Oliver; Doerig, Christian			An Essential Role for the Plasmodium Nek-2 Nima-related Protein Kinase in the Sexual Development of Malaria Parasites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; ASPERGILLUS-NIDULANS; OSMIOPHILIC BODIES; FALCIPARUM; EXPRESSION; GAMETOCYTE; MOSQUITO; GAMETE; SENSITIVITY; CENTRIOLES	The molecular control of cell division and development in malaria parasites is far from understood. We previously showed that a Plasmodium gametocyte-specific NIMA-related protein kinase, nek-4, is required for completion of meiosis in the ookinete, the motile form that develops from the zygote in the mosquito vector. Here, we show that another NIMA-related kinase, Pfnek-2, is also predominantly expressed in gametocytes, and that Pfnek-2 is an active enzyme displaying an in vitro substrate preference distinct from that of Pfnek-4. A functional nek-2 gene is required for transmission of both Plasmodium falciparum and the rodent malaria parasite Plasmodium berghei to the mosquito vector, which is explained by the observation that disruption of the nek-2 gene in P. berghei causes dysregulation of DNA replication during meiosis and blocks ookinete development. This has implications (i) in our understanding of sexual development of malaria parasites and (ii) in the context of control strategies aimed at interfering with malaria transmission.	[Tewari, Rita] Univ Nottingham, Sch Biol, Inst Genet, Nottingham NG7 2UH, England; [Reininger, Luc; Fennell, Clare; Holland, Zoe; Doerig, Christian] Univ Glasgow, Biomed Res Ctr, Wellcome Ctr Mol Parasitol, INSERM,U609, Glasgow G12 8TA, Lanark, Scotland; [Ranford-Cartwright, Lisa] Univ Glasgow, Fac Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8TA, Lanark, Scotland; [Goldring, Dean] Univ KwaZulu Natal, Sch Biochem Genet Microbiol & Plant Pathol, Dept Biochem, ZA-3209 Scottsville, South Africa; [Billker, Oliver] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; [Tewari, Rita; Billker, Oliver] Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, London SW7 2AZ, England; [Doerig, Christian] Ecole Polytech Fed Lausanne EPFL, INSERM, Global Hlth Inst, U609, CH-1015 Lausanne, Switzerland	University of Nottingham; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Dundee; University of Glasgow; University of Glasgow; University of Kwazulu Natal; Wellcome Trust Sanger Institute; Imperial College London; Institut National de la Sante et de la Recherche Medicale (Inserm); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Tewari, R (corresponding author), Univ Nottingham, Sch Biol, Inst Genet, Nottingham NG7 2UH, England.	rita.tewari@nottingham.ac.uk; christian.doerig@epfl.ch	Ranford-Cartwright, Lisa C/H-4701-2013; Doerig, Christian/Q-9900-2019; Reininger, Luc/O-5301-2015; Tewari, Rita/M-5698-2014	Ranford-Cartwright, Lisa C/0000-0003-1992-3940; Doerig, Christian/0000-0002-3188-094X; Goldring, James Philip Dean/0000-0001-6713-9515; Billker, Oliver/0000-0003-1716-168X; REININGER, LUC/0000-0002-7014-7783; Tewari, Rita/0000-0003-3943-1847	Burroughs Wellcome Fund; Wellcome Trust; National Institutes of Health (NIAID); U.S. Department of Defense; Military Infectious Diseases Research Program; French Institut National de la Sante et de la Recherche Medicale (Inserm); European Commission; Novartis Institute for Tropical Diseases (NITD, Singapore); Medical Research Council; MRC [G0501670] Funding Source: UKRI; Medical Research Council [G0501670] Funding Source: researchfish	Burroughs Wellcome Fund(Burroughs Wellcome Fund); Wellcome Trust(Wellcome Trust); National Institutes of Health (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); U.S. Department of Defense(United States Department of Defense); Military Infectious Diseases Research Program; French Institut National de la Sante et de la Recherche Medicale (Inserm)(Institut National de la Sante et de la Recherche Medicale (Inserm)); European Commission(European CommissionEuropean Commission Joint Research Centre); Novartis Institute for Tropical Diseases (NITD, Singapore); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Work at the Plasmodium Genome Consortium was supported by the Burroughs Wellcome Fund, the Wellcome Trust, the National Institutes of Health (NIAID), and the U.S. Department of Defense, Military Infectious Diseases Research Program. Financial support for PlasmoDB was provided by the Burroughs Wellcome Fund. Work in the laboratory of C. D. was supported by the French Institut National de la Sante et de la Recherche Medicale (Inserm), FP6 (SIGMAL and ANTIMAL projects, BioMalPar Network of Excellence) and FP7 (MALSIG project) programs of the European Commission, and by a grant from the Novartis Institute for Tropical Diseases (NITD, Singapore). The work on P. berghei was supported by grants from the Wellcome Trust (to R. T. and O.B.) and the Medical Research Council (to O.B.).	Alano P, 1995, MOL BIOCHEM PARASIT, V74, P143, DOI 10.1016/0166-6851(95)02491-3; Arama E, 1998, ONCOGENE, V16, P1813, DOI 10.1038/sj.onc.1201710; Bahl A, 2003, NUCLEIC ACIDS RES, V31, P212, DOI 10.1093/nar/gkg081; Belham C, 2003, J BIOL CHEM, V278, P34897, DOI 10.1074/jbc.M303663200; Billker O, 1998, NATURE, V392, P289, DOI 10.1038/32667; Billker O, 2004, CELL, V117, P503, DOI 10.1016/S0092-8674(04)00449-0; Breman JG, 2004, AM J TROP MED HYG, V71, P1; Carter R, 1993, Methods Mol Biol, V21, P67; Davies JR, 2004, EUKARYOT CELL, V3, P1433, DOI 10.1128/EC.3.6.1433-1444.2004; de Koning-Ward TF, 2008, MOL MICROBIOL, V67, P278, DOI 10.1111/j.1365-2958.2007.06039.x; Dorin D, 2001, EUR J BIOCHEM, V268, P2600, DOI 10.1046/j.1432-1327.2001.02151.x; Dorin-Semblat D, 2007, MOL MICROBIOL, V65, P1170, DOI 10.1111/j.1365-2958.2007.05859.x; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Hayward DG, 2006, CANCER LETT, V237, P155, DOI 10.1016/j.canlet.2005.06.017; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200; Lye YM, 2006, FEBS LETT, V580, P6083, DOI 10.1016/j.febslet.2006.10.003; Mair GR, 2006, SCIENCE, V313, P667, DOI 10.1126/science.1125129; Malumbres M, 2007, CURR OPIN GENET DEV, V17, P60, DOI 10.1016/j.gde.2006.12.008; Motose H, 2008, PLANT J, V54, P829, DOI 10.1111/j.1365-313X.2008.03445.x; Nagasato C, 2005, J PLANT RES, V118, P361, DOI 10.1007/s10265-005-0244-0; O'Regan L, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-25; OAKLEY BR, 1983, J CELL BIOL, V96, P1155, DOI 10.1083/jcb.96.4.1155; PALERMO G, 1994, HUM REPROD, V9, P1220, DOI 10.1093/oxfordjournals.humrep.a138682; Reininger L, 2005, J BIOL CHEM, V280, P31957, DOI 10.1074/jbc.M504523200; Rellos P, 2007, J BIOL CHEM, V282, P6833, DOI 10.1074/jbc.M609721200; Rhee K, 1997, DEVELOPMENT, V124, P2167; Ringwald P, 1999, J CLIN MICROBIOL, V37, P700, DOI 10.1128/JCM.37.3.700-705.1999; SATHANANTHAN AH, 1991, P NATL ACAD SCI USA, V88, P4806, DOI 10.1073/pnas.88.11.4806; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; Sidhu ABS, 2005, MOL MICROBIOL, V57, P913, DOI 10.1111/j.1365-2958.2005.04729.x; Silvestrini F, 2000, PARASITOLOGY, V121, P465, DOI 10.1017/S0031182099006691; SINDEN RE, 1978, PROC R SOC SER B-BIO, V201, P375, DOI 10.1098/rspb.1978.0051; Tonkin CJ, 2004, MOL BIOCHEM PARASIT, V137, P13, DOI 10.1016/j.molbiopara.2004.05.009; Ward P, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-79; Zimmermann GR, 2007, DRUG DISCOV TODAY, V12, P34, DOI 10.1016/j.drudis.2006.11.008	36	68	69	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20858	20868		10.1074/jbc.M109.017988	http://dx.doi.org/10.1074/jbc.M109.017988			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19491095	Green Published, hybrid			2022-12-25	WOS:000268316100049
J	Deward, AD; Alberts, AS				Deward, Aaron D.; Alberts, Arthur S.			Ubiquitin-mediated Degradation of the Formin mDia2 upon Completion of Cell Division	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST; AUTOREGULATORY DOMAIN; ACTIN NUCLEATION; HOMOLOGY PROTEIN; CONTRACTILE RING; CENTRAL SPINDLE; CYTOKINESIS; MICROTUBULES; MECHANISM; PROFILIN	Formins assemble non-branched actin filaments and modulate microtubule dynamics during cell migration and cell division. At the end of mitosis formins contribute to the generation of actin filaments that form the contractile ring. Rho small GTP-binding proteins activate mammalian diaphanous-related (mDia) formins by directly binding and disrupting an intramolecular autoinhibitory mechanism. Although the Rho-regulated activation mechanism is well characterized, little is known about how formins are switched off. Here we reveal a novel mechanism of formin regulation during cytokinesis based on the following observations; 1) mDia2 is degraded at the end of mitosis, 2) mDia2 is targeted for disposal by post-translational ubiquitin modification, 3) forced expression of activated mDia2 yields binucleate cells due to failed cytokinesis, and 4) the cytokinesis block is dependent upon mDia2-mediated actin assembly as versions of mDia2 incapable of nucleating actin but that still stabilize microtubules have no effect on cytokinesis. We propose that the tight control of mDia2 expression and ubiquitin-mediated degradation is essential for the completion of cell division. Because of the many roles for formins in cell morphology, we discuss the relevance of mDia protein turnover in other processes where ubiquitin-mediated proteolysis is an essential component.	[Deward, Aaron D.; Alberts, Arthur S.] Van Andel Res Inst, Lab Cell Struct & Signal Integrat, Grand Rapids, MI 49503 USA; [Deward, Aaron D.] Michigan State Univ, Program Cell & Mol Biol, E Lansing, MI 48824 USA	Van Andel Institute; Michigan State University	Alberts, AS (corresponding author), 333 Bostwick Ave, Grand Rapids, MI 49503 USA.	art.alberts@vai.org			Van Andel Foundation	Van Andel Foundation	This work was supported by the Van Andel Foundation.	Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Albertson R, 2008, J CELL BIOL, V181, P777, DOI 10.1083/jcb.200803096; Bartolini F, 2008, J CELL BIOL, V181, P523, DOI 10.1083/jcb.200709029; Canman JC, 2003, NATURE, V424, P1074, DOI 10.1038/nature01860; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Denis NJ, 2007, PROTEOMICS, V7, P868, DOI 10.1002/pmic.200600410; DeWard AD, 2008, CURR BIOL, V18, pR605, DOI 10.1016/j.cub.2008.06.001; Dong YQ, 2003, J CELL BIOL, V161, P1081, DOI 10.1083/jcb.200212040; Eisenmann KM, 2007, J BIOL CHEM, V282, P25152, DOI 10.1074/jbc.M703243200; Eisenmann KM, 2007, CURR BIOL, V17, P579, DOI 10.1016/j.cub.2007.03.024; Fernandez-Borja M, 2005, J CELL SCI, V118, P2661, DOI 10.1242/jcs.02384; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; Goode BL, 2007, ANNU REV BIOCHEM, V76, P593, DOI 10.1146/annurev.biochem.75.103004.142647; Gupton SL, 2007, J CELL SCI, V120, P3475, DOI 10.1242/jcs.006049; Harris ES, 2006, J BIOL CHEM, V281, P14383, DOI 10.1074/jbc.M510923200; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Higgs HN, 2005, TRENDS BIOCHEM SCI, V30, P342, DOI 10.1016/j.tibs.2005.04.014; Kamasani U, 2007, CANCER BIOL THER, V6, P1422; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kovar DR, 2006, CURR BIOL, V16, pR535, DOI 10.1016/j.cub.2006.06.039; Li F, 2005, J BIOL CHEM, V280, P6986, DOI 10.1074/jbc.M411605200; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Martin SG, 2006, CURR BIOL, V16, P1161, DOI 10.1016/j.cub.2006.04.040; Montagnac G, 2008, CURR OPIN CELL BIOL, V20, P454, DOI 10.1016/j.ceb.2008.03.011; Moulding DA, 2007, J EXP MED, V204, P2213, DOI 10.1084/jem.20062324; Mukai A, 2008, J CELL SCI, V121, P1325, DOI 10.1242/jcs.027417; Nezami AG, 2006, STRUCTURE, V14, P257, DOI 10.1016/j.str.2005.12.003; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Paul A, 2008, CURR BIOL, V18, P9, DOI 10.1016/j.cub.2007.11.062; Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2; Peng J, 2007, CANCER RES, V67, P7565, DOI 10.1158/0008-5472.CAN-07-1467; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Pollard TD, 2008, BIOCHEM SOC T, V36, P425, DOI 10.1042/BST0360425; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Satoh S, 2001, J BIOL CHEM, V276, P39290, DOI 10.1074/jbc.M107026200; Severson AF, 2002, CURR BIOL, V12, P2066, DOI 10.1016/S0960-9822(02)01355-6; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Tully GH, 2009, MOL BIOL CELL, V20, P1201, DOI 10.1091/mbc.E08-08-0822; Vavylonis D, 2008, SCIENCE, V319, P97, DOI 10.1126/science.1151086; Wallar BJ, 2006, J BIOL CHEM, V281, P4300, DOI 10.1074/jbc.M510277200; Wallar BJ, 2007, EXP CELL RES, V313, P560, DOI 10.1016/j.yexcr.2006.10.033; Watanabe S, 2008, MOL BIOL CELL, V19, P2328, DOI 10.1091/mbc.E07-10-1086; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; Werner M, 2008, BIOCHEM SOC T, V36, P371, DOI 10.1042/BST0360371; Yonetani A, 2008, MOL BIOL CELL, V19, P2208, DOI 10.1091/mbc.E07-07-0731	47	43	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20061	20069		10.1074/jbc.M109.000885	http://dx.doi.org/10.1074/jbc.M109.000885			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19457867	Green Published, hybrid			2022-12-25	WOS:000268097400033
J	Nembrini, C; Kisielow, J; Shamshiev, AT; Tortola, L; Coyle, AJ; Kopf, M; Marsland, BJ				Nembrini, Chiara; Kisielow, Jan; Shamshiev, Abdijapar T.; Tortola, Luigi; Coyle, Anthony J.; Kopf, Manfred; Marsland, Benjamin J.			The Kinase Activity of Rip2 Determines Its Stability and Consequently Nod1-and Nod2-mediated Immune Responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE; INNATE; NOD2; RECEPTOR; PEPTIDOGLYCAN; CELLS; IDENTIFICATION; INFLAMMATION; RECOGNITION	Rip2 (RICK, CARD3) has been identified as a key effector molecule downstream of the pattern recognition receptors, Nod1 and Nod2; however, its mechanism of action remains to be elucidated. In particular, it is unclear whether its kinase activity is required for signaling or for maintaining protein stability. We have investigated the expression level of different retrovirally expressed kinase-dead Rip2 mutants and the role of Rip2 kinase activity in the signaling events that follow Nod1 and Nod2 stimulation. We show that in primary cells expressing kinase-inactive Rip2, protein levels were severely compromised, and stability could not be reconstituted by the addition of a phospho-mimetic mutation in its autophosphorylation site. Consequently, inflammatory cytokine production in response to Nod1 and Nod2 ligands was abrogated both in vitro and in vivo in the absence of Rip2 kinase activity. Our results highlight the central role that Rip2 kinase activity plays in conferring stability to the protein and thus in the preservation of Nod1- and Nod2-mediated innate immune responses.	[Marsland, Benjamin J.] Swiss Fed Inst Technol, Inst Integrat Biol, CH-8952 Zurich, Switzerland; [Coyle, Anthony J.] Millennium Pharmaceut Inc, Inflammat Div, Cambridge, MA 01239 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Marsland, BJ (corresponding author), Swiss Fed Inst Technol, Inst Integrat Biol, Wagistr 27, CH-8952 Zurich, Switzerland.	marsland@env.ethz.ch	Kopf, Manfred/B-6907-2009	Kopf, Manfred/0000-0002-0628-7140; Tortola, Luigi/0000-0002-8480-2080; Kisielow, Jan/0000-0002-4482-5202	Swiss National Science Foundation [310000-116675]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This work was supported by Swiss National Science Foundation Grant 310000-116675.	Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Chamaillard M, 2003, P NATL ACAD SCI USA, V100, P3455, DOI 10.1073/pnas.0530276100; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Crcareva A, 2005, EXP HEMATOL, V33, P1459, DOI 10.1016/j.exphem.2005.09.001; Dorsch M, 2006, CELL SIGNAL, V18, P2223, DOI 10.1016/j.cellsig.2006.05.005; Fritz JH, 2006, NAT IMMUNOL, V7, P1250, DOI 10.1038/ni1412; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Harton JA, 2002, J IMMUNOL, V169, P4088, DOI 10.4049/jimmunol.169.8.4088; Hasegawa M, 2008, EMBO J, V27, P373, DOI 10.1038/sj.emboj.7601962; Hotchkiss RS, 2006, NAT REV IMMUNOL, V6, P813, DOI 10.1038/nri1943; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Kim JY, 2008, J BIOL CHEM, V283, P137, DOI 10.1074/jbc.M704746200; Kim JG, 2004, INFECT IMMUN, V72, P1487, DOI 10.1128/IAI.72.3.1487-1495.2004; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Kufer TA, 2006, ANN NY ACAD SCI, V1072, P19, DOI 10.1196/annals.1326.020; Lu CF, 2005, J BIOL CHEM, V280, P16278, DOI 10.1074/jbc.M410114200; Masumoto J, 2006, J EXP MED, V203, P203, DOI 10.1084/jem.20051229; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Navas TA, 1999, J BIOL CHEM, V274, P33684, DOI 10.1074/jbc.274.47.33684; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Park JH, 2007, J IMMUNOL, V179, P514, DOI 10.4049/jimmunol.179.1.514; Park JH, 2007, J IMMUNOL, V178, P2380, DOI 10.4049/jimmunol.178.4.2380; Ruefli-Brasse AA, 2004, J BIOL CHEM, V279, P1570, DOI 10.1074/jbc.C300460200; Strober W, 2006, NAT REV IMMUNOL, V6, P9, DOI 10.1038/nri1747; Swift S., 2001, CURRENT PROTOCOLS IM; Tada H, 2005, INFECT IMMUN, V73, P7967, DOI 10.1128/IAI.73.12.7967-7976.2005; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Windheim M, 2007, BIOCHEM J, V404, P179, DOI 10.1042/BJ20061704	36	68	70	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19183	19188		10.1074/jbc.M109.006353	http://dx.doi.org/10.1074/jbc.M109.006353			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19473975	Green Published, hybrid			2022-12-25	WOS:000267908300007
J	Seibold, MA; Reese, TA; Choudhry, S; Salam, MT; Beckman, K; Eng, C; Atakilit, A; Meade, K; Lenoir, M; Watson, HG; Thyne, S; Kumar, R; Weiss, KB; Grammer, LC; Avila, P; Schleimer, RP; Fahy, JV; Rodriguez-Santana, J; Rodriguez-Cintron, W; Boot, RG; Sheppard, D; Gilliland, FD; Locksley, RM; Burchard, EG				Seibold, Max A.; Reese, Tiffany A.; Choudhry, Shweta; Salam, Muhammad T.; Beckman, Kenny; Eng, Celeste; Atakilit, Amha; Meade, Kelley; Lenoir, Michael; Watson, H. Geoffrey; Thyne, Shannon; Kumar, Rajesh; Weiss, Kevin B.; Grammer, Leslie C.; Avila, Pedro; Schleimer, Robert P.; Fahy, John V.; Rodriguez-Santana, Jose; Rodriguez-Cintron, William; Boot, Rolf G.; Sheppard, Dean; Gilliland, Frank D.; Locksley, Richard M.; Burchard, Esteban G.			Differential Enzymatic Activity of Common Haplotypic Versions of the Human Acidic Mammalian Chitinase Protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOUTHERN CALIFORNIA COMMUNITIES; DIFFERING LEVELS; AIR-POLLUTION; ENVIRONMENT; RESIDUES; CELL	Mouse models have shown the importance of acidic mammalian chitinase activity in settings of chitin exposure and allergic inflammation. However, little is known regarding genetic regulation of AMCase enzymatic activity in human allergic diseases. Resequencing the AMCase gene exons we identified 8 non-synonymous single nucleotide polymorphisms including three novel variants (A290G, G296A, G339T) near the gene area coding for the enzyme active site, all in linkage disequilibrium. AMCase protein isoforms, encoded by two gene-wide haplotypes, and differentiated by these three single nucleotide polymorphisms, were recombinantly expressed and purified. Biochemical analysis revealed the isoform encoded by the variant haplotype displayed a distinct pH profile exhibiting greater retention of chitinase activity at acidic and basic pH values. Determination of absolute kinetic activity found the variant isoform encoded by the variant haplotype was 4-, 2.5-, and 10-fold more active than the wild type AMCase isoform at pH 2.2, 4.6, and 7.0, respectively. Modeling of the AMCase isoforms revealed positional changes in amino acids critical for both pH specificity and substrate binding. Genetic association analyses of AMCase haplotypes for asthma revealed significant protective associations between the variant haplotype in several asthma cohorts. The structural, kinetic, and genetic data regarding the AMCase isoforms are consistent with the Th2-priming effects of environmental chitin and a role for AMCase in negatively regulating this stimulus.	[Seibold, Max A.; Reese, Tiffany A.; Choudhry, Shweta; Eng, Celeste; Fahy, John V.; Sheppard, Dean; Locksley, Richard M.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Seibold, Max A.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; [Seibold, Max A.; Choudhry, Shweta; Eng, Celeste; Atakilit, Amha; Sheppard, Dean; Burchard, Esteban G.] Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA; [Choudhry, Shweta; Burchard, Esteban G.] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA; [Thyne, Shannon] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Fahy, John V.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Locksley, Richard M.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; [Salam, Muhammad T.; Gilliland, Frank D.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; [Beckman, Kenny] CHORI, Oakland, CA 94609 USA; [Lenoir, Michael] Bay Area Pediat, Oakland, CA 94609 USA; [Watson, H. Geoffrey] James A Watson Wellness Ctr, Oakland, CA 94608 USA; [Kumar, Rajesh] Northwestern Univ, Childrens Mem Hosp, Chicago, IL 60611 USA; [Weiss, Kevin B.] Northwestern Univ, Inst Hlth Care Studies, Chicago, IL 60611 USA; [Grammer, Leslie C.; Avila, Pedro; Schleimer, Robert P.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA; [Rodriguez-Santana, Jose] Profess Serv Corp, Ctr Neumol Pediat, San Juan, PR 00927 USA; [Rodriguez-Cintron, William] Vet Caribbean Hlth Care Syst, San Juan, PR 00927 USA; [Boot, Rolf G.] Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 AZ Amsterdam, Netherlands	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Southern California; Children's Hospital Oakland Research Institute; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Northwestern University; Northwestern University; University of Amsterdam; Academic Medical Center Amsterdam	Seibold, MA (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	seiboldm@njc.org		Salam, Muhammad/0000-0002-3565-8916; Reese, Tiffany/0000-0003-2325-6546; Grammer, Leslie/0000-0001-6860-2014; Kumar, Rajesh/0000-0002-1962-7108; Boot, Rolf/0000-0002-7031-3390	National Institutes of Health [HL078885, HL088133, U19 AI077439, ES015794]; Flight Attendant Medical Research Institute (FAMRI),; R.W.J. Amos Medical Faculty Development Award; National Institutes of Health NHLBI [5U01 HL072478-05, 5R01HL61768, 5R01HL76647]; Sandler Asthma Basic Research Center (SABRE),; Sandler Program for Asthma Research (SPAR); Sandler Family Supporting Foundation; Southern California Environmental Health Sciences Center [5P30ES007048]; National Institute of Environmental Health Sciences, Children's Environmental Health [5P01ES009581, R826708-01, RD831861-01, 5P01ES011627]; Hastings Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072478, R01HL088133, R01HL076647, R01HL061768, R01HL078885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011627, P30ES007048, R01ES015794, P01ES009581] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Flight Attendant Medical Research Institute (FAMRI),; R.W.J. Amos Medical Faculty Development Award; National Institutes of Health NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Sandler Asthma Basic Research Center (SABRE),; Sandler Program for Asthma Research (SPAR); Sandler Family Supporting Foundation; Southern California Environmental Health Sciences Center; National Institute of Environmental Health Sciences, Children's Environmental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Hastings Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported, in whole or in part, by National Institutes of Health Grants HL078885, HL088133, U19 AI077439, and ES015794 (to E. G. B.), the Flight Attendant Medical Research Institute (FAMRI), and the R.W.J. Amos Medical Faculty Development Award (to E. G. B.).; The Chicago Initiative to Raise Asthma Health Equity (CHIRAH) and the Asthma Clinical Research Network are supported by National Institutes of Health NHLBI Grant 5U01 HL072478-05, Sandler Asthma Basic Research Center (SABRE), Sandler Program for Asthma Research (SPAR), and the Sandler Family Supporting Foundation. The Children's Health Study was supported by NHLBI Grants 5R01HL61768 and 5R01HL76647, Southern California Environmental Health Sciences Center Grant 5P30ES007048 supported by the National Institute of Environmental Health Sciences, Children's Environmental Health Center Grants 5P01ES009581, R826708-01, and RD831861-01 supported by the National Institute of Environmental Health Sciences and the Environmental Protection Agency, National Institute of Environmental Health Sciences Grant 5P01ES011627, and the Hastings Foundation.	Aguilera B, 2003, J BIOL CHEM, V278, P40911, DOI 10.1074/jbc.M301804200; ARAUJO ACG, 1993, J HISTOCHEM CYTOCHEM, V41, P571, DOI 10.1177/41.4.8450196; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bierbaum S, 2005, AM J RESP CRIT CARE, V172, P1505, DOI 10.1164/rccm.200506-890OC; Boot RG, 2001, J BIOL CHEM, V276, P6770, DOI 10.1074/jbc.M009886200; Bussink AP, 2007, GENETICS, V177, P959, DOI 10.1534/genetics.107.075846; Bussink AP, 2006, INT REV CYTOL, V252, P71, DOI 10.1016/S0074-7696(06)52001-7; Cash HL, 2006, SCIENCE, V313, P1126, DOI 10.1126/science.1127119; *CDCP, 1982, MMWR-MORBID MORTAL W, V31, P95; Chatterjee R, 2008, J ALLERGY CLIN IMMUN, V122, P202, DOI 10.1016/j.jaci.2008.04.030; Chen HC, 2002, FEMS MICROBIOL LETT, V209, P53, DOI 10.1111/j.1574-6968.2002.tb11108.x; Chou YT, 2006, BIOCHEMISTRY-US, V45, P4444, DOI 10.1021/bi0525977; DEBONO M, 1994, ANNU REV MICROBIOL, V48, P471, DOI 10.1146/annurev.mi.48.100194.002351; FUHRMAN JA, 1985, MOL BIOCHEM PARASIT, V17, P93, DOI 10.1016/0166-6851(85)90130-6; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D; Li XB, 2004, P NATL ACAD SCI USA, V101, P627, DOI 10.1073/pnas.0307645100; Lin DY, 2005, GENET EPIDEMIOL, V29, P299, DOI 10.1002/gepi.20098; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Miller BT, 2008, J CHEM INF MODEL, V48, P1920, DOI 10.1021/ci800133b; NACLERIO RM, 1999, LUNG BIOL HEALTH DIS, V123, P23; NEVILLE AC, 1976, J CELL SCI, V21, P73; Noverr MC, 2005, INFECT IMMUN, V73, P30, DOI 10.1128/IAI.73.1.30-38.2005; Olland AM, 2009, PROTEIN SCI, V18, P569, DOI 10.1002/pro.63; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760, DOI 10.1164/ajrccm.159.3.9804143; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768, DOI 10.1164/ajrccm.159.3.9804144; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; SHAHABUDDIN M, 1994, EXP PARASITOL, V79, P85, DOI 10.1006/expr.1994.1066; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336	31	44	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19650	19658		10.1074/jbc.M109.012443	http://dx.doi.org/10.1074/jbc.M109.012443			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19435888	Green Submitted, Green Published, hybrid			2022-12-25	WOS:000267908300056
J	McDonald, RE; Fleming, RI; Beeley, JG; Bovell, DL; Lu, JR; Zhao, XB; Cooper, A; Kennedy, MW				McDonald, Rhona E.; Fleming, Rachel I.; Beeley, John G.; Bovell, Douglas L.; Lu, Jian R.; Zhao, Xiubo; Cooper, Alan; Kennedy, Malcolm W.			Latherin: A Surfactant Protein of Horse Sweat and Saliva	PLOS ONE			English	Article								Horses are unusual in producing protein-rich sweat for thermoregulation, a major component of which is latherin, a highly surface-active, non-glycosylated protein. The amino acid sequence of latherin, determined from cDNA analysis, is highly conserved across four geographically dispersed equid species (horse, zebra, onager, ass), and is similar to a family of proteins only found previously in the oral cavity and associated tissues of mammals. Latherin produces a significant reduction in water surface tension at low concentrations (<= 1 mg ml(-1)), and therefore probably acts as a wetting agent to facilitate evaporative cooling through a waterproofed pelt. Neutron reflection experiments indicate that this detergent-like activity is associated with the formation of a dense protein layer, about 10 A thick, at the air-water interface. However, biophysical characterization (circular dichroism, differential scanning calorimetry) in solution shows that latherin behaves like a typical globular protein, although with unusual intrinsic fluorescence characteristics, suggesting that significant conformational change or unfolding of the protein is required for assembly of the air-water interfacial layer. RT-PCR screening revealed latherin transcripts in horse skin and salivary gland but in no other tissues. Recombinant latherin produced in bacteria was also found to be the target of IgE antibody from horse-allergic subjects. Equids therefore may have adapted an oral/salivary mucosal protein for two purposes peculiar to their lifestyle, namely their need for rapid and efficient heat dissipation and their specialisation for masticating and processing large quantities of dry food material.			McDonald, RE (corresponding author), Univ Glasgow, Fac Biomed & Life Sci, Glasgow, Lanark, Scotland.	malcolm.kennedy@bio.gla.ac.uk	Cooper, Alan/F-7813-2011; Zhao, Xiubo/A-1690-2011; Zhao, Xiubo/AAZ-9058-2021	Cooper, Alan/0000-0001-6709-7343; Zhao, Xiubo/0000-0002-4620-2893; Zhao, Xiubo/0000-0002-4620-2893; Yu, Hai/0000-0002-6386-9761	Wellcome Trust [GR070994MA] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alston RW, 2008, BIOPHYS J, V94, P2280, DOI 10.1529/biophysj.107.116921; Alston RW, 2008, BIOPHYS J, V94, P2288, DOI 10.1529/biophysj.107.116954; Beamer LJ, 1998, PROTEIN SCI, V7, P906; BEELEY JG, 1986, BIOCHEM J, V235, P645, DOI 10.1042/bj2350645; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bingle CD, 2004, INT J BIOCHEM CELL B, V36, P2144, DOI 10.1016/j.biocel.2004.05.002; Bingle CD, 2004, TRENDS IMMUNOL, V25, P53, DOI 10.1016/j.it.2003.11.007; Bingle CD, 2004, PROTEIN SCI, V13, P422, DOI 10.1110/ps.03332704; Bingle CD, 2002, HUM MOL GENET, V11, P937, DOI 10.1093/hmg/11.8.937; Bingle L, 2004, J PATHOL, V204, p45A; Botros HG, 2001, EUR J BIOCHEM, V268, P3126, DOI 10.1046/j.1432-1327.2001.02217.x; Cameotra SS, 2004, CURR OPIN MICROBIOL, V7, P262, DOI 10.1016/j.mib.2004.04.006; Clarkson JR, 1999, J COLLOID INTERF SCI, V215, P333, DOI 10.1006/jcis.1999.6256; Cooper A, 2005, BIOPHYS J, V88, P2114, DOI 10.1529/biophysj.104.046268; D'Innocenzo B, 2006, BIOCHEMISTRY-US, V45, P13418, DOI 10.1021/bi061409p; DAYHOFF MO, 1979, ATLAS PROTEIN SEQUEN; EFTINK MR, 1977, BIOCHEMISTRY-US, V16, P5546, DOI 10.1021/bi00644a024; EFTINK MR, 1984, BIOCHEMISTRY-US, V23, P3891, DOI 10.1021/bi00312a016; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Egland KA, 2003, P NATL ACAD SCI USA, V100, P1099, DOI 10.1073/pnas.0337425100; Elsbach P, 1998, CURR OPIN IMMUNOL, V10, P45, DOI 10.1016/S0952-7915(98)80030-7; Fenton MJ, 1998, J LEUKOCYTE BIOL, V64, P25, DOI 10.1002/jlb.64.1.25; FLEMING RI, 2009, P ROYAL S B IN PRESS; FOLK GE, 1991, INT J BIOMETEOROL, V35, P180, DOI 10.1007/BF01049065; Gregoire C, 1996, J BIOL CHEM, V271, P32951, DOI 10.1074/jbc.271.51.32951; Hakanpaa J, 2006, ACTA CRYSTALLOGR D, V62, P356, DOI 10.1107/S0907444906000862; Hakanpaa J, 2004, J BIOL CHEM, V279, P534, DOI 10.1074/jbc.M309650200; Hakanpaa J, 2006, PROTEIN SCI, V15, P2129, DOI 10.1110/ps.062326706; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Jenkinson DM, 2006, VET DERMATOL, V17, P361, DOI 10.1111/j.1365-3164.2006.00545.x; Kankavi O, 2006, CROAT MED J, V47, P155; Kankavi O, 2007, ANIM REPROD SCI, V98, P259, DOI 10.1016/j.anireprosci.2006.03.009; Kennedy MW, 2000, CELL MOL LIFE SCI, V57, P1379, DOI 10.1007/PL00000623; Kim JK, 2007, AM J PHYSIOL-LUNG C, V292, pL879, DOI 10.1152/ajplung.00156.2006; Lascombe MB, 2000, J BIOL CHEM, V275, P21572, DOI 10.1074/jbc.M002854200; LeClair EE, 2001, BIOCHEM BIOPH RES CO, V284, P792, DOI 10.1006/bbrc.2001.5024; Lu JR, 2007, CURR OPIN COLLOID IN, V12, P9, DOI 10.1016/j.cocis.2007.02.001; Lu JR, 2000, ADV COLLOID INTERFAC, V84, P143, DOI 10.1016/S0001-8686(99)00019-6; Lu JR, 1998, J CHEM SOC FARADAY T, V94, P3279, DOI 10.1039/a805731a; Lu JR, 1999, J COLLOID INTERF SCI, V213, P426, DOI 10.1006/jcis.1999.6157; Lu JR, 1998, J CHEM SOC FARADAY T, V94, P995, DOI 10.1039/a707853f; Lu JR, 2003, J AM CHEM SOC, V125, P3751, DOI 10.1021/ja0292290; Lu JR, 1999, LANGMUIR, V15, P6975, DOI 10.1021/la990131h; MACKENZIE CD, 2009, BIOPHYSICAL IN PRESS; McGuire JF, 2002, INT J PEDIATR OTORHI, V66, P1, DOI 10.1016/S0165-5876(02)00203-3; MONTGOMERY I, 1982, J ANAT, V135, P13; Mulero JJ, 2002, IMMUNOGENETICS, V54, P293, DOI 10.1007/s00251-002-0467-3; Porter AMW, 2001, J ROY SOC MED, V94, P236, DOI 10.1177/014107680109400509; Possmayer F, 2001, COMP BIOCHEM PHYS A, V129, P209, DOI 10.1016/S1095-6433(01)00317-8; Singh P, 2004, TRENDS BIOTECHNOL, V22, P142, DOI 10.1016/j.tibtech.2004.01.010; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528	53	63	65	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5726	10.1371/journal.pone.0005726	http://dx.doi.org/10.1371/journal.pone.0005726			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451SH	19478940	Green Submitted, gold, Green Published, Green Accepted			2022-12-25	WOS:000266490000005
J	Krueger, KAD; Tsuji, S; Fukuda, Y; Takahashi, Y; Goto, J; Mitsui, J; Ishiura, H; Dalton, JC; Miller, MB; Day, JW; Ranum, LPW				Krueger, Katherine A. Dick; Tsuji, Shoji; Fukuda, Yoko; Takahashi, Yuji; Goto, Jun; Mitsui, Jun; Ishiura, Hiroyuki; Dalton, Joline C.; Miller, Michael B.; Day, John W.; Ranum, Laura P. W.			SNP Haplotype Mapping in a Small ALS Family	PLOS ONE			English	Article								The identification of genes for monogenic disorders has proven to be highly effective for understanding disease mechanisms, pathways and gene function in humans. Nevertheless, while thousands of Mendelian disorders have not yet been mapped there has been a trend away from studying single-gene disorders. In part, this is due to the fact that many of the remaining single-gene families are not large enough to map the disease locus to a single site in the genome. New tools and approaches are needed to allow researchers to effectively tap into this genetic gold-mine. Towards this goal, we have used haploid cell lines to experimentally validate the use of high-density single nucleotide polymorphism (SNP) arrays to define genome-wide haplotypes and candidate regions, using a small amyotrophic lateral sclerosis (ALS) family as a prototype. Specifically, we used haploid-cell lines to determine if high-density SNP arrays accurately predict haplotypes across entire chromosomes and show that haplotype information significantly enhances the genetic information in small families. Panels of haploid-cell lines were generated and a 5 centimorgan (cM) short tandem repeat polymorphism (STRP) genome scan was performed. Experimentally derived haplotypes for entire chromosomes were used to directly identify regions of the genome identical-by-descent in 5 affected individuals. Comparisons between experimentally determined and in silico haplotypes predicted from SNP arrays demonstrate that SNP analysis of diploid DNA accurately predicted chromosomal haplotypes. These methods precisely identified 12 candidate intervals, which are shared by all 5 affected individuals. Our study illustrates how genetic information can be maximized using readily available tools as a first step in mapping single-gene disorders in small families.			Krueger, KAD (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.	ranum001@umn.edu	Mitsui, Jun/B-5455-2012	Mitsui, Jun/0000-0001-7425-4765; Fukuda-Yuzawa, Yoko/0000-0002-9887-9820; Day, John/0000-0002-0086-9529	NHLBI NIH HHS [N01HV48141] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonarakis SE, 2006, NAT REV GENET, V7, P277, DOI 10.1038/nrg1826; Battistini S, 2005, J NEUROL, V252, P782, DOI 10.1007/s00415-005-0742-y; Berger MM, 2000, NEUROLOGY, V54, P20, DOI 10.1212/WNL.54.1.20; Cleveland DW, 1999, NEURON, V24, P515, DOI 10.1016/S0896-6273(00)81108-3; Douglas JA, 2001, NAT GENET, V28, P361, DOI 10.1038/ng582; Ervasti JM, 2007, BBA-MOL BASIS DIS, V1772, P108, DOI 10.1016/j.bbadis.2006.05.010; Gudbjartsson DF, 2005, NAT GENET, V37, P1015, DOI 10.1038/ng1005-1015; *J HOPK U I GEN ME, 2008, ONL MEND INH MAN OMI; Jackson M, 1997, ANN NEUROL, V42, P803, DOI 10.1002/ana.410420518; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Kwiatkowski TJ, 2009, SCIENCE, V323, P1205, DOI 10.1126/science.1166066; Morita M, 2006, NEUROLOGY, V66, P839, DOI 10.1212/01.wnl.0000200048.53766.b4; Nishimura AL, 2004, J MED GENET, V41, P315, DOI 10.1136/jmg.2003.013029; Nishimura AL, 2004, AM J HUM GENET, V75, P822, DOI 10.1086/425287; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; PAPADOPOULOS N, 1995, NAT GENET, V11, P99, DOI 10.1038/ng0995-99; Pasinelli P, 2006, NAT REV NEUROSCI, V7, P710, DOI 10.1038/nrn1971; Ropers HH, 2007, AM J HUM GENET, V81, P199, DOI 10.1086/520679; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rustgi AK, 2007, GENE DEV, V21, P2525, DOI 10.1101/gad.1593107; Shaw CE, 1998, ANN NEUROL, V43, P390, DOI 10.1002/ana.410430319; Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; Vance C, 2006, BRAIN, V129, P868, DOI 10.1093/brain/awl030; Vance C, 2009, SCIENCE, V323, P1208, DOI 10.1126/science.1165942; Yan H, 2000, NATURE, V403, P723, DOI 10.1038/35001659; YAN J, 2006, 58 ANN M AM AC NEUR	27	11	12	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2009	4	5							e5687	10.1371/journal.pone.0005687	http://dx.doi.org/10.1371/journal.pone.0005687			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LI	19479031	Green Published, gold, Green Submitted			2022-12-25	WOS:000266331700014
J	Olsen, I; Tollefsen, S; Aagaard, C; Reitan, LJ; Bannantine, JP; Andersen, P; Sollid, LM; Lundin, KEA				Olsen, Ingrid; Tollefsen, Stig; Aagaard, Claus; Reitan, Liv J.; Bannantine, John P.; Andersen, Peter; Sollid, Ludvig M.; Lundin, Knut E. A.			Isolation of Mycobacterium avium Subspecies paratuberculosis Reactive CD4 T Cells from Intestinal Biopsies of Crohn's Disease Patients	PLOS ONE			English	Article							GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; IDENTIFICATION; AUTOPHAGY; TUBERCULOSIS; ANTIGENS; SEQUENCE; GENE; NOD2; ENTEROBACTERIA	Background: Crohn's disease (CD) is a chronic granulomatous inflammation of the intestine. The etiology is unknown, but an excessive immune response to bacteria in genetically susceptible individuals is probably involved. The response is characterized by a strong Th1/Th17 response, but the relative importance of the various bacteria is not known. Methodology/Principal Findings: In an attempt to address this issue, we made T-cell lines from intestinal biopsies of patients with CD (n = 11), ulcerative colitis (UC) (n = 13) and controls (n = 10). The T-cell lines were tested for responses to various bacteria. A majority of the CD patients with active disease had a dominant response to Mycobacterium avium subspecies paratuberculosis (MAP). The T cells from CD patients also showed higher proliferation in response to MAP compared to UC patients (p<0.025). MAP reactive CD4 T-cell clones (n = 28) were isolated from four CD patients. The T-cell clones produced IL-17 and/or IFN-gamma, while minimal amounts of IL-4 were detected. To further characterize the specificity, the responses to antigen preparations from different mycobacterial species were tested. One T-cell clone responded only to MAP and the very closely related M. avium subspecies avium (MAA) while another responded to MAP, MAA and Mycobacterium intracellulare. A more broadly reactive T-cell clone reacted to MAP1508 which belongs to the esx protein family. Conclusions/Significance: The presence of MAP reactive T cells with a Th1 or Th1/Th17 phenotype may suggest a possible role of mycobacteria in the inflammation seen in CD. The isolation of intestinal T cells followed by characterization of their specificity is a valuable tool to study the relative importance of different bacteria in CD.			Olsen, I (corresponding author), Natl Vet Inst, Dept Anim Hlth, Oslo, Norway.	ingrid.olsen@vetinst.no	Lundin, Knut E. A./AAW-9519-2021; Sollid, Ludvig/N-9691-2015	Lundin, Knut E. A./0000-0003-1713-5545; Sollid, Ludvig/0000-0001-8860-704X; Bannantine, John/0000-0002-5692-7898; Andersen, Peter/0000-0002-5869-2551				Abubakar I, 2008, INFLAMM BOWEL DIS, V14, P401, DOI 10.1002/ibd.20276; Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; AZUMA I, 1970, BIOCHIM BIOPHYS ACTA, V208, P444, DOI 10.1016/0304-4165(70)90217-5; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Baumgart DC, 2007, LANCET, V369, P1627, DOI 10.1016/S0140-6736(07)60750-8; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Boudeau J, 1999, INFECT IMMUN, V67, P4499, DOI 10.1128/IAI.67.9.4499-4509.1999; Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416; Coler RN, 2009, VACCINE, V27, P223, DOI 10.1016/j.vaccine.2008.10.056; DALTON HR, 1992, GUT, V33, P324, DOI 10.1136/gut.33.3.324; Duchmann R, 1996, SCAND J IMMUNOL, V44, P71, DOI 10.1046/j.1365-3083.1996.d01-273.x; Duchmann R, 1999, GUT, V44, P812, DOI 10.1136/gut.44.6.812; Eckmann L, 2005, IMMUNITY, V22, P661, DOI 10.1016/j.immuni.2005.06.004; Feller M, 2007, LANCET INFECT DIS, V7, P607, DOI 10.1016/S1473-3099(07)70211-6; Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100; Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954; Hemmer B, 1999, NAT MED, V5, P1375; Hiemstra HS, 1997, P NATL ACAD SCI USA, V94, P10313, DOI 10.1073/pnas.94.19.10313; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Li LL, 2005, P NATL ACAD SCI USA, V102, P12344, DOI 10.1073/pnas.0505662102; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Molberg O, 2003, GASTROENTEROLOGY, V125, P337, DOI 10.1016/S0016-5085(03)00890-4; MOLBERG O, 2000, CELIAC DIS METHODS P, P105; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Olsen I, 2000, INFECT IMMUN, V68, P801, DOI 10.1128/IAI.68.2.801-808.2000; Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061; Pinedo PJ, 2009, VET MICROBIOL, V134, P346, DOI 10.1016/j.vetmic.2008.09.052; Raymond JB, 2005, J BIOL CHEM, V280, P326, DOI 10.1074/jbc.M411006200; Rich KA, 2003, CELL MICROBIOL, V5, P455, DOI 10.1046/j.1462-5822.2003.00292.x; Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032; SELDENRIJK CA, 1990, GUT, V31, P529, DOI 10.1136/gut.31.5.529; Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577; Strober W, 2007, J CLIN INVEST, V117, P514, DOI 10.1172/JCI30587; van Beelen AJ, 2007, IMMUNITY, V27, P660, DOI 10.1016/j.immuni.2007.08.013; van Pinxteren LAH, 2000, CLIN DIAGN LAB IMMUN, V7, P155, DOI 10.1128/CDLI.7.2.155-160.2000	36	43	45	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2009	4	5							e5641	10.1371/journal.pone.0005641	http://dx.doi.org/10.1371/journal.pone.0005641			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LD	19479064	Green Submitted, Green Published, gold			2022-12-25	WOS:000266331200001
J	Raychaudhuri, S; Dey, S; Bhattacharyya, NP; Mukhopadhyay, D				Raychaudhuri, Swasti; Dey, Sucharita; Bhattacharyya, Nitai P.; Mukhopadhyay, Debashis			The Role of Intrinsically Unstructured Proteins in Neurodegenerative Diseases	PLOS ONE			English	Article							DISORDERED PROTEINS; TOPOLOGICAL FEATURES; INTERACTION DATASETS; INTERACTION NETWORKS; HUNTINGTONS-DISEASE; STRUCTURAL DISORDER; ALPHA-SYNUCLEIN; ENERGY CONTENT; SEQUENCE; POLYGLUTAMINE	The number and importance of intrinsically disordered proteins (IUP), known to be involved in various human disorders, are growing rapidly. To test for the generalized implications of intrinsic disorders in proteins involved in Neurodegenerative diseases, disorder prediction tools have been applied to three datasets comprising of proteins involved in Huntington Disease (HD), Parkinson's disease (PD), Alzheimer's disease (AD). Results show, in general, proteins in disease datasets possess significantly enhanced intrinsic unstructuredness. Most of these disordered proteins in the disease datasets are found to be involved in neuronal activities, signal transduction, apoptosis, intracellular traffic, cell differentiation etc. Also these proteins are found to have more number of interactors and hence as the proportion of disorderedness (i.e., the length of the unfolded stretch) increased, the size of the interaction network simultaneously increased. All these observations reflect that, "Moonlighting" i.e. the contextual acquisition of different structural conformations (transient), eventually may allow these disordered proteins to act as network "hubs" and thus they may have crucial influences in the pathogenecity of neurodegenerative diseases.			Raychaudhuri, S (corresponding author), Saha Inst Nucl Phys, Struct Genom Sect, Kolkata, India.	debashis.mukhopadhyay@saha.ac.in	Raychaudhuri, Swasti/AAZ-2748-2020	Dey, Sucharita/0000-0003-0605-2576				Agorogiannis EI, 2004, NEUROPATH APPL NEURO, V30, P215, DOI 10.1111/j.1365-2990.2004.00558.x; BAXENDALE S, 1995, NAT GENET, V10, P67, DOI 10.1038/ng0595-67; Bordoli L, 2007, PROTEINS, V69, P129, DOI 10.1002/prot.21671; Bork P, 2004, CURR OPIN STRUC BIOL, V14, P292, DOI 10.1016/j.sbi.2004.05.003; Cheng Y, 2006, TRENDS BIOTECHNOL, V24, P435, DOI 10.1016/j.tibtech.2006.07.005; Cheng YG, 2006, BIOCHEMISTRY-US, V45, P10448, DOI 10.1021/bi060981d; Crocker SF, 2006, BRAIN RES, V1088, P176, DOI 10.1016/j.brainres.2006.02.102; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Dosztanyi Z, 2005, BIOINFORMATICS, V21, P3433, DOI 10.1093/bioinformatics/bti541; Dosztanyi Z, 2005, J MOL BIOL, V347, P827, DOI 10.1016/j.jmb.2005.01.071; Dosztanyi Z, 2006, J PROTEOME RES, V5, P2985, DOI 10.1021/pr060171o; Dunker AK, 2008, CURR OPIN STRUC BIOL, V18, P756, DOI 10.1016/j.sbi.2008.10.002; Dunker AK, 2000, P WORKSH GEN INF, V11, P161; Feldman I, 2008, P NATL ACAD SCI USA, V105, P4323, DOI 10.1073/pnas.0701722105; Gandhi TKB, 2006, NAT GENET, V38, P285, DOI 10.1038/ng1747; Goehler H, 2004, MOL CELL, V15, P853, DOI 10.1016/j.molcel.2004.09.016; Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104; Haynes C, 2006, PLOS COMPUT BIOL, V2, P890, DOI 10.1371/journal.pcbi.0020100; Iakoucheva LM, 2002, J MOL BIOL, V323, P573, DOI 10.1016/S0022-2836(02)00969-5; JONSSON PF, BIOINFORMATICS, V22, P2291; Kaltenbach L., 2007, PLOS GENET; Kransnoslobodtsev AV, 2005, NANOMED-NANOTECHNOL, V1, P300, DOI 10.1016/j.nano.2005.10.005; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; Linding R, 2003, NUCLEIC ACIDS RES, V31, P3701, DOI 10.1093/nar/gkg519; Linding R, 2003, STRUCTURE, V11, P1453, DOI 10.1016/j.str.2003.10.002; Masino L, 2002, FEBS LETT, V513, P267, DOI 10.1016/S0014-5793(02)02335-9; Patil A, 2006, FEBS LETT, V580, P2041, DOI 10.1016/j.febslet.2006.03.003; Prilusky J, 2005, BIOINFORMATICS, V21, P3435, DOI 10.1093/bioinformatics/bti537; Raychaudhuri S, 2008, PROTEINS, V71, P1686, DOI 10.1002/prot.21856; Romero, 1997, Genome Inform Ser Workshop Genome Inform, V8, P110; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Sickmeier M, 2007, NUCLEIC ACIDS RES, V35, pD786, DOI 10.1093/nar/gkl893; Skrabana R, 2006, CELL MOL NEUROBIOL, V26, P1085, DOI 10.1007/s10571-006-9083-3; SPIEGEL MR, 2000, THEORY PROBLEMS PROB, P241; Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109; STICHT H, 1995, EUR J BIOCHEM, V233, P293, DOI 10.1111/j.1432-1033.1995.293_1.x; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Tompa P, 2005, TRENDS BIOCHEM SCI, V30, P484, DOI 10.1016/j.tibs.2005.07.008; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Tompa P, 2008, TRENDS BIOCHEM SCI, V33, P2, DOI 10.1016/j.tibs.2007.10.003; Uversky VN, 2008, ANNU REV BIOPHYS, V37, P215, DOI 10.1146/annurev.biophys.37.032807.125924; Uversky VN, 2008, CURR ALZHEIMER RES, V5, P260, DOI 10.2174/156720508784533312; Uversky VN, 2007, J NEUROCHEM, V103, P17, DOI 10.1111/j.1471-4159.2007.04764.x; Uversky VN, 2004, BBA-PROTEINS PROTEOM, V1698, P131, DOI 10.1016/j.bbapap.2003.12.008; Uversky VN, 2003, J BIOMOL STRUCT DYN, V21, P211, DOI 10.1080/07391102.2003.10506918; Vitalis A, 2007, BIOPHYS J, V93, P1923, DOI 10.1529/biophysj.107.110080; Vonsattel JPG, 1998, J NEUROPATH EXP NEUR, V57, P369; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; XU J, BIOINFORMATICS, V22, P2800; Yang ZR, 2005, BIOINFORMATICS, V21, P3369, DOI 10.1093/bioinformatics/bti534	52	50	52	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5566	10.1371/journal.pone.0005566	http://dx.doi.org/10.1371/journal.pone.0005566			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440375	Green Submitted, gold, Green Published			2022-12-25	WOS:000266107400010
J	Schweiger, MR; Kerick, M; Timmermann, B; Albrecht, MW; Borodina, T; Parkhomchuk, D; Zatloukal, K; Lehrach, H				Schweiger, Michal R.; Kerick, Martin; Timmermann, Bernd; Albrecht, Marcus W.; Borodina, Tatjana; Parkhomchuk, Dmitri; Zatloukal, Kurt; Lehrach, Hans			Genome-Wide Massively Parallel Sequencing of Formaldehyde Fixed-Paraffin Embedded (FFPE) Tumor Tissues for Copy-Number- and Mutation-Analysis	PLOS ONE			English	Article								Background: Cancer re-sequencing programs rely on DNA isolated from fresh snap frozen tissues, the preparation of which is combined with additional preservation efforts. Tissue samples at pathology departments are routinely stored as formalin-fixed and paraffin-embedded (FFPE) samples and their use would open up access to a variety of clinical trials. However, FFPE preparation is incompatible with many down-stream molecular biology techniques such as PCR based amplification methods and gene expression studies. Methodology/Principal Findings: Here we investigated the sample quality requirements of FFPE tissues for massively parallel short-read sequencing approaches. We evaluated key variables of pre-fixation, fixation related and post-fixation processes that occur in routine medical service (e. g. degree of autolysis, duration of fixation and of storage). We also investigated the influence of tissue storage time on sequencing quality by using material that was up to 18 years old. Finally, we analyzed normal and tumor breast tissues using the Sequencing by Synthesis technique (Illumina Genome Analyzer, Solexa) to simultaneously localize genome-wide copy number alterations and to detect genomic variations such as substitutions and point-deletions and/or insertions in FFPE tissue samples. Conclusions/Significance: The application of second generation sequencing techniques on small amounts of FFPE material opens up the possibility to analyze tissue samples which have been collected during routine clinical work as well as in the context of clinical trials. This is in particular important since FFPE samples are amply available from surgical tumor resections and histopathological diagnosis, and comprise tissue from precursor lesions, primary tumors, lymphogenic and/or hematogenic metastases. Large-scale studies using this tissue material will result in a better prediction of the prognosis of cancer patients and the early identification of patients which will respond to therapy.			Schweiger, MR (corresponding author), Max Planck Inst Mol Genet, Dept Vertebrate Genom, Berlin, Germany.	mschweig@molgen.mpg.de	Kerick, Martin/AAD-8303-2022; Ferron, Gwenael/P-6193-2014; Schweiger, Michal R/H-5270-2015; ALEXANDRE, JEROME/O-8350-2017	Ferron, Gwenael/0000-0002-8545-4700; Schweiger, Michal R/0000-0002-4672-0623; Borodina, Tatiana/0000-0002-6978-016X; Kerick, Martin/0000-0002-6298-4514				Asslaber M, 2007, PATHOBIOLOGY, V74, P251, DOI 10.1159/000104453; Campbell PJ, 2008, NAT GENET, V40, P722, DOI 10.1038/ng.128; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Gilbert MTP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000537; Haverty PM, 2008, GENE CHROMOSOME CANC, V47, P530, DOI 10.1002/gcc.20558; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Le Tourneau C, 2008, DRUG RESIST UPDATE, V11, P99, DOI 10.1016/j.drup.2008.04.001; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389; Shendure J, 2008, NAT BIOTECHNOL, V26, P1135, DOI 10.1038/nbt1486; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Sultan M, 2008, SCIENCE, V321, P956, DOI 10.1126/science.1160342; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Velculescu VE, 2007, NAT BIOTECHNOL, V25, P878, DOI 10.1038/nbt0807-878; Venkatraman ES, 2007, BIOINFORMATICS, V23, P657, DOI 10.1093/bioinformatics/btl646	18	128	178	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2009	4	5							e5548	10.1371/journal.pone.0005548	http://dx.doi.org/10.1371/journal.pone.0005548			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FX	19440246	Green Published, gold			2022-12-25	WOS:000266107300013
J	Maddocks, ODK; Short, AJ; Donnenberg, MS; Bader, S; Harrison, DJ				Maddocks, Oliver D. K.; Short, Abigail J.; Donnenberg, Michael S.; Bader, Scott; Harrison, David J.			Attaching and Effacing Escherichia coli Downregulate DNA Mismatch Repair Protein In Vitro and Are Associated with Colorectal Adenocarcinomas in Humans	PLOS ONE			English	Article								Background: Mucosa-associated Escherichia coli are frequently found in the colonic mucosa of patients with colorectal adenocarcinoma, but rarely in healthy controls. Chronic mucosal E. coli infection has therefore been linked to colonic tumourigenesis. E. coli strains carrying eae (encoding the bacterial adhesion protein intimin) attach intimately to the intestinal mucosa and are classed as attaching and effacing E. coli (AEEC). Enteropathogenic Escherichia coli (EPEC) are the most common form of AEEC identified in man. EPEC utilise a type III secretion system to translocate effector proteins into host cells and infection induces wide-ranging effects on the host cell proteome. We hypothesised that EPEC infection could influence molecular pathways involved in colorectal tumourigenesis. Methodology/Principal Findings: When co-cultured with human colorectal cell lines, EPEC dramatically downregulated the expression of key DNA mismatch repair proteins MSH2 and MLH1 in an attachment specific manner. Cytochrome c staining and TUNEL analysis confirmed that this effect was not a consequence of apoptosis/necrosis. Ex vivo human colonic mucosa was co-cultured with EPEC and probed by immunofluorescence to locate adherent bacteria. EPEC entered 10% of colonic crypts and adhered to crypt epithelial cells, often in the proliferative compartment. Adenocarcinoma and normal colonic mucosa from colorectal cancer patients (n = 20) was probed by immunofluorescence and PCR for AEEC. Mucosa-associated E. coli were found on 10/20 (50%) adenocarcinomas and 3/20 (15%) normal mucosa samples (P < 0.05). AEEC were detected on 5/20 (25%) adenocarcinomas, but not normal mucosa samples (P < 0.05). Significance/Conclusions: The ability of EPEC to downregulate DNA mismatch repair proteins represents a novel gene-environment interaction that could increase the susceptibility of colonic epithelial cells to mutations and therefore promote colonic tumourigenesis. The potential role of AEEC in colorectal tumourigenesis warrants further investigation.			Maddocks, ODK (corresponding author), Univ Edinburgh, Western Gen Hosp, Inst Genet & Mol Med, Div Pathol, Edinburgh, Midlothian, Scotland.	olivermaddocks@yahoo.co.uk	Maddocks, Oliver/K-5410-2012	Maddocks, Oliver/0000-0002-5551-9091; harrison, david/0000-0001-9041-9988; Donnenberg, Michael/0000-0002-8818-3184	NATIONAL CANCER INSTITUTE [R21CA141038] Funding Source: NIH RePORTER; Cancer Research UK [C505/A7328, 617SUR R40245] Funding Source: Medline; Medical Research Council [MRCDTGG122/5] Funding Source: Medline; NCI NIH HHS [R21 CA141038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afset JE, 2004, J MED MICROBIOL, V53, P1137, DOI 10.1099/jmm.0.45719-0; Baranovskaya S, 2001, P NATL ACAD SCI USA, V98, P15107, DOI 10.1073/pnas.251234498; BARTHOLD SW, 1977, CANCER RES, V37, P4352; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Beutin L, 2003, INFECT IMMUN, V71, P3995, DOI 10.1128/IAI.71.7.3995-4002.2003; BLASER MJ, 1995, CANCER RES, V55, P2111; Blasi MF, 2006, CANCER RES, V66, P9036, DOI 10.1158/0008-5472.CAN-06-1896; BROWNING TH, 1969, J CLIN INVEST, V48, P1423, DOI 10.1172/JCI106108; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; CHANTRET I, 1988, CANCER RES, V48, P1936; Clarke SC, 2003, CLIN MICROBIOL REV, V16, P365, DOI 10.1128/CMR.16.3.365-378.2003; Cleary J, 2004, MICROBIOL-SGM, V150, P527, DOI 10.1099/mic.0.26740-0; Crane JK, 1997, INFECT IMMUN, V65, P3277, DOI 10.1128/IAI.65.8.3277-3285.1997; de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453; DONNENBERG MS, 1993, J BACTERIOL, V175, P4670, DOI 10.1128/JB.175.15.4670-4680.1993; ETZLER ME, 1974, J CELL BIOL, V62, P329, DOI 10.1083/jcb.62.2.329; Giovannucci E, 2005, JNCI-J NATL CANCER I, V97, P1317, DOI 10.1093/jnci/dji305; Glaab WE, 1999, MUTAT RES-FUND MOL M, V427, P67, DOI 10.1016/S0027-5107(99)00091-3; Goosney DL, 2001, INFECT IMMUN, V69, P3315, DOI 10.1128/IAI.69.5.3315-3322.2001; HAKOMORI S, 1985, CANCER RES, V45, P2405; Hardwidge PR, 2004, J BIOL CHEM, V279, P20127, DOI 10.1074/jbc.M401228200; Hernandez-Pigeon H, 2004, FEBS LETT, V562, P40, DOI 10.1016/S0014-5793(04)00181-4; Hicks S, 1998, INFECT IMMUN, V66, P1570, DOI 10.1128/IAI.66.4.1570-1578.1998; Hyland RM, 2006, INFECT IMMUN, V74, P5419, DOI 10.1128/IAI.00739-06; Kane MF, 1997, CANCER RES, V57, P808; Kenny B, 1997, INFECT IMMUN, V65, P2528, DOI 10.1128/IAI.65.7.2528-2536.1997; Kim JJ, 2002, GASTROENTEROLOGY, V123, P542, DOI 10.1053/gast.2002.34751; KIM YS, 1971, J BIOL CHEM, V246, P5466; KNUTTON S, 1987, INFECT IMMUN, V55, P69, DOI 10.1128/IAI.55.1.69-77.1987; Lei XF, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh098; LEVINE MM, 1984, EPIDEMIOL REV, V6, P31, DOI 10.1093/oxfordjournals.epirev.a036274; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Mager DL, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-14; Malladi V, 2004, MICROBES INFECT, V6, P38, DOI 10.1016/j.micinf.2003.09.022; Marti TM, 2003, DNA REPAIR, V2, P571, DOI 10.1016/S1568-7864(03)00023-5; Martin HM, 2004, GASTROENTEROLOGY, V127, P80, DOI 10.1053/j.gastro.2004.03.054; McNamara BP, 2001, J CLIN INVEST, V107, P621, DOI 10.1172/JCI11138; MOON HW, 1983, INFECT IMMUN, V41, P1340, DOI 10.1128/IAI.41.3.1340-1351.1983; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998; Nougayrede JP, 2004, CELL MICROBIOL, V6, P1097, DOI 10.1111/j.1462-5822.2004.00421.x; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Pabst WL, 2003, J CLIN MICROBIOL, V41, P2289, DOI 10.1128/JCM.41.6.2289-2293.2003; Phillips AD, 2000, J INFECT DIS, V181, P1496, DOI 10.1086/315404; Robins-Browne RM, 2004, EMERG INFECT DIS, V10, P1797, DOI 10.3201/eid1010.031086; Rosenshine I, 1996, INFECT IMMUN, V64, P966, DOI 10.1128/IAI.64.3.966-973.1996; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Samowitz WS, 2007, MOL CANCER RES, V5, P165, DOI 10.1158/1541-7786.MCR-06-0398; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; SCHAUER DB, 1995, J CLIN MICROBIOL, V33, P2064, DOI 10.1128/JCM.33.8.2064-2068.1995; Schuller S, 2007, CELL MICROBIOL, V9, P1352, DOI 10.1111/j.1462-5822.2006.00879.x; Segal ED, 1996, P NATL ACAD SCI USA, V93, P1259, DOI 10.1073/pnas.93.3.1259; Shifrin Y, 2002, CELL MICROBIOL, V4, P235, DOI 10.1046/j.1462-5822.2002.00188.x; SMOOT DT, 1993, INFECT IMMUN, V61, P350, DOI 10.1128/IAI.61.1.350-355.1993; Sohn KJ, 2003, CARCINOGENESIS, V24, P217, DOI 10.1093/carcin/24.2.217; Stewart BW, 2003, WORLD CANC REPORT, P198; Swidsinski A, 1998, GASTROENTEROLOGY, V115, P281, DOI 10.1016/S0016-5085(98)70194-5; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vogelmann R, 2007, CURR OPIN MICROBIOL, V10, P76, DOI 10.1016/j.mib.2006.12.004; WEISER MM, 1973, J BIOL CHEM, V248, P2542; Youn CK, 2005, NAT CELL BIOL, V7, P137, DOI 10.1038/ncb1215; Zhang SL, 2002, ENVIRON MOL MUTAGEN, V40, P243, DOI 10.1002/em.10113; Zhu WB, 1998, MUTAT RES-FUND MOL M, V398, P93, DOI 10.1016/S0027-5107(97)00244-3	64	87	91	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5517	10.1371/journal.pone.0005517	http://dx.doi.org/10.1371/journal.pone.0005517			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444WA	19436735	Green Published, Green Submitted, Green Accepted, gold			2022-12-25	WOS:000266009900010
J	SanGiovanni, JP; Arking, DE; Iyengar, SK; Elashoff, M; Clemons, TE; Reed, GF; Henning, AK; Sivakumaran, TA; Xu, XM; Dewan, A; Agron, E; Rochtchina, E; Sue, CM; Wang, JJ; Mitchell, P; Hoh, J; Francis, PJ; Klein, ML; Chew, EY; Chakravarti, A				SanGiovanni, John Paul; Arking, Dan E.; Iyengar, Sudha K.; Elashoff, Michael; Clemons, Traci E.; Reed, George F.; Henning, Alice K.; Sivakumaran, Theru A.; Xu, Xuming; DeWan, Andrew; Agron, Elvira; Rochtchina, Elena; Sue, Carolyn M.; Wang, Jie Jin; Mitchell, Paul; Hoh, Josephine; Francis, Peter J.; Klein, Michael L.; Chew, Emily Y.; Chakravarti, Aravinda			Mitochondrial DNA Variants of Respiratory Complex I that Uniquely Characterize Haplogroup T2 Are Associated with Increased Risk of Age-Related Macular Degeneration	PLOS ONE			English	Article								Background: Age-related macular degeneration (AMD), a chronic neurodegenerative and neovascular retinal disease, is the leading cause of blindness in elderly people of western European origin. While structural and functional alterations in mitochondria (mt) and their metabolites have been implicated in the pathogenesis of chronic neurodegenerative and vascular diseases, the relationship of inherited variants in the mitochondrial genome and mt haplogroup subtypes with advanced AMD has not been reported in large prospective cohorts. Methodology/Prinicipal Findings: We examined the relationship of inherited mtDNA variants with advanced AMD in 1168 people using a three-stage design on samples from 12-year and 10-year prospective studies on the natural history of age-related eye disease. In Stage I we resequenced the entire genome in 99 elderly AMD-free controls and 215 people with advanced AMD from the 12-year study. A consistent association with AMD in 14 of 17 SNPs characterizing the mtDNA T haplogroup emerged. Further analysis revealed these associations were driven entirely by the T2 haplogroup, and characterized by two variants in Complex I genes (A11812G of MT-ND4 and A14233G of MT-ND6). We genotyped T haplogroups in an independent sample of 490 cases and 61 controls from the same study (Stage II) and in 56 cases and 246 controls from the 10-year study (Stage III). People in the T2 haplogroup were approximately 2.5 times more likely to have advanced AMD than their peers (odds ratio [OR] = 2.54, 95%CI 1.36-4.80, P <= 0.004) after considering the totality of evidence. Findings persisted after considering the impact of AMD-associated variants A69S and Y402H (OR = 5.19, 95%CI 1.19-22.69, P <= 0.029). Conclusion: Loci defining the mtDNA T2 haplogroup and Complex I are reasonable targets for novel functional analyses and therapeutic research in AMD.			SanGiovanni, JP (corresponding author), NEI, NIH, Bethesda, MD 20892 USA.	jpsangio@post.harvard.edu	Wang, Jie Jin/P-1499-2014; SanGiovanni, John Paul/AAU-3895-2020; wang, jie/GRS-0942-2022; Mitchell, Paul/P-1498-2014; /S-1190-2019	Wang, Jie Jin/0000-0001-9491-4898; /0000-0001-7488-250X; DeWan, Andrew/0000-0002-7679-8704	Intramural NIH HHS [Z99 EY999999, ZIA EY000489-01] Funding Source: Medline; NEI NIH HHS [EY015810, 01-EY-0-2127, R01 EY015771, R01EY015771, R01 EY012203, R01-EY12203, R01 EY015810] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012203, R01EY015810, ZIAEY000489, ZIEEY000487, N01EY002127] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		*AREDS RES GROUP, 2008, DEF FIN AG REL MAC D; Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091; Chomyn A, 2001, J BIOENERG BIOMEMBR, V33, P251, DOI 10.1023/A:1010791204961; Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477; Cutler DJ, 2001, GENOME RES, V11, P1913, DOI 10.1101/gr.197201; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012; Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564; Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170; Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001; Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235; Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104; Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040; La Morgia C, 2008, NEUROLOGY, V70, P762, DOI 10.1212/01.wnl.0000295505.74234.d0; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Maitra A, 2004, GENOME RES, V14, P812, DOI 10.1101/gr.2228504; MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450; Novembre J, 2008, NATURE, V456, P98, DOI 10.1038/nature07331; Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3; Samuels DC, 2006, AM J HUM GENET, V78, P713, DOI 10.1086/502682; Saxena R, 2006, AM J HUM GENET, V79, P54, DOI 10.1086/504926; Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793; Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102; Vogel RO, 2007, J BIOL CHEM, V282, P7582, DOI 10.1074/jbc.M609410200; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017; Wright AF, 2004, NAT GENET, V36, P1153, DOI 10.1038/ng1448	30	71	76	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 12	2009	4	5							e5508	10.1371/journal.pone.0005508	http://dx.doi.org/10.1371/journal.pone.0005508			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444VZ	19434233	Green Submitted, gold, Green Published			2022-12-25	WOS:000266009800006
J	Congdon, EE; Figueroa, YH; Wang, LL; Toneva, G; Chang, E; Kuret, J; Conrad, C; Duff, KE				Congdon, Erin E.; Figueroa, Yvette H.; Wang, Lili; Toneva, Galina; Chang, Edward; Kuret, Jeff; Conrad, Christopher; Duff, Karen E.			Inhibition of Tau Polymerization with a Cyanine Dye in Two Distinct Model Systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; NEUROFIBRILLARY TANGLES; ALZHEIMER-DISEASE; CELL MODELS; PHOTOPHYSICAL PROPERTIES; TRANSGENIC MICE; NEURONAL LOSS; IN-VITRO; AGGREGATION; TAUOPATHY	In a host of neurodegenerative diseases Tau, a microtubule-associated protein, aggregates into insoluble lesions within neurons. Previous studies have utilized cyanine dyes as Tau aggregation inhibitors in vitro. Herein we utilize cyanine dye 3,3'-diethyl-9-methyl-thiacarbocyanine iodide (C11) to modulate Tau polymerization in two model systems, an organotypic slice culture model derived from Tau transgenic mice and a split green fluorescent protein complementation assay in Tau-expressing cells. In slice cultures, submicromolar concentrations (0.001 mu M) of C11 produced a significant reduction of aggregated Tau and a corresponding increase in unpolymerized Tau. In contrast, treatment with a 1 mu M dose promoted aggregation of Tau. These results were recapitulated in the complementation assay where administration of 1 mu M C11 produced a significant increase in polymerized Tau relative to control, whereas treatment of cells with 0.01 mu M C11 resulted in a marked reduction of aggregated Tau. In the organotypic slice cultures, modulation of Tau aggregation was independent of changes in phosphorylation at disease and microtubule binding relevant epitopes for both dosing regimes. Furthermore, treatment with 0.001 mu M C11 resulted in a decrease in both total filament mass and number. There was no evidence of apoptosis or loss of synaptic integrity at either dose, however, whereas submicromolar concentrations of C11 did not interfere with microtubule binding, higher doses resulted in a decrease in the levels of microtubule-bound Tau. Overall, a cyanine dye can dissociate aggregated Tau in an ex vivo model of tauopathy with little toxicity and exploration of the use of these type of dyes as therapeutic agents is warranted.	[Duff, Karen E.] Columbia Univ, Med Ctr, Taub Inst, Dept Pathol, New York, NY 10032 USA; [Congdon, Erin E.; Figueroa, Yvette H.; Wang, Lili; Toneva, Galina; Conrad, Christopher; Duff, Karen E.] New York State Psychiat Inst & Hosp, Dept Integrat Neurosci, New York, NY 10032 USA; [Chang, Edward] Ohio State Univ, Integrated Biomed Sci Program, Columbus, OH 43210 USA; [Kuret, Jeff] Ohio State Univ, Dept Cellular & Mol Biol, Columbus, OH 43210 USA	Columbia University; New York State Psychiatry Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Duff, KE (corresponding author), Columbia Univ, Med Ctr, Taub Inst, Dept Pathol, P&S 12th Floor,Rm 12-461, New York, NY 10032 USA.	ked2115@columbia.edu	Duff, Karen EK/C-2510-2009	Duff, Karen/0000-0002-6177-868X; Congdon, Erin/0000-0001-8322-6176	National Institutes of Health [NS047447, AG14452]; NINDS; Alzheimer Drug Discovery Foundation/Institute for the Study of Aging; Rosalinde and Arthur Gilbert Foundation/American Federation for Aging Research New Investigator Award in Alzheimer Disease; American Health Assistance Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047447] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014452] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Alzheimer Drug Discovery Foundation/Institute for the Study of Aging; Rosalinde and Arthur Gilbert Foundation/American Federation for Aging Research New Investigator Award in Alzheimer Disease; American Health Assistance Foundation(BrightFocus Foundation); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported, in whole or in part, by National Institutes of Health Grants NS047447 (to K. D.) and AG14452 (to J.K.) from the NINDS. This work was also supported by the Alzheimer Drug Discovery Foundation/Institute for the Study of Aging, a Rosalinde and Arthur Gilbert Foundation/American Federation for Aging Research New Investigator Award in Alzheimer Disease, and the American Health Assistance Foundation.	Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Bandyopadhyay B, 2007, J BIOL CHEM, V282, P16454, DOI 10.1074/jbc.M700192200; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z; CALLAHAN LM, 1995, NEUROBIOL AGING, V16, P311, DOI 10.1016/0197-4580(95)00035-D; Callahan LM, 2002, J NEUROPATH EXP NEUR, V61, P384, DOI 10.1093/jnen/61.5.384; Chalmers KA, 2007, J NEUROPATH EXP NEUR, V66, P158, DOI 10.1097/nen.0b013e3180303b93; CHANG E, 2009, J MED CHEM IN PRESS; Chirita C, 2004, BIOCHEMISTRY-US, V43, P2879, DOI 10.1021/bi036094h; Chirita CN, 2005, BIOCHEMISTRY-US, V44, P5862, DOI 10.1021/bi0500123; Chun WJ, 2007, J NEUROCHEM, V103, P2529, DOI 10.1111/j.1471-4159.2007.04941.x; Congdon EE, 2008, J BIOL CHEM, V283, P13806, DOI 10.1074/jbc.M800247200; Congdon EE, 2007, ARCH BIOCHEM BIOPHYS, V465, P127, DOI 10.1016/j.abb.2007.05.004; CRAS P, 1995, ACTA NEUROPATHOL, V89, P291; Crowe A, 2007, BIOCHEM BIOPH RES CO, V358, P1, DOI 10.1016/j.bbrc.2007.03.056; Duff K, 2000, NEUROBIOL DIS, V7, P87, DOI 10.1006/nbdi.1999.0279; Duff K, 2002, J MOL NEUROSCI, V19, P317, DOI 10.1385/JMN:19:3:317; Eckermann K, 2007, J BIOL CHEM, V282, P31755, DOI 10.1074/jbc.M705282200; Farah CA, 2006, CELL MOTIL CYTOSKEL, V63, P710, DOI 10.1002/cm.20157; Giannakopoulos P, 2003, NEUROLOGY, V60, P1495, DOI 10.1212/01.WNL.0000063311.58879.01; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Hoglinger GU, 2005, J NEUROCHEM, V95, P930, DOI 10.1111/j.1471-4159.2005.03493.x; Jeganathan S, 2008, J BIOL CHEM, V283, P32066, DOI 10.1074/jbc.M805300200; Khlistunova I, 2006, J BIOL CHEM, V281, P1205, DOI 10.1074/jbc.M507753200; Khlistunova I, 2007, CURR ALZHEIMER RES, V4, P544, DOI 10.2174/156720507783018307; Kraemer BC, 2003, P NATL ACAD SCI USA, V100, P9980, DOI 10.1073/pnas.1533448100; Licha K, 2000, PHOTOCHEM PHOTOBIOL, V72, P392, DOI 10.1562/0031-8655(2000)072<0392:HCDACA>2.0.CO;2; Liu F, 2007, EUR J NEUROSCI, V26, P3429, DOI 10.1111/j.1460-9568.2007.05955.x; Magnani E, 2007, EMBO J, V26, P4546, DOI 10.1038/sj.emboj.7601878; Necula M, 2005, BIOCHEMISTRY-US, V44, P10227, DOI 10.1021/bi050387o; Necula M, 2004, ANAL BIOCHEM, V329, P238, DOI 10.1016/j.ab.2004.02.023; Noble W, 2005, P NATL ACAD SCI USA, V102, P6990, DOI 10.1073/pnas.0500466102; Perez M, 2003, J ALZHEIMERS DIS, V5, P301, DOI 10.3233/JAD-2003-5405; Petrov NK, 2003, J PHYS CHEM A, V107, P6341, DOI 10.1021/jp0345654; Pickhardt A, 2007, CURR ALZHEIMER RES, V4, P397, DOI 10.2174/156720507781788765; Pickhardt M, 2005, J BIOL CHEM, V280, P3628, DOI 10.1074/jbc.M410984200; Pickhardt M, 2007, BIOCHEMISTRY-US, V46, P10016, DOI 10.1021/bi700878g; Rankin CA, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-12; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; Smith DL, 2001, NEUROBIOL DIS, V8, P1017, DOI 10.1006/nbdi.2001.0438; Taniguchi S, 2005, J BIOL CHEM, V280, P7614, DOI 10.1074/jbc.M408714200; Tsai CC, 2006, SHOCK, V26, P601, DOI 10.1097/01.shk.0000230298.01387.d8; Tseng HY, 2005, BIOORG MED CHEM LETT, V15, P2027, DOI 10.1016/j.bmcl.2005.02.063; Tucker KL, 2001, NAT NEUROSCI, V4, P29, DOI 10.1038/82868; Vogelsberg-Ragaglia V, 2000, MOL BIOL CELL, V11, P4093, DOI 10.1091/mbc.11.12.4093; Volkova KD, 2007, J BIOCHEM BIOPH METH, V70, P727, DOI 10.1016/j.jbbm.2007.03.008; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; von Bergen M, 2005, BBA-MOL BASIS DIS, V1739, P158, DOI 10.1016/j.bbadis.2004.09.010; Wischik CM, 1996, P NATL ACAD SCI USA, V93, P11213, DOI 10.1073/pnas.93.20.11213	53	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20830	20839		10.1074/jbc.M109.016089	http://dx.doi.org/10.1074/jbc.M109.016089			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19478088	Green Published, hybrid			2022-12-25	WOS:000268316100046
J	Murakami, T; Felinski, EA; Antonetti, DA				Murakami, Tomoaki; Felinski, Edward A.; Antonetti, David A.			Occludin Phosphorylation and Ubiquitination Regulate Tight Junction Trafficking and Vascular Endothelial Growth Factor-induced Permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; DIABETIC-RETINOPATHY; EPITHELIAL-CELLS; PARACELLULAR PERMEABILITY; MEMBRANE-PROTEIN; LIGASE ITCH; MECHANISMS; MICE; INTERNALIZATION; ENDOCYTOSIS	Vascular endothelial growth factor (VEGF) alters tight junctions (TJs) and promotes vascular permeability in many retinal and brain diseases. However, the molecular mechanisms of barrier regulation are poorly understood. Here we demonstrate that occludin phosphorylation and ubiquitination regulate VEGF-induced TJ protein trafficking and concomitant vascular permeability. VEGF treatment induced TJ fragmentation and occludin trafficking from the cell border to early and late endosomes, concomitant with increased occludin phosphorylation on Ser-490 and ubiquitination. Furthermore, both co-immunoprecipitation and immunocytochemistry demonstrated that VEGF treatment increased the interaction between occludin and modulators of intracellular trafficking that contain the ubiquitin interacting motif, including Epsin-1, epidermal growth factor receptor pathway substrate 15 (Eps15), and hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs). Inhibiting occludin phosphorylation by mutating Ser-490 to Ala suppressed VEGF-induced ubiquitination, inhibited trafficking of TJ proteins, and prevented the increase in endothelial permeability. In addition, an occludin-ubiquitin chimera disrupted TJs and increased permeability without VEGF. These data demonstrate a novel mechanism of VEGF- induced occludin phosphorylation and ubiquitination that contributes to TJ trafficking and subsequent vascular permeability.	[Murakami, Tomoaki; Felinski, Edward A.; Antonetti, David A.] Penn State Coll Med, Dept Cellular & Mol Physiol & Ophthalmol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Antonetti, DA (corresponding author), Penn State Coll Med, Dept Cellular & Mol Physiol & Ophthalmol, Hershey, PA 17033 USA.	dantonetti@psu.edu		antonetti, david/0000-0003-1130-6577	National Institutes of Health [EY 016413, EY 012021]; Juvenile Diabetes Research Foundation International; NATIONAL EYE INSTITUTE [R01EY012021, R01EY016413] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Juvenile Diabetes Research Foundation International(Juvenile Diabetes Research Foundation); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported, in whole or in part, by National Institutes of Health Grants EY 016413 and EY 012021 (to D. A. A.). This work was also supported by the Juvenile Diabetes Research Foundation International (to D. A. A.).	Aiello LP, 1997, INVEST OPHTH VIS SCI, V38, P1647; Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Antonetti David A, 2003, Methods Mol Med, V89, P365; Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Barber AJ, 2000, INVEST OPHTH VIS SCI, V41, P3561; Barber AJ, 2003, INVEST OPHTH VIS SCI, V44, P5410, DOI 10.1167/iovs.03-0244; Barriere H, 2006, TRAFFIC, V7, P282, DOI 10.1111/j.1600-0854.2006.00384.x; Barriere H, 2007, MOL BIOL CELL, V18, P3952, DOI 10.1091/mbc.E07-07-0678; Bojarski C, 2004, J CELL SCI, V117, P2097, DOI 10.1242/jcs.01071; Chang YS, 2000, MICROVASC RES, V59, P265, DOI 10.1006/mvre.1999.2225; Dallasta LM, 1999, AM J PATHOL, V155, P1915, DOI 10.1016/S0002-9440(10)65511-3; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017; Duncan LM, 2006, EMBO J, V25, P1635, DOI 10.1038/sj.emboj.7601056; Duval M, 2003, J BIOL CHEM, V278, P20091, DOI 10.1074/jbc.M301410200; Dvorak AM, 1996, J LEUKOCYTE BIOL, V59, P100, DOI 10.1002/jlb.59.1.100; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 2006, TRENDS CELL BIOL, V16, P181, DOI 10.1016/j.tcb.2006.02.006; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Gardner TW, 2008, CURR DIABETES REP, V8, P263, DOI 10.1007/s11892-008-0047-5; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Harhaj NS, 2006, INVEST OPHTH VIS SCI, V47, P5106, DOI 10.1167/iovs.06-0322; Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007; Hirase T, 1997, J CELL SCI, V110, P1603; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Ivanov AI, 2004, MOL BIOL CELL, V15, P176, DOI 10.1091/mbc.E03-05-0319; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li YH, 2005, J MOL BIOL, V352, P151, DOI 10.1016/j.jmb.2005.07.017; Lui WY, 2005, J CELL PHYSIOL, V203, P564, DOI 10.1002/jcp.20254; Machein MR, 2000, J NEURO-ONCOL, V50, P109, DOI 10.1023/A:1006416003964; Matsuda M, 2004, J CELL SCI, V117, P1247, DOI 10.1242/jcs.00972; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Phillips BE, 2008, INVEST OPHTH VIS SCI, V49, P2568, DOI 10.1167/iovs.07-1204; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Scheppke L, 2008, J CLIN INVEST, V118, P2337, DOI [10.1172/JC133361, 10.1172/JCI33361]; Schulzke JD, 2005, BBA-BIOMEMBRANES, V1669, P34, DOI 10.1016/j.bbamem.2005.01.008; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shen L, 2005, MOL BIOL CELL, V16, P3919, DOI 10.1091/mbc.E04-12-1089; Sundstrom JM, 2009, J PROTEOME RES, V8, P808, DOI 10.1021/pr7007913; Traweger A, 2002, J BIOL CHEM, V277, P10201, DOI 10.1074/jbc.M111384200; Woelk T, 2006, NAT CELL BIOL, V8, P1246, DOI 10.1038/ncb1484; Yamamura R, 2008, MOL BIOL CELL, V19, P971, DOI 10.1091/mbc.E07-06-0551	51	258	265	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					21036	21046		10.1074/jbc.M109.016766	http://dx.doi.org/10.1074/jbc.M109.016766			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19478092	Green Published, hybrid			2022-12-25	WOS:000268316100066
J	Korkmaz, B; Jaillet, J; Jourdan, ML; Gauthier, A; Gauthier, F; Attucci, S				Korkmaz, Brice; Jaillet, Jerome; Jourdan, Marie-Lise; Gauthier, Alexandre; Gauthier, Francis; Attucci, Sylvie			Catalytic Activity and Inhibition of Wegener Antigen Proteinase 3 on the Cell Surface of Human Polymorphonuclear Neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PROTEINASE-3; PR3-ANCA-ASSOCIATED VASCULITIS; ALPHA-1-PROTEASE INHIBITOR; RHEUMATOID-ARTHRITIS; PLASMA-MEMBRANE; CATHEPSIN-G; EXPRESSION; ELASTASE; PR3; GRANULOMATOSIS	Proteinase 3 (Pr3), the main target of anti-neutrophil cytoplasmic antibodies, is a neutrophil serine protease that may be constitutively expressed at the surface of quiescent circulating neutrophils. This raises the question of the simultaneous presence in the circulation of constitutive membrane-bound Pr3 (mPr3) and its plasma inhibitor alpha 1-protease inhibitor (alpha 1-Pi). We have looked at the fate of constitutive mPr3 at the surface of circulating blood neutrophils and of induced mPr3 on triggered neutrophils. We found significant Pr3 activity at the surface of activated neutrophils but not at the surface of quiescent neutrophils whatever the constitutive expression. This suggests that constitutive mPr3 is enzymatically inactive or its active site is not accessible to the substrate. Supporting this conclusion, we have not been able to demonstrate any interaction between constitutive mPr3 and alpha 1-Pi, whereas induced mPr3 is cleared from the cell surface when activated cells are incubated with this inhibitor. But, unlike membrane-bound elastase that is also cleared from the surface of activated cells, mPr3 remained bound to the membrane when inhibited by elafin or by a low molecular weight chloromethyl ketone inhibitor, which shows that it binds more tightly to the neutrophil membrane. mPr3 may thus be present at the surface of circulating neutrophils in an environment replete with alpha 1-Pi. The permanent presence of inactive Pr3 at the surface of quiescent neutrophils may explain why Pr3 is a major target of anti-neutrophil cytoplasmic antibodies, whose binding activates neutrophils and triggers inflammation, as in Wegener granulomatosis.	[Korkmaz, Brice; Jaillet, Jerome; Gauthier, Alexandre; Gauthier, Francis; Attucci, Sylvie] INSERM, U618, Fac Med, F-37032 Tours, France; [Korkmaz, Brice; Jaillet, Jerome; Gauthier, Alexandre; Gauthier, Francis; Attucci, Sylvie] Univ Tours, F-37041 Tours, France; [Jourdan, Marie-Lise] Ctr Hosp Reg Univ, F-37042 Tours, France; [Jourdan, Marie-Lise] INSERM Nutr, U921, Fac Med, F-37032 Tours, France; [Jourdan, Marie-Lise; Gauthier, Francis; Attucci, Sylvie] Inst Federatif Rech 135, F-37044 Tours, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; CHU Tours; Institut National de la Sante et de la Recherche Medicale (Inserm)	Gauthier, F (corresponding author), INSERM, U618, Fac Med, 10 Bd Tonnelle, F-37032 Tours, France.	francis.gauthier@univ-tours.fr		KORKMAZ, BRICE/0000-0002-5159-8706				Abdel-Salam B, 2004, KIDNEY INT, V66, P1009, DOI 10.1111/j.1523-1755.2004.00849.x; Attucci S, 2006, J PHARMACOL EXP THER, V318, P803, DOI 10.1124/jpet.106.103440; Bauer S, 2007, J LEUKOCYTE BIOL, V81, P458, DOI 10.1189/jlb.0806514; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; CALAFAT J, 1990, BLOOD, V75, P242; Campbell EJ, 2000, J IMMUNOL, V165, P3366, DOI 10.4049/jimmunol.165.6.3366; CSERNOK E, 1990, AM J PATHOL, V137, P1113; David A, 2005, EXP CELL RES, V308, P156, DOI 10.1016/j.yexcr.2005.03.034; David A, 2003, J LEUKOCYTE BIOL, V74, P551, DOI 10.1189/jlb.1202624; Fridlich R, 2006, J CELL BIOCHEM, V99, P117, DOI 10.1002/jcb.20901; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Goldmann WH, 1999, EUR J BIOCHEM, V261, P155, DOI 10.1046/j.1432-1327.1999.00259.x; Hajjar E, 2008, PROTEINS, V71, P1655, DOI 10.1002/prot.21853; HALBWACHSMECARELLI L, 1995, FEBS LETT, V374, P29, DOI 10.1016/0014-5793(95)01073-N; Hu N, 2009, AUTOIMMUN REV, V8, P510, DOI 10.1016/j.autrev.2008.01.003; Kantari C, 2007, BLOOD, V110, P4086, DOI 10.1182/blood-2007-03-080457; Korkmaz B, 2002, J BIOL CHEM, V277, P39074, DOI 10.1074/jbc.M202918200; Korkmaz B, 2005, J IMMUNOL, V175, P3329, DOI 10.4049/jimmunol.175.5.3329; Korkmaz B, 2005, AM J RESP CELL MOL, V32, P553, DOI 10.1165/rcmb.2004-0374OC; Korkmaz B, 2004, AM J RESP CELL MOL, V30, P801, DOI 10.1165/rcmb.2003-0139OC; Korkmaz B, 2008, NAT PROTOC, V3, P991, DOI 10.1038/nprot.2008.63; Korkmaz B, 2008, BIOCHIMIE, V90, P227, DOI 10.1016/j.biochi.2007.10.009; Korkmaz B, 2007, J BIOL CHEM, V282, P1989, DOI 10.1074/jbc.M608700200; Korkmaz B, 2008, J BIOL CHEM, V283, P35976, DOI 10.1074/jbc.M806754200; Matsumoto T, 2008, CLIN APPL THROMB-HEM, V14, P186, DOI 10.1177/1076029607303961; Owen CA, 2008, INT J BIOCHEM CELL B, V40, P1246, DOI 10.1016/j.biocel.2008.01.020; Pham CTN, 2006, NAT REV IMMUNOL, V6, P541, DOI 10.1038/nri1841; Rarok AA, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000028642.26222.00; Rooney CP, 2001, AM J RESP CELL MOL, V24, P747, DOI 10.1165/ajrcmb.24.6.4147; Schreiber A, 2004, KIDNEY INT, V65, P2172, DOI 10.1111/j.1523-1755.2004.00640.x; Schreiber A, 2003, J AM SOC NEPHROL, V14, P68, DOI 10.1097/01.ASN.0000040751.83734.D1; SERVEAU C, 1992, FEBS LETT, V309, P405, DOI 10.1016/0014-5793(92)80817-Z; Skold S, 1999, BLOOD, V93, P849, DOI 10.1182/blood.V93.3.849.403k07_849_856; Taggart CC, 2005, AM J RESP CRIT CARE, V171, P1070, DOI 10.1164/rccm.200407-881PP; Van der Geld YM, 2002, CLIN EXP IMMUNOL, V129, P562; Van Rossum AP, 2005, KIDNEY INT, V68, P537, DOI 10.1111/j.1523-1755.2005.00431.x; van Rossum AP, 2004, J LEUKOCYTE BIOL, V76, P1162, DOI 10.1189/jlb.0604319; van Rossum AP, 2003, CLIN EXP RHEUMATOL, V21, pS64; von Vietinghoff S, 2008, CLIN EXP IMMUNOL, V152, P508, DOI 10.1111/j.1365-2249.2008.03663.x; von Vietinghoff S, 2005, CLIN NEPHROL, V64, P453; von Vietinghoff S, 2007, BLOOD, V109, P4487, DOI 10.1182/blood-2006-10-055327; Witko-Sarsat V, 1999, BLOOD, V94, P2487, DOI 10.1182/blood.V94.7.2487.419k07_2487_2496; Witko-Sarsat V, 1999, J AM SOC NEPHROL, V10, P1224	43	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					19896	19902		10.1074/jbc.M901471200	http://dx.doi.org/10.1074/jbc.M901471200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19447886	Green Submitted, hybrid, Green Published			2022-12-25	WOS:000268097400016
J	Guy, JE; Stahl, U; Lindqvist, Y				Guy, Jodie E.; Stahl, Ulf; Lindqvist, Ylva			Crystal Structure of a Class XIB Phospholipase A(2) (PLA(2)) RICE (ORYZA SATIVA) ISOFORM-2 PLA(2) AND AN OCTANOATE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COBRA-VENOM PHOSPHOLIPASE-A2; ARABIDOPSIS-THALIANA; BACTERIAL EXPRESSION; ESCHERICHIA-COLI; SYNTHETIC GENE; ACTIVE-SITE; PURIFICATION; SUPERFAMILY; SPECIFICITY; FACE	Phospholipase A(2) catalyzes the specific hydrolysis of the sn-2 acyl bond of various glycerophospholipids, producing fatty acids and lysophospholipids. Phospholipase A(2)s (PLA(2)s) constitute a large superfamily of enzymes whose products are important for a multitude of signal transduction processes, lipid mediator release, lipid metabolism, development, plant stress responses, and host defense. The crystal structure of rice (Oryza sativa) isoform 2 phospholipase A(2) has been determined to 2.0 angstrom resolution using sulfur SAD phasing, and shows that the class XIb phospholipases have a unique structure compared with other secreted PLA(2)s. The N-terminal half of the chain contains mainly loop structure, including the conserved Ca2+-binding loop, but starts with a short 3(10)-helix and also includes two short anti-parallel beta-strands. The C-terminal half is folded into three anti-parallel alpha-helices, of which the two first are also present in other secreted PLA(2)s and contain the conserved catalytic histidine and calcium liganding aspartate residues. The structure is stabilized by six disulfide bonds. The water structure around the calcium ion binding site suggests the involvement of a second water molecule in the mechanism for hydrolysis, the water-assisted calcium-coordinate oxyanion mechanism. The octanoate molecule in the complex structure is bound in a hydrophobic pocket, which extends to the likely membrane interface and is proposed to model the binding of the product fatty acid. Due to the differences in structure, the suggested surface for binding to the membrane has a different morphology in the rice PLA(2) compared with other phospholipases.	[Guy, Jodie E.; Lindqvist, Ylva] Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; [Stahl, Ulf] Swedish Univ Agr Sci, Dept Plant Biol & Forest Genet, S-75007 Uppsala, Sweden	Karolinska Institutet; Swedish University of Agricultural Sciences	Lindqvist, Y (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	Ylva.Lindqvist@ki.se	Lindqvist, Ylva/F-9009-2010	Lindqvist, Ylva/0000-0003-3162-8661; Guy, Jodie/0000-0003-0331-0699	Swedish Research Council; Medical Research Council [G0500367] Funding Source: researchfish; MRC [G0500367] Funding Source: UKRI	Swedish Research Council(Swedish Research CouncilEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by a grant from the Swedish Research Council ( to Y. L.).	Bahn SC, 2003, FEBS LETT, V553, P113, DOI 10.1016/S0014-5793(03)00982-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNIE S, 1985, J BIOL CHEM, V260, P9742; Chapman KD, 1998, TRENDS PLANT SCI, V3, P419, DOI 10.1016/S1360-1385(98)01326-0; Cowtan K, 2000, ACTA CRYSTALLOGR D, V56, P1612, DOI 10.1107/S0907444900013263; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; Edwards SH, 2002, BIOCHEMISTRY-US, V41, P15468, DOI 10.1021/bi020485z; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Epstein TM, 2001, BIOCHEMISTRY-US, V40, P11411, DOI 10.1021/bi011228h; Han SK, 1998, BIOCHEM J, V331, P353, DOI 10.1042/bj3310353; Han SK, 1997, BBA-LIPID LIPID MET, V1346, P185, DOI 10.1016/S0005-2760(97)00034-9; Holm L, 2008, BIOINFORMATICS, V24, P2780, DOI 10.1093/bioinformatics/btn507; Jain MK, 2006, CURR OPIN CHEM BIOL, V10, P473, DOI 10.1016/j.cbpa.2006.08.015; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLEY MJ, 1992, BIOCHIM BIOPHYS ACTA, V1118, P107, DOI 10.1016/0167-4838(92)90136-2; Kim JY, 1999, BBA-GENE STRUCT EXPR, V1489, P389, DOI 10.1016/S0167-4781(99)00193-1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee HY, 2005, PROG LIPID RES, V44, P52, DOI 10.1016/j.plipres.2004.10.002; Lee HY, 2003, PLANT CELL, V15, P1990, DOI 10.1105/tpc.014423; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Mansfeld J, 2006, BIOCHEMISTRY-US, V45, P5687, DOI 10.1021/bi052563z; Mansfeld J, 2007, CHEM PHYS LIPIDS, V150, P156, DOI 10.1016/j.chemphyslip.2007.07.001; Matoba Y, 2002, J BIOL CHEM, V277, P20059, DOI 10.1074/jbc.M200263200; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Munnik T, 1998, BBA-LIPID LIPID MET, V1389, P222, DOI 10.1016/S0005-2760(97)00158-6; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Othman R, 1996, BBA-LIPID LIPID MET, V1303, P92, DOI 10.1016/0005-2760(96)00083-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan YH, 2002, J BIOL CHEM, V277, P29086, DOI 10.1074/jbc.M202531200; Pan YH, 2001, BIOCHEMISTRY-US, V40, P609, DOI 10.1021/bi002514g; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rogers J, 1996, BIOCHEMISTRY-US, V35, P9375, DOI 10.1021/bi960526p; Ryu SB, 2004, TRENDS PLANT SCI, V9, P229, DOI 10.1016/j.tplants.2004.03.004; Schaloske RH, 2006, BBA-MOL CELL BIOL L, V1761, P1246, DOI 10.1016/j.bbalip.2006.07.011; Scherer GFE, 2002, PLANT MOL BIOL, V49, P357, DOI 10.1023/A:1015290510483; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; Sekar K, 1998, ACTA CRYSTALLOGR D, V54, P334, DOI 10.1107/S090744499701247X; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Stahl U, 1998, PLANT PHYSIOL, V117, P197, DOI 10.1104/pp.117.1.197; Stahl U, 1999, PLANT MOL BIOL, V41, P481, DOI 10.1023/A:1006323405788; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; Valentin E, 2000, BIOCHEM BIOPH RES CO, V279, P223, DOI 10.1006/bbrc.2000.3908; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; Wang XM, 2004, CURR OPIN PLANT BIOL, V7, P329, DOI 10.1016/j.pbi.2004.03.012; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Xu S, 2003, ACTA CRYSTALLOGR D, V59, P1574, DOI 10.1107/S0907444903014598; Yu BZ, 1998, BIOCHEMISTRY-US, V37, P12576, DOI 10.1021/bi9728607	58	18	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19371	19379		10.1074/jbc.M109.008466	http://dx.doi.org/10.1074/jbc.M109.008466			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19457861	Green Published, hybrid			2022-12-25	WOS:000267908300028
J	Khoshnan, A; Ko, J; Tescu, S; Brundin, P; Patterson, PH				Khoshnan, Ali; Ko, Jan; Tescu, Simona; Brundin, Patrick; Patterson, Paul H.			IKK alpha and IKK beta Regulation of DNA Damage-Induced Cleavage of Huntingtin	PLOS ONE			English	Article							NF-KAPPA-B; MUTANT HUNTINGTIN; WILD-TYPE; MOUSE MODEL; ACTIVATION; DISEASE; KINASE; PHOSPHORYLATION; INHIBITION; SURVIVAL	Background: Proteolysis of huntingtin (Htt) plays a key role in the pathogenesis of Huntington's disease (HD). However, the environmental cues and signaling pathways that regulate Htt proteolysis are poorly understood. One stimulus may be the DNA damage that accumulates in neurons over time, and the subsequent activation of signaling pathways such as those regulated by I kappa B kinase (IKK), which can influence neurodegeneration in HD. Methodology/Principal Findings: We asked whether DNA damage induces the proteolysis of Htt and if activation of IKK plays a role. We report that treatment of neurons with the DNA damaging agent etoposide or gamma-irradiation promotes cleavage of wild type (WT) and mutant Htt, generating N-terminal fragments of 80-90 kDa. This event requires IKK beta and is suppressed by IKK alpha. Elevated levels of IKK alpha, or inhibition of IKK beta expression by a specific small hairpin RNA (shRNA) or its activity by sodium salicylate, prevents Htt proteolysis and increases neuronal resistance to DNA damage. Moreover, IKK beta phosphorylates the anti-apoptotic protein Bcl-xL, a modification known to reduce Bcl-xL levels, and activates caspases that can cleave Htt. When IKK beta expression is blocked, etoposide treatment does not decrease Bcl-xL and activation of caspases is diminished. Similar to silencing of IKK beta, increasing the level of Bcl-xL in neurons prevents etoposide-induced caspase activation and Htt proteolysis. Conclusions/Significance: These results indicate that DNA damage triggers cleavage of Htt and identify IKK beta as a prominent regulator. Moreover, IKK beta-dependent reduction of Bcl-xL is important in this process. Thus, inhibition of IKK beta may promote neuronal survival in HD as well as other DNA damage-induced neurodegenerative disorders.	[Khoshnan, Ali; Ko, Jan; Tescu, Simona; Patterson, Paul H.] CALTECH, Biol Div 216 76, Pasadena, CA 91125 USA; [Brundin, Patrick] Wallenberg Neurosci Ctr, Neuronal Survival Unit, Dept Expt Med Sci, Lund, Sweden	California Institute of Technology	Khoshnan, A (corresponding author), CALTECH, Biol Div 216 76, Pasadena, CA 91125 USA.	khoshnan@caltech.edu			NINDS [5RO1NS55298]; Hereditary Disease Foundation (HDF); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS055298] Funding Source: NIH RePORTER	NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Hereditary Disease Foundation (HDF); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	NINDS 5RO1NS55298 and Hereditary Disease Foundation (HDF)(www.hdfoundation.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	Anne SL, 2007, J NEUROSCI, V27, P7318, DOI 10.1523/JNEUROSCI.1831-07.2007; Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005; Baxter FO, 2006, DEVELOPMENT, V133, P3485, DOI 10.1242/dev.02502; Bjorkqvist M, 2008, J EXP MED, V205, P1869, DOI 10.1084/jem.20080178; Bogdanov MB, 2001, J NEUROCHEM, V79, P1246, DOI 10.1046/j.1471-4159.2001.00689.x; Cho IH, 2008, BRAIN, V131, P3019, DOI 10.1093/brain/awn230; Cittelly DM, 2007, J NEUROSCI RES, V85, P1894, DOI 10.1002/jnr.21313; De Luca G, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000266; Dragatsis I, 2000, NAT GENET, V26, P300, DOI 10.1038/81593; Du LH, 2005, ONCOGENE, V24, P107, DOI 10.1038/sj.onc.1208189; Enokido Y, 2008, BIOCHEM BIOPH RES CO, V376, P128, DOI 10.1016/j.bbrc.2008.08.108; Feng Z, 2006, ONCOGENE, V25, P1, DOI 10.1038/sj.onc.1209021; Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Ghosh A, 2007, P NATL ACAD SCI USA, V104, P18754, DOI 10.1073/pnas.0704908104; Gines S, 2003, J BIOL CHEM, V278, P50514, DOI 10.1074/jbc.M309348200; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; HACKER H, 2006, SCI STKE, V357, pRE13, DOI DOI 10.1126/STKE.3572006RE13; Herrmann O, 2005, NAT MED, V11, P1322, DOI 10.1038/nm1323; Huang WC, 2007, MOL CELL, V26, P75, DOI 10.1016/j.molcel.2007.02.019; Jonas E, 2006, MOL INTERV, V6, P208, DOI 10.1124/mi.6.4.7; Khoshnan A, 2004, J NEUROSCI, V24, P7999, DOI 10.1523/JNEUROSCI.2675-04.2004; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Kruman II, 2004, NEURON, V41, P549, DOI 10.1016/S0896-6273(04)00017-0; Kuo LJ, 2008, IN VIVO, V22, P305; Leavitt BR, 2006, J NEUROCHEM, V96, P1121, DOI 10.1111/j.1471-4159.2005.03605.x; Lee ST, 2006, BRAIN RES, V1118, P199, DOI 10.1016/j.brainres.2006.08.035; Li QT, 2005, P NATL ACAD SCI USA, V102, P12425, DOI 10.1073/pnas.0505997102; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lotharius J, 2002, J BIOL CHEM, V277, P38884, DOI 10.1074/jbc.M205518200; Lubin FD, 2007, NEURON, V55, P942, DOI 10.1016/j.neuron.2007.07.039; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mattson MP, 2006, CELL DEATH DIFFER, V13, P852, DOI 10.1038/sj.cdd.4401837; Politis M, 2008, BRAIN, V131, P2860, DOI 10.1093/brain/awn244; Qi ML, 2007, NAT CELL BIOL, V9, P402, DOI 10.1038/ncb1553; Ratovitski T, 2007, CELL CYCLE, V6, P2970, DOI 10.4161/cc.6.23.4992; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Tai YF, 2007, BRAIN, V130, P1759, DOI 10.1093/brain/awm044; Valerio A, 2006, EUR J NEUROSCI, V23, P1711, DOI 10.1111/j.1460-9568.2006.04722.x; van Loo G, 2006, NAT IMMUNOL, V7, P954, DOI 10.1038/ni1372; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Wexler NS, 2004, P NATL ACAD SCI USA, V101, P3498, DOI 10.1073/pnas.0308479101; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhang Y, 2006, EMBO J, V25, P5896, DOI 10.1038/sj.emboj.7601445; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	46	30	30	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2009	4	6							e5768	10.1371/journal.pone.0005768	http://dx.doi.org/10.1371/journal.pone.0005768			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453CI	19488402	Green Published, Green Submitted, Green Accepted, gold			2022-12-25	WOS:000266587400011
J	Randhawa, HS; Mutti, JS; Kidwell, K; Morris, CF; Chen, XM; Gill, KS				Randhawa, Harpinder S.; Mutti, Jasdeep S.; Kidwell, Kim; Morris, Craig F.; Chen, Xianming; Gill, Kulvinder S.			Rapid and Targeted Introgression of Genes into Popular Wheat Cultivars Using Marker-Assisted Background Selection	PLOS ONE			English	Article							RUST PUCCINIA-STRIIFORMIS; RESISTANCE; SEGMENTS; SIZE	A marker-assisted background selection (MABS)-based gene introgression approach in wheat (Triticum aestivum L.) was optimized, where 97% or more of a recurrent parent genome (RPG) can be recovered in just two backcross (BC) generations. A four-step MABS method was developed based on 'Plabsim' computer simulations and wheat genome structure information. During empirical optimization of this method, double recombinants around the target gene were selected in a step-wise fashion during the two BC cycles followed by selection for recurrent parent genotype on non-carrier chromosomes. The average spacing between carrier chromosome markers was <4 cM. For non-carrier chromosome markers that flanked each of the 48 wheat gene-rich regions, this distance was similar to 12 cM. Employed to introgress seedling stripe rust (Puccinia striiformis f. sp. tritici) resistance gene Yr15 into the spring wheat cultivar 'Zak', marker analysis of 2,187 backcross-derived progeny resulted in the recovery of a BC2F2:3 plant with 97% of the recurrent parent genome. In contrast, only 82% of the recurrent parent genome was recovered in phenotypically selected BC4F7 plants developed without MABS. Field evaluation results from 17 locations indicated that the MABS-derived line was either equal or superior to the recurrent parent for the tested agronomic characteristics. Based on these results, MABS is recommended as a strategy for rapidly introgressing a targeted gene into a wheat genotype in just two backcross generations while recovering 97% or more of the recurrent parent genotype.			Randhawa, HS (corresponding author), Washington State Univ, Dept Crop & Soil Sci, Pullman, WA 99164 USA.	ksgill@wsu.edu	Randhawa, Harpinder/AAQ-7207-2021	Morris, Craig/0000-0003-0311-2449				Allard R.W., 1999, PRINCIPLES PLANT BRE; Chen XM, 2005, CAN J PLANT PATHOL, V27, P314; CHEN XM, 1992, PHYTOPATHOLOGY, V82, P1428, DOI 10.1094/Phyto-82-1428; Erayman M, 2004, NUCLEIC ACIDS RES, V32, P3546, DOI 10.1093/nar/gkh639; Frisch M, 2000, J HERED, V91, P86, DOI 10.1093/jhered/91.1.86; Frisch M, 1999, CROP SCI, V39, P1295, DOI 10.2135/cropsci1999.3951295x; GRAMA A, 1974, EUPHYTICA, V23, P393, DOI 10.1007/BF00035884; Hospital F, 2001, GENETICS, V158, P1363; Hospital F, 2002, J HERED, V93, P383, DOI 10.1093/jhered/93.5.383; Kidwell KK, 2002, CROP SCI, V42, P661, DOI 10.2135/cropsci2002.661a; Prigge V, 2008, THEOR APPL GENET, V116, P739, DOI 10.1007/s00122-007-0707-x; RAGOT M, 1995, COLLOQ INRA, P45; Sidhu D., 2004, Plant Cell, Tissue and Organ Culture, V79, P257, DOI 10.1007/s11240-005-2487-9; Somers DJ, 2004, THEOR APPL GENET, V109, P1105, DOI 10.1007/s00122-004-1740-7; TANKSLEY SD, 1989, BIO-TECHNOL, V7, P257, DOI 10.1038/nbt0389-257; YOUNG ND, 1989, THEOR APPL GENET, V77, P353, DOI 10.1007/BF00305828	16	56	60	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2009	4	6							e5752	10.1371/journal.pone.0005752	http://dx.doi.org/10.1371/journal.pone.0005752			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	452GL	19484121	gold, Green Published, Green Submitted			2022-12-25	WOS:000266528200005
J	Di Giuseppe, M; Gambelli, F; Hoyle, GW; Lungarella, G; Studer, SM; Richards, T; Yousem, S; McCurry, K; Dauber, J; Kaminski, N; Leikauf, G; Ortiz, LA				Di Giuseppe, Michelangelo; Gambelli, Federica; Hoyle, Gary W.; Lungarella, Giuseppe; Studer, Sean M.; Richards, Thomas; Yousem, Sam; McCurry, Ken; Dauber, James; Kaminski, Naftali; Leikauf, George; Ortiz, Luis A.			Systemic Inhibition of NF-kappa B Activation Protects from Silicosis	PLOS ONE			English	Article								Background: Silicosis is a complex lung disease for which no successful treatment is available and therefore lung transplantation is a potential alternative. Tumor necrosis factor alpha (TNF alpha) plays a central role in the pathogenesis of silicosis. TNF alpha signaling is mediated by the transcription factor, Nuclear Factor (NF)-kappa B, which regulates genes controlling several physiological processes including the innate immune responses, cell death, and inflammation. Therefore, inhibition of NF-kappa B activation represents a potential therapeutic strategy for silicosis. Methods/Findings: In the present work we evaluated the lung transplant database (May 1986-July 2007) at the University of Pittsburgh to study the efficacy of lung transplantation in patients with silicosis (n = 11). We contrasted the overall survival and rate of graft rejection in these patients to that of patients with idiopathic pulmonary fibrosis (IPF, n = 79) that was selected as a control group because survival benefit of lung transplantation has been identified for these patients. At the time of lung transplantation, we found the lungs of silica-exposed subjects to contain multiple foci of inflammatory cells and silicotic nodules with proximal TNF alpha expressing macrophage and NF-kappa B activation in epithelial cells. Patients with silicosis had poor survival (median survival 2.4 yr; confidence interval (CI): 0.16-7.88 yr) compared to IPF patients (5.3 yr; CI: 2.8-15 yr; p = 0.07), and experienced early rejection of their lung grafts (0.9 yr; CI: 0.22-0.9 yr) following lung transplantation (2.4 yr; CI: 1.5-3.6 yr; p<0.05). Using a mouse experimental model in which the endotracheal instillation of silica reproduces the silica-induced lung injury observed in humans we found that systemic inhibition of NF-kappa B activation with a pharmacologic inhibitor (BAY 11-7085) of IkB alpha phosphorylation decreased silica-induced inflammation and collagen deposition. In contrast, transgenic mice expressing a dominant negative IkB alpha mutant protein under the control of epithelial cell specific promoters demonstrate enhanced apoptosis and collagen deposition in their lungs in response to silica. Conclusions: Although limited by its size, our data support that patients with silicosis appear to have poor outcome following lung transplantation. Experimental data indicate that while the systemic inhibition of NF-kappa B protects from silica-induced lung injury, epithelial cell specific NF-kappa B inhibition appears to aggravate the outcome of experimental silicosis.			Di Giuseppe, M (corresponding author), Univ Pittsburgh, Dept Environm & Occupat Hlth, Div Occupat & Environm Med, Pittsburgh, PA 15260 USA.	lao1@pitt.edu	ortiz, luis a/H-9851-2013	ortiz, luis a/0000-0003-4510-7066; Kaminski, Naftali/0000-0001-5917-4601; LUNGARELLA, Giuseppe/0000-0002-3796-7317; Leikauf, George/0000-0002-4514-7060	NHLBI NIH HHS [HL073745, R01 HL085655, R01 HL077763, R01 HL073745, HL071953, R01 HL065612, R01 HL071953] Funding Source: Medline; NIEHS NIH HHS [ES10859, R01 ES010859, U01 ES015675, R01 ES010562] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085655, R01HL071953, R01HL073745, R01HL077763, R01HL065612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010859, U01ES015675, R01ES010562] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		*AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00; American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, 2002, AM J RESP CRIT CARE, V165, P277, DOI [DOI 10.1164/AJRCCM.165.2.ATS01, 10.1164/ajrccm.165.2.ats01]; [Anonymous], 2005, MORBIDITY MORTALITY, V54; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Beckett W, 1997, AM J RESP CRIT CARE, V155, P761, DOI 10.1164/ajrccm.155.2.9032226; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; Borges VM, 2001, J EXP MED, V194, P155, DOI 10.1084/jem.194.2.155; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Burton CM, 2005, J HEART LUNG TRANSPL, V24, P1834, DOI 10.1016/j.healun.2005.03.001; Cavarra E, 2001, EUR RESPIR J, V17, P474, DOI 10.1183/09031936.01.17304740; Chen F, 2002, MOL CELL BIOCHEM, V234, P169, DOI 10.1023/A:1015915000265; Cherla RP, 2001, J IMMUNOL, V166, P3067, DOI 10.4049/jimmunol.166.5.3067; Corbett EL, 2002, AM J RESP CRIT CARE, V165, P690, DOI 10.1164/ajrccm.165.5.2010050; Corti M, 1996, AM J RESP CELL MOL, V14, P309, DOI 10.1165/ajrcmb.14.4.8600933; Estenne M, 2002, J HEART LUNG TRANSPL, V21, P297, DOI 10.1016/S1053-2498(02)00398-4; FULOP GM, 1983, CELL IMMUNOL, V75, P91, DOI 10.1016/0008-8749(83)90308-8; Gambelli F, 2004, J BIOL CHEM, V279, P2020, DOI 10.1074/jbc.M309763200; Giangreco A, 2002, AM J PATHOL, V161, P173, DOI 10.1016/S0002-9440(10)64169-7; Goodwin SS, 2003, AM J IND MED, V44, P304, DOI 10.1002/ajim.10260; Gozal E, 2002, AM J RESP CELL MOL, V27, P91, DOI 10.1165/ajrcmb.27.1.4790; Hashimoto N, 2004, J CLIN INVEST, V113, P243, DOI 10.1172/JCI200418847; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Hoyle GW, 1998, AM J RESP CELL MOL, V18, P149, DOI 10.1165/ajrcmb.18.2.2803m; Hubbard AK, 2002, AM J PHYSIOL-LUNG C, V282, pL968, DOI 10.1152/ajplung.00327.2001; Kang JL, 2000, TOXICOL APPL PHARM, V169, P59, DOI 10.1006/taap.2000.9039; Kuwano K, 1999, J CLIN INVEST, V104, P13, DOI 10.1172/JCI5628; Langley RJ, 2004, AM J RESP CELL MOL, V30, P823, DOI 10.1165/rcmb.2003-0284OC; Mossman BT, 1998, AM J RESP CRIT CARE, V157, P1666, DOI 10.1164/ajrccm.157.5.9707141; Ortiz LA, 1999, AM J RESP CELL MOL, V20, P825, DOI 10.1165/ajrcmb.20.4.3193; Ortiz LA, 2001, AM J RESP CRIT CARE, V163, P244, DOI 10.1164/ajrccm.163.1.2002123; OSHA, 2003, FED REG, V68, P30583; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; PIGUET PF, 1994, EUR RESPIR J, V7, P515, DOI 10.1183/09031936.94.07030515; PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0; Porter DW, 2004, TOXICOL SCI, V79, P370, DOI 10.1093/toxsci/kfh110; Porter DW, 2002, INHAL TOXICOL, V14, P349, DOI 10.1080/08958370252870998; RICH IN, 1980, BLUT, V40, P297; Rosenman KD, 2003, AM J IND MED, V44, P141, DOI 10.1002/ajim.10243; Sacks M, 1998, BIOCHEM BIOPH RES CO, V253, P181, DOI 10.1006/bbrc.1998.9763; Schins RPF, 2000, TOXICOL APPL PHARM, V167, P107, DOI 10.1006/taap.2000.8982; Skerrett SJ, 2004, AM J PHYSIOL-LUNG C, V287, pL143, DOI 10.1152/ajplung.00030.2004; THALBUT G, 2003, J THORACIC CARDIOVAS, V126, P469; VERMEIRE P, 1972, AM REV RESPIR DIS, V106, P515, DOI 10.1164/arrd.1972.106.4.515; Warshamana GS, 2001, EXP MOL PATHOL, V71, P13, DOI 10.1006/exmp.2001.2376; *WHO, 2000, 238 WHO; Yassin A, 2005, ENVIRON HEALTH PERSP, V113, P255, DOI 10.1289/ehp.7384; Yatera K, 2001, ENVIRON HEALTH PERSP, V109, P795, DOI 10.2307/3454821	50	53	54	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2009	4	5							e5689	10.1371/journal.pone.0005689	http://dx.doi.org/10.1371/journal.pone.0005689			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LI	19479048	Green Published, Green Accepted, gold			2022-12-25	WOS:000266331700016
J	Tsibris, AMN; Korber, B; Arnaout, R; Russ, C; Lo, CC; Leitner, T; Gaschen, B; Theiler, J; Paredes, R; Su, ZH; Hughes, MD; Gulick, RM; Greaves, W; Coakley, E; Flexner, C; Nusbaum, C; Kuritzkes, DR				Tsibris, Athe M. N.; Korber, Bette; Arnaout, Ramy; Russ, Carsten; Lo, Chien-Chi; Leitner, Thomas; Gaschen, Brian; Theiler, James; Paredes, Roger; Su, Zhaohui; Hughes, Michael D.; Gulick, Roy M.; Greaves, Wayne; Coakley, Eoin; Flexner, Charles; Nusbaum, Chad; Kuritzkes, Daniel R.			Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; V3 LOOP; TYPE-1; CORECEPTOR; PROGRESSION; VICRIVIROC; RESISTANCE; MARAVIROC; DISEASE	High-throughput sequencing platforms provide an approach for detecting rare HIV-1 variants and documenting more fully quasispecies diversity. We applied this technology to the V3 loop-coding region of env in samples collected from 4 chronically HIV-infected subjects in whom CCR5 antagonist (vicriviroc [VVC]) therapy failed. Between 25,000-140,000 amplified sequences were obtained per sample. Profound baseline V3 loop sequence heterogeneity existed; predicted CXCR4-using populations were identified in a largely CCR5-using population. The V3 loop forms associated with subsequent virologic failure, either through CXCR4 use or the emergence of high-level VVC resistance, were present as minor variants at 0.8-2.8% of baseline samples. Extreme, rapid shifts in population frequencies toward these forms occurred, and deep sequencing provided a detailed view of the rapid evolutionary impact of VVC selection. Greater V3 diversity was observed post-selection. This previously unreported degree of V3 loop sequence diversity has implications for viral pathogenesis, vaccine design, and the optimal use of HIV-1 CCR5 antagonists.			Tsibris, AMN (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.	dkuritzkes@partners.org	Su, Zhaohui/HIK-0448-2022	Su, Zhaohui/0000-0003-2005-9504; Korber, Bette/0000-0002-2026-5757	NCRR NIH HHS [K24 RR016482] Funding Source: Medline; NIAID NIH HHS [T32 AI007387, K08 AI081547, U01 AI069472, R37 AI553537, U01 AI067854, P30 AI060354] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [K24RR016482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI067854, K08AI081547, U01AI069472, P30AI060354, T32AI007387] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Anastassopoulou CG, 2009, P NATL ACAD SCI USA, V106, P5318, DOI 10.1073/pnas.0811713106; BROCKMAN W, 2008, GENOME RES; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Fatkenheuer G, 2008, NEW ENGL J MED, V359, P1442, DOI 10.1056/NEJMoa0803154; Gulick RM, 2008, NEW ENGL J MED, V359, P1429, DOI 10.1056/NEJMoa0803152; Gulick RM, 2007, J INFECT DIS, V196, P304, DOI 10.1086/518797; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; Jensen MA, 2003, J VIROL, V77, P13376, DOI 10.1128/JVI.77.24.13376-13388.2003; Kearney M, 2008, AIDS, V22, P497, DOI 10.1097/QAD.0b013e3282f29478; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; Kuhmann SE, 2004, J VIROL, V78, P2790, DOI 10.1128/JVI.78.6.2790-2807.2004; Low AJ, 2007, AIDS, V21, pF19, DOI 10.1097/QAD.0b013e3282ef81ea; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Palmer S, 2006, AIDS, V20, P701, DOI 10.1097/01.aids.0000216370.69066.7f; Ping LH, 1999, J VIROL, V73, P6271, DOI 10.1128/JVI.73.8.6271-6281.1999; Ribeiro RM, 2000, P NATL ACAD SCI USA, V97, P7681, DOI 10.1073/pnas.97.14.7681; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; Ronaghi M, 1998, SCIENCE, V281, P363, DOI 10.1126/science.281.5375.363; Salazar-Gonzalez JF, 2008, J VIROL, V82, P3952, DOI 10.1128/JVI.02660-07; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Strizki JM, 2005, ANTIMICROB AGENTS CH, V49, P4911, DOI 10.1128/AAC.49.12.4911-4919.2005; Thomas RK, 2006, NAT MED, V12, P852, DOI 10.1038/nm1437; Tsibris AMN, 2008, J VIROL, V82, P8210, DOI 10.1128/JVI.00444-08; Wang CL, 2007, GENOME RES, V17, P1195, DOI 10.1101/gr.6468307; Westby M, 2006, J VIROL, V80, P4909, DOI 10.1128/JVI.80.10.4909-4920.2006; Whitcomb JM, 2007, ANTIMICROB AGENTS CH, V51, P566, DOI 10.1128/AAC.00853-06; WOOD N, 2008, PLOS COMPUT IN PRESS	32	185	189	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2009	4	5							e5683	10.1371/journal.pone.0005683	http://dx.doi.org/10.1371/journal.pone.0005683			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LI	19479085	Green Published, gold, Green Submitted			2022-12-25	WOS:000266331700011
J	Morrhaye, G; Kermani, H; Legros, JJ; Baron, F; Beguin, Y; Moutschen, M; Cheynier, R; Martens, HJ; Geenen, V				Morrhaye, Gabriel; Kermani, Hamid; Legros, Jean-Jacques; Baron, Frederic; Beguin, Yves; Moutschen, Michel; Cheynier, Remi; Martens, Henri J.; Geenen, Vincent			Impact of Growth Hormone (GH) Deficiency and GH Replacement upon Thymus Function in Adult Patients	PLOS ONE			English	Article								Background: Despite age-related adipose involution, T cell generation in the thymus (thymopoiesis) is maintained beyond puberty in adults. In rodents, growth hormone (GH), insulin-like growth factor-1 (IGF-1), and GH secretagogues reverse age-related changes in thymus cytoarchitecture and increase thymopoiesis. GH administration also enhances thymic mass and function in HIV-infected patients. Until now, thymic function has not been investigated in adult GH deficiency (AGHD). The objective of this clinical study was to evaluate thymic function in AGHD, as well as the repercussion upon thymopoiesis of GH treatment for restoration of GH/IGF-1 physiological levels. Methodology/Principal Findings: Twenty-two patients with documented AGHD were enrolled in this study. The following parameters were measured: plasma IGF-1 concentrations, signal-joint T-cell receptor excision circle (sjTREC) frequency, and sj/beta TREC ratio. Analyses were performed at three time points: firstly on GH treatment at maintenance dose, secondly one month after GH withdrawal, and thirdly one month after GH resumption. After 1-month interruption of GH treatment, both plasma IGF-1 concentrations and sjTREC frequency were decreased (p<0.001). Decreases in IGF-1 and sjTREC levels were correlated (r = 0.61, p<0.01). There was also a decrease in intrathymic T cell proliferation as indicated by the reduced sj/beta TREC ratio (p<0.01). One month after reintroduction of GH treatment, IGF-1 concentration and sjTREC frequency regained a level equivalent to the one before GH withdrawal. The sj/beta TREC ratio also increased with GH resumption, but did not return to the level measured before GH withdrawal. Conclusions: In patients with AGHD under GH treatment, GH withdrawal decreases thymic T cell output, as well as intrathymic T cell proliferation. These parameters of thymus function are completely or partially restored one month after GH resumption. These data indicate that the functional integrity of the somatotrope GH/IGF-1 axis is important for the maintenance of a normal thymus function in human adults. Trial Registration: ClinicalTrials.gov NTC00601419			Morrhaye, G (corresponding author), Univ Liege, Ctr Immunol, Lab Immunoendocrinol, Inst Pathol, CHU-B23, Liege, Belgium.	hmartens@ulg.ac.be	Cheynier, Remi/E-9921-2010	Cheynier, Remi/0000-0003-1146-660X; Geenen, Vincent/0000-0002-8733-7284; Martens, Henri/0000-0003-4713-8982; Moutschen, Michel/0000-0002-6405-1785				ARKINS S, 1993, ENDOCRINOLOGY, V133, P2334, DOI 10.1210/en.133.5.2334; BINZ K, 1990, P NATL ACAD SCI USA, V87, P3690, DOI 10.1073/pnas.87.10.3690; Castermans E, 2008, HAEMATOLOGICA, V93, P240, DOI 10.3324/haematol.11708; Chu YW, 2008, BLOOD, V112, P2836, DOI 10.1182/blood-2008-04-149435; Clark R, 1997, ENDOCR REV, V18, P157, DOI 10.1210/er.18.2.157; Coelho VDM, 2002, NEUROENDOCRINOLOGY, V75, P139, DOI 10.1159/000048230; Dion ML, 2004, IMMUNITY, V21, P757, DOI 10.1016/j.immuni.2004.10.013; Dixit VD, 2007, J CLIN INVEST, V117, P2778, DOI 10.1172/JCI30248; Dorshkind K, 2001, BIOESSAYS, V23, P288, DOI 10.1002/1521-1878(200103)23:3<288::AID-BIES1039>3.0.CO;2-P; Dorshkind K, 2000, ENDOCR REV, V21, P292, DOI 10.1210/er.21.3.292; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Dulude G, 2008, J IMMUNOL, V181, P7818, DOI 10.4049/jimmunol.181.11.7818; Foster MP, 2000, CLIN IMMUNOL, V96, P140, DOI 10.1006/clim.2000.4889; Geenen V, 2003, J ENDOCRINOL, V176, P305, DOI 10.1677/joe.0.1760305; GEENEN V, 1993, THYMUS, V21, P115; Geenen V, 2004, IMMUNOENDOCRINOLOGY, P337; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; Hinton PS, 1998, AM J PHYSIOL-REG I, V274, pR912, DOI 10.1152/ajpregu.1998.274.4.R912; Kecha O, 2000, ENDOCRINOLOGY, V141, P1209, DOI 10.1210/en.141.3.1209; Kecha O, 1999, J NEUROENDOCRINOL, V11, P435; KELLEY KW, 1986, P NATL ACAD SCI USA, V83, P5663, DOI 10.1073/pnas.83.15.5663; Kong FK, 2002, J IMMUNOL, V168, P6500, DOI 10.4049/jimmunol.168.12.6500; Kong FK, 1998, IMMUNITY, V8, P97, DOI 10.1016/S1074-7613(00)80462-8; KOOIJMAN R, 1995, J ENDOCRINOL, V147, P203, DOI 10.1677/joe.0.1470203; LEONARD WJ, 2003, FUNDAMENTAL IMMUNOLO, P701; Molitch ME, 2006, J CLIN ENDOCR METAB, V91, P1621, DOI 10.1210/jc.2005-2227; Montecino-Rodriguez E, 1998, ENDOCRINOLOGY, V139, P4120, DOI 10.1210/en.139.10.4120; MURPHY WJ, 1993, J EXP MED, V178, P231, DOI 10.1084/jem.178.1.231; Napolitano LA, 2002, AIDS, V16, P1103, DOI 10.1097/00002030-200205240-00003; Napolitano LA, 2008, J CLIN INVEST, V118, P1085, DOI 10.1172/JCI32830; PIERPAOLI W, 1968, J IMMUNOL, V101, P1036; Poulin JF, 1999, J EXP MED, V190, P479, DOI 10.1084/jem.190.4.479; Redelman D, 2008, CELL IMMUNOL, V252, P111, DOI 10.1016/j.cellimm.2007.12.003; Savino W, 2002, SCAND J IMMUNOL, V55, P442, DOI 10.1046/j.1365-3083.2002.01077.x; Savino W, 2000, ENDOCR REV, V21, P412, DOI 10.1210/er.21.4.412; Smith PE, 1930, ANAT REC, V47, P119, DOI 10.1002/ar.1090470110; Sneppen SB, 2002, CLIN ENDOCRINOL, V57, P787, DOI 10.1046/j.1365-2265.2002.01670.x; Sportes C, 2008, J EXP MED, V205, P1701, DOI 10.1084/jem.20071681; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; TAUB DD, 1994, J CLIN INVEST, V94, P293, DOI 10.1172/JCI117320; van den Dool C, 2006, J IMMUNOL, V177, P4391, DOI 10.4049/jimmunol.177.7.4391	41	39	41	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2009	4	5							e5668	10.1371/journal.pone.0005668	http://dx.doi.org/10.1371/journal.pone.0005668			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LD	19479077	Green Published, gold			2022-12-25	WOS:000266331200006
J	Dye, MWG; Hauser, PC; Bavelier, D				Dye, Matthew W. G.; Hauser, Peter C.; Bavelier, Daphne			Is Visual Selective Attention in Deaf Individuals Enhanced or Deficient? The Case of the Useful Field of View	PLOS ONE			English	Article							MOVEMENT DETECTION TASK; NORMAL-HEARING ADULTS; CONGENITALLY DEAF; SPATIAL-DISTRIBUTION; AUDITORY DEPRIVATION; SIGN-LANGUAGE; SEARCH; SPACE; AUDITION; PEOPLE	Background: Early deafness leads to enhanced attention in the visual periphery. Yet, whether this enhancement confers advantages in everyday life remains unknown, as deaf individuals have been shown to be more distracted by irrelevant information in the periphery than their hearing peers. Here, we show that, in a complex attentional task, a performance advantage results for deaf individuals. Methodology/Principal Findings: We employed the Useful Field of View (UFOV) which requires central target identification concurrent with peripheral target localization in the presence of distractors - a divided, selective attention task. First, the comparison of deaf and hearing adults with or without sign language skills establishes that deafness and not sign language use drives UFOV enhancement. Second, UFOV performance was enhanced in deaf children, but only after 11 years of age. Conclusions/Significance: This work demonstrates that, following early auditory deprivation, visual attention resources toward the periphery slowly get augmented to eventually result in a clear behavioral advantage by pre-adolescence on a selective visual attention task.			Dye, MWG (corresponding author), Univ Rochester, Dept Brain & Cognit Sci, Rochester, NY 14627 USA.	mdye@bcs.rochester.edu	Dye, Matthew William Geoffrey/AAW-1407-2020	Dye, Matthew/0000-0001-6260-641X; Bavelier, Daphne/0000-0002-5904-1240				BALL KK, 1988, J OPT SOC AM A, V5, P2210, DOI 10.1364/JOSAA.5.002210; Bavelier D, 2002, NAT REV NEUROSCI, V3, P443, DOI 10.1038/nrn848; Bavelier D, 2001, J NEUROSCI, V21, P8931, DOI 10.1523/JNEUROSCI.21-22-08931.2001; Bavelier D, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-17-j0001.2000; Bavelier D, 2006, TRENDS COGN SCI, V10, P512, DOI 10.1016/j.tics.2006.09.006; Bosworth RG, 2002, BRAIN COGNITION, V49, P170, DOI 10.1006/brcg.2001.1498; Bosworth RG, 2002, BRAIN COGNITION, V49, P152, DOI 10.1006/brcg.2001.1497; Chen Q, 2006, BRAIN RES, V1109, P117, DOI 10.1016/j.brainres.2006.06.043; Clay OJ, 2005, OPTOMETRY VISION SCI, V82, P724, DOI 10.1097/01.opx.0000175009.08626.65; Dye M., 2008, DEAF COGNITION FDN O, P250, DOI [10.1093/acprof:oso/9780195368673.003.0009, DOI 10.1093/ACPROF:OSO/9780195368673.003.0009]; Dye MWG, 2007, NEUROPSYCHOLOGIA, V45, P1801, DOI 10.1016/j.neuropsychologia.2006.12.019; Edwards JD, 2005, J CLIN EXP NEUROPSYC, V27, P529, DOI 10.1080/13803390490515432; ENNS JT, 1989, CHILD DEV, V60, P1188, DOI 10.1111/j.1467-8624.1989.tb03549.x; Fine I, 2005, J COGNITIVE NEUROSCI, V17, P1621, DOI 10.1162/089892905774597173; Forster S, 2007, PSYCHOL SCI, V18, P377, DOI 10.1111/j.1467-9280.2007.01908.x; Green CS, 2006, J EXP PSYCHOL HUMAN, V32, P1465, DOI 10.1037/0096-1523.32.6.1465; Green CS, 2003, NATURE, V423, P534, DOI 10.1038/nature01647; LOKE WH, 1991, B PSYCHONOMIC SOC, V29, P437; Maurer D, 2007, DEVELOPMENTAL SCI, V10, P40, DOI 10.1111/j.1467-7687.2007.00562.x; Mitchell TV, 1996, J CLIN CHILD PSYCHOL, V25, P83, DOI 10.1207/s15374424jccp2501_10; Nava E, 2008, EXP BRAIN RES, V190, P179, DOI 10.1007/s00221-008-1459-9; NEVILLE HJ, 1987, BRAIN RES, V405, P253, DOI 10.1016/0006-8993(87)90295-2; NEVILLE HJ, 1987, BRAIN RES, V405, P284, DOI 10.1016/0006-8993(87)90297-6; NEVILLE HJ, 1987, BRAIN RES, V405, P268, DOI 10.1016/0006-8993(87)90296-4; NEVILLE HJ, 1983, BRAIN RES, V266, P127, DOI 10.1016/0006-8993(83)91314-8; Proksch J, 2002, J COGNITIVE NEUROSCI, V14, P687, DOI 10.1162/08989290260138591; QUITTNER AL, 1994, PSYCHOL SCI, V5, P347, DOI 10.1111/j.1467-9280.1994.tb00284.x; Rettenbach R, 1999, J COGNITIVE NEUROSCI, V11, P560, DOI 10.1162/089892999563616; Sladen DP, 2005, J SPEECH LANG HEAR R, V48, P1529, DOI 10.1044/1092-4388(2005/106); Smith LB, 1998, DEV PSYCHOL, V34, P840, DOI 10.1037/0012-1649.34.5.840; Stevens C, 2006, J COGNITIVE NEUROSCI, V18, P701, DOI 10.1162/jocn.2006.18.5.701; Stivalet P, 1998, COGNITIVE BRAIN RES, V6, P227, DOI 10.1016/S0926-6410(97)00026-8	32	105	110	2	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5640	10.1371/journal.pone.0005640	http://dx.doi.org/10.1371/journal.pone.0005640			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	448AY	19462009	Green Published, Green Submitted, gold			2022-12-25	WOS:000266234700025
J	Kumamoto, Y; Denda-Nagai, K; Aida, S; Higashi, N; Irimura, T				Kumamoto, Yosuke; Denda-Nagai, Kaori; Aida, Satoshi; Higashi, Nobuaki; Irimura, Tatsuro			MGL2(+) Dermal Dendritic Cells Are Sufficient to Initiate Contact Hypersensitivity In Vivo	PLOS ONE			English	Article								Background: Dendritic cells (DCs) are the most potent antigen-presenting cells in the mammalian immune system. In the skin, epidermal Langerhans cells (LCs) and dermal dendritic cells (DDCs) survey for invasive pathogens and present antigens to T cells after migration to the cutaneous lymph nodes (LNs). So far, functional and phenotypic differences between these two DC subsets remain unclear due to lack of markers to identify DDCs. Methodology/Principal Findings: In the present report, we demonstrated that macrophage galactose-type C-type lectin (MGL) 2 was exclusively expressed in the DDC subset in the skin-to-LN immune system. In the skin, MGL2 was expressed on the majority (about 88%) of MHCII(+)CD11c(+) cells in the dermis. In the cutaneous LN, MGL2 expression was restricted to B220(-)CD8 alpha(lo)CD11b(+)CD11c(+)MHCII(hi) tissue-derived DC. MGL2(+)DDC migrated from the dermis into the draining LNs within 24 h after skin sensitization with FITC. Distinct from LCs, MGL2(+)DDCs localized near the high endothelial venules in the outer T cell cortex. In FITC-induced contact hypersensitivity (CHS), adoptive transfer of FITC(+)MGL2(+)DDCs, but not FITC(+)MGL2(-)DCs into naive mice resulted in the induction of FITC-specific ear swelling, indicating that DDCs played a key role in initiation of immune responses in the skin. Conclusions/Significance: These results demonstrated the availability of MGL2 as a novel marker for DDCs and suggested the contribution of MGL2(+) DDCs for initiating CHS.			Kumamoto, Y (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA.	irimura@mol.f.u-tokyo.ac.jp		Kumamoto, Yosuke/0000-0001-9369-4934; Denda-Nagai, Kaori/0000-0001-8325-3289				Allan RS, 2006, IMMUNITY, V25, P153, DOI 10.1016/j.immuni.2006.04.017; Anjuere F, 1999, BLOOD, V93, P590, DOI 10.1182/blood.V93.2.590.402k11_590_598; Asselin-Paturel C, 2003, J IMMUNOL, V171, P6466, DOI 10.4049/jimmunol.171.12.6466; Bajenoff M, 2006, J EXP MED, V203, P619, DOI 10.1084/jem.20051474; Bajenoff M, 2003, J EXP MED, V198, P715, DOI 10.1084/jem.20030167; Bennett CL, 2005, J CELL BIOL, V169, P569, DOI 10.1083/jcb.200501071; Bogunovic M, 2006, J EXP MED, V203, P2627, DOI 10.1084/jem.20060667; BURSCH LS, 2007, J EXP MED; Denda-Nagai K, 2002, GLYCOBIOLOGY, V12, P443, DOI 10.1093/glycob/cwf061; Douillard P, 2005, J INVEST DERMATOL, V125, P983, DOI 10.1111/j.0022-202X.2005.23951.x; Dupasquier M, 2006, J LEUKOCYTE BIOL, V80, P838, DOI 10.1189/jlb.1005564; GINHOUX F, 2007, J EXP MED; Gray DHD, 2002, J IMMUNOL METHODS, V260, P15, DOI 10.1016/S0022-1759(01)00493-8; Henri S, 2001, J IMMUNOL, V167, P741, DOI 10.4049/jimmunol.167.2.741; Ingulli E, 2002, J IMMUNOL, V169, P2247, DOI 10.4049/jimmunol.169.5.2247; Itano AA, 2003, NAT IMMUNOL, V4, P733, DOI 10.1038/ni957; Itano AA, 2003, IMMUNITY, V19, P47, DOI 10.1016/S1074-7613(03)00175-4; Kabashima K, 2007, AM J PATHOL, V171, P1249, DOI 10.2353/ajpath.2007.070225; Kamath AT, 2002, BLOOD, V100, P1734, DOI 10.1182/blood.V100.5.1734.h81702001734_1734_1741; Kaplan DH, 2005, IMMUNITY, V23, P611, DOI 10.1016/j.immuni.2005.10.008; Katakai T, 2004, INT IMMUNOL, V16, P1133, DOI 10.1093/intimm/dxh113; Kimber I, 1998, CURR OPIN IMMUNOL, V10, P614, DOI 10.1016/S0952-7915(98)80078-2; KIMURA T, 1995, J BIOL CHEM, V270, P16056, DOI 10.1074/jbc.270.27.16056; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; Kissenpfennig A, 2005, MOL CELL BIOL, V25, P88, DOI 10.1128/MCB.25.1.88-99.2005; KRIPKE ML, 1990, J IMMUNOL, V145, P2833; LENZ A, 1993, J CLIN INVEST, V92, P2587, DOI 10.1172/JCI116873; Leon B, 2008, BLOOD, V111, P3126, DOI 10.1182/blood-2007-07-100610; Lindquist RL, 2004, NAT IMMUNOL, V5, P1243, DOI 10.1038/ni1139; MACATONIA SE, 1987, J EXP MED, V166, P1654, DOI 10.1084/jem.166.6.1654; Mizuochi S, 1997, GLYCOBIOLOGY, V7, P137, DOI 10.1093/glycob/7.1.137; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; Ohl L, 2004, IMMUNITY, V21, P279, DOI 10.1016/j.immuni.2004.06.014; Onami TM, 2002, MOL CELL BIOL, V22, P5173, DOI 10.1128/MCB.22.14.5173-5181.2002; POULIN LF, 2007, J EXP MED; Qu CF, 2004, J EXP MED, V200, P1231, DOI 10.1084/jem.20032152; Raes G, 2005, J LEUKOCYTE BIOL, V77, P321, DOI 10.1189/jlb.0304212; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; Randolph GJ, 1998, SCIENCE, V282, P480, DOI 10.1126/science.282.5388.480; Randolph GJ, 2008, CURR OPIN IMMUNOL, V20, P52, DOI 10.1016/j.coi.2007.10.010; Ruedl C, 2000, J IMMUNOL, V165, P4910, DOI 10.4049/jimmunol.165.9.4910; Sato K, 2005, BLOOD, V106, P207, DOI 10.1182/blood-2004-12-4943; Sato K, 2005, INT IMMUNOL, V17, P559, DOI 10.1093/intimm/dxh235; Sato K, 1998, J IMMUNOL, V161, P6835; SHELLEY WB, 1976, NATURE, V261, P46, DOI 10.1038/261046a0; SILBERBERGSINAKIN I, 1976, CELL IMMUNOL, V25, P137, DOI 10.1016/0008-8749(76)90105-2; Stoitzner P, 2003, J INVEST DERMATOL, V120, P266, DOI 10.1046/j.1523-1747.2003.12042.x; Tacke F, 2006, IMMUNOBIOLOGY, V211, P609, DOI 10.1016/j.imbio.2006.05.025; TANG AM, 1993, NATURE, V361, P82, DOI 10.1038/361082a0; TOEWS GB, 1980, J IMMUNOL, V124, P445; Tsuiji M, 2002, J BIOL CHEM, V277, P28892, DOI 10.1074/jbc.M203774200; Valladeau J, 2000, IMMUNITY, V12, P71, DOI 10.1016/S1074-7613(00)80160-0; Valladeau J, 2002, J IMMUNOL, V168, P782, DOI 10.4049/jimmunol.168.2.782; Vremec D, 1997, J IMMUNOL, V159, P565; WITMERPACK MD, 1995, CELL IMMUNOL, V163, P157, DOI 10.1006/cimm.1995.1110	55	45	45	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5619	10.1371/journal.pone.0005619	http://dx.doi.org/10.1371/journal.pone.0005619			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19440334	Green Published, Green Submitted, gold			2022-12-25	WOS:000266161200019
J	Prieur, A; Nacerddine, K; van Lohuizen, M; Peeper, DS				Prieur, Alexandre; Nacerddine, Karim; van Lohuizen, Maarten; Peeper, Daniel S.			SUMOylation of DRIL1 Directs Its Transcriptional Activity Towards Leukocyte Lineage-Specific Genes	PLOS ONE			English	Article								DRIL1 is an ARID family transcription factor that can immortalize primary mouse fibroblasts, bypass RAS(V12)-induced cellular senescence and collaborate with RAS(V12) or MYC in mediating oncogenic transformation. It also activates immunoglobulin heavy chain transcription and engages in heterodimer formation with E2F to stimulate E2F-dependent transcription. Little, however, is known about the regulation of DRIL1 activity. Recently, DRIL1 was found to interact with the SUMO-conjugating enzyme Ubc9, but the functional relevance of this association has not been assessed. Here, we show that DRIL1 is sumoylated both in vitro and in vivo at lysine 398. Moreover, we provide evidence that PIASy functions as a specific SUMO E3-ligase for DRIL1 and promotes its sumoylation both in vitro and in vivo. Furthermore, consistent with the subnuclear localization of PIASy in the Matrix-Associated Region (MAR), SUMO-modified DRIL1 species are found exclusively in the MAR fraction. This post-translational modification interferes neither with the subcellular localization nor the DNA-binding activity of the protein. In contrast, DRIL1 sumoylation impairs its interaction with E2F1 in vitro and modifies its transcriptional activity in vivo, driving transcription of subset of genes regulating leukocyte fate. Taken together, these results identify sumoylation as a novel post-translational modification of DRIL1 that represents an important mechanism for targeting and modulating DRIL1 transcriptional activity.			Prieur, A (corresponding author), Inst Genom Fonct, Equipe Plasticite Genome & Vieillissement, Montpellier, France.	d.peeper@nki.nl	Peeper, Daniel/AAA-2430-2020					Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Binda O, 2006, MOL CELL BIOL, V26, P1917, DOI 10.1128/MCB.26.5.1917-1931.2006; Callery EM, 2005, DEV BIOL, V278, P542, DOI 10.1016/j.ydbio.2004.11.017; Fukuyo Y, 2004, CELL DEATH DIFFER, V11, P747, DOI 10.1038/sj.cdd.4401412; Gao HW, 2002, J BIOL CHEM, V277, P38827, DOI 10.1074/jbc.M206224200; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Gregory SL, 1996, MOL CELL BIOL, V16, P792; Kim D, 2006, MOL CELL BIOL, V26, P2187, DOI 10.1128/MCB.26.6.2187-2201.2006; Kim D, 2007, J BIOL CHEM, V282, P15768, DOI 10.1074/jbc.M700397200; Kortschak RD, 1998, GENOMICS, V51, P288, DOI 10.1006/geno.1998.5259; Liu B, 2008, CURR OPIN CELL BIOL, V20, P288, DOI 10.1016/j.ceb.2008.03.014; Lopez-Soto A, 2006, J BIOL CHEM, V281, P30419, DOI 10.1074/jbc.M604868200; Ma KW, 2003, MOL CANCER RES, V1, P438; Nixon JC, 2004, J BIOL CHEM, V279, P52465, DOI 10.1074/jbc.M403028200; Patsialou A, 2005, NUCLEIC ACIDS RES, V33, P66, DOI 10.1093/nar/gki145; Peeper DS, 2002, NAT CELL BIOL, V4, P148, DOI 10.1038/ncb742; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Schymeinsky J, 2007, THROMB HAEMOSTASIS, V98, P262, DOI 10.1160/TH07-02-0156; Shandala T, 2002, INT J DEV BIOL, V46, P423; Siatecka M, 2007, MOL CELL BIOL, V27, P8547, DOI 10.1128/MCB.00589-07; Suzuki M, 1998, ONCOGENE, V17, P853, DOI 10.1038/sj.onc.1202163; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; WEBB CF, 1991, MOL CELL BIOL, V11, P5206, DOI 10.1128/MCB.11.10.5206; Webb CF, 2000, J IMMUNOL, V165, P6956, DOI 10.4049/jimmunol.165.12.6956; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Wilsker D, 2005, GENOMICS, V86, P242, DOI 10.1016/j.ygeno.2005.03.013; Zheng Q, 2008, NUCLEIC ACIDS RES, V36, pW358, DOI 10.1093/nar/gkn276	29	7	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2009	4	5							e5542	10.1371/journal.pone.0005542	http://dx.doi.org/10.1371/journal.pone.0005542			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FX	19436740	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107300008
J	Ben-Tzvi, O; Kiflawi, M; Polak, O; Abelson, A				Ben-Tzvi, Ofer; Kiflawi, Moshe; Polak, Omer; Abelson, Avigdor			The Effect of Adult Aggression on Habitat Selection by Settlers of Two Coral-Dwelling Damselfishes	PLOS ONE			English	Article								Coral-reef fishes experience a major challenge when facing settlement in a multi-threat environment, within which, using settlement cues, they need to select a suitable site. Studies in laboratories and artificial setups have shown that the presence of conspecific adults often serves as a positive settlement cue, whose value is explained by the increased survival of juveniles in an already proven fit environment. However, settlement in already inhabited corals may expose the recruits to adult aggression. Daily observations and manipulation experiments were used in the present study, which was conducted in the natural reef. We revealed differential strategies of settlers, which do not necessarily join conspecific adults. Dascyllus aruanus prefer to settle near (not with) their aggressive adults, and to join them only after gaining in size; whereas Dascyllus marginatus settlers in densely populated reefs settle independently of their adult distribution. Our results present different solutions to the challenges faced by fish recruits while selecting their microhabitat, and emphasize the complexity of habitat selection by the naive settlers. Although laboratory experiments are important to the understanding of fish habitat selection, further studies in natural habitats are essential in order to elucidate the actual patterns of settlement and habitat selection, which are crucial for the survival of coral-reef fish populations.			Ben-Tzvi, O (corresponding author), Interuniv Inst Marine Sci Eilat, Elat, Israel.	obentzvi@gmail.com	KIFLAWI, MOSHE/AAH-7991-2021	Kiflawi, Moshe/0000-0002-9705-6486				Almany GR, 2004, ECOLOGY, V85, P2872, DOI 10.1890/03-3166; Almany GR, 2003, ECOLOGY, V84, P1920, DOI 10.1890/0012-9658(2003)084[1920:PEICRF]2.0.CO;2; Almany GR, 2004, OECOLOGIA, V141, P105, DOI 10.1007/s00442-004-1617-0; Bednekoff PA, 1998, TRENDS ECOL EVOL, V13, P284, DOI 10.1016/S0169-5347(98)01327-5; Bednekoff PA, 2003, BEHAV PROCESS, V63, P135, DOI 10.1016/S0376-6357(03)00008-1; Ben-Tzvi O, 2008, J FISH BIOL, V73, P1005, DOI 10.1111/j.1095-8649.2008.02003.x; Ben-Tzvi O, 2007, LIMNOL OCEANOGR, V52, P2618, DOI 10.4319/lo.2007.52.6.2618; Bertram B.C.R., 1978, P64; BOOTH DJ, 1992, J EXP MAR BIOL ECOL, V155, P85, DOI 10.1016/0022-0981(92)90029-A; Booth DJ, 2004, ECOLOGY, V85, P2881, DOI 10.1890/03-0535; BOOTH DJ, 1995, ECOLOGY, V76, P91, DOI 10.2307/1940634; CARR MH, 1995, MAR ECOL PROG SER, V124, P31, DOI 10.3354/meps124031; CLARK CW, 1986, THEOR POPUL BIOL, V30, P45, DOI 10.1016/0040-5809(86)90024-9; COATES D, 1980, J ANIM ECOL, V49, P335, DOI 10.2307/4292; COATES D, 1980, Z TIERPSYCHOL, V52, P347; COATES D, 1980, Z TIERPSYCHOL, V52, P355; Doherty Peter J., 2002, P327, DOI 10.1016/B978-012615185-5/50019-0; DUFOUR V, 1993, MAR ECOL PROG SER, V102, P143, DOI 10.3354/meps102143; ELLIOTT JK, 1995, MAR BIOL, V122, P377, DOI 10.1007/BF00350870; FORRESTER GE, 1991, ANIM BEHAV, V42, P701, DOI 10.1016/S0003-3472(05)80116-2; FORRESTER GE, 1990, ECOLOGY, V71, P1666, DOI 10.2307/1937576; FRICKE HW, 1974, NATURWISSENSCHAFTEN, V61, P367, DOI 10.1007/BF00600312; FRICKE HW, 1977, HELGOLAND WISS MEER, V30, P412, DOI 10.1007/BF02207851; FRICKE HW, 1980, ANIM BEHAV, V28, P561, DOI 10.1016/S0003-3472(80)80065-0; HIXON MA, 1993, ECOL MONOGR, V63, P77, DOI 10.2307/2937124; Holbrook SJ, 2002, ECOLOGY, V83, P2855, DOI 10.2307/3072021; Jones G.P., 1991, P294; Karplus I, 2006, MAR ECOL PROG SER, V319, P215, DOI 10.3354/meps319215; KATZIR G, 1981, ANIM BEHAV, V29, P835, DOI 10.1016/S0003-3472(81)80018-8; Lecchini D, 2007, J EXP MAR BIOL ECOL, V341, P85, DOI 10.1016/j.jembe.2006.10.006; Lecchini D, 2005, BEHAV ECOL SOCIOBIOL, V58, P18, DOI 10.1007/s00265-004-0905-3; Lecchini D, 2005, OECOLOGIA, V143, P326, DOI 10.1007/s00442-004-1805-y; McCormick MI, 1997, MAR ECOL PROG SER, V153, P247, DOI 10.3354/meps153247; Motro R, 2005, CORAL REEFS, V24, P95, DOI 10.1007/s00338-004-0451-5; Munday PL, 1998, OCEANOGR MAR BIOL<D>, V36, P373; Myrberg Arthur A. Jr, 2002, P123, DOI 10.1016/B978-012615185-5/50009-8; Pulliam HR., 1984, BEHAVIOURAL ECOLOGY, P122; Sandin SA, 2005, ECOLOGY, V86, P1520, DOI 10.1890/03-0654; Shima JS, 2001, ECOLOGY, V82, P2190, DOI 10.2307/2680225; SHPIGEL M, 1986, ENVIRON BIOL FISH, V17, P253, DOI 10.1007/BF00001492; Sponaugle S, 1996, MAR FRESHWATER RES, V47, P433, DOI 10.1071/MF9960433; Stamps J, 2005, ECOLOGY, V86, P2860, DOI 10.1890/05-0290; SWEATMAN H, 1988, J EXP MAR BIOL ECOL, V124, P163, DOI 10.1016/0022-0981(88)90170-0; SWEATMAN HPA, 1983, MAR BIOL, V75, P225, DOI 10.1007/BF00406006; SWEATMAN HPA, 1985, ECOL MONOGR, V55, P469, DOI 10.2307/2937132; SWEATMAN HPA, 1985, 5TH P INT COR REEF C, V5, P367; White JW, 2007, ECOLOGY, V88, P3044, DOI 10.1890/06-1949.1; Wright KJ, 2005, MAR BIOL, V147, P1425, DOI 10.1007/s00227-005-0028-z	48	21	21	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5511	10.1371/journal.pone.0005511	http://dx.doi.org/10.1371/journal.pone.0005511			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444WA	19436725	Green Published, Green Submitted, gold			2022-12-25	WOS:000266009900004
J	Barbas, A; Matos, RG; Amblar, M; Lopez-Vinas, E; Gomez-Puertas, P; Arraiano, CM				Barbas, Ana; Matos, Rute G.; Amblar, Monica; Lopez-Vinas, Eduardo; Gomez-Puertas, Paulino; Arraiano, Cecilia M.			Determination of Key Residues for Catalysis and RNA Cleavage Specificity ONE MUTATION TURNS RNase II INTO A "SUPER-ENZYME"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RIBONUCLEASE-II; YEAST EXOSOME CORE; ESCHERICHIA-COLI; MESSENGER-RNA; STRUCTURAL-ANALYSIS; DEGRADATION; EXPRESSION; COMPLEX; DECAY; EXORIBONUCLEASES	RNase II is the prototype of a ubiquitous family of enzymes that are crucial for RNA metabolism. In Escherichia coli this protein is a single-stranded-specific 3'-exoribonuclease with a modular organization of four functional domains. In eukaryotes, the RNase II homologue Rrp44 (also known as Dis3) is the catalytic subunit of the exosome, an exoribonuclease complex essential for RNA processing and decay. In this work we have performed a functional characterization of several highly conserved residues located in the RNase II catalytic domain to address their precise role in the RNase II activity. We have constructed a number of RNase II mutants and compared their activity and RNA binding to the wild type using different single- or double-stranded substrates. The results presented in this study substantially improve the RNase II model for RNA degradation. We have identified the residues that are responsible for the discrimination of cleavage of RNA versus DNA. We also show that the Arg-500 residue present in the RNase II active site is crucial for activity but not for RNA binding. The most prominent finding presented is the extraordinary catalysis observed in the E542A mutant that turns RNase II into a "super-enzyme."	[Barbas, Ana; Matos, Rute G.; Arraiano, Cecilia M.] Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal; [Amblar, Monica] Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid 28029, Spain; [Lopez-Vinas, Eduardo] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CB06 03, Madrid 28029, Spain; [Lopez-Vinas, Eduardo; Gomez-Puertas, Paulino] Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain	Universidade Nova de Lisboa; Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM); CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Arraiano, CM (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Apartado 127, P-2781901 Oeiras, Portugal.	cecilia@itqb.unl.pt	Matos, Rute/J-4983-2013; Gomez-Puertas, Paulino/G-8821-2014; López-Viñas, Eduardo/AAT-1124-2021; Amblar, 2405/C-3941-2011; Amblar, Monica/E-2366-2016	Gomez-Puertas, Paulino/0000-0003-3131-729X; Amblar, Monica/0000-0003-3530-615X; Matos Luis, Rute/0000-0002-9788-7562; Barbas, Ana/0000-0002-6245-8549; Arraiano, Cecilia/0000-0003-1934-9301	Ministerio de Educacion y Ciencia, Spain [SAF2007-61926]; Fundacion Ramon Arecesm; Fundacao para a Ciencia e a Tecnologia, Portugal	Ministerio de Educacion y Ciencia, Spain(Spanish Government); Fundacion Ramon Arecesm; Fundacao para a Ciencia e a Tecnologia, Portugal(Portuguese Foundation for Science and Technology)	The work was supported by Ministerio de Educacion y Ciencia, Spain, Grant SAF2007-61926, an institutional grant from the "Fundacion Ramon Arecesm," and by Fundacao para a Ciencia e a Tecnologia, Portugal.	Amblar M, 2005, FEBS J, V272, P363, DOI 10.1111/j.1742-4658.2004.04477.x; Amblar M, 2007, RNA, V13, P317, DOI 10.1261/rna.220407; Amblar M, 2006, J MOL BIOL, V360, P921, DOI 10.1016/j.jmb.2006.05.043; Andrade JM, 2006, MOL MICROBIOL, V60, P219, DOI 10.1111/j.1365-2958.2006.05092.x; Andrade JM, 2009, PROG MOL BIOL TRANSL, V85, P187, DOI 10.1016/S0079-6603(08)00805-2; Arraiano CM, 2008, METHOD ENZYMOL, V447, P131, DOI 10.1016/S0076-6879(08)02208-8; Barbas A, 2008, J BIOL CHEM, V283, P13070, DOI 10.1074/jbc.M709989200; Cairrao F, 2006, BIOCHEM BIOPH RES CO, V343, P731, DOI 10.1016/j.bbrc.2006.03.040; Cairrao F, 2003, MOL MICROBIOL, V50, P1349, DOI 10.1046/j.1365-2958.2003.03766.x; Cairrao F, 2001, MOL MICROBIOL, V276, P19172; CANNISTRARO VJ, 1994, J MOL BIOL, V243, P930, DOI 10.1006/jmbi.1994.1693; Cannistraro VJ, 2001, METHOD ENZYMOL, V342, P309, DOI 10.1016/S0076-6879(01)42555-9; Case D, 2006, AMBER 9; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; CASE DA, 2004, AMBER 8; Cheng ZF, 2005, MOL CELL, V17, P313, DOI 10.1016/j.molcel.2004.11.048; Cheng ZF, 1998, J BIOL CHEM, V273, P14077, DOI 10.1074/jbc.273.23.14077; Coburn GA, 1996, J BIOL CHEM, V271, P1048, DOI 10.1074/jbc.271.2.1048; DEUTSCHER MP, 1991, P NATL ACAD SCI USA, V88, P3277, DOI 10.1073/pnas.88.8.3277; Dziembowski A, 2007, NAT STRUCT MOL BIOL, V14, P15, DOI 10.1038/nsmb1184; Frazao C, 2006, NATURE, V443, P110, DOI 10.1038/nature05080; Grossman D, 2006, NAT STRUCT MOL BIOL, V13, P760, DOI 10.1038/nsmb0906-760; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUPTA RS, 1977, J BIOL CHEM, V252, P8945; Higuchi R., 1990, PCR PROTOCOLS GUIDE; Lebreton A, 2008, NATURE, V456, P993, DOI 10.1038/nature07480; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; Liu QS, 2006, CELL, V127, P1223, DOI 10.1016/j.cell.2006.10.037; Lorentzen E, 2008, MOL CELL, V29, P717, DOI 10.1016/j.molcel.2008.02.018; Marujo PE, 2000, RNA, V6, P1185, DOI 10.1017/S135583820000073X; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)90806-H; McVey CE, 2006, ACTA CRYSTALLOGR F, V62, P684, DOI 10.1107/S1744309106021506; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Park SM, 2000, MOL CELL BIOL, V20, P4765, DOI 10.1128/MCB.20.13.4765-4772.2000; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Schaeffer D, 2009, NAT STRUCT MOL BIOL, V16, P56, DOI 10.1038/nsmb.1528; Schneider C, 2007, MOL CELL, V27, P324, DOI 10.1016/j.molcel.2007.06.006; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAYLOR RG, 1993, NUCLEIC ACIDS RES, V21, P1677, DOI 10.1093/nar/21.7.1677; Wang HW, 2007, P NATL ACAD SCI USA, V104, P16844, DOI 10.1073/pnas.0705526104; ZILHAO R, 1993, MOL MICROBIOL, V8, P43, DOI 10.1111/j.1365-2958.1993.tb01201.x; Zilhao R, 1996, MOL MICROBIOL, V20, P1033, DOI 10.1111/j.1365-2958.1996.tb02544.x; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017; Zuo YH, 2006, MOL CELL, V24, P149, DOI 10.1016/j.molcel.2006.09.004	45	33	33	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20486	20498		10.1074/jbc.M109.020693	http://dx.doi.org/10.1074/jbc.M109.020693			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19458082	hybrid, Green Published			2022-12-25	WOS:000268316100010
J	Jang, SW; Svaren, J				Jang, Sung-Wook; Svaren, John			Induction of Myelin Protein Zero by Early Growth Response 2 through Upstream and Intragenic Elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-NERVE MYELINATION; SCHWANN-CELL DIFFERENTIATION; TRANSCRIPTION FACTOR SOX10; REPORTER GENE-EXPRESSION; HUMAN GENOME; TRANSGENIC MICE; LIVING MICE; EGR2; BINDING; KROX-20	The Mpz (myelin protein zero) gene codes for the principal component of myelin in the peripheral nervous system, and mutations in this gene cause human peripheral myelinopathies. Expression of the Mpz gene is controlled by two major transactivators that coordinate Schwann cell development: Egr2/Krox20 and Sox10. Our in vivo ChIP-chip analysis in myelinating peripheral nerve identified major sites of Egr2 interaction within the first intron of the Mpz gene and similar to 5 kb upstream of the transcription start site. In addition, the sites of Egr2 binding display many of the hallmarks associated with enhancer elements. Interestingly, the upstream Egr2 binding sites lie proximal to the divergently transcribed succinate dehydrogenase C gene, but Sdhc expression was not affected by the massive induction of Mpz mediated by Egr2. Mpz induction was greatly enhanced in the presence of the Egr2 binding sites, and removal of them markedly diminished transgenic expression of a construct derived from the Mpz locus. Sox10 was also found to be associated with the upstream region, and its binding was required for Egr2-mediated activation in this distal regulatory region. Our findings highlight that peripheral nerve-specific expression of Mpz is primarily regulated by both upstream and intron-associated regulatory elements. Overall, these results provide a locus-wide analysis of the role and activity of Egr2 in regulation of the Mpz gene within its native chromosomal context.	[Svaren, John] Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; [Jang, Sung-Wook; Svaren, John] Univ Wisconsin, Grad Program Cellular & Mol Biol, Madison, WI 53705 USA; [Svaren, John] Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Svaren, J (corresponding author), Univ Wisconsin, Waisman Ctr, 1500 Highland Dr, Madison, WI 53705 USA.	jpsvaren@wisc.edu	Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921	National Institutes of Health, NICHD [HD41590]; Core [P30 HD03352]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003352] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041590] Funding Source: NIH RePORTER	National Institutes of Health, NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Core(Luxembourg National Research Fund); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported, in whole or in part, by National Institutes of Health, NICHD, Grant HD41590 (to J. S.) and Core Grant P30 HD03352 (to the Waisman Center).	Arthur-Farraj P, 2006, NEUROBIOL DIS, V24, P159, DOI 10.1016/j.nbd.2006.06.006; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; BHATTACHARYYA A, 1991, NEURON, V7, P831, DOI 10.1016/0896-6273(91)90285-8; Bhaumik S, 2002, P NATL ACAD SCI USA, V99, P377, DOI 10.1073/pnas.012611099; Bieda M, 2006, GENOME RES, V16, P595, DOI 10.1101/gr.4887606; Bondurand N, 2001, HUM MOL GENET, V10, P2783, DOI 10.1093/hmg/10.24.2783; Brown AM, 1997, J BIOL CHEM, V272, P28939, DOI 10.1074/jbc.272.46.28939; Crawford GE, 2006, GENOME RES, V16, P123, DOI 10.1101/gr.4074106; Decker L, 2006, J NEUROSCI, V26, P9771, DOI 10.1523/JNEUROSCI.0716-06.2006; Feltri ML, 1999, EUR J NEUROSCI, V11, P1577, DOI 10.1046/j.1460-9568.1999.00568.x; Fraser P, 2006, CURR OPIN GENET DEV, V16, P490, DOI 10.1016/j.gde.2006.08.002; GREENFIELD S, 1973, J NEUROCHEM, V20, P1207, DOI 10.1111/j.1471-4159.1973.tb00089.x; Hai M, 2002, J NEUROSCI RES, V69, P497, DOI 10.1002/jnr.10327; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Jang SW, 2006, J NEUROCHEM, V98, P1678, DOI 10.1111/j.1471-4159.2006.04069.x; Johnson KD, 2001, MOL CELL, V8, P465, DOI 10.1016/S1097-2765(01)00309-4; Jones EA, 2007, NEURON GLIA BIOL, V3, P377, DOI 10.1017/S1740925X08000173; Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833; Le N, 2005, P NATL ACAD SCI USA, V102, P2596, DOI 10.1073/pnas.0407836102; LeBlanc SE, 2007, MOL CELL BIOL, V27, P3521, DOI 10.1128/MCB.01689-06; LeBlanc SE, 2005, J NEUROCHEM, V93, P737, DOI 10.1111/j.1471-4159.2005.03056.x; LeBlanc SE, 2006, J BIOL CHEM, V281, P5453, DOI 10.1074/jbc.M512159200; Lee MJ, 1997, MOL CELL NEUROSCI, V8, P336, DOI 10.1006/mcne.1996.0589; LEMKE G, 1988, DEVELOPMENT, V102, P499; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; Nagarajan R, 2002, P NATL ACAD SCI USA, V99, P8998, DOI 10.1073/pnas.132080999; Nagarajan R, 2001, NEURON, V30, P355, DOI 10.1016/S0896-6273(01)00282-3; O'Geen H, 2006, BIOTECHNIQUES, V41, P577, DOI 10.2144/000112268; Oberley MJ, 2004, METHOD ENZYMOL, V376, P315; Peirano RI, 2000, MOL CELL BIOL, V20, P3198, DOI 10.1128/MCB.20.9.3198-3209.2000; Previtali SC, 2000, J CELL BIOL, V151, P1035, DOI 10.1083/jcb.151.5.1035; Sabo PJ, 2006, NAT METHODS, V3, P511, DOI 10.1038/NMETH890; Schreiner S, 2007, DEVELOPMENT, V134, P3271, DOI 10.1242/dev.003350; Slutsky SG, 2003, J BIOL CHEM, V278, P8960, DOI 10.1074/jbc.M210569200; STAHL N, 1990, MOL BRAIN RES, V8, P209, DOI 10.1016/0169-328X(90)90018-9; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Topilko P, 1997, J NEUROSCI RES, V50, P702, DOI 10.1002/(SICI)1097-4547(19971201)50:5<702::AID-JNR7>3.0.CO;2-L; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; Verheijen MHG, 2003, GENE DEV, V17, P2450, DOI 10.1101/gad.1116203; Vernimmen D, 2007, EMBO J, V26, P2041, DOI 10.1038/sj.emboj.7601654; Wrabetz L, 2000, J CELL BIOL, V148, P1021, DOI 10.1083/jcb.148.5.1021; WRABETZ L, 2004, MYELIN BIOL DISORDER, P905; Wu JC, 2001, MOL THER, V4, P297, DOI 10.1006/mthe.2001.0460; Zorick TS, 1999, DEVELOPMENT, V126, P1397; Zorick TS, 1996, MOL CELL NEUROSCI, V8, P129, DOI 10.1006/mcne.1996.0052	48	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20111	20120		10.1074/jbc.M109.022426	http://dx.doi.org/10.1074/jbc.M109.022426			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19487693	hybrid, Green Published			2022-12-25	WOS:000268097400038
J	Rottenberg, H; Covian, R; Trumpower, BL				Rottenberg, Hagai; Covian, Raul; Trumpower, Bernard L.			Membrane Potential Greatly Enhances Superoxide Generation by the Cytochrome bc(1) Complex Reconstituted into Phospholipid Vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Q-CYCLE; C REDUCTASE; Q(O) SITE; OXIDOREDUCTASE COMPLEX; UBIQUINOL OXIDATION; MITOCHONDRIA; ELECTRON; MECHANISM; TRANSPORT; TISSUE	The mitochondrial cytochrome bc(1) complex (ubiquinol/cytochrome c oxidoreductase) is generally thought to generate superoxide anion that participates in cell signaling and contributes to cellular damage in aging and degenerative disease. However, the isolated, detergent-solubilized bc(1) complex does not generate measurable amounts of superoxide except when inhibited by antimycin. In addition, indirect measurements of superoxide production by cells and isolated mitochondria have not clearly resolved the contribution of the bc(1) complex to the generation of superoxide by mitochondria in vivo, nor did they establish the effect, if any, of membrane potential on superoxide formation by this enzyme complex. In this study we show that the yeast cytochrome bc(1) complex does generate significant amounts of superoxide when reconstituted into phospholipid vesicles. The rate of superoxide generation by the reconstituted bc(1) complex increased exponentially with increased magnitude of the membrane potential, a finding that is compatible with the suggestion that membrane potential inhibits electron transfer from the cytochrome b(L) to b(H) hemes, thereby promoting the formation of a ubisemiquinone radical that interacts with oxygen to generate superoxide. When the membrane potential was further increased, by the addition of nigericin or by the imposition of a diffusion potential, the rate of generation of superoxide was further accelerated and approached the rate obtained with antimycin. These findings suggest that the bc(1) complex may contribute significantly to superoxide generation by mitochondria in vivo, and that the rate of superoxide generation can be controlled by modulation of the mitochondrial membrane potential.	[Rottenberg, Hagai; Covian, Raul; Trumpower, Bernard L.] Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Trumpower, BL (corresponding author), Dartmouth Med Sch, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.	rotteh@hotmail.com; Trumpower@Dartmouth.edu			National Institutes of Health [20379]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant GM 20379.	Adam-Vizi V, 2005, ANTIOXID REDOX SIGN, V7, P1140, DOI 10.1089/ars.2005.7.1140; Banfi C, 2009, J THROMB HAEMOST, V7, P206, DOI 10.1111/j.1538-7836.2008.03204.x; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bell EL, 2007, J CELL BIOL, V177, P1029, DOI 10.1083/jcb.200609074; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; Brand MD, 2004, BIOCHEM SOC SYMP, V71, P203; Cape JL, 2007, P NATL ACAD SCI USA, V104, P7887, DOI 10.1073/pnas.0702621104; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Drose S, 2008, J BIOL CHEM, V283, P21649, DOI 10.1074/jbc.M803236200; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Forquer I, 2006, J BIOL CHEM, V281, P38459, DOI 10.1074/jbc.M605119200; Guzy RD, 2007, ANTIOXID REDOX SIGN, V9, P1317, DOI 10.1089/ars.2007.1708; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; KATZ Y, 1974, J MEMBRANE BIOL, V17, P87, DOI 10.1007/BF01870174; Kawamata H, 2008, HUM MOL GENET, V17, P3303, DOI 10.1093/hmg/ddn226; Klimova T, 2008, CELL DEATH DIFFER, V15, P660, DOI 10.1038/sj.cdd.4402307; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Kudin AP, 2008, BBA-BIOENERGETICS, V1777, P689, DOI 10.1016/j.bbabio.2008.05.010; Lambert AJ, 2004, BIOCHEM J, V382, P511, DOI 10.1042/BJ20040485; LEUNG KH, 1975, J BIOL CHEM, V250, P8467; Lin X, 2008, P NATL ACAD SCI USA, V105, P174, DOI 10.1073/pnas.0706585104; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; Muller F, 2002, BIOCHEMISTRY-US, V41, P7866, DOI 10.1021/bi025581e; Muller FL, 2003, BIOCHEMISTRY-US, V42, P6493, DOI 10.1021/bi0342160; Muller FL, 2008, BIOCHEM J, V409, P491, DOI 10.1042/BJ20071162; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; ROTTENBERG H, 1979, BIOCHIM BIOPHYS ACTA, V549, P225, DOI 10.1016/0304-4173(79)90001-6; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Snyder C, 1998, BBA-BIOENERGETICS, V1365, P125, DOI 10.1016/S0005-2728(98)00052-8; Soberanes S, 2009, J BIOL CHEM, V284, P2176, DOI 10.1074/jbc.M808844200; Tahara EB, 2009, FREE RADICAL BIO MED, V46, P1283, DOI 10.1016/j.freeradbiomed.2009.02.008; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; Wenz T, 2007, J BIOL CHEM, V282, P3977, DOI 10.1074/jbc.M606482200; YANG XH, 1988, J BIOL CHEM, V263, P11962; YU CA, 1972, J BIOL CHEM, V247, P1012; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972; Zhao YG, 2003, J BIOL CHEM, V278, P2356, DOI 10.1074/jbc.M209681200; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391; ZOCCARATO F, 1988, BIOCHEM BIOPH RES CO, V154, P727, DOI 10.1016/0006-291X(88)90200-8	41	77	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19203	19210		10.1074/jbc.M109.017376	http://dx.doi.org/10.1074/jbc.M109.017376			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19478336	Green Published, hybrid			2022-12-25	WOS:000267908300010
J	Zhou, YD; Mancarella, S; Wang, YJ; Yue, CY; Ritchie, M; Gill, DL; Soboloff, J				Zhou, Yandong; Mancarella, Salvatore; Wang, Youjun; Yue, Chanyu; Ritchie, Michael; Gill, Donald L.; Soboloff, Jonathan			The Short N-terminal Domains of STIM1 and STIM2 Control the Activation Kinetics of Orai1 Channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORE-INDEPENDENT MODES; OPERATED CA2+ ENTRY; I-CRAC; OLIGOMERIZATION; INITIATION; PROTEINS; REGION; INFLUX	STIM1 and STIM2 are dynamic transmembrane endoplasmic reticulum Ca2+ sensors, coupling directly to activate plasma membrane Orai Ca2+ entry channels. Despite extensive sequence homology, the STIM proteins are functionally distinct. We reveal that the short variable N-terminal random coil sequences of STIM1 and STIM2 confer profoundly different activation properties. Using Orai1-expressing HEK293 cells, chimeric replacement of the 43-amino-acid STIM1 N terminus with that of STIM2 attenuates Orai1-mediated Ca2+ entry and drastically slows store-induced Orai1 channel activation. Conversely, the 55-amino-acid STIM2 terminus substituted within STIM1 strikingly enhances both Orai1-mediated Ca2+ entry and constitutive coupling to activate Orai1 channels. Hence, STIM N termini are powerful coupling modifiers, functioning in STIM2 to "brake" the otherwise constitutive activation of Orai1 channels afforded by its high sensitivity to luminal Ca2+.	[Zhou, Yandong; Mancarella, Salvatore; Wang, Youjun; Yue, Chanyu; Ritchie, Michael; Gill, Donald L.; Soboloff, Jonathan] Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Gill, DL (corresponding author), Temple Univ, Sch Med, Dept Biochem, 3400 N Broad St, Philadelphia, PA 19140 USA.	dgill@temple.edu; soboloff@temple.edu	Yue, Chanyu/H-1792-2015; Wang, Youjun/H-4016-2013; Soboloff, Jonathan/I-6995-2012	Wang, Youjun/0000-0003-0961-1716; Soboloff, Jonathan/0000-0001-5192-1297	Pennsylvania Department of Health; American Heart Association [0730184N]; National Institutes of Health [AI058173]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058173] Funding Source: NIH RePORTER	Pennsylvania Department of Health; American Heart Association(American Heart Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grants from the Pennsylvania Department of Health ( to J. S.), American Heart Association Grant 0730184N ( to J. S.), and National Institutes of Health Grant AI058173 ( to D. L. G.).	Brandman O, 2007, CELL, V131, P1327, DOI 10.1016/j.cell.2007.11.039; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Hewavitharana T, 2008, J BIOL CHEM, V283, P26252, DOI 10.1074/jbc.M802239200; Hewavitharana T, 2007, CELL CALCIUM, V42, P173, DOI 10.1016/j.ceca.2007.03.009; Hogan PG, 2007, TRENDS BIOCHEM SCI, V32, P235, DOI 10.1016/j.tibs.2007.03.009; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Li ZZ, 2007, J BIOL CHEM, V282, P29448, DOI 10.1074/jbc.M703573200; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Luik RM, 2007, TRENDS MOL MED, V13, P103, DOI 10.1016/j.molmed.2007.01.004; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Muik M, 2009, J BIOL CHEM, V284, P8421, DOI 10.1074/jbc.C800229200; Oh-Hora M, 2008, NAT IMMUNOL, V9, P432, DOI 10.1038/ni1574; Park CY, 2009, CELL, V136, P876, DOI 10.1016/j.cell.2009.02.014; Parvez S, 2008, FASEB J, V22, P752, DOI 10.1096/fj.07-9449com; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Soboloff J, 2005, J BIOL CHEM, V280, P39786, DOI 10.1074/jbc.M506064200; Soboloff J, 2006, CURR BIOL, V16, P1465, DOI 10.1016/j.cub.2006.05.051; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Stathopulos PB, 2008, CELL, V135, P110, DOI 10.1016/j.cell.2008.08.006; Stathopulos PB, 2006, J BIOL CHEM, V281, P35855, DOI 10.1074/jbc.M608247200; Stathopulos PB, 2009, J BIOL CHEM, V284, P728, DOI 10.1074/jbc.C800178200; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Wang YJ, 2009, P NATL ACAD SCI USA, V106, P7391, DOI 10.1073/pnas.0900293106; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; Yuan JP, 2009, NAT CELL BIOL, V11, P337, DOI 10.1038/ncb1842; Zhang SYL, 2008, J BIOL CHEM, V283, P17662, DOI 10.1074/jbc.M801536200; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zheng L, 2008, BIOCHEM BIOPH RES CO, V369, P240, DOI 10.1016/j.bbrc.2007.12.129	29	87	90	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19164	19168		10.1074/jbc.C109.010900	http://dx.doi.org/10.1074/jbc.C109.010900			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19487696	Green Published, hybrid			2022-12-25	WOS:000267908300003
J	Meitzler, JL; de Montellano, PRO				Meitzler, Jennifer L.; de Montellano, Paul R. Ortiz			Caenorhabditis elegans and Human Dual Oxidase 1 (DUOX1) "Peroxidase" Domains INSIGHTS INTO HEME BINDING AND CATALYTIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN COVALENT BONDS; RESPIRATORY-TRACT EPITHELIUM; CYTOCHROME-C PEROXIDASE; FAMILY NADPH OXIDASES; HORSERADISH-PEROXIDASE; MAMMALIAN PEROXIDASES; THYROID PEROXIDASE; HOST-DEFENSE; CONGENITAL HYPOTHYROIDISM; ANGSTROM RESOLUTION	The seven members of the NOX/DUOX family are responsible for generation of the superoxide and H2O2 required for a variety of host defense and cell signaling functions in nonphagocytic cells. Two members, the dual oxidase isozymes DUOX1 and DUOX2, share a structurally unique feature: an N-terminal peroxidase-like domain. Despite sequence similarity to the mammalian peroxidases, the absence of key active site residues makes their binding of heme and their catalytic function uncertain. To explore this domain we have expressed in a baculovirus system and purified the Caenorhabditis elegans CeDUOX1(1-589)) and human hDUOX1(1-593)) DUOX1 "peroxidase" domains. Evaluation of these proteins demonstrated that the isolated hDUOX1(1-593) does not bind heme and has no intrinsic peroxidase activity. In contrast, CeDUOX1(1-589) binds heme covalently, exhibits a modest peroxidase activity, but does not oxidize bromide ion. Surprisingly, the heme appears to have two covalent links to the protein despite the absence of a second conserved carboxyl group in the active site. Although the N-terminal dual oxidase motif has been proposed to directly convert superoxide to H2O2, neither DUOX1 domain demonstrated significant superoxide dismutase activity. These results strengthen the in vivo conclusion that the CeDUOX1 protein supports controlled peroxidative polymerization of tyrosine residues and indicate that the hDUOX1 protein either has a unique function or must interact with other protein factors to express its catalytic activity.	[Meitzler, Jennifer L.; de Montellano, Paul R. Ortiz] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 600 16th St, San Francisco, CA 94158 USA.	ortiz@cgl.ucsf.edu		Meitzler, Jennifer/0000-0001-9798-2124	National Institutes of Health [GM32488]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant GM32488.	Andersson LA, 1996, J BIOL CHEM, V271, P3406, DOI 10.1074/jbc.271.7.3406; Babior B M, 1995, Curr Opin Hematol, V2, P55; BANGA JP, 1990, FEBS LETT, V266, P133, DOI 10.1016/0014-5793(90)81524-R; BASILE G, 1980, J BIOL CHEM, V255, P7181; Boscolo B, 2007, BBA-PROTEINS PROTEOM, V1774, P1164, DOI 10.1016/j.bbapap.2007.07.003; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caillou B, 2001, J CLIN ENDOCR METAB, V86, P3351, DOI 10.1210/jc.86.7.3351; CHILDS RE, 1975, BIOCHEM J, V145, P93, DOI 10.1042/bj1450093; Colas C, 2004, J BIOL CHEM, V279, P24131, DOI 10.1074/jbc.M401687200; DE D, 2002, EXP CELL RES, V273, P187; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; DePillis GD, 1997, J BIOL CHEM, V272, P8857; DOLMAN D, 1968, BIOCHEMISTRY-US, V7, P3991, DOI 10.1021/bi00851a028; Donko A, 2005, PHILOS T R SOC B, V360, P2301, DOI 10.1098/rstb.2005.1767; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; El Hassani RA, 2005, AM J PHYSIOL-GASTR L, V288, pG933, DOI 10.1152/ajpgi.00198.2004; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; Fiedler TJ, 2000, J BIOL CHEM, V275, P11964, DOI 10.1074/jbc.275.16.11964; FOLZ RJ, 1994, GENOMICS, V22, P162, DOI 10.1006/geno.1994.1357; Franzen S, 2006, BIOCHEMISTRY-US, V45, P9085, DOI 10.1021/bi060020z; Geiszt M, 2003, FASEB J, V17, P1502, DOI 10.1096/fj.02-1104fje; Grandvaux N, 2007, BIOCHIMIE, V89, P1113, DOI 10.1016/j.biochi.2007.04.008; Grasberger H, 2006, J BIOL CHEM, V281, P18269, DOI 10.1074/jbc.C600095200; Harper RW, 2006, FEBS LETT, V580, P5150, DOI 10.1016/j.febslet.2006.08.048; Harper RW, 2005, FEBS LETT, V579, P4911, DOI 10.1016/j.febslet.2005.08.002; Hildebrandt A G, 1978, Methods Enzymol, V52, P342; Howes BD, 1997, BIOCHEMISTRY-US, V36, P1532, DOI 10.1021/bi962502o; Huang LS, 2006, J BIOL CHEM, V281, P18983, DOI 10.1074/jbc.M602307200; Huang LS, 2006, ARCH BIOCHEM BIOPHYS, V446, P77, DOI 10.1016/j.abb.2005.11.011; Johnson KR, 2007, MOL ENDOCRINOL, V21, P1593, DOI 10.1210/me.2007-0085; Krause KH, 2004, JPN J INFECT DIS, V57, pS28; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Leto TL, 2006, ANTIOXID REDOX SIGN, V8, P1549, DOI 10.1089/ars.2006.8.1549; Lockney D, 2006, J PHYS CHEM B, V110, P24165, DOI 10.1021/jp0641233; Luxen S, 2008, CANCER RES, V68, P1037, DOI 10.1158/0008-5472.CAN-07-5782; Morand S, 2009, FASEB J, V23, P1205, DOI 10.1096/fj.08-120006; Moreno JC, 2002, NEW ENGL J MED, V347, P95, DOI 10.1056/NEJMoa012752; Newmyer SL, 1996, J BIOL CHEM, V271, P14891, DOI 10.1074/jbc.271.25.14891; OHTAKI S, 1985, J BIOL CHEM, V260, P441; Ohye H, 2008, THYROID, V18, P561, DOI 10.1089/thy.2007.0258; Pacquelet S, 2008, J BIOL CHEM, V283, P24649, DOI 10.1074/jbc.M709108200; Palamakumbura AH, 1999, BIOCHEMISTRY-US, V38, P15653, DOI 10.1021/bi991498o; Peskin AV, 2000, CLIN CHIM ACTA, V293, P157, DOI 10.1016/S0009-8981(99)00246-6; POCIOT F, 1993, DIS MARKERS, V11, P267, DOI 10.1155/1993/678310; Potter SZ, 2007, J AM CHEM SOC, V129, P4575, DOI 10.1021/ja066690+; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Rokutan K, 2008, SEMIN IMMUNOPATHOL, V30, P315, DOI 10.1007/s00281-008-0124-5; Shao MXG, 2005, P NATL ACAD SCI USA, V102, P767, DOI 10.1073/pnas.0408932102; Shin K, 2001, BIOCHEM BIOPH RES CO, V281, P1024, DOI 10.1006/bbrc.2001.4448; Singh AK, 2008, J MOL BIOL, V376, P1060, DOI 10.1016/j.jmb.2007.12.012; STUGARD CE, 1989, INFECT IMMUN, V57, P3534, DOI 10.1128/IAI.57.11.3534-3539.1989; Tanaka T, 2003, BIOSCI BIOTECH BIOCH, V67, P2254, DOI 10.1271/bbb.67.2254; TAUROG A, 1991, ARCH BIOCHEM BIOPHYS, V287, P288, DOI 10.1016/0003-9861(91)90481-W; THONYMEYER L, 1994, BBA-BIOENERGETICS, V1187, P260, DOI 10.1016/0005-2728(94)90123-6; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; Wesley UV, 2007, J BIOL CHEM, V282, P3213, DOI 10.1074/jbc.M606533200; Xie ZY, 1996, J BIOL CHEM, V271, P4632; Zederbauer M, 2007, NAT PROD REP, V24, P571, DOI 10.1039/b604178g; Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X; Zhou JY, 2006, J PHARMACEUT BIOMED, V40, P1143, DOI 10.1016/j.jpba.2005.09.022	62	65	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18634	18643		10.1074/jbc.M109.013581	http://dx.doi.org/10.1074/jbc.M109.013581			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19460756	Green Published, hybrid			2022-12-25	WOS:000267711500012
J	Wolyniec, K; Wotton, S; Kilbey, A; Jenkins, A; Terry, A; Peters, G; Stocking, C; Cameron, E; Neil, JC				Wolyniec, K.; Wotton, S.; Kilbey, A.; Jenkins, A.; Terry, A.; Peters, G.; Stocking, C.; Cameron, E.; Neil, J. C.			RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress	ONCOGENE			English	Article						RUNX1; RUNX1-ETO; premature senescence	ONCOGENE-INDUCED SENESCENCE; ACUTE MYELOID-LEUKEMIA; CELLULAR SENESCENCE; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; MURINE FIBROBLASTS; TUMOR-SUPPRESSOR; PROTEIN-KINASE; RAS; P53	A role for the RUNX genes in cancer fail-safe processes has been suggested by their induction of senescence-like growth arrest in primary murine. broblasts and the failure of RAS-induced senescence in Runx2-deficient cells. We now show that RUNX1 induces senescence in human primary. broblasts. High-affinity DNA binding is necessary but not sufficient, as shown by the functional attenuation of the truncated RUNX1/AML1a isoform and the TEL-RUNX1 fusion oncoprotein. However, a similar phenotype was potently induced by the RUNX1-ETO (AML1-ETO) oncoprotein, despite its dominant-negative potential. A detailed comparison of H-RAS(V12), RUNX1 and RUNX1-ETO senescent phenotypes showed that the RUNX effectors induce earlier growth stasis with only low levels of DNA damage signaling and a lack of chromatin condensation, a marker of irreversible growth arrest. In human. broblasts, all effectors induced p53 in the absence of detectable p14(Arf), whereas only RUNX1-ETO induced senescence in p16(Ink4a)-null cells. Correlation was noted between induction of p53, reactive oxygen species and phospho-p38, whereas p38(MAPK) inhibition rescued cell growth markedly. These findings indicate a role for replication-independent pathways in RUNX and RUNX1-ETO senescence, and show that the context-specific oncogenic activity of RUNX1 fusion proteins is mirrored in their distinctive interactions with fail-safe responses. Oncogene ( 2009) 28, 2502-2512; doi: 10.1038/onc.2009.101; published online 18 May 2009	[Wolyniec, K.; Wotton, S.; Kilbey, A.; Jenkins, A.; Terry, A.; Cameron, E.; Neil, J. C.] Univ Glasgow, Inst Comparat Med, Fac Vet Med, Oncol Mol Lab, Glasgow G61 1QH, Lanark, Scotland; [Stocking, C.] Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-2000 Hamburg, Germany; [Peters, G.] London Res Inst, Lincolns Inn Fields Labs, London, England	University of Glasgow; Heinrich Pette Institute; University of Hamburg	Neil, JC (corresponding author), Univ Glasgow, Inst Comparat Med, Fac Vet Med, Oncol Mol Lab, Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.	J.C.Neil@vet.gla.ac.uk			Cancer Research UK; Leukemia Research Fund	Cancer Research UK(Cancer Research UK); Leukemia Research Fund	Primary support for this work was provided by Cancer Research UK and the Leukemia Research Fund. We thank Janice Rowe for excellent technical assistance and Scott Hiebert (Vanderbilt University) for generous supply of reagents and useful discussions.	Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bernardin F, 2002, CANCER RES, V62, P3904; Blyth K, 2006, CANCER RES, V66, P2195, DOI 10.1158/0008-5472.CAN-05-3558; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Cammenga J, 2007, CANCER RES, V67, P537, DOI 10.1158/0008-5472.CAN-06-1903; Colavitti R, 2005, IUBMB LIFE, V57, P277, DOI 10.1080/15216540500091890; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Kilbey A, 2008, CELL CYCLE, V7, P2333; Kilbey A, 2007, CANCER RES, V67, P11263, DOI 10.1158/0008-5472.CAN-07-3016; Krejci O, 2008, BLOOD, V111, P2190, DOI 10.1182/blood-2007-06-093682; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; LENNY N, 1995, ONCOGENE, V11, P1761; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Motoda L, 2007, STEM CELLS, V25, P2976, DOI 10.1634/stemcells.2007-0061; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Peterson LF, 2007, BLOOD, V109, P4392, DOI 10.1182/blood-2006-03-012575; Robinson KA, 1999, J NEUROSCI RES, V55, P724, DOI 10.1002/(SICI)1097-4547(19990315)55:6<724::AID-JNR7>3.3.CO;2-0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Swantek D, 2004, DEVELOPMENT, V131, P2281, DOI 10.1242/dev.01109; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tsuzuki S, 2007, PLOS MED, V4, P880, DOI 10.1371/journal.pmed.0040172; Viale A, 2009, NATURE, V457, P51, DOI 10.1038/nature07618; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Wotton S, 2008, ONCOGENE, V27, P5856, DOI 10.1038/onc.2008.195; Wotton SF, 2004, ONCOGENE, V23, P5476, DOI 10.1038/sj.onc.1207729; Zaidi SK, 2007, P NATL ACAD SCI USA, V104, P19861, DOI 10.1073/pnas.0709650104; Zhang RG, 2007, MOL CELL BIOL, V27, P2343, DOI 10.1128/MCB.02019-06	40	28	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2502	2512		10.1038/onc.2009.101	http://dx.doi.org/10.1038/onc.2009.101			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448675	Green Accepted			2022-12-25	WOS:000267806800003
J	de Nooijer, S; Holland, BR; Penny, D				de Nooijer, Silvester; Holland, Barbara R.; Penny, David			The Emergence of Predators in Early Life: There was No Garden of Eden	PLOS ONE			English	Article							COPES RULE; EVOLUTION; ORIGIN; CELLS; CLASSIFICATION; MITOCHONDRIA; HYPOTHESIS; SIZE	Background: Eukaryote cells are suggested to arise somewhere between 0.85 similar to 2.7 billion years ago. However, in the present world of unicellular organisms, cells that derive their food and metabolic energy from larger cells engulfing smaller cells (phagocytosis) are almost exclusively eukaryotic. Combining these propositions, that eukaryotes were the first phagocytotic predators and that they arose only 0.85 similar to 2.7 billion years ago, leads to an unexpected prediction of a long period (similar to 1-3 billion years) with no phagocytotes - a veritable Garden of Eden. Methodology: We test whether such a long period is reasonable by simulating a population of very simple unicellular organisms - given only basic physical, biological and ecological principles. Under a wide range of initial conditions, cellular specialization occurs early in evolution; we find a range of cell types from small specialized primary producers to larger opportunistic or specialized predators. Conclusions: Both strategies, specialized smaller cells and phagocytotic larger cells are apparently fundamental biological strategies that are expected to arise early in cellular evolution. Such early predators could have been 'prokaryotes', but if the earliest cells on the eukaryote lineage were predators then this explains most of their characteristic features.			de Nooijer, S (corresponding author), Massey Univ, Allan Wilson Ctr Mol Ecol & Evolut, Palmerston North, New Zealand.	d.penny@massey.ac.nz	Holland, Barbara/G-1646-2013; Penny, David/E-9410-2011	Holland, Barbara/0000-0002-4628-7938; 				Alroy J, 1998, SCIENCE, V280, P731, DOI 10.1126/science.280.5364.731; Bengtson Stefan, 2002, Paleontological Society Papers, V8, P289; Bidle KD, 2004, NAT REV MICROBIOL, V2, P643, DOI 10.1038/nrmicro956; BOERLIJST MC, 1991, PHYSICA D, V48, P17, DOI 10.1016/0167-2789(91)90049-F; Brandt H, 2006, P NATL ACAD SCI USA, V103, P495, DOI 10.1073/pnas.0507229103; Burtsev M, 2006, NATURE, V440, P1041, DOI 10.1038/nature04470; Cavalier-Smith T, 2002, INT J SYST EVOL MICR, V52, P297, DOI 10.1099/00207713-52-2-297; Ceulemans H, 2006, BIOESSAYS, V28, P316, DOI 10.1002/bies.20373; Collins L, 2005, MOL BIOL EVOL, V22, P1053, DOI 10.1093/molbev/msi091; Collins LJ, 2009, TRENDS GENET, V25, P120, DOI 10.1016/j.tig.2008.12.003; DAWKINS R, 1979, PROC R SOC SER B-BIO, V205, P489, DOI 10.1098/rspb.1979.0081; Embley TM, 2006, NATURE, V440, P623, DOI 10.1038/nature04546; Enquist BJ, 2003, NATURE, V423, P639, DOI 10.1038/nature01671; Forde SE, 2008, NATURE, V455, P220, DOI 10.1038/nature07152; Forterre P, 2006, P NATL ACAD SCI USA, V103, P3669, DOI 10.1073/pnas.0510333103; Gardner PP, 2003, P ROY SOC B-BIOL SCI, V270, P1177, DOI 10.1098/rspb.2003.2355; Guillard RR, 1977, BIOL DIATOMS, V13, P372; HANSEN B, 1994, LIMNOL OCEANOGR, V39, P395, DOI 10.4319/lo.1994.39.2.0395; Hedges SB, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-2; Hone DWE, 2005, TRENDS ECOL EVOL, V20, P4, DOI 10.1016/j.tree.2004.10.012; Irimia M, 2008, NUCLEIC ACIDS RES, V36, P1703, DOI 10.1093/nar/gkn012; Jeffares DC, 2006, TRENDS GENET, V22, P16, DOI 10.1016/j.tig.2005.10.006; JURKEVITCH E, 2007, MICROBE, V2, P67; Kerr B, 2002, NATURE, V418, P171, DOI 10.1038/nature00823; Koonin EV, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r7; Kurland CG, 2006, SCIENCE, V312, P1011, DOI 10.1126/science.1121674; Martin W, 2003, PHILOS T R SOC B, V358, P59, DOI 10.1098/rstb.2002.1183; Martin W, 1999, P ROY SOC B-BIOL SCI, V266, P1387, DOI 10.1098/rspb.1999.0792; MOROWITZ HJ, 1968, ENERGY FLOW BIOL BIO, DOI DOI 10.1126/SCIENCE.164.3880.683-A; Nowak MA, 2005, NATURE, V437, P1291, DOI 10.1038/nature04131; Ohtsuki H, 2006, NATURE, V441, P502, DOI 10.1038/nature04605; Penny D, 1999, CURR OPIN GENET DEV, V9, P672, DOI 10.1016/S0959-437X(99)00020-9; PENNY D, 1982, J THEOR BIOL, V96, P129, DOI 10.1016/0022-5193(82)90216-8; Poole AM, 2003, BIOSYSTEMS, V69, P163, DOI 10.1016/S0303-2647(02)00131-4; Poole AM, 2007, BIOESSAYS, V29, P74, DOI 10.1002/bies.20516; Scheffer M, 2006, P NATL ACAD SCI USA, V103, P6230, DOI 10.1073/pnas.0508024103; Schoener TW, 2001, NATURE, V412, P183, DOI 10.1038/35084071; Szabo P, 2002, NATURE, V420, P340, DOI 10.1038/nature01187; West GB, 2002, P NATL ACAD SCI USA, V99, P2473, DOI 10.1073/pnas.012579799; Woodhams MD, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-S1-S13	40	11	12	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2009	4	6							e5507	10.1371/journal.pone.0005507	http://dx.doi.org/10.1371/journal.pone.0005507			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453PV	19492046	Green Published, Green Submitted, gold			2022-12-25	WOS:000266624300001
J	Karaulanov, E; Bottcher, RT; Stannek, P; Wu, W; Rau, M; Ogata, S; Cho, KWY; Niehrs, C				Karaulanov, Emil; Boettcher, Ralph T.; Stannek, Peter; Wu, Wei; Rau, Marlene; Ogata, Souichi; Cho, Ken W. Y.; Niehrs, Christof			Unc5B Interacts with FLRT3 and Rnd1 to Modulate Cell Adhesion in Xenopus Embryos	PLOS ONE			English	Article								The FLRT family of transmembrane proteins has been implicated in the regulation of FGF signalling, neurite outgrowth, homotypic cell sorting and cadherin-mediated adhesion. In an expression screen we identified the Netrin receptors Unc5B and Unc5D as high-affinity FLRT3 interactors. Upon overexpression, Unc5B phenocopies FLRT3 and both proteins synergize in inducing cell deadhesion in Xenopus embryos. Morpholino knock-downs of Unc5B and FLRT3 synergistically affect Xenopus development and induce morphogenetic defects. The small GTPase Rnd1, which transmits FLRT3 deadhesion activity, physically and functionally interacts with Unc5B, and mediates its effect on cell adhesion. The results suggest that FLRT3, Unc5B and Rnd1 proteins interact to modulate cell adhesion in early Xenopus development.			Karaulanov, E (corresponding author), German Canc Res Ctr, DKFZ ZMBH Alliance, Div Mol Embryol, D-6900 Heidelberg, Germany.	niehrs@dkfz-heidelberg.de						Aoki J, 2000, BIOCHEM BIOPH RES CO, V278, P604, DOI 10.1006/bbrc.2000.3842; Arakawa H, 2005, CELL DEATH DIFFER, V12, P1057, DOI 10.1038/sj.cdd.4401601; Bottcher RT, 2004, NAT CELL BIOL, V6, P38, DOI 10.1038/ncb1082; Chardin P, 2006, NAT REV MOL CELL BIO, V7, P54, DOI 10.1038/nrm1788; Egea J, 2008, GENE DEV, V22, P3349, DOI 10.1101/gad.486708; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hammerschmidt M, 2008, DEVELOPMENT, V135, P3625, DOI 10.1242/dev.015701; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Kamachi Y, 2008, GENESIS, V46, P1, DOI 10.1002/dvg.20361; Karaulanov EE, 2006, EMBO REP, V7, P283, DOI 10.1038/sj.embor.7400614; Kuhl M, 1996, DEV DYNAM, V207, P121, DOI 10.1002/(SICI)1097-0177(199610)207:2<121::AID-AJA1>3.0.CO;2-J; Lacy SE, 1999, GENOMICS, V62, P417, DOI 10.1006/geno.1999.6033; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; Lu XW, 2004, NATURE, V432, P179, DOI 10.1038/nature03080; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Maretto S, 2008, DEV BIOL, V318, P184, DOI 10.1016/j.ydbio.2008.03.021; Navankasattusas S, 2008, DEVELOPMENT, V135, P659, DOI 10.1242/dev.013623; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Ogata S, 2007, GENE DEV, V21, P1817, DOI 10.1101/gad.1541807; Robinson M, 2004, MOL CELL NEUROSCI, V27, P202, DOI 10.1016/j.mcn.2004.06.008; Solnica-Krezel L, 2006, CURR OPIN GENET DEV, V16, P433, DOI 10.1016/j.gde.2006.06.009; Tsuji L, 2004, BIOCHEM BIOPH RES CO, V313, P1086, DOI 10.1016/j.bbrc.2003.12.047	24	40	46	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5742	10.1371/journal.pone.0005742	http://dx.doi.org/10.1371/journal.pone.0005742			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451SH	19492039	Green Submitted, gold, Green Published			2022-12-25	WOS:000266490000016
J	Alipour, M; Suntres, ZE; Halwani, M; Azghani, AO; Omri, A				Alipour, Misagh; Suntres, Zacharias E.; Halwani, Majed; Azghani, Ali O.; Omri, Abdelwahab			Activity and Interactions of Liposomal Antibiotics in Presence of Polyanions and Sputum of Patients with Cystic Fibrosis	PLOS ONE			English	Article								Background: To compare the effectiveness of liposomal tobramycin or polymyxin B against Pseudomonas aeruginosa in the Cystic Fibrosis (CF) sputum and its inhibition by common polyanionic components such as DNA, F-actin, lipopolysaccharides (LPS), and lipoteichoic acid (LTA). Methodology: Liposomal formulations were prepared from a mixture of 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC) or 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC) and Cholesterol (Chol), respectively. Stability of the formulations in different biological milieus and antibacterial activities compared to conventional forms in the presence of the aforementioned inhibitory factors or CF sputum were evaluated. Results: The formulations were stable in all conditions tested with no significant differences compared to the controls. Inhibition of antibiotic formulations by DNA/F-actin and LPS/LTA was concentration dependent. DNA/F-actin (125 to 1000 mg/L) and LPS/LTA (1 to 1000 mg/L) inhibited conventional tobramycin bioactivity, whereas, liposome-entrapped tobramycin was inhibited at higher concentrations - DNA/F-actin (500 to 1000 mg/L) and LPS/LTA (100 to 1000 mg/L). Neither polymyxin B formulation was inactivated by DNA/F-actin, but LPS/LTA (1 to 1000 mg/L) inhibited the drug in conventional form completely and higher concentrations of the inhibitors (100 to 1000 mg/L) was required to inhibit the liposome-entrapped polymyxin B. Co-incubation with inhibitory factors (1000 mg/L) increased conventional (16-fold) and liposomal (4-fold) tobramycin minimum bactericidal concentrations (MBCs), while both polymyxin B formulations were inhibited 64-fold. Conclusions: Liposome-entrapment reduced antibiotic inhibition up to 100-fold and the CFU of endogenous P. aeruginosa in sputum by 4-fold compared to the conventional antibiotic, suggesting their potential applications in CF lung infections.			Alipour, M (corresponding author), Laurentian Univ, Dept Chem & Biochem, Novel Drug & Vaccine Delivery Syst Facil, Sudbury, ON P3E 2C6, Canada.	aomri@laurentian.ca	Azghani, Ali/GNW-5689-2022; Omri, Abdelwahab/G-3172-2010	Azghani, Ali/0000-0002-7626-5967; Omri, Abdelwahab/0000-0002-4093-5762; Halwani, Majed/0000-0002-2192-3264				Alipour M, 2008, INT J PHARM, V355, P293, DOI 10.1016/j.ijpharm.2007.11.035; Allison SD, 2007, J INFUS MURS, V30, P89, DOI 10.1097/01.NAN.0000264712.26219.67; BATAILLON V, 1992, J ANTIMICROB CHEMOTH, V29, P499, DOI 10.1093/jac/29.5.499; Boyle MP, 2007, JAMA-J AM MED ASSOC, V298, P1787, DOI 10.1001/jama.298.15.1787; Broughton-Head VJ, 2007, PULM PHARMACOL THER, V20, P708, DOI 10.1016/j.pupt.2006.08.008; Bucki R, 2007, EUR RESPIR J, V29, P624, DOI 10.1183/09031936.00080806; Bucki R, 2007, J ANTIMICROB CHEMOTH, V60, P535, DOI 10.1093/jac/dkm218; Cannella CA, 2006, AM J HEALTH-SYST PH, V63, P1858, DOI 10.2146/ajhp060196; Ceri H, 1999, J CLIN MICROBIOL, V37, P1771, DOI 10.1128/JCM.37.6.1771-1776.1999; Chuchalin Alexander, 2007, Paediatr Drugs, V9 Suppl 1, P21, DOI 10.2165/00148581-200709001-00004; Courtney J M, 2004, J Cyst Fibros, V3, P223, DOI 10.1016/j.jcf.2004.06.006; Davies JC, 2007, SEMIN RESP CRIT CARE, V28, P312, DOI 10.1055/s-2007-981652; DAVIES M, 1978, BIOCHIM BIOPHYS ACTA, V508, P260, DOI 10.1016/0005-2736(78)90329-2; DAVIS SD, 1978, AM REV RESPIR DIS, V117, P176; Driscoll JA, 2007, DRUGS, V67, P351, DOI 10.2165/00003495-200767030-00003; Eisenberg J, 1997, CHEST, V111, P955, DOI 10.1378/chest.111.4.955; Elizur A, 2008, CHEST, V133, P489, DOI 10.1378/chest.07-1631; Fabretti F, 2006, INFECT IMMUN, V74, P4164, DOI 10.1128/IAI.00111-06; Falagas ME, 2005, CLIN INFECT DIS, V40, P1333, DOI 10.1086/429323; Fernandes B, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006682.pub2; Geller DE, 2007, PEDIATR PULM, V42, P307, DOI 10.1002/ppul.20594; Govan J, 2002, HOSP MED, V63, P421, DOI 10.12968/hosp.2002.63.7.1987; Halwani M, 2007, J ANTIMICROB CHEMOTH, V60, P760, DOI 10.1093/jac/dkm289; Hancock R E, 2001, Lancet Infect Dis, V1, P156, DOI 10.1016/S1473-3099(01)00092-5; Hermann T, 2007, CELL MOL LIFE SCI, V64, P1841, DOI 10.1007/s00018-007-7034-x; Hodson ME, 2002, EUR RESPIR J, V20, P658, DOI 10.1183/09031936.02.00248102; Horianopoulou M, 2005, J CHEMOTHERAPY, V17, P536, DOI 10.1179/joc.2005.17.5.536; HUNT BE, 1995, ANTIMICROB AGENTS CH, V39, P34, DOI 10.1128/AAC.39.1.34; Iredell JR, 2007, SEMIN RESP CRIT CARE, V28, P656, DOI 10.1055/s-2007-996412; Kater A, 2007, ANN NY ACAD SCI, V1112, P140, DOI 10.1196/annals.1415.006; Kaye D, 2004, INFECT DIS CLIN N AM, V18, P669, DOI 10.1016/j.idc.2004.04.007; Kharitonov Sergei A., 2007, V14, P83, DOI 10.1159/000107056; Kirov SM, 2007, MICROBIOL-SGM, V153, P3264, DOI 10.1099/mic.0.2007/009092-0; Lahiri T, 2007, CLIN CHEST MED, V28, P307, DOI 10.1016/j.ccm.2007.02.003; Landry RM, 2006, MOL MICROBIOL, V59, P142, DOI 10.1111/j.1365-2958.2005.04941.x; Lenoir Gerard, 2007, Paediatr Drugs, V9 Suppl 1, P11, DOI 10.2165/00148581-200709001-00003; LETHEM MI, 1990, EUR RESPIR J, V3, P19; LEVY J, 1983, J INFECT DIS, V148, P1069, DOI 10.1093/infdis/148.6.1069; Macfarlane ELA, 1999, MOL MICROBIOL, V34, P305, DOI 10.1046/j.1365-2958.1999.01600.x; MARSHALL AJH, 1994, J ANTIMICROB CHEMOTH, V34, P465, DOI 10.1093/jac/34.4.465; Meers P, 2008, J ANTIMICROB CHEMOTH, V61, P859, DOI 10.1093/jac/dkn059; Merlo CA, 2007, CHEST, V132, P562, DOI 10.1378/chest.06-2888; Mozafari MR, 2006, J SCI FOOD AGR, V86, P2038, DOI 10.1002/jsfa.2576; Mozafari MR, 2008, J LIPOSOME RES, V18, P309, DOI [10.1080/08982100802465941 , 10.1080/08982100802465941]; Mugabe C, 2006, INT J PHARMACEUT, V307, P244, DOI 10.1016/j.ijpharm.2005.10.005; Mugabe C, 2006, ANTIMICROB AGENTS CH, V50, P2016, DOI 10.1128/AAC.01547-05; Murray TS, 2007, CURR OPIN PEDIATR, V19, P83, DOI 10.1097/MOP.0b013e3280123a5d; NICAS TI, 1980, J BACTERIOL, V143, P872, DOI 10.1128/JB.143.2.872-878.1980; Omri A, 2002, BIOCHEM PHARMACOL, V64, P1407, DOI 10.1016/S0006-2952(02)01346-1; POTTER JL, 1965, PEDIATRICS, V36, P714; RAMPHAL R, 1988, J ANTIMICROB CHEMOTH, V22, P483, DOI 10.1093/jac/22.4.483; Remmington T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005405; Rogan MP, 2004, J INFECT DIS, V190, P1245, DOI 10.1086/423821; Sagel Scott D, 2007, Proc Am Thorac Soc, V4, P406, DOI 10.1513/pats.200703-044BR; Sanders NN, 2000, AM J RESP CRIT CARE, V162, P1905, DOI 10.1164/ajrccm.162.5.9909009; Sanders NN, 2002, PHARMACEUT RES, V19, P451, DOI 10.1023/A:1015139527747; Sanders NN, 2001, AM J RESP CRIT CARE, V164, P486, DOI 10.1164/ajrccm.164.3.2011041; Schiffelers R, 2001, J ANTIMICROB CHEMOTH, V48, P333, DOI 10.1093/jac/48.3.333; Sobieszczyk ME, 2004, J ANTIMICROB CHEMOTH, V54, P566, DOI 10.1093/jac/dkh369; SOMEYA A, 1979, J ANTIBIOT, V32, P156, DOI 10.7164/antibiotics.32.156; Son MS, 2007, INFECT IMMUN, V75, P5313, DOI 10.1128/IAI.01807-06; Stern M, 1998, GENE THER, V5, P91, DOI 10.1038/sj.gt.3300556; Swan SK, 1997, SEMIN NEPHROL, V17, P27; Tang JX, 2005, AM J PHYSIOL-LUNG C, V289, pL599, DOI 10.1152/ajplung.00061.2005; Touw DJ, 2007, J CYST FIBROS, V6, P327, DOI 10.1016/j.jcf.2006.12.007; VASCONCELLOS CA, 1994, SCIENCE, V263, P969, DOI 10.1126/science.8310295; Walker TS, 2005, INFECT IMMUN, V73, P3693, DOI 10.1128/IAI.73.6.3693-3701.2005; Weiner DJ, 2003, AM J RESP CELL MOL, V28, P738, DOI 10.1165/rcmb.2002-0191OC; Westerman EM, 2007, J CYST FIBROS, V6, P284, DOI 10.1016/j.jcf.2006.10.010; Zavascki AP, 2007, J ANTIMICROB CHEMOTH, V60, P1206, DOI 10.1093/jac/dkm357	70	52	54	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2009	4	5							e5724	10.1371/journal.pone.0005724	http://dx.doi.org/10.1371/journal.pone.0005724			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QE	19479000	gold, Green Published, Green Submitted			2022-12-25	WOS:000266415100015
J	Newman, SH; Iverson, SA; Takekawa, JY; Gilbert, M; Prosser, DJ; Batbayar, N; Natsagdorj, T; Douglas, DC				Newman, Scott H.; Iverson, Samuel A.; Takekawa, John Y.; Gilbert, Martin; Prosser, Diann J.; Batbayar, Nyambyar; Natsagdorj, Tseveenmyadag; Douglas, David C.			Migration of Whooper Swans and Outbreaks of Highly Pathogenic Avian Influenza H5N1 Virus in Eastern Asia	PLOS ONE			English	Article							BIRDS; INFECTION; DUCKS	Evaluating the potential involvement of wild avifauna in the emergence of highly pathogenic avian influenza H5N1 (hereafter H5N1) requires detailed analyses of temporal and spatial relationships between wild bird movements and disease emergence. The death of wild swans (Cygnus spp.) has been the first indicator of the presence of H5N1 in various Asian and European countries; however their role in the geographic spread of the disease remains poorly understood. We marked 10 whooper swans (Cygnus cygnus) with GPS transmitters in northeastern Mongolia during autumn 2006 and tracked their migratory movements in relation to H5N1 outbreaks. The prevalence of H5N1 outbreaks among poultry in eastern Asia during 2003-2007 peaked during winter, concurrent with whooper swan movements into regions of high poultry density. However outbreaks involving poultry were detected year round, indicating disease perpetuation independent of migratory waterbird presence. In contrast, H5N1 outbreaks involving whooper swans, as well as other migratory waterbirds that succumbed to the disease in eastern Asia, tended to occur during seasons (late spring and summer) and in habitats (areas of natural vegetation) where their potential for contact with poultry is very low to nonexistent. Given what is known about the susceptibility of swans to H5N1, and on the basis of the chronology and rates of whooper swan migration movements, we conclude that although there is broad spatial overlap between whooper swan distributions and H5N1 outbreak locations in eastern Asia, the likelihood of direct transmission between these groups is extremely low. Thus, our data support the hypothesis that swans are best viewed as sentinel species, and moreover, that in eastern Asia, it is most likely that their infections occurred through contact with asymptomatic migratory hosts (e. g., wild ducks) at or near their breeding grounds.			Newman, SH (corresponding author), Food & Agr Org United Nations, Anim Prod & Hlth Div, Emergency Ctr Transboundary Anim Dis, EMPRES Wildlife Unit,Infect Dis Grp, Rome, Italy.	scott.newman@fao.org	Batbayar, Nyambayar/N-7066-2015; Batbayar, Nyambayar/N-3761-2019; Douglas, David C./AAU-1087-2021	Batbayar, Nyambayar/0000-0002-9138-9626; Batbayar, Nyambayar/0000-0002-9138-9626; Douglas, David C./0000-0003-0186-1104; Prosser, Diann/0000-0002-5251-1799; Gilbert, Martin/0000-0002-9930-4383				Albertsen JO, 2002, WATERBIRDS, V25, P74; Brown JD, 2008, EMERG INFECT DIS, V14, P136, DOI 10.3201/eid1401.070740; Brown JD, 2006, EMERG INFECT DIS, V12, P1663, DOI 10.3201/eid1211.060652; Chen H, 2005, NATURE, V436, P191, DOI 10.1038/nature03974; Chen HL, 2006, J VIROL, V80, P5976, DOI 10.1128/JVI.00110-06; *FAO, 2008, FAO EMPRES I DAT; *FAO, 2006, EMPRES WATCH EV HIGH; Gaidet N, 2007, EMERG INFECT DIS, V13, P626, DOI 10.3201/eid1304.061011; Gauthier-Clerc M, 2007, IBIS, V149, P202, DOI 10.1111/j.1474-919X.2007.00699.x; Gilbert M, 2007, AGR ECOSYST ENVIRON, V119, P409, DOI 10.1016/j.agee.2006.09.001; Gilbert M, 2006, EMERG INFECT DIS, V12, P1650, DOI 10.3201/eid1211.060223; Kalthoff D, 2008, EMERG INFECT DIS, V14, P1267, DOI 10.3201/eid1408.080078; Lee YJ, 2008, EMERG INFECT DIS, V14, P487, DOI 10.3201/eid1403.070767; Liu CM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000191; Liu J, 2005, SCIENCE, V309, P1206, DOI 10.1126/science.1115273; Mel'nikov Yuri I., 2006, P357; Munster VJ, 2007, PLOS PATHOG, V3, P630, DOI 10.1371/journal.ppat.0030061; MUZAFFAR SB, 2006, WATERBIRDS, V29, P243, DOI DOI 10.1675/1524-4695(2006)29[243:AIAEAE]2.0.CO;2; Nolet BA, 2002, J ANIM ECOL, V71, P979, DOI 10.1046/j.1365-2656.2002.00662.x; *OIE, 2008, UPD HIGHL PATH AV IN; Olsen B, 2006, SCIENCE, V312, P384, DOI 10.1126/science.1122438; Robinson Timothy P, 2007, Vet Ital, V43, P745; Sabirovic M, 2006, SITUATION ANAL OUTBR; Salzberg SL, 2007, EMERG INFECT DIS, V13, P713, DOI 10.3201/eid1305.070013; Spackman E, 2002, J CLIN MICROBIOL, V40, P3256, DOI 10.1128/JCM.40.9.3256-3260.2002; Sturm-Ramirez KM, 2005, J VIROL, V79, P11269, DOI 10.1128/JVI.79.17.11269-11279.2005; Syroechkovski EE, 2002, WATERBIRDS, V25, P100; Teifke JP, 2007, VET PATHOL, V44, P137, DOI 10.1354/vp.44-2-137; Terregino C, 2006, VET REC, V158, P491, DOI 10.1136/vr.158.14.491; van Gils JA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000184; Weber TP, 2007, EMERG INFECT DIS, V13, P1139, DOI 10.3201/eid1308.070319; Whitworth D., 2007, WILD BIRDS AVIAN INF; Yasue M, 2006, BIOSCIENCE, V56, P923, DOI 10.1641/0006-3568(2006)56[923:TEOHAI]2.0.CO;2; 2006, SCIENCE, V312, P1451	34	37	42	3	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2009	4	5							e5729	10.1371/journal.pone.0005729	http://dx.doi.org/10.1371/journal.pone.0005729			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QE	19479053	Green Submitted, Green Published, gold			2022-12-25	WOS:000266415100018
J	Yang, CS; Hoelzle, M; Disanza, A; Scita, G; Svitkina, T				Yang, Changsong; Hoelzle, Matthew; Disanza, Andrea; Scita, Giorgio; Svitkina, Tatyana			Coordination of Membrane and Actin Cytoskeleton Dynamics during Filopodia Protrusion	PLOS ONE			English	Article								Leading edge protrusion of migrating cells involves tightly coordinated changes in the plasma membrane and actin cytoskeleton. It remains unclear whether polymerizing actin filaments push and deform the membrane, or membrane deformation occurs independently and is subsequently stabilized by actin filaments. To address this question, we employed an ability of the membrane-binding I-BAR domain of IRSp53 to uncouple the membrane and actin dynamics and to induce filopodia in expressing cells. Using time-lapse imaging and electron microscopy of IRSp53-I-BAR-expressing B16F1 melanoma cells, we demonstrate that cells are not able to protrude or maintain durable long extensions without actin filaments in their interior, but I-BAR-dependent membrane deformation can create a small and transient space at filopodial tips that is subsequently filled with actin filaments. Moreover, the expressed I-BAR domain forms a submembranous coat that may structurally support these transient actin-free protrusions until they are further stabilized by the actin cytoskeleton. Actin filaments in the I-BAR-induced filopodia, in contrast to normal filopodia, do not have a uniform length, are less abundant, poorly bundled, and display erratic dynamics. Such unconventional structural organization and dynamics of actin in I-BAR-induced filopodia suggests that a typical bundle of parallel actin filaments is not necessary for generation and mechanical support of the highly asymmetric filopodial geometry. Together, our data suggest that actin filaments may not directly drive the protrusion, but only stabilize the space generated by the membrane deformation; yet, such stabilization is necessary for efficient protrusion.			Yang, CS (corresponding author), Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.	svitkina@sas.upenn.edu	Scita, Giorgio/J-9670-2012	Scita, Giorgio/0000-0001-7984-1889; Disanza, Andrea/0000-0001-5101-2907	NCRR NIH HHS [RR 22482, S10 RR022482] Funding Source: Medline; NIGMS NIH HHS [GM 70898, R01 GM070898] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR022482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070898] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bereiter-Hahn J, 2005, MED ENG PHYS, V27, P743, DOI 10.1016/j.medengphy.2005.04.021; Chhabra ES, 2007, NAT CELL BIOL, V9, P1110, DOI 10.1038/ncb1007-1110; Dawson JC, 2006, TRENDS CELL BIOL, V16, P493, DOI 10.1016/j.tcb.2006.08.004; Disanza A, 2006, NAT CELL BIOL, V8, P1337, DOI 10.1038/ncb1502; Doherty GJ, 2008, ANNU REV BIOPHYS, V37, P65, DOI 10.1146/annurev.biophys.37.032807.125912; Frost A, 2008, CELL, V132, P807, DOI 10.1016/j.cell.2007.12.041; Fujiwara T, 2000, BIOCHEM BIOPH RES CO, V271, P626, DOI 10.1006/bbrc.2000.2671; Itoh T, 2006, BBA-MOL CELL BIOL L, V1761, P897, DOI 10.1016/j.bbalip.2006.06.015; Krugmann S, 2001, CURR BIOL, V11, P1645, DOI 10.1016/S0960-9822(01)00506-1; Le Clainche C, 2008, PHYSIOL REV, V88, P489, DOI 10.1152/physrev.00021.2007; Lee SH, 2007, STRUCTURE, V15, P145, DOI 10.1016/j.str.2006.12.005; LEWIS AK, 1992, J CELL BIOL, V119, P1219, DOI 10.1083/jcb.119.5.1219; Lim KB, 2008, J BIOL CHEM, V283, P20454, DOI 10.1074/jbc.M710185200; Loitto VM, 2002, J LEUKOCYTE BIOL, V71, P212; Mallavarapu A, 1999, J CELL BIOL, V146, P1097, DOI 10.1083/jcb.146.5.1097; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Mattila PK, 2007, J CELL BIOL, V176, P953, DOI 10.1083/jcb.200609176; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Millard TH, 2005, EMBO J, V24, P240, DOI 10.1038/sj.emboj.7600535; Millard TH, 2007, J CELL SCI, V120, P1663, DOI 10.1242/jcs.001776; Nakagawa H, 2003, J CELL SCI, V116, P2577, DOI 10.1242/jcs.00462; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Saarikangas J, 2008, J CELL SCI, V121, P1444, DOI 10.1242/jcs.027466; Saarikangas J, 2009, CURR BIOL, V19, P95, DOI 10.1016/j.cub.2008.12.029; Scita G, 2008, TRENDS CELL BIOL, V18, P52, DOI 10.1016/j.tcb.2007.12.002; Small J V, 1988, Electron Microsc Rev, V1, P155; Small JV, 1999, MICROSC RES TECHNIQ, V47, P3; Suetsugu S, 2006, J BIOL CHEM, V281, P35347, DOI 10.1074/jbc.M606814200; Svitkina T, 2007, METHOD CELL BIOL, V79, P295, DOI 10.1016/S0091-679X(06)79012-4; Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174; SVITKINA TM, 2006, CELL BIOL LAB HDB, V3, P277; Weiss SM, 2009, CELL HOST MICROBE, V5, P244, DOI 10.1016/j.chom.2009.02.003; Yamagishi A, 2004, J BIOL CHEM, V279, P14929, DOI 10.1074/jbc.M309408200; Yang C, 2007, PLOS BIOL, V5, P2624, DOI 10.1371/journal.pbio.0050317	34	79	80	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2009	4	5							e5678	10.1371/journal.pone.0005678	http://dx.doi.org/10.1371/journal.pone.0005678			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LI	19479071	Green Published, Green Submitted, gold			2022-12-25	WOS:000266331700006
J	Granlund, I; Hall, M; Kieselbach, T; Schroder, WP				Granlund, Irene; Hall, Michael; Kieselbach, Thomas; Schroder, Wolfgang P.			Light Induced Changes in Protein Expression and Uniform Regulation of Transcription in the Thylakoid Lumen of Arabidopsis thaliana	PLOS ONE			English	Article								In plants oxygenic photosynthesis is performed by large protein complexes found in the thylakoid membranes of chloroplasts. The soluble thylakoid lumen space is a narrow and compressed region within the thylakoid membrane which contains 80-200 proteins. Because the thylakoid lumen proteins are in close proximity to the protein complexes of photosynthesis, it is reasonable to assume that the lumen proteins are highly influenced by the presence of light. To identify light regulated proteins in the thylakoid lumen of Arabidopsis thaliana we developed a faster thylakoid preparation and combined this with difference gel electrophoresis (DIGE) of dark-adapted and light-adapted lumen proteomes. The DIGE experiments revealed that 19 lumen proteins exhibit increased relative protein levels after eight hour light exposure. Among the proteins showing increased abundance were the PsbP and PsbQ subunits of Photosystem II, major plastocyanin and several other proteins of known or unknown function. In addition, co-expression analysis of publicly available transcriptomic data showed that the co-regulation of lumen protein expression is not limited to light but rather that lumen protein genes exhibit a high uniformity of expression. The large proportion of thylakoid lumen proteins displaying increased abundance in light-adapted plants, taken together with the observed uniform regulation of transcription, implies that the majority of thylakoid lumen proteins have functions that are related to photosynthetic activity. This is the first time that an analysis of the differences in protein level during a normal day/night cycle has been performed and it shows that even a normal cycle of light significantly influences the thylakoid lumen proteome. In this study we also show for the first time, using co-expression analysis, that the prevalent lumenal chloroplast proteins are very similarly regulated at the level of transcription.			Granlund, I (corresponding author), Swedish Univ Agr Sci, Dept Forest Genet & Plant Physiol, S-90183 Umea, Sweden.	wolfgang.schroder@chem.umu.se	Kieselbach, Thomas/O-6023-2015	Kieselbach, Thomas/0000-0001-5577-2938; Schroder, Wolfgang/0000-0001-9831-1533				Alban A, 2003, PROTEOMICS, V3, P36, DOI 10.1002/pmic.200390006; Aoki K, 2007, PLANT CELL PHYSIOL, V48, P381, DOI 10.1093/pcp/pcm013; Blasing OE, 2005, PLANT CELL, V17, P3257, DOI 10.1105/tpc.105.035261; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dodd AN, 2005, SCIENCE, V309, P630, DOI 10.1126/science.1115581; Fankhauser C, 2002, PLANTA, V216, P1, DOI 10.1007/s00425-002-0831-4; Fu A, 2007, P NATL ACAD SCI USA, V104, P15947, DOI 10.1073/pnas.0707851104; Harmer SL, 2000, SCIENCE, V290, P2110, DOI 10.1126/science.290.5499.2110; Hashimoto A, 1996, FEBS LETT, V391, P29; Ifuku K, 2005, PLANT PHYSIOL, V139, P1175, DOI 10.1104/pp.105.068643; Ishihara S, 2007, PLANT PHYSIOL, V145, P668, DOI 10.1104/pp.107.105866; Kapri-Pardes E, 2007, PLANT CELL, V19, P1039, DOI 10.1105/tpc.106.046573; Kieselbach T, 2003, PHOTOSYNTH RES, V78, P249, DOI 10.1023/B:PRES.0000006913.86689.f1; Kieselbach T, 1998, J BIOL CHEM, V273, P6710, DOI 10.1074/jbc.273.12.6710; Kovalenko IB, 2006, PHYS BIOL, V3, P121, DOI 10.1088/1478-3975/3/2/004; Lima A, 2006, P NATL ACAD SCI USA, V103, P12631, DOI 10.1073/pnas.0605452103; Lintala M, 2007, PLANT J, V49, P1041, DOI 10.1111/j.1365-313X.2006.03014.x; Manfield IW, 2006, NUCLEIC ACIDS RES, V34, pW504, DOI 10.1093/nar/gkl204; Melis A, 1999, TRENDS PLANT SCI, V4, P130, DOI 10.1016/S1360-1385(99)01387-4; Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286; Michael TP, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040014; Peltier JB, 2002, PLANT CELL, V14, P211, DOI 10.1105/tpc.010304; Pesaresi P, 2009, MOL PLANT, V2, P236, DOI 10.1093/mp/ssn041; Pfannschmidt T, 2001, PHYSIOL PLANTARUM, V112, P1, DOI 10.1034/j.1399-3054.2001.1120101.x; Plucken H, 2002, FEBS LETT, V532, P85, DOI 10.1016/S0014-5793(02)03634-7; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V972, P163; Saito K, 2008, TRENDS PLANT SCI, V13, P36, DOI 10.1016/j.tplants.2007.10.006; Schubert M, 2002, J BIOL CHEM, V277, P8354, DOI 10.1074/jbc.M108575200; Schutze K, 2008, PHYSIOL PLANTARUM, V133, P557, DOI 10.1111/j.1399-3054.2008.01118.x; Sirpio S, 2007, BIOCHEM J, V406, P415, DOI 10.1042/BJ20070460; Sun Q, 2009, NUCLEIC ACIDS RES, V37, pD969, DOI 10.1093/nar/gkn654; Sun XW, 2007, PLANT CELL, V19, P1347, DOI 10.1105/tpc.106.049510; THOMPSON WF, 1991, ANNU REV PLANT PHYS, V42, P423, DOI 10.1146/annurev.pp.42.060191.002231; Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133; VORST O, 1993, PLANT J, V4, P933, DOI 10.1046/j.1365-313X.1993.04060933.x; Westermeier R, 2002, PROTEOMICS PRACTICE; Winter D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000718; Yi XP, 2006, J BIOL CHEM, V281, P26260, DOI 10.1074/jbc.M603582200; Yonekura-Sakakibara K, 2007, J BIOL CHEM, V282, P14932, DOI 10.1074/jbc.M611498200; Zybailov B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001994	40	21	22	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2009	4	5							e5649	10.1371/journal.pone.0005649	http://dx.doi.org/10.1371/journal.pone.0005649			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LB	19461964	Green Published, Green Submitted, gold			2022-12-25	WOS:000266331000008
J	Xiao, ZJ; Ma, CQ; Xu, P; Lu, JR				Xiao, Zijun; Ma, Cuiqing; Xu, Ping; Lu, Jian R.			Acetoin Catabolism and Acetylbutanediol Formation by Bacillus pumilus in a Chemically Defined Medium	PLOS ONE			English	Article								Background: Most low molecular diols are highly water-soluble, hygroscopic, and reactive with many organic compounds. In the past decades, microbial research to produce diols, e. g. 1,3-propanediol and 2,3-butanediol, were considerably expanded due to their versatile usages especially in polymer synthesis and as possible alternatives to fossil based feedstocks from the bioconversion of renewable natural resources. This study aimed to provide a new way for bacterial production of an acetylated diol, i.e. acetylbutanediol (ABD, 3,4-dihydroxy-3-methylpentan-2-one), by acetoin metabolism. Methodology/Principal Findings: When Bacillus pumilus ATCC 14884 was aerobically cultured in a chemically defined medium with acetoin as the sole carbon and energy source, ABD was produced and identified by gas chromatography chemical ionization mass spectrometry and NMR spectroscopy. Conclusions/Significance: Although the key enzyme leading to ABD from acetoin has not been identified yet at this stage, this study proposed a new metabolic pathawy to produce ABD in vivo from using renewable resources - in this case acetoin, which could be reproduced from glucose in this study - making it the first facility in the world to prepare this new bio-based diol product.			Xiao, ZJ (corresponding author), China Univ Petr, Ctr Bioengn Biotechnol, Qingdao, Peoples R China.	pingxu@sjtu.edu.cn; j.lu@manchester.ac.uk	Lu, Jian/GRY-4556-2022	, zijun/0000-0003-1141-8149; Yu, Hai/0000-0002-6386-9761; Ma, Cuiqing/0000-0002-7468-1027				Berkout VD, 2001, J AM SOC MASS SPECTR, V12, P641, DOI 10.1016/S1044-0305(01)00250-1; Biebl H, 1999, APPL MICROBIOL BIOT, V52, P289, DOI 10.1007/s002530051523; *BRIT PHARM COMM, 2003, BRIT PHARM APP 14; *BRIT STAND I, 2000, 8664 BS EN BRIT STAN; *EUR PHARM COMM, 1997, EP272 EUR PHARM COMM; GARG SK, 1995, BIORESOURCE TECHNOL, V51, P103, DOI 10.1016/0960-8524(94)00136-O; Gioia J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000928; Holt J., 1994, BERGEYS MANUAL DETER; JUNI E, 1956, J BACTERIOL, V71, P425, DOI 10.1128/JB.71.4.425-432.1956; MILLER PE, 1986, INT J MASS SPECTROM, V72, P223, DOI 10.1016/0168-1176(86)80021-0; Nagradova N, 2003, IUBMB LIFE, V55, P459, DOI 10.1080/15216540310001602805; OPPERMANN FB, 1991, J BACTERIOL, V173, P757, DOI 10.1128/jb.173.2.757-767.1991; SERGEANT TP, 1957, J BACTERIOL, V74, P728, DOI 10.1128/JB.74.6.728-736.1957; Syu MJ, 2001, APPL MICROBIOL BIOT, V55, P10, DOI 10.1007/s002530000486; Ui S, 1998, J FERMENT BIOENG, V85, P79, DOI 10.1016/S0922-338X(97)80358-3; Xiao ZJ, 2007, APPL MICROBIOL BIOT, V74, P61, DOI 10.1007/s00253-006-0646-5; Xiao ZJ, 2007, CRIT REV MICROBIOL, V33, P127, DOI 10.1080/10408410701364604; XU P, 2006, Patent No. 2006053480	18	25	30	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5627	10.1371/journal.pone.0005627	http://dx.doi.org/10.1371/journal.pone.0005627			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448AY	19461961	gold, Green Submitted, Green Published			2022-12-25	WOS:000266234700014
J	Chen, ZJ; Leskinen, H; Liimatta, E; Sormunen, RT; Miinalainen, IJ; Hassinen, IE; Hiltunen, JK				Chen, Zhijun; Leskinen, Hanna; Liimatta, Erkki; Sormunen, Raija T.; Miinalainen, Ilkka J.; Hassinen, Ilmo E.; Hiltunen, J. Kalervo			Myocardial Overexpression of Mecr, a Gene of Mitochondrial FAS II Leads to Cardiac Dysfunction in Mouse	PLOS ONE			English	Article							FATTY-ACID SYNTHASE; 2-ENOYL THIOESTER REDUCTASE; TRANSGENIC MICE; SACCHAROMYCES-CEREVISIAE; LIPOIC ACID; EXPRESSION; HEART; CLONING; HYPERPLASIA; PHYSIOLOGY	It has been recently recognized that mammalian mitochondria contain most, if not all, of the components of fatty acid synthesis type II (FAS II). Among the components identified is 2-enoyl thioester reductase/mitochondrial enoyl-CoA reductase (Etr1/Mecr), which catalyzes the NADPH-dependent reduction of trans-2-enoyl thioesters, generating saturated acyl-groups. Although the FAS type II pathway is highly conserved, its physiological role in fatty acid synthesis, which apparently occurs simultaneously with breakdown of fatty acids in the same subcellular compartment in mammals, has remained an enigma. To study the in vivo function of the mitochondrial FAS in mammals, with special reference to Mecr, we generated mice overexpressing Mecr under control of the mouse metallothionein-1 promoter. These Mecr transgenic mice developed cardiac abnormalities as demonstrated by echocardiography in vivo, heart perfusion ex vivo, and electron microscopy in situ. Moreover, the Mecr transgenic mice showed decreased performance in endurance exercise testing. Our results showed a ventricular dilatation behind impaired heart function upon Mecr overexpression, concurrent with appearance of dysmorphic mitochondria. Furthermore, the data suggested that inappropriate expression of genes of FAS II can result in the development of hereditary cardiomyopathy.			Chen, ZJ (corresponding author), Univ Oulu, Bioctr Oulu, Oulu, Finland.	kalervo.hiltunen@oulu.fi	Chen, Zhijun/V-3228-2019	Miinalainen, Ilkka/0000-0002-3922-3442; Hiltunen, Kalervo/0000-0002-3073-9602				Alhonen L, 1996, BIOCHEM J, V314, P405, DOI 10.1042/bj3140405; Autio KJ, 2008, FASEB J, V22, P569, DOI 10.1096/fj.07-8986; Baggio L, 2000, J BIOL CHEM, V275, P34471, DOI 10.1074/jbc.M005119200; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; Boluyt MO, 2005, AM J HYPERTENS, V18, P202, DOI 10.1016/j.amjhyper.2004.08.034; Borutaite V, 2003, FEBS LETT, V541, P1, DOI 10.1016/S0014-5793(03)00278-3; CHAIN EB, 1969, BIOCHEM J, V115, P537, DOI 10.1042/bj1150537; Chen ZJ, 2008, J MOL BIOL, V379, P830, DOI 10.1016/j.jmb.2008.04.041; Coats Andrew J. S., 2001, Cardiology Clinics, V19, P517, DOI 10.1016/S0733-8651(05)70233-2; Cronan JE, 2005, FEBS LETT, V579, P4892, DOI 10.1016/j.febslet.2005.07.077; Denic V, 2007, CELL, V130, P663, DOI 10.1016/j.cell.2007.06.031; Finck BN, 2007, CIRCULATION, V115, P2540, DOI 10.1161/CIRCULATIONAHA.107.670588; Finck BN, 2007, CARDIOVASC RES, V73, P269, DOI 10.1016/j.cardiores.2006.08.023; Fukuda T, 2005, MOL CELL BIOL, V25, P5270, DOI 10.1128/MCB.25.12.5270-5281.2005; GAWEHN K, 1970, METHODEN ENZYMATISCH, P2156; HASSINEN I, 1968, BIOCHEM BIOPH RES CO, V31, P895, DOI 10.1016/0006-291X(68)90536-6; Joshi AK, 2003, J BIOL CHEM, V278, P33142, DOI 10.1074/jbc.M305459200; Kastaniotis AJ, 2004, MOL MICROBIOL, V53, P1407, DOI 10.1111/j.1365-2958.2004.04191.x; Lamprecht W., 1970, METHODEN ENZYMATISCH, P2024; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637; Massett MP, 2005, AM J PHYSIOL-REG I, V288, pR1006, DOI 10.1152/ajpregu.00476.2004; Miinalainen IJ, 2003, J BIOL CHEM, V278, P20154, DOI 10.1074/jbc.M302851200; Morikawa T, 2001, FEBS LETT, V498, P16, DOI 10.1016/S0014-5793(01)02469-3; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Schlame M, 1999, J LIPID RES, V40, P1585; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; Schneider R, 1997, CURR GENET, V32, P384, DOI 10.1007/s002940050292; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Suppola S, 1999, BIOCHEM J, V338, P311, DOI 10.1042/0264-6021:3380311; Torkko JM, 2001, MOL CELL BIOL, V21, P6243, DOI 10.1128/MCB.21.18.6243-6253.2001; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664; White SW, 2005, ANNU REV BIOCHEM, V74, P791, DOI 10.1146/annurev.biochem.74.082803.133524; Williamson J R, 1979, Methods Enzymol, V55, P200; Witkowski A, 2007, J BIOL CHEM, V282, P14178, DOI 10.1074/jbc.M701486200; Yi XW, 2005, MOL CELL BIOL, V25, P8387, DOI 10.1128/MCB.25.18.8387-8392.2005; Zhang L, 2005, J BIOL CHEM, V280, P12422, DOI 10.1074/jbc.M413686200; Zhang L, 2003, J BIOL CHEM, V278, P40067, DOI 10.1074/jbc.M306121200; Zhang WY, 2003, J BIOL CHEM, V278, P21459, DOI 10.1074/jbc.M301652200	40	23	24	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5589	10.1371/journal.pone.0005589	http://dx.doi.org/10.1371/journal.pone.0005589			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440339	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107500017
J	Yoshizawa-Sugata, N; Masai, H				Yoshizawa-Sugata, Naoko; Masai, Hisao			Roles of Human AND-1 in Chromosome Transactions in S Phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID COHESION; DNA-POLYMERASE-ALPHA; DOUBLE-STRAND BREAKS; HOMOLOGOUS RECOMBINATION REPAIR; STALLED REPLICATION FORKS; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; CDC7 KINASE; EFFICIENT PROGRESSION; CHECKPOINT RESPONSE	Coordinated execution of DNA replication, checkpoint activation, and postreplicative chromatid cohesion is intimately related to the replication fork machinery. Human AND-1/chromosome transmission fidelity 4 is localized adjacent to replication foci and is required for efficient DNA synthesis. In S phase, AND-1 is phosphorylated in response to replication arrest in a manner dependent on checkpoint kinase, ataxia telangiectasia-mutated, ataxia telangiectasia-mutated and Rad3-related protein, and Cdc7 kinase but not on Chk1. Depletion of AND-1 increases DNA damage, delays progression of S phase, leads to accumulation of late S and/or G(2) phase cells, and induces cell death in cancer cells. It also elevated UV-radioresistant DNA synthesis and caused premature recovery of replication after hydroxyurea arrest, indicating that lack of AND-1 compromises checkpoint activation. This may be partly due to the decreased levels of Chk1 protein in AND-1-depleted cells. Furthermore, AND-1 interacts with cohesin proteins Smc1, Smc3, and Rad21/Scc1, consistent with proposed roles of yeast counterparts of AND-1 in sister chromatid cohesion. Depletion of AND-1 leads to significant inhibition of homologous recombination repair of an I-SceI-driven double strand break. Based on these data, we propose that AND-1 coordinates multiple cellular events in S phase and G(2) phase, such as DNA replication, checkpoint activation, sister chromatid cohesion, and DNA damage repair, thus playing a pivotal role in maintenance of genome integrity.	[Yoshizawa-Sugata, Naoko; Masai, Hisao] Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Setagaya Ku, Tokyo 1568506, Japan	Tokyo Metropolitan Institute of Medical Science	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan.	masai-hs@igakuken.or.jp		Yoshizawa-Sugata, Naoko/0000-0001-8792-8669	Ministry of Education, Science, Sports and Culture; Astellas Foundation for Research on Metabolic Disorders	Ministry of Education, Science, Sports and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Astellas Foundation for Research on Metabolic Disorders	This work was supported by grants-in-aid for scientific research "A" and scientific research on priority areas "Chromosome Cycle" (to H. M.), by scientific research "C" (to N.Y.) from the Ministry of Education, Science, Sports and Culture, and by Astellas Foundation for Research on Metabolic Disorders (to H. M.).	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bailis JM, 2003, NAT CELL BIOL, V5, P1111, DOI 10.1038/ncb1069; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bennett CB, 2001, NAT GENET, V29, P426, DOI 10.1038/ng778; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P10237, DOI 10.1073/pnas.1434308100; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chan RC, 2003, NATURE, V423, P1002, DOI 10.1038/nature01697; Chou DM, 2006, P NATL ACAD SCI USA, V103, P18143, DOI 10.1073/pnas.0609251103; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Collis SJ, 2007, NAT CELL BIOL, V9, P391, DOI 10.1038/ncb1555; Cortes-Ledesma F, 2006, EMBO REP, V7, P919, DOI 10.1038/sj.embor.7400774; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; DESJARDINS LM, 1995, EXP CELL RES, V216, P380, DOI 10.1006/excr.1995.1048; Errico A, 2007, P NATL ACAD SCI USA, V104, P14929, DOI 10.1073/pnas.0706347104; Formosa T, 1999, GENETICS, V151, P1459; Gambus A, 2006, NAT CELL BIOL, V8, P358, DOI 10.1038/ncb1382; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Gotter AL, 2007, J MOL BIOL, V366, P36, DOI 10.1016/j.jmb.2006.10.097; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hanna JS, 2001, MOL CELL BIOL, V21, P3144, DOI 10.1128/MCB.21.9.3144-3158.2001; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Johnson RD, 2001, BIOCHEM SOC T, V29, P196, DOI 10.1042/BST0290196; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kim JM, 2008, ONCOGENE, V27, P3475, DOI 10.1038/sj.onc.1210994; Kim JM, 2002, EMBO J, V21, P2168, DOI 10.1093/emboj/21.9.2168; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Kohler A, 1997, J CELL SCI, V110, P1051; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Lengronne A, 2006, MOL CELL, V23, P787, DOI 10.1016/j.molcel.2006.08.018; Li J, 2005, J BIOL CHEM, V280, P37948, DOI 10.1074/jbc.M509299200; Liu QH, 2000, GENE DEV, V14, P1448; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; Masai H, 2006, J BIOL CHEM, V281, P39249, DOI 10.1074/jbc.M608935200; Matsuura K, 2008, J BIOL CHEM, V283, P25485, DOI 10.1074/jbc.M803111200; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; Mayer ML, 2004, MOL BIOL CELL, V15, P1736, DOI 10.1091/mbc.E03-08-0619; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Mohindra A, 2002, HUM MOL GENET, V11, P2189, DOI 10.1093/hmg/11.18.2189; Montagnoli A, 2004, CANCER RES, V64, P7110, DOI 10.1158/0008-5472.CAN-04-1547; Naiki T, 2001, MOL CELL BIOL, V21, P5838, DOI 10.1128/MCB.21.17.5838-5845.2001; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Niida H, 2007, MOL CELL BIOL, V27, P2572, DOI 10.1128/MCB.01611-06; Nomura M, 2005, BIOCHEM BIOPH RES CO, V335, P900, DOI 10.1016/j.bbrc.2005.07.160; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Ogiwara H, 2007, BIOCHEM BIOPH RES CO, V354, P222, DOI 10.1016/j.bbrc.2006.12.185; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Pacek M, 2006, MOL CELL, V21, P581, DOI 10.1016/j.molcel.2006.01.030; Pan XW, 2006, CELL, V124, P1069, DOI 10.1016/j.cell.2005.12.036; Petronczki M, 2004, J CELL SCI, V117, P3547, DOI 10.1242/jcs.01231; Potts PR, 2006, EMBO J, V25, P3377, DOI 10.1038/sj.emboj.7601218; Ricke RM, 2004, MOL CELL, V16, P173, DOI 10.1016/j.molcel.2004.09.017; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; Saberi A, 2007, MOL CELL BIOL, V27, P2562, DOI 10.1128/MCB.01243-06; Saleh-Gohari N, 2005, MOL CELL BIOL, V25, P7158, DOI 10.1128/MCB.25.16.7158-7169.2005; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Schar P, 2004, NUCLEIC ACIDS RES, V32, P3921, DOI 10.1093/nar/gkh716; Sjogren C, 2001, CURR BIOL, V11, P991, DOI 10.1016/S0960-9822(01)00271-8; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Smits VAJ, 2006, CURR BIOL, V16, P150, DOI 10.1016/j.cub.2005.11.066; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Strom L, 2007, CURR OPIN CELL BIOL, V19, P344, DOI 10.1016/j.ceb.2007.04.003; Sugata N, 2000, HUM MOL GENET, V9, P2919, DOI 10.1093/hmg/9.19.2919; Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Tanaka S, 2007, NATURE, V445, P328, DOI 10.1038/nature05465; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Tsao CC, 2004, EMBO J, V23, P4660, DOI 10.1038/sj.emboj.7600463; Tsutsui Y, 2005, CURR GENET, V48, P34, DOI 10.1007/s00294-005-0584-2; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Unsal-Kacmaz K, 2005, MOL CELL BIOL, V25, P3109, DOI 10.1128/MCB.25.8.3109-3116.2005; Unsal-Kacmaz K, 2007, MOL CELL BIOL, V27, P3131, DOI 10.1128/MCB.02190-06; Warren CD, 2004, MOL BIOL CELL, V15, P1724, DOI 10.1091/mbc.E03-09-0637; Williams DR, 2002, EUKARYOT CELL, V1, P758, DOI 10.1128/EC.1.5.758-773.2002; Wittmeyer J, 1997, MOL CELL BIOL, V17, P4178, DOI 10.1128/MCB.17.7.4178; Xu H, 2004, MOL CELL BIOL, V24, P7082, DOI 10.1128/MCB.24.16.7082-7090.2004; Yabuuchi H, 2006, EMBO J, V25, P4663, DOI 10.1038/sj.emboj.7601347; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Yoshizawa-Sugata N, 2005, J BIOL CHEM, V280, P13062, DOI 10.1074/jbc.M411653200; Yoshizawa-Sugata N, 2007, J BIOL CHEM, V282, P2729, DOI 10.1074/jbc.M605596200; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou YJ, 2004, MOL CELL BIOL, V24, P9568, DOI 10.1128/MCB.24.21.9568-9579.2004; Zhu WG, 2007, GENE DEV, V21, P2288, DOI 10.1101/gad.1585607; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	90	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20718	20728		10.1074/jbc.M806711200	http://dx.doi.org/10.1074/jbc.M806711200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19439411	Green Published, hybrid			2022-12-25	WOS:000268316100034
J	Kelly, TJ; Lerin, C; Haas, W; Gygi, SP; Puigserver, P				Kelly, Timothy J.; Lerin, Carles; Haas, Wilhelm; Gygi, Steven P.; Puigserver, Pere			GCN5-mediated Transcriptional Control of the Metabolic Coactivator PGC-1 beta through Lysine Acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA COACTIVATOR-1; FATTY-ACID OXIDATION; MITOCHONDRIAL BIOGENESIS; SKELETAL-MUSCLE; RECEPTOR-ALPHA; ERR-ALPHA; ENERGY-EXPENDITURE; INSULIN-RESISTANCE; PGC-1-ALPHA; ACTIVATION	Changes in expression levels of genes encoding for proteins that control metabolic pathways are essential to maintain nutrient and energy homeostasis in individual cells as well as in organisms. An important regulated step in this process is accomplished through covalent chemical modifications of proteins that form complexes with the chromatin of gene promoters. The peroxisome proliferators gamma co-activator 1 (PGC-1) family of transcriptional co-activators comprises important components of a number of these complexes and participates in a large array of glucose and lipid metabolic adaptations. Here, we show that PGC-1 beta is acetylated on at least 10 lysine residues distributed along the length of the protein by the acetyl transferase general control of amino-acid synthesis (GCN5) and that this acetylation reaction is reversed by the deacetylase sirtuin 1 (SIRT1). GCN5 strongly interacts with PGC-1 beta and represses its transcriptional activity associated with transcription factors such as ERR alpha, NRF-1, and HNF4 alpha, however acetylation and transcriptional repression do not occur when a catalytically inactive GCN5 is co-expressed. Transcriptional repression coincides with PGC-1 beta redistribution to nuclear foci where it co-localizes with GCN5. Furthermore, knockdown of GCN5 ablates PGC-1 beta acetylation and increases transcriptional activity. In primary skeletal muscle cells, PGC-1 beta induction of endogenous target genes, including MCAD and GLUT4, is largely repressed by GCN5. Functionally, this translates to a blunted response to PGC-1 beta-induced insulin-mediated glucose transport. These results suggest that PGC-1 beta acetylation by GCN5 might be an important step in the control of glucose and lipid pathways and its dysregulation could contribute to metabolic diseases.	[Puigserver, Pere] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Kelly, Timothy J.; Lerin, Carles; Haas, Wilhelm; Gygi, Steven P.; Puigserver, Pere] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Kelly, Timothy J.] Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Johns Hopkins University	Puigserver, P (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 1 Jimmy Fund Way,Smith 932C, Boston, MA 02115 USA.	pere_puigserver@dfci.harvard.edu	Lerin, Carles/AAP-9916-2020	Lerin, Carles/0000-0003-0950-4363	National Institutes of Health [RO1 DK069966]; Ellison Medical Foundation New Scholar Award; American Diabetes Association; U.S. Dept. of Defense; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069966] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ellison Medical Foundation New Scholar Award(Lawrence Ellison Foundation); American Diabetes Association(American Diabetes Association); U.S. Dept. of Defense(United States Department of Defense); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grant RO1 DK069966 (to P. P.). This work was also supported by an Ellison Medical Foundation New Scholar Award, by the American Diabetes Association, and by the U.S. Dept. of Defense.	Anderson RM, 2008, AGING CELL, V7, P101, DOI 10.1111/j.1474-9726.2007.00357.x; Arany Z, 2007, CELL METAB, V5, P35, DOI 10.1016/j.cmet.2006.12.003; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cunningham JT, 2007, NATURE, V450, P736, DOI 10.1038/nature06322; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794; Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633; Haas W, 2006, MOL CELL PROTEOMICS, V5, P1326, DOI 10.1074/mcp.M500339-MCP200; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Housley MP, 2009, J BIOL CHEM, V284, P5148, DOI 10.1074/jbc.M808890200; Imoberdorf RM, 2006, MOL CELL BIOL, V26, P1610, DOI 10.1128/MCB.26.5.1610-1616.2006; Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kressler D, 2002, J BIOL CHEM, V277, P13918, DOI 10.1074/jbc.M201134200; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lelliott CJ, 2006, PLOS BIOL, V4, P2042, DOI 10.1371/journal.pbio.0040369; Lerin C, 2006, CELL METAB, V3, P429, DOI 10.1016/j.cmet.2006.04.013; Li XH, 2007, NATURE, V447, P1012, DOI 10.1038/nature05861; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; Ling C, 2007, DIABETOLOGIA, V50, P1615, DOI 10.1007/s00125-007-0729-6; Lonard DM, 2007, ENDOCR REV, V28, P575, DOI 10.1210/er.2007-0012; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Nagai Y, 2009, CELL METAB, V9, P252, DOI 10.1016/j.cmet.2009.01.011; Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200; Olson BL, 2008, GENE DEV, V22, P252, DOI 10.1101/gad.1624208; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Rodgers JT, 2007, P NATL ACAD SCI USA, V104, P12861, DOI 10.1073/pnas.0702509104; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Sabourin LA, 1999, J CELL BIOL, V144, P631, DOI 10.1083/jcb.144.4.631; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sonoda J, 2007, GENE DEV, V21, P1909, DOI 10.1101/gad.1553007; Stafford JM, 2001, J BIOL CHEM, V276, P39885, DOI 10.1074/jbc.M105370200; Teyssier C, 2005, GENE DEV, V19, P1466, DOI 10.1101/gad.1295005; Uldry M, 2006, CELL METAB, V3, P333, DOI 10.1016/j.cmet.2006.04.002; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Vianna CR, 2006, CELL METAB, V4, P453, DOI 10.1016/j.cmet.2006.11.003; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X	46	94	97	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					19945	19952		10.1074/jbc.M109.015164	http://dx.doi.org/10.1074/jbc.M109.015164			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19491097	Green Published, hybrid			2022-12-25	WOS:000268097400021
J	Aberg, E; Torgersen, KM; Johansen, B; Keyse, SM; Perander, M; Seternes, OM				Aberg, Espen; Torgersen, Knut Martin; Johansen, Bjarne; Keyse, Stephen M.; Perander, Maria; Seternes, Ole-Morten			Docking of PRAK/MK5 to the Atypical MAPKs ERK3 and ERK4 Defines a Novel MAPK Interaction Motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; PATHWAY; BINDING; SPECIFICITY; SUBSTRATE; PROTEIN-KINASE-5; PHOSPHORYLATION; IDENTIFICATION; MECHANISM; MUTANTS	ERK3 and ERK4 are atypical MAPKs in which the canonical TXY motif within the activation loop of the classical MAPKs is replaced by SEG. Both ERK3 and ERK4 bind, translocate, and activate the MAPK-activated protein kinase (MK) 5. The classical MAPKs ERK1/2 and p38 interact with downstream MKs (RSK1-3 and MK2-3, respectively) through conserved clusters of acidic amino acids, which constitute the common docking (CD) domain. In contrast to the classical MAPKs, the interaction between ERK3/4 and MK5 is strictly dependent on phosphorylation of the SEG motif of these kinases. Here we report that the conserved CD domain is dispensable for the interaction of ERK3 and ERK4 with MK5. Using peptide overlay assays, we have defined a novel MK5 interaction motif (FRIEDE) within both ERK4 and ERK3 that is essential for binding to the C-terminal region of MK5. This motif is located within the L16 extension lying C-terminal to the CD domain in ERK3 and ERK4 and a single isoleucine to lysine substitution in FRIEDE totally abrogates binding, activation, and translocation of MK5 by both ERK3 and ERK4. These findings are the first to demonstrate binding of a physiological substrate via this region of the L16 loop in a MAPK. Furthermore, the link between activation loop phosphorylation and accessibility of the FRIEDE interaction motif suggests a switch mechanism for these atypical MAPKs in which the phosphorylation status of the activation loop regulates the ability of both ERK3 and ERK4 to bind to a downstream effector.	[Aberg, Espen; Seternes, Ole-Morten] Univ Tromso, Inst Pharm, N-9037 Tromso, Norway; [Johansen, Bjarne; Perander, Maria] Univ Tromso, Inst Med Biol, N-9037 Tromso, Norway; [Torgersen, Knut Martin] Univ Oslo, Biotechnol Ctr Oslo, N-0317 Oslo, Norway; [Keyse, Stephen M.] Ninewells Hosp & Med Sch, Canc Res UK Stress Response Lab, Biomed Res Inst, Dundee DD1 9SY, Scotland	UiT The Arctic University of Tromso; UiT The Arctic University of Tromso; University of Oslo; University of Dundee	Seternes, OM (corresponding author), Univ Tromso, Inst Pharm, N-9037 Tromso, Norway.	ole-morten.seternes@uit.no	Seternes, Ole Morten/M-9520-2019; Keyse, Stephen M./B-9575-2009	Seternes, Ole Morten/0000-0001-8537-3612; Keyse, Stephen M./0000-0002-5150-8221; Perander, Maria/0000-0002-1177-2407	National Programme for Research in Functional Genomics in Norway of the Research Council of Norway; Norwegian Cancer Society; Blix Family Foundation; Cancer Research UK Programme grant	National Programme for Research in Functional Genomics in Norway of the Research Council of Norway; Norwegian Cancer Society(Norwegian Cancer Society); Blix Family Foundation; Cancer Research UK Programme grant(Cancer Research UK)	This work was supported by the National Programme for Research in Functional Genomics in Norway of the Research Council of Norway, the Norwegian Cancer Society, the Blix Family Foundation, and a Cancer Research UK Programme grant ( to S. M. K.).	Aberg E, 2006, J BIOL CHEM, V281, P35499, DOI 10.1074/jbc.M606225200; Avruch J, 2007, BBA-MOL CELL RES, V1773, P1150, DOI 10.1016/j.bbamcr.2006.11.006; Bhattacharyya RP, 2006, ANNU REV BIOCHEM, V75, P655, DOI 10.1146/annurev.biochem.75.103004.142710; Bogoyevitch MA, 2004, CELL SIGNAL, V16, P1345, DOI 10.1016/j.cellsig.2004.05.004; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Coulombe P, 2003, MOL CELL BIOL, V23, P4542, DOI 10.1128/MCB.23.13.4542-4558.2003; Cuenda A, 2007, BBA-MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010; Deleris P, 2008, J CELL PHYSIOL, V217, P778, DOI 10.1002/jcp.21560; Diskin R, 2004, J BIOL CHEM, V279, P47040, DOI 10.1074/jbc.M404595200; Diskin R, 2007, J MOL BIOL, V365, P66, DOI 10.1016/j.jmb.2006.08.043; Gaestel M, 2006, NAT REV MOL CELL BIO, V7, P120, DOI 10.1038/nrm1834; Goldsmith EJ, 2007, CHEM REV, V107, P5065, DOI 10.1021/cr068221w; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kant S, 2006, J BIOL CHEM, V281, P35511, DOI 10.1074/jbc.M606693200; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kostich M, 2002, GENOME BIOL, V3; Kramer A, 1998, METH MOL B, V87, P25; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Mooney LM, 2004, J BIOL CHEM, V279, P11843, DOI 10.1074/jbc.M311841200; Perander M, 2008, BIOCHEM J, V411, P613, DOI 10.1042/BJ20071369; Qi MS, 2005, J CELL SCI, V118, P3569, DOI 10.1242/jcs.02470; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Ranganathan A, 2006, ARCH BIOCHEM BIOPHYS, V449, P8, DOI 10.1016/j.abb.2006.02.023; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Salvador JM, 2005, NAT IMMUNOL, V6, P390, DOI 10.1038/ni1177; Schumacher S, 2004, EMBO J, V23, P4770, DOI 10.1038/sj.emboj.7600467; Seternes OM, 2004, EMBO J, V23, P4780, DOI 10.1038/sj.emboj.7600489; Seternes OM, 2002, MOL CELL BIOL, V22, P6931, DOI 10.1128/MCB.22.20.6931-6945.2002; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Smith JK, 2000, J BIOL CHEM, V275, P31588, DOI 10.1074/jbc.M005892200; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Turjanski AG, 2007, ONCOGENE, V26, P3240, DOI 10.1038/sj.onc.1210415; Wilsbacher JL, 2006, BIOCHEMISTRY-US, V45, P13175, DOI 10.1021/bi061041w; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Zhang JL, 2003, J BIOL CHEM, V278, P29901, DOI 10.1074/jbc.M303909200	41	28	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19392	19401		10.1074/jbc.M109.023283	http://dx.doi.org/10.1074/jbc.M109.023283			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19473979	hybrid, Green Published			2022-12-25	WOS:000267908300030
J	Haque, MM; Fadlalla, M; Wang, ZQ; Ray, SS; Panda, K; Stuehr, DJ				Haque, Mohammad Mahfuzul; Fadlalla, Mohammed; Wang, Zhi-Qiang; Ray, Sougata Sinha; Panda, Koustubh; Stuehr, Dennis J.			Neutralizing a Surface Charge on the FMN Subdomain Increases the Activity of Neuronal Nitric-oxide Synthase by Enhancing the Oxygen Reactivity of the Enzyme Heme-Nitric Oxide Complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAPROTEIN ELECTRON-TRANSFER; C-TERMINAL TAIL; CONFORMATIONAL EQUILIBRIUM; CATALYTIC PROFILES; OUTPUT STATE; NO SYNTHASE; DOMAIN; REDUCTION; CALMODULIN; FLAVIN	Nitric-oxide synthases (NOSs) are calmodulin-dependent flavoheme enzymes that oxidize L-Arg to nitric oxide ( NO) and L-citrulline. Their catalytic behaviors are complex and are determined by their rates of heme reduction (k(r)), ferric heme-NO dissociation (k(d)), and ferrous heme-NO oxidation (k(ox)). We found that point mutation (E762N) of a conserved residue on the enzyme's FMN subdomain caused the NO synthesis activity to double compared with wild type nNOS. However, in the absence of L-Arg, NADPH oxidation rates suggested that electron flux through the heme was slower in E762N nNOS, and this correlated with the mutant having a 60% slower k(r). During NO synthesis, little heme-NO complex accumulated in the mutant, compared with similar to 50-70% of the wild-type nNOS accumulating as this complex. This suggested that the E762N nNOS is hyperactive because it minimizes buildup of an inactive ferrous heme-NO complex during NO synthesis. Indeed, we found that k(ox) was 2 times faster in the E762N mutant than in wild-type nNOS. The mutational effect on k(ox) was independent of calmodulin. Computer simulation and experimental measures both indicated that the slower k(r) and faster k(ox) of E762N nNOS combine to lower its apparent K-m,K-O2 for NO synthesis by at least 5-fold, which in turn increases its V/K-m value and enables it to be hyperactive in steady-state NO synthesis. Our work underscores how sensitive nNOS activity is to changes in the k(ox) and reveals a novel means for the FMN module or protein-protein interactions to alter nNOS activity.	[Haque, Mohammad Mahfuzul; Fadlalla, Mohammed; Wang, Zhi-Qiang; Ray, Sougata Sinha; Stuehr, Dennis J.] Cleveland Clin, Dept Pathol, Lerner Res Inst, Cleveland, OH 44195 USA; [Wang, Zhi-Qiang] Kent State Univ Tuscarawas, Dept Chem, New Philadelphia, OH 44663 USA; [Panda, Koustubh] Univ Calcutta, Ctr Genet Engn & Biotechnol, Kolkata 700019, India	Cleveland Clinic Foundation; University System of Ohio; Kent State University; Kent State University Tuscarawas; University of Calcutta	Stuehr, DJ (corresponding author), Cleveland Clin, Dept Pathol NC22, 9500 Euclid Ave, Cleveland, OH 44195 USA.	stuehrd@ccf.org	Panda, Koustubh/E-5273-2017	Panda, Koustubh/0000-0002-4783-2221; HAQUE, MOHAMMAD/0000-0003-0852-6368	National Institutes of Health [GM51491, CA53914, HL58883]; NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants GM51491,CA53914,and HL58883 ( to D. J. S.).	ABU SH, 1993, P NATL ACAD SCI USA, V90, P10769; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Adak S, 1999, J BIOL CHEM, V274, P26907, DOI 10.1074/jbc.274.38.26907; Adak S, 2000, J BIOL CHEM, V275, P17434, DOI 10.1074/jbc.M000846200; Adak S, 2001, J BIOL CHEM, V276, P23246, DOI 10.1074/jbc.M102509200; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 2001, J INORG BIOCHEM, V83, P301, DOI 10.1016/S0162-0134(00)00176-8; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Couture M, 2001, J BIOL CHEM, V276, P38280; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Dunford AJ, 2007, BIOCHEMISTRY-US, V46, P5018, DOI 10.1021/bi7001339; Feng CJ, 2007, J AM CHEM SOC, V129, P5621, DOI 10.1021/ja068685b; Feng CJ, 2006, BIOCHEMISTRY-US, V45, P6354, DOI 10.1021/bi060223n; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Garcin ED, 2004, J BIOL CHEM, V279, P37918, DOI 10.1074/jbc.M406204200; Ghosh DK, 2006, J BIOL CHEM, V281, P14173, DOI 10.1074/jbc.M509937200; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Golser R, 2000, J BIOL CHEM, V275, P5291, DOI 10.1074/jbc.275.8.5291; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Haque MM, 2007, P NATL ACAD SCI USA, V104, P9254, DOI 10.1073/pnas.0700332104; Ilagan RP, 2009, BIOCHEMISTRY-US, V48, P3864, DOI 10.1021/bi8021087; Ilagan RP, 2008, J BIOL CHEM, V283, P19603, DOI 10.1074/jbc.M802914200; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kobayashi K, 2001, J BIOL CHEM, V276, P39864, DOI 10.1074/jbc.M102537200; Konas DW, 2006, BIOCHEMISTRY-US, V45, P12596, DOI 10.1021/bi061011t; Konas DW, 2004, J BIOL CHEM, V279, P35412, DOI 10.1074/jbc.M400872200; Kone BC, 2000, ACTA PHYSIOL SCAND, V168, P27; Li HY, 2008, J BIOL CHEM, V283, P34762, DOI 10.1074/jbc.M806949200; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Ost TWB, 2005, J BIOL CHEM, V280, P965, DOI 10.1074/jbc.M411191200; Panda K, 2004, J BIOL CHEM, V279, P18323, DOI 10.1074/jbc.M310391200; Panda K, 2003, J BIOL CHEM, V278, P37122, DOI 10.1074/jbc.M304456200; Panda K, 2001, J BIOL CHEM, V276, P23349, DOI 10.1074/jbc.M100687200; Panda K, 2006, J BIOL CHEM, V281, P36819, DOI 10.1074/jbc.M606129200; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Salerno JC, 2008, FEBS LETT, V582, P1395, DOI 10.1016/j.febslet.2008.03.051; Sam KA, 2008, J BIOL CHEM, V283, P12555, DOI 10.1074/jbc.M800954200; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Santolini J, 2001, J BIOL CHEM, V276, P1233, DOI 10.1074/jbc.M006858200; Sato Y, 2004, J BIOL CHEM, V279, P8827, DOI 10.1074/jbc.M310327200; Sempombe J, 2009, J AM CHEM SOC, V131, P6940, DOI 10.1021/ja902141v; Shimanuki T, 1999, J BIOL CHEM, V274, P26956, DOI 10.1074/jbc.274.38.26956; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Song Y, 2001, AM J PHYSIOL-CELL PH, V281, pC1819, DOI 10.1152/ajpcell.2001.281.6.C1819; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; Tiso M, 2005, J BIOL CHEM, V280, P39208, DOI 10.1074/jbc.M507775200; Tiso M, 2007, BIOCHEMISTRY-US, V46, P14418, DOI 10.1021/bi701646k; Wang ZQ, 2004, J BIOL CHEM, V279, P19018, DOI 10.1074/jbc.M311663200; Wang ZQ, 2005, BIOCHEMISTRY-US, V44, P4676, DOI 10.1021/bi047508p; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350	59	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19237	19247		10.1074/jbc.M109.013144	http://dx.doi.org/10.1074/jbc.M109.013144			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19473991	Green Published, hybrid			2022-12-25	WOS:000267908300014
J	Xu, DM; Sillaots, S; Davison, J; Hu, WQ; Jiang, B; Kauffman, S; Martel, N; Ocampo, P; Oh, C; Trosok, S; Veillette, K; Wang, H; Yang, MH; Zhang, L; Becker, J; Martin, CE; Roemer, T				Xu, Deming; Sillaots, Susan; Davison, John; Hu, Wenqi; Jiang, Bo; Kauffman, Sarah; Martel, Nick; Ocampo, Pam; Oh, Chanseok; Trosok, Steve; Veillette, Karynn; Wang, Hao; Yang, Minghui; Zhang, Li; Becker, Jeffrey; Martin, Charles E.; Roemer, Terry			Chemical Genetic Profiling and Characterization of Small-molecule Compounds That Affect the Biosynthesis of Unsaturated Fatty Acids in Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FUNGAL PATHOGEN; SACCHAROMYCES-CEREVISIAE; BIOLOGICAL-ACTIVITY; LARGE-SCALE; YEAST; DESATURASE; GENOME; EXPRESSION; OLE1; INHERITANCE	The balance between saturated and unsaturated fatty acids plays a crucial role in determining the membrane fluidity. In the diploid fungal pathogen Candida albicans, the gene for fatty acid Delta 9 desaturase, OLE1, is essential for viability. Using a reverse genetic approach, termed the fitness test, we identified a group of structurally related synthetic compounds that induce specific hypersensitivity of the OLE1(+/-) strain. Genetic repression of OLE1 and chemical inhibition by two selected compounds, ECC145 and ECC188, resulted in a marked decrease in the total unsaturated fatty acids and impaired hyphal development. The resulting auxotroph of both was suppressed by the exogenous monounsaturated fatty acids (16:1 Delta 9 and 18:1 Delta 9). These correlations suggest that both compounds affect the level of unsaturated fatty acids, likely by impairing Ole1p directly or indirectly. However, the residual levels of monounsaturated fatty acids (MUFAs) resulted from chemical inhibition were significantly higher than OLE1 repression, indicating even partial inhibition of MUFAs is sufficient to stop cellular proliferation. Although the essentiality of OLE1 was suppressed by MUFAs in vitro, we demonstrated that it was required for virulence in a murine model of systemic candidiasis even when the animals were supplemented with a high fat diet. Thus, the fungal fatty acid desaturase is an attractive antifungal drug target. Taking advantage of the inhibitors and the relevant conditional shut-off strains, we validated several chemical genetic interactions observed in the fitness test profiles that reveal novel genetic interactions between OLE1/unsaturated fatty acids and other cellular processes.	[Xu, Deming; Sillaots, Susan; Davison, John; Hu, Wenqi; Jiang, Bo; Martel, Nick; Ocampo, Pam; Trosok, Steve; Veillette, Karynn; Wang, Hao; Yang, Minghui; Zhang, Li; Roemer, Terry] Merck Frosst Canada Ltd, Ctr Fungal Genet, Montreal, PQ H9H 3L1, Canada; [Kauffman, Sarah; Becker, Jeffrey] Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA; [Oh, Chanseok; Martin, Charles E.] Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA; [Roemer, Terry] Merck & Co Inc, Dept Infect Dis, Rahway, NJ 07065 USA	Merck & Company; University of Tennessee System; University of Tennessee Knoxville; Rutgers State University New Brunswick; Merck & Company	Xu, DM (corresponding author), Merck Frosst Canada Ltd, Ctr Fungal Genet, Montreal, PQ H9H 3L1, Canada.	xu_deming@hotmail.com	Hu, wenqi/GSI-7291-2022; Martel, Nick/ABD-3138-2020	Hu, wenqi/0000-0003-0813-6001; Martel, Nick/0000-0003-2003-4147	Genome Canada; Genome Quebec	Genome Canada(Genome Canada); Genome Quebec	This work was supported in part by Genome Canada and Genome Quebec.	Biswas S, 2007, MICROBIOL MOL BIOL R, V71, P348, DOI 10.1128/MMBR.00009-06; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; Braun BR, 2005, PLOS GENET, V1, P36, DOI 10.1371/journal.pgen.0010001; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Cassola A, 2004, EUKARYOT CELL, V3, P190, DOI 10.1128/EC.3.1.190-199.2004; CHIRALA SS, 1992, P NATL ACAD SCI USA, V89, P10232, DOI 10.1073/pnas.89.21.10232; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Erb-Downward JR, 2007, INFECT IMMUN, V75, P3498, DOI 10.1128/IAI.00232-07; Giaever G, 2004, P NATL ACAD SCI USA, V101, P793, DOI 10.1073/pnas.0307490100; Gonzalez CI, 1996, J BIOL CHEM, V271, P25801, DOI 10.1074/jbc.271.42.25801; Herath K, 2009, BIOORGAN MED CHEM, V17, P1361, DOI 10.1016/j.bmc.2008.12.009; Jiang B, 2008, CHEM BIOL, V15, P363, DOI 10.1016/j.chembiol.2008.02.016; Jones T, 2004, P NATL ACAD SCI USA, V101, P7329, DOI 10.1073/pnas.0401648101; Kadereit B, 2008, P NATL ACAD SCI USA, V105, P94, DOI 10.1073/pnas.0708579105; Krishnamurthy S, 2004, MICROBIOL-SGM, V150, P1991, DOI 10.1099/mic.0.27029-0; Lum PY, 2004, CELL, V116, P121, DOI 10.1016/S0092-8674(03)01035-3; Martin CE, 2007, BBA-MOL CELL BIOL L, V1771, P271, DOI 10.1016/j.bbalip.2006.06.010; MISHRA P, 1992, BIOCHIM BIOPHYS ACTA, V1127, P1, DOI 10.1016/0005-2760(92)90194-Z; MITCHELL AG, 1995, J BIOL CHEM, V270, P29766; Murayama SY, 2006, MICROBIOL-SGM, V152, P1551, DOI 10.1099/mic.0.28751-0; Noble SM, 2007, ANNU REV GENET, V41, P193, DOI 10.1146/annurev.genet.41.042007.170146; Oh CS, 2006, J BIOL CHEM, V281, P7030, DOI 10.1074/jbc.M510746200; Ondeyka J, 2009, J NAT PROD, V72, P136, DOI 10.1021/np800511r; Pfaller MA, 2007, CLIN MICROBIOL REV, V20, P133, DOI 10.1128/CMR.00029-06; Rodriguez-Suarez R, 2007, CHEM BIOL, V14, P1163, DOI 10.1016/j.chembiol.2007.09.009; Roemer T, 2003, MOL MICROBIOL, V50, P167, DOI 10.1046/j.1365-2958.2003.03697.x; Schneiter R, 1997, CELL, V88, P431, DOI 10.1016/S0092-8674(00)81882-6; Sherman D, 2004, NUCLEIC ACIDS RES, V32, pD315, DOI 10.1093/nar/gkh091; STEWART LC, 1991, J CELL BIOL, V115, P1249, DOI 10.1083/jcb.115.5.1249; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; Uhl MA, 2003, EMBO J, V22, P2668, DOI 10.1093/emboj/cdg256; Wenz P, 2001, NUCLEIC ACIDS RES, V29, P4625, DOI 10.1093/nar/29.22.4625; Xu DM, 2007, PLOS PATHOG, V3, P835, DOI 10.1371/journal.ppat.0030092	33	54	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19754	19764		10.1074/jbc.M109.019877	http://dx.doi.org/10.1074/jbc.M109.019877			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19487691	Green Published, hybrid			2022-12-25	WOS:000267908300065
J	Wong, J; Weickert, CS				Wong, Jenny; Weickert, Cynthia Shannon			Transcriptional Interaction of an Estrogen Receptor Splice Variant and ErbB4 Suggests Convergence in Gene Susceptibility Pathways in Schizophrenia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; PREFRONTAL CORTEX; BREAST-CANCER; WILD-TYPE; PREOPTIC AREA; IN-VITRO; ER-ALPHA; EXPRESSION; NEUREGULIN-1; ESTRADIOL	Mounting evidence from clinical and basic research suggests that estrogen signaling may be altered in the brains of people with schizophrenia. Previously, we found that DNA sequence variation in the estrogen receptor (ER) alpha gene, lower ER alpha mRNA levels, and/or blunted ER alpha signaling is associated with schizophrenia. In this study, we asked whether the naturally occurring truncated ER alpha isoform, Delta 7, which acts as a dominant negative, can attenuate gene expression induced by the wildtype (WT) receptor in an estrogen-dependent manner in neuronal (SHSY5Y) and non-neuronal (CHOK1 and HeLa) cells. In addition, we determined the extent to which ER alpha interacts with NRG1-ErbB4, a leading schizophrenia susceptibility pathway. Reductions in the transcriptionally active form of ErbB4 comprising the intracytoplasmic domain (ErbB4-ICD) have been found in schizophrenia, and we hypothesized that ER alpha and ErbB4 may converge to control gene expression. In the present study, we show that truncated Delta 7-ER alpha attenuates WT-ER alpha-driven gene expression across a wide range of estrogen concentrations in cells that express functional ER alpha at base line or upon co-transfection of full-length ER alpha. Furthermore, we find that ErbB4-ICD can potentiate the transcriptional activity of WT-ER alpha at EREs in two cell lines and that this potentiation effect is abolished by the presence of Delta 7-ER alpha. Immunofluorescence microscopy revealed nuclear co-localization of WT-ER alpha, Delta 7-ER alpha, and ErbB4-ICD, whereas immunoprecipitation assays showed direct interaction. Our findings demonstrate convergence between ER alpha and ErbB4-ICD in the transcriptional control of ER alpha-target gene expression and suggest that this may represent a convergent pathway that may be disrupted in schizophrenia.	[Wong, Jenny; Weickert, Cynthia Shannon] Schizophrenia Res Inst, Sydney, NSW 2052, Australia; [Wong, Jenny; Weickert, Cynthia Shannon] Univ New S Wales, Fac Med, Sch Med Sci, Sydney, NSW 2052, Australia; Univ New S Wales, Fac Med, Sch Psychiat, Sydney, NSW 2052, Australia; [Wong, Jenny; Weickert, Cynthia Shannon] Prince Wales Med Res Inst, Schizophrenia Res Lab, Randwick, NSW 2031, Australia	University of New South Wales Sydney; University of New South Wales Sydney; Prince Wales Medical Research Institute	Weickert, CS (corresponding author), Univ New S Wales, Dept Psychiat, Prince Wales Med Res Inst, Schizophrenia Res Lab, Corner Barker & Easy St, Sydney, NSW 2031, Australia.	c.weickert@powmri.edu.au	Weickert, Cynthia Shannon/G-3171-2011	Shannon Weickert, Cynthia/0000-0002-4560-0259	Schizophrenia Research Institute, New South Wales Health, Macquarie Group Foundation; Prince of Wales Medical Research Institute; University of New South Wales	Schizophrenia Research Institute, New South Wales Health, Macquarie Group Foundation; Prince of Wales Medical Research Institute; University of New South Wales	This work was supported by the Schizophrenia Research Institute, New South Wales Health, Macquarie Group Foundation, Prince of Wales Medical Research Institute, and the University of New South Wales.	Arai Y, 1996, NEUROSCI RES, V25, P403; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Beyer C, 2000, J NEUROSCI RES, V59, P107, DOI 10.1002/(SICI)1097-4547(20000101)59:1<107::AID-JNR13>3.0.CO;2-W; Bollig A, 2000, MOL ENDOCRINOL, V14, P634, DOI 10.1210/me.14.5.634; Cheng CM, 2001, FASEB J, V15, P907, DOI 10.1096/fj.00-0398com; Chong VZ, 2008, SCHIZOPHR RES, V100, P270, DOI 10.1016/j.schres.2007.12.474; Di Paolo T, 1994, Rev Neurosci, V5, P27; DODSON RE, 1988, J COMP NEUROL, V275, P623, DOI 10.1002/cne.902750410; Dominguez R, 2004, J NEUROSCI, V24, P982, DOI 10.1523/JNEUROSCI.2586-03.2004; Erenburg I, 1997, MOL ENDOCRINOL, V11, P2004, DOI 10.1210/me.11.13.2004; Ferro P, 2003, INT J MOL MED, V12, P355; Fleming JGW, 2006, ENDOCRINOLOGY, V147, P899, DOI 10.1210/en.2005-1120; FUQUA SAW, 1992, CANCER RES, V52, P483; Gorski R A, 1985, J Anim Sci, V61 Suppl 3, P38; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; Grigoriadis S, 2002, CAN J PSYCHIAT, V47, P437, DOI 10.1177/070674370204700504; Hahn CG, 2006, NAT MED, V12, P824, DOI 10.1038/nm1418; Hao JD, 2006, J NEUROSCI, V26, P2571, DOI 10.1523/JNEUROSCI.3440-05.2006; HARLAN RE, 1988, MOL NEUROBIOL, V2, P183, DOI 10.1007/BF02935345; Harrison PJ, 2006, BIOL PSYCHIAT, V60, P132, DOI 10.1016/j.biopsych.2005.11.002; Horvath G, 2000, INT J GYNECOL CANCER, V10, P128, DOI 10.1046/j.1525-1438.2000.00009.x; Horvath G, 2002, GYNECOL ONCOL, V84, P271, DOI 10.1006/gyno.2001.6509; Ishunina TA, 2005, J CLIN ENDOCR METAB, V90, P3757, DOI 10.1210/jc.2004-1858; KOEHORST SGA, 1993, J STEROID BIOCHEM, V45, P227, DOI 10.1016/0960-0760(93)90336-U; Kulkarni J, 2002, Arch Womens Ment Health, V5, P99, DOI 10.1007/s00737-002-0001-5; Kulkarni J, 1996, SCHIZOPHR RES, V20, P247, DOI 10.1016/0920-9964(96)82949-5; Kulkarni J, 2001, SCHIZOPHR RES, V48, P137, DOI 10.1016/S0920-9964(00)00088-8; Kulkarni J, 2008, ARCH GEN PSYCHIAT, V65, P955, DOI 10.1001/archpsyc.65.8.955; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; Law AJ, 2007, HUM MOL GENET, V16, P129, DOI 10.1093/hmg/ddl449; Leung A, 2000, ACTA PSYCHIAT SCAND, V101, P3; LIAW JJ, 1992, MOL BRAIN RES, V13, P231, DOI 10.1016/0169-328X(92)90031-6; Liu CM, 2005, AM J MED GENET B, V134B, P79, DOI 10.1002/ajmg.b.20161; LUSTIG RH, 1994, HORM BEHAV, V28, P383, DOI 10.1006/hbeh.1994.1035; MATSUMOTO A, 1976, CELL TISSUE RES, V169, P143; McEwen BS, 2001, J APPL PHYSIOL, V91, P2785, DOI 10.1152/jappl.2001.91.6.2785; MCEWEN BS, 1994, EXP GERONTOL, V29, P431, DOI 10.1016/0531-5565(94)90022-1; McGrath J, 2008, EPIDEMIOL REV, V30, P67, DOI 10.1093/epirev/mxn001; MIKSICEK RJ, 1993, BREAST CANCER RES TR, V26, P163, DOI 10.1007/BF00689689; MIRANDA RC, 1994, HORM BEHAV, V28, P367, DOI 10.1006/hbeh.1994.1033; Montague D, 2008, J NEUROENDOCRINOL, V20, P893, DOI 10.1111/j.1365-2826.2008.01743.x; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Osterlund MK, 2000, SYNAPSE, V35, P39; Pedrero JMG, 2003, ENDOCRINOLOGY, V144, P2967, DOI 10.1210/en.2002-0027; Perlman WR, 2005, BIOL PSYCHIAT, V58, P812, DOI 10.1016/j.biopsych.2005.04.047; Perlman WR, 2005, NEUROSCIENCE, V134, P81, DOI 10.1016/j.neuroscience.2005.03.055; Poola I, 2001, J STEROID BIOCHEM, V78, P459, DOI 10.1016/S0960-0760(01)00118-2; PULVER AE, 1995, AM J MED GENET, V60, P252, DOI 10.1002/ajmg.1320600316; Riecher-Rossler A, 2002, Arch Womens Ment Health, V5, P91, DOI 10.1007/s007370200026; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Seeman MV, 1997, AM J PSYCHIAT, V154, P1641, DOI 10.1176/ajp.154.12.1641; SEEMAN MV, 1986, ACTA PSYCHIAT SCAND, V73, P609, DOI 10.1111/j.1600-0447.1986.tb02732.x; Silberberg G, 2006, AM J MED GENET B, V141B, P142, DOI 10.1002/ajmg.b.30275; Singer CA, 1998, BRAIN RES, V789, P343, DOI 10.1016/S0006-8993(98)00142-5; SOHRABJI F, 1995, P NATL ACAD SCI USA, V92, P11110, DOI 10.1073/pnas.92.24.11110; Srivastava DP, 2008, P NATL ACAD SCI USA, V105, P14650, DOI 10.1073/pnas.0801581105; Stefansson H, 2003, AM J HUM GENET, V72, P83, DOI 10.1086/345442; Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734; Sundvall M, 2007, ONCOGENE, V26, P6905, DOI 10.1038/sj.onc.1210501; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORANALLERAND CD, 1976, BRAIN RES, V106, P407; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Wang H, 1999, MOL CELL ENDOCRINOL, V156, P159, DOI 10.1016/S0303-7207(99)00125-2; WANG L, 2002, SCI STKE, pPE29; Weickert CS, 2008, HUM MOL GENET, V17, P2293, DOI 10.1093/hmg/ddn130; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Woolley CS, 1997, J NEUROSCI, V17, P1848; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549; Zhu Y, 2006, CANCER RES, V66, P7991, DOI 10.1158/0008-5472.CAN-05-4397	70	26	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18824	18832		10.1074/jbc.M109.013243	http://dx.doi.org/10.1074/jbc.M109.013243			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19439407	Green Published, hybrid			2022-12-25	WOS:000267711500032
J	Steinmann, S; Schulte, K; Beck, K; Chachra, S; Bujnicki, T; Klempnauer, KH				Steinmann, S.; Schulte, K.; Beck, K.; Chachra, S.; Bujnicki, T.; Klempnauer, K-H			v-Myc inhibits C/EBP beta activity by preventing C/EBP beta-induced phosphorylation of the co-activator p300	ONCOGENE			English	Article						Myc; C/EBP beta; p300; HIPK2; phosphorylation	BINDING-PROTEIN-BETA; ACUTE MYELOID LEUKEMIAS; C-MYC; ADIPOCYTE DIFFERENTIATION; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; ALPHA; CELLS; PROLIFERATION; ASSOCIATION	Myc, a key regulator of cellular proliferation, differentiation and apoptosis, exerts its biological functions by activating or suppressing the transcription of specific sets of target genes. C/EBP transcription factors play important roles during differentiation of various cell types and have been identified as critical targets for v-Myc- and c-Myc-dependent suppression of myeloid and fat cell differentiation. Here, we have addressed the mechanism by which v-Myc suppresses the activity of C/EBP beta. We show that v-Myc is recruited to the aminoterminal domain of C/EBP beta and interferes with the cooperation of C/EBP beta and the co-activator p300 by preventing C/EBP beta-induced phosphorylation of p300. We have identified the protein kinase responsible for C/EBP beta-induced phosphorylation of p300 as homeo-domain interacting protein kinase 2 (HIPK2) and show that v-Myc displaces the kinase from the C/EBP beta-p300 complex. Overall, our findings that the modulation of the C/EBP beta-induced phosphorylation of p300 as a new mechanism of transcriptional suppression by v-Myc. Oncogene (2009) 28, 2446-2455; doi:10.1038/onc.2009.90;published online 18 May 2009	[Steinmann, S.; Schulte, K.; Beck, K.; Chachra, S.; Bujnicki, T.; Klempnauer, K-H] Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de		Bujnicki, Tuyen/0000-0002-7191-8455; Schachtrup, Kristina/0000-0002-9385-8254				Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Calkhoven CF, 2000, GENE DEV, V14, P1920; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Cesena TI, 2007, J BIOL CHEM, V282, P956, DOI 10.1074/jbc.M511451200; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Heath VJ, 2000, EXP CELL RES, V254, P91, DOI 10.1006/excr.1999.4736; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Izumi H, 2001, J CELL SCI, V114, P1533; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Joo M, 2004, J BIOL CHEM, V279, P6658, DOI 10.1074/jbc.M306267200; Kleine-Kohlbrecher D, 2006, CURR TOP MICROBIOL, V302, P51; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lee CM, 1999, ONCOGENE, V18, P2997, DOI 10.1038/sj.onc.1202786; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Nerlov C, 2004, NAT REV CANCER, V4, P394, DOI 10.1038/nrc1363; Nerlov C, 2007, TRENDS CELL BIOL, V17, P318, DOI 10.1016/j.tcb.2007.07.004; Otto TC, 2005, CRIT REV BIOCHEM MOL, V40, P229, DOI 10.1080/10409230591008189; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Reiter F, 2007, ONCOGENE, V26, P1769, DOI 10.1038/sj.onc.1209975; Rinaldo C, 2007, BIOCHEM CELL BIOL, V85, P411, DOI 10.1139/O07-071; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; SYMONDS G, 1986, MOL CELL BIOL, V6, P1796, DOI 10.1128/MCB.6.5.1796; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tinel M, 2003, J HEPATOL, V39, P171, DOI 10.1016/S0168-8278(03)00238-1; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zahnow CA, 2001, CANCER RES, V61, P261; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	57	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2446	2455		10.1038/onc.2009.90	http://dx.doi.org/10.1038/onc.2009.90			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19448669				2022-12-25	WOS:000267601400003
J	Choi, S; Min, HJ; Kim, M; Hwang, ES; Lee, K				Choi, Sunghee; Min, Hyun Jung; Kim, Miyoung; Hwang, Eun Sook; Lee, Kyunglim			Proton Pump Inhibitors Exert Anti-Allergic Effects by Reducing TCTP Secretion	PLOS ONE			English	Article								Background: Extracellular translationally controlled tumor protein (TCTP) is known to play a role in human allergic responses. TCTP has been identified outside of macrophages, in activated mononuclear cells, and in biological fluids from allergic patients. Even TCTP devoid of signal sequences, is secreted to extracellular environment by an yet undefined mechanism. This study is aimed at understanding the mechanism of TCTP release and its regulation. A secondary goal is to see if inhibitors of TCTP release can serve as potential anti-allergic asthmatic drugs. Methodology/Principal Findings: Using Western blotting assay in HEK293 and U937 cells, we found that TCTP secretion is reduced by omeprazole and pantoprazole, both of which are proton pump inhibitors. We then transfected HEK293 cells with proton pump expression vectors to search for the effects of exogeneously overexpressed H+/ K+-ATPase on the TCTP secretion. Based on these in vitro data we checked the in vivo effects of pantoprazole in a murine model of ovalbumin-induced allergy. Omeprazole and pantoprazole reduced TCTP secretion from HEK293 and U937 cells in a concentration-dependent fashion and the secretion of TCTP from HEK293 cells increased when they over-expressed H+/K+-ATPase. In a murine model of ovalbumin-induced allergy, pretreatment with pantoprazole reduced infiltration of inflammatory cells, increased goblet cells, and increased TCTP secretion induced by OVA challenge. Conclusion: Since Omeprazole and pantoprazole decrease the secretion of TCTP which is associated with the development of allergic reaction, they may have the potential to serve as anti-allergic (asthmatic) drugs.			Choi, S (corresponding author), Ewha Womans Univ, Ctr Cell Signaling & Drug Discovery Res, Coll Pharm, Seoul, South Korea.	klyoon@ewha.ac.kr	Min, Hyunjung/ABA-8709-2020					Agastya G, 2000, IMMUNOPHARM IMMUNOT, V22, P357, DOI 10.3109/08923970009016425; Amzallag N, 2004, J BIOL CHEM, V279, P46104, DOI 10.1074/jbc.M404850200; BELL NJV, 1992, GUT, V33, P118, DOI 10.1136/gut.33.1.118; Bheekha-Escura R, 2000, BLOOD, V96, P2191; Bommer UA, 2002, RNA, V8, P478, DOI 10.1017/S1355838202022586; de Oliveira RM, 2007, INFLAMM RES, V56, P105, DOI 10.1007/s00011-006-6127-6; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; Grant RL, 1996, IN VITRO CELL DEV-AN, V32, P38, DOI 10.1007/BF02722992; Holm A, 1999, MED BIOL ENG COMPUT, V37, P410, DOI 10.1007/BF02513321; IM WB, 1985, J BIOL CHEM, V260, P9452; Jiang SP, 2002, ANTIMICROB AGENTS CH, V46, P2569, DOI 10.1128/AAC.46.8.2569-2574.2002; KUCHLER K, 1992, ENDOCR REV, V13, P499, DOI 10.1210/er.13.3.499; LICHTENSTEIN LM, 1988, J ALLERGY CLIN IMMUN, V81, P814, DOI 10.1016/0091-6749(88)90936-0; LIU MC, 1986, J IMMUNOL, V136, P2588; LORENTZON P, 1987, BIOCHIM BIOPHYS ACTA, V897, P41, DOI 10.1016/0005-2736(87)90313-0; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MACDONALD SM, 1995, SCIENCE, V269, P688, DOI 10.1126/science.7542803; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; Naseri E, 2006, EUR J PHARMACOL, V531, P226, DOI 10.1016/j.ejphar.2005.12.025; Nickel W, 2005, TRAFFIC, V6, P607, DOI 10.1111/j.1600-0854.2005.00302.x; Nielsen HV, 1998, ALLERGY, V53, P642, DOI 10.1111/j.1398-9995.1998.tb03950.x; PASMANS SGMA, 1994, INT ARCH ALLERGY IMM, V103, P44, DOI 10.1159/000236604; Schroeder JT, 1997, J IMMUNOL, V159, P447; Suzuki M, 1999, J GASTROEN HEPATOL, V14, P27, DOI 10.1046/j.1440-1746.1999.01809.x; Teshima S, 1998, J IMMUNOL, V161, P6356; WANDALL JH, 1992, GUT, V33, P617, DOI 10.1136/gut.33.5.617; WARNER JA, 1986, J IMMUNOL, V136, P2583; YOON KL, 1994, J BIOL CHEM, V269, P28249; Yoshida N, 2000, ALIMENT PHARM THERAP, V14, P74, DOI 10.1046/j.1365-2036.2000.014s1074.x; Zedtwitz-Liebenstein K, 2002, CRIT CARE MED, V30, P1118, DOI 10.1097/00003246-200205000-00026	30	9	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2009	4	6							e5732	10.1371/journal.pone.0005732	http://dx.doi.org/10.1371/journal.pone.0005732			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	452GL	19484128	Green Submitted, Green Published, gold			2022-12-25	WOS:000266528200001
J	Gao, D; Yang, YK; Wang, RP; Zhou, X; Diao, FC; Li, MD; Zhai, ZH; Jiang, ZF; Chen, DY				Gao, Dong; Yang, Yong-Kang; Wang, Rui-Peng; Zhou, Xiang; Diao, Fei-Ci; Li, Min-Dian; Zhai, Zhong-He; Jiang, Zheng-Fan; Chen, Dan-Ying			REUL Is a Novel E3 Ubiquitin Ligase and Stimulator of Retinoic-Acid-Inducible Gene-I	PLOS ONE			English	Article								RIG-I and MDA5 are cytoplasmic sensors that recognize different species of viral RNAs, leads to activation of the transcription factors IRF3 and NF-kappa B, which collaborate to induce type I interferons. In this study, we identified REUL, a RING-finger protein, as a specific RIG-I-interacting protein. REUL was associated with RIG-I, but not MDA5, through its PRY and SPRY domains. Overexpression of REUL potently potentiated RIG-I-, but not MDA5-mediated downstream signalling and antiviral activity. In contrast, the RING domain deletion mutant of REUL suppressed Sendai virus (SV)-induced, but not cytoplasmic polyI:C-induced activation of IFN-beta promoter. Knockdown of endogenous REUL by RNAi inhibited SV-triggered IFN-beta expression, and also increased VSV replication. Full-length RIG-I, but not the CARD domain deletion mutant of RIG-I, underwent ubiquitination induced by REUL. The Lys 154, 164, and 172 residues of the RIG-I CARD domain were critical for efficient REUL-mediated ubiquitination, as well as the ability of RIG-I to induce activation of IFN-beta promoter. These findings suggest that REUL is an E3 ubiquitin ligase of RIG-I and specifically stimulates RIG-I-mediated innate antiviral activity.			Gao, D (corresponding author), Peking Univ, Coll Life Sci, Minist Educ, Key Lab Cell Proliferat & Differentiat, Beijing 100871, Peoples R China.	dychen@pku.edu.cn	Wang, Ruipeng/I-1407-2013; Li, Min-Dian/F-1721-2015; YANG, YONGKANG/AEP-2772-2022	Wang, Ruipeng/0000-0002-1003-1420; Li, Min-Dian/0000-0002-3650-1507; YANG, YONGKANG/0000-0002-0333-7712; Gao, Dong/0000-0003-1821-2741				Arimoto KI, 2007, P NATL ACAD SCI USA, V104, P7500, DOI 10.1073/pnas.0611551104; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Douglas J, 2007, NAT GENET, V39, P963, DOI 10.1038/ng2083; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Friedman CS, 2008, EMBO REP, V9, P930, DOI 10.1038/embor.2008.136; Gack MU, 2007, NATURE, V446, P916, DOI 10.1038/nature05732; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Jenne DE, 2003, GENE CHROMOSOME CANC, V37, P111, DOI 10.1002/gcc.10206; Jenne DE, 2001, AM J HUM GENET, V69, P516, DOI 10.1086/323043; Jounai N, 2007, P NATL ACAD SCI USA, V104, P14050, DOI 10.1073/pnas.0704014104; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kim MJ, 2008, J VIROL, V82, P1474, DOI 10.1128/JVI.01650-07; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; ORIMO A, 1995, J BIOL CHEM, V270, P24406, DOI 10.1074/jbc.270.41.24406; Oshiumi H, 2009, J BIOL CHEM, V284, P807, DOI 10.1074/jbc.M804259200; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Rothenfusser S, 2005, J IMMUNOL, V175, P5260, DOI 10.4049/jimmunol.175.8.5260; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Takeuchi O, 2007, IMMUNOL REV, V220, P214, DOI 10.1111/j.1600-065X.2007.00562.x; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Zhang MY, 2008, J BIOL CHEM, V283, P18621, DOI 10.1074/jbc.M801451200	26	97	104	3	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2009	4	6							e5760	10.1371/journal.pone.0005760	http://dx.doi.org/10.1371/journal.pone.0005760			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	452GL	19484123	gold, Green Submitted, Green Published			2022-12-25	WOS:000266528200012
J	Karapetyan, YE; Saa, P; Mahal, SP; Sferrazza, GF; Sherman, A; Sales, N; Weissmann, C; Lasmezas, CI				Karapetyan, Yervand Eduard; Saa, Paula; Mahal, Sukhvir Paul; Sferrazza, Gian Franco; Sherman, Alexandra; Sales, Nicole; Weissmann, Charles; Lasmezas, Corinne Ida			Prion Strain Discrimination Based on Rapid In Vivo Amplification and Analysis by the Cell Panel Assay	PLOS ONE			English	Article							CREUTZFELDT-JAKOB-DISEASE; SINGLE AMINO-ACID; INCUBATION-TIME; NERVOUS-SYSTEM; PROTEIN; SCRAPIE; PRP; MICE; EXPRESSION; AGENT	Prion strain identification has been hitherto achieved using time-consuming incubation time determinations in one or more mouse lines and elaborate neuropathological assessment. In the present work, we make a detailed study of the properties of PrP-overproducing Tga20 mice. We show that in these mice the four prion strains examined are rapidly and faithfully amplified and can subsequently be discriminated by a cell-based procedure, the Cell Panel Assay.			Karapetyan, YE (corresponding author), Scripps Res Inst, Dept Infectol, Jupiter, FL USA.	lasmezas@scripps.edu	, Karapetyan/AAN-1433-2020; Saa, Paula/AAB-6607-2019	Saa, Paula/0000-0001-6077-4532	NINDS NIH HHS [R01 NS059543] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barron RM, 2001, EMBO J, V20, P5070, DOI 10.1093/emboj/20.18.5070; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; Brown KL, 2000, MICROSC RES TECHNIQ, V50, P40, DOI 10.1002/1097-0029(20000701)50:1<40::AID-JEMT7>3.0.CO;2-M; Bruce ME, 2002, J GEN VIROL, V83, P695, DOI 10.1099/0022-1317-83-3-695; BRUCE ME, 1993, BRIT MED BULL, V49, P822, DOI 10.1093/oxfordjournals.bmb.a072649; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; Cohen E, 2003, EMBO J, V22, P404, DOI 10.1093/emboj/cdg045; Couzin J, 2004, SCIENCE, V305, P589; CRONIER S, 2008, BIOCH J; Dell'Omo G, 2002, EUR J NEUROSCI, V16, P735, DOI 10.1046/j.1460-9568.2002.02128.x; DICKINSON AG, 1989, UNCONVENTIONAL VIRUS, P446; Dickinson AG., 1979, SLOW TRANSMISSIBLE D, P13; DOI S, 1988, J GEN VIROL, V69, P955, DOI 10.1099/0022-1317-69-4-955; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Ford MJ, 2002, NEUROSCIENCE, V111, P533, DOI 10.1016/S0306-4522(01)00603-0; FRASER H, 1968, J COMP PATHOL, V78, P301, DOI 10.1016/0021-9975(68)90006-6; FRASER H, 1973, J COMP PATHOL, V83, P29, DOI 10.1016/0021-9975(73)90024-8; Glatzel M, 2000, J GEN VIROL, V81, P2813, DOI 10.1099/0022-1317-81-11-2813; Grenier C, 2006, J NEUROCHEM, V97, P1456, DOI 10.1111/j.1471-4159.2006.03837.x; Haeberle AM, 2000, MICROSC RES TECHNIQ, V50, P66, DOI 10.1002/1097-0029(20000701)50:1<66::AID-JEMT10>3.0.CO;2-3; KIMBERLIN RH, 1986, J GEN VIROL, V67, P255, DOI 10.1099/0022-1317-67-2-255; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P11666, DOI 10.1073/pnas.1834432100; Laine J, 2001, EUR J NEUROSCI, V14, P47, DOI 10.1046/j.0953-816x.2001.01621.x; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Lasmezas CI, 2001, P NATL ACAD SCI USA, V98, P4142, DOI 10.1073/pnas.041490898; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Liu T, 2001, BRAIN RES, V896, P118, DOI 10.1016/S0006-8993(01)02050-9; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Mahal SP, 2007, P NATL ACAD SCI USA, V104, P20908, DOI 10.1073/pnas.0710054104; Manson JC, 1999, EMBO J, V18, P6855, DOI 10.1093/emboj/18.23.6855; Montrasio F, 2001, P NATL ACAD SCI USA, V98, P4034, DOI 10.1073/pnas.051609398; Owen JP, 2007, MOL BIOTECHNOL, V35, P161, DOI 10.1007/BF02686111; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; REED L. J., 1938, AMER JOUR HYG, V27, P493; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Seeger H, 2005, SCIENCE, V310, P324, DOI 10.1126/science.1118829; SEGADE F, 1995, J IMMUNOL, V154, P2384; Sun R, 2008, VIRAL IMMUNOL, V21, P293, DOI 10.1089/vim.2008.0039; Thackray AM, 2003, J VIROL, V77, P7991, DOI 10.1128/JVI.77.14.7991-7998.2003; Thackray AM, 2002, J VIROL, V76, P2510, DOI 10.1128/JVI.76.5.2510-2517.2002; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4; Watts JC, 2007, EMBO J, V26, P4038, DOI 10.1038/sj.emboj.7601830; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0; WESTAWAY D, 1994, P NATL ACAD SCI USA, V91, P6418, DOI 10.1073/pnas.91.14.6418; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Williamson RA, 1998, J VIROL, V72, P9413, DOI 10.1128/JVI.72.11.9413-9418.1998	50	40	40	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5730	10.1371/journal.pone.0005730	http://dx.doi.org/10.1371/journal.pone.0005730			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451SH	19478942	Green Published, gold, Green Submitted			2022-12-25	WOS:000266490000007
J	Ukkola, LT; Onkamo, P; Raijas, P; Karma, K; Jarvela, I				Ukkola, Liisa T.; Onkamo, Paivi; Raijas, Pirre; Karma, Kai; Jarvela, Irma			Musical Aptitude Is Associated with AVPR1A-Haplotypes	PLOS ONE			English	Article							SEROTONIN TRANSPORTER GENE; REGION 5-HTTLPR; PROMOTER REGION; RECEPTOR GENE; VASOPRESSIN; POLYMORPHISM; AVPR1A; BEHAVIOR; BRAIN; IDENTIFICATION	Artistic creativity forms the basis of music culture and music industry. Composing, improvising and arranging music are complex creative functions of the human brain, which biological value remains unknown. We hypothesized that practicing music is social communication that needs musical aptitude and even creativity in music. In order to understand the neurobiological basis of music in human evolution and communication we analyzed polymorphisms of the arginine vasopressin receptor 1A (AVPR1A), serotonin transporter (SLC6A4), catecol-O-methyltranferase (COMT), dopamin receptor D2 (DRD2) and tyrosine hydroxylase 1 (TPH1), genes associated with social bonding and cognitive functions in 19 Finnish families (n = 343 members) with professional musicians and/or active amateurs. All family members were tested for musical aptitude using the auditory structuring ability test (Karma Music test; KMT) and Carl Seashores tests for pitch (SP) and for time (ST). Data on creativity in music (composing, improvising and/or arranging music) was surveyed using a web-based questionnaire. Here we show for the first time that creative functions in music have a strong genetic component (h(2) = .84; composing h(2) = .40; arranging h(2) = .46; improvising h(2) = .62) in Finnish multigenerational families. We also show that high music test scores are significantly associated with creative functions in music (p <.0001). We discovered an overall haplotype association with AVPR1A gene (markers RS1 and RS3) and KMT (p = 0.0008; corrected p = 0.00002), SP (p = 0.0261; corrected p = 0.0072) and combined music test scores (COMB) (p = 0.0056; corrected p = 0.0006). AVPR1A haplotype AVR+RS1 further suggested a positive association with ST (p = 0.0038; corrected p = 0.00184) and COMB (p = 0.0083; corrected p = 0.0040) using haplotype-based association test HBAT. The results suggest that the neurobiology of music perception and production is likely to be related to the pathways affecting intrinsic attachment behavior.			Ukkola, LT (corresponding author), Univ Helsinki, Dept Med Genet, Helsinki, Finland.	irma.jarvela@kolumbus.fi	Jarvela, Irma E/L-5836-2013; Ukkola-Vuoti, Liisa/E-6564-2016	Jarvela, Irma E/0000-0002-1770-6187; Ukkola-Vuoti, Liisa/0000-0002-0770-361X				Abecasis GR, 2000, AM J HUM GENET, V66, P279, DOI 10.1086/302698; Aguilera M, 2008, AM J MED GENET B, V147B, P898, DOI 10.1002/ajmg.b.30705; Aleman A, 2008, BIOL PSYCHOL, V79, P58, DOI 10.1016/j.biopsycho.2008.01.009; Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844; Bachner-Melman R, 2005, PLOS GENET, V1, P394, DOI 10.1371/journal.pgen.0010042; Bachner-Melman R., 2005, J INDIVID DIFFER, V26, P2, DOI DOI 10.1027/1614-0001.26.1.2; Barnett JH, 2007, AM J PSYCHIAT, V164, P142, DOI 10.1176/appi.ajp.164.1.142; Bengtsson SL, 2007, J COGNITIVE NEUROSCI, V19, P830, DOI 10.1162/jocn.2007.19.5.830; Bondy B, 2006, MOL PSYCHIATR, V11, P336, DOI 10.1038/sj.mp.4001803; Brown S, 2006, EUR J NEUROSCI, V23, P2791, DOI 10.1111/j.1460-9568.2006.04785.x; Chen JS, 2004, AM J HUM GENET, V75, P807, DOI 10.1086/425589; COKER J, 1986, IMPROVISING JAZZ; COOPER JR, 1961, J PHARMACOL EXP THER, V132, P265; CSIKSZENTMIHALY.M, 1990, FLOW PSYCHOL OPTIMAL, P33; Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668; Ekman A, 2007, EUR J EPIDEMIOL, V22, P293, DOI 10.1007/s10654-006-9091-0; Emanuele E, 2007, NEUROENDOCRINOL LETT, V28, P815; Fink S, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-176; Gagne F, 1997, ROEPER REV, V20, P76; Gosling SD, 2004, AM PSYCHOL, V59, P93, DOI 10.1037/0003-066X.59.2.93; Gosso MF, 2008, EUR J HUM GENET, V16, P1075, DOI 10.1038/ejhg.2008.57; GRANDY DK, 1993, HUM MOL GENET, V2, P2197, DOI 10.1093/hmg/2.12.2197-a; Granota RY, 2007, EVOL HUM BEHAV, V28, P313, DOI 10.1016/j.evolhumbehav.2007.05.003; Hammock EAD, 2006, PHILOS T R SOC B, V361, P2187, DOI 10.1098/rstb.2006.1939; HASSLER M, 1992, PSYCHONEUROENDOCRINO, V17, P55, DOI 10.1016/0306-4530(92)90076-J; Hu XZ, 2006, AM J HUM GENET, V78, P815, DOI 10.1086/503850; Ijmker S, 2008, SCAND J WORK ENV HEA, V34, P113, DOI 10.5271/sjweh.1220; Insel TR, 2001, NAT REV NEUROSCI, V2, P129, DOI 10.1038/35053579; Justus T, 2005, MUSIC PERCEPT, V23, P1, DOI 10.1525/mp.2005.23.1.1; Karma K., 1994, PSYCHOL MUSIC, V22, P20, DOI DOI 10.1177/0305735694221002; Karma K., 2007, PSYCHOMUSICOLOGY, V19, P79, DOI [10.1037/h0094033, DOI 10.1037/H0094033]; Kim SJ, 2002, MOL PSYCHIATR, V7, P503, DOI 10.1038/sj.mp.4001125; Kirsch P, 2006, NEUROSCI LETT, V405, P196, DOI 10.1016/j.neulet.2006.07.030; Klein TA, 2007, SCIENCE, V318, P1642, DOI 10.1126/science.1145044; Knafo A, 2008, GENES BRAIN BEHAV, V7, P266, DOI 10.1111/j.1601-183X.2007.00341.x; Kremer I, 2005, AM J PSYCHIAT, V162, P924, DOI 10.1176/appi.ajp.162.5.924; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D; Lang UE, 2007, NEUROPSYCHOPHARMACOL, V32, P1950, DOI 10.1038/sj.npp.1301335; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Levitin DJ, 2005, ANN NY ACAD SCI, V1060, P325, DOI 10.1196/annals.1360.027; Limb CJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001679; MARTINDALE C, 2006, HDB CREATIVITY, P137; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; PALADE GE, 2001, ORIGINS CREATIVITY, P145; Peretz I, 2006, COGNITION, V100, P1, DOI 10.1016/j.cognition.2005.11.004; PIIRTO J, 2004, UNDERSTANDING CREATI, P360; Pulli K, 2008, J MED GENET, V45, P451, DOI 10.1136/jmg.2007.056366; Rasmussen HB, 2007, PSYCHIAT GENET, V17, P287, DOI 10.1097/YPG.0b013e328133f331; Rauceo S, 2008, BEHAV BRAIN RES, V187, P133, DOI 10.1016/j.bbr.2007.09.003; Reuter M, 2006, BRAIN RES, V1069, P190, DOI 10.1016/j.brainres.2005.11.046; Reuter M, 2005, BEHAV BRAIN RES, V164, P93, DOI 10.1016/j.bbr.2005.06.002; Reuter M, 2005, AM J MED GENET B, V134B, P20, DOI 10.1002/ajmg.b.30153; Seashore CE., 1960, SEASHORE MEASURES MU; Shaw P, 2007, BIOESSAYS, V29, P962, DOI 10.1002/bies.20641; Sloboda JA., 2001, MUSIC EMOTION THEORY; Sternberg RJ, 2006, INTERNATIONAL HANDBOOK OF CREATIVITY, P1; Thibonnier M, 1996, GENOMICS, V31, P327, DOI 10.1006/geno.1996.0055; Thompson R, 2004, PSYCHONEUROENDOCRINO, V29, P35, DOI 10.1016/S0306-4530(02)00133-6; Walther DJ, 2003, BIOCHEM PHARMACOL, V66, P1673, DOI 10.1016/S0006-2952(03)00556-2; Walum H, 2008, P NATL ACAD SCI USA, V105, P14153, DOI 10.1073/pnas.0803081105; Wassink TH, 2004, MOL PSYCHIATR, V9, P968, DOI 10.1038/sj.mp.4001503; WEINSHILBOUM R, 1977, NEUROPHARMACOLOGY, V16, P703, DOI 10.1016/0028-3908(77)90124-1; Wichers M, 2008, NEUROPSYCHOPHARMACOL, V33, P3030, DOI 10.1038/sj.npp.1301520; Wigginton JE, 2005, BIOINFORMATICS, V21, P3445, DOI 10.1093/bioinformatics/bti529; Winner E., 1996, GIFTED CHILDREN MYTH; Yirmiya N, 2006, MOL PSYCHIATR, V11, P488, DOI 10.1038/sj.mp.4001812; Yonan AL, 2006, PSYCHIAT GENET, V16, P31, DOI 10.1097/01.ypg.0000174393.79883.05; Zalsman G, 2006, AM J PSYCHIAT, V163, P1588, DOI 10.1176/appi.ajp.163.9.1588; Zatorre R, 2005, NATURE, V434, P312, DOI 10.1038/434312a; Zeki S, 2007, FEBS LETT, V581, P2575, DOI 10.1016/j.febslet.2007.03.094	70	74	79	0	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5534	10.1371/journal.pone.0005534	http://dx.doi.org/10.1371/journal.pone.0005534			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	448AY	19461995	Green Published, gold, Green Submitted			2022-12-25	WOS:000266234700001
J	Bodewes, R; Kreijtz, JHCM; Baas, C; Geelhoed-Mieras, MM; de Mutsert, G; van Amerongen, G; van den Brand, JMA; Fouchier, RAM; Osterhaus, ADME; Rimmelzwaan, GF				Bodewes, Rogier; Kreijtz, Joost H. C. M.; Baas, Chantal; Geelhoed-Mieras, Martina M.; de Mutsert, Gerrie; van Amerongen, Geert; van den Brand, Judith M. A.; Fouchier, Ron A. M.; Osterhaus, Albert D. M. E.; Rimmelzwaan, Guus F.			Vaccination against Human Influenza A/H3N2 Virus Prevents the Induction of Heterosubtypic Immunity against Lethal Infection with Avian Influenza A/H5N1 Virus	PLOS ONE			English	Article								Annual vaccination against seasonal influenza viruses is recommended for certain individuals that have a high risk for complications resulting from infection with these viruses. Recently it was recommended in a number of countries including the USA to vaccinate all healthy children between 6 and 59 months of age as well. However, vaccination of immunologically naive subjects against seasonal influenza may prevent the induction of heterosubtypic immunity against potentially pandemic strains of an alternative subtype, otherwise induced by infection with the seasonal strains. Here we show in a mouse model that the induction of protective heterosubtypic immunity by infection with a human A/H3N2 influenza virus is prevented by effective vaccination against the A/H3N2 strain. Consequently, vaccinated mice were no longer protected against a lethal infection with an avian A/H5N1 influenza virus. As a result H3N2-vaccinated mice continued to loose body weight after A/H5N1 infection, had 100-fold higher lung virus titers on day 7 post infection and more severe histopathological changes than mice that were not protected by vaccination against A/H3N2 influenza. The lack of protection correlated with reduced virus-specific CD8+ T cell responses after A/H5N1 virus challenge infection. These findings may have implications for the general recommendation to vaccinate all healthy children against seasonal influenza in the light of the current pandemic threat caused by highly pathogenic avian A/H5N1 influenza viruses.			Bodewes, R (corresponding author), Erasmus MC, Dept Virol, Rotterdam, Netherlands.	g.rimmelzwaan@erasmusmc.nl	Fouchier, Ron A/A-1911-2014	Fouchier, Ron A/0000-0001-8095-2869; Osterhaus, Albert/0000-0002-6074-1172; Bodewes, Rogier/0000-0002-0689-7889				Belz GT, 2000, J VIROL, V74, P3486, DOI 10.1128/JVI.74.8.3486-3493.2000; Cassetti Maria Cristina, 2005, Vaccine, V23, P1529, DOI 10.1016/j.vaccine.2004.09.004; Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; de Bree GJ, 2005, J EXP MED, V202, P1433, DOI 10.1084/jem.20051365; de Wit E, 2005, J VIROL, V79, P12401, DOI 10.1128/JVI.79.19.12401-12407.2005; deJong JC, 1997, NATURE, V389, P554, DOI 10.1038/39218; DOHERTY PC, 1978, J EXP MED, V148, P534, DOI 10.1084/jem.148.2.534; Epstein SL, 2006, J INFECT DIS, V193, P49, DOI 10.1086/498980; Epstein SL, 1997, J IMMUNOL, V158, P1222; Fiore Anthony E., 2008, Morbidity and Mortality Weekly Report, V57, P1; Flynn KJ, 1998, IMMUNITY, V8, P683, DOI 10.1016/S1074-7613(00)80573-7; FRANK AL, 1980, J CLIN MICROBIOL, V12, P426, DOI 10.1128/JCM.12.3.426-432.1980; Girard MP, 2008, VACCINE, V26, P3969, DOI [10.1016/j.vaccine.2008.04.051, 10.1016/j.vaccine.2008.03.006]; GREBE KM, 2008, MICROBES INFECT; Haanen JBAG, 1999, EUR J IMMUNOL, V29, P1168, DOI 10.1002/(SICI)1521-4141(199904)29:04<1168::AID-IMMU1168>3.0.CO;2-J; He XS, 2006, J VIROL, V80, P11756, DOI 10.1128/JVI.01460-06; Heikkinen T, 2006, EUR J PEDIATR, V165, P223, DOI 10.1007/s00431-005-0040-9; Hogan RJ, 2001, J IMMUNOL, V166, P1813, DOI 10.4049/jimmunol.166.3.1813; Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402; Jameson J, 1999, J IMMUNOL, V162, P7578; Karber G, 1931, EXP PATHOL PHARM, V162, P480; Kohlmeier JE, 2007, J IMMUNOL, V178, P4721, DOI 10.4049/jimmunol.178.8.4721; Kreijtz JHCM, 2008, J VIROL, V82, P5161, DOI 10.1128/JVI.02694-07; Kreijtz JHCM, 2007, VACCINE, V25, P612, DOI 10.1016/j.vaccine.2006.08.036; LEE LY, 2008, J CLIN INVEST; Liu WL, 2004, IMMUNOL LETT, V93, P131, DOI 10.1016/j.imlet.2004.03.003; Luce BR, 2008, VACCINE, V26, P2841, DOI 10.1016/j.vaccine.2008.03.046; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; Moyron-Quiroz JE, 2004, NAT MED, V10, P927, DOI 10.1038/nm1091; Neuzil KM, 2002, J INFECT DIS, V185, P147, DOI 10.1086/338363; O'Neill E, 2000, J GEN VIROL, V81, P2689, DOI 10.1099/0022-1317-81-11-2689; Palmer DF, 1975, ADV LAB TECHNIQUES I, P25; Philippa J, 2007, VACCINE, V25, P3800, DOI 10.1016/j.vaccine.2007.01.121; Rimmelzwaan GF, 1998, J VIROL METHODS, V74, P57, DOI 10.1016/S0166-0934(98)00071-8; Rimmelzwaan GF, 2001, J VIROL, V75, P6687, DOI 10.1128/JVI.75.14.6687-6691.2001; Rimmelzwaan GF, 2007, CURR OPIN BIOTECH, V18, P529, DOI 10.1016/j.copbio.2007.11.002; Ritzwoller DP, 2005, PEDIATRICS, V116, P153, DOI 10.1542/peds.2005-0049; Salo H, 2006, VACCINE, V24, P4934, DOI 10.1016/j.vaccine.2006.03.057; SCHULMAN JL, 1965, J BACTERIOL, V89, P170, DOI 10.1128/JB.89.1.170-174.1965; Seo SH, 2002, J VIROL, V76, P4886, DOI 10.1128/JVI.76.10.4886-4890.2002; Seo SH, 2001, J VIROL, V75, P2516, DOI 10.1128/JVI.75.6.2516-2525.2001; Shuler CM, 2007, PEDIATRICS, V119, pE587, DOI 10.1542/peds.2006-1878; Smallman-Raynor M, 2007, EMERG INFECT DIS, V13, P510, DOI 10.3201/eid1303.060849; VESIKARI T, 2008, SS04 3 MF59T ADJUVAN; Voeten JTM, 1999, VACCINE, V17, P1942, DOI 10.1016/S0264-410X(98)00464-2; WEBSTER RG, 1980, EUR J IMMUNOL, V10, P396, DOI 10.1002/eji.1830100515; *WHO, 2008, CONF HUM CAS AV INFL; Williams MA, 2004, J IMMUNOL, V173, P6694, DOI 10.4049/jimmunol.173.11.6694; *WRIT COMM 2 WHO C, 2008, NEW ENGL J MED, P261; Zangwill KM, 2004, PEDIATR INFECT DIS J, V23, P189, DOI 10.1097/01.inf.0000116292.46143.d6	50	83	84	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2009	4	5							e5538	10.1371/journal.pone.0005538	http://dx.doi.org/10.1371/journal.pone.0005538			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FX	19440239	gold, Green Published, Green Submitted			2022-12-25	WOS:000266107300005
J	Kasuga, T; Mannhaupt, G; Glass, NL				Kasuga, Takao; Mannhaupt, Gertrud; Glass, N. Louise			Relationship between Phylogenetic Distribution and Genomic Features in Neurospora crassa	PLOS ONE			English	Article								In the post-genome era, insufficient functional annotation of predicted genes greatly restricts the potential of mining genome data. We demonstrate that an evolutionary approach, which is independent of functional annotation, has great potential as a tool for genome analysis. We chose the genome of a model filamentous fungus Neurospora crassa as an example. Phylogenetic distribution of each predicted protein coding gene (PCG) in the N. crassa genome was used to classify genes into six mutually exclusive lineage specificity (LS) groups, i.e. Eukaryote/Prokaryote- core, Dikarya-core, Ascomycota-core, Pezizomycotina-specific, N. crassa-orphans and Others. Functional category analysis revealed that only similar to 23% of PCGs in the two most highly lineage-specific grouping, Pezizomycotina-specific and N. crassa-orphans, have functional annotation. In contrast, similar to 76% of PCGs in the remaining four LS groups have functional annotation. Analysis of chromosomal localization of N. crassa-orphan PCGs and genes encoding for secreted proteins showed enrichment in subtelomeric regions. The origin of N. crassa-orphans is not known. We found that 11% of N. crassa-orphans have paralogous N. crassa-orphan genes. Of the paralogous N. crassa-orphan gene pairs, 33% were tandemly located in the genome, implying a duplication origin of N. crassa-orphan PCGs in the past. LS grouping is thus a useful tool to explore and understand genome organization, evolution and gene function in fungi.			Kasuga, T (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	tkasuga@ucdavis.edu	Glass, N. Louise/ABA-7303-2021	Aramayo, Rodolfo/0000-0001-9702-6204	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM068087] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM068087, GM068087] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 2000, P NATL ACAD SCI USA, V97, P11319, DOI 10.1073/pnas.200346997; Arnold R, 2005, BIOINFORMATICS, V21, P42, DOI 10.1093/bioinformatics/bti1107; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cai JJ, 2006, J MOL EVOL, V63, P1, DOI 10.1007/s00239-004-0372-5; Cuomo CA, 2007, SCIENCE, V317, P1400, DOI 10.1126/science.1143708; Dufayard JF, 2005, BIOINFORMATICS, V21, P2596, DOI 10.1093/bioinformatics/bti325; Fabre E, 2005, MOL BIOL EVOL, V22, P856, DOI 10.1093/molbev/msi070; Fan C, 2008, MOL PLANT, V1, P839, DOI 10.1093/mp/ssn050; Fischer D, 1999, BIOINFORMATICS, V15, P759, DOI 10.1093/bioinformatics/15.9.759; Freitas-Junior LH, 2005, CELL, V121, P25, DOI 10.1016/j.cell.2005.01.037; Frishman D, 2001, BIOINFORMATICS, V17, P44, DOI 10.1093/bioinformatics/17.1.44; Galagan JE, 2004, TRENDS GENET, V20, P417, DOI 10.1016/j.tig.2004.07.007; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Kasuga T, 2008, EUKARYOT CELL, V7, P1549, DOI 10.1128/EC.00195-08; Kondrashov FA, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-2-research0008; Koonin EV, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r7; Linardopoulou EV, 2005, NATURE, V437, P94, DOI 10.1038/nature04029; Mannhaupt G, 2003, NUCLEIC ACIDS RES, V31, P1944, DOI 10.1093/nar/gkg293; Marcello L, 2007, GENOME RES, V17, P1344, DOI 10.1101/gr.6421207; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Margolin BS, 1998, GENETICS, V149, P1787; Nei M., 2000, MOL EVOLUTION PHYLOG; Ohno S., 1970, EVOLUTION GENE DUPLI; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Rattei T, 2006, NUCLEIC ACIDS RES, V34, pD252, DOI 10.1093/nar/gkj106; Rost B, 1999, PROTEIN ENG, V12, P85, DOI 10.1093/protein/12.2.85; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Ruepp A, 2004, NUCLEIC ACIDS RES, V32, P5539, DOI 10.1093/nar/gkh894; Scherf A, 2001, CURR OPIN MICROBIOL, V4, P409, DOI 10.1016/S1369-5274(00)00227-7; Selker EU, 1997, TRENDS GENET, V13, P296, DOI 10.1016/S0168-9525(97)01201-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Turner BC, 2001, FUNGAL GENET BIOL, V32, P67, DOI 10.1006/fgbi.2001.1247; Tyler BM, 2006, SCIENCE, V313, P1261, DOI 10.1126/science.1128796; Watters MK, 1999, GENETICS, V153, P705; WOOTTON JC, 1993, COMPUT CHEM, V17, P149, DOI 10.1016/0097-8485(93)85006-X; Wortman JR, 2006, MED MYCOL, V44, pS3, DOI 10.1080/13693780600835799	39	36	37	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 21	2009	4	4							e5286	10.1371/journal.pone.0005286	http://dx.doi.org/10.1371/journal.pone.0005286			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437VA	19461939	Green Submitted, Green Published, gold			2022-12-25	WOS:000265513800017
J	Santi, CM; Butler, A; Kuhn, J; Wei, A; Salkoff, L				Santi, Celia M.; Butler, Alice; Kuhn, Julia; Wei, Aguan; Salkoff, Lawrence			Bovine and Mouse SLO3 K+ Channels EVOLUTIONARY DIVERGENCE POINTS TO AN RCK1 REGION OF CRITICAL FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; REPRODUCTIVE-TRACT PROTEINS; RAPID EVOLUTION; DROSOPHILA-MELANOGASTER; DEPENDENT ACTIVATION; CALCIUM SENSITIVITY; POSITIVE SELECTION; SIGNALING PATHWAYS; SPERM; PH	The slo3 gene encodes a K+ channel found only in mammalian testis. This is in contrast to slo1, which is expressed in many tissues. Genes pertaining to male reproduction, especially those involved in sperm production, evolve morphologically and functionally much faster than their nonsexual counterparts. A comparison of SLO3 channel amino acid sequences from several species revealed a high degree of structural divergence relative to their SLO1 channel paralogues. To reveal any biophysical differences accompanying this rapid structural divergence, we analyzed the functional properties of SLO3 channels from two species, bovine and mouse. We observed several functional differences including voltage range of activation, kinetics, and pH sensitivity. Although SLO3 channel proteins from these two species lack conservation in many structural regions, we found that the first two of these three functional differences map to the same loop structure in their RCK1 (regulator of K+ conductance 1) domain, which links the intermediate RCK1 subdomain to the C-terminal subdomain. We found that small structural changes in this region produce major changes in the voltage range of activation and kinetics. This rapidly evolving loop peptide shows the greatest length and sequence polymorphisms within RCK1 domains from many different species. In SLO3 channels this region may permit evolutionary changes that tune the gating properties in different species.	[Santi, Celia M.; Butler, Alice; Kuhn, Julia; Wei, Aguan; Salkoff, Lawrence] WA Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Santi, CM (corresponding author), WA Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid,Campus Box 8108, St Louis, MO 63110 USA.	santic@pcg.wustl.edu			National Institutes of Health [R21 HD056444, R24 RR017342, R01 GM067154]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R21HD056444] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR017342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067154] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants R21 HD056444 (to C. S.) and R24 RR017342 and R01 GM067154 (to L. S.).	Arnoult C, 1999, P NATL ACAD SCI USA, V96, P6757, DOI 10.1073/pnas.96.12.6757; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; Bezanilla F, 2008, NAT REV MOL CELL BIO, V9, P323, DOI 10.1038/nrm2376; Breitbart H, 2003, CELL MOL BIOL, V49, P321; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Cai XJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003569; Civetta A, 1995, J MOL EVOL, V41, P1085, DOI 10.1007/BF00173190; COULTHART MB, 1988, MOL BIOL EVOL, V5, P182; Darszon A, 2005, INT REV CYTOL, V243, P79, DOI 10.1016/S0074-7696(05)43002-8; Duret L, 2000, MOL BIOL EVOL, V17, P68, DOI 10.1093/oxfordjournals.molbev.a026239; Fay JC, 2001, GENETICS, V158, P1227; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Kim HJ, 2006, J BIOL CHEM, V281, P38573, DOI 10.1074/jbc.M604769200; Martinez-Lopez P, 2009, BIOCHEM BIOPH RES CO, V381, P204, DOI 10.1016/j.bbrc.2009.02.008; Navarro B, 2007, P NATL ACAD SCI USA, V104, P7688, DOI 10.1073/pnas.0702018104; Orio P, 2002, NEWS PHYSIOL SCI, V17, P156, DOI 10.1152/nips.01387.2002; Podlaha O, 2005, MOL BIOL EVOL, V22, P1845, DOI 10.1093/molbev/msi178; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; Schreiber M, 1999, NAT NEUROSCI, V2, P416, DOI 10.1038/8077; Schreiber M, 1998, J BIOL CHEM, V273, P3509, DOI 10.1074/jbc.273.6.3509; Singh RS, 2000, GENES GENET SYST, V75, P119, DOI 10.1266/ggs.75.119; Swanson WJ, 2002, NAT REV GENET, V3, P137, DOI 10.1038/nrg733; Torgerson DG, 2002, MOL BIOL EVOL, V19, P1973, DOI 10.1093/oxfordjournals.molbev.a004021; Visconti PE, 2002, J REPROD IMMUNOL, V53, P133, DOI 10.1016/S0165-0378(01)00103-6; Wang ZW, 2001, NEURON, V32, P867, DOI 10.1016/S0896-6273(01)00522-0; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; Wyckoff GJ, 2000, NATURE, V403, P304, DOI 10.1038/35002070; Xia XM, 2004, J NEUROSCI, V24, P5585, DOI 10.1523/JNEUROSCI.1296-04.2004; Ye S, 2006, CELL, V126, P1161, DOI 10.1016/j.cell.2006.08.029; Zhang X, 2006, J GEN PHYSIOL, V128, P301, DOI 10.1085/jgp.200609551	30	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	2009	284	32					21589	21598		10.1074/jbc.M109.015040	http://dx.doi.org/10.1074/jbc.M109.015040			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478CC	19473978	Green Published, hybrid			2022-12-25	WOS:000268564400053
J	Durr, KL; Abe, K; Tavraz, NN; Friedrich, T				Duerr, Katharina L.; Abe, Kazuhiro; Tavraz, Neslihan N.; Friedrich, Thomas			E2P State Stabilization by the N-terminal Tail of the H,K-ATPase beta-Subunit Is Critical for Efficient Proton Pumping under in Vivo Conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLTAGE-CLAMP FLUOROMETRY; SITE-DIRECTED MUTAGENESIS; P-TYPE ATPASES; ALPHA-SUBUNIT; NA+/K+-ATPASE; FUNCTIONAL-SIGNIFICANCE; CRYSTAL-STRUCTURE; DISULFIDE BONDS; CALCIUM-PUMP; NA,K-ATPASE	The catalytic alpha-subunits of Na,K-and H, K-ATPase require an accessory beta-subunit for proper folding, maturation, and plasma membrane delivery but also for cation transport. To investigate the functional significance of the beta-N terminus of the gastric H, K-ATPase in vivo, several N-terminally truncated beta-variants were expressed in Xenopus oocytes, together with the S806C alpha-subunit variant. Upon labeling with the reporter fluorophore tetramethylrhodamine-6-maleimide, this construct can be used to determine the voltage-dependent distribution between E1P/E2P states. Whereas the E1P/E2P conformational equilibrium was unaffected for the shorter N-terminal deletions beta Delta 4 and beta Delta 8, we observed significant shifts toward E1P for the two larger deletions beta Delta 13 and beta Delta 29. Moreover, the reduced Delta F/F ratios of beta Delta 13 and beta Delta 29 indicated an increased reverse reaction via E2P -> E1P + ADP -> E-1 + ATP, because cell surface expression was completely unaffected. This interpretation is supported by the reduced sensitivity of the mutants toward the E2P-specific inhibitor SCH28080, which becomes especially apparent at high concentrations (100 mu M). Despite unaltered apparent Rb+ affinities, the maximal Rb+ uptake of these mutants was also significantly lowered. Considering the two putative interaction sites between the beta-N terminus and alpha-subunit revealed by the recent cryo-EM structure, the N-terminal tail of the H, K-ATPase beta-subunit may stabilize the pump in the E2P conformation, thereby increasing the efficiency of proton release against the million-fold proton gradient of the stomach lumen. Finally, we demonstrate that a similar truncation of the beta-N terminus of the closely related Na, K-ATPase does not affect the E1P/E2P distribution or pump activity, indicating that the E2P-stabilizing effect by the beta-N terminus is apparently a unique property of the H, K-ATPase.	[Duerr, Katharina L.; Tavraz, Neslihan N.; Friedrich, Thomas] Tech Univ Berlin, Inst Chem, D-10623 Berlin, Germany; [Abe, Kazuhiro] Kyoto Univ, Dept Biophys, Fac Sci, Sakyo Ku, Kyoto 6068502, Japan	Technical University of Berlin; Kyoto University	Durr, KL (corresponding author), Tech Univ Berlin, Inst Chem, Secr PC 14,Str 17 Juni 135, D-10623 Berlin, Germany.	katharina.duerr@TU-berlin.de	Abe, Kazuhiro/D-7662-2013; Friedrich, Thomas/AAA-3418-2022; Duerr, Katharina/A-6975-2015	Abe, Kazuhiro/0000-0003-2681-5921; Duerr, Katharina/0000-0002-3245-4088	Deutsche Forschungsgemeinschaft [SFB 740]; Japan New Energy and Industrial Technology Development Organization	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Japan New Energy and Industrial Technology Development Organization(New Energy and Industrial Technology Development Organization (NEDO))	This work was supported by Deutsche Forschungsgemeinschaft Grant SFB 740 and Cluster of Excellence "UNICAT" and Grants-in aid for Specially Promoted Research and by the Japan New Energy and Industrial Technology Development Organization.	Abe K, 2009, EMBO J, V28, P1637, DOI 10.1038/emboj.2009.102; Abriel H, 1999, BBA-BIOMEMBRANES, V1418, P85, DOI 10.1016/S0005-2736(99)00025-5; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; CHOW DC, 1995, J EXP BIOL, V198, P1; Crambert G, 2000, J BIOL CHEM, V275, P1976, DOI 10.1074/jbc.275.3.1976; DEMAREST JR, 1985, AM J PHYSIOL, V249, pC535, DOI 10.1152/ajpcell.1985.249.5.C535; Dempski RE, 2005, J GEN PHYSIOL, V125, P505, DOI 10.1085/jgp.200409186; Durr KL, 2009, J BIOL CHEM, V284, P3842, DOI 10.1074/jbc.M808101200; Durr KL, 2008, BIOCHEMISTRY-US, V47, P4288, DOI 10.1021/bi800092k; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; Geibel S, 2003, ANN NY ACAD SCI, V986, P31, DOI 10.1111/j.1749-6632.2003.tb07136.x; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; Gribble FM, 2000, J BIOL CHEM, V275, P30046, DOI 10.1074/jbc.M001010200; Hasler U, 2001, J BIOL CHEM, V276, P16356, DOI 10.1074/jbc.M008778200; Hasler U, 1998, J BIOL CHEM, V273, P30826, DOI 10.1074/jbc.273.46.30826; Hu YK, 2000, J BIOL CHEM, V275, P30734, DOI 10.1074/jbc.M003737200; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; KAWAMURA M, 1985, BIOCHIM BIOPHYS ACTA, V821, P115, DOI 10.1016/0005-2736(85)90161-0; KEELING DJ, 1989, J BIOL CHEM, V264, P5545; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MATHEWS PM, 1995, AM J PHYSIOL-CELL PH, V268, pC1207, DOI 10.1152/ajpcell.1995.268.5.C1207; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MENDLEIN J, 1990, J BIOL CHEM, V265, P5030; MORI Y, 1989, GASTROENTEROLOGY, V97, P364, DOI 10.1016/0016-5085(89)90072-3; Morth JP, 2007, NATURE, V450, P1043, DOI 10.1038/nature06419; NOGUCHI S, 1994, FEBS LETT, V341, P233, DOI 10.1016/0014-5793(94)80463-X; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; SACHS G, 1976, J BIOL CHEM, V251, P7690; Sachs G, 2007, J CLIN GASTROENTEROL, V41, pS226, DOI 10.1097/MCG.0b013e31803233b7; Shainskaya A, 1996, J BIOL CHEM, V271, P10309, DOI 10.1074/jbc.271.17.10309; Shainskaya A, 2000, J BIOL CHEM, V275, P2019, DOI 10.1074/jbc.275.3.2019; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WALLMARK B, 1983, BIOCHIM BIOPHYS ACTA, V728, P31, DOI 10.1016/0005-2736(83)90433-9; WALLMARK B, 1990, J INTERN MED, V228, P3, DOI 10.1111/j.1365-2796.1990.tb01465.x	41	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20147	20154		10.1074/jbc.M109.005769	http://dx.doi.org/10.1074/jbc.M109.005769			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19491099	Green Published, hybrid			2022-12-25	WOS:000268097400042
J	Ding, B; Kirkiles-Smith, NC; Pober, JS				Ding, Bo; Kirkiles-Smith, Nancy C.; Pober, Jordan S.			FOXO3a Regulates Oxygen-responsive Expression of Tumor Necrosis Factor Receptor 2 in Human Dermal Microvascular Endothelial Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ISCHEMIA-MEDIATED ARTERIOGENESIS; TRANSCRIPTION FACTOR FOXO3A; SIGNALING PATHWAYS; TERMINAL KINASE; UP-REGULATION; HUMAN KIDNEY; FACTOR-ALPHA; APOPTOSIS; ACTIVATION	Microvascular endothelial cell (EC) expression of tumor necrosis factor receptor (TNFR) 2 is induced in situ by ischemia/reperfusion injury. To assess effects of molecular oxygen on TNFR2 expression, we subjected cultured human dermal microvascular ECs (HDMECs) to hypoxic conditions (1% O-2) or to hypoxic conditions followed by return to normoxic conditions. TNFR2 mRNA and protein are expressed under normoxic conditions but are rapidly reduced by hypoxia; they fall even further upon reoxygenation but rebound by 6-9 h. TNFR1 expression is unaffected by hypoxia or reoxygenation in these same cells. We identified a potential FOXO3a binding site in the 5' enhancer region of the TNFR2 gene. FOXO3a from normoxic but not hypoxic HDMECs binds an oligonucleotide sequence matching this site, and the endogenous enhancer binds FOXO3a at this site in HDMECs under normoxic but not hypoxic conditions. Unphosphorylated FOXO3a is present in the nucleus of HDMECs under normoxic conditions. Hypoxia leads to FOXO3a phosphorylation at an Akt/protein kinase B target site and subsequent nuclear export; these processes are reversed by reoxygenation and blocked by LY294002, a phosphatidylinositol 3-kinase inhibitor that blocks Akt activation. LY294002 also prevents the hypoxia-mediated decrease in TNFR2 expression. Transiently transfected FOXO3a activates a TNFR2 promoter/reporter construct in HDMECs, whereas small interference RNA knockdown of FOXO3a reduces TNFR2 but not TNFR1 expression under normoxic conditions. Reduction in TNFR2 by small interference RNA sensitizes HDMECs to TNFR1-mediated apoptosis. We conclude that FOXO3a regulates oxygen-dependent changes in expression of TNFR2 in HDMECs, controlling sensitivity to TNF-mediated apoptosis.	[Ding, Bo; Kirkiles-Smith, Nancy C.; Pober, Jordan S.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA	Yale University	Pober, JS (corresponding author), POB 208089, New Haven, CT 06520 USA.	jordan.pober@yale.edu			National Institutes of Health [HL36003]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036003, R37HL036003] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported, in whole or in part, by National Institutes of Health Grant HL36003.	Al-Lamki RS, 2008, J AM SOC NEPHROL, V19, P953, DOI 10.1681/ASN.2007060706; Al-Lamki RS, 2005, FASEB J, V19, P1637, DOI 10.1096/fj.05-3841com; Al-Lamki RS, 2003, AM J PATHOL, V163, P401, DOI 10.1016/S0002-9440(10)63670-X; Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287; Cornell LD, 2008, ANNU REV PATHOL-MECH, V3, P189, DOI 10.1146/annurev.pathmechdis.3.121806.151508; Danese S, 2007, J IMMUNOL, V178, P6017, DOI 10.4049/jimmunol.178.10.6017; De Palma C, 2006, ARTERIOSCL THROM VAS, V26, P99, DOI 10.1161/01.ATV.0000194074.59584.42; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Grethe S, 2006, BIOCHEM BIOPH RES CO, V347, P781, DOI 10.1016/j.bbrc.2006.06.159; Haridas V, 1998, J IMMUNOL, V160, P3152; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; He Y, 2006, J CLIN INVEST, V116, P2344, DOI 10.1172/JCI28123; Hehlgans T, 2001, J INTERF CYTOK RES, V21, P757, DOI 10.1089/107999001753124480; Hoffmann G, 2004, EXP DERMATOL, V13, P113, DOI 10.1111/j.0906-6705.2004.00142.x; Kluger MS, 2002, J IMMUNOL, V168, P2091, DOI 10.4049/jimmunol.168.5.2091; Krol J, 2007, MOL CANCER THER, V6, P3169, DOI 10.1158/1535-7163.MCT-07-0507; Lee HY, 2008, ARTERIOSCL THROM VAS, V28, P112, DOI 10.1161/ATVBAHA.107.153304; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Luo DH, 2006, AM J PATHOL, V169, P1886, DOI 10.2353/ajpath.2006.060603; Mandinova A, 2008, EMBO J, V27, P1243, DOI 10.1038/emboj.2008.45; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Santee SM, 1996, J BIOL CHEM, V271, P21151, DOI 10.1074/jbc.271.35.21151; Schattenberg JM, 2006, LIVER INT, V26, P904, DOI 10.1111/j.1478-3231.2006.01324.x; Seitz C, 2001, J BIOL CHEM, V276, P19390, DOI 10.1074/jbc.M101336200; Seitz C, 1998, GENOMICS, V48, P111, DOI 10.1006/geno.1997.5161; Takada Y, 2004, J IMMUNOL, V173, P1066, DOI 10.4049/jimmunol.173.2.1066; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Yamanaka Y, 2006, J ORTHOP RES, V24, P1349, DOI 10.1002/jor.20199	32	11	11	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19331	19339		10.1074/jbc.M109.006536	http://dx.doi.org/10.1074/jbc.M109.006536			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19473970	Green Published, hybrid			2022-12-25	WOS:000267908300024
J	Lund, C; Olsen, CM; Skogtvedt, S; Tveit, H; Prydz, K; Tranulis, MA				Lund, Christoffer; Olsen, Christel M.; Skogtvedt, Susan; Tveit, Heidi; Prydz, Kristian; Tranulis, Michael A.			Alternative Translation Initiation Generates Cytoplasmic Sheep Prion Protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; ENDOPLASMIC-RETICULUM; TRANSGENIC MICE; PRIMARY NEURONS; PRP; SCRAPIE; LOCALIZATION; EXPRESSION; TRANSMEMBRANE; DISEASE	Cytoplasmic localization of the prion protein (PrP) has been observed in different species and cell types. We have investigated this poorly understood phenomenon by expressing fusion proteins of sheep prion protein and green fluorescent protein ((PrP)-Pr-GFP) in N2a cells, with variable sequence context surrounding the start codon Met(1). (PrP)-Pr-GFP expressed with the wild-type sequence was transported normally through the secretory pathway to the cell surface with acquisition of N-glycan groups, but two N-terminal fragments of (PrP)-Pr-GFP were detected intracellularly, starting in frame from Met(17). When (PrP)-Pr-GFP was expressed with a compromised Kozak sequence ((PrP)-Pr-GFP*), dispersed intracellular fluorescence was observed. A similar switch from pericellular to intracellular PrP localization was seen when analogous constructs of sheep PrP, without inserted GFP, were expressed, showing that this phenomenon is not caused by the GFP tag. Western blotting revealed a reduction in glycosylated forms of (PrP)-Pr-GFP*, whereas the N-terminal fragments starting from Met(17) were still present. Formation of these N-terminal fragments was completely abolished when Met(17) was replaced by Thr, indicating that leaky ribosomal scanning occurs for normal sheep PrP and that translation from Met(17) is the cause of the aberrant cytoplasmic localization observed for a fraction of the protein. In contrast, the same phenomenon was not detected upon expression of similar constructs for mouse PrP. Analysis of samples from sheep brain allowed immunological detection of N-terminal PrP fragments, indicating that sheep PrP is subject to similar processing mechanisms in vivo.	[Lund, Christoffer; Olsen, Christel M.; Skogtvedt, Susan; Tranulis, Michael A.] Norwegian Sch Vet Sci, Dept Biochem & Physiol, Inst Basic Sci & Aquat Med, N-0033 Oslo, Norway; [Tveit, Heidi; Prydz, Kristian] Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway	Norwegian University of Life Sciences; University of Oslo	Tranulis, MA (corresponding author), Norwegian Sch Vet Sci, Dept Biochem & Physiol, Inst Basic Sci & Aquat Med, Box 8146, N-0033 Oslo, Norway.	Michael.Tranulis@veths.no			Norwegian Research Council; Torsted's Fund for Animal Welfare	Norwegian Research Council(Research Council of NorwayEuropean Commission); Torsted's Fund for Animal Welfare	This work was supported by the Norwegian Research Council and the Torsted's Fund for Animal Welfare.	Aguzzi A, 2008, ANNU REV NEUROSCI, V31, P439, DOI 10.1146/annurev.neuro.31.060407.125620; Bailly Y, 2004, J COMP NEUROL, V473, P244, DOI 10.1002/cne.20117; Barmada S, 2004, NEUROBIOL DIS, V16, P527, DOI 10.1016/j.nbd.2004.05.005; Chesebro B, 2005, SCIENCE, V308, P1435, DOI 10.1126/science.1110837; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Fevrier B, 2004, P NATL ACAD SCI USA, V101, P9683, DOI 10.1073/pnas.0308413101; Fioriti L, 2005, J BIOL CHEM, V280, P11320, DOI 10.1074/jbc.M412441200; Fournier JG, 2008, CELL TISSUE RES, V332, P1, DOI 10.1007/s00441-007-0565-5; Gonzalez L, 2005, J COMP PATHOL, V132, P273, DOI 10.1016/j.jcpa.2004.10.004; Hegde RS, 2003, TRENDS NEUROSCI, V26, P337, DOI 10.1016/S0166-2236(03)00143-7; Heggebo R, 2000, J GEN VIROL, V81, P2327, DOI 10.1099/0022-1317-81-9-2327; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Heller U, 2003, J BIOL CHEM, V278, P36139, DOI 10.1074/jbc.M304002200; Juanes ME, 2009, J BIOL CHEM, V284, P2787, DOI 10.1074/jbc.M804051200; Kang SW, 2006, CELL, V127, P999, DOI 10.1016/j.cell.2006.10.032; Kozak M, 2003, GENE, V318, P1, DOI 10.1016/S0378-1119(03)00774-1; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; Laine J, 2001, EUR J NEUROSCI, V14, P47, DOI 10.1046/j.0953-816x.2001.01621.x; Levine CG, 2005, MOL BIOL CELL, V16, P279, DOI 10.1091/mbc.E04-06-0508; Lorenz H, 2002, J BIOL CHEM, V277, P8508, DOI 10.1074/jbc.M110197200; Lorenz H, 2006, NAT PROTOC, V1, P276, DOI 10.1038/nprot.2006.42; Lund C, 2007, J NEUROSCI METH, V165, P183, DOI 10.1016/j.jneumeth.2007.06.005; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Mironov A, 2003, J NEUROSCI, V23, P7183, DOI 10.1523/JNEUROSCI.23-18-07183.2003; Morris RJ, 2006, FEBS LETT, V580, P5565, DOI 10.1016/j.febslet.2006.07.053; Norstrom EM, 2007, J VIROL, V81, P2831, DOI 10.1128/JVI.02157-06; Orsi A, 2006, J BIOL CHEM, V281, P30431, DOI 10.1074/jbc.M605320200; Park KW, 2008, BIOCHEM BIOPH RES CO, V372, P697, DOI 10.1016/j.bbrc.2008.05.132; Parkin ET, 2004, J BIOL CHEM, V279, P11170, DOI 10.1074/jbc.M312105200; Pergami P, 1996, ANAL BIOCHEM, V236, P63, DOI 10.1006/abio.1996.0132; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200; Sales N, 1998, EUR J NEUROSCI, V10, P2464, DOI 10.1046/j.1460-9568.1998.00258.x; Smith E, 2005, NUCLEIC ACIDS RES, V33, P1298, DOI 10.1093/nar/gki248; Stewart RS, 2003, J BIOL CHEM, V278, P45960, DOI 10.1074/jbc.M307833200; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Strom A, 2007, LAB INVEST, V87, P139, DOI 10.1038/labinvest.3700500; Sunyach C, 2003, EMBO J, V22, P3591, DOI 10.1093/emboj/cdg344; Thuring CMA, 2005, J COMP PATHOL, V132, P59, DOI 10.1016/j.jcpa.2004.06.004; Tveit H, 2005, BIOCHEM BIOPH RES CO, V337, P232, DOI 10.1016/j.bbrc.2005.09.031; VANKEULEN LJM, 1995, VET PATHOL, V32, P299, DOI 10.1177/030098589503200312; Wang XH, 2006, J BIOL CHEM, V281, P13559, DOI 10.1074/jbc.M512306200; Weissmann C, 1996, INT J EXP PATHOL, V77, P283; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zhao HX, 2006, VIRUS RES, V115, P43, DOI 10.1016/j.virusres.2005.07.004; Zou WQ, 2005, CELL, V121, P155, DOI 10.1016/j.cell.2005.04.002	50	7	7	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19668	19678		10.1074/jbc.M109.003566	http://dx.doi.org/10.1074/jbc.M109.003566			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19451655	Green Published, hybrid			2022-12-25	WOS:000267908300058
J	Reitinger, S; Mullegger, J; Greiderer, B; Nielsen, JE; Lepperdinger, G				Reitinger, Stephan; Muellegger, Johannes; Greiderer, Brigitte; Nielsen, Jens Erik; Lepperdinger, Guenter			Designed Human Serum Hyaluronidase 1 Variant, HYAL1(Delta L), Exhibits Activity up to pH 5.9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POISSON-BOLTZMANN EQUATION; TESTICULAR HYALURONIDASE; PK(A) CALCULATIONS; SWISS-MODEL; PROTEIN; ENZYME; PH-20; PURIFICATION; ENVIRONMENT; EXPRESSION	Hyaluronidases from diverse species and sources have different pH optima. Distinct mechanisms with regard to dynamic structural changes, which control hyaluronidase activity at varying pH, are unknown. Human serum hyaluronidase 1 (HYAL1) is active solely below pH 5.1. Here we report the design of a HYAL1 variant that degrades hyaluronan up to pH 5.9. Besides highly conserved residues in close proximity of the active site of most hyaluronidases, we identified a bulky loop formation located at the end of the substrate binding crevice of HYAL1 to be crucial for substrate hydrolysis. The stretch between cysteine residues 207 and 221, which normally contains 13 amino acids, could be replaced by a tetrapeptide sequence of alternating glycine serine residues, thereby yielding an active enzyme with an extended binding cleft. This variant exhibited hyaluronan degradation at elevated pH. This is indicative for appropriate substrate binding and proper positioning being decisively affected by sites far off from the active center.	[Reitinger, Stephan; Greiderer, Brigitte; Lepperdinger, Guenter] Austrian Acad Sci, Inst Biomed Aging Res, Extracellular Matrix Res Grp, A-6020 Innsbruck, Austria; [Muellegger, Johannes] Zymeworks Inc, Vancouver, BC V6H 3V9, Canada; [Nielsen, Jens Erik] Univ Coll Dublin, Conway Inst, Ctr Synth & Chem Biol, Sch Biomol & Biomed Sci, Dublin 4, Ireland	Austrian Academy of Sciences; University College Dublin	Lepperdinger, G (corresponding author), Austrian Acad Sci, Inst Biomed Aging Res, Extracellular Matrix Res Grp, Rennweg 10, A-6020 Innsbruck, Austria.	Guenter.Lepperdinger@oeaw.ac.at		Nielsen, Jens Erik/0000-0002-2831-7718; Lepperdinger, Gunter/0000-0002-4265-4489				Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P304, DOI 10.1093/nar/28.1.304; Chao KL, 2007, BIOCHEMISTRY-US, V46, P6911, DOI 10.1021/bi700382g; Cherr GN, 1996, DEV BIOL, V175, P142, DOI 10.1006/dbio.1996.0102; Csoka TB, 1997, FEBS LETT, V417, P307, DOI 10.1016/S0014-5793(97)01309-4; Frost GI, 1997, BIOCHEM BIOPH RES CO, V236, P10, DOI 10.1006/bbrc.1997.6773; GMACHL M, 1993, FEBS LETT, V336, P545, DOI 10.1016/0014-5793(93)80873-S; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; Joshi MD, 2001, BIOCHEMISTRY-US, V40, P10115, DOI 10.1021/bi0105429; KREIL G, 1995, PROTEIN SCI, V4, P1666, DOI 10.1002/pro.5560040902; Lepperdinger G, 2004, CHEMISTRY AND BIOLOGY OF HYALURONAN, P585; Lepperdinger G, 2001, MATRIX BIOL, V20, P509, DOI 10.1016/S0945-053X(01)00170-6; Lepperdinger G, 2004, CHEMISTRY AND BIOLOGY OF HYALURONAN, P71; Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6; Menzel EJ, 1998, CANCER LETT, V131, P3, DOI 10.1016/S0304-3835(98)00195-5; Meyer MF, 1997, FEBS LETT, V413, P385, DOI 10.1016/S0014-5793(97)00936-8; Mullegger J, 2002, MECH DEVELOP, V111, P25, DOI 10.1016/S0925-4773(01)00593-7; Mullegger J, 2001, ANAL BIOCHEM, V293, P291, DOI 10.1006/abio.2001.5125; Natowicz MR, 1996, CLIN CHIM ACTA, V245, P1, DOI 10.1016/0009-8981(95)06182-7; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Nielsen JE, 2001, PROTEINS, V43, P403, DOI 10.1002/prot.1053; Nielsen JE, 1999, PROTEIN ENG, V12, P657, DOI 10.1093/protein/12.8.657; Nielsen JE, 2003, PROTEIN SCI, V12, P313, DOI 10.1110/ps.0229903; Nielsen JE, 2007, J MOL GRAPH MODEL, V25, P691, DOI 10.1016/j.jmgm.2006.05.007; Oettl M, 2003, EUR J PHARM SCI, V18, P267, DOI 10.1016/S0928-0987(03)00022-8; Podyma KA, 1997, BIOCHEM BIOPH RES CO, V241, P446, DOI 10.1006/bbrc.1997.7829; Reitinger S, 2001, FEBS LETT, V505, P213, DOI 10.1016/S0014-5793(01)02813-7; Reitinger S, 2008, PROTEIN EXPRES PURIF, V57, P226, DOI 10.1016/j.pep.2007.10.001; Reitinger S, 2007, BIOCHEM J, V401, P79, DOI 10.1042/BJ20060598; Skov LK, 2006, ACTA CRYSTALLOGR D, V62, P595, DOI 10.1107/S0907444906010687; Sondergaard CR, 2008, J MOL BIOL, V376, P269, DOI 10.1016/j.jmb.2007.09.070; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; W DeLano, 2002, PYMOL RELEASE 0 99	35	7	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19173	19177		10.1074/jbc.C109.004358	http://dx.doi.org/10.1074/jbc.C109.004358			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19478093	Green Published, hybrid			2022-12-25	WOS:000267908300005
J	Chen, J; Kobayashi, M; Darmanin, S; Qiao, Y; Gully, C; Zhao, R; Yeung, SC; Lee, MH				Chen, J.; Kobayashi, M.; Darmanin, S.; Qiao, Y.; Gully, C.; Zhao, R.; Yeung, S. C.; Lee, M. H.			Pim-1 plays a pivotal role in hypoxia-induced chemoresistance	ONCOGENE			English	Article						Pim-1; hypoxia; apoptosis; chemoresistance; mitochondrial transmembrane potential	OXYGEN DISTRIBUTION; INHIBITS APOPTOSIS; CANCER-CELLS; HUMAN TUMORS; KINASE; EXPRESSION; PHOSPHORYLATION; ACTIVATION; PROTEIN; DEATH	Hypoxia changes the responses of cancer cells to many chemotherapy agents, resulting in chemoresistance. The underlying molecular mechanism of hypoxia-induced drug resistance remains unclear. Pim-1 is a survival kinase, which phosphorylates Bad at serine 112 to antagonize drug-induced apoptosis. Here we show that hypoxia increases Pim-1 in a hypoxia-inducible factor-1 alpha-independent manner. Inhibition of Pim-1 function by dominant-negative Pim-1 dramatically restores the drug sensitivity to apoptosis induced by chemotherapy under hypoxic conditions in both in vitro and in vivo tumor models. Introduction of siRNAs for Pim-1 also resensitizes cancer cells to chemotherapy drugs under hypoxic conditions, whereas forced overexpression of Pim-1 endows solid tumor cells with resistance to cisplatin, even under normoxia. Dominant-negative Pim-1 prevents a decrease in mitochondrial transmembrane potential in solid tumor cells, which is normally induced by cisplatin (CDDP), followed by the reduced activity of Caspase-3 and Caspase-9, indicating that Pim-1 participates in hypoxia-induced drug resistance through the stabilization of mitochondrial transmembrane potential. Our results demonstrate that Pim-1 is a pivotal regulator involved in hypoxia-induced chemoresistance. Targeting Pim-1 may improve the chemotherapeutic strategy for solid tumors. Oncogene (2009) 28, 2581-2592; doi: 10.1038/onc.2009.124; published online 1 June 2009	[Chen, J.; Qiao, Y.; Gully, C.; Zhao, R.; Lee, M. H.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Chen, J.; Darmanin, S.; Qiao, Y.] Hokkaido Univ, Inst Med Genet, Div Canc Related Genes, Sapporo, Hokkaido, Japan; [Chen, J.] Hokkaido Univ, Grad Sch Med, Dept Surg Oncol, Sapporo, Hokkaido, Japan; [Kobayashi, M.] Hokkaido Univ, Div Canc Biol, Inst Med Genet, Sapporo, Hokkaido, Japan; [Yeung, S. C.] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA; [Yeung, S. C.] Univ Texas MD Anderson Canc Ctr, Dept Gen Internal Med Ambulatory Treatment & Emer, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Hokkaido University; Hokkaido University; Hokkaido University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lee, MH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 79,1515 Holcombe Blvd, Houston, TX 77030 USA.	syeung@mdanderson.org; mhlee@mdanderson.org	Yeung, Sai-Ching/AAI-6178-2021; Yeung, Sai-Ching/AAP-8079-2020	Yeung, Sai-Ching/0000-0001-5170-0822; Lee, Mong-Hong/0000-0001-8675-8215	NIHRO1CA [089266]; Japan Society for the Promotion of Science (JSPS); Japanese Ministry of Education, Culture, Sports, Science and Technology; US Department of Defense Breast Cancer Research Program of the Office of the Congressionally Directed Medical Research Programs [DOD SIDA BC062166]; Cancer Center Core [CA16672]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA089266, R56CA089266] Funding Source: NIH RePORTER	NIHRO1CA; Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); US Department of Defense Breast Cancer Research Program of the Office of the Congressionally Directed Medical Research Programs(United States Department of Defense); Cancer Center Core; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the NIHRO1CA (089266 Lee MH), Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) (Chen J), Grants-in-Aid for Cancer Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (Kobayashi M), US Department of Defense Breast Cancer Research Program of the Office of the Congressionally Directed Medical Research Programs (DOD SIDA BC062166 Yeung SJ & Lee MH) and Cancer Center Core Grant (CA16672). We thank Dr BQ Vuong for providing the pCDNA3.1-His-SOCS1 plasmid. We thank Mrs Shirley Ware-Gully for her assistance in preparing the article.	Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Arsham AM, 2004, CANCER RES, V64, P3500, DOI 10.1158/0008-5472.CAN-03-2239; BANDYOPADHYAY RS, 1995, BBA-GENE STRUCT EXPR, V1264, P72, DOI 10.1016/0167-4781(95)00116-X; Cardenas-Navia LI, 2004, CANCER RES, V64, P6010, DOI 10.1158/0008-5472.CAN-03-0947; Chen J, 2003, AM J PATHOL, V162, P1283, DOI 10.1016/S0002-9440(10)63924-7; CHEN J, 2009, AM J PATHOL IN PRESS; Comerford KM, 2002, CANCER RES, V62, P3387; CUYPERS HT, 1984, CELL, V37, P141; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Eichmann A, 2000, ONCOGENE, V19, P1215, DOI 10.1038/sj.onc.1203355; GATENBY RA, 1988, INT J RADIAT ONCOL, V14, P831, DOI 10.1016/0360-3016(88)90002-8; KOH WJ, 1992, INT J RADIAT ONCOL, V22, P199, DOI 10.1016/0360-3016(92)91001-4; KOONG AC, 1994, CANCER RES, V54, P1425; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Lilly M, 1997, CANCER RES, V57, P5348; Liu LL, 2008, CANCER SCI, V99, P121, DOI 10.1111/j.1349-7006.2007.00643.x; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mizukami Y, 2004, CANCER RES, V64, P1765, DOI 10.1158/0008-5472.CAN-03-3017; Niizeki H, 2002, BRIT J CANCER, V86, P1914, DOI 10.1038/sj.bjc.6600331; Pierce AC, 2008, J MED CHEM, V51, P1972, DOI 10.1021/jm701248t; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Teh Beng-gwan, 2004, Hokkaido Journal of Medical Science, V79, P19; TEICHER BA, 1981, CANCER RES, V41, P73; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Toffoli S, 2008, FEBS J, V275, P2991, DOI 10.1111/j.1742-4658.2008.06454.x; Valdman A, 2004, PROSTATE, V60, P367, DOI 10.1002/pros.20064; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VAUPEL P, 1991, CANCER RES, V51, P3316; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Winn LM, 2003, CELL CYCLE, V2, P258, DOI 10.4161/cc.2.3.383; Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200; YOSHIDA A, 1989, J SURG ONCOL, V41, P1, DOI 10.1002/jso.2930410104; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zippo A, 2004, BLOOD, V103, P4536, DOI 10.1182/blood-2003-11-3827; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	37	80	82	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2009	28	28					2581	2592		10.1038/onc.2009.124	http://dx.doi.org/10.1038/onc.2009.124			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	471LJ	19483729	Green Accepted			2022-12-25	WOS:000268058900004
J	Naidu, SR; Love, IM; Imbalzano, AN; Grossman, SR; Androphy, EJ				Naidu, S. R.; Love, I. M.; Imbalzano, A. N.; Grossman, S. R.; Androphy, E. J.			The SWI/SNF chromatin remodeling subunit BRG1 is a critical regulator of p53 necessary for proliferation of malignant cells	ONCOGENE			English	Article						chromatin remodeling; p53; proteasomal degradation	CREB-BINDING-PROTEIN; DNA-DAMAGE RESPONSE; TUMOR-SUPPRESSOR; UBIQUITIN LIGASE; RETINOBLASTOMA PROTEIN; CYCLE PROGRESSION; GENE ACTIVATION; RNAI SCREEN; STEM-CELLS; IN-VIVO	The tumor suppressor p53 preserves genome integrity by inducing transcription of genes controlling growth arrest or apoptosis. Transcriptional activation involves nucleosomal perturbation by chromatin remodeling enzymes. Mammalian SWI/SNF remodeling complexes incorporate either the Brahma-related gene 1(BRG1) or Brahma (Brm) as the ATPase subunit. The observation that tumor cell lines harboring wild-type p53 specifically maintain expression of BRG1 and that BRG1 complexes with p53 prompted us to examine the role of BRG1 in regulation of p53. Remarkably, RNAi depletion of BRG1, but not Brm, led to the activation of endogenous wild-type p53 and cell senescence. We found a proline-rich region unique to BRG1 was required for binding to the histone acetyl transferase protein, CBP, as well as to p53. Ectopic expression of a proline-rich region deletion mutant BRG1 that is defective for CBP binding inhibited p53 destabilization. Importantly, RNAi knockdown of BRG1 and CBP reduced p53 poly-ubiquitination in vivo. In support of p53 inactivation by the combined activities of BRG1 and CBP, we show that DNA damage signals promoted disassociation of BRG1 from CBP, thereby allowing p53 accumulation. Our data demonstrate a novel function of the evolutionarily conserved chromatin remodeling subunit BRG1, which cooperates with CBP to constrain p53 activity and permit cancer cell proliferation. Oncogene ( 2009) 28, 2492-2501; doi: 10.1038/onc.2009.121; published online 18 May 2009	[Naidu, S. R.; Love, I. M.; Grossman, S. R.; Androphy, E. J.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; [Imbalzano, A. N.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; [Grossman, S. R.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Androphy, EJ (corresponding author), Univ Massachusetts, Sch Med, Dept Med, 364 Plantation St,LRB 328, Worcester, MA 01605 USA.	elliot.androphy@umassmed.edu		Naidu, Samisubbu/0000-0001-9411-660X; Androphy, Elliot/0000-0002-8104-0703	SRG [R01 CA107532]; ANI [R01 GM56244]; EJA [R01 CA107394]; NATIONAL CANCER INSTITUTE [R01CA107394, R01CA107532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056244] Funding Source: NIH RePORTER	SRG; ANI; EJA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Marius Pop and Andrew King for CBP and p300 shRNA, Andrew Turnell for GST-CBP fusion constructs, Yuval Bibi Nitzan for comments and assistance with the figures and Neal Silverman for assistance with baculovirus protein production. R01 CA107532 to SRG, R01 GM56244 to ANI and R01 CA107394 to EJA supported this work.	Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Awasthi S, 2005, MOL CELL BIOL, V25, P6178, DOI 10.1128/MCB.25.14.6178-6198.2005; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Downs JA, 2007, NATURE, V447, P951, DOI 10.1038/nature05980; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Fazzio TG, 2008, CELL, V134, P162, DOI 10.1016/j.cell.2008.05.031; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Hussain MA, 2006, MOL CELL BIOL, V26, P7747, DOI 10.1128/MCB.02353-05; Ionov Y, 2004, P NATL ACAD SCI USA, V101, P1273, DOI 10.1073/pnas.0307276101; Isakoff MS, 2005, P NATL ACAD SCI USA, V102, P17745, DOI 10.1073/pnas.0509014102; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; LANE DP, 1992, NATURE, V358, P16; Le Cam L, 2006, CELL, V127, P775, DOI 10.1016/j.cell.2006.09.031; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Matsumoto S, 2006, DEV BIOL, V289, P372, DOI 10.1016/j.ydbio.2005.10.044; Miyabayashi T, 2007, P NATL ACAD SCI USA, V104, P5668, DOI 10.1073/pnas.0701331104; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541; Napolitano MA, 2007, J CELL SCI, V120, P2904, DOI 10.1242/jcs.004002; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Papamichos-Chronakis M, 2006, GENE DEV, V20, P2437, DOI 10.1101/gad.1440206; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Soussi T, 2007, CANCER CELL, V12, P303, DOI 10.1016/j.ccr.2007.10.001; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521; Szutorisz H, 2006, CELL, V127, P1375, DOI 10.1016/j.cell.2006.10.045; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Turnell AS, 2005, NATURE, V438, P690, DOI 10.1038/nature04151; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Yarnamichi N, 2007, CANCER RES, V67, P10727, DOI 10.1158/0008-5472.CAN-07-2601; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	62	88	95	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2492	2501		10.1038/onc.2009.121	http://dx.doi.org/10.1038/onc.2009.121			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448667	Green Accepted			2022-12-25	WOS:000267806800002
J	Carnemolla, A; Fossale, E; Agostoni, E; Michelazzi, S; Calligaris, R; De Maso, L; Del Sal, G; MacDonald, ME; Persichetti, F				Carnemolla, Alisia; Fossale, Elisa; Agostoni, Elena; Michelazzi, Silvia; Calligaris, Raffaella; De Maso, Luca; Del Sal, Giannino; MacDonald, Marcy E.; Persichetti, Francesca			Rrs1 Is Involved in Endoplasmic Reticulum Stress Response in Huntington Disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KNOCK-IN MICE; PROTEIN L11-BINDING PROTEIN; CAG REPEAT INSTABILITY; 5S RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; CELL-DEATH; NEURODEGENERATIVE DISEASE; NUCLEAR-ENVELOPE; GENE-EXPRESSION; ER STRESS	The induction of Rrs1 expression is one of the earliest events detected in a presymptomatic knock-in mouse model of Huntington disease (HD). Rrs1 up-regulation fulfills the HD criteria of dominance, striatal specificity, and polyglutamine dependence. Here we show that mammalian Rrs1 is localized both in the nucleolus as well as in the endoplasmic reticulum ( ER) of neurons. This dual localization is shared with its newly identified molecular partner 3D3/lyric. We then show that both genes are induced by ER stress in neurons. Interestingly, we demonstrate that ER stress is an early event in a presymptomatic HD mouse model that persists throughout the life span of the rodent. We further show that ER stress also occurs in postmortem brains of HD patients.	[Carnemolla, Alisia; Agostoni, Elena; Michelazzi, Silvia; Calligaris, Raffaella; De Maso, Luca; Persichetti, Francesca] Scuola Int Super Studi Avanzati, Sector Neurobiol, I-34151 Trieste, Italy; [Fossale, Elisa; MacDonald, Marcy E.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA; [Del Sal, Giannino] Area Sci Pk Padriciano, Lab Nazl CIB, I-34149 Trieste, Italy; [Del Sal, Giannino] Univ Trieste, Dipartimento Sci Vita, I-34127 Trieste, Italy	International School for Advanced Studies (SISSA); Harvard University; Massachusetts General Hospital; University of Trieste	Persichetti, F (corresponding author), Univ Piemonte Orientale, Dipartimento Sci Ambiente & Vita, Alessandria, Italy.	persiche@sissa.it		Persichetti, Francesca/0000-0002-9804-644X; DEL SAL, GIANNINO/0000-0003-2185-6003	Telethon Foundation of Italy [GGP06264]; Italian Government; Comitato Interministerale per la Programmazione Economica/Friuli Venezia Giulia, Italy	Telethon Foundation of Italy(Fondazione Telethon); Italian Government; Comitato Interministerale per la Programmazione Economica/Friuli Venezia Giulia, Italy	This work was supported by Telethon Foundation of Italy Grant GGP06264, by the Italian Government ( Brain Gain Program, Ministero dell'Istruzione, dell'Universita e della Ricerca), and by Comitato Interministerale per la Programmazione Economica/Friuli Venezia Giulia, Italy Grant GRAND.	Atwal RS, 2008, AUTOPHAGY, V4, P91, DOI 10.4161/auto.5201; Duennwald ML, 2008, GENE DEV, V22, P3308, DOI 10.1101/gad.1673408; Fossale E, 2002, HUM MOL GENET, V11, P2233, DOI 10.1093/hmg/11.19.2233; Fricker M, 1997, J CELL BIOL, V136, P531, DOI 10.1083/jcb.136.3.531; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hilditch-Maguire P, 2000, HUM MOL GENET, V9, P2789, DOI 10.1093/hmg/9.19.2789; Isaac C, 2001, J CELL SCI, V114, P4253; Kang DC, 2005, GENE, V353, P8, DOI [10.1016/j.gene.2005.04.006, 10.1016/j.gene.2005.04.005]; Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778; Lloret A, 2006, HUM MOL GENET, V15, P2015, DOI 10.1093/hmg/ddl125; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Menalled Liliana B, 2005, NeuroRx, V2, P465, DOI 10.1602/neurorx.2.3.465; Miyoshi K, 2004, FEBS LETT, V565, P106, DOI 10.1016/j.febslet.2004.03.087; Miyoshi K, 2002, J BIOL CHEM, V277, P18334, DOI 10.1074/jbc.M201667200; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; Nariai M, 2005, NUCLEIC ACIDS RES, V33, P4553, DOI 10.1093/nar/gki772; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Politz JC, 2000, P NATL ACAD SCI USA, V97, P55, DOI 10.1073/pnas.97.1.55; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Reijonen S, 2008, EXP CELL RES, V314, P950, DOI 10.1016/j.yexcr.2007.12.025; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Sutherland HGE, 2004, EXP CELL RES, V294, P94, DOI 10.1016/j.yexcr.2003.11.020; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; Tsuno A, 2000, MOL CELL BIOL, V20, P2066, DOI 10.1128/MCB.20.6.2066-2074.2000; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wade C, 2001, MOL CELL BIOL, V21, P8638, DOI 10.1128/MCB.21.24.8638-8650.2001; Wheeler VC, 1999, HUM MOL GENET, V8, P115, DOI 10.1093/hmg/8.1.115; Wheeler VC, 2002, HUM MOL GENET, V11, P633, DOI 10.1093/hmg/11.6.633; White JK, 1997, NAT GENET, V17, P404, DOI 10.1038/ng1297-404; Wyttenbach A, 2001, HUM MOL GENET, V10, P1829, DOI 10.1093/hmg/10.17.1829; Zhang JY, 2007, GENE DEV, V21, P2580, DOI 10.1101/gad.1569307	32	115	120	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	2009	284	27					18167	18173		10.1074/jbc.M109.018325	http://dx.doi.org/10.1074/jbc.M109.018325			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BW	19433866	Green Published, hybrid			2022-12-25	WOS:000267712400028
J	Lange, AW; Keiser, AR; Wells, JM; Zorn, AM; Whitsett, JA				Lange, Alexander W.; Keiser, Angela R.; Wells, James M.; Zorn, Aaron M.; Whitsett, Jeffrey A.			Sox17 Promotes Cell Cycle Progression and Inhibits TGF-beta/Smad3 Signaling to Initiate Progenitor Cell Behavior in the Respiratory Epithelium	PLOS ONE			English	Article							EMBRYONIC STEM-CELLS; TRANSCRIPTION FACTOR; BETA-CATENIN; BRANCHING MORPHOGENESIS; ENDODERM FORMATION; LUNG DEVELOPMENT; REDUNDANT ROLES; II CELLS; EXPRESSION; DIFFERENTIATION	The Sry-related high mobility group box transcription factor Sox17 is required for diverse developmental processes including endoderm formation, vascular development, and fetal hematopoietic stem cell maintenance. Expression of Sox17 in mature respiratory epithelial cells causes proliferation and lineage respecification, suggesting that Sox17 can alter adult lung progenitor cell fate. In this paper, we identify mechanisms by which Sox17 influences lung epithelial progenitor cell behavior and reprograms cell fate in the mature respiratory epithelium. Conditional expression of Sox17 in epithelial cells of the adult mouse lung demonstrated that cell cluster formation and respecification of alveolar progenitor cells toward proximal airway lineages were rapidly reversible processes. Prolonged expression of Sox17 caused the ectopic formation of bronchiolar-like structures with diverse respiratory epithelial cell characteristics in alveolar regions of lung. During initiation of progenitor cell behavior, Sox17 induced proliferation and increased the expression of the progenitor cell marker Sca-1 and genes involved in cell cycle progression. Notably, Sox17 enhanced cyclin D1 expression in vivo and activated cyclin D1 promoter activity in vitro. Sox17 decreased the expression of transforming growth factor-beta (TGF-beta)-responsive cell cycle inhibitors in the adult mouse lung, including p15, p21, and p57, and inhibited TGF-beta 1-mediated transcriptional responses in vitro. Further, Sox17 interacted with Smad3 and blocked Smad3 DNA binding and transcriptional activity. Together, these data show that a subset of mature respiratory epithelial cells retains remarkable phenotypic plasticity and that Sox17, a gene required for early endoderm formation, activates the cell cycle and reinitiates multipotent progenitor cell behavior in mature lung cells.			Lange, AW (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH USA.	Jeffrey.Whitsett@chmcc.org			NHLBI NIH HHS [T32 HL007752, R01 HL090156, HL007752, R01 HL095580, P01 HL061646, HL61646, HL090156] Funding Source: Medline; NIDDK NIH HHS [R01 DK070858] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL061646, T32HL007752, R01HL090156, R01HL095580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070858] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander J, 1999, CURR BIOL, V9, P1147, DOI 10.1016/S0960-9822(00)80016-0; Besnard V, 2007, PRINCIPLES OF TISSUE ENGINEERING, 3RD EDITION, P1113, DOI 10.1016/B978-012370615-7/50077-9; Bhaskaran M, 2007, J BIOL CHEM, V282, P3968, DOI 10.1074/jbc.M609060200; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Blundell R, 2004, EXP LUNG RES, V30, P447, DOI 10.1080/01902140490476373; Buckley S, 1997, AM J PHYSIOL-LUNG C, V273, pL572, DOI 10.1152/ajplung.1997.273.3.L572; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200; Clements D, 2000, MECH DEVELOP, V99, P65, DOI 10.1016/S0925-4773(00)00476-7; Corroyer S, 1997, ENDOCRINOLOGY, V138, P3677, DOI 10.1210/en.138.9.3677; Donjerkovic D, 2000, CELL RES, V10, P179, DOI 10.1038/sj.cr.7290047; DUNN TL, 1995, GENE, V161, P223, DOI 10.1016/0378-1119(95)00280-J; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Gontan C, 2008, DEV BIOL, V317, P296, DOI 10.1016/j.ydbio.2008.02.035; HERBER B, 1994, ONCOGENE, V9, P1295; Hudson C, 1997, CELL, V91, P397, DOI 10.1016/S0092-8674(00)80423-7; Iguchi H, 2007, J BIOL CHEM, V282, P19052, DOI 10.1074/jbc.M700460200; Kanai Y, 1996, J CELL BIOL, V133, P667, DOI 10.1083/jcb.133.3.667; Kanai-Azuma M, 2002, DEVELOPMENT, V129, P2367; Kang Y, 2000, MOL CARCINOGEN, V29, P112, DOI 10.1002/1098-2744(200010)29:2<112::AID-MC8>3.0.CO;2-9; Keijzer R, 2001, DEVELOPMENT, V128, P503; Kim CF, 2007, AM J PHYSIOL-LUNG C, V293, pL1092, DOI 10.1152/ajplung.00015.2007; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim I, 2007, CELL, V130, P470, DOI 10.1016/j.cell.2007.06.011; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kubo A, 2004, DEVELOPMENT, V131, P1651, DOI 10.1242/dev.01044; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; Liu C, 2002, AM J PHYSIOL-LUNG C, V283, pL468, DOI 10.1152/ajplung.00044.2002; Maeda Y, 2007, PHYSIOL REV, V87, P219, DOI 10.1152/physrev.00028.2006; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Matsui T, 2006, J CELL SCI, V119, P3513, DOI 10.1242/jcs.03081; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nabeyrat E, 2000, AM J PHYSIOL-LUNG C, V278, pL42, DOI 10.1152/ajplung.2000.278.1.L42; Otto WR, 2002, J PATHOL, V197, P527, DOI 10.1002/path.1160; Pajalunga D, 2007, J CELL BIOL, V176, P807, DOI 10.1083/jcb.200608109; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Park KS, 2007, J CLIN INVEST, V117, P978, DOI 10.1172/JCI29176; Park KS, 2006, DEV BIOL, V294, P192, DOI 10.1016/j.ydbio.2006.02.038; Perl AKT, 2002, TRANSGENIC RES, V11, P21, DOI 10.1023/A:1013986627504; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Perl AKT, 2005, GENESIS, V41, P23, DOI 10.1002/gene.20093; Perl AK, 2009, AM J RESP CELL MOL, V40, P1, DOI 10.1165/rcmb.2008-0011ED; Rippon HJ, 2006, STEM CELLS, V24, P1389, DOI 10.1634/stemcells.2005-0465; Sakamoto Y, 2007, BIOCHEM BIOPH RES CO, V360, P539, DOI 10.1016/j.bbrc.2007.06.093; Seguin CA, 2008, CELL STEM CELL, V3, P182, DOI 10.1016/j.stem.2008.06.018; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; Sinner D, 2007, MOL CELL BIOL, V27, P7802, DOI 10.1128/MCB.02179-06; Sock E, 2004, MOL CELL BIOL, V24, P6635, DOI 10.1128/mcb.24.15.6635-6644.2004; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takash W, 2001, NUCLEIC ACIDS RES, V29, P4274, DOI 10.1093/nar/29.21.4274; Tamamori-Adachi M, 2003, CIRC RES, V92, pE12, DOI 10.1161/01.RES.0000049105.15329.1C; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wan HJ, 2005, J BIOL CHEM, V280, P13809, DOI 10.1074/jbc.M414122200; Weiss MA, 2001, MOL ENDOCRINOL, V15, P353, DOI 10.1210/me.15.3.353; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; Winkler ME, 2008, CLONING STEM CELLS, V10, P49, DOI 10.1089/clo.2007.0075; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhang FJ, 2004, AM J RESP CELL MOL, V31, P679, DOI 10.1165/rcmb.2004-0182OC; Zhang W, 2008, CANCER RES, V68, P2764, DOI 10.1158/0008-5472.CAN-07-6349; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou Q, 2008, CELL STEM CELL, V3, P382, DOI 10.1016/j.stem.2008.09.015	67	44	46	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2009	4	5							e5711	10.1371/journal.pone.0005711	http://dx.doi.org/10.1371/journal.pone.0005711			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QD	19479035	Green Submitted, Green Published, gold			2022-12-25	WOS:000266415000020
J	Xanthopoulos, K; Polymenidou, M; Bellworthy, SJ; Benestad, SL; Sklaviadis, T				Xanthopoulos, Konstantinos; Polymenidou, Magdalini; Bellworthy, Sue J.; Benestad, Sylvie L.; Sklaviadis, Theodoros			Species and Strain Glycosylation Patterns of PrPSc	PLOS ONE			English	Article								Background: A key event in transmissible spongiform encephalopathies (TSEs) is the conversion of the soluble, protease-sensitive glycosylated prion protein (PrPC) to an abnormally structured, aggregated and partially protease-resistant isoform (PrPSc). Both PrP isoforms bear two potential glycosylation sites and thus in a typical western blot with an anti-PrP antibody three distinct bands appear, corresponding to the di-, mono- or unglycosylated forms of the protein. The relative intensity and electrophoretic mobility of the three bands are characteristic of each TSE strain and have been used to discriminate between them. Methodology/Principal Findings: In the present study we used lectin-based western blotting to evaluate possible variations in composition within sugar chains carried by PrPSc purified from subjects affected with different TSEs. Our findings indicate that in addition to the already well-documented differences in electrophoretic mobility and amounts of the glycosylated PrPSc forms, TSE strains also vary in the abundance of specific N-linked sugars of the PrPSc protein. Conclusions/Significance: These results imply that PrP glycosylation might fine-tune the conversion of PrPC to PrPSc and could play an accessory role in the appearance of some of the characteristic features of TSE strains. The differences in sugar composition could also be used as an additional tool for discrimination between the various TSEs.			Xanthopoulos, K (corresponding author), Aristotle Univ Thessaloniki, Pharmacol Lab, Dept Pharm, GR-54006 Thessaloniki, Greece.	sklaviad@auth.gr	Sklaviadis, Theoodoros/AGK-6763-2022; Dafou, Dimitra/N-6094-2015; Polymenidou, Magdalini/D-2254-2014	Dafou, Dimitra/0000-0003-4170-0612; Sklaviadis, Theodoros/0000-0002-0246-3100				Arsac JN, 2007, EMERG INFECT DIS, V13, P58, DOI 10.3201/eid1301.060393; Barret A, 2005, J BIOL CHEM, V280, P10516, DOI 10.1074/jbc.M412635200; Beringue V, 2003, BRAIN, V126, P2065, DOI 10.1093/brain/awg205; Biacabe AG, 2004, EMBO REP, V5, P110, DOI 10.1038/sj.embor.7400054; Booth S, 2004, BIOCHEM BIOPH RES CO, V325, P1339, DOI 10.1016/j.bbrc.2004.10.150; Canello T, 2008, BIOCHEMISTRY-US, V47, P8866, DOI 10.1021/bi800801f; Casalone C, 2004, P NATL ACAD SCI USA, V101, P3065, DOI 10.1073/pnas.0305777101; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; COLLINGE J, 1996, CJD NATURE, V383, P685; Collinge J, 2007, SCIENCE, V318, P930, DOI 10.1126/science.1138718; DeArmond SJ, 1999, J NEUROPATH EXP NEUR, V58, P1000, DOI 10.1097/00005072-199909000-00010; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; Ermonval M, 2009, GLYCOCONJUGATE J, V26, P477, DOI 10.1007/s10719-008-9198-5; Goh AXH, 2007, J NEUROCHEM, V100, P841, DOI 10.1111/j.1471-4159.2006.04268.x; Gonzalez L, 2003, J GEN VIROL, V84, P1339, DOI 10.1099/vir.0.18800-0; GUILLERMEBOSSEL.F, 2009, GLYCOBIOLOG IN PRESS; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; Harmeyer S, 1998, J GEN VIROL, V79, P937, DOI 10.1099/0022-1317-79-4-937; Hwang D, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.10; Klingeborn M, 2006, J GEN VIROL, V87, P1751, DOI 10.1099/vir.0.81618-0; Lawson VA, 2001, J BIOL CHEM, V276, P35265, DOI 10.1074/jbc.M103799200; Levavasseur E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002786; Neuendorf E, 2004, J BIOL CHEM, V279, P53306, DOI 10.1074/jbc.M410796200; Nielsen D, 2004, BIOCHEM J, V380, P571, DOI 10.1042/BJ20040010; Nishina KA, 2006, BIOCHEMISTRY-US, V45, P14129, DOI 10.1021/bi061526k; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pan T, 2005, J CLIN MICROBIOL, V43, P1118, DOI 10.1128/JCM.43.3.1118-1126.2005; Pastrana MA, 2006, BIOCHEMISTRY-US, V45, P15710, DOI 10.1021/bi0615442; PIRO JR, 2009, J VIROL IN PRESS; Plaitakis A, 2001, ANN NEUROL, V50, P227, DOI 10.1002/ana.1285; Polymenidou M, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-23; Priola SA, 2001, EMBO J, V20, P6692, DOI 10.1093/emboj/20.23.6692; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; Rudd PM, 2001, BIOCHEMISTRY-US, V40, P3759, DOI 10.1021/bi002625f; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Sharon N, 2004, GLYCOBIOLOGY, V14, p53R, DOI 10.1093/glycob/cwh122; Skinner PJ, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-114; SKLAVIADIS T, 1986, P NATL ACAD SCI USA, V83, P6146, DOI 10.1073/pnas.83.16.6146; Somerville RA, 1999, J GEN VIROL, V80, P1865, DOI 10.1099/0022-1317-80-7-1865; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Stimson E, 1999, BIOCHEMISTRY-US, V38, P4885, DOI 10.1021/bi982330q; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; Triantaphyllidou IE, 2006, ANAL BIOCHEM, V359, P176, DOI 10.1016/j.ab.2006.10.002; Tuzi NL, 2008, PLOS BIOL, V6, P872, DOI 10.1371/journal.pbio.0060100; Vorberg I, 2002, J BIOL CHEM, V277, P36775, DOI 10.1074/jbc.M206865200; Yokoyama T, 2007, ARCH VIROL, V152, P603, DOI 10.1007/s00705-006-0858-0	51	10	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5633	10.1371/journal.pone.0005633	http://dx.doi.org/10.1371/journal.pone.0005633			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448AY	19461968	Green Submitted, gold, Green Published			2022-12-25	WOS:000266234700020
J	Franci, C; Gallen, M; Alameda, F; Baro, T; Iglesias, M; Virtanen, I; de Herreros, AG				Franci, Clara; Gallen, Manel; Alameda, Francesc; Baro, Teresa; Iglesias, Mar; Virtanen, Ismo; Garcia de Herreros, Antonio			Snail1 Protein in the Stroma as a New Putative Prognosis Marker for Colon Tumours	PLOS ONE			English	Article								Over-expression of Snail1 gene transcriptional repressor promotes an epithelial-to-mesenchymal transition in epithelial tumour cell lines. Expression of Snail1 RNA has been associated to the pathogenesis of a number of malignancies; however, the lack of good monoclonal antibodies against this protein has precluded a definitive analysis of Snail1 protein. In this study, we aimed to determine the expression of this transcriptional factor in colorectal tumours. Using a Snail1 well-characterized monoclonal antibody developed in our laboratories we have analyzed by immunohistochemistry a cohort of 162 human colorectal tumours. Ninety tumours (56%) showed nuclear expression in the tumoral tissue and the adjacent stroma; in 34 (21%), Snail1 was detected just in the stroma, whereas in only 4 the expression of Snail1 was detected in the tumoral tissue and the stroma was negative. No correlation was found between the presence of Snail1 in the tumour and tumour stage; however, a trend (p = 0.054) was detected when the expression of this factor in the stroma was considered. Snail1 immunoreactivity in this compartment was associated with presence of distant metastasis (p = 0.006). Moreover, expression of Snail1 in the tumor stroma correlated with lower specific survival of cancer patients (p = 0.011). Interestingly, this correlation was also detected in stage I and II tumors. Therefore, our results indicate that the presence of nuclear Snail1 immunoreactive cells in the stroma may be an informative indicator of prognosis of colon tumours especially useful in those corresponding to lower stages and identify a new marker suitable to label activated stroma in colon tumours.			Franci, C (corresponding author), IMIM Hosp Mar, Programa Recerca Canc, Barcelona, Spain.	agarcia@imim.es	de Herreros, A Garcia/H-3104-2014	de Herreros, A Garcia/0000-0001-5270-0808				Blechschmidt K, 2008, BRIT J CANCER, V98, P489, DOI 10.1038/sj.bjc.6604115; Blechschmidt K, 2007, DIAGN MOL PATHOL, V16, P222, DOI 10.1097/PDM.0b013e31806219ae; Boutet A, 2006, EMBO J, V25, P5603, DOI 10.1038/sj.emboj.7601421; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Escriva M, 2008, MOL CELL BIOL, V28, P1528, DOI 10.1128/MCB.02061-07; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Locascio A, 2002, J BIOL CHEM, V277, P38803, DOI 10.1074/jbc.M205358200; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Peinado H, 2008, CANCER RES, V68, P4541, DOI 10.1158/0008-5472.CAN-07-6345; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Rosivatz E, 2006, VIRCHOWS ARCH, V448, P277, DOI 10.1007/s00428-005-0118-9; Scheel C, 2007, CANCER RES, V67, P11476, DOI 10.1158/0008-5472.CAN-07-1653; Sobin, 2009, UICC TNM CLASSIFICAT; Takkunen M, 2006, J HISTOCHEM CYTOCHEM, V54, P1263, DOI 10.1369/jhc.6A6958.2006; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	25	85	86	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5595	10.1371/journal.pone.0005595	http://dx.doi.org/10.1371/journal.pone.0005595			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440385	Green Published, gold, Green Submitted			2022-12-25	WOS:000266107500022
J	Kobrinsky, E; Abrahimi, P; Duong, SQ; Thomas, S; Harry, JB; Patel, C; Lao, QZ; Soldatov, NM				Kobrinsky, Evgeny; Abrahimi, Parwiz; Duong, Son Q.; Thomas, Sam; Harry, Jo Beth; Patel, Chirag; Lao, Qi Zong; Soldatov, Nikolai M.			Effect of Ca-v beta Subunits on Structural Organization of Ca(v)1.2 Calcium Channels	PLOS ONE			English	Article							FLUORESCENT PROTEIN; MOLECULAR ARCHITECTURE; FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; RELEASE UNITS; FRET; MODULATION; INACTIVATION; CALMODULIN; MYOCYTES	Background: Voltage-gated Ca(v)1.2 calcium channels play a crucial role in Ca2+ signaling. The pore-forming alpha(1C) subunit is regulated by accessory Ca-v beta subunits, cytoplasmic proteins of various size encoded by four different genes (Ca-v beta(1) - beta(4)) and expressed in a tissue-specific manner. Methods and Results: Here we investigated the effect of three major Ca-v beta types, beta(1b), beta(2d) and beta(3), on the structure of Ca(v)1.2 in the plasma membrane of live cells. Total internal reflection fluorescence microscopy showed that the tendency of Ca(v)1.2 to form clusters depends on the type of the Ca-v beta subunit present. The highest density of Ca(v)1.2 clusters in the plasma membrane and the smallest cluster size were observed with neuronal/cardiac beta(1b) present. Ca(v)1.2 channels containing beta(3), the predominant Ca-v beta subunit of vascular smooth muscle cells, were organized in a significantly smaller number of larger clusters. The inter- and intramolecular distances between alpha(1C) and Ca-v beta in the plasma membrane of live cells were measured by three-color FRET microscopy. The results confirm that the proximity of Ca(v)1.2 channels in the plasma membrane depends on the Ca-v beta type. The presence of different Ca-v beta subunits does not result in significant differences in the intramolecular distance between the termini of alpha(1C), but significantly affects the distance between the termini of neighbor alpha(1C) subunits, which varies from 67 angstrom with beta(1b) to 79 A with beta(3). Conclusions: Thus, our results show that the structural organization of Ca(v)1.2 channels in the plasma membrane depends on the type of Ca-v beta subunits present.			Kobrinsky, E (corresponding author), NIA, NIH, Baltimore, MD 21224 USA.	soldatovN@grc.nia.nih.gov			Intramural NIH HHS [Z01 AG000294] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [Z01AG000294, ZIAAG000294] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berney C, 2003, BIOPHYS J, V84, P3992, DOI 10.1016/S0006-3495(03)75126-1; Bers DM, 2008, ANNU REV PHYSIOL, V70, P23, DOI 10.1146/annurev.physiol.70.113006.100455; Calin-Jageman I, 2008, J NEUROCHEM, V105, P573, DOI 10.1111/j.1471-4159.2008.05286.x; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; Chen H, 2006, BIOPHYS J, V91, pL39, DOI 10.1529/biophysj.106.088773; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; Chen-Izu Y, 2006, BIOPHYS J, V91, P1, DOI 10.1529/biophysj.105.077180; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; COLLIN T, 1994, EUR J BIOCHEM, V220, P257, DOI 10.1111/j.1432-1033.1994.tb18621.x; Di Biase V, 2005, J CELL BIOL, V171, P695, DOI 10.1083/jcb.200503077; Di Biase V, 2008, J NEUROSCI, V28, P13845, DOI 10.1523/JNEUROSCI.3213-08.2008; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; FALLON JL, 2009, P NATL ACAD SCI USA, P1; Floyd R, 2007, CELL CALCIUM, V42, P467, DOI 10.1016/j.ceca.2007.05.011; Franzini-Armstrong C, 1998, ANN NY ACAD SCI, V853, P20, DOI 10.1111/j.1749-6632.1998.tb08253.x; Franzini-Armstrong C, 2005, ANN NY ACAD SCI, V1047, P76, DOI 10.1196/annals.1341.007; Galperin E, 2004, NAT METHODS, V1, P209, DOI 10.1038/NMETH720; Gathercole DV, 2000, J MOL CELL CARDIOL, V32, P1981, DOI 10.1006/jmcc.2000.1230; Harms GS, 2001, BIOPHYS J, V81, P2639, DOI 10.1016/S0006-3495(01)75907-3; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; Herzig S, 2007, FASEB J, V21, P1527, DOI 10.1096/fj.06-7377com; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Inoue M, 2003, CIRC RES, V92, P532, DOI 10.1161/01.RES.0000064175.70693.EC; Kammermeier PJ, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-1; Kepplinger KJF, 2000, FEBS LETT, V477, P161, DOI 10.1016/S0014-5793(00)01791-9; Kobrinsky E, 2005, J BIOL CHEM, V280, P12474, DOI 10.1074/jbc.M412140200; Kobrinsky E, 2004, BIOPHYS J, V87, P844, DOI 10.1529/biophysj.104.041152; Koushik SV, 2006, BIOPHYS J, V91, pL99, DOI 10.1529/biophysj.106.096206; Kremers GJ, 2006, BIOCHEMISTRY-US, V45, P6570, DOI 10.1021/bi0516273; Lakowicz J.R., 1999, PRINCIPLES FLUORESCE, V2nd, DOI 10.1007/978-0-387-46312-4; Lao QZ, 2008, J BIOL CHEM, V283, P15577, DOI 10.1074/jbc.M802035200; LEE KL, 2005, NOVEL WAVELET STAT B, P7664; LIPSCOMBE D, 1988, P NATL ACAD SCI USA, V85, P2398, DOI 10.1073/pnas.85.7.2398; Mager DE, 2007, BIOPHYS J, V93, P2900, DOI 10.1529/biophysj.106.102582; Malo GD, 2007, BIOCHEMISTRY-US, V46, P9865, DOI 10.1021/bi602664c; Merzlyak EM, 2007, NAT METHODS, V4, P555, DOI 10.1038/NMETH1062; Murakami M, 2003, J BIOL CHEM, V278, P43261, DOI 10.1074/jbc.M211380200; Opatowsky Y, 2004, NEURON, V42, P387, DOI 10.1016/S0896-6273(04)00250-8; Papadopoulos A, 2008, COMPUT BIOL MED, V38, P1045, DOI 10.1016/j.compbiomed.2008.07.006; Papadopoulos S, 2004, J BIOL CHEM, V279, P44046, DOI 10.1074/jbc.M405317200; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; POWERS PA, 1992, J BIOL CHEM, V267, P22967; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Protasi F, 1996, DEV BIOL, V173, P265, DOI 10.1006/dbio.1996.0022; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Rizzo MA, 2005, BIOPHYS J, V88, pL14, DOI 10.1529/biophysj.104.055442; Scriven DRL, 2002, ANN NY ACAD SCI, V976, P488; Shuai JW, 2003, P NATL ACAD SCI USA, V100, P506, DOI 10.1073/pnas.0236032100; SILVER RA, 1990, NATURE, V343, P751, DOI 10.1038/343751a0; SUN XH, 1995, J CELL BIOL, V129, P659, DOI 10.1083/jcb.129.3.659; Takagishi Y, 2000, AM J PHYSIOL-CELL PH, V279, pC1963, DOI 10.1152/ajpcell.2000.279.6.C1963; Takahashi SX, 2003, BIOPHYS J, V84, P3007, DOI 10.1016/S0006-3495(03)70027-7; Vacher H, 2008, PHYSIOL REV, V88, P1407, DOI 10.1152/physrev.00002.2008; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; Wang SQ, 2001, NATURE, V410, P592, DOI 10.1038/35069083; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; Wheeler DG, 2008, J CELL BIOL, V183, P849, DOI 10.1083/jcb.200805048; Wiedenmann J, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1854680; Woo SH, 2003, J PHYSIOL-LONDON, V552, P437, DOI 10.1113/jphysiol.2003.048330; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang R, 2005, FASEB J, V19, P1153, DOI 10.1096/fj.04-3283fje; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	65	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5587	10.1371/journal.pone.0005587	http://dx.doi.org/10.1371/journal.pone.0005587			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19492014	gold, Green Submitted, Green Published			2022-12-25	WOS:000266107500016
J	Liu, H; Buus, R; Clague, MJ; Urbe, S				Liu, Han; Buus, Richard; Clague, Michael J.; Urbe, Sylvie			Regulation of ErbB2 Receptor Status by the Proteasomal DUB POH1	PLOS ONE			English	Article							TYROSINE KINASES; DOWN-REGULATION; ENDOCYTOSIS; UBIQUITIN; DEGRADATION; MONOUBIQUITINATION; PHOSPHORYLATION; TRASTUZUMAB	Understanding the factors, which control ErbB2 and EGF receptor (EGFR) status in cells is likely to inform future therapeutic approaches directed at these potent oncogenes. ErbB2 is resistant to stimulus-induced degradation and high levels of overexpression can inhibit EGF receptor down-regulation. We now show that for HeLa cells expressing similar numbers of EGFR and ErbB2, EGFR down-regulation is efficient and insensitive to reduction of ErbB2 levels. Deubiquitinating enzymes (DUBs) may extend protein half-lives by rescuing ubiquitinated substrates from proteasomal degradation or from ubiquitin-dependent lysosomal sorting. Using a siRNA library directed at the full complement of human DUBs, we identified POH1 (also known as Rpn11 or PSMD14), a component of the proteasome lid, as a critical DUB controlling the apparent ErbB2 levels. Moreover, the effects on ErbB2 levels can be reproduced by administration of proteasomal inhibitors such as epoxomicin used at maximally tolerated doses. However, the extent of this apparent loss and specificity for ErbB2 versus EGFR could not be accounted for by changes in transcription or degradation rate. Further investigation revealed that cell surface ErbB2 levels are only mildly affected by POH1 knock-down and that the apparent loss can at least partially be explained by the accumulation of higher molecular weight ubiquitinated forms of ErbB2 that are detectable with an extracellular but not intracellular domain directed antibody. We propose that POH1 may deubiquitinate ErbB2 and that this activity is not necessarily coupled to proteasomal degradation.			Liu, H (corresponding author), Sch Biomed Sci, Physiol Lab, Liverpool, Merseyside, England.	clague@liv.ac.uk; urbe@liv.ac.uk	Urbe, Sylvie/S-1433-2018; Clague, Michael J/A-7199-2008	Urbe, Sylvie/0000-0003-4735-9814; Clague, Michael J/0000-0003-3355-9479; Liu, Han/0000-0002-0014-4675; Buus, Richard/0000-0002-3386-3465	Cancer Research UK [C20535/A6999] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)		Alwan HAJ, 2007, J BIOL CHEM, V282, P1658, DOI 10.1074/jbc.M604711200; Austin CD, 2004, MOL BIOL CELL, V15, P5268, DOI 10.1091/mbc.E04-07-0591; BERKERS JAM, 1991, J BIOL CHEM, V266, P922; Cardoso F, 2006, MOL CANCER THER, V5, P3042, DOI 10.1158/1535-7163.MCT-06-0104; Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407; Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002; Daviet L, 2008, BIOCHIMIE, V90, P270, DOI 10.1016/j.biochi.2007.09.013; Finley D., 2004, CELL, V116, pS32; Finley Daniel, 2004, Cell, VS116, pS29, DOI 10.1016/S0092-8674(03)00971-1; Geetha T, 2008, TRAFFIC, V9, P1146, DOI 10.1111/j.1600-0854.2008.00751.x; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haslekas C, 2005, MOL BIOL CELL, V16, P5832, DOI 10.1091/mbc.E05-05-0456; Koulich E, 2008, MOL BIOL CELL, V19, P1072, DOI 10.1091/mbc.E07-10-1040; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Lerdrup M, 2006, J CELL SCI, V119, P85, DOI 10.1242/jcs.02707; Marx C, 2007, MOL PHARMACOL, V71, P1525, DOI 10.1124/mol.107.034090; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Pedersen NM, 2008, MOL CANCER RES, V6, P491, DOI 10.1158/1541-7786.MCR-07-0191; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Row PE, 2005, BIOCHEM J, V389, P629, DOI 10.1042/BJ20050067; Shen F, 2008, CELL SIGNAL, V20, P779, DOI 10.1016/j.cellsig.2007.12.021; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Urbe S, 2000, MOL CELL BIOL, V20, P7685, DOI 10.1128/MCB.20.20.7685-7692.2000; Urbe S, 2005, ESSAYS BIOCHEM, V41, P81, DOI 10.1042/EB0410081; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Yang S, 2007, J CELL SCI, V120, P2763, DOI 10.1242/jcs.007658; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	34	40	43	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2009	4	5							e5544	10.1371/journal.pone.0005544	http://dx.doi.org/10.1371/journal.pone.0005544			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FX	19436748	gold, Green Published, Green Submitted			2022-12-25	WOS:000266107300009
J	Duval, L; Nerrienet, E; Rousset, D; Mba, SAS; Houze, S; Fourment, M; Le Bras, J; Robert, V; Ariey, F				Duval, Linda; Nerrienet, Eric; Rousset, Dominique; Mba, Serge Alain Sadeuh; Houze, Sandrine; Fourment, Mathieu; Le Bras, Jacques; Robert, Vincent; Ariey, Frederic			Chimpanzee Malaria Parasites Related to Plasmodium ovale in Africa	PLOS ONE			English	Article							RIBOSOMAL-RNA; RESERVOIRS; PHYLOGENY; EVOLUTION; MONKEYS; GENE	Since the 1970's, the diversity of Plasmodium parasites in African great apes has been neglected. Surprisingly, P. reichenowi, a chimpanzee parasite, is the only such parasite to have been molecularly characterized. This parasite is closely phylogenetically related to P. falciparum, the principal cause of the greatest malaria burden in humans. Studies of malaria parasites from anthropoid primates may provide relevant phylogenetic information, improving our understanding of the origin and evolutionary history of human malaria species. In this study, we screened 130 DNA samples from chimpanzees (Pan troglodytes) and gorillas (Gorilla gorilla) from Cameroon for Plasmodium infection, using cytochrome b molecular tools. Two chimpanzees from the subspecies Pan t. troglodytes presented single infections with Plasmodium strains molecularly related to the human malaria parasite P. ovale. These chimpanzee parasites and 13 human strains of P. ovale originated from a various sites in Africa and Asia were characterized using cytochrome b and cytochrome c oxidase 1 mitochondrial partial genes and nuclear ldh partial gene. Consistent with previous findings, two genetically distinct types of P. ovale, classical and variant, were observed in the human population from a variety of geographical locations. One chimpanzee Plasmodium strain was genetically identical, on all three markers tested, to variant P. ovale type. The other chimpanzee Plasmodium strain was different from P. ovale strains isolated from humans. This study provides the first evidence of possibility of natural cross-species exchange of P. ovale between humans and chimpanzees of the subspecies Pan t. troglodytes.	[Duval, Linda; Robert, Vincent] Museum Natl Hist Nat, USM 504, Lab Biol Fonct Protozoaires, F-75231 Paris, France; [Duval, Linda] Inst Pasteur, Lab Pathogen virale, Paris, France; [Nerrienet, Eric] Inst Pasteur Cambodge, Lab HIV Hepatites, Phnom Penh, Cambodia; [Rousset, Dominique; Mba, Serge Alain Sadeuh] Cte Pasteur Cameroun, Unite Virol, Yaounde, Cameroon; [Houze, Sandrine; Le Bras, Jacques] AP HP, Hop Bichat Claude Bernard, Ctr Natl Reference Paludisme, Paris, France; [Fourment, Mathieu] Inst Pasteur Cambodge, Unite Virol, Phnom Penh, Cambodia; [Fourment, Mathieu] Macquarie Univ, Dept Biol Sci, Sydney, NSW, Australia; [Robert, Vincent] Inst Rech Dev, Unite Rech Caracterisat controle popul vecteurs, UR 16, Montpellier, France; [Ariey, Frederic] Inst Pasteur Cambodge, Unite Epidemiol Mol, Phnom Penh, Cambodia	Museum National d'Histoire Naturelle (MNHN); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Cambodia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Cambodia; Macquarie University; Institut de Recherche pour le Developpement (IRD); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Cambodia	Duval, L (corresponding author), Museum Natl Hist Nat, USM 504, Lab Biol Fonct Protozoaires, F-75231 Paris, France.	lduval@pasteur.fr	Fourment, Mathieu/E-4665-2012; ariey, frederic/P-1185-2017; Rousset, Dominique/S-5400-2019; sandrine, houze/M-3260-2017	Fourment, Mathieu/0000-0001-8153-9822; ariey, frederic/0000-0002-0680-1090; Rousset, Dominique/0000-0002-1473-3147; SADEUH-MBA, Serge Alain/0000-0003-3377-8225; sandrine, houze/0000-0001-9016-3847; ROBERT, Vincent/0000-0003-1738-1842				BRAY RS, 1957, AM J TROP MED HYG, V6, P638, DOI 10.4269/ajtmh.1957.6.638; CADIGAN FC, 1969, T ROY SOC TROP MED H, V63, P681, DOI 10.1016/0035-9203(69)90194-1; Calattini S, 2006, J MED PRIMATOL, V35, P59, DOI 10.1111/j.1600-0684.2006.00149.x; COATNEY GR, 1971, PRIMATE MALARIAS; Collins WE, 2005, CLIN MICROBIOL REV, V18, P570, DOI 10.1128/CMR.18.3.570-581.2005; CONTACOS PG, 1970, AM J TROP MED HYG, V19, P190, DOI 10.4269/ajtmh.1970.19.190; Cornu M, 1986, Med Trop (Mars), V46, P131; Duval L, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-157; Escalante AA, 1998, P NATL ACAD SCI USA, V95, P8124, DOI 10.1073/pnas.95.14.8124; Fandeur T, 2000, PARASITOLOGY, V120, P11, DOI 10.1017/S0031182099005168; Faye FBK, 1998, T ROY SOC TROP MED H, V92, P522, DOI 10.1016/S0035-9203(98)90900-2; Garnham PCC, 1966, MALARIA PARASITES OT; GLEASON NN, 1970, B WORLD HEALTH ORGAN, V42, P399; Guerra CA, 2006, TRENDS PARASITOL, V22, P353, DOI 10.1016/j.pt.2006.06.006; Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Hagner SC, 2007, PARASITOL RES, V101, P493, DOI 10.1007/s00436-007-0499-6; Hajibabaei M, 2007, TRENDS GENET, V23, P167, DOI 10.1016/j.tig.2007.02.001; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Hayakawa T, 2008, MOL BIOL EVOL, V25, P2233, DOI 10.1093/molbev/msn171; Haydon DT, 2003, EMERG INFECT DIS, V9, P1495; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Incardona S, 2005, AM J TROP MED HYG, V72, P719, DOI 10.4269/ajtmh.2005.72.719; LYSENKO AJ, 1969, B WORLD HEALTH ORGAN, V40, P383; MACFIE TS, 2009, MOL BIOL EVOL   0130; Martinsen ES, 2008, MOL PHYLOGENET EVOL, V47, P261, DOI 10.1016/j.ympev.2007.11.012; Mueller I, 2007, TRENDS PARASITOL, V23, P278, DOI 10.1016/j.pt.2007.04.009; Ollomo B, 1997, AM J TROP MED HYG, V56, P440, DOI 10.4269/ajtmh.1997.56.440; Perkins SL, 2007, INFECT GENET EVOL, V7, P74, DOI 10.1016/j.meegid.2006.04.005; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Duarte AMRD, 2008, ACTA TROP, V107, P179, DOI 10.1016/j.actatropica.2008.05.020; Rodhain J., 1955, Annales de la Societe Belge de Medecine Tropicale, V35, P757; SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V58, P283, DOI 10.1016/0166-6851(93)90050-8; Tachibana M, 2002, MOL BIOCHEM PARASIT, V122, P223, DOI 10.1016/S0166-6851(02)00101-9; Talman AM, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-140; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANRIPER C, 1986, ECOL MONOGR, V56, P327, DOI 10.2307/1942550; Win TT, 2004, EMERG INFECT DIS, V10, P1235, DOI 10.3201/eid1007.030411; Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371	39	53	56	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5520	10.1371/journal.pone.0005520	http://dx.doi.org/10.1371/journal.pone.0005520			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444WA	19436742	Green Published, Green Submitted, gold			2022-12-25	WOS:000266009900013
J	Miyoshi, K; Kasahara, K; Miyazaki, I; Shimizu, S; Taniguchi, M; Matsuzaki, S; Tohyama, M; Asanuma, M				Miyoshi, Ko; Kasahara, Kyosuke; Miyazaki, Ikuko; Shimizu, Shoko; Taniguchi, Manabu; Matsuzaki, Shinsuke; Tohyama, Masaya; Asanuma, Masato			Pericentrin, a centrosomal protein related to microcephalic primordial dwarfism, is required for olfactory cilia assembly in mice	FASEB JOURNAL			English	Article						kendrin; ciliogenesis; olfaction	POLYCYSTIC KIDNEY-DISEASE; CG-NAP; INTRAFLAGELLAR TRANSPORT; ADENYLYL-CYCLASE; SHARES HOMOLOGY; GENE; DISRUPTION; COMPLEX; MOUSE; ORGANIZATION	The Drosophila pericentrin-like protein has been shown to be essential for the formation of the sensory cilia of chemosensory and mechanosensory neurons by mutant analysis in flies, while the in vivo function of pericentrin, a well-studied mammalian centrosomal protein related to microcephalic primordial dwarfism, has been unclear. To determine whether pericentrin is required for ciliogenesis in mammals, we generated and analyzed mice with a hypomorphic mutation of Pcnt encoding the mouse pericentrin. Immunofluorescence analysis demonstrated that olfactory cilia of chemosensory neurons in the nasal olfactory epithelium were malformed in the homozygous mutant mice. On the other hand, the assembly of motile and primary cilia of non-neuronal epithelial cells and the formation of sperm flagella were not affected in the Pcnt-mutant mice. The defective assembly of olfactory cilia in the mutant was apparent from birth. The mutant animals displayed reduced olfactory performance in agreement with the compromised assembly of olfactory cilia. Our findings suggest that pericentrin is essential for the assembly of chemosensory cilia of olfactory receptor neurons, but it is not globally required for cilia formation in mammals.-Miyoshi, K., Kasahara, K., Miyazaki, I., Shimizu, S., Taniguchi, M., Matsuzaki, S., Tohyama, M., Asanuma, M. Pericentrin, a centrosomal protein related to microcephalic primordial dwarfism, is required for olfactory cilia assembly in mice. FASEB J. 23, 3289-3297 ( 2009). www.fasebj.org	[Miyoshi, Ko; Kasahara, Kyosuke; Miyazaki, Ikuko; Asanuma, Masato] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Brain Sci, Okayama 7008558, Japan; [Shimizu, Shoko; Taniguchi, Manabu; Matsuzaki, Shinsuke; Tohyama, Masaya] Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Osaka, Japan; [Matsuzaki, Shinsuke; Tohyama, Masaya] Osaka Univ, Grad Sch Med, Osaka Hamamatsu Joint Res Ctr Child Mental Dev, Osaka, Japan	Okayama University; Osaka University; Osaka University	Miyoshi, K (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Brain Sci, 2-5-1 Shikatacho, Okayama 7008558, Japan.	miyoshi@cc.okayama-u.ac.jp			Grants-in-Aid for Scientific Research [19591355]	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Grants-in-Aid for Scientific Research (Kakenhi; grant 19591355).	Araki K, 1999, CELL MOL BIOL, V45, P737; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; Cano DA, 2004, DEVELOPMENT, V131, P3457, DOI 10.1242/dev.01189; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; Flory MR, 2000, P NATL ACAD SCI USA, V97, P5919, DOI 10.1073/pnas.97.11.5919; Flory MR, 2003, GENOMICS, V82, P401, DOI 10.1016/S0888-7543(03)00119-8; Gillingham AK, 2000, EMBO REP, V1, P524; Griffith E, 2008, NAT GENET, V40, P232, DOI 10.1038/ng.2007.80; Jurczyk A, 2004, J CELL BIOL, V166, P637, DOI 10.1083/jcb.200405023; Kawaguchi S, 2004, MOL BIOL CELL, V15, P37, DOI 10.1091/mbc.E03-03-0191; Kim J, 2008, HUM MOL GENET, V17, P3796, DOI 10.1093/hmg/ddn277; Kubo A, 2003, J CELL SCI, V116, P919, DOI 10.1242/jcs.00282; Kulaga HM, 2004, NAT GENET, V36, P994, DOI 10.1038/ng1418; Liu QQ, 2001, J CELL SCI, V114, P797; Marshall WF, 2008, J CELL BIOL, V180, P17, DOI 10.1083/jcb.200710085; Martinez-Campos M, 2004, J CELL BIOL, V165, P673, DOI 10.1083/jcb.200402130; Miura K, 2006, BIOCHEM BIOPH RES CO, V341, P132, DOI 10.1016/j.bbrc.2005.12.151; Miyoshi K, 2006, BIOCHEM BIOPH RES CO, V351, P745, DOI 10.1016/j.bbrc.2006.10.101; Miyoshi K, 2006, DEV GENES EVOL, V216, P537, DOI 10.1007/s00427-006-0065-8; MOYER JH, 1994, SCIENCE, V264, P1329, DOI 10.1126/science.8191288; Mykytyn K, 2004, P NATL ACAD SCI USA, V101, P8664, DOI 10.1073/pnas.0402354101; Nachury MV, 2007, CELL, V129, P1201, DOI 10.1016/j.cell.2007.03.053; Nishimura DY, 2004, P NATL ACAD SCI USA, V101, P16588, DOI 10.1073/pnas.0405496101; Pan JM, 2005, LAB INVEST, V85, P452, DOI 10.1038/labinvest.3700253; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Rauch A, 2008, SCIENCE, V319, P816, DOI 10.1126/science.1151174; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Ross AJ, 2005, NAT GENET, V37, P1135, DOI 10.1038/ng1644; Takahashi M, 2002, MOL BIOL CELL, V13, P3235, DOI 10.1091/mbc.E02-02-0112; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Taniwaki T, 2005, DEV GROWTH DIFFER, V47, P163; Taulman PD, 2001, MOL BIOL CELL, V12, P589, DOI 10.1091/mbc.12.3.589; Wong ST, 2000, NEURON, V27, P487, DOI 10.1016/S0896-6273(00)00060-X; Yamamura K, 2008, CANCER SCI, V99, P1, DOI 10.1111/j.1349-7006.2007.00611.x; Zhang QH, 2005, LAB INVEST, V85, P45, DOI 10.1038/labinvest.3700207; Zimmerman WC, 2004, MOL BIOL CELL, V15, P3642, DOI 10.1091/mbc.E03-11-0796	39	33	34	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3289	3297		10.1096/fj.08-124420	http://dx.doi.org/10.1096/fj.08-124420			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19470799				2022-12-25	WOS:000270354300006
J	McDonough, H; Charles, PC; Hilliard, EG; Qian, SB; Min, JN; Portbury, A; Cyr, DM; Patterson, C				McDonough, Holly; Charles, Peter C.; Hilliard, Eleanor G.; Qian, Shu-Bing; Min, Jin-Na; Portbury, Andrea; Cyr, Douglas M.; Patterson, Cam			Stress-dependent Daxx-CHIP Interaction Suppresses the p53 Apoptotic Program	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; UBIQUITIN LIGASE; TRANSCRIPTIONAL ACTIVITY; C-TERMINUS; CELL-DEATH; ACTIVATION; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION; INDUCTION	Our previous studies have implicated CHIP (carboxyl terminus of Hsp70-interacting protein) as a co-chaperone/ubiquitin ligase whose activities yield protection against stress-induced apoptotic events. In this report, we demonstrate a stress-dependent interaction between CHIP and Daxx (death domain-associated protein). This interaction interferes with the stress-dependent association of HIPK2 with Daxx, blocking phosphorylation of serine 46 in p53 and inhibiting the p53-dependent apoptotic program. Microarray analysis confirmed suppression of the p53-dependent transcriptional portrait in CHIP+/+ but not in CHIP-/- heat shocked mouse embryonic fibroblasts. The interaction between CHIP and Daxx results in ubiquitination of Daxx, which is then partitioned to an insoluble compartment of the cell. In vitro ubiquitination of Daxx by CHIP revealed that ubiquitin chain formation utilizes non-canonical lysine linkages associated with resistance to proteasomal degradation. The ubiquitination of Daxx by CHIP utilizes lysines 630 and 631 and competes with the sumoylation machinery of the cell at these residues. These studies implicate CHIP as a stress-dependent regulator of Daxx that counters the pro-apoptotic influence of Daxx in the cell. By abrogating p53-dependent apoptotic pathways and by ubiquitination competitive with Daxx sumoylation, CHIP integrates the proteotoxic stress response of the cell with cell cycle pathways that influence cell survival.	[Patterson, Cam] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; [Cyr, Douglas M.; Patterson, Cam] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; [Patterson, Cam] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; [McDonough, Holly; Charles, Peter C.; Hilliard, Eleanor G.; Qian, Shu-Bing; Min, Jin-Na; Portbury, Andrea; Patterson, Cam] Univ N Carolina, Crolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA; [Patterson, Cam] Univ N Carolina, Div Cardiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Patterson, C (corresponding author), Univ N Carolina, Div Cardiol, 8200 Med Biomol Res Bldg, Chapel Hill, NC 27599 USA.	cpatters@med.unc.edu		Cyr, Douglas/0000-0002-4928-3414	National Institutes of Health [AG024282, GM61728]; American Heart Association Scientist Development [0635100N]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG024282] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association Scientist Development(American Heart Association); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported, in whole or in part, by National Institutes of Health Grants AG024282 and GM61728.; Supported in part by American Heart Association Scientist Development Grant 0635100N.	Al'Qteishat A, 2006, BRAIN, V129, P2158, DOI 10.1093/brain/awl139; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Beere HM, 2005, J CLIN INVEST, V115, P2633, DOI 10.1172/JCI26471; Boellmann F, 2004, P NATL ACAD SCI USA, V101, P4100, DOI 10.1073/pnas.0304768101; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Bourguignon LYW, 2007, J BIOL CHEM, V282, P19426, DOI 10.1074/jbc.M610054200; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483; Chen H, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-147; Chen LY, 2003, MOL CELL BIOL, V23, P7108, DOI 10.1128/MCB.23.20.7108-7121.2003; Collins CS, 2006, P NATL ACAD SCI USA, V103, P3775, DOI 10.1073/pnas.0600040103; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Copanaki E, 2007, BBA-MOL CELL RES, V1773, P157, DOI 10.1016/j.bbamcr.2006.10.002; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Ecsedy JA, 2003, MOL CELL BIOL, V23, P950, DOI 10.1128/MCB.23.3.950-960.2003; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Grivennikov S, 2008, CANCER CELL, V13, P7, DOI 10.1016/j.ccr.2007.12.020; He XR, 2004, BIOTECHNIQUES, V37, P464, DOI 10.2144/04373RT02; Hwang JR, 2005, CELL STRESS CHAPERON, V10, P147, DOI 10.1379/CSC-90R.1; Ishov AM, 2004, J CELL SCI, V117, P3807, DOI 10.1242/jcs.01230; Jang MS, 2002, BIOCHEM BIOPH RES CO, V295, P495, DOI 10.1016/S0006-291X(02)00699-X; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Jiang P, 2006, MOL CELL BIOL, V26, P9071, DOI 10.1128/MCB.01025-06; Kim HT, 2007, J BIOL CHEM, V282, P17375, DOI 10.1074/jbc.M609659200; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Kwon JE, 2006, J BIOL CHEM, V281, P12664, DOI 10.1074/jbc.M600204200; Li QX, 2007, CANCER RES, V67, P66, DOI 10.1158/0008-5472.CAN-06-1671; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; Matsumoto K, 2007, J BIOL CHEM, V282, P17053, DOI 10.1074/jbc.M701956200; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; Meray RK, 2007, J BIOL CHEM, V282, P10567, DOI 10.1074/jbc.M611153200; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Mohammed KA, 2007, LUNG, V185, P355, DOI 10.1007/s00408-007-9046-6; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Muromoto R, 2006, J IMMUNOL, V177, P1160, DOI 10.4049/jimmunol.177.2.1160; Muto A, 2002, J BIOL CHEM, V277, P20724, DOI 10.1074/jbc.M112003200; Nakamura Y, 2006, CANCER SCI, V97, P633, DOI 10.1111/j.1349-7006.2006.00214.x; Nefkens I, 2003, J CELL SCI, V116, P513, DOI 10.1242/jcs.00253; Nesbit CE, 1998, BLOOD, V92, P1003; Qian SB, 2006, NATURE, V440, P551, DOI 10.1038/nature04600; Riva A, 2005, COMPUT BIOL CHEM, V29, P319, DOI 10.1016/j.compbiolchem.2005.08.006; Salomoni P, 2006, TRENDS CELL BIOL, V16, P97, DOI 10.1016/j.tcb.2005.12.002; Schmitz C, 2005, MOL BIOL CELL, V16, P1319, DOI 10.1091/mbc.E04-05-0425; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Song JJ, 2003, J BIOL CHEM, V278, P47245, DOI 10.1074/jbc.M213201200; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Storey John D, 2003, Methods Mol Biol, V224, P149; Sugimoto M, 2006, MOL CELL BIOL, V26, P502, DOI 10.1128/MCB.26.2.502-512.2006; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; Tripathi V, 2007, J BIOL CHEM, V282, P28441, DOI 10.1074/jbc.M703698200; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wu SY, 2002, NEOPLASIA, V4, P486, DOI 10.1038/sj.neo.7900264; Xu Z, 2006, BIOCHEMISTRY-US, V45, P4749, DOI 10.1021/bi0601508; Yu H, 2005, GENE, V352, P75, DOI 10.1016/j.gene.2005.03.033; Zhang CL, 2005, AM J PHYSIOL-HEART C, V288, pH2836, DOI 10.1152/ajpheart.01122.2004	58	25	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20649	20659		10.1074/jbc.M109.011767	http://dx.doi.org/10.1074/jbc.M109.011767			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19465479	Green Published, hybrid			2022-12-25	WOS:000268316100026
J	Sun, L; Haun, S; Jones, RC; Edmondson, RD; Machaca, K				Sun, Lu; Haun, Shirley; Jones, Richard C.; Edmondson, Ricky D.; Machaca, Khaled			Kinase-dependent Regulation of Inositol 1,4,5-Trisphosphate-dependent Ca2+ Release during Oocyte Maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING DIFFERENTIATION; CALCIUM-RELEASE; PROTEIN-KINASE; XENOPUS-LAEVIS; ENDOPLASMIC-RETICULUM; STATISTICAL-MODEL; EGG ACTIVATION; CELL-CYCLE; RECEPTOR; PHOSPHORYLATION	Fertilization induces a species-specific Ca2+ transient with specialized spatial and temporal dynamics, which are essential to temporally encode egg activation events such as the block to polyspermy and resumption of meiosis. Eggs acquire the competence to produce the fertilization-specific Ca2+ transient during oocyte maturation, which encompasses dramatic potentiation of inositol 1,4,5-trisphosphate (IP3)-dependent Ca2+ release. Here we show that increased IP3 receptor (IP3R) sensitivity is initiated at the germinal vesicle breakdown stage of maturation, which correlates with maturation promoting factor (MPF) activation. Extensive phosphopeptide mapping of the IP3R resulted in similar to 70% coverage and identified three residues, Thr-931, Thr-1136, and Ser-114, which are specifically phosphorylated during maturation. Phospho-specific antibody analyses show that Thr-1136 phosphorylation requires MPF activation. Activation of either MPF or the mitogen-activated protein kinase cascade independently, functionally sensitizes IP3-dependent Ca2+ release. Collectively, these data argue that the kinase cascades driving meiotic maturation potentiates IP3-dependent Ca2+ release, possibly trough direct phosphorylation of the IP3R.	[Sun, Lu; Haun, Shirley; Machaca, Khaled] Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA; [Jones, Richard C.; Edmondson, Ricky D.] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA; [Machaca, Khaled] Qatar Fdn, Weill Cornell Med Coll, Doha, Qatar	University of Arkansas System; University of Arkansas Medical Sciences; US Food & Drug Administration (FDA); Qatar Foundation (QF); Weill Cornell Medical College Qatar	Machaca, K (corresponding author), POB 24144, Doha, Qatar.	khm2002@qatar-med.cornell.edu	Machaca, Khaled/AAF-3579-2019	Machaca, Khaled/0000-0001-6215-2411	National Institutes of Health, NIGMS [GM61829]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061829] Funding Source: NIH RePORTER	National Institutes of Health, NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant GM61829 from NIGMS.	Ben-Yehoshua LJ, 2007, MOL ENDOCRINOL, V21, P664, DOI 10.1210/me.2006-0256; CHARBONNEAU M, 1984, DEV BIOL, V102, P90, DOI 10.1016/0012-1606(84)90177-5; CHIBA K, 1990, DEV BIOL, V140, P300, DOI 10.1016/0012-1606(90)90080-3; Coblitz B, 2006, FEBS LETT, V580, P1531, DOI 10.1016/j.febslet.2006.02.014; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Ducibella T, 2002, DEV BIOL, V250, P280, DOI 10.1006/dbio.2002.0788; Edmondson RD, 2002, MOL CELL PROTEOMICS, V1, P421, DOI 10.1074/mcp.M100036-MCP200; El-Jouni W, 2005, DEV BIOL, V288, P514, DOI 10.1016/j.ydbio.2005.10.034; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FUJIWARA T, 1993, DEV BIOL, V156, P69, DOI 10.1006/dbio.1993.1059; Jellerette T, 2004, DEV BIOL, V274, P94, DOI 10.1016/j.ydbio.2004.06.020; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; LARABELL C, 1992, DEV BIOL, V153, P347, DOI 10.1016/0012-1606(92)90119-2; Lee B, 2006, DEVELOPMENT, V133, P4355, DOI 10.1242/dev.02624; Li XG, 2005, J IMMUNOL, V175, P6205, DOI 10.4049/jimmunol.175.9.6205; Lim D, 2003, J BIOL CHEM, V278, P42505, DOI 10.1074/jbc.M301851200; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Machaca K, 2004, DEV BIOL, V275, P170, DOI 10.1016/j.ydbio.2004.08.004; Machaca K, 2000, J BIOL CHEM, V275, P38710, DOI 10.1074/jbc.M007887200; Machaca K., 2001, CALCIUM ACTIVATES CH, P3; Machaca K, 2007, J CELL PHYSIOL, V213, P331, DOI 10.1002/jcp.21194; Malathi K, 2003, J CELL BIOCHEM, V90, P1186, DOI 10.1002/jcb.10720; MALLER JL, 1979, J BIOL CHEM, V254, P579; MEHLMANN LM, 1994, BIOL REPROD, V51, P1088, DOI 10.1095/biolreprod51.6.1088; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; NUCCITELLI R, 1993, DEV BIOL, V158, P200, DOI 10.1006/dbio.1993.1179; Ozil JP, 2005, DEV BIOL, V282, P39, DOI 10.1016/j.ydbio.2005.02.035; PARYS JB, 1994, DEV BIOL, V161, P466, DOI 10.1006/dbio.1994.1045; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Perdiguero E, 2004, CELL CYCLE, V3, P733; Santella L, 2003, BIOCHEM SOC T, V31, P79, DOI 10.1042/bst0310079; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; Sun L, 2004, J CELL BIOL, V165, P63, DOI 10.1083/jcb.200309138; Terasaki M, 2001, MOL BIOL CELL, V12, P1103, DOI 10.1091/mbc.12.4.1103; Ullah G, 2007, CELL CALCIUM, V42, P556, DOI 10.1016/j.ceca.2007.01.010; Villmann C, 1997, J NEUROSCI, V17, P7634, DOI 10.1523/jneurosci.17-20-07634.1997; Wagner LE, 2004, J BIOL CHEM, V279, P46242, DOI 10.1074/jbc.M405849200; Wagner LE, 2003, J BIOL CHEM, V278, P45811, DOI 10.1074/jbc.M306270200	42	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20184	20196		10.1074/jbc.M109.004515	http://dx.doi.org/10.1074/jbc.M109.004515			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19473987	Green Published, hybrid			2022-12-25	WOS:000268097400046
J	Wilson, MC; Meredith, D; Bunnun, C; Sessions, RB; Halestrap, AP				Wilson, Marieangela C.; Meredith, David; Bunnun, Chotirote; Sessions, Richard B.; Halestrap, Andrew P.			Studies on the DIDS-binding Site of Monocarboxylate Transporter 1 Suggest a Homology Model of the Open Conformation and a Plausible Translocation Cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE LACTATE TRANSPORTER; XENOPUS-LAEVIS OOCYTES; LACTOSE PERMEASE; IMMUNOGLOBULIN SUPERFAMILY; ANCILLARY PROTEIN; PLASMA-MEMBRANES; BASIGIN CD147; MCT1; INHIBITION; EXPRESSION	Site-directed mutagenesis of MCT1 was performed on exofacial lysines Lys(38), Lys(45), Lys(282), and Lys(413). K38Q-MCT1 and K38R-MCT1 were inactive when expressed at the plasma membrane of Xenopus laevis oocytes, whereas K45R/K282R/K413R-MCT1 and K45Q/K282Q/K413Q-MCT1 were active. The former exhibited normal reversible and irreversible inhibition by DIDS, whereas the latter showed less reversible and no irreversible inhibition. K45Q/K413Q-MCT1 retained some irreversible inhibition, whereas K45Q/K282Q-MCT1 and K282Q/K413Q-MCT1 did not. These data suggest that the twoDIDSSO(3)(-) groups interact with positively charged Lys(282) together with Lys(45) and/or Lys(413). This positions one DIDS isothiocyanate group close to Lys(38), leading to its covalent modification and irreversible inhibition. Additional mutagenesis revealed that DIDS cross-links MCT1 to its ancillary protein embigin using either Lys(38) or Lys(290) of MCT1 and Lys(160) or Lys(164) of embigin. We have modeled a possible structure for the outward facing (open) conformation of MCT1 by employing modest rotations of the C-terminal domain of the inner facing conformation modeled previously. The resulting model structure has a DIDS-binding site consistent with experimental data and locates Lys(38) in a hydrophobic environment at the bottom of a substrate-binding channel. Our model suggests a translocation cycle in which Lys(38) accepts a proton before binding lactate. Both the lactate and proton are then passed through the channel via Asp(302-) and Asp(306-), an ion pair already identified as important for transport and located adjacent to Phe(360), which controls channel selectivity. The cross-linking data have also been used to model a structure of MCT1 bound to embigin that is consistent with published data.	[Wilson, Marieangela C.; Meredith, David; Bunnun, Chotirote; Sessions, Richard B.; Halestrap, Andrew P.] Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Halestrap, AP (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	a.halestrap@bristol.ac.uk	Halestrap, Andrew P/G-7275-2011; Meredith, David/F-3664-2010	Sessions, Richard/0000-0003-0320-0895; Halestrap, Andrew/0000-0001-5374-2778; Wilson, Marieangela/0000-0001-6218-3533	Wellcome Trust [079792/z/06]	Wellcome Trust(Wellcome TrustEuropean Commission)	This work was supported by Project Grant 079792/z/06 from the Wellcome Trust.	Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Broer S, 1999, BIOCHEM J, V341, P529, DOI 10.1042/0264-6021:3410529; Broer S, 1998, BIOCHEM J, V333, P167, DOI 10.1042/bj3330167; CARPENTER L, 1994, BIOCHEM J, V304, P751, DOI 10.1042/bj3040751; DEUTICKE B, 1982, J MEMBRANE BIOL, V70, P89, DOI 10.1007/BF01870219; Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264-6021:3500219; Fox JEM, 2000, J PHYSIOL-LONDON, V529, P285, DOI 10.1111/j.1469-7793.2000.00285.x; Friesema ECH, 2003, J BIOL CHEM, V278, P40128, DOI 10.1074/jbc.M300909200; Galic S, 2003, BIOCHEM J, V376, P413, DOI 10.1042/BJ20030799; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; Grollman EF, 2000, BIOCHEMISTRY-US, V39, P9351, DOI 10.1021/bi000464+; Guan L, 2007, P NATL ACAD SCI USA, V104, P15294, DOI 10.1073/pnas.0707688104; Guenette RS, 1997, DEV GENET, V21, P268, DOI 10.1002/(SICI)1520-6408(1997)21:4<268::AID-DVG4>3.0.CO;2-5; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; Kim DK, 2001, J BIOL CHEM, V276, P17221, DOI 10.1074/jbc.M009462200; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Law CJ, 2008, ANNU REV MICROBIOL, V62, P289, DOI 10.1146/annurev.micro.61.080706.093329; Manoharan C, 2006, MOL MEMBR BIOL, V23, P486, DOI 10.1080/09687860600841967; Muramatsu T, 2003, HISTOL HISTOPATHOL, V18, P981, DOI 10.14670/HH-18.981; POOLE RC, 1990, BIOCHEM SOC T, V18, P1245, DOI 10.1042/bst0181245; POOLE RC, 1991, BIOCHEM J, V275, P307, DOI 10.1042/bj2750307; POOLE RC, 1992, BIOCHEM J, V283, P855, DOI 10.1042/bj2830855; POOLE RC, 1988, BIOCHEM J, V254, P385, DOI 10.1042/bj2540385; POOLE RC, 1991, BIOCHIM BIOPHYS ACTA, V1070, P69, DOI 10.1016/0005-2736(91)90147-Z; Poole RC, 1996, BIOCHEM J, V320, P817, DOI 10.1042/bj3200817; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; Poole RC, 1997, J BIOL CHEM, V272, P14624, DOI 10.1074/jbc.272.23.14624; Rahman B, 1999, BIOCHEMISTRY-US, V38, P11577, DOI 10.1021/bi990973f; Smirnova I, 2007, P NATL ACAD SCI USA, V104, P16504, DOI 10.1073/pnas.0708258104; Wilson MC, 2005, J BIOL CHEM, V280, P27213, DOI 10.1074/jbc.M411950200; Wilson MC, 2002, J BIOL CHEM, V277, P3666, DOI 10.1074/jbc.M109658200; Zhou YG, 2008, P NATL ACAD SCI USA, V105, P3774, DOI 10.1073/pnas.0800825105	33	68	73	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20011	20021		10.1074/jbc.M109.014217	http://dx.doi.org/10.1074/jbc.M109.014217			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19473976	Green Published, hybrid			2022-12-25	WOS:000268097400028
J	Danos, AM; Osmanovic, S; Brady, MJ				Danos, Arpad M.; Osmanovic, Senad; Brady, Matthew J.			Differential Regulation of Glycogenolysis by Mutant Protein Phosphatase-1 Glycogen-targeting Subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETIC-RATS; AMINO-ACID-SEQUENCE; 3T3-L1 ADIPOCYTES; BINDING-PROTEIN; STARVED RATS; PHOSPHORYLASE; INSULIN; LIVER; HEPATOCYTES; METABOLISM	PTG and G(L) are hepatic protein phosphatase-1 (PP1) glycogen-targeting subunits, which direct PP1 activity against glycogen synthase (GS) and/or phosphorylase (GP). The C-terminal 16 amino residues of G(L) comprise a high affinity binding site for GP that regulates bound PP1 activity against GS. In this study, a truncated G(L) construct lacking the GP-binding site (G(L)tr) and a chimeric PTG molecule containing the C-terminal site (PTG-G(L)) were generated. As expected, GP binding to glutathione S-transferase (GST)-G(L)tr was reduced, whereas GP binding to GST-PTG-G(L) was increased 2- to 3-fold versus GST-PTG. In contrast, PP1 binding to all proteins was equivalent. Primary mouse hepatocytes were infected with adenoviral constructs for each subunit, and their effects on glycogen metabolism were investigated. G(L)tr expression was more effective at promoting GP inactivation, GS activation, and glycogen accumulation than G(L). Removal of the regulatory GP-binding site from G(L)tr completely blocked the inactivation of GS seen in G(L)-expressing cells following a drop in extracellular glucose. As a result, G(L)tr expression prevented glycogen mobilization under 5 mM glucose conditions. In contrast, equivalent overexpression of PTG or PTG-G(L) caused a similar increase in glycogen-targeted PP1 levels and GS dephosphorylation. Surprisingly, GP dephosphorylation was significantly reduced in PTG-G(L)-overexpressing cells. As a result, PTG-G(L) expression permitted glycogenolysis under 5 mM glucose conditions that was prevented in PTG-expressing cells. Thus, expression of constructs that contained the high affinity GP-binding site (G(L) and PTG-G(L)) displayed reduced glycogen accumulation and enhanced glycogenolysis compared with their respective controls, albeit via different mechanisms.	Univ Chicago, Dept Med, Sect Endocrinol Diabet & Metab, Chicago, IL 60637 USA; Univ Chicago, Comm Mol Metab & Nutr, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Brady, MJ (corresponding author), MC1027,5841 S Maryland Ave, Chicago, IL 60637 USA.	mbrady@medicine.bsd.uchicago.edu			National Institutes of Health Grant [R01 DK064772]; American Diabetes Association; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064772] Funding Source: NIH RePORTER	National Institutes of Health Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grant R01 DK064772. This work was also supported by a Career Development Award from the American Diabetes Association.	Aiston S, 2004, BIOCHEM J, V377, P195, DOI 10.1042/BJ20031191; Aiston S, 2003, EUR J BIOCHEM, V270, P2773, DOI 10.1046/j.1432-1033.2003.03648.x; ALEMANY S, 1986, FEBS LETT, V198, P194, DOI 10.1016/0014-5793(86)80404-5; Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Armstrong CG, 1998, BIOCHEM J, V336, P699, DOI 10.1042/bj3360699; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Brady MJ, 1997, J BIOL CHEM, V272, P20198, DOI 10.1074/jbc.272.32.20198; Browne GJ, 2001, BIOCHEM J, V360, P449, DOI 10.1042/0264-6021:3600449; Ceulemans H, 2002, BIOESSAYS, V24, P371, DOI 10.1002/bies.10069; COATS WS, 1991, J BIOL CHEM, V266, P16113; Cohen P, 2006, NAT REV MOL CELL BIO, V7, P867, DOI 10.1038/nrm2043; Doherty MJ, 1998, BIOCHEM J, V333, P253, DOI 10.1042/bj3330253; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Fong NM, 2000, J BIOL CHEM, V275, P35034, DOI 10.1074/jbc.M005541200; Gasa R, 2000, J BIOL CHEM, V275, P26396, DOI 10.1074/jbc.M002427200; GILBOE DP, 1972, ANAL BIOCHEM, V47, P20, DOI 10.1016/0003-2697(72)90274-6; Green AR, 2004, J BIOL CHEM, V279, P46474, DOI 10.1074/jbc.M405660200; Greenberg CC, 2006, MOL CELL BIOL, V26, P334, DOI 10.1128/MCB.26.1.334-342.2006; Greenberg CC, 2003, J BIOL CHEM, V278, P30835, DOI 10.1074/jbc.M303846200; HERS HG, 1976, ANNU REV BIOCHEM, V45, P167, DOI 10.1146/annurev.bi.45.070176.001123; Kelsall IR, 2007, FEBS LETT, V581, P4749, DOI 10.1016/j.febslet.2007.08.073; Kelsall IR, 2009, CELL SIGNAL, V21, P1123, DOI 10.1016/j.cellsig.2009.03.001; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; Munro S, 2005, FEBS J, V272, P1478, DOI 10.1111/j.1742-4658.2005.04585.x; O'Doherty RM, 2000, J CLIN INVEST, V105, P479, DOI 10.1172/JCI8673; Pautsch A, 2008, J BIOL CHEM, V283, P8913, DOI 10.1074/jbc.M706612200; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; PRINTEN JA, 1994, GENETICS, V138, P609; Ros S, 2009, J BIOL CHEM, V284, P6370, DOI 10.1074/jbc.M808576200; STALMANS W, 1971, EUR J BIOCHEM, V18, P582, DOI 10.1111/j.1432-1033.1971.tb01279.x; TANG PM, 1991, J BIOL CHEM, V266, P15782; Yang RJ, 2003, J BIOL CHEM, V278, P23418, DOI 10.1074/jbc.M213112200; Yang RJ, 2002, J BIOL CHEM, V277, P1514, DOI 10.1074/jbc.M107001200; Zhou XY, 2004, NAT MED, V10, P633, DOI 10.1038/nm1050; Zibrova D, 2008, BIOCHEM J, V412, P359, DOI 10.1042/BJ20071483	37	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19544	19553		10.1074/jbc.M109.015073	http://dx.doi.org/10.1074/jbc.M109.015073			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19487702	Green Published, hybrid			2022-12-25	WOS:000267908300046
J	Noel, G; Tham, DKL; Moukhles, H				Noel, Geoffroy; Tham, Daniel Kai Long; Moukhles, Hakima			Interdependence of Laminin-mediated Clustering of Lipid Rafts and the Dystrophin Complex in Astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; NEUROMUSCULAR-JUNCTION; WATER CHANNEL; CULTURED ASTROCYTES; NULL MICE; MDX-MICE; DYSTROGLYCAN; AQUAPORIN-4; MEMBRANE; AGRIN	Astrocyte endfeet surrounding blood vessels are active domains involved in water and potassium ion transport crucial to the maintenance of water and potassium ion homeostasis in brain. A growing body of evidence points to a role for dystroglycan and its interaction with perivascular laminin in the targeting of the dystrophin complex and the water-permeable channel, aquaporin 4 (AQP4), at astrocyte endfeet. However, the mechanisms underlying such compartmentalization remain poorly understood. In the present study we found that AQP4 resided in Triton X-100-insoluble fraction, whereas dystroglycan was recovered in the soluble fraction in astrocytes. Cholesterol depletion resulted in the translocation of a pool of AQP4 to the soluble fraction indicating that its distribution is indeed associated with cholesterol-rich membrane domains. Upon laminin treatment AQP4 and the dystrophin complex, including dystroglycan, reorganized into laminin-associated clusters enriched for the lipid raft markers GM1 and flotillin-1 but not caveolin-1. Reduced diffusion rates of GM1 in the laminin-induced clusters were indicative of the reorganization of raft components in these domains. In addition, both cholesterol depletion and dystroglycan silencing reduced the number and area of laminin-induced clusters of GM1, AQP4, and dystroglycan. These findings demonstrate the interdependence between laminin binding to dystroglycan and GM1-containing lipid raft reorganization and provide novel insight into the dystrophin complex regulation of AQP4 polarization in astrocytes.	[Moukhles, Hakima] Univ British Columbia, Dept Cellular & Physiol Sci, Life Sci Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Moukhles, H (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, Life Sci Ctr, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	moukhles@interchange.ubc.ca		Noel, Geoffroy/0000-0003-2192-7756	Canadian Institutes of Health Research; University Graduate Fellowship	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); University Graduate Fellowship	This work was supported by grants from the Canadian Institutes of Health Research, Muscular Dystrophy Canada, and Amyotrophic Lateral Sclerosis Society of Canada (to H.M.) and by a University Graduate Fellowship (to G.N.).	Amiry-Moghaddam M, 2004, FASEB J, V18, P542, DOI 10.1096/fj.03-0869fje; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Arikawa-Hirasawa E, 2002, NAT NEUROSCI, V5, P119, DOI 10.1038/nn801; Baron W, 2003, CURR BIOL, V13, P151, DOI 10.1016/S0960-9822(02)01437-9; BARRANTES FJ, 1993, BRAZ J MED BIOL RES, V26, P553; Benfenati V, 2007, J NEUROCHEM, V100, P87, DOI 10.1111/j.1471-4159.2006.04164.x; Blake DJ, 1999, J CELL BIOL, V147, P645, DOI 10.1083/jcb.147.3.645; Campagna JA, 2006, NEUROSCIENCE, V138, P123, DOI 10.1016/j.neuroscience.2005.11.019; Dalloz C, 2003, HUM MOL GENET, V12, P1543, DOI 10.1093/hmg/ddg170; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Fort PE, 2008, GLIA, V56, P597, DOI 10.1002/glia.20633; Frigeri A, 2001, FASEB J, V15, P90, DOI 10.1096/fj.00-0260com; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Glebov OO, 2006, NAT CELL BIOL, V8, P46, DOI 10.1038/ncb1342; Guadagno E, 2004, GLIA, V47, P138, DOI 10.1002/glia.20039; Hering H, 2003, J NEUROSCI, V23, P3262; Hibino H, 2007, EUR J NEUROSCI, V26, P2539, DOI 10.1111/j.1460-9568.2007.05876.x; Huk KH, 2002, MOL NEUROBIOL, V25, P79; Ichikawa N, 2009, J CELL SCI, V122, P289, DOI 10.1242/jcs.030338; Ishikawa Y, 2006, BBA-BIOMEMBRANES, V1758, P1053, DOI 10.1016/j.bbamem.2006.03.026; Kenworthy Anne K., 2007, V398, P179, DOI 10.1007/978-1-59745-513-8_13; Khan AA, 2001, SCIENCE, V292, P1681, DOI 10.1126/science.1056594; Lajoie P, 2007, J CELL BIOL, V179, P341, DOI 10.1083/jcb.200611106; Marangi PA, 2002, J CELL BIOL, V157, P883, DOI 10.1083/jcb.200202110; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Moukhles H, 2001, J NEUROCHEM, V78, P824, DOI 10.1046/j.1471-4159.2001.00466.x; Nicchia GP, 2003, FASEB J, V17, P1508, DOI 10.1096/fj.02-1183fje; Nico B, 2003, GLIA, V42, P235, DOI 10.1002/glia.10216; Nishimune H, 2008, J CELL BIOL, V182, P1201, DOI 10.1083/jcb.200805095; Noel G, 2005, J NEUROCHEM, V94, P691, DOI 10.1111/j.1471-4159.2005.03191.x; Noell S, 2007, EUR J NEUROSCI, V26, P2109, DOI 10.1111/j.1460-9568.2007.05850.x; Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200; Ramseger R, 2009, J BIOL CHEM, V284, P7697, DOI 10.1074/jbc.M806719200; Rash JE, 2004, NEUROSCIENCE, V129, P915, DOI 10.1016/j.neuroscience.2004.06.076; Romanenko VG, 2002, BIOPHYS J, V83, P3211, DOI 10.1016/S0006-3495(02)75323-X; Ruegg MA, 1998, TRENDS NEUROSCI, V21, P22, DOI 10.1016/S0166-2236(97)01154-5; Rurak J, 2007, J NEUROCHEM, V103, P1940, DOI 10.1111/j.1471-4159.2007.04886.x; Sasaki H, 1996, CELL STRUCT FUNCT, V21, P133, DOI 10.1247/csf.21.133; Shah WA, 2006, J GEN VIROL, V87, P673, DOI 10.1099/vir.0.81444-0; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stetzkowski-Marden F, 2006, J MOL NEUROSCI, V30, P37, DOI 10.1385/JMN:30:1:37; Stetzkowski-Marden F, 2006, J LIPID RES, V47, P2121, DOI 10.1194/jlr.M600182-JLR200; Susuki K, 2007, GLIA, V55, P746, DOI 10.1002/glia.20503; Vajda Z, 2002, P NATL ACAD SCI USA, V99, P13131, DOI 10.1073/pnas.192457099; Verbavatz JM, 1997, J CELL SCI, V110, P2855; Willmann R, 2006, EMBO J, V25, P4050, DOI 10.1038/sj.emboj.7601288; Zaccaria ML, 2001, NEUROSCIENCE, V104, P311, DOI 10.1016/S0306-4522(01)00092-6	48	34	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19694	19704		10.1074/jbc.M109.010090	http://dx.doi.org/10.1074/jbc.M109.010090			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19451651	hybrid, Green Published			2022-12-25	WOS:000267908300060
J	Yeung, ML; Houzet, L; Yedavalli, VSRK; Jeang, KT				Yeung, Man Lung; Houzet, Laurent; Yedavalli, Venkat S. R. K.; Jeang, Kuan-Teh			A Genome-wide Short Hairpin RNA Screening of Jurkat T-cells for Human Proteins Contributing to Productive HIV-1 Replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; GENE; ACTIVATION; ESCAPE; PPAR	Short interfering RNAs (siRNAs) have been used to inhibit HIV-1 replication. The durable inhibition of HIV-1 replication by RNA interference has been impeded, however, by a high mutation rate when viral sequences are targeted and by cytotoxicity when cellular genes are knocked down. To identify cellular proteins that contribute to HIV-1 replication that can be chronically silenced without significant cytotoxicity, we employed a shRNA library that targets 54,509 human transcripts. We used this library to select a comprehensive population of Jurkat T-cell clones, each expressing a single discrete shRNA. The Jurkat clones were then infected with HIV-1. Clones that survived viral infection represent moieties silenced for a human mRNA needed for virus replication, but whose chronic knockdown did not cause cytotoxicity. Overall, 252 individual Jurkat mRNAs were identified. Twenty-two of these mRNAs were secondarily verified for their contributions to HIV-1 replication. Five mRNAs, NRF1, STXBP2, NCOA3, PRDM2, and EXOSC5, were studied for their effect on steps of the HIV-1 life cycle. We discuss the similarities and differences between our shRNA findings for HIV-1 using a spreading infection assay in human Jurkat T-cells and results from other investigators who used siRNA-based screenings in HeLa or 293T cells.	[Yeung, Man Lung; Houzet, Laurent; Yedavalli, Venkat S. R. K.; Jeang, Kuan-Teh] NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jeang, KT (corresponding author), Bldg 4,Rm 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kj7e@nih.gov	Jeang, Kuan-Teh/A-2424-2008; Yeung, Man Lung/E-9903-2010	Yeung, Man Lung/0000-0002-6117-7884	NIAID; Office of the Director, NIH; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000547, Z01AI000547] Funding Source: NIH RePORTER	NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Office of the Director, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported, in whole or in part, by National Institutes of Health intramural research funds from NIAID. This work was also supported by the IATAP program from the Office of the Director, NIH.	ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Arimura A, 2004, J BIOL CHEM, V279, P31105, DOI 10.1074/jbc.M404428200; Bennasser Y, 2007, BIODRUGS, V21, P17, DOI 10.2165/00063030-200721010-00003; Berkhout B, 2007, J BIOL CHEM, V282, P26641, DOI 10.1074/jbc.R700023200; Boden D, 2003, J VIROL, V77, P11531, DOI 10.1128/JVI.77.21.11531-11535.2003; Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725; Brouwer R, 2001, J BIOL CHEM, V276, P6177, DOI 10.1074/jbc.M007603200; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Goff SP, 2008, CELL, V135, P417, DOI 10.1016/j.cell.2008.10.007; Goff SP, 2007, NAT REV MICROBIOL, V5, P253, DOI 10.1038/nrmicro1541; Green S, 1995, MUTAT RES-FUND MOL M, V333, P101, DOI 10.1016/0027-5107(95)00136-0; Huang W, 2008, J NEUROCHEM, V107, P497, DOI 10.1111/j.1471-4159.2008.05626.x; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Konig R, 2008, CELL, V135, P49, DOI 10.1016/j.cell.2008.07.032; Kumar A, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-26; Lama J, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-52; Lewinski MK, 2005, J VIROL, V79, P6610, DOI 10.1128/JVI.79.11.6610-6619.2005; Luciano-Montalvo C, 2008, PLACENTA, V29, P1016, DOI 10.1016/j.placenta.2008.09.005; Mahalingam S, 1995, VIROLOGY, V214, P647, DOI 10.1006/viro.1995.0079; Michienzi A, 2003, ANN NY ACAD SCI, V1002, P63, DOI 10.1196/annals.1281.008; Moriuchi M, 1999, AIDS RES HUM RETROV, V15, P821, DOI 10.1089/088922299310728; Munier S, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-73; Naito Y, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-80; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Riento K, 2000, J BIOL CHEM, V275, P13476, DOI 10.1074/jbc.275.18.13476; Ringrose J, 2008, J VIROL, V82, P4320, DOI 10.1128/JVI.01819-07; Stavru F, 2006, J CELL BIOL, V173, P477, DOI 10.1083/jcb.200601002; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Westerhout EM, 2005, NUCLEIC ACIDS RES, V33, P796, DOI 10.1093/nar/gki220; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241; Zhou HL, 2008, CELL HOST MICROBE, V4, P495, DOI 10.1016/j.chom.2008.10.004	35	194	196	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19463	19473		10.1074/jbc.M109.010033	http://dx.doi.org/10.1074/jbc.M109.010033			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19460752	Green Published, hybrid			2022-12-25	WOS:000267908300038
J	Minor, JS; Tang, HY; Pereira, FA; Alford, RL				Minor, Jacob S.; Tang, Hsiao-Yuan; Pereira, Fred A.; Alford, Raye Lynn			DNA Sequence Analysis of SLC26A5, Encoding Prestin, in a Patient-Control Cohort: Identification of Fourteen Novel DNA Sequence Variations	PLOS ONE			English	Article								Background: Prestin, encoded by the gene SLC26A5, is a transmembrane protein of the cochlear outer hair cell (OHC). Prestin is required for the somatic electromotile activity of OHCs, which is absent in OHCs and causes severe hearing impairment in mice lacking prestin. In humans, the role of sequence variations in SLC26A5 in hearing loss is less clear. Although prestin is expected to be required for functional human OHCs, the clinical significance of reported putative mutant alleles in humans is uncertain. Methodology/Principal Findings: To explore the hypothesis that SLC26A5 may act as a modifier gene, affecting the severity of hearing loss caused by an independent etiology, a patient-control cohort was screened for DNA sequence variations in SLC26A5 using sequencing and allele specific methods. Patients in this study carried known pathogenic or controversial sequence variations in GJB2, encoding Connexin 26, or confirmed or suspected sequence variations in SLC26A5; controls included four ethnic populations. Twenty-three different DNA sequence variations in SLC26A5, 14 of which are novel, were observed: 4 novel sequence variations were found exclusively among patients; 7 novel sequence variations were found exclusively among controls; and, 12 sequence variations, 3 of which are novel, were found in both patients and controls. Twenty-one of the 23 DNA sequence variations were located in non-coding regions of SLC26A5. Two coding sequence variations, both novel, were observed only in patients and predict a silent change, p. S434S, and an amino acid substitution, p. I663V. In silico analysis of the p. I663V amino acid variation suggested this variant might be benign. Using Fisher's exact test, no statistically significant difference was observed between patients and controls in the frequency of the identified DNA sequence variations. Haplotype analysis using HaploView 4.0 software revealed the same predominant haplotype in patients and controls and derived haplotype blocks in the patient-control cohort similar to those generated from the International HapMap Project. Conclusions/Significance: Although these data fail to support a hypothesis that SLC26A5 acts as a modifier gene of GJB2-related hearing loss, the sample size is small and investigation of a larger population might be more informative. The 14 novel DNA sequence variations in SLC26A5 reported here will serve as useful research tools for future studies of prestin.			Minor, JS (corresponding author), Univ Colorado, Denver Hlth Sci Ctr, Dept Otolaryngol, Aurora, CO USA.	ralford@bcm.edu		Pereira, Fred/0000-0003-2100-0280	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R21DC008134, R01DC004585, R01DC000354, R01DC009622, F32DC000354] Funding Source: NIH RePORTER; NIDCD NIH HHS [R21 DC008134, R01 DC000354, F32 DC000354, R01 DC009622, DC008134-01, R01 DC004585, DC00354] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		*APPL BIOS YST, 2008, TAQMAN SNP GEN ASS; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; CONNERS BW, 2002, MED PHYSL CELLULAR M, P325; Dallos P, 2002, NAT REV MOL CELL BIO, V3, P104, DOI 10.1038/nrm730; DALLOS P, 1992, J NEUROSCI, V12, P4575; Dallos P, 2006, J PHYSIOL-LONDON, V576, P37, DOI 10.1113/jphysiol.2006.114652; Database of Single Nucleotide Polymorphisms, 2008, DATABASE SINGLE NUCL; Deak L, 2005, J PHYSIOL-LONDON, V563, P483, DOI 10.1113/jphysiol.2004.078857; den Dunnen JT, 2001, HUM GENET, V109, P121, DOI 10.1007/s004390100505; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Green GE, 1999, JAMA-J AM MED ASSOC, V281, P2211, DOI 10.1001/jama.281.23.2211; Liberman MC, 2002, NATURE, V419, P300, DOI 10.1038/nature01059; Liu XZ, 2003, HUM MOL GENET, V12, P1155, DOI 10.1093/hmg/ddg127; Mount DB, 2004, PFLUG ARCH EUR J PHY, V447, P710, DOI 10.1007/s00424-003-1090-3; Navaratnam D, 2005, BIOPHYS J, V89, P3345, DOI 10.1529/biophysj.105.068759; Ng PC, 2002, GENOME RES, V12, P436, DOI 10.1101/gr.212802; Ogino S, 2007, J MOL DIAGN, V9, P1, DOI 10.2353/jmoldx.2007.060081; Oliver D, 2001, SCIENCE, V292, P2340, DOI 10.1126/science.1060939; Rajagopalan L, 2006, J NEUROSCI, V26, P12727, DOI 10.1523/JNEUROSCI.2734-06.2006; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Schaechinger TJ, 2007, P NATL ACAD SCI USA, V104, P7693, DOI 10.1073/pnas.0608583104; Tang HY, 2006, AM J MED GENET A, V140A, P2401, DOI 10.1002/ajmg.a.31525; Tang HY, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-30; Toth T, 2007, INT J MOL MED, V20, P545; VANCAMP G, 2008, HEREDITARY HEARING L; Zheng J, 2000, NATURE, V405, P149, DOI 10.1038/35012009; Zheng J, 2003, MAMM GENOME, V14, P87, DOI 10.1007/s00335-002-2227-y	27	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2009	4	6							e5762	10.1371/journal.pone.0005762	http://dx.doi.org/10.1371/journal.pone.0005762			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453CI	19492055	Green Published, Green Submitted, gold			2022-12-25	WOS:000266587400005
J	Blum, R; Gupta, R; Burger, PE; Ontiveros, CS; Salm, SN; Xiong, XZ; Kamb, A; Wesche, H; Marshall, L; Cutler, G; Wang, XY; Zavadil, J; Moscatelli, D; Wilson, EL				Blum, Roy; Gupta, Rashmi; Burger, Patricia E.; Ontiveros, Christopher S.; Salm, Sarah N.; Xiong, Xiaozhong; Kamb, Alexander; Wesche, Holger; Marshall, Lisa; Cutler, Gene; Wang, Xiangyun; Zavadil, Jiri; Moscatelli, David; Wilson, E. Lynette			Molecular Signatures of Prostate Stem Cells Reveal Novel Signaling Pathways and Provide Insights into Prostate Cancer	PLOS ONE			English	Article							HEMATOPOIETIC STEM; GENE-EXPRESSION; PROXIMAL REGION; FUNCTIONAL-CHARACTERIZATION; COORDINATE REGULATION; TGF-BETA; IN-UTERO; RECEPTOR; PROTEIN; DIFFERENTIATION	Background: The global gene expression profiles of adult and fetal murine prostate stem cells were determined to define common and unique regulators whose misexpression might play a role in the development of prostate cancer. Methodology/Principal Findings: A distinctive core of transcriptional regulators common to both fetal and adult primitive prostate cells was identified as well as molecules that are exclusive to each population. Elements common to fetal and adult prostate stem cells include expression profiles of Wnt, Shh and other pathways identified in stem cells of other organs, signatures of the aryl-hydrocarbon receptor, and up-regulation of components of the aldehyde dehydrogenase/retinoic acid receptor axis. There is also a significant lipid metabolism signature, marked by overexpression of lipid metabolizing enzymes and the presence of the binding motif for Srebp1. The fetal stem cell population, characterized by more rapid proliferation and self-renewal, expresses regulators of the cell cycle, such as E2f, Nfy, Tead2 and Ap2, at elevated levels, while adult stem cells show a signature in which TGF-beta has a prominent role. Finally, comparison of the signatures of primitive prostate cells with previously described profiles of human prostate tumors identified stem cell molecules and pathways with deregulated expression in prostate tumors including chromatin modifiers and the oncogene, Erg. Conclusions/Significance: Our data indicate that adult prostate stem or progenitor cells may acquire characteristics of self-renewing primitive fetal prostate cells during oncogenesis and suggest that aberrant activation of components of prostate stem cell pathways may contribute to the development of prostate tumors.			Blum, R (corresponding author), NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA.	Elaine.Wilson@nyumc.org	Zavadil, Jiri/ABG-1780-2020	Zavadil, Jiri/0000-0003-0640-5562; Moscatelli, David/0000-0002-4627-4213; Blum, Roy/0000-0002-3987-7198	NATIONAL CANCER INSTITUTE [R01CA132641, R01CA090593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK071468] Funding Source: NIH RePORTER; NCI NIH HHS [CA132641, R01 CA090593-04, R01 CA132641, CA 90593, R01 CA090593] Funding Source: Medline; NIDDK NIH HHS [5F32DK071468, F32 DK071468] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; Aparicio LMA, 2007, CLIN TRANSL ONCOL, V9, P66, DOI 10.1007/s12094-007-0015-6; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Burger PE, 2005, P NATL ACAD SCI USA, V102, P7180, DOI 10.1073/pnas.0502761102; Chang TY, 2006, ANNU REV CELL DEV BI, V22, P129, DOI 10.1146/annurev.cellbio.22.010305.104656; Clarke AR, 2006, ONCOGENE, V25, P7512, DOI 10.1038/sj.onc.1210065; Corti S, 2006, HUM MOL GENET, V15, P167, DOI 10.1093/hmg/ddi446; Cunha G R, 1987, Prog Clin Biol Res, V239, P273; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; Fanayan S, 2000, J BIOL CHEM, V275, P39146, DOI 10.1074/jbc.M006964200; Ficazzola MA, 2001, CARCINOGENESIS, V22, P1271, DOI 10.1093/carcin/22.8.1271; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; Fritz WA, 2007, CARCINOGENESIS, V28, P497, DOI 10.1093/carcin/bgl179; Garcia-Gonzalo FR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001384; Gipp J, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-19; Goto K, 2006, STEM CELLS, V24, P1859, DOI 10.1634/stemcells.2005-0585; Groszer M, 2006, P NATL ACAD SCI USA, V103, P111, DOI 10.1073/pnas.0509939103; Gu GY, 2007, CANCER RES, V67, P4807, DOI 10.1158/0008-5472.CAN-06-4608; Habib FK, 2003, CLIN CANCER RES, V9, P1815; Hess DA, 2004, BLOOD, V104, P1648, DOI 10.1182/blood-2004-02-0448; Hoei-Hansen CE, 2006, J PATHOL, V209, P25, DOI 10.1002/path.1948; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Honda M, 2005, BIOCHEM BIOPH RES CO, V333, P1334, DOI 10.1016/j.bbrc.2005.05.202; Huang L, 2003, J BIOL CHEM, V278, P51085, DOI 10.1074/jbc.M308321200; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Kaneko KJ, 2004, MOL CELL BIOL, V24, P1968, DOI 10.1128/MCB.24.5.1968-1982.2004; Kohle C, 2007, BIOCHEM PHARMACOL, V73, P1853, DOI 10.1016/j.bcp.2007.01.009; Kues WA, 2005, BIOL REPROD, V72, P1020, DOI 10.1095/biolreprod.104.031229; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Lin TM, 2003, TOXICOL SCI, V76, P171, DOI 10.1093/toxsci/kfg218; Lin TM, 2002, TOXICOL SCI, V68, P479, DOI 10.1093/toxsci/68.2.479; LOUGHRAN SJ, 2008, NAT IMMUNOL; Mehra R, 2008, CANCER RES, V68, P3584, DOI 10.1158/0008-5472.CAN-07-6154; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Murante FG, 2000, TOXICOL SCI, V54, P374, DOI 10.1093/toxsci/54.2.374; Nishimori T, 2006, PROTEOMICS, V6, P1011, DOI 10.1002/pmic.200500262; Ory DS, 2004, CIRC RES, V95, P660, DOI 10.1161/01.RES.0000143422.83209.be; Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033; Petkov PM, 2004, HEPATOLOGY, V39, P617, DOI 10.1002/hep.20088; Purton LE, 2007, PPAR RES, V2007, DOI 10.1155/2007/87934; Qian H, 2007, BLOOD, V110, P2399, DOI 10.1182/blood-2006-10-051276; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Sakai R, 2003, TOXICOL SCI, V72, P84, DOI 10.1093/toxsci/kfg002; Salm SN, 2005, J CELL BIOL, V170, P81, DOI 10.1083/jcb.200412015; Seo J, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-395; Sessler RJ, 2005, MOL CELL, V18, P343, DOI 10.1016/j.molcel.2005.03.026; Shah US, 2006, HUM PATHOL, V37, P401, DOI 10.1016/j.humpath.2005.11.022; Shamir R, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-232; Shetty RS, 2005, MOL CELL NEUROSCI, V30, P583, DOI 10.1016/j.mcn.2005.06.003; Signoretti S, 2007, SEMIN CANCER BIOL, V17, P219, DOI 10.1016/j.semcancer.2006.04.004; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Szatmari I, 2007, BLOOD, V110, P3271, DOI 10.1182/blood-2007-06-096222; TAMIMI Y, 1993, CANCER RES, V53, P5512; Titus MA, 2005, CLIN CANCER RES, V11, P4653, DOI 10.1158/1078-0432.CCR-05-0525; Traynor P, 2008, DIS MARKERS, V24, P157, DOI 10.1155/2008/918087; Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523-1747.2003.12088.x; Tsujimura A, 2002, J CELL BIOL, V157, P1257, DOI 10.1083/jcb.200202067; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; van Leenders GJLH, 2007, EUR UROL, V52, P455, DOI 10.1016/j.eururo.2006.11.020; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang YZ, 2001, DIFFERENTIATION, V68, P270, DOI 10.1046/j.1432-0436.2001.680414.x; Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199; Wenzel PL, 2007, GENE DEV, V21, P85, DOI 10.1101/gad.1485307; Wildwater M, 2005, CELL, V123, P1337, DOI 10.1016/j.cell.2005.09.042; Winkler S, 2007, CANCER GENET CYTOGEN, V177, P98, DOI 10.1016/j.cancergencyto.2007.06.008; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Yamada K, 2006, CANCER SCI, V97, P106, DOI 10.1111/j.1349-7006.2006.00147.x; Yamazaki S, 2006, EMBO J, V25, P3515, DOI 10.1038/sj.emboj.7601236; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zhou ZX, 2007, CANCER RES, V67, P5683, DOI 10.1158/0008-5472.CAN-07-0768; Zhu J, 2005, P NATL ACAD SCI USA, V102, P11728, DOI 10.1073/pnas.0503405102	79	51	51	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5722	10.1371/journal.pone.0005722	http://dx.doi.org/10.1371/journal.pone.0005722			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451SH	19478945	Green Published, gold			2022-12-25	WOS:000266490000004
J	Jones, HP; Schmitz, OJ				Jones, Holly P.; Schmitz, Oswald J.			Rapid Recovery of Damaged Ecosystems	PLOS ONE			English	Article							SUSTAINABILITY SCIENCE; RESTORATION ECOLOGY; RESILIENCE; STABILITY; RESISTANCE; SYSTEMS	Background: Recent reports on the state of the global environment provide evidence that humankind is inflicting great damage to the very ecosystems that support human livelihoods. The reports further predict that ecosystems will take centuries to recover from damages if they recover at all. Accordingly, there is despair that we are passing on a legacy of irreparable damage to future generations which is entirely inconsistent with principles of sustainability. Methodology/Principal Findings: We tested the prediction of irreparable harm using a synthesis of recovery times compiled from 240 independent studies reported in the scientific literature. We provide startling evidence that most ecosystems globally can, given human will, recover from very major perturbations on timescales of decades to half-centuries. Significance/Conclusions: Accordingly, we find much hope that humankind can transition to more sustainable use of ecosystems.			Jones, HP (corresponding author), Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USA.	holly.jones@yale.edu		Jones, Holly/0000-0002-5512-9958	Direct For Biological Sciences [0816504] Funding Source: National Science Foundation	Direct For Biological Sciences(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))		[Anonymous], 2005, EC HUM WELL BEING SY; Baumol W., 1996, ENVIRON DEV ECON, V3, P221, DOI 10.1017/S1355770X98240125; Beisner BE, 2003, FRONT ECOL ENVIRON, V1, P376, DOI 10.1890/1540-9295(2003)001[0376:ASSIE]2.0.CO;2; Carpenter SR, 2000, ECOSYSTEMS, V3, P495, DOI 10.1007/s100210000043; Clark WC, 2003, P NATL ACAD SCI USA, V100, P8059, DOI 10.1073/pnas.1231333100; Dobson AP, 1997, SCIENCE, V277, P515, DOI 10.1126/science.277.5325.515; DUDZIK M, 1975, STABILITY INDICATORS; Foley JA, 2005, SCIENCE, V309, P570, DOI 10.1126/science.1111772; Gunderson LH, 2000, ANNU REV ECOL SYST, V31, P425, DOI 10.1146/annurev.ecolsys.31.1.425; Halpern BS, 2008, SCIENCE, V319, P948, DOI 10.1126/science.1149345; Harris Jim A., 2006, P3; HARRISON GW, 1980, ECOL MODEL, V10, P227, DOI 10.1016/0304-3800(80)90061-7; HARRISON GW, 1979, AM NAT, V113, P659, DOI 10.1086/283424; HARWELL MA, 1977, ECOLOGY, V58, P660, DOI 10.2307/1939016; *HJ HEINZ CTR SCI, 2005, STAT NAT EC 2008; Hobbs RJ, 2001, RESTOR ECOL, V9, P239, DOI 10.1046/j.1526-100x.2001.009002239.x; Holling C.S., 1973, Annual Rev Ecol Syst, V4, P1, DOI 10.1146/annurev.es.04.110173.000245; IVES AR, 1995, ECOL MONOGR, V65, P217, DOI 10.2307/2937138; Kareiva P, 2007, SCIENCE, V316, P1866, DOI 10.1126/science.1140170; Kates RW, 2001, SCIENCE, V292, P641, DOI 10.1126/science.1059386; LEWONTIN RC, 1969, BROOKHAVEN SYM BIOL, P13; McLauchlan KK, 2007, P NATL ACAD SCI USA, V104, P7466, DOI 10.1073/pnas.0701779104; Scheffer M, 2001, NATURE, V413, P591, DOI 10.1038/35098000; Shurin JB, 2006, P ROY SOC B-BIOL SCI, V273, P1, DOI 10.1098/rspb.2005.3377	24	214	217	2	118	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2009	4	5							e5653	10.1371/journal.pone.0005653	http://dx.doi.org/10.1371/journal.pone.0005653			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QD	19471645	Green Published, Green Submitted, gold			2022-12-25	WOS:000266415000002
J	Bleeker, FE; Lamba, S; Zanon, C; van Tilborg, AA; Leenstra, S; Troost, D; Hulsebos, T; Vandertop, WP; Bardelli, A				Bleeker, Fonnet E.; Lamba, Simona; Zanon, Carlo; van Tilborg, Angela A.; Leenstra, Sieger; Troost, Dirk; Hulsebos, Theo; Vandertop, W. Peter; Bardelli, Alberto			Absence of AKT1 Mutations in Glioblastoma	PLOS ONE			English	Article								Background: Oncogenic activation of the PI3K signalling pathway plays a pivotal role in the development of glioblastoma multiforme (GBM). A central node in PI3K downstream signalling is controlled by the serine-threonine kinase AKT1. A somatic mutation affecting residue E17 of the AKT1 gene has recently been identified in breast and colon cancer. The E17K change results in constitutive AKT1 activation, induces leukaemia in mice, and accordingly, may be therapeutically exploited to target the PI3K pathway. Assessing whether AKT1 is activated by somatic mutations in GBM is relevant to establish its role in this aggressive disease. Methodology/Principal Findings: We performed a systematic mutational analysis of the complete coding sequence of the AKT1 gene in a panel of 109 tumor GBM samples and nine high grade astrocytoma cell lines. However, no somatic mutations were detected in the coding region of AKT1. Conclusions/Significance: Our data indicate that in GBM oncogenic deregulation of the PI3K pathway does not involve somatic mutations in the coding region of AKT1.			Bleeker, FE (corresponding author), Univ Amsterdam, Acad Med Ctr, Neurosurg Ctr Amsterdam, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	f.e.bleeker@amc.uva.nl	Vandertop, William P./K-9288-2018; van Tilborg, Angela/M-5704-2015; BARDELLI, Alberto/J-9721-2018	van Tilborg, Angela/0000-0003-3968-5345; BARDELLI, Alberto/0000-0003-1647-5070; Zanon, Carlo/0000-0003-2539-7238; Vandertop, William/0000-0001-5417-0265; Lamba, Simona Elena/0000-0003-3207-1594				Balakrishnan A, 2007, CANCER RES, V67, P3545, DOI 10.1158/0008-5472.CAN-07-0065; Benvenuti S, 2008, HUM MUTAT, V29, P284, DOI 10.1002/humu.20648; Bleeker FE, 2008, ONCOGENE, V27, P5648, DOI 10.1038/onc.2008.170; Bleeker FE, 2009, HUM MUTAT, V30, P7, DOI 10.1002/humu.20937; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Hartmann C, 2005, ACTA NEUROPATHOL, V109, P639, DOI 10.1007/s00401-005-1000-1; Kim MS, 2008, BRIT J CANCER, V98, P1533, DOI 10.1038/sj.bjc.6604212; Kita D, 2007, ACTA NEUROPATHOL, V113, P295, DOI 10.1007/s00401-006-0186-1; Knobbe CB, 2005, NEUROPATH APPL NEURO, V31, P486, DOI 10.1111/j.1365-2990.2005.00660.x; Lee JC, 2006, PLOS MED, V3, P2264, DOI 10.1371/journal.pmed.0030485; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Malanga D, 2008, CELL CYCLE, V7, P665, DOI 10.4161/cc.7.5.5485; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schuller U, 2008, ACTA NEUROPATHOL, V115, P367, DOI 10.1007/s00401-007-0334-2; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720	22	16	16	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5638	10.1371/journal.pone.0005638	http://dx.doi.org/10.1371/journal.pone.0005638			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448AY	19461960	Green Published, Green Submitted, gold			2022-12-25	WOS:000266234700024
J	Nevin, KP; Kim, BC; Glaven, RH; Johnson, JP; Woodard, TL; Methe, BA; DiDonato, RJ; Covalla, SF; Franks, AE; Liu, A; Lovley, DR				Nevin, Kelly P.; Kim, Byoung-Chan; Glaven, Richard H.; Johnson, Jessica P.; Woodard, Trevor L.; Methe, Barbara A.; DiDonato, Raymond J., Jr.; Covalla, Sean F.; Franks, Ashley E.; Liu, Anna; Lovley, Derek R.			Anode Biofilm Transcriptomics Reveals Outer Surface Components Essential for High Density Current Production in Geobacter sulfurreducens Fuel Cells	PLOS ONE			English	Article							FE(III) REDUCTION; ELECTRON-TRANSFER; GENETIC-CHARACTERIZATION; HARVESTING ELECTRICITY; DNA MICROARRAY; EXPRESSION; ENERGY; OMCB; CYTOCHROMES; EFFICIENCIES	The mechanisms by which Geobacter sulfurreducens transfers electrons through relatively thick (> 50 mu m) biofilms to electrodes acting as a sole electron acceptor were investigated. Biofilms of Geobacter sulfurreducens were grown either in flow-through systems with graphite anodes as the electron acceptor or on the same graphite surface, but with fumarate as the sole electron acceptor. Fumarate-grown biofilms were not immediately capable of significant current production, suggesting substantial physiological differences from current-producing biofilms. Microarray analysis revealed 13 genes in current-harvesting biofilms that had significantly higher transcript levels. The greatest increases were for pilA, the gene immediately downstream of pilA, and the genes for two outer c-type membrane cytochromes, OmcB and OmcZ. Down-regulated genes included the genes for the outer-membrane c-type cytochromes, OmcS and OmcT. Results of quantitative RT-PCR of gene transcript levels during biofilm growth were consistent with microarray results. OmcZ and the outer-surface c-type cytochrome, OmcE, were more abundant and OmcS was less abundant in current-harvesting cells. Strains in which pilA, the gene immediately downstream from pilA, omcB, omcS, omcE, or omcZ was deleted demonstrated that only deletion of pilA or omcZ severely inhibited current production and biofilm formation in current-harvesting mode. In contrast, these gene deletions had no impact on biofilm formation on graphite surfaces when fumarate served as the electron acceptor. These results suggest that biofilms grown harvesting current are specifically poised for electron transfer to electrodes and that, in addition to pili, OmcZ is a key component in electron transfer through differentiated G. sulfurreducens biofilms to electrodes.			Nevin, KP (corresponding author), Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA.	knevin@microbio.umass.edu	Nevin, Kelly/AAA-4626-2019	Franks, Ashley/0000-0003-1664-6060; Johnson, Jessica/0000-0001-6367-4561				Bond DR, 2002, SCIENCE, V295, P483, DOI 10.1126/science.1066771; Bond DR, 2003, APPL ENVIRON MICROB, V69, P1548, DOI 10.1128/AEM.69.3.1548-1555.2003; Butler JE, 2006, J BACTERIOL, V188, P450, DOI 10.1128/JB.188.2.450-455.2006; Coppi MV, 2007, MICROBIOL-SGM, V153, P3572, DOI 10.1099/mic.0.2007/006478-0; Coppi MV, 2001, APPL ENVIRON MICROB, V67, P3180, DOI 10.1128/AEM.67.7.3180-3187.2001; Debabov VG, 2008, MICROBIOLOGY+, V77, P123, DOI 10.1134/S002626170802001X; DiDonato LN, 2006, J BACTERIOL, V188, P8469, DOI 10.1128/JB.01278-06; Du ZW, 2007, BIOTECHNOL ADV, V25, P464, DOI 10.1016/j.biotechadv.2007.05.004; FRANCIS RT, 1984, ANAL BIOCHEM, V136, P509, DOI 10.1016/0003-2697(84)90253-7; Holmes DE, 2006, ENVIRON MICROBIOL, V8, P1805, DOI 10.1111/j.1462-2920.2006.01065.x; Holmes DE, 2004, MICROB ECOL, V48, P178, DOI 10.1007/s00248-003-0004-4; Ishii S, 2008, APPL ENVIRON MICROB, V74, P7348, DOI 10.1128/AEM.01639-08; Jung S, 2007, APPL MICROBIOL BIOT, V77, P393, DOI 10.1007/s00253-007-1162-y; Kim BC, 2006, J BACTERIOL, V188, P3138, DOI 10.1128/JB.188.8.3138-3142.2006; Kim BC, 2005, J BACTERIOL, V187, P4505, DOI 10.1128/JB.187.13.4505-4513.2005; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Krushkal J, 2007, FUNCT INTEGR GENOMIC, V7, P229, DOI 10.1007/s10142-007-0048-5; Leang C, 2005, MICROBIOL-SGM, V151, P1761, DOI 10.1099/mic.0.27870-0; Leang C, 2003, J BACTERIOL, V185, P2096, DOI 10.1128/JB.185.7.2096-2103.2003; Leang C, 2005, J BACTERIOL, V187, P5918, DOI 10.1128/JB.187.17.5918-5926.2005; Lee HS, 2008, WATER RES, V42, P1501, DOI 10.1016/j.watres.2007.10.036; Liu Y, 2008, BIOSENS BIOELECTRON, V24, P1006, DOI 10.1016/j.bios.2008.08.001; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lloyd JR, 2003, BIOCHEM J, V369, P153, DOI 10.1042/BJ20020597; Lovley D, 2006, SCIENTIST, V20, P46; Lovley DR, 2006, CURR OPIN BIOTECH, V17, P327, DOI 10.1016/j.copbio.2006.04.006; Lovley DR, 2006, NAT REV MICROBIOL, V4, P497, DOI 10.1038/nrmicro1442; LOVLEY DR, 1988, APPL ENVIRON MICROB, V54, P1472, DOI 10.1128/AEM.54.6.1472-1480.1988; Mehta T, 2005, APPL ENVIRON MICROB, V71, P8634, DOI 10.1128/AEM.71.12.8634-8641.2005; Methe BA, 2005, APPL ENVIRON MICROB, V71, P2530, DOI 10.1128/AEM.71.5.2530-2538.2005; Murphy KC, 2000, GENE, V246, P321, DOI 10.1016/S0378-1119(00)00071-8; Nevin KP, 2008, ENVIRON MICROBIOL, V10, P2505, DOI 10.1111/j.1462-2920.2008.01675.x; Nunez C, 2006, J BACTERIOL, V188, P2792, DOI 10.1128/JB.188.8.2792-2800.2006; ONEIL RA, 2008, INVESTIGATION UNPUB; Postier B, 2008, J MICROBIOL METH, V74, P26, DOI 10.1016/j.mimet.2007.07.004; Qian XL, 2007, FEMS MICROBIOL LETT, V277, P21, DOI 10.1111/j.1574-6968.2007.00915.x; Rabaey K, 2005, TRENDS BIOTECHNOL, V23, P291, DOI 10.1016/j.tibtech.2005.04.008; Reguera G, 2005, NATURE, V435, P1098, DOI 10.1038/nature03661; Reguera G, 2007, J BACTERIOL, V189, P2125, DOI 10.1128/JB.01284-06; Reguera G, 2006, APPL ENVIRON MICROB, V72, P7345, DOI 10.1128/AEM.01444-06; Reyne JA, 2004, APPL ENVIRON MICROB, V70, P6181, DOI 10.1128/AEM.70.10.6181-6187.2004; RICHTER H, 2009, ENERGY ENV IN PRESS; Richter H, 2007, APPL ENVIRON MICROB, V73, P5347, DOI 10.1128/AEM.00804-07; Rozen S, 2000, Methods Mol Biol, V132, P365; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Srikanth S, 2008, BIOTECHNOL BIOENG, V99, P1065, DOI 10.1002/bit.21671; Strycharz SM, 2008, APPL ENVIRON MICROB, V74, P5943, DOI 10.1128/AEM.00961-08; Teal TK, 2006, APPL ENVIRON MICROB, V72, P7324, DOI 10.1128/AEM.01163-06; Tender LM, 2002, NAT BIOTECHNOL, V20, P821, DOI 10.1038/nbt716; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Torres CI, 2007, APPL MICROBIOL BIOT, V77, P689, DOI 10.1007/s00253-007-1198-z	52	291	301	8	119	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5628	10.1371/journal.pone.0005628	http://dx.doi.org/10.1371/journal.pone.0005628			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448AY	19461962	Green Published, gold			2022-12-25	WOS:000266234700015
J	Alvarez-Blasco, F; Martinez-Garcia, MA; Luque-Ramirez, M; Parraza, N; Millan, JLS; Escobar-Morreale, HF				Alvarez-Blasco, Francisco; Martinez-Garcia, Ma Angeles; Luque-Ramirez, Manuel; Parraza, Naiara; Millan, Jose L. San; Escobar-Morreale, Hector F.			Role of Haptoglobin in Polycystic Ovary Syndrome (PCOS), Obesity and Disorders of Glucose Tolerance in Premenopausal Women	PLOS ONE			English	Article								Background: Hp(2) alleles of the haptoglobin alpha-chain polymorphism reduce the anti-oxidant properties and increase the proinflammatory actions of this acute-phase protein in a gene-dosage fashion. We hypothesized that the haptoglobin polymorphism might contribute to the increased oxidative stress and low-grade chronic inflammation frequently associated with polycystic ovary syndrome, obesity, and abnormalities of glucose tolerance. Methodology/Principal Findings: Serum haptoglobin and the haptoglobin alpha-chain polymorphism were determined in 141 patients with polycystic ovary syndrome and 102 non-hyperandrogenic women. Of the whole group of 243 premenopausal women, 117 were obese and 51 showed abnormal glucose tolerance. Although serum haptoglobin concentrations were similar in PCOS patients and controls, the former presented with an increased frequency of Hp(2) alleles (62% vs. 52%, P = 0.023). Circulating haptoglobin levels increased with obesity (P<0.001), yet no association was found between obesity and haptoglobin genotypes. No differences were observed in haptoglobin levels or genotype frequencies depending on glucose tolerance. Fifty percent of the variation in serum haptoglobin concentrations was explained by the variability in serum C-reactive protein concentrations, BMI, insulin sensitivity and haptoglobin genotypes. Conclusions/Significance: Serum haptoglobin concentrations in premenopausal women are largely dependent on the haptoglobin polymorphism and on the presence of obesity, with insulin resistance and chronic inflammation possibly modulating this relationship. The association of polycystic ovary syndrome with Hp(2) alleles suggests that the anti-oxidant and anti-inflammatory properties of haptoglobin may be reduced in these patients.			Alvarez-Blasco, F (corresponding author), Hosp Univ Ramon & Cajal, Dept Endocrinol, Madrid, Spain.	hescobarm.hrc@salud.madrid.org	Ramírez, Manuel Luque/AAN-6775-2021; Luque-Ramírez, Manuel/AAG-4264-2019; San-Millán, José L./F-9944-2015; García, María Ángeles Martínez/B-9712-2014; Escobar-Morreale, Héctor F/G-5468-2010; Ramírez, Manuel Luque/G-5037-2015	Luque-Ramírez, Manuel/0000-0002-6002-4237; García, María Ángeles Martínez/0000-0002-8354-7284; Escobar-Morreale, Héctor F/0000-0002-6890-1644; Ramírez, Manuel Luque/0000-0002-6002-4237				Alvarez-Blasco F, 2006, ARCH INTERN MED, V166, P2081, DOI 10.1001/archinte.166.19.2081; Amer Diabet Assoc, 2008, DIABETES CARE, V31, pS55, DOI 10.2337/dc08-S055; Asleh R, 2003, CIRC RES, V92, P1193, DOI 10.1161/01.RES.0000076889.23082.F1; AZZIZ R, 2008, FERTIL STERIL   1022; Azziz R, 2006, J CLIN ENDOCR METAB, V91, P4237, DOI 10.1210/jc.2006-0178; Botella-Carretero JI, 2006, DIABETES CARE, V29, P2556, DOI 10.2337/dc06-1655; Bowman, 1993, HEPATIC PLASMA PROTE, P159; Chiellini C, 2004, J CLIN ENDOCR METAB, V89, P2678, DOI 10.1210/jc.2003-031965; Christian RC, 2003, J CLIN ENDOCR METAB, V88, P2562, DOI 10.1210/jc.2003-030334; Codner E, 2007, J CLIN ENDOCR METAB, V92, P1209, DOI 10.1210/jc.2006-2641; Conn JJ, 2000, CLIN ENDOCRINOL, V52, P81, DOI 10.1046/j.1365-2265.2000.00884.x; Dati F, 1996, EUR J CLIN CHEM CLIN, V34, P517; De Pergola G, 2007, J ENDOCRINOL INVEST, V30, P399, DOI 10.1007/BF03346317; Delanghe JR, 2002, ATHEROSCLEROSIS, V160, P471, DOI 10.1016/S0021-9150(01)00607-4; Escobar-Morreale HF, 2005, DIABETES CARE, V28, P2042, DOI 10.2337/diacare.28.8.2042; Escobar-Morreale HF, 2005, ENDOCR REV, V26, P251, DOI 10.1210/er.2004-0004; Escobar-Morreale HF, 2003, DIABETOLOGIA, V46, P625, DOI 10.1007/s00125-003-1090-z; Escobar-Morreale HF, 2000, J CLIN ENDOCR METAB, V85, P4182, DOI 10.1210/jc.85.11.4182; Fernandez-Real JM, 2002, DIABETES, V51, P2348, DOI 10.2337/diabetes.51.8.2348; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; INSENSER M, 2008, DIFFERENTIAL EXPRESI; Kelly CCJ, 2001, J CLIN ENDOCR METAB, V86, P2453, DOI 10.1210/jc.86.6.2453; Koch W, 2002, CLIN CHEM, V48, P1377; Langlois MR, 2000, CLIN CHEM, V46, P1619; Langlois MR, 1996, CLIN CHEM, V42, P1589; Legro RS, 2003, ENDOCR REV, V24, P302, DOI 10.1210/er.2003-0004; Levy AP, 2007, ARTERIOSCL THROM VAS, V27, P134, DOI 10.1161/01.ATV.0000251020.24399.a2; Levy AP, 2000, NEW ENGL J MED, V343, P969, DOI 10.1056/NEJM200009283431313; Luque-Ramirez M, 2007, HUM REPROD, V22, P3197, DOI 10.1093/humrep/dem324; Luque-Ramirez M, 2007, DIABETES CARE, V30, P2309, DOI 10.2337/dc07-0642; Matharoo-Ball B, 2007, J PROTEOME RES, V6, P3321, DOI 10.1021/pr070124b; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; Moirand R, 1997, ANN INTERN MED, V127, P105, DOI 10.7326/0003-4819-127-2-199707150-00002; Sabuncu T, 2001, CLIN BIOCHEM, V34, P407, DOI 10.1016/S0009-9120(01)00245-4; Vermeulen A, 1999, J CLIN ENDOCR METAB, V84, P3666, DOI 10.1210/jc.84.10.3666; Zawadzki J, 1992, POLYCYSTIC OVARY SYN, P377	36	30	30	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5606	10.1371/journal.pone.0005606	http://dx.doi.org/10.1371/journal.pone.0005606			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19440331	gold, Green Published, Green Submitted			2022-12-25	WOS:000266161200009
J	Tanaka, M; Oikawa, K; Takanashi, M; Kudo, M; Ohyashiki, J; Ohyashiki, K; Kuroda, M				Tanaka, Masami; Oikawa, Kosuke; Takanashi, Masakatsu; Kudo, Motoshige; Ohyashiki, Junko; Ohyashiki, Kazuma; Kuroda, Masahiko			Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients	PLOS ONE			English	Article							ACUTE MYELOID-LEUKEMIA; LUNG CANCERS; MICRORNAS; EXPRESSION; EXOSOMES; MIR-17-92; ACCUMULATION; POLYCISTRON; MECHANISM; BEARING	Background: MicroRNAs are a family of 19- to 25-nucleotides noncoding small RNAs that primarily function as gene regulators. Aberrant microRNA expression has been described for several human malignancies, and this new class of small regulatory RNAs has both oncogenic and tumor suppressor functions. Despite this knowledge, there is little information regarding microRNAs in plasma especially because microRNAs in plasma, if exist, were thought to be digested by RNase. Recent studies, however, have revealed that microRNAs exist and escape digestion in plasma. Methodology/Principal Findings: We performed microRNA microaray to obtain insight into microRNA deregulation in the plasma of a leukemia patient. We have revealed that microRNA-638 (miR-638) is stably present in human plasmas, and microRNA-92a (miR-92a) dramatically decreased in the plasmas of acute leukemia patients. Especially, the ratio of miR-92a/miR-638 in plasma was very useful for distinguishing leukemia patients from healthy body. Conclusions/Significance: The ratio of miR-92a/miR-638 in plasma has strong potential for clinical application as a novel biomarker for detection of leukemia.			Tanaka, M (corresponding author), Tokyo Med & Dent Univ, Dept Pathol, Tokyo, Japan.	kuroda@tokyo-med.ac.jp						Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Blanchard N, 2002, J IMMUNOL, V168, P3235, DOI 10.4049/jimmunol.168.7.3235; Chim SSC, 2008, CLIN CHEM, V54, P482, DOI 10.1373/clinchem.2007.097972; Connolly E, 2008, AM J PATHOL, V173, P856, DOI 10.2353/ajpath.2008.080096; Dixon-McIver A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002141; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Etzioni R, 2003, NAT REV CANCER, V3, P243, DOI 10.1038/nrc1041; Garzon R, 2008, BLOOD, V111, P3183, DOI 10.1182/blood-2007-07-098749; Garzon R, 2008, P NATL ACAD SCI USA, V105, P3945, DOI 10.1073/pnas.0800135105; Gilad S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003148; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Jongen-Lavrencic M, 2008, BLOOD, V111, P5078, DOI 10.1182/blood-2008-01-133355; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Lawrie CH, 2008, BRIT J HAEMATOL, V141, P672, DOI 10.1111/j.1365-2141.2008.07077.x; Li ZJ, 2008, P NATL ACAD SCI USA, V105, P15535, DOI 10.1073/pnas.0808266105; Li ZJ, 2009, CANCER RES, V69, P1109, DOI 10.1158/0008-5472.CAN-08-3381; Matsubara H, 2007, ONCOGENE, V26, P6099, DOI 10.1038/sj.onc.1210425; Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046; Mears R, 2004, PROTEOMICS, V4, P4019, DOI 10.1002/pmic.200400876; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Osada H, 2007, CARCINOGENESIS, V28, P2, DOI 10.1093/carcin/bgl185; PAN BT, 1983, CELL, V33, P967, DOI 10.1016/0092-8674(83)90040-5; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631; Takakura S, 2008, CANCER SCI, V99, P1147, DOI 10.1111/j.1349-7006.2008.00800.x; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van Niel G, 2001, GASTROENTEROLOGY, V121, P337, DOI 10.1053/gast.2001.26263; van Niel G, 2006, J BIOCHEM, V140, P13, DOI 10.1093/jb/mvj128	32	221	248	2	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2009	4	5							e5532	10.1371/journal.pone.0005532	http://dx.doi.org/10.1371/journal.pone.0005532			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FX	19440243	gold, Green Submitted, Green Published			2022-12-25	WOS:000266107300002
J	Perrot, R; Julien, JP				Perrot, Rodolphe; Julien, Jean-Pierre			Real-time imaging reveals defects of fast axonal transport induced by disorganization of intermediate filaments	FASEB JOURNAL			English	Article						lysosomes; mitochondria; neurofilament; peripherin	AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DISEASE; MARIE-TOOTH-DISEASE; KINESIN HEAVY-CHAIN; MITOCHONDRIAL ALTERATIONS; NEUROFILAMENT PROTEIN; ALZHEIMERS-DISEASE; IN-VIVO; PERIPHERIN; DEATH	Intermediate filament ( IF) abnormalities frequently appear in neurodegenerative disorders, but how they may contribute to neuronal dysfunction remains unclear. Here, we examined the effects of IF disorganization on the fast axonal transport using time-lapse microscopy. We studied the axonal transport of mitochondria and lysosomes in cultured primary dorsal root ganglion (DRG) neurons derived from mice deficient for neurofilament light (NFL-/-), mice overexpressing peripherin (Per), and mice double transgenic Per; NFL-/-. Unexpectedly, a net retrograde transport of mitochondria was detected in Per; NFL-/- neurons, opposite to the net anterograde transport of these organelles observed in wild-type (Wt), NFL-/-, and Per neurons. A detailed analysis of the kinetic properties of mitochondrial movements revealed an increased frequency of retrograde movements and an increase of their velocity in Per; NFL-/- neurons compared to Wt, NFL-/-, and Per neurons. We also noticed that the depletion of axonal neurofilaments (NFs) in NFL-/- and Per; NFL-/- neurons induced longer and more persistent movements of mitochondria and lysosomes in both directions, which suggests that the NF network hampers the traffic of these organelles. The finding that an upregulation of peripherin in context of NFL deficiency can provoke a net retrograde transport of mitochondria is a phenomenon that may contribute to pathogenic changes in some neurodegenerative disorders with IF protein accumulations.-Perrot, R., Julien, J.-P. Realtime imaging reveals defects of fast axonal transport induced by disorganization of intermediate filaments. FASEB J. 23, 3213-3225 ( 2009). www.fasebj.org	[Perrot, Rodolphe; Julien, Jean-Pierre] Univ Laval, Dept Anat & Physiol, Ctr Hosp Univ Quebec, Ctr Rech, Quebec City, PQ G1V 4G2, Canada	Laval University	Julien, JP (corresponding author), Univ Laval, Dept Anat & Physiol, Ctr Hosp Univ Quebec, Ctr Rech, Pavillon CHUL,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	jean-pierre.julien@crchul.ulaval.ca			Canadian Institute of Health and Research (CIHR)	Canadian Institute of Health and Research (CIHR)(Canadian Institutes of Health Research (CIHR))	We thank R. Paradis and R. Lariviere for technical assistance. We are grateful to M. Simard and M.-C. Richer of the Research Center of Centre Hospitalier de l'Universite Laval for technical assistance with animals. This work was supported by the Canadian Institute of Health and Research (CIHR). J.-P.J. holds a Canada Research Chair in neurodegeneration. R. P. is the recipient of the Tim E. Noel Fellowship (ALS Society of Canada).	Amiri M, 2008, DEV NEUROBIOL, V68, P1348, DOI 10.1002/dneu.20668; Baloh RH, 2007, J NEUROSCI, V27, P422, DOI 10.1523/JNEUROSCI.4798-06.2007; Beaulieu JM, 1999, J CELL BIOL, V147, P531, DOI 10.1083/jcb.147.3.531; Beaulieu JM, 2000, J NEUROSCI, V20, P5321, DOI 10.1523/JNEUROSCI.20-14-05321.2000; BERGERON C, 1994, J NEUROPATH EXP NEUR, V53, P221, DOI 10.1097/00005072-199405000-00002; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Brown A, 2003, J CELL BIOL, V160, P817, DOI 10.1083/jcb.200212017; Brownlees J, 2002, HUM MOL GENET, V11, P2837, DOI 10.1093/hmg/11.23.2837; Cairns NJ, 2004, AM J PATHOL, V164, P2153, DOI 10.1016/S0002-9440(10)63773-X; Chevalier-Larsen E, 2006, BBA-MOL BASIS DIS, V1762, P1094, DOI 10.1016/j.bbadis.2006.04.002; Cho KI, 2007, TRAFFIC, V8, P1722, DOI 10.1111/j.1600-0854.2007.00647.x; CORBO M, 1992, J NEUROPATH EXP NEUR, V51, P531, DOI 10.1097/00005072-199209000-00008; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; De Vos KJ, 2005, CURR BIOL, V15, P678, DOI 10.1016/j.cub.2005.02.064; De Vos KJ, 2008, ANNU REV NEUROSCI, V31, P151, DOI 10.1146/annurev.neuro.31.061307.090711; De Vos KJ, 2007, HUM MOL GENET, V16, P2720, DOI 10.1093/hmg/ddm226; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Fischer LR, 2007, NEURODEGENER DIS, V4, P431, DOI 10.1159/000107704; Fransson A, 2006, BIOCHEM BIOPH RES CO, V344, P500, DOI 10.1016/j.bbrc.2006.03.163; Glater EE, 2006, J CELL BIOL, V173, P545, DOI 10.1083/jcb.200601067; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167, DOI 10.1152/physrev.1980.60.4.1167; HIRANO A, 1984, J NEUROPATH EXP NEUR, V43, P461, DOI 10.1097/00005072-198409000-00001; ISHII T, 1979, ACTA NEUROPATHOL, V48, P105, DOI 10.1007/BF00691151; Jimenez-Mateos EM, 2006, BIOCHEM J, V397, P53, DOI 10.1042/BJ20060205; Julien JP, 1998, PROG NUCLEIC ACID RE, V61, P1, DOI 10.1016/S0079-6603(08)60823-5; Lecomte MJ, 1998, J NEUROCHEM, V70, P971; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; MIGHELI A, 1993, LAB INVEST, V68, P185; Millecamps S, 2007, J NEUROSCI, V27, P4947, DOI 10.1523/JNEUROSCI.5299-06.2007; Millecamps S, 2006, J NEUROCHEM, V98, P926, DOI 10.1111/j.1471-4159.2006.03932.x; Miller KE, 2006, J CELL BIOL, V173, P373, DOI 10.1083/jcb.200510097; MORRIS RL, 1993, J CELL SCI, V104, P917; MORRIS RL, 1995, J CELL BIOL, V131, P1315, DOI 10.1083/jcb.131.5.1315; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; PEIFFER J, 1977, ACTA NEUROPATHOL, V40, P213, DOI 10.1007/BF00691956; Perrot R, 2008, MOL NEUROBIOL, V38, P27, DOI 10.1007/s12035-008-8033-0; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Robertson J, 2001, J CELL BIOL, V155, P217, DOI 10.1083/jcb.200107058; Rouleau GA, 1996, ANN NEUROL, V39, P128, DOI 10.1002/ana.410390119; Rui YF, 2006, J NEUROSCI, V26, P10480, DOI 10.1523/JNEUROSCI.3231-06.2006; Sasaki S, 2007, ACTA NEUROPATHOL, V114, P633, DOI 10.1007/s00401-007-0299-1; Sasaki S, 2007, J NEUROPATH EXP NEUR, V66, P10, DOI 10.1097/nen.0b013e31802c396b; Stagi M, 2005, J NEUROSCI, V25, P352, DOI 10.1523/JNEUROSCI.3887-04.2005; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Sterneck E, 1996, J NEUROCHEM, V67, P1365; StraubeWest K, 1996, J CELL SCI, V109, P2319; Takeuchi H, 2005, J BIOL CHEM, V280, P10444, DOI 10.1074/jbc.M413863200; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; Trimmer PA, 2005, ANTIOXID REDOX SIGN, V7, P1101, DOI 10.1089/ars.2005.7.1101; Trinczek B, 1999, J CELL SCI, V112, P2355; Trushina E, 2004, MOL CELL BIOL, V24, P8195, DOI 10.1128/MCB.24.18.8195-8209.2004; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Wagner OI, 2003, J NEUROSCI, V23, P9046; Wong NKY, 2000, J NEUROPATH EXP NEUR, V59, P972, DOI 10.1093/jnen/59.11.972; Zhu QZ, 1997, EXP NEUROL, V148, P299, DOI 10.1006/exnr.1997.6654	55	36	36	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3213	3225		10.1096/fj.09-129585	http://dx.doi.org/10.1096/fj.09-129585			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19451279				2022-12-25	WOS:000270241000043
J	Bally, I; Rossi, V; Lunardi, T; Thielens, NM; Gaboriaud, C; Arlaud, GJ				Bally, Isabelle; Rossi, Veronique; Lunardi, Thomas; Thielens, Nicole M.; Gaboriaud, Christine; Arlaud, Gerard J.			Identification of the C1q-binding Sites of Human C1r and C1s A REFINED THREE-DIMENSIONAL MODEL OF THE C1 COMPLEX OF COMPLEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNAN-BINDING LECTIN; COMPLEMENT PROTEASE C1R; X-RAY-STRUCTURE; CRYSTAL-STRUCTURE; SERINE PROTEASES; STRUCTURAL BIOLOGY; 1ST COMPONENT; CUB DOMAIN; L-FICOLIN; ACTIVATION	The C1 complex of complement is assembled from a recognition protein C1q and C1s-C1r-C1r-C1s, a Ca2+-dependent tetramer of two modular proteases C1r and C1s. Resolution of the x-ray structure of the N-terminal CUB1-epidermal growth factor (EGF) C1s segment has led to a model of the C1q/C1s-C1r-C1r-C1s interaction where the C1q collagen stem binds at the C1r/C1s interface through ionic bonds involving acidic residues contributed by the C1r EGF module (Gregory, L. A., Thielens, N. M., Arlaud, G. J., Fontecilla-Camps, J. C., and Gaboriaud, C. (2003) J. Biol. Chem. 278, 32157-32164). To identify the C1q-binding sites of C1s-C1r-C1r-C1s, a series of C1r and C1s mutants was expressed, and the C1q binding ability of the resulting tetramer variants was assessed by surface plasmon resonance. Mutations targeting the Glu137-Glu-Asp139 stretch in the C1r EGF module had no effect on C1 assembly, ruling out our previous interaction model. Additional mutations targeting residues expected to participate in the Ca2+-binding sites of the C1r and C1s CUB modules provided evidence for high affinity C1q-binding sites contributed by the C1r CUB1 and CUB2 modules and lower affinity sites contributed by C1s CUB1. All of the sites implicate acidic residues also contributing Ca2+ ligands. C1s-C1r-C1r-C1s thus contributes six C1q-binding sites, one per C1q stem. Based on the location of these sites and available structural information, we propose a refined model of C1 assembly where the CUB1-EGF-CUB2 interaction domains of C1r and C1s are entirely clustered inside C1q and interact through six binding sites with reactive lysines of the C1q stems. This mechanism is similar to that demonstrated for mannan-binding lectin (MBL)-MBL-associated serine protease and ficolin-MBL-associated serine protease complexes.	[Bally, Isabelle; Rossi, Veronique; Lunardi, Thomas; Thielens, Nicole M.; Arlaud, Gerard J.] Univ Grenoble 1, CEA, CNRS,UMR 5075, Lab Enzymol Mol,Inst Biol Struct Jean Pierre Ebel, F-38027 Grenoble 1, France; [Gaboriaud, Christine] Univ Grenoble 1, CEA, CNRS,UMR 5075, Lab Cristallog & Cristallogenese Prot,Inst Biol S, F-38027 Grenoble 1, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Arlaud, GJ (corresponding author), Univ Grenoble 1, CEA, CNRS,UMR 5075, Lab Enzymol Mol,Inst Biol Struct Jean Pierre Ebel, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.	gerard.arlaud@ibs.fr	Thielens, Nicole M/F-2512-2013; Rossi, Véronique/AAF-3412-2021	Thielens, Nicole M/0000-0002-7354-0302; Rossi, Véronique/0000-0002-6700-3578	Commissariat a l'Energie Atomique; Centre National de la Recherche Scientifique; Universite Joseph Fourier, Grenoble	Commissariat a l'Energie Atomique(French Atomic Energy Commission); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Universite Joseph Fourier, Grenoble	This work was supported by the Commissariat a l'Energie Atomique, the Centre National de la Recherche Scientifique, and the Universite Joseph Fourier, Grenoble.	ARLAUD GJ, 1987, IMMUNOL TODAY, V8, P106, DOI 10.1016/0167-5699(87)90860-7; Arlaud GJ, 2002, MOL IMMUNOL, V39, P383, DOI 10.1016/S0161-5890(02)00143-8; Arlaud GJ, 2001, IMMUNOL REV, V180, P136, DOI 10.1034/j.1600-065X.2001.1800112.x; ARLAUD GJ, 1979, MOL IMMUNOL, V16, P445, DOI 10.1016/0161-5890(79)90069-5; Bally I, 2005, J IMMUNOL, V175, P4536, DOI 10.4049/jimmunol.175.7.4536; Bersch B, 1998, BIOCHEMISTRY-US, V37, P1204, DOI 10.1021/bi971851v; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Budayova-Spano M, 2002, EMBO J, V21, P231, DOI 10.1093/emboj/21.3.231; BUSBY TF, 1990, BIOCHEMISTRY-US, V29, P4613, DOI 10.1021/bi00471a016; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Chen CB, 2001, J BIOL CHEM, V276, P25894, DOI 10.1074/jbc.M103539200; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; Cseh S, 2002, J IMMUNOL, V169, P5735, DOI 10.4049/jimmunol.169.10.5735; Feinberg H, 2003, EMBO J, V22, P2348, DOI 10.1093/emboj/cdg236; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; Gaboriaud C, 2004, TRENDS IMMUNOL, V25, P368, DOI 10.1016/j.it.2004.04.008; GAL P, 1989, COMPLEMENT INFLAMMAT, V6, P433; Gregory LA, 2004, J BIOL CHEM, V279, P29391, DOI 10.1074/jbc.M402687200; Gregory LA, 2003, J BIOL CHEM, V278, P32157, DOI 10.1074/jbc.M305175200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOURNET A, 1986, BIOCHEM J, V240, P783, DOI 10.1042/bj2400783; KING LA, 1992, BACULOVIRUS EXPRESSI, P111; Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X; Lacroix M, 1997, BIOCHEMISTRY-US, V36, P6270, DOI 10.1021/bi962719i; Lacroix M, 2009, J IMMUNOL, V182, P456, DOI 10.4049/jimmunol.182.1.456; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUO C, 1992, BIOCHEMISTRY-US, V31, P4254, DOI 10.1021/bi00132a015; PERKINS SJ, 1984, J MOL BIOL, V179, P547, DOI 10.1016/0022-2836(84)90079-2; REID KBM, 1986, IMMUNOL TODAY, V7, P230, DOI 10.1016/0167-5699(86)90110-6; Romero A, 1997, NAT STRUCT BIOL, V4, P783, DOI 10.1038/nsb1097-783; STRANG CJ, 1982, P NATL ACAD SCI-BIOL, V79, P586, DOI 10.1073/pnas.79.2.586; Teillet F, 2008, J BIOL CHEM, V283, P25715, DOI 10.1074/jbc.M803551200; Teillet F, 2007, J IMMUNOL, V178, P5710, DOI 10.4049/jimmunol.178.9.5710; Thielens NM, 1999, J BIOL CHEM, V274, P9149, DOI 10.1074/jbc.274.14.9149; Thielens NM, 2001, J IMMUNOL, V166, P5068, DOI 10.4049/jimmunol.166.8.5068; THIELENS NM, 1990, J BIOL CHEM, V265, P14469; THIELENS NM, 1994, BIOCHEM J, V301, P378; Tsai SW, 1997, MOL IMMUNOL, V34, P1273, DOI 10.1016/S0161-5890(97)00149-1; Zundel S, 2004, J IMMUNOL, V172, P4342, DOI 10.4049/jimmunol.172.7.4342	39	65	69	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19340	19348		10.1074/jbc.M109.004473	http://dx.doi.org/10.1074/jbc.M109.004473			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19473974	Green Published, hybrid			2022-12-25	WOS:000267908300025
J	Kim, BY; Olzmann, JA; Choi, SI; Ahn, SY; Kim, TI; Cho, HS; Suh, H; Kim, EK				Kim, Bong-Yoon; Olzmann, James A.; Choi, Seung-il; Ahn, So Yeon; Kim, Tae-im; Cho, Hyun-Soo; Suh, Hwal; Kim, Eung Kweon			Corneal Dystrophy-associated R124H Mutation Disrupts TGFBI Interaction with Periostin and Causes Mislocalization to the Lysosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MATRIX PROTEIN BETA-IG-H3; KERATO-EPITHELIN MUTATIONS; FASCICLIN-I; COLON-CANCER; COLLAGEN-VI; CELL-LINE; GENE; INTEGRIN; EXPRESSION	The 5q31-linked corneal dystrophies are heterogeneous autosomal-dominant eye disorders pathologically characterized by the progressive accumulation of aggregated proteinaceous deposits in the cornea, which manifests clinically as severe vision impairment. The 5q31-linked corneal dystrophies are commonly caused by mutations in the TGFBI (transforming growth (f) under bar actor-(beta) under bar-(i) under bar nduced) gene. However, despite the identification of the culprit gene, the cellular roles of TGFBI and the molecular mechanisms underlying the pathogenesis of corneal dystrophy remain poorly understood. Here we report the identification of periostin, a molecule that is highly related to TGFBI, as a specific TGFBI-binding partner. The association of TGFBI and periostin is mediated by the amino-terminal cysteine-rich EMI domains of TGFBI and periostin. Our results indicate that the endogenous TGFBI and periostin colocalize within the trans-Golgi network and associate prior to secretion. The corneal dystrophy-associated R124H mutation in TGFBI severely impairs interaction with periostin in vivo. In addition, the R124H mutation causes aberrant redistribution of the mutant TGFBI into lysosomes. We also find that the periostin-TGFBI interaction is disrupted in corneal fibroblasts cultured from granular corneal dystrophy type II patients and that periostin accumulates in TGFBI-positive corneal deposits in granular corneal dystrophy type II (also known as Avellino corneal dystrophy). Together, our findings suggest that TGFBI and periostin may play cooperative cellular roles and that periostin may be involved in the pathogenesis of 5q31-linked corneal dystrophies.	[Kim, Bong-Yoon; Choi, Seung-il; Ahn, So Yeon; Kim, Tae-im; Kim, Eung Kweon] Yonsei Univ, Dept Ophthalmol, Coll Med, Seoul 120752, South Korea; [Kim, Bong-Yoon; Choi, Seung-il; Ahn, So Yeon; Kim, Tae-im; Kim, Eung Kweon] Yonsei Univ, Corneal Dystrophy Res Inst, Coll Med, Seoul 120752, South Korea; [Kim, Bong-Yoon; Suh, Hwal] Yonsei Univ, Dept Med Engn, Coll Med, Seoul 120752, South Korea; [Kim, Bong-Yoon; Kim, Tae-im; Suh, Hwal; Kim, Eung Kweon] Yonsei Univ, Brain Korean Project 21, Coll Med, Team Nanobiomat Cell Based Implants, Seoul 120752, South Korea; [Cho, Hyun-Soo] Yonsei Univ, Dept Biol, Coll Life Sci & Biotechnol, Seoul 120749, South Korea; [Olzmann, James A.] Stanford Univ, Dept Biol, Stanford, CA 94305 USA	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Stanford University	Kim, EK (corresponding author), Yonsei Univ, Dept Ophthalmol, Coll Med, 134 Shinchon Dong, Seoul 120752, South Korea.	eungkkim@yuhs.ac		Kim, Eung Kweon/0000-0002-1453-8042; Kim, Tae-im/0000-0001-6414-3842; Olzmann, James/0000-0001-7751-8316; choi, seung-il/0000-0001-7168-8795	Ministry for Health, Welfare, and Family Affairs, Republic of Korea [A080320]	Ministry for Health, Welfare, and Family Affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This study was supported by Korea Healthcare Technology R&D Project, Ministry for Health, Welfare, and Family Affairs, Republic of Korea, Grant A080320.	ARAKISASAKI K, 1995, INVEST OPHTH VIS SCI, V36, P614; Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; Billings PC, 2002, J BIOL CHEM, V277, P28003, DOI 10.1074/jbc.M106837200; Brodsky JL, 2007, AUTOPHAGY, V3, P623, DOI 10.4161/auto.4906; Butcher JT, 2007, DEV BIOL, V302, P256, DOI 10.1016/j.ydbio.2006.09.048; Callebaut I, 2003, BIOCHEM BIOPH RES CO, V300, P619, DOI 10.1016/S0006-291X(02)02904-2; Clout N, 2003, MOL VIS, V9, P440; Clout NJ, 2003, STRUCTURE, V11, P197, DOI 10.1016/S0969-2126(03)00002-9; Dighiero P, 2001, OPHTHALMOLOGY, V108, P818, DOI 10.1016/S0161-6420(00)00662-X; Doliana R, 2000, FEBS LETT, V484, P164, DOI 10.1016/S0014-5793(00)02140-2; El Kochairi I, 2006, MOL VIS, V12, P461; El-Ashry MF, 2003, BRIT J OPHTHALMOL, V87, P839, DOI 10.1136/bjo.87.7.839; GILLAN L, 2002, CANCER RES, V62, P5385; Hanssen E, 2003, J BIOL CHEM, V278, P24334, DOI 10.1074/jbc.M303455200; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; Jester JV, 2003, INVEST OPHTH VIS SCI, V44, P1850, DOI 10.1167/iovs.02-0973; Kannabiran C, 2006, HUM MUTAT, V27, P615, DOI 10.1002/humu.20334; Kern CB, 2005, ANAT REC PART A, V284A, P415, DOI 10.1002/ar.a.20193; Kim BY, 2001, J BIOL CHEM, V276, P29393, DOI 10.1074/jbc.M101778200; Kim HJ, 2008, INT J BIOCHEM CELL B, V40, P991, DOI 10.1016/j.biocel.2007.11.001; Kim JE, 2002, J BIOL CHEM, V277, P46159, DOI 10.1074/jbc.M207055200; Kim JE, 2002, INVEST OPHTH VIS SCI, V43, P656; Korvatska E, 1999, INVEST OPHTH VIS SCI, V40, P2213; Korvatska E, 1998, AM J HUM GENET, V62, P320, DOI 10.1086/301720; Kudo Y, 2007, HISTOL HISTOPATHOL, V22, P1167, DOI 10.14670/HH-22.1167; Kuhn B, 2007, NAT MED, V13, P962, DOI 10.1038/nm1619; Lee SH, 2003, KIDNEY INT, V64, P1012, DOI 10.1046/j.1523-1755.2003.00158.x; Lindsley A, 2005, GENE EXPR PATTERNS, V5, P593, DOI 10.1016/j.modgep.2005.03.005; Ma C, 2008, GENE DEV, V22, P308, DOI 10.1101/gad.1632008; Mashima Y, 1999, ARCH OPHTHALMOL-CHIC, V117, P90; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; Nam EJ, 2006, ARTHRITIS RHEUM-US, V54, P2734, DOI 10.1002/art.22076; Nam JO, 2003, J BIOL CHEM, V278, P25902, DOI 10.1074/jbc.M300358200; Okada M, 1998, AM J OPHTHALMOL, V126, P535, DOI 10.1016/S0002-9394(98)00135-4; Park SJ, 2004, PEPTIDES, V25, P199, DOI 10.1016/j.peptides.2003.12.002; Pieramici SF, 2006, CURR OPIN OPHTHALMOL, V17, P361, DOI 10.1097/01.icu.0000233955.94347.84; Poulaki Vasilliki, 2008, Semin Ophthalmol, V23, P9, DOI 10.1080/08820530701745173; Rawe IM, 1997, INVEST OPHTH VIS SCI, V38, P893; Reinboth B, 2006, J BIOL CHEM, V281, P7816, DOI 10.1074/jbc.M511316200; Runager K, 2008, EXP EYE RES, V87, P298, DOI 10.1016/j.exer.2007.12.001; Sekijima Y, 2005, CELL, V121, P73, DOI 10.1016/j.cell.2005.01.018; Shimazaki M, 2008, J EXP MED, V205, P295, DOI 10.1084/jem.20071297; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; STONE EM, 1994, NAT GENET, V6, P47, DOI 10.1038/ng0194-47; Streeten BW, 1999, ARCH OPHTHALMOL-CHIC, V117, P67; Takacs L, 1998, EXP EYE RES, V66, P739, DOI 10.1006/exer.1998.0471; Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; Thapa N, 2007, INT J BIOCHEM CELL B, V39, P2183, DOI 10.1016/j.biocel.2007.06.004; Yoshioka N, 2002, EXP CELL RES, V279, P91, DOI 10.1006/excr.2002.5590	51	49	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19580	19591		10.1074/jbc.M109.013607	http://dx.doi.org/10.1074/jbc.M109.013607			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19478074	hybrid, Green Published			2022-12-25	WOS:000267908300050
J	Hernando, E; Sarmentero-Estrada, J; Koppie, T; Belda-Iniesta, C; de Molina, VR; Cejas, P; Ozu, C; Le, C; Sanchez, JJ; Gonzalez-Baron, M; Koutcher, J; Cordon-Cardo, C; Bochner, BH; Lacal, JC; de Molina, AR				Hernando, E.; Sarmentero-Estrada, J.; Koppie, T.; Belda-Iniesta, C.; de Molina, V. Ramirez; Cejas, P.; Ozu, C.; Le, C.; Sanchez, J. J.; Gonzalez-Baron, M.; Koutcher, J.; Cordon-Cardo, C.; Bochner, B. H.; Lacal, J. C.; de Molina, A. Ramirez			A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas	ONCOGENE			English	Article						bladder cancer; choline kinase; therapeutic target; tumor promoter	TRANSITIONAL-CELL CARCINOMA; ONCOGENE ADDICTION; RADICAL CYSTECTOMY; HUMAN CANCER; INHIBITION; CARCINOGENESIS; PROLIFERATION; MECHANISM; STRATEGY; THERAPY	Bladder cancer is one of the most common causes of death in industrialized countries. New tumor markers and therapeutic approaches are still needed to improve the management of bladder cancer patients. Choline kinase-alpha (ChoK alpha) is a metabolic enzyme that has a role in cell proliferation and transformation. Inhibitors of ChoK alpha show antitumoral activity and are expected to be introduced soon in clinical trials. This study aims to assess whether ChoK alpha plays a role in the aggressiveness of bladder tumors and constitutes a new approach for bladder cancer treatment. We show here that ChoK alpha is constitutively altered in human bladder tumor cells. Furthermore, in vivo murine models, including an orthotopic model to mimic as much as possible the physiological conditions, revealed that increased levels of ChoK alpha potentiate both tumor formation (P <= 0.0001) and aggressiveness of the disease on different end points (P = 0.011). Accordingly, increased levels of ChoK alpha significantly reduce survival of mice with bladder cancer (P = 0.05). Finally, treatment with a ChoK alpha-specific inhibitor resulted in a significant inhibition of tumor growth (P = 0.02) and in a relevant increase in survival (P = 0.03). Oncogene (2009) 28, 2425-2435; doi:10.1038/onc.2009.91; published online 18 May 2009	[Sarmentero-Estrada, J.; Lacal, J. C.; de Molina, A. Ramirez] Natl Biotechnol Ctr, TCD Pharma, Madrid 28049, Spain; [Bochner, B. H.] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA; [Belda-Iniesta, C.; Cejas, P.; Gonzalez-Baron, M.] CSIC UAM La Paz, Hosp Univ La Paz, Div Med Oncol, Translat Oncol Unit, Madrid, Spain; [de Molina, V. Ramirez] Hosp Clin San Carlos, Madrid, Spain; [Sanchez, J. J.] Univ Autonoma Madrid, Dept Stat, E-28049 Madrid, Spain; [Lacal, J. C.; de Molina, A. Ramirez] CSIC UAM La Paz, Translat Oncol Unit, Inst Invest Biomed, Madrid, Spain	Memorial Sloan Kettering Cancer Center; Consejo Superior de Investigaciones Cientificas (CSIC); Hospital Universitario La Paz; Hospital Clinico San Carlos; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	de Molina, AR (corresponding author), Natl Biotechnol Ctr, TCD Pharma, Darwin 3, Madrid 28049, Spain.	aramirez@cnb.csic.es	estrada, jacinto sarmentero/C-6777-2019; Le, Hongbiao/H-4735-2011; de Molina, Ana Ramirez/AAA-3848-2019; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	estrada, jacinto sarmentero/0000-0002-0118-4919; Bochner, Bernard/0000-0003-0846-0848; Hernando, Eva/0000-0003-1023-0312; Belda Iniesta, Cristobal/0000-0003-3254-7492; Lacal, Juan Carlos/0000-0002-1908-2777	NCI NIH HHS [R24 CA083084, R24 CA083084-08, 1R24CA83084] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA083084] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Saffar NMS, 2006, CANCER RES, V66, P427, DOI 10.1158/0008-5472.CAN-05-1338; Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001; Banez-Coronel M, 2008, CURR CANCER DRUG TAR, V8, P709, DOI 10.2174/156800908786733432; CHIN J, 1991, J UROLOGY, V145, P1297, DOI 10.1016/S0022-5347(17)38618-4; CordonCardo C, 1997, CANCER RES, V57, P1217; Gallego-Ortega D, 2006, INT J ONCOL, V29, P335; GALLEGOORTEGA D, DIFFERENTIAL R UNPUB; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Glunde K, 2005, CANCER RES, V65, P11034, DOI 10.1158/0008-5472.CAN-05-1807; Glunde K, 2007, LANCET ONCOL, V8, P855, DOI 10.1016/S1470-2045(07)70289-9; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jonkers J, 2004, CANCER CELL, V6, P535, DOI 10.1016/j.ccr.2004.12.002; Kikuchi E, 2004, CLIN CANCER RES, V10, P1835, DOI 10.1158/1078-0432.CCR-03-0099; Kikuchi E, 2003, J UROLOGY, V170, P1375, DOI 10.1097/01.ju.0000075504.13456.41; Lacal J C, 2001, IDrugs, V4, P419; Lu ML, 2002, CLIN CANCER RES, V8, P171; Mullerad M, 2005, J UROLOGY, V174, P741, DOI 10.1097/01.ju.0000164730.38431.5c; Nakagami K, 1999, JPN J CANCER RES, V90, P419, DOI 10.1111/j.1349-7006.1999.tb00764.x; Oliveira P. A., 2006, Experimental Oncology, V28, P2; Quek ML, 2005, J UROLOGY, V174, P103, DOI 10.1097/01.ju.0000163267.93769.d8; Ramirez de Molina A, 2005, CANCER RES, V65, P5647, DOI 10.1158/0008-5472.CAN-04-4416; Ramirez de Molina A, 2002, BIOCHEM BIOPH RES CO, V296, P580, DOI 10.1016/S0006-291X(02)00920-8; Ramirez de Molina A, 2004, CANCER RES, V64, P6732, DOI 10.1158/0008-5472.CAN-04-0489; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; Ramirez de Molina A, 2007, LANCET ONCOL, V8, P889, DOI 10.1016/S1470-2045(07)70279-6; Rodriguez-Gonzalez A, 2005, INT J ONCOL, V26, P999; Rodriguez-Gonzalez A, 2003, ONCOGENE, V22, P8803, DOI 10.1038/sj.onc.1207062; Rodriguez-Gonzalez A, 2004, ONCOGENE, V23, P8247, DOI 10.1038/sj.onc.1208045; Sanderson KM, 2007, J UROLOGY, V177, P2088, DOI 10.1016/j.juro.2007.01.133; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697	34	52	56	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2425	2435		10.1038/onc.2009.91	http://dx.doi.org/10.1038/onc.2009.91			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19448670	Green Accepted			2022-12-25	WOS:000267601400001
J	Odawara, H; Iwasaki, T; Horiguchi, J; Rokutanda, N; Hirooka, K; Miyazaki, W; Koibuchi, Y; Shimokawa, N; Iino, Y; Takeyoshi, I; Koibuchi, N				Odawara, Hiroki; Iwasaki, Toshiharu; Horiguchi, Jun; Rokutanda, Nana; Hirooka, Kazumi; Miyazaki, Wataru; Koibuchi, Yukio; Shimokawa, Noriaki; Iino, Yuichi; Takeyoshi, Izumi; Koibuchi, Noriyuki			Activation of Aromatase Expression by Retinoic Acid Receptor-related Orphan Receptor (ROR) alpha in Breast Cancer Cells IDENTIFICATION OF A NOVEL ROR RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-CHAIN-REACTION; AMINO-TERMINAL DOMAINS; ESTROGEN BIOSYNTHESIS; REVERSE TRANSCRIPTION; CYP19 EXPRESSION; MESSENGER-RNA; STROMAL CELLS; GENE; TISSUE; CYTOCHROME-P-450	Estrogen is a key regulator of the proliferation and differentiation of breast cancer cells. In addition to the estrogen supply from the ovary, estrogen is produced locally from androgen by aromatase. However, the regulation of aromatase gene expression in breast cancer has not yet been fully clarified. Retinoic acid receptor-related orphan receptor (ROR) alpha plays an important role in the differentiation of many organs by regulating the transcription of target genes. Because aromatase and ROR alpha are expressed in breast cancer, the effect of ROR alpha on aromatase gene expression was studied. ROR alpha significantly augmented the expression of aromatase mRNA, particularly those containing exon I.4, in MCF7 cells, and aromatase activities in T47D and MCF7 cells. ROR alpha also stimulated the proliferation of these cells. Transient transfection-based reporter gene assays using the promoter at exon I. 4 showed that ROR alpha augmented the transcription. A series of truncated mutation studies revealed that ROR alpha activated the transcription through -147 to +14 bp of the promoter I.4. Furthermore, ROR alpha bound to the fragment containing -119 to -107 bp of the promoter in vitro, indicating that this region may contain a novel ROR response element. Chromatin immunoprecipitation assay showed that ROR alpha bound to the region containing this site of the promoter I. 4 in MCF7 cells. Moreover, we examined clinical samples and found a correlation between ROR alpha and aromatase expression. These results suggest that ROR alpha directly activates the aromatase expression to accelerate the local production of estrogen, which results in the proliferation of breast cancer cells.	[Iwasaki, Toshiharu; Hirooka, Kazumi; Miyazaki, Wataru; Shimokawa, Noriaki; Koibuchi, Noriyuki] Gunma Univ, Grad Sch Med, Dept Integrat Physiol, Gunma 3718511, Japan; [Koibuchi, Yukio; Takeyoshi, Izumi] Gunma Univ, Grad Sch Med, Dept Thorac & Visceral Organ Surg, Gunma 3718511, Japan; [Iino, Yuichi] Gunma Univ, Grad Sch Med, Dept Emergency Med, Gunma 3718511, Japan	Gunma University; Gunma University; Gunma University	Iwasaki, T (corresponding author), Gunma Univ, Grad Sch Med, Dept Integrat Physiol, 3-39-22 Showa Machi, Gunma 3718511, Japan.	tiwasaki@med.gunma-u.ac.jp		Koibuchi, Noriyuki/0000-0002-2247-9740	Ministry of Education, Culture, Sports, Science and Technology of Japan [17591319, 16591247, 18790928]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by Grants-in-Aid for Scientific Research 17591319 (to J.H. and T.I.), 16591247 (to Y.K. and N.K.), and 18790928 (to H.O.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	ACKERMAN GE, 1981, J CLIN ENDOCR METAB, V53, P412, DOI 10.1210/jcem-53-2-412; Atkins GB, 1999, MOL ENDOCRINOL, V13, P1550, DOI 10.1210/me.13.9.1550; BOLUFER P, 1992, J CLIN ONCOL, V10, P438, DOI 10.1200/JCO.1992.10.3.438; Bulun SE, 2005, PHARMACOL REV, V57, P359, DOI 10.1124/pr.57.3.6; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622; Bulun SE, 2003, J STEROID BIOCHEM, V86, P219, DOI 10.1016/S0960-0760(03)00359-5; CALBERG C, 1994, MOL ENDOCRINOL, V8, P757; Chen SU, 2001, J STEROID BIOCHEM, V79, P35, DOI 10.1016/S0960-0760(01)00132-7; Chetrite GS, 2000, J STEROID BIOCHEM, V72, P23, DOI 10.1016/S0960-0760(00)00040-6; Dal J, 2001, MOL CELL ENDOCRINOL, V176, P111, DOI 10.1016/S0303-7207(01)00449-X; EVANS CT, 1986, P NATL ACAD SCI USA, V83, P6387, DOI 10.1073/pnas.83.17.6387; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FISHMAN J, 1981, J BIOL CHEM, V256, P4466; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; HARADA N, 1990, BIOCHEM BIOPH RES CO, V166, P365, DOI 10.1016/0006-291X(90)91954-Q; Harris JM, 2002, MOL ENDOCRINOL, V16, P998, DOI 10.1210/me.16.5.998; JAMES V H T, 1987, Steroids, V50, P269, DOI 10.1016/0039-128X(83)90077-6; Kallen J, 2004, J BIOL CHEM, V279, P14033, DOI 10.1074/jbc.M400302200; Kinoshita Y, 2003, CANCER RES, V63, P3546; Koibuchi N, 1999, ENDOCRINOLOGY, V140, P1356, DOI 10.1210/en.140.3.1356; Lau P, 1999, NUCLEIC ACIDS RES, V27, P411, DOI 10.1093/nar/27.2.411; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; MEANS GD, 1989, J BIOL CHEM, V264, P19385; Miki Y, 2007, CANCER RES, V67, P3945, DOI 10.1158/0008-5472.CAN-06-3105; MILLER W R, 1987, Steroids, V50, P537, DOI 10.1016/0039-128X(87)90037-7; MILLER WR, 1990, J STEROID BIOCHEM, V37, P1055, DOI 10.1016/0960-0760(90)90465-W; MILLER WR, 1991, J STEROID BIOCHEM, V39, P783, DOI 10.1016/0960-0760(91)90026-2; Miyazaki W, 2004, J BIOL CHEM, V279, P18195, DOI 10.1074/jbc.M310531200; Miyoshi Y, 2001, INT J CANCER, V94, P685, DOI 10.1002/ijc.1525; NAKAJIN S, 1986, BIOCHEM BIOPH RES CO, V134, P704, DOI 10.1016/S0006-291X(86)80477-6; Plant N, 2007, BBA-GEN SUBJECTS, V1770, P478, DOI 10.1016/j.bbagen.2006.09.024; Sasano H, 1998, ENDOCR REV, V19, P593, DOI 10.1210/er.19.5.593; Sebastian S, 2001, J CLIN ENDOCR METAB, V86, P4600, DOI 10.1210/jc.86.10.4600; Shao WL, 2004, BREAST CANCER RES, V6, P39, DOI 10.1186/bcr742; SIMPSON ER, 1994, ENDOCR REV, V15, P342, DOI 10.1210/er.15.3.342; Smith IE, 2003, NEW ENGL J MED, V348, P2431, DOI 10.1056/NEJMra023246; Suzuki T, 2005, ENDOCR-RELAT CANCER, V12, P701, DOI 10.1677/erc.1.00834; THOMPSON EA, 1974, J BIOL CHEM, V249, P5373; Utsumi T, 1996, J CLIN ENDOCR METAB, V81, P2344, DOI 10.1210/jc.81.6.2344; VANLANDEGHEM AAJ, 1985, CANCER RES, V45, P2900; Watanabe M, 2005, EUR J ENDOCRINOL, V152, P619, DOI 10.1530/eje.1.01882; ZHAO Y, 1995, MOL ENDOCRINOL, V9, P340, DOI 10.1210/me.9.3.340; Zhou CB, 1996, J STEROID BIOCHEM, V59, P163, DOI 10.1016/S0960-0760(96)00100-8	44	36	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	2009	284	26					17711	17719		10.1074/jbc.M109.009241	http://dx.doi.org/10.1074/jbc.M109.009241			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	460QP	19439415	Green Published, hybrid			2022-12-25	WOS:000267202500037
J	Song, JW; Cavnar, SP; Walker, AC; Luker, KE; Gupta, M; Tung, YC; Luker, GD; Takayama, S				Song, Jonathan W.; Cavnar, Stephen P.; Walker, Ann C.; Luker, Kathryn E.; Gupta, Mudit; Tung, Yi-Chung; Luker, Gary D.; Takayama, Shuichi			Microfluidic Endothelium for Studying the Intravascular Adhesion of Metastatic Breast Cancer Cells	PLOS ONE			English	Article								Background: The ability to properly model intravascular steps in metastasis is essential in identifying key physical, cellular, and molecular determinants that can be targeted therapeutically to prevent metastatic disease. Research on the vascular microenvironment has been hindered by challenges in studying this compartment in metastasis under conditions that reproduce in vivo physiology while allowing facile experimental manipulation. Methodology/Principal Findings: We present a microfluidic vasculature system to model interactions between circulating breast cancer cells with microvascular endothelium at potential sites of metastasis. The microfluidic vasculature produces spatially-restricted stimulation from the basal side of the endothelium that models both organ-specific localization and polarization of chemokines and many other signaling molecules under variable flow conditions. We used this microfluidic system to produce site-specific stimulation of microvascular endothelium with CXCL12, a chemokine strongly implicated in metastasis. Conclusions/Significance: When added from the basal side, CXCL12 acts through receptor CXCR4 on endothelium to promote adhesion of circulating breast cancer cells, independent of CXCL12 receptors CXCR4 or CXCR7 on tumor cells. These studies suggest that targeting CXCL12-CXCR4 signaling in endothelium may limit metastases in breast and other cancers and highlight the unique capabilities of our microfluidic device to advance studies of the intravascular microenvironment in metastasis.			Song, JW (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Charlestown, MA USA.	gluker@med.umich.edu; takayama@umich.edu	Tung, Yi-Chung/A-1163-2007; Song, Jonathan W./C-1922-2013	Tung, Yi-Chung/0000-0002-6170-2992; Song, Jonathan W./0000-0002-6991-5298; Luker, Kathryn/0000-0001-8314-3370; luker, gary/0000-0001-6832-2581	NATIONAL CANCER INSTITUTE [R01CA136829, P50CA093990, R01CA136553] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084370] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA093990, R01 CA136829, R01 CA136553, 1 R01 CA136553, 1 R01 CA136829] Funding Source: Medline; NHLBI NIH HHS [R01 HL084370, HL084370, R01 HL084370-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ali S, 2007, CANCER METAST REV, V26, P401, DOI 10.1007/s10555-007-9073-z; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BEUTLER B, 1988, ENDOCR REV, V9, P57, DOI 10.1210/edrv-9-1-57; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; Cardones AR, 2003, CANCER RES, V63, P6751; Chaigneau E, 2003, P NATL ACAD SCI USA, V100, P13081, DOI 10.1073/pnas.2133652100; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Chen BPC, 2001, PHYSIOL GENOMICS, V7, P55, DOI 10.1152/physiolgenomics.2001.7.1.55; Chiu JJ, 2003, BLOOD, V101, P2667, DOI 10.1182/blood-2002-08-2560; CHRISTOPHER MJ, 2009, BLOOD; Chueh BH, 2007, ANAL CHEM, V79, P3504, DOI 10.1021/ac062118p; Cinamon G, 2001, NAT IMMUNOL, V2, P515, DOI 10.1038/88710; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; DESJARDINS C, 1990, AM J PHYSIOL, V258, pH647, DOI 10.1152/ajpheart.1990.258.3.H647; Dong C, 2005, FRONT BIOSCI-LANDMRK, V10, P379, DOI 10.2741/1535; Farokhzad OC, 2005, ANAL CHEM, V77, P5453, DOI 10.1021/ac050312q; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Garcia-Cardena G, 2001, P NATL ACAD SCI USA, V98, P4478, DOI 10.1073/pnas.071052598; Gaver DP, 1998, BIOPHYS J, V75, P721, DOI 10.1016/S0006-3495(98)77562-9; Gomes N, 2003, BIORHEOLOGY, V40, P41; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; GROBER JS, 1993, J CLIN INVEST, V91, P2609, DOI 10.1172/JCI116500; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; Hastings NE, 2007, AM J PHYSIOL-CELL PH, V293, pC1824, DOI 10.1152/ajpcell.00385.2007; Hatse S, 2002, FEBS LETT, V527, P255, DOI 10.1016/S0014-5793(02)03143-5; Heo YS, 2007, ANAL CHEM, V79, P1126, DOI 10.1021/ac061990v; Huh D, 2007, P NATL ACAD SCI USA, V104, P18886, DOI 10.1073/pnas.0610868104; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; JORNESKOG G, 1995, DIABETOLOGIA, V38, P474; Kanda S, 2003, J BIOL CHEM, V278, P257, DOI 10.1074/jbc.M204771200; Konstantopoulos K, 1998, ADV DRUG DELIVER REV, V33, P141, DOI 10.1016/S0169-409X(98)00024-6; Kryczek I, 2005, CANCER RES, V65, P465; Luker GD, 2003, NAT MED, V9, P969, DOI 10.1038/nm894; Luker KE, 2006, CANCER LETT, V238, P30, DOI 10.1016/j.canlet.2005.06.021; Luker KE, 2001, CANCER RES, V61, P6540; Mazzinghi B, 2008, J EXP MED, V205, P479, DOI 10.1084/jem.20071903; MORZYCKI W, 1990, IMMUNOL LETT, V25, P331, DOI 10.1016/0165-2478(90)90204-4; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Rivera R, 2007, VIROLOGY, V363, P48, DOI 10.1016/j.virol.2007.01.033; Sallusto F, 2008, NAT IMMUNOL, V9, P949, DOI 10.1038/ni.f.214; Schrage A, 2008, HEPATOLOGY, V48, P1262, DOI 10.1002/hep.22443; Sipkins DA, 2005, NATURE, V435, P969, DOI 10.1038/nature03703; Smith ML, 2004, J EXP MED, V200, P935, DOI 10.1084/jem.20040424; Song JW, 2005, ANAL CHEM, V77, P3993, DOI 10.1021/ac050131o; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Ulbrich H, 2003, TRENDS PHARMACOL SCI, V24, P640, DOI 10.1016/j.tips.2003.10.004; Wang JH, 2006, CANCER METAST REV, V25, P573, DOI 10.1007/s10555-006-9019-x; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Weinbaum S, 2007, ANNU REV BIOMED ENG, V9, P121, DOI 10.1146/annurev.bioeng.9.060906.151959; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F	54	235	240	3	79	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2009	4	6							e5756	10.1371/journal.pone.0005756	http://dx.doi.org/10.1371/journal.pone.0005756			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	452GL	19484126	Green Published, gold, Green Submitted			2022-12-25	WOS:000266528200009
J	Campbell, MS; Gottlieb, GS; Hawes, SE; Nickle, DC; Wong, KG; Deng, WJ; Lampinen, TM; Kiviat, NB; Mullins, JI				Campbell, Mary S.; Gottlieb, Geoffrey S.; Hawes, Stephen E.; Nickle, David C.; Wong, Kim G.; Deng, Wenjie; Lampinen, Thomas M.; Kiviat, Nancy B.; Mullins, James I.			HIV-1 Superinfection in the Antiretroviral Therapy Era: Are Seroconcordant Sexual Partners at Risk?	PLOS ONE			English	Article								Background: Acquisition of more than one strain of human immunodeficiency virus type 1 (HIV-1) has been reported to occur both during and after primary infection, but the risks and repercussions of dual and superinfection are incompletely understood. In this study, we evaluated a longitudinal cohort of chronically HIV-infected men who were sexual partners to determine if individuals acquired their partners' viral strains. Methodology: Our cohort of HIV-positive men consisted of 8 couples that identified themselves as long-term sexual partners. Viral sequences were isolated from each subject and analyzed using phylogenetic methods. In addition, strain-specific PCR allowed us to search for partners' viruses present at low levels. Finally, we used computational algorithms to evaluate for recombination between partners' viral strains. Principal Findings/Conclusions: All couples had at least one factor associated with increased risk for acquisition of new HIV strains during the study, including detectable plasma viral load, sexually transmitted infections, and unprotected sex. One subject was dually HIV-1 infected, but neither strain corresponded to that of his partner. Three couples' sequences formed monophyletic clusters at the entry visit, with phylogenetic analysis suggesting that one member of the couple had acquired an HIV strain from his identified partner or that both had acquired it from the same source outside their partnership. The 5 remaining couples initially displayed no evidence of dual infection, using phylogenetic analysis and strain-specific PCR. However, in 1 of these couples, further analysis revealed recombinant viral strains with segments of viral genomes in one subject that may have derived from the enrolled partner. Thus, chronically HIV-1 infected individuals may become superinfected with additional HIV strains from their seroconcordant sexual partners. In some cases, HIV-1 superinfection may become apparent when recombinant viral strains are detected.			Campbell, MS (corresponding author), Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.	msc6@u.washington.edu	Nickle, David/ABF-2727-2020	Gottlieb, Geoffrey/0000-0002-5749-481X	NCI NIH HHS [R01 CA055488, R01CA055488] Funding Source: Medline; NIAID NIH HHS [P01AI57005, T32 AI007044, K08 AI074424, R37AI047734, P30AI27757, T32AI007044, K08AI074424, R37 AI047734, P30 AI027757, P01 AI057005] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757, K08AI074424, R37AI047734, P01AI057005, T32AI007044] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200; Anderson JP, 2003, MOL BIOL EVOL, V20, P1168, DOI 10.1093/molbev/msg128; ARTENSTEIN AW, 1995, J INFECT DIS, V171, P805, DOI 10.1093/infdis/171.4.805; Battegay M, 2006, LANCET INFECT DIS, V6, P280, DOI 10.1016/S1473-3099(06)70463-7; Becker-Pergola G, 2000, AIDS RES HUM RETROV, V16, P1099, DOI 10.1089/088922200414938; Brenner B, 2004, AIDS, V18, P1653, DOI 10.1097/01.aids.0000131377.28694.04; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; Chakraborty B, 2004, AIDS, V18, P132, DOI 10.1097/01.aids.0000096893.73209.0e; Chohan B, 2005, J VIROL, V79, P10701, DOI 10.1128/JVI.79.16.10701-10708.2005; DIAZ RS, 1995, J VIROL, V69, P3272; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; Fang WB, 2004, J GEOPHYS ENG, V1, P153, DOI 10.1088/1742-2132/1/2/008; Gerhardt M, 2005, J VIROL, V79, P8249, DOI 10.1128/JVI.79.13.8249-8261.2005; Golden MR, 2008, JAIDS-J ACQ IMM DEF, V49, P212, DOI 10.1097/QAI.0b013e31818455e8; Gonzales MJ, 2003, J INFECT DIS, V188, P397, DOI 10.1086/376534; Gottlieb GS, 2008, J INFECT DIS, V197, P1011, DOI 10.1086/529206; Gottlieb GS, 2007, CLIN INFECT DIS, V45, P501, DOI 10.1086/520024; Gottlieb GS, 2004, LANCET, V363, P619, DOI 10.1016/S0140-6736(04)15596-7; Grobler J, 2004, J INFECT DIS, V190, P1355, DOI 10.1086/423940; Herbinger KH, 2006, AIDS RES HUM RETROV, V22, P599, DOI 10.1089/aid.2006.22.599; Janini LM, 1998, J INFECT DIS, V177, P227, DOI 10.1086/517360; Jost S, 2002, NEW ENGL J MED, V347, P731, DOI 10.1056/NEJMoa020263; Koelsch KK, 2003, AIDS, V17, pF11, DOI 10.1097/00002030-200305020-00001; Kozaczynska K, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-59; Lampinen TM, 2000, AIDS, V14, pF69, DOI 10.1097/00002030-200003310-00001; Learn GH, 1996, J VIROL, V70, P5720, DOI 10.1128/JVI.70.8.5720-5730.1996; Liu SL, 1997, J VIROL, V71, P4284, DOI 10.1128/JVI.71.6.4284-4295.1997; Liu SL, 1996, SCIENCE, V273, P415, DOI 10.1126/science.273.5274.415; MADDISON WP, 2001, MACCLADE ANAL PHYLOG, P503; Manigart O, 2004, AIDS, V18, P1645, DOI 10.1097/01.aids.0000131333.30548.db; Mills EJ, 2006, PLOS MED, V3, P2039, DOI 10.1371/journal.pmed.0030438; Pernas M, 2006, JAIDS-J ACQ IMM DEF, V42, P12, DOI 10.1097/01.qai.0000214810.65292.73; PIANTADOSI A, 2008, AIDS RES HUM RETROVI; Piantadosi A, 2007, PLOS PATHOG, V3, P1745, DOI 10.1371/journal.ppat.0030177; Plantier JC, 2004, AIDS, V18, P2444; Ramos A, 2002, J VIROL, V76, P7444, DOI 10.1128/JVI.76.15.7444-7452.2002; Rodrigo AG, 1997, AIDS RES HUM RETROV, V13, P737, DOI 10.1089/aid.1997.13.737; Rousseau CM, 2007, J VIROL, V81, P4492, DOI 10.1128/JVI.02050-06; Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999; Smith DM, 2006, VIROLOGY, V355, P1, DOI 10.1016/j.virol.2006.08.009; Smith DM, 2005, AIDS, V19, P1251, DOI 10.1097/01.aids.0000180095.12276.ac; Smith DM, 2004, JAMA-J AM MED ASSOC, V292, P1177, DOI 10.1001/jama.292.10.1177; Streeck H, 2008, J EXP MED, V205, P1789, DOI 10.1084/jem.20080281; Swofford D. L., 1999, PAUP 4 0 PHYLOGENETI; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsui R, 2004, J VIROL, V78, P94, DOI 10.1128/JVI.78.1.94-103.2004; van der Kuyl AC, 2005, NEW ENGL J MED, V352, P2557, DOI 10.1056/NEJM200506163522420; Vernazza P, 2008, B MED SUISSES, V89, P165; Willberg CB, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000185; Yerly S, 2004, AIDS, V18, P1413, DOI 10.1097/01.aids.0000131330.28762.0c	50	35	35	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2009	4	5							e5690	10.1371/journal.pone.0005690	http://dx.doi.org/10.1371/journal.pone.0005690			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QE	19479055	gold, Green Published, Green Submitted			2022-12-25	WOS:000266415100004
J	Williams, R; Yao, HH; Dhillon, NK; Buch, SJ				Williams, Rachel; Yao, Honghong; Dhillon, Navneet K.; Buch, Shilpa J.			HIV-1 Tat Co-Operates with IFN-gamma and TNF-alpha to Increase CXCL10 in Human Astrocytes	PLOS ONE			English	Article								HIV-associated neurological disorders (HAND) are estimated to affect 60% of the HIV infected population. HIV-encephalitis (HIVE), the pathological correlate of the most severe form of HAND is often characterized by glial activation, cytokine/chemokine dysregulation, and neuronal damage and loss. However, the severity of HIVE correlates better with glial activation rather than viral load. One of the characteristic features of HIVE is the increased amount of the neurotoxic chemokine, CXCL10. This chemokine can be released from astroglia activated with the pro-inflammatory cytokines IFN-gamma and TNF-alpha, in conjunction with HIV-1 Tat, all of which are elevated in HIVE. In an effort to understand the pathogenesis of HAND, this study was aimed at exploring the regulation of CXCL10 by cellular and viral factors during astrocyte activation. Specifically, the data herein demonstrate that the combined actions of HIV-1 Tat and the pro-inflammatory cytokines, IFN-gamma and TNF-alpha, result in the induction of CXCL10 at both the RNA and protein level. Furthermore, CXCL10 induction was found to be regulated transcriptionally by the activation of the p38, Jnk, and Akt signaling pathways and their downstream transcription factors, NF-kappa B and STAT-1 alpha. Since CXCL10 levels are linked to disease severity, understanding its regulation could aid in the development of therapeutic intervention strategies for HAND.			Williams, R (corresponding author), Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66103 USA.	sbuch@kumc.edu		Buch, Shilpa/0000-0002-3103-6685	NCRR NIH HHS [RR016443, P20 RR016443] Funding Source: Medline; NIDA NIH HHS [DA023397, DA020392, R01 DA020392, R21 DA023397, R01 DA024442, DA024442] Funding Source: Medline; NIMH NIH HHS [R01 MH068212, MH62969, MH068212] Funding Source: Medline; NINDS NIH HHS [F31NS062665, F31 NS062665] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH068212, R03MH062969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS062665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA020392, R21DA023397, R01DA024442] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Albright AV, 2003, J NEUROVIROL, V9, P222, DOI 10.1080/13550280390194073; Andras IE, 2003, J NEUROSCI RES, V74, P255, DOI 10.1002/jnr.10762; Arai K, 2003, GLIA, V43, P254, DOI 10.1002/glia.10255; Asensio VC, 2001, J VIROL, V75, P7067, DOI 10.1128/JVI.75.15.7067-7077.2001; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Bonavia R, 2001, BIOCHEM BIOPH RES CO, V288, P301, DOI 10.1006/bbrc.2001.5743; Brabers NACH, 2006, EUR J CLIN INVEST, V36, P447, DOI 10.1111/j.1365-2362.2006.01657.x; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chong ZZ, 2005, HISTOL HISTOPATHOL, V20, P299, DOI 10.14670/HH-20.299; Conant K, 1996, J VIROL, V70, P1384, DOI 10.1128/JVI.70.3.1384-1389.1996; Croitoru-Lamoury J, 2003, GLIA, V41, P354, DOI 10.1002/glia.10181; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Davis RL, 2004, NEUROSCI LETT, V362, P220, DOI 10.1016/j.neulet.2004.03.015; Davis RL, 2002, ALCOHOL CLIN EXP RES, V26, P1404, DOI 10.1097/01.ALC.0000030841.92766.80; Dhillon NK, 2007, J IMMUNOL, V179, P2722, DOI 10.4049/jimmunol.179.5.2722; Dhillon NK, 2007, AM J PHYSIOL-LUNG C, V292, pL1233, DOI 10.1152/ajplung.00293.2006; Dou HY, 2006, GLIA, V54, P81, DOI 10.1002/glia.20358; Gelbard HA, 1999, ANN NY ACAD SCI, V890, P312, DOI 10.1111/j.1749-6632.1999.tb08008.x; Gilgun-Sherki Y, 2001, NEUROPHARMACOLOGY, V40, P959, DOI 10.1016/S0028-3908(01)00019-3; Giunta B, 2006, BRAIN RES, V1123, P216, DOI 10.1016/j.brainres.2006.09.057; Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527; Hayashi K, 2006, J CEREBR BLOOD F MET, V26, P1052, DOI 10.1038/sj.jcbfm.9600254; HURWITZ AA, 1995, J NEUROIMMUNOL, V57, P193, DOI 10.1016/0165-5728(95)00011-P; Kaul M, 2006, CURR HIV RES, V4, P307, DOI 10.2174/157016206777709384; Kolb SA, 1999, J NEUROIMMUNOL, V93, P172, DOI 10.1016/S0165-5728(98)00223-9; Kolson DL, 2002, CLIN LAB MED, V22, P703, DOI 10.1016/S0272-2712(02)00009-4; Kutsch O, 2000, J VIROL, V74, P9214, DOI 10.1128/JVI.74.19.9214-9221.2000; Lawrence DMP, 2006, GLIA, V53, P81, DOI 10.1002/glia.20261; Lee SJ, 2000, J IMMUNOL, V165, P4658, DOI 10.4049/jimmunol.165.8.4658; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; Majumder S, 1998, J IMMUNOL, V161, P4736; Majumder S, 1998, J NEUROSCI RES, V54, P169, DOI 10.1002/(SICI)1097-4547(19981015)54:2<169::AID-JNR5>3.0.CO;2-C; McArthur JC, 1999, SEMIN NEUROL, V19, P129, DOI 10.1055/s-2008-1040831; Means TK, 2000, J LEUKOCYTE BIOL, V67, P885, DOI 10.1002/jlb.67.6.885; Miller RJ, 1999, TRENDS NEUROSCI, V22, P471, DOI 10.1016/S0166-2236(99)01408-3; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; OHMORI Y, 1995, J IMMUNOL, V154, P5235; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; Oshima T, 2000, AIDS, V14, P475, DOI 10.1097/00002030-200003310-00002; Ozdener H, 2005, J BIOSCIENCES, V30, P391, DOI 10.1007/BF02703676; Paludan SR, 2000, J LEUKOCYTE BIOL, V67, P18, DOI 10.1002/jlb.67.1.18; Park IW, 2001, BLOOD, V97, P352, DOI 10.1182/blood.V97.2.352; Popik W, 1998, J VIROL, V72, P6406, DOI 10.1128/JVI.72.8.6406-6413.1998; Prendergast MA, 2002, BRAIN RES, V954, P300, DOI 10.1016/S0006-8993(02)03360-7; Saha RN, 2003, J NEUROCHEM, V86, P1057, DOI 10.1046/j.1471-4159.2003.01942.x; Sanders VJ, 1998, AIDS, V12, P1021, DOI 10.1097/00002030-199809000-00008; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; Shapiro L, 1998, P NATL ACAD SCI USA, V95, P7422, DOI 10.1073/pnas.95.13.7422; Shapshak P, 2004, FRONT BIOSCI-LANDMRK, V9, P1073, DOI 10.2741/1271; Sheng WS, 2003, BIOCHEM PHARMACOL, V65, P9, DOI 10.1016/S0006-2952(02)01480-6; Speth C, 2002, J VIROL, V76, P3179, DOI 10.1128/JVI.76.7.3179-3188.2002; Sui YJ, 2006, EUR J NEUROSCI, V23, P957, DOI 10.1111/j.1460-9568.2006.04631.x; Sui YJ, 2004, AM J PATHOL, V164, P1557, DOI 10.1016/S0002-9440(10)63714-5; Turchan-Cholewo J, 2009, ANTIOXID REDOX SIGN, V11, P193, DOI [10.1089/ars.2008.2097, 10.1089/ARS.2008.2097]; TYOR WR, 1992, ANN NEUROL, V31, P349, DOI 10.1002/ana.410310402; van Marle G, 2004, VIROLOGY, V329, P302, DOI 10.1016/j.virol.2004.08.024; Van Wagoner NJ, 2000, J NEUROCHEM, V75, P563, DOI 10.1046/j.1471-4159.2000.0750563.x; Wang ZY, 2004, J NEUROVIROL, V10, P25, DOI 10.1080/13550280490270851; Wesselingh SL, 1997, J NEUROIMMUNOL, V74, P1, DOI 10.1016/S0165-5728(96)00160-9; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WILLIAMS R, 2008, GLIA; Yan MJ, 2007, BRAIN RES, V1184, P28, DOI 10.1016/j.brainres.2007.09.082; Zhao H, 2006, MOL NEUROBIOL, V34, P249, DOI 10.1385/MN:34:3:249	67	46	46	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2009	4	5							e5709	10.1371/journal.pone.0005709	http://dx.doi.org/10.1371/journal.pone.0005709			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QE	19479051	Green Submitted, gold, Green Published			2022-12-25	WOS:000266415100009
J	Wildgruber, M; Lee, H; Chudnovskiy, A; Yoon, TJ; Etzrodt, M; Pittet, MJ; Nahrendorf, M; Croce, K; Libby, P; Weissleder, R; Swirski, FK				Wildgruber, Moritz; Lee, Hakho; Chudnovskiy, Aleksey; Yoon, Tae-Jong; Etzrodt, Martin; Pittet, Mikael J.; Nahrendorf, Matthias; Croce, Kevin; Libby, Peter; Weissleder, Ralph; Swirski, Filip K.			Monocyte Subset Dynamics in Human Atherosclerosis Can Be Profiled with Magnetic Nano-Sensors	PLOS ONE			English	Article								Monocytes are circulating macrophage and dendritic cell precursors that populate healthy and diseased tissue. In humans, monocytes consist of at least two subsets whose proportions in the blood fluctuate in response to coronary artery disease, sepsis, and viral infection. Animal studies have shown that specific shifts in the monocyte subset repertoire either exacerbate or attenuate disease, suggesting a role for monocyte subsets as biomarkers and therapeutic targets. Assays are therefore needed that can selectively and rapidly enumerate monocytes and their subsets. This study shows that two major human monocyte subsets express similar levels of the receptor for macrophage colony stimulating factor (MCSFR) but differ in their phagocytic capacity. We exploit these properties and custom-engineer magnetic nanoparticles for ex vivo sensing of monocytes and their subsets. We present a two-dimensional enumerative mathematical model that simultaneously reports number and proportion of monocyte subsets in a small volume of human blood. Using a recently described diagnostic magnetic resonance (DMR) chip with 1 mu l sample size and high throughput capabilities, we then show that application of the model accurately quantifies subset fluctuations that occur in patients with atherosclerosis.			Wildgruber, M (corresponding author), Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.	rweissleder@mgh.harvard.edu; fswirski@mgh.harvard.edu	Pittet, Mikael/ABD-6300-2021; Libby, Peter/AAY-6404-2021; Etzrodt, Martin/P-3325-2015; Swirski, Filip/AAF-1340-2019	Libby, Peter/0000-0002-1502-502X; Etzrodt, Martin/0000-0003-1928-3904; Swirski, Filip/0000-0002-3163-9152; /0000-0003-0828-4143	NATIONAL CANCER INSTITUTE [P50CA086355, P01CA069246] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL086672, R01HL095629, R01HL096576, U01HL080731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB004626] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA086355, P01 CA069246, R24 CA69246, P50 CA86355] Funding Source: Medline; NHLBI NIH HHS [U01 HL080731, K08 HL086672, R01 HL096576, R01 HL095629] Funding Source: Medline; NIBIB NIH HHS [R01-EB004626] Funding Source: Medline; PHS HHS [P01-A154904] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		An GY, 2008, CIRCULATION, V117, P3227, DOI 10.1161/CIRCULATIONAHA.108.771048; AUFFRAY C, 2009, ANN REV IMMUNOL; Dragu R, 2008, ATHEROSCLEROSIS, V196, P405, DOI 10.1016/j.atherosclerosis.2006.11.022; Draude G, 1999, AM J PHYSIOL-HEART C, V276, pH1144, DOI 10.1152/ajpheart.1999.276.4.H1144; FINGERLE G, 1993, BLOOD, V82, P3170; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882; Harisinghani MG, 2003, NEW ENGL J MED, V348, P2491, DOI 10.1056/NEJMoa022749; Josephson L, 2002, BIOCONJUGATE CHEM, V13, P554, DOI 10.1021/bc015555d; Lee H, 2008, NAT MED, V14, P869, DOI 10.1038/nm.1711; Lee JH, 2007, NAT MED, V13, P95, DOI [10.1038/nm1467, 10.20659/jfp.13.1_95]; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Libby P, 2008, CIRCULATION, V117, P3168, DOI 10.1161/CIRCULATIONAHA.108.783068; Metz S, 2004, EUR RADIOL, V14, P1851, DOI 10.1007/s00330-004-2405-2; Murdoch C, 2007, J IMMUNOL, V178, P7405, DOI 10.4049/jimmunol.178.11.7405; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; PASSLICK B, 1989, BLOOD, V74, P2527, DOI 10.1182/blood.V74.7.2527.2527; Pulliam L, 1997, LANCET, V349, P692, DOI 10.1016/S0140-6736(96)10178-1; Schinkel C, 1998, J TRAUMA, V44, P743, DOI 10.1097/00005373-199805000-00001; Schlitt A, 2004, THROMB HAEMOSTASIS, V92, P419, DOI 10.1160/TH04-02-0095; Schmidt H, 2005, BRIT J CANCER, V93, P273, DOI 10.1038/sj.bjc.6602702; Simon GH, 2006, EUR RADIOL, V16, P738, DOI 10.1007/s00330-005-0031-2; Stroh A, 2006, NEUROIMAGE, V33, P886, DOI 10.1016/j.neuroimage.2006.07.009; Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950; Swirski FK, 2006, P NATL ACAD SCI USA, V103, P10340, DOI 10.1073/pnas.0604260103; Szaflarska A, 2004, EXP HEMATOL, V32, P748, DOI 10.1016/j.exphem.2004.05.027; Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549; Ulrich C, 2006, NEPHROL DIAL TRANSPL, V21, P1596, DOI 10.1093/ndt/gfl008; Waldo SW, 2008, AM J PATHOL, V172, P1112, DOI 10.2353/ajpath.2008.070513; Waterhouse DF, 2008, VASC HEALTH RISK MAN, V4, P177, DOI 10.2147/vhrm.2008.04.01.177; Weber C, 2008, NAT REV IMMUNOL, V8, P802, DOI 10.1038/nri2415; WEISSLEDER R, 1989, AM J ROENTGENOL, V152, P167, DOI 10.2214/ajr.152.1.167; Wunderbaldinger P, 2002, ACAD RADIOL, V9, pS304, DOI 10.1016/S1076-6332(03)80210-6; ZIEGLERHEITBROCK HWL, 1993, EUR J IMMUNOL, V23, P2053, DOI 10.1002/eji.1830230902	34	50	54	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2009	4	5							e5663	10.1371/journal.pone.0005663	http://dx.doi.org/10.1371/journal.pone.0005663			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LD	19461894	gold, Green Published, Green Submitted			2022-12-25	WOS:000266331200003
J	Lester, RT; Yao, XD; Ball, TB; McKinnon, LR; Omange, WR; Kaul, R; Wachihi, C; Jaoko, W; Rosenthal, KL; Plummer, FA				Lester, Richard T.; Yao, Xiao-Dan; Ball, T. Blake; McKinnon, Lyle R.; Omange, Were R.; Kaul, Rupert; Wachihi, Charles; Jaoko, Walter; Rosenthal, Kenneth L.; Plummer, Francis A.			HIV-1 RNA Dysregulates the Natural TLR Response to Subclinical Endotoxemia in Kenyan Female Sex-Workers	PLOS ONE			English	Article							SINGLE-STRANDED RNA; IMMUNE ACTIVATION; MICROBIAL TRANSLOCATION; RECEPTOR LIGANDS; TOLERANCE; INFECTION; RECOGNITION; EXPRESSION; PATHOGENESIS; THERAPY	Background: Subclinical endotoxemia has been reported in HIV-1 infected persons and may drive systemic immune activation and pathogenesis. Proinflammatory responsiveness to endotoxin (LPS) is mediated by Toll-like receptor 4 (TLR4). We therefore examined the association between plasma LPS levels, HIV RNA, and TLR4 expression and cytokine responses in the blood of HIV infected and uninfected participants in a cohort of female sex-workers in Kenya. Methodology/Principal Findings: Ex vivo plasma and peripheral blood mononuclear cells (PBMC) were assessed for LPS and TLR mRNA, respectively. The effects of HIV single stranded RNA, a TLR8 ligand, on TLR4 and LPS signaling were further assessed in short term PBMC culture. Both HIV uninfected and infected subjects frequently had low detectable LPS levels in their plasmas. Significantly increased LPS levels were associated with chronic HIV-1 infection, both treated and untreated, but not with other acute or semi-chronic conditions reported. In HIV-uninfected subjects, TLR4 mRNA expression levels correlated inversely with plasma LPS levels, suggesting chronic endotoxin 'tolerance' in vivo. A similar effect of reduced TLR4 mRNA was seen in short term PBMC culture after stimulation with LPS. Interestingly, the apparent in vivo tolerance effect was diminished in subjects with HIV infection. Additionally, pre-stimulation of PBMC with LPS lead to proinflammatory (TNF-alpha) tolerance to subsequent LPS stimulation; however, pre-treatment of PBMC with HIV single-stranded RNA40, could enhance TLR4-mediated LPS responsiveness in vitro. Conclusions/Significance: Thus, dysregulation of endotoxin tolerance by HIV-1 RNA may exacerbate HIV chronic immune activation and pathogenesis.			Lester, RT (corresponding author), Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada.	rlester.id@gmail.com	Jaoko, Walter/AAN-5048-2020; Omange, Were/F-1454-2016	Jaoko, Walter/0000-0002-7134-6581; Kaul, Rupert/0000-0002-1586-4093; McKinnon, Lyle/0000-0002-7157-0700; Omange, Were/0000-0002-0421-110X				Ancuta P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002516; Bafica A, 2004, J LEUKOCYTE BIOL, V75, P460, DOI 10.1189/jlb.0803388; Boasso A, 2008, CLIN IMMUNOL, V126, P235, DOI 10.1016/j.clim.2007.08.015; Brenchley JM, 2008, MUCOSAL IMMUNOL, V1, P23, DOI 10.1038/mi.2007.1; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Broad A, 2006, CURR MED CHEM, V13, P2487, DOI 10.2174/092986706778201675; Cavaillon JM, 2006, CRIT CARE, V10, DOI 10.1186/cc5055; Dandekar Satya, 2007, Curr HIV/AIDS Rep, V4, P10, DOI 10.1007/s11904-007-0002-0; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Douek Daniel, 2007, Top HIV Med, V15, P114; Fonck K, 2001, SEX TRANSM INFECT, V77, P271, DOI 10.1136/sti.77.4.271; Fowke KR, 1996, LANCET, V348, P1347, DOI 10.1016/S0140-6736(95)12269-2; Funderburg N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001915; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Hunt Peter W, 2007, Curr HIV/AIDS Rep, V4, P42, DOI 10.1007/s11904-007-0007-8; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jiang W, 2009, J INFECT DIS, V199, P1177, DOI 10.1086/597476; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Lester RT, 2008, AIDS, V22, P685, DOI 10.1097/QAD.0b013e3282f4de35; Marchetti G, 2008, AIDS, V22, P2035, DOI 10.1097/QAD.0b013e3283112d29; MEIER A, 2007, J VIROL; Meier A, 2007, J VIROL, V81, P8180, DOI 10.1128/JVI.00421-07; Opal SM, 2007, INT J MED MICROBIOL, V297, P365, DOI 10.1016/j.ijmm.2007.03.006; Paiardini M, 2008, AIDS REV, V10, P36; Pandrea I, 2008, TRENDS IMMUNOL, V29, P419, DOI 10.1016/j.it.2008.05.004; Parker LC, 2005, J LEUKOCYTE BIOL, V78, P1301, DOI 10.1189/jlb.0405236; Pearce CB, 2005, WORLD J GASTROENTERO, V11, P7142, DOI 10.3748/wjg.v11.i45.7142; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Sato S, 2002, INT IMMUNOL, V14, P783, DOI 10.1093/intimm/dxf046; Schmitz JE, 2001, BLOOD, V98, P3757, DOI 10.1182/blood.V98.13.3757; Walson JL, 2008, AIDS, V22, P1601, DOI 10.1097/QAD.0b013e32830a502e	32	54	57	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2009	4	5							e5644	10.1371/journal.pone.0005644	http://dx.doi.org/10.1371/journal.pone.0005644			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LB	19461969	Green Published, gold, Green Submitted			2022-12-25	WOS:000266331000003
J	Bonett, RM; Chippindale, PT; Moler, PE; Van Devender, RW; Wake, DB				Bonett, Ronald M.; Chippindale, Paul T.; Moler, Paul E.; Van Devender, R. Wayne; Wake, David B.			Evolution of Gigantism in Amphiumid Salamanders	PLOS ONE			English	Article							LIFE-HISTORY EVOLUTION; BODY-SIZE EVOLUTION; PHYLOGENETIC-RELATIONSHIPS; PLETHODONTID SALAMANDERS; AMBYSTOMATID SALAMANDER; MOLECULAR EVOLUTION; DIVERGENCE TIMES; ABSOLUTE RATES; RANGE SIZES; DIVERSIFICATION	The Amphiumidae contains three species of elongate, permanently aquatic salamanders with four diminutive limbs that append one, two, or three toes. Two of the species, Amphiuma means and A. tridactylum, are among the largest salamanders in the world, reaching lengths of more than one meter, whereas the third species (A. pholeter), extinct amphiumids, and closely related salamander families are relatively small. Amphiuma means and A. tridactylum are widespread species and live in a wide range of lowland aquatic habitats on the Coastal Plain of the southeastern United States, whereas A. pholeter is restricted to very specialized organic muck habitats and is syntopic with A. means. Here we present analyses of sequences of mitochondrial and nuclear loci from across the distribution of the three taxa to assess lineage diversity, relationships, and relative timing of divergence in amphiumid salamanders. In addition we analyze the evolution of gigantism in the clade. Our analyses indicate three lineages that have diverged since the late Miocene, that correspond to the three currently recognized species, but the two gigantic species are not each other's closest relatives. Given that the most closely related salamander families and fossil amphiumids from the Upper Cretaceous and Paleocene are relatively small, our results suggest at least two extreme changes in body size within the Amphuimidae. Gigantic body size either evolved once as the ancestral condition of modern amphiumas, with a subsequent strong size reduction in A. pholeter, or gigantism independently evolved twice in the modern species, A. means and A. tridactylum. These patterns are concordant with differences in habitat breadth and range size among lineages, and have implications for reproductive isolation and diversification of amphiumid salamanders.			Bonett, RM (corresponding author), Univ Tulsa, Dept Biol Sci, Tulsa, OK 74104 USA.	ron-bonett@utulsa.edu						*AMPHIBIAWEB, 2009, AMPHIBIAWEB INFORM A; AREVALO E, 1994, SYST BIOL, V43, P387, DOI 10.2307/2413675; BANCROFT GT, 1983, A835 US ARM ENG WAT; BEHLER JL, 1998, AUDUBON SOC FIELD GU; Blackburn TM, 1996, PHILOS T R SOC B, V351, P897, DOI 10.1098/rstb.1996.0083; BOUNDY J, 2005, AMPHIBIAN DECLINES C, P00646; Brandle M, 2002, EVOL ECOL RES, V4, P993; Brandley MC, 2005, SYST BIOL, V54, P373, DOI 10.1080/10635150590946808; Chase J.M., 2009, ECOLOGICAL NICHES LI; Chippindale PT, 2004, EVOLUTION, V58, P2809; CLARK JM, 1985, J HERPETOL, V19, P41, DOI 10.2307/1564418; CONANT R, 1998, FIELD GUIDE AMPHIBIA; Erwin DH, 1998, TRENDS ECOL EVOL, V13, P344, DOI 10.1016/S0169-5347(98)01436-0; Estes R., 1969, Breviora, VNo. 322, P1; Etienne RS, 2004, AM NAT, V163, P69, DOI 10.1086/380582; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Fontenot CL, 1999, J HERPETOL, V33, P100, DOI 10.2307/1565548; Gao KQ, 2003, NATURE, V422, P424, DOI 10.1038/nature01491; Gardner JD, 2003, J VERTEBR PALEONTOL, V23, P769, DOI 10.1671/1828-4; GOOD DA, 1992, U CALIFORNIA PUBLICA, V126; Gould Gina C., 2004, Bulletin of the American Museum of Natural History, V285, P219, DOI 10.1206/0003-0090(2004)285<0219:C>2.0.CO;2; HILL IR, 1954, TULANE STUD ZOOL, V12, P191; Hoegg S, 2004, MOL BIOL EVOL, V21, P1188, DOI 10.1093/molbev/msh081; HOLMAN JA, 1977, HERPETOLOGICA, V33, P391; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Hunt G, 2006, P NATL ACAD SCI USA, V103, P1347, DOI 10.1073/pnas.0510550103; Johnson SA, 2005, AMPHIBIAN DECLINES: THE CONSERVATION STATUS OF UNITED STATES SPECIES, P642; Karlin A.A., 1993, AM MIDLAND NATURALIS, V132, P1; Kozak KH, 2005, EVOLUTION, V59, P2000; Lemmon AR, 2004, SYST BIOL, V53, P265, DOI 10.1080/10635150490423520; Lomolino MV, 2005, J BIOGEOGR, V32, P1683, DOI 10.1111/j.1365-2699.2005.01314.x; LOSOS JB, 1992, SYST BIOL, V41, P403, DOI 10.2307/2992583; MACHOVINA BL, 1994, THESIS FLORIDA INT U; Maddison W.P., 2008, MESQUITE MODULAR SYS; McClain CR, 2006, J BIOGEOGR, V33, P1578, DOI 10.1111/j.1365-2699.2006.01545.x; MEANS DB, 2005, AMPHIBIAN DECLINES C, P645; MEANS DB, 1996, AMPHIUMA PHOLETER; Meiri S, 2007, GLOBAL ECOL BIOGEOGR, V16, P702, DOI 10.1111/j.1466-8238.2007.00327.x; Moen DS, 2009, EVOLUTION, V63, P195, DOI 10.1111/j.1558-5646.2008.00538.x; MORITZ C, 1992, SYST BIOL, V41, P273, DOI 10.2307/2992567; Mueller RL, 2004, P NATL ACAD SCI USA, V101, P13820, DOI 10.1073/pnas.0405785101; Nagel L, 1998, EVOLUTION, V52, P209, DOI 10.1111/j.1558-5646.1998.tb05154.x; NAYLOR BG, 1993, CAN J EARTH SCI, V30, P814, DOI 10.1139/e93-067; Nylander J, 2004, MR MODELTEST V2 PROG; Palumbi S., 2002, SIMPLE FOOLS GUIDE P; Payne JL, 2009, P NATL ACAD SCI USA, V106, P24, DOI 10.1073/pnas.0806314106; Petranka, 1998, SALAMANDERS US CANAD; Pfennig DW, 2006, ECOLOGY, V87, P769, DOI 10.1890/05-0787; Pyron M, 1999, J BIOGEOGR, V26, P549, DOI 10.1046/j.1365-2699.1999.00303.x; Roelants K, 2007, P NATL ACAD SCI USA, V104, P887, DOI 10.1073/pnas.0608378104; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Samuels AK, 2005, GENE, V349, P43, DOI 10.1016/j.gene.2004.12.037; San Mauro D, 2005, AM NAT, V165, P590, DOI 10.1086/429523; Sanderson MJ, 2002, MOL BIOL EVOL, V19, P101, DOI 10.1093/oxfordjournals.molbev.a003974; Sanderson MJ, 2003, BIOINFORMATICS, V19, P301, DOI 10.1093/bioinformatics/19.2.301; Shimodaira H, 1999, MOL BIOL EVOL, V16, P1114, DOI 10.1093/oxfordjournals.molbev.a026201; Streelman JT, 2003, TRENDS ECOL EVOL, V18, P126; Swofford D.L., 2001, PAUP PHYLOGENETIC AN; TIHEN JA, 1981, J HERPETOL, V15, P35, DOI 10.2307/1563644; Van Valen L., 1973, EVOL THEORY, V1, P1, DOI DOI 10.1038/344864A0; Vences M, 2005, PHILOS T R SOC B, V360, P1859, DOI 10.1098/rstb.2005.1717; Vieites DR, 2007, P NATL ACAD SCI USA, V104, P19903, DOI 10.1073/pnas.0705056104; Weisrock DW, 2005, SYST BIOL, V54, P758, DOI 10.1080/10635150500234641; Wiens JJ, 2005, SYST BIOL, V54, P91, DOI 10.1080/10635150590906037; Wirta H, 2008, MOL PHYLOGENET EVOL, V47, P1076, DOI 10.1016/j.ympev.2008.03.010	65	17	18	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5615	10.1371/journal.pone.0005615	http://dx.doi.org/10.1371/journal.pone.0005615			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448AY	19461997	Green Submitted, Green Published, gold			2022-12-25	WOS:000266234700008
J	Chechko, N; Wehrle, R; Erhardt, A; Holsboer, F; Czisch, M; Samann, PG				Chechko, Natalya; Wehrle, Renate; Erhardt, Angelika; Holsboer, Florian; Czisch, Michael; Saemann, Philipp G.			Unstable Prefrontal Response to Emotional Conflict and Activation of Lower Limbic Structures and Brainstem in Remitted Panic Disorder	PLOS ONE			English	Article							ANTERIOR CINGULATE CORTEX; COGNITIVE CONTROL MECHANISMS; COUNTING STROOP; FUNCTIONAL NEUROANATOMY; RESOLVE CONFLICT; ANXIETY DISORDER; FACIAL AFFECT; AMYGDALA; INFORMATION; FMRI	Background: The neural mechanisms of panic disorder (PD) are only incompletely understood. Higher sensitivity of patients to unspecific fear cues and similarities to conditioned fear suggest involvement of lower limbic and brainstem structures. We investigated if emotion perception is altered in remitted PD as a trait feature. Methodology/Principal Findings: We used blood oxygenation level-dependent (BOLD) functional magnetic resonance imaging (fMRI) to study neural and behavioural responses of 18 remitted PD patients and 18 healthy subjects to the emotional conflict paradigm that is based on the presentation of emotionally congruent and incongruent face/word pairs. We observed that patients showed stronger behavioural interference and lower adaptation to interference conflict. Overall performance in patients was slower but not less accurate. In the context of preceding congruence, stronger dorsal anterior cingulate cortex (dACC) activation during conflict detection was found in patients. In the context of preceding incongruence, controls expanded dACC activity and succeeded in reducing behavioural interference. In contrast, patients demonstrated a dropout of dACC and dorsomedial prefrontal cortex (dmPFC) recruitment but activation of the lower limbic areas (including right amygdala) and brainstem. Conclusions/Significance: This study provides evidence that stimulus order in the presentation of emotional stimuli has a markedly larger influence on the brain's response in remitted PD than in controls, leading to abnormal responses of the dACC/dmPFC and lower limbic structures (including the amygdala) and brainstem. Processing of non-panic related emotional stimuli is disturbed in PD patients despite clinical remission.			Chechko, N (corresponding author), Max Planck Inst Psychiat, Munich, Germany.	saemann@mpipsykl.mpg.de						American Psychiatric Association DSM-IV, 1994, DSM 4 DIAGN STAT MAN; Anderson IM, 2007, NEUROREPORT, V18, P1351, DOI 10.1097/WNR.0b013e3282742115; Arce E, 2008, PSYCHOPHARMACOLOGY, V196, P661, DOI 10.1007/s00213-007-1004-8; Asami T, 2008, PSYCHIAT CLIN NEUROS, V62, P322, DOI 10.1111/j.1440-1819.2008.01800.x; Bandelow B., 1999, PANIC AGORAPHOBIA SC; Battaglia M, 2005, NEUROSCI BIOBEHAV R, V29, P169, DOI 10.1016/j.neubiorev.2004.06.013; Beck A. T., 1961, ARCH GEN PSYCHIAT; BENKELFAT C, 1995, AM J PSYCHIAT, V152, P1180; Berkowitz RL, 2007, REV NEUROSCIENCE, V18, P191; Bienvenu OJ, 2006, BRIT J PSYCHIAT, V188, P432, DOI 10.1192/bjp.bp.105.010827; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Bouton ME, 2001, PSYCHOL REV, V108, P4, DOI 10.1037//0033-295X.108.1.4; Browning M, 2007, J PSYCHOPHARMACOL, V21, P684, DOI 10.1177/0269881106074062; Bush G, 2006, NAT PROTOC, V1, P230, DOI 10.1038/nprot.2006.35; Bystritsky A, 2001, NEUROREPORT, V12, P3953, DOI 10.1097/00001756-200112210-00020; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Carter CS, 2000, P NATL ACAD SCI USA, V97, P1944, DOI 10.1073/pnas.97.4.1944; DECORT K, 2007, DEPRESS ANXIETY; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Dieler AC, 2008, CURR PHARM DESIGN, V14, P3492, DOI 10.2174/138161208786848801; Drevets W. C., 1994, Society for Neuroscience Abstracts, V20, P368; Egner T, 2005, NAT NEUROSCI, V8, P1784, DOI 10.1038/nn1594; Egner T, 2005, J COGNITIVE NEUROSCI, V17, P1774, DOI 10.1162/089892905774589226; Egner T, 2005, NEUROIMAGE, V24, P539, DOI 10.1016/j.neuroimage.2004.09.007; Egner T, 2008, CEREB CORTEX, V18, P1475, DOI 10.1093/cercor/bhm179; Egner T, 2007, NEUROIMAGE, V35, P940, DOI 10.1016/j.neuroimage.2006.11.061; Ekman P., 1976, PICTURES FACIAL AFFE; ESER D, 2007, HUM BRAIN MAPP; Etkin A, 2004, NEURON, V44, P1043, DOI 10.1016/j.neuron.2004.12.006; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Etkin A, 2006, NEURON, V51, P871, DOI 10.1016/j.neuron.2006.07.029; FRISTON KJ, 1995, NEUROIMAGE, V2, P166, DOI 10.1006/nimg.1995.1019; Gorman JM, 2000, AM J PSYCHIAT, V157, P493, DOI 10.1176/appi.ajp.157.4.493; GRATTON G, 1992, J EXP PSYCHOL GEN, V121, P480, DOI 10.1037/0096-3445.121.4.480; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hoehn-Saric R, 2004, PSYCHIAT RES-NEUROIM, V131, P11, DOI 10.1016/j.pscychresns.2004.02.003; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Laux L., 1981, STATE TRAIT ANGSTINV; LeDoux J, 2003, CELL MOL NEUROBIOL, V23, P727, DOI 10.1023/A:1025048802629; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; MARTIN M, 1991, BEHAV RES THER, V29, P147, DOI 10.1016/0005-7967(91)90043-3; Massana G, 2003, NEUROIMAGE, V19, P80, DOI 10.1016/S1053-8119(03)00036-3; Mayr U, 2003, NAT NEUROSCI, V6, P450, DOI 10.1038/nn1051; MCNALLY RJ, 1994, BEHAV RES THER, V32, P119, DOI 10.1016/0005-7967(94)90092-2; Merens W, 2007, J AFFECT DISORDERS, V103, P43, DOI 10.1016/j.jad.2007.01.032; Milad MR, 2007, BIOL PSYCHIAT, V62, P1191, DOI 10.1016/j.biopsych.2007.04.032; Most SB, 2006, NEUROIMAGE, V31, P934, DOI 10.1016/j.neuroimage.2005.12.031; Nash JR, 2004, EUR NEUROPSYCHOPHARM, V14, pS322, DOI 10.1016/S0924-977X(04)80424-3; Neumeister A, 2004, J NEUROSCI, V24, P589, DOI 10.1523/JNEUROSCI.4921-03.2004; Nitschke JB, 2006, NEUROIMAGE, V29, P106, DOI 10.1016/j.neuroimage.2005.06.068; ONODA K, 2007, NEUROPSYCHOLOGIA; Paul MA, 2007, AVIAT SPACE ENVIR MD, V78, P693; Peterson BS, 1999, BIOL PSYCHIAT, V45, P1237, DOI 10.1016/S0006-3223(99)00056-6; Petrovic P, 2005, NEURON, V46, P957, DOI 10.1016/j.neuron.2005.05.023; Pezawas L, 2005, NAT NEUROSCI, V8, P828, DOI 10.1038/nn1463; Pfleiderer B, 2007, WORLD J BIOL PSYCHIA, V8, P269, DOI 10.1080/15622970701216673; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Pillay SS, 2007, J ANXIETY DISORD, V21, P381, DOI 10.1016/j.janxdis.2006.04.001; Pillay SS, 2006, J AFFECT DISORDERS, V94, P173, DOI 10.1016/j.jad.2006.04.007; Protopopescu X, 2006, NEUROREPORT, V17, P361, DOI 10.1097/01.wnr.0000203354.80438.1; Rose EJ, 2006, PSYCHOPHARMACOLOGY, V185, P339, DOI 10.1007/s00213-006-0334-2; Roy-Byrne PP, 2006, LANCET, V368, P1023, DOI 10.1016/S0140-6736(06)69418-X; Sakai Y, 2005, NEUROREPORT, V16, P927, DOI 10.1097/00001756-200506210-00010; Schneider S, 2008, PSYCHOPATHOLOGY, V41, P179, DOI 10.1159/000120986; Simpson JR, 2001, P NATL ACAD SCI USA, V98, P688, DOI 10.1073/pnas.98.2.688; Spielberger C. D., 1973, MANUAL STATE TRAIT I; Teachman BA, 2007, BEHAV RES THER, V45, P1791, DOI 10.1016/j.brat.2007.01.009; Thomason ME, 2005, NEUROIMAGE, V25, P824, DOI 10.1016/j.neuroimage.2004.12.026; Uchida RR, 2008, PSYCHIAT RES-NEUROIM, V163, P21, DOI 10.1016/j.pscychresns.2007.04.015; Ullsperger M, 2005, COGN AFFECT BEHAV NE, V5, P467, DOI 10.3758/CABN.5.4.467; van den Heuvel OA, 2005, ARCH GEN PSYCHIAT, V62, P922, DOI 10.1001/archpsyc.62.8.922; Vaswani M, 2003, PROG NEURO-PSYCHOPH, V27, P85, DOI 10.1016/S0278-5846(02)00338-X; Wadsworth EJK, 2005, HUM PSYCHOPHARM CLIN, V20, P561, DOI 10.1002/hup.725; Wenzel Amy, 2006, Cognitive Behaviour Therapy, V35, P129, DOI 10.1080/16506070600583130; Whalen PJ, 2006, NAT PROTOC, V1, P293, DOI 10.1038/nprot.2006.45; Whalen PJ, 1998, BIOL PSYCHIAT, V44, P1219, DOI 10.1016/S0006-3223(98)00251-0; Wittchen HU, 1998, SOC PSYCH PSYCH EPID, V33, P568, DOI 10.1007/s001270050095; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O	79	62	63	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5537	10.1371/journal.pone.0005537	http://dx.doi.org/10.1371/journal.pone.0005537			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	448AY	19462002	Green Published, Green Submitted, gold			2022-12-25	WOS:000266234700003
J	Baugh, LA; Marotta, JJ				Baugh, Lee A.; Marotta, Jonathan J.			When What's Left Is Right: Visuomotor Transformations in an Aged Population	PLOS ONE			English	Article							PRISM ADAPTATION; SENSORIMOTOR ADAPTATION; PARKINSONS-DISEASE; INTERNAL-MODELS; VISUAL FEEDBACK; CEREBRAL-CORTEX; SEX-DIFFERENCES; MOTOR-SEQUENCE; OLDER-ADULTS; PLASTICITY	Background: There has been little consensus as to whether age-related visuomotor adaptation effects are readily observable. Some studies have found slower adaptation, and/or reduced overall levels. In contrast, other methodologically similar studies have found no such evidence of aging effects on visuomotor adaptation. A crucial early step in successful adaptation is the ability to perform the necessary transformation to complete the task at hand. The present study describes the use of a viewing window paradigm to examine the effects of aging in a visuomotor transformation task. Methods: Two groups of participants, a young adult control group (age range 18-33 years old, mean age = 22) and an older adult group (age range 62-74, mean age = 68) completed a viewing window task that was controlled by the user via a computer touchscreen. Four visuomotor "flip" conditions were created by varying the relationship between the participant's movement, and the resultant on-screen movement of the viewing window: 1) No flip 2) X-Axis and Y-axis body movements resulted in the opposite direction of movement of the viewing window. In each of the 3) Flip-X and 4) Flip-Y conditions, the solitary X- or Y-axes were reversed. Response times and movement of the window were recorded. Conclusions: Older participants demonstrated impairments in performing a required visuomotor transformation, as evidenced by more complex scanning patterns and longer scanning times when compared to younger control participants. These results provide additional evidence that the mechanisms involved in visuomotor transformation are negatively affected by age.			Baugh, LA (corresponding author), Univ Manitoba, Dept Psychol, Percept & Act Lab, Winnipeg, MB R3T 2N2, Canada.	umbaughL@cc.umanitoba.ca		Baugh, Lee/0000-0001-6227-497X; Marotta, Jonathan/0000-0001-6635-4694				ABED F, 1991, J CROSS CULTURAL PSY, V22; Baugh LA, 2007, J NEUROSCI METH, V160, P128, DOI 10.1016/j.jneumeth.2006.09.002; Bennett PJ, 2001, ACTA PSYCHOL, V107, P249, DOI 10.1016/S0001-6918(01)00037-3; Bock O, 2002, NEUROSCI BIOBEHAV R, V26, P761, DOI 10.1016/S0149-7634(02)00063-5; BOUCHER JL, 1991, PERCEPT MOTOR SKILL, V72, P507, DOI 10.2466/PMS.72.2.507-512; Boyd LA, 2003, PHYS THER, V83, P976, DOI 10.1093/ptj/83.11.976; Buch ER, 2003, LEARN MEMORY, V10, P55, DOI 10.1101/lm.50303; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; CANAVAN AGM, 1990, NEUROPSYCHOLOGIA, V28, P969, DOI 10.1016/0028-3932(90)90112-2; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; CUNNINGHAM HA, 1989, J EXP PSYCHOL HUMAN, V15, P493, DOI 10.1037/0096-1523.15.3.493; DIAMOND MC, 1985, EXP NEUROL, V87, P309, DOI 10.1016/0014-4886(85)90221-3; FERCHMIN PA, 1986, DEV PSYCHOBIOL, V19, P511, DOI 10.1002/dev.420190604; Fernandez-Ruiz J, 2003, EUR J NEUROSCI, V18, P689, DOI 10.1046/j.1460-9568.2003.02785.x; Fernandez-Ruiz J, 2000, COGNITIVE BRAIN RES, V9, P223, DOI 10.1016/S0926-6410(99)00057-9; Flanagan JR, 1997, J NEUROSCI, V17, P1519; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gorbet DJ, 2007, EUR J NEUROSCI, V25, P1228, DOI 10.1111/j.1460-9568.2007.05358.x; Grieve SM, 2005, HUM BRAIN MAPP, V25, P391, DOI 10.1002/hbm.20115; HARRINGTON DL, 1992, PSYCHOL AGING, V7, P425, DOI 10.1037/0882-7974.7.3.425; Heuer H, 2008, PSYCHOL AGING, V23, P190, DOI 10.1037/0882-7974.23.1.190; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; Kaas JH, 1999, NEURON, V22, P657, DOI 10.1016/S0896-6273(00)80725-4; KIM WS, 1987, IEEE T SYST MAN CYB, V17, P61, DOI 10.1109/TSMC.1987.289333; Krakauer JW, 1999, NAT NEUROSCI, V2, P1026, DOI 10.1038/14826; Kucera H., 1967, COMPUTATIONAL ANAL P; Lehmbeck JT, 2006, NEUROREPORT, V17, P467, DOI 10.1097/01.wnr.0000209012.24341.7f; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; Marotta JJ, 2005, J NEUROPHYSIOL, V93, P1104, DOI 10.1152/jn.00859.2004; Michel C, 2007, J COGNITIVE NEUROSCI, V19, P341, DOI 10.1162/jocn.2007.19.2.341; Newport R, 2006, CORTEX, V42, P720, DOI 10.1016/S0010-9452(08)70410-6; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PARSONS TD, 2007, AGING NEUROPSYCHOL C, V12, P78; Pohl PS, 2006, CLIN REHABIL, V20, P246, DOI 10.1191/0269215506cr916oa; Redding GM, 2005, NEUROSCI BIOBEHAV R, V29, P431, DOI 10.1016/j.neubiorev.2004.12.004; ROBYBRAMI A, 1995, COGNITIVE BRAIN RES, V2, P229, DOI 10.1016/0926-6410(95)90014-4; Roller CA, 2002, NEUROBIOL AGING, V23, P117, DOI 10.1016/S0197-4580(01)00264-0; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Seidler RD, 2007, LEARN MEMORY, V14, P17, DOI 10.1101/lm.394707; Seidler RD, 2006, BRAIN RES BULL, V70, P337, DOI 10.1016/j.brainresbull.2006.06.008; Seidler-Dobrin RD, 1998, EXP BRAIN RES, V119, P467, DOI 10.1007/s002210050362; Smith CD, 2007, NEUROBIOL AGING, V28, P1075, DOI 10.1016/j.neurobiolaging.2006.05.018; Teulings HL, 2002, J NEUROL NEUROSUR PS, V72, P315, DOI 10.1136/jnnp.72.3.315; van den Dobbelsteen JJ, 2004, J NEUROPHYSIOL, V92, P416, DOI 10.1152/jn.00764.2003; Vetter P, 1999, J NEUROPHYSIOL, V81, P935, DOI 10.1152/jn.1999.81.2.935; VURPILLOT E, 1976, TRAVAIL HUMAIN, V39; Wolpert DM, 1998, NEURAL NETWORKS, V11, P1317, DOI 10.1016/S0893-6080(98)00066-5	47	9	9	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5484	10.1371/journal.pone.0005484	http://dx.doi.org/10.1371/journal.pone.0005484			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	444WA	19436727	gold, Green Published, Green Submitted			2022-12-25	WOS:000266009900002
J	Li, YJ; Brodsky, B; Baum, J				Li, Yingjie; Brodsky, Barbara; Baum, Jean			NMR Conformational and Dynamic Consequences of a Gly to Ser Substitution in an Osteogenesis Imperfecta Collagen Model Peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELIX; MOLECULAR-STRUCTURE; I COLLAGEN; C-13/N-15-ENRICHED PROTEINS; CRYSTAL-STRUCTURE; BINDING SITES; NATURAL BREAK; MUTATIONS; SPECTROSCOPY; GLYCINE	Close packing of three chains in a standard collagen triple helix requires Gly as every third residue. Missense mutations replacing one Gly by a larger residue in the tripeptide repeating sequence in type I collagen are common molecular causes of osteogenesis imperfecta. The structural and dynamic consequences of such mutations are addressed here by NMR studies on a peptide with a Gly-to-Ser substitution within an alpha 1(I) sequence. Distances derived from nuclear Overhauser effects indicate that the three Ser residues are still packed in the center of the triple helix and that the standard 1-residue stagger is maintained. NMR dynamics using H-exchange and temperature-dependent amide chemical shifts indicate a greater disruption of hydrogen bonding and/or increased conformational flexibility C-terminal to the Ser site when compared with N terminal. This is consistent with recent suggestions relating clinical severity with an asymmetric effect of residues N-versus C-terminal to a mutation site. Dynamic studies also indicate that the relative position between a Gly in one chain and the mutation site in a neighboring staggered chain influences the disruption of the standard hydrogen-bonding pattern. The structural and dynamic alterations reported here may play a role in the etiology of osteogenesis imperfecta by affecting collagen secretion or interactions with other matrix molecules.	[Li, Yingjie; Baum, Jean] Rutgers State Univ, BIOMAPS Inst, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA; [Brodsky, Barbara] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Baum, J (corresponding author), Rutgers State Univ, BIOMAPS Inst, Dept Chem & Chem Biol, 610 Taylor Rd, Piscataway, NJ 08854 USA.	jean.baum@rutgers.edu			National Institutes of Health [GM45302, GM60048]; National Science Foundation [DBI-0320746, DBI-0403062]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045302, R29GM045302, R01GM060048] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants GM45302 (to J.B.) and GM60048 (to B. B.). This work was also supported by National Science Foundation Grants DBI-0320746 (to J.B.) and DBI-0403062 (to J.B.).	Baum Jean, 1999, Current Opinion in Structural Biology, V9, P122, DOI 10.1016/S0959-440X(99)80016-5; Baxter NJ, 1997, J BIOMOL NMR, V9, P359, DOI 10.1023/A:1018334207887; Beck K, 2000, P NATL ACAD SCI USA, V97, P4273, DOI 10.1073/pnas.070050097; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Berisio R, 2002, PROTEIN SCI, V11, P262, DOI 10.1110/ps.32602; Bodian DL, 2008, BIOCHEMISTRY-US, V47, P5424, DOI 10.1021/bi800026k; Brodsky B, 2005, ADV PROTEIN CHEM, V70, P301, DOI 10.1016/S0065-3233(05)70009-7; Buevich A, 2001, PHILOS T R SOC B, V356, P159, DOI 10.1098/rstb.2000.0761; Byers P, 2002, CONNECTIVE TISSUE IT, P385, DOI DOI 10.1002/0471221929.CH8; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; Gauba V, 2008, J AM CHEM SOC, V130, P7509, DOI 10.1021/ja801670v; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Hyde TJ, 2006, J BIOL CHEM, V281, P36937, DOI 10.1074/jbc.M605135200; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; Li YJ, 2007, J BIOL CHEM, V282, P22699, DOI 10.1074/jbc.M702910200; LIU X, 1997, THESIS STATE U NEW J, P101; Madhan B, 2008, J AM CHEM SOC, V130, P13520, DOI 10.1021/ja805496v; Makareeva E, 2008, J BIOL CHEM, V283, P4787, DOI 10.1074/jbc.M705773200; Marini JC, 2007, HUM MUTAT, V28, P209, DOI 10.1002/humu.20429; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MESSERLE BA, 1989, J MAGN RESON, V85, P608, DOI 10.1016/0022-2364(89)90252-7; Mohs A, 2005, BIOCHEMISTRY-US, V44, P1793, DOI 10.1021/bi0482708; Mohs A, 2006, J BIOL CHEM, V281, P17197, DOI 10.1074/jbc.M601763200; Mooney SD, 2002, MOL CELL PROTEOMICS, V1, P868, DOI 10.1074/mcp.M200064-MCP200; Mooney SD, 2001, BIOPOLYMERS, V58, P347, DOI 10.1002/1097-0282(200103)58:3<347::AID-BIP1011>3.0.CO;2-M; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; POWERS R, 1991, J MAGN RESON, V94, P209, DOI 10.1016/0022-2364(91)90312-H; RAMACHANDRAN GN, 1967, TREATISE COLLAGEN, P103; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Xu K, 2008, J BIOL CHEM, V283, P34337, DOI 10.1074/jbc.M805485200; ZHU GA, 1992, J MAGN RESON, V98, P192, DOI 10.1016/0022-2364(92)90124-P	37	28	29	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20660	20667		10.1074/jbc.M109.018077	http://dx.doi.org/10.1074/jbc.M109.018077			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19451653	Green Published, hybrid			2022-12-25	WOS:000268316100027
J	Kyle, JW; Berthoud, VM; Kurutz, J; Minogue, PJ; Greenspan, M; Hanck, DA; Beyer, EC				Kyle, John W.; Berthoud, Viviana M.; Kurutz, Josh; Minogue, Peter J.; Greenspan, Michael; Hanck, Dorothy A.; Beyer, Eric C.			The N Terminus of Connexin37 Contains an alpha-Helix That Is Required for Channel Function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; GAP-JUNCTION CHANNEL; MARIE-TOOTH-DISEASE; AMINO-ACID-RESIDUES; 3-DIMENSIONAL STRUCTURE; ALTERED TRAFFICKING; GATING POLARITY; RAT CONNEXIN40; MUTATIONS; CHARGE	The cytoplasmic N-terminal domain of connexins has been implicated in multiple aspects of gap junction function, including connexin trafficking/assembly and channel gating. A synthetic peptide corresponding to the first 23 amino acids of human connexin37 was prepared, and circular dichroism and nuclear magnetic resonance studies showed that this N-terminal peptide was predominantly alpha-helical between glycine 5 and glutamate 16. The importance of this structure for localization of the protein at appositional membranes and channel function was tested by expression of site-directed mutants of connexin37 in which amino acids leucine 10 and glutamine 15 were replaced with prolines or alanines. Wild type connexin37 and both substitution mutants localized to appositional membranes between transfected HeLa cells. The proline mutant did not allow intercellular transfer of microinjected neurobiotin; the alanine mutant allowed transfer, but less extensively than wild type connexin37. When expressed alone in Xenopus oocytes, wild type connexin37 produced hemichannel currents, but neither of the double substitution mutants produced detectable currents. The proline mutant ( but not the alanine mutant) inhibited co-expressed wild type connexin37. Taken together, our data suggest that the alpha-helical structure of the connexin37 N terminus may be dispensable for protein localization, but it is required for channel and hemichannel function.	[Berthoud, Viviana M.; Minogue, Peter J.; Greenspan, Michael; Beyer, Eric C.] Univ Chicago, Dept Pediat, Hematol Oncol Sect, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Cardiol Sect, Chicago, IL 60637 USA; [Kurutz, Josh] Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Beyer, EC (corresponding author), Univ Chicago, Dept Pediat, Hematol Oncol Sect, MC4060,5841 S Maryland Ave, Chicago, IL 60637 USA.	ebeyer@peds.bsd.uchicago.edu	Greenspan, Michael/I-2466-2019; Beyer, Eric/V-1317-2019; Kurutz, Josh/AAE-4641-2022	Beyer, Eric/0000-0001-8044-1356; Kurutz, Josh/0000-0002-3566-0514	National Institutes of Health [HL59199, EY08368]; Bernice Meltzer Fund for Pediatric Cancer Research; NATIONAL EYE INSTITUTE [R29EY008368, R01EY008368] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059199] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bernice Meltzer Fund for Pediatric Cancer Research; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported, in whole or in part, by National Institutes of Health Grants HL59199 and EY08368 (to E. C. B.). This work was also supported by the Bernice Meltzer Fund for Pediatric Cancer Research.	Arita K, 2006, AM J PATHOL, V169, P416, DOI 10.2353/ajpath.2006.051242; Beahm DL, 2002, BIOPHYS J, V82, P2016, DOI 10.1016/S0006-3495(02)75550-1; Beyer Eric C., 2009, P3, DOI 10.1007/978-1-59745-489-6_1; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Common JEA, 2003, CELL COMMUN ADHES, V10, P347, DOI 10.1080/15419060390263128; D'Andrea P, 2002, BIOCHEM BIOPH RES CO, V296, P685, DOI 10.1016/S0006-291X(02)00891-4; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; Deschenes SM, 1997, J NEUROSCI, V17, P9077; Dong LX, 2006, J PHYSIOL-LONDON, V576, P787, DOI 10.1113/jphysiol.2006.113837; Ebihara L, 2003, BIOPHYS J, V84, P277, DOI 10.1016/S0006-3495(03)74848-6; Essenfelder GM, 2004, HUM MOL GENET, V13, P1703, DOI 10.1093/hmg/ddh191; Falk MM, 2001, MICROSC RES TECHNIQ, V52, P251, DOI 10.1002/1097-0029(20010201)52:3<251::AID-JEMT1011>3.0.CO;2-#; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; GIMLICH RL, 1990, J CELL BIOL, V110, P597, DOI 10.1083/jcb.110.3.597; GIRVIN ME, 1994, J MAGN RESON SER A, V108, P99, DOI 10.1006/jmra.1994.1095; Grifa A, 1999, NAT GENET, V23, P16, DOI 10.1038/12612; Kumar N M, 1992, Semin Cell Biol, V3, P3; Kyle JW, 2008, J CELL SCI, V121, P2744, DOI 10.1242/jcs.032482; Kyle JW, 2009, BIOPHYS J, V96, p287A, DOI 10.1016/j.bpj.2008.12.1422; Lagree V, 2003, J CELL SCI, V116, P3189, DOI 10.1242/jcs.00604; Laird DW, 2001, MICROSC RES TECHNIQ, V52, P263, DOI 10.1002/1097-0029(20010201)52:3<263::AID-JEMT1012>3.0.CO;2-Q; Larson D. M., 2000, Molecular Cell Biology Research Communications, V3, P115, DOI 10.1006/mcbr.2000.0200; Lin XM, 2006, J PHYSIOL-LONDON, V570, P251, DOI 10.1113/jphysiol.2005.097188; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; Maeda S, 2009, NATURE, V458, P597, DOI 10.1038/nature07869; Matsuyama W, 2001, J HUM GENET, V46, P307, DOI 10.1007/s100380170064; Minogue PJ, 2005, J BIOL CHEM, V280, P40788, DOI 10.1074/jbc.M504765200; Musa H, 2004, J PHYSIOL-LONDON, V557, P863, DOI 10.1113/jphysiol.2003.059386; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; Oh S, 2000, J GEN PHYSIOL, V116, P13, DOI 10.1085/jgp.116.1.13; Oh S, 2008, J PHYSIOL-LONDON, V586, P2445, DOI 10.1113/jphysiol.2008.150805; Oshima A, 2003, J BIOL CHEM, V278, P1807, DOI 10.1074/jbc.M207713200; Oshima A, 2007, P NATL ACAD SCI USA, V104, P10034, DOI 10.1073/pnas.0703704104; Puljung MC, 2004, J GEN PHYSIOL, V124, P587, DOI 10.1085/jgp.200409023; Purnick PEM, 2000, ARCH BIOCHEM BIOPHYS, V381, P181, DOI 10.1006/abbi.2000.1989; Purnick PEM, 2000, BIOPHYS J, V79, P2403, DOI 10.1016/S0006-3495(00)76485-X; REED KE, 1993, J CLIN INVEST, V91, P997, DOI 10.1172/JCI116321; Ressot C, 1998, J NEUROSCI, V18, P4063; Richard G, 2003, J INVEST DERMATOL, V120, P601, DOI 10.1046/j.1523-1747.2003.12080.x; Rouan F, 2003, EXP DERMATOL, V12, P191, DOI 10.1034/j.1600-0625.2003.120210.x; Shibayama J, 2005, CIRC RES, V96, pE83, DOI 10.1161/01.RES.0000168369.79972.d2; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sultana N, 2008, P NATL ACAD SCI USA, V105, P4763, DOI 10.1073/pnas.0708451105; Thomas BC, 2008, INVEST OPHTH VIS SCI, V49, P2549, DOI 10.1167/iovs.07-1658; Tong JJ, 2004, BIOPHYS J, V87, P2397, DOI 10.1529/biophysj.104.039594; Tong JJ, 2006, BIOPHYS J, V91, P2142, DOI 10.1529/biophysj.106.082859; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; VEENSTRA RD, 1994, BIOPHYS J, V66, P1915, DOI 10.1016/S0006-3495(94)80985-3; VERSELIS VK, 1994, NATURE, V368, P348, DOI 10.1038/368348a0; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wong CW, 2006, NAT MED, V12, P950, DOI 10.1038/nm1441	55	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20418	20427		10.1074/jbc.M109.016907	http://dx.doi.org/10.1074/jbc.M109.016907			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19478091	hybrid, Green Published			2022-12-25	WOS:000268097400067
J	Swietach, P; Patiar, S; Supuran, CT; Harris, AL; Vaughan-Jones, RD				Swietach, Pawel; Patiar, Shalini; Supuran, Claudiu T.; Harris, Adrian L.; Vaughan-Jones, Richard D.			The Role of Carbonic Anhydrase 9 in Regulating Extracellular and Intracellular pH in Three-dimensional Tumor Cell Growths	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA; RAT; TRANSPORT; PROTEIN; IX; CARBONIC-ANHYDRASE-9; MICROENVIRONMENT; CONSEQUENCES; FIBROBLASTS; GLYCOLYSIS	We have studied the role of carbonic anhydrase 9 (CA9), a cancer-associated extracellular isoform of the enzyme carbonic anhydrase in multicellular spheroid growths (radius of similar to 300 mu m) of human colon carcinoma HCT116 cells. Spheroids were transfected with CA9 (or empty vector) and imaged confocally (using fluorescent dyes) for both intracellular pH (pH(i)) and pH in the restricted extracellular spaces (pH(e)). With no CA9 expression, spheroids developed very low pHi (similar to 6.3) and reduced pH(e) (similar to 6.9) at their core, associated with a diminishing gradient of acidity extending out to the periphery. With CA9 expression, core intracellular acidity was less prominent (pH(i) = similar to 6.6), whereas extracellular acidity was enhanced (pH(e) = similar to 6.6), so that radial pHi gradients were smaller and radial pHe gradients were larger. These effects were reversed by eliminating CA9 activity with membrane-impermeant CA inhibitors. The observation that CA9 activity reversibly reduces pHe indicates the enzyme is facilitating CO2 excretion from cells (by converting vented CO2 to extracellular H+), rather than facilitating membrane H+ transport (such as H+ associated with metabolically generated lactic acid). This latter process requires titration of exported H+ ions with extracellular HCO3-, which would reduce rather than increase extracellular acidity. In a multicellular structure, the net effect of CA9 on pHe will depend on the cellular CO2/lactic acid emission ratio (set by local oxygenation and membrane HCO3- uptake). Our results suggest that CO2-producing tumors may express CA9 to facilitate CO2 excretion, thus raising pHi and reducing pHe, which promotes tumor proliferation and survival. The results suggest a possible basis for attenuating tumor development through inhibiting CA9 activity.	[Swietach, Pawel; Vaughan-Jones, Richard D.] Burdon Sanderson Cardiac Sci Ctr, Dept Physiol Anat & Genet, Oxford OX1 3PT, England; [Patiar, Shalini; Harris, Adrian L.] Weatherall Inst Mol Med, Oxford OX3 9DS, England; [Supuran, Claudiu T.] Univ Florence, Lab Chim Bioinorgan, I-50019 Florence, Italy	University of Oxford; University of Oxford; University of Florence	Vaughan-Jones, RD (corresponding author), Burdon Sanderson Cardiac Sci Ctr, Dept Physiol Anat & Genet, Oxford OX1 3PT, England.	richard.vaughan-jones@dpag.ox.ac.uk	Swietach, Pawel/AAK-4169-2020; Harris, Adrian L/ABA-3343-2020; Supuran, Claudiu T/A-5151-2008	Swietach, Pawel/0000-0002-9945-9473; Harris, Adrian L/0000-0003-1376-8409; Supuran, Claudiu/0000-0003-4262-0323	Royal Society and Medical Research Council; British Heart Foundation; Wellcome Trust; EUROXY; Cancer Research UK; British Heart Foundation [RG/08/016/26423] Funding Source: researchfish; Medical Research Council [G0700698] Funding Source: researchfish; MRC [G0700698] Funding Source: UKRI	Royal Society and Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome TrustEuropean Commission); EUROXY; Cancer Research UK(Cancer Research UK); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by funds from the Royal Society and Medical Research Council (to P. S.), the British Heart Foundation and Wellcome Trust (to R. D. V.-J.), EUROXY, and Cancer Research UK (to A. L. H.).	Airley RE, 2003, INT J CANCER, V104, P85, DOI 10.1002/ijc.10904; Boron WF, 2004, ADV PHYSIOL EDUC, V28, P160, DOI 10.1152/advan.00045.2004; CARLSSON J, 1988, INT J CANCER, V42, P715, DOI 10.1002/ijc.2910420515; CHAMBARD JC, 1986, EXP CELL RES, V164, P282, DOI 10.1016/0014-4827(86)90029-7; Chiche J, 2009, CANCER RES, V69, P358, DOI 10.1158/0008-5472.CAN-08-2470; Gatenby RA, 2006, CANCER RES, V66, P5216, DOI 10.1158/0008-5472.CAN-05-4193; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Geers C, 2000, PHYSIOL REV, V80, P681, DOI 10.1152/physrev.2000.80.2.681; Gillies RJ, 2002, J MAGN RESON IMAGING, V16, P430, DOI 10.1002/jmri.10181; Gillies RJ, 2008, J NUCL MED, V49, p24S, DOI 10.2967/jnumed.107.047258; Griffiths J R, 2001, Novartis Found Symp, V240, P46; GRIFFITHS JR, 1981, BIOSCIENCE REP, V1, P319, DOI 10.1007/BF01114871; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; HOLM E, 1995, CANCER RES, V55, P1373; Huang WC, 2008, CURR BIOL, V18, P781, DOI 10.1016/j.cub.2008.04.049; JEAN T, 1985, J BIOL CHEM, V260, P9678; KATO Y, 1992, J BIOL CHEM, V267, P11424; Kunz-Schughart L, 2000, AM J PHYSIOL-CELL PH, V278, pC765, DOI 10.1152/ajpcell.2000.278.4.C765; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Marroquin LD, 2007, TOXICOL SCI, V97, P539, DOI 10.1093/toxsci/kfm052; Morgan PE, 2007, AM J PHYSIOL-CELL PH, V293, pC738, DOI 10.1152/ajpcell.00157.2007; PASTOREK J, 1994, ONCOGENE, V9, P2877; Pastorekova S, 1997, GASTROENTEROLOGY, V112, P398, DOI 10.1053/gast.1997.v112.pm9024293; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sterling D, 2001, J BIOL CHEM, V276, P47886, DOI 10.1074/jbc.M105959200; Stewart AK, 2009, J BIOL CHEM, V284, P6126, DOI 10.1074/jbc.M802051200; Stock C, 2007, CELL PHYSIOL BIOCHEM, V20, P679, DOI 10.1159/000107550; Stubbs M, 2000, MOL MED TODAY, V6, P15, DOI 10.1016/S1357-4310(99)01615-9; Supuran CT, 2008, NAT REV DRUG DISCOV, V7, P168, DOI 10.1038/nrd2467; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Svastova E, 2004, FEBS LETT, V577, P439, DOI 10.1016/j.febslet.2004.10.043; Swietach P, 2005, J PHYSIOL-LONDON, V566, P793, DOI 10.1113/jphysiol.2005.086165; Swietach P, 2008, J BIOL CHEM, V283, P20473, DOI 10.1074/jbc.M801330200; Swietach P, 2007, CANCER METAST REV, V26, P299, DOI 10.1007/s10555-007-9064-0; VAUPEL P, 1989, CANCER RES, V49, P6449; Villafuerte FC, 2007, FASEB J, V21, pA1284; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Wallace KB, 2000, ANNU REV PHARMACOL, V40, P353, DOI 10.1146/annurev.pharmtox.40.1.353; Wykoff CC, 2000, CANCER RES, V60, P7075	42	213	216	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20299	20310		10.1074/jbc.M109.006478	http://dx.doi.org/10.1074/jbc.M109.006478			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19458084	Green Published, hybrid			2022-12-25	WOS:000268097400056
J	Wang, JH; Lee, B; Cai, S; Fukui, L; Hu, WD; Chen, Y				Wang, Jianghai; Lee, Brian; Cai, Sheng; Fukui, Lisa; Hu, Weidong; Chen, Yuan			Conformational Transition Associated with E1-E2 Interaction in Small Ubiquitin-like Modifications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACKBONE DYNAMICS; ACTIVATING ENZYME; NMR RELAXATION; CHEMICAL-SHIFT; PROTEIN; DOMAIN; SYSTEM; SUMO; E2; INSIGHTS	Ubiquitin-like modifications regulate nearly every aspect of cellular functions. A key step in these modifications is the recognition of the carrier enzyme (E2) by the activating enzyme (E1). In this study, we have found that a critical E2-binding surface on the E1 of the small ubiquitin-like modifier has unusually high populations in both ordered and disordered states. Upon binding the E2, the disordered state is converted to the ordered state, which resembles the structure of the bound conformation, providing a mechanism to resolve the "Levinthal Paradox" search problem in a folding-upon-binding process. The significance of the folding-unfolding equilibrium is shown by the loss of functions of the mutations that shift the equilibrium to the folded state. This study highlights the importance of conformational flexibility in the molecular recognition event.	[Wang, Jianghai; Lee, Brian; Cai, Sheng; Fukui, Lisa; Hu, Weidong; Chen, Yuan] Beckman Res Inst City Hope, Div Immunol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Chen, Y (corresponding author), Beckman Res Inst City Hope, Div Immunol, Duarte, CA 91010 USA.	ychen@coh.org	Moore, Lisa/A-3640-2013	Moore, Lisa/0000-0003-4345-6318	National Institutes of Health [R01GM074748, R01GM086171]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074748, R01GM086171] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants R01GM074748 and R01GM086171.	CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Ebert MO, 2008, BIOCHEMISTRY-US, V47, P1299, DOI 10.1021/bi701767j; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280; Farrow NA, 1997, BIOCHEMISTRY-US, V36, P2390, DOI 10.1021/bi962548h; Guo B, 2007, BIOCHEM SOC T, V35, P1414, DOI 10.1042/BST0351414; HAAS AL, 1982, J BIOL CHEM, V257, P329; Haas AL, 1997, FASEB J, V11, P1257; Henzler-Wildman KA, 2007, NATURE, V450, P913, DOI 10.1038/nature06407; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang DT, 2007, NATURE, V445, P394, DOI 10.1038/nature05490; Huang DT, 2005, MOL CELL, V17, P341, DOI 10.1016/j.molcel.2004.12.020; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Karplus M, 1997, FOLD DES, V2, pS69, DOI 10.1016/S1359-0278(97)00067-9; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Lee I, 2008, CELL, V134, P268, DOI 10.1016/j.cell.2008.05.046; Liu Q, 1999, J BIOL CHEM, V274, P16979, DOI 10.1074/jbc.274.24.16979; Lois LM, 2005, EMBO J, V24, P439, DOI 10.1038/sj.emboj.7600552; Peng T, 2007, NAT STRUCT MOL BIOL, V14, P325, DOI 10.1038/nsmb1207; Penkett CJ, 1998, BIOCHEMISTRY-US, V37, P17054, DOI 10.1021/bi9814080; Receveur-Brechot V, 2006, PROTEINS, V62, P24, DOI 10.1002/prot.20750; Schwarzinger S, 2002, BIOCHEMISTRY-US, V41, P12681, DOI 10.1021/bi020381o; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Siepmann TJ, 2003, J BIOL CHEM, V278, P9448, DOI 10.1074/jbc.M211240200; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Walden H, 2003, NATURE, V422, P330, DOI 10.1038/nature01456; Wang JH, 2007, MOL CELL, V27, P228, DOI 10.1016/j.molcel.2007.05.023; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777	33	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20340	20348		10.1074/jbc.M109.000257	http://dx.doi.org/10.1074/jbc.M109.000257			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19443651	hybrid, Green Published			2022-12-25	WOS:000268097400060
J	Bellapadrona, G; Stefanini, S; Zamparelli, C; Theil, EC; Chiancone, E				Bellapadrona, Giuliano; Stefanini, Simonetta; Zamparelli, Carlotta; Theil, Elizabeth C.; Chiancone, Emilia			Iron Translocation into and out of Listeria innocua Dps and Size Distribution of the Protein-enclosed Nanomineral Are Modulated by the Electrostatic Gradient at the 3-fold "Ferritin-like" Pores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE DETOXIFICATION; BINDING PROTEIN; H-CHAIN; DODECAMERIC FERRITIN; ESCHERICHIA-COLI; CORE FORMATION; HUMAN-LIVER; SITE; APOFERRITIN; MECHANISM	Elucidating pore function at the 3-fold channels of 12-subunit, microbial Dps proteins is important in understanding their role in the management of iron/hydrogen peroxide. The Dps pores are called "ferritin-like" because of the structural resemblance to the 3-fold channels of 24-subunit ferritins used for iron entry and exit to and from the protein cage. In ferritins, negatively charged residues lining the pores generate a negative electrostatic gradient that guides iron ions toward the ferroxidase centers for catalysis with oxidant and destined for the mineralization cavity. To establish whether the set of three aspartate residues that line the pores in Listeria innocua Dps act in a similar fashion, D121N, D126N, D130N, and D121N/D126N/D130N proteins were produced; kinetics of iron uptake/release and the size distribution of the iron mineral in the protein cavity were compared. The results, discussed in the framework of crystal growth in a confined space, indicate that iron uses the hydrophilic 3-fold pores to traverse the protein shell. For the first time, the strength of the electrostatic potential is observed to modulate kinetic cooperativity in the iron uptake/release processes and accordingly the size distribution of the microcrystalline iron minerals in the Dps protein population.	[Bellapadrona, Giuliano; Stefanini, Simonetta; Zamparelli, Carlotta; Chiancone, Emilia] Univ Roma La Sapienza, Dept Biochem Sci A Rossi Fanelli, Inst Mol Biol & Pathol, CNR, I-00185 Rome, Italy; [Theil, Elizabeth C.] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Chiancone, E (corresponding author), Univ Roma La Sapienza, Dept Biochem Sci A Rossi Fanelli, Inst Mol Biol & Pathol, CNR, Pl Moro 5, I-00185 Rome, Italy.	emilia.chiancone@uniroma1.it	Stefanini, Simonetta/D-5083-2009		National Institutes of Health [DK 20251]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK020251, R56DK020251, R01DK020251] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grant DK 20251 (to G. B. and E. C. T.).	Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; Chasteen ND, 1999, J STRUCT BIOL, V126, P182, DOI 10.1006/jsbi.1999.4118; Chiancone E, 2004, BIOMETALS, V17, P197, DOI 10.1023/B:BIOM.0000027692.24395.76; Chiaraluce R, 2000, EUR J BIOCHEM, V267, P5733, DOI 10.1046/j.1432-1327.2000.01639.x; Courteix A, 1996, AICHE J, V42, P829, DOI 10.1002/aic.690420321; DELANO W, 2006, PYMOL VERSION 0 99; Douglas T, 1998, PROTEIN SCI, V7, P1083, DOI 10.1002/pro.5560070502; Franceschini S, 2006, FEBS J, V273, P4913, DOI 10.1111/j.1742-4658.2006.05490.x; HILTY S, 1994, J INORG BIOCHEM, V56, P173, DOI 10.1016/0162-0134(94)85004-6; Ilari A, 2000, NAT STRUCT BIOL, V7, P38; Ilari A, 2005, BIOCHEMISTRY-US, V44, P5579, DOI 10.1021/bi050005e; Ilari A, 2002, J BIOL CHEM, V277, P37619, DOI 10.1074/jbc.M206186200; Ishikawa T, 2003, J BACTERIOL, V185, P1010, DOI 10.1128/JB.185.3.1010-1017.2003; Jin WL, 2001, BIOCHEMISTRY-US, V40, P7525, DOI 10.1021/bi002509c; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; Levi S, 1996, BIOCHEM J, V317, P467, DOI 10.1042/bj3170467; LEVI S, 1988, J BIOL CHEM, V263, P18086; Liu XF, 2003, P NATL ACAD SCI USA, V100, P3653, DOI 10.1073/pnas.0636928100; Liu XF, 2005, ACCOUNTS CHEM RES, V38, P167, DOI 10.1021/ar0302336; Liu XS, 2007, J BIOL CHEM, V282, P31821, DOI 10.1074/jbc.C700153200; MACARA IG, 1972, BIOCHEM J, V126, P151, DOI 10.1042/bj1260151; Morikawa K, 2006, GENES CELLS, V11, P409, DOI 10.1111/j.1365-2443.2006.00949.x; RICARD J, 1989, BIOPHYS J, V56, P477, DOI 10.1016/S0006-3495(89)82695-5; STEFANINI S, 1989, BIOCHEMISTRY-US, V28, P378, DOI 10.1021/bi00427a052; STEFANINI S, 1976, MOL CELL BIOCHEM, V13, P55, DOI 10.1007/BF01732396; Su MH, 2005, BIOCHEMISTRY-US, V44, P5572, DOI 10.1021/bi0472705; SUN SJ, 1993, BIOCHEMISTRY-US, V32, P9362, DOI 10.1021/bi00087a015; Takagi H, 1998, J BIOL CHEM, V273, P18685, DOI 10.1074/jbc.273.30.18685; Takahashi T, 2003, BIOPHYS J, V84, P2256, DOI 10.1016/S0006-3495(03)75031-0; TREFFRY A, 1993, BIOCHEM J, V296, P721, DOI 10.1042/bj2960721; Ueshima J, 2003, INFECT IMMUN, V71, P1170, DOI 10.1128/IAI.71.3.1170-1178.2003; Yamamoto Y, 2002, J BACTERIOL, V184, P2931, DOI 10.1128/JB.184.11.2931-2939.2002; Zhao GH, 2002, J BIOL CHEM, V277, P27689, DOI 10.1074/jbc.M202094200	34	50	50	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					19101	19109		10.1074/jbc.M109.014670	http://dx.doi.org/10.1074/jbc.M109.014670			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19457858	Green Published, hybrid			2022-12-25	WOS:000267711500058
J	Bajpai, S; Feng, YF; Krishnamurthy, R; Longmore, GD; Wirtz, D				Bajpai, Saumendra; Feng, Yunfeng; Krishnamurthy, Ranjini; Longmore, Gregory D.; Wirtz, Denis			Loss of alpha-Catenin Decreases the Strength of Single E-cadherin Bonds between Human Cancer Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULE FORCE SPECTROSCOPY; RECEPTOR-LIGAND BINDING; TUMOR PROGRESSION; EXPRESSION; ADHESION; CARCINOMA; JUNCTIONS; COMPLEX	The progression of several human cancers correlates with the loss of cytoplasmic protein alpha-catenin from E-cadherin-rich intercellular junctions and loss of adhesion. However, the potential role of alpha-catenin in directly modulating the adhesive function of individual E-cadherin molecules in human cancer is unknown. Here we use single-molecule force spectroscopy to probe the tensile strength, unstressed bond lifetime, and interaction energy between E-cadherins expressed on the surface of live human parental breast cancer cells lacking alpha-catenin and these cells where alpha-catenin is re-expressed. We find that the tensile strength and the lifetime of single E-cadherin/E-cadherin bonds between parental cells are significantly lower over a wide range of loading rates. Statistical analysis of the force displacement spectra reveals that single cadherin bonds between cancer cells feature an exceedingly low energy barrier against tensile forces and low molecular stiffness. Disassembly of filamentous actin using latrunculin B has no significant effect on the strength of single intercellular E-cadherin bonds. The absence of alpha-catenin causes a dominant negative effect on both global cell-cell adhesion and single E-cadherin bond strength. These results suggest that the loss of alpha-catenin alone drastically reduces the adhesive force between individual cadherin pairs on adjoining cells, explain the global loss of cell adhesion in human breast cancer cells, and show that the forced expression of alpha-catenin in cancer cells can restore both higher intercellular avidity and intercellular E-cadherin bond strength.	[Bajpai, Saumendra; Krishnamurthy, Ranjini; Wirtz, Denis] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Feng, Yunfeng; Longmore, Gregory D.] Washington Univ, Sch Med, Dept Physiol, St Louis, MO 63110 USA; [Feng, Yunfeng; Longmore, Gregory D.] Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA; [Wirtz, Denis] Johns Hopkins Univ, Sch Med, Johns Hopkins Kimmel Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA	Johns Hopkins University; Washington University (WUSTL); Washington University (WUSTL); Johns Hopkins University; Johns Hopkins Medicine	Wirtz, D (corresponding author), Johns Hopkins Univ, Dept Chem, 3400 N Charles St, Baltimore, MD 21218 USA.	wirtz@jhu.edu	Ladoux, Benoit/A-9879-2013; Wirtz, Denis/A-3257-2010; Bajpai, Saumendra/B-8120-2014	Bajpai, Saumendra/0000-0002-9397-2102; Feng, Yunfeng/0000-0001-9150-7795	National Institutes of Health [GM080673, CA137891]; American Heart Association [0855319E]; NATIONAL CANCER INSTITUTE [R21CA137891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080673] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants GM080673 ( to G. D. L.) and CA137891 ( to D. W.). This work was also supported by Grant-in-aid 0855319E from the American Heart Association ( to D. W.).	Bajpai S, 2008, P NATL ACAD SCI USA, V105, P18331, DOI 10.1073/pnas.0806783105; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; Carico E, 2001, GYNECOL ONCOL, V80, P156, DOI 10.1006/gyno.2000.6035; CAVELLERO U, 2004, NAT REV CELL MOL BIO, V4, P118; Chesla SE, 1998, BIOPHYS J, V75, P1553, DOI 10.1016/S0006-3495(98)74074-3; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; Dobrowsky TM, 2008, METHOD CELL BIOL, V89, P411, DOI 10.1016/S0091-679X(08)00615-8; Dudko OK, 2008, P NATL ACAD SCI USA, V105, P15755, DOI 10.1073/pnas.0806085105; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hanley WD, 2004, J CELL SCI, V117, P2503, DOI 10.1242/jcs.01088; KADOWAKI T, 1994, CANCER RES, V54, P291; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Konstantopoulos K, 2003, CURR BIOL, V13, pR611, DOI 10.1016/S0960-9822(03)00529-3; Lee JSH, 2007, BIOPHYS J, V93, P2542, DOI 10.1529/biophysj.106.102426; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Marie H, 2003, J BIOL CHEM, V278, P1220, DOI 10.1074/jbc.M205391200; Marshall BT, 2005, BIOPHYS J, V88, P1458, DOI 10.1529/biophysj.104.050567; Nakopoulou L, 2002, HISTOPATHOLOGY, V40, P536, DOI 10.1046/j.1365-2559.2002.01392.x; Panorchan P, 2006, J MOL BIOL, V358, P665, DOI 10.1016/j.jmb.2006.02.021; Panorchan P, 2006, J CELL SCI, V119, P66, DOI 10.1242/jcs.02719; Patel SD, 2003, CURR OPIN STRUC BIOL, V13, P690, DOI 10.1016/j.sbi.2003.10.007; Perez-Moreno M, 2006, DEV CELL, V11, P601, DOI 10.1016/j.devcel.2006.10.010; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; Ray C, 2007, LANGMUIR, V23, P6076, DOI 10.1021/la070131e; Ropponen KM, 1999, J CLIN PATHOL, V52, P10, DOI 10.1136/jcp.52.1.10; SHIOZAKI H, 1994, AM J PATHOL, V144, P667; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tseng Y, 2002, BIOPHYS J, V83, P3162, DOI 10.1016/S0006-3495(02)75319-8; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020; Yu J, 2000, GUT, V46, P639, DOI 10.1136/gut.46.5.639	32	47	48	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	2009	284	27					18252	18259		10.1074/jbc.M109.000661	http://dx.doi.org/10.1074/jbc.M109.000661			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BW	19458087	hybrid, Green Published			2022-12-25	WOS:000267712400038
J	Hu, XT; Zhang, FB; Fan, YC; Shu, XS; Wong, AHY; Zhou, W; Shi, QL; Tang, HM; Fu, L; Guan, XY; Rha, SY; Tao, Q; He, C				Hu, X-T; Zhang, F-B; Fan, Y-C; Shu, X-S; Wong, A. H. Y.; Zhou, W.; Shi, Q-L; Tang, H-M; Fu, L.; Guan, X-Y; Rha, S. Y.; Tao, Q.; He, C.			Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer	ONCOGENE			English	Article						Phospholipase C delta 1; tumor suppressor gene; methylation; 3p22; gastric cancer	ACTIN-DEPOLYMERIZING FACTOR; GTPASE-ACTIVATING PROTEIN; MATRIX METALLOPROTEINASE-7; BINDING PROTEIN; EXPRESSION; GENE; ESOPHAGEAL; MATRILYSIN; CELLS; NASOPHARYNGEAL	Located at the important tumor suppressor locus, 3p22, PLCD1 encodes an enzyme that mediates regulatory signaling of energy metabolism, calcium homeostasis and intracellular movements. We identified PLCD1 as a downregulated gene in aerodigestive carcinomas through expression pro. ling and epigenetic characterization. We found that PLCD1 was expressed in all normal adult tissues but low or silenced in 84% (16/19) gastric cancer cell lines, well correlated with its CpG island (CGI) methylation status. Methylation was further detected in 62% (61/98) gastric primary tumors, but none of normal gastric mucosa tissues. PLCD1 methylation was significantly correlated with tumor high stage. Detailed methylation analysis of 37 CpG sites at the PLCD1 CGI by bisulfite genomic sequencing confirmed its methylation. PLCD1 silencing could be reversed by pharmacological demethylation with 5-aza-2'-deoxycytidine, indicating a direct epigenetic silencing. Ectopic expression of PLCD1 in silenced gastric tumor cells dramatically inhibited their clonogenicity and migration, possibly through downregulating MMP7 expression and hampering the reorganization of cytoskeleton through cofilin inactivation by phosphorylation. Thus, epigenetic inactivation of PLCD1 is common and tumor-specific in gastric cancer, and PLCD1 acts as a functional tumor suppressor involved in gastric carcinogenesis. Oncogene (2009) 28, 2466-2475; doi: 10.1038/onc.2009.92; published online 18 May 2009	[Hu, X-T; Zhang, F-B; Shi, Q-L; Tang, H-M; He, C.] Zhejiang Univ, Biomed Res Ctr, Sir Run Run Shaw Hosp, Hangzhou 310016, Zhejiang, Peoples R China; [Hu, X-T; Zhang, F-B; Shi, Q-L; Tang, H-M; He, C.] Key Lab Biotherapy Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China; [Fan, Y-C; Shu, X-S; Wong, A. H. Y.; Tao, Q.] Chinese Univ Hong Kong, Hong Kong Canc Inst, Canc Epigenet Lab,Dept Clin Oncol, State Key Lab Oncol S China,Sir YK Pao Ctr Canc, Hong Kong, Hong Kong, Peoples R China; [Fan, Y-C; Shu, X-S; Wong, A. H. Y.; Tao, Q.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Zhou, W.; He, C.] Zhejiang Univ, Dept Colorectal Surg, Sir Run Run Shaw Hosp, Hangzhou 310016, Zhejiang, Peoples R China; [Rha, S. Y.] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea	Zhejiang University; Chinese University of Hong Kong; Chinese University of Hong Kong; Zhejiang University; Yonsei University; Yonsei University Health System	He, C (corresponding author), Zhejiang Univ, Biomed Res Ctr, Sir Run Run Shaw Hosp, Hangzhou 310016, Zhejiang, Peoples R China.	qtao@clo.cuhk.edu.hk; drhe_srrsh@sina.com	Hu, Xiao-tong/K-5820-2019; Tao, Qian/T-4743-2018; Fu, Li/F-7182-2010; Guan, Xin-Yuan/A-3639-2009	Tao, Qian/0000-0001-5383-4808; Fu, Li/0000-0003-2643-6278; Rha, Sun Young/0000-0002-2512-4531; Guan, Xin-Yuan/0000-0002-4485-6017	Chinese University of Hong Kong; National Natural Science Foundation of China [30770920/C03030202]; Natural Science Foundation of Zhejiang Province [Y206090]	Chinese University of Hong Kong(Chinese University of Hong Kong); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province)	This study was supported by a grant from the Chinese University of Hong Kong, a grant from National Natural Science Foundation of China ( Grant no. 30770920/C03030202) and a grant from Natural Science Foundation of Zhejiang Province ( Grant no. Y206090).	Adachi Y, 1998, INT J ONCOL, V13, P1031; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Carvou N, 2007, CELL SIGNAL, V19, P42, DOI 10.1016/j.cellsig.2006.05.023; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fu L, 2007, CANCER RES, V67, P10720, DOI 10.1158/0008-5472.CAN-07-2411; FUCHS CS, 1995, NEW ENGL J MED, V333, P32, DOI 10.1056/NEJM199507063330107; Fukami K, 2002, J BIOCHEM, V131, P293, DOI 10.1093/oxfordjournals.jbchem.a003102; Hesson LB, 2007, ONCOGENE, V26, P7283, DOI 10.1038/sj.onc.1210547; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Honda M, 1996, GUT, V39, P444, DOI 10.1136/gut.39.3.444; Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555; Irino Y, 2004, BIOCHEM BIOPH RES CO, V320, P537, DOI 10.1016/j.bbrc.2004.05.206; Janetopoulos C, 2006, J CELL BIOL, V174, P485, DOI 10.1083/jcb.200603156; Kaminishi M, 2005, ONCOLOGY-BASEL, V69, P1, DOI 10.1159/000086624; Kawai K, 2004, BIOCHEM SOC T, V32, P1107, DOI 10.1042/BST0321107; Kitoh T, 2004, J GASTROENTEROL, V39, P434, DOI 10.1007/s00535-003-1316-3; Liu XP, 2002, JPN J CANCER RES, V93, P291, DOI 10.1111/j.1349-7006.2002.tb02171.x; Maehara Y, 2000, BRIT J SURG, V87, P353, DOI 10.1046/j.1365-2168.2000.01358.x; Mori M, 2002, SURGERY, V131, pS39, DOI 10.1067/msy.2002.119292; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Murray PG, 2004, ONCOGENE, V23, P1326, DOI 10.1038/sj.onc.1207313; Nagashima Y, 1997, INT J CANCER, V72, P441, DOI 10.1002/(SICI)1097-0215(19970729)72:3<441::AID-IJC11>3.0.CO;2-F; Nakahara M, 2005, J BIOL CHEM, V280, P29128, DOI 10.1074/jbc.M503817200; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Ochocka AM, 2003, ACTA BIOCHIM POL, V50, P1097; Panani AD, 2008, CANCER LETT, V266, P99, DOI 10.1016/j.canlet.2008.02.053; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Qiu GH, 2008, J HEPATOL, V48, P433, DOI 10.1016/j.jhep.2007.11.015; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sako A, 2004, CANCER RES, V64, P3624, DOI 10.1158/0008-5472.CAN-04-0304; Santarius M, 2006, BIOCHEM J, V398, P1, DOI 10.1042/BJ20060565; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Senota A, 1998, CLIN EXP METASTAS, V16, P313; Singer CF, 1999, EUR J BIOCHEM, V259, P40, DOI 10.1046/j.1432-1327.1999.00001.x; TAKAISHI K, 1994, ONCOGENE, V9, P273; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644; Yonemura Y, 2001, CLIN CANCER RES, V7, P1647; Yonemura Yutaka, 2000, Gastric Cancer, V3, P63, DOI 10.1007/PL00011698	43	57	60	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2466	2475		10.1038/onc.2009.92	http://dx.doi.org/10.1038/onc.2009.92			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19448674				2022-12-25	WOS:000267601400005
J	Hu, VW; Nguyen, A; Kim, KS; Steinberg, ME; Sarachana, T; Scully, MA; Soldin, SJ; Luu, T; Lee, NH				Hu, Valerie W.; Nguyen, AnhThu; Kim, Kyung Soon; Steinberg, Mara E.; Sarachana, Tewarit; Scully, Michele A.; Soldin, Steven J.; Luu, Truong; Lee, Norman H.			Gene Expression Profiling of Lymphoblasts from Autistic and Nonaffected Sib Pairs: Altered Pathways in Neuronal Development and Steroid Biosynthesis	PLOS ONE			English	Article							DOPAMINE-BETA-HYDROXYLASE; LEMLI-OPITZ-SYNDROME; CENTRAL-NERVOUS-SYSTEM; CHAIN FATTY-ACIDS; FACTOR-KAPPA-B; SPECTRUM DISORDERS; GASTROINTESTINAL SYMPTOMS; CELL-LINES; CYTOKINE PRODUCTION; FETAL TESTOSTERONE	Despite the identification of numerous autism susceptibility genes, the pathobiology of autism remains unknown. The present "case-control'' study takes a global approach to understanding the molecular basis of autism spectrum disorders based upon large-scale gene expression profiling. DNA microarray analyses were conducted on lymphoblastoid cell lines from over 20 sib pairs in which one sibling had a diagnosis of autism and the other was not affected in order to identify biochemical and signaling pathways which are differentially regulated in cells from autistic and nonautistic siblings. Bioinformatics and gene ontological analyses of the data implicate genes which are involved in nervous system development, inflammation, and cytoskeletal organization, in addition to genes which may be relevant to gastrointestinal or other physiological symptoms often associated with autism. Moreover, the data further suggests that these processes may be modulated by cholesterol/steroid metabolism, especially at the level of androgenic hormones. Elevation of male hormones, in turn, has been suggested as a possible factor influencing susceptibility to autism, which affects similar to 4 times as many males as females. Preliminary metabolic profiling of steroid hormones in lymphoblastoid cell lines from several pairs of siblings reveals higher levels of testosterone in the autistic sibling, which is consistent with the increased expression of two genes involved in the steroidogenesis pathway. Global gene expression profiling of cultured cells from ASD probands thus serves as a window to underlying metabolic and signaling deficits that may be relevant to the pathobiology of autism.			Hu, VW (corresponding author), George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA.	bcmvwh@gwumc.edu	Kim, Joanna/U-5556-2018	Kim, Joanna/0000-0001-7877-9446; Steinberg Lowe, Mara/0000-0002-3129-0755; Hu, Valerie/0000-0002-3357-0777	NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH073393] Funding Source: NIH RePORTER; NIMH NIH HHS [R21 MH073393-01A2, R21 MH073393-02, R21 MH073393] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANTON ES, 1995, J NEUROSCI, V15, P584; BAILEY A, 1995, PSYCHOL MED, V25, P63, DOI 10.1017/S0033291700028099; BANERJEE SA, 1995, MOL CELL NEUROSCI, V6, P462, DOI 10.1006/mcne.1995.1034; Baron CA, 2006, J AUTISM DEV DISORD, V36, P973, DOI 10.1007/s10803-006-0134-x; Baron-Cohen S, 2005, SCIENCE, V310, P819, DOI 10.1126/science.1115455; Bauman ML, 2005, INT J DEV NEUROSCI, V23, P183, DOI 10.1016/j.ijdevneu.2004.09.006; BOLTON P, 1994, J CHILD PSYCHOL PSYC, V35, P877, DOI 10.1111/j.1469-7610.1994.tb02300.x; Butler MG, 2005, J MED GENET, V42, P318, DOI 10.1136/jmg.2004.024646; Buxbaum JD, 2007, AM J MED GENET B, V144B, P484, DOI 10.1002/ajmg.b.30493; Campbell DB, 2007, ANN NEUROL, V62, P243, DOI 10.1002/ana.21180; Campbell DB, 2006, P NATL ACAD SCI USA, V103, P16834, DOI 10.1073/pnas.0605296103; Chauhan A, 2004, LIFE SCI, V75, P2539, DOI 10.1016/j.lfs.2004.04.038; Chauhan Abha, 2006, Pathophysiology, V13, P171, DOI 10.1016/j.pathophys.2006.05.007; Chuan Y, 2005, INT J ANDROL, V28, P291, DOI 10.1111/j.1365-2605.2005.00552.x; Cohly HHP, 2005, INT REV NEUROBIOL, V71, P317, DOI 10.1016/S0074-7742(05)71013-8; Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; Corbett BA, 2006, PSYCHONEUROENDOCRINO, V31, P59, DOI 10.1016/j.psyneuen.2005.05.011; Croonenberghs J, 2002, NEUROPSYCHOBIOLOGY, V45, P1, DOI 10.1159/000048665; Durand CM, 2007, NAT GENET, V39, P25, DOI 10.1038/ng1933; Ellis JA, 2001, CLIN EXP PHARMACOL P, V28, P1053, DOI 10.1046/j.1440-1681.2001.03579.x; Fatemi SH, 2001, J AUTISM DEV DISORD, V31, P529, DOI 10.1023/A:1013234708757; Feng JN, 2006, NEUROSCI LETT, V409, P10, DOI 10.1016/j.neulet.2006.08.017; Finegold SM, 2002, CLIN INFECT DIS, V35, pS6, DOI 10.1086/341914; FOLSTEIN S, 1977, J CHILD PSYCHOL PSYC, V18, P297, DOI 10.1111/j.1469-7610.1977.tb00443.x; Ford GD, 2008, BIOCHEM BIOPH RES CO, V377, P556, DOI 10.1016/j.bbrc.2008.10.033; Freeman SJ, 2005, DIABETES CARE, V28, P925, DOI 10.2337/diacare.28.4.925; GARNIER C, 1986, J AUTISM DEV DISORD, V16, P23, DOI 10.1007/BF01531575; Geier DA, 2007, NEUROENDOCRINOL LETT, V28, P565; Gregg JP, 2008, GENOMICS, V91, P22, DOI 10.1016/j.ygeno.2007.09.003; Guo TD, 2006, CLIN CHIM ACTA, V372, P76, DOI 10.1016/j.cca.2006.03.034; Gupta AR, 2007, BIOL PSYCHIAT, V61, P429, DOI 10.1016/j.biopsych.2006.06.020; Hallmayer J, 2002, AM J HUM GENET, V71, P941, DOI 10.1086/342990; Herbert MR, 2006, NEUROTOXICOLOGY, V27, P671, DOI 10.1016/j.neuro.2006.03.017; Hong SJ, 2008, NEUROCHEM RES, V33, P1821, DOI 10.1007/s11064-008-9639-3; Horvath K, 1999, J PEDIATR-US, V135, P559, DOI 10.1016/S0022-3476(99)70052-1; Horvath Karoly, 2002, Curr Gastroenterol Rep, V4, P251, DOI 10.1007/s11894-002-0071-6; Hu VW, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-118; Iafusco D, 2006, DIABETES CARE, V29, P1985, DOI 10.2337/dc06-0842; Ingram JL, 2000, TERATOLOGY, V62, P393, DOI 10.1002/1096-9926(200012)62:6<393::AID-TERA6>3.3.CO;2-M; Ingudomnuku E, 2007, HORM BEHAV, V51, P597, DOI 10.1016/j.yhbeh.2007.02.001; Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136; Jamain S, 2002, MOL PSYCHIATR, V7, P302, DOI 10.1038/sj.mp.4000979; James SJ, 2006, AM J MED GENET B, V141B, P947, DOI 10.1002/ajmg.b.30366; Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935; Jones MB, 2004, AM J MED GENET B, V126B, P58, DOI 10.1002/ajmg.b.20172; Jyonouchi H, 2005, NEUROPSYCHOBIOLOGY, V51, P77, DOI 10.1159/000084164; Jyonouchi H, 2001, J NEUROIMMUNOL, V120, P170, DOI 10.1016/S0165-5728(01)00421-0; Kagawa T, 1997, J NEUROSCI RES, V50, P312, DOI 10.1002/(SICI)1097-4547(19971015)50:2<312::AID-JNR19>3.0.CO;2-9; KALIMI M, 1994, MOL CELL BIOCHEM, V131, P99, DOI 10.1007/BF00925945; Kelley R I, 2000, Adv Pediatr, V47, P1; Kimonides VG, 1999, NEUROSCIENCE, V89, P429, DOI 10.1016/S0306-4522(98)00347-9; Knickmeyer R, 2005, J CHILD PSYCHOL PSYC, V46, P198, DOI 10.1111/j.1469-7610.2004.00349.x; Knickmeyer R, 2006, HORM BEHAV, V50, P148, DOI 10.1016/j.yhbeh.2006.02.006; Knickmeyer RC, 2006, J CHILD NEUROL, V21, P825, DOI 10.1177/08830738060210101601; Kwon CH, 2006, NEURON, V50, P377, DOI 10.1016/j.neuron.2006.03.023; Lathe R., 2006, AUTISM BRAIN ENV; Lee Norman H, 2007, Methods Mol Biol, V353, P265; Levy SE, 2007, BIOL PSYCHIAT, V61, P492, DOI 10.1016/j.biopsych.2006.07.013; Ma DQ, 2005, AM J HUM GENET, V77, P377, DOI 10.1086/433195; MacFabe D., 2008, AM J BIOCH BIOTECHNO, V4, P146, DOI 10.3844/ajbbsp.2008.146.166; MacFabe DF, 2007, BEHAV BRAIN RES, V176, P149, DOI 10.1016/j.bbr.2006.07.025; MacLusky NJ, 2006, NEUROSCIENCE, V138, P957, DOI 10.1016/j.neuroscience.2005.12.054; Matigian NA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002412; Middleton FA, 2005, AM J MED GENET B, V136B, P12, DOI 10.1002/ajmg.b.30171; Motoyama M, 2005, J BIOL CHEM, V280, P7444, DOI 10.1074/jbc.M412738200; Muta T, 2006, VITAM HORM, V74, P301, DOI 10.1016/S0083-6729(06)74012-2; Nardelli J, 1999, DEV BIOL, V210, P305, DOI 10.1006/dbio.1999.9278; Nishimura Y, 2007, HUM MOL GENET, V16, P1682, DOI 10.1093/hmg/ddm116; Noebels JL, 2002, NOVART FDN SYMP, V241, P109; Palmen SJMC, 2004, BRAIN, V127, P2572, DOI 10.1093/brain/awh287; Pardo CA, 2006, INT REV PSYCHIATR, V17, P485, DOI 10.1080/02646830500381930; Pickett J, 2005, J NEUROPATH EXP NEUR, V64, P925, DOI 10.1097/01.jnen.0000186921.42592.6c; Polleux F, 2004, MENT RETARD DEV D R, V10, P303, DOI 10.1002/mrdd.20044; Purcell AE, 2001, NEUROLOGY, V57, P1618, DOI 10.1212/WNL.57.9.1618; Robinson PD, 2001, AM J MED GENET, V100, P30, DOI 10.1002/ajmg.1187; Saemundsen E, 2007, EPILEPSIA, V48, P1724, DOI 10.1111/j.1528-1167.2007.01150.x; Santangelo SL, 2005, AM J PHARMACOGENOMIC, V5, P71, DOI 10.2165/00129785-200505020-00001; Sebat J, 2007, SCIENCE, V316, P445, DOI 10.1126/science.1138659; Shultz SR, 2008, NEUROPHARMACOLOGY, V54, P901, DOI 10.1016/j.neuropharm.2008.01.013; Sikora DM, 2006, AM J MED GENET A, V140A, P1511, DOI 10.1002/ajmg.a.31294; Simon R, 2003, BRIT J CANCER, V89, P1599, DOI 10.1038/sj.bjc.6601326; SPENCE SJ, 2009, PEDIAT RES IN PRESS; Strous RD, 2005, EUR NEUROPSYCHOPHARM, V15, P305, DOI 10.1016/j.euroneuro.2004.12.004; Stumm R, 2007, J MOL ENDOCRINOL, V38, P377, DOI 10.1677/JME-06-0032; Sullivan PF, 2006, AM J MED GENET B, V141B, P261, DOI 10.1002/ajmg.b.30272; Szatmari P, 2007, NAT GENET, V39, P319, DOI 10.1038/ng1985; Talebizadeh Z, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.036897; Tierney E, 2000, MENT RETARD DEV D R, V6, P131, DOI 10.1002/1098-2779(2000)6:2<131::AID-MRDD7>3.0.CO;2-R; Tierney E, 2006, AM J MED GENET B, V141B, P666, DOI 10.1002/ajmg.b.30368; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Valicenti-McDermott M, 2006, J DEV BEHAV PEDIATR, V27, pS128, DOI 10.1097/00004703-200604002-00011; Varga EA, 2009, GENET MED, V11, P111, DOI 10.1097/GIM.0b013e31818fd762; Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315; VOLKMAR FR, 1994, AM J PSYCHIAT, V151, P1361; Waage-Baudet H, 2005, DEV NEUROSCI-BASEL, V27, P378, DOI 10.1159/000088453; Walker SJ, 2006, NEUROTOXICOLOGY, V27, P685, DOI 10.1016/j.neuro.2006.06.003; Wassink TH, 2001, AM J MED GENET, V105, P406, DOI 10.1002/ajmg.1401; Yonan AL, 2003, GENES BRAIN BEHAV, V2, P303, DOI 10.1034/j.1601-183X.2003.00041.x; Zamani MR, 2000, J NEUROPHYSIOL, V84, P1800, DOI 10.1152/jn.2000.84.4.1800; Zecavati N, 2009, CURR NEUROL NEUROSCI, V9, P129, DOI 10.1007/s11910-009-0021-x; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhu JF, 2006, CELL RES, V16, P3, DOI 10.1038/sj.cr.7310002; 2003, GENOME BIOL, V4, pP3	103	116	119	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2009	4	6							e5775	10.1371/journal.pone.0005775	http://dx.doi.org/10.1371/journal.pone.0005775			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453PV	19492049	Green Published, gold, Green Submitted			2022-12-25	WOS:000266624300012
J	Cadotte, MW; Cavender-Bares, J; Tilman, D; Oakley, TH				Cadotte, Marc W.; Cavender-Bares, Jeannine; Tilman, David; Oakley, Todd H.			Using Phylogenetic, Functional and Trait Diversity to Understand Patterns of Plant Community Productivity	PLOS ONE			English	Article								Background: Two decades of research showing that increasing plant diversity results in greater community productivity has been predicated on greater functional diversity allowing access to more of the total available resources. Thus, understanding phenotypic attributes that allow species to partition resources is fundamentally important to explaining diversity-productivity relationships. Methodology/Principal Findings: Here we use data from a long-term experiment ( Cedar Creek, MN) and compare the extent to which productivity is explained by seven types of community metrics of functional variation: 1) species richness, 2) variation in 10 individual traits, 3) functional group richness, 4) a distance-based measure of functional diversity, 5) a hierarchical multivariate clustering method, 6) a nonmetric multidimensional scaling approach, and 7) a phylogenetic diversity measure, summing phylogenetic branch lengths connecting community members together and may be a surrogate for ecological differences. Although most of these diversity measures provided significant explanations of variation in productivity, the presence of a nitrogen fixer and phylogenetic diversity were the two best explanatory variables. Further, a statistical model that included the presence of a nitrogen fixer, seed weight and phylogenetic diversity was a better explanation of community productivity than other models. Conclusions: Evolutionary relationships among species appear to explain patterns of grassland productivity. Further, these results reveal that functional differences among species involve a complex suite of traits and that perhaps phylogenetic relationships provide a better measure of the diversity among species that contributes to productivity than individual or small groups of traits.			Cadotte, MW (corresponding author), Univ Calif Santa Barbara, Natl Ctr Ecol Anal & Synth, Santa Barbara, CA 93106 USA.	cadotte@nceas.ucsb.edu	Cavender-Bares, Jeannine/K-5716-2013; Oakley, Todd/A-5419-2008; Tilman, David/ABD-5309-2021; Cadotte, Marc/AAG-8147-2020	Oakley, Todd/0000-0002-4478-915X; Cadotte, Marc/0000-0002-5816-7693; Cavender-Bares, Jeannine/0000-0003-3375-9630				Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453; Benson DA, 2005, NUCLEIC ACIDS RES, V33, pD34, DOI 10.1093/nar/gki063; Butler MA, 2004, AM NAT, V164, P683, DOI 10.1086/426002; Cadotte MW, 2008, P NATL ACAD SCI USA, V105, P17012, DOI 10.1073/pnas.0805962105; Cadotte MW, 2009, DIVERS DISTRIB, V15, P481, DOI 10.1111/j.1472-4642.2009.00560.x; Cardinale BJ, 2007, P NATL ACAD SCI USA, V104, P18123, DOI 10.1073/pnas.0709069104; Cardinale BJ, 2006, NATURE, V443, P989, DOI 10.1038/nature05202; Cavender-Bares J, 2003, ECOLOGY, V84, P592, DOI 10.1890/0012-9658(2003)084[0592:IMAMPI]2.0.CO;2; Cavender-Bares J, 2006, ECOLOGY, V87, pS109, DOI 10.1890/0012-9658(2006)87[109:PSOFPC]2.0.CO;2; CAVENDERBARES J, 2009, ECOLOGY LET IN PRESS; Darwin C., 1859, ORIGIN SPECIES MEANS; Davies TJ, 2008, P NATL ACAD SCI USA, V105, P11556, DOI 10.1073/pnas.0801917105; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Edwards EJ, 2007, TRENDS ECOL EVOL, V22, P243, DOI 10.1016/j.tree.2007.02.002; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; Flombaum P, 2008, P NATL ACAD SCI USA, V105, P6087, DOI 10.1073/pnas.0704801105; Fornara DA, 2008, J ECOL, V96, P314, DOI 10.1111/j.1365-2745.2007.01345.x; GIVNISH TJ, 1976, AM NAT, V110, P743, DOI 10.1086/283101; GRIME JP, 1974, NATURE, V250, P26, DOI 10.1038/250026a0; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Haddad NM, 2002, ECOL LETT, V5, P110, DOI 10.1046/j.1461-0248.2002.00293.x; Hansen TF, 1996, EVOLUTION, V50, P1404, DOI 10.1111/j.1558-5646.1996.tb03914.x; Hansen TF, 1997, EVOLUTION, V51, P1341, DOI 10.1111/j.1558-5646.1997.tb01457.x; Harpole WS, 2007, NATURE, V446, P791, DOI 10.1038/nature05684; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Hector A, 1999, SCIENCE, V286, P1123, DOI 10.1126/science.286.5442.1123; Heemsbergen DA, 2004, SCIENCE, V306, P1019, DOI 10.1126/science.1101865; Johnson JB, 2004, TRENDS ECOL EVOL, V19, P101, DOI 10.1016/j.tree.2003.10.013; Kent M., 2012, VEGETATION DESCRIPTI, V2nd; Knops JMH, 1999, ECOL LETT, V2, P286, DOI 10.1046/j.1461-0248.1999.00083.x; Lanta V, 2006, ACTA OECOL, V29, P85, DOI 10.1016/j.actao.2005.08.003; Legendre P., 1998, NUMERICAL ECOLOGY, V24; Maherali H, 2007, SCIENCE, V316, P1746, DOI 10.1126/science.1143082; Mokany K, 2008, J ECOL, V96, P884, DOI 10.1111/j.1365-2745.2008.01395.x; NAEEM S, 1994, NATURE, V368, P734, DOI 10.1038/368734a0; Oakley TH, 2005, MOL BIOL EVOL, V22, P40, DOI 10.1093/molbev/msh257; Petchey OL, 2004, ECOLOGY, V85, P847, DOI 10.1890/03-0226; Petchey OL, 2002, ECOL LETT, V5, P402, DOI 10.1046/j.1461-0248.2002.00339.x; Posada D, 2001, SYST BIOL, V50, P580, DOI 10.1080/106351501750435121; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Prinzing A, 2008, ECOL LETT, V11, P809, DOI 10.1111/j.1461-0248.2008.01189.x; Rasband W., 2006, IMAGEJ; Reich PB, 2004, P NATL ACAD SCI USA, V101, P10101, DOI 10.1073/pnas.0306602101; Sack L, 2003, PLANT CELL ENVIRON, V26, P1343, DOI 10.1046/j.0016-8025.2003.01058.x; Suding KN, 2006, OECOLOGIA, V149, P141, DOI 10.1007/s00442-006-0421-4; Tilman D, 1997, SCIENCE, V277, P1300, DOI 10.1126/science.277.5330.1300; Tilman D, 1999, ECOLOGY, V80, P1455, DOI 10.1890/0012-9658(1999)080[1455:TECOCI]2.0.CO;2; Tilman D, 1996, NATURE, V379, P718, DOI 10.1038/379718a0; Tilman D, 2001, SCIENCE, V294, P843, DOI 10.1126/science.1060391; Tilman D, 2006, NATURE, V441, P629, DOI 10.1038/nature04742; Walker B, 1999, ECOSYSTEMS, V2, P95, DOI 10.1007/s100219900062; Webb CO, 2002, ANNU REV ECOL SYST, V33, P475, DOI 10.1146/annurev.ecolsys.33.010802.150448; Westoby M, 1998, PLANT SOIL, V199, P213, DOI 10.1023/A:1004327224729; Wiens JJ, 2005, ANNU REV ECOL EVOL S, V36, P519, DOI 10.1146/annurev.ecolsys.36.102803.095431; Wohl DL, 2004, ECOLOGY, V85, P1534, DOI 10.1890/03-3050; Wright IJ, 2004, NATURE, V428, P821, DOI 10.1038/nature02403; Wright JP, 2006, ECOL LETT, V9, P111, DOI 10.1111/j.1461-0248.2005.00850.x	57	461	488	11	346	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2009	4	5							e5695	10.1371/journal.pone.0005695	http://dx.doi.org/10.1371/journal.pone.0005695			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QD	19479086	Green Submitted, Green Published, gold			2022-12-25	WOS:000266415000008
J	Knieke, K; Hoff, H; Maszyna, F; Kolar, P; Schrage, A; Hamann, A; Debes, GF; Brunner-Weinzierl, MC				Knieke, Karin; Hoff, Holger; Maszyna, Frank; Kolar, Paula; Schrage, Arnhild; Hamann, Alf; Debes, Gudrun F.; Brunner-Weinzierl, Monika C.			CD152 (CTLA-4) Determines CD4 T Cell Migration In Vitro and In Vivo	PLOS ONE			English	Article							HIGH ENDOTHELIAL VENULES; LYMPHOCYTE ANTIGEN-4; UP-REGULATION; PERIPHERAL-TISSUES; SIGNAL STRENGTH; DENDRITIC CELLS; CHEMOKINES; ACTIVATION; RESPONSES; LOCALIZATION	Background: Migration of antigen-experienced T cells to secondary lymphoid organs and the site of antigenic-challenge is a mandatory prerequisite for the precise functioning of adaptive immune responses. The surface molecule CD152 (CTLA-4) is mostly considered as a negative regulator of T cell activation during immune responses. It is currently unknown whether CD152 can also influence chemokine-driven T cell migration. Methodology/Principal Findings: We analyzed the consequences of CD152 signaling on Th cell migration using chemotaxis assays in vitro and radioactive cell tracking in vivo. We show here that the genetic and serological inactivation of CD152 in Th1 cells reduced migration towards CCL4, CXCL12 and CCL19, but not CXCL9, in a G-protein dependent manner. In addition, retroviral transduction of CD152 cDNA into CD152 negative cells restored Th1 cell migration. Crosslinking of CD152 together with CD3 and CD28 stimulation on activated Th1 cells increased expression of the chemokine receptors CCR5 and CCR7, which in turn enhanced cell migration. Using sensitive liposome technology, we show that mature dendritic cells but not activated B cells were potent at inducing surface CD152 expression and the CD152-mediated migration-enhancing signals. Importantly, migration of CD152 positive Th1 lymphocytes in in vivo experiments increased more than 200% as compared to CD152 negative counterparts showing that indeed CD152 orchestrates specific migration of selected Th1 cells to sites of inflammation and antigenic challenge in vivo. Conclusions/Significance: We show here, that CD152 signaling does not just silence cells, but selects individual ones for migration. This novel activity of CD152 adds to the already significant role of CD152 in controlling peripheral immune responses by allowing T cells to localize correctly during infection. It also suggests that interference with CD152 signaling provides a tool for altering the cellular composition at sites of inflammation and antigenic challenge.			Knieke, K (corresponding author), Otto Von Guericke Univ, Univ Kinderklin, Magdeburg, Germany.	monika.brunner-weinzierl@med.ovgu.de	Brunner-Weinzierl, Monika/AAB-8813-2019	Brunner-Weinzierl, Monika/0000-0002-6838-3568; Debes, Gudrun/0000-0003-4208-7362				Bleul CC, 1998, J EXP MED, V187, P753, DOI 10.1084/jem.187.5.753; Bromley SK, 2005, NAT IMMUNOL, V6, P895, DOI 10.1038/ni1240; Brunner M, 1995, EUR J IMMUNOL, V25, P3285, DOI 10.1002/eji.1830251213; Brunner MC, 1999, J IMMUNOL, V162, P5813; Brunner-Weinzierl MC, 2004, ARTHRITIS RES THER, V6, P45, DOI 10.1186/ar1158; Campbell DJ, 2003, IMMUNOL REV, V195, P58, DOI 10.1034/j.1600-065X.2003.00067.x; Casares Sofia, 2001, Current Molecular Medicine (Hilversum), V1, P357; Chambers CA, 1998, EUR J IMMUNOL, V28, P3137, DOI 10.1002/(SICI)1521-4141(199810)28:10<3137::AID-IMMU3137>3.0.CO;2-X; Chambers CA, 1996, IMMUNOL REV, V153, P27, DOI 10.1111/j.1600-065X.1996.tb00919.x; Debes GF, 2002, J IMMUNOL, V168, P5441, DOI 10.4049/jimmunol.168.11.5441; Debes GF, 2005, NAT IMMUNOL, V6, P889, DOI 10.1038/ni1238; Doyle AM, 2001, J EXP MED, V194, P893, DOI 10.1084/jem.194.7.893; Dudda JC, 2005, EUR J IMMUNOL, V35, P1056, DOI 10.1002/eji.200425817; Egen JG, 2002, NAT IMMUNOL, V3, P611, DOI 10.1038/ni0702-611; Egen JG, 2002, IMMUNITY, V16, P23, DOI 10.1016/S1074-7613(01)00259-X; Fedyk ER, 1999, J LEUKOCYTE BIOL, V66, P667, DOI 10.1002/jlb.66.4.667; Foxman EF, 1999, J CELL BIOL, V147, P577, DOI 10.1083/jcb.147.3.577; Gett AV, 2003, NAT IMMUNOL, V4, P355, DOI 10.1038/ni908; Gimsa U, 2004, J MOL MED-JMM, V82, P364, DOI 10.1007/s00109-004-0531-6; Hamann A, 2005, LEUKOCYTE TRAFFICKING: MOLECULAR MECHANISMS, THERAPEUTIC TARGETS, AND METHODS, P1, DOI 10.1002/352760779X; Hjelmstrom P, 2000, AM J PATHOL, V156, P1133, DOI 10.1016/S0002-9440(10)64981-4; HOFF H, 2009, JI; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Kolar P, 2009, ARTHRITIS RHEUM-US, V60, P123, DOI 10.1002/art.24181; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Linsley PS, 1996, IMMUNITY, V4, P535, DOI 10.1016/S1074-7613(00)80480-X; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; Maszyna F, 2003, J IMMUNOL, V171, P3459, DOI 10.4049/jimmunol.171.7.3459; Mora JR, 2005, J EXP MED, V201, P303, DOI 10.1084/jem.20041645; Murdoch C, 2000, IMMUNOL REV, V177, P175, DOI 10.1034/j.1600-065X.2000.17715.x; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Mustelin T, 2006, SCIENCE, V313, P1902, DOI 10.1126/science.1133578; Okada T, 2002, J EXP MED, V196, P65, DOI 10.1084/jem.20020201; OLSSON T, 1995, IMMUNOL REV, V144, P245, DOI 10.1111/j.1600-065X.1995.tb00072.x; Pandiyan P, 2004, J EXP MED, V199, P831, DOI 10.1084/jem.20031058; POWRIE F, 1993, IMMUNOL TODAY, V14, P270, DOI 10.1016/0167-5699(93)90044-L; Reape TJ, 1999, AM J PATHOL, V154, P365, DOI 10.1016/S0002-9440(10)65283-2; SCHEFFOLD A, 1995, IMMUNOTECHNOLOGY, V1, P127, DOI 10.1016/1380-2933(95)00014-3; Scheffold A, 2000, NAT MED, V6, P107, DOI 10.1038/71441; Schenkel AR, 2004, NAT IMMUNOL, V5, P393, DOI 10.1038/ni1051; Schneider H, 2005, P NATL ACAD SCI USA, V102, P12861, DOI 10.1073/pnas.0505802102; Schneider H, 2002, J IMMUNOL, V169, P3475, DOI 10.4049/jimmunol.169.7.3475; Schneider H, 2006, SCIENCE, V313, P1972, DOI 10.1126/science.1131078; Shen HM, 2001, J IMMUNOL, V166, P5027, DOI 10.4049/jimmunol.166.8.5027; SIMON AK, 1994, P NATL ACAD SCI USA, V91, P8562, DOI 10.1073/pnas.91.18.8562; Stein JV, 2000, J EXP MED, V191, P61, DOI 10.1084/jem.191.1.61; Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942; Thelen M, 2008, NAT IMMUNOL, V9, P953, DOI 10.1038/ni.f.207; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Warnock RA, 2000, J EXP MED, V191, P77, DOI 10.1084/jem.191.1.77; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Weninger W, 2003, J IMMUNOL, V170, P4638, DOI 10.4049/jimmunol.170.9.4638	55	23	24	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2009	4	5							e5702	10.1371/journal.pone.0005702	http://dx.doi.org/10.1371/journal.pone.0005702			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QD	19479036	Green Published, gold, Green Submitted			2022-12-25	WOS:000266415000014
J	Miller, AW; Reynolds, AC; Sobrino, C; Riedel, GF				Miller, A. Whitman; Reynolds, Amanda C.; Sobrino, Cristina; Riedel, Gerhardt F.			Shellfish Face Uncertain Future in High CO2 World: Influence of Acidification on Oyster Larvae Calcification and Growth in Estuaries	PLOS ONE			English	Article							CARBON-DIOXIDE; OCEAN ACIDIFICATION; CALCIUM-CARBONATE; ALKALINITY; SEAWATER; IMPACT; RIVERS; WATER	Background: Human activities have increased atmospheric concentrations of carbon dioxide by 36% during the past 200 years. One third of all anthropogenic CO2 has been absorbed by the oceans, reducing pH by about 0.1 of a unit and significantly altering their carbonate chemistry. There is widespread concern that these changes are altering marine habitats severely, but little or no attention has been given to the biota of estuarine and coastal settings, ecosystems that are less pH buffered because of naturally reduced alkalinity. Methodology/Principal Findings: To address CO2-induced changes to estuarine calcification, veliger larvae of two oyster species, the Eastern oyster (Crassostrea virginica), and the Suminoe oyster (Crassostrea ariakensis) were grown in estuarine water under four pCO(2) regimes, 280, 380, 560 and 800 mu atm, to simulate atmospheric conditions in the pre-industrial era, present, and projected future concentrations in 50 and 100 years respectively. CO2 manipulations were made using an automated negative feedback control system that allowed continuous and precise control over the pCO(2) in experimental aquaria. Larval growth was measured using image analysis, and calcification was measured by chemical analysis of calcium in their shells. C. virginica experienced a 16% decrease in shell area and a 42% reduction in calcium content when pre-industrial and end of 21(st) century pCO(2) treatments were compared. C. ariakensis showed no change to either growth or calcification. Both species demonstrated net calcification and growth, even when aragonite was undersaturated, a result that runs counter to previous expectations for invertebrate larvae that produce aragonite shells. Conclusions and Significance: Our results suggest that temperate estuarine and coastal ecosystems are vulnerable to the expected changes in water chemistry due to elevated atmospheric CO2 and that biological responses to acidification, especially calcifying biota, will be species-specific and therefore much more variable and complex than reported previously.			Miller, AW (corresponding author), Smithsonian Environm Res Ctr, POB 28, Edgewater, MD 21037 USA.	millerw@si.edu	Sobrino, Cristina/J-3534-2012; Miller, Whitman/C-7811-2017	Sobrino, Cristina/0000-0003-0431-1220; Miller, Whitman/0000-0003-0484-182X				[Anonymous], [No title captured]; [Anonymous], 2007, CO2SYS XLS CALCULATO; Bijma J, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2002GC000388; BREESE WP, 1977, AQUACULTURE, V12, P123, DOI 10.1016/0044-8486(77)90178-8; Breitburg Denise L., 2005, P167; Burke K, 2008, J SHELLFISH RES, V27, P701, DOI 10.2983/0730-8000(2008)27[701:LQOANB]2.0.CO;2; Cai WJ, 1998, LIMNOL OCEANOGR, V43, P657, DOI 10.4319/lo.1998.43.4.0657; Cai WJ, 1999, LIMNOL OCEANOGR, V44, P639, DOI 10.4319/lo.1999.44.3.0639; Caldeira K, 2005, J GEOPHYS RES-OCEANS, V110, DOI 10.1029/2004JC002671; Caldeira K, 2003, NATURE, V425, P365, DOI 10.1038/425365a; Canadell JG, 2007, P NATL ACAD SCI USA, V104, P18866, DOI 10.1073/pnas.0702737104; Carpenter KE, 2008, SCIENCE, V321, P560, DOI 10.1126/science.1159196; CARRIKER MR, 1979, P NATL SHELLFISH ASS, V69, P102; *CHES BAY PROGR, CHES BAY PROGR WAT Q; Doney SC, 2009, ANNU REV MAR SCI, V1, P169, DOI 10.1146/annurev.marine.010908.163834; EDMOND JM, 1970, DEEP-SEA RES, V17, P737, DOI 10.1016/0011-7471(70)90038-0; Fabry VJ, 2008, SCIENCE, V320, P1020, DOI 10.1126/science.1157130; Fabry VJ, 2008, ICES J MAR SCI, V65, P414, DOI 10.1093/icesjms/fsn048; Feely RA, 2004, SCIENCE, V305, P362, DOI 10.1126/science.1097329; Feely RA, 2008, SCIENCE, V320, P1490, DOI 10.1126/science.1155676; Frankignoulle M, 1998, SCIENCE, V282, P434, DOI 10.1126/science.282.5388.434; Gattuso JP, 1998, GLOBAL PLANET CHANGE, V18, P37, DOI 10.1016/S0921-8181(98)00035-6; Gazeau F, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028554; Green MA, 2004, LIMNOL OCEANOGR, V49, P727, DOI 10.4319/lo.2004.49.3.0727; HALLSPENCER JM, 2008, NATURE ONLINE, DOI DOI 10.1038/NATURE07051; Iglesias-Rodriguez MD, 2008, SCIENCE, V320, P336, DOI 10.1126/science.1154122; John E., 2007, CRC HDB CHEM PHYS; Kennedy Victor S., 1996, P371; Kirby MX, 2004, P NATL ACAD SCI USA, V101, P13096, DOI 10.1073/pnas.0405150101; Kleypas JA, 2006, WORKSH HELD 18 20 AP; Kurihara H, 2007, AQUAT BIOL, V1, P91, DOI 10.3354/ab00009; Leggett J., 1992, CLIMATE CHANGE 1992, P69; MORGAN SG, 1996, ECOLOGY MARINE INVER, P279; Orr JC, 2005, NATURE, V437, P681, DOI 10.1038/nature04095; *OSB, 2004, NONN OYST CHES BAY; Pechenik JA, 2006, INTEGR COMP BIOL, V46, P323, DOI 10.1093/icb/icj028; Pechenik JA, 1999, MAR ECOL PROG SER, V177, P269, DOI 10.3354/meps177269; Sabine CL, 2004, SCIENCE, V305, P367, DOI 10.1126/science.1097403; Salisbury J., 2008, EOS T AM GEOPHYS UN, V89, P513, DOI [10.1029/2008EO500001, DOI 10.1029/2008EO500001]; *SCION CORP, SCION IM WIND REL AL; Smith SV, 1997, ECOL MONOGR, V67, P509, DOI 10.1890/0012-9615(1997)067[0509:ACAIVO]2.0.CO;2; The Royal Society, 2005, 1205 ROYAL SOC; Turley C., 2006, AVOIDING DANGEROUS C, V8, P65; UNDERWOOD AJ, 1989, TRENDS ECOL EVOL, V4, P16, DOI 10.1016/0169-5347(89)90008-6; Weiner S, 2003, REV MINERAL GEOCHEM, V54, P1, DOI 10.2113/0540001; Weiss IM, 2002, J EXP ZOOL, V293, P478, DOI 10.1002/jez.90004; WONG GTF, 1979, LIMNOL OCEANOGR, V24, P970, DOI 10.4319/lo.1979.24.5.0970	47	257	268	2	155	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2009	4	5							e5661	10.1371/journal.pone.0005661	http://dx.doi.org/10.1371/journal.pone.0005661			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QD	19478855	gold, Green Submitted, Green Published			2022-12-25	WOS:000266415000003
J	Fu, Y; Tian, W; Pratt, EB; Dirling, LB; Shyng, SL; Meshul, CK; Cohen, DM				Fu, Yi; Tian, Wei; Pratt, Emily B.; Dirling, Lisa B.; Shyng, Show-Ling; Meshul, Charles K.; Cohen, David M.			Down-Regulation of ZnT8 Expression in INS-1 Rat Pancreatic Beta Cells Reduces Insulin Content and Glucose-Inducible Insulin Secretion	PLOS ONE			English	Article							GENOME-WIDE ASSOCIATION; ZINC-TRANSPORTER; GENE-EXPRESSION; RISK LOCI; FLUORESCENT-PROBE; ALLELIC VARIATION; TYPE-2; POLYMORPHISMS; CDKAL1; COMMON	The SLC30A8 gene codes for a pancreatic beta-cell-expressed zinc transporter, ZnT8. A polymorphism in the SLC30A8 gene is associated with susceptibility to type 2 diabetes, although the molecular mechanism through which this phenotype is manifest is incompletely understood. Such polymorphisms may exert their effect via impacting expression level of the gene product. We used an shRNA-mediated approach to reproducibly downregulate ZnT8 mRNA expression by >90% in the INS-1 pancreatic beta cell line. The ZnT8-downregulated cells exhibited diminished uptake of exogenous zinc, as determined using the zinc-sensitive reporter dye, zinquin. ZnT8-downregulated cells showed reduced insulin content and decreased insulin secretion (expressed as percent of total insulin content) in response to hyperglycemic stimulus, as determined by insulin immunoassay. ZnT8-depleted cells also showed fewer dense-core vesicles via electron microscopy. These data indicate that reduced ZnT8 expression in cultured pancreatic beta cells gives rise to a reduced insulin response to hyperglycemia. In addition, although we provide no direct evidence, these data suggest that an SLC30A8 expression-level polymorphism could affect insulin secretion and the glycemic response in vivo.			Fu, Y (corresponding author), Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97201 USA.	cohend@ohsu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057699] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK057699, R01 DK057699-09] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Buckland PR, 2006, BBA-MOL BASIS DIS, V1762, P17, DOI 10.1016/j.bbadis.2005.10.004; Buckland PR, 2004, HUM MOL GENET, V13, pR255, DOI 10.1093/hmg/ddh227; Cauchi S, 2008, J MOL MED, V86, P341, DOI 10.1007/s00109-007-0295-x; Chausmer AB, 1998, J AM COLL NUTR, V17, P109, DOI 10.1080/07315724.1998.10718735; Chimienti F, 2004, DIABETES, V53, P2330, DOI 10.2337/diabetes.53.9.2330; Chimienti F, 2006, J CELL SCI, V119, P4199, DOI 10.1242/jcs.03164; Cousins RJ, 2006, J BIOL CHEM, V281, P24085, DOI 10.1074/jbc.R600011200; COYLE P, 1994, BIOCHEM J, V303, P781, DOI 10.1042/bj3030781; Frisk P, 2007, PANCREAS, V35, pE37, DOI 10.1097/mpa.0b013e3180986e84; Furukawa Y, 2008, J CLIN ENDOCR METAB, V93, P310, DOI 10.1210/jc.2007-1029; Horikoshi M, 2007, DIABETOLOGIA, V50, P2461, DOI 10.1007/s00125-007-0827-5; Hudson TJ, 2003, NAT GENET, V33, P439, DOI 10.1038/ng0403-439; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kirchhoff K, 2008, DIABETOLOGIA, V51, P597, DOI 10.1007/s00125-008-0926-y; Liu GH, 2004, MOL PHARMACOL, V65, P1269, DOI 10.1124/mol.65.5.1269; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603; MacDonald PE, 2007, PHYSIOLOGY, V22, P113, DOI 10.1152/physiol.00047.2006; Min L, 2007, J BIOL CHEM, V282, P33530, DOI 10.1074/jbc.M703402200; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Omori S., 2008, Diabetes (New York), V57, P791, DOI 10.2337/db07-0979; PALMER ND, 2008, DIABETES; Pascoe L, 2007, DIABETES, V56, P3101, DOI 10.2337/db07-0634; RAYNER MH, 1995, BIOMETALS, V8, P188; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Scott WJ, 2007, RES J BIOTECHNOL, V2, P5; Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616; Smidt K, 2007, MOL CELL ENDOCRINOL, V264, P68, DOI 10.1016/j.mce.2006.10.010; Sondergaard LG, 2005, HORM METAB RES, V37, P133, DOI 10.1055/s-2005-861290; Spielman RS, 2007, NAT GENET, V39, P226, DOI 10.1038/ng1955; Staiger H, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000832; Steinthorsdottir V, 2007, NAT GENET, V39, P770, DOI 10.1038/ng2043; Wenzlau JM, 2007, P NATL ACAD SCI USA, V104, P17040, DOI 10.1073/pnas.0705894104; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545; ZALEWSKI PD, 1993, BIOCHEM J, V296, P403, DOI 10.1042/bj2960403; Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364; NATURE, V447, P661	40	57	62	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2009	4	5							e5679	10.1371/journal.pone.0005679	http://dx.doi.org/10.1371/journal.pone.0005679			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LI	19479076	Green Submitted, gold, Green Published			2022-12-25	WOS:000266331700007
J	Peng, H; Dong, ZZ; Qi, J; Yang, YY; Liu, Y; Li, ZM; Xu, JK; Zhang, JT				Peng, Hui; Dong, Zizheng; Qi, Jing; Yang, Youyun; Liu, Yang; Li, Zhaomin; Xu, Junkang; Zhang, Jian-Ting			A Novel Two Mode-Acting Inhibitor of ABCG2-Mediated Multidrug Transport and Resistance in Cancer Chemotherapy	PLOS ONE			English	Article								Background: Multidrug resistance (MDR) is a major problem in successful treatment of cancers. Human ABCG2, a member of the ATP-binding cassette transporter superfamily, plays a key role in MDR and an important role in protecting cancer stem cells. Knockout of ABCG2 had no apparent adverse effect on the mice. Thus, ABCG2 is an ideal target for development of chemo-sensitizing agents for better treatment of drug resistant cancers and helping eradicate cancer stem cells. Methods/Preliminary Findings: Using rational screening of representatives from a chemical compound library, we found a novel inhibitor of ABCG2, PZ-39 (N-(4-chlorophenyl)-2-[(6-{[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]amino}-1,3-benzothiazol-2-yl) sulfanyl]acetamide), that has two modes of actions by inhibiting ABCG2 activity and by accelerating its lysosome-dependent degradation. PZ-39 has no effect on ABCB1 and ABCC1-mediated drug efflux, resistance, and their expression, indicating that it may be specific to ABCG2. Analyses of its analogue compounds showed that the pharmacophore of PZ-39 is benzothiazole linked to a triazine ring backbone. Conclusion/Significance: Unlike any previously known ABCG2 transporter inhibitors, PZ-39 has a novel two-mode action by inhibiting ABCG2 activity, an acute effect, and by accelerating lysosome-dependent degradation, a chronic effect. PZ-39 is potentially a valuable probe for structure-function studies of ABCG2 and a lead compound for developing therapeutics targeting ABCG2-mediated MDR in combinational cancer chemotherapy.			Peng, H (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Dept Mol Immunol, Beijing 100730, Peoples R China.	jianzhan@iupui.edu	Zhang, Jian-Ting/L-8334-2015		NATIONAL CANCER INSTITUTE [R01CA113384, R01CA120221] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007519] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA113384, R01 CA120221] Funding Source: Medline; NHLBI NIH HHS [T32 HL07910, T32 HL007910] Funding Source: Medline; NIDDK NIH HHS [T32 DK07519, T32 DK007519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed-Belkacem A, 2005, CANCER RES, V65, P4852, DOI 10.1158/0008-5472.CAN-04-1817; Ahmed-Belkacem A, 2006, ANTI-CANCER DRUG, V17, P239, DOI 10.1097/00001813-200603000-00001; Allen JD, 2002, MOL CANCER THER, V1, P417; Chen Q, 2006, J BIOL CHEM, V281, P31152, DOI 10.1074/jbc.M603529200; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Henrich CJ, 2006, J BIOMOL SCREEN, V11, P176, DOI 10.1177/1087057105284576; Henrich CJ, 2007, MOL CANCER THER, V6, P3271, DOI 10.1158/1535-7163.MCT-07-0352; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Horton JK, 1998, CELL PHYSIOL BIOCHEM, V8, P246, DOI 10.1159/000016287; Imai Y, 2004, CANCER RES, V64, P4346, DOI 10.1158/0008-5472.CAN-04-0078; Liu Y, 2006, CANCER RES, V66, P3248, DOI 10.1158/0008-5472.CAN-05-3801; Liu Y, 2005, MOL PHARMACOL, V68, P430, DOI 10.1124/mol.105.011015; McDevitt CA, 2006, STRUCTURE, V14, P1623, DOI 10.1016/j.str.2006.08.014; Nakamura Y, 2005, CANCER RES, V65, P1541, DOI 10.1158/0008-5472.CAN-03-2417; Ozvegy-Laczka C, 2005, J BIOL CHEM, V280, P4219, DOI 10.1074/jbc.M411338200; Rabindran SK, 1998, CANCER RES, V58, P5850; Rabindran SK, 2000, CANCER RES, V60, P47; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; Wakabayashi K, 2007, J BIOL CHEM, V282, P27841, DOI 10.1074/jbc.C700133200; Whiteley CG, 2000, CELL BIOCHEM BIOPHYS, V33, P217, DOI 10.1385/CBB:33:3:217; Xu JK, 2004, J BIOL CHEM, V279, P19781, DOI 10.1074/jbc.M310785200; Xu JK, 2007, CANCER RES, V67, P4373, DOI 10.1158/0008-5472.CAN-06-3169; Xu JK, 2007, CURR MED CHEM, V14, P689, DOI 10.2174/092986707780059580; Yang YY, 2002, J BIOL CHEM, V277, P44268, DOI 10.1074/jbc.M207003200; Zhang Jian-Ting, 2007, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V32, P531; Zhang SZ, 2004, MOL PHARMACOL, V65, P1208, DOI 10.1124/mol.65.5.1208; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999	27	40	42	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2009	4	5							e5676	10.1371/journal.pone.0005676	http://dx.doi.org/10.1371/journal.pone.0005676			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LH	19479068	gold, Green Published, Green Submitted			2022-12-25	WOS:000266331600001
J	Lamm, N; Ordan, E; Shponkin, R; Richler, C; Aker, M; Tzfati, Y				Lamm, Noa; Ordan, Elly; Shponkin, Rotem; Richler, Carmelit; Aker, Memet; Tzfati, Yehuda			Diminished Telomeric 3 ' Overhangs Are Associated with Telomere Dysfunction in Hoyeraal-Hreidarsson Syndrome	PLOS ONE			English	Article								Background: Eukaryotic chromosomes end with telomeres, which in most organisms are composed of tandem DNA repeats associated with telomeric proteins. These DNA repeats are synthesized by the enzyme telomerase, whose activity in most human tissues is tightly regulated, leading to gradual telomere shortening with cell divisions. Shortening beyond a critical length causes telomere uncapping, manifested by the activation of a DNA damage response (DDR) and consequently cell cycle arrest. Thus, telomere length limits the number of cell divisions and provides a tumor-suppressing mechanism. However, not only telomere shortening, but also damaged telomere structure, can cause telomere uncapping. Dyskeratosis Congenita (DC) and its severe form Hoyeraal-Hreidarsson Syndrome (HHS) are genetic disorders mainly characterized by telomerase deficiency, accelerated telomere shortening, impaired cell proliferation, bone marrow failure, and immunodeficiency. Methodology/Principal Findings: We studied the telomere phenotypes in a family affected with HHS, in which the genes implicated in other cases of DC and HHS have been excluded, and telomerase expression and activity appears to be normal. Telomeres in blood leukocytes derived from the patients were severely short, but in primary fibroblasts they were normal in length. Nevertheless, a significant fraction of telomeres in these fibroblasts activated DDR, an indication of their uncapped state. In addition, the telomeric 3' overhangs are diminished in blood cells and fibroblasts derived from the patients, consistent with a defect in telomere structure common to both cell types. Conclusions/Significance: Altogether, these results suggest that the primary defect in these patients lies in the telomere structure, rather than length. We postulate that this defect hinders the access of telomerase to telomeres, thus causing accelerated telomere shortening in blood cells that rely on telomerase to replenish their telomeres. In addition, it activates the DDR and impairs cell proliferation, even in cells with normal telomere length such as fibroblasts. This work demonstrates a telomere length-independent pathway that contributes to a telomere dysfunction disease.			Lamm, N (corresponding author), Hebrew Univ Jerusalem, Dept Genet, Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	tzfati@cc.huji.ac.il		Tzfati, Yehuda/0000-0001-7720-435X				Autexier C, 2006, ANNU REV BIOCHEM, V75, P493, DOI 10.1146/annurev.biochem.75.103004.142412; Calado RT, 2008, BLOOD, V111, P4446, DOI 10.1182/blood-2007-08-019729; Cesare AJ, 2008, MECH AGEING DEV, V129, P99, DOI 10.1016/j.mad.2007.11.006; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; DOKAL I, 1992, BLOOD, V80, P3090; Fu D, 2003, MOL CELL, V11, P1361, DOI 10.1016/S1097-2765(03)00196-5; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Gilson E, 2007, NAT REV MOL CELL BIO, V8, P825, DOI 10.1038/nrm2259; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Gu BW, 2008, P NATL ACAD SCI USA, V105, P10173, DOI 10.1073/pnas.0803559105; Gu BW, 2009, CELL CYCLE, V8, P6, DOI 10.4161/cc.8.1.7265; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; Hockemeyer D, 2005, EMBO J, V24, P2667, DOI 10.1038/sj.emboj.7600733; Hockemeyer D, 2007, NAT STRUCT MOL BIOL, V14, P754, DOI 10.1038/nsmb1270; Hockemeyer D, 2006, CELL, V126, P63, DOI 10.1016/j.cell.2006.04.044; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Kataoka H, 1997, DIFFERENTIATION, V62, P203; Kedde M, 2006, J BIOL CHEM, V281, P40503, DOI 10.1074/jbc.M607676200; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kirwan M, 2008, CLIN GENET, V73, P103, DOI 10.1111/j.1399-0004.2007.00923.x; Knight SW, 1999, BRIT J HAEMATOL, V107, P335, DOI 10.1046/j.1365-2141.1999.01690.x; Marrone A, 2007, BLOOD, V110, P4198, DOI 10.1182/blood-2006-12-062851; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Poon SSS, 2001, METHOD CELL BIOL, V64, P69; Rog O, 2008, CURR OPIN GENET DEV, V18, P212, DOI 10.1016/j.gde.2008.01.011; Savage SA, 2008, AM J HUM GENET, V82, P501, DOI 10.1016/j.ajhg.2007.10.004; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Verdun RE, 2007, NATURE, V447, P924, DOI 10.1038/nature05976; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Vulliamy T, 2004, NAT GENET, V36, P447, DOI 10.1038/ng1346; Vulliamy TJ, 2008, BIOCHIMIE, V90, P122, DOI 10.1016/j.biochi.2007.07.017; Vulliamy T, 2008, P NATL ACAD SCI USA, V105, P8073, DOI 10.1073/pnas.0800042105; Walne AJ, 2008, BLOOD, V112, P3594, DOI 10.1182/blood-2008-05-153445; Walne AJ, 2007, HUM MOL GENET, V16, P1619, DOI 10.1093/hmg/ddm111; Wang F, 2007, NATURE, V445, P506, DOI 10.1038/nature05454; Wong JMY, 2006, GENE DEV, V20, P2848, DOI 10.1101/gad.1476206; Xin HW, 2007, NATURE, V445, P559, DOI 10.1038/nature05469; Yaghmai R, 2000, J PEDIATR-US, V136, P390, DOI 10.1067/mpd.2000.104295; Yehezkel S, 2008, HUM MOL GENET, V17, P2776, DOI 10.1093/hmg/ddn177; Zhao Y, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkm1063; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	47	27	28	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2009	4	5							e5666	10.1371/journal.pone.0005666	http://dx.doi.org/10.1371/journal.pone.0005666			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LD	19461895	Green Published, gold, Green Submitted			2022-12-25	WOS:000266331200005
J	Li, OTW; Chan, MCW; Leung, CSW; Chan, RWY; Guan, Y; Nicholls, JM; Poon, LLM				Li, Olive T. W.; Chan, Michael C. W.; Leung, Cynthia S. W.; Chan, Renee W. Y.; Guan, Yi; Nicholls, John M.; Poon, Leo L. M.			Full Factorial Analysis of Mammalian and Avian Influenza Polymerase Subunits Suggests a Role of an Efficient Polymerase for Virus Adaptation	PLOS ONE			English	Article							DETERMINES HOST-RANGE; A H5N1 VIRUSES; RNA-POLYMERASE; HIGH VIRULENCE; PB1 PROTEIN; AMINO-ACID; COMPLEX-FORMATION; VIRAL POLYMERASE; GENES CONTRIBUTE; NUCLEAR IMPORT	Amongst all the internal gene segments (PB2, PB1, PA, NP, M and NS), the avian PB1 segment is the only one which was reassorted into the human H2N2 and H3N2 pandemic strains. This suggests that the reassortment of polymerase subunit genes between mammalian and avian influenza viruses might play roles for interspecies transmission. To test this hypothesis, we tested the compatibility between PB2, PB1, PA and NP derived from a H5N1 virus and a mammalian H1N1 virus. All 16 possible combinations of avian-mammalian chimeric viral ribonucleoproteins (vRNPs) were characterized. We showed that recombinant vRNPs with a mammalian PB2 and an avian PB1 had the strongest polymerase activities in human cells at all studied temperature. In addition, viruses with this specific PB2-PB1 combination could grow efficiently in cell cultures, especially at a high incubation temperature. These viruses were potent inducers of proinflammatory cytokines and chemokines in primary human macrophages and pneumocytes. Viruses with this specific PB2-PB1 combination were also found to be more capable to generate adaptive mutations under a new selection pressure. These results suggested that the viral polymerase activity might be relevant for the genesis of influenza viruses of human health concern.			Li, OTW (corresponding author), Univ Hong Kong, Dept Microbiol, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.	llmpoon@hkucc.hku.hk	Chan, Renee/D-4799-2012; Poon, Leo Lit Man/C-4382-2009; Poon, Leo/AAP-6887-2020; Chan, Renee Wan Yi/AAA-6598-2020; Chan, Michael Chi Wai/C-4212-2009; Nicholls, John Malcolm/C-4375-2009	Poon, Leo Lit Man/0000-0002-9101-7953; Chan, Renee Wan Yi/0000-0001-6485-0926; Chan, Michael Chi Wai/0000-0001-8174-8405; Nicholls, John Malcolm/0000-0001-7217-7444; Guan, Yi/0000-0001-6057-9243	NIAID NIH HHS [HHSN266200700005C] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMOND JW, 1977, NATURE, V270, P617, DOI 10.1038/270617a0; Aoki FY, 2007, ANTIVIR THER, V12, P603; BARCENA J, 1994, J VIROL, V68, P6900; Basler CF, 2001, P NATL ACAD SCI USA, V98, P2746, DOI 10.1073/pnas.031575198; Basler CF, 2008, ANTIVIR RES, V79, P166, DOI 10.1016/j.antiviral.2008.04.006; Capua I, 2006, AVIAN PATHOL, V35, P189, DOI 10.1080/03079450600717174; CASTRUCCI MR, 1993, J VIROL, V67, P759, DOI 10.1128/JVI.67.2.759-764.1993; Chan AY, 2006, VIROLOGY, V351, P210, DOI 10.1016/j.virol.2006.03.005; Chan MCW, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-135; Chen HL, 2006, J VIROL, V80, P5976, DOI 10.1128/JVI.00110-06; Chen H, 2007, VIRUS RES, V128, P159, DOI 10.1016/j.virusres.2007.04.017; Chen LM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000072; Chen WS, 2001, NAT MED, V7, P1306, DOI 10.1038/nm1201-1306; Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; Cheung TKW, 2005, J GEN VIROL, V86, P1447, DOI 10.1099/vir.0.80727-0; Conenello GM, 2007, PLOS PATHOG, V3, P1414, DOI 10.1371/journal.ppat.0030141; Crescenzo-Chaigne B, 2002, VIROLOGY, V303, P240, DOI 10.1006/viro.2002.1637; de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477; Deng T, 2005, J VIROL, V79, P8669, DOI 10.1128/JVI.79.13.8669-8674.2005; Deng T, 2006, J VIROL, V80, P11911, DOI 10.1128/JVI.01565-06; DIGARD P, 1989, VIROLOGY, V171, P162, DOI 10.1016/0042-6822(89)90523-0; Ducatez MF, 2007, J GEN VIROL, V88, P2297, DOI 10.1099/vir.0.82939-0; Duffy S, 2008, NAT REV GENET, V9, P267, DOI 10.1038/nrg2323; Engelhardt OG, 2005, J VIROL, V79, P5812, DOI 10.1128/JVI.79.9.5812-5818.2005; Engelhardt OG, 2006, REV MED VIROL, V16, P329, DOI 10.1002/rmv.512; Fodor E, 2004, J VIROL, V78, P9144, DOI 10.1128/JVI.78.17.9144-9153.2004; Fodor E, 1999, J VIROL, V73, P9679, DOI 10.1128/JVI.73.11.9679-9682.1999; Fouchier RAM, 2005, J VIROL, V79, P2814, DOI 10.1128/JVI.79.5.2814-2822.2005; Fujii K, 2005, J VIROL, V79, P3766, DOI 10.1128/JVI.79.6.3766-3774.2005; Gabriel G, 2007, J VIROL, V81, P9601, DOI 10.1128/JVI.00666-07; Gabriel G, 2005, P NATL ACAD SCI USA, V102, P18590, DOI 10.1073/pnas.0507415102; Gabriel G, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040011; GIESENDORF B, 1986, VIRUS RES, V5, P27, DOI 10.1016/0168-1702(86)90063-8; Gomez-Puertas P, 1999, J GEN VIROL, V80, P1635, DOI 10.1099/0022-1317-80-7-1635; Gonzalez S, 1996, NUCLEIC ACIDS RES, V24, P4456, DOI 10.1093/nar/24.22.4456; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; He XJ, 2008, NATURE, V454, P1123, DOI 10.1038/nature07120; Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697; Hoffmann E, 2001, ARCH VIROL, V146, P2275, DOI 10.1007/s007050170002; Honda A, 2007, GENES CELLS, V12, P133, DOI 10.1111/j.1365-2443.2007.01047.x; Hulse-Post DJ, 2007, J VIROL, V81, P8515, DOI 10.1128/JVI.00435-07; IWATSUKIHORIMOT.K, 2008, VIRUS RES; Jorba N, 2008, PROTEOMICS, V8, P2077, DOI 10.1002/pmic.200700508; KAWAOKA Y, 1989, J VIROL, V63, P4603, DOI 10.1128/JVI.63.11.4603-4608.1989; Keech M, 1998, OCCUP MED-OXFORD, V48, P85, DOI 10.1093/occmed/48.2.85; Kleiman FE, 2005, GENE DEV, V19, P1227, DOI 10.1101/gad.1309505; Labadie K, 2007, VIROLOGY, V362, P271, DOI 10.1016/j.virol.2006.12.027; Lam YW, 2002, MOL BIOL CELL, V13, P2461, DOI 10.1091/mbc.02-03-0034; Li CJ, 2008, J VIROL, V82, P11880, DOI 10.1128/JVI.01445-08; Liu J, 2005, SCIENCE, V309, P1206, DOI 10.1126/science.1115273; Luo G, 1993, Virus Res, V29, P321; Maines TR, 2005, J VIROL, V79, P11788, DOI 10.1128/JVI.79.18.11788-11800.2005; Massin P, 2005, J VIROL, V79, P13811, DOI 10.1128/JVI.79.21.13811-13816.2005; Massin P, 2001, J VIROL, V75, P5398, DOI 10.1128/JVI.75.11.5398-5404.2001; Murphy B.R, 1996, FIELDS VIROLOGY, P1397; Naffakh N, 2000, J GEN VIROL, V81, P1283, DOI 10.1099/0022-1317-81-5-1283; Naffakh N, 2008, ANNU REV MICROBIOL, V62, P403, DOI 10.1146/annurev.micro.62.081307.162746; Naito T, 2007, J VIROL, V81, P1339, DOI 10.1128/JVI.01917-06; Obayashi E, 2008, NATURE, V454, P1127, DOI [10.1038/nature07225, 10.5940/jcrsj.50.329]; Ohtsu Y, 2002, MICROBIOL IMMUNOL, V46, P167, DOI 10.1111/j.1348-0421.2002.tb02682.x; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Pappas C, 2008, P NATL ACAD SCI USA, V105, P3064, DOI 10.1073/pnas.0711815105; PEREZ DR, 1995, J VIROL, V69, P6932; Perrone LA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000115; Poole EL, 2007, FEBS LETT, V581, P5300, DOI 10.1016/j.febslet.2007.10.025; Rodriguez A, 2007, J VIROL, V81, P5315, DOI 10.1128/JVI.02129-06; Salomon R, 2006, J EXP MED, V203, P689, DOI 10.1084/jem.20051938; Seo SH, 2004, VIRUS RES, V103, P107, DOI 10.1016/j.virusres.2004.02.022; Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757; Shinya K, 2004, VIROLOGY, V320, P258, DOI 10.1016/j.virol.2003.11.030; SNYDER MH, 1987, J VIROL, V61, P2857, DOI 10.1128/JVI.61.9.2857-2863.1987; Somesh BP, 2005, CELL, V121, P913, DOI 10.1016/j.cell.2005.04.010; STERN H, 1963, LANCET, V1, P1301; Stray SJ, 2001, VIRUS RES, V77, P3, DOI 10.1016/S0168-1702(01)00260-X; SUBBARAO EK, 1993, J VIROL, V67, P1761, DOI 10.1128/JVI.67.4.1761-1764.1993; Taubenberger JK, 1997, SCIENCE, V275, P1793, DOI 10.1126/science.275.5307.1793; Taubenberger JK, 2005, NATURE, V437, P889, DOI 10.1038/nature04230; Toyoda T, 1996, J GEN VIROL, V77, P2149, DOI 10.1099/0022-1317-77-9-2149; Tumpey TM, 2004, P NATL ACAD SCI USA, V101, P3166, DOI 10.1073/pnas.0308391100; Ueda M, 2008, VIRUS RES, V136, P91, DOI 10.1016/j.virusres.2008.04.028; Varich NL, 2008, ARCH VIROL, V153, P1149, DOI 10.1007/s00705-008-0070-5; Vreede FT, 2004, J VIROL, V78, P9568, DOI 10.1128/JVI.78.17.9568-9572.2004; Wasilenko JL, 2008, J VIROL, V82, P4544, DOI 10.1128/JVI.02642-07; Webster RG, 1997, FEMS IMMUNOL MED MIC, V18, P275, DOI 10.1016/S0928-8244(97)00058-8; WHO, 2021, CUM NUMB CONF HUM CA; WOLFF T, 2008, BIOL CHEM; Yano T, 2008, MICROBIOL IMMUNOL, V52, P216, DOI 10.1111/j.1348-0421.2008.00034.x	87	48	50	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2009	4	5							e5658	10.1371/journal.pone.0005658	http://dx.doi.org/10.1371/journal.pone.0005658			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LB	19462010	gold, Green Published, Green Submitted			2022-12-25	WOS:000266331000016
J	Schleheck, D; Barraud, N; Klebensberger, J; Webb, JS; McDougald, D; Rice, SA; Kjelleberg, S				Schleheck, David; Barraud, Nicolas; Klebensberger, Janosch; Webb, Jeremy S.; McDougald, Diane; Rice, Scott A.; Kjelleberg, Staffan			Pseudomonas aeruginosa PAO1 Preferentially Grows as Aggregates in Liquid Batch Cultures and Disperses upon Starvation	PLOS ONE			English	Article								In both natural and artificial environments, bacteria predominantly grow in biofilms, and bacteria often disperse from biofilms as freely suspended single-cells. In the present study, the formation and dispersal of planktonic cellular aggregates, or 'suspended biofilms', by Pseudomonas aeruginosa in liquid batch cultures were closely examined, and compared to biofilm formation on a matrix of polyester (PE) fibers as solid surface in batch cultures. Plankton samples were analyzed by laser-diffraction particle-size scanning (LDA) and microscopy of aggregates. Interestingly, LDA indicated that up to 90% of the total planktonic biomass consisted of cellular aggregates in the size range of 10-400 mm in diameter during the growth phase, as opposed to individual cells. In cultures with PE surfaces, P. aeruginosa preferred to grow in biofilms, as opposed to planktonicly. However, upon carbon, nitrogen or oxygen limitation, the planktonic aggregates and PE-attached biofilms dispersed into single cells, resulting in an increase in optical density (OD) independent of cellular growth. During growth, planktonic aggregates and PE-attached biofilms contained densely packed viable cells and extracellular DNA (eDNA), and starvation resulted in a loss of viable cells, and an increase in dead cells and eDNA. Furthermore, a release of metabolites and infective bacteriophage into the culture supernatant, and a marked decrease in intracellular concentration of the second messenger cyclic di-GMP, was observed in dispersing cultures. Thus, what traditionally has been described as planktonic, individual cell cultures of P. aeruginosa, are in fact suspended biofilms, and such aggregates have behaviors and responses (e. g. dispersal) similar to surface associated biofilms. In addition, we suggest that this planktonic biofilm model system can provide the basis for a detailed analysis of the synchronized biofilm life cycle of P. aeruginosa.			Schleheck, D (corresponding author), Univ Konstanz, Dept Biol, Constance, Germany.	s.kjelleberg@unsw.edu.au	Rice, Scott/A-6084-2019; Kjelleberg, Staffan/C-9229-2015; Barraud, Nicolas/D-1569-2010; McDougald, Diane/AAF-4799-2020; Kjelleberg, Staffan/AAB-4641-2020; McDougald, Diane/B-5564-2009	Rice, Scott/0000-0002-9486-2343; Kjelleberg, Staffan/0000-0003-4271-6413; Barraud, Nicolas/0000-0002-1807-7765; McDougald, Diane/0000-0001-5827-8441; Kjelleberg, Staffan/0000-0003-4271-6413; McDougald, Diane/0000-0001-5827-8441; Klebensberger, Janosch/0000-0003-2740-3769; Webb, Jeremy/0000-0003-2068-8589	BBSRC [BB/C520655/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/C520655/1] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ALLDREDGE AL, 1986, LIMNOL OCEANOGR, V31, P68, DOI 10.4319/lo.1986.31.1.0068; Allesen-Holm M, 2006, MOL MICROBIOL, V59, P1114, DOI 10.1111/j.1365-2958.2005.05008.x; [Anonymous], 2007, BIOFILM PRIMER; APPLEGATE DH, 1991, BIOTECHNOL BIOENG, V37, P17, DOI 10.1002/bit.260370105; Barraud N, 2006, J BACTERIOL, V188, P7344, DOI 10.1128/JB.00779-06; Biggs CA, 2000, WATER RES, V34, P2542, DOI 10.1016/S0043-1354(99)00431-5; BYNG GS, 1979, J BACTERIOL, V138, P846, DOI 10.1128/JB.138.3.846-852.1979; Chandrasekaran EV, 1980, METHODS CARBOHYDRATE, P89; Chayabutra C, 2001, BIOTECHNOL BIOENG, V72, P25, DOI 10.1002/1097-0290(20010105)72:1<25::AID-BIT4>3.0.CO;2-J; COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431; D'Argenio DA, 2002, J BACTERIOL, V184, P6481, DOI 10.1128/JB.184.23.6481-6489.2002; Davies DG, 2009, J BACTERIOL, V191, P1393, DOI 10.1128/JB.01214-08; DELAQUIS PJ, 1989, MICROBIAL ECOL, V18, P199, DOI 10.1007/BF02075808; Fakhruddin ANM, 2007, BIODEGRADATION, V18, P189, DOI 10.1007/s10532-006-9054-x; Gjermansen M, 2005, ENVIRON MICROBIOL, V7, P894, DOI 10.1111/j.1462-2920.2005.00775.x; GROSSART HP, 1993, LIMNOL OCEANOGR, V38, P532, DOI 10.4319/lo.1993.38.3.0532; Hickman JW, 2008, MOL MICROBIOL, V69, P376, DOI 10.1111/j.1365-2958.2008.06281.x; Hunt SM, 2004, APPL ENVIRON MICROB, V70, P7418, DOI 10.1128/AEM.70.12.7418-7425.2004; Jenal U, 2006, ANNU REV GENET, V40, P385, DOI 10.1146/annurev.genet.40.110405.090423; KENNEDY SIT, 1968, BIOCHEM J, V107, P497, DOI 10.1042/bj1070497; KISAALITA WS, 1994, BIOTECHNOL TECH, V8, P747, DOI 10.1007/BF00151481; Kjelleberg S, 2007, BIOFILM MODE LIFE ME, P5; Kjelleberg S., 1993, STARVATION BACTERIA; Klebensberger J, 2006, ARCH MICROBIOL, V185, P417, DOI 10.1007/s00203-006-0111-y; Lee VT, 2007, MOL MICROBIOL, V65, P1474, DOI 10.1111/j.1365-2958.2007.05879.x; Mason C.A., 1993, STARVATION BACTERIA, P81, DOI DOI 10.1007/978-1-4899-2439-1_4; Meissner A, 2007, ENVIRON MICROBIOL, V9, P2475, DOI 10.1111/j.1462-2920.2007.01366.x; Nielsen PH, 2004, WATER SCI TECHNOL, V49, P51, DOI 10.2166/wst.2004.0606; Rice SA, 2009, ISME J, V3, P271, DOI 10.1038/ismej.2008.109; Sauer K, 2004, J BACTERIOL, V186, P7312, DOI 10.1128/JB.186.21.7312-7326.2004; Sawyer LK, 2000, WATER SCI TECHNOL, V41, P139, DOI 10.2166/wst.2000.0437; Schleheck D, 2004, INT J SYST EVOL MICR, V54, P1489, DOI 10.1099/ijs.0.03020-0; Schleheck D, 2004, APPL ENVIRON MICROB, V70, P4053, DOI 10.1128/AEM.70.7.4053-4063.2004; Schleheck D, 2000, APPL ENVIRON MICROB, V66, P1911, DOI 10.1128/AEM.66.5.1911-1916.2000; Simm R, 2004, MOL MICROBIOL, V53, P1123, DOI 10.1111/j.1365-2958.2004.04206.x; Spormann AM, 2008, CURR TOP MICROBIOL, V322, P17; Thormann KM, 2006, J BACTERIOL, V188, P2681, DOI 10.1128/JB.188.7.2681-2691.2006; Thormann KM, 2005, J BACTERIOL, V187, P1014, DOI 10.1128/JB.187.3.1014-1021.2005; Tischler AD, 2005, INFECT IMMUN, V73, P5873, DOI 10.1128/IAI.73.9.5873-5882.2005; Tlemcani LL, 2008, ARCH MICROBIOL, V190, P141, DOI 10.1007/s00203-008-0380-8; Wagner M, 2002, ANTON LEEUW INT J G, V81, P665, DOI 10.1023/A:1020586312170; Webb JS, 2003, J BACTERIOL, V185, P4585, DOI 10.1128/JB.185.15.4585-4592.2003	42	138	146	2	81	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5513	10.1371/journal.pone.0005513	http://dx.doi.org/10.1371/journal.pone.0005513			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444WA	19436737	Green Published, Green Submitted, gold, Green Accepted			2022-12-25	WOS:000266009900006
J	Millet, C; Yamashita, M; Heller, M; Yu, LR; Veenstra, TD; Zhang, YE				Millet, Caroline; Yamashita, Motozo; Heller, Mary; Yu, Li-Rong; Veenstra, Timothy D.; Zhang, Ying E.			A Negative Feedback Control of Transforming Growth Factor-beta Signaling by Glycogen Synthase Kinase 3-mediated Smad3 Linker Phosphorylation at Ser-204	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; CRYSTAL-STRUCTURE; BMP; PATHWAYS; DOMAIN; IDENTIFICATION; DEGRADATION; SPECIFICITY; ACTIVATION; MECHANISM	Through the action of its membrane-bound type I receptor, transforming growth factor-beta (TGF-beta) elicits a wide range of cellular responses that regulate cell proliferation, differentiation, and apoptosis. Many of these signaling responses are mediated by Smad proteins. As such, controlling Smad activity is crucial for proper signaling by TGF-beta and its related factors. Here, we show that TGF-beta induces phosphorylation at three sites in the Smad3 linker region in addition to the two C-terminal residues, and glycogen synthase kinase 3 is responsible for phosphorylation at one of these sites, namely Ser-204. Alanine substitution at Ser-204 and/or the neighboring Ser-208, the priming site for glycogen synthase kinase 3 in vivo activity, strengthened the affinity of Smad3 to CREB-binding protein, suggesting that linker phosphorylation may be part of a negative feedback loop that modulates Smad3 transcriptional activity. Thus, our findings reveal a novel aspect of the Smad3 signaling mechanism that controls the final amplitude of cellular responses to TGF-beta.	[Millet, Caroline; Yamashita, Motozo; Heller, Mary; Zhang, Ying E.] NCI, Ctr Canc Res, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA; [Yu, Li-Rong] US FDA, Natl Ctr Toxicol Res, Ctr Prote, Div Syst Toxicol, Jefferson, AR 72079 USA; [Veenstra, Timothy D.] SAIC Frederick Inc, Lab Prote & Analyt Technol, Adv Technol Program, Frederick, MD 21702 USA; [Veenstra, Timothy D.] NCI, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhang, YE (corresponding author), NCI, Ctr Canc Res, Cellular & Mol Biol Lab, NIH, 37 Convent Dr,Bldg 37,Rm 2056B, Bethesda, MD 20892 USA.	yingz@helix.nih.gov	Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601; Yu, Li-Rong/0000-0001-6084-991X	National Institutes of Health, NCI, Center for Cancer Research, Intramural Research Program; NCI [N01-CO-12400]; NATIONAL CANCER INSTITUTE [ZIABC010419] Funding Source: NIH RePORTER	National Institutes of Health, NCI, Center for Cancer Research, Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by the National Institutes of Health, NCI, Center for Cancer Research, Intramural Research Program and is funded in part by National Institutes of Health Contract N01-CO-12400 from NCI.	Aubin J, 2004, GENE DEV, V18, P1482, DOI 10.1101/gad.1202604; Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chacko BM, 2004, MOL CELL, V15, P813, DOI 10.1016/j.molcel.2004.07.016; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Derynck Rik, 2008, P29; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuura I, 2005, BIOCHEMISTRY-US, V44, P12546, DOI 10.1021/bi050560g; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Mori S, 2004, ONCOGENE, V23, P7416, DOI 10.1038/sj.onc.1207981; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Pera EM, 2003, GENE DEV, V17, P3023, DOI 10.1101/gad.1153603; Prokova V, 2005, NUCLEIC ACIDS RES, V33, P3708, DOI 10.1093/nar/gki679; Sapkota G, 2007, MOL CELL, V25, P441, DOI 10.1016/j.molcel.2007.01.006; Schmierer B, 2005, MOL CELL BIOL, V25, P9845, DOI 10.1128/MCB.25.22.9845-9858.2005; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Wang GN, 2005, BIOCHEM J, V386, P29, DOI 10.1042/BJ20041820; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Ying SX, 2003, J BIOL CHEM, V278, P39029, DOI 10.1074/jbc.M301193200; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Yu LR, 2004, MOL CELL PROTEOMICS, V3, P896, DOI 10.1074/mcp.M400034-MCP200; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	39	60	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					19808	19816		10.1074/jbc.M109.016667	http://dx.doi.org/10.1074/jbc.M109.016667			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19458083	hybrid, Green Published			2022-12-25	WOS:000268097400007
J	Brent, MM; Iwata, A; Carten, J; Zhao, KH; Marmorstein, R				Brent, Michael M.; Iwata, Ayaka; Carten, Juliana; Zhao, Kehao; Marmorstein, Ronen			Structure and Biochemical Characterization of Protein Acetyltransferase from Sulfolobus solfataricus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEAL CHROMATIN PROTEIN; HISTONE ACETYLTRANSFERASE; CATALYTIC MECHANISM; TRANSCRIPTIONAL COACTIVATOR; MOLECULAR-GRAPHICS; ACETYLATION; RTT109; SIR2; P300/CBP; ENZYME	The Sulfolobus solfataricus protein acetyltransferase (PAT) acetylates ALBA, an abundant nonspecific DNA-binding protein, on Lys(16) to reduce its DNA affinity, and the Sir2 deacetylase reverses the modification to cause transcriptional repression. This represents a "primitive" model for chromatin regulation analogous to histone modification in eukaryotes. We report the 1.84-angstrom crystal structure of PAT in complex with coenzyme A. The structure reveals homology to both prokaryotic GNAT acetyltransferases and eukaryotic histone acetyltransferases (HATs), with an additional "bent helix" proximal to the substrate binding site that might play an autoregulatory function. Investigation of active site mutants suggests that PAT does not use a single general base or acid residue for substrate deprotonation and product reprotonation, respectively, and that a diffusional step, such as substrate binding, may be rate-limiting. The catalytic efficiency of PAT toward ALBA is low relative to other acetyltransferases, suggesting that there may be better, unidentified substrates for PAT. The structural similarity of PAT to eukaryotic HATs combined with its conserved role in chromatin regulation suggests that PAT is evolutionarily related to the eukaryotic HATs.	[Brent, Michael M.; Iwata, Ayaka; Carten, Juliana; Zhao, Kehao; Marmorstein, Ronen] Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA; [Brent, Michael M.; Iwata, Ayaka; Marmorstein, Ronen] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania	Marmorstein, R (corresponding author), 3601 Spruce St, Philadelphia, PA 19104 USA.	marmor@wistar.org			National Institutes of Health Grant [GM060293]; NATIONAL CANCER INSTITUTE [T32CA009171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060293] Funding Source: NIH RePORTER	National Institutes of Health Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant GM060293 ( to R. M.).	Avalos JL, 2002, MOL CELL, V10, P523, DOI 10.1016/S1097-2765(02)00628-7; Barry ER, 2006, MICROBIOL MOL BIOL R, V70, P876, DOI 10.1128/MMBR.00029-06; Bell SD, 2002, SCIENCE, V296, P148, DOI 10.1126/science.1070506; Berndsen CE, 2007, BIOCHEMISTRY-US, V46, P623, DOI 10.1021/bi602513x; Braman J, 1996, Methods Mol Biol, V57, P31; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Driscoll R, 2007, SCIENCE, V315, P649, DOI 10.1126/science.1135862; Edmondson SP, 2001, METHOD ENZYMOL, V334, P129; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fillingham J, 2008, MOL CELL BIOL, V28, P4342, DOI 10.1128/MCB.00182-08; Han JH, 2007, J BIOL CHEM, V282, P14158, DOI 10.1074/jbc.M700611200; Harris TK, 2002, IUBMB LIFE, V53, P85, DOI 10.1080/15216540211468; Hodawadekar SC, 2007, ONCOGENE, V26, P5528, DOI 10.1038/sj.onc.1210619; Liu X, 2008, NATURE, V451, P846, DOI 10.1038/nature06546; Marsh VL, 2005, J BIOL CHEM, V280, P21122, DOI 10.1074/jbc.M501280200; Mehler EL, 2002, PROTEINS, V48, P283, DOI 10.1002/prot.10153; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Potterton L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716; Sandman K, 2005, CURR OPIN MICROBIOL, V8, P656, DOI 10.1016/j.mib.2005.10.007; Scheibner KA, 2002, J BIOL CHEM, V277, P18118, DOI 10.1074/jbc.M200595200; Starai VJ, 2004, J MOL BIOL, V340, P1005, DOI 10.1016/j.jmb.2004.05.010; Tang Y, 2008, NAT STRUCT MOL BIOL, V15, P738, DOI 10.1038/nsmb.1448; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tsubota T, 2007, MOL CELL, V25, P703, DOI 10.1016/j.molcel.2007.02.006; Vetting MW, 2005, ARCH BIOCHEM BIOPHYS, V433, P212, DOI 10.1016/j.abb.2004.09.003; Vetting MW, 2004, CHEM BIOL, V11, P565, DOI 10.1016/j.chembiol.2004.03.017; Wang L, 2008, CURR OPIN STRUC BIOL, V18, P741, DOI 10.1016/j.sbi.2008.09.004; Wardleworth BN, 2002, EMBO J, V21, P4654, DOI 10.1093/emboj/cdf465; Wardleworth BN, 2001, ACTA CRYSTALLOGR D, V57, P1893, DOI 10.1107/S0907444901015517; Yan Y, 2002, NAT STRUCT BIOL, V9, P862, DOI 10.1038/nsb849	33	17	18	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19412	19419		10.1074/jbc.M109.014951	http://dx.doi.org/10.1074/jbc.M109.014951			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19473964	Green Published, hybrid			2022-12-25	WOS:000267908300032
J	Kasiviswanathan, R; Longley, MJ; Chan, SSL; Copeland, WC				Kasiviswanathan, Rajesh; Longley, Matthew J.; Chan, Sherine S. L.; Copeland, William C.			Disease Mutations in the Human Mitochondrial DNA Polymerase Thumb Subdomain Impart Severe Defects in Mitochondrial DNA Replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; TYPE-1 REVERSE-TRANSCRIPTASE; P55 ACCESSORY SUBUNIT; I KLENOW FRAGMENT; ALPERS-SYNDROME; POLG MUTATIONS; FRAMESHIFT FIDELITY; ANGSTROM RESOLUTION; AUTOSOMAL-DOMINANT; NUCLEOSIDE ANALOGS	Forty-five different point mutations in POLG, the gene encoding the catalytic subunit of the human mitochondrial DNA polymerase (pol gamma), cause the early onset mitochondrial DNA depletion disorder, Alpers syndrome. Sequence analysis of the C-terminal polymerase region of pol gamma revealed a cluster of four Alpers mutations at highly conserved residues in the thumb subdomain (G848S, c.2542g -> a; T851A, c.2551a -> g; R852C, c.2554c -> t; R853Q, c.2558g -> a) and two Alpers mutations at less conserved positions in the adjacent palm subdomain (Q879H, c.2637g -> t and T885S, c.2653a -> t). Biochemical characterization of purified, recombinant forms of pol gamma revealed that Alpers mutations in the thumb subdomain reduced polymerase activity more than 99% relative to the wild-type enzyme, whereas the palm subdomain mutations retained 50-70% wildtype polymerase activity. All six mutant enzymes retained physical and functional interaction with the pol gamma accessory subunit (p55), and none of the six mutants exhibited defects in misinsertion fidelity in vitro. However, differential DNA binding by these mutants suggests a possible orientation of the DNA with respect to the polymerase during catalysis. To our knowledge this study represents the first structure-function analysis of the thumb subdomain in pol gamma and examines the consequences of mitochondrial disease mutations in this region.	[Kasiviswanathan, Rajesh; Longley, Matthew J.; Chan, Sherine S. L.; Copeland, William C.] NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Copeland, WC (corresponding author), NIEHS, Mol Genet Lab, NIH, 111 TW Alexander Dr,Bldg 101,Rm E316, Res Triangle Pk, NC 27709 USA.	copelan1@niehs.nih.gov	Kasiviswanathan, Rajesh/D-2744-2012; Copeland, William/C-4242-2019	Copeland, William/0000-0002-0359-0953	National Institutes of Health Grant [ES 065078]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R00ES015555, Z01ES065078, ZIAES065078] Funding Source: NIH RePORTER	National Institutes of Health Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported, in whole or in part, by National Institutes of Health Grant ES 065078 ( Intramural Research Program of the NIEHS).	Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002; Ashley N, 2008, HUM MOL GENET, V17, P2496, DOI 10.1093/hmg/ddn150; Baruffini E, 2007, BBA-MOL BASIS DIS, V1772, P1225, DOI 10.1016/j.bbadis.2007.10.002; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424; Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007; Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010; Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200; Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646; Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831; Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498; de Vries MC, 2007, EUR J PEDIATR, V166, P229, DOI 10.1007/s00431-006-0234-9; Deschauer M, 2007, NEUROLOGY, V68, P1741, DOI 10.1212/01.wnl.0000261929.92478.3e; Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410; Gonzalez-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107; Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805; Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d; HARDING BN, 1995, J NEUROL NEUROSUR PS, V58, P320, DOI 10.1136/jnnp.58.3.320; Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088; Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455; Kollberg G, 2005, EUR J HUM GENET, V13, P463, DOI 10.1038/sj.ejhg.5201341; Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e; Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278; Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4; Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200; Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197; Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303; Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w; Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200; Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196; McFarland R, 2008, ARCH DIS CHILD, V93, P151, DOI 10.1136/adc.2007.122911; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079; Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B; Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026; Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OLLIS DL, 1985, NATURE, V313, P818, DOI 10.1038/313818a0; REARDON JE, 1990, J BIOL CHEM, V265, P20302; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180; Taanman JW, 2009, HUM MUTAT, V30, P248, DOI 10.1002/humu.20852; Wiltshire E, 2008, ARCH NEUROL-CHICAGO, V65, P121, DOI 10.1001/archneurol.2007.14; Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824; Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200	54	39	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19501	19510		10.1074/jbc.M109.011940	http://dx.doi.org/10.1074/jbc.M109.011940			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19478085	Green Published, hybrid			2022-12-25	WOS:000267908300042
J	Martinelli, DC; Fan, CM				Martinelli, David C.; Fan, Chen-Ming			A Sonic Hedgehog Missense Mutation Associated with Holoprosencephaly Causes Defective Binding to GAS1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE LIMB; GENE; PATHWAY; MICE; IDENTIFICATION; EXPRESSION; INDUCTION; PROTEIN; GLI3; CDO	Holoprosencephaly (HPE) is a common birth defect predominantly affecting the forebrain and face and has been linked to mutations in the sonic hedgehog (SHH) gene. HPE is genetically heterogeneous, and clinical presentation represents a spectrum of phenotypes. We have previously shown that Gas1 encodes a cell-autonomous Hedgehog signaling enhancer. Combining cell surface binding, in vitro activity, and explant culture assays, we provide evidence that SHH contains a previously unknown unique binding surface for its interaction with GAS1 and that this surface is also important for maximal signaling activity. Within this surface, the Asn-115 residue of human SHH has been documented to associate with HPE when mutated to lysine (N115K). We provide evidence that HPE associated with this mutation can be mechanistically explained by a severely reduced binding of SHH to GAS1, and we predict a similar result if a mutation were to occur at Tyr-80. Our data should encourage future searches for mutations in GAS1 as possible modifiers contributing to the wide spectrum of HPE.	[Martinelli, David C.; Fan, Chen-Ming] Carnegie Inst Sci, Dept Embryol, Baltimore, MD 21218 USA; [Martinelli, David C.] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Carnegie Institution for Science; Johns Hopkins University	Fan, CM (corresponding author), Carnegie Inst Sci, Dept Embryol, 3520 San Martin Dr, Baltimore, MD 21218 USA.	fan@ciwemb.edu		Martinelli, David/0000-0002-8318-3986	NIDDK NIH HHS [R01 DK084963, R01 DK084963-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK084963] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; Buttitta L, 2003, DEVELOPMENT, V130, P6233, DOI 10.1242/dev.00851; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Fuse N, 1999, P NATL ACAD SCI USA, V96, P10992, DOI 10.1073/pnas.96.20.10992; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; Lee CS, 2001, MECH DEVELOP, V101, P293, DOI 10.1016/S0925-4773(01)00283-0; Lee CS, 2001, P NATL ACAD SCI USA, V98, P11347, DOI 10.1073/pnas.201418298; Maity T, 2005, P NATL ACAD SCI USA, V102, P17026, DOI 10.1073/pnas.0507848102; Martinelli DC, 2007, CELL CYCLE, V6, P2650, DOI 10.4161/cc.6.21.4877; Martinelli DC, 2007, GENE DEV, V21, P1231, DOI 10.1101/gad.1546307; MATSUNAGA E, 1977, TERATOLOGY, V16, P261, DOI 10.1002/tera.1420160304; McLellan JS, 2008, NATURE, V455, P979, DOI 10.1038/nature07358; Nanni L, 1999, HUM MOL GENET, V8, P2479, DOI 10.1093/hmg/8.13.2479; Odent S, 1999, HUM MOL GENET, V8, P1683, DOI 10.1093/hmg/8.9.1683; Pepinsky RB, 2000, J BIOL CHEM, V275, P10995, DOI 10.1074/jbc.275.15.10995; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Schachter KA, 2008, CURR TOP DEV BIOL, V84, P139, DOI 10.1016/S0070-2153(08)00603-0; Seppala M, 2007, J CLIN INVEST, V117, P1575, DOI 10.1172/JCI32032; Tenzen T, 2006, DEV CELL, V10, P647, DOI 10.1016/j.devcel.2006.04.004; Tsujita Y, 2006, P NATL ACAD SCI USA, V103, P11946, DOI 10.1073/pnas.0510138103; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Yao SQ, 2006, CELL, V125, P343, DOI 10.1016/j.cell.2006.02.040; Zhang W, 2006, DEV CELL, V10, P657, DOI 10.1016/j.devcel.2006.04.005; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	26	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19169	19172		10.1074/jbc.C109.011957	http://dx.doi.org/10.1074/jbc.C109.011957			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19478089	Green Published, hybrid			2022-12-25	WOS:000267908300004
J	Nakajima, M; Nishimoto, M; Kitaoka, M				Nakajima, Masahiro; Nishimoto, Mamoru; Kitaoka, Motomitsu			Characterization of Three beta-Galactoside Phosphorylases from Clostridium phytofermentans DISCOVERY OF D-GALACTOSYL-beta 1 -> 4-L-RHAMNOSE PHOSPHORYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-BIOSE PHOSPHORYLASE; GLYCOSIDE HYDROLASE FAMILY; CELLOBIOSE PHOSPHORYLASE; BIFIDOBACTERIUM-LONGUM; REACTION-MECHANISM; METABOLIC PATHWAY; MOLECULAR-CLONING; SIGNAL PEPTIDES; BINDING PROTEIN; IDENTIFICATION	We characterized three D-galactosyl-beta 1 -> 3-N-acetyl-D-hexosamine phosphorylase (EC 2.4.1.211) homologs from Clostridium phytofermentans (Cphy0577, Cphy1920, and Cphy3030 proteins). Cphy0577 and Cphy3030 proteins exhibited similar activity on galacto-N-biose (GNB; D-Gal-beta 1 -> 3-D-GalNAc) and lacto-N-biose I (LNB; D-Gal-beta 1 -> 3-D-GlcNAc), thus indicating that they are D-galactosyl-beta 1 -> 3-N-acetyl-D-hexosamine phosphorylases, subclassified as GNB/LNB phosphorylase. In contrast, Cphy1920 protein phosphorolyzed neither GNB nor LNB. It showed the highest activity with L-rhamnose as the acceptor in the reverse reaction using alpha-D-galactose 1-phosphate as the donor. The reaction product was D-galactosyl-beta 1 -> 4-L-rhamnose. The enzyme also showed activity on L-mannose, L-lyxose, D-glucose, 2-deoxy-D-glucose, and D-galactose in this order. When D-glucose derivatives were used as acceptors, reaction products were beta-1,3-galactosides. Kinetic parameters of phosphorolytic activity on D-galactosyl-beta 1 -> 4-L-rhamnose were k(cat) = 45 s(-1) and K-m = 7.9 mM, thus indicating that these values are common among other phosphorylases. We propose D-galactosyl-beta 1 -> 4-L-rhamnose phosphorylase as the name for Cphy1920 protein.	[Nakajima, Masahiro; Nishimoto, Mamoru; Kitaoka, Motomitsu] Natl Agr & Food Res Org, Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan	National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan	Kitaoka, M (corresponding author), Natl Agr & Food Res Org, Natl Food Res Inst, 2-1-12 Kannondai, Tsukuba, Ibaraki 3058642, Japan.	mkitaoka@affrc.go.jp	Nakajima, Masahiro/J-3566-2019; Kitaoka, Motomitsu/R-1536-2019	Nakajima, Masahiro/0000-0002-3182-0859; Kitaoka, Motomitsu/0000-0002-0083-1838				Andersson U, 2001, J BIOL CHEM, V276, P42707, DOI 10.1074/jbc.M108279200; Ashida H, 2008, GLYCOBIOLOGY, V18, P727, DOI 10.1093/glycob/cwn053; ASPINALL GO, 1978, CAN J CHEM, V56, P685, DOI 10.1139/v78-112; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bubb WA, 1997, CARBOHYD RES, V301, P41, DOI 10.1016/S0008-6215(97)00083-9; Cantarel BL, 2009, NUCLEIC ACIDS RES, V37, pD233, DOI 10.1093/nar/gkn663; Coutinho PM, 1999, ROY SOC CH, P3; DEBRUYN A, 1976, CARBOHYD RES, V47, P158, DOI 10.1016/S0008-6215(00)83559-4; Derensy-Dron D, 1999, BIOTECHNOL APPL BIOC, V29, P3; Fujita K, 2005, J BIOL CHEM, V280, P37415, DOI 10.1074/jbc.M506874200; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Hidaka M, 2002, J MOL BIOL, V322, P79, DOI 10.1016/S0022-2836(02)00746-5; Hidaka M, 2006, BIOCHEM J, V398, P37, DOI 10.1042/BJ20060274; Hidaka M, 2009, J BIOL CHEM, V284, P7273, DOI 10.1074/jbc.M808525200; Honda Y, 2004, BIOCHEM J, V377, P225, DOI 10.1042/BJ20031171; Katayama T, 2004, J BACTERIOL, V186, P4885, DOI 10.1128/JB.186.15.4885-4893.2004; Kim YK, 2002, J BIOCHEM, V132, P197, DOI 10.1093/oxfordjournals.jbchem.a003210; KITAOKA M, 1992, BIOSCI BIOTECH BIOCH, V56, P652, DOI 10.1271/bbb.56.652; Kitaoka M, 2005, APPL ENVIRON MICROB, V71, P3158, DOI 10.1128/AEM.71.6.3158-3162.2005; Kitaoka M, 2002, TRENDS GLYCOSCI GLYC, V14, P35, DOI 10.4052/tigg.14.35; KITAOKA M, 1993, ARCH BIOCHEM BIOPHYS, V304, P508, DOI 10.1006/abbi.1993.1383; Koutsioulis D, 2008, GLYCOBIOLOGY, V18, P799, DOI 10.1093/glycob/cwn069; LOWRY OH, 1946, J BIOL CHEM, V162, P421; Mega T, 2007, BIOSCI BIOTECH BIOCH, V71, P2893, DOI 10.1271/bbb.70240; MURAO S, 1985, AGR BIOL CHEM TOKYO, V49, P2113, DOI 10.1080/00021369.1985.10867024; Nagae M, 2007, J BIOL CHEM, V282, P18497, DOI 10.1074/jbc.M702246200; Nakajima M, 2008, APPL ENVIRON MICROB, V74, P6333, DOI 10.1128/AEM.02846-07; Nakajima M, 2008, APPL MICROBIOL BIOT, V78, P465, DOI 10.1007/s00253-007-1319-8; Nakajima M, 2009, APPL MICROBIOL BIOT, V83, P109, DOI 10.1007/s00253-008-1838-y; Nidetzky B, 2000, BIOCHEM J, V351, P649, DOI 10.1042/0264-6021:3510649; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nihira T, 2007, ANAL BIOCHEM, V371, P259, DOI 10.1016/j.ab.2007.07.012; Nishimoto M, 2007, BIOSCI BIOTECH BIOCH, V71, P2101, DOI 10.1271/bbb.70320; Nishimoto M, 2007, APPL ENVIRON MICROB, V73, P6444, DOI 10.1128/AEM.01425-07; Nishimoto M, 2007, BIOSCI BIOTECH BIOCH, V71, P1587, DOI 10.1271/bbb.70064; Polle AY, 2002, CARBOHYD POLYM, V49, P337, DOI 10.1016/S0144-8617(01)00346-0; Rajashekhara E, 2002, BIOSCI BIOTECH BIOCH, V66, P2578, DOI 10.1271/bbb.66.2578; SILVERSTEIN R, 1967, J BIOL CHEM, V242, P1338; STORVICK WO, 1960, J BIOL CHEM, V235, P303; Suzuki R, 2008, J BIOL CHEM, V283, P13165, DOI 10.1074/jbc.M709777200; SWISHER EJ, 1964, J BACTERIOL, V88, P817, DOI 10.1128/JB.88.4.817-820.1964; TSUMURAYA Y, 1990, ARCH BIOCHEM BIOPHYS, V281, P58, DOI 10.1016/0003-9861(90)90412-R; Wada J, 2008, APPL ENVIRON MICROB, V74, P3996, DOI 10.1128/AEM.00149-08; Wada J, 2007, ACTA CRYSTALLOGR F, V63, P751, DOI 10.1107/S1744309107036263; Warnick TA, 2002, INT J SYST EVOL MICR, V52, P1155, DOI [10.1099/ijs.0.02125-0, 10.1099/00207713-52-4-1155]	45	32	36	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19220	19227		10.1074/jbc.M109.007666	http://dx.doi.org/10.1074/jbc.M109.007666			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19491100	Green Published, hybrid			2022-12-25	WOS:000267908300012
J	Mateo, F; Vidal-Laliena, M; Canela, N; Busino, L; Martinez-Balbas, MA; Pagano, M; Agell, N; Bachs, O				Mateo, F.; Vidal-Laliena, M.; Canela, N.; Busino, L.; Martinez-Balbas, M. A.; Pagano, M.; Agell, N.; Bachs, O.			Degradation of cyclin A is regulated by acetylation	ONCOGENE			English	Article						acetylation; cyclin A; degradation; P/CAF; ubiquitylation	SPINDLE ASSEMBLY CHECKPOINT; DEPENDENT KINASES; DNA-DAMAGE; CELL-CYCLE; S-PHASE; MITOSIS; CDC20; UBIQUITINATION; DESTRUCTION; COMPLEX	Cyclin A accumulates at the onset of S phase, remains high during G(2) and early mitosis and is degraded at prometaphase. Here, we report that the acetyltransferase P/CAF directly interacts with cyclin A that as a consequence becomes acetylated at lysines 54,68, 95 and 112. Maximal acetylation occurs simultaneously to ubiquitylation at mitosis, indicating importance of acetylation on cyclin A stability. This was further confirmed by the observation that the pseudoacetylated cyclin A mutant can be ubiquitylated whereas the nonacetylatable mutant cannot. The nonacetylatable mutant is more stable than cyclin A WT (cycA WT) and arrests cell cycle at mitosis. Moreover, in cells treated with histone deacetylase inhibitors cyclin A acetylation increases and its stability decreases, thus supporting the function of acetylation on cyclin A degradation. Although the nonacetylatable mutant cannot be ubiquitylated, it interacts with the proteins needed for its degradation (cdks, Cks, Cdc 20, Cdh1 and APC/C). In fact, its association with cdks is increased and its complexes with these kinases display higher activity than control cycA WT-cdk complexes. All these results indicate that cyclin A acetylation at specific lysines is crucial for cyclin A stability and also has a function in the regulation of cycA-cdk activity. Oncogene (2009) 28, 2654-2666; doi: 10.1038/onc.2009.127; published online 1 June 2009	[Mateo, F.; Vidal-Laliena, M.; Canela, N.; Agell, N.; Bachs, O.] Univ Barcelona, Dept Pathol & Cell Biol, Fac Med, E-08036 Barcelona, Spain; [Busino, L.; Pagano, M.] NYU, Sch Med, Dept Pathol, NYU Canc Inst,Smilow Res Ctr, New York, NY USA; [Martinez-Balbas, M. A.] CSIC, Inst Biol Mol Barcelona, Barcelona, Spain; [Pagano, M.] NYU, Sch Med, Howard Hughes Med Inst, New York, NY USA	University of Barcelona; New York University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Howard Hughes Medical Institute; New York University	Bachs, O (corresponding author), Univ Barcelona, Dept Pathol & Cell Biol, Fac Med, Casanova 143, E-08036 Barcelona, Spain.	obachs@ub.edu	Mateo, Francesca/K-7746-2015; Agell, Neus/E-9640-2016; Canela, Núria/I-5401-2015	Mateo, Francesca/0000-0002-2342-7010; Agell, Neus/0000-0002-1205-6074; Canela, Núria/0000-0003-0261-2396; Martinez-Balbas, Marian/0000-0003-0173-0964; pagano, michele/0000-0003-3210-2442	Ministerio de Educacion y Ciencia of Spain [SAF2006-05212, SAF2007-60491]; RETICS [RD06/0020/0010]; Instituto de Salud Carlos III; National Institutes of Health [R01-GM57587, R37-CA76584, R21-CA125173]; Multiple Myeloma Research foundation to Michele Pagano; Michele Pagano is an Investigator with the Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [R21CA125173, R21CA161108, R37CA076584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER	Ministerio de Educacion y Ciencia of Spain(Spanish Government); RETICS; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Multiple Myeloma Research foundation to Michele Pagano; Michele Pagano is an Investigator with the Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by grants SAF2006-05212 and SAF2007-60491 from the Ministerio de Educacion y Ciencia of Spain and RETICS RD06/0020/0010 from the Instituto de Salud Carlos III. It was also supported by grants from the National Institutes of Health (R01-GM57587, R37-CA76584, and R21-CA125173) and the Multiple Myeloma Research foundation to Michele Pagano. Michele Pagano is an Investigator with the Howard Hughes Medical Institute.	Abramova MV, 2006, J BIOL CHEM, V281, P21040, DOI 10.1074/jbc.M511059200; Baek SY, 2006, NEUROSCI LETT, V396, P230, DOI 10.1016/j.neulet.2005.11.041; Bloom J, 2007, NAT REV MOL CELL BIO, V8, P149, DOI 10.1038/nrm2105; Canela N, 2006, J BIOL CHEM, V281, P35942, DOI 10.1074/jbc.M603511200; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fung TK, 2005, CELL CYCLE, V4, P1411, DOI 10.4161/cc.4.10.2046; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Galbiati L, 2005, CELL CYCLE, V4, P930, DOI 10.4161/cc.4.7.1784; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gong DQ, 2007, CURR BIOL, V17, P85, DOI 10.1016/j.cub.2006.11.066; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Klotzbucher A, 1996, EMBO J, V15, P3053, DOI 10.1002/j.1460-2075.1996.tb00668.x; Leduc C, 2006, ONCOGENE, V25, P4147, DOI 10.1038/sj.onc.1209446; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Linares LK, 2007, NAT CELL BIOL, V9, P331, DOI 10.1038/ncb1545; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nagy Z, 2007, ONCOGENE, V26, P5341, DOI 10.1038/sj.onc.1210604; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; PAGANO M, 1991, Progress in Growth Factor Research, V3, P267, DOI 10.1016/0955-2235(91)90004-N; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Ramachandran V, 2007, CELL CYCLE, V6, P171, DOI 10.4161/cc.6.2.3716; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; Sadoul K, 2008, BIOCHIMIE, V90, P306, DOI 10.1016/j.biochi.2007.06.009; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schiltz RL, 2000, BBA-REV CANCER, V1470, pM37, DOI 10.1016/S0304-419X(99)00037-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimazu T, 2006, ONCOGENE, V25, P7391, DOI 10.1038/sj.onc.1209731; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Sullivan M, 2007, NAT REV MOL CELL BIO, V8, P894, DOI 10.1038/nrm2276; van Leuken R, 2008, BBA-REV CANCER, V1786, P49, DOI 10.1016/j.bbcan.2008.05.002; Wolthuis R, 2008, MOL CELL, V30, P290, DOI 10.1016/j.molcel.2008.02.027	42	45	48	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2654	2666		10.1038/onc.2009.127	http://dx.doi.org/10.1038/onc.2009.127			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19483727	Green Submitted, Green Accepted			2022-12-25	WOS:000268211200004
J	Gispert, S; Ricciardi, F; Kurz, A; Azizov, M; Hoepken, HH; Becker, D; Voos, W; Leuner, K; Muller, WE; Kudin, AP; Kunz, WS; Zimmermann, A; Roeper, J; Wenzel, D; Jendrach, M; Garcia-Arencibia, M; Fernandez-Ruiz, J; Huber, L; Rohrer, H; Barrera, M; Reichert, AS; Rub, U; Chen, A; Nussbaum, RL; Auburger, G				Gispert, Suzana; Ricciardi, Filomena; Kurz, Alexander; Azizov, Mekhman; Hoepken, Hans-Hermann; Becker, Dorothea; Voos, Wolfgang; Leuner, Kristina; Mueller, Walter E.; Kudin, Alexei P.; Kunz, Wolfram S.; Zimmermann, Annabelle; Roeper, Jochen; Wenzel, Dirk; Jendrach, Marina; Garcia-Arencibia, Moises; Fernandez-Ruiz, Javier; Huber, Leslie; Rohrer, Hermann; Barrera, Miguel; Reichert, Andreas S.; Rueb, Udo; Chen, Amy; Nussbaum, Robert L.; Auburger, Georg			Parkinson Phenotype in Aged PINK1-Deficient Mice Is Accompanied by Progressive Mitochondrial Dysfunction in Absence of Neurodegeneration	PLOS ONE			English	Article								Background: Parkinson's disease (PD) is an adult-onset movement disorder of largely unknown etiology. We have previously shown that loss-of-function mutations of the mitochondrial protein kinase PINK1 (PTEN induced putative kinase 1) cause the recessive PARK6 variant of PD. Methodology/Principal Findings: Now we generated a PINK1 deficient mouse and observed several novel phenotypes: A progressive reduction of weight and of locomotor activity selectively for spontaneous movements occurred at old age. As in PD, abnormal dopamine levels in the aged nigrostriatal projection accompanied the reduced movements. Possibly in line with the PARK6 syndrome but in contrast to sporadic PD, a reduced lifespan, dysfunction of brainstem and sympathetic nerves, visible aggregates of alpha-synuclein within Lewy bodies or nigrostriatal neurodegeneration were not present in aged PINK1-deficient mice. However, we demonstrate PINK1 mutant mice to exhibit a progressive reduction in mitochondrial preprotein import correlating with defects of core mitochondrial functions like ATP-generation and respiration. In contrast to the strong effect of PINK1 on mitochondrial dynamics in Drosophila melanogaster and in spite of reduced expression of fission factor Mtp18, we show reduced fission and increased aggregation of mitochondria only under stress in PINK1-deficient mouse neurons. Conclusion: Thus, aging Pink1(-/-) mice show increasing mitochondrial dysfunction resulting in impaired neural activity similar to PD, in absence of overt neuronal death.	Univ Bonn, Med Ctr, Dept Epileptol, Bonn, Germany	University of Bonn	Gispert, S (corresponding author), Univ Med Sch, Dept Neurol, Frankfurt, Germany.	auburger@em.uni-frankfurt.de	Reichert, Andreas/A-4090-2012; Garcia-Arencibia, Moises/K-9920-2013; Kunz, Wolfram/K-1232-2019; Garcia-Arencibia, Moises/B-5538-2012; Friedland, Kristina/G-4651-2015; FERNANDEZ RUIZ, JOSE JAVIER/S-3875-2018	Garcia-Arencibia, Moises/0000-0002-1618-4487; Kunz, Wolfram/0000-0003-1113-3493; Reichert, Andreas/0000-0001-9340-3113; Friedland, Kristina/0000-0001-8603-5957; FERNANDEZ RUIZ, JOSE JAVIER/0000-0002-4490-0604; Muller, Werner E.G./0000-0002-8223-3689; Roeper, Jochen/0000-0003-2145-8742				Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769; Bentivoglio AR, 2001, MOVEMENT DISORD, V16, P999, DOI 10.1002/mds.10034; Chandra S, 2004, P NATL ACAD SCI USA, V101, P14966, DOI 10.1073/pnas.0406283101; Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779; CROUCH SPM, 1993, J IMMUNOL METHODS, V160, P81, DOI 10.1016/0022-1759(93)90011-U; Dagda R. K., 2009, J BIOL CHEM; David DC, 2005, J BIOL CHEM, V280, P23802, DOI 10.1074/jbc.M500356200; Deng HS, 2008, P NATL ACAD SCI USA, V105, P14503, DOI 10.1073/pnas.0803998105; Duvezin-Caubet S, 2006, J BIOL CHEM, V281, P37972, DOI 10.1074/jbc.M606059200; Exner N, 2007, J NEUROSCI, V27, P12413, DOI 10.1523/JNEUROSCI.0719-07.2007; Gandhi S, 2009, MOL CELL, V33, P627, DOI 10.1016/j.molcel.2009.02.013; Gautier CA, 2008, P NATL ACAD SCI USA, V105, P11364, DOI 10.1073/pnas.0802076105; Gispert S, 2003, MOL CELL NEUROSCI, V24, P419, DOI 10.1016/S1044-7431(03)00198-2; Hoepken HH, 2008, EXP NEUROL, V212, P307, DOI 10.1016/j.expneurol.2008.04.004; Hoepken HH, 2007, NEUROBIOL DIS, V25, P401, DOI 10.1016/j.nbd.2006.10.007; Johnston AJ, 2002, J BIOL CHEM, V277, P42197, DOI 10.1074/jbc.M205613200; Kahle PJ, 2008, ACTA NEUROPATHOL, V115, P87, DOI 10.1007/s00401-007-0302-x; Keil U, 2006, BRIT J PHARMACOL, V147, P199, DOI 10.1038/sj.bjp.0706459; KENNEDY WR, 1984, NEUROSCIENCE, V11, P741, DOI 10.1016/0306-4522(84)90057-5; Kim Y, 2008, BIOCHEM BIOPH RES CO, V377, P975, DOI 10.1016/j.bbrc.2008.10.104; KITADA T, 2007, P NATL ACAD SCI US; Krohn AJ, 1998, J NEUROSCI, V18, P8186; Kun E, 1979, Methods Enzymol, V55, P115; Lastres-Becker I, 2005, NEUROBIOL DIS, V19, P96, DOI 10.1016/j.nbd.2004.11.009; Liss B, 2005, NAT NEUROSCI, V8, P1742, DOI 10.1038/nn1570; Martella G, 2009, EXP NEUROL, V215, P388, DOI 10.1016/j.expneurol.2008.11.001; Mattson MP, 2007, NEUROCHEM RES, V32, P707, DOI 10.1007/s11064-006-9170-3; McBride HM, 2008, J CELL BIOL, V183, P757, DOI 10.1083/jcb.200810184; Nakajima A, 2003, CANCER LETT, V201, P195, DOI 10.1016/S0304-3835(03)00443-9; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788; PICCOLI C, 2008, NEUROCHEM RES; Plun-Favreau H, 2007, NAT CELL BIOL, V9, P1243, DOI 10.1038/ncb1644; Poole AC, 2008, P NATL ACAD SCI USA, V105, P1638, DOI 10.1073/pnas.0709336105; Pridgeon JW, 2007, PLOS BIOL, V5, P1494, DOI 10.1371/journal.pbio.0050172; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Schestatsky P, 2006, MOVEMENT DISORD, V21, P1744, DOI 10.1002/mds.21006; Silvestri L, 2005, HUM MOL GENET, V14, P3477, DOI 10.1093/hmg/ddi377; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Stanke M, 2006, DEVELOPMENT, V133, P141, DOI 10.1242/dev.02189; Tondera D, 2005, J CELL SCI, V118, P3049, DOI 10.1242/jcs.02415; Tondera D, 2004, J BIOL CHEM, V279, P31544, DOI 10.1074/jbc.M404704200; Truscott KN, 1999, BIOL CHEM, V380, P1151, DOI 10.1515/BC.1999.146; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; von Coelln R, 2004, P NATL ACAD SCI USA, V101, P10744, DOI 10.1073/pnas.0401297101; Wang DL, 2006, P NATL ACAD SCI USA, V103, P13520, DOI 10.1073/pnas.0604661103; Wood-Kaczmar A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002455; Yang YF, 2008, P NATL ACAD SCI USA, V105, P7070, DOI 10.1073/pnas.0711845105; Zhou C, 2008, P NATL ACAD SCI USA, V105, P12022, DOI 10.1073/pnas.0802814105	49	264	269	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2009	4	6							e5777	10.1371/journal.pone.0005777	http://dx.doi.org/10.1371/journal.pone.0005777			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453PV	19492057	Green Submitted, gold, Green Published			2022-12-25	WOS:000266624300013
J	Duda, TF; Lee, T				Duda, Thomas F., Jr.; Lee, Taehwan			Ecological Release and Venom Evolution of a Predatory Marine Snail at Easter Island	PLOS ONE			English	Article								Background: Ecological release is coupled with adaptive radiation and ecological diversification yet little is known about the molecular basis of phenotypic changes associated with this phenomenon. The venomous, predatory marine gastropod Conus miliaris has undergone ecological release and exhibits increased dietary breadth at Easter Island. Methodology/Principal Findings: We examined the extent of genetic differentiation of two genes expressed in the venom of C. miliaris among samples from Easter Island, American Samoa and Guam. The population from Easter Island exhibits unique frequencies of alleles that encode distinct peptides at both loci. Levels of divergence at these loci exceed observed levels of divergence observed at a mitochondrial gene region at Easter Island. Conclusions/Significance: Patterns of genetic variation at two genes expressed in the venom of this C. miliaris suggest that selection has operated at these genes and contributed to the divergence of venom composition at Easter Island. These results show that ecological release is associated with strong selection pressures that promote the evolution of new phenotypes.			Duda, TF (corresponding author), Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA.	tfduda@umich.edu						Abzhanov A, 2004, SCIENCE, V305, P1462, DOI 10.1126/science.1098095; Beaumont MA, 2005, TRENDS ECOL EVOL, V20, P435, DOI 10.1016/j.tree.2005.05.017; Binford GJ, 2001, BIOL J LINN SOC, V74, P581, DOI 10.1111/j.1095-8312.2001.tb01415.x; BIRKY CW, 1983, GENETICS, V103, P513; Bolnick DI, 2007, P NATL ACAD SCI USA, V104, P10075, DOI 10.1073/pnas.0703743104; Bolnick DI, 2003, AM NAT, V161, P1, DOI 10.1086/343878; Clement M, 2000, MOL ECOL, V9, P1657, DOI 10.1046/j.1365-294x.2000.01020.x; Creer S, 2003, J MOL EVOL, V56, P317, DOI 10.1007/s00239-002-2403-4; Daltry JC, 1996, NATURE, V379, P537, DOI 10.1038/379537a0; Duda TF, 2008, MOL ECOL, V17, P3018, DOI 10.1111/j.1365-294X.2008.03804.x; Duda TF, 1999, P NATL ACAD SCI USA, V96, P6820, DOI 10.1073/pnas.96.12.6820; Duda TF, 2001, BIOL J LINN SOC, V73, P391, DOI 10.1006/bijl.2001.0544; DUDA TF, 2009, MARINE BIOL IN PRESS; Gibbs HL, 2008, J MOL EVOL, V66, P151, DOI 10.1007/s00239-008-9067-7; Hedrick PW, 1999, EVOLUTION, V53, P313, DOI 10.1111/j.1558-5646.1999.tb03767.x; JUKES T H, 1969, P21; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KOHN AJ, 1978, ECOL MONOGR, V48, P323, DOI 10.2307/2937234; Kohn AJ, 2001, CORAL REEFS, V20, P25; Lewis RJ, 2000, J BIOL CHEM, V275, P35335, DOI 10.1074/jbc.M002252200; LEWONTIN RC, 1973, GENETICS, V74, P175; Nosil P, 2005, BIOL J LINN SOC, V86, P297, DOI 10.1111/j.1095-8312.2005.00517.x; Olivera BM, 1999, ANN NY ACAD SCI, V870, P223, DOI 10.1111/j.1749-6632.1999.tb08883.x; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Rehder HA., 1980, SMITHSONIAN CONTRIB, V239, P1, DOI [10.5479/si.00810282.289, DOI 10.5479/SI.00810282.289]; Rockel D, 1995, MANUAL LIVING CONIDA; Schluter D., 2000, ECOLOGY ADAPTIVE RAD; SCHNEIDER S, 2000, ARLEQUIN VER 2 0 SOF; Shapiro MD, 2004, NATURE, V428, P717, DOI 10.1038/nature02415; Simpson G. G., 1953, MAJOR FEATURES EVOLU, DOI DOI 10.7312/SIMP93764; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; TAYLOR MFJ, 1995, SCIENCE, V270, P1497, DOI 10.1126/science.270.5241.1497; TEMPLETON AR, 1992, GENETICS, V132, P619; Van VALEN LEIGH, 1965, AMER NATUR, V99, P377, DOI 10.1086/282379; Vermeij GJ, 2000, PALEOBIOLOGY, V26, P19, DOI 10.1666/0094-8373(2000)026<0019:TMGSRP>2.0.CO;2; WILSON EO, 1961, AM NAT, V95, P169, DOI 10.1086/282174; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555	37	28	28	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5558	10.1371/journal.pone.0005558	http://dx.doi.org/10.1371/journal.pone.0005558			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448AY	19462001	Green Published, Green Submitted, gold			2022-12-25	WOS:000266234700006
J	Haridas, V; Nishimura, G; Xu, ZX; Connolly, F; Hanausek, M; Walaszek, Z; Zoltaszek, R; Gutterman, JU				Haridas, Valsala; Nishimura, Goshi; Xu, Zhi-Xiang; Connolly, Fiona; Hanausek, Margaret; Walaszek, Zbigniew; Zoltaszek, Robert; Gutterman, Jordan U.			Avicin D: A Protein Reactive Plant Isoprenoid Dephosphorylates Stat 3 by Regulating Both Kinase and Phosphatase Activities	PLOS ONE			English	Article							ACACIA-VICTORIAE BENTHAM; TRITERPENOID SAPONINS; SERINE PHOSPHORYLATION; JAK/STAT PATHWAY; NATURAL-PRODUCTS; VEGF EXPRESSION; ACTIVATION; TRANSCRIPTION; APOPTOSIS; CARCINOMA	Avicins, a class of electrophilic triterpenoids with pro-apoptotic, anti-inflammatory and antioxidant properties, have been shown to induce redox-dependant post-translational modification of cysteine residues to regulate protein function. Based on (a) the cross-talk that occurs between redox and phosphorylation processes, and (b) the role of Stat3 in the process of apoptosis and carcinogenesis, we chose to study the effects of avicins on the processes of phosphorylation/ dephosphorylation in Stat3. Avicins dephosphorylate Stat3 in a variety of human tumor cell lines, leading to a decrease in the transcriptional activity of Stat3. The expression of Stat3-regulated proteins such as c-myc, cyclin D1, Bcl2, survivin and VEGF were reduced in response to avicin treatment. Underlying avicin-induced dephosphorylation of Stat3 was dephosphorylation of JAKs, as well as activation of protein phosphatase-1. Downregulation of both Stat3 activity and expression of Stat 3-controlled pro-survival proteins, contributes to the induction of apoptosis in avicin treated tumor cells. Based on the role of Stat3 in inflammation and wounding, and the in vivo inhibition of VEGF by avicins in a mouse skin carcinogenesis model, it is likely that avicin-induced inhibition of Stat3 activity results in the suppression of the pro-inflammatory and pro-oxidant stromal environment of tumors. Activation of PP-1, which also acts as a cellular economizer, combined with the redox regulation by avicins, can aid in redirecting metabolism from growth promoting anabolic to energy sparing pathways.			Haridas, V (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.	vharidas@mdanderson.org						Alvarez JV, 2004, CANCER BIOL THER, V3, P1045, DOI 10.4161/cbt.3.11.1172; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863; Bhattacharya S, 2003, J CLIN INVEST, V111, P553, DOI 10.1172/JCI200315372; Blackstone NW, 2005, P ROY SOC B-BIOL SCI, V272, P527, DOI 10.1098/rspb.2004.2981; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Caceres-Cortes JR, 2008, ANTI-CANCER AGENT ME, V8, P717, DOI 10.2174/187152008785914752; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Dauer DJ, 2005, ONCOGENE, V24, P3397, DOI 10.1038/sj.onc.1208469; DePinho RA, 2003, J CLIN INVEST, V111, pS9; Drahl C, 2005, ANGEW CHEM INT EDIT, V44, P5788, DOI 10.1002/anie.200500900; Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x; Frank DA, 1999, MOL MED, V5, P432; Fung MM, 2003, CELL SIGNAL, V15, P625, DOI 10.1016/S0898-6568(03)00003-2; Gaikwad A, 2005, CLIN CANCER RES, V11, P1953, DOI 10.1158/1078-0432.CCR-04-1704; Gibbons JA, 2005, J BIOL CHEM, V280, P15903, DOI 10.1074/jbc.M500871200; Hanausek M, 2001, P NATL ACAD SCI USA, V98, P11551, DOI 10.1073/pnas.191363198; Haridas V, 2005, P NATL ACAD SCI USA, V102, P10088, DOI 10.1073/pnas.0504430102; Haridas V, 2004, J CLIN INVEST, V113, P65, DOI 10.1172/JCI200418699; Haridas V, 2001, P NATL ACAD SCI USA, V98, P5821, DOI 10.1073/pnas.101619098; Haridas V, 2001, P NATL ACAD SCI USA, V98, P11557, DOI 10.1073/pnas.191363498; Haridas V, 2007, MITOCHONDRION, V7, P234, DOI 10.1016/j.mito.2006.12.005; Harris TJ, 2007, J IMMUNOL, V179, P4313, DOI 10.4049/jimmunol.179.7.4313; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jayatilake GS, 2003, J NAT PROD, V66, P779, DOI 10.1021/np020400v; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Klampfer L, 2006, CURR CANCER DRUG TAR, V6, P107, DOI 10.2174/156800906776056491; Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/nrd1657; Kuroki M, 1999, BIOCHEM J, V341, P691, DOI 10.1042/0264-6021:3410691; Lemeshko VV, 2006, ARCH BIOCHEM BIOPHYS, V454, P114, DOI 10.1016/j.abb.2006.08.008; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lovato P, 2003, J BIOL CHEM, V278, P16777, DOI 10.1074/jbc.M207999200; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Masuda M, 2003, CLIN CANCER RES, V9, P3486; MITSIADES CS, 2004, BLOOD, V104, P2403; Mujoo K, 2001, CANCER RES, V61, P5486; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Padilla PA, 2002, MOL BIOL CELL, V13, P1473, DOI 10.1091/mbc.01-12-0594; Paterson I, 2005, SCIENCE, V310, P451, DOI 10.1126/science.1116364; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Sandberg EM, 2005, J MED CHEM, V48, P2526, DOI 10.1021/jm049470k; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schultz JC, 2002, NATURE, V416, P267, DOI 10.1038/416267a; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Ulukaya E, 2004, CHEMOTHERAPY, V50, P43, DOI 10.1159/000077285; Walsh C., 2006, POSTTRANSLATIONAL MO; Walsh CT, 2005, ANGEW CHEM INT EDIT, V44, P7342, DOI 10.1002/anie.200501023; Walsh CT, 2005, NAT CHEM BIOL, V1, P122, DOI 10.1038/nchembio0805-122; Woetmann A, 1999, P NATL ACAD SCI USA, V96, P10620, DOI 10.1073/pnas.96.19.10620; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Xu ZX, 2007, CELL DEATH DIFFER, V14, P1948, DOI 10.1038/sj.cdd.4402207; Yang JB, 2007, GENE DEV, V21, P1396, DOI 10.1101/gad.1553707; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhang CL, 2008, J INVEST DERMATOL, V128, P2728, DOI 10.1038/jid.2008.138; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607	65	18	20	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5578	10.1371/journal.pone.0005578	http://dx.doi.org/10.1371/journal.pone.0005578			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440292	gold, Green Published, Green Submitted			2022-12-25	WOS:000266107500009
J	Vuilleumier, S; Chistoserdova, L; Lee, MC; Bringel, F; Lajus, A; Zhou, Y; Gourion, B; Barbe, V; Chang, J; Cruveiller, S; Dossat, C; Gillett, W; Gruffaz, C; Haugen, E; Hourcade, E; Levy, R; Mangenot, S; Muller, E; Nadalig, T; Pagni, M; Penny, C; Peyraud, R; Robinson, DG; Roche, D; Rouy, Z; Saenampechek, C; Salvignol, G; Vallenet, D; Wu, ZN; Marx, CJ; Vorholt, JA; Olson, MV; Kaul, R; Weissenbach, J; Medigue, C; Lidstrom, ME				Vuilleumier, Stephane; Chistoserdova, Ludmila; Lee, Ming-Chun; Bringel, Francoise; Lajus, Aurelie; Zhou, Yang; Gourion, Benjamin; Barbe, Valerie; Chang, Jean; Cruveiller, Stephane; Dossat, Carole; Gillett, Will; Gruffaz, Christelle; Haugen, Eric; Hourcade, Edith; Levy, Ruth; Mangenot, Sophie; Muller, Emilie; Nadalig, Thierry; Pagni, Marco; Penny, Christian; Peyraud, Remi; Robinson, David G.; Roche, David; Rouy, Zoe; Saenampechek, Channakhone; Salvignol, Gregory; Vallenet, David; Wu, Zaining; Marx, Christopher J.; Vorholt, Julia A.; Olson, Maynard V.; Kaul, Rajinder; Weissenbach, Jean; Medigue, Claudine; Lidstrom, Mary E.			Methylobacterium Genome Sequences: A Reference Blueprint to Investigate Microbial Metabolism of C1 Compounds from Natural and Industrial Sources	PLOS ONE			English	Article							ACETIC-ACID BACTERIUM; EXTORQUENS AM1; METHANOL DEHYDROGENASE; METHYLOTROPHIC BACTERIA; SP-NOV.; METHYLOBACILLUS-FLAGELLATUS; OBLIGATE METHYLOTROPHY; INSERTION SEQUENCES; UTILIZATION GENES; SERINE CYCLE	Background: Methylotrophy describes the ability of organisms to grow on reduced organic compounds without carbon-carbon bonds. The genomes of two pink-pigmented facultative methylotrophic bacteria of the Alpha-proteobacterial genus Methylobacterium, the reference species Methylobacterium extorquens strain AM1 and the dichloromethane-degrading strain DM4, were compared. Methodology/Principal Findings: The 6.88 Mb genome of strain AM1 comprises a 5.51 Mb chromosome, a 1.26 Mb megaplasmid and three plasmids, while the 6.12 Mb genome of strain DM4 features a 5.94 Mb chromosome and two plasmids. The chromosomes are highly syntenic and share a large majority of genes, while plasmids are mostly strain-specific, with the exception of a 130 kb region of the strain AM1 megaplasmid which is syntenic to a chromosomal region of strain DM4. Both genomes contain large sets of insertion elements, many of them strain-specific, suggesting an important potential for genomic plasticity. Most of the genomic determinants associated with methylotrophy are nearly identical, with two exceptions that illustrate the metabolic and genomic versatility of Methylobacterium. A 126 kb dichloromethane utilization (dcm) gene cluster is essential for the ability of strain DM4 to use DCM as the sole carbon and energy source for growth and is unique to strain DM4. The methylamine utilization (mau) gene cluster is only found in strain AM1, indicating that strain DM4 employs an alternative system for growth with methylamine. The dcm and mau clusters represent two of the chromosomal genomic islands (AM1: 28; DM4: 17) that were defined. The mau cluster is flanked by mobile elements, but the dcm cluster disrupts a gene annotated as chelatase and for which we propose the name "island integration determinant'' (iid). Conclusion/Significance: These two genome sequences provide a platform for intra- and interspecies genomic comparisons in the genus Methylobacterium, and for investigations of the adaptive mechanisms which allow bacterial lineages to acquire methylotrophic lifestyles.			Vuilleumier, S (corresponding author), Univ Strasbourg, Dept Microorganismes, CNRS, UMR7156, Strasbourg, France.	vuilleumier@unistra.fr; milachis@u.washington.edu	Peyraud, Rémi/G-5226-2010; Vuilleumier, Stéphane/D-2647-2012; Muller, Emilie/J-8727-2019; Vorholt, Julia/K-3514-2016; Bringel, Francoise/AAQ-6484-2021; Muller, emilie/B-3418-2015; Gourion, Benjamin/AAG-9063-2019; Chistoserdova, Ludmila/K-2364-2017	Peyraud, Rémi/0000-0002-7580-042X; Vuilleumier, Stéphane/0000-0003-2232-7023; Muller, Emilie/0000-0002-3750-2966; Vorholt, Julia/0000-0002-6011-4910; Bringel, Francoise/0000-0002-4529-5143; Muller, emilie/0000-0002-3750-2966; Gourion, Benjamin/0000-0001-5768-6961; Chistoserdova, Ludmila/0000-0002-5777-0263; Vallenet, David/0000-0001-6648-0332; Kaul, Rajinder/0000-0002-7895-9284; Pagni, Marco/0000-0001-9292-9463; Gruffaz, Christelle/0000-0001-5709-0527; Haugen, Eric/0000-0001-7444-8981	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058933] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 58933, R01 GM058933] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abanda-Nkpwatt D, 2006, J EXP BOT, V57, P4025, DOI 10.1093/jxb/erl173; Afolabi PR, 2001, BIOCHEMISTRY-US, V40, P9799, DOI 10.1021/bi002932l; Anthony C., 1982, BIOCH METHYLOTROPHS; Bauer M, 2004, J MOL EVOL, V59, P571, DOI 10.1007/s00239-004-2643-6; Bocs S, 2003, NUCLEIC ACIDS RES, V31, P3723, DOI 10.1093/nar/gkg590; Bosch G, 2008, PROTEOMICS, V8, P3494, DOI 10.1002/pmic.200800152; Boyer F, 2005, BIOINFORMATICS, V21, P4209, DOI 10.1093/bioinformatics/bti711; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Cevallos MA, 2008, PLASMID, V60, P19, DOI 10.1016/j.plasmid.2008.03.001; Chandler M, 2002, MOBILE DNA, V2, P305; CHISTOSERDOV AY, 1994, J BACTERIOL, V176, P4052, DOI 10.1128/JB.176.13.4052-4065.1994; Chistoserdova L, 2005, ASM NEWS, V71, P521; Chistoserdova L, 2004, MOL BIOL EVOL, V21, P1234, DOI 10.1093/molbev/msh113; Chistoserdova L, 1998, SCIENCE, V281, P99, DOI 10.1126/science.281.5373.99; Chistoserdova L, 2000, MICROBIOL-SGM, V146, P233, DOI 10.1099/00221287-146-1-233; Chistoserdova L, 1997, MICROBIOL-UK, V143, P1729, DOI 10.1099/00221287-143-5-1729; Chistoserdova L, 2003, J BACTERIOL, V185, P2980, DOI 10.1128/JB.185.10.2980-2987.2003; Chistoserdova L, 2007, J BACTERIOL, V189, P9076, DOI 10.1128/JB.01229-07; Chistoserdova L, 2007, J BACTERIOL, V189, P4020, DOI 10.1128/JB.00045-07; CHISTOSERDOVA LV, 1994, J BACTERIOL, V176, P7398, DOI 10.1128/JB.176.23.7398-7404.1994; Crowther GJ, 2008, J BACTERIOL, V190, P5057, DOI 10.1128/JB.00228-08; Davidson VL, 2001, ADV PROTEIN CHEM, V58, P95; Denef VJ, 2005, J BACTERIOL, V187, P7996, DOI 10.1128/JB.187.23.7996-8005.2005; Doronina NV, 2000, SYST APPL MICROBIOL, V23, P210, DOI 10.1016/S0723-2020(00)80007-7; Erb TJ, 2007, P NATL ACAD SCI USA, V104, P10631, DOI 10.1073/pnas.0702791104; Fukuda N, 2005, J MUSCLE RES CELL M, V26, P319, DOI 10.1007/s10974-005-9038-1; Galbally IE, 2002, J ATMOS CHEM, V43, P195, DOI 10.1023/A:1020684815474; GALLI R, 1985, CONSERV RECYCLING, V8, P91, DOI 10.1016/0361-3658(85)90028-1; Galperin MY, 1998, GENOME RES, V8, P779, DOI 10.1101/gr.8.8.779; Giovannoni SJ, 2008, ENVIRON MICROBIOL, V10, P1771, DOI 10.1111/j.1462-2920.2008.01598.x; Gisi D, 1999, ARCH TOXICOL, V73, P71, DOI 10.1007/s002040050589; Gordon D, 2001, GENOME RES, V11, P614, DOI 10.1101/gr.171401; Greenberg DE, 2007, J BACTERIOL, V189, P8727, DOI 10.1128/JB.00793-07; Greenberg DE, 2006, INT J SYST EVOL MICR, V56, P2609, DOI 10.1099/ijs.0.64412-0; Guo XF, 2008, BIOTECHNOL BIOENG, V99, P929, DOI 10.1002/bit.21652; Hou SB, 2008, BIOL DIRECT, V3, DOI 10.1186/1745-6150-3-26; Jourand P, 2004, INT J SYST EVOL MICR, V54, P2269, DOI 10.1099/ijs.0.02902-0; Kalyuzhnaya MG, 2008, NAT BIOTECHNOL, V26, P1029, DOI 10.1038/nbt.1488; Kalyuzhnaya MG, 2008, J BACTERIOL, V190, P3817, DOI 10.1128/JB.00180-08; Kalyuzhnaya MG, 2006, INT J SYST EVOL MICR, V56, P2517, DOI 10.1099/ijs.0.64422-0; Kalyuzhnaya MG, 2005, J BACTERIOL, V187, P7511, DOI 10.1128/JB.187.21.7511-7517.2005; Kane SR, 2007, J BACTERIOL, V189, P1931, DOI 10.1128/JB.01259-06; Kato Y, 2005, J GEN APPL MICROBIOL, V51, P287, DOI 10.2323/jgam.51.287; Kayser MF, 2002, MICROBIOL-SGM, V148, P1915, DOI 10.1099/00221287-148-6-1915; Kayser MF, 2001, J BACTERIOL, V183, P5209, DOI 10.1128/JB.183.17.5209-5212.2001; KEITH LH, 1979, ENVIRON SCI TECHNOL, V13, P416, DOI 10.1021/es60152a601; Khalil MAK, 1999, J GEOPHYS RES-ATMOS, V104, P8333, DOI 10.1029/1998JD100079; Kiefer P, 2008, ANAL BIOCHEM, V382, P94, DOI 10.1016/j.ab.2008.07.010; Lidstrom ME, 2006, PROKARYOTES: A HANDBOOK ON THE BIOLOGY OF BACTERIA, VOL 2, THIRD EDITION, P618, DOI 10.1007/0-387-30742-7_20; Lidstrom ME, 2002, J BACTERIOL, V184, P1818, DOI 10.1128/JB.184.7.1818.2002; Marx Christopher J, 2008, BMC Res Notes, V1, P1, DOI 10.1186/1756-0500-1-1; Marx CJ, 2005, PLOS BIOL, V3, P244, DOI 10.1371/journal.pbio.0030016; Marx CJ, 2004, J BACTERIOL, V186, P2173, DOI 10.1128/JB.186.7.2173-2178.2004; Marx CJ, 2003, J BACTERIOL, V185, P7169, DOI 10.1128/JB.185.24.7169-7175.2003; Marx CJ, 2003, J BACTERIOL, V185, P7160, DOI 10.1128/JB.185.23.7160-7168.2003; Marx CJ, 2004, MICROBIOL-SGM, V150, P9, DOI 10.1099/mic.0.26587-0; Marx CJ, 2003, J BACTERIOL, V185, P669, DOI 10.1128/JB.185.2.669-673.2003; Marx CJ, 2001, MICROBIOL-SGM, V147, P2065, DOI 10.1099/00221287-147-8-2065; McCulloch A, 1999, J GEOPHYS RES-ATMOS, V104, P8417, DOI 10.1029/1999JD900011; McPherran M. L., 2002, BIOTECHNOLOGY ENV ST, V35, P105; Moran MA, 2004, NATURE, V432, P910, DOI 10.1038/nature03170; Necsulea A, 2007, MOL BIOL EVOL, V24, P2169, DOI 10.1093/molbev/msm148; Neff JC, 2002, BIOGEOCHEMISTRY, V57, P99, DOI 10.1023/A:1015791622742; NIETOPENALVER CG, 2006, J BACTERIOL, V188, P7321; Okubo Y, 2007, OMICS, V11, P325, DOI 10.1089/omi.2007.0027; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; PEEL D, 1961, BIOCHEM J, V81, P465, DOI 10.1042/bj0810465; Peyraud R, 2009, P NATL ACAD SCI USA, V106, P4846, DOI 10.1073/pnas.0810932106; Pomper BK, 1999, EUR J BIOCHEM, V261, P475, DOI 10.1046/j.1432-1327.1999.00291.x; RAS J, 1995, J BACTERIOL, V177, P247, DOI 10.1128/jb.177.1.247-251.1995; Rohmer L, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-r102; SchmidAppert M, 1997, MICROBIOL-SGM, V143, P2557, DOI 10.1099/00221287-143-8-2557; Schrader J, 2009, TRENDS BIOTECHNOL, V27, P107, DOI 10.1016/j.tibtech.2008.10.009; Siguier P, 2006, NUCLEIC ACIDS RES, V34, pD32, DOI 10.1093/nar/gkj014; Siguier P, 2006, CURR OPIN MICROBIOL, V9, P526, DOI 10.1016/j.mib.2006.08.005; Starkenburg SR, 2008, APPL ENVIRON MICROB, V74, P2852, DOI 10.1128/AEM.02311-07; Starr TB, 2006, TOXICOL SCI, V91, P20, DOI 10.1093/toxsci/kfj145; Sy A, 2005, APPL ENVIRON MICROB, V71, P7245, DOI 10.1128/AEM.71.11.7245-7252.2005; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; TAYLOR IJ, 1976, J GEN MICROBIOL, V93, P259, DOI 10.1099/00221287-93-2-259; Vallenet D, 2006, NUCLEIC ACIDS RES, V34, P53, DOI 10.1093/nar/gkj406; Vallenet D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001805; Van Aken B, 2004, APPL ENVIRON MICROB, V70, P508, DOI 10.1128/AEM.70.1.508-517.2004; Van Dien SJ, 2003, MICROBIOL-SGM, V149, P601, DOI 10.1099/mic.0.25955-0; Vernikos GS, 2006, BIOINFORMATICS, V22, P2196, DOI 10.1093/bioinformatics/btl369; Vorholt JA, 1998, J BACTERIOL, V180, P5351, DOI 10.1128/JB.180.20.5351-5356.1998; Vorholt JA, 1999, J BACTERIOL, V181, P5750, DOI 10.1128/JB.181.18.5750-5757.1999; Vorholt JA, 2000, J BACTERIOL, V182, P6645, DOI 10.1128/JB.182.23.6645-6650.2000; Vuilleumier S, 2001, MICROBIOL-SGM, V147, P611, DOI 10.1099/00221287-147-3-611; Wagner A, 2007, NUCLEIC ACIDS RES, V35, P5284, DOI 10.1093/nar/gkm597; Ward N, 2004, PLOS BIOL, V2, P1616, DOI 10.1371/journal.pbio.0020303; Williams PA, 2005, ACTA CRYSTALLOGR D, V61, P75, DOI 10.1107/S0907444904026964; Wilson SM, 2008, MICROBIOL-SGM, V154, P296, DOI 10.1099/mic.0.2007/011346-0	93	168	249	1	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5584	10.1371/journal.pone.0005584	http://dx.doi.org/10.1371/journal.pone.0005584			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440302	Green Published, gold			2022-12-25	WOS:000266107500013
J	Vitalo, A; Fricchione, J; Casali, M; Berdichevsky, Y; Hoge, EA; Rauch, SL; Berthiaume, F; Yarmush, ML; Benson, H; Fricchione, GL; Levine, JB				Vitalo, Antonia; Fricchione, Jonathan; Casali, Monica; Berdichevsky, Yevgeny; Hoge, Elizabeth A.; Rauch, Scott L.; Berthiaume, Francois; Yarmush, Martin L.; Benson, Herbert; Fricchione, Gregory L.; Levine, John B.			Nest Making and Oxytocin Comparably Promote Wound Healing in Isolation Reared Rats	PLOS ONE			English	Article								Background: Environmental enrichment (EE) fosters attachment behavior through its effect on brain oxytocin levels in the hippocampus and other brain regions, which in turn modulate the hypothalamic-pituitary axis (HPA). Social isolation and other stressors negatively impact physical healing through their effect on the HPA. Therefore, we reasoned that: 1) provision of a rat EE (nest building with NestletsH) would improve wound healing in rats undergoing stress due to isolation rearing and 2) that oxytocin would have a similar beneficial effect on wound healing. Methodology/Principal Findings: In the first two experiments, we provided isolation reared rats with either EE or oxytocin and compared their wound healing to group reared rats and isolation reared rats that did not receive Nestlets or oxytocin. In the third experiment, we examined the effect of Nestlets on open field locomotion and immediate early gene (IEG) expression. We found that isolation reared rats treated with Nestlets a) healed significantly better than without Nestlets, 2) healed at a similar rate to rats treated with oxytocin, 3) had decreased hyperactivity in the open field test, and 4) had normalized IEG expression in brain hippocampus. Conclusions/Significance: This study shows that when an EE strategy or oxytocin is given to isolation reared rats, the peripheral stress response, as measured by burn injury healing, is decreased. The findings indicate an association between the effect of nest making on wound healing and administration of the pro-bonding hormone oxytocin. Further elucidation of this animal model should lead to improved understanding of how EE strategies can ameliorate poor wound healing and other symptoms that result from isolation stress.			Vitalo, A (corresponding author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.	gfricchione@partners.org; jblevine@partners.org	Berthiaume, Francois/ABD-2139-2020; Hoge, Elizabeth A/H-5879-2012; Levine, John/G-6221-2015	Hoge, Elizabeth A/0000-0002-5513-2292; Berdichevsky, Yevgeny/0000-0001-7539-601X; Yarmush, Martin/0000-0003-4986-8444				Antonawich FJ, 1997, BRAIN RES, V764, P249, DOI 10.1016/S0006-8993(97)00488-5; Belz EE, 2003, PHARMACOL BIOCHEM BE, V76, P481, DOI 10.1016/j.pbb.2003.09.005; Bond TLY, 2002, PHYSIOL BEHAV, V75, P551, DOI 10.1016/S0031-9384(02)00659-5; Calamandrei Gemma, 2004, Ann Ist Super Sanita, V40, P195; Champagne FA, 2007, BEHAV NEUROSCI, V121, P1353, DOI 10.1037/0735-7044.121.6.1353; DeVries AC, 2007, PSYCHONEUROENDOCRINO, V32, P587, DOI 10.1016/j.psyneuen.2007.04.007; Cui SS, 2001, J NEUROSCI, V21, P9867, DOI 10.1523/JNEUROSCI.21-24-09867.2001; De Kloet ER, 2004, ANN NY ACAD SCI, V1032, P14, DOI 10.1196/annals.1314.003; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; Deacon RMJ, 2006, NAT PROTOC, V1, P1117, DOI 10.1038/nprot.2006.170; DEKLOET ER, 1994, PSYCHONEUROENDOCRINO, V19, P121, DOI 10.1016/0306-4530(94)90002-7; Detillion CE, 2004, PSYCHONEUROENDOCRINO, V29, P1004, DOI 10.1016/j.psyneuen.2003.10.003; Diaz-Cabiale Z, 2004, J NEUROENDOCRINOL, V16, P183, DOI 10.1111/j.0953-8194.2004.01146.x; Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668; GALLITANOMENDEL A, 2007, NEUROSCIENCE; Glaser R, 1999, ARCH GEN PSYCHIAT, V56, P450, DOI 10.1001/archpsyc.56.5.450; Glasper ER, 2005, BRAIN BEHAV IMMUN, V19, P61, DOI 10.1016/j.bbi.2004.03.002; Guzowski JF, 1999, NAT NEUROSCI, V2, P1120, DOI 10.1038/16046; Herrera DG, 1996, PROG NEUROBIOL, V50, P83, DOI 10.1016/S0301-0082(96)00021-4; Holst S, 2002, AUTON NEUROSCI-BASIC, V99, P85, DOI 10.1016/S1566-0702(02)00134-0; Iseri SO, 2008, BURNS, V34, P361, DOI 10.1016/j.burns.2007.03.022; JACOBSON L, 1991, ENDOCR REV, V12, P118, DOI 10.1210/edrv-12-2-118; Kiecolt-Glaser JK, 2005, ARCH GEN PSYCHIAT, V62, P1377, DOI 10.1001/archpsyc.62.12.1377; KIECOLTGLASER JK, 1991, PSYCHOSOM MED, V53, P345, DOI 10.1097/00006842-199107000-00001; Kovacs GL, 1998, PSYCHONEUROENDOCRINO, V23, P945; Lapiz M D S, 2003, Neurosci Behav Physiol, V33, P13, DOI 10.1023/A:1021171129766; Levine JB, 2008, NEUROSCIENCE, V151, P589, DOI 10.1016/j.neuroscience.2007.10.014; Levine JB, 2007, NEUROSCIENCE, V145, P42, DOI 10.1016/j.neuroscience.2006.11.063; Li X, 2006, LIFE SCI, V78, P1933, DOI 10.1016/j.lfs.2005.08.002; Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659; Marucha PT, 1998, PSYCHOSOM MED, V60, P362, DOI 10.1097/00006842-199805000-00025; Meaney MJ, 2000, J NEUROSCI, V20, P3926, DOI 10.1523/JNEUROSCI.20-10-03926.2000; Mercado AM, 2002, BRAIN BEHAV IMMUN, V16, P150, DOI 10.1006/brbi.2001.0623; Mercado AM, 2002, J NEUROIMMUNOL, V129, P74, DOI 10.1016/S0165-5728(02)00174-1; Moriceau S, 2005, DEV PSYCHOBIOL, V47, P230, DOI 10.1002/dev.20093; Padgett DA, 1998, BRAIN BEHAV IMMUN, V12, P64, DOI 10.1006/brbi.1997.0512; PETERSOHN D, 1995, J BIOL CHEM, V270, P24361, DOI 10.1074/jbc.270.41.24361; Petersson M, 1999, NEUROSCI LETT, V264, P41, DOI 10.1016/S0304-3940(99)00159-7; Petersson M, 1998, N-S ARCH PHARMACOL, V357, P701, DOI 10.1007/PL00005227; Petersson M, 2005, MATURITAS, V51, P426, DOI 10.1016/j.maturitas.2004.10.005; Petersson M, 2003, NEUROSCI LETT, V343, P97, DOI 10.1016/S0304-3940(03)00334-3; Quirk GJ, 2006, BIOL PSYCHIAT, V60, P337, DOI 10.1016/j.biopsych.2006.03.010; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Ring RH, 2006, PSYCHOPHARMACOLOGY, V185, P218, DOI 10.1007/s00213-005-0293-z; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tarrier N, 2005, BURNS, V31, P45, DOI 10.1016/j.burns.2004.06.010; Yamaguchi S, 2004, J NEUROSCI, V24, P5356, DOI 10.1523/JNEUROSCI.4587-03.2004	47	38	39	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5523	10.1371/journal.pone.0005523	http://dx.doi.org/10.1371/journal.pone.0005523			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444WA	19436750	Green Published, gold			2022-12-25	WOS:000266009900015
J	Haurigot, V; Villacampa, P; Ribera, A; Llombart, C; Bosch, A; Nacher, V; Ramos, D; Ayuso, E; Segovia, JC; Bueren, JA; Ruberte, J; Bosch, F				Haurigot, Virginia; Villacampa, Pilar; Ribera, Albert; Llombart, Cristina; Bosch, Assumpcio; Nacher, Victor; Ramos, David; Ayuso, Eduard; Segovia, Jose C.; Bueren, Juan A.; Ruberte, Jesus; Bosch, Fatima			Increased Intraocular Insulin-like Growth Factor-I Triggers Blood-Retinal Barrier Breakdown	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETIC-RETINOPATHY; BINDING-PROTEINS; ADHESION MOLECULE-1; TRANSGENIC MICE; TIGHT JUNCTIONS; MACULAR EDEMA; IGF-I; EXPRESSION; OCCLUDIN; LOCALIZATION	Blood-retinal barrier (BRB) breakdown is a key event in diabetic retinopathy and other ocular disorders that leads to increased retinal vascular permeability. This causes edema and tissue damage resulting in visual impairment. Insulin-like growth factor-I (IGF-I) is involved in these processes, although the relative contribution of increased systemic versus intraocular IGF-I remains controversial. Here, to elucidate the role of this factor in BRB breakdown, transgenic mice with either local or systemic elevations of IGF-I have been examined. High intraocular IGF-I, resulting from overexpression of IGF-I in the retina, increased IGF-I receptor content and signaling and led to accumulation of vascular endothelial growth factor. This was parallel to up-regulation of vascular Intercellular adhesion molecule I and retinal infiltration by bone marrow-derived microglial cells. These alterations resulted in increased vessel paracellular permeability to both low and high molecular weight compounds in IGF-I-overexpressing retinas and agreed with the loss of vascular tight junction integrity observed by electron microscopy and the altered junctional protein content. In contrast, mice with chronically elevated serum IGF-I did not show alterations in the retinal vasculature structure and permeability, indicating that circulating IGF-I cannot initiate BRB breakdown. Consistent with a key role of IGF-I signaling in retinal diseases, a strong up-regulation of the IGF-I receptor in human retinas with marked gliosis was also observed. Thus, this study demonstrates that intraocular IGF-I, but not systemic IGF-I, is sufficient to trigger processes leading to BRB breakdown and increased retinal vascular permeability. Therefore, therapeutic interventions designed to counteract local IGF-I effects may prove successful to prevent BRB disruption.	[Haurigot, Virginia; Villacampa, Pilar; Ribera, Albert; Llombart, Cristina; Bosch, Assumpcio; Nacher, Victor; Ramos, David; Ayuso, Eduard; Ruberte, Jesus; Bosch, Fatima] Univ Autonoma Barcelona, Ctr Anim Biotechnol & Gene Therapy, E-08193 Barcelona, Spain; [Haurigot, Virginia; Villacampa, Pilar; Ribera, Albert; Bosch, Assumpcio; Ayuso, Eduard; Bosch, Fatima] Univ Autonoma Barcelona, Sch Vet Med, Dept Biochem & Mol Biol, E-08193 Barcelona, Spain; [Llombart, Cristina; Nacher, Victor; Ramos, David; Ruberte, Jesus] Univ Autonoma Barcelona, Sch Vet Med, Dept Anim Hlth & Anat, E-08193 Barcelona, Spain; [Haurigot, Virginia; Villacampa, Pilar; Ribera, Albert; Nacher, Victor; Ayuso, Eduard; Ruberte, Jesus; Bosch, Fatima] CIBER Diabet & Associated Metab Disorders CIBERDE, Barcelona 08036, Spain; [Segovia, Jose C.; Bueren, Juan A.] CIEMAT, Hematopoiesis & Gene Therapy Div, E-28040 Madrid, Spain; [Segovia, Jose C.; Bueren, Juan A.] Biomed Ctr Rare Dis CIBERER, Valencia 46010, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona; Autonomous University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERDEM; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; CIBER - Centro de Investigacion Biomedica en Red; CIBERER	Bosch, F (corresponding author), Univ Autonoma Barcelona, Ctr Anim Biotechnol & Gene Therapy, Edifici H, E-08193 Barcelona, Spain.	fatima.bosch@uab.es	Segovia, Jose Carlos/L-2922-2014; Ribera, Albert/K-9744-2014; AYUSO LOPEZ, Eduardo/I-7686-2017; Ruberte, Jesus/AAS-9240-2021; Bosch, Assumpcio/C-7593-2015; Villacampa, Pilar/B-1801-2019; Bueren, Juan/L-6112-2014	Segovia, Jose Carlos/0000-0003-4101-6124; Ribera, Albert/0000-0002-7120-4276; Bosch, Assumpcio/0000-0002-7205-2796; Villacampa, Pilar/0000-0002-2860-7475; Bueren, Juan/0000-0002-3228-7013; Ayuso, Eduard/0000-0003-0811-2229; Haurigot, Virginia A./0000-0002-9772-2565; Nacher, Victor/0000-0002-1340-4675; RUBERTE, JESUS/0000-0003-1540-1432; BOSCH, FATIMA/0000-0002-7705-5515	Instituto de Salud Carlos III [PI 061417]; CIBER de Diabetes y Enfermedades Metabolicas Asociadas), Spain; European Community FP6 EUGENE2 [LSHM-CT-2004-512013]; European Foundation for the Study of Diabetes/Juvenile Diabetes Research Foundation/Novo Nordisk	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); CIBER de Diabetes y Enfermedades Metabolicas Asociadas), Spain; European Community FP6 EUGENE2(European Commission); European Foundation for the Study of Diabetes/Juvenile Diabetes Research Foundation/Novo Nordisk(Novo NordiskJuvenile Diabetes Research Foundation)	This study was supported by grants from Instituto de Salud Carlos III (PI 061417 and CIBER de Diabetes y Enfermedades Metabolicas Asociadas), Spain, and the European Community FP6 EUGENE2 (Grant LSHM-CT-2004-512013) and European Foundation for the Study of Diabetes/Juvenile Diabetes Research Foundation/Novo Nordisk.	Adamis AP, 2002, BRIT J OPHTHALMOL, V86, P363, DOI 10.1136/bjo.86.4.363; Amin RH, 1997, INVEST OPHTH VIS SCI, V38, P36; Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953; BALLINTINE EJ, 1981, ARCH INTERN MED, V141, P1625, DOI 10.1001/archinte.141.12.1625; Barber AJ, 2003, INVEST OPHTH VIS SCI, V44, P5410, DOI 10.1167/iovs.03-0244; Blank D, 2000, J CLIN ENDOCR METAB, V85, P634, DOI 10.1210/jc.85.2.634; Burren CP, 1996, INVEST OPHTH VIS SCI, V37, P1459; Dal Monte M, 2007, INVEST OPHTH VIS SCI, V48, P3480; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Derevjanik NL, 2002, INVEST OPHTH VIS SCI, V43, P2462; Fischer S, 2002, MICROVASC RES, V63, P70, DOI 10.1006/mvre.2001.2367; Frystyk J, 2005, HORM METAB RES, V37, pS44, DOI 10.1055/s-2005-861362; Funatsu H, 2006, OPHTHALMOLOGY, V113, P294, DOI 10.1016/j.ophtha.2005.10.030; Funatsu H, 2002, AM J OPHTHALMOL, V133, P70, DOI 10.1016/S0002-9394(01)01269-7; Gardner TW, 2002, SURV OPHTHALMOL, V47, pS253, DOI 10.1016/S0039-6257(02)00387-9; Gerhardinger C, 2001, DIABETES, V50, P175, DOI 10.2337/diabetes.50.1.175; GRANT M, 1986, DIABETES, V35, P416, DOI 10.2337/diabetes.35.4.416; Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007; Joussen AM, 2002, AM J PATHOL, V160, P501, DOI 10.1016/S0002-9440(10)64869-9; Kaneko H, 2008, INVEST OPHTH VIS SCI, V49, P4162, DOI 10.1167/iovs.08-1738; Kent D, 2000, BRIT J OPHTHALMOL, V84, P542, DOI 10.1136/bjo.84.5.542; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MCLEOD DS, 1995, AM J PATHOL, V147, P642; MERIMEE TJ, 1983, NEW ENGL J MED, V309, P527, DOI 10.1056/NEJM198309013090904; Mizutani M, 1998, DIABETES, V47, P445, DOI 10.2337/diabetes.47.3.445; Morcos Y, 2001, J NEUROCYTOL, V30, P107, DOI 10.1023/A:1011982906125; Musaro A, 2004, P NATL ACAD SCI USA, V101, P1206, DOI 10.1073/pnas.0303792101; Navaratna D, 2007, DIABETES, V56, P2380, DOI 10.2337/db06-1694; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Patel JI, 2006, EXP EYE RES, V82, P798, DOI 10.1016/j.exer.2005.10.002; Poulaki V, 2004, AM J PATHOL, V165, P457, DOI 10.1016/S0002-9440(10)63311-1; Prahalada S, 1999, HORM METAB RES, V31, P133, DOI 10.1055/s-2007-978710; Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619; Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408; Ruberte J, 2004, J CLIN INVEST, V113, P1149, DOI 10.1172/JCI200419478; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; Shaw LC, 2004, REV ENDOCR METAB DIS, V5, P199, DOI 10.1023/B:REMD.0000032408.18015.b1; Spoerri PE, 1998, GROWTH HORM IGF RES, V8, P125, DOI 10.1016/S1096-6374(98)80102-0; VALERA A, 1993, FASEB J, V7, P791, DOI 10.1096/fasebj.7.9.8330686; VORBRODT AW, 1986, J HISTOCHEM CYTOCHEM, V34, P251, DOI 10.1177/34.2.3753715; Xu HP, 2005, INVEST OPHTH VIS SCI, V46, P2487, DOI 10.1167/iovs.04-1333	41	46	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	2009	284	34					22961	22969		10.1074/jbc.M109.014787	http://dx.doi.org/10.1074/jbc.M109.014787			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	483KG	19473988	Green Published, hybrid			2022-12-25	WOS:000268963100049
J	Li, HQ; Gakh, O; Smith, DY; Isaya, G				Li, Hongqiao; Gakh, Oleksandr; Smith, Douglas Y., IV; Isaya, Grazia			Oligomeric Yeast Frataxin Drives Assembly of Core Machinery for Mitochondrial Iron-Sulfur Cluster Synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; SACCHAROMYCES-CEREVISIAE; FRIEDREICH ATAXIA; SCAFFOLD PROTEIN; BINDING PROTEIN; ISCU; BIOSYNTHESIS; BIOGENESIS; MATURATION; DAMAGE	Mitochondrial biosynthesis of iron-sulfur clusters (ISCs) is a vital process involving the delivery of elemental iron and sulfur to a scaffold protein via molecular interactions that are still poorly defined. Analysis of highly conserved components of the yeast ISC assembly machinery shows that the iron-chaperone, Yfh1, and the sulfur-donor complex, Nfs1-Isd11, directly bind to each other. This interaction is mediated by direct Yfh1-Isd11 contacts. Moreover, both Yfh1 and Nfs1-Isd11 can directly bind to the scaffold, Isu1. Binding of Yfh1 to Nfs1-Isd11 or Isu1 requires oligomerization of Yfh1 and can occur in an iron-independent manner. However, more stable contacts are formed when Yfh1 oligomerization is normally coupled with the binding and oxidation of Fe2+. Our observations challenge the view that iron delivery for ISC synthesis is mediated by Fe2+-loaded monomeric Yfh1. Rather, we find that the iron oxidation-driven oligomerization of Yfh1 promotes the assembly of stable multicomponent complexes in which the iron donor and the sulfur donor simultaneously interact with each other as well as with the scaffold. Moreover, the ability to store ferric iron enables oligomeric Yfh1 to adjust iron release depending on the presence of Isu1 and the availability of elemental sulfur and reducing equivalents. In contrast, the use of anaerobic conditions that prevent Yfh1 oligomerization results in inhibition of ISC assembly on Isu1. These findings suggest that iron-dependent oligomerization is a mechanism by which the iron donor promotes assembly of the core machinery for mitochondrial ISC synthesis.	[Isaya, Grazia] Mayo Clin, Coll Med, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Isaya, G (corresponding author), Mayo Clin, Coll Med, Dept Pediat & Adolescent Med, 200 1st St SW,Stabile 7-52, Rochester, MN 55905 USA.	isaya@mayo.edu			National Institutes of Health [AG15709]; Friedreich Ataxia Research Alliance and the Muscular Dystrophy Association; Mayo Clinic Department of Pediatric & Adolescent Medicine; NATIONAL INSTITUTE ON AGING [R01AG015709] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Friedreich Ataxia Research Alliance and the Muscular Dystrophy Association; Mayo Clinic Department of Pediatric & Adolescent Medicine; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported in part by National Institutes of Health Grant AG15709. This work was also supported by the Friedreich Ataxia Research Alliance and the Muscular Dystrophy Association and by a fellowship from the Mayo Clinic Department of Pediatric & Adolescent Medicine (to H. L.).	Adam AC, 2006, EMBO J, V25, P174, DOI 10.1038/sj.emboj.7600905; Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; Adinolfi S, 2009, NAT STRUCT MOL BIOL, V16, P390, DOI 10.1038/nsmb.1579; Aloria K, 2004, EMBO REP, V5, P1096, DOI 10.1038/sj.embor.7400272; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Cook JD, 2006, BIOCHEMISTRY-US, V45, P7767, DOI 10.1021/bi060424r; Foury F, 2007, EMBO REP, V8, P194, DOI 10.1038/sj.embor.7400881; Gakh O, 2006, HUM MOL GENET, V15, P467, DOI 10.1093/hmg/ddi461; Gakh O, 2008, J BIOL CHEM, V283, P31500, DOI 10.1074/jbc.M805415200; Gerber J, 2004, MOL CELL BIOL, V24, P4848, DOI 10.1128/MCB.24.11.4848-4857.2004; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; He YN, 2004, BIOCHEMISTRY-US, V43, P16254, DOI 10.1021/bi0488193; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Karlberg T, 2006, STRUCTURE, V14, P1535, DOI 10.1016/j.str.2006.08.010; Karthikeyan G, 2003, HUM MOL GENET, V12, P3331, DOI 10.1093/hmg/ddg349; Layer G, 2006, J BIOL CHEM, V281, P16256, DOI 10.1074/jbc.M513569200; Li KY, 2006, J BIOL CHEM, V281, P12344, DOI 10.1074/jbc.M600582200; Lill R, 2008, ANNU REV BIOCHEM, V77, P669, DOI 10.1146/annurev.biochem.76.052705.162653; Marelja Z, 2008, J BIOL CHEM, V283, P25178, DOI 10.1074/jbc.M804064200; Nichol H, 2003, BIOCHEMISTRY-US, V42, P5971, DOI 10.1021/bi027021l; Park S, 2003, J BIOL CHEM, V278, P31340, DOI 10.1074/jbc.M303158200; Park S, 2003, J BACTERIOL, V185, P1942, DOI 10.1128/JB.185.6.1942-1950.2003; Park S, 2002, J BIOL CHEM, V277, P38589, DOI 10.1074/jbc.M206711200; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Ramazzotti A, 2004, FEBS LETT, V557, P215, DOI 10.1016/S0014-5793(03)01498-4; Ramelot TA, 2004, J MOL BIOL, V344, P567, DOI 10.1016/j.jmb.2004.08.038; Raulfs EC, 2008, P NATL ACAD SCI USA, V105, P8591, DOI 10.1073/pnas.0803173105; Rouault TA, 2008, TRENDS GENET, V24, P398, DOI 10.1016/j.tig.2008.05.008; Schagerlof U, 2008, BIOCHEMISTRY-US, V47, P4948, DOI 10.1021/bi800052m; Shan YX, 2007, HUM MOL GENET, V16, P929, DOI 10.1093/hmg/ddm038; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Stehling O, 2004, HUM MOL GENET, V13, P3007, DOI 10.1093/hmg/ddh324; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Vivas E, 2006, J BACTERIOL, V188, P1175, DOI 10.1128/JB.188.3.1175-1179.2006; Wang T, 2008, J BIOL CHEM, V283, P12674, DOI 10.1074/jbc.M800399200	35	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	2009	284	33					21971	21980		10.1074/jbc.M109.011197	http://dx.doi.org/10.1074/jbc.M109.011197			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481CE	19491103	hybrid, Green Published			2022-12-25	WOS:000268783700021
J	Guth, E; Farris, M; Bovee, M; Francklyn, CS				Guth, Ethan; Farris, Mindy; Bovee, Michael; Francklyn, Christopher S.			Asymmetric Amino Acid Activation by Class II Histidyl-tRNA Synthetase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OF-SITES REACTIVITY; RATE-LIMITING STEP; KINETIC MECHANISM; CRYSTAL-STRUCTURE; LIGAND-BINDING; BEEF PANCREAS; AMINOACYLATION; ADENYLATE; CATALYSIS; ENZYME	Aminoacyl-tRNA synthetases (ARSs) join amino acids to their cognate tRNAs to initiate protein synthesis. Class II ARS possess a unique catalytic domain fold, possess active site signature sequences, and are dimers or tetramers. The dimeric class I enzymes, notably TyrRS, exhibit half-of-sites reactivity, but its mechanistic basis is unclear. In class II histidyl-tRNA synthetase (HisRS), amino acid activation occurs at different rates in the two active sites when tRNA is absent, but half-of-sites reactivity has not been observed. To investigate the mechanistic basis of the asymmetry, and explore the relationship between adenylate formation and conformational events in HisRS, a fluorescently labeled version of the enzyme was developed by conjugating 7-diethylamino-3-((((2-maleimidyl)ethyl)amino)carbonyl)coumarin (MDCC) to a cysteine introduced at residue 212, located in the insertion domain. The binding of the substrates histidine, ATP, and 5'-O-[N-(L-histidyl)sulfamoyl] adenosine to MDCC-HisRS produced fluorescence quenches on the order of 6-15%, allowing equilibrium dissociation constants to be measured. The rates of adenylate formation measured by rapid quench and domain closure as measured by stopped-flow fluorescence were similar and asymmetric with respect to the two active sites of the dimer, indicating that conformational change may be rate-limiting for product formation. Fluorescence resonance energy transfer experiments employing differential labeling of the two monomers in the dimer suggested that rigid body rotation of the insertion domain accompanies adenylate formation. The results support an alternating site model for catalysis in HisRS that may prove to be common to other class II aminoacyl-tRNA synthetases.	[Guth, Ethan; Farris, Mindy; Bovee, Michael; Francklyn, Christopher S.] Univ Vermont, Dept Biochem, Coll Med, Burlington, VT 05405 USA	University of Vermont	Francklyn, CS (corresponding author), Univ Vermont, Dept Biochem, Coll Med, Hlth Sci Complex,89 Beaumont Ave, Burlington, VT 05405 USA.	Christopher.Francklyn@uvm.edu			National Institutes of Health [RO1 GM54899, F32 GM19739]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019739, R01GM054899] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants RO1 GM54899 (to C.S.F.) and F32 GM19739 (to M. L. B.).	Aberg A, 1997, BIOCHEMISTRY-US, V36, P3084, DOI 10.1021/bi9618373; Arnez JG, 1997, P NATL ACAD SCI USA, V94, P7144, DOI 10.1073/pnas.94.14.7144; ARNEZ JG, 1995, EMBO J, V14, P4143, DOI 10.1002/j.1460-2075.1995.tb00088.x; ATKINSON DE, 1968, BIOCHEMISTRY-US, V7, P4030, DOI 10.1021/bi00851a033; BEDOUELLE H, 2005, AMINOACYL TRANS SYNT, P111; BLANQUET S, 1972, EUR J BIOCHEM, V24, P461, DOI 10.1111/j.1432-1033.1972.tb19707.x; Bovee ML, 2003, BIOCHEMISTRY-US, V42, P15102, DOI 10.1021/bi0355701; CARTER CW, 2005, AMINOACYL TRNA SYNTH, P99; COMMANS S, 1995, BIOCHEMISTRY-US, V34, P8180, DOI 10.1021/bi00025a025; Cusack S, 1997, CURR OPIN STRUC BIOL, V7, P881, DOI 10.1016/S0959-440X(97)80161-3; DIBBELT L, 1980, NUCLEIC ACIDS RES, V8, P4021, DOI 10.1093/nar/8.17.4021; DIBBELT L, 1981, FEBS LETT, V129, P173, DOI 10.1016/0014-5793(81)80783-1; DINATALE P, 1976, EUR J BIOCHEM, V62, P293; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FASIOLO F, 1977, EUR J BIOCHEM, V73, P7, DOI 10.1111/j.1432-1033.1977.tb11286.x; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P5, DOI 10.1021/bi00672a002; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P13, DOI 10.1021/bi00672a003; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; First E.A., 2005, AMINOACYL TRNA SYNTH, P328; FRANCKLYN C, 1994, J MOL BIOL, V241, P275, DOI 10.1006/jmbi.1994.1498; Francklyn CS, 2008, METHODS, V44, P100, DOI 10.1016/j.ymeth.2007.09.007; FREEDMAN R, 1985, J BIOL CHEM, V260, P10063; Guth E, 2005, BIOCHEMISTRY-US, V44, P3785, DOI 10.1021/bi047923h; Guth EC, 2007, MOL CELL, V25, P531, DOI 10.1016/j.molcel.2007.01.015; Hauenstein SI, 2008, J BIOL CHEM, V283, P21997, DOI 10.1074/jbc.M801838200; Heacock D, 1996, BIOORG CHEM, V24, P273, DOI 10.1006/bioo.1996.0025; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; JAKES R, 1975, BIOCHEMISTRY-US, V14, P3344, DOI 10.1021/bi00686a009; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P369, DOI DOI 10.1007/978-1-4757-3061-6; LAZDUNSKI M, 1971, EUR J BIOCHEM, V20, P124, DOI 10.1111/j.1432-1033.1971.tb01370.x; MAZAT JP, 1982, EUR J BIOCHEM, V128, P389; Minajigi A, 2008, P NATL ACAD SCI USA, V105, P17748, DOI 10.1073/pnas.0804247105; Pope AJ, 1998, J BIOL CHEM, V273, P31680, DOI 10.1074/jbc.273.48.31680; Qiu XY, 1999, BIOCHEMISTRY-US, V38, P12296, DOI 10.1021/bi990482v; Takita T, 1998, J BIOCHEM-TOKYO, V124, P45, DOI 10.1093/oxfordjournals.jbchem.a022095; TREZEGUET V, 1986, BIOCHEMISTRY-US, V25, P7125, DOI 10.1021/bi00370a055; WARD WHJ, 1988, BIOCHEMISTRY-US, V27, P1041, DOI 10.1021/bi00403a029; WARD WHJ, 1988, BIOCHEMISTRY-US, V27, P5525, DOI 10.1021/bi00415a021; Yan W, 1996, BIOCHEMISTRY-US, V35, P6559, DOI 10.1021/bi952889f; Yaremchuk A, 2002, EMBO J, V21, P3829, DOI 10.1093/emboj/cdf373	40	15	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					20753	20762		10.1074/jbc.M109.021311	http://dx.doi.org/10.1074/jbc.M109.021311			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19487703	Green Published, hybrid			2022-12-25	WOS:000268316100037
J	Korzeniowski, MK; Popovic, MA; Szentpetery, Z; Varnai, P; Stojilkovic, SS; Balla, T				Korzeniowski, Marek K.; Popovic, Marko A.; Szentpetery, Zsofia; Varnai, Peter; Stojilkovic, Stanko S.; Balla, Tamas			Dependence of STIM1/Orai1-mediated Calcium Entry on Plasma Membrane Phosphoinositides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; PHOSPHATIDYLINOSITOL 4-KINASE; CHANNEL ACTIVATION; ENDOTHELIAL-CELLS; HUMAN PLATELETS; CRAC CHANNELS; CA2+ CHANNELS; LIVING CELLS; STIM1; ORAI1	Recent studies identified two main components of store-operated calcium entry (SOCE): the endoplasmic reticulum-localized Ca2+ sensor protein, STIM1, and the plasma membrane (PM)-localized Ca2+ channel, Orai1/CRACM1. In the present study, we investigated the phosphoinositide dependence of Orai1 channel activation in the PM and of STIM1 movements from the tubular to PM-adjacent endoplasmic reticulum regions during Ca2+ store depletion. Phosphatidylinositol 4,5-bisphosphate ( PtdIns( 4,5)P-2) levels were changed either with agonist stimulation or by chemically induced recruitment of a phosphoinositide 5-phosphatase domain to the PM, whereas PtdIns4P levels were decreased by inhibition or down-regulation of phosphatidylinositol 4-kinases (PI4Ks). Agonist-induced phospholipase C activation and PI4K inhibition, but not isolated PtdIns(4,5)P-2 depletion, substantially reduced endogenous or STIM1/Orai1-mediated SOCE without preventing STIM1 movements toward the PM upon Ca2+ store depletion. Patch clamp analysis of cells overexpressing STIM1 and Orai1 proteins confirmed that phospholipase C activation or PI4K inhibition greatly reduced I-CRAC currents. These results suggest an inositide requirement of Orai1 activation but not STIM1 movements and indicate that PtdIns4P rather than PtdIns(4,5)P-2 is a likely determinant of Orai1 channel activity.	[Korzeniowski, Marek K.; Szentpetery, Zsofia; Balla, Tamas] NICHD, NIH, Sect Mol Signal Transduct, Program Dev Neurosci, Bethesda, MD 20892 USA; [Popovic, Marko A.; Stojilkovic, Stanko S.] NICHD, NIH, Sect Cellular Signaling, Program Dev Neurosci, Bethesda, MD 20892 USA; [Varnai, Peter] Semmelweis Univ, Fac Med, Dept Physiol, H-1094 Budapest, Hungary	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Semmelweis University	Balla, T (corresponding author), NICHD, NIH, Sect Mol Signal Transduct, Program Dev Neurosci, Bldg 49,Rm 6A35,49 Convent Dr, Bethesda, MD 20892 USA.	ballat@mail.nih.gov	Korzeniowski, Marek/G-7214-2011	Balla, Tamas/0000-0002-9077-3335; Korzeniowski, Marek/0000-0002-5264-7303	NICHD; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000196, ZIAHD000195] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000195, Z01HD000196] Funding Source: NIH RePORTER	NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported, in whole or in part, by a National Institutes of Health grant from the Intramural Research Program of the NICHD.	Balla A, 2006, TRENDS CELL BIOL, V16, P351, DOI 10.1016/j.tcb.2006.05.003; Balla A, 2008, MOL BIOL CELL, V19, P711, DOI 10.1091/mbc.E07-07-0713; Balla T, 2007, J PHYSIOL-LONDON, V582, P927, DOI 10.1113/jphysiol.2007.132795; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Gamper N, 2007, NAT REV NEUROSCI, V8, P921, DOI 10.1038/nrn2257; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P17078; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Hewavitharana T, 2007, CELL CALCIUM, V42, P173, DOI 10.1016/j.ceca.2007.03.009; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Lewis RS, 2007, NATURE, V446, P284, DOI 10.1038/nature05637; Li ZZ, 2007, J BIOL CHEM, V282, P29448, DOI 10.1074/jbc.M703573200; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liou J, 2007, P NATL ACAD SCI USA, V104, P9301, DOI 10.1073/pnas.0702866104; Muik M, 2008, J BIOL CHEM, V283, P8014, DOI 10.1074/jbc.M708898200; NAKANISHI S, 1994, J BIOL CHEM, V269, P6528; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Park CY, 2009, CELL, V136, P876, DOI 10.1016/j.cell.2009.02.014; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Putney JW, 2007, CELL CALCIUM, V42, P103, DOI 10.1016/j.ceca.2007.01.011; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Rosado JA, 2000, J BIOL CHEM, V275, P9110, DOI 10.1074/jbc.275.13.9110; Roy A, 2004, J BIOL CHEM, V279, P44683, DOI 10.1074/jbc.M401583200; SARKADI B, 1990, BIOCHIM BIOPHYS ACTA, V1027, P130, DOI 10.1016/0005-2736(90)90076-Z; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Stiber J, 2008, NAT CELL BIOL, V10, P688, DOI 10.1038/ncb1731; Suh BC, 2006, SCIENCE, V314, P1454, DOI 10.1126/science.1131163; Takahashi R, 1997, BIOCHEM BIOPH RES CO, V235, P657, DOI 10.1006/bbrc.1997.6856; Varnai P, 2007, J BIOL CHEM, V282, P29678, DOI 10.1074/jbc.M704339200; Varnai P, 2006, J CELL BIOL, V175, P377, DOI 10.1083/jcb.200607116; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Warashina A, 1999, ARCH BIOCHEM BIOPHYS, V367, P303, DOI 10.1006/abbi.1999.1273; Watanabe H, 1996, BIOCHEM BIOPH RES CO, V225, P777, DOI 10.1006/bbrc.1996.1250; Willars GB, 1998, J BIOL CHEM, V273, P5037, DOI 10.1074/jbc.273.9.5037; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8; Yuan JP, 2009, NAT CELL BIOL, V11, P337, DOI 10.1038/ncb1842; Zeng WZ, 2008, MOL CELL, V32, P439, DOI 10.1016/j.molcel.2008.09.020; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103	42	112	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	2009	284	31					21027	21035		10.1074/jbc.M109.012252	http://dx.doi.org/10.1074/jbc.M109.012252			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474WV	19483082	hybrid, Green Published			2022-12-25	WOS:000268316100065
J	Fan, Y; Menon, RK; Cohen, P; Hwang, D; Clemens, T; DiGirolamo, DJ; Kopchick, JJ; Le Roith, D; Trucco, M; Sperling, MA				Fan, Yong; Menon, Ram K.; Cohen, Pinchas; Hwang, David; Clemens, Thomas; DiGirolamo, Douglas J.; Kopchick, John J.; Le Roith, Derek; Trucco, Massimo; Sperling, Mark A.			Liver-specific Deletion of the Growth Hormone Receptor Reveals Essential Role of Growth Hormone Signaling in Hepatic Lipid Metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IGF-I; INSULIN-RESISTANCE; BONE-GROWTH; MICE; INSULIN-LIKE-GROWTH-FACTOR-1; EXPRESSION; MOUSE; GENE; TISSUE; PLATE	Growth hormone (GH) plays a pivotal role in growth and metabolism, with growth promotion mostly attributed to generation of insulin-like growth factor I (IGF-I) in liver or at local sites of GH action, whereas the metabolic effects of GH are considered to be intrinsic to GH itself. To distinguish the effects of GH from those of IGF-I, we developed a Cre-lox-mediated model of tissue-specific deletion of the growth hormone receptor (GHR). Near total deletion of the GHR in liver (GHRLD) had no effect on total body or bone linear growth despite a >90% suppression of circulating IGF-I; however, total bone density was significantly reduced. Circulating GH was increased 4-fold, and GHRLD displayed insulin resistance, glucose intolerance, and increased circulating free fatty acids. Livers displayed marked steatosis, the result of increased triglyceride synthesis and decreased efflux; reconstitution of hepatic GHR signaling via adenoviral expression of GHR restored triglyceride output to normal, whereas IGF-I infusion did not correct steatosis despite restoration of circulating GH to normal. Thus, with near total absence of circulating IGF-I, GH action at the growth plate, directly and via locally generated IGF-I, can regulate bone growth, but at the expense of diabetogenic, lipolytic, and hepatosteatotic consequences. Our results indicate that IGF-I is essential for bone mineral density, whereas hepatic GH signaling is essential to regulate intrahepatic lipid metabolism. We propose that circulating IGF-I serves to amplify the growth-promoting effects of GH, while simultaneously dampening the catabolic effects of GH.	[Fan, Yong; Trucco, Massimo; Sperling, Mark A.] Univ Pittsburgh, Dept Pediat, Sch Med, Pittsburgh, PA 15260 USA; [Menon, Ram K.] Univ Michigan, Dept Pediat, Sch Med, Ann Arbor, MI 48109 USA; [Cohen, Pinchas; Hwang, David] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90095 USA; [Clemens, Thomas; DiGirolamo, Douglas J.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; [Kopchick, John J.] Ohio Univ, Dept Biomed Sci, Athens, OH 45701 USA; [Le Roith, Derek] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan; University of California System; University of California Los Angeles; University of Alabama System; University of Alabama Birmingham; University System of Ohio; Ohio University; Icahn School of Medicine at Mount Sinai	Sperling, MA (corresponding author), Childrens Hosp Pittsburgh, 530 45th St, Pittsburgh, PA 15201 USA.	masp@pitt.edu			National Institutes of Health [RO1-AR052746-01, RO1-DK049845-11A2]; Henry Hillman Endowment Chair; Department of Defense [W81XWH-06-1-0317]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049845] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Henry Hillman Endowment Chair; Department of Defense(United States Department of Defense); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grants RO1-AR052746-01 (to T. C. and M. A. S.) and RO1-DK049845-11A2 (to R. K. M. and M. A. S.). This work was also supported in part by a grant from the Henry Hillman Endowment Chair in Pediatric Immunology and by Department of Defense Grant W81XWH-06-1-0317 (to M. T.).	Clemmons David Robert, 2002, Pituitary, V5, P181, DOI 10.1023/A:1023321421760; Cui Y, 2007, HEPATOLOGY, V46, P504, DOI 10.1002/hep.21713; del Rincon JP, 2007, DIABETES, V56, P1638, DOI 10.2337/db06-0299; Delarue J, 2007, CURR OPIN CLIN NUTR, V10, P142, DOI 10.1097/MCO.0b013e328042ba90; Fan Y, 1999, DEV BIOL, V210, P481, DOI 10.1006/dbio.1999.9279; Goldenberg N, 2007, ENDOCRIN METAB CLIN, V36, P37, DOI 10.1016/j.ecl.2006.11.003; Hwang DL, 2008, GROWTH HORM IGF RES, V18, P65, DOI 10.1016/j.ghir.2007.07.007; Imberti B, 2007, J AM SOC NEPHROL, V18, P2921, DOI 10.1681/ASN.2006121318; Johannsson G., 1999, Journal of Endocrinological Investigation, V22, P41; Kaplan SA, 2007, J CLIN ENDOCR METAB, V92, P4529, DOI 10.1210/jc.2007-0526; KOSTYO JL, 1959, SCIENCE, V130, P1653, DOI 10.1126/science.130.3389.1653; LeRoith D, 2007, NAT CLIN PRACT ENDOC, V3, P302, DOI 10.1038/ncpendmet0427; LeRoith Derek, 2008, Pediatr Endocrinol Rev, V5 Suppl 2, P739; Liu JL, 2000, P SOC EXP BIOL MED, V223, P344, DOI 10.1046/j.1525-1373.2000.22349.x; Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104; Lupu F, 2001, DEV BIOL, V229, P141, DOI 10.1006/dbio.2000.9975; Millar JS, 2005, J LIPID RES, V46, P2023, DOI 10.1194/jlr.D500019-JLR200; NILSSON A, 1986, SCIENCE, V233, P571, DOI 10.1126/science.3523759; Nilsson O, 2005, HORM RES, V64, P157, DOI 10.1159/000088791; Rosenfeld RG, 2007, TRENDS ENDOCRIN MET, V18, P134, DOI 10.1016/j.tem.2007.03.004; SHERWIN RS, 1983, DIABETOLOGIA, V24, P155; Shimano H, 2007, J MOL MED, V85, P437, DOI 10.1007/s00109-007-0158-5; Sjogren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088; Sjogren M, 2002, ENDOCRINE, V19, P249, DOI 10.1385/ENDO:19:3:249; Svensson J, 2007, J ENDOCRINOL, V193, P359, DOI 10.1677/JOE-07-0024; Wang J, 2004, J ENDOCRINOL, V180, P247, DOI 10.1677/joe.0.1800247; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Yakar S, 2002, J CLIN INVEST, V110, P771, DOI 10.1172/JCI200215463; Yakar S, 2004, J CLIN INVEST, V113, P96, DOI 10.1172/JCI200417763; Zhou YH, 1997, P NATL ACAD SCI USA, V94, P13215, DOI 10.1073/pnas.94.24.13215	30	188	190	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					19937	19944		10.1074/jbc.M109.014308	http://dx.doi.org/10.1074/jbc.M109.014308			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19460757	hybrid, Green Published			2022-12-25	WOS:000268097400020
J	Lin, IJ; Zhou, Z; Crusselle-Davis, VJ; Moghimi, B; Gandhi, K; Anantharaman, A; Pantic, D; Huang, S; Jayandharan, G; Zhong, L; Srivastava, A; Bungert, J				Lin, I-Ju; Zhou, Zhuo; Crusselle-Davis, Valerie J.; Moghimi, Babak; Gandhi, Kunjal; Anantharaman, Archana; Pantic, Dorjan; Huang, Suming; Jayandharan, Giridhararao; Zhong, Li; Srivastava, Arun; Bungert, Joerg			Calpeptin Increases the Activity of Upstream Stimulatory Factor and Induces High Level Globin Gene Expression in Erythroid Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; MURINE ERYTHROLEUKEMIA-CELLS; LOOP-HELIX PROTEINS; TFII-I; TRANSCRIPTION FACTORS; STEM-CELLS; DIFFERENTIATION; CALPAIN; COMMITMENT; PROMOTER	Differentiation of erythroid cells is regulated by cell signaling pathways including those that change the intracellular concentration of calcium. Calcium-dependent proteases have been shown previously to process and regulate the activity of specific transcription factors. We show here that the protein levels of upstream stimulatory factor (USF) increase during differentiation of murine erythroleukemia (MEL) cells. USF was subject to degradation by the Ca2+-dependent protease m-calpain in undifferentiated but not in differentiated MEL cells. Treatment of MEL cells with the specific calpain inhibitor calpeptin increased the levels of USF and strongly induced expression of the adult alpha- and beta-globin genes. The induction of globin gene expression was associated with an increase in the association of USF and RNA polymerase II with regulatory elements of the beta-globin gene locus. Calpeptin also induced high level alpha- and beta-globin gene expression in primary CD71-positive erythroid progenitor cells. The combined data suggest that inhibition of calpain activity is required for erythroid differentiation-associated increase in globin gene expression.	[Lin, I-Ju; Zhou, Zhuo; Crusselle-Davis, Valerie J.; Moghimi, Babak; Gandhi, Kunjal; Anantharaman, Archana; Pantic, Dorjan; Huang, Suming; Bungert, Joerg] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; [Jayandharan, Giridhararao; Zhong, Li; Srivastava, Arun] Univ Florida, Coll Med, Div Cellular & Mol Therapy, Dept Pediat, Gainesville, FL 32610 USA; [Srivastava, Arun] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; [Bungert, Joerg] Univ Florida, Coll Med, Ctr Epigenet, Gainesville, FL 32610 USA; [Srivastava, Arun] Univ Florida, Coll Med, Powell Gene Therapy Ctr, Gainesville, FL 32610 USA; [Srivastava, Arun; Bungert, Joerg] Univ Florida, Coll Med, Genet Inst, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Bungert, J (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, 1600 Archer Rd,POB 100245, Gainesville, FL 32610 USA.	jbungert@ufl.edu	Zhong, Li/GZM-4358-2022	Zhong, Li/0000-0003-1611-5171	National Institutes of Health [DK052356, HL090589]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052356] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grants DK052356 (to J. B.) and HL090589 (to S. H.).	BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BRIDGES K, 1981, J CELL BIOL, V90, P542, DOI 10.1083/jcb.90.2.542; Caraveo G, 2006, SCIENCE, V314, P122, DOI 10.1126/science.1127815; Choe C, 2005, EXP CELL RES, V302, P1, DOI 10.1016/j.yexcr.2004.08.013; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Corre S, 2005, PIGM CELL RES, V18, P337, DOI 10.1111/j.1600-0749.2005.00262.x; Crusselle-Davis VJ, 2007, FEBS J, V274, P6065, DOI 10.1111/j.1742-4658.2007.06128.x; Crusselle-Davis VJ, 2006, MOL CELL BIOL, V26, P6832, DOI 10.1128/MCB.01770-05; Dahl JA, 2007, STEM CELLS, V25, P1037, DOI 10.1634/stemcells.2006-0430; Elnitski L, 1997, J BIOL CHEM, V272, P369; FALETTO DL, 1985, J BIOL CHEM, V260, P4884; Giannola DM, 2000, J EXP MED, V192, P1479, DOI 10.1084/jem.192.10.1479; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092; HENSOLD JO, 1991, BLOOD, V77, P1362; INOMATA M, 1993, BIOCHIM BIOPHYS ACTA, V1178, P207, DOI 10.1016/0167-4889(93)90011-D; Kim DW, 2000, MOL CELL BIOL, V20, P1140, DOI 10.1128/MCB.20.4.1140-1148.2000; Leach KM, 2003, NUCLEIC ACIDS RES, V31, P1292, DOI 10.1093/nar/gkg209; Mabaera R, 2008, EXP HEMATOL, V36, P1057, DOI 10.1016/j.exphem.2008.06.014; Mammoto A, 2009, NATURE, V457, P1103, DOI 10.1038/nature07765; Oh-Hora M, 2008, CURR OPIN IMMUNOL, V20, P250, DOI 10.1016/j.coi.2008.04.004; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Richmond TD, 2005, TRENDS CELL BIOL, V15, P146, DOI 10.1016/j.tcb.2005.01.007; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Song SH, 2007, MOL CELL, V28, P810, DOI 10.1016/j.molcel.2007.09.025; Vieira KF, 2004, J BIOL CHEM, V279, P50350, DOI 10.1074/jbc.M408883200; Wang JH, 2006, CELL BIOCHEM BIOPHYS, V45, P147, DOI 10.1385/CBB:45:2:147; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; Wood MA, 2009, BIOL REPROD, V80, P24, DOI 10.1095/biolreprod.108.070037; Yajima Y, 2002, BIOL CHEM, V383, P757, DOI 10.1515/BC.2002.079	32	3	3	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20130	20135		10.1074/jbc.M109.001461	http://dx.doi.org/10.1074/jbc.M109.001461			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19491096	Green Published, hybrid			2022-12-25	WOS:000268097400040
J	Nock, A; Ascano, JM; Jones, T; Barrero, MJ; Sugiyama, N; Tomita, M; Ishihama, Y; Malik, S				Nock, Adam; Ascano, Janice M.; Jones, Tara; Barrero, Maria J.; Sugiyama, Naoyuki; Tomita, Masaru; Ishihama, Yasushi; Malik, Sohail			Identification of DNA-dependent Protein Kinase as a Cofactor for the Forkhead Transcription Factor FoxA2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN AI GENE; RNA-POLYMERASE-II; BINDING PROTEIN; HISTONE H1; IN-VIVO; PHOSPHORYLATION; EXPRESSION; ACTIVATION; CHROMATIN; COMPLEX	Forkhead factors are important regulators of animal development and homeostasis. They are among the earliest to bind quiescent genes, which they activate in conjunction with other transcription factors. Many liver-specific genes are under the control of FoxA2, a liver-enriched forkhead protein. Here we confirmed by chromatin immunoprecipitation that FoxA2 is one of the factors bound to the promoter-proximal enhancer of the gene encoding apolipoprotein AI (a component of high density lipoprotein) and that it functions in synergy with the nuclear receptor hepatocyte nuclear factor-4 alpha. Furthermore, toward identifying additional cofactors that could potentially regulate FoxA2 activity, we identified DNA-dependent protein kinase (DNA-PK) as a FoxA2-associated factor upon affinity purification of epitope-tagged FoxA2. We show that FoxA2, found to be a phosphoprotein in vivo, is also an efficient substrate for DNA-PK, which targets serine 283. This residue is contained within a conserved serine-glutamine phosphorylation signal for DNA-PK, located within the C-terminal third of the polypeptide, just distal to its winged-helix DNA binding domain. We establish that this residue is critical for FoxA2 function because FoxA2 bearing a mutation at this site is severely compromised in its ability to activate a reporter gene under the control of its cognate DNA-binding site (apoAI site B). Complementary experiments rule out that this mutation compromises the ability of FoxA2 to either translocate to the nucleus or to bind site B. We therefore conclude that DNA-PK-dependent phosphorylation of FoxA2 plays a critical role in its transcriptional activation function per se.	[Malik, Sohail] Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10065 USA; [Sugiyama, Naoyuki; Tomita, Masaru; Ishihama, Yasushi] Keio Univ, Inst Adv Biosci, Yamagata 9970017, Japan; [Ishihama, Yasushi] Japan Sci & Technol Agcy, PRESTO, Tokyo 1020075, Japan	Rockefeller University; Keio University; Japan Science & Technology Agency (JST)	Malik, S (corresponding author), Rockefeller Univ, Biochem & Mol Biol Lab, 1230 York Ave, New York, NY 10065 USA.	maliks@rockefeller.edu	Nock, Adam/C-5287-2011; Barrero, Maria J./Q-1785-2017; Ishihama, Yasushi/B-3101-2016	Nock, Adam/0000-0003-2142-5334; Barrero, Maria J./0000-0002-5990-7040; Ishihama, Yasushi/0000-0001-7714-203X; Sugiyama, Naoyuki/0000-0001-7633-8495	National Institutes of Health [RO1 DK060764]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060764] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grant RO1 DK060764 (to S.M.).	Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Barrero MJ, 2006, MOL CELL, V24, P233, DOI 10.1016/j.molcel.2006.09.020; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Chibazakura T, 1997, EUR J BIOCHEM, V247, P1166, DOI 10.1111/j.1432-1033.1997.01166.x; Cirillo LA, 1999, MOL CELL, V4, P961, DOI 10.1016/S1097-2765(00)80225-7; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Collins GA, 2006, CURR OPIN GENET DEV, V16, P197, DOI 10.1016/j.gde.2006.02.009; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Dou YL, 2005, MOL CELL BIOL, V25, P3914, DOI 10.1128/MCB.25.10.3914-3922.2005; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; DVIR A, 1993, J BIOL CHEM, V268, P10440; Friedman JR, 2006, CELL MOL LIFE SCI, V63, P2317, DOI 10.1007/s00018-006-6095-6; Glass CK, 2000, GENE DEV, V14, P121; Harnish DC, 1996, J BIOL CHEM, V271, P13621, DOI 10.1074/jbc.271.23.13621; HARNISH DC, 1994, J BIOL CHEM, V269, P28220; Ishihama Y, 2002, J CHROMATOGR A, V979, P233, DOI 10.1016/S0021-9673(02)01402-4; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Ko L, 2003, J BIOL CHEM, V278, P11471, DOI 10.1074/jbc.M209723200; Koop R, 2003, EMBO J, V22, P588, DOI 10.1093/emboj/cdg052; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Kyono Y, 2008, J PROTEOME RES, V7, P4585, DOI 10.1021/pr800305y; Kysela B, 2005, P NATL ACAD SCI USA, V102, P1877, DOI 10.1073/pnas.0401179102; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Malik S, 2003, METHOD ENZYMOL, V364, P257; Malik S, 2003, FRONT BIOSCI, V8, pD360, DOI 10.2741/1005; MALIK S, 2003, HDB CELL SIGNALING, V3, P11; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Rada-Iglesias A, 2005, HUM MOL GENET, V14, P3435, DOI 10.1093/hmg/ddi378; Rochette-Egly C, 2005, J BIOL CHEM, V280, P32565, DOI 10.1074/jbc.R500008200; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SLADEK FM, 1993, RECEPTOR, V3, P223; Tuteja G, 2007, CELL, V130, DOI 10.1016/j.cell.2007.09.005; Wolfrum C, 2003, P NATL ACAD SCI USA, V100, P11624, DOI 10.1073/pnas.1931483100; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047; Wong RHF, 2009, CELL, V136, P1056, DOI 10.1016/j.cell.2008.12.040; Woodard RL, 1999, J BIOL CHEM, V274, P478, DOI 10.1074/jbc.274.1.478; Wu RC, 2007, CELL, V129, P1125, DOI 10.1016/j.cell.2007.04.039; Zannis VI, 2001, FRONT BIOSCI-LANDMRK, V6, pD456, DOI 10.2741/Zannis	50	6	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					19915	19926		10.1074/jbc.M109.016295	http://dx.doi.org/10.1074/jbc.M109.016295			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19478084	hybrid, Green Published			2022-12-25	WOS:000268097400018
J	Itoh, T; Nozawa, Y; Akao, Y				Itoh, Tomohiro; Nozawa, Yoshinori; Akao, Yukihiro			MicroRNA-141 and-200a Are Involved in Bone Morphogenetic Protein-2-induced Mouse Pre-osteoblast Differentiation by Targeting Distal-less Homeobox 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; SKELETAL DEVELOPMENT; OSTERIX EXPRESSION; UP-REGULATION; SMALL RNAS; DLX5; RUNX2; PATHWAYS; PROTEINS; ELEGANS	MicroRNAs (miRs) are endogenously expressed 18-25-nucleotide RNAs that regulate gene expression through translational repression by binding to a target mRNA. Recently, it was indicated that miRs act as key regulators in cell differentiation, cell growth, and cell death. In osteogenesis, several miRs ( for example miR-26a, -125b, -133, and -135) regulate osteoblast cell growth or differentiation in human adipose tissue-derived stem cells, mouse mesenchymal ST2 stem cells, and mouse premyogenic C2C12 cells. Additionally, Smad proteins control Drosha-mediated miR maturation. Therefore, miRs are closely related to osteogenesis. Here we investigated miR expression profile by an miR array and identified the candidate miRs, miR-141 and -200a, as pre-osteoblast differentiation-related miRs. The effects of miR-141 and -200a on pre-osteoblast differentiation were examined by using transfection of murine pre-osteoblastic MC3T3-E1 cells with mature miR-141 or -200a and antisense inhibitor for miR-141 or -200a. It was shown that miR-141 and -200a remarkably modulated the BMP-2-induced pre-osteoblast differentiation through the translational repression of Dlx5, which is a bone-generating transcription factor expressed in pre-osteoblast differentiation. Furthermore, it was indicated that Dlx5 is a common target of miR-141 and -200a by using a luciferase reporter assay. Thus, we have observed for the first time that miR-141 and -200a are involved in pre-osteoblast differentiation in part by regulating the expression of Dlx5.	[Itoh, Tomohiro; Nozawa, Yoshinori; Akao, Yukihiro] Gifu Int Inst Biotechnol, Gifu 5040838, Japan		Itoh, T (corresponding author), Gifu Int Inst Biotechnol, 1-1 Naka Fudogaoka, Gifu 5040838, Japan.	titoh@giib.or.jp	ITOH, Tomohiro/ABG-7076-2020					Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Celil AB, 2005, J CELL BIOCHEM, V95, P518, DOI 10.1002/jcb.20429; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; Fukuda T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577; Kim YJ, 2004, J BIOL CHEM, V279, P50773, DOI 10.1074/jbc.M404145200; Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Lee MH, 2005, J BIOL CHEM, V280, P35579, DOI 10.1074/jbc.M502267200; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105; Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011; Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030; Mizuno Y, 2008, BIOCHEM BIOPH RES CO, V368, P267, DOI 10.1016/j.bbrc.2008.01.073; Naguibneva Irina, 2007, Journal de la Societe de Biologie, V201, P367, DOI 10.1051/jbio:2007902; Nelson P, 2003, TRENDS BIOCHEM SCI, V28, P534, DOI 10.1016/j.tibs.2003.08.005; Robledo RF, 2002, GENE DEV, V16, P1089, DOI 10.1101/gad.988402; Shirakabe K, 2001, GENES CELLS, V6, P851, DOI 10.1046/j.1365-2443.2001.00466.x; Sugatani T, 2007, J CELL BIOCHEM, V101, P996, DOI 10.1002/jcb.21335; Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200; Wang Y, 2008, J BIOL CHEM, V283, P13205, DOI 10.1074/jbc.M707629200; Yu JY, 2008, EXP CELL RES, V314, P2618, DOI 10.1016/j.yexcr.2008.06.002; Zhang J, 2008, BIOCHEM BIOPH RES CO, V377, P136, DOI 10.1016/j.bbrc.2008.09.089	30	163	188	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19272	19279		10.1074/jbc.M109.014001	http://dx.doi.org/10.1074/jbc.M109.014001			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19454767	Green Published, hybrid			2022-12-25	WOS:000267908300018
J	Lamprecht, G; Hsieh, CJ; Lissner, S; Nold, L; Heil, A; Gaco, V; Schafer, J; Turner, JR; Gregor, M				Lamprecht, Georg; Hsieh, Chih-Jen; Lissner, Simone; Nold, Lilia; Heil, Andreas; Gaco, Veronika; Schaefer, Julia; Turner, Jerrold R.; Gregor, Michael			Intestinal Anion Exchanger Down-regulated in Adenoma (DRA) Is Inhibited by Intracellular Calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER NA+/H+ EXCHANGER; PROTEIN-KINASE-C; CONGENITAL CHLORIDE DIARRHEA; BRUSH-BORDER; CL-/HCO3-EXCHANGER; PDZ-DOMAIN; CA2+-DEPENDENT INHIBITION; EPITHELIAL TRANSPORT; RECEPTOR SUBTYPES; NHE3 INHIBITION	The Na/H exchanger 3 (NHE3) and the Cl/HCO3 exchanger down-regulated in adenoma (DRA) together facilitate intestinal electroneutral NaCl absorption. Elevated Ca-i(2+) inhibits NHE3 through mechanisms involving the PDZ domain proteins NHE3 kinase A regulatory protein (E3KARP) or PDZ kidney 1 (PDZK1). DRA also possesses a PDZ-binding motif, but the roles of interactions with E3KARP or PDZK1 and Ca-i(2+) in DRA regulation are unknown. Wild type DRA and a mutant lacking the PDZ interaction motif (DRA-ETKFminus) were expressed constitutively in human embryonic kidney (HEK) and inducibly in Caco-2/BBE cells. DRA-mediated Cl/HCO3 exchange was measured as intracellular pH changes. Ca-i(2+) was assessed fluorometrically. DRA was induced 8 - 16-fold and was delivered to the apical surface of polarized Caco-2 cells. Putative anion transporter 1 and cystic fibrosis transmembrane regulator did not contribute to Cl/HCO3 exchange in transfected Caco-2 cells. The calcium ionophore 4Br-A23187 inhibited DRA and DRA-ETKFminus in HEK cells, but only full-length DRA was inhibited in Caco-2 cells. In contrast, 100 mu M UTP, which increased Ca-i(2+), inhibited full-length DRA but not DRA-ETKFminus in Caco-2 and HEK cells. In HEK cells, which express little PDZK1, additional transfection of PDZK1 was required for UTP to inhibit DRA. As HEK cells do not express cystic fibrosis transmembrane regulator or NHE3, the data indicate that Ca-i(2+)-dependent DRA inhibition is not because of modulation of other transport activities. In polarized epithelium, this inhibition requires interaction of DRA with PDZK1. Together with data from PDZK1(-/-) mice, these data underscore the prominent role of PDZK1 in Ca-i(2+)-mediated inhibition of colonic NaCl absorption.	[Lamprecht, Georg; Hsieh, Chih-Jen; Lissner, Simone; Nold, Lilia; Heil, Andreas; Gaco, Veronika; Schaefer, Julia; Gregor, Michael] Univ Tubingen, Dept Med 1, D-72076 Tubingen, Germany; [Turner, Jerrold R.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	Eberhard Karls University of Tubingen; University of Chicago	Lamprecht, G (corresponding author), Univ Tubingen, Dept Med 1, D-72076 Tubingen, Germany.	hans-georg.lamprecht@uni-tuebingen.de	Turner, Jerrold/H-1502-2019; Turner, Jerrold R/A-6895-2009	Turner, Jerrold R/0000-0003-0627-9455	Deutsche Forschungsgemeinschaft [La 1066/3-2, La 1066/3-3]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by Deutsche Forschungsgemeinschaft Grants La 1066/3-2 and La 1066/3-3.	Anzai N, 2004, J BIOL CHEM, V279, P45942, DOI 10.1074/jbc.M406724200; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; Bucheimer RE, 2004, J PHYSIOL-LONDON, V555, P311, DOI 10.1113/jphysiol.2003.056697; Chapman JM, 2002, CANCER RES, V62, P5083; Chernova MN, 2003, J PHYSIOL-LONDON, V549, P3, DOI 10.1113/jphysiol.2003.039818; Cinar A, 2007, J PHYSIOL-LONDON, V581, P1235, DOI 10.1113/jphysiol.2007.131722; Clayburgh DR, 2006, J CLIN INVEST, V116, P2682, DOI 10.1172/JCI29218; COHEN ME, 1991, J CLIN INVEST, V88, P855, DOI 10.1172/JCI115387; Donowitz M, 2005, J PHYSIOL-LONDON, V567, P1, DOI 10.1113/jphysiol.2005.089698; Donowitz M, 2007, PHYSIOL REV, V87, P825, DOI 10.1152/physrev.00030.2006; Fam SR, 2005, P NATL ACAD SCI USA, V102, P8042, DOI 10.1073/pnas.0408818102; Field M, 2003, J CLIN INVEST, V111, P931, DOI 10.1172/JCI200318326; Fischer W, 2005, N-S ARCH PHARMACOL, V371, P466, DOI 10.1007/s00210-005-1070-6; Hayashi H, 2009, AM J PHYSIOL-CELL PH, V296, pC1279, DOI 10.1152/ajpcell.00638.2008; Hu MC, 2001, J BIOL CHEM, V276, P26906, DOI 10.1074/jbc.M011338200; Inoue CN, 1997, AM J PHYSIOL-CELL PH, V272, pC1862, DOI 10.1152/ajpcell.1997.272.6.C1862; Jacob P, 2002, GASTROENTEROLOGY, V122, P709, DOI 10.1053/gast.2002.31875; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; Kim JH, 2002, J BIOL CHEM, V277, P23714, DOI 10.1074/jbc.M200835200; Ko SBH, 2004, NAT CELL BIOL, V6, P343, DOI 10.1038/ncb1115; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; Lamprecht G, 2006, AM J PHYSIOL-GASTR L, V291, pG766, DOI 10.1152/ajpgi.00135.2006; Lamprecht G, 2005, PFLUG ARCH EUR J PHY, V449, P479, DOI 10.1007/s00424-004-1342-x; Lamprecht G, 2002, BIOCHEMISTRY-US, V41, P12336, DOI 10.1021/bi0259103; Lamprecht G, 2006, PFLUG ARCH EUR J PHY, V452, P307, DOI 10.1007/s00424-006-0049-6; Lee-Kwon W, 2003, AM J PHYSIOL-CELL PH, V285, pC1527, DOI 10.1152/ajpcell.00017.2003; Leipziger J, 2003, AM J PHYSIOL-RENAL, V284, pF419, DOI 10.1152/ajprenal.00075.2002; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; Li XH, 2004, J PHYSIOL-LONDON, V556, P791, DOI 10.1113/jphysiol.2004.060921; Liedtke CM, 2002, J BIOL CHEM, V277, P22925, DOI 10.1074/jbc.M201917200; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; McAlroy HL, 2000, BRIT J PHARMACOL, V131, P1651, DOI 10.1038/sj.bjp.0703743; Melvin JE, 1999, J BIOL CHEM, V274, P22855, DOI 10.1074/jbc.274.32.22855; Moseley RH, 1999, AM J PHYSIOL-GASTR L, V276, pG185, DOI 10.1152/ajpgi.1999.276.1.G185; Mount DB, 2004, PFLUG ARCH EUR J PHY, V447, P710, DOI 10.1007/s00424-003-1090-3; Musch MW, 2009, AM J PHYSIOL-GASTR L, V296, pG202, DOI 10.1152/ajpgi.90350.2008; Rossmann H, 2005, BIOCHEMISTRY-US, V44, P4477, DOI 10.1021/bi048828b; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schweinfest CW, 2006, J BIOL CHEM, V281, P37962, DOI 10.1074/jbc.M607527200; Shcheynikov N, 2006, J GEN PHYSIOL, V127, P511, DOI 10.1085/jgp.200509392; Shen L, 2006, J CELL SCI, V119, P2095, DOI 10.1242/jcs.02915; Thomson RB, 2005, P NATL ACAD SCI USA, V102, P13331, DOI 10.1073/pnas.0506578102; Walker NM, 2009, GASTROENTEROLOGY, V136, P893, DOI 10.1053/j.gastro.2008.11.016; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zachos NC, 2006, GASTROENTEROLOGY, V130, pA51	45	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19744	19753		10.1074/jbc.M109.004127	http://dx.doi.org/10.1074/jbc.M109.004127			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19447883	Green Published, hybrid			2022-12-25	WOS:000267908300064
J	Thomas, SR; McTamney, PM; Adler, JM; LaRonde-LeBlanc, N; Rokita, SE				Thomas, Seth R.; McTamney, Patrick M.; Adler, Jennifer M.; LaRonde-LeBlanc, Nicole; Rokita, Steven E.			Crystal Structure of Iodotyrosine Deiodinase, a Novel Flavoprotein Responsible for Iodide Salvage in Thyroid Glands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE STABILIZATION; ACYL-COA DEHYDROGENASES; ESCHERICHIA-COLI; NUCLEOTIDE BINDING; REDOX PROPERTIES; REDUCTASE P; FLAVIN; NITROREDUCTASE; DEHALOGENASE; RESOLUTION	The flavoprotein iodotyrosine deiodinase (IYD) salvages iodide from mono- and diiodotyrosine formed during the biosynthesis of the thyroid hormone thyroxine. Expression of a soluble domain of this membrane-bound enzyme provided sufficient material for crystallization and characterization by x-ray diffraction. The structures of IYD and two co-crystals containing substrates, mono- and diiodotyrosine, alternatively, were solved at resolutions of 2.0, 2.45, and 2.6 A, respectively. The structure of IYD is homologous to others in the NADH oxidase/flavin reductase superfamily, but the position of the active site lid in IYD defines a new subfamily within this group that includes BluB, an enzyme associated with vitamin B-12 biosynthesis. IYD and BluB also share key interactions involving their bound flavin mononucleotide that suggest a unique catalytic behavior within the superfamily. Substrate coordination to IYD induces formation of an additional helix and coil that act as an active site lid to shield the resulting substrate center dot flavin complex from solvent. This complex is stabilized by aromatic stacking and extensive hydrogen bonding between the substrate and flavin. The carbon-iodine bond of the substrate is positioned directly over the C-4a/N-5 region of the flavin to promote electron transfer. These structures now also provide a molecular basis for understanding thyroid disease based on mutations of IYD.	[Thomas, Seth R.; McTamney, Patrick M.; Adler, Jennifer M.; LaRonde-LeBlanc, Nicole; Rokita, Steven E.] Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA; [Thomas, Seth R.; LaRonde-LeBlanc, Nicole] Univ Maryland, Ctr Biomol Struct & Org, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	LaRonde-LeBlanc, N (corresponding author), Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.	nlaronde@umd.edu; rokita@umd.edu	Rokita, Steven E/C-4793-2009; LaRonde-LeBlanc, Nicole A/C-3399-2009	LaRonde-LeBlanc, Nicole A/0000-0002-2778-8358	Herman Kraybill Biochemistry fellowship; National Center for Research Resources at the National Institutes of Health [RR-15301]; United States Department of Energy, Office of Basic Energy Sciences [DE-AC02-06CH11357]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER	Herman Kraybill Biochemistry fellowship; National Center for Research Resources at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); United States Department of Energy, Office of Basic Energy Sciences(United States Department of Energy (DOE)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by a Herman Kraybill Biochemistry fellowship (to P.M.).; We thank Chiwei Hung and Prof. Bentley for help with protein expression in Sf9 cells. This work is based upon research conducted in part at the Northeastern Collaborative Access Team beamlines of the Advanced Photon Source supported by Award RR-15301 from the National Center for Research Resources at the National Institutes of Health. Use of the Advanced Photon Source is supported by the United States Department of Energy, Office of Basic Energy Sciences, under Contract DE-AC02-06CH11357. We are grateful to the excellent staff at the Northeastern Collaborative Access Team for assistance with data collection and analysis.	Afink G, 2008, J CLIN ENDOCR METAB, V93, P4894, DOI 10.1210/jc.2008-0865; Auffinger P, 2004, P NATL ACAD SCI USA, V101, P16789, DOI 10.1073/pnas.0407607101; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; CODY V, 1984, J MOL STRUCT, V112, P189, DOI 10.1016/0022-2860(84)85061-9; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; De Colibus L, 2006, CURR OPIN STRUC BIOL, V16, P722, DOI 10.1016/j.sbi.2006.10.003; DeLano W, 2002, PYMOL 0 99; Dohan O, 2003, ENDOCR REV, V24, P48, DOI 10.1210/er.2001-0029; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; Friedman JE, 2006, J BIOL CHEM, V281, P2812, DOI 10.1074/jbc.M510365200; Gales L, 2005, BIOCHEM J, V388, P615, DOI 10.1042/BJ20042035; Gnidehou S, 2004, FASEB J, V18, P1574, DOI 10.1096/fj.04-2023fje; GOSWAMI A, 1977, ENDOCRINOLOGY, V101, P331, DOI 10.1210/endo-101-2-331; GOSWAMI A, 1979, J BIOL CHEM, V254, P2326; Haynes CA, 2002, J BIOL CHEM, V277, P11513, DOI 10.1074/jbc.M111334200; HECHT HJ, 1995, NAT STRUCT BIOL, V2, P1109, DOI 10.1038/nsb1295-1109; Holm L, 2000, BIOINFORMATICS, V16, P566, DOI 10.1093/bioinformatics/16.6.566; Johansson E, 2003, J MED CHEM, V46, P4009, DOI 10.1021/jm030843b; Joosten V, 2007, CURR OPIN CHEM BIOL, V11, P195, DOI 10.1016/j.cbpa.2007.01.010; Kobori T, 2001, J BIOL CHEM, V276, P2816, DOI 10.1074/jbc.M002617200; Koike H, 1998, J MOL BIOL, V280, P259, DOI 10.1006/jmbi.1998.1871; Kunishima M, 1999, J AM CHEM SOC, V121, P4722, DOI 10.1021/ja990693n; Legrand YM, 2003, J AM CHEM SOC, V125, P15789, DOI 10.1021/ja036940b; Lovering AL, 2001, J MOL BIOL, V309, P203, DOI 10.1006/jmbi.2001.4653; Lyubimov AY, 2006, NAT CHEM BIOL, V2, P259, DOI 10.1038/nchembio784; Mansoorabadi SO, 2007, J ORG CHEM, V72, P6329, DOI 10.1021/jo0703092; Matter H, 2009, ANGEW CHEM INT EDIT, V48, P2911, DOI 10.1002/anie.200806219; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Metrangolo P, 2008, ANGEW CHEM INT EDIT, V47, P6114, DOI 10.1002/anie.200800128; Moreno JC, 2008, NEW ENGL J MED, V358, P1811, DOI 10.1056/NEJMoa0706819; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; O'Reilly D., 1994, BACULOVIRUS EXPRESSI, P130; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pape T, 2004, J APPL CRYSTALLOGR, V37, P843, DOI 10.1107/S0021889804018047; Parkinson GN, 2000, J MED CHEM, V43, P3624, DOI 10.1021/jm000159m; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Solis-S JC, 2004, J ENDOCRINOL, V181, P385, DOI 10.1677/joe.0.1810385; Suzuki T, 2003, TRENDS GLYCOSCI GLYC, V15, P329, DOI 10.4052/tigg.15.329; Taga ME, 2007, NATURE, V446, P449, DOI 10.1038/nature05611; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P13531, DOI 10.1021/bi961400v; Tanner JJ, 1999, PROTEIN SCI, V8, P1725, DOI 10.1110/ps.8.9.1725; THORPE C, 1995, FASEB J, V9, P718, DOI 10.1096/fasebj.9.9.7601336; Tu SC, 2001, ANTIOXID REDOX SIGN, V3, P881, DOI 10.1089/15230860152665046; van Pee KH, 2006, APPL MICROBIOL BIOT, V70, P631, DOI 10.1007/s00253-005-0232-2; Vock P, 1998, BIOCHEMISTRY-US, V37, P1848, DOI 10.1021/bi971827h; Watson JA, 2008, CHEMBIOCHEM, V9, P504, DOI 10.1002/cbic.200700562; Yang KY, 2007, BIOCHEMISTRY-US, V46, P2289, DOI 10.1021/bi0616293	48	58	60	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19659	19667		10.1074/jbc.M109.013458	http://dx.doi.org/10.1074/jbc.M109.013458			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19436071	Green Published, hybrid			2022-12-25	WOS:000267908300057
J	Kashima, L; Toyota, M; Mita, H; Suzuki, H; Idogawa, M; Ogi, K; Sasaki, Y; Tokino, T				Kashima, L.; Toyota, M.; Mita, H.; Suzuki, H.; Idogawa, M.; Ogi, K.; Sasaki, Y.; Tokino, T.			CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-kappa B	ONCOGENE			English	Article						CHFR; NF-kappa B; IL-8; tumor suppressor; angiogenesis	MITOTIC CHECKPOINT PROTEIN; NECROSIS-FACTOR-ALPHA; CANCER-CELL-LINES; GENE-EXPRESSION; GASTRIC-CANCER; EPIGENETIC INACTIVATION; MICROTUBULE INHIBITORS; TRANSCRIPTION FACTORS; BREAST CANCERS; NUCLEAR-FACTOR	The mitotic checkpoint gene CHFR (checkpoint with forkhead and ring finger domains) is silenced in various human cancers by promoter hypermethylation, suggesting that CHFR is a tumor suppressor. Here, we show that CHFR functions as a negative regulator of the nuclear factor-kappa B (NF-kappa B) pathway. Expression of CHFR inhibited NF-kappa B reporter activity, whereas knockdown of CHFR activated reporter activity. These activities are independent of its RING finger domain. Furthermore, we found that CHFR physically interacts with p65 in cells. Electrophoretic mobility shift assays (EMSAs) and ELISA-based NF-kappa B-binding assays showed that CHFR negatively regulated transcriptional activity of p65. In addition, our data show that interleukin (IL)-8 is significantly downregulated by CHFR, and that the migration of human endothelial cells is suppressed in culture medium conditioned from CHFR-expressing cancer cells. Using a xenograft model, we show that neovascularization is suppressed by adenovirus-mediated transfer of CHFR. These results indicate that expression of CHFR markedly reduces the expression of IL-8 through the inhibition of NF-kappa B. As the NF-kappa B signaling pathway plays a critical role in the development and progression of cancer, our findings show the functional relationship between epigenetic alteration and inflammation/angiogenesis in human cancer cells, thereby showing several potential targets for therapeutic intervention. Oncogene (2009) 28, 2643 -2653; doi: 10.1038/onc.2009.123; published online 18 May 2009	[Kashima, L.; Toyota, M.; Mita, H.; Suzuki, H.; Idogawa, M.; Ogi, K.; Sasaki, Y.; Tokino, T.] Sapporo Med Univ, Dept Mol Biol, Canc Res Inst, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; [Toyota, M.; Suzuki, H.] Sapporo Med Univ, Dept Internal Med, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University; Sapporo Medical University	Tokino, T (corresponding author), Sapporo Med Univ, Dept Mol Biol, Canc Res Inst, Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	tokino@sapmed.ac.jp	Idogawa, Masashi/B-5208-2008; Tokino, Takashi/AAI-9887-2021; Sasaki, Yasushi/AAA-3079-2019	Idogawa, Masashi/0000-0002-8507-1726; Sasaki, Yasushi/0000-0002-3500-8059	Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) [pcDNA3-Flag-p65]	Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This research was supported by a grant to TT (KAKENHI (20390519)) from the Grants-in-Aid for Scienti. c Research (B) program of the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT). We thank Dr Toshiharu Suzuki (Hokkaido University, Japan) for the pcDNA3-Flag-p65 construct.	AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cude K, 2007, J CELL BIOL, V177, P253, DOI 10.1083/jcb.200609166; Cuenca R E, 1992, Surg Oncol, V1, P323, DOI 10.1016/0960-7404(92)90094-2; Daniels MJ, 2004, NAT STRUCT MOL BIOL, V11, P1114, DOI 10.1038/nsmb837; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Emmerich F, 2003, J PATHOL, V201, P413, DOI 10.1002/path.1454; Fukuda T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001776; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kang Dongmin, 2004, Methods Mol Biol, V280, P229; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kawai N, 2005, DEV BIOL, V277, P80, DOI 10.1016/j.ydbio.2004.09.007; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kontermann RE, 2008, J IMMUNOTHER, V31, P225, DOI 10.1097/CJI.0b013e31816a88f9; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Lee KH, 2004, ONCOLOGY-BASEL, V66, P210, DOI 10.1159/000077997; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Mumm JB, 2008, ONCOGENE, V27, P5913, DOI 10.1038/onc.2008.275; Nishikawa N, 2007, CANCER RES, V67, P9649, DOI 10.1158/0008-5472.CAN-06-4111; Nurnberg W, 1999, J PATHOL, V189, P546, DOI 10.1002/(SICI)1096-9896(199912)189:4<546::AID-PATH487>3.0.CO;2-L; Ogi K, 2005, CANCER BIOL THER, V4, P773, DOI 10.4161/cbt.4.7.1896; Privette LM, 2007, CANCER RES, V67, P6064, DOI 10.1158/0008-5472.CAN-06-4109; Privette LM, 2008, TRANSL ONCOL, V1, P57, DOI 10.1593/tlo.08109; Rakitina TV, 2003, CANCER RES, V63, P8600; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Sasaki Y, 2001, GENE THER, V8, P1401, DOI 10.1038/sj.gt.3301538; Sathe SS, 2004, P NATL ACAD SCI USA, V101, P192, DOI 10.1073/pnas.0306812101; Satoh A, 2003, CANCER RES, V63, P8606; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Starczynowski DT, 2007, ONCOGENE, V26, P2685, DOI 10.1038/sj.onc.1210089; Tomita S, 2000, J BIOL CHEM, V275, P13056, DOI 10.1074/jbc.C000019200; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; Wan FY, 2007, CELL, V131, P927, DOI 10.1016/j.cell.2007.10.009; Williams JL, 2008, CARCINOGENESIS, V29, P390, DOI 10.1093/carcin/bgm275; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538; Yuan A, 2005, FRONT BIOSCI-LANDMRK, V10, P853, DOI 10.2741/1579	48	28	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2643	2653		10.1038/onc.2009.123	http://dx.doi.org/10.1038/onc.2009.123			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19448676				2022-12-25	WOS:000268211200003
J	Mintzes, B; Morgan, S; Wright, JM				Mintzes, Barbara; Morgan, Steve; Wright, James M.			Twelve Years' Experience with Direct-to-Consumer Advertising of Prescription Drugs in Canada: A Cautionary Tale	PLOS ONE			English	Article							ADVERTISEMENTS; TELEVISION	Background: Direct-to-consumer advertising (DTCA) of prescription drugs is illegal in Canada as a health protection measure, but is permitted in the United States. However, in 2000, Canadian policy was changed to allow 'reminder' advertising of prescription drugs. This is a form of advertising that states the brand name without health claims. 'Reminder' advertising is prohibited in the US for drugs that have 'black box' warnings of serious risks. This study examines spending on DTCA in Canada from 1995 to 2006, 12 years spanning this policy shift. We ask how annual per capita spending compares to that in the US, and whether drugs with Canadian or US regulatory safety warnings are advertised to the Canadian public in reminder advertising. Methodology/Principal Findings: Prescription drug advertising spending data were extracted from a data set on health sector spending in Canada obtained from a market research company, TNS Media Inc. Spending was adjusted for inflation and compared with US spending. Inflation-adjusted spending on branded DTCA in Canada grew from under CAD$2 million per year before 1999 to over $22 million in 2006. The major growth was in broadcast advertising, accounting for 83% of spending in 2006. US annual per capita spending was on average 24 times Canadian levels. Celebrex (celecoxib), which has a US black box and was subject to three safety advisories in Canada, was the most heavily advertised drug on Canadian television in 2005 and 2006. Of 8 brands with >$500,000 spending, which together accounted for 59% of branded DTCA in all media, 6 were subject to Canadian safety advisories, and 4 had US black box warnings. Conclusions/Significance: Branded 'reminder' advertising has grown rapidly in Canada since 2000, mainly due to a growth in television advertising. Although DTCA spending per capita is much lower in Canada than in the US, there is no evidence of safer content or product choice; many heavily-advertised drugs in Canada have been subject to safety advisories. For governments searching for compromise solutions to industry pressure for expanded advertising, Canada's experience stands as a stark warning.			Mintzes, B (corresponding author), Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada.		Morgan, Steven/J-8814-2015; Mintzes, Barbara/AFK-6613-2022	Mintzes, Barbara/0000-0002-8671-915X; Morgan, Steven/0000-0002-7529-0028				Bell RA, 2000, J FAM PRACTICE, V49, P1092; Brownfield ED, 2004, J HEALTH COMMUN, V9, P491, DOI 10.1080/10810730490523115; Cotter J, 2005, CAN MED ASSOC J, V172, P1299, DOI 10.1503/cmaj.050456; Donohue JM, 2007, NEW ENGL J MED, V357, P673, DOI 10.1056/NEJMsa070502; FDA Alert, 2007, INF HEALTHC PROF ER; Frosch DL, 2007, ANN FAM MED, V5, P6, DOI 10.1370/afm.611; Frosst Merck, 1996, DIRECT TO CONSUMER A; Gardner DM, 2003, CAN MED ASSOC J, V169, P425; Graham DJ, 2005, LANCET, V365, P475, DOI 10.1016/S0140-6736(05)17864-7; Health Canada, 2005, HLTH CAN HAS ASK PFI; *HLTH CAN, 2004, UPD SAF INF INCR CAR; *HLTH CAN, 2003, PUBL ADV DIAN 35 RIS; IMS Health, 2008, TOT US PROM SPEND TY; Institute of Medicine of the National Academies, 2006, FUT DRUG SAF PROM PR; Kallen A, 2007, HEALTH AFFAIR, V26, P1392, DOI 10.1377/hlthaff.26.5.1392; Kaphingst KA, 2005, J HEALTH COMMUN, V10, P609, DOI 10.1080/10810730500267647; Law MR, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1055; *MARK HLTH PROD DI, 2002, IMP SAF CONC US DIAN; Mintzes B, 2005, CAN MED ASSOC J, V173, P1313, DOI 10.1503/cmaj.050567; Mintzes B, 2003, CAN MED ASSOC J, V169, P405; NICHOLS DM, 2005, DISTINCTION ADVERTIS; PhRMA, 2005, GUID PRINC DIR TO CO; Rosenthal MB, 2002, NEW ENGL J MED, V346, P498, DOI 10.1056/NEJMsa012075; ROWSELL LB, 2000, ADVERTISING CAMPAIGN; Standing Committee on Health, 2004, OP MED CAB 1 REP HLT; STUPAK B, 2008, DIRECT TO CONSUMER A; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; U. S. Food and Drug Administration, 2005, FDA UPD LAB ORTH EVR; *US GOV ACC OFF, 2006, PRESCR DRUGS IMPR NE; Woloshin S, 2001, LANCET, V358, P1141, DOI 10.1016/S0140-6736(01)06254-7; 2002, ADVISORY        0523; 2005, ADVISORY        0726; 2005, MED MARKETING M 0802	33	23	24	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2009	4	5							e5699	10.1371/journal.pone.0005699	http://dx.doi.org/10.1371/journal.pone.0005699			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	450QD	19479084	Green Submitted, Green Published, gold			2022-12-25	WOS:000266415000011
J	Di Santo, S; Yang, ZJ; von Ballmoos, MW; Voelzmann, J; Diehm, N; Baumgartner, I; Kalka, C				Di Santo, Stefano; Yang, Zijiang; von Ballmoos, Moritz Wyler; Voelzmann, Jan; Diehm, Nicolas; Baumgartner, Iris; Kalka, Christoph			Novel Cell-Free Strategy for Therapeutic Angiogenesis: In Vitro Generated Conditioned Medium Can Replace Progenitor Cell Transplantation	PLOS ONE			English	Article								Background: Current evidence suggests that endothelial progenitor cells (EPC) contribute to ischemic tissue repair by both secretion of paracrine factors and incorporation into developing vessels. We tested the hypothesis that cell-free administration of paracrine factors secreted by cultured EPC may achieve an angiogenic effect equivalent to cell therapy. Methodology/Principal Findings: EPC-derived conditioned medium (EPC-CM) was obtained from culture expanded EPC subjected to 72 hours of hypoxia. In vitro, EPC-CM significantly inhibited apoptosis of mature endothelial cells and promoted angiogenesis in a rat aortic ring assay. The therapeutic potential of EPC-CM as compared to EPC transplantation was evaluated in a rat model of chronic hindlimb ischemia. Serial intramuscular injections of EPC-CM and EPC both significantly increased hindlimb blood flow assessed by laser Doppler (81.2 +/- 2.9% and 83.7 +/- 3.0% vs. 53.5 +/- 2.4% of normal, P < 0.01) and improved muscle performance. A significantly increased capillary density (1.62 +/- 0.03 and 1.68 +/- 0.05/muscle fiber, P < 0.05), enhanced vascular maturation (8.6 +/- 0.3 and 8.1 +/- 0.4/HPF, P < 0.05) and muscle viability corroborated the findings of improved hindlimb perfusion and muscle function. Furthermore, EPC-CM transplantation stimulated the mobilization of bone marrow (BM)-derived EPC compared to control (678.7 +/- 44.1 vs. 340.0 +/- 29.1 CD34(+)/CD45(-) cells/1x10(5) mononuclear cells, P < 0.05) and their recruitment to the ischemic muscles (5.9 +/- 0.7 vs. 2.6 +/- 0.4CD34(+) cells/HPF, P < 0.001) 3 days after the last injection. Conclusions/Significance: Intramuscular injection of EPC-CM is as effective as cell transplantation for promoting tissue revascularization and functional recovery. Owing to the technical and practical limitations of cell therapy, cell free conditioned media may represent a potent alternative for therapeutic angiogenesis in ischemic cardiovascular diseases.			Di Santo, S (corresponding author), Univ Bern, Univ Hosp Bern, Inselspital, Dept Vasc Med,Swiss Cardiovasc Ctr, Bern, Switzerland.	vascmed.unibe@gmail.com	Di Santo, Stefano/K-5739-2014; Yang, Zijiang/E-8837-2012; Reardon, Michael/ABF-8880-2021; Di Santo, Stefano/P-2433-2019	Di Santo, Stefano/0000-0002-4032-999X; Di Santo, Stefano/0000-0002-4032-999X				Akita T, 2003, LAB INVEST, V83, P65, DOI 10.1097/01.LAB.0000050761.67879.E4; Aplin AC, 2008, METHOD ENZYMOL, V443, P119, DOI 10.1016/S0076-6879(08)02007-7; Aranguren XL, 2009, J MOL MED, V87, P3, DOI 10.1007/s00109-008-0394-3; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Asahara T, 1997, CIRCULATION, V96, pI; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Blau HM, 2001, NAT MED, V7, P532, DOI 10.1038/87850; Bonheur JA, 2004, J SURG RES, V116, P55, DOI 10.1016/S0022-4804(03)00232-4; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Chen JH, 2005, NAT MED, V11, P1188, DOI 10.1038/nm1307; Cho HJ, 2007, J EXP MED, V204, P3257, DOI 10.1084/jem.20070166; Collinson DJ, 2004, EUR J VASC ENDOVASC, V28, P9, DOI 10.1016/j.ejvs.2004.03.021; Doyle B, 2008, STEM CELLS DEV, V17, P941, DOI 10.1089/scd.2007.0214; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Goukassian DA, 2007, CIRCULATION, V115, P752, DOI 10.1161/CIRCULATIONAHA.106.647255; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Hofmann M, 2005, CIRCULATION, V111, P2198, DOI 10.1161/01.CIR.0000163546.27639.AA; Hristov M, 2004, J CELL MOL MED, V8, P498, DOI 10.1111/j.1582-4934.2004.tb00474.x; ISNER JM, 1994, LANCET, V344, P1653, DOI 10.1016/S0140-6736(94)90454-5; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jujo K, 2008, J MOL CELL CARDIOL, V45, P530, DOI 10.1016/j.yjmcc.2008.08.003; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57; Korf-Klingebiel M, 2008, EUR HEART J, V29, P2851, DOI 10.1093/eurheartj/ehn456; Korpisalo P, 2008, CIRC RES, V103, P1092, DOI 10.1161/CIRCRESAHA.108.182287; Kuhlmann MT, 2007, VASA-J VASCULAR DIS, V36, P253, DOI 10.1024/0301-1526.36.4.253; Lazarous DF, 2000, J AM COLL CARDIOL, V36, P1239, DOI 10.1016/S0735-1097(00)00882-2; LEONE AM, 2009, EUR HEART J IN PRESS; Lu HX, 2007, P NATL ACAD SCI USA, V104, P12140, DOI 10.1073/pnas.0704966104; Matoba S, 2008, AM HEART J, V156, P1010, DOI 10.1016/j.ahj.2008.06.025; Meyer GP, 2006, CIRCULATION, V113, P1287, DOI 10.1161/CIRCULATIONAHA.105.575118; Murayama T, 2002, EXP HEMATOL, V30, P967, DOI 10.1016/S0301-472X(02)00867-6; Nikol S, 2008, MOL THER, V16, P972, DOI 10.1038/mt.2008.33; Nissen LJ, 2007, J CLIN INVEST, V117, P2766, DOI 10.1172/JCI32479; Post MJ, 2001, CARDIOVASC RES, V49, P522, DOI 10.1016/S0008-6363(00)00216-9; Pula G, 2009, CIRC RES, V104, P32, DOI 10.1161/CIRCRESAHA.108.182261; Rauscher FM, 2003, CIRCULATION, V108, P457, DOI 10.1161/01.CIR.0000082924.75945.48; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; RUIZ DA, 2006, CELL, V124, P18; Sasaki K, 2006, P NATL ACAD SCI USA, V103, P14537, DOI 10.1073/pnas.0604144103; SCHEUBEL RJ, 2008, INT J CARDI IN PRESS; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; Tongers J, 2008, CIRCULATION, V118, P9, DOI 10.1161/CIRCULATIONAHA.108.784371; Tse HF, 2007, EUR J HEART FAIL, V9, P747, DOI 10.1016/j.ejheart.2007.03.008; Unger EF, 2000, AM J CARDIOL, V85, P1414, DOI 10.1016/S0002-9149(00)00787-6; Urbich C, 2003, CIRCULATION, V108, P2511, DOI 10.1161/01.CIR.0000096483.29777.50; Urbich C, 2005, J MOL CELL CARDIOL, V39, P733, DOI 10.1016/j.yjmcc.2005.07.003; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694; Zisch AH, 2004, CURR OPIN BIOTECH, V15, P424, DOI 10.1016/j.copbio.2004.08.005	53	176	183	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2009	4	5							e5643	10.1371/journal.pone.0005643	http://dx.doi.org/10.1371/journal.pone.0005643			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LB	19479066	Green Published, gold			2022-12-25	WOS:000266331000002
J	Romano, RA; Ortt, K; Birkaya, B; Smalley, K; Sinha, S				Romano, Rose-Anne; Ortt, Kori; Birkaya, Barbara; Smalley, Kirsten; Sinha, Satrajit			An Active Role of the Delta N Isoform of p63 in Regulating Basal Keratin Genes K5 and K14 and Directing Epidermal Cell Fate	PLOS ONE			English	Article								Background: One major defining characteristic of the basal keratinocytes of the stratified epithelium is the expression of the keratin genes K5 and K14. The temporal and spatial expression of these two genes is usually tightly and coordinately regulated at the transcriptional level. This ensures the obligate pairing of K5 and K14 proteins to generate an intermediate filament (IF) network that is essential for the structure and function of the proliferative keratinocytes. Our previous studies have shown that the basal-keratinocyte restricted transcription factor p63 is a direct regulator of K14 gene. Methodology/Principal Findings: Here we provide evidence that p63, specifically the Delta N isoform also regulates the expression of the K5 gene by binding to a conserved enhancer within the 59 upstream region. By using specific antibodies against Delta Np63, we show a concordance in the expression between basal keratins and Delta Np63 proteins but not the TAp63 isoforms during early embryonic skin development. We demonstrate, that contrary to a previous report, transgenic mice expressing Delta Np63 in lung epithelium exhibit squamous metaplasia with de novo induction of K5 and K14 as well as transdifferentiation to the epidermal cell lineage. Interestingly, the in vivo epidermal inductive properties of Delta Np63 do not require the C-terminal SAM domain. Finally, we show that Delta Np63 alone can restore the expression of the basal keratins and reinitiate the failed epidermal differentiation program in the skin of p63 null animals. Significance: Delta Np63 is a critical mediator of keratinocyte stratification program and directly regulates the basal keratin genes.			Romano, RA (corresponding author), SUNY Buffalo, Dept Biochem, Ctr Excellence Bioinformat & Life Sci, Buffalo, NY 14214 USA.	ssinha2@buffalo.edu			NIAMS NIH HHS [R01 AR049238, R01AR049238] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049238] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Barbieri CE, 2006, EXP CELL RES, V312, P695, DOI 10.1016/j.yexcr.2005.11.028; Barbieri CE, 2005, CANCER RES, V65, P2314, DOI 10.1158/0008-5472.CAN-04-3449; Birkaya B, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-43; Boldrup L, 2007, J PATHOL, V213, P384, DOI 10.1002/path.2237; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; Cheng W, 2006, DEVELOPMENT, V133, P4783, DOI 10.1242/dev.02621; Chikh A, 2007, BIOCHEM BIOPH RES CO, V361, P1, DOI 10.1016/j.bbrc.2007.06.069; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; Della Gatta G, 2008, GENOME RES, V18, P939, DOI 10.1101/gr.073601.107; Diamond I, 2000, J INVEST DERMATOL, V115, P788, DOI 10.1046/j.1523-1747.2000.00144.x; Fuchs E, 2007, NATURE, V445, P834, DOI 10.1038/nature05659; Guttormsen J, 2008, DEV BIOL, V317, P187, DOI 10.1016/j.ydbio.2008.02.017; Helton ES, 2006, J BIOL CHEM, V281, P2533, DOI 10.1074/jbc.M507964200; Jordan JJ, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000104; Kaufman CK, 2002, MOL CELL BIOL, V22, P4293, DOI 10.1128/MCB.22.12.4293-4308.2002; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; King KE, 2007, MOL CARCINOGEN, V46, P716, DOI 10.1002/mc.20337; Koster MI, 2007, ANNU REV CELL DEV BI, V23, P93, DOI 10.1146/annurev.cellbio.23.090506.123357; Koster MI, 2007, CELL CYCLE, V6, P269, DOI 10.4161/cc.6.3.3792; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Koster MI, 2004, CELL CYCLE, V3, P411; Kurita T, 2005, MECH DEVELOP, V122, P1043, DOI 10.1016/j.mod.2005.04.008; Larouche D, 2008, FASEB J, V22, P1404, DOI 10.1096/fj.07-8109com; Laurikkala J, 2006, DEVELOPMENT, V133, P1553, DOI 10.1242/dev.02325; Lee H, 2002, DEV CELL, V2, P607, DOI 10.1016/S1534-5807(02)00166-1; Lu H, 2005, EUR J CELL BIOL, V84, P709, DOI 10.1016/j.ejcb.2005.04.001; Maeda Y, 2007, PHYSIOL REV, V87, P219, DOI 10.1152/physrev.00028.2006; McKeon F, 2004, GENE DEV, V18, P465, DOI 10.1101/gad.1190504; Medawar A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003441; Mikaelian I, 2006, VET PATHOL, V43, P36, DOI 10.1354/vp.43-1-36; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moll R, 2008, HISTOCHEM CELL BIOL, V129, P705, DOI 10.1007/s00418-008-0435-6; Nagarajan P, 2008, CRIT REV EUKAR GENE, V18, P57; Nylander K, 2002, J PATHOL, V198, P417, DOI 10.1002/path.1231; Ortt K, 2008, J CELL BIOCHEM, V104, P1204, DOI 10.1002/jcb.21700; Ortt K, 2006, FEBS LETT, V580, P4544, DOI 10.1016/j.febslet.2006.07.004; Perez CA, 2007, ONCOGENE, V26, P7363, DOI 10.1038/sj.onc.1210561; Perl AKT, 2002, TRANSGENIC RES, V11, P21, DOI 10.1023/A:1013986627504; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Romano RA, 2007, J INVEST DERMATOL, V127, P1175, DOI 10.1038/sj.jid.5700652; Romano RA, 2006, J INVEST DERMATOL, V126, P1469, DOI 10.1038/sj.jid.5700297; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Sinha S, 2001, P NATL ACAD SCI USA, V98, P2455, DOI 10.1073/pnas.051633598; Sinha S, 2000, MOL CELL BIOL, V20, P2543, DOI 10.1128/MCB.20.7.2543-2555.2000; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; Truong AB, 2007, CELL CYCLE, V6, P295, DOI 10.4161/cc.6.3.3753; Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018	54	125	129	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5623	10.1371/journal.pone.0005623	http://dx.doi.org/10.1371/journal.pone.0005623			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448AY	19461998	gold, Green Published, Green Submitted			2022-12-25	WOS:000266234700010
J	Hayashi, S; Shimoda, T; Nakajima, M; Tsukada, Y; Sakumura, Y; Dale, JK; Maroto, M; Kohno, K; Matsui, T; Bessho, Y				Hayashi, Shinichi; Shimoda, Taiju; Nakajima, Masato; Tsukada, Yuki; Sakumura, Yuichi; Dale, J. Kim; Maroto, Miguel; Kohno, Kenji; Matsui, Takaaki; Bessho, Yasumasa			Sprouty4, an FGF Inhibitor, Displays Cyclic Gene Expression under the Control of the Notch Segmentation Clock in the Mouse PSM	PLOS ONE			English	Article								Background: During vertebrate embryogenesis, somites are generated at regular intervals, the temporal and spatial periodicity of which is governed by a gradient of fibroblast growth factor (FGF) and/or Wnt signaling activity in the presomitic mesoderm (PSM) in conjunction with oscillations of gene expression of components of the Notch, Wnt and FGF signaling pathways. Principal Findings: Here, we show that the expression of Sprouty4, which encodes an FGF inhibitor, oscillates in 2-h cycles in the mouse PSM in synchrony with other oscillating genes from the Notch signaling pathway, such as lunatic fringe. Sprouty4 does not oscillate in Hes7-null mutant mouse embryos, and Hes7 can inhibit FGF-induced transcriptional activity of the Sprouty4 promoter. Conclusions: Thus, periodic expression of Sprouty4 is controlled by the Notch segmentation clock and may work as a mediator that links the temporal periodicity of clock gene oscillations with the spatial periodicity of boundary formation which is regulated by the gradient of FGF/Wnt activity.			Hayashi, S (corresponding author), Nara Inst Sci & Technol, Lab Gene Regulat Res, Grad Sch Biol Sci, Ikoma, Japan.	ybessho@bs.naist.jp	Kohno, Kenji/AAZ-6573-2020; Dale, Kim J/A-4480-2016	Kohno, Kenji/0000-0002-3503-6551; Dale, Kim J/0000-0002-9294-947X	MRC [G120/989] Funding Source: UKRI; Medical Research Council [G120/989] Funding Source: Medline; Wellcome Trust [089357] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Aulehla A, 2003, DEV CELL, V4, P395, DOI 10.1016/S1534-5807(03)00055-8; Aulehla A, 1999, DEV BIOL, V207, P49, DOI 10.1006/dbio.1998.9164; Bessho Y, 2003, GENE DEV, V17, P1451, DOI 10.1101/gad.1092303; Bessho Y, 2003, CURR OPIN GENET DEV, V13, P379, DOI 10.1016/S0959-437X(03)00083-2; Bessho Y, 2001, GENE DEV, V15, P2642, DOI 10.1101/gad.930601; Bessho Y, 2001, GENES CELLS, V6, P175, DOI 10.1046/j.1365-2443.2001.00409.x; Dale JK, 2006, DEV CELL, V10, P355, DOI 10.1016/j.devcel.2006.02.011; Dale JK, 2003, NATURE, V421, P275, DOI 10.1038/nature01244; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; Dequeant ML, 2008, NAT REV GENET, V9, P370, DOI 10.1038/nrg2320; Dequeant ML, 2006, SCIENCE, V314, P1595, DOI 10.1126/science.1133141; Ding W, 2004, AM J PHYSIOL-LUNG C, V287, pL52, DOI 10.1152/ajplung.00430.2003; Dubrulle J, 2004, NATURE, V427, P419, DOI 10.1038/nature02216; Dubrulle J, 2001, CELL, V106, P219, DOI 10.1016/S0092-8674(01)00437-8; Elmasri H, 2004, GENE EXPR PATTERNS, V4, P553, DOI 10.1016/j.modgep.2004.02.003; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; Forsberg H, 1998, CURR BIOL, V8, P1027, DOI 10.1016/S0960-9822(07)00424-1; Henry CA, 2002, DEVELOPMENT, V129, P3693; Holley SA, 2000, GENE DEV, V14, P1678; Holley SA, 2002, DEVELOPMENT, V129, P1175; IKEDA K, 1993, EUR J BIOCHEM, V218, P195, DOI 10.1111/j.1432-1033.1993.tb18365.x; Ishikawa A, 2004, MECH DEVELOP, V121, P1443, DOI 10.1016/j.mod.2004.08.003; Jouve C, 2000, DEVELOPMENT, V127, P1421; Kawamura A, 2005, GENE DEV, V19, P1156, DOI 10.1101/gad.1291205; Klein T, 1998, DEVELOPMENT, V125, P2951; Maroto M, 2005, INT J DEV BIOL, V49, P309, DOI 10.1387/ijdb.041958mm; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; Matsui T, 2005, GENE DEV, V19, P164, DOI 10.1101/gad.1253605; McGrew MJ, 1998, CURR BIOL, V8, P979, DOI 10.1016/S0960-9822(98)70401-4; Minowada G, 1999, DEVELOPMENT, V126, P4465; Niwa Y, 2007, DEV CELL, V13, P298, DOI 10.1016/j.devcel.2007.07.013; Oates AC, 2002, DEVELOPMENT, V129, P2929; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Pourquie O, 2001, ANNU REV CELL DEV BI, V17, P311, DOI 10.1146/annurev.cellbio.17.1.311; Pourquie O, 2001, DEV CELL, V1, P619, DOI 10.1016/S1534-5807(01)00082-X; Prince VE, 2001, MECH DEVELOP, V105, P175, DOI 10.1016/S0925-4773(01)00398-7; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Sawada A, 2001, DEVELOPMENT, V128, P4873; Sawano A, 2000, Nucleic Acids Res, V28, pE78, DOI 10.1093/nar/28.16.e78; Shim K, 2005, DEV CELL, V8, P553, DOI 10.1016/j.devcel.2005.02.009; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Taketomi T, 2005, NAT NEUROSCI, V8, P855, DOI 10.1038/nn1485; Taniguchi K, 2007, BIOCHEM BIOPH RES CO, V352, P896, DOI 10.1016/j.bbrc.2006.11.107; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	44	21	21	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5603	10.1371/journal.pone.0005603	http://dx.doi.org/10.1371/journal.pone.0005603			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19440349	Green Published, gold, Green Submitted			2022-12-25	WOS:000266161200006
J	Rodriguez-Almazan, C; Zavala, LE; Munoz-Garay, C; Jimenez-Juarez, N; Pacheco, S; Masson, L; Soberon, M; Bravo, A				Rodriguez-Almazan, Claudia; Enrique Zavala, Luis; Munoz-Garay, Carlos; Jimenez-Juarez, Nuria; Pacheco, Sabino; Masson, Luke; Soberon, Mario; Bravo, Alejandra			Dominant Negative Mutants of Bacillus thuringiensis Cry1Ab Toxin Function as Anti-Toxins: Demonstration of the Role of Oligomerization in Toxicity	PLOS ONE			English	Article								Background: Bacillus thuringiensis Cry toxins, that are used worldwide in insect control, kill insects by a mechanism that depends on their ability to form oligomeric pores that insert into the insect-midgut cells. These toxins are being used worldwide in transgenic plants or spray to control insect pests in agriculture. However, a major concern has been the possible effects of these insecticidal proteins on non-target organisms mainly in ecosystems adjacent to agricultural fields. Methodology/Principal Findings: We isolated and characterized 11 non-toxic mutants of Cry1Ab toxin affected in different steps of the mechanism of action namely binding to receptors, oligomerization and pore-formation. These mutant toxins were analyzed for their capacity to block wild type toxin activity, presenting a dominant negative phenotype. The dominant negative phenotype was analyzed at two levels, in vivo by toxicity bioassays against susceptible Manduca sexta larvae and in vitro by pore formation activity in black lipid bilayers. We demonstrate that some mutations located in helix alpha-4 completely block the wild type toxin activity at sub-stoichiometric level confirming a dominant negative phenotype, thereby functioning as potent antitoxins. Conclusions/Significance: This is the first reported case of a Cry toxin dominant inhibitor. These data demonstrate that oligomerization is a fundamental step in Cry toxin action and represent a potential mechanism to protect special ecosystems from the possible effect of Cry toxins on non-target organisms.			Rodriguez-Almazan, C (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotecnol, Morelos, Mexico.	bravo@ibt.unam.mx	Pacheco, Sabino/AFJ-9017-2022; de la Parra, Maria Alejandra Bravo/R-6740-2017	Munoz-Garay, Carlos/0000-0002-7218-4027; Pacheco, Sabino/0000-0002-0208-0046; Bravo, Alejandra/0000-0002-7573-7475	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI066014] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI066014, 1R01 AI066014-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beauregard KE, 2000, CELL MICROBIOL, V2, P251, DOI 10.1046/j.1462-5822.2000.00052.x; Bohn T, 2008, ARCH ENVIRON CON TOX, V55, P584, DOI 10.1007/s00244-008-9150-5; Bravo A, 2004, BBA-BIOMEMBRANES, V1667, P38, DOI 10.1016/j.bbamem.2004.08.013; Chen M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002284; Douville M, 2009, ECOTOX ENVIRON SAFE, V72, P17, DOI 10.1016/j.ecoenv.2008.02.006; Girard F, 2008, APPL ENVIRON MICROB, V74, P2565, DOI 10.1128/AEM.00094-08; Gomez I, 2002, FEBS LETT, V513, P242, DOI 10.1016/S0014-5793(02)02321-9; Jimenez-Juarez N, 2007, J BIOL CHEM, V282, P21222, DOI 10.1074/jbc.M701314200; Kramarz PE, 2007, ENVIRON TOXICOL CHEM, V26, P73, DOI 10.1897/06-095R.1; Masson L, 1999, J BIOL CHEM, V274, P31996, DOI 10.1074/jbc.274.45.31996; Maynard JA, 2002, NAT BIOTECHNOL, V20, P597, DOI 10.1038/nbt0602-597; Mendelsohn M, 2003, NAT BIOTECHNOL, V21, P1003, DOI 10.1038/nbt0903-1003; MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0; Pacheco S, 2009, PEPTIDES, V30, P583, DOI 10.1016/j.peptides.2008.08.006; Parker MW, 2005, PROG BIOPHYS MOL BIO, V88, P91, DOI 10.1016/j.pbiomolbio.2004.01.009; Rainey GJA, 2004, NAT REV MICROBIOL, V2, P721, DOI 10.1038/nrmicro977; Rajamohan F, 1996, J BIOL CHEM, V271, P25220, DOI 10.1074/jbc.271.41.25220; Romeis J, 2006, NAT BIOTECHNOL, V24, P63, DOI 10.1038/nbt1180; Rosi-Marshall EJ, 2007, P NATL ACAD SCI USA, V104, P16204, DOI 10.1073/pnas.0707177104; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Sellman BR, 2001, SCIENCE, V292, P695, DOI 10.1126/science.109563; SINGH Y, 1989, J BIOL CHEM, V264, P19103; Smedley DP, 1996, MICROBIOL-SGM, V142, P1617, DOI 10.1099/13500872-142-7-1617; Soberon M, 2007, SCIENCE, V318, P1640, DOI 10.1126/science.1146453; THOMAS WE, 1983, J CELL SCI, V60, P181; Vachon V, 2004, APPL ENVIRON MICROB, V70, P6123, DOI 10.1128/AEM.70.10.6123-6130.2004; Vinion-Dubiel AD, 1999, J BIOL CHEM, V274, P37736, DOI 10.1074/jbc.274.53.37736; Wai SN, 2003, J BACTERIOL, V185, P5491, DOI 10.1128/JB.185.18.5491-5499.2003; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; WU D, 1992, J BIOL CHEM, V267, P2311; Xie RY, 2005, J BIOL CHEM, V280, P8416, DOI 10.1074/jbc.M408403200; Yan M, 2003, MOL MED, V9, P46, DOI 10.1007/BF03402106; Zhang XB, 2006, P NATL ACAD SCI USA, V103, P9897, DOI 10.1073/pnas.0604017103; Zhuang MB, 2002, J BIOL CHEM, V277, P13863, DOI 10.1074/jbc.M110057200; Zwahlen C, 2003, MOL ECOL, V12, P1077, DOI 10.1046/j.1365-294X.2003.01799.x	36	39	40	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2009	4	5							e5545	10.1371/journal.pone.0005545	http://dx.doi.org/10.1371/journal.pone.0005545			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FX	19440244	Green Published, gold, Green Submitted			2022-12-25	WOS:000266107300010
J	Sonne, SB; Dalgaard, MD; Nielsen, JE; Hoei-Hansen, CE; Meyts, ERD; Gjerdrum, LM; Leffers, H				Sonne, Si Brask; Dalgaard, Marlene D.; Nielsen, John Erik; Hoei-Hansen, Christina E.; Meyts, Ewa Rajpert-De; Gjerdrum, Lise Mette; Leffers, Henrik			Optimizing Staining Protocols for Laser Microdissection of Specific Cell Types from the Testis Including Carcinoma In Situ	PLOS ONE			English	Article								Microarray and RT-PCR based methods are important tools for analysis of gene expression; however, in tissues containing many different cells types, such as the testis, characterization of gene expression in specific cell types can be severely hampered by noise from other cells. The laser microdissection technology allows for enrichment of specific cell types. However, when the cells are not morphologically distinguishable, it is necessary to use a specific staining method for the target cells. In this study we have tested different fixatives, storage conditions for frozen sections and staining protocols, and present two staining protocols for frozen sections, one for fast and specific staining of fetal germ cells, testicular carcinoma in situ cells, and other cells with embryonic stem cell-like properties that express the alkaline phosphatase, and one for specific staining of lipid droplet-containing cells, which is useful for isolation of the androgen-producing Leydig cells. Both protocols retain a morphology that is compatible with laser microdissection and yield RNA of a quality suitable for PCR and microarray analysis.			Sonne, SB (corresponding author), Rigshosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark.	si@bsonne.dk	Rajpert-De Meyts, Ewa/H-6526-2019; Sonne, Si Brask/A-4851-2012; Hoei-Hansen, Christina Engel/ABB-2281-2020	Rajpert-De Meyts, Ewa/0000-0002-5946-7559; Sonne, Si Brask/0000-0003-3194-3805; Hoi-Hansen, Christina Engel/0000-0002-6191-694X; Gjerdrum, Lise Mette Rahbek/0000-0003-4377-3209				Abrahamsen HN, 2003, J MOL DIAGN, V5, P34, DOI 10.1016/S1525-1578(10)60449-7; Almstrup K, 2004, CANCER RES, V64, P4736, DOI 10.1158/0008-5472.CAN-04-0679; Almstrup K, 2004, BIOL REPROD, V70, P1751, DOI 10.1095/biolreprod.103.026575; BERTHELSEN JG, 1981, SCAND J UROL NEPHROL, V15, P165, DOI 10.3109/00365598109179596; Buckanovich RJ, 2006, CANCER BIOL THER, V5, P635, DOI 10.4161/cbt.5.6.2676; Cox ML, 2006, EXP MOL PATHOL, V80, P183, DOI 10.1016/j.yexmp.2005.10.002; Dabare AANPM, 1997, BRIT J UROL, V79, P455, DOI 10.1046/j.1464-410X.1997.03526.x; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fisher JS, 2003, HUM REPROD, V18, P1383, DOI 10.1093/humrep/deg273; Frank M, 2007, VIRCHOWS ARCH, V450, P699, DOI 10.1007/s00428-007-0412-9; Gaskell TL, 2004, BIOL REPROD, V71, P2012, DOI 10.1095/biolreprod.104.028381; Ivell R, 2002, E SCHERING RES FDN W, P99; JACOBSEN GK, 1984, ACTA PATH MICRO IM A, V92, P323; Lillie RD, 1976, HISTOPATHOLOGIC TECH, V4th; Lindegaard MLS, 2005, J LIPID RES, V46, P439, DOI 10.1194/jlr.M400417-JLR200; Masuda N, 1999, NUCLEIC ACIDS RES, V27, P4436, DOI 10.1093/nar/27.22.4436; Metzdorff SB, 2007, TOXICOL SCI, V98, P87, DOI 10.1093/toxsci/kfm079; Mosselman S, 1996, P NATL ACAD SCI USA, V93, P2884, DOI 10.1073/pnas.93.7.2884; O'Connor MD, 2008, STEM CELLS, V26, P1109, DOI 10.1634/stemcells.2007-0801; Ottesen AM, 2003, GENE CHROMOSOME CANC, V38, P117, DOI 10.1002/gcc.10244; Plummer S, 2007, TOXICOL SCI, V97, P520, DOI 10.1093/toxsci/kfm062; Ravo M, 2008, LAB INVEST, V88, P430, DOI 10.1038/labinvest.2008.11; Schoor O, 2003, BIOTECHNIQUES, V35, P1192, DOI 10.2144/03356rr01; Sharpe RM, 2006, BEST PRACT RES CL EN, V20, P91, DOI 10.1016/j.beem.2005.09.005; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; SKAKKEBAEK NE, 1972, LANCET, V2, P516; Sluka P, 2008, PROG HISTOCHEM CYTO, V42, P173, DOI 10.1016/j.proghi.2007.10.001; SONNE SB, 2009, CANC RES IN PRESS; Stoop H, 2005, HUM REPROD, V20, P1466, DOI 10.1093/humrep/deh800; Szaniszlo P, 2004, CYTOM PART A, V59A, P191, DOI 10.1002/cyto.a.20055; Thompson KL, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-57; Vinggaard AM, 2005, TOXICOL SCI, V85, P886, DOI 10.1093/toxsci/kfi150	32	19	19	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2009	4	5							e5536	10.1371/journal.pone.0005536	http://dx.doi.org/10.1371/journal.pone.0005536			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FX	19436754	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107300004
J	Plouffe, BD; Kniazeva, T; Mayer, JE; Murthy, SK; Sales, VL				Plouffe, Brian D.; Kniazeva, Tatiana; Mayer, John E., Jr.; Murthy, Shashi K.; Sales, Virna L.			Development of microfluidics as endothelial progenitor cell capture technology for cardiovascular tissue engineering and diagnostic medicine	FASEB JOURNAL			English	Article						stem cell separation; immunophenotyping; cell adhesion; shear stress; device	SMOOTH-MUSCLE; SHEAR-STRESS; STEM-CELLS; ADHESION; FLOW; DIFFERENTIATION; CANCER	We have developed a unique microfluidic platform capable of capturing circulating endothelial progenitor cells (EPCs) by understanding surface chemistries and adhesion profiles. The surface of a variable-shear-stress microfluidic device was conjugated with 6 different antibodies [anti-CD34, -CD31, -vascular endothelial growth factor receptor-2 (VEGFR-2), -CD146, -CD45, and -von Willebrand factor (vWF)] designed to match the surface antigens on ovine peripheral blood-derived EPCs. Microfluidic analysis showed a shear-stress-dependent decrease in EPC adhesion on attached surface antigens. EPCs exhibited increased adhesion to antibodies against CD34, VEGFR-2, CD31, and CD146 compared to CD45, consistent with their endothelial cell-specific surface profile, when exposed to a minimum shear stress of 1.47 dyn/cm(2). Bone-marrow-derived mesenchymal stem cells and artery-derived endothelial and smooth muscle cells were used to demonstrate the specificity of the EPC microfluidic device. Coated hematopoietic specific-surface ( CD45) and granular vWF antibodies, as well as uncoated bare glass and substrate (1% BSA), were utilized as controls. Microfluidic devices have been developed as an EPC capture platform using immobilized antibodies targeted as EPC surface antigens. This EPC chip may provide a new and effective tool for addressing challenges in cardiovascular disease and tissue engineering.-Plouffe, B. D., Kniazeva, T., Mayer, J. E., Jr., Murthy, S. K., Sales, V. L. Development of microfluidics as endothelial progenitor cell capture technology for cardiovascular tissue engineering and diagnostic medicine. FASEB J. 23, 3309-3314 ( 2009). www.fasebj.org	[Plouffe, Brian D.; Kniazeva, Tatiana; Murthy, Shashi K.] Northeastern Univ, Dept Chem Engn, Boston, MA 02115 USA; [Mayer, John E., Jr.; Sales, Virna L.] Harvard Univ, Childrens Hosp, Sch Med, Dept Cardiac Surg, Boston, MA 02115 USA	Northeastern University; Harvard University; Boston Children's Hospital; Harvard Medical School	Murthy, SK (corresponding author), Northeastern Univ, Dept Chem Engn, 360 Huntington Ave,342 Snell Engn, Boston, MA 02115 USA.	smurthy@coe.neu.edu; virna.sales@childrens.harvard.edu	Plouffe, Brian/O-2520-2015; Plouffe, Brian/GON-3496-2022	Plouffe, Brian/0000-0002-1576-5714; 	American Health Assistance Foundation [H2007-017]; National Institutes of Health [HL-60463]; Center for Integration of Medicine and Innovative Technology (CIMIT); Gross Cardiovascular Fund and Center; American Heart Association Scientist Development [0635620T]; CIMIT [W81XWH-07-2-0011]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060463] Funding Source: NIH RePORTER	American Health Assistance Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Integration of Medicine and Innovative Technology (CIMIT); Gross Cardiovascular Fund and Center; American Heart Association Scientist Development(American Heart Association); CIMIT; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Michael Blaze, Ph.D. for editorial expertise. This work was supported by the National Heart Foundation, a program of the American Health Assistance Foundation, grant H2007-017 ( S. K. M.); the National Institutes of Health, grant HL-60463; the National Institute of Standards and Technology, grant NANB2H3053; the Center for Integration of Medicine and Innovative Technology (CIMIT); and the Gross Cardiovascular Fund and Center (J.E.M). V. L. S is the recipient of an American Heart Association Scientist Development grant (0635620T), a CIMIT Career Development grant, and a Miles and Eleanor Shore Fellowship. This work was supported by CIMIT under U. S. Army Medical Research Acquisition Activity Cooperative Agreement W81XWH-07-2-0011. The information contained herein does not necessarily reflect the position or policy of the U. S. government, and no official endorsement should be inferred. The authors report no conflicts of interest.	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006-0709; Bardin N, 2001, BLOOD, V98, P3677, DOI 10.1182/blood.V98.13.3677; Boos CJ, 2006, J AM COLL CARDIOL, V48, P1538, DOI 10.1016/j.jacc.2006.02.078; CLAUSEN J, 1981, LAB TECHNIQUES BIOCH, V1, P387; COZENSROBERTS C, 1990, BIOPHYS J, V58, P107, DOI 10.1016/S0006-3495(90)82357-2; CRAENENBROECK EMF, 2008, J IMMUNOL METHODS, V332, P31; Dvorin EL, 2003, TISSUE ENG, V9, P487, DOI 10.1089/107632703322066660; Dzau VJ, 2005, HYPERTENSION, V46, P7, DOI 10.1161/01.HYP.0000168923.92885.f7; Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035; Lee S, 2007, P NATL ACAD SCI USA, V104, P9609, DOI 10.1073/pnas.0702668104; Leor J, 2006, J AM COLL CARDIOL, V48, P1588, DOI 10.1016/j.jacc.2006.07.032; Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035; Mettler BA, 2008, ANN THORAC SURG, V86, P132, DOI 10.1016/j.athoracsur.2008.02.074; Miwa J, 2008, J MICROELECTROMECH S, V17, P611, DOI 10.1109/JMEMS.2008.921706; Murthy SK, 2004, LANGMUIR, V20, P11649, DOI 10.1021/la048047b; Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385; Patel M, 2007, J FAM PRACTICE, V56, P64; Plouffe BD, 2008, LAB CHIP, V8, P462, DOI 10.1039/b715707j; Plouffe BD, 2007, LANGMUIR, V23, P5050, DOI 10.1021/la0700220; Rafii S, 2002, GENE THER, V9, P631, DOI 10.1038/sj.gt.3301723; Roncalli JG, 2008, TRENDS BIOTECHNOL, V26, P276, DOI 10.1016/j.tibtech.2008.01.005; Sales VL, 2007, CIRCULATION, V116, pI55, DOI 10.1161/CIRCULATIONAHA.106.6806637; Sales VL, 2007, TISSUE ENG, V13, P525, DOI 10.1089/ten.2006.0128; Timmermans F, 2009, J CELL MOL MED, V13, P87, DOI 10.1111/j.1582-4934.2008.00598.x; Toner M, 2005, ANNU REV BIOMED ENG, V7, P77, DOI 10.1146/annurev.bioeng.7.011205.135108; USAMI S, 1993, ANN BIOMED ENG, V21, P77, DOI 10.1007/BF02368167; Ward MR, 2007, CATHETER CARDIO INTE, V70, P983, DOI 10.1002/ccd.21302; Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471	30	75	77	0	44	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3309	3314		10.1096/fj.09-130260	http://dx.doi.org/10.1096/fj.09-130260			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19487310	Green Published			2022-12-25	WOS:000270354300008
J	Crispin, M; Chang, VT; Harvey, DJ; Dwek, RA; Evans, EJ; Stuart, DI; Jones, EY; Lord, JM; Spooner, RA; Davis, SJ				Crispin, Max; Chang, Veronica T.; Harvey, David J.; Dwek, Raymond A.; Evans, Edward J.; Stuart, David I.; Jones, E. Yvonne; Lord, J. Michael; Spooner, Robert A.; Davis, Simon J.			A Human Embryonic Kidney 293T Cell Line Mutated at the Golgi alpha-Mannosidase II Locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCANS; HAMSTER OVARY CELLS; ELECTROPHORESIS-ELECTROSPRAY-TIME; LASER-DESORPTION IONIZATION; FLIGHT-MASS-SPECTROMETRY; RICIN-RESISTANT MUTANT; HIGH-LEVEL EXPRESSION; ENDOPLASMIC-RETICULUM; CONGENITAL DISORDER; NEGATIVE-IONS	Disruption of Golgi alpha-mannosidase II activity can result in type II congenital dyserythropoietic anemia and induce lupus-like autoimmunity in mice. Here, we isolated a mutant human embryonic kidney (HEK) 293T cell line called Lec36, which displays sensitivity to ricin that lies between the parental HEK 293T cells, in which the secreted and membrane-expressed proteins are dominated by complex-type glycosylation, and 293S Lec1 cells, which produce only oligomannose-type N-linked glycans. Stem cell marker 19A was transiently expressed in the HEK 293T Lec36 cells and in parental HEK 293T cells with and without the potent Golgi alpha-mannosidase II inhibitor, swainsonine. Negative ion nano-electrospray ionization mass spectra of the 19A N-linked glycans from HEK 293T Lec36 and swainsonine-treated HEK 293T cells were qualitatively indistinguishable and, as shown by collision-induced dissociation spectra, were dominated by hybrid-type glycosylation. Nucleotide sequencing revealed mutations in each allele of MAN2A1, the gene encoding Golgi alpha-mannosidase II: a point mutation that mapped to the active site was found in one allele, and an in-frame deletion of 12 nucleotides was found in the other allele. Expression of the wild type but not the mutant MAN2A1 alleles in Lec36 cells restored processing of the 19A reporter glycoprotein to complex-type glycosylation. The Lec36 cell line will be useful for expressing therapeutic glycoproteins with hybrid-type glycans and as a sensitive host for detecting mutations in human MAN2A1 causing type II congenital dyserythropoietic anemia.	[Lord, J. Michael; Spooner, Robert A.] Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; [Crispin, Max; Harvey, David J.; Dwek, Raymond A.] Univ Oxford, Dept Biochem, Oxford Glycobiol Inst, Oxford OX1 3QU, England; [Chang, Veronica T.; Evans, Edward J.; Davis, Simon J.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Weatherall Inst Mol Med, Oxford OX3 9DS, England; [Jones, E. Yvonne] Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England	University of Warwick; University of Oxford; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics	Spooner, RA (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	r.a.spooner@warwick.ac.uk; simon.davis@ndm.ox.ac.uk	Harvey, David/A-5579-2013; Spooner, Robert/A-9870-2010; Jones, Yvonne/N-8111-2019; Jones, Yvonne/J-2293-2016; Crispin, Max/AAG-4098-2020	Spooner, Robert/0000-0001-9593-0195; Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Crispin, Max/0000-0002-1072-2694; Stuart, David/0000-0002-3426-4210; Harvey, David/0000-0003-0544-771X	National Institutes of Health [5 U01AI 65869]; Wellcome Trust; Cancer Research UK; United Kingdom Medical Research Council; European Commission [QLG2-CT-2002-00988]; MRC [G0500365, G9900061] Funding Source: UKRI; Medical Research Council [G9900061, G0500365] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI065869] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission); Cancer Research UK(Cancer Research UK); United Kingdom Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Commission(European CommissionEuropean Commission Joint Research Centre); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported in part, by National Institutes of Health Grant 5 U01AI 65869 (to J. M. L. and R. A. S.). This work was also supported by the Wellcome Trust, Cancer Research UK, the United Kingdom Medical Research Council, and the Oxford Glycobiology Institute Endowment and by Structural Proteomics in Europe (SPINE) Contract QLG2-CT-2002-00988 from the European Commission under the Integrated Programme "Quality of Life and Management of Living Resources."	Aghi M, 1998, J NATL CANCER I, V90, P370, DOI 10.1093/jnci/90.5.370; Aricescu AR, 2006, ACTA CRYSTALLOGR D, V62, P1243, DOI 10.1107/S0907444906029799; Balaguer E, 2006, ELECTROPHORESIS, V27, P2638, DOI 10.1002/elps.200600075; BEBBINGTON C, 1987, DNA CLONING, V3, P168; BORNSEN KO, 1995, RAPID COMMUN MASS SP, V9, P1031, DOI 10.1002/rcm.1290091112; Butler M, 2003, GLYCOBIOLOGY, V13, P601, DOI 10.1093/glycob/cwg079; Butters TD, 1999, PROTEIN SCI, V8, P1696, DOI 10.1110/ps.8.8.1696; Chang VT, 2007, STRUCTURE, V15, P267, DOI 10.1016/j.str.2007.01.011; Chen W, 2003, GLYCOBIOLOGY, V13, P43, DOI 10.1093/glycob/cwg003; Choi BK, 2003, P NATL ACAD SCI USA, V100, P5022, DOI 10.1073/pnas.0931263100; Crispin M, 2006, GLYCOBIOLOGY, V16, P748, DOI 10.1093/glycob/cwj119; Crispin M, 2007, FEBS LETT, V581, P1963, DOI 10.1016/j.febslet.2007.04.020; DAVIS SJ, 1993, PROTEIN ENG, V6, P229, DOI 10.1093/protein/6.2.229; DAVIS SJ, 1995, J BIOL CHEM, V270, P369, DOI 10.1074/jbc.270.1.369; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Dwek RA, 1998, DEV BIOL STAND, V96, P43; FODDY L, 1986, BIOCHEM J, V233, P697, DOI 10.1042/bj2330697; Foulquier F, 2006, P NATL ACAD SCI USA, V103, P3764, DOI 10.1073/pnas.0507685103; FUKUDA MN, 1992, BRIT J HAEMATOL, V82, P745, DOI 10.1111/j.1365-2141.1992.tb06953.x; FUKUDA MN, 1990, P NATL ACAD SCI USA, V87, P7443, DOI 10.1073/pnas.87.19.7443; GLEESON PA, 1985, BIOCHEMISTRY-US, V24, P493, DOI 10.1021/bi00323a037; Green RS, 2007, IMMUNITY, V27, P308, DOI 10.1016/j.immuni.2007.06.008; Hamilton SR, 2003, SCIENCE, V301, P1244, DOI 10.1126/science.1088166; Hamilton SR, 2006, SCIENCE, V313, P1441, DOI 10.1126/science.1130256; Harvey DJ, 2008, ANAL BIOCHEM, V376, P44, DOI 10.1016/j.ab.2008.01.025; Harvey DJ, 2008, RAPID COMMUN MASS SP, V22, P1047, DOI 10.1002/rcm.3470; Harvey DJ, 2005, J AM SOC MASS SPECTR, V16, P622, DOI 10.1016/j.jasms.2005.01.004; Harvey DJ, 2005, J AM SOC MASS SPECTR, V16, P647, DOI 10.1016/j.jasms.2005.01.006; Harvey DJ, 2005, J AM SOC MASS SPECTR, V16, P631, DOI 10.1016/j.jasms.2005.01.005; Herscovics A, 2001, BIOCHIMIE, V83, P757, DOI 10.1016/S0300-9084(01)01319-0; Hong Y, 2004, J BIOL CHEM, V279, P49894, DOI 10.1074/jbc.M410121200; Hoppe H, 2000, J BIOTECHNOL, V76, P259, DOI 10.1016/S0168-1656(99)00165-0; HUGHES RC, 1983, CARBOHYD RES, V120, P215; HUGHES RC, 1986, EUR J BIOCHEM, V158, P227, DOI 10.1111/j.1432-1033.1986.tb09742.x; Jaeken J, 2007, ANNU REV GENOM HUM G, V8, P261, DOI 10.1146/annurev.genom.8.080706.092327; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; Lal A, 1998, GLYCOBIOLOGY, V8, P981, DOI 10.1093/glycob/8.10.981; Li HJ, 2006, NAT BIOTECHNOL, V24, P210, DOI 10.1038/nbt1178; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; Martinez-Duncker I, 2005, BLOOD, V105, P2671, DOI 10.1182/blood-2004-09-3509; Moremen KW, 2002, BBA-GEN SUBJECTS, V1573, P225, DOI 10.1016/S0304-4165(02)00388-4; Neususs C, 2005, ELECTROPHORESIS, V26, P1442, DOI 10.1002/elps.200410269; Oh-eda M, 2001, EUR J BIOCHEM, V268, P1280, DOI 10.1046/j.1432-1327.2001.01992.x; Olsnes S., 1982, MOL ACTION TOXINS VI, P51; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Paschinger K, 2006, J BIOL CHEM, V281, P28265, DOI 10.1074/jbc.M602878200; Patnaik SK, 2006, METHOD ENZYMOL, V416, P159, DOI 10.1016/S0076-6879(06)16011-5; Paulson JC, 2007, CELL, V130, P589, DOI 10.1016/j.cell.2007.08.009; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13419, DOI 10.1073/pnas.212519299; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; Sethuraman N, 2006, CURR OPIN BIOTECH, V17, P341, DOI 10.1016/j.copbio.2006.06.010; Shah N, 2008, P NATL ACAD SCI USA, V105, P9570, DOI 10.1073/pnas.0802206105; Spooner RA, 2004, BIOCHEM J, V383, P285, DOI 10.1042/BJ20040742; Spooner RA, 2008, P NATL ACAD SCI USA, V105, P17408, DOI 10.1073/pnas.0809013105; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; Tremblay LO, 2000, J BIOL CHEM, V275, P31655, DOI 10.1074/jbc.M004935200; Watson P, 2006, ADV DRUG DELIVER REV, V58, P1581, DOI 10.1016/j.addr.2006.09.016; Wu XH, 2004, NAT MED, V10, P518, DOI 10.1038/nm1041	61	31	35	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	2009	284	32					21684	21695		10.1074/jbc.M109.006254	http://dx.doi.org/10.1074/jbc.M109.006254			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478CC	19465480	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000268564400061
J	Lapointe, J; Stepanyan, Z; Bigras, E; Hekimi, S				Lapointe, Jerome; Stepanyan, Zaruhi; Bigras, Eve; Hekimi, Siegfried			Reversal of the Mitochondrial Phenotype and Slow Development of Oxidative Biomarkers of Aging in Long-lived Mclk1(+/-) Mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE RELEASE; CAENORHABDITIS-ELEGANS; LIFE-SPAN; CALORIC RESTRICTION; STRESS HYPOTHESIS; OXIDANT STRESS; COENZYME-Q; DAMAGE; CLK-1; MOUSE	Although there is a consensus that mitochondrial function is somehow linked to the aging process, the exact role played by mitochondria in this process remains unresolved. The discovery that reduced activity of the mitochondrial enzyme CLK-1/MCLK1 (also known as COQ7) extends lifespan in both Caenorhabditis elegans and mice has provided a genetic model to test mitochondrial theories of aging. We have recently shown that the mitochondria of young, long-lived, Mclk(+/-) mice are dysfunctional, exhibiting reduced energy metabolism and a substantial increase in oxidative stress. Here we demonstrate that this altered mitochondrial condition in young animals paradoxically results in an almost complete protection from the age-dependent loss of mitochondrial function as well as in a significant attenuation of the rate of development of oxidative biomarkers of aging. Moreover, we show that reduction in MCLK1 levels can also gradually prevent the deterioration of mitochondrial function and associated increase of global oxidative stress that is normally observed in Sod2(+/-) mutants. We hypothesize that the mitochondrial dysfunction observed in young Mclk1(+/-) mutants induces a physiological state that ultimately allows for their slow rate of aging. Thus, our study provides for a unique vertebrate model in which an initial alteration in a specific mitochondrial function is linked to long term beneficial effects on biomarkers of aging and, furthermore, provides for new evidence which indicates that mitochondrial oxidative stress is not causal to aging.	[Lapointe, Jerome; Stepanyan, Zaruhi; Bigras, Eve; Hekimi, Siegfried] McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	McGill University	Hekimi, S (corresponding author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.	Siegfried.Hekimi@McGill.ca			National Science and Engineering Research Council of Canada; Canadian Institutes of Health Research	National Science and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was funded in part by grants from the National Science and Engineering Research Council of Canada and the Canadian Institutes of Health Research ( to S. H.).	Andziak B, 2006, AGING CELL, V5, P463, DOI 10.1111/j.1474-9726.2006.00237.x; [Anonymous], 1922, BIOL DEATH; Arguelles S, 2004, BBA-GEN SUBJECTS, V1674, P251, DOI 10.1016/j.bbagen.2004.06.023; Asimakis GK, 2002, CIRCULATION, V105, P981, DOI 10.1161/hc0802.104502; Austad S, 2008, AGING CELL, V7, P119, DOI 10.1111/j.1474-9726.2008.00374.x; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Branicky R, 2006, MOL CELL BIOL, V26, P3976, DOI 10.1128/MCB.26.10.3976-3985.2006; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Cai WJ, 2007, AM J PATHOL, V170, P1893, DOI 10.2353/ajpath.2007.061281; Chiou CC, 2003, CLIN CHIM ACTA, V334, P87, DOI 10.1016/S0009-8981(03)00191-8; Choksi KB, 2007, BIOCHEM BIOPH RES CO, V364, P761, DOI 10.1016/j.bbrc.2007.10.100; Davies SMK, 2001, FREE RADICAL BIO MED, V31, P181, DOI 10.1016/S0891-5849(01)00576-7; de Magalhaes JP, 2005, GENETICS, V169, P265, DOI 10.1534/genetics.104.032292; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; Gonzales S, 2005, WORLD J GASTROENTERO, V11, P3533, DOI 10.3748/wjg.v11.i23.3533; Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Hekimi S, 2006, NAT GENET, V38, P985, DOI 10.1038/ng1881; Hihi AK, 2003, J BIOL CHEM, V278, P41013, DOI 10.1074/jbc.M305034200; Huang TTK, 2001, OBES RES, V9, P283, DOI 10.1038/oby.2001.35; Jiang N, 2001, J BIOL CHEM, V276, P29218, DOI 10.1074/jbc.M103686200; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Lambert AJ, 2007, AGING CELL, V6, P417, DOI 10.1111/j.1474-9726.2007.00316.x; Lapointe J, 2008, J BIOL CHEM, V283, P26217, DOI 10.1074/jbc.M803287200; Levavasseur F, 2001, J BIOL CHEM, V276, P46160, DOI 10.1074/jbc.M108980200; Liu XX, 2005, GENE DEV, V19, P2424, DOI 10.1101/gad.1352905; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Montuschi P, 2004, FASEB J, V18, P1791, DOI 10.1096/fj.04-2330rev; Morrow JD, 2000, DRUG METAB REV, V32, P377, DOI 10.1081/DMR-100102340; Muller FL, 2007, FREE RADICAL BIO MED, V43, P477, DOI 10.1016/j.freeradbiomed.2007.03.034; Navarro A, 2007, AM J PHYSIOL-CELL PH, V292, pC670, DOI 10.1152/ajpcell.00213.2006; Nulton-Persson AC, 2001, J BIOL CHEM, V276, P23357, DOI 10.1074/jbc.M100320200; Park KS, 2001, DIABETES, V50, P2837, DOI 10.2337/diabetes.50.12.2837; Perez VI, 2009, AGING CELL, V8, P73, DOI 10.1111/j.1474-9726.2008.00449.x; Pospisilik JA, 2007, CELL, V131, P476, DOI 10.1016/j.cell.2007.08.047; RIGGS JE, 1992, MECH AGEING DEV, V62, P191, DOI 10.1016/0047-6374(92)90055-I; Schulz TJ, 2007, CELL METAB, V6, P280, DOI 10.1016/j.cmet.2007.08.011; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SHIGENAGA MK, 1994, METHOD ENZYMOL, V234, P16; SOHAL RS, 1993, FREE RADICAL BIO MED, V14, P583, DOI 10.1016/0891-5849(93)90139-L; SOHAL RS, 1991, MECH AGEING DEV, V57, P187, DOI 10.1016/0047-6374(91)90034-W; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Sohal RS, 2002, FREE RADICAL BIO MED, V33, P573, DOI 10.1016/S0891-5849(02)00885-7; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; Sohal RS, 2002, FREE RADICAL BIO MED, V33, P575, DOI 10.1016/S0891-5849(02)00886-9; Speakman JR, 2005, J EXP BIOL, V208, P1717, DOI 10.1242/jeb.01556; Stepanyan Z, 2006, EXP GERONTOL, V41, P940, DOI 10.1016/j.exger.2006.06.041; Turunen M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/j.bbamem.2003.11.012; Van Raamsdonk JM, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000361; Van Remmen H, 1999, ARCH BIOCHEM BIOPHYS, V363, P91, DOI 10.1006/abbi.1998.1060; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; Yang W, 2007, GENETICS, V177, P2063, DOI 10.1534/genetics.107.080788	56	72	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20364	20374		10.1074/jbc.M109.006569	http://dx.doi.org/10.1074/jbc.M109.006569			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19478076	Green Published, hybrid			2022-12-25	WOS:000268097400062
J	Simic, M; De Jonge, N; Loris, R; Vesnaver, G; Lah, J				Simic, Mario; De Jonge, Natalie; Loris, Remy; Vesnaver, Gorazd; Lah, Jurij			Driving Forces of Gyrase Recognition by the Addiction Toxin CcdB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA GYRASE; BREAKAGE-REUNION DOMAIN; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; STRUCTURAL FEATURES; PROTEIN-STRUCTURE; MOLECULAR-BASIS; ANTIDOTE MAZE; A-PROTEIN; BINDING	Gyrase, an essential bacterial topoisomerase, is the target of several antibiotics (e. g. quinolones) as well as of bacterial toxin CcdB. This toxin, encoded by Escherichia coli toxinantitoxin module ccd, poisons gyrase by causing inhibition of both transcription and replication. Because the molecular driving forces of gyrase unfolding and CcdB-gyrase binding were unknown, the nature of the CcdB-gyrase recognition remained elusive. Therefore, we performed a detailed thermodynamic analysis of CcdB binding to several fragments of gyrase A subunit (GyrA) that contain the CcdB-binding site. Binding of CcdB to the shorter fragments was studied directly by isothermal titration calorimetry. Its binding to the longer GyrA59 fragment in solution is kinetically limited and was therefore investigated via urea induced unfolding of the GyrA59-CcdB complex and unbound GyrA59 and CcdB, monitored by circular dichroism spectroscopy. Model analysis of experimental data, in combination with the relevant structural information, indicates that CcdB binding to gyrase is an enthalpic process driven mainly by specific interactions between CcdB and the highly stable dimerization domain of the GyrA. The dissection of binding energetics indicates that CcdB-gyrase recognition is accompanied by opening of the tower and catalytic domain of GyrA. Such extensive structural rearrangements appear to be crucial driving forces for the functioning of the ccd toxin-antitoxin module.	[Simic, Mario; Vesnaver, Gorazd; Lah, Jurij] Univ Ljubljana, Fac Chem & Chem Technol, Ljubljana 1000, Slovenia; [De Jonge, Natalie; Loris, Remy] Vrije Univ Brussels, Inst Mol Biol, Lab Ultrastrutuur, B-1050 Brussels, Belgium; [De Jonge, Natalie; Loris, Remy] Vrije Univ Brussel VIB, B-1050 Brussels, Belgium	University of Ljubljana; Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Lah, J (corresponding author), Univ Ljubljana, Fac Chem & Chem Technol, Askerceva 5, Ljubljana 1000, Slovenia.	jurij.lah@fkkt.uni-lj.si	Loris, Remy/GPG-0894-2022	Loris, Remy/0000-0002-8862-3338	Ministry of Higher Education, Science and Technology [P1-0201, J1-6653]; Fonds Wetenschappelijk Onderzoek-Vlaanderen; Instituut voor de Aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen (IWT); Vrije Universiteit Brussel in Belgium	Ministry of Higher Education, Science and Technology; Fonds Wetenschappelijk Onderzoek-Vlaanderen(FWO); Instituut voor de Aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen (IWT)(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); Vrije Universiteit Brussel in Belgium	This work was supported by the Ministry of Higher Education, Science and Technology, by Republic of Slovenia Agency for Research Grants P1-0201 and J1-6653, and by Fonds Wetenschappelijk Onderzoek-Vlaanderen, Instituut voor de Aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen (IWT), and the Onzerzoeksraad of the Vrije Universiteit Brussel in Belgium.	Bahassi EM, 1999, J BIOL CHEM, V274, P10936, DOI 10.1074/jbc.274.16.10936; Bajaj K, 2004, BIOCHEM J, V380, P409, DOI 10.1042/BJ20031528; Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BERNARD P, 1992, J MOL BIOL, V226, P735, DOI 10.1016/0022-2836(92)90629-X; Bradshaw JM, 1998, BIOCHEMISTRY-US, V37, P15400, DOI 10.1021/bi9814991; Buts L, 2005, TRENDS BIOCHEM SCI, V30, P672, DOI 10.1016/j.tibs.2005.10.004; Buts L, 2005, ACTA CRYSTALLOGR F, V61, P949, DOI [10.1107/S1744309105029258, 10.1107/s1744309105029258]; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; Chaires JB, 1997, BIOPOLYMERS, V44, P201, DOI 10.1002/(SICI)1097-0282(1997)44:3<201::AID-BIP2>3.0.CO;2-Z; Dao-Thi MH, 2000, J MOL BIOL, V299, P1373, DOI 10.1006/jmbi.2000.3815; Dao-Thi MH, 2005, J MOL BIOL, V348, P1091, DOI 10.1016/j.jmb.2005.03.049; Dao-Thi MH, 2004, ACTA CRYSTALLOGR D, V60, P1132, DOI 10.1107/S0907444904007814; Dao-Thi MH, 2002, J BIOL CHEM, V277, P3733, DOI 10.1074/jbc.M105505200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hubbard S. J., 1993, NACCESS; Kampranis SC, 1999, J MOL BIOL, V293, P733, DOI 10.1006/jmbi.1999.3182; Ladbury J.E., 1998, BIOCALORIMETRY APPL; Lah J, 2005, BIOCHEMISTRY-US, V44, P13883, DOI 10.1021/bi0512952; Lah J, 2005, J BIOL CHEM, V280, P17397, DOI 10.1074/jbc.M501128200; Lah J, 2004, J MOL BIOL, V342, P73, DOI 10.1016/j.jmb.2004.07.005; Lah J, 2003, J BIOL CHEM, V278, P14101, DOI 10.1074/jbc.M209855200; Lah J, 2008, NUCLEIC ACIDS RES, V36, P897, DOI 10.1093/nar/gkm1110; Lah J, 2006, J PHYS CHEM B, V110, P23279, DOI 10.1021/jp062796f; Lah N, 2003, J BIOL CHEM, V278, P24673, DOI 10.1074/jbc.M303194200; LEE KH, 1994, PROTEINS, V20, P68, DOI 10.1002/prot.340200108; Lopez Maria M, 2002, Methods Mol Biol, V173, P121; Loris R, 2003, J BIOL CHEM, V278, P28252, DOI 10.1074/jbc.M302336200; Loris R, 1999, J MOL BIOL, V285, P1667, DOI 10.1006/jmbi.1998.2395; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; MIKI T, 1992, J MOL BIOL, V225, P39, DOI 10.1016/0022-2836(92)91024-J; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Nollmann M, 2007, BIOCHIMIE, V89, P490, DOI 10.1016/j.biochi.2007.02.012; Press W.H., 1992, NUMERICAL RECIPES, V2, P650; REECE RJ, 1989, J BIOL CHEM, V264, P19648; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; REECE RJ, 1991, J BIOL CHEM, V266, P3540; Robertson AD, 1997, CHEM REV, V97, P1251, DOI 10.1021/cr960383c; Schoeffler AJ, 2005, BIOCHEM SOC T, V33, P1465, DOI 10.1042/BST0331465; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; XIE D, 1994, PROTEINS, V19, P291, DOI 10.1002/prot.340190404	44	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20002	20010		10.1074/jbc.M109.014035	http://dx.doi.org/10.1074/jbc.M109.014035			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19465484	Green Published, hybrid			2022-12-25	WOS:000268097400027
J	Winkler, A; Motz, K; Riedl, S; Puhl, M; Macheroux, P; Gruber, K				Winkler, Andreas; Motz, Kerstin; Riedl, Sabrina; Puhl, Martin; Macheroux, Peter; Gruber, Karl			Structural and Mechanistic Studies Reveal the Functional Role of Bicovalent Flavinylation in Berberine Bridge Enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY ATTACHED FAD; TRIMETHYLAMINE DEHYDROGENASE; CHOLESTEROL OXIDASE; PICHIA-PASTORIS; C30A MUTANT; REDOX; OVEREXPRESSION; SECRETION; BINDING	Berberine bridge enzyme (BBE) is a member of the recently discovered family of bicovalently flavinylated proteins. In this group of enzymes, the FAD cofactor is linked via its 8 alpha-methyl group and the C-6 atom to conserved histidine and cysteine residues, His-104 and Cys-166 for BBE, respectively. 6-S-Cysteinylation has recently been shown to have a significant influence on the redox potential of the flavin cofactor; however, 8 alpha-histidylation evaded a closer characterization due to extremely low expression levels upon substitution. Co-overexpression of protein disulfide isomerase improved expression levels and allowed isolation and purification of the H104A protein variant. To gain more insight into the functional role of the unusual dual mode of cofactor attachment, we solved the x-ray crystal structures of two mutant proteins, H104A and C166A BBE, each lacking one of the covalent linkages. Information from a structure of wild type enzyme in complex with the product of the catalyzed reaction is combined with the kinetic and structural characterization of the protein variants to demonstrate the importance of the bicovalent linkage for substrate binding and efficient oxidation. In addition, the redox potential of the flavin cofactor is enhanced additively by the dual mode of cofactor attachment. The reduced level of expression for the H104A mutant protein and the difficulty of isolating even small amounts of the protein variant with both linkages removed (H104A-C166A) also points toward a possible role of covalent flavinylation during protein folding.	[Winkler, Andreas; Motz, Kerstin; Riedl, Sabrina; Puhl, Martin; Macheroux, Peter] Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria; [Gruber, Karl] Graz Univ, Inst Mol Biosci, A-8010 Graz, Austria	Graz University of Technology; University of Graz	Macheroux, P (corresponding author), Graz Univ Technol, Inst Biochem, Petersgasse 12-2, A-8010 Graz, Austria.	peter.macheroux@tugraz.at; karl.gruber@uni-graz.at	Gruber, Karl/GPP-6706-2022; Macheroux, Peter/AAB-5157-2019	Gruber, Karl/0000-0002-3485-9740; Macheroux, Peter/0000-0002-0242-454X; Winkler, Andreas/0000-0001-6221-9671	Austrian Science Fund, Doktoratskolleg "Molecular Enzymology" [W901-B05]; Austrian Science Fund (FWF) [W 901] Funding Source: researchfish	Austrian Science Fund, Doktoratskolleg "Molecular Enzymology"(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	This work was supported by the Austrian Science Fund (Fonds zur Forderung der Wissenschaftlichen Forschung (FWF)) through the Doktoratskolleg "Molecular Enzymology" Grant W901-B05 (to K.G. and P.M.).	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Alexeev I, 2007, P NATL ACAD SCI USA, V104, P6170, DOI 10.1073/pnas.0700579104; Caldinelli L, 2005, J BIOL CHEM, V280, P22572, DOI 10.1074/jbc.M500549200; DITTRICH H, 1991, P NATL ACAD SCI USA, V88, P9969, DOI 10.1073/pnas.88.22.9969; Edmondson DE, 2001, ANTIOXID REDOX SIGN, V3, P789, DOI 10.1089/15230860152664984; Efimov I, 2001, BIOCHEMISTRY-US, V40, P2155, DOI 10.1021/bi001644m; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fraaije MW, 1999, J BIOL CHEM, V274, P35514, DOI 10.1074/jbc.274.50.35514; Hassan-Abdallah A, 2006, BIOCHEMISTRY-US, V45, P9454, DOI 10.1021/bi0607352; Heuts DPHM, 2008, BIOCHEM J, V413, P175, DOI 10.1042/BJ20071591; Huang CH, 2005, J BIOL CHEM, V280, P38831, DOI 10.1074/jbc.M506078200; Huang LX, 1996, J BIOL CHEM, V271, P13401, DOI 10.1074/jbc.271.23.13401; Inan M, 2006, BIOTECHNOL BIOENG, V93, P771, DOI 10.1002/bit.20762; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kao CY, 2008, J BIOL CHEM, V283, P15309, DOI [10.1074/jbc.M708289200, 10.1074/jbc.M804331200]; Kim J, 1995, J BIOL CHEM, V270, P31202, DOI 10.1074/jbc.270.52.31202; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; Leferink NGH, 2008, ARCH BIOCHEM BIOPHYS, V474, P292, DOI 10.1016/j.abb.2008.01.027; Li YS, 2007, J AM CHEM SOC, V129, P13384, DOI 10.1021/ja075748x; Lim L, 2006, BIOCHEM J, V400, P13, DOI 10.1042/BJ20060664; Lin-Cereghino J, 2005, BIOTECHNIQUES, V38, P44, DOI 10.2144/05381BM04; Massey V, 1990, FLAVINS FLAVOPROTEIN, P59; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; Motteran L, 2001, J BIOL CHEM, V276, P18024, DOI 10.1074/jbc.M010953200; Rand T, 2006, FEBS J, V273, P2693, DOI 10.1111/j.1742-4658.2006.05285.x; ROBINSON AS, 1994, BIO-TECHNOL, V12, P381, DOI 10.1038/nbt0494-381; SINGER TP, 1956, ARCH BIOCHEM BIOPHYS, V60, P255, DOI 10.1016/0003-9861(56)90415-5; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; Trickey P, 2000, BIOCHEMISTRY-US, V39, P7678, DOI 10.1021/bi9927181; Weis R, 2004, FEMS YEAST RES, V5, P179, DOI 10.1016/j.femsyr.2004.06.016; Winkler A, 2008, NAT CHEM BIOL, V4, P739, DOI 10.1038/nchembio.123; Winkler A, 2007, J BIOL CHEM, V282, P24437, DOI 10.1074/jbc.M703642200; Winkler A, 2006, J BIOL CHEM, V281, P21276, DOI 10.1074/jbc.M603267200	34	34	37	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					19993	20001		10.1074/jbc.M109.015727	http://dx.doi.org/10.1074/jbc.M109.015727			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19457868	Green Published, hybrid			2022-12-25	WOS:000268097400026
J	Yang, XM; Li, HC; Zhou, ZN; Wang, WH; Deng, AP; Andrisani, O; Liu, XQ				Yang, Xiaoming; Li, Hongchang; Zhou, Zinan; Wang, Wen-Horng; Deng, Anping; Andrisani, Ourania; Liu, Xiaoqi			Plk1-mediated Phosphorylation of Topors Regulates p53 Stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-I-BINDING; POLO-LIKE KINASES; PLK1 PHOSPHORYLATION; TUMOR-SUPPRESSOR; CANCER-CELLS; PROTEIN; IDENTIFICATION; UBIQUITIN; LIGASE; VITRO	Polo-like kinase 1 (Plk1) overexpression is associated with tumorigenesis by an unknown mechanism. Likewise, Plk1 was suggested to act as a negative regulator of tumor suppressor p53, but the mechanism remains to be determined. Herein, we have identified topoisomerase I-binding protein (Topors), a p53-binding protein, as a Plk1 target. We show that Plk1 phosphorylates Topors on Ser(718) in vivo. Significantly, expression of a Plk1-unphosphorylatable Topors mutant (S718A) leads to a dramatic accumulation of p53 through inhibition of p53 degradation. Topors is an ubiquitin and small ubiquitin-like modifier ubiquitin-protein isopeptide ligase (SUMO E3) ligase. Plk1-mediated phosphorylation of Topors inhibits Topors-mediated sumoylation of p53, whereas p53 ubiquitination is enhanced, leading to p53 degradation. These results demonstrate that Plk1 modulates Topors activity in suppressing p53 function and identify a likely mechanism for the tumorigenic potential of Plk1.	[Yang, Xiaoming; Li, Hongchang; Zhou, Zinan; Liu, Xiaoqi] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; [Yang, Xiaoming; Deng, Anping] Sichuan Univ, Coll Chem, Chengdu 610064, Peoples R China; [Wang, Wen-Horng; Andrisani, Ourania] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Sichuan University; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Liu, XQ (corresponding author), Purdue Univ, Dept Biochem, 175 S Univ St, W Lafayette, IN 47907 USA.	liu8@purdue.edu	Li, Hongchang/GQO-9662-2022	Andrisani, Ourania/0000-0002-6230-0303	National Institutes of Health [K01 CA114401]; NATIONAL CANCER INSTITUTE [K01CA114401] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by the National Institutes of Health Howard Temin Award K01 CA114401 through the NCI.	Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Andrisani OM, 1999, INT J ONCOL, V15, P373; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Guan B, 2008, J BIOL CHEM, V283, P4834, DOI 10.1074/jbc.M708630200; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Hammer E, 2007, FEBS LETT, V581, P5418, DOI 10.1016/j.febslet.2007.10.040; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Mauri F, 2008, J BIOL CHEM, V283, P20848, DOI 10.1074/jbc.M710186200; Mok TSK, 2002, CANCER, V95, P1511, DOI 10.1002/cncr.10836; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Park HJ, 2008, BIOCHEMISTRY-US, V47, P13887, DOI 10.1021/bi801904q; Rajendra R, 2004, J BIOL CHEM, V279, P36440, DOI 10.1074/jbc.C400300200; Rasheed ZA, 2002, EXP CELL RES, V277, P152, DOI 10.1006/excr.2002.5550; Saleem A, 2004, ONCOGENE, V23, P5293, DOI 10.1038/sj.onc.1207700; STUDACH LL, 2009, HEPATOLOGY IN PRESS; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; TAKANO YS, 1991, J PATHOL, V163, P329, DOI 10.1002/path.1711630410; Watson IR, 2006, NEOPLASIA, V8, P655, DOI 10.1593/neo.06439; Weger S, 2005, FEBS LETT, V579, P5007, DOI 10.1016/j.febslet.2005.07.088; Wu ZQ, 2008, J BIOL CHEM, V283, P25503, DOI 10.1074/jbc.M803304200; Wu ZQ, 2008, P NATL ACAD SCI USA, V105, P1919, DOI 10.1073/pnas.0712063105; Yang ML, 2006, J BIOL CHEM, V281, P8264, DOI 10.1074/jbc.M510364200; Zhou R, 1999, GENE, V235, P93, DOI 10.1016/S0378-1119(99)00203-6; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	28	78	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18588	18592		10.1074/jbc.C109.001560	http://dx.doi.org/10.1074/jbc.C109.001560			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19473992	hybrid, Green Published			2022-12-25	WOS:000267711500007
J	Wright, TM; Brannon, AR; Gordan, JD; Mikels, AJ; Mitchell, C; Chen, S; Espinosa, I; van de Rijn, M; Pruthi, R; Wallen, E; Edwards, L; Nusse, R; Rathmell, WK				Wright, T. M.; Brannon, A. R.; Gordan, J. D.; Mikels, A. J.; Mitchell, C.; Chen, S.; Espinosa, I.; van de Rijn, M.; Pruthi, R.; Wallen, E.; Edwards, L.; Nusse, R.; Rathmell, W. K.			Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; Ror2; tyrosine kinase; cancer; cell signaling	RECEPTOR TYROSINE KINASE; KIDNEY; CANCER; GENES; MOUSE; MICROENVIRONMENT; ANGIOGENESIS; EXPRESSION; FAMILY; TUBULE	Inappropriate kinase expression and subsequent promiscuous activity defines the transformation of many solid tumors including renal cell carcinoma (RCC). Thus, the expression of novel tumor-associated kinases has the potential to dramatically shape tumor cell behavior. Further, identifying tumor-associated kinases can lend insight into patterns of tumor growth and characteristics. Here, we report the identification of the RTK-like orphan receptor 2 (Ror2), a new tumor-associated kinase in RCC cell lines and primary tumors. Ror2 is an orphan receptor tyrosine kinase with physiological expression normally seen in the embryonic kidney. However, in RCC, Ror2 expression correlated with expression of genes involved at the extracellular matrix, including Twist and matrix metalloprotease-2 (MMP2). Expression of MMP2 in RCC cells was suppressed by Ror2 knockdown, placing Ror2 as a mediator of MMP2 regulation in RCC and a potential regulator of extracellular matrix remodeling. The suppression of Ror2 not only inhibited cell migration, but also inhibited anchorage-independent growth in soft agar and growth in an orthotopic xenograft model. These findings suggest a novel pathway of tumor-promoting activity by Ror2 within a subset of renal carcinomas, with significant implications for unraveling the tumorigenesis of RCC. Oncogene ( 2009) 28, 2513-2523; doi: 10.1038/onc.2009.116; published online 18 May 2009	[Wright, T. M.; Brannon, A. R.; Rathmell, W. K.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; [Wright, T. M.; Brannon, A. R.; Chen, S.; Pruthi, R.; Wallen, E.; Rathmell, W. K.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Gordan, J. D.] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Mikels, A. J.; Nusse, R.] Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; [Mikels, A. J.; Nusse, R.] Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; [Mitchell, C.; Edwards, L.] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA; [Espinosa, I.; van de Rijn, M.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Pruthi, R.; Wallen, E.] Univ N Carolina, Dept Urol, Chapel Hill, NC 27599 USA; [Rathmell, W. K.] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; Pennsylvania Medicine; Stanford University; Howard Hughes Medical Institute; Stanford University; University of North Carolina; University of North Carolina Chapel Hill; Stanford University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Rathmell, WK (corresponding author), Univ N Carolina, Lineberger Canc Ctr, 450 W Dr CB 7295, Chapel Hill, NC 27599 USA.	rathmell@med.unc.edu	Edwards, Lloyd/N-2759-2019; Ariel, Pablo/AGJ-4118-2022	Edwards, Lloyd/0000-0002-7788-4575; van de Rijn, Matt/0000-0002-1909-9739	Doris Duke Charitable Fund and the V foundation (WKR); Initiative for Maximizing Student Diversity Training [NIH-R25GM055336, NCI-F31CA132543]; MSTP [T32]; UNC Tumor Procurement Facility; UNC Lineberger Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [F31CA132543, K08CA098410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM055336] Funding Source: NIH RePORTER	Doris Duke Charitable Fund and the V foundation (WKR); Initiative for Maximizing Student Diversity Training; MSTP; UNC Tumor Procurement Facility; UNC Lineberger Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Rathmell Lab members and the Lineberger Cancer Center community for thoughtful insights/advice. Additional thanks to the Microscopy Services Laboratory for use of their facilities, the Lineberger Animal Core Studies Facility and the Baldwin Lab for use of reagents. We also thank Dr H Shelton Earp, Dr Ian Davis and Dr Jon Serody for paper critiques. Funding for this project was provided in part by the Doris Duke Charitable Fund and the V foundation (WKR), Initiative for Maximizing Student Diversity Training Grant NIH-R25GM055336 (TMW and CM) and NCI-F31CA132543 ( TMW). Funding for JDG was provided by a MSTP grant and a T32 grant in hemostasis and thrombosis. Human tumor samples were collected by the UNC Tumor Procurement Facility, supported by the UNC Lineberger Comprehensive Cancer Center.	*AM CANC SOC INC, 2008, CANC FACTS FIG; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Billiard J, 2005, MOL ENDOCRINOL, V19, P90, DOI 10.1210/me.2004-0153; Coombs GS, 2008, CURR DRUG TARGETS, V9, P513, DOI 10.2174/138945008784911796; Cowey CL, 2008, EXPERT OPIN DRUG DIS, V3, P311, DOI 10.1517/17460441.3.3.311; Davies JA, 1996, ACTA ANAT, V156, P187; de Castro-Carpeno J, 2008, CLIN TRANSL ONCOL, V10, P6, DOI 10.1007/s12094-008-0147-3; De Luca A, 2008, J CELL PHYSIOL, V214, P559, DOI 10.1002/jcp.21260; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Kurban G, 2006, CANCER RES, V66, P1313, DOI 10.1158/0008-5472.CAN-05-2560; Linehan WM, 2003, J UROLOGY, V170, P2163, DOI 10.1097/01.ju.0000096060.92397.ed; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; Matsuda T, 2001, MECH DEVELOP, V105, P153, DOI 10.1016/S0925-4773(01)00383-5; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Oishi I, 1997, J BIOL CHEM, V272, P11916, DOI 10.1074/jbc.272.18.11916; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; Rathmell WK, 2005, EXPERT REV ANTICANC, V5, P1031, DOI 10.1586/14737140.5.6.1031; SAXEN L, 1987, PEDIATR NEPHROL, V1, P385, DOI 10.1007/BF00849241; Schwabe GC, 2004, DEV DYNAM, V229, P400, DOI 10.1002/dvdy.10466; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365-2443.2000.00300.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Amerongen R, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.135re9; Yoda A, 2003, J RECEPT SIG TRANSD, V23, P1, DOI 10.1081/RRS-120018757; Zhang XH, 2002, INT J UROL, V9, P509, DOI 10.1046/j.1442-2042.2002.00511.x	29	83	85	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2513	2523		10.1038/onc.2009.116	http://dx.doi.org/10.1038/onc.2009.116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448672	Green Submitted, Green Accepted			2022-12-25	WOS:000267806800004
J	Lubin, M; Lubin, A				Lubin, Martin; Lubin, Adam			Selective Killing of Tumors Deficient in Methylthioadenosine Phosphorylase: A Novel Strategy	PLOS ONE			English	Article								Background: The gene for methylthioadenosine phosphorylase (MTAP) lies on 9p21, close to the gene CDKN2A that encodes the tumor suppressor proteins p16 and p14ARF. MTAP and CDKN2A are homozygously co-deleted, with a frequency of 35 to 70%, in lung and pancreatic cancer, glioblastoma, osteosarcoma, soft-tissue sarcoma, mesothelioma, and T-cell acute lymphoblastic leukemia. In normal cells, but not in tumor cells lacking MTAP, MTAP cleaves the natural substrate, 5'-deoxy-5-methylthioadenosine (MTA), to adenine and 5-methylthioribose-1-phosphate (MTR-1-P), which are then converted to adenine nucleotides and methionine. This distinct difference between normal MTAP-positive cells and tumor MTAP-negative cells led to several proposals for therapy. We offer a novel strategy in which both MTA and a toxic adenine analog, such as 2,6-diaminopurine (DAP), 6-methylpurine (MeP), or 2-fluoroadenine (F-Ade), are administered. In MTAP-positive cells, abundant adenine, generated from supplied MTA, competitively blocks the conversion of an analog, by adenine phosphoribosyltransferase (APRT), to its active nucleotide form. In MTAP-negative tumor cells, the supplied MTA cannot generate adenine; hence conversion of the analog is not blocked. Principal Findings: We show that this combination treatment - adenine analog plus MTA - kills MTAP-negative A549 lung tumor cells, while MTAP-positive human fibroblasts (HF) are protected. In co-cultures of the breast tumor cell line, MCF-7, and HF cells, MCF-7 is inhibited or killed, while HF cells proliferate robustly. 5-fluorouracil (5-FU) and 6-thioguanine (6-TG) may also be used with our strategy. Though neither analog is activated by APRT, in MTAP-positive cells, adenine produced from supplied MTA blocks conversion of 5-FU and 6-TG to their toxic nucleotide forms by competing for 5-phosphoribosyl-1-pyrophosphate (PRPP). The combination of MTA with 5-FU or 6-TG, in the treatment of MTAP-negative tumors, may produce a significantly improved therapeutic index. Conclusion: We describe a selective strategy to kill tumor cells lacking MTAP.			Lubin, M (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA.	martin.lubin@dartmouth.edu						Basu I, 2007, J BIOL CHEM, V282, P21477, DOI 10.1074/jbc.M702287200; Batova A, 2006, BLOOD, V107, P898, DOI 10.1182/blood-2005-06-2430; Batova A, 1996, BLOOD, V88, P3083, DOI 10.1182/blood.V88.8.3083.bloodjournal8883083; Behrmann I, 2003, AM J PATHOL, V163, P683, DOI 10.1016/S0002-9440(10)63695-4; BERTINO JR, 1993, J CLIN ONCOL, V11, P5, DOI 10.1200/JCO.1993.11.1.5; BURCHENAL JH, 1951, CANCER-AM CANCER SOC, V4, P549, DOI 10.1002/1097-0142(195105)4:3<549::AID-CNCR2820040308>3.0.CO;2-J; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; *CLINICALTRIALS GO, NCT00075894 CLINICAL; *CLINICALTRIALS GO, NCT00062283 CLINICAL; De Carvalho GSG, 2009, TETRAHEDRON LETT, V50, P463, DOI 10.1016/j.tetlet.2008.11.039; DELLARAGIONE F, 1995, ONCOGENE, V10, P827; Gadi VK, 2003, J PHARMACOL EXP THER, V304, P1280, DOI 10.1124/jpet.102.044743; Garcia-Castellano JM, 2002, CLIN CANCER RES, V8, P782; HASHIMOTO H, 1990, LEUKEMIA RES, V14, P1061, DOI 10.1016/0145-2126(90)90120-X; HEIMER R, 1983, BIOCHEM PHARMACOL, V32, P199, DOI 10.1016/0006-2952(83)90544-0; Ikeguchi Y, 2006, J BIOCHEM, V139, P1, DOI 10.1093/jb/mvj019; Illei PB, 2003, CLIN CANCER RES, V9, P2108; KAMATANI N, 1981, P NATL ACAD SCI-BIOL, V78, P1219, DOI 10.1073/pnas.78.2.1219; Karikari CA, 2005, MOL CANCER THER, V4, P1860, DOI 10.1158/1535-7163.MCT-05-0103; KINDLER HL, 2008, INVEST NEW DRUGS; Kung PP, 2005, BIOORG MED CHEM LETT, V15, P2829, DOI 10.1016/j.bmcl.2005.03.107; Li WW, 2004, ONCOL RES, V14, P373, DOI 10.3727/0965040041292332; LUBIN M, 2009, P AM ASS CANC RES S; MONTGOMERY JA, 1974, J MED CHEM, V17, P1197, DOI 10.1021/jm00257a014; Moratti EM, 1998, Patent No. 5753213; NOBORI T, 1991, CANCER RES, V51, P3193; NOBORI T, 1993, CANCER RES, V53, P1098; PEGG AE, 1969, BIOCHEM J, V115, P241, DOI 10.1042/bj1150241; PEGG AE, 1981, BIOCHEM J, V194, P79, DOI 10.1042/bj1940079; RISCOE MK, 1984, J BIOL CHEM, V259, P5465; Russo G L, 1988, Adv Exp Med Biol, V250, P229; SANTELLI G, 1980, J NATL CANCER I, V64, P69; SAVARESE TM, 1984, BIOCHEM PHARMACOL, V34, P361; Simile MM, 2001, J HEPATOL, V34, P386, DOI 10.1016/S0168-8278(00)00078-7; Sufrin JR, 2008, ANTIMICROB AGENTS CH, V52, P211, DOI 10.1128/AAC.00480-07; TISDALE MJ, 1983, BIOCHEM PHARMACOL, V32, P2915, DOI 10.1016/0006-2952(83)90396-9; TOOHEY JI, 1978, BIOCHEM BIOPH RES CO, V83, P27, DOI 10.1016/0006-291X(78)90393-5; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X; WOLFORD RW, 1984, EXP HEMATOL, V12, P867; Wu H, 2008, J BIOL CHEM, V283, P16135, DOI 10.1074/jbc.M710323200; Zhang Y, 2005, CURR TOP MED CHEM, V5, P1259, DOI 10.2174/156802605774463105	41	51	52	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2009	4	5							e5735	10.1371/journal.pone.0005735	http://dx.doi.org/10.1371/journal.pone.0005735			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451SH	19478948	Green Published, Green Submitted, gold			2022-12-25	WOS:000266490000011
J	Chisamore, MJ; Cunningham, ME; Flores, O; Wilkinson, HA; Chen, JD				Chisamore, Michael J.; Cunningham, Michael E.; Flores, Osvaldo; Wilkinson, Hilary A.; Chen, J. Don			Characterization of a Novel Small Molecule Subtype Specific Estrogen-Related Receptor alpha Antagonist in MCF-7 Breast Cancer Cells	PLOS ONE			English	Article								Background: The orphan nuclear receptor estrogen-related receptor alpha (ERR alpha) is a member of the nuclear receptor superfamily. It was identified through a search for genes encoding proteins related to estrogen receptor alpha (ER alpha). An endogenous ligand has not been found. Novel ERR alpha antagonists that are highly specific for binding to the ligand binding domain (LBD) of ERR alpha have been recently reported. Research suggests that ERR alpha may be a novel drug target to treat breast cancer and/or metabolic disorders and this has led to an effort to characterize the mechanisms of action of N-[(2Z)-3-(4,5-dihydro-1,3-thiazol-2- yl)-1,3-thiazolidin-2-ylidene]-5H dibenzo[a,d][7]annulen-5-amine, a novel ERR alpha specific antagonist. Methodology/Principal Findings: We demonstrate this ERR alpha ligand inhibits ERR alpha transcriptional activity in MCF-7 cells by luciferase assay but does not affect mRNA levels measured by real-time RT-PCR. Also, ER alpha (ESR1) mRNA levels were not affected upon treatment with the ERR alpha antagonist, but other ERR alpha (ESRRA) target genes such as pS2 (TFF1), osteopontin (SPP1), and aromatase (CYP19A1) mRNA levels decreased. In vitro, the ERR alpha antagonist prevents the constitutive interaction between ERR alpha and nuclear receptor coactivators. Furthermore, we use Western blots to demonstrate ERR alpha protein degradation via the ubiquitin proteasome pathway is increased by the ERR alpha-subtype specific antagonist. We demonstrate by chromatin immunoprecipitation (ChIP) that the interaction between ACADM, ESRRA, and TFF1 endogenous gene promoters and ERR alpha protein is decreased when cells are treated with the ligand. Knocking-down ERR alpha (shRNA) led to similar genomic effects seen when MCF-7 cells were treated with our ERR alpha antagonist. Conclusions/Significance: We report the mechanism of action of a novel ERR alpha specific antagonist that inhibits transcriptional activity of ERR alpha, disrupts the constitutive interaction between ERR alpha and nuclear coactivators, and induces proteasome-dependent ERR alpha protein degradation. Additionally, we confirmed that knocking-down ERR alpha lead to similar genomic effects demonstrated in vitro when treated with the ERR alpha specific antagonist.			Chisamore, MJ (corresponding author), Merck Res Labs, Dept Mol Endocrinol, West Point, PA USA.	michael_chisamore@merck.com			NIDDK NIH HHS [R01 DK052888, R01 DK52888] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052888] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		American Cancer Society, 2008, CANC FACTS FIG 2008; Ariazi EA, 2006, CURR TOP MED CHEM, V6, P203, DOI 10.2174/1568026610606030203; Ariazi EA, 2002, CANCER RES, V62, P6510; Barry JB, 2005, CANCER RES, V65, P6120, DOI 10.1158/0008-5472.CAN-05-0922; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; Bross PF, 2003, CLIN CANCER RES, V9, P4309; Busch BB, 2004, J MED CHEM, V47, P5593, DOI 10.1021/jm049334f; Chisamore MJ, 2008, DRUG DEVELOP RES, V69, P203, DOI 10.1002/ddr.20246; Chisarnore MJ, 2009, MOL CANCER THER, V8, P672, DOI 10.1158/1535-7163.MCT-08-1028; Coward P, 2001, P NATL ACAD SCI USA, V98, P8880, DOI 10.1073/pnas.151244398; Fan MY, 2003, MOL ENDOCRINOL, V17, P356, DOI 10.1210/me.2002-0323; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; HORWITZ KB, 1978, CANCER RES, V38, P2434; Howell A, 2002, J CLIN ONCOL, V20, P3396, DOI 10.1200/JCO.2002.10.057; Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079-9091.2004; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Ichida M, 2002, J BIOL CHEM, V277, P50991, DOI 10.1074/jbc.M210262200; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; Kallen J, 2004, J BIOL CHEM, V279, P49330, DOI 10.1074/jbc.M407999200; Kallen J, 2007, J BIOL CHEM, V282, P23231, DOI 10.1074/jbc.M703337200; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Kraus RJ, 2002, J BIOL CHEM, V277, P24826, DOI 10.1074/jbc.M202952200; Laganiere J, 2004, J BIOL CHEM, V279, P18504, DOI 10.1074/jbc.M313543200; Lanvin O, 2007, J BIOL CHEM, V282, P28328, DOI 10.1074/jbc.M704295200; Liu DX, 2003, ENDOCRINOLOGY, V144, P4894, DOI 10.1210/en.2003-0432; Lu DS, 2001, CANCER RES, V61, P6755; MARSELOS M, 1992, EUR J CANCER, V28A, P1182, DOI 10.1016/0959-8049(92)90482-H; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Pettersson K, 1996, MECH DEVELOP, V54, P211, DOI 10.1016/0925-4773(95)00479-3; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Schaufele F, 2000, MOL ENDOCRINOL, V14, P2024, DOI 10.1210/me.14.12.2024; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Stein RA, 2006, ENDOCR-RELAT CANCER, V13, pS25, DOI 10.1677/erc.1.01292; Suzuki T, 2004, CANCER RES, V64, P4670, DOI 10.1158/0008-5472.CAN-04-0250; Tremblay GB, 2001, ENDOCRINOLOGY, V142, P4572, DOI 10.1210/en.142.10.4572; Tremblay GB, 2001, GENE DEV, V15, P833, DOI 10.1101/gad.873401; Vanacker JM, 1998, CELL GROWTH DIFFER, V9, P1007; Vega RB, 1997, J BIOL CHEM, V272, P31693, DOI 10.1074/jbc.272.50.31693; Wende AR, 2005, MOL CELL BIOL, V25, P10684, DOI 10.1128/MCB.25.24.10684-10694.2005; Wijayaratne AL, 1999, ENDOCRINOLOGY, V140, P5828, DOI 10.1210/en.140.12.5828; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Yang C, 1998, CANCER RES, V58, P5695; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795; Zhang ZP, 2000, J BIOL CHEM, V275, P20837, DOI 10.1074/jbc.M001880200	46	41	42	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2009	4	5							e5624	10.1371/journal.pone.0005624	http://dx.doi.org/10.1371/journal.pone.0005624			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448AY	19462000	Green Published, gold, Green Submitted			2022-12-25	WOS:000266234700011
J	Batista, MD; Ferreira, S; Sauer, MM; Tomiyama, H; Giret, MTM; Pannuti, CS; Diaz, RS; Sabino, EC; Kallas, EG				Batista, Mariana Dias; Ferreira, Suzete; Sauer, Mariana M.; Tomiyama, Helena; Maidana Giret, Maria Teresa; Pannuti, Claudio S.; Diaz, Ricardo S.; Sabino, Ester C.; Kallas, Esper G.			High Human Herpesvirus 8 (HHV-8) Prevalence, Clinical Correlates and High Incidence among Recently HIV-1-Infected Subjects in Sao Paulo, Brazil	PLOS ONE			English	Article								Background: Human herpesvirus 8 (HHV-8) is the etiological agent for Kaposi Sarcoma, which occurs especially in HIV-infected subjects. HHV-8 infection and its clinical correlates have not been well characterized in recently HIV-1-infected subjects, especially men who have sex with men (MSM). Methodology/Principal Findings: We assessed the HHV-8 seroprevalence, clinical correlates, and incidence after one year of follow-up in a cohort of 228 recently HIV-1-infected individuals, of whom 83.6% were MSM, using indirect immunofluorescence assay. The prevalence of HHV-8 infection at the time of cohort enrollment was 25.9% (59/228). In the univariate model, there were significant associations with male gender, black ethnicity, MSM practice, and previous hepatitis B virus and syphilis infections. In the multivariate model we could still demonstrate association with MSM, hepatitis B, and black ethnicity. No differences in mean CD4+ cell counts or HIV viral load according to HHV-8 status were found. In terms of incidence, there were 23/127 (18.1%) seroconversions in the cohort after 1 year. Conclusions: HHV-8 is highly prevalent among recently HIV-1-infected subjects. Correlations with other sexually transmitted infections suggest common transmission routes.			Batista, MD (corresponding author), Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.	esper.kallas@gmail.com	Sabino, Ester C/F-7750-2010; Diaz, Ricardo/K-3978-2012; Pannuti, Claudio/B-7649-2012; Ferreira, Suzete Cleusa/K-1626-2016; Kallas, Esper G/C-9539-2012	Sabino, Ester C/0000-0003-2623-5126; Ferreira, Suzete Cleusa/0000-0002-4190-0238; Kallas, Esper/0000-0003-2026-6925				Ait-Arkoub Z, 2003, AIDS, V17, P1394, DOI 10.1097/00002030-200306130-00016; Barbour JD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001080; Bassichetto KC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001423; Biggar RJ, 2003, J INFECT DIS, V187, P12, DOI 10.1086/345866; Cannon MJ, 2001, NEW ENGL J MED, V344, P637, DOI 10.1056/NEJM200103013440904; Caselli E, 2001, J GEN VIROL, V82, P1965, DOI 10.1099/0022-1317-82-8-1965; Caselli E, 2005, BLOOD, V106, P2790, DOI 10.1182/blood-2005-04-1390; Caselli E, 2003, J GEN VIROL, V84, P1123, DOI 10.1099/vir.0.18799-0; Casper C, 2002, J INFECT DIS, V185, P990, DOI 10.1086/339605; Casper C, 2007, J INFECT DIS, V195, P30, DOI 10.1086/509621; Caterino-De-Araujo A, 1999, J INFECT DIS, V179, P1591, DOI 10.1086/314789; Crum NF, 2003, SEX TRANSM DIS, V30, P713, DOI 10.1097/01.OLQ.0000078627.30743.4A; Diamond C, 2001, SEX TRANSM DIS, V28, P176, DOI 10.1097/00007435-200103000-00010; Dukers NHTM, 2000, AM J EPIDEMIOL, V151, P213, DOI 10.1093/oxfordjournals.aje.a010195; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Giuliani M, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-143; Greene JT, 2001, ADV INV AN, V8, P183; Harris AH, 2002, SUPPORT CARE CANCER, V10, P486, DOI 10.1007/s00520-002-0363-2; Hyun TS, 2001, J VIROL, V75, P8761, DOI 10.1128/JVI.75.18.8761-8771.2001; Jacobson LP, 2000, J INFECT DIS, V181, P1940, DOI 10.1086/315503; Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Mercader M, 2000, AM J PATHOL, V156, P1961, DOI 10.1016/S0002-9440(10)65069-9; Nascimento MC, 2007, J CLIN MICROBIOL, V45, P715, DOI 10.1128/JCM.01264-06; Pierrotti LC, 2005, SEX TRANSM DIS, V32, P57, DOI 10.1097/01.olq.0000148300.33428.6e; Renwick N, 1998, AIDS, V12, P2481, DOI 10.1097/00002030-199818000-00018; Smith NA, 1999, J INFECT DIS, V180, P600, DOI 10.1086/314926; Strathdee S A, 1996, AIDS, V10 Suppl A, pS51, DOI 10.1097/00002030-199601001-00008; de Souza VAUF, 2007, J MED VIROL, V79, P1562, DOI 10.1002/jmv.20949; Varthakavi V, 2002, VIROLOGY, V297, P270, DOI 10.1006/viro.2002.1434; Zago A, 2000, SEX TRANSM DIS, V27, P468, DOI 10.1097/00007435-200009000-00009; Zeng Y, 2007, J VIROL, V81, P2401, DOI 10.1128/JVI.02024-06	33	19	19	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2009	4	5							e5613	10.1371/journal.pone.0005613	http://dx.doi.org/10.1371/journal.pone.0005613			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446ZK	19479040	Green Published, Green Submitted, gold			2022-12-25	WOS:000266161200014
J	Muzard, J; Sarda-Mantel, L; Loyau, S; Meulemans, A; Louedec, L; Bantsimba-Malanda, C; Hervatin, F; Marchal-Somme, J; Michel, JB; Le Guludec, D; Billiald, P; Jandrot-Perrus, M				Muzard, Julien; Sarda-Mantel, Laure; Loyau, Stephane; Meulemans, Alain; Louedec, Liliane; Bantsimba-Malanda, Claudie; Hervatin, Florence; Marchal-Somme, Joelle; Michel, Jean Baptiste; Le Guludec, Dominique; Billiald, Philippe; Jandrot-Perrus, Martine			Non-Invasive Molecular Imaging of Fibrosis Using a Collagen-Targeted Peptidomimetic of the Platelet Collagen Receptor Glycoprotein VI	PLOS ONE			English	Article							BINDING; IDENTIFICATION; EXPRESSION; PEPTIDES; EPITOPE; ALPHA; GPVI; MRI	Background: Fibrosis, which is characterized by the pathological accumulation of collagen, is recognized as an important feature of many chronic diseases, and as such, constitutes an enormous health burden. We need non-invasive specific methods for the early diagnosis and follow-up of fibrosis in various disorders. Collagen targeting molecules are therefore of interest for potential in vivo imaging of fibrosis. In this study, we developed a collagen-specific probe using a new approach that takes advantage of the inherent specificity of Glycoprotein VI (GPVI), the main platelet receptor for collagens I and III. Methodology/Principal Findings: An anti-GPVI antibody that neutralizes collagen-binding was used to screen a bacterial random peptide library. A cyclic motif was identified, and the corresponding peptide (designated collagelin) was synthesized. Solid-phase binding assays and histochemical analysis showed that collagelin specifically bound to collagen (Kd 10(-7) M) in vitro, and labelled collagen fibers ex vivo on sections of rat aorta and rat tail. Collagelin is therefore a new specific probe for collagen. The suitability of collagelin as an in vivo probe was tested in a rat model of healed myocardial infarctions (MI). Injecting Tc-99m-labelled collagelin and scintigraphic imaging showed that uptake of the probe occurred in the cardiac area of rats with MI, but not in controls. Post mortem autoradiography and histological analysis of heart sections showed that the labeled areas coincided with fibrosis. Scintigraphic molecular imaging with collagelin provides high resolution, and good contrast between the fibrotic scars and healthy tissues. The capacity of collagelin to image fibrosis in vivo was confirmed in a mouse model of lung fibrosis. Conclusion/Significance: Collagelin is a new collagen-targeting agent which may be useful for non-invasive detection of fibrosis in a broad spectrum of diseases.			Muzard, J (corresponding author), Hop Bichat Claude Bernard, INSERM, U698, F-75877 Paris, France.	martine.jandrot-perrus@inserm.fr	Sarda-Mantel, Laure/R-8223-2018; BILLIALD, Philippe/ABF-7417-2021; Jandrot-Perrus, Martine/GZM-1526-2022; Michel, Jean-Baptiste/AAH-9336-2020	Sarda-Mantel, Laure/0000-0003-2926-1717; BILLIALD, Philippe/0000-0001-8148-5297; JANDROT-PERRUS, Martine/0000-0002-8450-9247; Loyau, stephane/0000-0001-8748-501X				Aina OH, 2007, MOL PHARMACEUT, V4, P631, DOI 10.1021/mp700073y; Caravan P, 2007, ANGEW CHEM INT EDIT, V46, P8171, DOI 10.1002/anie.200700700; Cauwenberghs N, 2001, BLOOD, V98, P652, DOI 10.1182/blood.V98.3.652; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; de Ledinghen V, 2007, J PEDIATR GASTR NUTR, V45, P443, DOI 10.1097/MPG.0b013e31812e56ff; Depraetere H, 1998, BLOOD, V92, P4207, DOI 10.1182/blood.V92.11.4207.423a02_4207_4211; Dilsizian V, 2007, J NUCL MED, V48, P182; Fabre A, 2008, EUR RESPIR J, V32, P426, DOI 10.1183/09031936.00126907; FISHBEIN MC, 1978, AM J PATHOL, V90, P57; Gawaz M, 2005, THROMB HAEMOSTASIS, V93, P910, DOI 10.1160/TH04-10-0660; Helm PA, 2008, RADIOLOGY, V247, P788, DOI 10.1148/radiol.2473070975; Inoue O, 2006, BLOOD, V107, P1405, DOI 10.1182/blood-2005-06-2406; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; Krahn KN, 2006, ANAL BIOCHEM, V350, P177, DOI 10.1016/j.ab.2006.01.013; Lagrue-Lak-Hal AH, 2001, J BIOL CHEM, V276, P15316, DOI 10.1074/jbc.M009117200; Lecut C, 2004, J BIOL CHEM, V279, P52293, DOI 10.1074/jbc.M406342200; Lecut C, 2003, J THROMB HAEMOST, V1, P2653, DOI 10.1111/j.1538-7836.2003.00495.x; Massberg S, 2003, FASEB J, V17, P397, DOI 10.1096/f.03-0464.fje; Megens RTA, 2007, MOL IMAGING, V6, P247, DOI 10.2310/7290.2007.00021; Miura Y, 2002, J BIOL CHEM, V277, P46197, DOI 10.1074/jbc.M204029200; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Nahrendorf M, 2008, CIRCULATION, V117, P379, DOI 10.1161/CIRCULATIONAHA.107.741181; Nelson TJ, 2007, J BIOL CHEM, V282, P31238, DOI 10.1074/jbc.M705558200; OHLMANN P, 2008, J THROMB HAEMOST; Petegnief Y, 1998, PHYS MED BIOL, V43, P3629, DOI 10.1088/0031-9155/43/12/018; Talwalkar JA, 2007, CLIN GASTROENTEROL H, V5, P1214, DOI 10.1016/j.cgh.2007.07.020; Taouli B, 2007, AM J ROENTGENOL, V189, P799, DOI 10.2214/AJR.07.2086; van den Borne SWM, 2009, JACC-CARDIOVASC IMAG, V2, P187, DOI 10.1016/j.jcmg.2008.11.011; van den Borne SWM, 2008, J AM COLL CARDIOL, V52, P2017, DOI 10.1016/j.jacc.2008.07.067; Vanhoorelbeke K, 2003, J BIOL CHEM, V278, P37815, DOI 10.1074/jbc.M304289200; Verjans JWH, 2008, JACC-CARDIOVASC IMAG, V1, P354, DOI 10.1016/j.jcmg.2007.11.007; Viaene A, 2001, J PARASITOL, V87, P619, DOI 10.1645/0022-3395(2001)087[0619:IOACBP]2.0.CO;2	32	62	62	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5585	10.1371/journal.pone.0005585	http://dx.doi.org/10.1371/journal.pone.0005585			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440310	Green Published, Green Submitted, gold			2022-12-25	WOS:000266107500014
J	Lengyel, S; Gove, AD; Latimer, AM; Majer, JD; Dunn, RR				Lengyel, Szabolcs; Gove, Aaron D.; Latimer, Andrew M.; Majer, Jonathan D.; Dunn, Robert R.			Ants Sow the Seeds of Global Diversification in Flowering Plants	PLOS ONE			English	Article								Background: The extraordinary diversification of angiosperm plants in the Cretaceous and Tertiary periods has produced an estimated 250,000-300,000 living angiosperm species and has fundamentally altered terrestrial ecosystems. Interactions with animals as pollinators or seed dispersers have long been suspected as drivers of angiosperm diversification, yet empirical examples remain sparse or inconclusive. Seed dispersal by ants (myrmecochory) may drive diversification as it can reduce extinction by providing selective advantages to plants and can increase speciation by enhancing geographical isolation by extremely limited dispersal distances. Methodology/Principal Findings: Using the most comprehensive sister-group comparison to date, we tested the hypothesis that myrmecochory leads to higher diversification rates in angiosperm plants. As predicted, diversification rates were substantially higher in ant-dispersed plants than in their non-myrmecochorous relatives. Data from 101 angiosperm lineages in 241 genera from all continents except Antarctica revealed that ant-dispersed lineages contained on average more than twice as many species as did their non-myrmecochorous sister groups. Contrasts in species diversity between sister groups demonstrated that diversification rates did not depend on seed dispersal mode in the sister group and were higher in myrmecochorous lineages in most biogeographic regions. Conclusions/Significance: Myrmecochory, which has evolved independently at least 100 times in angiosperms and is estimated to be present in at least 77 families and 11 000 species, is a key evolutionary innovation and a globally important driver of plant diversity. Myrmecochory provides the best example to date for a consistent effect of any mutualism on large-scale diversification.			Lengyel, S (corresponding author), N Carolina State Univ, Dept Biol, Raleigh, NC 27695 USA.	szabolcslengyel@yahoo.com	Lengyel, Szabolcs/A-3483-2011; Dunn, Robert/B-1360-2013	Lengyel, Szabolcs/0000-0002-7049-0100; Latimer, Andrew/0000-0001-8098-0448; Dunn, Robert/0000-0002-6030-4837				Barraclough TG, 2001, EVOLUTION, V55, P677, DOI 10.1554/0014-3820(2001)055[0677:ERASDI]2.0.CO;2; Beattie A. J., 1985, EVOLUTIONARY ECOLOGY; BENNINGTON CC, 1994, ECOLOGY, V75, P717, DOI 10.2307/1941729; BERG RY, 1975, AUST J BOT, V23, P475, DOI 10.1071/BT9750475; BOESEWINKEL FD, 1984, EMBRYOLOGY ANGIOSPER, P567, DOI DOI 10.1007/978-3-642-69302-1_12; Bolmgren K, 2005, OIKOS, V109, P255, DOI 10.1111/j.0030-1299.2005.12663.x; BOND W, 1984, ECOLOGY, V65, P1031, DOI 10.2307/1938311; BOND WJ, 1983, S AFR J SCI, V79, P231; Bronstein JL, 2006, NEW PHYTOL, V172, P412, DOI 10.1111/j.1469-8137.2006.01864.x; Calvino-Cancela M, 2008, DIVERS DISTRIB, V14, P11, DOI 10.1111/j.1472-4642.2007.00402.x; Cardillo M, 2005, ECOLOGY, V86, P2278, DOI 10.1890/05-0112; CRANE PR, 1995, NATURE, V374, P27, DOI 10.1038/374027a0; CREPET WL, 1984, ANN MO BOT GARD, V71, P607, DOI 10.2307/2399041; Davies TJ, 2004, P NATL ACAD SCI USA, V101, P1904, DOI 10.1073/pnas.0308127100; de Queiroz A, 2002, SYST BIOL, V51, P917, DOI 10.1080/10635150290155980; Dodd ME, 1999, EVOLUTION, V53, P732, DOI [10.2307/2640713, 10.1111/j.1558-5646.1999.tb05367.x]; DUNN RR, 2008, INSETOS SOCIAIS BIOL, P323; Edwards W, 2006, J ECOL, V94, P687, DOI 10.1111/j.1365-2745.2006.01116.x; ERIKSSON O, 1992, EVOLUTION, V46, P258, DOI [10.2307/2409820, 10.1111/j.1558-5646.1992.tb02000.x]; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; Forest F, 2007, EVOLUTION, V61, P1675, DOI 10.1111/j.1558-5646.2007.00138.x; Frohlich MW, 2007, NATURE, V450, P1184, DOI 10.1038/nature06393; Giladi I, 2006, OIKOS, V112, P481, DOI 10.1111/j.0030-1299.2006.14258.x; Gomez C, 1998, J BIOGEOGR, V25, P573, DOI 10.1046/j.1365-2699.1998.2530573.x; Gorb, 2003, SEED DISPERSAL ANTS; Goudet J, 1999, AM NAT, V153, P549, DOI 10.1086/303190; HANDEL SN, 1981, B TORREY BOT CLUB, V108, P430, DOI 10.2307/2484443; HE TH, NEW PHYTOL, V181, P725; HERRERA CM, 1989, AM NAT, V133, P309, DOI 10.1086/284921; Hu SS, 2008, P NATL ACAD SCI USA, V105, P240, DOI 10.1073/pnas.0707989105; Jansson R, 2008, ECOL LETT, V11, P173, DOI 10.1111/j.1461-0248.2007.01138.x; Jensen JM, 2006, ENVIRON ENTOMOL, V35, P326, DOI 10.1603/0046-225X-35.2.326; Kalisz S, 1999, ECOLOGY, V80, P2620, DOI 10.1890/0012-9658(1999)080[2620:AMSDAP]2.0.CO;2; Kalisz S, 2001, EVOLUTION, V55, P1560, DOI 10.1111/j.0014-3820.2001.tb00675.x; Koh LP, 2004, SCIENCE, V305, P1632, DOI 10.1126/science.1101101; LENGYEL S, PERSPECTIVE IN PRESS; Mabberley D. J., 2008, MABBERLEYS PLANT BOO; McConway KJ, 2004, EVOLUTION, V58, P12; McPeek MA, 1996, ECOLOGY, V77, P1355, DOI 10.2307/2265533; MITTER C, 1988, AM NAT, V132, P107, DOI 10.1086/284840; Nee Sean, 1996, P230; PEMBERTON RW, 1990, WEED SCI, V38, P615, DOI 10.1017/S0043174500051584; Pinheiro J, 2001, MIXED EFFECTS MODELS; Purvis Andy, 1996, P153; R Core Team, 2022, R LANG ENV STAT COMP; REGAL PJ, 1977, SCIENCE, V196, P622, DOI 10.1126/science.196.4290.622; Richardson DM, 2000, BIOL REV, V75, P65, DOI 10.1017/S0006323199005435; RICKLEFS RE, 1994, EVOLUTION, V48, P1619, DOI 10.1111/j.1558-5646.1994.tb02200.x; RICOGRAY V, 2007, ECOLOGY EVOLUTION AN; Sanderson MJ, 1996, TRENDS ECOL EVOL, V11, P15, DOI 10.1016/0169-5347(96)81059-7; SLOWINSKI JB, 1993, AM NAT, V142, P1019, DOI 10.1086/285586; Smith JF, 2001, AM NAT, V157, P646, DOI 10.1086/320625; SOLTIS DE, 2008, YEAR EVOLUTIONARY BI, P3; Stanley S. M., 1979, MACROEVOLUTION PATTE; STEBBINS GL, 1981, BIOSCIENCE, V31, P573, DOI 10.2307/1308219; Stevens PF, 2008, ANGIOSPERM PHYLOGENY; TIFFNEY BH, 1995, EVOL ECOL, V9, P93, DOI 10.1007/BF01237700; TIFFNEY BH, 1984, ANN MO BOT GARD, V71, P551, DOI 10.2307/2399037; Vamosi SM, 2005, EVOL ECOL RES, V7, P567; Van der Pijl L, 1982, PRINCIPLES DISPERSAL, V214; Vellend M, 2006, ECOL LETT, V9, P316, DOI 10.1111/j.1461-0248.2005.00878.x; Wallace AR., 1876, GEOGRAPHICAL DISTRIB; WESTOBY M, 1990, ECOLOGY, V71, P1307, DOI 10.2307/1938268; Zhou HP, 2007, J HERED, V98, P317, DOI 10.1093/jhered/esm032	64	136	143	2	65	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5480	10.1371/journal.pone.0005480	http://dx.doi.org/10.1371/journal.pone.0005480			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444WA	19436714	Green Published, gold, Green Accepted			2022-12-25	WOS:000266009900001
J	Nitsch, D; Tranchevent, LC; Thienpont, B; Thorrez, L; Van Esch, H; Devriendt, K; Moreau, Y				Nitsch, Daniela; Tranchevent, Leon-Charles; Thienpont, Bernard; Thorrez, Lieven; Van Esch, Hilde; Devriendt, Koenraad; Moreau, Yves			Network Analysis of Differential Expression for the Identification of Disease-Causing Genes	PLOS ONE			English	Article							POLYCYSTIC-OVARY-SYNDROME; GERM-CELLS; INTERACTOME; PRIORITIZATION; DATABASE; HOMOLOG; FAMILY; WOMEN; PIWI; VASA	Genetic studies (in particular linkage and association studies) identify chromosomal regions involved in a disease or phenotype of interest, but those regions often contain many candidate genes, only a few of which can be followed-up for biological validation. Recently, computational methods to identify (prioritize) the most promising candidates within a region have been proposed, but they are usually not applicable to cases where little is known about the phenotype (no or few confirmed disease genes, fragmentary understanding of the biological cascades involved). We seek to overcome this limitation by replacing knowledge about the biological process by experimental data on differential gene expression between affected and healthy individuals. Considering the problem from the perspective of a gene/protein network, we assess a candidate gene by considering the level of differential expression in its neighborhood under the assumption that strong candidates will tend to be surrounded by differentially expressed neighbors. We define a notion of soft neighborhood where each gene is given a contributing weight, which decreases with the distance from the candidate gene on the protein network. To account for multiple paths between genes, we define the distance using the Laplacian exponential diffusion kernel. We score candidates by aggregating the differential expression of neighbors weighted as a function of distance. Through a randomization procedure, we rank candidates by p-values. We illustrate our approach on four monogenic diseases and successfully prioritize the known disease causing genes.			Nitsch, D (corresponding author), Katholieke Univ Leuven, Dept Elect Engn, ESAT SCD, Louvain, Belgium.	Daniela.Nitsch@esat.kuleuven.be	Van+Esch, Hilde/AAU-5688-2020; Thorrez, Lieven/A-2583-2011; Thienpont, Bernard/AAG-5423-2019	Thorrez, Lieven/0000-0002-5896-6823; Van Esch, Hilde/0000-0002-9604-5726; Thienpont, Bernard/0000-0002-8772-6845; Moreau, Yves/0000-0002-4647-6560; Tranchevent, Leon-Charles/0000-0002-1257-4824				Aerts S, 2006, NAT BIOTECHNOL, V24, P537, DOI 10.1038/nbt1203; Bach F.R., 2005, P 22 INT C MACH LEAR, P33, DOI DOI 10.1145/1102351.1102356; Bach FR, 2002, J MACHINE LEARNING R, V3, P1; Bakay M, 2006, BRAIN, V129, P996, DOI 10.1093/brain/awl023; Barrett T, 2007, NUCLEIC ACIDS RES, V35, pD760, DOI 10.1093/nar/gkl887; BECKER P E, 1957, Acta Genet Stat Med, V7, P303; Bubendorf L, 2001, EUR UROL, V40, P231, DOI 10.1159/000049777; Chuang HY, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100180; Corton M, 2007, J CLIN ENDOCR METAB, V92, P328, DOI 10.1210/jc.2006-1665; Cox DN, 1998, GENE DEV, V12, P3715, DOI 10.1101/gad.12.23.3715; DRAGHICI S, 2003, DATA ANAL TOOLS DNA, P345; Fine S, 2002, J MACH LEARN RES, V2, P243, DOI 10.1162/15324430260185619; Fouss F, 2006, IEEE DATA MINING, P863; Franke L, 2006, AM J HUM GENET, V78, P1011, DOI 10.1086/504300; Franks S, 2006, FERTIL STERIL, V86, pS15, DOI 10.1016/j.fertnstert.2006.04.016; Gandhi TKB, 2006, NAT GENET, V38, P285, DOI 10.1038/ng1747; Ina S, 2003, GENE EXPR PATTERNS, V3, P635, DOI 10.1016/S1567-133X(03)00111-X; Johnson J, 2005, CELL, V122, P303, DOI 10.1016/j.cell.2005.06.031; Jones MR, 2007, MOL HUM REPROD, V13, P237, DOI 10.1093/molehr/gal120; Kohler S, 2008, AM J HUM GENET, V82, P949, DOI 10.1016/j.ajhg.2008.02.013; Kondor R. I., 2002, PROC 19 INT C MACH L, P315; Kotaja N, 2006, P NATL ACAD SCI USA, V103, P2647, DOI 10.1073/pnas.0509333103; Kuramochi-Miyagawa S, 2004, DEVELOPMENT, V131, P839, DOI 10.1242/dev.00973; Kyo K, 2001, J HUM GENET, V46, P5, DOI 10.1007/s100380170118; Lage K, 2007, NAT BIOTECHNOL, V25, P309, DOI 10.1038/nbt1295; Malmberg EK, 2006, AM J PHYSIOL-GASTR L, V291, pG203, DOI 10.1152/ajpgi.00491.2005; Moehle C, 2006, J MOL MED, V84, P1055, DOI 10.1007/s00109-006-0100-2; Moretti P, 2006, CURR OPIN GENET DEV, V16, P276, DOI 10.1016/j.gde.2006.04.009; Mount DB, 2004, PFLUG ARCH EUR J PHY, V447, P710, DOI 10.1007/s00424-003-1090-3; Nishimura Y, 2007, HUM MOL GENET, V16, P1682, DOI 10.1093/hmg/ddm116; Noce T, 2001, CELL STRUCT FUNCT, V26, P131, DOI 10.1247/csf.26.131; Parkinson H, 2007, NUCLEIC ACIDS RES, V35, pD747, DOI 10.1093/nar/gkl995; Probst FJ, 2007, AM J MED GENET A, V143A, P1358, DOI 10.1002/ajmg.a.31781; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rosenberg EH, 2004, AM J HUM GENET, V75, P97, DOI 10.1086/422102; Simoni M, 2008, HUM REPROD UPDATE, V14, P459, DOI 10.1093/humupd/dmn024; Tanaka SS, 2000, GENE DEV, V14, P841; Urbanek M, 2005, J CLIN ENDOCR METAB, V90, P6623, DOI 10.1210/jc.2005-0622; Urbanek M, 2007, J CLIN ENDOCR METAB, V92, P4191, DOI 10.1210/jc.2007-0761; von Mering C, 2007, NUCLEIC ACIDS RES, V35, pD358, DOI 10.1093/nar/gkl825; Watanabe T, 2008, NATURE, V453, P539, DOI 10.1038/nature06908; Wright JM, 2006, AM J RESP CELL MOL, V35, P327, DOI 10.1165/rcmb.2005-0359OC; Yao ZZ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-319; Yip AM, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-22	44	50	50	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2009	4	5							e5526	10.1371/journal.pone.0005526	http://dx.doi.org/10.1371/journal.pone.0005526			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444WA	19436755	Green Published, Green Submitted, gold			2022-12-25	WOS:000266009900018
J	Drake, PMW; Barbi, T; Sexton, A; McGowan, E; Stadlmann, J; Navarre, C; Paul, MJ; Ma, JKC				Drake, Pascal M. W.; Barbi, Tommaso; Sexton, Amy; McGowan, Edward; Stadlmann, Johannes; Navarre, Catherine; Paul, Matthew J.; Ma, Julian K. -C.			Development of rhizosecretion as a production system for recombinant proteins from hydroponic cultivated tobacco	FASEB JOURNAL			English	Article						transgenic plants; molecular farming; plant growth regulators; proteases; glycosylation	MONOCLONAL-ANTIBODIES; HAIRY ROOTS; PLANT-CELLS; PHARMACEUTICALS; GLYCOSYLATION	Rhizosecretion is an attractive technology for the production of recombinant proteins from transgenic plants. However, to date, yields of plant-derived recombinant pharmaceuticals by this method have been too low for commercial viability. Studies conducted focused on three transgenic plant lines grown in hydroponic culture medium, two expressing monoclonal antibodies Guy's 13 and 4E10 and one expressing a small microbicide polypeptide cyanovirin-N. Rhizosecretion rates increased significantly by the addition of the plant growth regulator alpha-naphthalene acetic acid. The maximum rhizosecretion rates achieved were 58 mu g/g root dry weight/24 h for Guy's 13, 10.43 mu g/g root dry weight/24 h for 4E10, and 766 mu g/g root dry weight/24 h for cyanovirin-N, the highest figures so far reported for a full-length antibody and a recombinant protein, respectively. The plant growth regulators indolebutyric acid, 6-benzylaminopurine, and kinetin were also demonstrated to increase rhizosecretion of Guy's 13. The effect of the growth regulators differed, as alpha-naphthalene acetic acid and indole-butyric acid increased the root dry weight of hydroponic plants, whereas the cytokinins benzylaminopurine and kinetin increased rhizosecretion without affecting root mass. A comparative glycosylation analysis between MAb Guy's 13 purified from either hydroponic culture medium or from leaf extracts demonstrated a similar pattern of glycosylation comprising high mannose to complex glycoforms. Analysis of the hydroponic culture medium at harvest revealed significantly lower and less complex levels of proteolytic enzymes, in comparison with leaf extracts, which translated to a higher proportion of intact Guy's 13 IgG in relation to other IgG products. Hydroponic medium could be added directly to a chromatography column for affinity purification, allowing simple and rapid production of high purity Guy's 13 antibody. In addition to the attractiveness of controlled cultivation within a contained environment for pharmaceutical-producing plants, this study demonstrates advantages with respect to the quality and downstream purification of recombinant proteins.-Drake, P. M. W., Barbi, T., Sexton, A., McGowan, E., Stadlmann, J., Navarre, C., Paul, M. J., Ma, J. K.- C. Development of rhizosecretion as a production system for recombinant proteins	[Drake, Pascal M. W.; Barbi, Tommaso; Sexton, Amy; McGowan, Edward; Paul, Matthew J.; Ma, Julian K. -C.] Univ London, Sch Med, St Georges Hosp, Dept Cellular & Mol Med,Mol Immunol Unit, London SW17 0RE, England; [Stadlmann, Johannes] Univ Nat Resources & Appl Life Sci Vienna, Inst Chem, A-1180 Vienna, Austria; [Navarre, Catherine] Univ Catholique Louvain, Inst Sci Vie, B-1348 Louvain, Belgium	St Georges University London; University of London; University College London; UCL Medical School; University of Natural Resources & Life Sciences, Vienna; Universite Catholique Louvain	Drake, PMW (corresponding author), Univ London, Sch Med, St Georges Hosp, Dept Cellular & Mol Med,Mol Immunol Unit, Cranmer Terrace, London SW17 0RE, England.	pdrake@sgul.ac.uk	Stadlmann, Johannes/AAC-3157-2021	Stadlmann, Johannes/0000-0001-5693-6690; Drake, Pascal/0000-0002-6181-0600; Ma, Julian/0000-0003-0767-0042; Paul, Mathew/0000-0002-0852-8788	St. George's University of London/Royal Holloway University of London	St. George's University of London/Royal Holloway University of London	We thank Sir Joseph Hotung for funding P. M. W. D. and J.K.-C.M. We are grateful to Dr. Dietmar Katinger (Polymun Scientific GmbH, Vienna, Austria) for providing the 4E10 peptide and to Dr. Barry O'Keefe (National Cancer Institute, Frederick, MD, USA) for providing the rabbit anti-CV-N antiserum. T. B. is funded by a joint St. George's University of London/Royal Holloway University of London Ph. D. studentship.	Boehm R, 2007, ANN NY ACAD SCI, V1102, P121, DOI 10.1196/annals.1408.009; Borisjuk NV, 1999, NAT BIOTECHNOL, V17, P466, DOI 10.1038/8643; Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521, DOI 10.1128/AAC.41.7.1521; Cabanes-Macheteau M, 1999, GLYCOBIOLOGY, V9, P365, DOI 10.1093/glycob/9.4.365; CARPITA N, 1979, SCIENCE, V205, P1144, DOI 10.1126/science.205.4411.1144; Delannoy M, 2008, PROTEOMICS, V8, P2285, DOI 10.1002/pmic.200700507; Drake PMW, 2003, PLANT MOL BIOL, V52, P233, DOI 10.1023/A:1023909331482; FIREK S, 1994, PLANT MOL BIOL, V24, P833; Gaume A, 2003, PLANT CELL REP, V21, P1188, DOI 10.1007/s00299-003-0660-3; Gleba D, 1999, P NATL ACAD SCI USA, V96, P5973, DOI 10.1073/pnas.96.11.5973; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Johri MM, 2001, CURR SCI INDIA, V80, P199; Kneer R, 1999, J EXP BOT, V50, P1553, DOI 10.1093/jexbot/50.339.1553; Komarnytsky S, 2006, PLANT PHYSIOL, V141, P1185, DOI 10.1104/pp.105.074419; Ma JKC, 2005, EMBO REP, V6, P593, DOI 10.1038/sj.embor.7400470; MA JKC, 1994, EUR J IMMUNOL, V24, P131, DOI 10.1002/eji.1830240120; Magnuson NS, 1996, PROTEIN EXPRES PURIF, V7, P220, DOI 10.1006/prep.1996.0030; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; SEXTON A, 2005, FASEB J, V19; Sexton A, 2006, FASEB J, V20, P356, DOI 10.1096/fj.05-4742fje; Sparrow PAC, 2007, TRANSGENIC RES, V16, P147, DOI 10.1007/s11248-007-9074-2; Stadlmann J, 2008, PROTEOMICS, V8, P2858, DOI 10.1002/pmic.200700968; van Dolleweerd CJ, 2003, INFECT IMMUN, V71, P754, DOI 10.1128/IAI.71.2.754-765.2003; Wongsamuth R, 1997, BIOTECHNOL BIOENG, V54, P401, DOI 10.1002/(SICI)1097-0290(19970605)54:5&lt;401::AID-BIT1&gt;3.0.CO;2-I	24	56	57	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2009	23	10					3581	3589		10.1096/fj.09-131771	http://dx.doi.org/10.1096/fj.09-131771			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19470800				2022-12-25	WOS:000270354300034
J	Legleiter, J; Lotz, GP; Miller, J; Ko, J; Ng, C; Williams, GL; Finkbeiner, S; Patterson, PH; Muchowski, PJ				Legleiter, Justin; Lotz, Gregor P.; Miller, Jason; Ko, Jan; Ng, Cheping; Williams, Geneva L.; Finkbeiner, Steve; Patterson, Paul H.; Muchowski, Paul J.			Monoclonal Antibodies Recognize Distinct Conformational Epitopes Formed by Polyglutamine in a Mutant Huntingtin Fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCLUSION-BODY FORMATION; AMYLOID-LIKE FIBRILS; IN-VITRO; PROTEIN; DISEASE; AGGREGATION; MODEL; TOXICITY; OLIGOMERS; BINDING	Huntington disease (HD) is a neurodegenerative disorder caused by an expansion of a polyglutamine (polyQ) domain in the N-terminal region of huntingtin (htt). PolyQ expansion above 35-40 results in disease associated with htt aggregation into inclusion bodies. It has been hypothesized that expanded polyQ domains adopt multiple potentially toxic conformations that belong to different aggregation pathways. Here, we used atomic force microscopy to analyze the effect of a panel of anti-htt antibodies (MW1-MW5, MW7, MW8, and 3B5H10) on aggregate formation and the stability of a mutant htt-exon1 fragment. Two antibodies, MW7 (polyproline-specific) and 3B5H10 (polyQ-specific), completely inhibited fibril formation and disaggregated preformed fibrils, whereas other polyQ-specific antibodies had widely varying effects on aggregation. These results suggest that expanded polyQ domains adopt multiple conformations in solution that can be readily distinguished by monoclonal antibodies, which has important implications for understanding the structural basis for polyQ toxicity and the development of intrabody-based therapeutics for HD.	[Legleiter, Justin; Lotz, Gregor P.; Miller, Jason; Ng, Cheping; Williams, Geneva L.; Finkbeiner, Steve; Muchowski, Paul J.] Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; [Legleiter, Justin; Lotz, Gregor P.; Finkbeiner, Steve; Muchowski, Paul J.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA; [Miller, Jason] Univ Calif San Francisco, Dept Chem & Chem Biol, Grad Program, San Francisco, CA 94158 USA; [Miller, Jason; Finkbeiner, Steve] Univ Calif San Francisco, Med Scientist Training Program, San Francisco, CA 94158 USA; [Finkbeiner, Steve] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94158 USA; [Muchowski, Paul J.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA; [Finkbeiner, Steve; Muchowski, Paul J.] CALTECH, Taube Koret Ctr Huntingtons Dis Res, Pasadena, CA 91125 USA; [Ko, Jan; Patterson, Paul H.] CALTECH, Div Biol, Pasadena, CA 91125 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Institute of Technology; California Institute of Technology	Muchowski, PJ (corresponding author), Gladstone Inst Neurol Dis, 1650 Owens St, San Francisco, CA 94158 USA.	pmuchowski@gladstone.ucsf.edu		Lotz, Gregor/0000-0002-0231-5503; Legleiter, Justin/0000-0002-5262-1867; Miller, Jason/0000-0002-2784-9560	National Institutes of Health [R01NS047237, R01NS054753, P01AG022074, R01NS039074, R01NS045091, R01NS055298]; Hereditary Disease Foundation; Cure Huntington's Disease Initiative; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047237, R01NS055298, R01NS045091, R01NS054753, R01NS039074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG022074] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hereditary Disease Foundation; Cure Huntington's Disease Initiative; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported, in whole or in part, by National Institutes of Health Grants R01NS047237 and R01NS054753 (to P. J. M.), P01AG022074 (to S. F.), R01NS039074 (to S. F.), and R01NS045091 and R01NS055298 (to P. H. P.). This work was also supported by the Hereditary Disease Foundation and the Cure Huntington's Disease Initiative.	Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bennett MJ, 2002, P NATL ACAD SCI USA, V99, P11634, DOI 10.1073/pnas.182393899; Bhattacharyya A, 2006, J MOL BIOL, V355, P524, DOI 10.1016/j.jmb.2005.10.053; Brooks Elizabeth, 2004, V277, P103; Buxbaum JN, 2003, TRENDS BIOCHEM SCI, V28, P585, DOI 10.1016/j.tibs.2003.09.009; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Chen SM, 2002, BIOCHEMISTRY-US, V41, P7391, DOI 10.1021/bi011772q; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Colby DW, 2004, J MOL BIOL, V342, P901, DOI 10.1016/j.jmb.2004.07.054; Colby DW, 2004, P NATL ACAD SCI USA, V101, P17616, DOI 10.1073/pnas.0408134101; Crick SL, 2006, P NATL ACAD SCI USA, V103, P16764, DOI 10.1073/pnas.0608175103; Dahlgren PR, 2005, NANOMED-NANOTECHNOL, V1, P52, DOI 10.1016/j.nano.2004.11.004; Darnell G, 2007, J MOL BIOL, V374, P688, DOI 10.1016/j.jmb.2007.09.023; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Diaz-Hernandez M, 2004, J NEUROSCI, V24, P9361, DOI 10.1523/JNEUROSCI.2365-04.2004; Duennwald ML, 2006, P NATL ACAD SCI USA, V103, P11045, DOI 10.1073/pnas.0604547103; Duennwald ML, 2006, P NATL ACAD SCI USA, V103, P11051, DOI 10.1073/pnas.0604548103; Ehrnhoefer DE, 2006, HUM MOL GENET, V15, P2743, DOI 10.1093/hmg/ddl210; FRANKLIN EC, 1972, P SOC EXP BIOL MED, V140, P565; Ghoshal N, 2001, J NEUROCHEM, V77, P1372, DOI 10.1046/j.1471-4159.2001.00346.x; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; JACKSON GR, 2004, SOC NEUR ABSTR, V30; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Khoshnan A, 2002, P NATL ACAD SCI USA, V99, P1002, DOI 10.1073/pnas.022631799; Ko J, 2001, BRAIN RES BULL, V56, P319, DOI 10.1016/S0361-9230(01)00599-8; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lecerf JM, 2001, P NATL ACAD SCI USA, V98, P4764, DOI 10.1073/pnas.071058398; Li PW, 2007, NAT STRUCT MOL BIOL, V14, P381, DOI 10.1038/nsmb1234; LINKE RP, 1973, J IMMUNOL, V111, P10; Lunkes A, 1998, HUM MOL GENET, V7, P1355, DOI 10.1093/hmg/7.9.1355; McLear JA, 2008, FASEB J, V22, P2003, DOI 10.1096/fj.07-099689; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Nagai Y, 2007, NAT STRUCT MOL BIOL, V14, P332, DOI 10.1038/nsmb1215; Nekooki-Machida Y, 2009, P NATL ACAD SCI USA, V106, P9679, DOI 10.1073/pnas.0812083106; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; Paramithiotis E, 2003, NAT MED, V9, P893, DOI 10.1038/nm883; Peters-Libeu C, 2005, ACTA CRYSTALLOGR F, V61, P1065, DOI 10.1107/S1744309105036547; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Qin ZH, 2004, J NEUROSCI, V24, P269, DOI 10.1523/JNEUROSCI.1409-03.2004; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Soreghan B, 2002, NEUROMOL MED, V1, P81; Southwell AL, 2008, J NEUROSCI, V28, P9013, DOI 10.1523/JNEUROSCI.2747-08.2008; Tanaka M, 2001, J BIOL CHEM, V276, P45470, DOI 10.1074/jbc.M107502200; Tobin AJ, 2000, TRENDS CELL BIOL, V10, P531, DOI 10.1016/S0962-8924(00)01853-5; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; Vitalis A, 2008, J MOL BIOL, V384, P279, DOI 10.1016/j.jmb.2008.09.026; Vitalis A, 2007, BIOPHYS J, V93, P1923, DOI 10.1529/biophysj.107.110080; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860; Wang CE, 2008, J CELL BIOL, V181, P803, DOI 10.1083/jcb.200710158; Wang XL, 2006, PROTEINS, V63, P297, DOI 10.1002/prot.20761; Williamson RA, 1998, J VIROL, V72, P9413, DOI 10.1128/JVI.72.11.9413-9418.1998; Wolfgang WJ, 2005, P NATL ACAD SCI USA, V102, P11563, DOI 10.1073/pnas.0505321102; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; YANG AJ, 1995, J BIOL CHEM, V270, P14786, DOI 10.1074/jbc.270.24.14786; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	63	73	76	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	2009	284	32					21647	21658		10.1074/jbc.M109.016923	http://dx.doi.org/10.1074/jbc.M109.016923			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478CC	19491400	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000268564400058
J	Li, F; Xie, P; Fan, YN; Zhang, H; Zheng, LF; Gu, DF; Patterson, C; Li, HH				Li, Fang; Xie, Ping; Fan, Yongna; Zhang, Hua; Zheng, Lianfang; Gu, Dongfeng; Patterson, Cam; Li, Huihua			C Terminus of Hsc70-interacting Protein Promotes Smooth Muscle Cell Proliferation and Survival through Ubiquitin-mediated Degradation of FoxO1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; DEPENDENT CARDIAC-HYPERTROPHY; HEAT-SHOCK PROTEINS; NF-KAPPA-B; PROTEASOMAL DEGRADATION; NEOINTIMAL HYPERPLASIA; PHOSPHORYLATED TAU; INHIBITS APOPTOSIS; HUMAN HEPATOCYTES; CHIP	Forkhead transcription factors (FoxOs) play a pivotal role in controlling cellular proliferation and survival. The cellular level of these factors is tightly regulated through the phosphoinositide 3-kinase/Akt and ubiquitin-mediated degradation. However, the ubiquitin ligases responsible for the degradation of FoxO1 and the relevance of this regulation to smooth muscle cell (SMC) proliferation and survival have not been fully identified. Here we showed that overexpression of C terminus of Hsc70-interacting protein (CHIP) promoted ubiquitination and degradation of FoxO1 in SMCs in response to tumor necrosis factor-alpha. Both the U-box (containing ubiquitin ligase activity) and the charged (essential for FoxO1 binding) domains within CHIP were required for CHIP-mediated FoxO1 down-regulation. Moreover, interaction and ubiquitination of FoxO1 by CHIP depended on phosphorylation of FoxO1 at Ser-256. Furthermore, overexpression of CHIP repressed FoxO1-mediated transactivation and its proapoptotic function following tumor necrosis factor-alpha treatment. In contrast, knockdown of CHIP by small interfering RNA enhanced FoxO1-mediated transactivation and its effect on SMC proliferation and survival. Taken together, our data indicate that CHIP is a negative regulator of FoxO1 activity through ubiquitin-mediated degradation, and inhibition of CHIP may serve as a potential therapeutic target for reducing proliferative arterial diseases.	[Xie, Ping; Fan, Yongna; Zhang, Hua] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Pathol, Beijing 100005, Peoples R China; [Xie, Ping; Fan, Yongna; Zhang, Hua] Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; [Xie, Ping; Fan, Yongna; Zhang, Hua] Peking Union Med Coll, Beijing 100005, Peoples R China; [Li, Fang; Zheng, Lianfang; Li, Huihua] Peking Union Med Hosp, Dept Nucl Med, Beijing 100730, Peoples R China; [Gu, Dongfeng] Peking Union Med Coll, Beijing 100037, Peoples R China; [Gu, Dongfeng] Chinese Acad Med Sci, Fuwai Hosp, Beijing 100037, Peoples R China; [Gu, Dongfeng] Cardiovasc Inst, Div Populat Genet & Prevent, Beijing 100037, Peoples R China; [Patterson, Cam] Univ N Carolina, Div Cardiol & Carolina Cardiovasc Biol, Chapel Hill, NC 27599 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; University of North Carolina; University of North Carolina Chapel Hill	Li, HH (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Dept Pathol, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.	hhli1935@yahoo.cn			China Natural Science Foundation [2006CB910306, 2006CB503805, 30670860]; Ministry of Education of China [20060023051]	China Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China)	This work was supported by the China Natural Science Foundation (Grants 2006CB910306, 2006CB503805, and 30670860 to H. L.) and by The Ph. D. Programs Foundation of Ministry of Education of China (Grant 20060023051 to H. L.).	Abid MR, 2006, J BIOL CHEM, V281, P35544, DOI 10.1074/jbc.M608620200; Abid MR, 2005, J BIOL CHEM, V280, P29864, DOI 10.1074/jbc.M502149200; Al-Ramahi I, 2006, J BIOL CHEM, V281, P26714, DOI 10.1074/jbc.M601603200; Alberti S, 2004, MOL BIOL CELL, V15, P4003, DOI 10.1091/mbc.E04-04-0293; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Brenkman AB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002819; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Choi JY, 2007, MOL CELL NEUROSCI, V34, P69, DOI 10.1016/j.mcn.2006.10.002; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Dickey CA, 2007, J CLIN INVEST, V117, P648, DOI 10.1172/JCI29715; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Esser C, 2004, BBA-MOL CELL RES, V1695, P171, DOI 10.1016/j.bbamcr.2004.09.020; Galigniana MD, 2004, MOL BRAIN RES, V123, P27, DOI 10.1016/j.molbrainres.2003.12.015; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Hwang JR, 2005, CELL STRESS CHAPERON, V10, P147, DOI 10.1379/CSC-90R.1; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kosik KS, 2005, BBA-MOL BASIS DIS, V1739, P298, DOI 10.1016/j.bbadis.2004.10.011; Kumar A, 1997, CIRCULATION, V96, P4333; Lee HY, 2007, CIRC RES, V100, P372, DOI 10.1161/01.RES.0000257945.97958.77; Li HH, 2004, J CLIN INVEST, V114, P1058, DOI 10.1172/JCl200422220; Li HH, 2007, J CLIN INVEST, V117, P3211, DOI 10.1172/JCI31757; Liu ZP, 2005, DEV CELL, V9, P261, DOI 10.1016/j.devcel.2005.05.017; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Osawa Y, 2002, INFECT IMMUN, V70, P6294, DOI 10.1128/IAI.70.11.6294-6301.2002; Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173; Owens G, 2007, DIS MANAGE, V10, P74, DOI 10.1089/dis.2006.638; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Ozes ON, 1999, NATURE, V401, P82; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Park KW, 2005, ARTERIOSCL THROM VAS, V25, P742, DOI 10.1161/01.ATV.0000156288.70849.26; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Potente M, 2005, J CLIN INVEST, V115, P2382, DOI 10.1172/JCI23126; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Xie P, 2009, MOL CELL BIOL, V29, P2398, DOI 10.1128/MCB.01737-08; Zhang CL, 2005, AM J PHYSIOL-HEART C, V288, pH2836, DOI 10.1152/ajpheart.01122.2004	43	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20090	20098		10.1074/jbc.M109.017046	http://dx.doi.org/10.1074/jbc.M109.017046			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19483080	hybrid, Green Published			2022-12-25	WOS:000268097400036
J	Sengupta, S; George, M; Miller, KK; Naik, K; Chou, J; Cheatham, MA; Dallos, P; Naramura, M; Band, H; Zheng, J				Sengupta, Soma; George, Manju; Miller, Katharine K.; Naik, Khurram; Chou, Jonathan; Cheatham, Mary Ann; Dallos, Peter; Naramura, Mayumi; Band, Hamid; Zheng, Jing			EHD4 and CDH23 Are Interacting Partners in Cochlear Hair Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; EARLY ENDOSOMAL TRANSPORT; TIP-LINK; MAMMALIAN-CELLS; PLASMA-MEMBRANE; FAMILY PROTEINS; SENSORY CELLS; WALTZER MICE; CADHERIN-23; ENDOCYTOSIS	Cadherin 23 (CDH23), a transmembrane protein localized near the tips of hair cell stereocilia in the mammalian inner ear, is important for delivering mechanical signals to the mechanoelectric transducer channels. To identify CDH23-interacting proteins, a membrane-based yeast two-hybrid screen of an outer hair cell (OHC) cDNA library was performed. EHD4, a member of the C-terminal EH domain containing a protein family involved in endocytic recycling, was identified as a potential interactor. To confirm the interaction, we first demonstrated the EHD4 mRNA expression in hair cells using in situ hybridization. Next, we showed that EHD4 co-localizes and co-immunoprecipitates with CDH23 in mammalian cells. Interestingly, the co-immunoprecipitation was found to be calcium-sensitive. To investigate the role of EHD4 in hearing, compound action potentials were measured in EHD4 knockout (KO) mice. Although EHD4 KO mice have normal hearing sensitivity, analysis of mouse cochlear lysates revealed a 2-fold increase in EHD1, but no increase in EHD2 or EHD3, in EHD4 KO cochleae compared with wild type, suggesting that a compensatory increase in EHD1 levels may account for the absence of a hearing defect in EHD4 KO mice. Taken together, these data indicate that EHD4 is a novel CDH23-interacting protein that could regulate CDH23 trafficking/localization in a calcium-sensitive manner.	[Sengupta, Soma; Miller, Katharine K.; Naik, Khurram; Chou, Jonathan; Cheatham, Mary Ann; Dallos, Peter; Zheng, Jing] Northwestern Univ, Dept Commun Sci & Disorders, Hugh Knowles Ctr, Evanston, IL 60208 USA; [George, Manju; Naramura, Mayumi; Band, Hamid] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Coll Med, Omaha, NE 68198 USA; [Band, Hamid] Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Coll Med, Omaha, NE 68198 USA; [Band, Hamid] Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Coll Med, Omaha, NE 68198 USA	Northwestern University; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Zheng, J (corresponding author), Northwestern Univ, Dept Commun Sci & Disorders, Hugh Knowles Ctr, 2240 Campus Dr, Evanston, IL 60208 USA.	jzh215@northwestern.edu	Dallos, Peter/Q-9360-2019; Miller, Katharine K/O-6804-2015; Zheng, Jing/F-5273-2017	Dallos, Peter/0000-0002-9731-6591; Miller, Katharine K/0000-0002-0690-7426; Zheng, Jing/0000-0003-2790-1143; Naramura, Mayumi/0000-0003-3658-0767	National Institutes of Health [DC00089, DC006412, CA87986, CA105489, CA99900, CA116552, CA99163]; The Hugh Knowles Center Leadership Fund; NATIONAL CANCER INSTITUTE [R01CA116552, R01CA087986, R01CA099900, R01CA105489, R01CA099163] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000089, R01DC006412] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); The Hugh Knowles Center Leadership Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was supported, in whole or in part, by National Institutes of Health Grants DC00089 (to P. D.), DC006412 (to J. Z.), CA87986, CA105489, CA99900, CA116552, and CA99163 (to H. B.) and The Hugh Knowles Center Leadership Fund (to J. Z.).	Adato A, 2005, HUM MOL GENET, V14, P347, DOI 10.1093/hmg/ddi031; Beurg M, 2008, J NEUROSCI, V28, P1798, DOI 10.1523/JNEUROSCI.4653-07.2008; Beutner D, 2001, NEURON, V29, P681, DOI 10.1016/S0896-6273(01)00243-4; Blume JJ, 2007, EXP CELL RES, V313, P219, DOI 10.1016/j.yexcr.2006.10.006; Boeda B, 2002, EMBO J, V21, P6689, DOI 10.1093/emboj/cdf689; Caplan S, 2002, EMBO J, V21, P2557, DOI 10.1093/emboj/21.11.2557; Cheatham MA, 2004, J PHYSIOL-LONDON, V560, P821, DOI 10.1113/jphysiol.2004.069559; El-Amraoui A, 2005, J CELL SCI, V118, P4593, DOI 10.1242/jcs.02636; Fettiplace R, 2003, CURR OPIN NEUROBIOL, V13, P446, DOI 10.1016/S0959-4388(03)00094-1; Frolenkov GI, 2004, NAT REV GENET, V5, P489, DOI 10.1038/nrg1377; George M, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-3; Gokool S, 2007, TRAFFIC, V8, P1873, DOI 10.1111/j.1600-0854.2007.00652.x; Grant BD, 2008, TRAFFIC, V9, P2043, DOI 10.1111/j.1600-0854.2008.00834.x; Guilherme A, 2004, J BIOL CHEM, V279, P10593, DOI 10.1074/jbc.M307702200; Hackney CM, 2005, J NEUROSCI, V25, P7867, DOI 10.1523/JNEUROSCI.1196-05.2005; HOWARD J, 1987, P NATL ACAD SCI USA, V84, P3064, DOI 10.1073/pnas.84.9.3064; Judice TN, 2002, BRAIN RES PROTOC, V9, P65, DOI 10.1016/S1385-299X(01)00138-6; Kazmierczak P, 2007, NATURE, V449, P87, DOI 10.1038/nature06091; Kuo HJ, 2001, J BIOL CHEM, V276, P43103, DOI 10.1074/jbc.M106128200; Lagziel A, 2005, DEV BIOL, V280, P295, DOI 10.1016/j.ydbio.2005.01.015; Lee DW, 2005, J BIOL CHEM, V280, P17213, DOI 10.1074/jbc.M412751200; LeMasurier M, 2005, NEURON, V48, P403, DOI 10.1016/j.neuron.2005.10.017; Lin SX, 2001, NAT CELL BIOL, V3, P567, DOI 10.1038/35078543; Liu PT, 2003, GENOME RES, V13, P476, DOI 10.1101/gr.749203; Michel V, 2005, DEV BIOL, V280, P281, DOI 10.1016/j.ydbio.2005.01.014; Mintz L, 1999, GENOMICS, V59, P66, DOI 10.1006/geno.1999.5800; Naslavsky N, 2006, MOL BIOL CELL, V17, P163, DOI 10.1091/mbc.e05-05-0466; Naslavsky N, 2007, J BIOL CHEM, V282, P16612, DOI 10.1074/jbc.M609493200; Naslavsky N, 2007, BIOCHEM BIOPH RES CO, V357, P792, DOI 10.1016/j.bbrc.2007.04.022; Naslavsky N, 2009, J CELL SCI, V122, P389, DOI 10.1242/jcs.037051; Park SY, 2004, BIOCHEMISTRY-US, V43, P7552, DOI 10.1021/bi049970f; Petit C, 2006, TRENDS MOL MED, V12, P57, DOI 10.1016/j.molmed.2005.12.006; PICKLES JO, 1984, HEARING RES, V15, P103, DOI 10.1016/0378-5955(84)90041-8; Pohl U, 2000, GENOMICS, V63, P255, DOI 10.1006/geno.1999.6087; Rotem-Yehudar R, 2001, J BIOL CHEM, V276, P33054, DOI 10.1074/jbc.M009913200; Seiler C, 1999, J NEUROBIOL, V41, P424, DOI 10.1002/(SICI)1097-4695(19991115)41:3<424::AID-NEU10>3.0.CO;2-G; Shao YF, 2002, J CELL BIOL, V157, P679, DOI 10.1083/jcb.200201063; Sharma M, 2008, TRAFFIC, V9, P995, DOI 10.1111/j.1600-0854.2008.00732.x; Siemens J, 2004, NATURE, V428, P950, DOI 10.1038/nature02483; Siemens J, 2002, P NATL ACAD SCI USA, V99, P14946, DOI 10.1073/pnas.232579599; Smith CA, 2004, MOL BIOL CELL, V15, P3698, DOI 10.1091/mbc.E04-01-0026; Sollner C, 2004, NATURE, V428, P955, DOI 10.1038/nature02484; Stagljar I, 2002, TRENDS BIOCHEM SCI, V27, P559, DOI 10.1016/S0968-0004(02)02197-7; Vollrath MA, 2007, ANNU REV NEUROSCI, V30, P339, DOI 10.1146/annurev.neuro.29.051605.112917; Wilson SM, 2001, GENOMICS, V74, P228, DOI 10.1006/geno.2001.6554; Xu ZG, 2008, J NEUROSCI, V28, P11269, DOI 10.1523/JNEUROSCI.3833-08.2008; Zheng J, 2001, NEUROREPORT, V12, P1929, DOI 10.1097/00001756-200107030-00032; Zheng J, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-127	48	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20121	20129		10.1074/jbc.M109.025668	http://dx.doi.org/10.1074/jbc.M109.025668			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19487694	Green Published, hybrid			2022-12-25	WOS:000268097400039
J	Tanaka, R; Owaki, T; Kamiya, S; Matsunaga, T; Shimoda, K; Kodama, H; Hayashi, R; Abe, T; Harada, YP; Shimonaka, M; Yajima, H; Terada, H; Fukai, F				Tanaka, Rika; Owaki, Toshiyuki; Kamiya, Sadahiro; Matsunaga, Takuya; Shimoda, Kazuya; Kodama, Hiroaki; Hayashi, Ryo; Abe, Takashi; Harada, Yosei P.; Shimonaka, Motoyuki; Yajima, Hirofumi; Terada, Hiroshi; Fukai, Fumio			VLA-5-mediated Adhesion to Fibronectin Accelerates Hemin-stimulated Erythroid Differentiation of K562 Cells through Induction of VLA-4 Expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; P38 MAP KINASE; TENASCIN-C; EXTRACELLULAR-MATRIX; MEGAKARYOCYTIC DIFFERENTIATION; HEMATOPOIETIC MICROENVIRONMENT; DEPENDENT ERYTHROPOIESIS; ERYTHROLEUKEMIA-CELLS; ANTIADHESIVE SITE; BINDING-SITE	Fibronectin plays important roles in erythropoiesis through the fibronectin receptors VLA-4 and VLA-5. However, the substantial role of these fibronectin receptors and their functional assignment in erythroid differentiation are not yet fully understood. Here, we investigated the effects of cell adhesion to fibronectin on erythroid differentiation using K562 human erythroid progenitor cells. Erythroid differentiation could be induced in K562 cells in suspension by stimulating with hemin. This hemin-stimulated erythroid differentiation was highly accelerated when cells were induced to adhere to fibronectin by treatment with TNIIIA2, a peptide derived from tenascin-C, which has recently been found to induce beta 1-integrin activation. Another integrin activator, Mn2+, also accelerated hemin-stimulated erythroid differentiation. Adhesive interaction with fibronectin via VLA-4 as well as VLA-5 was responsible for acceleration of the hemin-stimulated erythroid differentiation in response to TNIIIA2, although K562 cells should have been lacking in VLA-4. Adhesion to fibronectin forced by TNIIIA2 causally induced VLA-4 expression in K562 cells, and this was blocked by the RGD peptide, an antagonist for VLA-5. The resulting adhesive interaction with fibronectin via VLA-4 strongly enhanced the hemin-stimulated activation of p38 mitogen-activated protein kinase, which was shown to serve as a signaling molecule crucial for erythroid differentiation. Suppression of VLA-4 expression by RNA interference abrogated acceleration of hemin-stimulated erythroid differentiation in response to TNIIIA2. Thus, VLA-4 and VLA-5 may contribute to erythropoiesis at different stages of erythroid differentiation.	[Fukai, Fumio] Tokyo Univ Sci, Dept Mol Pathophysiol, Fac Pharmaceut Sci, Noda, Chiba 2788510, Japan; [Owaki, Toshiyuki; Terada, Hiroshi; Fukai, Fumio] Tokyo Univ Sci, Ctr Drug Delivery Res, Noda, Chiba 2788510, Japan; [Abe, Takashi; Shimonaka, Motoyuki; Yajima, Hirofumi] Tokyo Univ Sci, Dept Appl Chem, Noda, Chiba 2788510, Japan; [Kamiya, Sadahiro] Josai Int Univ, Dept Clin Sci, Fac Pharmaceut Sci, Chiba 2838555, Japan; [Matsunaga, Takuya; Shimoda, Kazuya] Miyazaki Univ, Dept Gastroenterol & Hematol, Fac Med, Miyazaki 8891692, Japan; [Kodama, Hiroaki; Hayashi, Ryo] Saga Univ, Dept Biochem, Fac Sci & Engn, Saga 8490922, Japan	Tokyo University of Science; Tokyo University of Science; Tokyo University of Science; University of Miyazaki; Saga University	Fukai, F (corresponding author), Tokyo Univ Sci, Dept Mol Pathophysiol, Fac Pharmaceut Sci, 2641 Yamazaki, Noda, Chiba 2788510, Japan.	fukai@rs.noda.tus.ac.jp			MEXT (Ministry for Education, Culture, Sports, Science and Technology) of Japan; Vehicle Racing Commemorative Foundation	MEXT (Ministry for Education, Culture, Sports, Science and Technology) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Vehicle Racing Commemorative Foundation	This work was supported, in part, by the "High-Tech Research Center" Project for Private Universities with a matching fund subsidy from MEXT (Ministry for Education, Culture, Sports, Science and Technology) of Japan, 2004-2008, and by the Vehicle Racing Commemorative Foundation.	CHILOSI M, 1993, AM J PATHOL, V143, P1348; CLARK BR, 1992, BAILLIERE CLIN HAEM, V5, P619, DOI 10.1016/S0950-3536(11)80010-7; COULOMBEL L, 1988, BLOOD, V71, P329; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; DAVIS GE, 1993, J IMMUNOL, V151, P7138; Di Pietro R, 2007, J CELL BIOCHEM, V100, P1070, DOI 10.1002/jcb.21106; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; Eshghi S, 2007, J CELL BIOL, V177, P871, DOI 10.1083/jcb.200702080; Fischer D, 1997, J CELL SCI, V110, P1513; Fukai F, 1996, BIOCHEM BIOPH RES CO, V220, P394, DOI 10.1006/bbrc.1996.0416; Fukai F, 1997, J BIOCHEM-TOKYO, V121, P189; Hamamura K, 1996, BLOOD, V87, P2513, DOI 10.1182/blood.V87.6.2513.bloodjournal8762513; Janowska-Wieczorek A, 1999, BLOOD, V93, P3379, DOI 10.1182/blood.V93.10.3379.410k09_3379_3390; Kamiya SL, 2002, BIOCHEMISTRY-US, V41, P3270, DOI 10.1021/bi015660a; Kapur R, 2001, BLOOD, V97, P1975, DOI 10.1182/blood.V97.7.1975; KLEIN G, 1993, J CELL BIOL, V123, P1027, DOI 10.1083/jcb.123.4.1027; MINEGISHI N, 1994, J BIOL CHEM, V269, P27700; Murti KG, 1996, EXP CELL RES, V226, P47, DOI 10.1006/excr.1996.0201; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Ni HY, 1998, J BIOL CHEM, V273, P7981, DOI 10.1074/jbc.273.14.7981; OCKLIND G, 1993, J HISTOCHEM CYTOCHEM, V41, P1163, DOI 10.1177/41.8.7687262; Ohta M, 1998, BLOOD, V91, P4074; Papayannopoulou T, 1998, BLOOD, V91, P2231, DOI 10.1182/blood.V91.7.2231.2231_2231_2239; Park JI, 2001, CELL GROWTH DIFFER, V12, P481; PATEL VP, 1987, J CELL BIOL, V105, P3105, DOI 10.1083/jcb.105.6.3105; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; Saito Y, 2008, BIOL PHARM BULL, V31, P1003, DOI 10.1248/bpb.31.1003; Saito Y, 2007, J BIOL CHEM, V282, P34929, DOI 10.1074/jbc.M705608200; Seki M, 2006, EXP HEMATOL, V34, P519, DOI 10.1016/j.exphem.2006.01.001; StetlerStevenson WG, 1996, AM J PATHOL, V148, P1345; Tada T, 2006, ANAT HISTOL EMBRYOL, V35, P235, DOI 10.1111/j.1439-0264.2005.00671.x; Takagi J, 1997, J BIOCHEM, V121, P914; van der Loo JCM, 1998, J CLIN INVEST, V102, P1051, DOI 10.1172/JCI3687; VU TH, 1998, GELATINASE B, P115; VUILLETGAUGLER MH, 1990, BLOOD, V75, P865; Watanabe K, 2000, BIOCHEMISTRY-US, V39, P7138, DOI 10.1021/bi992670r; WEINSTEIN R, 1989, BLOOD, V73, P111; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0; WILLIAMS DA, 1994, PEDIATR RES, V36, P557, DOI 10.1203/00006450-199411000-00001; Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779; Witt O, 2000, BLOOD, V95, P2391, DOI 10.1182/blood.V95.7.2391.007k21_2391_2396; YANAI N, 1994, BLOOD, V83, P2844, DOI 10.1182/blood.V83.10.2844.2844; ZUTTER MM, 1992, J BIOL CHEM, V267, P20233; Zutter MM, 1999, BLOOD, V93, P1600, DOI 10.1182/blood.V93.5.1600.405k04_1600_1611	46	21	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					19817	19825		10.1074/jbc.M109.009860	http://dx.doi.org/10.1074/jbc.M109.009860			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19460753	Green Published, hybrid			2022-12-25	WOS:000268097400008
J	Volpato, JP; Yachnin, BJ; Blanchet, J; Guerrero, V; Poulin, L; Fossati, E; Berghuis, AM; Pelletier, JN				Volpato, Jordan P.; Yachnin, Brahm J.; Blanchet, Jonathan; Guerrero, Vanessa; Poulin, Lucie; Fossati, Elena; Berghuis, Albert M.; Pelletier, Joelle N.			Multiple Conformers in Active Site of Human Dihydrofolate Reductase F31R/Q35E Double Mutant Suggest Structural Basis for Methotrexate Resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY CRYSTAL COMPLEXES; PNEUMOCYSTIS-CARINII; INHIBITOR BINDING; VARIANTS; ENZYME; NADPH; SUBSTITUTIONS; MUTATIONS; SELECTION; FOLATE	Methotrexate is a slow, tight-binding, competitive inhibitor of human dihydrofolate reductase (hDHFR), an enzyme that provides key metabolites for nucleotide biosynthesis. In an effort to better characterize ligand binding in drug resistance, we have previously engineered hDHFR variant F31R/Q35E. This variant displays a > 650-fold decrease in methotrexate affinity, while maintaining catalytic activity comparable to the native enzyme. To elucidate the molecular basis of decreased methotrexate affinity in the doubly substituted variant, we determined kinetic and inhibitory parameters for the simple variants F31R and Q35E. This demonstrated that the important decrease of methotrexate affinity in variant F31R/Q35E is a result of synergistic effects of the combined substitutions. To better understand the structural cause of this synergy, we obtained the crystal structure of hDHFR variant F31R/Q35E complexed with methotrexate at 1.7-angstrom resolution. The mutated residue Arg-31 was observed in multiple conformers. In addition, seven native active-site residues were observed in more than one conformation, which is not characteristic of the wild-type enzyme. This suggests that increased residue disorder underlies the observed methotrexate resistance. We observe a considerable loss of van der Waals and polar contacts with the p-aminobenzoic acid and glutamate moieties. The multiple conformers of Arg-31 further suggest that the amino acid substitutions may decrease the isomerization step required for tight binding of methotrexate. Molecular docking with folate corroborates this hypothesis.	[Blanchet, Jonathan; Guerrero, Vanessa; Poulin, Lucie; Pelletier, Joelle N.] Univ Montreal, Dept Chim, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada; [Volpato, Jordan P.; Fossati, Elena; Pelletier, Joelle N.] Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; [Yachnin, Brahm J.; Berghuis, Albert M.] McGill Univ, Dept Biochem, Montreal, PQ H3G 0B1, Canada; [Berghuis, Albert M.] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3G 0B1, Canada	Universite de Montreal; Universite de Montreal; McGill University; McGill University	Pelletier, JN (corresponding author), Univ Montreal, Dept Chim, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	joelle.pelletier@umontreal.ca	Yachnin, Brahm/AAP-3910-2021; Berghuis, Albert M/A-6495-2008	Yachnin, Brahm/0000-0001-6812-6329; Berghuis, Albert/0000-0002-2663-025X	Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada (NSERC)	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC))	This work was supported by grants from the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada (NSERC).	Allay JA, 1998, NAT MED, V4, P1136, DOI 10.1038/2632; APPLEMAN JR, 1988, J BIOL CHEM, V263, P10304; Blakley RL, 1998, HUM MUTAT, V11, P259, DOI 10.1002/(SICI)1098-1004(1998)11:4<259::AID-HUMU1>3.3.CO;2-N; CHUNDURU SK, 1994, J BIOL CHEM, V269, P9547; Cody V, 2005, ACTA CRYSTALLOGR D, V61, P147, DOI 10.1107/S0907444904030422; Cody V, 2004, ACTA CRYSTALLOGR D, V60, P646, DOI 10.1107/S0907444904002094; Cody V, 2003, ACTA CRYSTALLOGR D, V59, P654, DOI 10.1107/S0907444903001951; Cody V, 2003, ACTA CRYSTALLOGR D, V59, P1603, DOI 10.1107/S0907444903014963; Cody V, 1998, ANTI-CANCER DRUG DES, V13, P307; Cody V, 1997, BIOCHEMISTRY-US, V36, P13897, DOI 10.1021/bi971711l; Cody V, 2006, PROTEINS, V65, P959, DOI 10.1002/prot.21131; DAVIES JF, 1990, BIOCHEMISTRY-US, V29, P9467, DOI 10.1021/bi00492a021; Daw NC, 2006, CANCER-AM CANCER SOC, V106, P403, DOI 10.1002/cncr.21626; DOUCET N, 2009, PROTEIN ENG HDB, P187; Doucet N, 2007, J BIOL CHEM, V282, P21448, DOI 10.1074/jbc.M609777200; Eisenmesser EZ, 2005, NATURE, V438, P117, DOI 10.1038/nature04105; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ErcikanAbali EA, 1996, CANCER RES, V56, P4142; ErcikanAbali EA, 1996, MOL PHARMACOL, V49, P430; FERNANDEZPATRON C, 1992, BIOTECHNIQUES, V12, P564; FLASSHOVE M, 1995, BLOOD, V85, P566; Flintoff WF, 2004, BBA-MOL BASIS DIS, V1690, P110, DOI 10.1016/j.bbadis.2004.05.008; Fossati E, 2008, J BIOMOL SCREEN, V13, P504, DOI 10.1177/1087057108318783; Gangjee A, 1998, J MED CHEM, V41, P3426, DOI 10.1021/jm980081y; Klon AE, 2002, J MOL BIOL, V320, P677, DOI 10.1016/S0022-2836(02)00469-2; LEWIS WS, 1995, J BIOL CHEM, V270, P5057, DOI 10.1074/jbc.270.10.5057; MCTIGUE MA, 1992, BIOCHEMISTRY-US, V31, P7264, DOI 10.1021/bi00147a009; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAKANO T, 1994, BIOCHEMISTRY-US, V33, P9945, DOI 10.1021/bi00199a017; Nobeli I, 2009, NAT BIOTECHNOL, V27, P157, DOI 10.1038/nbt1519; OEFNER C, 1988, EUR J BIOCHEM, V174, P377, DOI 10.1111/j.1432-1033.1988.tb14108.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patel M, 1997, HUM GENE THER, V8, P2069, DOI 10.1089/hum.1997.8.17-2069; Ramanan AV, 2003, ARCH DIS CHILD, V88, P197, DOI 10.1136/adc.88.3.197; Segel I. H., 1993, ENZYME KINETICS BEHA, P100; SLAMON DJ, 2006, CLIN ADV HEMATOL S1, V4, P4; Spencer HT, 1996, LEUKEMIA, V10, P439; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Strojan P, 2005, J SURG ONCOL, V92, P278, DOI 10.1002/jso.20422; Takemura Y, 1999, ANTI-CANCER DRUG, V10, P677, DOI 10.1097/00001813-199908000-00008; Teague SJ, 2003, NAT REV DRUG DISCOV, V2, P527, DOI 10.1038/nrd1129; THOMPSON PD, 1991, BIOCHEMISTRY-US, V30, P8124, DOI 10.1021/bi00247a005; Volpato JP, 2007, J MOL BIOL, V373, P599, DOI 10.1016/j.jmb.2007.07.076; Volpato JP, 2009, DRUG RESIST UPDATE, V12, P28, DOI 10.1016/j.drup.2009.02.001; Watt ED, 2007, P NATL ACAD SCI USA, V104, P11981, DOI 10.1073/pnas.0702551104	45	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20079	20089		10.1074/jbc.M109.018010	http://dx.doi.org/10.1074/jbc.M109.018010			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19478082	Green Published, hybrid			2022-12-25	WOS:000268097400035
J	Wu, Y; Fishkin, NE; Pande, A; Pande, J; Sparrow, JR				Wu, Yalin; Fishkin, Nathan E.; Pande, Ajay; Pande, Jayanti; Sparrow, Janet R.			Novel Lipofuscin Bisretinoids Prominent in Human Retina and in a Model of Recessive Stargardt Disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGE PIGMENT A2-E; MACULAR DEGENERATION; MOUSE MODEL; EPITHELIAL-CELLS; RPE LIPOFUSCIN; OUTER SEGMENTS; VISUAL CYCLE; A2E; FLUOROPHORE; ABCR	Bisretinoid adducts accumulate as lipofuscin in retinal pigment epithelial (RPE) cells of the eye and are implicated in the pathology of inherited and age-related macular degeneration. Characterization of the bisretinoids A2E and the all-trans-retinal dimer series has shown that these pigments form from reactions in photoreceptor cell outer segments that involve all-trans-retinal, the product of photoisomerization of the visual chromophore 11-cis-retinal. Here we have identified two related but previously unknown RPE lipofuscin compounds. By high performance liquid chromatography-electrospray ionization-tandem mass spectrometry, we determined that the first of these compounds is a phosphatidyl-dihydropyridine bisretinoid; to indicate this structure and its formation from two vitamin A-aldehyde (A2), we will refer to it as A2-dihydropyridine-phosphatidylethanolamine (A2-DHP-PE). The second pigment, A2-dihydropyridine-ethanolamine, forms from phosphate hydrolysis of A2-DHP-PE. The structure of A2-DHP-PE was corroborated by Fourier transform infrared spectroscopy, and density functional theory confirmed the presence of a dihydropyridine ring. This lipofuscin pigment is a fluorescent compound with absorbance maxima at similar to 490 and 330 nm, and it was identified in human, mouse, and bovine eyes. We found that A2-DHP-PE forms in reaction mixtures of all-trans-retinal and phosphatidylethanolamine, and in mouse eyecups we observed an age-related accumulation. As compared with wild-type mice, A2-DHP-PE is more abundant in mice with a null mutation in Abca4 (ATP-binding cassette transporter 4), the gene causative for recessive Stargardt macular degeneration. Efforts to clarify the composition of RPE lipofuscin are important because these compounds are targets of gene-based and drug therapies that aim to alleviate ABCA4-related retinal disease.	[Wu, Yalin; Sparrow, Janet R.] Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA; [Sparrow, Janet R.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Fishkin, Nathan E.] ImmunoGen Inc, Waltham, MA 02451 USA; [Pande, Ajay; Pande, Jayanti] SUNY Albany, Dept Chem, Albany, NY 12222 USA	Columbia University; Columbia University; ImmunoGen, Inc.; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Sparrow, JR (corresponding author), 630 W 168th St, New York, NY 10032 USA.	jrs88@columbia.edu			National Institutes of Health [EY 12951, EY 10535]; Kaplen Foundation; Department of Ophthalmology, Columbia University; NATIONAL EYE INSTITUTE [R01EY010535, R01EY012951] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Kaplen Foundation; Department of Ophthalmology, Columbia University; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported, in whole or in part, by National Institutes of Health Grants EY 12951 (to J. R. S.) and EY 10535 (to J. P.). This work was also supported by funds from the Kaplen Foundation (to J. R. S.) and unrestricted funds from Research to Prevent Blindness (to the Department of Ophthalmology, Columbia University).	Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allocca M, 2008, J CLIN INVEST, V118, P1955, DOI 10.1172/JCI34316; Beharry S, 2004, J BIOL CHEM, V279, P53972, DOI 10.1074/jbc.M405216200; Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2; Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200; BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211; BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664; Bravaya K, 2007, J AM CHEM SOC, V129, P13035, DOI 10.1021/ja0732126; BUNTMILAM AH, 1983, INVEST OPHTH VIS SCI, V24, P458; Chalupa L.M., 2008, EYE RETINA VISUAL SY, P539; DALVIE D, 1992, J ORG CHEM, V57, P7321, DOI 10.1021/jo00052a056; Dillon J, 2004, EXP EYE RES, V79, P537, DOI 10.1016/j.exer.2004.06.024; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; Fishkin N, 2004, CHIRALITY, V16, P637, DOI 10.1002/chir.20084; Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102; Jang YP, 2005, J BIOL CHEM, V280, P39732, DOI 10.1074/jbc.M504933200; KATZ ML, 1986, MECH AGEING DEV, V35, P291, DOI 10.1016/0047-6374(86)90131-4; Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023; KATZ ML, 1987, MECH AGEING DEV, V39, P81, DOI 10.1016/0047-6374(87)90088-1; Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104; Kim SR, 2007, BIOCHEMISTRY-US, V46, P10122, DOI 10.1021/bi7009635; Kim SR, 2004, P NATL ACAD SCI USA, V101, P11668, DOI 10.1073/pnas.0403499101; Kong J, 2008, GENE THER, V15, P1311, DOI 10.1038/gt.2008.78; Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199; Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200; Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; ONERUS TA, 1978, CAN J CHEM, V56, P1026; Pang JJ, 2005, MOL VIS, V11, P152; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820; Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100; Ren RXF, 1997, J AM CHEM SOC, V119, P3619, DOI 10.1021/ja9700414; Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g; Schroer J, 1997, J ORG CHEM, V62, P3220, DOI 10.1021/jo962179v; Sieving PA, 2001, P NATL ACAD SCI USA, V98, P1835, DOI 10.1073/pnas.041606498; Sparrow J., 2007, ATLAS AUTOFLUORESCEN, P1; Sparrow JR, 2008, ADV EXP MED BIOL, V613, P393, DOI 10.1007/978-0-387-74904-4_46; Sparrow JR, 2006, ADV EXP MED BIOL, V572, P63; Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; SZAMIER RB, 1977, INVEST OPHTH VIS SCI, V16, P947; TAYLOR KE, 1976, J AM CHEM SOC, V98, P5689, DOI 10.1021/ja00434a047; Tombran-Tink J, 2007, RETINAL DEGENERATION, P213; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9	46	82	92	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20155	20166		10.1074/jbc.M109.021345	http://dx.doi.org/10.1074/jbc.M109.021345			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19478335	hybrid, Green Published			2022-12-25	WOS:000268097400043
J	Ghosh, A; Kuppusamy, H; Pilarski, LM				Ghosh, Anirban; Kuppusamy, Hemalatha; Pilarski, Linda M.			Aberrant Splice Variants of HAS1 (Hyaluronan Synthase 1) Multimerize with and Modulate Normally Spliced HAS1 Protein A POTENTIAL MECHANISM PROMOTING HUMAN CANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN D1; STREPTOCOCCUS-PYOGENES; MUTATIONAL SPECTRUM; MULTIPLE-MYELOMA; MATRIX RETENTION; CARCINOMA-CELLS; MSH2 MISSENSE; EXPRESSION; GENE; BREAST	Most human genes undergo alternative splicing, but aberrant splice forms are hallmarks of many cancers, usually resulting from mutations initiating abnormal exon skipping, intron retention, or the introduction of a new splice sites. We have identified a family of aberrant splice variants of HAS1 (the hyaluronan synthase 1 gene) in some B lineage cancers, characterized by exon skipping and/or partial intron retention events that occur either together or independently in different variants, apparently due to accumulation of inherited and acquired mutations. Cellular, biochemical, and oncogenic properties of full-length HAS1 (HAS1-FL) and HAS1 splice variants Va, Vb, and Vc (HAS1-Vs) are compared and characterized. When co-expressed, the properties of HAS1-Vs are dominant over those of HAS1-FL. HAS1-FL appears to be diffusely expressed in the cell, but HAS1-Vs are concentrated in the cytoplasm and/or Golgi apparatus. HAS1-Vs synthesize detectable de novo HA intracellularly. Each of the HAS1-Vs is able to relocalize HAS1-FL protein from diffuse cytoskeleton-anchored locations to deeper cytoplasmic spaces. This HAS1-Vs-mediated relocalization occurs through strong molecular interactions, which also serve to protect HAS1-FL from its otherwise high turnover kinetics. In co-transfected cells, HAS1-FL and HAS1-Vs interact with themselves and with each other to form heteromeric multiprotein assemblies. HAS1-Vc was found to be transforming in vitro and tumorigenic in vivo when introduced as a single oncogene to untransformed cells. The altered distribution and half-life of HAS1-FL, coupled with the characteristics of the HAS1-Vs suggest possible mechanisms whereby the aberrant splicing observed in human cancer may contribute to oncogenesis and disease progression.	[Pilarski, Linda M.] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 1Z2, Canada	University of Alberta; University of Alberta	Pilarski, LM (corresponding author), Cross Canc Inst, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	lpilarsk@ualberta.ca			Alberta Cancer Research Institute and the Canadian Institutes of Health Research	Alberta Cancer Research Institute and the Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by grants from the Alberta Cancer Research Institute and the Canadian Institutes of Health Research.	Adamia S, 2007, HAEMATOL-HEMATOL J, V92, P104; Adamia S, 2004, BLOOD, V104, p383A; Adamia S, 2005, BLOOD, V105, P4836, DOI 10.1182/blood-2004-10-3825; Adamia S, 2003, SEMIN ONCOL, V30, P165, DOI 10.1053/sonc.2003.50042; Adamia Sophia, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P3, DOI 10.2174/1568006053005056; Adamia S, 2008, BLOOD, V112, P5111, DOI 10.1182/blood-2008-02-141770; Agrawal S, 2005, HUM MOL GENET, V14, P2459, DOI 10.1093/hmg/ddi246; Anttila MA, 2000, CANCER RES, V60, P150; Auclair J, 2006, HUM MUTAT, V27, P145, DOI 10.1002/humu.20280; Auvinen P, 2000, AM J PATHOL, V156, P529, DOI 10.1016/S0002-9440(10)64757-8; Auvinen PK, 1997, INT J CANCER, V74, P477, DOI 10.1002/(SICI)1097-0215(19971021)74:5<477::AID-IJC1>3.3.CO;2-X; BANSAL MK, 1986, BIOCHEM J, V236, P515, DOI 10.1042/bj2360515; Ben-Dov C, 2008, J BIOL CHEM, V283, P1229, DOI 10.1074/jbc.R700033200; Bullard KM, 2003, INT J CANCER, V107, P739, DOI 10.1002/ijc.11475; Buratti E, 2006, NUCLEIC ACIDS RES, V34, P3494, DOI 10.1093/nar/gkl498; Burd CJ, 2006, P NATL ACAD SCI USA, V103, P2190, DOI 10.1073/pnas.0506281103; Colgin L M, 1999, Hum Mutat, V14, P92, DOI 10.1002/(SICI)1098-1004(1999)14:1<92::AID-HUMU24>3.0.CO;2-#; Durocher F, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-230; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Golshani R, 2007, INT J CANCER, V120, P1712, DOI 10.1002/ijc.22222; Gordon LB, 2003, HUM GENET, V113, P178, DOI 10.1007/s00439-003-0958-9; Heldermon CD, 2001, GLYCOBIOLOGY, V11, P1017, DOI 10.1093/glycob/11.12.1017; Ichikawa T, 1999, J INVEST DERMATOL, V113, P935, DOI 10.1046/j.1523-1747.1999.00804.x; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 2004, J BIOL CHEM, V279, P18679, DOI 10.1074/jbc.M313178200; Itano N, 1999, CANCER RES, V59, P2499; Kalnina Z, 2005, GENE CHROMOSOME CANC, V42, P342, DOI 10.1002/gcc.20156; Kanomata N, 2005, VIRCHOWS ARCH, V446, P246, DOI 10.1007/s00428-004-1197-8; Knudsen KE, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-15; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Kosaki R, 1999, CANCER RES, V59, P1141; Kultti A, 2006, J BIOL CHEM, V281, P15821, DOI 10.1074/jbc.M512840200; Kyossev Z, 2007, ANAL BIOCHEM, V371, P62, DOI 10.1016/j.ab.2007.08.025; Lastella P, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-243; LAURENT UBG, 1991, EXP PHYSIOL, V76, P695, DOI 10.1113/expphysiol.1991.sp003536; Lee JW, 2006, APMIS, V114, P646, DOI 10.1111/j.1600-0463.2006.apm_417.x; Liu NF, 2001, CANCER RES, V61, P5207; Lu FM, 2003, CANCER RES, V63, P7056; Ludes-Meyers JH, 2003, CYTOGENET GENOME RES, V100, P101, DOI 10.1159/000072844; Maxwell CA, 2004, BLOOD, V104, P1151, DOI 10.1182/blood-2003-11-4079; Maxwell CA, 2005, CANCER RES, V65, P850; Maxwell CA, 2003, MOL BIOL CELL, V14, P2262, DOI 10.1091/mbc.e02-07-0377; MIAN N, 1986, BIOCHEM J, V237, P333, DOI 10.1042/bj2370333; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; Moon SD, 2005, J CLIN ENDOCR METAB, V90, P878, DOI 10.1210/jc.2004-0991; Nascimento M, 2006, J BIOL CHEM, V281, P36257, DOI 10.1074/jbc.M606256200; NG CK, 1989, BIOCHEM J, V263, P761, DOI 10.1042/bj2630761; Nichols KE, 2005, HUM MUTAT, V25, P566, DOI 10.1002/humu.20184; Pagenstecher C, 2006, HUM GENET, V119, P9, DOI 10.1007/s00439-005-0107-8; Pilarski LM, 1999, BLOOD, V93, P2918; PILARSKI LM, 2005, HYALURONAN STRUCTURE, P329; Pros E, 2006, HUM MUTAT, V27, P1104, DOI 10.1002/humu.20396; Rilla K, 2005, J BIOL CHEM, V280, P31890, DOI 10.1074/jbc.M504736200; Schaffner C, 1999, BLOOD, V94, P748, DOI 10.1182/blood.V94.2.748.414k02_748_753; Serra E, 2001, HUM GENET, V108, P416; Setala LP, 1999, BRIT J CANCER, V79, P1133, DOI 10.1038/sj.bjc.6690180; Sharp Andrew, 2004, Hum Mutat, V24, P272, DOI 10.1002/humu.9267; Simpson MA, 2002, AM J PATHOL, V161, P849, DOI 10.1016/S0002-9440(10)64245-9; Simpson MA, 2002, J BIOL CHEM, V277, P10050, DOI 10.1074/jbc.M110069200; Simpson MA, 2001, J BIOL CHEM, V276, P17949, DOI 10.1074/jbc.M010064200; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Spicer AP, 1997, GENOMICS, V41, P493, DOI 10.1006/geno.1997.4696; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Staalesen V, 2004, ONCOGENE, V23, P8535, DOI 10.1038/sj.onc.1207928; Stewart D, 2005, J VIROL, V79, P8773, DOI 10.1128/JVI.79.14.8773-8783.2005; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4239, DOI 10.1074/jbc.274.7.4239; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; Upadhyaya M, 2004, HUM MUTAT, V23, P134, DOI 10.1002/humu.10305; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Venables JP, 2006, BIOESSAYS, V28, P378, DOI 10.1002/bies.20390; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Yabushita H, 2005, ONCOL REP, V13, P1101; Yabushita H, 2004, ONCOL REP, V12, P739; Yamada Y, 2004, CLIN EXP METASTAS, V21, P57, DOI 10.1023/B:CLIN.0000017203.71293.e0	79	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	2009	284	28					18840	18850		10.1074/jbc.M109.013813	http://dx.doi.org/10.1074/jbc.M109.013813			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	467BP	19451652	Green Published, hybrid			2022-12-25	WOS:000267711500034
J	Simeonov, A; Kulkarni, A; Dorjsuren, D; Jadhav, A; Shen, M; McNeill, DR; Austin, CP; Wilson, DM				Simeonov, Anton; Kulkarni, Avanti; Dorjsuren, Dorjbal; Jadhav, Ajit; Shen, Min; McNeill, Daniel R.; Austin, Christopher P.; Wilson, David M., III			Identification and Characterization of Inhibitors of Human Apurinic/apyrimidinic Endonuclease APE1	PLOS ONE			English	Article								APE1 is the major nuclease for excising abasic (AP) sites and particular 3'-obstructive termini from DNA, and is an integral participant in the base excision repair (BER) pathway. BER capacity plays a prominent role in dictating responsiveness to agents that generate oxidative or alkylation DNA damage, as well as certain chain-terminating nucleoside analogs and 5-fluorouracil. We describe within the development of a robust, 1536-well automated screening assay that employs a deoxyoligonucleotide substrate operating in the red-shifted fluorescence spectral region to identify APE1 endonuclease inhibitors. This AP site incision assay was used in a titration-based high-throughput screen of the Library of Pharmacologically Active Compounds (LOPAC(1280)), a collection of well-characterized, drug-like molecules representing all major target classes. Prioritized hits were authenticated and characterized via two high-throughput screening assays - a Thiazole Orange fluorophore-DNA displacement test and an E. coli endonuclease IV counterscreen - and a conventional, gel-based radiotracer incision assay. The top, validated compounds, i.e. 6-hydroxy-DL-DOPA, Reactive Blue 2 and myricetin, were shown to inhibit AP site cleavage activity of whole cell protein extracts from HEK 293T and HeLa cell lines, and to enhance the cytotoxic and genotoxic potency of the alkylating agent methylmethane sulfonate. The studies herein report on the identification of novel, small molecule APE1-targeted bioactive inhibitor probes, which represent initial chemotypes towards the development of potential pharmaceuticals.			Simeonov, A (corresponding author), NHGRI, NIH, Chem Genom Ctr, Bethesda, MD 20892 USA.	wilsonda@mail.nih.gov	Wilson, David M/AAK-5409-2021	Wilson, David M/0000-0002-8945-0395; Jadhav, Ajit/0000-0001-7955-1451	Intramural NIH HHS Funding Source: Medline; NIMH NIH HHS [1 R03 MH086444] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG200319] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000750] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812; BAPAT A, 2009, GOING APE APPROACH C; BENCHOKROUN Y, 1995, BIOCHEM PHARMACOL, V49, P305, DOI 10.1016/0006-2952(94)00465-X; Berquist BR, 2008, J MOL BIOL, V379, P17, DOI 10.1016/j.jmb.2008.03.053; BINASTEIN M, 1976, MOL PHARMACOL, V12, P191; BO XN, 1994, BRIT J PHARMACOL, V112, P1151, DOI 10.1111/j.1476-5381.1994.tb13204.x; Brown J, 2002, VASC PHARMACOL, V39, P309, DOI 10.1016/S1537-1891(03)00030-2; BURTON SJ, 1988, J CHROMATOGR, V435, P127, DOI 10.1016/S0021-9673(01)82168-3; Case D.A., 2002, AMBER, V7; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; DAS M, 1987, CANCER RES, V47, P767; Demple B, 2005, DNA REPAIR, V4, P1442, DOI 10.1016/j.dnarep.2005.09.004; DEWOLFF FA, 1995, BRIT MED J, V310, P1216, DOI 10.1136/bmj.310.6989.1216; Eastwood BJ, 2006, J BIOMOL SCREEN, V11, P253, DOI 10.1177/1087057105285611; Erzberger JP, 1998, NUCLEIC ACIDS RES, V26, P2771, DOI 10.1093/nar/26.11.2771; Fishel ML, 2007, MOL ASPECTS MED, V28, P375, DOI 10.1016/j.mam.2007.04.005; Fung H, 2005, MOL CELL, V17, P463, DOI 10.1016/j.molcel.2004.12.029; GILBERTOGONZALEZ R, 1980, BIOCHEMISTRY-US, V19, P4299, DOI 10.1021/bi00559a023; Hakkinen SH, 1999, J AGR FOOD CHEM, V47, P2274, DOI 10.1021/jf9811065; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI [10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P, 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X]; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Horton JK, 2007, DNA REPAIR, V6, P530, DOI 10.1016/j.dnarep.2006.10.016; IMOTO M, 1993, J ANTIBIOT, V46, P1342, DOI 10.7164/antibiotics.46.1342; Inglese J, 2007, NAT CHEM BIOL, V3, P466, DOI 10.1038/nchembio.2007.17; Inglese J, 2006, P NATL ACAD SCI USA, V103, P11473, DOI 10.1073/pnas.0604348103; Izumi T, 2005, P NATL ACAD SCI USA, V102, P5739, DOI 10.1073/pnas.0500986102; JONSSON G, 1973, BIOCHEM PHARMACOL, V22, P1709, DOI 10.1016/0006-2952(73)90384-5; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; Lee KW, 2007, CARCINOGENESIS, V28, P1918, DOI 10.1093/carcin/bgm110; Lu J, 2006, CANCER RES, V66, P4410, DOI 10.1158/0008-5472.CAN-05-3310; Madhusudan S, 2005, NUCLEIC ACIDS RES, V33, P4711, DOI 10.1093/nar/gki781; McNeill DR, 2007, MOL CANCER RES, V5, P61, DOI 10.1158/1541-7786.MCR-06-0329; McNeill DR, 2004, ENVIRON HEALTH PERSP, V112, P799, DOI 10.1289/ehp.7038; Michael S, 2008, ASSAY DRUG DEV TECHN, V6, P637, DOI 10.1089/adt.2008.150; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Mol CD, 2000, MUTAT RES-DNA REPAIR, V460, P211, DOI 10.1016/S0921-8777(00)00028-8; Nakamura J, 1998, CANCER RES, V58, P222; Ong KC, 1997, GEN PHARMACOL-VASC S, V29, P121, DOI 10.1016/S0306-3623(96)00421-1; Paz-Elizur T, 2007, DNA REPAIR, V6, P45, DOI 10.1016/j.dnarep.2006.08.003; Perez-Ruiz T, 2001, ELECTROPHORESIS, V22, P134, DOI 10.1002/1522-2683(200101)22:1<134::AID-ELPS134>3.3.CO;2-O; Seiple LA, 2008, MOL PHARMACOL, V73, P669, DOI 10.1124/mol.107.042622; Simeonov A, 2008, J MED CHEM, V51, P2363, DOI 10.1021/jm701301m; Sokhansanj BA, 2002, NUCLEIC ACIDS RES, V30, P1817, DOI 10.1093/nar/30.8.1817; Tse WC, 2004, ACCOUNTS CHEM RES, V37, P61, DOI 10.1021/ar030113y; UYETA M, 1981, MUTAT RES, V88, P233, DOI 10.1016/0165-1218(81)90035-5; Wilson DM, 2007, DNA REPAIR, V6, P544, DOI 10.1016/j.dnarep.2006.10.017; Wilson DM, 2001, MUTAT RES-DNA REPAIR, V485, P283, DOI 10.1016/S0921-8777(01)00063-5; Wilson DM, 2005, J MOL BIOL, V345, P1003, DOI 10.1016/j.jmb.2004.11.028; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wyatt MD, 2009, CELL MOL LIFE SCI, V66, P788, DOI 10.1007/s00018-008-8557-5; Wyatt MD, 2006, CHEM RES TOXICOL, V19, P1580, DOI 10.1021/tx060164e; Yasgar Adam, 2008, JALA Charlottesv Va, V13, P79, DOI 10.1016/j.jala.2007.12.004; Zaremba T, 2007, ANTI-CANCER AGENT ME, V7, P515, DOI 10.2174/187152007781668715; Zawahir Z, 2009, J MED CHEM, V52, P20, DOI 10.1021/jm800739m; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	55	83	90	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2009	4	6							e5740	10.1371/journal.pone.0005740	http://dx.doi.org/10.1371/journal.pone.0005740			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	452GL	19484131	Green Submitted, Green Published, gold			2022-12-25	WOS:000266528200002
J	Stephens, CR; Heau, JG; Gonzalez, C; Ibarra-Cerdena, CN; Sanchez-Cordero, V; Gonzalez-Salazar, C				Stephens, Christopher R.; Gimenez Heau, Joaquin; Gonzalez, Camila; Ibarra-Cerdena, Carlos N.; Sanchez-Cordero, Victor; Gonzalez-Salazar, Constantino			Using Biotic Interaction Networks for Prediction in Biodiversity and Emerging Diseases	PLOS ONE			English	Article								Networks offer a powerful tool for understanding and visualizing inter-species ecological and evolutionary interactions. Previously considered examples, such as trophic networks, are just representations of experimentally observed direct interactions. However, species interactions are so rich and complex it is not feasible to directly observe more than a small fraction. In this paper, using data mining techniques, we show how potential interactions can be inferred from geographic data, rather than by direct observation. An important application area for this methodology is that of emerging diseases, where, often, little is known about inter-species interactions, such as between vectors and reservoirs. Here, we show how using geographic data, biotic interaction networks that model statistical dependencies between species distributions can be used to infer and understand inter-species interactions. Furthermore, we show how such networks can be used to build prediction models. For example, for predicting the most important reservoirs of a disease, or the degree of disease risk associated with a geographical area. We illustrate the general methodology by considering an important emerging disease - Leishmaniasis. This data mining methodology allows for the use of geographic data to construct inferential biotic interaction networks which can then be used to build prediction models with a wide range of applications in ecology, biodiversity and emerging diseases.			Stephens, CR (corresponding author), Univ Nacl Autonoma Mexico, Ctr Ciencias Complejidad C3, Ciudad Mexico, Mexico City 04510, DF, Mexico.	stephens@nucleares.unam.mx	González, Camila/AAW-9144-2021; González-Salazar, Constantino/M-3913-2015	González-Salazar, Constantino/0000-0001-7347-714X; Ibarra-Cerdena, Carlos N./0000-0003-4980-4344; Gonzalez, Camila/0000-0001-8089-4056				[Anonymous], [No title captured]; BALASHOV YS, 1984, ANNU REV ENTOMOL, V29, P137, DOI 10.1146/annurev.en.29.010184.001033; BIAGI F, 1965, PRENSA MED MEX, V30, P276; Canto-Lara SB, 1999, MEM I OSWALDO CRUZ, V94, P305, DOI 10.1590/S0074-02761999000300005; Chaves LF, 2007, TRENDS PARASITOL, V23, P311, DOI 10.1016/j.pt.2007.05.003; Elith J, 2006, ECOGRAPHY, V29, P129, DOI 10.1111/j.2006.0906-7590.04596.x; *ER IV SOS BIB, 2004, DIAGN ID SUBG LEISHM; Graham CH, 2004, TRENDS ECOL EVOL, V19, P497, DOI 10.1016/j.tree.2004.07.006; Guevara-Chumacero L. M., 2001, Acta Zoologica Mexicana Nueva Serie, P35; Hall E.R., 1981, MAMMALS N AM, V2; Hall E. R., 1981, MAMMALS N AM, V1; Ibanez-Bernal S, 2004, MEM I OSWALDO CRUZ, V99, P127, DOI 10.1590/S0074-02762004000200002; KREBS CJ, 1995, SCIENCE, V269, P1112, DOI 10.1126/science.269.5227.1112; LIM BK, 2004, J BIODIV CONS, V11, P1237; Lomolino M. V., 2005, BIOGEOGRAPHY; LOSSOS J, 1996, ECOLOGY, V77, P1344; McCann K, 2007, NATURE, V446, P29, DOI 10.1038/446029a; Montoya JM, 2006, NATURE, V442, P259, DOI 10.1038/nature04927; Peterson AT, 2007, ECOGRAPHY, V30, P550, DOI 10.1111/j.2007.0906-7590.05102.x; Peterson AT, 2002, EMERG INFECT DIS, V8, P662, DOI 10.3201/eid0807.010454; Ponder WF, 2001, CONSERV BIOL, V15, P648, DOI 10.1046/j.1523-1739.2001.015003648.x; RebollarTellez EA, 1996, MEM I OSWALDO CRUZ, V91, P555, DOI 10.1590/S0074-02761996000500004; Soberon J, 2004, PHILOS T R SOC B, V359, P689, DOI 10.1098/rstb.2003.1439; Stockwell D, 1999, INT J GEOGR INF SCI, V13, P143, DOI 10.1080/136588199241391; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Thompson JN, 1999, SCIENCE, V284, P2116, DOI 10.1126/science.284.5423.2116; Van Wynsberghe NR, 2000, MEM I OSWALDO CRUZ, V95, P595, DOI 10.1590/S0074-02762000000500001; Volkov I, 2007, NATURE, V450, P45, DOI 10.1038/nature06197; Wolfe ND, 2007, NATURE, V447, P279, DOI 10.1038/nature05775	29	57	60	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2009	4	5							e5725	10.1371/journal.pone.0005725	http://dx.doi.org/10.1371/journal.pone.0005725			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QE	19478956	Green Published, gold, Green Submitted			2022-12-25	WOS:000266415100016
J	Drecoll, E; Gaertner, FC; Miederer, M; Blechert, B; Vallon, M; Muller, JM; Alke, A; Seidl, C; Bruchertseifer, F; Morgenstern, A; Senekowitsch-Schmidtke, R; Essler, M				Drecoll, Enken; Gaertner, Florian C.; Miederer, Matthias; Blechert, Birgit; Vallon, Mario; Mueller, Jan M.; Alke, Andrea; Seidl, Christof; Bruchertseifer, Frank; Morgenstern, Alfred; Senekowitsch-Schmidtke, Reingard; Essler, Markus			Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide Bi-213-DTPA-[F3](2) into the Nucleus of Tumor Cells	PLOS ONE			English	Article							IN-VIVO; ENDOTHELIAL-CELLS; ALPHA-THERAPY; CANCER; RADIOIMMUNOTHERAPY; VASCULATURE; GENERATOR; AC-225; TH-229	Background: alpha-particle emitting isotopes are effective novel tools in cancer therapy, but targeted delivery into tumors is a prerequisite of their application to avoid toxic side effects. Peritoneal carcinomatosis is a widespread dissemination of tumors throughout the peritoneal cavity. As peritoneal carcinomatosis is fatal in most cases, novel therapies are needed. F3 is a tumor homing peptide which is internalized into the nucleus of tumor cells upon binding to nucleolin on the cell surface. Therefore, F3 may be an appropriate carrier for alpha-particle emitting isotopes facilitating selective tumor therapies. Principal Findings: A dimer of the vascular tumor homing peptide F3 was chemically coupled to the alpha-emitter Bi-213(Bi-213-DTPA-[F3](2)). We found Bi-213-DTPA-[F3](2) to accumulate in the nucleus of tumor cells in vitro and in intraperitoneally growing tumors in vivo. To study the anti-tumor activity of Bi-213-DTPA-[F3](2) we treated mice bearing intraperitoneally growing xenograft tumors with Bi-213-DTPA-[F3](2). In a tumor prevention study between the days 4-14 after inoculation of tumor cells 6x1.85 MBq (50 mu Ci) of Bi-213-DTPA-[F3](2) were injected. In a tumor reduction study between the days 16-26 after inoculation of tumor cells 6x1.85 MBq of Bi-213-DTPA-[F3](2) were injected. The survival time of the animals was increased from 51 to 93.5 days in the prevention study and from 57 days to 78 days in the tumor reduction study. No toxicity of the treatment was observed. In bio-distribution studies we found Bi-213-DTPA-[F3](2) to accumulate in tumors but only low activities were found in control organs except for the kidneys, where Bi-213-DTPA-[F3](2) is found due to renal excretion. Conclusions/Significance: In conclusion we report that Bi-213-DTPA-[F3](2) is a novel tool for the targeted delivery of alpha-emitters into the nucleus of tumor cells that effectively controls peritoneal carcinomatosis in preclinical models and may also be useful in oncology.			Drecoll, E (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Dept Nucl Med, D-8000 Munich, Germany.	Markus.Essler@gmx.de	Miederer, Matthias/ABA-5988-2020; Miederer, Matthias/C-4405-2014	Miederer, Matthias/0000-0001-5075-5995; 				Akerman ME, 2002, P NATL ACAD SCI USA, V99, P12617, DOI 10.1073/pnas.152463399; Apostolidis C, 2005, ANAL CHEM, V77, P6288, DOI 10.1021/ac0580114; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Beck R, 2007, CANCER SCI, V98, P1215, DOI 10.1111/j.1349-7006.2007.00525.x; Beyer GJ, 2004, EUR J NUCL MED MOL I, V31, P547, DOI 10.1007/s00259-003-1413-9; Bloechl S, 2005, CLIN CANCER RES, V11, p7070S, DOI 10.1158/1078-0432.CCR-1004-0017; Borchardt PE, 2003, CANCER RES, V63, P5084; Buchhorn HM, 2007, EUR J NUCL MED MOL I, V34, P841, DOI 10.1007/s00259-006-0311-3; Cherukuri S, 2008, MOL BIOL CELL, V19, P1816, DOI 10.1091/mbc.E07-10-1018; Christian S, 2003, J CELL BIOL, V163, P871, DOI 10.1083/jcb.200304132; Glehen O, 2004, LANCET ONCOL, V5, P219, DOI 10.1016/S1470-2045(04)01425-1; Gunn AJ, 2007, EXPERT OPIN DRUG DEL, V4, P389, DOI 10.1517/17425247.4.4.389; Kinuya S, 2007, NUCL MED COMMUN, V28, P129, DOI 10.1097/MNM.0b013e328013e5a8; Koppe MJ, 2006, J NUCL MED, V47, P1867; McDevitt MR, 2001, SCIENCE, V294, P1537, DOI 10.1126/science.1064126; Miederer M, 2008, ADV DRUG DELIVER REV, V60, P1371, DOI 10.1016/j.addr.2008.04.009; Miederer M, 2008, CLIN CANCER RES, V14, P3555, DOI 10.1158/1078-0432.CCR-07-4647; Milenic D, 2004, CANCER BIOTHER RADIO, V19, P135, DOI 10.1089/108497804323071904; Nayak TK, 2007, NUCL MED BIOL, V34, P185, DOI 10.1016/j.nucmedbio.2006.11.006; Palm S, 2007, INT J RADIAT ONCOL, V69, P572, DOI 10.1016/j.ijrobp.2007.06.023; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Porkka K, 2002, P NATL ACAD SCI USA, V99, P7444, DOI 10.1073/pnas.062189599; Raja C, 2007, CANCER BIOL THER, V6, P846, DOI 10.4161/cbt.6.6.4089; Reubi JC, 2005, J NUCL MED, V46, p67S; Ruoslahti E, 2000, SEMIN CANCER BIOL, V10, P435, DOI 10.1006/scbi.2000.0334; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Stavila V, 2006, COORDIN CHEM REV, V250, P2782, DOI 10.1016/j.ccr.2006.02.032; Zielinska B, 2007, SOLVENT EXTR ION EXC, V25, P339, DOI 10.1080/07366290701285108	28	46	48	3	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2009	4	5							e5715	10.1371/journal.pone.0005715	http://dx.doi.org/10.1371/journal.pone.0005715			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QD	19479088	Green Published, Green Submitted, gold			2022-12-25	WOS:000266415000022
J	Morrison, LJ; Tweedie, A; Black, A; Pinchbeck, GL; Christley, RM; Schoenefeld, A; Hertz-Fowler, C; MacLeod, A; Turner, CMR; Tait, A				Morrison, Liam J.; Tweedie, Alison; Black, Alana; Pinchbeck, Gina L.; Christley, Robert M.; Schoenefeld, Andreas; Hertz-Fowler, Christiane; MacLeod, Annette; Turner, C. Michael R.; Tait, Andy			Discovery of Mating in the Major African Livestock Pathogen Trypanosoma congolense	PLOS ONE			English	Article							POPULATION-STRUCTURE; GENETIC EXCHANGE; SLEEPING SICKNESS; BRUCEI-GAMBIENSE; AGENT; PLASMODIUM; CRUZI; AMPLIFICATION; PREVALENCE; EVOLUTION	The protozoan parasite, Trypanosoma congolense, is one of the most economically important pathogens of livestock in Africa and, through its impact on cattle health and productivity, has a significant effect on human health and well being. Despite the importance of this parasite our knowledge of some of the fundamental biological processes is limited. For example, it is unknown whether mating takes place. In this paper we have taken a population genetics based approach to address this question. The availability of genome sequence of the parasite allowed us to identify polymorphic microsatellite markers, which were used to genotype T. congolense isolates from livestock in a discrete geographical area of The Gambia. The data showed a high level of diversity with a large number of distinct genotypes, but a deficit in heterozygotes. Further analysis identified cryptic genetic subdivision into four sub-populations. In one of these, parasite genotypic diversity could only be explained by the occurrence of frequent mating in T. congolense. These data are completely inconsistent with previous suggestions that the parasite expands asexually in the absence of mating. The discovery of mating in this species of trypanosome has significant consequences for the spread of critical traits, such as drug resistance, as well as for fundamental aspects of the biology and epidemiology of this neglected but economically important pathogen.			Morrison, LJ (corresponding author), Univ Glasgow, Wellcome Ctr Mol Parasitol, Glasgow Biomed Res Ctr, Glasgow, Lanark, Scotland.	lm78y@udcf.gla.ac.uk		Hamilton, Alana/0000-0001-5704-2293; Christley, Robert/0000-0001-9250-3032; Morrison, Liam/0000-0002-8304-9066; Hertz-Fowler, Christiane/0000-0002-0729-6479	Wellcome Trust [074732, 079703] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467, DOI 10.1093/oxfordjournals.molbev.a026247; Balloux F, 2003, GENETICS, V164, P1635; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; de Meeus T, 2007, INFECT GENET EVOL, V7, P308, DOI 10.1016/j.meegid.2006.07.003; El-Sayed NM, 2005, SCIENCE, V309, P409, DOI 10.1126/science.1112631; Evanno G, 2005, MOL ECOL, V14, P2611, DOI 10.1111/j.1365-294X.2005.02553.x; Faye D, 2001, VET PARASITOL, V101, P101, DOI 10.1016/S0304-4017(01)00503-9; GASHUMBA JK, 1988, PARASITOLOGY, V96, P475, DOI 10.1017/S0031182000080112; Gaunt MW, 2003, NATURE, V421, P936, DOI 10.1038/nature01438; Geerts S, 2001, TRENDS PARASITOL, V17, P25, DOI 10.1016/S1471-4922(00)01827-4; Gibson W, 2006, BIOCHEM SOC T, V34, P557, DOI 10.1042/BST0340557; GIBSON W, 1992, MOL BIOCHEM PARASIT, V51, P189, DOI 10.1016/0166-6851(92)90069-V; Gibson W, 1997, MICROBIOL-UK, V143, P909, DOI 10.1099/00221287-143-3-909; Gibson W, 1999, ADV PARASIT, V43, P1, DOI 10.1016/S0065-308X(08)60240-7; Hartl D.L., 1997, PRINCIPLES POPULATIO, V3rd ed.; Haubold B, 2000, BIOINFORMATICS, V16, P847, DOI 10.1093/bioinformatics/16.9.847; Hedrick WP, 2005, GENETICS POPULATIONS; HOARE AC, 1972, ZOOLOGICAL MONOGRAPH; HOLMES PH, 2004, TRYPANOSOMIASES; Hope M, 1999, MOL BIOCHEM PARASIT, V104, P1, DOI 10.1016/S0166-6851(99)00103-6; Hughes AL, 2003, MOL BIOL EVOL, V20, P644, DOI 10.1093/molbev/msg062; Jamonneau V, 2003, INFECT GENET EVOL, V3, P143, DOI 10.1016/S1567-1348(03)00069-8; Koffi M, 2009, P NATL ACAD SCI USA, V106, P209, DOI 10.1073/pnas.0811080106; LEWICKA K, 1995, EXP PARASITOL, V81, P20, DOI 10.1006/expr.1995.1088; MacLeod A, 2000, P NATL ACAD SCI USA, V97, P13442, DOI 10.1073/pnas.230434097; MACLEOD A, 2007, TRYPANOSOMES GENOME; MASIGA DK, 1992, INT J PARASITOL, V22, P909, DOI 10.1016/0020-7519(92)90047-O; MAYNARDSMITH J, 1993, P NATIONAL ACADEMY S, V90, P4384; Morrison LJ, 2008, INFECT GENET EVOL, V8, P121, DOI 10.1016/j.meegid.2007.10.010; Morrison LJ, 2007, AM J TROP MED HYG, V76, P1132, DOI 10.4269/ajtmh.2007.76.1132; Morrison LJ, 2008, INFECT GENET EVOL, V8, P847, DOI 10.1016/j.meegid.2008.08.005; Mzilahowa T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000613; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Peakall R, 2006, MOL ECOL NOTES, V6, P288, DOI 10.1111/j.1471-8286.2005.01155.x; Pinchbeck GL, 2008, BMC VET RES, V4, DOI 10.1186/1746-6148-4-7; Pritchard JK, 2000, GENETICS, V155, P945; Ramesh MA, 2005, CURR BIOL, V15, P185, DOI 10.1016/j.cub.2005.01.003; RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573; Razakandrainibe FG, 2005, P NATL ACAD SCI USA, V102, P17388, DOI 10.1073/pnas.0508871102; Schurko AM, 2008, BIOESSAYS, V30, P579, DOI 10.1002/bies.20764; Shaw APM, 2005, TRYPANOSOMIASES, P369, DOI 10.1079/9780851994758.0369; Stenberg P, 2003, MOL ECOL NOTES, V3, P329, DOI 10.1046/j.1471-8286.2003.00408.x; STERNBERG J, 1989, MOL BIOCHEM PARASIT, V34, P269, DOI 10.1016/0166-6851(89)90056-X; Stevens JR, 1999, PARASITOLOGY, V118, P107, DOI 10.1017/S0031182098003473; Stevens JR, 1996, PARASITOLOGY, V112, P481, DOI 10.1017/S0031182000076940; Tait A, 1996, MOL BIOCHEM PARASIT, V76, P31, DOI 10.1016/0166-6851(95)02528-6; TAIT A, 1980, NATURE, V287, P536, DOI 10.1038/287536a0; Tait A, 2007, MOL BIOCHEM PARASIT, V151, P133, DOI 10.1016/j.molbiopara.2006.10.009; TIBAYRENC M, 1990, P NATL ACAD SCI USA, V87, P2414, DOI 10.1073/pnas.87.7.2414; TIBAYRENC M, 1991, P NATL ACAD SCI USA, V88, P5129, DOI 10.1073/pnas.88.12.5129; TIBAYRENC M, 1986, P NATL ACAD SCI USA, V83, P115, DOI 10.1073/pnas.83.1.115; Weir W, 2007, MOL BIOCHEM PARASIT, V154, P170, DOI 10.1016/j.molbiopara.2007.04.015; YOUNG CJ, 1983, ANN TROP MED PARASIT, V77, P467, DOI 10.1080/00034983.1983.11811740	53	49	51	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5564	10.1371/journal.pone.0005564	http://dx.doi.org/10.1371/journal.pone.0005564			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440370	Green Accepted, gold, Green Submitted, Green Published			2022-12-25	WOS:000266107400008
J	Pant, K; Watt, J; Greenberg, M; Jones, M; Szczesna-Cordary, D; Moore, JR				Pant, Kiran; Watt, James; Greenberg, Michael; Jones, Michelle; Szczesna-Cordary, Danuta; Moore, Jeffrey R.			Removal of the cardiac myosin regulatory light chain increases isometric force production	FASEB JOURNAL			English	Article						lever arm; in vitro motility assay; optical trapping; flexibility	COILED-COIL; LEVER ARM; CONFORMATIONAL-CHANGES; MOLECULAR MOTOR; SCALLOP MYOSIN; CROSS-BRIDGE; NECK REGION; DOMAIN; ACTIN; GENERATION	The myosin neck, which is supported by the interactions between light chains and the underlying alpha-helical heavy chain, is thought to act as a lever arm to amplify movements originating in the globular motor domain. Here, we studied the role of the cardiac myosin regulatory light chains (RLCs) in the capacity of myosin to produce force using a novel optical-trap-based isometric force in vitro motility assay. We measured the isometric force and actin filament velocity for native porcine cardiac (PC) myosin, RLC-depleted PC (PCdepl) myosin, and PC myosin reconstituted with recombinant bacterially expressed human cardiac RLC (PCrecon). RLC depletion reduced unloaded actin filament velocity by 58% and enhanced the myosin-based isometric force similar to 2-fold. No significant change between PC and PCdepl preparations was observed in the maximal rate of actin-activated myosin ATPase activity. Reconstitution of PCdepl myosin with human RLC partially restored the velocity and force levels to near untreated values. The reduction in unloaded velocity after RLC extraction is consistent with the myosin neck acting as a lever, while the enhancement in isometric force can be directly related to enhancement of unitary force. The force data are consistent with a model in which the neck region behaves as a cantilevered beam.-Pant, K., Watt, J., Greenberg, M., Jones, M., Szczesna-Cordary, D., Moore, J. R. Removal of the cardiac myosin regulatory light chain increases isometric force production. FASEB J. 23, 3571-3580 (2009). www.fasebj.org	[Pant, Kiran; Watt, James; Greenberg, Michael; Moore, Jeffrey R.] Boston Univ, Dept Physiol & Biophys, Sch Med, Boston, MA 02118 USA; [Jones, Michelle; Szczesna-Cordary, Danuta] Univ Miami, L Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL USA	Boston University; University of Miami	Moore, JR (corresponding author), Boston Univ, Dept Physiol & Biophys, Sch Med, L-720,72 E Concord St, Boston, MA 02118 USA.	jxmoore@bu.edu		Moore, Jeffrey/0000-0001-7190-9332; Greenberg, Michael/0000-0003-1320-3547	National Institute of Health (NIH); American Heart Association (AHA) [NIH-HL077280, AHA-0435434T, AHA-0815704D, NIH-HL071778]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077280, R01HL071778] Funding Source: NIH RePORTER	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association (AHA)(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Tanya Mealy for help with the estimation of myosin on the bead surface. We also thank Dr. Katarzyna Kazmierczak for the contribution to actin-activated myosin ATPase assays. This work was supported by National Institute of Health (NIH) and American Heart Association (AHA) grants NIH-HL077280 and AHA-0435434T (to J.M.), AHA-0815704D (to M. G.), and NIH-HL071778 ( to D.S.-C.).	Baker JE, 1998, P NATL ACAD SCI USA, V95, P2944, DOI 10.1073/pnas.95.6.2944; Bing W, 2000, BIOCHEM J, V350, P693, DOI 10.1042/0264-6021:3500693; Corrie JET, 1999, NATURE, V400, P425, DOI 10.1038/22704; Dobbie I, 1998, NATURE, V396, P383, DOI 10.1038/24647; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Drabikowski W, 1964, BIOCH MUSCLE CONTRAC, P125; Fiske CH, 1925, J BIOL CHEM, V66, P375; Greenberg MJ, 2009, J MOL CELL CARDIOL, V46, P108, DOI 10.1016/j.yjmcc.2008.09.126; Hao YD, 2006, BIOPHYS J, V91, P4500, DOI 10.1529/biophysj.106.088492; HOFMANN PA, 1990, J GEN PHYSIOL, V95, P477, DOI 10.1085/jgp.95.3.477; Howard J, 1996, Proc Natl Acad Sci U S A, V93, P4462; Howard J., 2001, MECH MOTOR PROTEINS; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; Irving M, 2000, NAT STRUCT BIOL, V7, P482, DOI 10.1038/75890; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; JANSON LW, 1992, CELL MOTIL CYTOSKEL, V22, P274, DOI 10.1002/cm.970220407; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; Jontes JD, 1997, J CELL BIOL, V139, P683, DOI 10.1083/jcb.139.3.683; KIMURA M, 1984, BIOPHYS J, V45, P603, DOI 10.1016/S0006-3495(84)84198-3; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; Kohler J, 2002, P NATL ACAD SCI USA, V99, P3557, DOI 10.1073/pnas.062415899; Li Y, 2003, NATURE, V424, P341, DOI 10.1038/nature01801; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MARGOSSIAN SS, 1987, J MUSCLE RES CELL M, V8, P437, DOI 10.1007/BF01578433; Moore JR, 2004, J MUSCLE RES CELL M, V25, P29, DOI 10.1023/B:JURE.0000021394.48560.71; Moore JR, 2001, J CELL BIOL, V155, P625, DOI 10.1083/jcb.200103128; MOSS RL, 1982, J BIOL CHEM, V257, P8588; Purcell TJ, 2002, P NATL ACAD SCI USA, V99, P14159, DOI 10.1073/pnas.182539599; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Reck-Peterson SL, 2001, J CELL BIOL, V153, P1121, DOI 10.1083/jcb.153.5.1121; Root DD, 2006, BIOPHYS J, V90, P2852, DOI 10.1529/biophysj.105.071597; Sakamoto T, 2003, J BIOL CHEM, V278, P29201, DOI 10.1074/jbc.M303662200; Schwaiger I, 2002, NAT MATER, V1, P232, DOI 10.1038/nmat776; Shih WM, 2000, CELL, V102, P683, DOI 10.1016/S0092-8674(00)00090-8; Spink BJ, 2008, NAT STRUCT MOL BIOL, V15, P591, DOI 10.1038/nsmb.1429; Straub FB, 1942, STUD I MED CHEM U SZ, V2, P3; Straussman R, 2007, J MOL BIOL, V366, P1232, DOI 10.1016/j.jmb.2006.11.083; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; Swank DM, 2002, NAT CELL BIOL, V4, P312, DOI 10.1038/ncb776; Szczesna D, 1996, J BIOL CHEM, V271, P5246; Szczesna-Cordary D, 2007, FASEB J, V21, P3974, DOI 10.1096/fj.07-8630com; Taylor J.R., 1997, INTRO ERROR ANAL STU, P181; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; VANBUREN P, 1994, P NATL ACAD SCI USA, V91, P12403, DOI 10.1073/pnas.91.26.12403; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Wang EZ, 1996, ARCH BIOCHEM BIOPHYS, V329, P156, DOI 10.1006/abbi.1996.0204; Warshaw DM, 2000, J BIOL CHEM, V275, P37167, DOI 10.1074/jbc.M006438200; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	52	36	36	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3571	3580		10.1096/fj.08-126672	http://dx.doi.org/10.1096/fj.08-126672			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19470801	Green Published			2022-12-25	WOS:000270354300033
J	Sviderskaya, EV; Easty, DJ; Lawrence, MA; Sanchez, DP; Negulyaev, YA; Patel, RH; Anand, P; Korchev, YE; Bennett, DC				Sviderskaya, Elena V.; Easty, David J.; Lawrence, Mark A.; Sanchez, Daniel P.; Negulyaev, Yuri A.; Patel, Ricken H.; Anand, Praveen; Korchev, Yuri E.; Bennett, Dorothy C.			Functional neurons and melanocytes induced from immortal lines of postnatal neural crest-like stem cells	FASEB JOURNAL			English	Article						determination; differentiation; melanoma; chondrocyte; Schwann cell	FIBROBLAST-GROWTH-FACTOR; ROOT GANGLION NEURONS; MALIGNANT-MELANOMA; MOUSE MELANOCYTES; SENSORY NEURONS; PIGMENT-CELLS; SCHWANN-CELLS; ION-CHANNEL; ADULT SKIN; DIFFERENTIATION	Stem cells, that is, cells that can both reproduce themselves and differentiate into functional cell types, attract much interest as potential aids to healing and disease therapy. Embryonic neural crest is pluripotent and generates the peripheral nervous system, melanocytes, and some connective tissues. Neuralcrest-related stem cells have been reported previously in postnatal skin: committed melanocytic stem cells in the hair follicle, and pluripotent cell types from the hair follicle and papilla that can produce various sets of lineages. Here we describe novel pluripotent neural crest-like stem cells from neonatal mouse epidermis, with different potencies, isolated as 3 independent immortal lines. Using alternative regulatory factors, they could be converted to large numbers of either Schwann precursor cells, pigmented melanocytes, chondrocytes, or functional sensory neurons showing voltage-gated sodium channels. Some of the neurons displayed abundant active TRPV1 and TRPA1 receptors. Such functional neurons have previously been obtained in culture only with difficulty, by explantation. The system was also used to generate comparative gene expression data for the stem cells, melanocytes, and melanoblasts that sufficiently explain the lack of pigment in melanoblasts and provide a rationale for some genes expressed apparently ectopically in melanomas, such as ephrin receptors.-Sviderskaya, E. V., Easty, D. J., Lawrence, M. A., Sanchez, D. P., Negulyaev, Y. A., Patel, R. H., Anand, P., Korchev, Y. E., Bennett, D. C. Functional neurons and melanocytes induced from immortal lines of postnatal neural crest-like stem cells. FASEB J. 23, 3179-3192 ( 2009). www.fasebj.org	[Sviderskaya, Elena V.; Easty, David J.; Lawrence, Mark A.; Patel, Ricken H.; Bennett, Dorothy C.] St Georges Univ London, Div Basic Med Sci, Ctr Mol & Metab Signalling, London SW17 0RE, England; [Sanchez, Daniel P.; Korchev, Yuri E.] Univ London Imperial Coll Sci Technol & Med, Div Med, London Ctr Nanotechnol, London, England; [Negulyaev, Yuri A.] Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia; [Anand, Praveen] Univ London Imperial Coll Sci Technol & Med, Fac Med, Peripheral Neuropathy Unit, London, England	St Georges University London; Imperial College London; University of London; University College London; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; Imperial College London	Sviderskaya, EV (corresponding author), St Georges Univ London, Div Basic Med Sci, Ctr Mol & Metab Signalling, London SW17 0RE, England.	esviders@sgul.ac.uk	Negulyaev, Yuri/N-6531-2015; Bennett, Dorothy C/C-2418-2008; Sviderskaya, Elena V/D-2419-2009; babakinejad, babak/G-2674-2012; Herrera, Daniel P Sanchez/B-5141-2009	Negulyaev, Yuri/0000-0002-1773-9798; Bennett, Dorothy C/0000-0002-3639-7527; Herrera, Daniel P Sanchez/0000-0002-8556-562X; Korchev, Yuri/0000-0002-4872-8696	Wellcome Trust [064583, 078327, 081118]; Centre for Molecular and Metabolic Signaling; Russian Academy of Sciences; BBSRC [BB/D018595/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D018595/1] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Centre for Molecular and Metabolic Signaling; Russian Academy of Sciences(Russian Academy of Sciences); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We are grateful to Simon Hill and Yvette Bland for skilled technical assistance; to many colleagues for cDNA probes ( see Materials and Methods); Vince Hearing ( U. S. National Institutes of Health, Bethesda, MD, USA) for antibodies; Kris Jessen and Rhona Mirsky for valuable discussions; Marcio Hagel-Franco, Matt Todd, Sara Dexter, Rebecca Singleton, Natalie Atherton, Ming Fung, and Angela Brennan for preliminary experiments on NCLSCs; and Lynn Plowright for her contribution to Fig. 2. E. V. S. was supported by Wellcome Trust grants 064583 and 078327 ( Wellcome Trust University Award), M. A. L. by Wellcome Trust grant 081118 ( Student Elective Prize), D. P. S by the Imperial College London/GlaxoSmithKline collaborative program, and Y.A.N. by a grant from the Centre for Molecular and Metabolic Signaling, St. George's, and the Molecular and Cell Biology Program of the Russian Academy of Sciences.	BADER CR, 1983, NATURE, V305, P808, DOI 10.1038/305808a0; Baker MD, 2002, PROG BIOPHYS MOL BIO, V78, P83, DOI 10.1016/S0079-6107(02)00007-X; Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Bassi MT, 1996, GENOME RES, V6, P880, DOI 10.1101/gr.6.9.880; Bennett DC, 2003, PIGM CELL RES, V16, P333, DOI 10.1034/j.1600-0749.2003.00067.x; BENNETT DC, 1989, DEVELOPMENT, V105, P379; Carreira S, 1998, MOL CELL BIOL, V18, P5099, DOI 10.1128/MCB.18.9.5099; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cheung M, 2005, DEV CELL, V8, P179, DOI 10.1016/j.devcel.2004.12.010; Chi N, 2002, TRENDS GENET, V18, P41, DOI 10.1016/S0168-9525(01)02594-X; Cook AL, 2003, J INVEST DERMATOL, V121, P1150, DOI 10.1046/j.1523-1747.2003.12562.x; Coste B, 2004, MOL CELL NEUROSCI, V26, P123, DOI 10.1016/j.mcn.2004.01.015; Cummins TR, 1999, J NEUROSCI, V19, DOI 10.1523/JNEUROSCI.19-24-j0001.1999; Dhaka A, 2006, ANNU REV NEUROSCI, V29, P135, DOI 10.1146/annurev.neuro.29.051605.112958; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; Dunn KJ, 2000, P NATL ACAD SCI USA, V97, P10050, DOI 10.1073/pnas.97.18.10050; Easty DJ, 2000, MELANOMA RES, V10, P401, DOI 10.1097/00008390-200010000-00001; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; EISEN T, 1995, ONCOGENE, V11, P2157; Fernandes KJL, 2004, NAT CELL BIOL, V6, P1082, DOI 10.1038/ncb1181; Hagedorn L, 1999, DEVELOPMENT, V126, P3781; HALABAN R, 1984, IN VITRO CELL DEV B, V20, P447; HIROBE T, 1992, DEVELOPMENT, V114, P435; Hornyak TJ, 2000, J INVEST DERMATOL, V115, P106, DOI 10.1046/j.1523-1747.2000.00030.x; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HUSZAR D, 1991, DEVELOPMENT, V112, P131; ITO K, 1984, J EMBRYOL EXP MORPH, V84, P49; Jessen KR, 2002, J ANAT, V200, P367, DOI 10.1046/j.1469-7580.2002.00046.x; Joseph NM, 2004, DEVELOPMENT, V131, P5599, DOI 10.1242/dev.01429; Kawa Y, 2000, PIGM CELL RES, V13, P73, DOI 10.1034/j.1600-0749.13.s8.14.x; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; Kruger GM, 2002, NEURON, V35, P657, DOI 10.1016/S0896-6273(02)00827-9; Le Douarin NM, 2004, DEVELOPMENT, V131, P4637, DOI 10.1242/dev.01350; Le Douarin NM, 1999, NEURAL CREST, V2; LeMaster AM, 1999, J NEUROSCI, V19, P5919, DOI 10.1523/JNEUROSCI.19-14-05919.1999; Lentz SI, 1999, J NEUROSCI, V19, P1038; Maruyama H, 2004, PFLUG ARCH EUR J PHY, V449, P76, DOI 10.1007/s00424-004-1315-0; Nishimura EK, 2002, NATURE, V416, P854, DOI 10.1038/416854a; Ono H, 1998, PIGM CELL RES, V11, P291, DOI 10.1111/j.1600-0749.1998.tb00738.x; Opdecamp K, 1997, DEVELOPMENT, V124, P2377; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Real C, 2006, DEV BIOL, V300, P656, DOI 10.1016/j.ydbio.2006.09.032; RHEINWALD JG, 1975, CELL, V6, P317, DOI 10.1016/0092-8674(75)90183-X; Rush AM, 2007, J PHYSIOL-LONDON, V579, P1, DOI 10.1113/jphysiol.2006.121483; Sanchez-Martin MS, 2003, AM J MED GENET A, V122A, P125, DOI 10.1002/ajmg.a.20345; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Shioda T, 1996, P NATL ACAD SCI USA, V93, P12298, DOI 10.1073/pnas.93.22.12298; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; Sieber-Blum M, 2004, DEV DYNAM, V231, P258, DOI 10.1002/dvdy.20129; Sieber-Blum M, 2000, INT REV CYTOL, V197, P1, DOI 10.1016/S0074-7696(00)97001-3; SIEBERBLUM M, 1980, DEV BIOL, V80, P96, DOI 10.1016/0012-1606(80)90501-1; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Soriano P, 1997, DEVELOPMENT, V124, P2691; SPANAKIS E, 1992, DEVELOPMENT, V114, P675; Sviderskaya EV, 1998, DEV DYNAM, V213, P452, DOI 10.1002/(SICI)1097-0177(199812)213:4<452::AID-AJA10>3.0.CO;2-6; Sviderskaya EV, 1997, J INVEST DERMATOL, V108, P30, DOI 10.1111/1523-1747.ep12285621; SVIDERSKAYA EV, 1995, DEVELOPMENT, V121, P1547; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; Sviderskaya EV, 2001, DEV DYNAM, V221, P373, DOI 10.1002/dvdy.1153; Sviderskaya EV, 1998, GENETICS, V148, P381; SWOPE VB, 1995, EXP CELL RES, V217, P453, DOI 10.1006/excr.1995.1109; Teng L, 2006, ADV EXP MED BIOL, V589, P206; Vance KW, 2004, PIGM CELL RES, V17, P318, DOI 10.1111/j.1600-0749.2004.00164.x; Weerda HG, 1998, ACTA OTO-LARYNGOL, V118, P337; Wong CE, 2006, J CELL BIOL, V175, P1005, DOI 10.1083/jcb.200606062; Yu H, 2006, AM J PATHOL, V168, P1879, DOI 10.2353/ajpath.2006.051170; Zhang JM, 1997, DEV DYNAM, V208, P375	69	24	24	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2009	23	9					3179	3192		10.1096/fj.08-123596	http://dx.doi.org/10.1096/fj.08-123596			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	499QZ	19447881	Green Published, Green Accepted			2022-12-25	WOS:000270241000040
J	Nakayama, S; Murata, T; Murayama, K; Yasui, Y; Sato, Y; Kudoh, A; Iwahori, S; Isomura, H; Kanda, T; Tsurumi, T				Nakayama, Sanae; Murata, Takayuki; Murayama, Kazutaka; Yasui, Yoshihiro; Sato, Yoshitaka; Kudoh, Ayumi; Iwahori, Satoko; Isomura, Hiroki; Kanda, Teru; Tsurumi, Tatsuya			Epstein-Barr Virus Polymerase Processivity Factor Enhances BALF2 Promoter Transcription as a Coactivator for the BZLF1 Immediate-Early Protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EBV DNA-POLYMERASE; BMRF1 GENE-PRODUCTS; EA-D; REPLICATION COMPARTMENTS; ACCESSORY PROTEIN; LYTIC CYCLE; HUMAN CYTOMEGALOVIRUS; BINDING PROTEIN; INSECT CELLS; IN-VITRO	The Epstein-Barr virus (EBV) BMRF1 protein is an essential replication protein acting at viral replication forks as a viral DNA polymerase processivity factor, where as the BALF2 protein is a single stranded DNA-binding protein that also acts at replication forks and is most abundantly expressed during viral productive replication. Here we document that the BMRF1 protein evidently enhances viral BZLF1 transcription factor-mediated transactivation of the BALF2 gene promoter. Mutagenesis and electrophoretic mobility shift assays demonstrated the BALF2 promoter to harbor two BZLF1 protein-binding sites (BZLF1-responsive elements). Direct binding of the BZLF1 protein to BZLF1-responsive elements and physical interaction between BZLF1 and BMRF1 proteins are prerequisite for the BMRF1 protein up-regulation of the BALF2 gene promoter. A monomeric mutant, C95E, which is defective in homodimerization, could still interact and enhance BZLF1-mediated transactivation. Furthermore although EBV protein kinase phosphorylates BMRF1 protein extensively, it turned out that phosphorylation of the protein by the kinase is inhibitory to the enhancement of the BZLF1-mediated transactivation of BALF2 promoter. Exogenous expression of BMRF1 protein augmented BALF2 expression in HEK293 cells harboring the EBV genome but lacking BMRF1 and BALF5 genes, demonstrating functions as a transcriptional regulator in the context of viral infection. Overall the BMRF1 protein is a multifunctional protein that cannot only act as a DNA polymerase processivity factor but also enhances BALF2 promoter transcription as a coactivator for the BZLF1 protein, regulating the expression level of viral single-stranded DNA-binding protein.	[Nakayama, Sanae; Murata, Takayuki; Yasui, Yoshihiro; Sato, Yoshitaka; Kudoh, Ayumi; Iwahori, Satoko; Isomura, Hiroki; Kanda, Teru; Tsurumi, Tatsuya] Aichi Canc Ctr, Res Inst, Div Virol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; [Murayama, Kazutaka] Tohoku Univ, Grad Sch Biomed Engn, Div Biomed Measurements & Diagnost, Sendai, Miyagi 9808575, Japan	Aichi Cancer Center; Tohoku University	Tsurumi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Virol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	ttsurumi@aichi-cc.jp	Murata, Takayuki/I-2621-2013; Sato, Yoshitaka/P-9728-2015; Kanda, Teru/J-7313-2019; Iwahori, Satoko/L-1948-2019	Murata, Takayuki/0000-0001-7228-0839; Sato, Yoshitaka/0000-0002-8541-6413; Kanda, Teru/0000-0002-1391-3349	Ministry of Education, Science, Sports, Culture and Technology of Japan [21022055, 20012056, 20390137]	Ministry of Education, Science, Sports, Culture and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by Grants-in-aid for Scientific Research 21022055, 20012056, and 20390137 from the Ministry of Education, Science, Sports, Culture and Technology of Japan ( to T. T.).	Appleton BA, 2004, MOL CELL, V15, P233, DOI 10.1016/j.molcel.2004.06.018; Baumann M, 1999, EMBO J, V18, P6095, DOI 10.1093/emboj/18.21.6095; Chang PJ, 1998, J VIROL, V72, P5128, DOI 10.1128/JVI.72.6.5128-5136.1998; CHEN LW, 1995, VIROLOGY, V211, P593, DOI 10.1006/viro.1995.1443; Chen MR, 2000, J VIROL, V74, P3093, DOI 10.1128/JVI.74.7.3093-3104.2000; Chen XL, 2004, J BIOL CHEM, V279, P28375, DOI 10.1074/jbc.M400032200; CHIOU JF, 1985, P NATL ACAD SCI USA, V82, P5728, DOI 10.1073/pnas.82.17.5728; CHO MS, 1985, J VIROL, V56, P860, DOI 10.1128/JVI.56.3.860-866.1985; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; Daikoku T, 2006, J BIOL CHEM, V281, P11422, DOI 10.1074/jbc.M510314200; Daikoku T, 2005, J VIROL, V79, P3409, DOI 10.1128/JVI.79.6.3409-3418.2005; DECAUSSIN G, 1995, J VIROL, V69, P7309, DOI 10.1128/JVI.69.11.7309-7314.1995; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; FIXMAN ED, 1995, J VIROL, V69, P2998, DOI 10.1128/JVI.69.5.2998-3006.1995; FIXMAN ED, 1992, J VIROL, V66, P5030, DOI 10.1128/JVI.66.8.5030-5039.1992; FLEMINGTON EK, 1991, J VIROL, V65, P7073, DOI 10.1128/JVI.65.12.7073-7077.1991; Gershburg E, 2002, J VIROL, V76, P998, DOI 10.1128/JVI.76.3.998-1003.2002; Gershburg E, 2007, J VIROL, V81, P5407, DOI 10.1128/JVI.02398-06; HAMMERSCHMIDT W, 1988, CELL, V55, P427, DOI 10.1016/0092-8674(88)90028-1; Holley-Guthrie EA, 2005, J VIROL, V79, P745, DOI 10.1128/JVI.79.2.745-755.2005; Hung CH, 1999, J GEN VIROL, V80, P2747, DOI 10.1099/0022-1317-80-10-2747; Isomura H, 2004, J VIROL, V78, P12788, DOI 10.1128/JVI.78.23.12788-12799.2004; Isomura H, 2008, J VIROL, V82, P1638, DOI 10.1128/JVI.01917-07; KALLIN B, 1985, J VIROL, V54, P561, DOI 10.1128/JVI.54.2.561-568.1985; Kato K, 2003, J GEN VIROL, V84, P3381, DOI 10.1099/vir.0.19454-0; KIEHL A, 1991, VIROLOGY, V184, P330, DOI 10.1016/0042-6822(91)90849-7; KIEHL A, 1995, J VIROL, V69, P1669, DOI 10.1128/JVI.69.3.1669-1677.1995; KNIPE DM, 2002, FIELDS VIROLOGY, P2575; LI JS, 1987, J VIROL, V61, P2947, DOI 10.1128/JVI.61.9.2947-2949.1987; MCBRIDE AA, 1989, P NATL ACAD SCI USA, V86, P510, DOI 10.1073/pnas.86.2.510; Murata T, 2009, VIROLOGY, V389, P75, DOI 10.1016/j.virol.2009.04.007; Ohashi M, 2007, MICROBES INFECT, V9, P150, DOI 10.1016/j.micinf.2006.11.001; PEARSON GR, 1983, J VIROL, V47, P193, DOI 10.1128/JVI.47.1.193-201.1983; Petosa C, 2006, MOL CELL, V21, P565, DOI 10.1016/j.molcel.2006.01.006; Randell JC, 2001, MOL CELL, V8, P911, DOI 10.1016/S1097-2765(01)00355-0; SCHEPERS A, 1993, EMBO J, V12, P3921, DOI 10.1002/j.1460-2075.1993.tb06070.x; TAKAGI S, 1991, VIROLOGY, V185, P309, DOI 10.1016/0042-6822(91)90778-A; Tsurumi T, 1996, VIROLOGY, V222, P352, DOI 10.1006/viro.1996.0432; TSURUMI T, 1993, J VIROL, V67, P1681, DOI 10.1128/JVI.67.3.1681-1687.1993; TSURUMI T, 1993, J VIROL, V67, P7648, DOI 10.1128/JVI.67.12.7648-7653.1993; Tsurumi T, 2001, CURR TOP MICROBIOL, V258, P65; Wang JT, 2005, J GEN VIROL, V86, P3215, DOI 10.1099/vir.0.81313-0; Yang PW, 2008, J GEN VIROL, V89, P884, DOI 10.1099/vir.0.83546-0; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991; Yokoyama N, 2000, BBA-GENE STRUCT EXPR, V1493, P119, DOI 10.1016/S0167-4781(00)00170-6; Yokoyama N, 1999, J GEN VIROL, V80, P2879, DOI 10.1099/0022-1317-80-11-2879; Zhang Q, 1999, J GEN VIROL, V80, P69, DOI 10.1099/0022-1317-80-1-69; Zhang Q, 1997, VIROLOGY, V230, P22, DOI 10.1006/viro.1997.8470; Zhang Q, 1996, J VIROL, V70, P5131, DOI 10.1128/JVI.70.8.5131-5142.1996; Zuccola HJ, 2000, MOL CELL, V5, P267, DOI 10.1016/S1097-2765(00)80422-0	50	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	2009	284	32					21557	21568		10.1074/jbc.M109.015685	http://dx.doi.org/10.1074/jbc.M109.015685			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478CC	19491105	Green Published, hybrid			2022-12-25	WOS:000268564400050
J	Belyi, Y; Stahl, M; Sovkova, I; Kaden, P; Luy, B; Aktories, K				Belyi, Yury; Stahl, Michael; Sovkova, Irina; Kaden, Peter; Luy, Burkhard; Aktories, Klaus			Region of Elongation Factor 1A1 Involved in Substrate Recognition by Legionella pneumophila Glucosyltransferase Lgt1 IDENTIFICATION OF Lgt1 AS A RETAINING GLUCOSYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; SORDELLII LETHAL TOXIN; NMR-SPECTROSCOPY; HIGH-RESOLUTION; PROTEIN; GLUCOSYLATION; VIRULENCE; COMPLEX; CONSEQUENCES; EXCITATION	Lgt1 is one of the glucosyltransferases produced by the Gram-negative bacterium Legionella pneumophila. This enzyme modifies eukaryotic elongation factor 1A (eEF1A) at serine 53, which leads to inhibition of protein synthesis and death of target cells. Here we studied the region of eEF1A, which is essential for substrate recognition by Lgt1. We report that the decapeptide (50)GKGSFKYAWV(59) of eEF1A is efficiently modified by Lgt1. This peptide covers the loop of the helix-loop-helix region formed by helices A* and A' of eEF1A and is part of the first turn of helix A'. Substitution of either serine 53, phenylalanine 54, tyrosine 56, or tryptophan 58 by alanine abolished or severely decreased glucosylation. Lgt1 modified the decapeptide (50)GKGSFKYAWV(59) with a higher glucosylation rate than full-length eEF1A purified from yeast, suggesting that a specific conformation of eEF1A is the preferred substrate of Lgt1. A GenBank (TM) search on the basis of the substrate decapeptide for similar peptide sequences retrieved heat shock protein 70 subfamily B suppressor 1 (Hbs1) as a target for glucosylation by Lgt1. Recombinant Hbs1 and the corresponding fragment ((303)GKASFAYAWV(312)) were glucosylated by Lgt1. NMR studies with the glucosylated eEF1A-derived decapeptide identified an alpha-anomeric structure of the glucose-serine 53 bond and characterize Lgt1 as a retaining glucosyltransferase.	[Stahl, Michael; Aktories, Klaus] Univ Freiburg, Inst Expt & Clin Pharmacol & Toxicol, D-79104 Freiburg, Germany; [Belyi, Yury; Sovkova, Irina] NF Gamalei Inst Epidemiol & Microbiol, Moscow 123098, Russia; [Kaden, Peter; Luy, Burkhard] Tech Univ Munich, Dept Chem, D-85747 Garching, Germany	University of Freiburg; Russian Academy of Medical Sciences; Gamaleya National Research Center for Epidemiology & Microbiology, RAMS; Technical University of Munich	Aktories, K (corresponding author), Univ Freiburg, Inst Expt & Clin Pharmacol & Toxicol, Albertstr 25, D-79104 Freiburg, Germany.	Klaus.Aktories@pharmakol.uni-freiburg.de	Belyi, Yury/AAU-8092-2020; Kaden, Peter/F-6716-2013; Aktories, Klaus/CAJ-5682-2022; Luy, Burkhard/I-1918-2013	Kaden, Peter/0000-0002-9414-2936; Aktories, Klaus/0000-0002-5397-0436; Luy, Burkhard/0000-0001-9580-6397	Bundesministerium fur Bildung und Forschung [05-1000004-7756]; Deutsche Forschungsgemeinschaft (DFG)	Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	This work was supported in part by the Bundesministerium fur Bildung und Forschung, International Association for the Promotion of Co-operation with Scientists (Project 05-1000004-7756 to Y.B. and K. A.) and the Deutsche Forschungsgemeinschaft (DFG, to K. A.).	Andersen GR, 2000, MOL CELL, V6, P1261, DOI 10.1016/S1097-2765(00)00122-2; Andersen GR, 2001, COLD SPRING HARB SYM, V66, P425, DOI 10.1101/sqb.2001.66.425; Belyi I, 2003, INFECT IMMUN, V71, P181, DOI 10.1128/IAI.71.1.181-186.2003; Belyi Y, 2008, J BACTERIOL, V190, P3026, DOI 10.1128/JB.01798-07; Belyi Y, 2006, P NATL ACAD SCI USA, V103, P16953, DOI 10.1073/pnas.0601562103; Bitar DM, 2004, INT J MED MICROBIOL, V293, P519, DOI 10.1078/1438-4221-00286; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Byrne B, 1998, INFECT IMMUN, V66, P3029, DOI 10.1128/IAI.66.7.3029-3034.1998; Carr-Schmid A, 2002, MOL CELL BIOL, V22, P2564, DOI 10.1128/MCB.22.8.2564-2574.2002; Cohen Y, 2005, ANGEW CHEM INT EDIT, V44, P520, DOI 10.1002/anie.200300637; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; Doma MK, 2006, NATURE, V440, P561, DOI 10.1038/nature04530; EMSLEY L, 1990, CHEM PHYS LETT, V165, P469, DOI 10.1016/0009-2614(90)87025-M; Fields BS, 2002, CLIN MICROBIOL REV, V15, P506, DOI 10.1128/CMR.15.3.506-526.2002; FREEMAN R, 1971, J CHEM PHYS, V54, P301, DOI 10.1063/1.1674608; Furrer J, 2004, J MAGN RESON, V166, P39, DOI 10.1016/j.jmr.2003.09.013; Geyer M, 2003, BIOCHEMISTRY-US, V42, P11951, DOI 10.1021/bi034529v; Graille M, 2008, J BIOL CHEM, V283, P7145, DOI 10.1074/jbc.M708224200; HAASNOOT CAG, 1980, TETRAHEDRON, V36, P2783, DOI 10.1016/0040-4020(80)80155-4; Hammer BK, 1999, MOL MICROBIOL, V33, P721, DOI 10.1046/j.1365-2958.1999.01519.x; Ingmundson A, 2007, NATURE, V450, P365, DOI 10.1038/nature06336; Jank T, 2008, TRENDS MICROBIOL, V16, P222, DOI 10.1016/j.tim.2008.01.011; Jank T, 2006, J BIOL CHEM, V281, P19527, DOI 10.1074/jbc.M600863200; Juhas M, 2008, CELL MICROBIOL, V10, P2377, DOI 10.1111/j.1462-5822.2008.01187.x; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kahns S, 1998, NUCLEIC ACIDS RES, V26, P1884, DOI 10.1093/nar/26.8.1884; Kramer F, 2001, J MAGN RESON, V149, P58, DOI 10.1006/jmre.2000.2271; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lairson LL, 2008, ANNU REV BIOCHEM, V77, P521, DOI 10.1146/annurev.biochem.76.061005.092322; Lee HH, 2007, MOL CELL, V27, P938, DOI 10.1016/j.molcel.2007.07.019; Lerm M, 1999, J BIOL CHEM, V274, P28999, DOI 10.1074/jbc.274.41.28999; Murata T, 2006, NAT CELL BIOL, V8, P971, DOI 10.1038/ncb1463; Nagai H, 2002, SCIENCE, V295, P679, DOI 10.1126/science.1067025; Ninio S, 2007, TRENDS MICROBIOL, V15, P372, DOI 10.1016/j.tim.2007.06.006; OHBA M, 1994, FEBS LETT, V351, P263; STOTT K, 1995, J AM CHEM SOC, V117, P4199, DOI 10.1021/ja00119a048; Vetter IR, 2000, J MOL BIOL, V301, P1091, DOI 10.1006/jmbi.2000.4045; Wallrapp C, 1998, FEBS LETT, V440, P387, DOI 10.1016/S0014-5793(98)01492-6; WU DH, 1995, J MAGN RESON SER A, V115, P260, DOI 10.1006/jmra.1995.1176; Ziegler MOP, 2008, J MOL BIOL, V377, P1346, DOI 10.1016/j.jmb.2007.12.065	40	29	34	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20167	20174		10.1074/jbc.M109.008441	http://dx.doi.org/10.1074/jbc.M109.008441			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19478083	hybrid, Green Published			2022-12-25	WOS:000268097400044
J	Chu, PY; Huang, LY; Hsu, CH; Liang, CC; Guan, JL; Hung, TH; Shen, TL				Chu, Pei-Yu; Huang, Ling-Ya; Hsu, Chun-Hua; Liang, Chun-Chi; Guan, Jun-Lin; Hung, Ting-Hsuan; Shen, Tang-Long			Tyrosine Phosphorylation of Growth Factor Receptor-bound Protein-7 by Focal Adhesion Kinase in the Regulation of Cell Migration, Proliferation, and Tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; SH2 DOMAIN; SIGNAL-TRANSDUCTION; CYCLE PROGRESSION; INSULIN-RECEPTOR; ADAPTER PROTEIN; GRB7 FAMILY; ASSOCIATION; EXPRESSION; IDENTIFICATION	We have previously reported that growth factor receptor-bound protein-7 (Grb7), an Src-homology 2 (SH2)-containing adaptor protein, enables interaction with focal adhesion kinase (FAK) to regulate cell migration in response to integrin activation. To further elucidate the signaling events mediated by FAK.Grb7 complexes in promoting cell migration and other cellular functions, we firstly examined the phosphorylated tyrosine site(s) of Grb7 by FAK using an in vivo mutagenesis. We found that FAK was capable of phosphorylating at least 2 of 12 tyrosine residues within Grb7, Tyr-188 and Tyr-338. Moreover, mutations converting the identified Tyr to Phe inhibited integrin-dependent cell migration as well as impaired cell proliferation but not survival compared with the wild-type control. Interestingly, the above inhibitory effects caused by the tyrosine phosphorylation-deficient mutants are probably attributed to their down-regulation of phospho-Tyr-397 of FAK, thereby implying a mechanism by competing with wild-type Grb7 for binding to FAK. Consequently, these tyrosine phosphorylation-deficient mutants evidently altered the phospho-Tyr-118 of paxillin and phosphorylation of ERK1/2 but less on phospho-Ser-473 of AKT, implying their involvement in the FAK.Grb7-mediated cellular functions. Additionally, we also illustrated that the formation of FAK.Grb7 complexes and Grb7 phosphorylation by FAK in an integrin-dependent manner were essential for cell migration, proliferation and anchorage-independent growth in A431 epidermal carcinoma cells, indicating the importance of FAK.Grb7 complexes in tumorigenesis. Our data provide a better understanding on the signal transduction event for FAK.Grb7-mediated cellular functions as well as to shed light on a potential therapeutic in cancers.	[Chu, Pei-Yu; Huang, Ling-Ya; Hung, Ting-Hsuan; Shen, Tang-Long] Natl Taiwan Univ, Dept Plant Pathol & Microbiol, Taipei 106, Taiwan; [Hsu, Chun-Hua] Natl Taiwan Univ, Dept Agr Chem, Taipei 106, Taiwan; [Liang, Chun-Chi; Guan, Jun-Lin] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Liang, Chun-Chi; Guan, Jun-Lin] Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	National Taiwan University; National Taiwan University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Shen, TL (corresponding author), Natl Taiwan Univ, Dept Plant Pathol & Microbiol, Taipei 106, Taiwan.	shentl@ntu.edu.tw	Liang, Chun-Chi/D-7986-2016; HSU, CHUN-HUA/W-4554-2019; Shen, Tang-Long/C-7460-2011; Liang, Richard Chun-Chi/C-6989-2013	Liang, Chun-Chi/0000-0002-8345-8564; HSU, CHUN-HUA/0000-0002-0008-7383; HUNG, TING-HSUAN/0000-0002-7790-4193; Shen, Tang-Long/0000-0001-6264-3608	National Science Council [NSC-96-2311B-002-023-MY3]; National Taiwan University [97R0343]	National Science Council(Ministry of Science and Technology, Taiwan); National Taiwan University(National Taiwan University)	This work was supported by National Science Council Grant NSC-96-2311B-002-023-MY3 and Frontier Research Grant of National Taiwan University 97R0343 (to T.- L. S.).	Akiyama N, 1997, CANCER RES, V57, P3548; An JJ, 2007, J BIOCHEM MOL BIOL, V40, P189; Bai T, 2008, CARCINOGENESIS, V29, P473, DOI 10.1093/carcin/bgm221; Chen DY, 2003, ONCOGENE, V22, P4348, DOI 10.1038/sj.onc.1206532; Chu Peter, 2003, J Biol, V2, P21, DOI 10.1186/1475-4924-2-21; Dahlberg PS, 2004, ANN THORAC SURG, V78, P1790, DOI 10.1016/j.athoracsur.2004.05.037; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; de Vet ECJM, 2003, BIOCHEM J, V375, P207, DOI 10.1042/BJ20030293; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Han DC, 2002, J BIOL CHEM, V277, P45655, DOI 10.1074/jbc.M203165200; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; Haran M, 2004, LEUKEMIA, V18, P1948, DOI 10.1038/sj.leu.2403512; Hitchins M P, 2002, J Med Genet, V39, pE13, DOI 10.1136/jmg.39.3.e13; Hodgson JG, 2005, CANCER RES, V65, P9695, DOI 10.1158/0008-5472.CAN-05-0755; Holt LJ, 2005, BIOCHEM J, V388, P393, DOI 10.1042/BJ20050216; Itoh S, 2007, MOL CANCER RES, V5, P667, DOI 10.1158/1541-7786.MCR-06-0282; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Kao J, 2006, GENE CHROMOSOME CANC, V45, P761, DOI 10.1002/gcc.20339; Kasus-Jacobi A, 2000, ONCOGENE, V19, P2052, DOI 10.1038/sj.onc.1203469; Keegan K, 1996, ONCOGENE, V12, P1537; Kim CW, 2006, J KOREAN MED SCI, V21, P478, DOI 10.3346/jkms.2006.21.3.478; Kishi T, 1997, BIOCHEM BIOPH RES CO, V232, P5, DOI 10.1006/bbrc.1997.6218; Leavey SF, 1998, AM J PHYSIOL-RENAL, V275, pF770, DOI 10.1152/ajprenal.1998.275.5.F770; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Li HB, 2005, ONCOGENE, V24, P4206, DOI 10.1038/sj.onc.1208591; Manser J, 1997, DEV BIOL, V184, P150, DOI 10.1006/dbio.1997.8516; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Morrione A, 2000, INT J MOL MED, V5, P151; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Pero SC, 2007, BRIT J CANCER, V96, P1520, DOI 10.1038/sj.bjc.6603732; Pero SC, 2002, J BIOL CHEM, V277, P11918, DOI 10.1074/jbc.M111816200; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Reiske HR, 2000, FEBS LETT, V486, P275, DOI 10.1016/S0014-5793(00)02295-X; Rodriguez-Viciana P, 2004, MOL CELL BIOL, V24, P4943, DOI 10.1128/MCB.24.11.4943-4954.2004; Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155; Shen TL, 2001, FEBS LETT, V499, P176, DOI 10.1016/S0014-5793(01)02545-5; Shen TL, 2004, FRONT BIOSCI-LANDMRK, V9, P192, DOI 10.2741/1229; Shen TL, 2002, J BIOL CHEM, V277, P29069, DOI 10.1074/jbc.M203085200; Siamakpour-Reihani S, 2009, J MOL RECOGNIT, V22, P9, DOI 10.1002/jmr.916; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Skotheim RI, 2002, CANCER RES, V62, P2359; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Tanaka S, 2006, JNCI-J NATL CANCER I, V98, P491, DOI 10.1093/jnci/djj105; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; Tsai NP, 2008, EMBO J, V27, P715, DOI 10.1038/emboj.2008.19; Tsai NP, 2007, EMBO J, V26, P1522, DOI 10.1038/sj.emboj.7601598; van Agthoven T, 2009, BREAST CANCER RES TR, V114, P23, DOI 10.1007/s10549-008-9969-5; Vayssiere B, 2000, FEBS LETT, V467, P91, DOI 10.1016/S0014-5793(99)01530-6; Walch A, 2004, INT J CANCER, V112, P747, DOI 10.1002/ijc.20411; Wojcik J, 1999, BIOCHEM BIOPH RES CO, V259, P113, DOI 10.1006/bbrc.1999.0727; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; Yoon SW, 2005, PROTEOMICS, V5, P1987, DOI 10.1002/pmic.200401086	54	48	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					20215	20226		10.1074/jbc.M109.018259	http://dx.doi.org/10.1074/jbc.M109.018259			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19473962	Green Published, hybrid			2022-12-25	WOS:000268097400049
J	Ilien, B; Glasser, N; Clamme, JP; Didier, P; Piemont, E; Chinnappan, R; Daval, SB; Galzi, JL; Mely, Y				Ilien, Brigitte; Glasser, Nicole; Clamme, Jean-Pierre; Didier, Pascal; Piemont, Etienne; Chinnappan, Raja; Daval, Sandrine B.; Galzi, Jean-Luc; Mely, Yves			Pirenzepine Promotes the Dimerization of Muscarinic M1 Receptors through a Three-step Binding Process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED-RECEPTOR; FLUORESCENCE CORRELATION SPECTROSCOPY; RESONANCE ENERGY-TRANSFER; LIVING CELLS; LIVE CELLS; ACETYLCHOLINE-RECEPTORS; FLUCTUATION SPECTROSCOPY; COMPLEMENTARY SEQUENCE; CHOLINERGIC-RECEPTOR; NUCLEOCAPSID PROTEIN	Ligand binding to G protein-coupled receptors is a complex process that involves sequential receptor conformational changes, ligand translocation, and possibly ligand-induced receptor oligomerization. Binding events at muscarinic acetylcholine receptors are usually interpreted from radioligand binding studies in terms of two-step ligand-induced receptor isomerization. We report here, using a combination of fluorescence approaches, on the molecular mechanisms for Bodipypirenzepine binding to enhanced green fluorescent protein (EGFP)-fused muscarinic M1 receptors in living cells. Real time monitoring, under steady-state conditions, of the strong fluorescence energy transfer signal elicited by this interaction permitted a fine kinetic description of the binding process. Time-resolved fluorescence measurements allowed us to identify discrete EGFP lifetime species and to follow their redistribution upon ligand binding. Fluorescence correlation spectroscopy, with EGFP brightness analysis, showed that EGFP-fused muscarinic M1 receptors predominate as monomers in the absence of ligand and dimerize upon pirenzepine binding. Finally, all these experimental data could be quantitatively reconciled into a three-step mechanism, with four identified receptor conformational states. Fast ligand binding to a peripheral receptor site initiates a sequence of conformational changes that allows the ligand to access to inner regions of the protein and drives ligand-receptor complexes toward a high affinity dimeric state.	[Ilien, Brigitte; Daval, Sandrine B.; Galzi, Jean-Luc] Univ Strasbourg, Inst Rech, Dept Biotechnol Interact Mol, Ecole Biotechnol Strasbourg,FRE 3211, F-67412 Illkirch Graffenstaden, France; [Glasser, Nicole; Clamme, Jean-Pierre; Didier, Pascal; Piemont, Etienne; Chinnappan, Raja; Mely, Yves] Univ Strasbourg, Lab Biophoton & Pharmacol, UMR 7213, CNRS,Fac Pharm, F-67401 Illkirch Graffenstaden, France	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Ilien, B (corresponding author), Univ Strasbourg, Inst Rech, Dept Biotechnol Interact Mol, Ecole Biotechnol Strasbourg,FRE 3211, Bvd S Brant BP 10413, F-67412 Illkirch Graffenstaden, France.	ilien@esbs.u-strasbg.fr			CNRS; INSERM; Universite de Strasbourg	CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite de Strasbourg	This work was supported in part by CNRS, INSERM, and the Universite de Strasbourg.	Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Avilov SV, 2008, NUCLEIC ACIDS RES, V36, P885, DOI 10.1093/nar/gkm1109; Azoulay J, 2003, J MOL BIOL, V326, P691, DOI 10.1016/S0022-2836(02)01430-4; Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2002.5429; Bockaert J, 2004, PHARMACOL THERAPEUT, V103, P203, DOI 10.1016/j.pharmthera.2004.06.004; Briddon SJ, 2007, TRENDS PHARMACOL SCI, V28, P637, DOI 10.1016/j.tips.2007.09.008; Castro M, 2005, P NATL ACAD SCI USA, V102, P16084, DOI 10.1073/pnas.0503942102; Caulfield MP, 1998, PHARMACOL REV, V50, P279; Cezanne L, 2004, J BIOL CHEM, V279, P45057, DOI 10.1074/jbc.M404811200; Chabre M, 2005, BIOCHEMISTRY-US, V44, P9395, DOI 10.1021/bi050720o; Chen Y, 2005, BIOPHYS J, V88, P4366, DOI 10.1529/biophysj.105.059170; Chen Y, 2003, P NATL ACAD SCI USA, V100, P15492, DOI 10.1073/pnas.2533045100; Chen Y, 2002, BIOPHYS J, V82, P133, DOI 10.1016/S0006-3495(02)75380-0; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Chidiac P, 1997, BIOCHEMISTRY-US, V36, P7361, DOI 10.1021/bi961939t; Clamme JP, 2003, BIOPHYS J, V84, P1960, DOI 10.1016/S0006-3495(03)75004-8; Clayton AHA, 2002, BIOPHYS J, V83, P1631, DOI 10.1016/S0006-3495(02)73932-5; Deupi X, 2007, ADV PROTEIN CHEM, V74, P137, DOI 10.1016/S0065-3231(07)74004-4; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; ELLER M, 1988, NEUROCHEM INT, V12, P285, DOI 10.1016/0197-0186(88)90166-0; Elling CE, 2006, J BIOL CHEM, V281, P17337, DOI 10.1074/jbc.M512510200; Fotiadis D, 2006, CURR OPIN STRUC BIOL, V16, P252, DOI 10.1016/j.sbi.2006.03.013; Gambin Y, 2006, P NATL ACAD SCI USA, V103, P2098, DOI 10.1073/pnas.0511026103; Gautier I, 2001, BIOPHYS J, V80, P3000, DOI 10.1016/S0006-3495(01)76265-0; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Goin JC, 2006, J BIOL CHEM, V281, P5416, DOI 10.1074/jbc.M507476200; Grant M, 2004, J BIOL CHEM, V279, P36179, DOI 10.1074/jbc.M407310200; Gurevich VV, 2008, TRENDS PHARMACOL SCI, V29, P234, DOI 10.1016/j.tips.2008.02.004; Hanson MA, 2008, STRUCTURE, V16, P897, DOI 10.1016/j.str.2008.05.001; HEDLUND B, 1982, N-S ARCH PHARMACOL, V320, P3, DOI 10.1007/BF00499064; Heikal AA, 2001, CHEM PHYS, V274, P37, DOI 10.1016/S0301-0104(01)00486-4; HENIS YI, 1983, MOL PHARMACOL, V24, P357; Hermans E, 2003, PHARMACOL THERAPEUT, V99, P25, DOI 10.1016/S0163-7258(03)00051-2; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HIRSCHBERG BT, 1994, J BIOL CHEM, V269, P26127; Ilien B, 2003, J NEUROCHEM, V85, P768, DOI 10.1046/j.1471-4159.2003.01717.x; Jakubik J, 2000, J BIOL CHEM, V275, P18836, DOI 10.1074/jbc.M000112200; JARV J, 1979, J BIOL CHEM, V254, P5595; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Kenakin T, 2007, TRENDS PHARMACOL SCI, V28, P407, DOI 10.1016/j.tips.2007.06.009; Kim SA, 2007, NAT METHODS, V4, P963, DOI 10.1038/NMETH1104; KLEIN WL, 1980, BIOCHEM BIOPH RES CO, V93, P1058, DOI 10.1016/0006-291X(80)90596-3; KLOOG Y, 1978, BRAIN RES, V144, P31, DOI 10.1016/0006-8993(78)90433-X; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; Krichevsky O, 2002, REP PROG PHYS, V65, P251, DOI 10.1088/0034-4885/65/2/203; Lecat S, 2002, J BIOL CHEM, V277, P42034, DOI 10.1074/jbc.M203606200; Li JH, 2007, J BIOL CHEM, V282, P26284, DOI 10.1074/jbc.M704875200; Lidke DS, 2003, BIOCHEM SOC T, V31, P1020; Liu P, 2008, TRENDS ENDOCRIN MET, V19, P181, DOI 10.1016/j.tem.2008.02.004; Lohse MJ, 2007, ADV PROTEIN CHEM, V74, P167, DOI 10.1016/S0065-3233(07)74005-6; LUTHIN GR, 1984, MOL PHARMACOL, V26, P164; Ma AWS, 2007, BIOCHEMISTRY-US, V46, P7907, DOI 10.1021/bi6026105; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Meyer BH, 2006, P NATL ACAD SCI USA, V103, P2138, DOI 10.1073/pnas.0507686103; Muller JD, 2000, BIOPHYS J, V78, P474, DOI 10.1016/S0006-3495(00)76610-0; Palanche T, 2001, J BIOL CHEM, V276, P34853, DOI 10.1074/jbc.M104363200; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; Park PSH, 2003, BIOCHEMISTRY-US, V42, P12960, DOI 10.1021/bi034491m; Patel RC, 2002, P NATL ACAD SCI USA, V99, P3294, DOI 10.1073/pnas.042705099; Pepperkok R, 1999, CURR BIOL, V9, P269, DOI 10.1016/S0960-9822(99)80117-1; Perez DM, 2005, PHARMACOL REV, V57, P147, DOI 10.1124/pr.57.2.2; Philip F, 2007, J BIOL CHEM, V282, P19203, DOI 10.1074/jbc.M701558200; Pin JP, 2005, FEBS J, V272, P2947, DOI 10.1111/j.1742-4658.2005.04728.x; POTTER LT, 1991, MOL PHARMACOL, V39, P211; Reich J. G., 1992, CURVE FITTING MODELL; RIGLER R, 1993, EUR BIOPHYS J BIOPHY, V22, P169, DOI 10.1007/BF00185777; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Saffarian S, 2007, BIOPHYS J, V93, P1021, DOI 10.1529/biophysj.107.105494; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; Szidonya L, 2008, J ENDOCRINOL, V196, P435, DOI 10.1677/JOE-07-0573; Tahtaoui C, 2004, J MED CHEM, V47, P4300, DOI 10.1021/jm040800a; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Weill C, 1999, J NEUROCHEM, V73, P791, DOI 10.1046/j.1471-4159.1999.0730791.x; White JF, 2007, P NATL ACAD SCI USA, V104, P12199, DOI 10.1073/pnas.0705312104; Whorton MR, 2007, P NATL ACAD SCI USA, V104, P7682, DOI 10.1073/pnas.0611448104; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Ziessel R, 2007, NEW J CHEM, V31, P496, DOI 10.1039/b617972j	78	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	2009	284	29					19533	19543		10.1074/jbc.M109.017145	http://dx.doi.org/10.1074/jbc.M109.017145			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469OE	19451648	Green Published, hybrid			2022-12-25	WOS:000267908300045
J	Bouteille, N; Driouch, K; El Hage, P; Sin, S; Formstecher, E; Camonis, J; Lidereau, R; Lallemand, F				Bouteille, N.; Driouch, K.; El Hage, P.; Sin, S.; Formstecher, E.; Camonis, J.; Lidereau, R.; Lallemand, F.			Inhibition of the Wnt/beta-catenin pathway by the WWOX tumor suppressor protein	ONCOGENE			English	Article						WWOX; dishevelled; Wnt; beta-catenin; signaling pathway	CHROMOSOMAL FRAGILE SITE; WNT SIGNALING PATHWAY; KINASE-I-EPSILON; CANCER CELL-GROWTH; BREAST-CANCER; BETA-CATENIN; BINDING PROTEIN; GENE WWOX; C-JUN; EXPRESSION	The WWOX gene encodes a candidate tumor suppressor protein (WWOX) implicated in a variety of human diseases such as cancer. To better understand the molecular mechanisms of WWOX action, we investigated novel partners of this protein. Using the two-hybrid system and a coimmunoprecipitation assay, we observed a physical association between WWOX and the Dishevelled protein (Dvl) family signaling elements involved in the Wnt/beta-catenin pathway. We found that enforced WWOX expression inhibited, and inhibition of endogenous WWOX expression stimulated the transcriptional activity of the Wnt/beta-catenin pathway. Inhibition of endogenous WWOX expression also enhanced the effect of Wnt-3a on beta-catenin stability. Moreover, we observed the sequestration of Dvl-2 wild type and Dvl-2NESm, a mutated form of Dvl-2 predominantly localized in the nucleus, in the cytoplasm compartment by WWOX. Our results indicate that WWOX is a novel inhibitor of the Wnt/beta-catenin pathway. WWOX would act, at least in part, by preventing the nuclear import of the Dvl proteins. Oncogene (2009) 28, 2569-2580; doi: 10.1038/onc.2009.120; published online 25 May 2009	[Lallemand, F.] Ctr Rene Huguenin, Serv Oncogenet, INSERM, U528,FNCLCC, F-92210 St Cloud, France; [Bouteille, N.; Driouch, K.; El Hage, P.; Sin, S.; Lidereau, R.; Lallemand, F.] INSERM, U735, St Cloud, France; [Formstecher, E.] Hybrigenics, Paris, France; [Camonis, J.] Inst Curie, INSERM, U528, Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Lallemand, F (corresponding author), Ctr Rene Huguenin, Serv Oncogenet, INSERM, U528,FNCLCC, 35 Rue Dailly, F-92210 St Cloud, France.	f.lallemand@stcloud-huguenin.org		FORMSTECHER, Etienne/0000-0002-6410-4365	GenHomme Network [02490-6088]; Institut Curie	GenHomme Network; Institut Curie	We are grateful to Dr Trevor Dale for donating HA-Dvl-2 (mouse) expression vector, Dr Akira Kikuchi for donating pCCN/Dvl-1 (human) and pEF-BOS-myc/Dvl-3 (human) plasmids, Dr Howe PH for donating pCDNA3-myc/Axin (human) and Dr Shinji Takada for donating mouse. broblast L cells producing Wnt-3a and Lcells stably transfected with the pGKneo plasmid. We thank Ivan Bieche and Christian Gespash for useful comments, Florence Copigny and Cedrick Lefol for excellent technical assistance, and Philippe Leclerc (IFR 93, kremelin Bicetre, France) for immunofluorescence analysis. This work was supported by a GenHomme Network Grant (02490-6088) to Hybrigenics and Institut Curie. We thank all the Hybrigenics staff for their contribution and the staff of the Drosoman laboratory, headed by Jacques Camonis and supported by Institut Curie.	Aqeilan RI, 2007, CANCER RES, V67, P5606, DOI 10.1158/0008-5472.CAN-07-1081; Aqeilan RI, 2007, P NATL ACAD SCI USA, V104, P3949, DOI 10.1073/pnas.0609783104; Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Aqeilan RI, 2004, CANCER RES, V64, P8256, DOI 10.1158/0008-5472.CAN-04-2055; Aqeilian RI, 2007, CANCER RES, V67, P9330, DOI 10.1158/0008-5472.CAN-07-2147; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Brown AMC, 2001, BREAST CANCER RES, V3, P351, DOI 10.1186/bcr321; Chang NS, 2005, ONCOGENE, V24, P714, DOI 10.1038/sj.onc.1208124; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cong F, 2004, MOL CELL BIOL, V24, P2000, DOI 10.1128/MCB.24.5.2000-2011.2004; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273; Fabbri M, 2005, P NATL ACAD SCI USA, V102, P15611, DOI 10.1073/pnas.0505485102; Gan XQ, 2008, J CELL BIOL, V180, P1087, DOI 10.1083/jcb.200710050; Gaudio E, 2006, CANCER RES, V66, P11585, DOI 10.1158/0008-5472.CAN-06-3376; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Guler G, 2005, PATHOL INT, V55, P471, DOI 10.1111/j.1440-1827.2005.01855.x; Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137; HERBER B, 1994, ONCOGENE, V9, P1295; Hezova Renata, 2007, Biomedical Papers (Olomouc), V151, P11; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Hino SI, 2001, MOL CELL BIOL, V21, P330, DOI 10.1128/MCB.21.1.330-342.2001; Iliopoulos D, 2005, ONCOGENE, V24, P1625, DOI 10.1038/sj.onc.1208398; Iliopoulos D, 2007, CLIN CANCER RES, V13, P268, DOI 10.1158/1078-0432.CCR-06-2038; Ishii H, 2003, MOL CANCER RES, V1, P940; Itoh Keiji, 2005, J Biol, V4, P3, DOI 10.1186/jbiol20; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Klimowski LK, 2006, FEBS J, V273, P4594, DOI 10.1111/j.1742-4658.2006.05462.x; Kuroki T, 2004, CLIN CANCER RES, V10, P2459, DOI 10.1158/1078-0432.CCR-03-0096; Lallemand F, 2005, J BIOL CHEM, V280, P27645, DOI 10.1074/jbc.M500188200; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Ludes-Meyers JH, 2004, ONCOGENE, V23, P5049, DOI 10.1038/sj.onc.1207680; Ludes-Meyers JH, 2003, CYTOGENET GENOME RES, V100, P101, DOI 10.1159/000072844; Ludes-Meyers JH, 2007, GENE CHROMOSOME CANC, V46, P1129, DOI 10.1002/gcc.20497; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Nunez M, 2005, BREAST CANCER RES TR, V89, P99, DOI 10.1007/s10549-004-1474-x; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Paige AJW, 2000, CANCER RES, V60, P1690; Pimenta FJ, 2006, INT J CANCER, V118, P1154, DOI 10.1002/ijc.21446; Pluciennik E, 2006, EJSO-EUR J SURG ONC, V32, P153, DOI 10.1016/j.ejso.2005.11.002; Polakis P, 2000, GENE DEV, V14, P1837; Qin HR, 2007, MOL CANCER RES, V5, P957, DOI 10.1158/1541-7786.MCR-07-0211; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Shibamoto S, 1998, GENES CELLS, V3, P659; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Torres MA, 2000, J CELL BIOL, V149, P1433, DOI 10.1083/jcb.149.7.1433; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang X, 2009, TUMOR BIOL, V30, P8, DOI 10.1159/000197911; Watanabe A, 2003, CANCER RES, V63, P8629; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; Yokoyama Noriko, 2007, J Mol Signal, V2, P11, DOI 10.1186/1750-2187-2-11; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540	63	82	85	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2009	28	28					2569	2580		10.1038/onc.2009.120	http://dx.doi.org/10.1038/onc.2009.120			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	471LJ	19465938				2022-12-25	WOS:000268058900003
J	Foltz, G; Yoon, JG; Lee, H; Ryken, TC; Sibenaller, Z; Ehrich, M; Hood, L; Madan, A				Foltz, G.; Yoon, J-G; Lee, H.; Ryken, T. C.; Sibenaller, Z.; Ehrich, M.; Hood, L.; Madan, A.			DNA methyltransferase-mediated transcriptional silencing in malignant glioma: a combined whole-genome microarray and promoter array analysis	ONCOGENE			English	Article						epigenetics; histone modifications; methylation; glioblastoma	TUMOR-SUPPRESSOR GENES; CANCER-CELL-LINES; COLON-CARCINOMA CELLS; POLYMERASE-CHAIN-REACTION; DOWN-REGULATION; BRAIN-TUMORS; SYNDECAN-2 EXPRESSION; TUMORIGENIC ACTIVITY; COLORECTAL-CANCER; INITIATING CELLS	Epigenetic inactivation of tumor suppressor genes is a common feature in human cancer. Promoter hypermethylation and histone deacetylation are reversible epigenetic mechanisms associated with transcriptional regulation. DNA methyltransferases (DNMT1 and DNMT3b) regulate and maintain promoter methylation and are over-expressed in human cancer. We performed whole-genome microarray analysis to identify genes with altered expression after RNAi-induced suppression of DNMT in a glioblastoma multiforme (GBM) cell line. We then identified genes with both decreased expression and evidence of promoter CpG island hypermethylation in GBM tissue samples using a combined whole-genome microarray transcriptome analysis in conjunction with a promoter array analysis after DNA immunoprecipitation with anti-5-methylcytidine. DNMT1 and 3b knockdown resulted in the restored expression of 308 genes that also contained promoter region hypermethylation. Of these, 43 were also found to be downregulated in GBM tissue samples. Three downregulated genes with hypermethylated promoters and restored expression in response to acute DNMT suppression were assayed for methylation changes using bisulfite sequence analysis of the promoter region after chronic DNMT suppression. Restoration of gene expression was not associated with changes in promoter region methylation, but rather with changes in histone methylation and chromatin conformation. Two of the identified genes exhibited growth suppressive activity in in vitro assays. Combining targeted genetic manipulations with comprehensive genomic and expression analyses provides a potentially powerful new approach for identifying epigenetically regulated genes in GBM. Oncogene (2009) 28, 2667-2677; doi: 10.1038/onc.2009.122; published online 25 May 2009	[Foltz, G.; Yoon, J-G; Lee, H.; Madan, A.] Swedish Neurosci Inst, Ctr Adv Brain Tumor Treatment, Seattle, WA 98122 USA; [Foltz, G.; Hood, L.; Madan, A.] Inst Syst Biol, Seattle, WA USA; [Ryken, T. C.; Sibenaller, Z.] Univ Iowa, Dept Neurosurg, Iowa City, IA USA; [Ehrich, M.] Sequenome Inc, San Diego, CA USA	Swedish Medical Center; Institute for Systems Biology (ISB); University of Iowa; Sequenom	Madan, A (corresponding author), Swedish Neurosci Inst, Ctr Adv Brain Tumor Treatment, James Tower Suite 570,500 17th Ave, Seattle, WA 98122 USA.	anup.madan@swedish.org						Abdullah JM, 2007, NEUROL RES, V29, P239, DOI 10.1179/016164107X158965; Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284; Arai E, 2006, INT J CANCER, V119, P288, DOI 10.1002/ijc.21807; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Calvanese V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003294; Chen WY, 2005, CELL CYCLE, V4, P10, DOI 10.4161/cc.4.1.1361; Choe G, 2003, CANCER RES, V63, P2742; Costello JF, 1996, CANCER RES, V56, P2405; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dahl C, 2007, APMIS, V115, P1161, DOI 10.1111/j.1600-0463.2007.apm_855.xml.x; Deng YC, 2003, INT J CANCER, V106, P342, DOI 10.1002/ijc.11228; Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Ehrich M, 2008, P NATL ACAD SCI USA, V105, P4844, DOI 10.1073/pnas.0712251105; Essner JJ, 2006, INT J BIOCHEM CELL B, V38, P152, DOI 10.1016/j.biocel.2005.08.012; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fang JY, 2004, WORLD J GASTROENTERO, V10, P3394; Fears CY, 2006, J BIOL CHEM, V281, P14533, DOI 10.1074/jbc.C600075200; Foltz G, 2006, CANCER RES, V66, P6665, DOI 10.1158/0008-5472.CAN-05-4453; Fontijn D, 2007, MOL CANCER THER, V6, P2807, DOI 10.1158/1535-7163.MCT-07-0044; Girault I, 2003, CLIN CANCER RES, V9, P4415; Gonzalez-Gomez P, 2003, INT J ONCOL, V22, P601; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gronbaek K, 2007, APMIS, V115, P1039, DOI 10.1111/j.1600-0463.2007.apm_636.xml.x; Hambardzumyan D, 2006, CANCER CELL, V10, P454, DOI 10.1016/j.ccr.2006.11.008; Han I, 2004, J MOL HISTOL, V35, P319; Hayashi H, 2007, HUM GENET, V120, P701, DOI 10.1007/s00439-006-0254-6; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Ibanez de Caceres I, 2004, CANCER RES, V64, P6476; James SR, 2006, ONCOGENE, V25, P6975, DOI 10.1038/sj.onc.1209678; Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2; Karpf AR, 2007, CURR OPIN MOL THER, V9, P231; Kim HJ, 2006, CANCER, V107, P1042, DOI 10.1002/cncr.22087; Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552; Kim Y, 2003, ONCOGENE, V22, P826, DOI 10.1038/sj.onc.1206068; Kusano Y, 2004, J BIOCHEM, V135, P129, DOI 10.1093/jb/mvh015; LORENTE A, 2008, BRAIN PATHOL; Martinez R, 2007, CARCINOGENESIS, V28, P1264, DOI 10.1093/carcin/bgm014; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Milutinovic S, 2004, J BIOL CHEM, V279, P27915, DOI 10.1074/jbc.M312823200; Miranda TB, 2007, J CELL PHYSIOL, V213, P384, DOI 10.1002/jcp.21224; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Modrowski D, 2005, BONE, V37, P180, DOI 10.1016/j.bone.2005.04.010; Mueller W, 2007, ONCOGENE, V26, P583, DOI 10.1038/sj.onc.1209805; Park H, 2002, J BIOL CHEM, V277, P29730, DOI 10.1074/jbc.M202435200; Park HJ, 2006, CANCER LETT, V233, P271, DOI 10.1016/j.canlet.2005.03.017; Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Rao SH, 2001, J IMMUNOL, V167, P4494, DOI 10.4049/jimmunol.167.8.4494; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581; Schiappacassi M, 2008, MOL CANCER THER, V7, P1164, DOI 10.1158/1535-7163.MCT-07-2154; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Shi HD, 2003, CANCER RES, V63, P2164; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Shostak KO, 2003, J SURG ONCOL, V82, P57, DOI 10.1002/jso.10180; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stone AR, 2004, AM J PATHOL, V165, P1151, DOI 10.1016/S0002-9440(10)63376-7; Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046; Tan SH, 2007, ONCOL REP, V18, P1225; Wang Z, 2008, CANCER RES, V68, P492, DOI 10.1158/0008-5472.CAN-07-2930; Yan L, 2003, CANCER BIOL THER, V2, P552, DOI 10.4161/cbt.2.5.469; Zhang W, 2007, DIS COLON RECTUM, V50, P1618, DOI 10.1007/s10350-007-0286-6	70	40	43	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2667	2677		10.1038/onc.2009.122	http://dx.doi.org/10.1038/onc.2009.122			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19465937				2022-12-25	WOS:000268211200005
J	Achilli, A; Bonfiglio, S; Olivieri, A; Malusa, A; Pala, M; Kashani, BH; Perego, UA; Ajmone-Marsan, P; Liotta, L; Semino, O; Bandelt, HJ; Ferretti, L; Torroni, A				Achilli, Alessandro; Bonfiglio, Silvia; Olivieri, Anna; Malusa, Arianna; Pala, Maria; Kashani, Baharak Hooshiar; Perego, Ugo A.; Ajmone-Marsan, Paolo; Liotta, Luigi; Semino, Ornella; Bandelt, Hans-Juergen; Ferretti, Luca; Torroni, Antonio			The Multifaceted Origin of Taurine Cattle Reflected by the Mitochondrial Genome	PLOS ONE			English	Article								A Neolithic domestication of taurine cattle in the Fertile Crescent from local aurochsen (Bos primigenius) is generally accepted, but a genetic contribution from European aurochsen has been proposed. Here we performed a survey of a large number of taurine cattle mitochondrial DNA (mtDNA) control regions from numerous European breeds confirming the overall clustering within haplogroups (T1, T2 and T3) of Near Eastern ancestry, but also identifying eight mtDNAs (1.3%) that did not fit in haplogroup T. Sequencing of the entire mitochondrial genome showed that four mtDNAs formed a novel branch (haplogroup R) which, after the deep bifurcation that gave rise to the taurine and zebuine lineages, constitutes the earliest known split in the mtDNA phylogeny of B. primigenius. The remaining four mtDNAs were members of the recently discovered haplogroup Q. Phylogeographic data indicate that R mtDNAs were derived from female European aurochsen, possibly in the Italian Peninsula, and sporadically included in domestic herds. In contrast, the available data suggest that Q mtDNAs and T subclades were involved in the same Neolithic event of domestication in the Near East. Thus, the existence of novel (and rare) taurine haplogroups highlights a multifaceted genetic legacy from distinct B. primigenius populations. Taking into account that the maternally transmitted mtDNA tends to underestimate the extent of gene flow from European aurochsen, the detection of the R mtDNAs in autochthonous breeds, some of which are endangered, identifies an unexpected reservoir of genetic variation that should be carefully preserved.			Achilli, A (corresponding author), Univ Pavia, Dipartimento Genet & Microbiol, Via Palestro 3, I-27100 Pavia, Italy.	lucaf@ipvgen.unipv.it; torroni@ipvgen.unipv.it	Torroni, Antonio/E-1557-2011; OLIVIERI, ANNA/I-9235-2012; Perego, Ugo/AAG-9327-2019; Bonfiglio, Silvia/AAC-1988-2019; Ferretti, Luca/D-2337-2013; Achilli, Alessandro/I-9236-2012; Liotta, Luigi/P-6190-2015; AJMONE MARSAN, Paolo/M-2466-2018	Torroni, Antonio/0000-0002-4163-4478; OLIVIERI, ANNA/0000-0002-3941-8098; Achilli, Alessandro/0000-0001-6871-3451; Bonfiglio, Silvia/0000-0002-4422-1580; SEMINO, Ornella/0000-0002-9675-9403; AJMONE MARSAN, Paolo/0000-0003-3165-4579; Ferretti, Luca/0000-0001-5044-8442; Pala, Maria/0000-0001-9202-8331; Liotta, Luigi/0000-0002-3242-1817				Achilli A, 2008, CURR BIOL, V18, pR157, DOI 10.1016/j.cub.2008.01.019; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; Anderung C, 2005, P NATL ACAD SCI USA, V102, P8431, DOI 10.1073/pnas.0503396102; Beja-Pereira A, 2006, P NATL ACAD SCI USA, V103, P8113, DOI 10.1073/pnas.0509210103; Bollongino R, 2006, BIOL LETTERS, V2, P155, DOI 10.1098/rsbl.2005.0404; Bollongino R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003418; Bradley DG, 1998, EVOL ANTHROPOL, V6, P79, DOI 10.1002/(SICI)1520-6505(1998)6:3<79::AID-EVAN2>3.0.CO;2-R; Bradley DG, 1996, P NATL ACAD SCI USA, V93, P5131, DOI 10.1073/pnas.93.10.5131; Carvajal-Carmona LG, 2003, GENETICS, V165, P1457; Cortes O, 2008, ANIM GENET, V39, P649, DOI 10.1111/j.1365-2052.2008.01782.x; Cymbron T, 1999, P ROY SOC B-BIOL SCI, V266, P597, DOI 10.1098/rspb.1999.0678; Edwards CJ, 2007, P ROY SOC B-BIOL SCI, V274, P1377, DOI 10.1098/rspb.2007.0020; Gotherstrom A, 2005, P ROY SOC B-BIOL SCI, V272, P2345, DOI 10.1098/rspb.2005.3243; Hiendleder S, 2008, CYTOGENET GENOME RES, V120, P150, DOI 10.1159/000118756; Lai SJ, 2006, MOL PHYLOGENET EVOL, V38, P146, DOI 10.1016/j.ympev.2005.06.013; Larson G, 2005, SCIENCE, V307, P1618, DOI 10.1126/science.1106927; Lei CZ, 2006, ANIM GENET, V37, P579, DOI 10.1111/j.1365-2052.2006.01524.x; Loftus RT, 1999, MOL ECOL, V8, P2015, DOI 10.1046/j.1365-294x.1999.00805.x; LOFTUS RT, 1994, P NATL ACAD SCI USA, V91, P2757, DOI 10.1073/pnas.91.7.2757; Mannen H, 2004, MOL PHYLOGENET EVOL, V32, P539, DOI 10.1016/j.ympev.2004.01.010; Pellecchia M, 2007, P R SOC B, V274, P1175, DOI 10.1098/rspb.2006.0258; Richards M, 2001, AM J HUM GENET, V68, P1315, DOI 10.1086/320615; Schlumbaum A, 2006, ANIM GENET, V37, P373, DOI 10.1111/j.1365-2052.2006.01435.x; STOCK F, 2009, ANIM GENET IN PRESS; Taberlet P, 1998, MOL ECOL, V7, P453, DOI 10.1046/j.1365-294x.1998.00289.x; Torroni A, 2006, TRENDS GENET, V22, P339, DOI 10.1016/j.tig.2006.04.001; Troy CS, 2001, NATURE, V410, P1088, DOI 10.1038/35074088	27	136	139	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2009	4	6							e5753	10.1371/journal.pone.0005753	http://dx.doi.org/10.1371/journal.pone.0005753			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	452GL	19484124	Green Published, Green Submitted, gold, Green Accepted			2022-12-25	WOS:000266528200006
J	Miller, CMD; Smith, NC; Ikin, RJ; Boulter, NR; Dalton, JP; Donnelly, S				Miller, Catherine M. D.; Smith, Nicholas C.; Ikin, Rowan J.; Boulter, Nicola R.; Dalton, John P.; Donnelly, Sheila			Immunological Interactions between 2 Common Pathogens, Th1-Inducing Protozoan Toxoplasma gondii and the Th2-Inducing Helminth Fasciola hepatica	PLOS ONE			English	Article								Background: The nature of the immune response to infection is dependent on the type of infecting organism. Intracellular organisms such as Toxoplasma gondii stimulate a Th1-driven response associated with production of IL-12, IFN-gamma, nitric oxide and IgG2a antibodies and classical activation of macrophages. In contrast, extracellular helminths such as Fasciola hepatica induce Th2 responses characterised by the production of IL-4, IL-5, IL-10 and IgG1 antibodies and alternative activation of macrophages. As co-infections with these types of parasites commonly exist in the field it is relevant to examine how the various facets of the immune responses induced by each may influence or counter-regulate that of the other. Principal Findings: Regardless, of whether F. hepatica infection preceded or succeeded T. gondii infection, there was little impact on the production of the Th1 cytokines IL-12, IFN-gamma or on the development of classically-activated macrophages induced by T. gondii. By contrast, the production of helminth-specific Th2 cytokines, such as IL-4 and IL-5, was suppressed by infection with T. gondii. Additionally, the recruitment and alternative activation of macrophages by F. hepatica was blocked or reversed by subsequent infection with T. gondii. The clinical symptoms of toxoplasmosis and the survival rate of infected mice were not significantly altered by the helminth. Conclusions: Despite previous studies showing that F. hepatica suppressed the classical activation of macrophages and the Th1-driven responses of mice to bystander microbial infection, as well as reduced their ability to reject these, here we found that the potent immune responses to T. gondii were capable of suppressing the responses to helminth infection. Clearly, the outcome of particular infections in polyparasitoses depends on the means and potency by which each pathogen controls the immune response.			Miller, CMD (corresponding author), Univ Technol Sydney, Sydney, NSW 2007, Australia.	Catherine.Miller@uts.edu.au	Donnelly, Sheila/H-7733-2014; Miller, Catherine/G-9368-2011; Dalton, John/K-4457-2014	Miller, Catherine/0000-0001-6071-5102; Donnelly, Sheila/0000-0003-2005-3698; Smith, Nicholas/0000-0002-7467-1451				Aliberti J, 2005, NAT REV IMMUNOL, V5, P162, DOI 10.1038/nri1547; Anthony RM, 2006, NAT MED, V12, P955, DOI 10.1038/nm1451; Araujo MI, 2001, INFECT IMMUN, V69, P1454, DOI 10.1128/IAI.69.3.1454-1462.2001; Boucher JL, 1999, CELL MOL LIFE SCI, V55, P1015, DOI 10.1007/s000180050352; Boyle JP, 2007, EXP PARASITOL, V116, P302, DOI 10.1016/j.exppara.2007.01.010; Brady MT, 1999, INFECT IMMUN, V67, P5372, DOI 10.1128/IAI.67.10.5372-5378.1999; Brunet LR, 2001, INT IMMUNOPHARMACOL, V1, P1457, DOI 10.1016/S1567-5769(01)00090-X; Chiu BC, 2002, PARASITE IMMUNOL, V24, P285, DOI 10.1046/j.1365-3024.2002.00466.x; De Nadai P, 2006, J IMMUNOL, V176, P6286, DOI 10.4049/jimmunol.176.10.6286; DEROUIN F, 2008, CLIN MICROBIOL  1115; Donnelly S, 2005, INFECT IMMUN, V73, P166, DOI 10.1128/IAI.73.1.166-173.2005; Fouts AE, 2007, INFECT IMMUN, V75, P634, DOI 10.1128/IAI.01228-06; GAZZINELLI RT, 1994, J IMMUNOL, V153, P2533; Jankovic D, 2001, TRENDS IMMUNOL, V22, P450, DOI 10.1016/S1471-4906(01)01975-5; Kodelja V, 1998, J IMMUNOL, V160, P1411; Liesenfeld O, 2004, INFECT IMMUN, V72, P3812, DOI 10.1128/IAI.72.7.3812-3822.2004; Loke P, 2000, EUR J IMMUNOL, V30, P1127, DOI 10.1002/(SICI)1521-4141(200004)30:4&lt;1127::AID-IMMU1127&gt;3.0.CO;2-#; Marshall AJ, 1999, J IMMUNOL, V163, P2089; Miller C, 2005, INT J PARASITOL, V35, P821, DOI 10.1016/j.ijpara.2005.03.006; Miller CMD, 2000, INT J PARASITOL, V30, P1467, DOI 10.1016/S0020-7519(00)00118-1; Montoya JG, 2004, LANCET, V363, P1965, DOI 10.1016/S0140-6736(04)16412-X; Mulcahy G, 1999, FASCIOLOSIS, P341; Nair MG, 2003, IMMUNOL LETT, V85, P173, DOI 10.1016/S0165-2478(02)00225-0; Nguyen TD, 1998, INFECT IMMUN, V66, P2991, DOI 10.1128/IAI.66.6.2991-2995.1998; O'Neill SM, 2001, PARASITE IMMUNOL, V23, P541, DOI 10.1046/j.1365-3024.2001.00411.x; O'Neill SM, 2000, PARASITE IMMUNOL, V22, P147, DOI 10.1046/j.1365-3024.2000.00290.x; Piedrafita D, 2000, PARASITE IMMUNOL, V22, P287, DOI 10.1046/j.1365-3024.2000.00300.x; Robben PM, 2004, J IMMUNOL, V172, P3686, DOI 10.4049/jimmunol.172.6.3686; Rodriguez-Sosa M, 2002, INFECT IMMUN, V70, P3656, DOI 10.1128/IAI.70.7.3656-3664.2002; Santiago HC, 1999, INFECT IMMUN, V67, P4939, DOI 10.1128/IAI.67.9.4939-4944.1999; Sasaki M, 2001, J MED MICROBIOL, V50, P952, DOI 10.1099/0022-1317-50-11-952; Stoicov C, 2004, J IMMUNOL, V173, P3329, DOI 10.4049/jimmunol.173.5.3329; VENKATESAN P, 1993, PARASITOL TODAY, V9, P228, DOI 10.1016/0169-4758(93)90020-G; Vulcano M, 2003, J IMMUNOL, V170, P3843, DOI 10.4049/jimmunol.170.7.3843	34	36	38	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2009	4	5							e5692	10.1371/journal.pone.0005692	http://dx.doi.org/10.1371/journal.pone.0005692			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LI	19478853	Green Accepted, Green Published, gold			2022-12-25	WOS:000266331700017
J	Ahier, A; Rondard, P; Gouignard, N; Khayath, N; Huang, S; Trolet, J; Donoghue, DJ; Gauthier, M; Pin, JP; Dissous, C				Ahier, Arnaud; Rondard, Philippe; Gouignard, Nadege; Khayath, Naji; Huang, Siluo; Trolet, Jacques; Donoghue, Daniel J.; Gauthier, Monique; Pin, Jean-Philippe; Dissous, Colette			A New Family of Receptor Tyrosine Kinases with a Venus Flytrap Binding Domain in Insects and Other Invertebrates Activated by Aminoacids	PLOS ONE			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; AGONIST-BINDING; PROTEIN; TRANSDUCTION; REPERTOIRE; PREDICTION; MECHANISM; EVOLUTION	Background: Tyrosine kinase receptors (RTKs) comprise a large family of membrane receptors that regulate various cellular processes in cell biology of diverse organisms. We previously described an atypical RTK in the platyhelminth parasite Schistosoma mansoni, composed of an extracellular Venus flytrap module (VFT) linked through a single transmembrane domain to an intracellular tyrosine kinase domain similar to that of the insulin receptor. Methods and Findings: Here we show that this receptor is a member of a new family of RTKs found in invertebrates, and particularly in insects. Sixteen new members of this family, named Venus Kinase Receptor (VKR), were identified in many insects. Structural and phylogenetic studies performed on VFT and TK domains showed that VKR sequences formed monophyletic groups, the VFT group being close to that of GABA(B) receptors and the TK one being close to that of insulin receptors. We show that a recombinant VKR is able to autophosphorylate on tyrosine residues, and report that it can be activated by L-arginine. This is in agreement with the high degree of conservation of the alpha amino acid binding residues found in many amino acid binding VFTs. The presence of high levels of vkr transcripts in larval forms and in female gonads indicates a putative function of VKR in reproduction and/or development. Conclusion: The identification of RTKs specific for parasites and insect vectors raises new perspectives for the control of human parasitic and infectious diseases.			Ahier, A (corresponding author), Univ Lille 2, INSERM, Inst Pasteur, U547, Lille, France.	colette.dissous@pasteur-lille.fr	Rondard, Philippe/N-9720-2018; Pin, Jean-Philippe/Y-6668-2019	Pin, Jean-Philippe/0000-0002-1423-345X; Gouignard, Nadege/0000-0001-8787-2503; Ahier, Arnaud/0000-0002-9999-3887; RONDARD, Philippe/0000-0003-1134-2738; Dissous, Colette/0000-0002-5003-8205				Acher FC, 2005, BIOPOLYMERS, V80, P357, DOI 10.1002/bip.20229; Alioto TS, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-173; Bjarndottir TK, 2005, GENE, V362, P70, DOI 10.1016/j.gene.2005.07.029; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; Brauner-Osborne H, 2007, CURR DRUG TARGETS, V8, P169, DOI 10.2174/138945007779315614; Catherinot V, 2004, BIOINFORMATICS, V20, P3694, DOI 10.1093/bioinformatics/bth429; Crossley C, 2007, NINETEEN CENT FR ST, V35, P491; Dalton R, 2009, NATURE, V457, P368, DOI 10.1038/457368a; Efron B, 1996, P NATL ACAD SCI USA, V93, P13429, DOI 10.1073/pnas.93.23.13429; GRAU Y, 2007, Patent No. 2007132090; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hansen IA, 2005, J BIOL CHEM, V280, P20565, DOI 10.1074/jbc.M500712200; Hansen IA, 2004, P NATL ACAD SCI USA, V101, P10626, DOI 10.1073/pnas.0403460101; He XL, 2001, SCIENCE, V293, P1657, DOI 10.1126/science.1062246; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Kucharski R., 2007, Invertebrate Neuroscience, V7, P99, DOI 10.1007/s10158-007-0045-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370; Lapraz F, 2006, DEV BIOL, V300, P132, DOI 10.1016/j.ydbio.2006.08.048; Lawson D, 2007, NUCLEIC ACIDS RES, V35, pD503, DOI 10.1093/nar/gkl960; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; Maurel D, 2008, NAT METHODS, V5, P561, DOI [10.1038/nmeth.1213, 10.1038/NMETH.1213]; Miller MA, 2000, DEV BIOL, V224, P286, DOI 10.1006/dbio.2000.9786; Mitri C, 2004, J BIOL CHEM, V279, P9313, DOI 10.1074/jbc.M310878200; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Ogawa H, 2004, J BIOL CHEM, V279, P28625, DOI 10.1074/jbc.M313222200; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Paoletti P, 2007, CURR OPIN PHARMACOL, V7, P39, DOI 10.1016/j.coph.2006.08.011; Pin JP, 2005, FEBS J, V272, P2947, DOI 10.1111/j.1742-4658.2005.04728.x; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Reidling JC, 2000, J BIOL CHEM, V275, P10323, DOI 10.1074/jbc.275.14.10323; Rondard P, 2008, EMBO J, V27, P1321, DOI 10.1038/emboj.2008.64; Rondard P, 2006, J BIOL CHEM, V281, P24653, DOI 10.1074/jbc.M602277200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Stanke M, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-62; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van der Werf MJ, 2003, ACTA TROP, V86, P125, DOI 10.1016/S0001-706X(03)00029-9; Vicogne J, 2003, MOL BIOCHEM PARASIT, V126, P51, DOI 10.1016/S0166-6851(02)00249-9; Webster MK, 1996, MOL CELL BIOL, V16, P4081; Wellendorph P, 2005, MOL PHARMACOL, V67, P589, DOI 10.1124/mol.104.007559; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	49	44	46	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2009	4	5							e5651	10.1371/journal.pone.0005651	http://dx.doi.org/10.1371/journal.pone.0005651			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LB	19461966	Green Published, Green Submitted, gold			2022-12-25	WOS:000266331000010
J	Herbst, KJ; Allen, MD; Zhang, J				Herbst, Katie J.; Allen, Michael D.; Zhang, Jin			The cAMP-Dependent Protein Kinase Inhibitor H-89 Attenuates the Bioluminescence Signal Produced by Renilla Luciferase	PLOS ONE			English	Article							ASSAYS; BIOSENSORS; DYNAMICS; FAMILY	Background: Investigations into the regulation and functional roles of kinases such as cAMP-dependent protein kinase (PKA) increasingly rely on cellular assays. Currently, there are a number of bioluminescence-based assays, for example reporter gene assays, that allow the study of the regulation, activity, and functional effects of PKA in the cellular context. Additionally there are continuing efforts to engineer improved biosensors that are capable of detecting real-time PKA signaling dynamics in cells. These cell-based assays are often utilized to test the involvement of PKA-dependent processes by using H-89, a reversible competitive inhibitor of PKA. Principal Findings: We present here data to show that H-89, in addition to being a competitive PKA inhibitor, attenuates the bioluminescence signal produced by Renilla luciferase (RLuc) variants in a population of cells and also in single cells. Using 10 mM of luciferase substrate and 10 mM H-89, we observed that the signal from RLuc and RLuc8, an eight-point mutation variant of RLuc, in cells was reduced to 50% (+/- 15%) and 54% (+/- 14%) of controls exposed to the vehicle alone, respectively. In vitro, we showed that H-89 decreased the RLuc8 bioluminescence signal but did not compete with coelenterazine-h for the RLuc8 active site, and also did not affect the activity of Firefly luciferase. By contrast, another competitive inhibitor of PKA, KT5720, did not affect the activity of RLuc8. Significance: The identification and characterization of the adverse effect of H-89 on RLuc signal will help deconvolute data previously generated from RLuc-based assays looking at the functional effects of PKA signaling. In addition, for the current application and future development of bioluminscence assays, KT5720 is identified as a more suitable PKA inhibitor to be used in conjunction with RLuc-based assays. These principal findings also provide an important lesson to fully consider all of the potential effects of experimental conditions on a cell-based assay readout before drawing conclusions from the data.			Herbst, KJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.	jzhang32@jhmi.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073368] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK073368] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen MD, 2006, BIOCHEM BIOPH RES CO, V348, P716, DOI 10.1016/j.bbrc.2006.07.136; Andorfer CA, 2000, DEV NEUROSCI-BASEL, V22, P303, DOI 10.1159/000017454; Auld DS, 2008, J MED CHEM, V51, P2372, DOI 10.1021/jm701302v; Auld DS, 2009, P NATL ACAD SCI USA, V106, P3585, DOI 10.1073/pnas.0813345106; Bakhtiarova A, 2006, BIOCHEM BIOPH RES CO, V351, P481, DOI 10.1016/j.bbrc.2006.10.057; Brovko Lubov Y., 2007, Science Progress, V90, P129, DOI 10.3184/003685007X215986; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Costanzo V, 1999, CURR BIOL, V9, P903, DOI 10.1016/S0960-9822(99)80395-9; Dalton GD, 2006, NEUROPEPTIDES, V40, P23, DOI 10.1016/j.npep.2005.10.002; Deroo BJ, 2002, J BIOL CHEM, V277, P20120, DOI 10.1074/jbc.C200173200; Fan F, 2008, ACS CHEM BIOL, V3, P346, DOI 10.1021/cb8000414; Fan F, 2007, ASSAY DRUG DEV TECHN, V5, P127, DOI 10.1089/adt.2006.053; Inglese J, 2007, NAT CHEM BIOL, V3, P466, DOI 10.1038/nchembio.2007.17; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; Loening AM, 2006, PROTEIN ENG DES SEL, V19, P391, DOI 10.1093/protein/gzl023; MATYAKHINA L, 2006, ANN NY ACAD SCI, V968, P148; MILLER WR, 2006, ANN NY ACAD SCI, V968, P37; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; Nesher R, 2002, DIABETES, V51, pS68, DOI 10.2337/diabetes.51.2007.S68; OKADA Y, 1995, J NEUROSCI, V15, P3053; Rocha S, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-9; ROSENBERG D, 2006, ANN NY ACAD SCI, V968, P65; Ruehr ML, 2004, J MOL CELL CARDIOL, V37, P653, DOI 10.1016/j.yjmcc.2004.04.017; Stefan E, 2007, P NATL ACAD SCI USA, V104, P16916, DOI 10.1073/pnas.0704257104; Taylor SS, 2008, BBA-PROTEINS PROTEOM, V1784, P16, DOI 10.1016/j.bbapap.2007.10.002; Woo JC, 2008, PROTEIN SCI, V17, P725, DOI 10.1110/ps.073355508; Zhang J, 2005, NATURE, V437, P569, DOI 10.1038/nature04140; Zhang J, 2007, MOL BIOSYST, V3, P759, DOI 10.1039/b706628g; Zhang LM, 2007, NAT MED, V13, P1114, DOI 10.1038/nm1608	30	21	22	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2009	4	5							e5642	10.1371/journal.pone.0005642	http://dx.doi.org/10.1371/journal.pone.0005642			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LB	19461967	Green Published, gold, Green Submitted			2022-12-25	WOS:000266331000001
J	Karaca, M; Castel, J; Tourrel-Cuzin, C; Brun, M; Geant, A; Dubois, M; Catesson, S; Rodriguez, M; Luquet, S; Cattan, P; Lockhart, B; Lang, JC; Ktorza, A; Magnan, C; Kargar, C				Karaca, Melis; Castel, Julien; Tourrel-Cuzin, Cecile; Brun, Manuel; Geant, Anne; Dubois, Mathilde; Catesson, Sandra; Rodriguez, Marianne; Luquet, Serge; Cattan, Pierre; Lockhart, Brian; Lang, Jochen; Ktorza, Alain; Magnan, Christophe; Kargar, Catherine			Exploring Functional beta-Cell Heterogeneity In Vivo Using PSA-NCAM as a Specific Marker	PLOS ONE			English	Article								Background: The mass of pancreatic beta-cells varies according to increases in insulin demand. It is hypothesized that functionally heterogeneous beta-cell subpopulations take part in this process. Here we characterized two functionally distinct groups of beta-cells and investigated their physiological relevance in increased insulin demand conditions in rats. Methods: Two rat beta-cell populations were sorted by FACS according to their PSA-NCAM surface expression, i.e. beta(high) and beta(low)-cells. Insulin release, Ca(2+) movements, ATP and cAMP contents in response to various secretagogues were analyzed. Gene expression profiles and exocytosis machinery were also investigated. In a second part, beta(high) and beta(low)-cell distribution and functionality were investigated in animal models with decreased or increased beta-cell function: the Zucker Diabetic Fatty rat and the 48 h glucose-infused rat. Results: We show that beta-cells are heterogeneous for PSA-NCAM in rat pancreas. Unlike beta(low)-cells, beta(high)-cells express functional beta-cell markers and are highly responsive to various insulin secretagogues. Whereas beta(low)-cells represent the main population in diabetic pancreas, an increase in beta(high)-cells is associated with gain of function that follows sustained glucose overload. Conclusion: Our data show that a functional heterogeneity of beta-cells, assessed by PSA-NCAM surface expression, exists in vivo. These findings pinpoint new target populations involved in endocrine pancreas plasticity and in beta-cell defects in type 2 diabetes.			Karaca, M (corresponding author), Univ Paris Diderot, Lab Physiopathol Nutr, CNRS, UMR 7059, Paris, France.	meliskaraca@gmail.com	Luquet, serge/AAT-1809-2021; Dubois, Mathilde/M-2971-2014; Lang, Jochen/B-1215-2010; magnan, christophe/AAJ-7622-2021; Lang, Jochen/F-5782-2014	Luquet, serge/0000-0001-8668-6645; Lang, Jochen/0000-0001-6847-5641; magnan, christophe/0000-0002-7044-2571; Lang, Jochen/0000-0001-6847-5641; CASTEL, JULIEN/0000-0003-4309-701X; Karaca, Melis/0000-0001-6951-3507; Tourrel-Cuzin, Cecile/0000-0002-5368-4018				Ahren B, 2003, J CLIN ENDOCR METAB, V88, P1264, DOI 10.1210/jc.2002-021547; Bernard C, 1998, DIABETES, V47, P1058, DOI 10.2337/diabetes.47.7.1058; Bernard-Kargar C, 2001, DIABETES, V50, pS125, DOI 10.2337/diabetes.50.2007.S125; Boal F, 2004, BIOCHEMISTRY-US, V43, P16212, DOI 10.1021/bi048612+; BOSCO D, 1991, ENDOCRINOLOGY, V129, P3157, DOI 10.1210/endo-129-6-3157; Bosco D, 2007, J ENDOCRINOL, V194, P21, DOI 10.1677/JOE-06-0169; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; Dachicourt N, 1996, AM J PHYSIOL-ENDOC M, V271, pE725, DOI 10.1152/ajpendo.1996.271.4.E725; Dubois M, 2007, ENDOCRINOLOGY, V148, P1605, DOI 10.1210/en.2006-1022; Eliasson L, 2008, J PHYSIOL-LONDON, V586, P3313, DOI 10.1113/jphysiol.2008.155317; Emre Y, 2007, P NATL ACAD SCI USA, V104, P19085, DOI 10.1073/pnas.0709557104; HIRIART M, 1991, ENDOCRINOLOGY, V128, P3193, DOI 10.1210/endo-128-6-3193; HIRIART M, 1995, BIOCHEM MOL MED, V54, P133, DOI 10.1006/bmme.1995.1019; HOWELL SL, 1982, DIABETOLOGIA, V22, P301; Karaca M, 2009, DIABETES METAB, V35, P77, DOI 10.1016/j.diabet.2008.09.007; KIEKENS R, 1992, J CLIN INVEST, V89, P117, DOI 10.1172/JCI115551; KISS JZ, 1994, EMBO J, V13, P5284, DOI 10.1002/j.1460-2075.1994.tb06862.x; KLOPPEL G, 1985, SURV SYN PATHOL RES, V4, P110; Leibowitz G, 2001, DIABETES, V50, P1799, DOI 10.2337/diabetes.50.8.1799; Ling ZD, 2006, DIABETES, V55, P78, DOI 10.2337/diabetes.55.01.06.db05-0820; Matschinsky F.M., 2001, HDB PHYSL 7, P125; Meier JJ, 2008, DIABETOLOGIA, V51, P703, DOI 10.1007/s00125-008-0936-9; NIELSEN DA, 1982, DIABETES, V31, P299, DOI 10.2337/diabetes.31.4.299; PARSONS JA, 1992, ENDOCRINOLOGY, V130, P1459, DOI 10.1210/en.130.3.1459; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; PIPELEERS DG, 1992, DIABETES, V41, P777, DOI 10.2337/diabetes.41.7.777; Prentki M, 2006, J CLIN INVEST, V116, P1802, DOI 10.1172/JCI29103; Quintens R, 2008, BIOCHEM SOC T, V36, P300, DOI 10.1042/BST0360300; SCHUIT FC, 1988, P NATL ACAD SCI USA, V85, P3865, DOI 10.1073/pnas.85.11.3865; Shibasaki T, 2007, P NATL ACAD SCI USA, V104, P19333, DOI 10.1073/pnas.0707054104; Theodosis DT, 1999, J NEUROSCI, V19, P10228; Tomas A, 2006, J CELL SCI, V119, P2156, DOI 10.1242/jcs.02942; Topp BG, 2007, AM J PHYSIOL-ENDOC M, V293, pE1730, DOI 10.1152/ajpendo.00572.2007; VANDEWINKEL M, 1983, BIOCHEM BIOPH RES CO, V114, P835, DOI 10.1016/0006-291X(83)90857-4; VANSCHRAVENDIJK CFH, 1992, J BIOL CHEM, V267, P21344; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; White P, 2008, DIABETES, V57, P654, DOI 10.2337/db07-1362; Yang JC, 2006, DIABETES, V55, P193, DOI 10.2337/diabetes.55.01.06.db05-0938	38	35	37	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2009	4	5							e5555	10.1371/journal.pone.0005555	http://dx.doi.org/10.1371/journal.pone.0005555			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FZ	19440374	Green Submitted, gold, Green Published			2022-12-25	WOS:000266107500002
J	Denuc, A; Bosch-Comas, A; Gonzalez-Duarte, R; Marfany, G				Denuc, Amanda; Bosch-Comas, Anna; Gonzalez-Duarte, Roser; Marfany, Gemma			The UBA-UIM Domains of the USP25 Regulate the Enzyme Ubiquitination State and Modulate Substrate Recognition	PLOS ONE			English	Article								USP25m is the muscle isoform of the deubiquitinating (DUB) enzyme USP25. Similarly to most DUBs, data on USP25 regulation and substrate recognition is scarce. In silico analysis predicted three ubiquitin binding domains (UBDs) at the Nterminus: one ubiquitin-associated domain (UBA) and two ubiquitin-interacting motifs (UIMs), whereas no clear structural homology at the extended C-terminal region outside the catalytic domains were detected. In order to asses the contribution of the UBDs and the C-terminus to the regulation of USP25m catalytic activity, ubiquitination state and substrate interaction, serial and combinatorial deletions were generated. Our results showed that USP25m catalytic activity did not strictly depend on the UBDs, but required a coiled-coil stretch between amino acids 679 to 769. USP25 oligomerized but this interaction did not require either the UBDs or the C-terminus. Besides, USP25 was monoubiquitinated and able to autodeubiquitinate in a possible loop of autoregulation. UBDs favored the monoubiquitination of USP25m at the preferential site lysine 99 (K99). This residue had been previously shown to be a target for SUMO and this modification inhibited USP25 activity. We showed that mutation of K99 clearly diminished USP25-dependent rescue of the specific substrate MyBPC1 from proteasome degradation, thereby supporting a new mechanistic model, in which USP25m is regulated through alternative conjugation of ubiquitin (activating) or SUMO (inhibiting) to the same lysine residue (K99), which may promote the interaction with distinct intramolecular regulatory domains.			Denuc, A (corresponding author), Univ Barcelona, Fac Biol, Dept Genet, Barcelona, Spain.	gmarfany@ub.edu	Marfany, Gemma/I-5668-2015	Marfany, Gemma/0000-0001-7941-983X				Avvakumov GV, 2006, J BIOL CHEM, V281, P38061, DOI 10.1074/jbc.M606704200; Berke SJS, 2005, J BIOL CHEM, V280, P32026, DOI 10.1074/jbc.M506084200; Bosch-Comas A, 2006, CELL MOL LIFE SCI, V63, P723, DOI 10.1007/s00018-005-5533-1; Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Groothuis TAM, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-21; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hurley JH, 2006, BIOCHEM J, V399, P361, DOI 10.1042/BJ20061138; Kim JH, 2003, J BIOCHEM, V134, P9, DOI 10.1093/jb/mvg107; Kirkin V, 2007, CURR OPIN CELL BIOL, V19, P199, DOI 10.1016/j.ceb.2007.02.002; Knipscheer P, 2007, CURR OPIN STRUC BIOL, V17, P665, DOI 10.1016/j.sbi.2007.09.001; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Marfany G, 2008, BIOCHEM SOC T, V36, P833, DOI 10.1042/BST0360833; Meek DW, 2003, MOL CANCER RES, V1, P1017; Meulmeester E, 2008, MOL CELL, V30, P610, DOI 10.1016/j.molcel.2008.03.021; Miller SLH, 2004, J BIOL CHEM, V279, P33528, DOI 10.1074/jbc.M313097200; Mohideen F, 2008, MOL CELL, V30, P539, DOI 10.1016/j.molcel.2008.05.010; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Shen CL, 2005, J BIOL CHEM, V280, P35967, DOI 10.1074/jbc.M505220200; Sigismund S, 2004, CURR TOP MICROBIOL, V286, P149; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Ulrich HD, 2005, TRENDS CELL BIOL, V15, P525, DOI 10.1016/j.tcb.2005.08.002; Valero R, 1999, GENOMICS, V62, P395, DOI 10.1006/geno.1999.6025; VALERO R, 2001, GENOME BIOL, V2; Ventii KH, 2008, BIOCHEM J, V414, P161, DOI 10.1042/BJ20080798; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8; Woelk T, 2006, NAT CELL BIOL, V8, P1246, DOI 10.1038/ncb1484	35	51	52	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5571	10.1371/journal.pone.0005571	http://dx.doi.org/10.1371/journal.pone.0005571			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440361	Green Submitted, gold, Green Published			2022-12-25	WOS:000266107400014
